FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Wang, M
   Cheng, LM
   Li, QB
   Chen, ZW
   Wang, SL
AF Wang, Mei
   Cheng, Liming
   Li, Quanbao
   Chen, Zhiwen
   Wang, Shilong
TI RETRACTED: Two-dimensional nanosheets associated with one-dimensional
   single-crystalline nanorods self-assembled into three-dimensional
   flower-like Mn3O4 hierarchical architectures (Retracted article. See
   vol. 19, pg. 25222, 2017)
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID MAGNETIC-PROPERTIES; MANGANESE OXIDE; NO DECOMPOSITION; NANOPARTICLES;
   MN2O3; NANOCRYSTALS; MORPHOLOGY; REDUCTION; NANOWIRES; BATTERIES
AB Three-dimensional (3D) flower-like hausmannite architectures of Mn3O4 with uniform morphology have been successfully synthesized by a novel chemical reaction route using cetyltrimethylammonium bromide as the template. Micro/nanostructures of the as-synthesized 3D flower-like Mn3O4 architectures were investigated in detail by a series of analytical techniques. The geometrical shape of 3D flower-like Mn3O4 architectures is structurally perfect, and they are produced with diameters in the range of several hundred nanometers to a few micrometers. Experimental results indicate that two-dimensional nanosheets associated with one-dimensional single-crystalline nanorods self-assembled into three-dimensional flower-like Mn3O4 architectures. The single-crystalline Mn3O4 nanorods are a few hundred nanometers long and several tens of nanometers wide. Different dimensional systems, such as two-dimensional nanosheets, one-dimensional nanorods, and three-dimensional nanoflowers, could provide different building blocks to constitute nanostructured materials. These specific building blocks, which constituted the complex hierarchical architectures with nanostructural features, may offer exciting opportunities for both fundamental research and technological applications.
C1 [Wang, Mei; Wang, Shilong] Tongji Univ, Sch Life Sci & Technol, Peoples Hosp 10, Shanghai 200092, Peoples R China.
   [Cheng, Liming] Tongji Hosp, Translat Ctr Stem Cell Res, Shanghai, Peoples R China.
   [Li, Quanbao; Chen, Zhiwen] Shanghai Univ, Sch Environm & Chem Engn, Shanghai, Peoples R China.
RP Cheng, LM (reprint author), Tongji Hosp, Translat Ctr Stem Cell Res, Shanghai, Peoples R China.
EM limingcheng@tongji.edu.cn; wsl@tongji.edu.cn
RI Chen, Zhiwen/S-7256-2016
OI Chen, Zhiwen/0000-0001-9625-8556
FU National Natural Science Foundation of China [11375111, 11428410,
   11074161]; Research Fund for the Doctoral Program of Higher Education of
   China [20133108110021]; Key Innovation Fund of Shanghai Municipal
   Education Commission [14ZZ098, 10ZZ64]; Science and Technology
   Commission of Shanghai Municipality [14JC1402000, 10JC1405400]; Shanghai
   Pujiang Program [10PJ1404100]
FX The work described in this article was financially supported by the
   National Natural Science Foundation of China (Project Numbers: 11375111,
   11428410 and 11074161), the Research Fund for the Doctoral Program of
   Higher Education of China (Project Number: 20133108110021), the Key
   Innovation Fund of Shanghai Municipal Education Commission (Project
   Numbers: 14ZZ098 and 10ZZ64), the Science and Technology Commission of
   Shanghai Municipality (Project Numbers: 14JC1402000 and 10JC1405400),
   and the Shanghai Pujiang Program (Project Number: 10PJ1404100).
CR An GM, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/27/275709
   Armstrong AR, 1996, NATURE, V381, P499, DOI 10.1038/381499a0
   Chen ZW, 2006, SCRIPTA MATER, V55, P735, DOI 10.1016/j.scriptamat.2006.05.041
   Chen ZW, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2199848
   Chen ZW, 1997, J CRYST GROWTH, V180, P280, DOI 10.1016/S0022-0248(97)00215-7
   Cheng FY, 2006, INORG CHEM, V45, P2038, DOI 10.1021/ic051715b
   Du J, 2006, NANOTECHNOLOGY, V17, P4923, DOI 10.1088/0957-4484/17/19/024
   EDWARDS HW, 1979, ENVIRON SCI TECHNOL, V13, P673, DOI 10.1021/es60154a013
   Grootendorst EJ, 1995, J CATAL, V157, P706, DOI 10.1006/jcat.1995.1336
   Hao XL, 2011, COLLOID SURFACE A, V374, P42, DOI 10.1016/j.colsurfa.2010.10.048
   Huang MH, 2001, ADV MATER, V13, P113, DOI 10.1002/1521-4095(200101)13:2<113::AID-ADMA113>3.0.CO;2-H
   ISHII M, 1972, SOLID STATE COMMUN, V11, P209, DOI 10.1016/0038-1098(72)91162-3
   Jiao F, 2007, ADV MATER, V19, P4063, DOI 10.1002/adma.200700336
   Law M., 2002, ANGEW CHEM, V114, P2511, DOI DOI 10.1002/1521-3757(20020703)114:13<2511::AID-ANGE2511>3.0.CO;2-N
   Leite ER, 2002, J NANOSCI NANOTECHNO, V2, P125, DOI 10.1166/jnn.2002.094
   Li P, 2010, CHEM MATER, V22, P4232, DOI 10.1021/cm100831q
   Mandakini B., 2011, J PHYS CHEM C, V115, P15440
   Milliron DJ, 2004, NATURE, V430, P190, DOI 10.1038/nature02695
   Oaki Y, 2007, ANGEW CHEM INT EDIT, V46, P4951, DOI 10.1002/anie.200700244
   Omomo Y, 2003, J AM CHEM SOC, V125, P3568, DOI 10.1021/ja021364p
   Pan ZW, 2001, SCIENCE, V291, P1947, DOI 10.1126/science.1058120
   Peng XS, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/1/015701
   Qin Y, 2008, NATURE, V451, P809, DOI [10.1038/nature06601, 10.1038/nature066O1]
   Salazar-Alvarez G, 2007, J AM CHEM SOC, V129, P9102, DOI 10.1021/ja0714282
   Seo WS, 2004, ANGEW CHEM INT EDIT, V43, P1115, DOI 10.1002/anie.200352400
   Shao CL, 2004, J SOLID STATE CHEM, V177, P2628, DOI 10.1016/j.ssc.2004.04.003
   Stobbe ER, 1999, CATAL TODAY, V47, P161, DOI 10.1016/S0920-5861(98)00296-X
   Sun XM, 2006, CHEM-EUR J, V12, P2039, DOI 10.1002/chem.200500660
   Tan YW, 2011, CHEM COMMUN, V47, P1172, DOI 10.1039/c0cc00978d
   Tang ZY, 2002, SCIENCE, V297, P237, DOI 10.1126/science.1072086
   Tian ZR, 1997, SCIENCE, V276, P926, DOI 10.1126/science.276.5314.926
   Vazquez-Olmos A, 2005, J COLLOID INTERF SCI, V291, P175, DOI 10.1016/j.jcis.2005.05.005
   Walia S, 2013, PROG MATER SCI, V58, P1443, DOI 10.1016/j.pmatsci.2013.06.003
   Walia S, 2013, J PHYS CHEM C, V117, P9137, DOI 10.1021/jp401731b
   Wang N, 2011, SCI CHINA PHYS MECH, V54, P1958, DOI 10.1007/s11433-011-4464-0
   Wang ZH, 2008, J CRYST GROWTH, V310, P4148, DOI 10.1016/j.jcrysgro.2008.06.025
   Yamashita T, 1996, J CATAL, V161, P254, DOI 10.1006/jcat.1996.0183
   Yamashita T, 1996, J CATAL, V163, P158, DOI 10.1006/jcat.1996.0315
   Yu T, 2009, CHEM MATER, V21, P2272, DOI 10.1021/cm900431b
   Zhang H, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/31/315604
   Zhang WX, 2004, J CRYST GROWTH, V263, P394, DOI 10.1016/j.jcrysgro.2003.11.099
NR 41
TC 11
Z9 11
U1 6
U2 55
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PD OCT 21
PY 2014
VL 16
IS 39
BP 21742
EP 21746
DI 10.1039/c4cp03407d
PG 5
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA AQ8JX
UT WOS:000343072900080
PM 25198309
DA 2018-12-27
ER

PT J
AU Li, J
   Luo, JL
   Wang, ZH
AF Li, Jin
   Luo, Jianlin
   Wang, Zaihong
TI RETRACTED: Periodic Solutions of Second Order Impulsive Differential
   Equations at Resonance via Variational Approach (Retracted article. See
   vol. 20, pg. 289, 2015)
SO MATHEMATICAL MODELLING AND ANALYSIS
LA English
DT Article; Retracted Publication
DE impulsive differential equations; Landesman-Lazer type condition;
   variational method
AB In this paper, we study the existence of periodic solutions of second order impulsive differential equations at resonance. We prove the existence of periodic solutions under a generalized Landesman-Lazer type condition by using variational method.
C1 [Li, Jin; Luo, Jianlin] Jiujiang Univ, Sch Sci, Jiujiang 332005, Peoples R China.
   [Li, Jin; Wang, Zaihong] Capital Normal Univ, Sch Math Sci, Beijing 100048, Peoples R China.
RP Li, J (reprint author), Jiujiang Univ, Sch Sci, Jiujiang 332005, Peoples R China.
EM lijin7912@gmail.com
FU Research Fund for the Doctoral Program of Higher Education of China
   [11AA0013, 11401274]; Beijing Natural Science Foundation [1112006];
   Beijing Education Committee [KZ201310028031]; Science and technology
   landing project of colleges and universities in Jiangxi Province
   [KJLD14092]; Natural Science Foundation Project of Science and
   Technology Department of Jiangxi province [20132BAB201012,
   20142BDH80027]
FX Research supported by Research Fund for the Doctoral Program of Higher
   Education of China, No. 11AA0013 and 11401274, Beijing Natural Science
   Foundation (Existence and multiplicity of periodic solutions in
   nonlinear oscillations), No. 1112006, the grant of Beijing Education
   Committee Key Project, No. KZ201310028031, Science and technology
   landing project of colleges and universities in Jiangxi Province, No.
   KJLD14092 and Natural Science Foundation Project of Science and
   Technology Department of Jiangxi province, No. 20132BAB201012 and
   20142BDH80027.
CR Bogun I, 2012, NONLINEAR ANAL-REAL, V13, P2701, DOI 10.1016/j.nonrwa.2012.03.014
   Ding W, 2010, NONLINEAR ANAL-REAL, V11, P2603, DOI 10.1016/j.nonrwa.2009.09.007
   Fuik S., 1980, SOLVABILITY NONLINEA
   Lakshmikantham V, 1989, THEORY IMPULSIVE DIF
   LANDESMAN EM, 1970, J MATH MECH, V19, P609
   Lazer A. C., 1969, ANN MAT PUR APPL, V82, P49
   LAZER AC, 1968, J MATH ANAL APPL, V21, P421, DOI 10.1016/0022-247X(68)90225-4
   Mawhin J., 1989, CRITICAL POINT THEOR
   Nieto JJ, 2009, NONLINEAR ANAL-REAL, V10, P680, DOI 10.1016/j.nonrwa.2007.10.022
   Qian DB, 2005, J MATH ANAL APPL, V303, P288, DOI 10.1016/j.jmaa.2004.08.034
   Sun JT, 2013, J MATH ANAL APPL, V404, P562, DOI 10.1016/j.jmaa.2013.03.036
   Suns HR, 2012, ABSTR APPL ANAL, V2012, P19
   Tian Y, 2008, P EDINBURGH MATH SOC, V51, P509, DOI 10.1017/S0013091506001532
   Tomiczek P, 2009, NONLINEAR ANAL-THEOR, V70, P735, DOI 10.1016/j.na.2008.01.006
   Xiao J, 2012, COMMUN NONLINEAR SCI, V17, P426, DOI 10.1016/j.cnsns.2011.05.015
   Zhang H, 2010, NONLINEAR ANAL-REAL, V11, P67, DOI 10.1016/j.nonrwa.2008.10.016
   Zhang XS, 2011, NONLINEAR ANAL-THEOR, V74, P1960, DOI 10.1016/j.na.2010.11.003
   Zhang ZH, 2010, NONLINEAR ANAL-REAL, V11, P155, DOI 10.1016/j.nonrwa.2008.10.044
NR 18
TC 3
Z9 3
U1 2
U2 20
PU VILNIUS GEDIMINAS TECH UNIV
PI VILNIUS
PA SAULETEKIO AL 11, VILNIUS, LT-10223, LITHUANIA
SN 1392-6292
EI 1648-3510
J9 MATH MODEL ANAL
JI Math. Model. Anal.
PD OCT 20
PY 2014
VL 19
IS 5
BP 664
EP 675
DI 10.3846/13926292.2014.980864
PG 12
WC Mathematics
SC Mathematics
GA AT9TW
UT WOS:000345270100004
OA Other Gold
DA 2018-12-27
ER

PT J
AU Jagadeesha, CB
AF Jagadeesha, C. B.
TI RETRACTED: Dissimilar friction stir welding between aluminum alloy and
   magnesium alloy at a low rotational speed (Retracted article. See vol.
   656, pg. 275, 2016)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Retracted Publication
DE Dissimilar friction stir welding; Magnesium alloy; Aluminum alloy;
   Intermetallic compounds; Tensile strength; Hardness distribution
ID 6061-T6 ALUMINUM; MATERIAL FLOW; MG ALLOY; MICROSTRUCTURE; AL
AB A sound weld was obtained between 2024-T3 Al alloy and AZ31B-O Mg alloy dissimilar metal plates of 5 mm thickness, at a rotational speed of 300 rev min(-1) and at a welding speed of 50 mm min(-1). One of the parameter studied was, the effect of interface offset variation, on the quality and properties of the welded samples and on the thickness of intermetallic layer formed in the welded samples. The intermetallic layer at the midst of the weld volume contains intermetallic compounds Al12Mg17 and Al3Mg2. Highest tensile strength of 106.86 MPa, corresponding tensile joint efficiency of 44.52% and corresponding elongation 1.33% were obtained for the tensile sample, with interface offset of 0.66 mm from zero interface offset in retreating side and with approximate least intermetallic thickness of 1.2 mu m. Dissimilar friction stir welded joint samples had failed completely in brittle fracture mode; the position of tensile fracture was located at the midst of intermetallic layer, which had maximum hardness and minimum ductility. The nano hardness values fluctuate in the weld nugget owing to dynamic recrystallization of alloy materials and formation of brittle intermetallic compounds of alloy materials in the weld nugget; maximum hardness of 10.74 GPa occurred for the sample with least intermetallic thickness of 1.2 mu m. (C) 2014 Elsevier B.V. All rights reserved.
C1 Indian Inst Sci, Dept Mech Engn, Bangalore 560012, Bengaluru, India.
RP Jagadeesha, CB (reprint author), Indian Inst Sci, Dept Mech Engn, Bangalore 560012, Bengaluru, India.
EM jagscb1966@gmail.com
FU DRDO, India [DRDO/MME/SVK/0618]; Indian Institute of Science
FX The author is grateful to DRDO, India (Grant No. DRDO/MME/SVK/0618) and
   Indian Institute of Science for their financial backing for this work
   and also the author would like to thank Prof. Satish V. Kailas,
   Department of Mechanical Engineering, Indian Institute of Science, for
   his useful suggestions.
CR Chen YC, 2008, SCRIPTA MATER, V58, P433, DOI 10.1016/j.scriptamat.2007.10.033
   Dawes CJ, 1996, WELD J, V75, P41
   Gere Timoshenko, 2002, MECH MAT
   Hirano S., 2003, Q J JPN WELD SOC, V21, P539
   Khodir SA, 2007, MATER TRANS, V48, P2501, DOI 10.2320/matertrans.MRA2007093
   Kostka A, 2009, SCRIPTA MATER, V60, P953, DOI 10.1016/j.scriptamat.2009.02.020
   Krishnan KN, 2002, MAT SCI ENG A-STRUCT, V327, P246, DOI 10.1016/S0921-5093(01)01474-5
   Kumar K, 2008, MAT SCI ENG A-STRUCT, V485, P367, DOI 10.1016/j.msea.2007.08.013
   Kumar K, 2010, SCI TECHNOL WELD JOI, V15, P305, DOI 10.1179/136217109X12568132624280
   Liu G, 1997, SCRIPTA MATER, V37, P355, DOI 10.1016/S1359-6462(97)00093-6
   Park S.H.C., 2002, P INT WELD JOIN C KO, P534
   Sato YS, 2004, SCRIPTA MATER, V50, P1233, DOI 10.1016/j.scriptamat.2004.02.002
   Somasekharan AC, 2004, MATER CHARACT, V52, P49, DOI 10.1016/j.matchar.2004.03.005
   Su JQ, 2003, ACTA MATER, V51, P713, DOI 10.1016/S1659-6454(02)00449-4
   Thomas WM, 1997, MATER DESIGN, V18, P269, DOI 10.1016/S0261-3069(97)00062-9
   Thomas WM, 1991, GB Patent, Patent No. 9125978
   Venkateswaran P, 2012, MAT SCI ENG A-STRUCT, V545, P26, DOI 10.1016/j.msea.2012.02.069
   Venkateswaran P, 2009, J MATER SCI, V44, P4140, DOI 10.1007/s10853-009-3607-4
   Wang HY, 2007, SCI TECHNOL WELD JOI, V12, P261, DOI 10.1179/174329307X159784
   Yan JC, 2005, SCRIPTA MATER, V53, P585, DOI 10.1016/j.scriptamat.2005.04.022
   YASHAN D, 1987, WELD J, V66, P27
   Zettler R, 2006, ADV ENG MATER, V8, P415, DOI 10.1002/adem.200600030
NR 22
TC 16
Z9 18
U1 3
U2 49
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD OCT 20
PY 2014
VL 616
BP 55
EP 62
DI 10.1016/j.msea.2014.07.090
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA AR1NR
UT WOS:000343352400007
DA 2018-12-27
ER

PT J
AU Son, YO
   Pratheeshkumar, P
   Roy, RV
   Hitron, JA
   Wang, L
   Zhang, Z
   Shi, XL
AF Son, Young-Ok
   Pratheeshkumar, Poyil
   Roy, Ram Vinod
   Hitron, John Andrew
   Wang, Lei
   Zhang, Zhuo
   Shi, Xianglin
TI RETRACTED: Nrf2/p62 Signaling in Apoptosis Resistance and Its Role in
   Cadmium-induced Carcinogenesis (Retracted article. See vol. 293, pg.
   15455, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; AUTOPHAGY; P62; CANCER;
   CELLS; ACTIVATION; PROTEIN; OVEREXPRESSION; TUMORIGENESIS
AB The cadmium-transformed human lung bronchial epithelial BEAS-2B cells exhibit a property of apoptosis resistance as compared with normal non-transformed BEAS-2B cells. The level of basal reactive oxygen species (ROS) is extremely low in transformed cells in correlation with elevated expressions of both antioxidant enzymes (catalase, SOD1, and SOD2) and antiapoptotic proteins (Bcl-2/Bcl-xL). Moreover, Nrf2 and p62 are highly expressed in these transformed cells. The knockdown of Nrf2 or p62 by siRNA enhances ROS levels and cadmium-induced apoptosis. The binding activities of Nrf2 on the antioxidant response element promoter regions of p62/Bcl-2/Bcl-xL were dramatically increased in the cadmium-exposed transformed cells. Cadmium exposure increased the formation of LC3-II and the frequency of GFP-LC3 punctal cells in non-transformed BEAS-2B cells, whereas these increases are not shown in transformed cells, an indication of autophagy deficiency of transformed cells. Furthermore, the expression levels of Nrf2 and p62 are dramatically increased during chronic long term exposure to cadmium in the BEAS-2B cells as well as antiapoptotic proteins and antioxidant enzymes. These proteins are overexpressed in the tumor tissues derived from xenograft mouse models. Moreover, the colony growth is significantly attenuated in the transformed cells by siRNA transfection specific for Nrf2 or p62. Taken together, this study demonstrates that cadmium-transformed cells have acquired autophagy deficiency, leading to constitutive p62 and Nrf2 overexpression. These overexpressions up-regulate the antioxidant proteins catalase and SOD and the antiapoptotic proteins Bcl-2 and Bcl-xL. The final consequences are decrease in ROS generation, apoptotic resistance, and increased cell survival, proliferation, and tumorigenesis.
C1 [Son, Young-Ok; Pratheeshkumar, Poyil; Roy, Ram Vinod; Wang, Lei; Shi, Xianglin] Univ Kentucky, Coll Med, Ctr Res Environm Dis, Lexington, KY 40536 USA.
   [Son, Young-Ok; Pratheeshkumar, Poyil; Roy, Ram Vinod; Hitron, John Andrew; Wang, Lei; Zhang, Zhuo; Shi, Xianglin] Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY 40536 USA.
RP Shi, XL (reprint author), Univ Kentucky, Coll Med, Ctr Res Environm Dis, Lexington, KY 40536 USA.
EM xshi5@email.uky.edu
RI Shi, Xianglin/B-8588-2012; Zhang, Zhuo/B-8601-2012; Son,
   Young-Ok/P-3675-2015
OI Son, Youngok/0000-0003-0154-4061
FU National Institutes of Health [R01 ES015518, R01 CA119028, R01 ES015375,
   R01 CA116697]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants R01 ES015518, R01 CA119028, R01 ES015375, and R01
   CA116697.
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Agency for Toxic Substances and Diseases Registry (ATSDR), 2013, PRIOR LIST HAZ SUBST
   [Anonymous], 1993, IARC Monogr Eval Carcinog Risks Hum, V58, P1
   Banning A, 2005, MOL CELL BIOL, V25, P4914, DOI 10.1128/MCB.25.12.4914-4923.2005
   Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185
   Faroon O., 2012, TOXICOLOGICAL PROFIL
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   He XQ, 2008, CHEM RES TOXICOL, V21, P1375, DOI 10.1021/tx800019a
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023
   Ishii T, 1997, BIOCHEM BIOPH RES CO, V232, P33, DOI 10.1006/bbrc.1997.6221
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jarup L, 2003, BRIT MED BULL, V68, P167, DOI 10.1093/bmb/ldg032
   Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728
   Kitamura H, 2006, HISTOPATHOLOGY, V48, P157, DOI 10.1111/j.1365-2559.2005.02313.x
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   L'Azou B, 2014, TOXICOL RES-UK, V3, P32, DOI 10.1039/c3tx50063b
   Lau A, 2013, MOL CELL BIOL, V33, P2436, DOI 10.1128/MCB.01748-12
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394
   Niture SK, 2013, FREE RADICAL BIO MED, V57, P119, DOI 10.1016/j.freeradbiomed.2012.12.014
   Niture SK, 2012, J BIOL CHEM, V287, P9873, DOI 10.1074/jbc.M111.312694
   Orrenius S, 2013, ANNU REV PHARMACOL, V53, P275, DOI 10.1146/annurev-pharmtox-011112-140210
   Pi JB, 2008, FREE RADICAL BIO MED, V45, P651, DOI 10.1016/j.freeradbiomed.2008.05.020
   Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312
   Satarug S, 2010, ENVIRON HEALTH PERSP, V118, P182, DOI 10.1289/ehp.0901234
   Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420
   Son YO, 2012, TOXICOL APPL PHARM, V264, P153, DOI 10.1016/j.taap.2012.07.028
   Son YO, 2011, TOXICOL SCI, V119, P335, DOI 10.1093/toxsci/kfq335
   Son YO, 2010, TOXICOL SCI, V113, P127, DOI 10.1093/toxsci/kfp259
   Stacy DR, 2006, HEAD NECK-J SCI SPEC, V28, P813, DOI 10.1002/hed.20430
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Wang SH, 2008, CELL MOL LIFE SCI, V65, P3640, DOI 10.1007/s00018-008-8383-9
   Wang SH, 2009, TOXICOL SCI, V108, P124, DOI 10.1093/toxsci/kfn266
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
NR 42
TC 42
Z9 50
U1 0
U2 20
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 10
PY 2014
VL 289
IS 41
BP 28660
EP 28675
DI 10.1074/jbc.M114.595496
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AR7NC
UT WOS:000343765400054
PM 25157103
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Kaptan, K
AF Kaptan, Kubilay
TI RETRACTED: An Organizational Metamodel for Hospital Emergency
   Departments (Retracted article. See vol. 12, pg. 548, 2018)
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article; Retracted Publication
DE Damage; disaster resilience; hospital; hospital capacity; organizational
   model; metamodel
ID SEISMIC RESILIENCE; POISSON PROCESSES; QUALITY; TIME; ARRIVAL; HEALTH;
   CARE
AB I introduce an organizational model describing the response of the hospital emergency department. The hybrid simulation/analytical model (called a "metamodel") can estimate a hospital's capacity and dynamic response in real time and incorporate the influence of damage to structural and nonstructural components on the organizational ones. The waiting time is the main parameter of response and is used to evaluate the disaster resilience of health care facilities. Waiting time behavior is described by using a double exponential function and its parameters are calibrated based on simulated data. The metamodel covers a large range of hospital configurations and takes into account hospital resources in terms of staff and infrastructures, operational efficiency, and the possible existence of an emergency plan; maximum capacity; and behavior both in saturated and overcapacitated conditions. The sensitivity of the model to different arrival rates, hospital configurations, and capacities and the technical and organizational policies applied during and before a disaster were investigated. This model becomes an important tool in the decision process either for the engineering profession or for policy makers.
C1 Int Blue Crescent Relief & Dev Fdn, Ctr Disaster Resilience, Istanbul, Turkey.
RP Kaptan, K (reprint author), Int Blue Crescent Relief & Dev Fdn, Ctr Disaster Resilience, Istanbul, Turkey.
EM kaptankubilay@gmail.com
CR Asmussen S., 2007, STOCHASTIC SIMULATIO
   Bruneau M, 2003, EARTHQ SPECTRA, V19, P733, DOI 10.1193/1.1623497
   Cimellaro G, 2009, MCEER090009
   Cimellaro GP, 2010, STRUCT INFRASTRUCT E, V6, P127, DOI 10.1080/15732470802663847
   Di Bartolomeo S, 2007, INJURY, V38, P305, DOI 10.1016/j.injury.2006.10.005
   Hick JL, 2004, ANN EMERG MED, V44, P253, DOI 10.1016/j.annemergmed.2004.04.011
   JAIN S, 2003, MODELING SIMULATION
   Kuhl ME, 2000, J STAT COMPUT SIM, V67, P75
   Kuhl ME, 2006, INFORMS J COMPUT, V18, P3, DOI 10.1287/ijoc.1040.0113
   Kuhl ME, 1997, IIE TRANS, V29, P201, DOI 10.1080/07408179708966327
   MAXWELL RJ, 1984, BRIT MED J, V288, P1470, DOI 10.1136/bmj.288.6428.1470
   McCarthy K., 2000, PSYCHOL HEALTH MED, V5, P287, DOI DOI 10.1080/713690194
   Paul JA, 2006, PREHOSPITAL DISASTER, V21, P223, DOI 10.1017/S1049023X00003757
   Richards ME, 2006, PREHOSP EMERG CARE, V10, P440, DOI 10.1080/10903120600725868
   Soong T.T., 2004, FUNDAMENTAL PROBABIL
   Thompson DA, 1996, ANN EMERG MED, V28, P657, DOI 10.1016/S0196-0644(96)70090-2
   Trofimov V, 2006, TECHNICAL REPORT
   Vieth TL, 2006, AM J EMERG MED, V24, P787, DOI 10.1016/j.ajem.2006.03.026
   Yi P, 2005, THESIS STATE U NEW Y
NR 19
TC 2
Z9 2
U1 3
U2 16
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD OCT
PY 2014
VL 8
IS 5
BP 436
EP 444
DI 10.1017/dmp.2014.101
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AX9RT
UT WOS:000347240400011
PM 25397658
DA 2018-12-27
ER

PT J
AU Castaneda, L
   Maldonado, A
   Perez, JV
   Olvera, MDL
   Torres-Torres, C
AF Castaneda, L.
   Maldonado, A.
   Vega Perez, J.
   Olvera, M. de la L.
   Torres-Torres, C.
TI RETRACTED: Electrical and optical properties of nanostructured indium
   doped zinc oxide thin films deposited by ultrasonic chemical spray
   technique, starting from zinc acetylacetonate and indium
   chloride(Retracted article. See vol. 79, pg. 171, 2018)
SO MATERIALS SCIENCE IN SEMICONDUCTOR PROCESSING
LA English
DT Article; Retracted Publication
DE Thin films; Semiconductor oxide; Zinc oxide; Ultrasonic spray pyrolysis
ID SENSITIZED SOLAR-CELL; SUBSTRATE-TEMPERATURE; PYROLYSIS TECHNIQUE;
   AEROSOL SOLUTION; ZNO; TRANSPARENT; TRANSPORT
AB The physical characteristics of indium-doped zinc oxide [ZnO:In] thin films deposited by the ultrasonic spray pyrolysis technique were studied. We report the use of zinc acetylacetonate and indium acetate as Zn and In precursors, respectively; achieving ZnO:In thin films with both fast growth rate and homogeneous morphology; although undesirable homogeneous reaction in gas phase over substrate surface, at substrate temperatures higher than 500 degrees C, leads to a rough and powdery film surface. The effect of both indium concentration and the substrate characteristics as temperature on the structure, morphology, optical, and electrical properties were measured. All the films, which were polycrystalline, fitted well with the hexagonal wurtzite type ZnO. A strong change in preferential growth, from (002) to (101) planes for indium doped samples was observed. ZnO films presented an electrical resistivity as low as 3.42 x 10(-3) Omega cm and an average optical transmittance in the visible-UV region as high as 80%. The surface morphology of the films showed an evolution from hexagonal slices to triangle shaped grains when the indium concentration increases. Derived from nonlinear optical explorations, the temporary optical response of the samples was evaluated to be close to 1 femtosecond. Potential applications in regards to the resulting low electrical resistance and high optical transparency of the studied samples were contemplated. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Castaneda, L.; Vega Perez, J.] Inst Politecn Nacl, Escuela Super Ingn Mecan, Mexico City 07340, DF, Mexico.
   [Castaneda, L.; Vega Perez, J.] Inst Politecn Nacl, Elect Unidad Ticoman, Mexico City 07340, DF, Mexico.
   [Maldonado, A.; Olvera, M. de la L.] Inst Politecn Nacl, CINVESTAV IPN, Ctr Invest & Estudios Avanzados, Dept Ingn Elect SEES, Mexico City 07000, DF, Mexico.
   [Torres-Torres, C.] Inst Politecn Nacl, ESIME ZAC, Secc Estudios Posgrado & Invest, Mexico City 07738, DF, Mexico.
RP Torres-Torres, C (reprint author), Inst Politecn Nacl, ESIME ZAC, Secc Estudios Posgrado & Invest, Mexico City 07738, DF, Mexico.
EM crstorres@yahoo.com.mx
OI Torres-Torres, Carlos/0000-0001-9255-2416
FU Instituto Politecnico Nacional [SIP-20140273]; CONACyT [155996]; Escuela
   Superior de Ingenieria Mecanica y Electrica Unidad Ticoman, Instituto
   Politecnico Nacional [SIP-20140729]
FX The authors wish to thanks M. A. Luna, A. Tavira and A. Palafox for
   technical assistance. Special thanks to Maria de Lourdes-Rojas, from
   Laboratorios Centrales-CINVESTAV-IPN for SEM analysis. Also gratefully
   acknowledge for the financial support from the Instituto Politecnico
   Nacional under Project SIP-20140273 and from CONACyT under 155996
   contract. L Castaneda gratefully acknowledges the financial support from
   the Escuela Superior de Ingenieria Mecanica y Electrica Unidad Ticoman,
   Instituto Politecnico Nacional, through Project no. SIP-20140729.
CR Bahadur L, 2013, J SOLID STATE ELECTR, V17, P2001, DOI 10.1007/s10008-013-2053-z
   Biswal R, 2012, MATERIALS, V5, P432, DOI 10.3390/ma5030432
   Castaneda L, 2006, THIN SOLID FILMS, V503, P212, DOI 10.1016/j.tsf.2005.12.263
   Castaneda L, 2012, PHYS SCRIPTA, V86, DOI 10.1088/0031-8949/86/05/055601
   CHOPRA KL, 1983, THIN SOLID FILMS, V102, P1, DOI 10.1016/0040-6090(83)90256-0
   Ellmer K, 2001, J PHYS D APPL PHYS, V34, P3097, DOI 10.1088/0022-3727/34/21/301
   Janotti A, 2009, REP PROG PHYS, V72, DOI 10.1088/0034-4885/72/12/126501
   Kumar PMR, 2005, SEMICOND SCI TECH, V20, P120, DOI 10.1088/0268-1242/20/2/003
   Lee CH, 2013, J CERAM PROCESS RES, V14, P145
   MINAMI T, 1994, JPN J APPL PHYS 2, V33, pL743, DOI 10.1143/JJAP.33.L743
   Patil PS, 1999, MATER CHEM PHYS, V59, P185, DOI 10.1016/S0254-0584(99)00049-8
   Quinones-Galvan JG, 2013, RESULTS PHYS, V3, P248, DOI 10.1016/j.rinp.2013.11.001
   Riad AS, 2001, PHYSICA B, V296, P319, DOI 10.1016/S0921-4526(00)00571-8
   Romero R, 2006, THIN SOLID FILMS, V515, P1942, DOI 10.1016/j.tsf.2006.07.152
   SHEIKBAHAE M, 1991, IEEE J QUANTUM ELECT, V27, P1296, DOI 10.1109/3.89946
   Smith A, 1999, THIN SOLID FILMS, V345, P192, DOI 10.1016/S0040-6090(99)00167-4
   SRIDHAR R, 2012, ASIAN J SCI RES, V5, P238, DOI DOI 10.3923/ajsr.2012.238.246
   Stadler A, 2012, MATERIALS, V5, P661, DOI 10.3390/ma5040661
   Trejo-Valdez M, 2013, OPT LASER TECHNOL, V49, P75, DOI 10.1016/j.optlastec.2012.12.026
   Vimalkumar TV, 2011, APPL SURF SCI, V257, P8334, DOI 10.1016/j.apsusc.2011.03.118
   Vimalkumar TV, 2010, PHYSICA B, V405, P4957, DOI 10.1016/j.physb.2010.10.001
   Vimalkumar TV, 2010, MATER SCI ENG B-ADV, V175, P29, DOI 10.1016/j.mseb.2010.06.012
   Vimalkumar TV, 2010, APPL SURF SCI, V256, P6025, DOI 10.1016/j.apsusc.2010.03.113
   Xua J., 2010, MAT SCI ENG B, V167, P182
   Yun S, 2010, J PHYS CHEM SOLIDS, V71, P1724, DOI 10.1016/j.jpcs.2010.08.020
NR 25
TC 9
Z9 9
U1 2
U2 32
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1369-8001
EI 1873-4081
J9 MAT SCI SEMICON PROC
JI Mater. Sci. Semicond. Process
PD OCT
PY 2014
VL 26
BP 288
EP 293
DI 10.1016/j.mssp.2014.05.011
PG 6
WC Engineering, Electrical & Electronic; Materials Science,
   Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Engineering; Materials Science; Physics
GA AT3GH
UT WOS:000344823400040
DA 2018-12-27
ER

PT J
AU Xu, ZH
   Zhang, ZX
   Wu, LJ
   Sun, YW
   Guo, YD
   Qin, GP
   Mu, SZ
   Fan, RH
   Wang, BF
   Gao, WJ
AF Xu, Zihan
   Zhang, Zhenxin
   Wu, Lijun
   Sun, Yaowen
   Guo, Yadong
   Qin, Gaoping
   Mu, Shengzhi
   Fan, Ronghui
   Wang, Benfeng
   Gao, Wenjie
TI RETRACTED: Tanshinone IIA Pretreatment Renders Free Flaps against
   Hypoxic Injury through Activating Wnt Signaling and Upregulating Stem
   Cell-Related Biomarkers (Retracted article. See vol. 17, pg. 768, 2016)
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article; Retracted Publication
DE free flap; epithelial cell; traditional Chinese medicine; Wnt; stem cell
ID PLANARIAN REGENERATION; EXPRESSION; RECONSTRUCTION; INHIBITION; PATHWAY;
   SKIN
AB Partial or total flap necrosis after flap transplantation is sometimes clinically encountered in reconstructive surgery, often as a result of a period of hypoxia that exceeds the tolerance of the flap tissue. In this study, we determine whether tanshinone IIA (TSA) pretreatment can protect flap tissue against hypoxic injury and improve its viability. Primary epithelial cells isolated from the dorsal skin of mice were pretreated with TSA for two weeks. Cell counting kit-8 and Trypan Blue assays were carried out to examine the proliferation of TSA-pretreated cells after exposure to cobalt chloride. Then, Polymerase chain reaction and Western blot analysis were used to determine the expression of beta-catenin, GSK-3 beta, SOX2, and OCT4 in TSA-treated cells. In vivo, after mice were pretreated with TSA for two weeks, a reproducible ischemic flap model was implemented, and the area of surviving tissue in the transplanted flaps was measured. Immunohistochemistry was also conducted to examine the related biomarkers mentioned above. Results show that epidermal cells, pretreated with TSA, showed enhanced resistance to hypoxia. Activation of the Wnt signaling pathway in TSA-pretreated cells was characterized by the upregulation of beta-catenin and the downregulation of GSK-3 beta. The expression of SOX2 and OCT4 controlled by Wnt signaling were also found higher in TSA pretreated epithelial cells. In the reproducible ischaemic flap model, pretreatment with TSA enhanced resistance to hypoxia and increased the area of surviving tissue in transplanted flaps. The expression of Wnt signaling pathway components, stem-cell related biomarkers, and CD34, which are involved in the regeneration of blood vessels, was also upregulated in TSA-pretreated flap tissue. The results show that TSA pretreatment protects free flaps against hypoxic injury and increases the area of surviving tissue by activating Wnt signaling and upregulating stem cell-related biomarkers.
C1 [Xu, Zihan; Zhang, Zhenxin; Sun, Yaowen; Guo, Yadong; Qin, Gaoping; Mu, Shengzhi; Fan, Ronghui; Wang, Benfeng; Gao, Wenjie] Shaanxi Prov Peoples Hosp, Dept Burns & Plast Surg, Xian 710068, Peoples R China.
   [Wu, Lijun] Soochow Univ, Affiliated Hosp 2, Dept Plast Surg, Suzhou 215004, Peoples R China.
RP Xu, ZH (reprint author), Shaanxi Prov Peoples Hosp, Dept Burns & Plast Surg, Xian 710068, Peoples R China.
EM xuzihan0925@163.com; zzsxa2006@163.com; ljwu1986@163.com;
   sunyaowen888@163.com; yadongg2000@163.com; qingaoping@163.com;
   mszping@163.com; doctorfanronghui@163.com; wangben.369@163.com;
   xuesonggaowenjie@163.com
FU Shaanxi science and technology development plan project [2011kjxx-26]
FX This research project was supported by grants from Shaanxi science and
   technology development plan project (No. 2011kjxx-26). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Agholme F, 2011, ACTA ORTHOP, V82, P125, DOI [10.3109/17453674.2011.625539, 10.3109/17453674.2011.572252]
   Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100
   Anderson EC, 2010, GASTROENTEROLOGY, V139, P718, DOI 10.1053/j.gastro.2010.07.012
   Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023
   Chen YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040165
   Clayton E, 2007, NATURE, V446, P185, DOI 10.1038/nature05574
   FANG J, 2010, DISCOVER, V31, P18
   Fu JJ, 2007, EUR J PHARMACOL, V568, P213, DOI 10.1016/j.ejphar.2007.04.031
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood-2008-11-191577
   FUSENIG NE, 1974, J INVEST DERMATOL, V63, P187, DOI 10.1111/1523-1747.ep12679346
   Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565
   Gao S, 2012, ATHEROSCLEROSIS, V220, P3, DOI 10.1016/j.atherosclerosis.2011.06.041
   Gurley KA, 2008, SCIENCE, V319, P323, DOI 10.1126/science.1150029
   Hermans KCM, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-16
   Ito M, 2007, NATURE, V447, P316, DOI 10.1038/nature05766
   Macfarlan TS, 2012, NATURE, V487, P57, DOI 10.1038/nature11244
   Nahabedian MY, 2004, PLAST RECONSTR SURG, V114, P74, DOI 10.1097/01.PRS.0000127798.69644.65
   Nguyen H, 2006, CELL, V127, P171, DOI 10.1016/j.cell.2006.07.036
   Park OK, 2012, FITOTERAPIA, V83, P1666, DOI 10.1016/j.fitote.2012.09.020
   Petersen CP, 2009, P NATL ACAD SCI USA, V106, P17061, DOI 10.1073/pnas.0906823106
   Potten CS, 2002, J INVEST DERMATOL, V119, P888, DOI 10.1046/j.1523-1747.2002.00020.x
   Ramachandran R, 2011, P NATL ACAD SCI USA, V108, P15858, DOI 10.1073/pnas.1107220108
   Reis M, 2013, EXP CELL RES, V319, P1317, DOI 10.1016/j.yexcr.2012.12.023
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tang FT, 2007, VASC PHARMACOL, V46, P427, DOI 10.1016/j.vph.2007.01.001
   Tang QQ, 2012, BRAIN RES, V1488, P81, DOI 10.1016/j.brainres.2012.09.034
   Wang WZ, 2009, MICROSURG, V29, P72, DOI 10.1002/micr.20587
   Wei FC, 2002, PLAST RECONSTR SURG, V109, P45, DOI 10.1097/00006534-200201000-00008
   Weng R, 2010, J PLAST RECONSTR AES, V63, P2152, DOI 10.1016/j.bjps.2010.02.001
   Whyte JL, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008078
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Xu SW, 2013, EXPERT OPIN THER PAT, V23, P149, DOI 10.1517/13543776.2013.743995
   Xu SW, 2012, TRANSL RES, V160, P114, DOI 10.1016/j.trsl.2012.01.008
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1172482
   Zhang L, 2012, CELL PHYSIOL BIOCHEM, V30, P843, DOI 10.1159/000341462
   Zhu B, 2010, PHARM BIOL, V48, P484, DOI 10.3109/13880200903179699
NR 36
TC 3
Z9 3
U1 2
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2014
VL 15
IS 10
BP 18117
EP 18130
DI 10.3390/ijms151018117
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA AS7TI
UT WOS:000344457200029
PM 25302618
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Xu, JQ
   Zhang, WB
   Wan, R
   Yang, YQ
AF Xu, Jian-Qiang
   Zhang, Wei-Bin
   Wan, Rong
   Yang, Yao-Qi
TI RETRACTED: MicroRNA-32 inhibits osteosarcoma cell proliferation and
   invasion by targeting Sox9 (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Osteosarcoma; Cell proliferation; MicroRNA; miR-32; Sox9
ID TRANSCRIPTION FACTOR SOX9; UP-REGULATION; TUMOR PROGRESSION;
   CARCINOMA-CELLS; PROSTATE-CANCER; EXPRESSION; DIFFERENTIATION;
   DYSREGULATION; METHYLATION; EPITHELIUM
AB Increasing reports suggest that discovery of microRNAs (miRNAs) might provide a novel therapeutical target for human cancers, including osteosarcoma. Previous studies have shown that miR-32 was dysregulated in breast and endometrial cancer. However, its biological roles in osteosarcoma remain unclear. In the current study, we found that miR-32 was significantly down-regulated in osteosarcoma tissues, compared with the adjacent normal tissues. In vitro studies further demonstrated that miR-32 mimics were able to suppress, while its antisense oligos promoted cell proliferation in Saos-2 and U2OS cells. At the molecular level, our data further revealed that expression of Sox9 was negatively regulated by miR-32. Therefore, our results identify an important role for miR-32 in the osteosarcoma through regulating Sox9 expression.
C1 [Xu, Jian-Qiang; Zhang, Wei-Bin; Wan, Rong; Yang, Yao-Qi] Shanghai Jiao Tong Univ, Dept Orthopaed, Ruijin Hosp, Sch Med, Shanghai 200025, Peoples R China.
RP Zhang, WB (reprint author), Shanghai Jiao Tong Univ, Dept Orthopaed, Ruijin Hosp, Sch Med, 197,Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
EM Wei_BinZhang@126.com
CR Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144
   Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611
   Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010
   Jiang SS, 2010, CLIN CANCER RES, V16, P4363, DOI 10.1158/1078-0432.CCR-10-0138
   Kordes U, 2006, J NEURO-ONCOL, V80, P151, DOI 10.1007/s11060-006-9180-7
   Lee S, 2014, STEM CELLS DEV
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Matheu A, 2012, CANCER RES, V72, P1301, DOI 10.1158/0008-5472.CAN-11-3660
   Miao JL, 2013, TUMOR BIOL, V34, P2093, DOI 10.1007/s13277-013-0940-7
   Nugent M, 2014, CANCER MANAG RES, V6, P15, DOI 10.2147/CMAR.S53928
   Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200
   Rani SB, 2013, NEURO-ONCOLOGY, V15, P1302, DOI 10.1093/neuonc/not090
   Saegusa M, 2012, AM J PATHOL, V181, P684, DOI 10.1016/j.ajpath.2012.05.008
   Sun KL, 2013, NAT REV GENET, V14, P535, DOI 10.1038/nrg3471
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Wang H, 2008, CANCER RES, V68, P1625, DOI 10.1158/0008-5472.CAN-07-5915
   Wang ZG, 2014, PEDIATR BLOOD CANCER, V61, P206, DOI 10.1002/pbc.24763
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Wegner M, 2010, INT J BIOCHEM CELL B, V42, P381, DOI 10.1016/j.biocel.2009.07.006
   Wu WY, 2013, GENE CHROMOSOME CANC, V52, P1133, DOI 10.1002/gcc.22108
   Wu WY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-30
   Zhang JF, 2014, ONCOL LETT, V7, P270
   Zhu HB, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-183
NR 26
TC 30
Z9 33
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2014
VL 35
IS 10
BP 9847
EP 9853
DI 10.1007/s13277-014-2229-x
PG 7
WC Oncology
SC Oncology
GA AS8ZF
UT WOS:000344532700049
PM 24989927
DA 2018-12-27
ER

PT J
AU Ding, H
   Zhu, Y
   Chu, TQ
   Wang, SZ
AF Ding, Hao
   Zhu, Yi
   Chu, Tianqing
   Wang, Shengzi
TI RETRACTED: Epidermal growth factor induces FoxO1 nuclear exclusion to
   activate MMP7-mediated metastasis of larynx carcinoma (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Epidermal growth factor; PI3 kinase; FoxO1; Larynx carcinoma; MMP7;
   Cancer invasiveness; Cancer metastasis
ID MATRIX METALLOPROTEINASE-7; CANCER; MATRILYSIN; INFLAMMATION; BIOLOGY;
   TARGET; MMP-7
AB The molecular mechanism underlying cancer invasiveness and metastasis of larynx carcinoma remains elusive. Here we reported a strong correlation between phosphorylated epidermal growth factor receptor (EGFR) and matrix metalloproteinase-7 (MMP7) levels in larynx carcinoma patients. To examine whether a causal link exists, we used a human larynx carcinoma line, Hep-2, to study the molecular basis of EGFR signaling and MMP7 activation. We found that EGF-induced EGFR phosphorylation in Hep-2 cells resulted in activation of MMP7 and, consequently, an increase in cancer invasiveness. An EGFR inhibitor efficiently blocked this EGF-induced activation of MMP7. Moreover, an inhibitor for PI3 kinase (PI3K)/Akt, but not an inhibitor for mitogen-activated protein kinase (MAPK) or an inhibitor for c-Jun N-terminal kinase (JNK), significantly inhibited the EGF-induced activation of MMP7, suggesting that PI3K/Akt signaling cascades may be responsible for EGF-activated MMP7. Further dissection of the pathway revealed that nuclear exclusion of Akt downstream target, FoxO1, was induced by EGF-induced Akt activation and could be inhibited by either the EGFR inhibitor or by the PI3K/Akt inhibitor. Expression of a constitutive nuclear form of FoxO1 significantly inhibited MMP7 activation induced by EGF. Taken together, these findings suggest that EGF/EGFR signaling activates downstream PI3K/Akt to induce FoxO1 nuclear exclusion, which activates MMP7 to promote larynx carcinoma metastasis. Thus, Akt and FoxO1 appear to be promising therapeutic targets for preventing the metastasis of larynx carcinoma.
C1 [Ding, Hao; Zhu, Yi; Wang, Shengzi] Fudan Univ, Dept Radiat Oncol, Eye & ENT Hosp, Shanghai 200031, Peoples R China.
   [Chu, Tianqing] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai 200030, Peoples R China.
RP Wang, SZ (reprint author), Fudan Univ, Dept Radiat Oncol, Eye & ENT Hosp, 83 Fenyang Rd, Shanghai 200031, Peoples R China.
EM magicbziming@163.com; shengzi_wang14@163.com
FU Shanghai Committee of Science and Technology, China [12JC1402102];
   National Natural Science Foundation of China [81302004]; Comprehensive
   Prevention and Control Project of Chronic Disease of Shanghai Shenkang
   Hospital Development Center, China [SHDC12012317]
FX This work was supported by the Key Project of Shanghai Committee of
   Science and Technology, China (No. 12JC1402102), the National Natural
   Science Foundation of China (No. 81302004), and the Comprehensive
   Prevention and Control Project of Chronic Disease of Shanghai Shenkang
   Hospital Development Center, China (No. SHDC12012317).
CR Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421
   Burke B, 2004, IMMUNOBIOLOGY, V209, P51, DOI 10.1016/j.imbio.2004.04.005
   Dufour A, 2013, TRENDS PHARMACOL SCI, V34, P233, DOI 10.1016/j.tips.2013.02.004
   Hirsch FR, 2013, J THORAC ONCOL, V8, P373, DOI 10.1097/JTO.0b013e31827ed0ff
   Ii M, 2006, EXP BIOL MED, V231, P20
   Kim S, 2009, CELL SIGNAL, V21, P892, DOI 10.1016/j.cellsig.2009.01.034
   Kobayashi K, 2013, TARGET ONCOL, V8, P27, DOI 10.1007/s11523-013-0258-9
   Koskensalo S, 2011, TUMOR BIOL, V32, P259, DOI 10.1007/s13277-010-0080-2
   Koskensalo S, 2010, TUMOR BIOL, V31, P149, DOI 10.1007/s13277-010-0020-1
   Li Z, 2014, TUMOR BIOL, V35, P3463, DOI 10.1007/s13277-013-1458-8
   Monsalve M, 2011, CURR DRUG TARGETS, V12, P1322, DOI 10.2174/138945011796150307
   Nadal A, 2003, VIRCHOWS ARCH, V442, P1, DOI 10.1007/s00428-002-0726-6
   Sasaki T, 2013, BIOMED RES INT, DOI 10.1155/2013/546318
   Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635
   Tanimoto H, 1999, TUMOR BIOL, V20, P88, DOI 10.1159/000030051
   Wielockx B, 2004, CYTOKINE GROWTH F R, V15, P111, DOI 10.1016/j.cytogfr.2003.12.001
NR 16
TC 19
Z9 19
U1 5
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2014
VL 35
IS 10
BP 9987
EP 9992
DI 10.1007/s13277-014-2067-x
PG 6
WC Oncology
SC Oncology
GA AS8ZF
UT WOS:000344532700065
PM 25008564
DA 2018-12-27
ER

PT J
AU Li, X
   Zhang, G
   Huai, YJ
   Cao, ZQ
AF Li, Xin
   Zhang, Geng
   Huai, Yong-Jun
   Cao, Zhi-Qiang
TI RETRACTED: Association between APE1 T1349G polymorphism and prostate
   cancer risk: evidence from a meta-analysis (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE APE1; Polymorphism; Prostate cancer; Meta-analysis
ID DNA-REPAIR GENES; NORTH INDIAN POPULATION; BASE-EXCISION; PATHWAY;
   XRCC1; MEN
AB APE1 T1349G polymorphism was considered to be associated with risk of cancer, but studies on the association between APE1 T1349G polymorphism and risk of prostate cancer remained inconclusive. A meta-analysis of published studies was performed to precisely assess the association between APE1 Asp148Glu polymorphismand prostate cancer risk. PubMed, Embase, andWanfang databases were searched for published case-control studies investigating the association between APE1 T1349G polymorphism and prostate cancer risk. Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were used to assess the strength of the association. Overall, seven studies with a total of 3,063 individuals were finally included into the meta-analysis. The heterogeneity analysis did not find obvious heterogeneity among those included studies. Meta-analysis of total seven studies did not find an obvious association between APE1 T1349G polymorphism and prostate cancer risk (G vs T OR (95 % CI) = 1.11 (0.99-1.24); GG vs TT OR (95 % CI) = 1.25 (0.96-1.62); TG vs TT OR (95 % CI) = 1.11 (0.95-1.30); GG/TG vs T OR (95 % CI) = 1.13 (0.97-1.32); GG vs TT/TG OR (95 % CI) = 1.16 (0.91-1.48)). Subgroup analyses by ethnicity showed that APE1 T1349G polymorphism was associated with increased risk of prostate cancer in Caucasians (G vs T OR (95 % CI) = 1.26 (1.02-1.56), P = 0.033; TG vs TT OR (95 % CI) = 1.44 (1.06-1.94), P = 0.019; GG/TG vs T OR (95 % CI) = 1.45 (1.08-1.94), P = 0.013). The meta-analysis suggests that APE1 T1349G polymorphism is associated with increased risk of prostate cancer, especially in Caucasians. More studies are needed to further identify the obvious association above.
C1 [Li, Xin; Cao, Zhi-Qiang] Gen Hosp Shenyang Mil Reg, Dept Urinary Surg, Shenyang 110840, Peoples R China.
   [Zhang, Geng] Fourth Mil Med Univ, Xijing Hosp, Dept Urinary Surg, Xian 710032, Peoples R China.
   [Huai, Yong-Jun] Gen Hosp Shenyang Mil Reg, Dept Pneumol, Shenyang 110840, Peoples R China.
RP Cao, ZQ (reprint author), Gen Hosp Shenyang Mil Reg, Dept Urinary Surg, Shenyang 110840, Peoples R China.
EM weiguochen@hotmail.com
FU Science Foundation of China [81101926]; Science Foundation of Liaoning
   Province [2013020195, 2013020221]
FX This study was funded by the Science Foundation of China (Grant No.
   81101926), and the Science Foundation of Liaoning Province (Grant No.
   2013020195 and Grant No. 2013020221).
CR Agalliu I, 2010, CANCER CAUSE CONTROL, V21, P289, DOI 10.1007/s10552-009-9461-5
   Amankwah EK, 2012, CARCINOGENESIS, V33, P1259, DOI 10.1093/carcin/bgs150
   Chen L, 2006, J UROLOGY, V175, P108, DOI 10.1016/S0022-5347(05)00042-X
   Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1
   Das A, 2006, DNA REPAIR, V5, P1439, DOI 10.1016/j.dnarep.2006.07.003
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gao R, 2010, CANCER BIOL THER, V10, P13, DOI 10.4161/cbt.10.1.12172
   Gu DY, 2009, MUTAGENESIS, V24, P507, DOI 10.1093/mutage/gep036
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hung RJ, 2005, AM J EPIDEMIOL, V162, P925, DOI 10.1093/aje/kwi318
   Jiang Jun, 2009, V471, P305, DOI 10.1007/978-1-59745-416-2_16
   Jin F, 2014, TUMOUR BIOL
   Jing B, 2013, CLIN LAB, V59, P163, DOI 10.7754/Clin.Lab.2012.120206
   Karahalil B, 2012, HUM EXP TOXICOL, V31, P981, DOI 10.1177/0960327112444476
   Kuasne H, 2011, MOL BIOL REP, V38, P1585, DOI 10.1007/s11033-010-0267-z
   Lavender NA, 2010, PROSTATE, V70, P113, DOI 10.1002/pros.21048
   Liu C, 2013, MOL BIOL REP, V40, P171, DOI 10.1007/s11033-012-2046-5
   Mandal RK, 2012, INDIAN J MED RES, V135, P64, DOI 10.4103/0971-5916.93426
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mittal RD, 2012, MECH AGEING DEV, V133, P127, DOI 10.1016/j.mad.2011.10.002
   Rodriguez C, 2005, AM J EPIDEMIOL, V161, P147, DOI 10.1093/aje/kwi334
   Schroder FH, 2012, NEW ENGL J MED, V366, P981, DOI 10.1056/NEJMoa1113135
   Wang YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066999
   Zhang HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068634
   Zhou B, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-521
   Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232
   Zou YF, 2013, GENET TEST MOL BIOMA, V17, P926, DOI 10.1089/gtmb.2013.0267
NR 28
TC 5
Z9 5
U1 3
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2014
VL 35
IS 10
BP 10111
EP 10119
DI 10.1007/s13277-014-2115-6
PG 9
WC Oncology
SC Oncology
GA AS8ZF
UT WOS:000344532700080
PM 25023401
DA 2018-12-27
ER

PT J
AU Gao, P
   Yang, JL
   Zhao, H
   You, JH
   Hu, Y
AF Gao, Ping
   Yang, Jun-Lan
   Zhao, Hong
   You, Jun-Hao
   Hu, Yi
TI RETRACTED: Common polymorphism in the MMP-13 gene may contribute to the
   risk of human cancers: a meta-analysis (Retracted article. See vol. 36,
   pg. 7321, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE MMP-13; Genetic polymorphism; Cancer; Meta-analysis
ID BREAST-CANCER; FUNCTIONAL POLYMORPHISMS; ALZHEIMERS-DISEASE;
   COLORECTAL-CANCER; LUNG-CANCER; EXPRESSION; ASSOCIATION; CARCINOMA
AB Cancer was viewed to be driven by accumulating genetic abnormalities that generally include chromosomal abnormalities, mutations in tumor-suppressor genes, and oncogenes. The aim of this meta-analysis was to systematically summarize the possible associations between MMP-13 rs2252070 A>G variant and cancer risks. We systematically reviewed studies focusing on MMP-13 polymorphisms with human cancer susceptibility that were published before April 30, 2014. Relevant articles were identified through research of PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, Google Scholar, CBM, and CNKI databases. All analyses were calculated using the Version 12.0 STATA software. Odds ratios (OR) and 95 % confidence interval (95 % CI) were calculated. Eleven independent case-control studies were included in the meta-analysis, which involved 3,465 patients with cancers and 4,073 healthy controls. The results identified a positive association between rs2252070 A>G polymorphism and susceptibility to cancer under five genetic models (all P < 0.05). Ethnicity subgroup analysis implied that significant difference was detected for rs2252070 A>G polymorphism with increased risk of cancers among Asians and Caucasians in majority of the groups. Our findings suggest significant association for MMP-13 rs2252070 A>G to increased susceptibility to human cancer, especially in the progression of lung carcinoma.
C1 [Gao, Ping; Yang, Jun-Lan; Hu, Yi] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing 100853, Peoples R China.
   [Zhao, Hong; You, Jun-Hao] Chinese Peoples Liberat Army Gen Hosp, Hainan Branch, Dept Oncol, Beijing 100853, Peoples R China.
RP Hu, Y (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM dr_jiao301@126.com
CR Balbin M, 1999, APMIS, V107, P45, DOI 10.1111/j.1699-0463.1999.tb01525.x
   Culhaci N, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-42
   da Costa BR, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000048
   del Casar Lizcano J M, 2003, Gastroenterol Hepatol, V26, P1
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Elena JW, 2013, JNCI-J NATL CANCER I, V105, P85, DOI 10.1093/jnci/djs473
   Gonzalez-Arriaga P, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-378
   Hadler-Olsen E, 2011, FEBS J, V278, P28, DOI 10.1111/j.1742-4658.2010.07920.x
   Hudson TJ, 2013, J INTERN MED, V274, P440, DOI 10.1111/joim.12097
   Hwang BM, 2013, BMB REP, V46, P533, DOI 10.5483/BMBRep.2013.46.11.053
   Ioannidis JPA, 2008, BRIT MED J, V336, P1413, DOI 10.1136/bmj.a117
   Izzo G, 2013, CLINICS, V68, P277, DOI [10.6061/clinics/2013(02)RC01, 10.6061/CLINICS/2013(02)RC01]
   Jackson D, 2012, STAT MED, V31, P3805, DOI 10.1002/sim.5453
   Jemal A, 2012, CANCER-AM CANCER SOC, V118, P4372, DOI 10.1002/cncr.27410
   Jia Jing-hui, 2010, Zhonghua Yixue Yichuanxue Zazhi, V27, P209, DOI 10.3760/cma.j.issn.1003-9406.2010.02.020
   Krane SM, 1996, J BIOL CHEM, V271, P28509, DOI 10.1074/jbc.271.45.28509
   Kwok JBJ, 2008, ANN NEUROL, V64, P446, DOI 10.1002/ana.21476
   Li Y, 2010, MOL BIOL REP, V37, P197, DOI 10.1007/s11033-009-9593-4
   Li Y, 2009, INT J GYNECOL CANCER, V19, P129, DOI 10.1111/IGC.0b013e31819a1d8e
   Meads C, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1127
   Mehnert A, 2013, CANCER-AM CANCER SOC, V119, P2151, DOI 10.1002/cncr.28067
   Moreno-Ortiz JM, 2014, GENET MOL RES, V13, P3537, DOI 10.4238/2014.February.14.1
   Nannuru KC, 2010, CANCER RES, V70, P3494, DOI 10.1158/0008-5472.CAN-09-3251
   Oskarsson T, 2013, BREAST, V22, pS66, DOI 10.1016/j.breast.2013.07.012
   Prendergast GC, 2010, AM J PATHOL, V176, P2082, DOI 10.2353/ajpath.2010.091173
   Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x
   Roeb E, 2004, INT J COLORECTAL DIS, V19, P518, DOI 10.1007/s00384-004-0592-6
   Sanli M, 2013, J SURG RES, V183, P517, DOI 10.1016/j.jss.2013.01.045
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Nguyen SV, 2013, ANTICANCER RES, V33, P3247
   Tannure PN, 2012, CARIES RES, V46, P401, DOI 10.1159/000339379
   Tardif Ginette, 2004, Mod Rheumatol, V14, P197
   Vairaktaris E, 2007, ANTICANCER RES, V27, P4027
   [王伟 Wang Wei], 2013, [中国现代医学杂志, China Journal of Modern Medicine], V23, P35
   Woo HD, 2013, WORLD J GASTROENTERO, V19, P1011, DOI 10.3748/wjg.v19.i7.1011
   Yamagata K, 2012, J BIOL CHEM, V287, P1588, DOI 10.1074/jbc.M111.315127
   Ye XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071522
   Yoon S, 2002, MATRIX BIOL, V21, P487, DOI 10.1016/S0945-053X(02)00053-7
   Zhai Y, 2007, GUT, V56, P445, DOI 10.1136/gut.2006.112706
   Zhang ML, 2012, ACTA U MED ANHUI, V47, P314
   Zhang Xiao-Juan, 2006, Yichuan, V28, P1500, DOI 10.1360/yc-006-1500
   Zhong HM, 2013, INT IMMUNOPHARMACOL, V17, P329, DOI 10.1016/j.intimp.2013.06.027
NR 42
TC 6
Z9 6
U1 2
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2014
VL 35
IS 10
BP 10137
EP 10148
DI 10.1007/s13277-014-2309-y
PG 12
WC Oncology
SC Oncology
GA AS8ZF
UT WOS:000344532700083
PM 25023404
DA 2018-12-27
ER

PT J
AU Yang, YQ
   Qi, J
   Xu, JQ
   Hao, P
AF Yang, Yao-Qi
   Qi, Jin
   Xu, Jian-Qiang
   Hao, Ping
TI RETRACTED: MicroRNA-142-3p, a novel target of tumor suppressor menin,
   inhibits osteosarcoma cell proliferation by down-regulation of FASN
   (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Osteosarcoma; Menin; MicroRNA; MicroRNA-142-3p; FASN
ID FATTY-ACID SYNTHASE; PULMONARY METASTASIS; CLINIC-PROGRESS; CANCER;
   EXPRESSION; INVASION; TRANSCRIPTION; ACTIVATION; MIGRATION; PATHWAY
AB Menin, encoded by MEN1 gene, has been viewed as a tumor suppressor in several types of tumors, such as insulinoma, parathyroid tumor, and adrenocortical and lung carcinoma. However, its expression and molecular regulation mechanism in osteosarcoma has not been elucidated. Here, our results show menin expression is significantly down-regulated in osteosarcoma tissues, compared with adjacent normal tissues. Besides, we report that MicroRNA-142-3p as a novel target of menin. Up-regulation of MicroRNA-142-3p by menin overexpression inhibits cell proliferation in U2OS and MG63 cells. At the molecular level, MicroRNA-142-3p inhibits the protein expression of FASN through binding to its 3'-untranslated region. Therefore, we elucidate a novel regulation pathway in osteosarcoma cells and suggest a potential therapeutic approach for the tumor therapy.
C1 [Yang, Yao-Qi; Xu, Jian-Qiang; Hao, Ping] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Orthopaed, Shanghai 200025, Peoples R China.
   [Qi, Jin] Shanghai Jiao Tong Univ, Shanghai Inst Traumatol & Orthopaed, Sch Med, Shanghai 200025, Peoples R China.
RP Xu, JQ (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Orthopaed, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
EM jianqiang_xu@yeah.net
FU Shanghai Jiao Tong University School of Medicine Project in China
   [12XJ10064]
FX This work was supported by the Shanghai Jiao Tong University School of
   Medicine Project in China, No. 12XJ10064
CR Alvelos MI, 2013, EUR J ENDOCRINOL, V168, P119, DOI 10.1530/EJE-12-0327
   Bidard FC, 2013, NAT REV CLIN ONCOL, V10, P169, DOI 10.1038/nrclinonc.2013.4
   Ding G, 2013, MOL BIOL REP, V40, P2461, DOI 10.1007/s11033-012-2326-0
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Gill J, 2013, PHARMACOL THERAPEUT, V137, P89, DOI 10.1016/j.pharmthera.2012.09.003
   Gurung B, 2014, J BIOL CHEM, V289, P9902, DOI 10.1074/jbc.M113.520692
   Gurung B, 2013, CANCER RES, V73, P2650, DOI 10.1158/0008-5472.CAN-12-3158
   Han G, 2012, ONCOL RES, V20, P149, DOI 10.3727/096504012X13522227232237
   Horiguchi K, 2009, CLIN CANCER RES, V15, P2620, DOI 10.1158/1078-0432.CCR-08-2473
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Liu ZL, 2012, ONCOL LETT, V4, P878, DOI 10.3892/ol.2012.862
   Liu ZL, 2012, INDIAN J PATHOL MICR, V55, P163, DOI 10.4103/0377-4929.97849
   Matkar S, 2013, TRENDS BIOCHEM SCI, V38, P394, DOI [10.1016/j.tibs.2013.05.005, 10.1016/j.tibs.2013.0S.005]
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162
   Shen WW, 2013, J MOL MED, V91, P989, DOI 10.1007/s00109-013-1037-x
   Shi K, 2013, ENDOCR-RELAT CANCER, V20, P111, DOI 10.1530/ERC-12-0077
   Sun KL, 2013, NAT REV GENET, V14, P535, DOI 10.1038/nrg3471
   Veschi S, 2012, INT J ONCOL, V41, P1221, DOI 10.3892/ijo.2012.1563
   Wu LF, 2011, FEBS LETT, V585, P1322, DOI 10.1016/j.febslet.2011.03.067
   Wu Y, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.382416
   Xu B, 2013, P NATL ACAD SCI USA, V110, P17480, DOI 10.1073/pnas.1312022110
   Yang YJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.98
   Zaytseva YY, 2012, CANCER RES, V72, P1504, DOI 10.1158/0008-5472.CAN-11-4057
   Zhang P, 2013, ONCOL REP, V30, P1753, DOI 10.3892/or.2013.2619
NR 25
TC 11
Z9 11
U1 4
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2014
VL 35
IS 10
BP 10287
EP 10293
DI 10.1007/s13277-014-2316-z
PG 7
WC Oncology
SC Oncology
GA AS8ZF
UT WOS:000344532700099
PM 25034529
DA 2018-12-27
ER

PT J
AU Xing, XJ
   Gu, XH
   Ma, TF
AF Xing, Xiao-Jing
   Gu, Xiao-Hu
   Ma, Tian-Fei
TI RETRACTED: Relationship of serum MMP-7 levels for colorectal cancer: a
   meta-analysis (Retracted article. See vol. 36, pg. 7323, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE MMP-7; Colorectal cancer; Meta-analysis
ID METALLOPROTEINASE 7 MMP-7; SQUAMOUS-CELL CARCINOMA; TUMOR-PROGRESSION;
   PUBLICATION BIAS; POOR-PROGNOSIS; EXPRESSION; INVASION; HETEROGENEITY;
   METASTASIS; MATRIX-METALLOPROTEINASE-7
AB This meta-analysis aimed to identify the value of serum matrix metalloproteinase-7 (MMP-7) levels for the diagnosis of colorectal cancer (CRC). Through searching the following electronic databases: Cochrane Library (Issue 12, 2014), Web of Science (1945 similar to 2014), PubMed (1966 similar to 2014), CINAHL (1982 similar to 2014), EMBASE (1980 similar to 2014), and CBM (1982 similar to 2014), related articles were determined without any language restrictions. Stata statistical software (Version 12.0, Stata Corporation, College Station, TX, USA) was chosen to deal with statistical data. Standard mean difference (SMD) and its corresponding 95 % confidence interval (95 % CI) were calculated to clarify the correlation between serum MMP-7 levels and CRC. Seven clinical case-control studies which recruited 430 CRC patients and 357 healthy subjects were selected for statistical analysis. The main findings of our meta-analysis showed that the serum MMP-7 level in CRC patients was significantly higher than that in control subjects (SMD=2.15, 95 % CI=1.46 similar to 2.84, P<0.001). Ethnicity-stratified analysis indicated a higher serum MMP-7 level in CRC patients than that of control subjects among the Asians and the Caucasians (Asians: SMD=2.83, 95 % CI=1.76 similar to 3.91, P<0.001; Caucasians: SMD= 1.06, 95 % CI=0.46 similar to 1.66, P=0.001; respectively). The present meta-analysis indicated that the increased serum level of MMP-7 may be connected with the development of CRC; thus, serum levels of MMP-7 could be an independent biomarker for CRC patients.
C1 [Xing, Xiao-Jing; Ma, Tian-Fei] Liaoning Canc Hosp & Inst, Dept Internal Oncol, Shenyang 110042, Liaoning Provin, Peoples R China.
   [Gu, Xiao-Hu] Liaoning Canc Hosp & Inst, Dept Surg Oncol, Shenyang 110042, Liaoning Provin, Peoples R China.
RP Xing, XJ (reprint author), Liaoning Canc Hosp & Inst, Dept Internal Oncol, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning Provin, Peoples R China.
EM xingxiaojian69@126.com
FU National Natural Science Foundation of China [81201968]; Natural Science
   Foundation of Liaoning Province [201102111]; Doctoral Starting
   Foundation of Liaoning Province [20091045]
FX This study was funded by the National Natural Science Foundation of
   China (81201968), Natural Science Foundation of Liaoning Province
   (201102111), and Doctoral Starting Foundation of Liaoning Province
   (20091045). We would like to acknowledge the reviewers for their helpful
   comments on this paper.
CR Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001
   Chen JQ, 2004, WORLD J GASTROENTERO, V10, P776
   Cheng SJ, 2013, INT J ONCOL, V42, P1869, DOI 10.3892/ijo.2013.1902
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gershtein ES, 2007, B EXP BIOL MED+, V143, P459, DOI 10.1007/s10517-007-0156-1
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hua H, 2011, CELL MOL LIFE SCI, V68, P3853, DOI 10.1007/s00018-011-0763-x
   Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343
   Ii M, 2006, EXP BIOL MED, V231, P20
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Koperek O, 2014, APMIS, V122, P476, DOI 10.1111/apm.12194
   Koskensalo S, 2011, TUMOR BIOL, V32, P259, DOI 10.1007/s13277-010-0080-2
   Koskensalo S, 2010, TUMOR BIOL, V31, P149, DOI 10.1007/s13277-010-0020-1
   Kuang RG, 2013, TURK J GASTROENTEROL, V24, P99, DOI 10.4318/tjg.2013.0571
   Lin MC, 2011, J AGR FOOD CHEM, V59, P11304, DOI 10.1021/jf202433f
   Liu D, 2007, LUNG CANCER, V58, P384, DOI 10.1016/j.lungcan.2007.07.005
   Liu TZ, 2011, J ZHENGZHOU U, V46, P726
   Maurel J, 2007, INT J CANCER, V121, P1066, DOI 10.1002/ijc.22799
   Meyer JE, 2010, CANCER-AM CANCER SOC, V116, P4354, DOI 10.1002/cncr.25432
   Mlecnik B, 2010, GASTROENTEROLOGY, V138, P1429, DOI 10.1053/j.gastro.2009.10.057
   Moss LAS, 2012, AM J PATHOL, V181, P1895, DOI 10.1016/j.ajpath.2012.08.044
   Ogino S, 2010, J NATL CANCER I, V102, P365, DOI 10.1093/jnci/djq031
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Polistena A, 2014, IN VIVO, V28, P105
   Pryczynicz A, 2013, FOLIA HISTOCHEM CYTO, V51, P206, DOI 10.5603/FHC.2013.0029
   Samukange V, 2012, J BIOCHEM, V151, P533, DOI 10.1093/jb/mvs025
   Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052
   Song FJ, 1998, BRIT MED J, V316, P471
   Spiller RC, 2010, AM J GASTROENTEROL, V105, P775, DOI 10.1038/ajg.2010.69
   Takeharu H, 2011, BBA-PROTEINS PROTEOM, V1814, P1940, DOI 10.1016/j.bbapap.2011.07.008
   Tanaka Takuji, 2009, J Carcinog, V8, P5
   Wang CL, 2010, J MOD ONCOL, V18, P1160
   Wu JY, 2010, ORAL ONCOL, V46, P226, DOI 10.1016/j.oraloncology.2010.01.007
   Yang B, 2011, ULTRASTRUCT PATHOL, V35, P256, DOI 10.3109/01913123.2011.610564
   Yang JD, 2011, SEMIN CANCER BIOL, V21, P35, DOI 10.1016/j.semcancer.2010.10.007
   Zhang PJ, 2013, FUTURE ONCOL, V9, P1017, DOI [10.2217/fon.13.71, 10.2217/FON.13.71]
   Zhou JH, 2011, WORLD J GASTROENTERO, V17, P1373, DOI 10.3748/wjg.v17.i10.1373
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 41
TC 6
Z9 6
U1 3
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2014
VL 35
IS 10
BP 10515
EP 10522
DI 10.1007/s13277-014-2349-3
PG 8
WC Oncology
SC Oncology
GA AS8ZF
UT WOS:000344532700124
PM 25060179
DA 2018-12-27
ER

PT J
AU Feng, DR
   Liu, J
   Liang, S
   Wang, YY
   Xu, Y
AF Feng Deri
   Liu Jiaan
   Liang Shuang
   Wang Yanyan
   Xu Youjun
TI RETRACTED: Synthesis and Biological Evaluation of Entecavir 4 '-Ester
   Derivatives (Retracted article. See vol. 31, pg. 1078, 2015)
SO CHEMICAL RESEARCH IN CHINESE UNIVERSITIES
LA English
DT Article; Retracted Publication
DE Entecavir; Anti-HBV activity; Intestinal membrane permeability
ID HEPATITIS-B-VIRUS; PHARMACOKINETICS; INFECTION; PRODRUG; POTENT; ACID;
   LAMIVUDINE; TRIAL; DRUG
AB Entecavir can significantly inhibit the replication of HBV-DNA, reduce the HBV-DNA level in blood serum. But suffering from low oral bioavailability, entecavir has low intestinal membrane permeability and poor metabolic stability. In this study, 12 different derivatives of entecavir 4'-ester were regioselectively synthesized and their apical-to-basolateral permeabilities across Caco-2 cells and HBV-DNA inhibitory efficacies were evaluated. Most of the compounds showed high permeabilities across Caco-2 cells compared with entecavir, compounds 5b and 5e also exhibited comparable anti-BBV activities with that of entecavir, especially.
C1 [Feng Deri; Liu Jiaan; Liang Shuang; Wang Yanyan; Xu Youjun] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China.
RP Xu, Y (reprint author), Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China.
EM xuyoujun65@163.com
FU National Natural Science Foundation of China [51209024]; Science and
   Technology Plan of Sichuan Province, China [2010JY0122]
FX Supported by the National Natural Science Foundation of
   China(No.51209024) and the Science and Technology Plan of Sichuan
   Province, China(No.2010JY0122).
CR Balimane PV, 1998, BIOCHEM BIOPH RES CO, V250, P246, DOI 10.1006/bbrc.1998.9298
   Benjahad A, 2004, J MED CHEM, V47, P5501, DOI 10.1021/jm0407658
   Bueno AB, 2005, J MED CHEM, V48, P5305, DOI 10.1021/jm050235r
   Buti M, 2003, J HEPATOL, V39, pS139, DOI 10.1016/S0168-8278(03)00316-7
   Chu CK, 2000, J MED CHEM, V43, P3906, DOI 10.1021/jm990113x
   Cullen JM, 2001, ANTIMICROB AGENTS CH, V45, P2740, DOI 10.1128/AAC.45.10.2740-2745.2001
   Daniel G., 2013, CLIN SCI, V124, P77
   DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501
   Fisicaro P, 2009, GUT, V58, P974, DOI 10.1136/gut.2008.163600
   Gregory Y., 1999, ANTIMICROB AGENTS CH, V43, P190
   Han QJ, 2013, SEMIN IMMUNOPATHOL, V35, P23, DOI 10.1007/s00281-012-0331-y
   Honkoop P, 2003, EXPERT OPIN INV DRUG, V12, P683, DOI 10.1517/13543784.12.4.683
   Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444, DOI 10.1128/AAC.41.7.1444
   Jensbukh M. D., 2013, HEPATOLOGY, V58, P1533
   Liu Y, 2013, CHEM RES CHINESE U, V29, P449, DOI 10.1007/s40242-013-2491-2
   Lv ZL, 2010, J MED CHEM, V53, P660, DOI 10.1021/jm901237x
   Marcellin P, 2004, HEPATOLOGY, V40, P140, DOI 10.1002/hep.20257
   Perkins EJ, 2007, DRUG METAB DISPOS, V35, P1903, DOI 10.1124/dmd.107.016154
   Pothakamuri V. S., 2012, HEPATOLOGY, V55, P695
   Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573
   Shi CC, 2012, J VIRAL HEPATITIS, V19, pE26, DOI 10.1111/j.1365-2893.2011.01496.x
   Stevens RC, 2004, CLIN INFECT DIS, V39, P877, DOI 10.1086/423810
   Sun YB, 2009, MOL PHARMACEUT, V6, P315, DOI 10.1021/mp800200a
   Tenney DJ, 2004, ANTIMICROB AGENTS CH, V48, P3498, DOI 10.1128/AAC.48.9.3498-3507.2004
   Yan ZT, 2011, MOL PHARMACEUT, V8, P319, DOI 10.1021/mp100376q
   Zhang YX, 2013, MOL PHARMACEUT, V10, P3195, DOI 10.1021/mp400233x
NR 26
TC 3
Z9 3
U1 5
U2 14
PU HIGHER EDUCATION PRESS
PI BEIJING
PA NO 4 DEWAI DAJIE, BEIJING 100120, PEOPLES R CHINA
SN 1005-9040
EI 2210-3171
J9 CHEM RES CHINESE U
JI Chem. Res. Chin. Univ.
PD OCT
PY 2014
VL 30
IS 5
BP 749
EP 754
DI 10.1007/s40242-014-4183-y
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA AS7PU
UT WOS:000344448400009
DA 2018-12-27
ER

PT J
AU Liu, CF
   Liu, QH
   Liu, EL
   Zhai, XW
   Zhang, L
   Luo, TE
   Zhang, WF
   Feng, QL
   Cui, XL
   Zhao, ZQ
   Cao, JM
   Wu, BW
AF Liu, Cheng-Fang
   Liu, Qing-Hua
   Liu, En-Li
   Zhai, Xu-Wen
   Zhang, Li
   Luo, Tian-E
   Zhang, Wei-Fang
   Feng, Qi-Long
   Cui, Xiang-Li
   Zhao, Zhi-Qing
   Cao, Ji-Min
   Wu, Bo-Wei
TI RETRACTED: Activation of I-K1 Channel by Zacopride Attenuates Left
   Ventricular Remodeling in Rats With Myocardial Infarction (Retracted
   article. See vol. 65, pg. 296, 2015)
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE cardiac remodeling; zacopride; I-K1 channel; mTOR; p70S6
ID CARDIAC POTASSIUM CHANNELS; 70-KDA S6 KINASE; HEART-FAILURE;
   CHLOROQUINE; INHIBITION; EXPRESSION; BLOCKADE; CURRENTS; PHARMACOLOGY;
   ARRHYTHMIAS
AB Activating I-K1 channels is considered to be a promising antiarrhythmic strategy. Zacopride has been identified as a selective I-K1 channel agonist and can suppress triggered arrhythmias. Whether this drug also exerts a beneficial effect on cardiac remodeling is unknown, and the present study sought to address this question. Cardiac remodeling was induced through coronary ligation-induced myocardial infarction (MI) in male Sprague-Dawley rats. Zacopride (15 mu g/kg) was administered (intraperitoneally) daily for 28 days after MI to determine whether it could attenuate MI-induced cardiac remodeling. A 4-week treatment with zacopride attenuated post-MI cardiac remodeling, as shown by the reduced left ventricular end-diastolic dimension and left ventricular end-systolic dimension and the increased ejection fraction and fractional shortening in zacopride-treated animals compared with animals treated with vehicle (all P < 0.05). Furthermore, zacopride significantly decreased myocardial collagen deposition, cardiomyocyte hypertrophy, the plasma level of brain natriuretic peptide, and cardiomyocyte ultrastructural injury. Zacopride also upregulated the expression of the I-K1 channel protein and downregulated the expression of phosphorylated p70S6 kinase (p-p70S6K) and mTOR. These beneficial effects of zacopride were partially abolished by the I-K1 channel blocker chloroquine. We conclude that the activation of I-K1 channel by zacopride attenuates post-MI cardiac remodeling by suppressing mTOR-p70S6 kinase signaling.
C1 [Liu, Cheng-Fang; Liu, Qing-Hua; Liu, En-Li; Zhai, Xu-Wen; Zhang, Li; Luo, Tian-E; Zhang, Wei-Fang; Feng, Qi-Long; Cui, Xiang-Li; Zhao, Zhi-Qing; Wu, Bo-Wei] Shanxi Med Univ, Dept Physiol, Taiyuan 030001, Peoples R China.
   [Zhao, Zhi-Qing] Mercer Univ, Dept Biomed Sci, Sch Med, Savannah, GA USA.
   [Cao, Ji-Min] Peking Union Med Coll, Dept Physiol, Sch Basic Med, Beijing 100021, Peoples R China.
RP Wu, BW (reprint author), Shanxi Med Univ, Dept Physiol, 56 Xinjian South Rd, Taiyuan 030001, Peoples R China.
EM qweasd299@163.com
FU National Natural Science Foundation of China [31200864, 31171088,
   81001294]
FX Supported by the National Natural Science Foundation of China (31200864
   to Q.-H.L., no. 31171088 to J.-M.C., and 81001294 to T.-E.L.).
CR Billman GE., 2010, NOVEL THERAPEUTIC TA, P373
   Borlak J, 2003, FASEB J, V17, P1592, DOI 10.1096/fj.02-0889com
   Bose AK, 2007, CARDIOVASC DRUG THER, V21, P253, DOI 10.1007/s10557-007-6030-6
   Buss SJ, 2009, J AM COLL CARDIOL, V54, P2435, DOI 10.1016/j.jacc.2009.08.031
   Chen YF, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-40
   Clemessy JL, 1996, CRIT CARE MED, V24, P1189, DOI 10.1097/00003246-199607000-00021
   Ding L, 2009, CIRCULATION, V120, P764, DOI 10.1161/CIRCULATIONAHA.109.870725
   Hibino H, 2010, PHYSIOL REV, V90, P291, DOI 10.1152/physrev.00021.2009
   Kelesidis I, 2013, CLIN CARDIOL, V36, P595, DOI 10.1002/clc.22164
   Lee TM, 2008, J AM COLL CARDIOL, V51, P1309, DOI 10.1016/j.jacc.2007.11.067
   Lee TM, 2007, BASIC RES CARDIOL, V102, P171, DOI 10.1007/s00395-006-0628-x
   Li GR, 2010, ADV PHARMACOL, V59, P93, DOI 10.1016/S1054-3589(10)59004-5
   Liu QH, 2012, J CARDIOVASC PHARM, V59, P37, DOI 10.1097/FJC.0b013e3182350bcc
   Lujan HL, 2013, MED HYPOTHESES, V81, P521, DOI 10.1016/j.mehy.2013.06.022
   Mill JG, 2011, BRAZ J MED BIOL RES, V44, P890, DOI 10.1590/S0100-879X2011000900010
   Mustapha KB, 2009, EUR J DRUG METAB PH, V34, P151
   Nagakura Y, 1999, PHARMACOL RES, V39, P375, DOI 10.1006/phrs.1998.0454
   Nattel S, 2003, J MOL CELL CARDIOL, V35, P1395, DOI 10.1016/j.yjmcc.2003.09.004
   Noujaim SF, 2010, FASEB J, V24, P4302, DOI 10.1096/fj.10-163246
   PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161
   REES SA, 1993, CIRCULATION, V87, P1979, DOI 10.1161/01.CIR.87.6.1979
   Rose J, 2005, AM J PHYSIOL-HEART C, V288, pH2077, DOI 10.1152/ajpheart.00526.2003
   Sanada S, 2002, J AM COLL CARDIOL, V40, P991, DOI 10.1016/S0735-1097(02)02057-0
   Sanchez-Capula JA, 2001, J PHARMACOL EXP THER, V297, P437
   Sussman MA, 2011, PHYSIOL REV, V91, P1023, DOI 10.1152/physrev.00024.2010
   Tamargo J, 2004, CARDIOVASC RES, V62, P9, DOI 10.1016/j.cardiores.2003.12.026
   Vilahur G, 2011, J MOL CELL CARDIOL, V50, P522, DOI 10.1016/j.yjmcc.2010.12.021
   Wang LH, 2011, PHYTOTHER RES, V25, P33, DOI 10.1002/ptr.3097
   Wu B, 2013, ARTIF ORGANS, V37, pE44, DOI 10.1111/j.1525-1594.2012.01547.x
   Wymore RS, 1997, CIRC RES, V80, P261, DOI 10.1161/01.RES.80.2.261
   Yamakuni H, 2006, J PHARMACOL SCI, V101, P99, DOI 10.1254/jphs.SCJ05007X
   Yin HQ, 2008, INFLAMMATION, V31, P65, DOI 10.1007/s10753-007-9050-2
   Zhang L, 2013, SCI CHINA LIFE SCI, V56, P788, DOI 10.1007/s11427-013-4531-z
NR 33
TC 4
Z9 5
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0160-2446
EI 1533-4023
J9 J CARDIOVASC PHARM
JI J. Cardiovasc. Pharmacol.
PD OCT
PY 2014
VL 64
IS 4
BP 345
EP 356
DI 10.1097/FJC.0000000000000127
PG 12
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA AS0KP
UT WOS:000343966400008
PM 25286360
DA 2018-12-27
ER

PT J
AU Ma, XY
   Chen, YC
   Zhao, XH
   Chen, JF
   Shen, C
   Yang, S
AF Ma, Xiangyu
   Chen, Yanchun
   Zhao, Xianghai
   Chen, Jinfeng
   Shen, Chong
   Yang, Song
TI RETRACTED: Association Study of TGFBR2 and miR-518 Gene Polymorphisms
   With Age at Natural Menopause, Premature Ovarian Failure, and Early
   Menopause Among Chinese Han Women (Retracted article. See vol. 93, 398,
   2014)
SO MEDICINE
LA English
DT Article; Retracted Publication
ID BREAST-CANCER RISK; CARDIOVASCULAR-DISEASE; REPRODUCTIVE LIFE;
   HEART-DISEASE; EXPRESSION; MENARCHE; NKX-2.5; GROWTH; CELLS; ACID
AB Age at natural menopause (ANM), a highly heritable phenotype, has been identified to be closely associated with major hormone-related diseases, including breast cancer and gynecological cancers. We previously identified an important role for the transforming growth factor, beta receptor II (TGFBR2) gene polymorphisms in breast cancer susceptibility among Asian women. Considering the important role of ANM in breast carcinogenesis, we hypothesized that TGFBR2 signals were involved in the formation of natural menopause.
   In a population-based study of 1844 Chinese women, we evaluated the effect of the genetic polymorphisms of TGFBR2 and miR-518 to determine if they are associated with ANM, premature ovarian failure (POF), and early menopause (EM) risk.
   No significant differences in the distribution of body mass index, education levels, smoking, drinking, and hypertension were detected between POF and EM cases and controls except for POF cases that were older (P = 0.015) than controls and more likely to have dyslipidemia (P = 0.002). The results showed that miR-518 rs7256241 was significantly associated with ANM. The carriers of minor allele G of rs7256241 have significantly higher ANM than those of the major allele homozygotes TT (beta = 0.385, P = 0.035). TGFBR2 rs3773661 was significantly associated with POF, with odds ratio (OR) (95% confidence intervals [dCIs]) of 0.66 (0.47-0.94) associated with per minor allele C (P = 0.023). The quartiles of genetic risk score were significantly associated with POF (OR, 1.27; 95% CI, 1.02-1.58; P-trend = 0.034). Sensitivity analyses confirmed the robustness of these findings and no significant interactions were detected.
   This study provides evidence to implicate TGFBR2 and miR-518 gene polymorphisms as novel susceptibility factors for ANM, POF, and EM in Asians. Further research on these genetic regions will enhance our understanding of the genetic basis of natural menopause.
C1 [Ma, Xiangyu] Third Mil Med Univ, Coll Prevent Med, Dept Epidemiol, Chongqing, Peoples R China.
   [Chen, Yanchun; Zhao, Xianghai; Chen, Jinfeng; Yang, Song] Jiangsu Univ, Peoples Hosp Yixing City, Affiliated Yixing Peoples Hosp, Dept Cardiol, Yixing 214200, Jiangsu, Peoples R China.
   [Shen, Chong] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing 211166, Jiangsu, Peoples R China.
RP Shen, C (reprint author), Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 818 Tianyuan Rd, Nanjing 211166, Jiangsu, Peoples R China.
EM sc100@126.com; yangsong@medmail.com.cn
FU National Natural Science Foundation of China [81273165, 81072367,
   81302498]; Natural Science Foundation of Jiangsu Province [BK2011776];
   Science and Technology Program of Wuxi [ZD1011, CSEW1N1112]; Priority
   Academic Program for the Development of Jiangsu Higher Education
   Institutions (Public Health and Preventive Medicine)
FX This study was supported by grants from the National Natural Science
   Foundation of China (Grant No. 81273165, No. 81072367, and No.
   81302498), the Natural Science Foundation of Jiangsu Province (No.
   BK2011776), the Science and Technology Program of Wuxi (No. ZD1011 and
   CSEW1N1112), and the Priority Academic Program for the Development of
   Jiangsu Higher Education Institutions (Public Health and Preventive
   Medicine). The funders had no role in study design, data collection and
   analysis, decision to publish, and preparation of the manuscript.
CR Amani D, 2014, TUMOR BIOL, V35, P4757, DOI 10.1007/s13277-014-1621-x
   Andersen SW, 2014, CANCER EPIDEMIOL, V38, P62, DOI 10.1016/j.canep.2013.12.001
   Barrett-Connor E, 2013, CURR OPIN PHARMACOL, V13, P186, DOI 10.1016/j.coph.2013.01.005
   Bauer SR, 2013, MEDICINE, V92, P123, DOI 10.1097/MD.0b013e3182943bc2
   Beral V, 2012, LANCET ONCOL, V13, P1141, DOI 10.1016/S1470-2045(12)70425-4
   Brewer AC, 2005, STEM CELLS DEV, V14, P425, DOI 10.1089/scd.2005.14.425
   Britt K, 2012, LANCET ONCOL, V13, P1071, DOI 10.1016/S1470-2045(12)70456-4
   Cai Hui, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P23
   CASAGRANDE J, 1976, J NATL CANCER I, V56, P839, DOI 10.1093/jnci/56.4.839
   Chen JF, 2014, MOL BIOL REP, V41, P2257, DOI 10.1007/s11033-014-3078-9
   Chism L, 2012, ADV NPS PAS, V3v, P25
   Chism Lisa, 2012, Adv NPs PAs, V3, P21
   De Vos M, 2010, LANCET, V376, P911, DOI 10.1016/S0140-6736(10)60355-8
   Dentice M, 2004, MOL CELL BIOL, V24, P7863, DOI 10.1128/MCB.24.18.7863-7877.2004
   Hadji P, 2012, ANN ONCOL, V23, P2782, DOI 10.1093/annonc/mds169
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Ishibashi O, 2012, HYPERTENSION, V59, P265, DOI 10.1161/HYPERTENSIONAHA.111.180232
   JICK H, 1977, LANCET, V1, P1354
   Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564
   Kushwaha R, 2014, STEM CELLS DEV, V44, P91
   Liang WN, 2014, INT J ONCOL, V44, P91, DOI 10.3892/ijo.2013.2155
   Ma XY, 2012, CANCER EPIDEM BIOMAR, V21, P1176, DOI 10.1158/1055-9965.EPI-12-0118
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Mondul AM, 2005, AM J EPIDEMIOL, V162, P1089, DOI 10.1093/aje/kwi324
   Nelson LM, 2009, NEW ENGL J MED, V360, P606, DOI 10.1056/NEJMcp0808697
   Perry JRB, 2013, HUM MOL GENET, V22, P1465, DOI 10.1093/hmg/dds551
   Pfeilschifter J, 1998, J BONE MINER RES, V13, P716, DOI 10.1359/jbmr.1998.13.4.716
   Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109
   PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K
   Qin YY, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-5
   Qiu CS, 2013, J CLIN ENDOCR METAB, V98, P1612, DOI 10.1210/jc.2012-2919
   Rodrigues P, 2012, INT J MOL SCI, V13, P16500, DOI 10.3390/ijms131216500
   Scott EL, 2014, MOL CELL ENDOCRINOL, V389, P2, DOI 10.1016/j.mce.2014.01.013
   Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208
   Skegg DCG, 2001, LANCET, V358, P1196, DOI 10.1016/S0140-6736(01)06336-X
   Snieder H, 1998, J CLIN ENDOCR METAB, V83, P1875, DOI 10.1210/jc.83.6.1875
   Stolk L, 2009, NAT GENET, V41, P645, DOI 10.1038/ng.387
   Tehrani FR, 2014, CLIMACTERIC, V17, P164, DOI 10.3109/13697137.2013.828197
   Thomas PS, 2001, ANAT REC, V263, P307, DOI 10.1002/ar.1106
   Vaidya D, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5170
   Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67
   Yang JJ, 2010, J WOMENS HEALTH, V19, P297, DOI 10.1089/jwh.2008.1317
   Zhang MX, 2012, FEBS LETT, V586, P3508, DOI 10.1016/j.febslet.2012.08.007
NR 43
TC 3
Z9 4
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT
PY 2014
VL 93
IS 20
AR e93
DI 10.1097/MD.0000000000000093
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA AS3AB
UT WOS:000344146400002
PM 25365407
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Renehan, AG
AF Renehan, Andrew G.
TI RETRACTED: The 'obesity paradox' and survival after colorectal cancer:
   true or false? (Retracted article. See vol. 26, pg. 1203, 2015)
SO CANCER CAUSES & CONTROL
LA English
DT Editorial Material; Retracted Publication
DE Obesity; Colorectal cancer; Survival; Collider bias
ID BODY-MASS INDEX; RENAL-CELL CARCINOMA; SMOKING STATUS; WEIGHT-LOSS;
   MORTALITY; ASSOCIATION; RISK; METAANALYSIS; DISEASE; OVERWEIGHT
AB Body mass index (BMI), as an approximation of general adiposity, is an established risk factor for incidence of several adult cancer types, including colorectal cancer (CRC). There is a common perception that these relationships extrapolate directly as adverse prognostic factors after diagnosis, but evidence for this is lacking. The paper from Sclesinger et al. in this issue of the journal adds a new dimension to this debate focusing on relationships of post-diagnosis BMI (as a marker of the steady-state weight among survivors) and survival, and provides evidence on a decreased mortality risk among overweight (post-diagnosis BMI 25.0-29.9 kg/m(2)) compared with normal weight (post-diagnosis BMI 18.5-24.9 kg/m(2)) CRC survivors-an example of an 'obesity paradox.' The observation of the 'obesity paradox' is well documented in the methodology literature, but perhaps, less familiar to the cancer readership. Three broad classes of explanation are posited: (1) the associations are true and plausible; (2) the associations are false and reflect methodological issues; or (3) the observations represent a specific form of selection bias, known as collider bias. The present author argues that the obesity paradox reflects the latter-a product of a statistical bias-and emphasizes that, while these findings are hypothesis generating, they will not alter clinical practice or recommendations.
C1 Univ Manchester, Dept Surg, Inst Canc Sci, Manchester Acad Hlth Sci Ctr,Christie NHS Fdn Tru, Manchester M20 4BX, Lancs, England.
RP Renehan, AG (reprint author), Univ Manchester, Dept Surg, Inst Canc Sci, Manchester Acad Hlth Sci Ctr,Christie NHS Fdn Tru, Wilmslow Rd, Manchester M20 4BX, Lancs, England.
EM andrew.renehan@ics.manchester.ac.uk
FU Economic and Social Research Council [ES/J010014/1, ES/F029721/1];
   Medical Research Council [MC_PC_13042, MR/K006665/1]
CR [AICR WCRF], 2007, FOOD NUTR PHYS ACT P
   CARMAN WJ, 1994, CIRCULATION, V89, P703, DOI 10.1161/01.CIR.89.2.703
   Carnethon MR, 2012, JAMA-J AM MED ASSOC, V308, P581, DOI 10.1001/jama.2012.9282
   Cole SR, 2010, INT J EPIDEMIOL, V39, P417, DOI 10.1093/ije/dyp334
   Crosbie EJ, 2012, EUR J CANCER, V48, P853, DOI 10.1016/j.ejca.2011.10.003
   Crosbie EJ, 2010, CANCER EPIDEM BIOMAR, V19, P3119, DOI 10.1158/1055-9965.EPI-10-0832
   Doyle C, 2006, CA-CANCER J CLIN, V56, P323, DOI 10.3322/canjclin.56.6.323
   Durazo-Arvizu RA, 2008, INT J OBESITY, V32, pS52, DOI 10.1038/ijo.2008.86
   Flegal KM, 2011, AM J EPIDEMIOL, V173, P1, DOI 10.1093/aje/kwq341
   Hakimi AA, 2013, JNCI-J NATL CANCER I, V105, P1862, DOI 10.1093/jnci/djt310
   Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43
   Hernandez-Diaz S, 2006, AM J EPIDEMIOL, V164, P1115, DOI 10.1093/aje/kwj275
   Landbo C, 1999, AM J RESP CRIT CARE, V160, P1856, DOI 10.1164/ajrccm.160.6.9902115
   Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068
   Lawlor DA, 2006, OBESITY, V14, P2294, DOI 10.1038/oby.2006.269
   Logue J, 2013, DIABETES CARE, V36, P887, DOI 10.2337/dc12-0944
   Oreopoulos A, 2008, AM HEART J, V156, P13, DOI 10.1016/j.ahj.2008.02.014
   Parker AS, 2006, UROLOGY, V68, P741, DOI 10.1016/j.urology.2006.05.024
   Parkin E, 2014, OBES REV, V15, P434, DOI 10.1111/obr.12140
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Renehan AG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt375
   Romero-Corral A, 2006, LANCET, V368, P666, DOI 10.1016/S0140-6736(06)69251-9
   Rothman KJ, 2008, INT J OBESITY, V32, pS56, DOI 10.1038/ijo.2008.87
   Schlesinger S, 2014, CANCER CAUSE CONTROL, V25, P1407, DOI 10.1007/s10552-014-0435-x
   Speakman JR, 2014, PHYSIOLOGY, V29, P88, DOI 10.1152/physiol.00053.2013
   Strandberg TE, 2013, AM J EPIDEMIOL, V178, P1452, DOI 10.1093/aje/kwt157
   Tobias DK, 2014, NEW ENGL J MED, V370, P233, DOI 10.1056/NEJMoa1304501
   Vina J, 2013, JAMA-J AM MED ASSOC, V309, P1679, DOI 10.1001/jama.2013.3080
   Yang XR, 2011, JNCI-J NATL CANCER I, V103, P250, DOI 10.1093/jnci/djq526
   Yoon HH, 2011, J CLIN ONCOL, V29, P4561, DOI 10.1200/JCO.2011.37.1260
NR 30
TC 6
Z9 6
U1 4
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
EI 1573-7225
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD OCT
PY 2014
VL 25
IS 10
BP 1419
EP 1422
DI 10.1007/s10552-014-0436-9
PG 4
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA AR6UP
UT WOS:000343718900018
PM 25084751
DA 2018-12-27
ER

PT J
AU Xiong, B
   Ma, L
   Cheng, Y
   Zhang, C
AF Xiong, B.
   Ma, L.
   Cheng, Y.
   Zhang, C.
TI RETRACTED: Clinical effectiveness of neoadjuvant chemotherapy in
   advanced gastric cancer: An updated meta-analysis of randomized
   controlled trials (Retracted article. See vol. 41, pg. 953, 2015)
SO EJSO
LA English
DT Article; Retracted Publication
DE Gastric cancer; Neoadjuvant chemotherapy; Survival; Randomized
   controlled trial; Meta-analysis
ID PERIOPERATIVE CHEMOTHERAPY; SURGERY; MORTALITY; ADJUVANT
AB Aims: To assess the efficacy and safety of neoadjuvant chemotherapy (NAC) for advanced gastric cancer (AGC).
   Methods: By searching electronic databases (PubMed, Embase, Cochrane Library) and ASCO proceedings from 1990 to 2012, all randomized controlled trials (RCTs) which compared the effect of NAC-combined surgery versus surgery alone in AGC were included. All calculations and statistical tests were performed using RevMan 5.0 software.
   Results: 12 RCTs with a total of 1820 patients were included. All patients had locally advanced but resectable gastric cancer and received NAC. NAC can slightly improve the survival rate (OR = 1.32, 95% Confidence interval (CI): 1.07-1.64, P = 0.01), with little or no significant benefits in subgroup analyses between either different population or regimens. NAC can significantly improve the 3-year progression-free survival (PFS) (OR: 1.85, 95% CI: 1.39-2.46, p < 0.0001), tumor down-staging rate (OR: 1.71, 95% CI: 1.26, 2.33, p = 0.0006) and R0 resection rate (OR: 1.38, 95% CI: 1.08-1.78, P -= 0.01) of patients with AGC. There was no difference between the two arms, in terms of relapse rates (OR: 1.03, 95% CI: 0.60-1.78, p = 0.92), operative complications (OR: 1.20, 95% CI: 0.90-1.58, p = 0.21), perioperative mortality (OR: 1.14, 95% CI: 0.64-2.05, p = 0.65) and grade 3/4 adverse effects: gastrointestinal problem (OR: 0.57, 95% CI: 0.25-1.30, p = 0.18), leukopenia (OR: 0.88, 95% CI: 0.41-1.91, p = 0.75), thrombocytopenia (OR: 1.27, 95% CI: 0.27-5.93, p = 0.76).
   Conclusion: NAC is effective and safe. However, further prospective multi-national and multi-center RCTs are still needed in order to investigate the long-term oncological and functional outcomes to define the clinical benefits of NAC and the most effective strategies for AGC. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Xiong, B.; Cheng, Y.; Zhang, C.] Chongqing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Chongqing 400016, Peoples R China.
   [Ma, L.] Chongqing Huaxi Hosp, Dept Internal Med, Chongqing 400054, Peoples R China.
RP Xiong, B (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Gen Surg, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM xbh791220@163.com; 351893768@qq.com; 280343115@qq.com
CR Biffi R, 2010, WORLD J GASTROENTERO, V16, P868, DOI 10.3748/wjg.v16.i7.868
   Bonenkamp JJ, 1999, NEW ENGL J MED, V340, P908, DOI 10.1056/NEJM199903253401202
   Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354
   Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531
   FREI E, 1982, CANCER, V50, P1979, DOI 10.1002/1097-0142(19821115)50:10<1979::AID-CNCR2820501002>3.0.CO;2-D
   Hartgrink HH, 2004, EJSO, V30, P643, DOI 10.1016/j.ejso.2004.04.013
   He Ling-Feng, 2008, Ai Zheng, V27, P407
   Higgins JPT, COCHRANE HDB SYSTEMA
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kang YK, 1996, ASCO ANN M
   Kobayashi T, 2000, Gan To Kagaku Ryoho, V27, P1521
   Li W, 2010, WORLD J GASTROENTERO, V16, P5621, DOI 10.3748/wjg.v16.i44.5621
   Lygidakis NJ, 1999, HEPATO-GASTROENTEROL, V46, P2035
   MacLehose R R, 2000, Health Technol Assess, V4, P1
   Moehler M, 2008, WORLD J GASTROENTERO, V14, P3773, DOI 10.3748/wjg.14.3773
   Ng K, 2007, CANCER J, V13, P168, DOI 10.1097/PPO.0b013e318074e351
   Nio Y, 2004, ANTICANCER RES, V24, P1879
   Qu Jian-jun, 2010, Zhonghua Wei Chang Wai Ke Za Zhi, V13, P664
   Sastre J, 2006, WORLD J GASTROENTERO, V12, P204, DOI 10.3748/wjg.v12.i2.204
   Schuhmacher C, 2010, J CLIN ONCOL, V28, P5210, DOI 10.1200/JCO.2009.26.6114
   Valenti V, 2011, J SURG ONCOL, V104, P124, DOI 10.1002/jso.21947
   Wang XL, 2000, ONCOL REP, V7, P241
   WILKE H, 1989, J CLIN ONCOL, V7, P1318, DOI 10.1200/JCO.1989.7.9.1318
   Wohrer SS, 2004, ANN ONCOL, V15, P1585, DOI 10.1093/annonc/mdh422
   Wu AW, 2007, COCHRANE DB SYST REV, V18
   Yang L, 2006, WORLD J GASTROENTERO, V12, P17, DOI 10.3748/wjg.v12.i1.17
   Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597
   YONEMURA Y, 1993, WORLD J SURG, V17, P256, DOI 10.1007/BF01658939
NR 29
TC 15
Z9 17
U1 4
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0748-7983
EI 1532-2157
J9 EJSO-EUR J SURG ONC
JI EJSO
PD OCT
PY 2014
VL 40
IS 10
BP 1321
EP 1330
DI 10.1016/j.ejso.2014.01.006
PG 10
WC Oncology; Surgery
SC Oncology; Surgery
GA AR1YN
UT WOS:000343380600022
PM 25239442
DA 2018-12-27
ER

PT J
AU Zhao, H
   Cai, W
   Su, S
   Zhi, D
   Lu, J
   Liu, S
AF Zhao, H.
   Cai, W.
   Su, S.
   Zhi, D.
   Lu, J.
   Liu, S.
TI RETRACTED: Screening genes crucial for pediatric pilocytic astrocytoma
   using weighted gene coexpression network analysis combined with
   methylation data analysis (Retracted article. See vol. 23, pg. 72, 2016)
SO CANCER GENE THERAPY
LA English
DT Article; Retracted Publication
ID SURVIVAL RATES; BRAIN-TUMORS; R PACKAGE; CANCER; EXPRESSION;
   POLYMORPHISMS; GLIOBLASTOMA; ACTIVATION; RECEPTORS; SUBSETS
AB To identify novel genes associated with pediatric pilocytic astrocytoma (PA) for better understanding the molecular mechanism underlying the pediatric PA pathogenesis. Gene expression profile data of GSE50161 and GSE44971 and the methylation data of GSE44684 were downloaded from Gene Expression Omnibus. The differentially expressed genes (DEGs) between PA and normal control samples were screened using the limma package in R, and then used to construct weighted gene coexpression network (WGCN) using the WGCN analysis (WGCNA) package in R. Significant modules of DEGs were selected using the clustering analysis. Function enrichment analysis of the DEGs in significant modules were performed using the WGCNA package and clusterprofiler package in R. Correlation between methylation sites of DEGs and PA was analyzed using the CpGassoc package in R. Totally, 3479 DEGs were screened in PA samples. Thereinto, 3424 DEGs were used to construct the WGCN. Several significant modules of DEGs were selected based on the WGCN, in which the turquoise module was positively related to PA, whereas blue module was negatively related to PA. DEGs (for example, DOCK2 (dedicator of cytokinesis 2), DOCK8 and FCGR2A (Fc fragment of IgG, low affinity IIa)) in blue module were mainly involved in Fc gamma R-mediated phagocytosis pathway and natural killer cell-mediated cytotoxicity pathway. Methylations of 14 DEGs among the top 30 genes in blue module were related to PA. Our data suggest that DOCK2, DOCK8 and FCGR2A may represent potential therapeutic targets in PA that merits further investigation.
C1 [Zhao, H.; Su, S.; Zhi, D.; Lu, J.; Liu, S.] China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang 110022, Peoples R China.
   [Cai, W.] China Med Univ, Shengjing Hosp, Dept Oncol, Shenyang 110022, Peoples R China.
RP Zhao, H (reprint author), China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang 110022, Peoples R China.
EM hongyuzhaohyz@163.com
FU National Natural Science Foundation grant from China National Science
   Foundation Committee [81172410]
FX This work was supported by National Natural Science Foundation grant
   from China National Science Foundation Committee (project code:
   81172410).
CR Barfield RT, 2012, BIOINFORMATICS, V28, P1280, DOI 10.1093/bioinformatics/bts124
   Bikowska-Opalach B, 2014, HISTOL HISTOPATHOL, V29, P1235, DOI 10.14670/HH-29.1235
   Burkhard C, 2003, J NEUROSURG, V98, P1170, DOI 10.3171/jns.2003.98.6.1170
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Christensen BC, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq497
   Cin H, 2011, ACTA NEUROPATHOL, V121, P763, DOI 10.1007/s00401-011-0817-z
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Dornan D, 2010, BLOOD, V116, P4212, DOI 10.1182/blood-2010-03-272765
   Dunham C, 2010, SEMIN DIAGN PATHOL, V27, P147, DOI 10.1053/j.semdp.2010.04.003
   Duthie SJ, 2011, J INHERIT METAB DIS, V34, P101, DOI 10.1007/s10545-010-9128-0
   Fonseca AL, 2012, GENE CHROMOSOME CANC, V51, P949, DOI 10.1002/gcc.21978
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gentleman R., 2005, BIOINFORMATICS COMPU
   Griesinger AM, 2013, J IMMUNOL, V191, P4880, DOI 10.4049/jimmunol.1301966
   Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582
   Hannani D, 2011, CANCER J, V17, P351, DOI 10.1097/PPO.0b013e3182325d4d
   Hawkins C, 2011, CLIN CANCER RES, V17, P4790, DOI 10.1158/1078-0432.CCR-11-0034
   Ho CY, 2013, NEURO-ONCOLOGY, V15, P69, DOI 10.1093/neuonc/nos269
   Huang H, 2005, J NEUROPATH EXP NEUR, V64, P891, DOI 10.1097/01.jnen.0000183345.19447.8e
   Hutt-Cabezas M, 2013, NEURO-ONCOLOGY, V15, P1604, DOI 10.1093/neuonc/not132
   Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097
   Jones DTW, 2012, CELL MOL LIFE SCI, V69, P1799, DOI 10.1007/s00018-011-0898-9
   Kyogoku C, 2002, GENES IMMUN, V3, P488, DOI 10.1038/sj.gene.6363921
   Lambert SR, 2013, ACTA NEUROPATHOL, V126, P291, DOI 10.1007/s00401-013-1124-7
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Lee HJ, 2014, WORLD J GASTROENTERO, V20, P1681, DOI 10.3748/wjg.v20.i7.1681
   Lindqvist BM, 2014, EPIGENETICS, V9, P8
   Mellor JD, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-1
   Montano CM, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r94
   Nakata S, 2013, BRAIN PATHOL, V23, P60, DOI 10.1111/j.1750-3639.2012.00618.x
   Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479
   Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Rodriguez EF, 2011, ACTA NEUROPATHOL, V121, P407, DOI 10.1007/s00401-010-0784-9
   Roggendorf W, 1996, ACTA NEUROPATHOL, V92, P288, DOI 10.1007/s004010050520
   Saito K, 2014, CHILD NERV SYST, V7, P7
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sharma MK, 2006, NEUROLOGY, V66, P127, DOI 10.1212/01.wnl.0000188667.66646.1c
   Takahashi K, 2006, INT J ONCOL, V28, P321
   Uhlmann K, 2003, INT J CANCER, V106, P52, DOI 10.1002/ijc.11175
   Wang L, 2010, BIOCHEM BIOPH RES CO, V395, P111, DOI 10.1016/j.bbrc.2010.03.148
   Yang I, 2011, J NEUROSURG, V115, P505, DOI 10.3171/2011.4.JNS101172
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang QA, 2010, DIS MARKERS, V29, P131, DOI 10.3233/DMA-2010-0737
NR 44
TC 13
Z9 13
U1 6
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
EI 1476-5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD OCT
PY 2014
VL 21
IS 10
BP 448
EP 455
DI 10.1038/cgt.2014.49
PG 8
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA AQ9ST
UT WOS:000343197400007
PM 25257306
DA 2018-12-27
ER

PT J
AU Ji, S
   Shao, Q
   Wang, Y
   Liu, J
AF Ji, S.
   Shao, Q.
   Wang, Y.
   Liu, J.
TI RETRACTED: Efficacy comparison between minimally invasive and
   conventional surgery for lumbar disc herniation in Chinese Han
   population: a meta-analysis (Retracted article. See vol. 55, pg. 626,
   2017)
SO SPINAL CORD
LA English
DT Article; Retracted Publication
ID DISKECTOMY; MICRODISCECTOMY
AB Study design: The pooled data were analyzed using RevMan 5.2 software.
   Objectives: The aim was to compare the efficacy of minimally invasive and conventional surgery for lumbar disc herniation (LDH) in Chinese Han population.
   Setting: China.
   Methods: An electronic search up to November 2013 was performed to retrieve all relevant articles. The overall standardized mean difference (SMD) for continuous outcomes and odds ratio (OR) for dichotomous variables as well as their 95% confidence intervals (CIs) were calculated to compare the efficacy of minimally invasive and conventional surgery.
   Results: A total of 23 studies involving 1913 patients treated by minimally invasive surgery and 2295 patients treated by conversational surgery were included in this meta-analysis. The overall estimate indicated that minimally invasive surgery could significantly decrease the hospitalization time (SMD = -2.03, 95% CI, -2.49 to 1.56, P<0.0001), blood loss (SMD = -2.65, 95% CI -3.33 to 1.97, P<0.0001), incision length (SMD = -3.57, 95% CI, -4.39 to 2.75, P<0.0001), recurrence rate (odds ratio (OR) = 0.22, 95 CI: 0.08-0.60, P = 0.003) and complications (OR = 0.47, 95% CI: 0.25-0.92, P = 0.03) and increase the postoperative excellent rate (OR = 1.82, 95% CI, 1.44-2.31, P<0.0001) compared with conventional surgery. In addition, the pooled data showed that there was no statistically significant difference in the operative time (SMD = -0.58, 95% CI, -1.32 to 0.15, P = 0.12) between LDH patients treated by minimally invasive and conventional surgery.
   Conclusion: In conclusion, minimally invasive surgery was a more safe and effective treatment for treating LDH in Chinese Han population when compared with conventional surgery.
C1 [Ji, S.; Shao, Q.; Wang, Y.; Liu, J.] Tongji Univ, Sch Med, East Hosp, Dept Emergency Trauma Surg, Shanghai 200120, Peoples R China.
RP Wang, Y (reprint author), Tongji Univ, Sch Med, East Hosp, Dept Emergency Trauma Surg, 150 Jimo Rd, Shanghai 200120, Peoples R China.
EM wang_yong82@163.com; lljianjun@yeah.net
CR Azimi P, 2012, J ORTHOP SCI, V17, P341, DOI 10.1007/s00776-012-0232-x
   Cheng J, 2012, CHINESE J PROG MODER, V12, P4718
   Dai SD, 2010, CHINESE J CERVICODYN, V31, P349
   Dai W, 2006, CHINESE J SPINE SPIN, V11, P005
   Dankelman J., 2004, ENG PATIENT SAFETY I
   Gao XJ, 2011, GUIDE CHINA MED, V9, P221
   Guo YF, 2013, CHINESE J MED GUIDE, V8, P049
   Han Y, 2008, CHINESE J MODEM OPER, V12, P353
   Hang ZQ, 2002, MED J CHINESE PEOPLE, V27, P95
   Hermantin FU, 1999, J BONE JOINT SURG AM, V81A, P958, DOI 10.2106/00004623-199907000-00008
   Huang Shi-Rong, 2012, Zhongguo Gu Shang, V25, P228
   Isaacs RE, 2005, J NEUROSURG-SPINE, V3, P98, DOI 10.3171/spi.2005.3.2.0098
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jiang H, 2012, ABDOMINAL IMAGING CO, P91
   Katayama Y, 2006, J SPINAL DISORD TECH, V19, P344, DOI 10.1097/01.bsd.0000211201.93125.1c
   Lau D, 2011, J CLIN NEUROSCI, V18, P81, DOI 10.1016/j.jocn.2010.04.040
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li Sheng-Hua, 2008, Zhongguo Gu Shang, V21, P349
   Li SK, 2010, CHINESE J HEBEI MED, V32, P3323
   Lin JF, 2013, NATL MED FRONT CHINA, V8, P47
   Liu J, 2013, CHIN J CLIN, V7, P3306
   Liu M, 2004, CHINESE J CERVICODYN, V25, P335
   Liu ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059421
   Lu XS, 2013, CHINESE J PRACT MED, V29, P387
   Luo M, 2013, CHINESE J CLIN ORTHO, V16, P389
   Mou MW, 2013, CHINESE J DIFFICULT, V12, P688
   Navia JL, 1996, ANN THORAC SURG, V62, P1542, DOI 10.1016/0003-4975(96)00779-5
   Peng YQ, 2003, CHINA J ENDOSCOP, V9, P1
   Pereira TV, 2007, AM HEART J, V153, P821, DOI 10.1060/j.ahj.2007.02.031
   Righesso O, 2007, NEUROSURGERY, V61, P545, DOI 10.1227/01.NEU0000280008.72190.15
   Rothoerl RD, 2002, NEUROSURG REV, V25, P162, DOI 10.1007/s101430100184
   Sun F, 2012, CHINA MODERN MED, V19, P37
   [唐国柯 Tang Guoke], 2012, [中国内镜杂志, China Journal of Endoscopy], V18, P1300
   [汤勇智 TANG Yongzhi], 2011, [中国矫形外科杂志, Orthopedic Journal of China], V19, P1609
   Tsushima Y, 2009, J MAGN RESON IMAGING, V30, P249, DOI 10.1002/jmri.21854
   Wang JA, 2011, EUR SPINE J, V20, P623, DOI 10.1007/s00586-010-1578-4
   Wu ZQ, 2012, TRAD MED TRAUM ORTHO, V20, P44
   Xie ZZ, 2012, GUANGXI MED J, V34, P444
   Yi RF, 2011, CHINESE FOREIGN MED, V9, P16
   [张大伟 ZHANG Da-Wei], 2009, [第四军医大学学报, Journal of the Fourth Military Medical University], V30, P1784
   Zhang S, 2008, J CLIN RES, V25, P2078
   Zhao Q, 2011, CHINA PRAC MED, V6, P53
   Zhao SL, 2011, CHINESE J HLTH CAR F, V18, P184
   王贵清, 2012, [广东医学, Guangdong Medical Journal], V33, P267
NR 44
TC 2
Z9 3
U1 2
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
EI 1476-5624
J9 SPINAL CORD
JI Spinal Cord
PD OCT
PY 2014
VL 52
IS 10
BP 734
EP 739
DI 10.1038/sc.2014.98
PG 6
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AR0CX
UT WOS:000343234800004
PM 24912547
OA Bronze
DA 2018-12-27
ER

PT J
AU Chou, HF
   Schneider, JK
AF Chou, Hsueh-Fen
   Schneider, Joanne Kraenzle
TI RETRACTED: Confirmatory factor analysis of the Menopausal
   Interpretations/Perceptions Questionnaire (Retracted article. See vol.
   23, pg. E1, 2016)
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article; Retracted Publication
DE Menopause; Representation; Confirmatory factor analysis; Common-sense
   model; Self-regulation
ID PERCEPTION QUESTIONNAIRE; CLIMACTERIC SCALE; IPQ-R; SYMPTOMS; WOMEN;
   ILLNESS; ATTITUDES; THERAPY; OPTIONS
AB Objective: This study aims to develop the Menopausal Interpretations/Perceptions Questionnaire (MIPQ) using confirmatory factor analysis.
   Methods: A descriptive cross-sectional design was used to examine the MIPQ. We recruited 228 women through mail-outs and word of mouth. The women were aged between 45 and 64 years (mean [SD], 55.6 [5.2] y) and were able to read and write English. Most were non-Hispanic white (63.4%), college-educated (74.2%), and postmenopausal (76.8%). We modified the Revised Illness Perception Questionnaire to reflect menopausal perception by substituting the word "menopause" or "menopausal symptoms" for the word "illness" to develop the MIPQ.
   Results: Using confirmatory factor analysis to test the MIPQ model, we deleted 22 items that did not reflect their respective subscales (latent variable). The fit indices indicated acceptable fit (chi(2)(209) = 425.5; P = 0.000; goodness of fit = 0.96; comparative fit index = 0.93; root mean square error of approximation = 0.07; 90% CI, 0.06-0.08; Akaike information criterion = 559.5). There were significant correlations among the MIPQ constructs. Correlations between the MIPQ subscales and the Greene Climacteric Scale were significant and in the expected direction, supporting construct validity. The intercorrelations between the MIPQ subscales supported the discriminant validity of the constructs.
   Conclusions: The MIPQ provides a comprehensive measure of menopausal experience to more fully understand women's interpretations/perceptions of their experiences. Future researchers should further examine the construct validity of the MIPQ.
C1 [Chou, Hsueh-Fen] Chang Gung Univ, Sch Nursing, Sch Med, Kwei Shan Tao Yuan 333, Taiwan.
   [Schneider, Joanne Kraenzle] St Louis Univ, Sch Nursing, St Louis, MO 63103 USA.
RP Chou, HF (reprint author), Chang Gung Univ, Sch Nursing, Sch Med, 259 Wen Hwa 1st Rd, Kwei Shan Tao Yuan 333, Taiwan.
EM hfchou@mail.cgu.edu.tw
FU Delta Lambda Chapter of Sigma Theta Tau
FX This study was supported by the Delta Lambda Chapter of Sigma Theta Tau.
CR Allen KM, 1997, WOMENS HLTH LIFESPAN
   Avis N E, 1997, Womens Health, V3, P103
   Bachmann GA, 2005, J REPROD MED, V50, P155
   Bagozzi R. P., 1988, J ACAD MARKET SCI, V16, P74, DOI DOI 10.1007/BF02723327
   Ballard K, 2003, UNDERSTANDING MENOPA
   Bloch A, 2002, MATURITAS, V41, P61, DOI 10.1016/S0378-5122(01)00252-3
   Boekhout AH, 2006, ONCOLOGIST, V11, P641, DOI 10.1634/theoncologist.11-6-641
   BOWLES C, 1986, NURS RES, V35, P81
   Cameron LD, 2003, SELF REGULATION HLTH, P1
   Chattha R, 2008, MATURITAS, V59, P22, DOI 10.1016/j.maturitas.2007.10.011
   Chou HF, 2012, MENOPAUSE, V19, P534, DOI 10.1097/gme.0b013e318238f74b
   Greene JG, 1998, MATURITAS, V29, P25, DOI 10.1016/S0378-5122(98)00025-5
   GREENE JG, 1976, J PSYCHOSOM RES, V20, P425, DOI 10.1016/0022-3999(76)90005-2
   Hagger MS, 2005, PSYCHOL HEALTH, V20, P161, DOI 10.1080/0887044042000334724
   Haines CJ, 2005, MATURITAS, V52, P264, DOI 10.1016/j.maturitas.2005.03.012
   HUNTER M, 2001, PSYCHOL HEALTH MED, V6, P65
   Keenan NL, 2003, MENOPAUSE, V10, P507, DOI 10.1097/01.GME.0000064865.58809.3E
   KELLER ML, 1989, ADV NURS SCI, V12, P54, DOI 10.1097/00012272-198910000-00008
   Khademi S, 2003, MATURITAS, V46, P113, DOI 10.1016/S0378-5122(03)00182-8
   Kline R. B., 2005, PRINCIPLES PRACTICE
   Kronenberg F, 1999, TREATMENT POSTMENOPA
   KUPPERMAN HS, 1953, J CLIN ENDOCR METAB, V13, P688, DOI 10.1210/jcem-13-6-688
   Leon P, 2007, MATURITAS, V57, P233, DOI 10.1016/j.maturitas.2007.01.003
   Leventhal H, 2001, SELF REGULATION HLTH
   Leventhal H., 2007, HDB HLTH PSYCHOL AGI, P341
   Leventhal HBY, 1997, PERCEPTIONS HLTH ILL, P19
   Morrissey DR, 2000, POSTGRAD MED, V108, P85, DOI 10.3810/pgm.2000.07.1159
   Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494
   Pimenta F, 2011, HEALTH CARE WOMEN IN, V32, P1111, DOI 10.1080/07399332.2011.603859
   Polit D., 2004, NURSING RES PRINCIPL
   SHAW CR, 1997, NURSE PRACT, V55, P61
   Sowers MFR, 2000, AGING CLIN EXP RES, V12, P85, DOI 10.1007/BF03339895
   Weinman J, 1996, PSYCHOL HEALTH, V11, P431, DOI 10.1080/08870449608400270
   Woods NF, 2005, AM J MED, V118, P1405, DOI 10.1016/j.amjmed.2005.10.008
   Yangin HB, 2010, J WOMEN AGING, V22, P290, DOI 10.1080/08952841.2010.518880
NR 35
TC 2
Z9 2
U1 4
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072-3714
EI 1530-0374
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD OCT
PY 2014
VL 21
IS 10
BP 1091
EP 1098
DI 10.1097/gme.0000000000000215
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AQ4LH
UT WOS:000342768000010
PM 24594864
DA 2018-12-27
ER

PT J
AU Chalopagorn, P
   Charoenpanich, J
   Choowongkomon, K
AF Chalopagorn, Pornchanok
   Charoenpanich, Jittima
   Choowongkomon, Kiattawee
TI RETRACTED: Genome Shuffling Enhances Lipase Production of Thermophilic
   Geobacillus sp (Retracted article. See vol. 183, pg. 1539, 2017)
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE Genome shuffling; Lipase; Strain improvement; Thermophilic bacteria;
   Geobacillus sp.
ID BACILLUS-THERMOLEOVORANS ID-1; IMPROVED ACID TOLERANCE;
   LACTOBACILLUS-RHAMNOSUS; PURIFICATION; CLONING
AB Thermostable lipases are potential enzymes for biocatalytic application. In this study, the lipase production of Geobacillus sp. CF03 (WT) was improved by genome shuffling. After two rounds of genome shuffling, one fusant strain (FB1) achieved increase lipase activity from the populations generated by ultraviolet irradiation and ethyl methylsulfonate (EMS) mutagenesis. The growth rate and lipase production of FB1 increased highest by 150 and 238 %, respectively, in comparison to the wild type. The fusant enzyme had a significant change in substrate specificity but still prefers the long-chain length substrates. It had an optimum activity at 60 A degrees C, pH at 7.0-8.0, with p-nitrophenyl palmitate (C16) as a substrate and retained about 50 % of their activity after 15 min at 70 A degrees C, pH 8.0. Furthermore, the fusant lipase showed the preference of sesame oil, waste palm oil, and canola oil. Therefore, the genome shuffling strategy has been successful to strain improvement and selecting strain with multiple desirable characteristics.
C1 [Chalopagorn, Pornchanok; Choowongkomon, Kiattawee] Kasetsart Univ, Fac Sci, Dept Biochem, 50 Ngam Wong Wan Rd, Bangkok 10900, Thailand.
   [Charoenpanich, Jittima] Burapha Univ, Dept Biochem, Fac Sci, Bangsaen 20131, Chonburi, Thailand.
   [Charoenpanich, Jittima] Burapha Univ, Ctr Excellence Innovat Chem PERCH CIC, Fac Sci, Bangsaen 20131, Chonburi, Thailand.
   [Charoenpanich, Jittima] Burapha Univ, Environm Sci Program, Fac Sci, Bangsaen 20131, Chonburi, Thailand.
   [Charoenpanich, Jittima] Minist Educ, Ctr Excellence Environm Hlth & Toxicol CHE, Bangkok, Thailand.
   [Choowongkomon, Kiattawee] Kasetsart Univ, Natl Res Univ, Ctr Adv Studies Trop Nat Resources, Thailand CAST NAR,NRU KU, Bangkok 10900, Thailand.
RP Choowongkomon, K (reprint author), Kasetsart Univ, Fac Sci, Dept Biochem, 50 Ngam Wong Wan Rd, Bangkok 10900, Thailand.
EM jittima@buu.ac.th; fsciktc@ku.ac.th
FU National Research Council of Thailand (NRCT), Thailand; Centre of
   Excellence on Environmental Health and Toxicology, Science AMP;
   Technology Postgraduate Education and Research Development Office
   (PERDO), Ministry of Education [ETM-R-05-003/2554]; Kasetsart
   University; Higher Education Research Promotion; National Research
   University Project of Thailand, Office of the Higher Education
   Commission
FX This research was supported financially by National Research Council of
   Thailand (NRCT), Thailand for PC, The Centre of Excellence on
   Environmental Health and Toxicology, Science & Technology Postgraduate
   Education and Research Development Office (PERDO), Ministry of Education
   (Grant no. ETM-R-05-003/2554) for JC, and Kasetsart University and the
   Higher Education Research Promotion and National Research University
   Project of Thailand, Office of the Higher Education Commission for KC.
CR Aly MM, 2012, AFR J MICROBIOL RES, V6, P1125, DOI 10.5897/AJMR11.1123
   Cho AR, 2000, FEMS MICROBIOL LETT, V186, P235, DOI 10.1111/j.1574-6968.2000.tb09110.x
   Dheeran P, 2010, APPL MICROBIOL BIOT, V86, P1857, DOI 10.1007/s00253-009-2430-9
   Gong JX, 2009, BIOTECHNOL ADV, V27, P996, DOI 10.1016/j.biotechadv.2009.05.016
   Jian X. K., 2011, PROCESS BIOCHEM, V46, P792
   Kang JX, 2011, PROCESS BIOCHEM, V46, P792, DOI 10.1016/j.procbio.2010.11.004
   Lane D. J., 1991, IN NUCLEIC ACID TECH
   Lee DW, 2001, ENZYME MICROB TECH, V29, P363, DOI 10.1016/S0141-0229(01)00408-2
   McMullan G, 2004, BIOCHEM SOC T, V32, P214, DOI 10.1042/BST0320214
   Patnaik R, 2002, NAT BIOTECHNOL, V20, P707, DOI 10.1038/nbt0702-707
   Salameh MA, 2007, APPL ENVIRON MICROB, V73, P7725, DOI 10.1128/AEM.01509-07
   SAMAD MYA, 1989, J MICROBIOL METH, V9, P51, DOI 10.1016/0167-7012(89)90030-4
   SchmidtDannert C, 1996, BBA-LIPID LIPID MET, V1301, P105, DOI 10.1016/0005-2760(96)00027-6
   Sharma R, 2001, BIOTECHNOL ADV, V19, P627, DOI 10.1016/S0734-9750(01)00086-6
   Shu CH, 2006, PROCESS BIOCHEM, V41, P734, DOI 10.1016/j.procbio.2005.09.007
   Simons JWFA, 1999, BIOCHEMISTRY-US, V38, P2, DOI 10.1021/bi981869l
   Singh AK, 2012, APPL BIOCHEM BIOTECH, V166, P486, DOI 10.1007/s12010-011-9444-3
   Sookkheo B, 2000, PROTEIN EXPRES PURIF, V20, P142, DOI 10.1006/prep.2000.1282
   Tyndall JDA, 2002, J MOL BIOL, V323, P859, DOI 10.1016/S0022-2836(02)01004-5
   Uttatree S, 2010, APPL BIOCHEM BIOTECH, V162, P1362, DOI 10.1007/s12010-010-8928-x
   Wang YH, 2007, J BIOTECHNOL, V129, P510, DOI 10.1016/j.jbiotec.2007.01.011
   Yu L, 2008, J BIOTECHNOL, V134, P154, DOI 10.1016/j.jbiotec.2008.01.008
   Zhang Y, 2010, J BIOTECHNOL, V148, P139, DOI 10.1016/j.jbiotec.2010.05.008
   Zhang YX, 2002, NATURE, V415, P644, DOI 10.1038/415644a
NR 24
TC 6
Z9 6
U1 2
U2 27
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0273-2289
EI 1559-0291
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD OCT
PY 2014
VL 174
IS 4
BP 1444
EP 1454
DI 10.1007/s12010-014-1109-6
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA AQ0SZ
UT WOS:000342494300018
PM 25119547
DA 2018-12-27
ER

PT J
AU Whitaker, JL
   Bushman, BJ
AF Whitaker, Jodi L.
   Bushman, Brad J.
TI RETRACTED: "Boom, Headshot!": Effect of Video Game Play and Controller
   Type on Firing Aim and Accuracy(Retracted article. See vol. 44, pg. 144,
   2014)
SO COMMUNICATION RESEARCH
LA English
DT Article; Retracted Publication
DE controller; gun; pistol; shooting accuracy; violent video game
ID AGGRESSION; ATTITUDES; REINFORCEMENT; CATHARSIS; MODELS; GUNS
AB Video games are excellent training tools. Some writers have called violent video games murder simulators. Can violent games train a person to shoot a gun? There are theoretical reasons to believe they can. Participants (N = 151) played a violent shooting game with humanoid targets that rewarded headshots, a nonviolent shooting game with bull's-eye targets, or a nonviolent nonshooting game. Those who played a shooting game used either a pistol-shaped or a standard controller. Next, participants shot a realistic gun at a mannequin. Participants who played a violent shooting game using a pistol-shaped controller had 99% more headshots and 33% more other shots than did other participants. These results remained significant even after controlling for firearm experience, gun attitudes, habitual exposure to violent shooting games, and trait aggressiveness. Habitual exposure to violent shooting games also predicted shooting accuracy. Thus, playing violent shooting video games can improve firing accuracy and can influence players to aim for the head.
C1 [Whitaker, Jodi L.; Bushman, Brad J.] Ohio State Univ, Columbus, OH 43210 USA.
   [Bushman, Brad J.] Vrije Univ Amsterdam, Amsterdam, Netherlands.
RP Bushman, BJ (reprint author), Ohio State Univ, Sch Commun, 3127 Derby Hall,154 North Oval Mall, Columbus, OH 43210 USA.
EM bushman.20@osu.edu
CR Atlas R., 1997, TRAINING RAPIDLY CHA, P281
   BANDURA A, 1961, J ABNORM SOC PSYCH, V63, P575, DOI 10.1037/h0045925
   BANDURA A, 1963, J ABNORM PSYCHOL, V67, P601, DOI 10.1037/h0045550
   BANDURA A, 1965, J PERS SOC PSYCHOL, V1, P589, DOI 10.1037/h0022070
   Bandura A, 1977, SOCIAL LEARNING THEO
   Bandura A, 1973, AGGRESSION SOCIAL LE
   BERKOWITZ L, 1974, PSYCHOL REV, V81, P165, DOI 10.1037/h0036094
   Betker AL, 2007, PHYS THER, V87, P1389, DOI 10.2522/ptj.20060229
   BRANSCOMBE NR, 1991, AGGRESSIVE BEHAV, V17, P261, DOI 10.1002/1098-2337(1991)17:5<261::AID-AB2480170503>3.0.CO;2-8
   Bushman BJ, 2002, PERS SOC PSYCHOL B, V28, P724, DOI 10.1177/0146167202289002
   Bushman BJ, 1999, J PERS SOC PSYCHOL, V76, P367, DOI 10.1037//0022-3514.76.3.367
   Bushman BJ, 2011, SOC PSYCHOL PERS SCI, V2, P29, DOI 10.1177/1948550610379506
   BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452
   Domjan M, 2003, PRINCIPLES LEARNING
   Duque G, 2008, J AM GERIATR SOC, V56, P1328, DOI 10.1111/j.1532-5415.2008.01759.x
   Entertainment Software Association, 2011, ESS FACTS COMP VID G
   Evans S. W., 1995, EXCEPTIONALITY, V5, P1
   Flynn Sheryl, 2007, J Neurol Phys Ther, V31, P180, DOI 10.1097/NPT.0b013e31815d00d5
   Gee JP, 2003, WHAT VIDEO GAMES HAVE TO TEACH US ABOUT LEARNING AND LITERACY, P1
   GEEN RG, 1977, ADV EXPT SOCIAL PSYC, V10, P1, DOI DOI 10.1016/S0065-2601(08)60353-6
   Gentile DA, 2008, J YOUTH ADOLESCENCE, V37, P127, DOI 10.1007/s10964-007-9206-2
   Gentile DA, 2011, CHILD DEV PERSPECT, V5, P75, DOI 10.1111/j.1750-8606.2011.00159.x
   GOPHER D, 1994, HUM FACTORS, V36, P387
   Green CS, 2003, NATURE, V423, P534, DOI 10.1038/nature01647
   GRIFFITH JL, 1983, PERCEPT MOTOR SKILL, V57, P155, DOI 10.2466/pms.1983.57.1.155
   Grossman D, 1995, KILLING PSYCHOL COST
   Grossman D., 1999, STOP TEACHING OUR KI
   Kirsh S. J, 2012, CHILDREN ADOLESCENTS
   Konijn EA, 2007, DEV PSYCHOL, V43, P1038, DOI 10.1037/0012-1649.43.4.1038
   Markey PM, 2009, COMPUT HUM BEHAV, V25, P407, DOI 10.1016/j.chb.2008.10.001
   Motion Picture Association of America, 2011, THEATR MARK STAT
   Onion CWR, 1998, FAM PRACT, V15, P99, DOI 10.1093/fampra/15.2.99
   Patrick U. W, 1989, HANDGUN WOUNDING FAC
   Raney AA, 2006, LEA COMMUN SER, P165
   Recording Industry Association of America, 2011, 2010 YEAR END SHIPM
   Rosenberg BH, 2005, J ENDOUROL, V19, P372, DOI 10.1089/end.2005.19.372
   Rosser JC, 2007, ARCH SURG-CHICAGO, V142, P181, DOI 10.1001/archsurg.142.2.181
   Shapiro JP, 1997, J CLIN CHILD PSYCHOL, V26, P311, DOI 10.1207/s15374424jccp2603_10
   Thorndike E. L., 1932, FUNDAMENTALS LEARNIN
   Vorderer P, 2000, LEA COMMUN SER, P21
NR 40
TC 10
Z9 10
U1 3
U2 37
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0093-6502
EI 1552-3810
J9 COMMUN RES
JI Commun. Res.
PD OCT
PY 2014
VL 41
IS 7
BP 879
EP 891
DI 10.1177/0093650212446622
PG 13
WC Communication
SC Communication
GA AQ2OX
UT WOS:000342627800001
DA 2018-12-27
ER

PT J
AU Zhou, C
   Chen, H
   Han, L
   Wang, A
   Chen, LA
AF Zhou, Chao
   Chen, Hao
   Han, Li
   Wang, An
   Chen, Liang-an
TI RETRACTED: Identification of featured biomarkers in different types of
   lung cancer with DNA microarray (Retracted article. See vol. 42, pg.
   1481, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Lung cancer; Differentially expressed gene; MiRNA; Function enrichment
   analysis; Biomarker
ID APOLIPOPROTEIN-E; EXPRESSION; MICRORNA; GENE; BLOOD; CELLS; PROGNOSIS;
   SURVIVAL; MIRNAS; MARKER
AB Lung cancer is a worldwide leading cause of cancer-related death. The aim of this study was to identify target genes and specific biomarkers for identification and treatment of different types of lung cancer with DNA microarray. Gene expression profile GSE6044 and miRNA microarray profile GSE17681 were downloaded from Gene Expression Omnibus database. The differentially expressed genes (DEGs) and miRNAs were screened with multtest package in R language. Then, functional enrichment analysis of identified DEGs was performed. Furthermore, the verified target genes based on screened miRNAs were selected from miRTarBase and miRecords databases. Then miRNA-target gene regulation network was constructed. APOE, CDC6 and ATP2B1were involved in most of the functions obtained for adenocarcinomas, small cell lung cancer and squamous cell carcinomas, respectively. The target DEGs of differentially expressed hsa-miR-29a included FGG in adenocarcinoma, RAN and COL4A1 in small cell lung cancer, GLUL in squamous cell carcinoma. The target DEGs of has-miR-7 were SNCA and SLC7A5 in adenocarcinoma and small cell lung cancer, respectively. ICAM1 and KIT were the target DEGs of hsa-miR-222 in adenocarcinoma and squamous cell carcinoma. The miRNAs and their differentially expressed target genes have the potential to be used in clinic for diagnosis and treatment of different kinds of lung cancer in the future.
C1 [Zhou, Chao; Chen, Hao; Han, Li; Wang, An] Zhou Pu Hosp, Dept Resp Med, Shanghai 201318, Peoples R China.
   [Chen, Liang-an] Chinese Peoples Liberat Army Gen Hosp, Dept Resp Med, Beijing 100853, Peoples R China.
RP Zhou, C (reprint author), Zhou Pu Hosp, Dept Resp Med, 1500 Zhouyuan Rd, Shanghai 201318, Peoples R China.
EM zhouchaoem@hotmail.com; chenlianganc@hotmail.com
CR Allison DB, 2006, NAT REV GENET, V7, P55, DOI 10.1038/nrg1749
   Ando S, 2004, ANTICANCER RES, V24, P1941
   Arnold CP, 2011, GENOME RES, V21, P798, DOI 10.1101/gr.111385.110
   Basaki Y, 2010, EUR J CANCER, V46, P954, DOI 10.1016/j.ejca.2009.12.024
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   Blagosklonny MV, 2001, CANCER RES, V61, P4301
   Boyle P, 2011, ANN ONCOL, V22, P383, DOI 10.1093/annonc/mdq361
   Brennan P, 2011, LANCET ONCOL, V12, P399, DOI 10.1016/S1470-2045(10)70126-1
   Cushing L, 2011, AM J RESP CELL MOL, V45, P287, DOI 10.1165/rcmb.2010-0323OC
   Dudoit S, 2003, STAT SCI, V18, P71, DOI 10.1214/ss/1056397487
   Eb WDT, 2004, PATHOLOGY
   Ebert W, 1996, ANTICANCER RES, V16, P2161
   Ettinger DS, 2010, J NATL COMPR CANC NE, V8, P740, DOI 10.6004/jnccn.2010.0056
   Fort A, 2010, BLOOD, V116, P2608, DOI 10.1182/blood-2010-02-268011
   Fujita Andre, 2006, BMC Bioinformatics, V7, P469
   Gilad S, 2012, J MOL DIAGN, V14, P510, DOI 10.1016/j.jmoldx.2012.03.004
   Guney N, 2008, MED ONCOL, V25, P194, DOI 10.1007/s12032-007-9026-y
   Guo L, 2013, MOL BIOL REP, V40, P3739, DOI 10.1007/s11033-012-2450-x
   Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107
   Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kaira K, 2008, BRIT J CANCER, V98, P742, DOI 10.1038/sj.bjc.6604235
   Keller A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-353
   Kido Y, 2001, J PHARM PHARMACOL, V53, P497, DOI 10.1211/0022357011775794
   Kobayashi Y, 2012, HYPERTENSION, V59, P854, DOI 10.1161/HYPERTENSIONAHA.110.165068
   Lewis C. I., 1918, SURVEY SYMBOLIC LOGI
   Lin QF, 2012, J CANCER RES CLIN, V138, P85, DOI 10.1007/s00432-011-1068-z
   Miko E, 2011, FEBS LETT, V585, P1191, DOI 10.1016/j.febslet.2011.03.039
   Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171
   Mulshine JL, 2005, NEW ENGL J MED, V352, P2714, DOI 10.1056/NEJMcp042630
   Nam D, 2008, BRIEF BIOINFORM, V9, P189, DOI 10.1093/bib/bbn001
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   Pastorino U, 2010, BRIT J CANCER, V102, P1681, DOI 10.1038/sj.bjc.6605660
   Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500
   Pirozynski M, 2009, RESP MED, V103, P1244, DOI 10.1016/j.rmed.2009.04.018
   Plaisier CL, 2012, GENOME RES, V22, P2302, DOI 10.1101/gr.133991.111
   Rabinowits G, 2009, CLIN LUNG CANCER, V10, P42, DOI 10.3816/CLC.2009.n.006
   Rohrbeck A, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-69
   Spies M, 2002, AM J PHYSIOL-REG I, V283, pR918, DOI 10.1152/ajpregu.00170.2002
   Su WP, 2011, LUNG CANCER, V71, P28, DOI 10.1016/j.lungcan.2010.04.009
   Thanopoulou E, 2012, TUMOR BIOL, V33, P1429, DOI 10.1007/s13277-012-0393-4
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Wang LS, 2010, NUCLEIC ACIDS RES, V38, pD665, DOI 10.1093/nar/gkp945
   Wang YM, 2013, CLIN CHIM ACTA, V421, P230, DOI 10.1016/j.cca.2013.03.013
   Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851
   Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380
   Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107
NR 48
TC 7
Z9 8
U1 2
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD OCT
PY 2014
VL 41
IS 10
BP 6357
EP 6363
DI 10.1007/s11033-014-3515-9
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AP9ZE
UT WOS:000342440000005
PM 25001589
DA 2018-12-27
ER

PT J
AU Xing, YL
   Wang, H
   Liu, XM
   Yu, XY
   Chen, R
   Wang, C
   Yu, XX
   Sun, L
AF Xing, Yanlin
   Wang, Hong
   Liu, Xiaomei
   Yu, Xianyi
   Chen, Rui
   Wang, Ce
   Yu, Xuexin
   Sun, Le
TI RETRACTED: Meta-analysis of the relationship between single nucleotide
   polymorphism rs72689236 of caspase-3 and Kawasaki disease (Retracted
   article. See vol. 42, pg. 1483, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Kawasaki disease; Case-control study; Rs72689236; Polymorphism;
   Meta-analysis
ID KOREAN CHILDREN; GENE; RISK
AB Kawasaki disease is a pediatric systemic vasculitis of unknown etiology, for which a genetic influence is suspected. But whether single nucleotide polymorphism (SNP) of caspase-3 rs72689236 is associated with Kawasaki disease is controversial. The aim of our study is to assess the association between the SNP of caspase-3 and risk for Kawasaki disease. We searched PubMed, MEDLINE, EMBASE, Springer, Elsevier Science Direct, Cochrane Library Google scholar, CNKI (China National Knowledge Infrastructure, in Chinese) and Wanfang database (in Chinese) to identify studies investigating the association between rs72689236 polymorphism and Kawasaki disease occurrence. There were five eligible studies, which included 4,241 (case group 1,560; control group 2,681) participants in this meta-analysis. Pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were calculated in a fixed-effects model (the Mantel-Haenszel method) or a random-effects model (the DerSimonian and Laird method) when appropriate. Significant associations were found under the overall ORs for A-allele comparison (A vs. G, pooled OR 1.33, 95 % CI 1.21-1.46), AA versus GG comparison (pooled OR 1.64, 95 % CI 1.35-2.00), GA versus GG comparison (pooled OR 1.42, 95 % CI 1.24-1.63), recessive model (AA vs. GG + GA, pooled OR 1.37, 95 % CI 1.15-1.64) and dominant model (AA + GA vs. GG, pooled OR 1.47, 95 % CI 1.29-1.67). This meta-analysis suggested that SNP rs72689236 of caspase-3 might be associated with susceptibility of Kawasaki disease and the allele A might increase the risk of Kawasaki disease in Asian samples such as Japanese and Chinese. In addition, individual studies with large sample size are needed to further evaluate the associations in various ethnic populations.
C1 [Xing, Yanlin; Wang, Hong; Yu, Xianyi; Chen, Rui; Wang, Ce; Yu, Xuexin; Sun, Le] China Med Univ, Shengjing Hosp, Dept Pediat, Shenyang 110004, Liaoning, Peoples R China.
   [Liu, Xiaomei] China Med Univ, Shengjing Hosp, Expt Res Ctr, Shenyang 110004, Liaoning, Peoples R China.
RP Yu, XY (reprint author), China Med Univ, Shengjing Hosp, Dept Pediat, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.
EM xianyiyu1688@hotmail.com
FU Liaoning Province Science and Technology Department, China [2013225089]
FX This work was funded by Liaoning Province Science and Technology
   Department, China (No. 2013225089).
CR Chi H, 2010, HUM MOL GENET, V19, P1147, DOI 10.1093/hmg/ddp586
   Deeks J. J., 2001, SYSTEMATIC REV HLTH, V2, P285, DOI DOI 10.1002/9780470693926.CH15
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ha KS, 2013, EUR J PEDIATR, V172, P343, DOI 10.1007/s00431-012-1891-5
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433
   Huang WC, 2009, PEDIATRICS, V123, pe401, DOI 10.1542/peds.2008-2187
   Huang YC, 2010, INT J IMMUNOGENET, V37, P439, DOI 10.1111/j.1744-313X.2010.00943.x
   Jhang WK, 2009, J CLIN IMMUNOL, V29, P22, DOI 10.1007/s10875-008-9218-z
   Jin HS, 2007, PEDIATR RES, V61, P584, DOI 10.1203/pdr.0b013e3180459fb5
   Kuo HC, 2011, ACTA PHARMACOL SIN, V32, P1193, DOI 10.1038/aps.2011.93
   Kuo HC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017370
   Kuo HC, 2011, J HUM GENET, V56, P161, DOI 10.1038/jhg.2010.154
   Mantel N, 2004, CHALLENGE EPIDEMIOLO, V1, P533
   Nakamura Y, 2008, PEDIATR INT, V50, P287, DOI 10.1111/j.1442-200X.2008.02572.x
   Onouchi Y, 2013, PHARMACOGENOMICS J, V13, P52, DOI 10.1038/tpj.2011.45
   Onouchi Y, 2008, NAT GENET, V40, P35, DOI 10.1038/ng.2007.59
   Onouchi Y, 2010, HUM MOL GENET, V19, P2898, DOI 10.1093/hmg/ddq176
   Peng Qian, 2013, Zhongguo Dang Dai Er Ke Za Zhi, V15, P477
   Peng Qian, 2013, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V30, P180, DOI 10.3760/cma.j.issn.1003-9406.2013.04.013
   Soung YH, 2004, HUM GENET, V115, P112, DOI 10.1007/s00439-004-1129-3
   Wei Chen H-YZ, 2013, SHANDONG MED J, V53, P20
NR 23
TC 6
Z9 7
U1 3
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD OCT
PY 2014
VL 41
IS 10
BP 6377
EP 6381
DI 10.1007/s11033-014-3517-7
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AP9ZE
UT WOS:000342440000007
PM 24990693
DA 2018-12-27
ER

PT J
AU Xia, X
   Qu, B
   Ma, Y
   Yang, LB
   Huang, HD
   Cheng, JM
   Yang, T
   Kong, B
   Liu, EY
   Zhao, K
   He, WQ
   Xing, XM
   Liang, L
   Fan, KX
   Sun, HD
   Zhou, HT
   Cheng, L
   Gu, JW
   Kuang, YQ
AF Xia, Xun
   Qu, Bo
   Ma, Yuan
   Yang, Li-bin
   Huang, Hai-dong
   Cheng, Jing-ming
   Yang, Tao
   Kong, Bin
   Liu, En-yu
   Zhao, Kai
   He, Wei-qi
   Xing, Xue-min
   Liang, Liang
   Fan, Ke-xia
   Sun, Hao-dong
   Zhou, Hu-tian
   Cheng, Lin
   Gu, Jian-wen
   Kuang, Yong-qin
TI RETRACTED: Analyzing time-series microarray data reveals key genes in
   spinal cord injury (Retracted article. See vol. 42, pg. 1485, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Spinal cord injury; Microarray; Differentially expressed genes;
   Protein-protein interaction network
ID FUNCTIONAL RECOVERY; EXPRESSION PROFILE; PROBE LEVEL; INFLAMMATION;
   INHIBITION; DENSITY; DEATH; IL-6
AB Although many scholars have utilized high-throughput microarrays to delineate gene expression patterns after spinal cord injury (SCI), no study has evaluated gene changes in raphe magnus (RM) and somatomotor cortex (SMTC), two areas in brain primarily affected by SCI. In present study, we aimed to analyze the differentially expressed genes (DEGs) of RM and SMTC between SCI model and sham injured control at 4, 24 h, 7, 14, 28 days, and 3 months using microarray dataset GSE2270 downloaded from gene expression omnibus and unpaired significance analysis of microarray method. Protein-protein interaction (PPI) network was constructed for DEGs at crucial time points and significant biological functions were enriched using DAVID. The results indicated that more DEGs were identified at 14 days in RM and at 4 h/3 months in SMTC after SCI. In the PPI network for DEGs at 14 days in RM, interleukin 6, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), FBJ murine osteosarcoma viral oncogene homolog (FOS), tumor necrosis factor, and nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) were the top 5 hub genes; In the PPI network for DEGs at 3 months in SMTC, the top 5 hub genes were ubiquitin B, RasaEurorelated C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1), FOS, Janus kinase 2 and vascular endothelial growth factor A. Hedgehog and Wnt signaling pathways were the top 2 significant pathways in RM. These hub DEGs and pathways may be underlying therapeutic targets for SCI.
C1 [Xia, Xun; Ma, Yuan; Yang, Li-bin; Huang, Hai-dong; Cheng, Jing-ming; Yang, Tao; Kong, Bin; Liu, En-yu; Zhao, Kai; He, Wei-qi; Xing, Xue-min; Liang, Liang; Fan, Ke-xia; Sun, Hao-dong; Zhou, Hu-tian; Cheng, Lin; Gu, Jian-wen; Kuang, Yong-qin] Chengdu Mil Gen Hosp, Dept Neurosurg, Chengdu 610083, Sichuan, Peoples R China.
   [Xia, Xun] Third Mil Med Univ, Postgrad Dept, Chongqing 400038, Peoples R China.
   [Qu, Bo] Chengdu Mil Gen Hosp, Dept Orthopaed, Chengdu 610083, Sichuan, Peoples R China.
RP Gu, JW (reprint author), Chengdu Mil Gen Hosp, Dept Neurosurg, 270 Rongdu Rd, Chengdu 610083, Sichuan, Peoples R China.
EM jianwengu2013@hotmail.com
CR Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009
   Bambakidis NC, 2003, J NEUROSURG, V99, P70, DOI 10.3171/spi.2003.99.1.0070
   Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006
   Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322
   David S, 2011, HDB CLIN NEUROL, V109, P485
   De Biase A, 2005, PHYSIOL GENOMICS, V22, P368, DOI 10.1152/physiolgenomics.00081.2005
   DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178
   Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472
   Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008
   Ernst J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-191
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jin LJ, 2014, MOL BIOL REP, V41, P3169, DOI 10.1007/s11033-014-3176-8
   Kruse F, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00026
   Lee JY, 2010, ENDOCRINOLOGY, V151, P3815, DOI 10.1210/en.2009-1416
   Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018
   Liu YB, 2008, J NEUROSCI, V28, P8376, DOI 10.1523/JNEUROSCI.1939-08.2008
   Malaspina A, 2007, BRAIN RES BULL, V71, P437, DOI 10.1016/j.brainresbull.2006.10.032
   Fernandez-Martos CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027000
   Miyashita T, 2009, J NEUROTRAUM, V26, P955, DOI 10.1089/neu.2008.0776
   Morse LR, 2012, J BONE MINER RES, V27, P352, DOI 10.1002/jbmr.546
   Nakamura M, 2005, CLIN REV ALLERG IMMU, V28, P197, DOI 10.1385/CRIAI:28:3:197
   Nesic O, 2010, J NEUROTRAUM, V27, P1793, DOI 10.1089/neu.2010.1351
   Nistor G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020692
   Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044
   Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281
   Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149
   Pratap A, 2010, PHARM RES-DORDR, V27, P2492, DOI 10.1007/s11095-010-0246-z
   Ryge J, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-365
   Segal JL, 1997, ARCH PHYS MED REHAB, V78, P44, DOI 10.1016/S0003-9993(97)90008-3
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410
NR 35
TC 4
Z9 5
U1 2
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD OCT
PY 2014
VL 41
IS 10
BP 6827
EP 6835
DI 10.1007/s11033-014-3568-9
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AP9ZE
UT WOS:000342440000054
PM 25063577
DA 2018-12-27
ER

PT J
AU Chen, YZ
   Liu, D
   Zhao, YX
   Wang, HT
   Gao, Y
   Chen, Y
AF Chen, Yan-Zhi
   Liu, Dan
   Zhao, Yu-Xia
   Wang, He-Tong
   Gao, Ya
   Chen, Ying
TI RETRACTED: Relationships Between p16 Gene Promoter Methylation and
   Clinicopathologic Features of Colorectal Cancer: A Meta-Analysis of 27
   Cohort Studies (Retracted article. See vol. 34, pg. 743, 2015)
SO DNA AND CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID TUMOR-SUPPRESSOR GENE; ABERRANT METHYLATION; DNA METHYLATION;
   MOLECULAR-DETECTION; BREAST-CANCER; COLON-CANCER; MICROSATELLITE
   INSTABILITY; PROGNOSTIC VALUE; CELL-LINES; MGMT GENES
AB Many existing studies have demonstrated that p16 promoter methylation might be correlated with the clinicopathologic features of colorectal cancer (CRC), but individually published results are inconclusive. This meta-analysis aimed to derive a more precise estimation of the relationships between p16 promoter methylation and the clinicopathologic features of CRC. We searched the CISCOM, CINAHL, Web of Science, PubMed, Google Scholar, EBSCO, Cochrane Library, and CBM databases from inception through August 1, 2013. Meta-analysis was performed using the STATA 12.0 software. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under fixed-or random-effects models. Twenty-seven clinical cohort studies were included with a total of 3311 CRC patients. Our meta-analysis results revealed that p16 promoter methylation was associated with pathological characteristics of CRC (tumor, nodes, metastasis stage: OR=1.55, 95% CI: 1.14-2.13, p = 0.006; lymph node metastasis: OR= 2.40, 95% CI: 1.37-4.19, p = 0.002; histologic grade: OR= 2.72, 95% CI: 1.63-4.54, p < 0.001; Dukes stage: OR= 2.06, 95% CI: 1.57-2.71, p = 0.002; tumor size: OR= 1.99, 95% CI: 1.03-3.85, p = 0.041; location: OR= 2.49, 95% CI: 1.95-3.18, p < 0.001, respectively). Subgroup analysis by ethnicity suggested that there were also significant correlations between p16 gene promoter methylation and pathological characteristics of CRC among both Caucasian and Asian populations (all p < 0.05). Our meta-analysis suggests that promoter methylation of the p16 gene may be strongly correlated with the clinicopathologic features of CRC. Thus, p16 gene promoter methylation may be a potential biomarker for CRC.
C1 [Chen, Yan-Zhi; Liu, Dan; Zhao, Yu-Xia; Wang, He-Tong; Gao, Ya; Chen, Ying] China Med Univ, Affiliated Hosp 4, Dept Radiotherapy, Shenyang 110032, Peoples R China.
RP Zhao, YX (reprint author), China Med Univ, Affiliated Hosp 4, Dept Radiotherapy, 4 Chongshan East, Shenyang 110032, Peoples R China.
EM cmu4h_zyx@yeah.net
CR Abbaszadegan MR, 2008, WORLD J GASTROENTERO, V14, P2055, DOI 10.3748/wjg.14.2055
   Aoyagi H, 2011, ONCOL REP, V25, P789, DOI 10.3892/or.2010.1118
   Arima Y, 2012, INT J CANCER, V130, P2568, DOI 10.1002/ijc.26271
   Chan AT, 2010, GASTROENTEROLOGY, V138, P2029, DOI 10.1053/j.gastro.2010.01.057
   [程苏琴 Cheng Suqin], 2003, [解放军医学杂志, Medical Journal of Chinese People's Liberation Army], V28, P616
   Dai W, 2013, CLIN CANCER RES, V19, P5788, DOI 10.1158/1078-0432.CCR-13-1217
   DELMER A, 1995, LEUKEMIA, V9, P1240
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2
   GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531
   Goto T, 2009, ANTICANCER RES, V29, P275
   GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387
   Harada H, 1999, CANCER RES, V59, P3783
   Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528
   Hibi K, 2001, CLIN CANCER RES, V7, P3135
   Hibi K, 2002, JPN J CANCER RES, V93, P883, DOI 10.1111/j.1349-7006.2002.tb01333.x
   HIRAMA T, 1995, BLOOD, V86, P841
   Holdt LM, 2012, ARTERIOSCL THROM VAS, V32, P196, DOI 10.1161/ATVBAHA.111.232678
   Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343
   Iacopetta B, 2006, INT J CANCER, V119, P2272, DOI 10.1002/ijc.22237
   Iida S, 2012, ONCOL LETT, V3, P565, DOI 10.3892/ol.2011.544
   Ishiguro A, 2006, J GASTROEN HEPATOL, V21, P1334, DOI 10.1111/j.1440-1746.2006.04137.x
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jeong YJ, 2013, ONCOL REP, V30, P2270, DOI 10.3892/or.2013.2668
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kazama Y, 2008, J SURG ONCOL, V97, P278, DOI 10.1002/jso.20960
   Kondo E, 2005, MOL CELL BIOL, V25, P4388, DOI 10.1128/MCB.25.11.4388-4396.2005
   Kriegl L, 2011, MODERN PATHOL, V24, P1015, DOI 10.1038/modpathol.2011.43
   Krtolica K, 2007, WORLD J GASTROENTERO, V13, P1187, DOI 10.3748/wjg.v13.i8.1187
   Lee JJ, 2012, KOREAN J PATHOL, V46, P554, DOI 10.4132/KoreanJPathol.2012.46.6.554
   LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203
   Li G., 2006, WORLD CHIN J DIGESTO, V14, P1699
   LI Y, 1994, CANCER RES, V54, P6078
   Liang JT, 1999, ONCOLOGY-BASEL, V57, P149, DOI 10.1159/000012023
   Limsui D, 2010, JNCI-J NATL CANCER I, V102, P1012, DOI 10.1093/jnci/djq201
   Liu Y, 2006, NEOPLASIA, V8, P46, DOI 10.1593/neo.05586
   Lopes EC, 2008, CANCER RES, V68, P7258, DOI 10.1158/0008-5472.CAN-08-0344
   Malesci A, 2007, CLIN CANCER RES, V13, P3831, DOI 10.1158/1078-0432.CCR-07-0366
   Mas S, 2007, ANTICANCER RES, V27, P1151
   Matsuda Y, 2013, MED MOL MORPHOL, V46, P185, DOI 10.1007/s00795-013-0047-7
   Miladi-Abdennadher I, 2011, BIOSCIENCE REP, V31, P257, DOI 10.1042/BSR20100023
   Miranda E, 2006, BRIT J CANCER, V95, P1101, DOI 10.1038/sj.bjc.6603337
   Nakayama G, 2007, ANTICANCER RES, V27, P1459
   Nakayama H, 2003, INT J CANCER, V105, P491, DOI 10.1002/ijc.11117
   Nakayama H, 2002, CANCER LETT, V188, P115, DOI 10.1016/S0304-3835(01)00839-4
   Norrie MWA, 2003, J SURG ONCOL, V84, P143, DOI 10.1002/jso.10310
   Pajcini KV, 2010, CELL STEM CELL, V7, P198, DOI 10.1016/j.stem.2010.05.022
   Paz MF, 2003, CANCER RES, V63, P1114
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149
   Sameer AS, 2012, MOL MED REP, V5, P1053, DOI 10.3892/mmr.2012.740
   Sans-Casla MT, 2005, DIGEST DIS, V23, P151, DOI 10.1159/000088597
   Semczuk A, 2004, CANCER LETT, V203, P1, DOI 10.1016/j.canlet.2003.09.012
   Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689
   Shima K, 2011, INT J CANCER, V128, P1080, DOI 10.1002/ijc.25432
   Shin CM, 2010, CANCER SCI, V101, P1337, DOI 10.1111/j.1349-7006.2010.01535.x
   Soreide K, 2009, SURG ONCOL, V18, P31, DOI 10.1016/j.suronc.2008.06.006
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Taioli E, 2009, AM J EPIDEMIOL, V170, P1207, DOI 10.1093/aje/kwp275
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   van Rijnsoever M, 2002, GUT, V51, P797, DOI 10.1136/gut.51.6.797
   de Castro SV, 2012, REV ESP ENFERM DIG, V104, P111, DOI 10.4321/s1130-01082012000300002
   Verdoodt B, 2011, PROSTATE CANCER P D, V14, P295, DOI 10.1038/pcan.2011.45
   Wang Z.W., 2001, ACTA U MED SEC SHAN, V21, P307
   Ward RL, 2003, J CLIN ONCOL, V21, P3729, DOI 10.1200/JCO.2003.03.123
   Wettergren Y, 2008, MOL MED, V14, P412, DOI 10.2119/2007-00096.Wettergren
   Wiencke JK, 1999, CANCER EPIDEM BIOMAR, V8, P501
   Xing X, 2013, BRIT J CANCER, V108, P2542, DOI 10.1038/bjc.2013.251
   Yang Yu-hua, 2003, Acta Genetica Sinica, V30, P1061
   Yi J, 2001, WORLD J GASTROENTERO, V7, P722
   Zennami K, 2011, ONCOL REP, V26, P327, DOI 10.3892/or.2011.1290
   Zhao P, 2003, WORLD J GASTROENTERO, V9, P2202
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   Zou Hongzhi, 2002, Zhonghua Yu Fang Yi Xue Za Zhi, V36, P499
NR 76
TC 7
Z9 7
U1 3
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD OCT
PY 2014
VL 33
IS 10
BP 729
EP 738
DI 10.1089/dna.2013.2253
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA AP8AD
UT WOS:000342299200010
PM 24979649
DA 2018-12-27
ER

PT J
AU Clemence, ME
AF Clemence, Marie-Emilie
TI RETRACTED: Pattern and timing of the Early Jurassic calcareous
   nannofossil crisis (Retracted article. See vol. 435, pg. 283, 2015)
SO PALAEOGEOGRAPHY PALAEOCLIMATOLOGY PALAEOECOLOGY
LA English
DT Article; Retracted Publication
DE Early Toarcian; Calcareous nannofossils; Biocalcification crisis;
   Carbonate production
ID OCEANIC ANOXIC EVENT; TOARCIAN; NANNOPLANKTON; SEDIMENTARY; BASIN;
   PHYTOPLANKTON; STRATIGRAPHY; CALIBRATION; DEPOSITION; DURATION
AB The Toarcian calcareous nannofossil crisis associated with the early Toarcian Oceanic Anoxic Event (T-OAE) in the Early Jurassic period is thought to represent one of the most important biocalcification crises during the Mesozoic, occurring simultaneously with a profound disturbance of the carbon cycle. However, the causes are still under debate, particularly with regard to the pattern, timing of the biocalcification crisis, relative roles of intrinsic and extrinsic processes as drivers of the crisis, and also causal mechanisms of the T-OAE.
   In this study, a new quantification of Toarcian calcareous nannofossil abundance and size is presented for the Sancerre borehole (Paris Basin, France). Beyond the recognition of a severe biocalcification crisis defined by the major drop in abundance, and the reduction in size of the most important pelagic carbonate producer Schizosphaerella punctulata, for the first time, this study proposes an insight into the pace and timing of the nannoplankton crisis. At Sancerre, the carbonate production of the lower Toarcian sediments previously attributed to obliquity forcing of climate allows to estimate a duration of similar to 210 kyr for the biocalcification crisis and of similar to 120 kyr for the shift towards lower carbon isotope values. The onset of the biocalcification crisis marked by a fertility event lasted similar to 60 kyr, and the calcium carbonate values remained low for similar to 150 kyr; the subsequent recovery of carbonate and nannoplankton lasted similar to 60 kyr and >550 kyr, respectively. Additionally, a link between the biocalcification crisis, the seawater palaeotemperature, and the carbon isotope steps can be demonstrated. This covariance provides compelling evidence of fundamental change in the response of the climatic warming and the carbon cycle systems triggering the biocalcification crisis. These observations indicate that the biocalcification crisis can be regarded as a direct or indirect consequence of a global warming. Moreover, a deficiency of the biological pump is proposed here as a complementary casual mechanism for explaining the negative carbon-isotope excursion. (c) 2014 Elsevier B.V. All rights reserved.
C1 [Clemence, Marie-Emilie] Univ Innsbruck, Inst Geol, Fac Geo & Atmospher Sci, A-6020 Innsbruck, Austria.
   [Clemence, Marie-Emilie] Univ Paris 06, CNRS UMR Ctr Rech Paleobiodiversite & Paleoenviro, F-75252 Paris 05, France.
RP Clemence, ME (reprint author), Univ Innsbruck, Inst Geol, Fac Geo & Atmospher Sci, Innrain 52, A-6020 Innsbruck, Austria.
EM Marie-Emilie.Clemence@uibk.ac.at
FU CNRS French programme "Eclipse II"
FX This study is the result of M.-E. Clemence Master's Thesis, which took
   place at Universite Pierre et Marie Curie, Paris 6, under the
   supervision of Silvia Gardin and Annachiara Bartolini. Funding for this
   project was provided by the CNRS French programme "Eclipse II". This
   manuscript benefited from fruitful discussions with Gregory Price and
   Emilia Huret. The author is grateful to Silvia Danise for statistical
   assistance. Many thanks to Angela Fraguas for comments and suggestions
   on a previous version of this manuscript. The author is very grateful to
   Editor Finn Surlyk and to the anonymous reviewer for critical review,
   many helpful suggestions and discussions of the manuscript
CR Aitchison J., 2002, CONT MATH SERIES, V287, P1
   Aksu AE, 2002, MAR GEOL, V190, P119, DOI 10.1016/S0025-3227(02)00345-6
   Armstrong RA, 2002, DEEP-SEA RES PT II, V49, P219
   Bailey TR, 2003, EARTH PLANET SC LETT, V212, P307, DOI 10.1016/S0012-821X(03)00278-4
   Barker S, 2003, PHILOS T R SOC A, V361, P1977, DOI 10.1098/rsta.2003.1238
   Bassoullet J.P., 1993, ATLAS TETHYS PALEOEN
   Bassoullet J. P., 1994, GEOBIOS, V17, P645, DOI 10.101650016-6995(94)80227-0
   Baudin F., 1990, AAPG STUDIES GEOLOGY, V30, P73
   Beerling DJ, 2002, AM J SCI, V302, P28, DOI 10.2475/ajs.302.1.28
   Bjerrum CJ, 2001, PALEOCEANOGRAPHY, V16, P390, DOI 10.1029/2000PA000512
   Boulila S, 2014, EARTH PLANET SC LETT, V386, P98, DOI 10.1016/j.epsl.2013.10.047
   Bown PR, 2004, COCCOLITHOPHORES: FROM MOLECULAR PROCESSES TO GLOBAL IMPACT, P481
   Brasier M.D., 1995, Geological Society Special Publication, V83, P113, DOI 10.1144/GSL.SP.1995.083.01.07
   Clarke K. R., 2006, PRIMER V6 USER MANUA
   Clarke K.R., 2001, CHANGE MARINE COMMUN
   Clarke KR, 2008, J EXP MAR BIOL ECOL, V366, P56, DOI 10.1016/j.jembe.2008.07.009
   Cobianchi M, 2001, PALAEOGEOGR PALAEOCL, V169, P219, DOI 10.1016/S0031-0182(01)00217-6
   Cohen AS, 2007, J GEOL SOC LONDON, V164, P1093, DOI 10.1144/0016-76492006-123
   Dromart G, 1996, B SOC GEOL FR, V167, P423
   Erba E, 2004, MAR MICROPALEONTOL, V52, P85, DOI 10.1016/j.marmicro.2004.04.007
   Fraguas A, 2012, MAR MICROPALEONTOL, V94-95, P58, DOI 10.1016/j.marmicro.2012.06.004
   Geisen M, 1999, MICROPALEONTOLOGY, V45, P437, DOI 10.2307/1486125
   Hermoso M, 2013, CLIM PAST, V9, P2703, DOI 10.5194/cp-9-2703-2013
   Hermoso M, 2014, PALAEOGEOGR PALAEOCL, V399, P385, DOI 10.1016/j.palaeo.2014.02.007
   Hermoso M, 2012, EARTH PLANET SC LETT, V319, P45, DOI 10.1016/j.epsl.2011.12.021
   Hermoso M, 2009, EARTH PLANET SC LETT, V277, P194, DOI 10.1016/j.epsl.2008.10.013
   Hesselbo SP, 2000, GEOL MAG, V137, P601, DOI 10.1017/S0016756800004672
   Hesselbo SP, 2007, EARTH PLANET SC LETT, V253, P455, DOI 10.1016/j.epsl.2006.11.009
   Hinnov LA, 2007, STRATIGRAPHY, V4, P239
   Huang C., 2013, GONDWANA RES
   JENKYNS HC, 1988, AM J SCI, V288, P101, DOI 10.2475/ajs.288.2.101
   Kemp DB, 2011, PALEOCEANOGRAPHY, V26, DOI 10.1029/2011PA002122
   Kemp DB, 2005, NATURE, V437, P396, DOI 10.1038/nature04037
   Klaas C, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001765
   Lorenz C., 1987, DOCUMENTS BUREAU REC, V136, P190
   LUDVIGSEN R, 1986, GEOSCI CAN, V13, P139
   Mailliot S, 2006, PALAEOGEOGR PALAEOCL, V240, P562, DOI 10.1016/j.palaeo.2006.02.016
   Mattioli E, 2004, J GEOL SOC LONDON, V161, P685, DOI 10.1144/0016-764903-074
   Mattioli E, 2004, PALAEOGEOGR PALAEOCL, V205, P295, DOI 10.1016/j.palaeo.2003.12.013
   Mattioli E, 2002, MAR MICROPALEONTOL, V45, P175, DOI 10.1016/S0377-8398(02)00039-7
   Mattioli E, 1997, PALAEOGEOGR PALAEOCL, V130, P113, DOI 10.1016/S0031-0182(96)00127-7
   Mattioli E., 2009, PALEOCEANOGRAPHY, V23
   Mattioli E, 2008, PALEOCEANOGRAPHY, V23, DOI 10.1029/2007PA001435
   McElwain JC, 2005, NATURE, V435, P479, DOI 10.1038/nature03618
   Noel D., 1991, MEM SCI GEOL B, V43, P63
   Noel Denise, 1994, Geobios Memoire Special (Villeurbanne), V17, P701
   Palfy J, 2000, CAN J EARTH SCI, V37, P923, DOI 10.1139/e00-002
   Palliani RB, 2002, MAR MICROPALEONTOL, V46, P223
   PALLIANI RB, 1995, P 3 EPA WORKSH BLACK, P60
   Rost B, 2004, COCCOLITHOPHORES: FROM MOLECULAR PROCESSES TO GLOBAL IMPACT, P99
   Saelen G, 1998, GEOLOGY, V26, P747, DOI 10.1130/0091-7613(1998)026<0747:EOROIL>2.3.CO;2
   Suan G, 2008, PALEOCEANOGRAPHY, V23, DOI 10.1029/2007PA001459
   Suan G, 2008, EARTH PLANET SC LETT, V267, P666, DOI 10.1016/j.epsl.2007.12.017
   Suan G, 2010, EARTH PLANET SC LETT, V290, P448, DOI 10.1016/j.epsl.2009.12.047
   Svensen H, 2007, EARTH PLANET SC LETT, V256, P554, DOI 10.1016/j.epsl.2007.02.013
   Sweeney E.N., 2001, THESIS MIT WOODS HOL
   Tremolada F, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2004PA001120
   van de Schootbrugge B, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2004PA001102
   Walsworth-Bell E.B., 2001, THESIS U COLL LONDON
   Ziegler PA, 1990, SHELL INT PETROLEUM, P1
NR 60
TC 8
Z9 8
U1 3
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0031-0182
EI 1872-616X
J9 PALAEOGEOGR PALAEOCL
JI Paleogeogr. Paleoclimatol. Paleoecol.
PD OCT 1
PY 2014
VL 411
BP 56
EP 64
DI 10.1016/j.palaeo.2014.06.022
PG 9
WC Geography, Physical; Geosciences, Multidisciplinary; Paleontology
SC Physical Geography; Geology; Paleontology
GA AP7PM
UT WOS:000342269200006
DA 2018-12-27
ER

PT J
AU Jiao, JT
   Jiang, C
   Huang, J
   Dai, MC
   Wang, C
   Cheng, C
   Shao, JF
AF Jiao, Jian-tong
   Jiang, Chen
   Huang, Jin
   Dai, Min-chao
   Wang, Cheng
   Cheng, Chao
   Shao, Jun-fei
TI RETRACTED: Metabolic syndrome factors and risk of postoperative
   depression in high-grade glioma patients in a 1.5-year prospective study
   (Retracted article. See vol. 34, art no 11, 2014)
SO MEDICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE High-grade glioma; Postoperative depression; Metabolic syndrome factors;
   Blood glucose
ID CANCER-PATIENTS; NERVOUS-SYSTEM; ENERGY-BALANCE; IMMUNE-SYSTEM;
   BRAIN-TUMORS; YOUNG-ADULTS; INSULIN; HYPERTENSION; COHORT; ASSOCIATION
AB To date, the relationship between metabolic syndrome factors and the risk of glioma-related depression is still unclear, and no study investigates this relationship. Our aim was to investigate the relationship between metabolic syndrome factors and the risk of postoperative depression in high-grade patients. A total of 386 high-grade glioma patients participated in blood sample collection for metabolic syndrome factors analysis and the hospital anxiety and depression scale testing. The association between metabolic syndrome factors and the risk of postoperative depression was assessed using Cox regression proportional hazards models, and Student's t tests were used to evaluate the differences in demographic variables and clinical characteristics in subgroups. The incidence of postoperative depression in our 1.5-year follow-up was 30.5 %. We found the risk of postoperative depression was elevated with increased blood glucose level [hazard ratios (HR) 2.277, 95 % confidence interval (CI) 1.201-4.320, top vs. bottom quartile]. The hazard ratio was increased for z-scores of blood glucose (HR 1.672 per unit standard deviation, 95 % CI 1.311-2.133] and of the combined metabolic syndrome score (HR 1.080, 95 % CI 1.000-1.167). In addition, risk of postoperative depression risk was increased in high-grade glioma patients with high blood glucose levels (>= 6.0 mmol/l) (HR 2.084, 95 % CI 1.235-3.515). However, we did not find significant associations between postoperative depression and other metabolic syndrome factors, including body mass index, systolic blood pressure, diastolic blood pressure, cholesterol, and triglycerides. Depression is prevalent among patients with high-grade glioma after operation. Blood glucose level is positively associated with the risk of postoperative depression, and might be involved in the etiology of postoperative depression, and may predict its development in high-grade glioma patients.
C1 [Jiao, Jian-tong; Jiang, Chen; Huang, Jin; Dai, Min-chao; Wang, Cheng; Cheng, Chao; Shao, Jun-fei] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Neurosurg, Wuxi 214023, Peoples R China.
RP Shao, JF (reprint author), Nanjing Med Univ, Wuxi Peoples Hosp, Dept Neurosurg, Wuxi 214023, Peoples R China.
EM tongjianjiao@126.com; wxhneurosurgery@126.com
FU National Natural Science Foundation of China (NSFC) [81272791]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC, 81272791).
CR ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7
   Akbaraly TN, 2009, DIABETES CARE, V32, P499, DOI 10.2337/dc08-1358
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Bailey RK, 2005, INT J GYNECOL CANCER, V15, P203, DOI 10.1111/j.1525-1438.2005.15204.x
   Brenner H, 2002, LANCET, V360, P1131, DOI 10.1016/S0140-6736(02)11199-8
   Catt S, 2008, LANCET ONCOL, V9, P884, DOI 10.1016/S1470-2045(08)70230-4
   Edlinger M, 2012, J HYPERTENS, V30, P290, DOI 10.1097/HJH.0b013e32834e9176
   Farooqui AA, 2012, CELL MOL LIFE SCI, V69, P741, DOI 10.1007/s00018-011-0840-1
   Frisardi V, 2010, J ALZHEIMERS DIS, V21, P57, DOI 10.3233/JAD-2010-100015
   Gasecki D, 2013, CURR HYPERTENS REP, V15, P547, DOI 10.1007/s11906-013-0398-4
   Herva A, 2006, PSYCHOSOM MED, V68, P213, DOI 10.1097/01.psy.0000203172.02305.ea
   Hildrum B, 2009, ACTA PSYCHIAT SCAND, V120, P14, DOI 10.1111/j.1600-0447.2008.01315.x
   Hoyer S, 2002, J NEURAL TRANSM, V109, P341, DOI 10.1007/s007020200028
   Kaaks R, 2001, P NUTR SOC, V60, P91, DOI 10.1079/PNS200070
   Kinder LS, 2004, PSYCHOSOM MED, V66, P316, DOI 10.1097/01.psy.0000124755.91880.f4
   Litofsky NS, 2009, J NEURO-ONCOL, V94, P153, DOI 10.1007/s11060-009-9825-4
   Litofsky NS, 2004, NEUROSURGERY, V54, P358, DOI 10.1227/01.NEU.0000103450.94724.A2
   Nation DA, 2010, J INT NEUROPSYCH SOC, V16, P933, DOI 10.1017/S1355617710000548
   Pace A, 2005, NEUROSURGERY, V56, pE628
   Pangilinan PH, 2007, COMMUNITY ONCOLOGY, V4, P533
   Peeters PHM, 1998, J HYPERTENS, V16, P941, DOI 10.1097/00004872-199816070-00007
   Perez-Tilve D, 2006, ENDOCRINOLOGY, V147, P1136, DOI 10.1210/en.2005-1586
   Pocai A, 2005, CELL METAB, V1, P53, DOI 10.1016/j.cmet.2004.11.001
   Rabkin SW, 2011, BLOOD PRESSURE, V20, P274, DOI 10.3109/08037051.2011.566246
   Raikkonen K, 1996, METABOLISM, V45, P1533, DOI 10.1016/S0026-0495(96)90184-5
   Raikkonen K, 2001, HYPERTENSION, V38, P798, DOI 10.1161/hyp.38.4.798
   Romanowski CAJ, 2011, NEURORADIOLOGY, V53, pS133, DOI 10.1007/s00234-011-0929-0
   Satin JR, 2009, CANCER-AM CANCER SOC, V115, P5349, DOI 10.1002/cncr.24561
   Seeley RJ, 2005, OBES REV, V6, P259, DOI 10.1111/j.1467-789X.2005.00193.x
   Stocks T, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000201
   Strader AD, 2005, GASTROENTEROLOGY, V128, P175, DOI 10.1053/j.gastro.2004.10.043
   Takahashi Y, 2011, INTERNAL MED, V50, P1671, DOI 10.2169/internalmedicine.50.4871
   Takeuchi T, 2009, DIABETES METAB, V35, P32, DOI 10.1016/j.diabet.2008.06.006
   Takeuchi T, 2009, DIABETES-METAB RES, V25, P762, DOI 10.1002/dmrr.1041
   Tulinius H, 1997, CANCER EPIDEM BIOMAR, V6, P863
   Wakefield JC, 2007, ARCH GEN PSYCHIAT, V64, P433, DOI 10.1001/archpsyc.64.4.433
   Weber-Hamann B, 2002, PSYCHOSOM MED, V64, P274, DOI 10.1097/00006842-200203000-00010
   Weitzner MA, 1999, CANCER INVEST, V17, P285, DOI 10.3109/07357909909040599
   Yirmiya R, 2000, WESTERN J MED, V173, P333, DOI 10.1136/ewjm.173.5.333
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 40
TC 4
Z9 5
U1 3
U2 7
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD OCT
PY 2014
VL 31
IS 10
AR 234
DI 10.1007/s12032-014-0234-y
PG 8
WC Oncology
SC Oncology
GA AP4WG
UT WOS:000342079600049
PM 25223530
DA 2018-12-27
ER

PT J
AU Anderson, DE
   Ester, EF
   Klee, D
   Vogel, EK
   Awh, E
AF Anderson, David E.
   Ester, Edward F.
   Klee, Daniel
   Vogel, Edward K.
   Awh, Edward
TI RETRACTED: Electrophysiological Evidence for Failures of Item
   Individuation in Crowded Visual Displays (Retracted article)
SO JOURNAL OF COGNITIVE NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID SPATIAL INTERACTION; WORKING-MEMORY; LETTER IDENTIFICATION; ORIENTATION
   SIGNALS; OBJECT RECOGNITION; DISCRETE RESOURCE; LATERAL MASKING; NEURAL
   MEASURES; ATTENTION; VISION
AB Visual perception is strongly impaired when peripheral targets are surrounded by nearby distractors, a phenomenon known as visual crowding. One common behavioral signature of visual crowding is an increased tendency for observers to mistakenly report the features of nearby distractors instead of the target item. Here, our goal was to distinguish between two possible explanations of such substitution errors. On the one hand, crowding may have its effects after the deployment of attention toward-and individuation of-targets and flankers, such that multiple individuated perceptual representations compete to guide the behavioral response. On the other hand, crowding may prevent the individuation of closely spaced stimuli, thereby reducing the number of apprehended items. We attempted to distinguish these alternatives using the N2pc, an ERP that has been shown to track the deployment of spatial attention and index the number of individuated items within a hemifield. N2pc amplitude increased monotonically with set size in uncrowded displays, but this set size effect was abolished in crowded visual displays. Moreover, these crowding-induced declines in N2pc amplitude predicted individual differences in the rate of substitution errors. Thus, crowding-induced confusions between targets and distractors may be a consequence of failures to individuate target and distractor stimuli during early stages of visual selection.
C1 [Anderson, David E.; Klee, Daniel; Vogel, Edward K.; Awh, Edward] Univ Oregon, Eugene, OR 97403 USA.
   [Ester, Edward F.] Univ Calif San Diego, San Diego, CA 92103 USA.
RP Anderson, DE (reprint author), 1227 Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
EM dendersn@gmail.com; awh@uoregon.edu
FU NIMH [R01-MH087214]
FX Supported by NIMH R01-MH087214 to E. A. and E. K. V. D. E. A. and E. A.
   conceived and designed the experiment. D. E. A. and D. K. collected the
   data. D. E. A. analyzed the data using software developed by D. E. A.
   All authors contributed to writing the manuscript.
CR Anderson DE, 2014, COGNITIVE ELECTROPHYSIOLOGY OF ATTENTION: SIGNALS OF THE MIND, P226, DOI 10.1016/B978-0-12-398451-7.00018-X
   Anderson DE, 2013, PSYCHOL SCI, V24, P929, DOI 10.1177/0956797612464380
   Anderson DE, 2013, J EXP PSYCHOL HUMAN, V39, P824, DOI 10.1037/a0030094
   Anderson DE, 2011, J NEUROSCI, V31, P1128, DOI 10.1523/JNEUROSCI.4125-10.2011
   BANKS WP, 1984, PERCEPT PSYCHOPHYS, V36, P285, DOI 10.3758/BF03206370
   BANKS WP, 1979, PERCEPT PSYCHOPHYS, V25, P447, DOI 10.3758/BF03213822
   Bays PM, 2009, J VISION, V9, DOI 10.1167/9.10.7
   Bex PJ, 2005, VISION RES, V45, P1385, DOI 10.1016/j.visres.2004.12.001
   BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   CHASTAIN G, 1982, PSYCHOL RES-PSYCH FO, V44, P51, DOI 10.1007/BF00308555
   Chung S. T. L., 2003, J VISION, V<IT>3</IT>, P815, DOI [DOI 10.1167/3.9.815, 10.1167/3.9.815.]
   Chung STL, 2001, VISION RES, V41, P1833, DOI 10.1016/S0042-6989(01)00071-2
   Drew T, 2008, J NEUROSCI, V28, P4183, DOI 10.1523/JNEUROSCI.0556-08.2008
   ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267
   Ester E. E., 2012, COGNITIVE NEUROSCIEN, P99
   Ester EF, 2014, J EXP PSYCHOL HUMAN, V40, P1022, DOI 10.1037/a0035377
   Ester EF, 2012, J NEUROSCI, V32, P7169, DOI 10.1523/JNEUROSCI.1218-12.2012
   ESTES WK, 1982, J EXP PSYCHOL HUMAN, V8, P353, DOI 10.1037/0096-1523.8.3.353
   ESTES WK, 1976, PERCEPT PSYCHOPHYS, V19, P1, DOI 10.3758/BF03199379
   ESTES WK, 1971, PSYCHON SCI, V25, P77
   GARDNER GT, 1973, COGNITIVE PSYCHOL, V4, P130, DOI 10.1016/0010-0285(73)90009-1
   Gheri C, 2008, VISION RES, V48, P2352, DOI 10.1016/j.visres.2008.07.022
   Hilimire MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012677
   Hilimire MR, 2009, PSYCHOPHYSIOLOGY, V46, P1080, DOI 10.1111/j.1469-8986.2009.00846.x
   Huckauf A, 2002, VIS COGN, V9, P889, DOI 10.1080/13506280143000548
   KOOI FL, 1994, SPATIAL VISION, V8, P255, DOI 10.1163/156856894X00350
   KRUMHANSL CL, 1977, PERCEPT PSYCHOPHYS, V21, P269, DOI 10.3758/BF03214239
   Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009
   Livne T, 2007, J VISION, V7, DOI 10.1167/7.2.4
   Livne T, 2011, J VISION, V11, DOI 10.1167/11.13.18
   Livne T, 2010, J VISION, V10, DOI 10.1167/10.3.1
   Luck SJ, 1997, COGNITIVE PSYCHOL, V33, P64, DOI 10.1006/cogp.1997.0660
   LUCK SJ, 1994, J EXP PSYCHOL HUMAN, V20, P1000, DOI 10.1037//0096-1523.20.5.1000
   Malania M, 2007, J VISION, V7, DOI 10.1167/7.2.1
   Manassi M, 2012, J VISION, V12, DOI 10.1167/12.10.13
   Mazza V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017453
   Mazza V, 2009, PSYCHOPHYSIOLOGY, V46, P771, DOI 10.1111/j.1469-8986.2009.00814.x
   MCINTYRE C, 1970, PERCEPT PSYCHOPHYS, V7, P328, DOI 10.3758/BF03208657
   Nandy AS, 2007, J VISION, V7, DOI 10.1167/7.2.5
   Pagano S, 2012, NEUROPSYCHOLOGIA, V50, P754, DOI 10.1016/j.neuropsychologia.2012.01.009
   Parkes L, 2001, NAT NEUROSCI, V4, P739, DOI 10.1038/89532
   Pelli DG, 2008, NAT NEUROSCI, V11, P1129, DOI 10.1038/nn.2187
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Poder E, 2007, J VISION, V7, DOI 10.1167/7.2.23
   PRINZMETAL W, 1981, PERCEPT PSYCHOPHYS, V30, P330, DOI 10.3758/BF03206147
   Saarela TP, 2010, J VISION, V10, DOI 10.1167/10.10.17
   Saarela TP, 2009, J VISION, V9, DOI 10.1167/9.2.5
   Sayim B, 2010, PSYCHOL SCI, V21, P641, DOI 10.1177/0956797610368811
   Sayim B, 2011, J VISION, V11, DOI 10.1167/11.1.6
   Sayim B, 2008, J VISION, V8, DOI 10.1167/8.8.12
   Scolari M, 2007, J VISION, V7, DOI 10.1167/7.2.7
   SHAW P, 1969, PERCEPT PSYCHOPHYS, V6, P257, DOI 10.3758/BF03210094
   SHIFFRIN RM, 1972, J EXP PSYCHOL, V93, P72, DOI 10.1037/h0032453
   STRANGERT B, 1975, PERCEPT PSYCHOPHYS, V17, P268, DOI 10.3758/BF03203210
   STRASBURGER H, 1991, PERCEPT PSYCHOPHYS, V49, P495, DOI 10.3758/BF03212183
   Strasburger H, 2005, J VISION, V5, P1024, DOI 10.1167/5.11.8
   TOET A, 1992, VISION RES, V32, P1349, DOI 10.1016/0042-6989(92)90227-A
   van den Berg R, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000646
   Vul E, 2009, J EXP PSYCHOL GEN, V138, P546, DOI 10.1037/a0017352
   Wilkinson F, 1997, J OPT SOC AM A, V14, P2057, DOI 10.1364/JOSAA.14.002057
   WOLFORD G, 1983, PERCEPT PSYCHOPHYS, V33, P129, DOI 10.3758/BF03202830
   WOLFORD G, 1980, PERCEPT PSYCHOPHYS, V27, P409, DOI 10.3758/BF03204459
   WOLFORD G, 1974, PERCEPT PSYCHOPHYS, V16, P437, DOI 10.3758/BF03198569
   WOLFORD G, 1975, PSYCHOL REV, V82, P184, DOI 10.1037/0033-295X.82.3.184
   Woodman GF, 1999, NATURE, V400, P867
NR 66
TC 4
Z9 4
U1 2
U2 19
PU MIT PRESS
PI CAMBRIDGE
PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA
SN 0898-929X
EI 1530-8898
J9 J COGNITIVE NEUROSCI
JI J. Cogn. Neurosci.
PD OCT
PY 2014
VL 26
IS 10
BP 2298
EP 2309
DI 10.1162/jocn_a_00649
PG 12
WC Neurosciences; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA AO7ZV
UT WOS:000341572600010
PM 24738774
OA Green Accepted, Green Published
DA 2018-12-27
ER

PT J
AU Salehi, I
   Hosseini, SM
   Haghighi, M
   Jahangard, L
   Bajoghli, H
   Gerber, M
   Puhse, U
   Kirov, R
   Holsboer-Trachsler, E
   Brand, S
AF Salehi, Iraj
   Hosseini, Seyed Mohammad
   Haghighi, Mohammad
   Jahangard, Leila
   Bajoghli, Hafez
   Gerber, Markus
   Puehse, Uwe
   Kirov, Roumen
   Holsboer-Trachsler, Edith
   Brand, Serge
TI RETRACTED: Electroconvulsive therapy and aerobic exercise training
   increased BDNF and ameliorated depressive symptoms in patients suffering
   from treatment-resistant major depressive disorder (Retracted article.
   See vol. 69, pg. 94, 2015)
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article; Retracted Publication
DE Treatment-resistant major depressive; disorder; Electroconvulsive
   therapy; Aerobic exercise training; BDNF
ID NEUROTROPHIC FACTOR BDNF; HIPPOCAMPAL VOLUME; RESIDUAL SYMPTOMS; BRAIN;
   SERUM; ECT; AMYGDALA; PLASMA; METAANALYSIS; PERFORMANCE
AB Background: To treat patients suffering from treatment-resistant major depressive disorder (TR-MDD), research has focused on electroconvulsive therapy (ECT) and aerobic exercise training (AET). Brain derived neurotrophic factor (BDNF) seems to be key in MDD. The aims of the present study were therefore two-fold, to investigate in a three-arm interventional study the differential effects of ECT, ECT plus AET, and AET alone in patients suffering from TR-MDD on 1. depressive symptoms and 2. BDNF.
   Methods: 60 patients with TR-MDD (mean age: 31 years; 31.6% female patients) were randomly assigned either to the ECT, ECT + AET, or AET condition. The AET condition consisted of treadmill exercise for 30 min, three times a week. Both depression severity and BDNF levels were assessed at baseline and 4 weeks later. All patients were further treated with an SSRI standard medication.
   Results: BDNF levels increased over time in all three study conditions. After completion of the intervention program, the ECT group showed significantly higher BDNF levels compared to the ECT + AET and the AET conditions. Depressive symptoms decreased in all three conditions over time. The combination of ECT + AET led to a significantly greater decrease than in either the ECT or AET alone conditions. BDNF levels were not associated with symptoms of depression.
   Conclusions: The pattern of results suggests that ECT, AET and particularly their combination are promising directions for treatment patients suffering from TR-MDD, and that it remains unclear to what extent BDNF is key and a reliable biomarker for TR-MDD. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Salehi, Iraj; Hosseini, Seyed Mohammad; Haghighi, Mohammad; Jahangard, Leila] Hamadan Univ Med Sci, Res Ctr Behav Disorders & Subst Abuse, Hamadan, Iran.
   [Bajoghli, Hafez] Univ Tehran Med Sci, Roozbeh Hosp, PPRC, Tehran, Iran.
   [Bajoghli, Hafez] Mahidol Univ, ASEAN Inst Hlth Dev, Phutthamonthon 73170, Nakhon Pathom, Thailand.
   [Gerber, Markus; Puehse, Uwe; Brand, Serge] Univ Basel, Div Sport Sci, Dept Sport Exercise & Hlth, Basel, Switzerland.
   [Kirov, Roumen] Bulgarian Acad Sci, Inst Neurobiol, Sofia, Bulgaria.
   [Holsboer-Trachsler, Edith; Brand, Serge] Univ Basel, Psychiat Clin, Ctr Affect Stress & Sleep Disorders ZASS, CH-4012 Basel, Switzerland.
RP Brand, S (reprint author), Univ Basel, Psychiat Clin, Ctr Affect Stress & Sleep Disorders, Wilhelm Klein Str 27, CH-4012 Basel, Switzerland.
EM serge.brand@upkbs.ch
RI Salehi, Iraj/M-5556-2017; Gerber, Markus/H-8654-2014; Jahangard,
   Leila/R-4159-2017; Haghighi, Mohammad/R-3453-2017
OI Salehi, Iraj/0000-0002-7996-013X; Jahangard, Leila/0000-0002-2834-4644;
   Haghighi, Mohammad/0000-0002-4875-1036
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Barekatain M, 2008, J ECT, V24, P199, DOI 10.1097/YCT.0b013e3181624b5d
   Beck A, 1961, BECK DEPRESSION INVE
   Beck J, 2013, J PSYCHIATR RES, V47, P1824, DOI 10.1016/j.jpsychires.2013.08.009
   Beste C, 2010, J NEUROSCI, V30, P10727, DOI 10.1523/JNEUROSCI.2493-10.2010
   Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308
   Bocchio-Chiavetto L, 2006, EUR NEUROPSYCHOPHARM, V16, P620, DOI 10.1016/j.euroneuro.2006.04.010
   Bowley MP, 2002, BIOL PSYCHIAT, V52, P404, DOI 10.1016/S0006-3223(02)01404-X
   Brunoni A.R., 2014, WORLD J BIOL PSYCHIA
   Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598
   Castren E, 2007, CURR OPIN PHARMACOL, V7, P18, DOI 10.1016/j.coph.2006.08.009
   Cho HC, 2012, NEUROSCI LETT, V519, P78, DOI 10.1016/j.neulet.2012.05.025
   Cotter D, 2001, ARCH GEN PSYCHIAT, V58, P545, DOI 10.1001/archpsyc.58.6.545
   Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013
   Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108
   Fava GA, 2002, PROG NEURO-PSYCHOPH, V26, P1019, DOI 10.1016/S0278-5846(02)00226-9
   Fernandes B, 2009, NEUROSCI LETT, V453, P195, DOI 10.1016/j.neulet.2009.02.032
   Gedge Laura, 2012, Front Psychiatry, V3, P12, DOI 10.3389/fpsyt.2012.00012
   Gerber M, 2013, PATIENT EDUC COUNS, V93, P146, DOI 10.1016/j.pec.2013.03.021
   Giese M, 2014, MOL PSYCHIATR, V19, P151, DOI 10.1038/mp.2013.10
   Giese M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076050
   Greden John F., 2001, Journal of Clinical Psychiatry, V62, P26
   Gronli O, 2009, WORLD J BIOL PSYCHIA, V10, P295, DOI 10.3109/15622970701586323
   Guilloux JP, 2012, MOL PSYCHIATR, V17, P1130, DOI 10.1038/mp.2011.113
   Haghighi M, 2013, J PSYCHIATR RES, V47, P908, DOI 10.1016/j.jpsychires.2013.03.006
   Hamidi M, 2004, BIOL PSYCHIAT, V55, P563, DOI 10.1016/j.biopsych.2003.11.006
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Hasselbalch BJ, 2012, ACTA PSYCHIAT SCAND, V126, P157, DOI 10.1111/j.1600-0447.2012.01831.x
   Hibel LC, 2013, HORM BEHAV, V63, P484, DOI 10.1016/j.yhbeh.2012.12.012
   Holsboer F, 2010, ANNU REV PSYCHOL, V61, pC1, DOI DOI 10.1146/ANNUREV.PSYCH.093008.100321
   Holsboer F, 2010, ANNU REV PSYCHOL, V61, P81, DOI 10.1146/annurev.psych.093008.100321
   Jenkins E, 2012, DEPRESS RES TREAT, P469
   Josefsson T, 2014, SCAND J MED SCI SPOR, V24, P259, DOI 10.1111/sms.12050
   Judd LL, 1998, J AFFECT DISORDERS, V50, P97, DOI 10.1016/S0165-0327(98)00138-4
   Karege F, 2002, PSYCHIAT RES, V109, P143, DOI 10.1016/S0165-1781(02)00005-7
   Keitner GI, 2012, PSYCHIAT CLIN N AM, V35, P249, DOI 10.1016/j.psc.2011.11.004
   Kennedy N, 2004, J AFFECT DISORDERS, V80, P135, DOI 10.1016/S0165-0327(03)00054-5
   Lindwall M., 2013, HLTH PSYCHOL
   Marano CM, 2007, J CLIN PSYCHIAT, V68, P512, DOI 10.4088/JCP.v68n0404
   Matrisciano F, 2008, J PSYCHIATR RES, V43, P247, DOI 10.1016/j.jpsychires.2008.03.014
   Mikoteit T, 2014, PSYCHOPHARMACOLOGY
   Molendijk ML, 2011, MOL PSYCHIATR, V16, P1088, DOI 10.1038/mp.2010.98
   Mota-Pereira J, 2011, J PSYCHIATR RES, V45, P1005, DOI 10.1016/j.jpsychires.2011.02.005
   Naert G, 2011, MOL CELL NEUROSCI, V46, P55, DOI 10.1016/j.mcn.2010.08.006
   Olchanski N, 2013, CLIN THER, V35, P512, DOI 10.1016/j.clinthera.2012.09.001
   Piccinni A, 2009, EUR NEUROPSYCHOPHARM, V19, P349, DOI 10.1016/j.euroneuro.2009.01.002
   Rajkowska G, 2001, BIOL PSYCHIAT, V49, P741, DOI 10.1016/S0006-3223(01)01080-0
   Rethorst CD, 2013, J PSYCHIATR PRACT, V19, P204, DOI 10.1097/01.pra.0000430504.16952.3e
   Sackeim Harold A., 2001, Journal of Clinical Psychiatry, V62, P10
   Scott BW, 2000, EXP NEUROL, V165, P231, DOI 10.1006/exnr.2000.7458
   Seifert T, 2010, AM J PHYSIOL-REG I, V298, pR372, DOI 10.1152/ajpregu.00525.2009
   Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005
   Serra-Millas M, 2011, PSYCHOPHARMACOLOGY, V216, P1, DOI 10.1007/s00213-011-2180-0
   Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002
   Siuciak JA, 1997, PHARMACOL BIOCHEM BE, V56, P131, DOI 10.1016/S0091-3057(96)00169-4
   Stanton R, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00046
   Toups MSP, 2011, J PSYCHIATR RES, V45, P1301, DOI 10.1016/j.jpsychires.2011.05.002
   Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957
   Wolkowitz OM, 2011, PROG NEURO-PSYCHOPH, V35, P1623, DOI 10.1016/j.pnpbp.2011.06.013
NR 59
TC 30
Z9 30
U1 4
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD OCT
PY 2014
VL 57
BP 117
EP 124
DI 10.1016/j.jpsychires.2014.06.018
PG 8
WC Psychiatry
SC Psychiatry
GA AO7RK
UT WOS:000341550100015
PM 25073431
DA 2018-12-27
ER

PT J
AU Eduok, UM
   Khaled, MM
AF Eduok, Ubong M.
   Khaled, Mazen M.
TI RETRACTED: Corrosion protection of steel sheets by chitosan from shrimp
   shells at acid pH (Retracted article. See vol. 22, pg. 925, 2015)
SO CELLULOSE
LA English
DT Article; Retracted Publication
DE Steel; Corrosion; Electrochemistry; Chitosan film; Shrimp shells
ID MILD-STEEL; INHIBITION; IRON; HCL
AB The corrosion behavior of mild steel (MS) sheets in 0.5 M H2SO4 in the presence of chitosan extracted from shrimp shells (CSS) has been studied using electrochemical techniques. The optimum concentration (10 A mu M) of this carbohydrate polymer inhibited MS corrosion up to 85 % in the solution of the acid electrolyte. Results reveal that CSS reduced the dissolution of MS linearly with its concentration, and this reduction could be attributed to the interfacial formation of CSS film at the MS-electrolyte boundary. CSS is a mixed-type inhibitor and the shapes of Nyquist capacitive and inductive loops obtained from the impedance results could be associated with double layer reactions and relaxation of corrosive ions adsorption in the presence of CSS, respectively, at the MS/solution interface. Surface analytical studies with atomic force microscope, scanning electron microscope and Fourier transform infra-red also confirm the adsorption of CSS on MS.
C1 [Eduok, Ubong M.; Khaled, Mazen M.] King Fahd Univ Petr & Minerals, Dept Chem, Dhahran 31261, Saudi Arabia.
RP Eduok, UM (reprint author), King Fahd Univ Petr & Minerals, Dept Chem, Dhahran 31261, Saudi Arabia.
EM ublook@yahoo.com
CR Cheng S, 2007, ELECTROCHIM ACTA, V52, P5932, DOI 10.1016/j.electacta.2007.03.038
   Eduok UM, 2012, ARAB J CHEM, V5, P325, DOI 10.1016/j.arabjc.2010.09.006
   El-Haddad MN, 2014, CARBOHYD POLYM, V112, P595, DOI 10.1016/j.carbpol.2014.06.032
   El-Haddad MN, 2013, INT J BIOL MACROMOL, V55, P142, DOI 10.1016/j.ijbiomac.2012.12.044
   Li ML, 2014, J COLLOID INTERF SCI, V417, P131, DOI 10.1016/j.jcis.2013.11.053
   Mohamed RR, 2011, INT J ELECTROCHEM SC, V6, P2488
   Rajeswari V, 2013, CARBOHYD POLYM, V95, P288, DOI 10.1016/j.carbpol.2013.02.069
   Umoren SA, 2016, ARAB J CHEM, V9, pS209, DOI 10.1016/j.arabjc.2011.03.008
   Umoren SA, 2010, CORROS SCI, V52, P1777, DOI 10.1016/j.corsci.2010.01.026
   Umoren SA, 2013, IND ENG CHEM RES, V52, P14855, DOI 10.1021/ie401737u
   Umoren SA, 2013, CELLULOSE, V20, P2529, DOI 10.1007/s10570-013-0021-5
NR 11
TC 2
Z9 2
U1 3
U2 49
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-0239
EI 1572-882X
J9 CELLULOSE
JI Cellulose
PD OCT
PY 2014
VL 21
IS 5
BP 3139
EP 3143
DI 10.1007/s10570-014-0384-2
PG 5
WC Materials Science, Paper & Wood; Materials Science, Textiles; Polymer
   Science
SC Materials Science; Polymer Science
GA AO6VF
UT WOS:000341489300001
DA 2018-12-27
ER

PT J
AU Hou, WJ
   Guan, JH
   Lu, H
   Dong, Q
   Han, YH
   Zhang, R
AF Hou, Wenjing
   Guan, Jianhua
   Lu, Huan
   Dong, Qian
   Han, Yuhong
   Zhang, Rong
TI RETRACTED: The effects of dexamethasone on the proliferation and
   apoptosis of human ovarian cancer cells induced by paclitaxel (Retracted
   article. See vol. 8, pg. 16, 2015)
SO JOURNAL OF OVARIAN RESEARCH
LA English
DT Article; Retracted Publication
DE Bcl-XL; Cleaved caspase-3; Dexamethasone; Ovarian cancer; Paclitaxel;
   Survivin
ID INDUCED CHEMOTHERAPY RESISTANCE; MULTIPLE-MYELOMA CELLS; GLIOMA-CELLS;
   SOLID TUMORS; GLUCOCORTICOIDS; DEATH; ACTIVATION; EXPRESSION; BREAST;
   MECHANISMS
AB Background: Dexamethasone (DEX) has been routinely used as a pre-treatment in the clinical application of paclitaxel (PTX) to treat ovarian cancer. However, PTX-induced apoptosis might be inhibited by DEX. This study was undertaken to investigate the effects of DEX on the apoptosis induced by PTX.
   Methods: Both of SKOV-3 and HO-8910 human ovarian cancer cells were divided into four groups: (1) untreated (Con); (2) treated with DEX (0.1 mu M) alone; ( 3) treated with PTX (50 nM); and (4) pre-treated with DEX ( 0.1 mu M), and 24 h later, treated with PTX (DEX + PTX). Cell proliferation was determined by the 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) dye uptake method, while cell apoptosis was analyzed by propidium iodide (PI) staining and flow cytometry. Then, reverse transcription polymerase chain reactions (RT-PCRs) were applied to semi-quantitative analysis, followed by western blot analysis. Statistical analysis was performed, with Fisher's least significant difference test.
   Results: Our results demonstrated that DEX can differentially inhibit SKOV-3 and HO-8910 cell proliferation induced by PTX and decrease the apoptosis rates in cancer cells. Pre-treatment with DEX could up-regulate the expressions of members of anti-apoptotic Bcl-2 family (Bcl-2 and Bcl-XL) and members of IAP family (survivin). The expression of cleaved caspase-3 was down-regulated by DEX, shown by semi-quantitative RT-PCRs and western blot analysis.
   Conclusions: Our data gained invaluable insights of the antagonistic mechanisms of DEX on PTX-induced cancer cell death and may provide new methods of using DEX as antineoplastic drugs or agents in the clinical treatment for ovarian cancer patients.
C1 [Hou, Wenjing; Guan, Jianhua; Lu, Huan; Dong, Qian; Han, Yuhong; Zhang, Rong] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Obstet & Gynecol, Fengxian Branch, Shanghai 201499, Peoples R China.
RP Zhang, R (reprint author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Obstet & Gynecol, Fengxian Branch, 6600 Nanfeng Rd, Shanghai 201499, Peoples R China.
EM rongzhangrz@hotmail.com
CR Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821
   Brenes O, 2007, BIOMED PHARMACOTHER, V61, P347, DOI 10.1016/j.biopha.2007.02.007
   Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj/onc/1205205
   Chen DWC, 2010, PHARMACOGENOMICS, V11, P1545, DOI [10.2217/pgs.10.125, 10.2217/PGS.10.125]
   Chen YX, 2010, ENDOCR-RELAT CANCER, V17, P39, DOI 10.1677/ERC-08-0296
   Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272
   Cuevas P, 2006, NEUROL RES, V28, P127, DOI 10.1179/016164106X97982
   Das A, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-36
   de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231
   Fan WM, 2004, CURR MED CHEM, V11, P403, DOI 10.2174/0929867043455990
   Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com
   Gascoyne DM, 2003, J BIOL CHEM, V278, P18022, DOI 10.1074/jbc.M301812200
   Gassler N, 2005, BRIT J CANCER, V92, P1084, DOI 10.1038/sj.bjc.6602453
   Gorman AM, 2000, NEUROSCIENCE, V96, P417, DOI 10.1016/S0306-4522(99)00565-5
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603
   Herr I, 2003, CANCER RES, V63, P3112
   Hippisley-Cox J, 2012, BMJ-BRIT MED J, V344
   Huang Y, 2001, ONCOL RES, V13, P113
   Huang Y, 2002, MOL PHARMACOL, V61, P105, DOI 10.1124/mol.61.1.105
   Huang Y, 2000, CANCER RES, V60, P4426
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0
   Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728
   Liu Q, 2003, BLOOD, V101, P4105, DOI 10.1182/blood-2002-10-3067
   Lorusso V, 2012, SUPPORT CARE CANCER, V20, P3241, DOI 10.1007/s00520-012-1469-9
   Machuca C, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-9
   Morita M, 2007, INT J ONCOL, V30, P187
   Ni Chonghaile T, 2006, APOPTOSIS, V11, P1247, DOI 10.1007/s10495-006-7233-1
   Quock J, 2002, CANCER INVEST, V20, P666, DOI 10.1081/CNV-120003535
   Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047
   Rose PG, 2003, GYNECOL ONCOL, V88, P130, DOI 10.1016/S0090-8258(02)00091-4
   Rutz HP, 2004, CANCER BIOL THER, V3, P715, DOI 10.4161/cbt.3.8.966
   Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2
   Schmidt M, 2001, J IMMUNOL, V166, P1344, DOI 10.4049/jimmunol.166.2.1344
   Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sui MH, 2006, INT J CANCER, V119, P712, DOI 10.1002/ijc.21743
   Wada T, 2005, J AM SOC NEPHROL, V16, P2615, DOI 10.1681/ASN.2005020142
   Wanke I, 2004, TOXICOLOGY, V204, P141, DOI 10.1016/j.tox.2004.06.020
   Wu W, 2005, J BIOL CHEM, V280, P4117, DOI 10.1074/jbc.M411200200
   Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546
   Yang N, 2011, HEPATO-GASTROENTEROL, V58, P1730, DOI 10.5754/hge11153
   Zhang C, 2006, CANCER LETT, V242, P104, DOI 10.1016/j.canlet.2005.10.037
   Zhang C, 2006, CANCER BIOL THER, V5, P59, DOI 10.4161/cbt.5.1.2272
   Zhang C, 2007, CANCER BIOL THER, V6, P278, DOI 10.4161/cbt.6.2.3652
   Zhang CW, 2006, INT J ONCOL, V29, P1295
   Zhang CW, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-61
   Zhang CW, 2006, INT J ONCOL, V28, P551
   Zhang Q, 2009, BIOMED PHARMACOTHER, V63, P603, DOI 10.1016/j.biopha.2008.10.001
NR 50
TC 2
Z9 3
U1 2
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757-2215
J9 J OVARIAN RES
JI J. Ovarian Res.
PD SEP 30
PY 2014
VL 7
AR 89
DI 10.1186/s13048-014-0089-z
PG 8
WC Reproductive Biology
SC Reproductive Biology
GA AW2CO
UT WOS:000346096100001
PM 25297825
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wen, JL
   Li, RB
   Wen, XF
   Chou, GM
   Lu, JS
   Wang, XL
   Jin, YC
AF Wen, Jiling
   Li, Rongbing
   Wen, Xiaofei
   Chou, Guangming
   Lu, Jiasun
   Wang, Xuelei
   Jin, Yongchao
TI RETRACTED: Dysregulation of cell cycle related genes and microRNAs
   distinguish the low- from high-risk of prostate cancer (Retracted
   article. See vol. 10, pg. 11, 2015)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer; Differentially expressed genes; MicroRNAs
ID ANDROGEN RECEPTOR; TUMOR-GROWTH; IDENTIFICATION; BRCA1
AB Background: Prostate cancer (PCa) is a biologically heterogeneous disease with considerable variation in clinical aggressiveness. In this study, bioinformatics was used to detect the patterns of gene expression alterations of PCa patients.
   Methods: The gene expression profile GSE21034 and GSE21036 were downloaded from Gene Expression Omnibus (GEO) database. Significantly changed mRNA transcripts and microRNAs were identified between subtypes with favorable (cluster 2) and unfavorable (cluster 5) prognosis by two-side unequal variances t test. MicroRNAs and their potential target genes were identified by TargetScan and miRTarBase, respectively. Besides, the overlapped genes between the target genes of microRNAs and mRNA transcripts were assessed by Fisher' exact test (one side). The functional annotation was performed by DAVID, followed by construction of protein-protein interaction (PPI) network.
   Results: Compared to cluster 2, 1556 up-regulated and 1288 down-regulated transcripts were identified in cluster 5. Total 28 microRNAs were up-regulated and 30 microRNAs were down-regulated in cluster 5. Besides, 12 microRNAs target transcripts were significantly overlapped with down-regulated transcripts in cluster 5 with none of them was found overlapped with up-regulated transcripts. Functional annotation showed that cell cycle was the most significant function. In the PPI network, BRCA1, CDK1, TK1 and TRAF2 were hub protein of signature genes in cluster 5, and TGFBR1, SMAD2 and SMAD4 were hub proteins of signature gnens in cluster 2.
   Conclusions: Our findings raise the possibility that genes related with cell cycle and dysregulated miRNA at diagnosis might have clinical utility in distinguishing low- from high-risk PCa patients.
C1 [Wen, Jiling; Li, Rongbing; Wen, Xiaofei; Chou, Guangming; Lu, Jiasun; Wang, Xuelei; Jin, Yongchao] Tongji Univ, East Hosp, Sch Med, Dept Urol, Shanghai 200120, Peoples R China.
RP Wen, XF (reprint author), Tongji Univ, East Hosp, Sch Med, Dept Urol, Jimo Rd, Shanghai 200120, Peoples R China.
EM wenxiaofei1972@163.com
CR Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031
   Chan JM, 2004, J UROLOGY, V172, pS17
   Chan June M, 2004, J Urol, V172, pS13, DOI 10.1097/01.ju.0000142068.66876.53
   Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103
   Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3
   Das J, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-92
   Daya S, 2002, EVID BASED OBSTET GY, V4, P3
   Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032
   Hoque MO, 2008, CANCER RES, V68, P2661, DOI 10.1158/0008-5472.CAN-07-5913
   Hoque MO, 2009, EXPERT REV MOL DIAGN, V9, P243, DOI [10.1586/erm.09.10, 10.1586/ERM.09.10]
   Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107
   Kojima S, 2012, BRIT J CANCER, V106, P405, DOI 10.1038/bjc.2011.462
   Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Mandal RK, 2010, UROL ONCOL, V30, P555
   Nogueira L, 2010, BJU INT, V105, P166, DOI 10.1111/j.1464-410X.2009.09088.x
   Park JJ, 2000, CANCER RES, V60, P5946
   Schilling D, 2010, BJU INT, V105, P452, DOI 10.1111/j.1464-410X.2009.09085.x
   Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Sun X, 2013, DIAGN PATHOL, V8, P1746
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Tian Y, 2014, DIAGN PATHOL, V9, P1746
   Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yang IP, 2012, CARCINOGENESIS, V33, P1522, DOI 10.1093/carcin/bgs166
   Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897
NR 30
TC 4
Z9 4
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD SEP 26
PY 2014
VL 9
AR 156
DI 10.1186/s13000-014-0156-1
PG 7
WC Pathology
SC Pathology
GA AS9IM
UT WOS:000344556500001
PM 25257132
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Sadhu, P
   Alla, SK
   Punniyamurthy, T
AF Sadhu, Pradeep
   Alla, Santhosh Kumar
   Punniyamurthy, Tharmalingam
TI RETRACTED: Room-Temperature Cu(II)-Catalyzed Chemo- and Regioselective
   Ortho-Nitration of Arenes via C-H Functionalization (Retracted article.
   See vol. 80, pg. 3358, 2015)
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article; Retracted Publication
ID BOND ACTIVATION; NITRO-COMPOUNDS; IPSO-NITRATION; COPPER; PALLADIUM;
   ALKYNES; MILD; (HETERO)ARENES; SULFOXIMINES; ALKYNYLATION
AB An efficient Cu-catalyzed chemo- and regioselective ortho-nitration of N,1-diaryl-5-aminotetrazoles and N,4-diaryl-3-amino-1,2,4-triazoles has been described with good functional group compatibility. The procedure features the use of an operationally simple protocol utilizing the commercially available less toxic CuCl2 center dot 2H(2)O as catalyst and Fe(NO3)(3)center dot 9H(2)O as nitration source at room temperature. Removal of the 5-aminotetrazole directing group has been demonstrated using base hydrolysis to afford substituted 2-nitroanilines.
C1 [Sadhu, Pradeep; Alla, Santhosh Kumar; Punniyamurthy, Tharmalingam] Indian Inst Technol Guwahati, Dept Chem, Gauhati 781039, India.
RP Punniyamurthy, T (reprint author), Indian Inst Technol Guwahati, Dept Chem, Gauhati 781039, India.
EM tpunni@iitg.ernet.in
FU Department of Science and Technology, New Delhi; Council of Scientific
   and Industrial Research, New Delhi; UGC
FX We gratefully acknowledge the Department of Science and Technology, New
   Delhi, and the Council of Scientific and Industrial Research, New Delhi,
   for financial support. P.S. thanks UGC for SRF Fellowship. We also thank
   Central Instrumental Facility, IIT Guwahati, for NMR facilities. We
   thank Prof. V. Manivannan for discussion of the ESI-MS analysis for the
   reaction mixture.
CR Alberico D, 2007, CHEM REV, V107, P174, DOI 10.1021/cr0509760
   Angelin M, 2006, EUR J ORG CHEM, P4323, DOI 10.1002/ejoc.200600288
   Ansari IA, 2002, ORG LETT, V4, P1507, DOI 10.1021/ol025721c
   Arockiam PB, 2012, CHEM REV, V112, P5879, DOI [10.1021/cr300153J, 10.1021/cr300153j]
   Asako S, 2013, J AM CHEM SOC, V135, P17755, DOI 10.1021/ja4106368
   Becker P, 2014, ANGEW CHEM INT EDIT, V53, P269, DOI 10.1002/anie.201307446
   BLANK B, 1972, J MED CHEM, V15, P694, DOI 10.1021/jm00276a040
   Bolm C, 2000, ORG LETT, V2, P1173, DOI 10.1021/ol005792g
   Bonnamour J, 2009, CHEM-EUR J, V15, P4543, DOI 10.1002/chem.200900169
   Chaudhari PS, 2012, J ORG CHEM, V77, P3716, DOI 10.1021/jo2025509
   Chen X, 2006, J AM CHEM SOC, V128, P6790, DOI 10.1021/ja061715q
   Chen X, 2009, ANGEW CHEM INT EDIT, V48, P5094, DOI 10.1002/anie.200806273
   Colby DA, 2010, CHEM REV, V110, P624, DOI 10.1021/cr900005n
   Dirk SM, 2000, ORG LETT, V2, P3405, DOI 10.1021/ol006539j
   Dong JW, 2014, ORG LETT, V16, P4540, DOI 10.1021/ol502090n
   Engle KM, 2012, ACCOUNTS CHEM RES, V45, P788, DOI 10.1021/ar200185g
   Fauchere J.-L., 2000, European Patent, Patent No. [1044970, EP1044970]
   Firouzabadi H, 2001, GREEN CHEM, V3, P131, DOI 10.1039/b100955i
   FORD RE, 1986, J MED CHEM, V29, P538, DOI 10.1021/jm00154a019
   Fors BP, 2009, J AM CHEM SOC, V131, P12898, DOI 10.1021/ja905768k
   Furniss BS, 2004, VOGELS TXB PRACTICAL, P928
   Gao K, 2010, J AM CHEM SOC, V132, P12249, DOI 10.1021/ja106814p
   GIRIJAVALLABHAN VM, 1988, Patent No. 274867
   Gomez-Gallego M, 2011, CHEM REV, V111, P4857, DOI 10.1021/cr100436k
   Gutekunst WR, 2014, J ORG CHEM, V79, P2430, DOI 10.1021/jo4027148
   Hickman AJ, 2012, NATURE, V484, P177, DOI 10.1038/nature11008
   Jadhav NC, 2013, TETRAHEDRON LETT, V54, P101, DOI 10.1016/j.tetlet.2012.10.114
   Katayev D, 2014, CHEM-EUR J, V20, P9902, DOI 10.1002/chem.201403363
   Kilpatrick B, 2013, CHEM COMMUN, V49, P514, DOI 10.1039/c2cc37481a
   Kim JY, 2012, J AM CHEM SOC, V134, P9110, DOI 10.1021/ja303527m
   Kuninobu Y, 2013, ANGEW CHEM INT EDIT, V52, P4431, DOI 10.1002/anie.201210328
   Lahm G, 2014, ORG LETT, V16, P4201, DOI 10.1021/ol501935d
   Li CJ, 2009, ACCOUNTS CHEM RES, V42, P335, DOI 10.1021/ar800164n
   Tran LD, 2012, J AM CHEM SOC, V134, P18237, DOI 10.1021/ja3092278
   Martinez AM, 2014, CHEM COMMUN, V50, P2801, DOI 10.1039/c3cc49633c
   Marino JP, 2007, J MED CHEM, V50, P3777, DOI 10.1021/jm061182w
   Martins A, 2008, ORG LETT, V10, P4351, DOI 10.1021/ol801763j
   Nishino M, 2012, ANGEW CHEM INT EDIT, V51, P6993, DOI 10.1002/anie.201201491
   Olah G. A., 1989, NITRATION METHODS AN
   OLAH GA, 1962, J AM CHEM SOC, V84, P3684, DOI 10.1021/ja00878a018
   OLAH GA, 1995, ENCYCLOPEDIA OF REAG, V6
   Ono N., 2001, THE NITRO GROUP IN O
   Padhi SK, 2006, INORG CHEM, V45, P7994, DOI 10.1021/ic060968h
   Parthasarathy K, 2014, CHEM-EUR J, V20, P4896, DOI 10.1002/chem.201304925
   PEET NP, 1986, J MED CHEM, V29, P2403, DOI 10.1021/jm00161a045
   Prakash GKS, 2010, ANGEW CHEM INT EDIT, V49, P1726, DOI 10.1002/anie.200906940
   Prakash GKS, 2004, ORG LETT, V6, P2205, DOI 10.1021/ol493249
   Ramana T, 2012, CHEM-EUR J, V18, P13279, DOI 10.1002/chem.201202215
   Rosen BR, 2013, ANGEW CHEM INT EDIT, V52, P7317, DOI 10.1002/anie.201303838
   Rozen S, 2003, J AM CHEM SOC, V125, P8118, DOI 10.1021/ja035616d
   Ruttink PJA, 2011, J MASS SPECTROM, V46, P223, DOI 10.1002/jms.1882
   Sadhu P, 2013, J ORG CHEM, V78, P6104, DOI 10.1021/jo400755q
   Schroder N, 2012, J AM CHEM SOC, V134, P8298, DOI 10.1021/ja302631j
   Shang M, 2014, J AM CHEM SOC, V136, P11590, DOI 10.1021/ja507704b
   Shang M, 2014, J AM CHEM SOC, V136, P3354, DOI 10.1021/ja412880r
   Shiota H, 2011, J AM CHEM SOC, V133, P14952, DOI 10.1021/ja206850s
   Simmons EM, 2012, ANGEW CHEM INT EDIT, V51, P3066, DOI 10.1002/anie.201107334
   Tani K, 1997, J AM CHEM SOC, V119, P1476, DOI 10.1021/ja963658e
   Truong T, 2013, J AM CHEM SOC, V135, P9342, DOI 10.1021/ja4047125
   Thirunavukkarasu VS, 2014, CHEM COMMUN, V50, P29, DOI 10.1039/c3cc47028h
   Tobisu M, 2009, ORG LETT, V11, P3250, DOI 10.1021/ol901049r
   Tsybizova A, 2014, EUR J INORG CHEM, V2014, P1407, DOI 10.1002/ejic.201400036
   Voica AF, 2012, NAT CHEM, V4, P629, DOI [10.1038/nchem.1385, 10.1038/NCHEM.1385]
   Wang L, 2014, ORG LETT, V16, P2661, DOI 10.1021/ol500963p
   Wencel-Delord J, 2013, NAT CHEM, V5, P369, DOI 10.1038/nchem.1607
   Wencel-Delord J, 2011, CHEM SOC REV, V40, P4740, DOI 10.1039/c1cs15083a
   Wendlandt AE, 2011, ANGEW CHEM INT EDIT, V50, P11062, DOI 10.1002/anie.201103945
   Xie F, 2013, ANGEW CHEM INT EDIT, V52, P11862, DOI 10.1002/anie.201305902
   Yan GB, 2013, ORG BIOMOL CHEM, V11, P2554, DOI 10.1039/c3ob27354g
   Yeung CS, 2011, CHEM REV, V111, P1215, DOI 10.1021/cr100280d
   Yokoyama Y, 2014, J ORG CHEM, V79, P7649, DOI 10.1021/jo501542b
   Yu DG, 2014, ANGEW CHEM INT EDIT, V53, P9650, DOI 10.1002/anie.201403782
   Zhang L, 2011, ORG LETT, V13, P6536, DOI 10.1021/ol2028288
   Zhang W, 2013, J ORG CHEM, V78, P5932, DOI 10.1021/jo400594j
   Zhang XG, 2012, J AM CHEM SOC, V134, P11948, DOI 10.1021/ja305259n
   Zhao DB, 2014, CHEM SCI, V5, P2869, DOI 10.1039/c4sc00628c
   Zolfigol MA, 2012, J ORG CHEM, V77, P3640, DOI 10.1021/jo300137w
   ZOLLINGER H, 1987, COLOR CHEMISTRY, V161
NR 78
TC 17
Z9 17
U1 6
U2 80
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD SEP 19
PY 2014
VL 79
IS 18
BP 8541
EP 8549
DI 10.1021/jo501617g
PG 9
WC Chemistry, Organic
SC Chemistry
GA AP5LQ
UT WOS:000342121100005
PM 25152219
DA 2018-12-27
ER

PT J
AU Luo, YS
   Li, ZQ
   Cui, S
   Shen, CF
   Zhao, JH
   Wu, ML
   Li, YY
   Wang, MZ
   Chen, R
   Liu, ZB
   Ge, RL
AF Luo, Yushuang
   Li, Zhanquan
   Cui, Sen
   Shen, Cunfang
   Zhao, Junhui
   Wu, Milu
   Li, Yuying
   Wang, Miaozhou
   Chen, Rong
   Liu, Zhibo
   Ge Ri-li
TI RETRACTED: Joint detection of ERCC1, TUBB3, and TYMS guidance selection
   of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy
   in advanced gastric cancer patients (Retracted article. See vol. 20, 29,
   2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Gastric cancer; ERCC1; TUBB3; TYMS; Chemotherapy
ID CELL LUNG-CANCER; THYMIDYLATE SYNTHASE; PHASE-III; EXPRESSION; THERAPY;
   RESISTANCE; CHEMOSENSITIVITY; FLUOROURACIL; TUBULIN
AB Background: To investigate the guidance selection of docetaxel (D), cisplatin (DDP) (C), and 5-fluorouracil (5-FU) (F) as individual chemotherapy agents via joint detection of ERCC1, TUBB3, and TYMS genes in patients with advanced gastric cancer (AGC).
   Method: Clinical data of 120 patients with AGC who enrolled in our hospital between May 2009 and May 2012 were analyzed. These patients were randomly assigned to experimental and control groups. The mRNA expression of ERCC1, TUBB3, and TYMS was measured by DNA chip technology in the experimental group. Different chemotherapies were administered according to the mRNA expression levels of the three genes, while DCF chemotherapy was directly applied to the control group. Correlation between the three genes' mRNA levels, efficiency rate, the median time to progression (MTP), median survival time (MST) and adverse reactions was evaluated.
   Results: As a result, there was a significant correlation between ERCC1 and TUBB3 mRNA expression (P = 0.005), but no obvious correlation between TUBB3 and TYMS or ERCC1 and TYMS. There was also no significant difference in the efficiency rate of chemotherapy (50% versus 55%; P = 0.357) and the MTP (10 months versus 7 months; P = 0.091) between the two groups. However, there was obvious significance in MST (13.7 months versus 11.6 months; P = 0.004). Additionally, the experimental group provided us with a more effective way for controlling adverse reactions to chemotherapy.
   Conclusion: Combination regimen of D, C, and F in AGC patients according to their ERCC1, TUBB3, and TYMS mRNA expression level may reduce adverse reactions and improve MST.
C1 [Luo, Yushuang; Li, Zhanquan; Cui, Sen; Shen, Cunfang; Zhao, Junhui; Wu, Milu; Li, Yuying; Wang, Miaozhou; Chen, Rong; Liu, Zhibo] Qinghai Univ, Affiliated Hosp, Xining 810001, Peoples R China.
   [Ge Ri-li] Qinghai Univ Med, Res Ctr High Altitude Med, Sch Med, Qinghai 810001, Peoples R China.
RP Li, ZQ (reprint author), Qinghai Univ, Affiliated Hosp, Kunlong Rd 16,Longren Rd 29, Xining 810001, Peoples R China.
EM qdfybg@163.com; geriligao@hotmail.com
FU scientific research project funds of Qinghai department [2010-N-504];
   Major State Basic Research Development Program [2012CB518200];
   Qinghai-Utah Joint Research key Lab for High Altitude Medicine [810001]
FX This study was supported by the scientific research project funds of
   Qinghai department (2010-N-504); Major State Basic Research Development
   Program (No. 2012CB518200) and Qinghai-Utah Joint Research key Lab for
   High Altitude Medicine, 810001.
CR Ajani JA, 2007, J CLIN ONCOL, V25, P3210, DOI 10.1200/JCO.2006.08.3956
   AXEL R, 1995, SCI AM, V273, P154, DOI 10.1038/scientificamerican1095-154
   Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23
   De Angelis PM, 2004, INT J ONCOL, V24, P1279
   Duraes C, 2014, VIRCHOWS ARCH, V464, P367, DOI 10.1007/s00428-013-1533-y
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Gao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052589
   Garrido M, 2014, EXPERT REV ANTICANC, V14, P887, DOI 10.1586/14737140.2014.915194
   Geng M, 2013, INT J CLIN EXP PATHO, V6, P2554
   He WT, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0950-3
   Hu GK, 2001, GENOME RES, V11, P1237, DOI 10.1101/gr.165501
   Hu HB, 2012, ASIAN PAC J CANCER P, V13, P261, DOI 10.7314/APJCP.2012.13.1.261
   Huang Jin, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P582, DOI 10.3969/j.issn.1672-7347.2013.06.006
   Huang Y, 2003, DRUG DISCOV TODAY, V8, P356, DOI 10.1016/S1359-6446(03)02654-0
   Hubner RA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025164
   Jo JC, 2012, BRIT J CANCER, V106, P1591, DOI 10.1038/bjc.2012.143
   Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803
   Keskin S, 2013, CLIN TRANSL ONCOL, V15, P403, DOI 10.1007/s12094-012-0942-8
   Ko JC, 2011, J PHARMACOL EXP THER, V338, P184, DOI 10.1124/jpet.111.179663
   Kwon HC, 2007, ANN ONCOL, V18, P504, DOI 10.1093/annonc/mdl430
   Lim Do H, 2010, BMC CANCER, V10, P583, DOI DOI 10.1186/1471-2407-10-583
   Liu HC, 2001, FERTIL STERIL, V75, P947, DOI 10.1016/S0015-0282(01)01706-X
   Lord RVN, 2002, CLIN CANCER RES, V8, P2286
   Lu M, 2011, CHINESE J CANCER RES, V23, P288, DOI 10.1007/s11670-011-0288-8
   Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570
   Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932
   Reed E, 2005, CLIN CANCER RES, V11, P6100, DOI 10.1158/1078-0432.CCR-05-1083
   Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429
   Wagner A.D., 2010, COCHRANE DB SYST REV, V17
   Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245
   Yoon SO, 2010, AM J SURG PATHOL, V34, P645, DOI 10.1097/PAS.0b013e3181d5d903
   Yuan MQ, 2014, ONCOL LETT, V8, P351, DOI 10.3892/ol.2014.2131
NR 32
TC 3
Z9 3
U1 1
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD SEP 16
PY 2014
VL 19
AR 50
DI 10.1186/s40001-014-0050-z
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AS9LL
UT WOS:000344564100001
PM 25223338
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhao, XY
   Sheng, L
   Wang, L
   Hong, J
   Yu, XH
   Sang, XZ
   Sun, QQ
   Ze, YG
   Hong, FS
AF Zhao, Xiaoyang
   Sheng, Lei
   Wang, Ling
   Hong, Jie
   Yu, Xiaohong
   Sang, Xuezi
   Sun, Qingqing
   Ze, Yuguan
   Hong, Fashui
TI RETRACTED: Mechanisms of nanosized titanium dioxide-induced testicular
   oxidative stress and apoptosis in male mice (Retracted article. See vol.
   12, 23, 2015)
SO PARTICLE AND FIBRE TOXICOLOGY
LA English
DT Article; Retracted Publication
DE Titanium dioxide nanoparticles; Testis; Oxidative stress; Sertoli cell
   apoptosis; Gene expression
ID CARBONIC-ANHYDRASE-III; LONG-TERM EXPOSURE; VITAMIN-C;
   SUPEROXIDE-DISMUTASE; MAMMALIAN-CELLS; LEYDIG-CELLS; IN-VITRO;
   NANOPARTICLES; DAMAGE; TESTIS
AB Background: Due to the increased application of titanium dioxide nanoparticles (TiO2 NPs) in the food industry and daily life, their potential toxic effects in humans and animals have been investigated. However, very few studies have focused on testicular oxidative stress and/or apoptosis.
   Methods: In order to understand the possible molecular mechanisms of testicular lesions following exposure to TiO2 NPs, male mice were exposed to 2.5, 5, or 10 mg/kg body weight TiO2 NPs for 90 consecutive days. Testicular oxidative stress and apoptosis were then evaluated, and the testicular mRNA expression of several genes and their proteins involved in oxidative stress and/or apoptosis was investigated.
   Results: TiO2 NPs entered Sertoli cells and caused severe testicular oxidative damage and/or apoptosis, accompanied by excessive production of reactive oxygen species and peroxidation of lipids, proteins and DNA as well as a significant reduction in antioxidant capacity. Furthermore, exposure to TiO2 NPs resulted in the up-regulation of caspase-3, Nrbp2, and cytochrome c expression, and caused down-regulation of SOD, CAT, GPx, GST, GR, Cyp1b1, Car3, Bcl-2, Acaa2, and Axud1 expression in mouse testis.
   Conclusions: TiO2 NPs entered Sertoli cells via the blood-testis barrier and were deposited in mouse seminiferous cord and/or Sertoli cells, causing oxidative damage and apoptosis.
C1 [Zhao, Xiaoyang; Sheng, Lei; Hong, Jie; Yu, Xiaohong; Sang, Xuezi; Sun, Qingqing; Ze, Yuguan; Hong, Fashui] Soochow Univ, Coll Med, Suzhou 215123, Peoples R China.
   [Wang, Ling] Soochow Univ, Suzhou 215123, Peoples R China.
   [Hong, Fashui] Soochow Univ, Jiangsu Prov Key Lab Stem Cell Res, Suzhou 215007, Peoples R China.
   [Hong, Fashui] Minist Sci & Technol & Jiangsu Prov, Cultivat Base State Key Lab Stem Cell & Biomat, Suzhou 215007, Peoples R China.
RP Hong, FS (reprint author), Soochow Univ, Coll Med, Suzhou 215123, Peoples R China.
EM hongfsh_cn@sina.com1
FU National Natural Science Foundation of China [81473007, 81273036,
   30901218]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions; Ministry of Science and Technology and Jiangsu
   Province
FX This work was supported by the National Natural Science Foundation of
   China (grant No. 81473007, 81273036, 30901218), A Project Funded by the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions, and the Foundation of Cultivation Base of State Key
   Laboratory of Stem Cell and Biomaterials built together by Ministry of
   Science and Technology and Jiangsu Province.
CR Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3
   Angulo C, 2011, BIOL RES, V44, P169, DOI /S0716-97602011000200009
   Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959
   Bai YH, 2010, NAT NANOTECHNOL, V5, P683, DOI [10.1038/NNANO.2010.153, 10.1038/nnano.2010.153]
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cao W, 2008, BBA-GEN SUBJECTS, V1780, P873, DOI 10.1016/j.bbagen.2008.02.007
   Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002
   Crawford N. M., 2000, BIOCH MOL BIOL PLANT, P786
   Cui YL, 2010, J HAZARD MATER, V183, P874, DOI 10.1016/j.jhazmat.2010.07.109
   Di Virgilio AL, 2010, J HAZARD MATER, V177, P711, DOI 10.1016/j.jhazmat.2009.12.089
   Ema M, 2010, REPROD TOXICOL, V30, P343, DOI 10.1016/j.reprotox.2010.06.002
   Fayaz AM, 2009, J AGR FOOD CHEM, V57, P6246, DOI 10.1021/jf900337h
   Gao GD, 2013, J HAZARD MATER, V258, P133, DOI 10.1016/j.jhazmat.2013.04.046
   Gao GD, 2012, J HAZARD MATER, V243, P19, DOI 10.1016/j.jhazmat.2012.08.049
   Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944
   Gimeno O, 2007, J AGR FOOD CHEM, V55, P9944, DOI 10.1021/jf072167i
   Gingras S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000808
   Goutailler G, 2002, J AGR FOOD CHEM, V50, P5115, DOI 10.1021/jf0202943
   GRIVEAU JF, 1995, J REPROD FERTIL, V103, P17
   Gui SX, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-4
   GUI SX, 2013, AGRIIC FOOD CHEM, V61, P8959
   Guo Li-li, 2009, Zhonghua Nan Ke Xue, V15, P517
   GUO LL, 2010, J MED POSTGRA, V23, P357
   Hou Juan, 2009, Academic Journal of Second Military Medical University, V30, P869
   Howard S, 2002, J NEUROCHEM, V83, P914, DOI 10.1046/j.1471-4159.2002.01198.x
   Hsieh YS, 1998, BIOCHEMISTRY-US, V37, P4731, DOI 10.1021/bi972395d
   Hu JH, 2010, J ANIM SCI, V88, P1657, DOI 10.2527/jas.2009-2335
   Hu RP, 2011, J HAZARD MATER, V191, P32, DOI 10.1016/j.jhazmat.2011.04.027
   Iavicoli I, 2011, EUR REV MED PHARMACO, V15, P481
   Iavicoli I., 2012, J NANOMATER, V2012, P1, DOI DOI 10.1155/2012/964381
   Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8
   ISCHI T, 2005, FREE RADICAL RES, V39, P695
   Jovanovic-Galovic A, 2004, ARCH INSECT BIOCHEM, V55, P79, DOI 10.1002/arch.10126
   Kim G, 2004, MOL CELL BIOL, V24, P9942, DOI 10.1128/MCB.24.22.9942-9947.2004
   Kodama H, 1997, FERTIL STERIL, V68, P519, DOI 10.1016/S0015-0282(97)00236-7
   Komatsu T, 2008, TOXICOL IN VITRO, V22, P1825, DOI 10.1016/j.tiv.2008.08.009
   Kutlubay R, 2007, INT J TOXICOL, V26, P297, DOI 10.1080/10915810701470952
   LA Z, 2012, NANOMED, V7, P579
   Larsson J, 2008, MOL CELL NEUROSCI, V39, P32, DOI 10.1016/j.mcn.2008.05.013
   Li B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055563
   Li N, 2010, TOXICOL LETT, V195, P161, DOI 10.1016/j.toxlet.2010.03.1116
   Liang HY, 2007, BIOCHEM BIOPH RES CO, V356, P893, DOI 10.1016/j.bbrc.2007.03.045
   Lopez-Moreno ML, 2010, J AGR FOOD CHEM, V58, P3689, DOI 10.1021/jf904472e
   Maiorino M, 2003, BIOL REPROD, V68, P1134, DOI 10.1095/biolreprod.102.007500
   Morishita Y, 2012, BIOCHEM BIOPH RES CO, V420, P297, DOI 10.1016/j.bbrc.2012.02.153
   Murugesan P, 2005, FREE RADICAL RES, V39, P1259, DOI 10.1080/10715760500308154
   NARRA VR, 1993, J NUCL MED, V34, P637
   Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339
   Oberdorster G, 2007, NANOTOXICOLOGY, V1, P2, DOI 10.1080/17435390701314761
   PONS E, 2003, 3 INT C EP, P74
   Powell JJ, 2010, J AUTOIMMUN, V34, pJ226, DOI 10.1016/j.jaut.2009.11.006
   Pryor WA, 2006, AM J PHYSIOL-REG I, V291, pR491, DOI 10.1152/ajpregu.00614.2005
   Raisanen SR, 1999, FASEB J, V13, P513
   Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963
   Sang XZ, 2013, J AGR FOOD CHEM, V61, P5590, DOI 10.1021/jf3035989
   Schefe JH, 2006, J MOL MED, V84, P901, DOI 10.1007/s00109-006-0097-6
   Shi HB, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-15
   Sikka SC, 2001, CURR MED CHEM, V8, P851, DOI 10.2174/0929867013373039
   Sivori JL, 1997, MEM I OSWALDO CRUZ, V92, P797, DOI 10.1590/S0074-02761997000600013
   Smirnoff N, 2005, BIOL SCI SER, P1, DOI 10.1002/9780470988565
   Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x
   Sun QQ, 2012, J BIOMED MATER RES A, V100A, P2554, DOI 10.1002/jbm.a.34190
   Suzuki H, 2007, ENVIRON SCI TECHNOL, V41, P3018, DOI 10.1021/es0625632
   Takeda K, 2009, J HEALTH SCI, V55, P95, DOI 10.1248/jhs.55.95
   Tang YX, 2009, BLOOD, V113, P744, DOI 10.1182/blood-2008-03-145219
   Tarabishy AB, 2008, J IMMUNOL, V181, P593, DOI 10.4049/jimmunol.181.1.593
   Walters J, 2009, BIOCHEM J, V424, P335, DOI 10.1042/BJ20090825
   Wang HH, 2009, ENVIRON POLLUT, V157, P1171, DOI 10.1016/j.envpol.2008.11.004
   Wang JJ, 2007, MUTAT RES-GEN TOX EN, V628, P99, DOI 10.1016/j.mrgentox.2006.12.003
   Weir A, 2012, ENVIRON SCI TECHNOL, V46, P2242, DOI 10.1021/es204168d
   Xiong DW, 2011, SCI TOTAL ENVIRON, V409, P1444, DOI 10.1016/j.scitotenv.2011.01.015
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   Yang P, 2002, MATER LETT, V57, P794, DOI 10.1016/S0167-577X(02)00875-3
   Yoshida S, 2009, INT J ANDROL, V32, P337, DOI [10.1111/j.1365-2605.2008.00865.x, 10.1111/j.1365-2605.2007.00865.x]
   ZHANG WF, 2000, PHYS D APPL PHYS, V33, P912
   Zini A, 1997, J UROLOGY, V158, P659, DOI 10.1016/S0022-5347(01)64578-6
NR 76
TC 18
Z9 19
U1 2
U2 23
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-8977
J9 PART FIBRE TOXICOL
JI Part. Fibre Toxicol.
PD SEP 12
PY 2014
VL 11
AR UNSP 47
DI 10.1186/s12989-014-0047-3
PG 14
WC Toxicology
SC Toxicology
GA AU8TL
UT WOS:000345869200001
PM 25209749
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, J
   Zheng, ML
AF Li, Jin
   Zheng, Meilin
TI RETRACTED: Landesman-Lazer type condition for second-order differential
   equations at resonance with impulsive effects (Retracted article. See
   Artn 204, 2015)
SO ADVANCES IN DIFFERENCE EQUATIONS
LA English
DT Article; Retracted Publication
DE impulsive differential equations; Landesman-Lazer type condition;
   variational method
ID VARIATIONAL APPROACH
AB In this paper, we study the existence of periodic solutions of second-order impulsive differential equations at resonance. We prove the existence of periodic solutions under a generalized Landesman-Lazer type condition by using the variational method. The impulses can generate a periodic solution.
C1 [Li, Jin] Jiujiang Univ, Sch Sci, Jiujiang 332005, Peoples R China.
   [Zheng, Meilin] Jiujiang Univ, Dept Sci Res Management, Jiujiang 332005, Peoples R China.
RP Li, J (reprint author), Jiujiang Univ, Sch Sci, Jiujiang 332005, Peoples R China.
EM lijin7912@gmail.com
CR Bogun I, 2012, NONLINEAR ANAL-REAL, V13, P2701, DOI 10.1016/j.nonrwa.2012.03.014
   Ding W, 2010, NONLINEAR ANAL-REAL, V11, P2603, DOI 10.1016/j.nonrwa.2009.09.007
   FUCIK S., 1980, SOLVABILITY NONLINEA
   Lakshmikantham V, 1989, THEORY IMPULSIVE DIF
   Landesman EM, 1970, J MATH MECH, V19, P60
   Lazer A. C., 1969, ANN MAT PUR APPL, V82, P49
   LAZER AC, 1968, J MATH ANAL APPL, V21, P421, DOI 10.1016/0022-247X(68)90225-4
   Mawhin J., 1989, CRITICAL POINT THEOR
   Nieto JJ, 2009, NONLINEAR ANAL-REAL, V10, P680, DOI 10.1016/j.nonrwa.2007.10.022
   Rabinowitz P. H., 1986, CBMS REG C SER MATH, V65
   Tomiczek P, 2009, NONLINEAR ANAL-THEOR, V70, P735, DOI 10.1016/j.na.2008.01.006
   Zhang H, 2010, NONLINEAR ANAL-REAL, V11, P67, DOI 10.1016/j.nonrwa.2008.10.016
   Zhang XS, 2011, NONLINEAR ANAL-THEOR, V74, P1960, DOI 10.1016/j.na.2010.11.003
   Zhang ZH, 2010, NONLINEAR ANAL-REAL, V11, P155, DOI 10.1016/j.nonrwa.2008.10.044
NR 14
TC 2
Z9 2
U1 3
U2 12
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1687-1847
J9 ADV DIFFER EQU-NY
JI Adv. Differ. Equ.
PD SEP 9
PY 2014
AR 235
DI 10.1186/1687-1847-2014-235
PG 13
WC Mathematics, Applied; Mathematics
SC Mathematics
GA AP6AB
UT WOS:000342158700003
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Cha, E
   Fu, ZY
   Ma, YT
   Zhu, Q
   Xie, X
   Liu, F
AF Cha, Erdenbat
   Fu, Zhen-Yan
   Ma, Yi-Tong
   Zhu, Qing
   Xie, Xiang
   Liu, Fen
TI RETRACTED: A novel polymorphism of the GP78 gene is associated with
   coronary artery disease in Han population in China (Retracted article.
   See vol. 14, 78, 2015)
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article; Retracted Publication
DE gp78; Single nucleotide polymorphism; Coronary artery disease;
   Case-control study; Haplotype
ID HMG-COA REDUCTASE; STEROL-REGULATED UBIQUITINATION; AUTOCRINE MOTILITY
   FACTOR; HEART-DISEASE; CHOLESTEROL-SYNTHESIS; RISK-FACTORS; HUMAN
   GENOME; DEGRADATION; PROTEIN; INSIG-1
AB Background: GP78 is a membrane-anchored ubiquitin ligase mediating the degradation of 3-hydroxy-3-methyl-glutaryl-CoA coenzyme A reductase (HMGCR) and Insig-1, which was very essential for the synthesis of cholesterol process. Cholesterol levels have a causal role in the development of cardiovascular disease. The aim of the present study was to assess the association between the human gp78 gene polymorphism and coronary artery disease (CAD) in a Han and Uygur population of China.
   Methods: We used two independent case-control studies: a Han population (602 CAD patients and 572control subjects) and a Uygur population (374 CAD patients and 376control subjects). All CAD patients and controls were genotyped for the same three single nucleotide polymorphisms (SNPs) (rs731119, rs2617849and rs2440472) of gp78 gene by a Real-time PCR instrument.
   Results: In the Han population, for total and men, the distribution of SNP3 (rs2440472) alleles and the dominant model (AA vs AG + GG) and recessive model (GG vs AG + AA) showed a significant difference between CAD and control participants (for allele: P = 0.003 and P = 0.002, respectively; for dominant model: P = 0.041 and P = 0.026, respectively; for recessive model: p = 0.004 and p = 0.004, respectively). The significant difference in both the two models was retained after adjustment for covariates (for dominant model OR:0.760, 95% confidence interval [CI]:0.584-0.99, P = 0.042; OR:0.686, 95% CI: 0.498-0.946, P = 0.022, respectively; for recessive model OR: 1.451, 95% CI: 1.067-1.974, P = 0.018; OR: 1.789, 95% CI: 1.219-2.627, P = 0.000). Our data was also assessed via haplotype-based case-control studies. For the Han population, for total, The G-T-G haplotype in CAD was significantly higher than that in the control group (P = 0.02), and the G-C-A haplotype in CAD was significantly lower than that in the control group (P = 0.0443), And for man, the G-T-G haplotype in CAD was significantly higher than that in the control group (P = 0.0048).
   Conclusions: The GG genotype and G allele of rs2440472 in gp78 gene could be a risk genetic marker of CAD in Han population in China.
C1 [Cha, Erdenbat; Fu, Zhen-Yan; Ma, Yi-Tong; Zhu, Qing; Xie, Xiang] Xinjiang Med Univ, Affiliated Hosp 1, Dept Cardiol, Urumqi 830054, Xinjiang, Peoples R China.
   [Liu, Fen] Xinjiang Key Lab Cardiovasc Dis Res, Urumqi 830054, Xinjiang, Peoples R China.
RP Ma, YT (reprint author), Xinjiang Med Univ, Affiliated Hosp 1, Dept Cardiol, Urumqi 830054, Xinjiang, Peoples R China.
EM myt-xj@163.com
FU National Natural Science Foundation of China [81260041]; Xinjiang
   project of science and technology [2013911111]
FX This work was supported by the grants from National Natural Science
   Foundation of China (No. 81260041) and Xinjiang project of science and
   technology (No. 2013911111).
CR Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   [Anonymous], 1997, Diabetes Care, V20 Suppl 1, pS1
   Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5
   Clarke R, 2007, ARCH INTERN MED, V167, P1373, DOI 10.1001/archinte.167.13.1373
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   DeBose-Boyd RA, 2008, CELL RES, V18, P609, DOI 10.1038/cr.2008.61
   Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5
   Ge L, 2008, CELL METAB, V7, P508, DOI 10.1016/j.cmet.2008.04.001
   GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9
   Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Gong Y, 2006, CELL METAB, V3, P15, DOI 10.1016/j.cmet.2005.11.014
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2
   Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423
   Lee JN, 2006, J BIOL CHEM, V281, P39308, DOI 10.1074/jbc.M608999200
   Liu TF, 2012, CELL METAB, V16, P213, DOI 10.1016/j.cmet.2012.06.014
   Mackay J, 2004, ATLAS HEART DIS STRO
   MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503
   Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301
   Miao HH, 2010, ACTA BIOCH BIOPH SIN, V42, P303, DOI 10.1093/abbs/gmq022
   Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200
   Shimizu K, 1999, FEBS LETT, V456, P295, DOI 10.1016/S0014-5793(99)00966-7
   Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001
   Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009
   Sun LP, 2005, J BIOL CHEM, V280, P26483, DOI 10.1074/jbc.M504041200
   WATANABE H, 1991, J BIOL CHEM, V266, P13442
   Zee RYL, 2006, STROKE, V37, P2007, DOI 10.1161/01.STR.0000229905.25080.01
NR 29
TC 3
Z9 3
U1 3
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD SEP 9
PY 2014
VL 13
AR 147
DI 10.1186/1476-511X-13-147
PG 11
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA AP2HP
UT WOS:000341893600001
PM 25200441
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kui, EL
   Kanazawa, A
   Poisson, JF
   Py, S
AF Kui, Evelyn Lieou
   Kanazawa, Alice
   Poisson, Jean-Francois
   Py, Sandrine
TI RETRACTED: Transition-Metal-Catalyzed Ring Expansion of
   Diazocarbonylated Cyclic N-Hydroxylamines: A New Approach to Cyclic
   Ketonitrones (Retracted article. See vol. 17 pg. 6282, 2015)
SO ORGANIC LETTERS
LA English
DT Article; Retracted Publication
ID DIAZO-COMPOUNDS; C-H; DIASTEREOSELECTIVE ADDITION; CYCLOADDITION
   REACTIONS; EFFICIENT SYNTHESIS; NITRONES; CARBENOIDS; INSERTION;
   HETEROCYCLES; PYRROLIZIDINES
AB Novel C-ethoxycarbonyl cyclic ketonitrones are synthesized from the Ag- or Cu-catalyzed ring expansion of beta-diazo cyclic hydroxylamines. The latter are themselves easily obtained by the addition of lithiated ethyl diazoacetate onto cyclic nitrones. The regioselective metal-catalyzed rearrangement of beta-diazo cyclic hydroxylamines proved highly efficient and resulted in a synthetically useful ring expansion to produce 6- or 7-membered ring functionalized nitrones. The outcome of the two steps, i.e. nucleophilic addition of alpha-diazoesters to nitrones and ring expansion, is a formal nitrone homologation.
C1 [Kanazawa, Alice] Univ Grenoble Alpes, DCM, F-38000 Grenoble, France.
   CNRS, DCM, F-38000 Grenoble, France.
RP Kanazawa, A (reprint author), Univ Grenoble Alpes, DCM, F-38000 Grenoble, France.
EM alice.kanazawa@ujf-grenoble.fr; sandrine.py@ujf-grenoble.fr
RI Py, Sandrine/A-6270-2018; Poisson, Jean-Francois/I-2177-2014
OI Poisson, Jean-Francois/0000-0002-4982-7098
FU ICMG [FR 2607]
FX E.L.K. is grateful to the Universite de Grenoble for a doctoral
   allocation. M. Carbo Lopez (DCM) is thanked for a gift of nitrone 4. We
   acknowledge support from ICMG FR 2607, Grenoble, through which NMR and
   MS analyses have been performed.
CR Bachmann S, 2004, ORG BIOMOL CHEM, V2, P3044, DOI 10.1039/b412053a
   Barluenga J, 2009, ANGEW CHEM INT EDIT, V48, P7569, DOI 10.1002/anie.200903902
   Brandi A, 2009, CHEM-EUR J, V15, P7808, DOI 10.1002/chem.200900707
   Capriati V, 2006, ORG LETT, V8, P3923, DOI 10.1021/ol061256y
   Chan TH, 2010, EUR J ORG CHEM, P5555, DOI 10.1002/ejoc.201001045
   Chang YF, 2011, MOL DIVERS, V15, P203, DOI 10.1007/s11030-010-9255-4
   Chen SF, 2006, SYNTHESIS-STUTTGART, P1705, DOI 10.1055/s-2006-926449
   Cicchi S, 2006, J ORG CHEM, V71, P1614, DOI 10.1021/jo0523518
   Cicchi S, 2002, J ORG CHEM, V67, P1678, DOI 10.1021/jo0157573
   Closa M, 1998, SYNTHETIC COMMUN, V28, P3443, DOI 10.1080/00397919808004452
   da Silva FD, 2012, CURR ORG CHEM, V16, P224
   Davies HML, 2003, CHEM REV, V103, P2861, DOI 10.1021/cr0200217
   Davies HML, 2008, NATURE, V451, P417, DOI 10.1038/nature06485
   Davies HML, 2007, CHEM SOC REV, V36, P1109, DOI 10.1039/b607983k
   Davies HML, 2005, MODERN RHODIUM-CATALYZED ORGANIC REACTIONS, P301, DOI 10.1002/3527604693.ch14
   Delso I, 2013, EUR J ORG CHEM, V2013, P5721, DOI 10.1002/ejoc.201300836
   Delso I, 2011, J ORG CHEM, V76, P4139, DOI 10.1021/jo200315k
   Demory E, 2012, J ORG CHEM, V77, P7901, DOI 10.1021/jo301114k
   Doyle M. P., 1998, MODERN CATALYTIC MET
   Hanquet G., 2009, ASTMMETRIC SYNTHESIS
   Hansen SR, 2012, ORG LETT, V14, P4626, DOI 10.1021/ol3020754
   Kui EL, 2013, TETRAHEDRON LETT, V54, P5103, DOI 10.1016/j.tetlet.2013.07.044
   Lebel H, 2003, CHEM REV, V103, P977, DOI 10.1021/cr010007e
   LIU JM, 1986, J ORG CHEM, V51, P1120, DOI 10.1021/jo00357a034
   Liu RH, 2013, CHEM COMMUN, V49, P4376, DOI 10.1039/c2cc34609e
   Lombardo M, 2002, CURR ORG CHEM, V6, P695, DOI 10.2174/1385272023373987
   Luisi R, 2003, J ORG CHEM, V68, P10187, DOI 10.1021/jo035360u
   Merino P, 2005, CR CHIM, V8, P775, DOI 10.1016/j.crci.2005.02.013
   MURAHASHI SI, 1990, J ORG CHEM, V55, P1736, DOI 10.1021/jo00293a013
   Nakamura I, 2014, CHEM-EUR J, V20, P10214, DOI 10.1002/chem.201403637
   Nakamura I, 2012, ANGEW CHEM INT EDIT, V51, P10816, DOI 10.1002/anie.201205285
   Padwa A, 1996, CHEM REV, V96, P223, DOI 10.1021/cr950022h
   Padwa A, 2009, CHEM SOC REV, V38, P3072, DOI 10.1039/b816701j
   Pillard C, 2007, TETRAHEDRON LETT, V48, P6209, DOI 10.1016/j.tetlet.2007.06.083
   Racine E, 2009, J ORG CHEM, V74, P1766, DOI 10.1021/jo802255t
   Revuelta J., 2007, SYNTHESIS-STUTTGART, P485
   Tamura O, 2002, SYNLETT, P1344, DOI 10.1055/s-2002-32988
   Thiverny M, 2010, ORG BIOMOL CHEM, V8, P864, DOI 10.1039/b918612c
   Thiverny M, 2011, TETRAHEDRON-ASYMMETR, V22, P1266, DOI 10.1016/j.tetasy.2011.07.002
   Thiverny M, 2011, TETRAHEDRON-ASYMMETR, V22, P1274, DOI 10.1016/j.tetasy.2011.07.022
   Tsou EL, 2009, TETRAHEDRON, V65, P93, DOI 10.1016/j.tet.2008.10.096
   vandenBroek LAGM, 1996, TETRAHEDRON, V52, P4467, DOI 10.1016/0040-4020(96)00094-4
   Vitale M, 2006, J AM CHEM SOC, V128, P2524, DOI 10.1021/ja057739z
   Wang WB, 2010, SYNLETT, P488, DOI 10.1055/s-0029-1219189
   Wee AGH, 2006, CURR ORG SYNTH, V3, P499
   Xu HD, 2008, ANGEW CHEM INT EDIT, V47, P8933, DOI 10.1002/anie.200803910
   Xu WY, 2013, ORG BIOMOL CHEM, V11, P4622, DOI 10.1039/c3ob40696b
   Xu XC, 2013, J AM CHEM SOC, V135, P1244, DOI 10.1021/ja311392m
   Zhang ZH, 2008, TETRAHEDRON, V64, P6577, DOI 10.1016/j.tet.2008.04.074
   Zhao H, 2013, CHINESE CHEM LETT, V24, P1059, DOI 10.1016/j.cclet.2013.06.027
   Zhao WB, 2013, J ORG CHEM, V78, P3208, DOI 10.1021/jo400130p
   Zhao X, 2012, CHEM COMMUN, V48, P10162, DOI 10.1039/c2cc34406h
   Zhu SF, 2012, ACCOUNTS CHEM RES, V45, P1365, DOI 10.1021/ar300051u
NR 53
TC 7
Z9 7
U1 8
U2 55
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1523-7060
EI 1523-7052
J9 ORG LETT
JI Org. Lett.
PD SEP 5
PY 2014
VL 16
IS 17
BP 4484
EP 4487
DI 10.1021/ol502029z
PG 4
WC Chemistry, Organic
SC Chemistry
GA AO4XL
UT WOS:000341344600035
DA 2018-12-27
ER

PT J
AU Li, W
   Shi, Q
   Wang, WB
   Liu, JR
   Li, Q
   Hou, FG
AF Li, Wen
   Shi, Qi
   Wang, Weibing
   Liu, Jianrong
   Li, Qi
   Hou, Fenggang
TI RETRACTED: Calcium Channel Blockers and Risk of Breast Cancer: A
   Meta-Analysis of 17 Observational Studies (Retracted article. See vol.
   13, pg. 2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ANTIHYPERTENSIVE MEDICATIONS; PUBLICATION BIAS; IN-VITRO; WOMEN;
   MORTALITY; COHORT; ANTAGONISTS; STATISTICS; CARCINOMA; APOPTOSIS
AB Purpose: Studies on the association between the use of calcium channel blockers (CCBs) and breast cancer risk have reported inconsistent results. We quantitatively assessed this association by conducting a meta-analysis based on the evidence from observational studies.
   Methods: We searched PubMed, MEDLINE, EMBASE and the Cochrane Library for relevant studies published up to and including December 31, 2013. We calculated pooled risk ratios (RRs) for cancer risk.
   Results: A total of 17 studies (9 cohort studies, 8 case-control studies) were selected for further study. These studies included 149,607 female subjects, of which 53,812 were CCBs users, who were followed for 2-16 years. The risks of breast cancer among patients receiving CCBs were significantly different for the pooled RRs (95% confidence interval) of cohort studies 1.08 (0.95, 1.20) and case-control studies 0.98 (0.86, 1.09). Differences were also noted for cancer risk, for CCBs use of <5 years 0.96 (0.78, 1.15), and for >5 years 1.01 (0.74, 1.28), as well as for ever used 1.08 (0.95, 1.20), and for current use 1.13 (0.83, 1.42). The RR for studies longer than 10 years was 1.71 (1.01, 2.42), and for studies evaluating nifedipine was 1.10 (0.87, 1.33) and diltiazem was 0.75 (0.40, 1.10).
   Conclusions: The long-term use of CCBs appears to have a significant relationship with breast cancer. Well-designed clinical trials are needed to optimize the doses and types of these drugs needed to minimize their carcinogenic potential.
C1 [Li, Wen; Shi, Qi; Liu, Jianrong; Hou, Fenggang] Shanghai TCM Univ, Shanghai Municipal Hosp Tradit Chinese Med, Dept Oncol, Shanghai, Peoples R China.
   [Wang, Weibing] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200433, Peoples R China.
   [Li, Qi] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Oncol, Shanghai, Peoples R China.
RP Hou, FG (reprint author), Shanghai TCM Univ, Shanghai Municipal Hosp Tradit Chinese Med, Dept Oncol, Shanghai, Peoples R China.
EM fghou555@126.com
FU Shanghai Municipal Education Commission [12YZ057, 10CG25]; Fundamental
   Research Funds for the Central Universities [78210021]
FX This work is supported by Innovation Project of Shanghai Municipal
   Education Commission (12YZ057), the Fundamental Research Funds for the
   Central Universities (78210021) and the Chenguang Program from Shanghai
   Municipal Education Commission (10CG25). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Altamirano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081222
   Assimes TL, 2008, PHARMACOEPIDEM DR S, V17, P1039, DOI 10.1002/pds.1656
   Beiderbeck-Noll AB, 2003, EUR J CANCER, V39, P98, DOI 10.1016/S0959-8049(02)00157-0
   Braun S, 1998, J AM COLL CARDIOL, V31, P804, DOI 10.1016/S0735-1097(98)00008-4
   CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E
   Chobanian AV, 1996, JAMA-J AM MED ASSOC, V276, P829, DOI 10.1001/jama.276.10.829
   Curry MC, 2013, BIOCH BIOPHYSICAL RE
   Das Arindam, 2013, Pigment Cell Melanoma Res, V26, P874, DOI 10.1111/pcmr.12155
   Davis S, 2007, EUR J EPIDEMIOL, V22, P319, DOI 10.1007/s10654-007-9135-0
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6
   Fryzek JP, 2006, BREAST CANCER RES TR, V97, P231, DOI 10.1007/s10549-005-9091-x
   Gonzalez-Perez A, 2004, PHARMACOEPIDEM DR S, V13, P581, DOI 10.1002/pds.910
   Handayani S, 2013, INDONESIAN J PHARM, V23
   Hole DJ, 1998, J HYPERTENS, V16, P119, DOI 10.1097/00004872-199816010-00017
   Holmes S, 2013, CANCER EPIDEMIOL, V37, P881, DOI 10.1016/j.canep.2013.09.001
   Hunter DJ, 2013, NEW ENGL J MED, V369, P1336, DOI 10.1056/NEJMra1109345
   Jang SJ, 2013, BIOORG MED CHEM LETT, V23, P6656, DOI 10.1016/j.bmcl.2013.10.049
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0
   Knobloch K, 2011, J CRANIO MAXILL SURG, V39, P91, DOI 10.1016/j.jcms.2010.11.001
   KONRADDALHOFF I, 1991, EUR J CLIN PHARMACOL, V41, P313, DOI 10.1007/BF00314958
   Li CI, 2013, JAMA INTERN MED, V173, P1629, DOI 10.1001/jamainternmed.2013.9071
   Li CI, 2003, CANCER, V98, P1504, DOI 10.1002/cncr.11663
   Lindberg G, 2002, PHARMACOEPIDEM DR S, V11, P493, DOI 10.1002/pds.737
   Meier CR, 2000, ARCH INTERN MED, V160, P349, DOI 10.1001/archinte.160.3.349
   Michels KB, 1998, CANCER, V83, P2003, DOI 10.1002/(SICI)1097-0142(19981101)83:9<2003::AID-CNCR17>3.0.CO;2-3
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Moon D, 2013, J SURG RES, V180, P208, DOI 10.1016/j.jss.2012.04.027
   Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091
   Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8
   Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7
   PAHOR M, 1994, J AM GERIATR SOC, V42, P50, DOI 10.1111/j.1532-5415.1994.tb06073.x
   Peters JL, 2007, STAT MED, V26, P4544, DOI 10.1002/sim.2889
   PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620
   QUINN M, 1995, BRIT MED J, V311, P1391, DOI 10.1136/bmj.311.7017.1391
   Rosenberg L, 1998, JAMA-J AM MED ASSOC, V279, P1000, DOI 10.1001/jama.279.13.1000
   Saltzman BS, 2013, CANCER CAUSE CONTROL, V24, P365, DOI 10.1007/s10552-012-0122-8
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sorensen HT, 2000, CANCER-AM CANCER SOC, V89, P165, DOI 10.1002/1097-0142(20000701)89:1<165::AID-CNCR21>3.0.CO;2-G
   STEIN G, 1990, ARCH TOXICOL, V64, P623, DOI 10.1007/BF01974690
   WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776
NR 43
TC 9
Z9 9
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 3
PY 2014
VL 9
IS 9
AR e105801
DI 10.1371/journal.pone.0105801
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3TB
UT WOS:000341257700025
PM 25184210
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Walker, S
   Danton, MHD
   Lang, AD
   Lyall, F
AF Walker, Susan
   Danton, Mark H. D.
   Lang, Alexander D.
   Lyall, Fiona
TI RETRACTED: Apelin Receptor (APJ) Expression during Cardiopulmonary
   Bypass in Children Undergoing Surgical Repair (Retracted article. See
   vol. 13, art. e0202136, 2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID HEART-FAILURE; MYOCARDIAL-INFARCTION; CYANOTIC TETRALOGY;
   BLOOD-PRESSURE; FALLOT; SYSTEM; TARGET; GENE
AB Background and Aims: In human adults, and animals, the Apelin-APJ ligand-receptor system is emerging as having a role in the pathogenesis of cardiovascular function and heart failure. The aim was to investigate expression, and regulation by oxygen, of the Apelin APJ receptor (APJ) in myocardium obtained from children undergoing corrective surgery with cardiopulmonary bypass for repair of congenital heart defects.
   Methods: Western blotting and Real-time PCR were used to determine if APJ was expressed in the infant myocardium, if expression was influenced by the duration of myocardial ischemia and if any relationship existed between APJ expression and early post-operative outcome. The next aim was to determine if there was a difference in mRNA expression of APJ in myocardium from cyanotic patients compared with acyanotic patients and if re-perfusing myocardium in vitro with either hypoxic, normoxic or hyperoxic oxygen affected APJ mRNA expression.
   Results: APJ was expressed in all myocardial samples and myocardium exposed to longer durations of ischemia and cardioplegia expressed higher levels of APJ (p<0.05). There was a significant correlation between APJ expression in myocardium resected after 10 min with both oxygen extraction ratio (p = 0.021, rho = -0.523) and mixed venous oxygen saturation (p = 0.028, rho 0.52). This association did not exist for myocardium collected before 10 min. There was no difference in APJ expression between cyanotic and acyanotic patients. No difference was found in APJ expression whether re-perfused with low, normal or high oxygen.
   Conclusions: Changes in APJ expression were observed during cardiopulmonary bypass in children and the reasons for this require further investigation.
C1 [Walker, Susan; Lang, Alexander D.; Lyall, Fiona] Univ Glasgow, Sch Med, Royal Hosp Sick Children, Inst Med Genet, Glasgow, Lanark, Scotland.
   [Danton, Mark H. D.] Royal Hosp Sick Children, Dept Paediat Cardiac Surg, Glasgow G3 8SJ, Lanark, Scotland.
RP Lyall, F (reprint author), Univ Glasgow, Sch Med, Royal Hosp Sick Children, Inst Med Genet, Glasgow, Lanark, Scotland.
EM fiona.lyall@glasgow.ac.uk
FU Yorkhill Children's Foundation
FX The work was supported by Yorkhill Children's Foundation. The funder had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abdulsid A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054540
   Atluri P, 2007, CELL MOL BIOL LETT, V12, P127, DOI 10.2478/s11658-006-0058-7
   Berry MF, 2004, CIRCULATION, V110, pII187, DOI 10.1161/01.CIR.0000138382.57325.5c
   Castan-Iaurell I, 2012, TRENDS ENDOCRIN MET, V23, P234, DOI 10.1016/j.tem.2012.02.005
   Chandrasekaran B, 2010, J CARD FAIL, V16, P556, DOI 10.1016/j.cardfail.2010.02.004
   Charo DN, 2009, AM J PHYSIOL-HEART C, V297, pH1904, DOI 10.1152/ajpheart.00686.2009
   CULLEN S, 1995, CIRCULATION, V91, P1782, DOI 10.1161/01.CIR.91.6.1782
   Falcao-Pires I, 2010, EXPERT OPIN THER TAR, V14, P633, DOI 10.1517/14728221003752743
   Farkasfalvi K, 2007, BIOCHEM BIOPH RES CO, V357, P889, DOI 10.1016/j.bbrc.2007.04.017
   Guihaire Julien, 2012, J Clin Exp Cardiolog, V8, P1
   Iturrioz X, 2010, FASEB J, V24, P1506, DOI 10.1096/fj.09-140715
   Japp AG, 2010, CIRCULATION, V121, P1818, DOI 10.1161/CIRCULATIONAHA.109.911339
   Japp AG, 2008, BIOCHEM PHARMACOL, V75, P1882, DOI 10.1016/j.bcp.2007.12.015
   Kleinz MJ, 2008, REGUL PEPTIDES, V146, P271, DOI 10.1016/j.regpep.2007.10.002
   Kleinz MJ, 2005, REGUL PEPTIDES, V126, P233, DOI 10.1016/j.regpep.2004.10.019
   Kuklinska AM, 2010, HEART VESSELS, V25, P363, DOI 10.1007/s00380-009-1217-3
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McCaig D, 2009, HYPERTENS PREGNANCY, V28, P457, DOI 10.3109/10641950802629691
   Melgar-Lesmes P, 2011, GUT, V60, P1404, DOI 10.1136/gut.2010.234690
   Messari SE, 2004, J NEUROCHEM, V90, P1290, DOI 10.1111/j.1471-4159.2004.02591.x
   ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O
   Pchejetski D, 2012, EUR HEART J, V33, P2360, DOI 10.1093/eurheartj/ehr389
   Peng EWK, 2011, J THORAC CARDIOV SUR, V141, P1184, DOI 10.1016/j.jtcvs.2011.01.047
   Ronkainen VP, 2007, FASEB J, V21, P1821, DOI 10.1096/fj.06-7294com
   Siddiquee K, 1998, BRIT J PHARMACOL, V168, P1104
   Starr JP, 2010, WORLD J SURG, V34, P658, DOI 10.1007/s00268-009-0296-8
   Tao JP, 2011, AM J PHYSIOL-HEART C, V301, pH1471, DOI 10.1152/ajpheart.00097.2011
   Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1
   Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489
   Tycinska AM, 2012, CLIN CHIM ACTA, V413, P406, DOI 10.1016/j.cca.2011.11.021
   Walker S, 2013, THESIS U GLASGOW
   Walker S, 2013, CELL STRESS CHAPERON, V18, P269, DOI 10.1007/s12192-012-0379-6
NR 32
TC 3
Z9 3
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 3
PY 2014
VL 9
IS 9
AR e106262
DI 10.1371/journal.pone.0106262
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3TB
UT WOS:000341257700048
PM 25184296
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Sun, CY
   Wang, Y
AF Sun Chuanyu
   Wang Yu
TI RETRACTED: Preparation of polyaniline nanostructures doped with
   different dicarboxylic acids through template-free method (Retracted
   article. See vol. 34, pg. 226, 2016)
SO MATERIALS SCIENCE-POLAND
LA English
DT Article; Retracted Publication
DE polyaniline; nanostructures; dicarboxylic acid; trans-cis isomerization
ID SEPARATIONS; GAS
AB In this article nanoscaled polyanilines (PANI) were prepared based on template-free method in the presence of dicarboxylic acid dopants (e. g. D-tartaric acid, succinic acid, maleic acid and fumaric acid). The trans-cis isomerization of butenedioic acid played an important role in the formation of nanostructures from the plane-like to nanofibers, and the PANI doped with maleic acid (MA) had larger diameter, higher crystallinity and conductivity than PANI doped with fumaric acid (FA).
C1 [Sun Chuanyu; Wang Yu] Yinuo Inst, Dept Chem Mat, Changchun 130033, Peoples R China.
RP Sun, CY (reprint author), Yinuo Inst, Dept Chem Mat, Changchun 130033, Peoples R China.
EM chuanyuvip@tom.com
CR ANDERSON MR, 1991, SCIENCE, V252, P1412, DOI 10.1126/science.252.5011.1412
   Gospodinova N, 1998, PROG POLYM SCI, V23, P1443, DOI 10.1016/S0079-6700(98)00008-2
   Kaner RB, 2001, SYNTHETIC MET, V125, P65, DOI 10.1016/S0379-6779(01)00512-4
   Stejskal J, 2004, POLYM INT, V53, P294, DOI 10.1002/pi.1406
   Sun CY, 2012, OPTOELECTRON ADV MAT, V6, P1037
   Sun CY, 2012, OPTOELECTRON ADV MAT, V6, P771
   Virji S, 2009, CHEM MATER, V21, P3056, DOI 10.1021/cm802397j
   Wang Y, 2005, LANGMUIR, V21, P833, DOI 10.1021/la047442z
   Wei ZX, 2002, LANGMUIR, V18, P917, DOI 10.1021/l0155799
   Xiong SX, 2004, MATER RES BULL, V39, P1569, DOI 10.1016/j.materresbull.2004.01.009
   Zhang ZM, 2009, MATER CHEM PHYS, V115, P275, DOI 10.1016/j.matchemphys.2008.12.005
NR 11
TC 3
Z9 3
U1 2
U2 15
PU DE GRUYTER OPEN LTD
PI WARSAW
PA BOGUMILA ZUGA 32A ST, 01-811 WARSAW, POLAND
SN 2083-134X
J9 MATER SCI-POLAND
JI Mater. Sci.
PD SEP
PY 2014
VL 32
IS 3
BP 419
EP 422
DI 10.2478/s13536-014-0221-1
PG 4
WC Materials Science, Multidisciplinary
SC Materials Science
GA AS0NN
UT WOS:000343974300016
OA Other Gold
DA 2018-12-27
ER

PT J
AU Amoros, BG
   de Puit, M
AF Amoros, Belen Gonzalez
   de Puit, M.
TI RETRACTED: A model study into the effects of light and temperature on
   the degradation of fingerprint constituents (Retracted article. See vol.
   55, pg. 218, 2015)
SO SCIENCE & JUSTICE
LA English
DT Article; Retracted Publication
DE Fingerprint; Age determination
ID AMINO-ACIDS; RESIDUE; MS
AB Determining the order of events in a criminal investigation can be crucial in many ways. Although the use of fingermarks is one of the most important forensic tools as a modality of individualisation, placing them in time is a long lasting difficulty. In the study presented in this paper we describe the effects of light and the temperature on depositions of standard solutions containing squalene and cholesterol on paper. The results obtained give a clear view on what type of processes take place during a temperature and a light influenced degradation of the two materials in this study. Using well known methods for the determination of reaction constants it was determined that the degradation mechanism of cholesterol is following a radical route, where the decay of squalene is more affected by temperature. (C) 2014 The Chartered Society of Forensic Sciences. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Amoros, Belen Gonzalez; de Puit, M.] Netherlands Forens Inst, NL-2497 GB The Hague, Netherlands.
RP de Puit, M (reprint author), Netherlands Forens Inst, Laan Ypenburg 6, NL-2497 GB The Hague, Netherlands.
EM m.de.puit@nfl.minvenj.nl
CR Archer NE, 2005, FORENSIC SCI INT, V154, P224, DOI 10.1016/j.forsciint.2004.09.120
   Atherton T, 2012, J SEP SCI, V35, P2994, DOI 10.1002/jssc.201200398
   Atkins PW, 1996, ELEMENTS PHYS CHEM
   Croxton RS, 2006, J FORENSIC SCI, V51, P1329, DOI 10.1111/j.1556-4029.2006.00203.x
   Croxton RS, 2010, FORENSIC SCI INT, V199, P93, DOI 10.1016/j.forsciint.2010.03.019
   Girod A, 2012, FORENSIC SCI INT, V223, P10, DOI 10.1016/j.forsciint.2012.05.018
   Mink T, 2013, SCI JUSTICE, V53, P301, DOI 10.1016/j.scijus.2013.04.008
   Mountfort KA, 2007, ANAL CHEM, V79, P2650, DOI 10.1021/ac0623944
   Puit M., 2013, J FORENSIC SCI, V1
   TOMKINS GM, 1953, J BIOL CHEM, V202, P487
   Weyermann C, 2012, SCI JUSTICE, V52, P68, DOI 10.1016/j.scijus.2011.09.003
   Weyermann C, 2011, J FORENSIC SCI, V56, P102, DOI 10.1111/j.1556-4029.2010.01523.x
NR 12
TC 1
Z9 1
U1 3
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1355-0306
EI 1876-4452
J9 SCI JUSTICE
JI Sci. Justice
PD SEP
PY 2014
VL 54
IS 5
BP 346
EP 350
DI 10.1016/j.scijus.2014.04.006
PG 5
WC Medicine, Legal; Pathology
SC Legal Medicine; Pathology
GA AR8TF
UT WOS:000343846500005
DA 2018-12-27
ER

PT J
AU Cen, G
   Ding, HH
   Liu, B
   Wu, WD
AF Cen, Gang
   Ding, Hong-Hua
   Liu, Bin
   Wu, Wei-Dong
TI RETRACTED: FBXL5 targets cortactin for ubiquitination-mediated
   destruction to regulate gastric cancer cell migration (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE FBXL5; Cortactin; Ubiquitylation; Gastric cancer
ID IRON HOMEOSTASIS; F-BOX; LIGASE; SUBSTRATE; INVASION; KINASES
AB Cortactin, an actin-interacting protein, is implicated in cytoskeletal architecture and often amplified in several types of cancer including gastric adenocarcinomas. Downregulation of cortactin decreases cell migration and invasion. However, how to regulate cortactin in gastric cancer remains largely unknown. Here, we report that FBXL5 interacts with and targets cortactin for ubiquitylation and subsequent proteasomal degradation. Furthermore, we showed that FBXL5-induced cortactin degradation is mediated by extracellular regulated signal kinase (ERK). Serine phosphorylation sites mutant, cortactinS405A/S418A, prevent FBXL5-induced cortactin degradation. Moreover, CortactinS405A/S418A exhibited stronger effects in promoting gastric cancer cell migration when compared to wild-type cortactin. Taken together, our data suggested a novel molecular mechanism for the negative regulation of cortactin by FBXL5 in gastric cancer cells migration.
C1 [Cen, Gang; Wu, Wei-Dong] Shanghai Jiao Tong Univ, Dept Gen Surg, Peoples Hosp 1, Shanghai 200080, Peoples R China.
   [Ding, Hong-Hua] Shanghai Jiao Tong Univ, Dept Oncol, Peoples Hosp 1, Shanghai 200080, Peoples R China.
   [Liu, Bin] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
RP Wu, WD (reprint author), Shanghai Jiao Tong Univ, Dept Gen Surg, Peoples Hosp 1, Shanghai 200080, Peoples R China.
EM wei_dongwu@126.com
CR Ambrosio EP, 2011, HUM PATHOL, V42, P1221, DOI 10.1016/j.humpath.2010.05.030
   Folio C, 2011, CANCER BIOMARK, V10, P35, DOI 10.3233/CBM-2012-0227
   Hsiang CY, 2004, TUMOR BIOL, V25, P313, DOI 10.1159/000081400
   Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770
   Kim SK, 2006, DRUG METAB DISPOS, V34, P683, DOI 10.1124/dmd.105.007666
   Liu B, 2012, J PROTEOME RES, V11, P1773, DOI 10.1021/pr2010204
   MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781
   Mezi S, 2012, INT J ONCOL, V41, P2128, DOI 10.3892/ijo.2012.1642
   Moroishi T, 2011, CELL METAB, V14, P339, DOI 10.1016/j.cmet.2011.07.011
   Nakane K, 2012, INT J UROL, V19, P71, DOI 10.1111/j.1442-2042.2011.02888.x
   Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005
   Ruiz JC, 2013, J BIOL CHEM, V288, P552, DOI 10.1074/jbc.M112.426171
   Salahudeen AA, 2009, SCIENCE, V326, P722, DOI 10.1126/science.1176326
   Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582
   Smyth EC, 2013, NAT REV CLIN ONCOL, V10, P73, DOI 10.1038/nrclinonc.2012.228
   Vashisht AA, 2009, SCIENCE, V326, P718, DOI 10.1126/science.1176333
   Villanueva M Teresa, 2011, Nat Rev Clin Oncol, V8, P690, DOI 10.1038/nrclinonc.2011.171
   WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417
   Yakirevich E, 2013, GASTROENTEROL CLIN N, V42, P261, DOI 10.1016/j.gtc.2013.01.004
   Zhao J, 2012, J BIOL CHEM, V287, P19105, DOI 10.1074/jbc.M112.339507
NR 20
TC 18
Z9 18
U1 6
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2014
VL 35
IS 9
BP 8633
EP 8638
DI 10.1007/s13277-014-2104-9
PG 6
WC Oncology
SC Oncology
GA AR5ZQ
UT WOS:000343662000033
PM 24867096
DA 2018-12-27
ER

PT J
AU Lu, H
   Li, H
   Mao, D
   Zhu, ZT
   Sun, HZ
AF Lu, Hang
   Li, Hua
   Mao, Dong
   Zhu, Zhitu
   Sun, Hongzhi
TI RETRACTED: Nrdp1 inhibits growth of colorectal cancer cells by nuclear
   retention of p27 (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Neuregulin receptor degradation protein-1 (Nrdp1); ErbB3;
   Extracellular-related kinase/mitogen-activated protein kinase
   (ERK/MAPK); Phosphatidylinositol 3-kinase (PI3K); Proteinkinase B(Akt);
   Colorectal cancer
ID CRC; PREVENTION; FOCUS
AB The molecular mechanism underlying the proliferation of colorectal cancer (CRC) cells is not completely understood. Here, we found that the level of neuregulin receptor degradation protein-1 (Nrdp1) E3 ubiquitin ligase was significantly decreased in CRC tissues, compared with the adjacent normal tissues from human patients. Knockdown of Nrdp1 enhanced the proliferation of CRC cells, while overexpression of Nrdp1 inhibited the proliferation of CRC cells. Further analysis showed that Nrdp1 may induce degradation of its target ErbB3 to inhibit activation of both ERK/MAPK and PI3K/Akt pathways in CRC cells, which seemed to affect cell proliferation via nuclear retention of a major cell-cycle inhibitor, p27. Taken together, these findings suggest that Nrdp1-mediated ErbB3 degradation suppresses cellular growth of CRC and that Nrdp1 loss in CRC may promote tumor progression, thus highlighting Nrdp1 as a novel target for CRC therapy.
C1 [Lu, Hang; Mao, Dong; Sun, Hongzhi] Liaoning Med Coll, Dept Gastrointestinal Surg, Affiliated Hosp 1, Jinzhou 121001, Peoples R China.
   [Li, Hua; Zhu, Zhitu] Liaoning Med Coll, Dept Oncol, Affiliated Hosp 1, Jinzhou 121001, Peoples R China.
RP Sun, HZ (reprint author), Liaoning Med Coll, Dept Gastrointestinal Surg, Affiliated Hosp 1, 5-2 People Rd, Jinzhou 121001, Peoples R China.
EM hongzhi_sun14@163.com
RI mao, maodong/K-6333-2016
FU First Affiliated Hospital, Liaoning Medical College, China
FX This work was supported by the internal funding of the First Affiliated
   Hospital, Liaoning Medical College, China.
CR Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   East JE, 2013, NAT REV GASTRO HEPAT, V10, P69, DOI 10.1038/nrgastro.2012.245
   Labianca R, 2005, ANN ONCOL, V16, P37, DOI 10.1093/annonc/mdi906
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Qi J, 2008, CURR DRUG TARGETS, V9, P548, DOI 10.2174/138945008784911769
   Van Schaeybroeck S, 2011, NAT REV CLIN ONCOL, V8, P222, DOI 10.1038/nrclinonc.2011.15
   von Kleist S, 1975, J Natl Cancer Inst, V55, P555
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Xu YF, 2007, HUM MOL GENET, V16, pR14, DOI 10.1093/hmg/ddl486
   Yao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078086
   Ye Q, 2014, ONCOGENE, V33, P1828, DOI 10.1038/onc.2013.122
   Yen L, 2006, CANCER RES, V66, P11279, DOI 10.1158/0008-5472.CAN-06-2319
NR 12
TC 11
Z9 11
U1 3
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2014
VL 35
IS 9
BP 8639
EP 8643
DI 10.1007/s13277-014-2132-5
PG 5
WC Oncology
SC Oncology
GA AR5ZQ
UT WOS:000343662000034
PM 24867101
DA 2018-12-27
ER

PT J
AU Wang, F
   Xiao, WZ
   Sun, JY
   Han, DH
   Zhu, YH
AF Wang, Fei
   Xiao, Weizhong
   Sun, Jiyong
   Han, Donghua
   Zhu, Youhou
TI RETRACTED: MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation
   via suppressing Akt phosphorylation in glioblastoma (Retracted article.
   See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Glioblastoma, miRNA-181c; Epidermal growth factor receptor;
   Phosphatidylinositol 3-kinase; Akt; MMP9
ID CELL-LINE; CANCER; EXPRESSION; INVASION; GROWTH; LUNG
AB As the most aggressive malignant primary human brain tumor, glioblastoma is noted with extremely poor patient survival. Previous studies have demonstrated that expression of matrix metalloproteinase-9 (MMP9) in glioblastoma cells is critical for cancer metastasis. However, the molecular signaling pathways that control MMP9 activation remain undefined. Here, we reported a strong negative correlation of microRNA (miRNA)-181c levels with either MMP9 levels or activation of epidermal growth factor receptor (EGFR) signaling in glioblastoma patients. EGF-induced activation of EGFR in a human glioblastoma line, A-172 cells, increased MMP9 expression through activation of phosphatidylinositol 3-kinase (PI3K)/Akt pathway, without affecting expression of miRNA-181c. On the other hand, overexpression of miRNA-181c in A-172 cells inhibited MMP9 expression by inhibiting Akt phosphorylation, but not phosphorylation of EGFR receptor. Taken together, these findings suggest that EGFR signaling activates downstream PI3K/Akt to increase MMP9 expression in glioblastoma, while phosphorylation of Akt is a control point by miRNA-181c. Our work thus provides new insights into the molecular basis underlying the metastasis of glioblastoma.
C1 [Wang, Fei; Zhu, Youhou] Tongji Univ, Tongji Hosp, Dept Neurosurg, Shanghai 200065, Peoples R China.
   [Xiao, Weizhong; Han, Donghua] Fudan Univ, Shanghai Pudong Hosp, Dept Neurol, Shanghai 201399, Peoples R China.
   [Sun, Jiyong] Nanjing Med Univ, Wuxi Hosp 2, Dept Neurosurg, Wuxi 214002, Jiangsu, Peoples R China.
RP Wang, F (reprint author), Tongji Univ, Tongji Hosp, Dept Neurosurg, 389 Xincun Rd, Shanghai 200065, Peoples R China.
EM fei_wang14@163.com; handongh@163.com
CR Chen J, 2014, TUMOUR BIOL
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   Feng XJ, 2014, TUMOR BIOL, V35, P149, DOI 10.1007/s13277-013-1018-2
   Kim S, 2009, CELL SIGNAL, V21, P892, DOI 10.1016/j.cellsig.2009.01.034
   Lee CC, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-85
   Li S, 2014, TUMOUR BIOL
   Liu QL, 2010, J NEURO-ONCOL, V100, P165, DOI 10.1007/s11060-010-0158-0
   Nguyen TLX, 2006, BIOCHEM BIOPH RES CO, V349, P789, DOI 10.1016/j.bbrc.2006.08.120
   Papi A, 2007, ONCOL REP, V18, P1015
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635
   Schonberg DL, 2013, NAT GENET, V45, P1105, DOI 10.1038/ng.2775
   Schutz A, 2002, TUMOR BIOL, V23, P179, DOI 10.1159/000064034
   Slaby O, 2010, NEOPLASMA, V57, P264, DOI 10.4149/neo_2010_03_264
   Sun GG, 2014, TUMOUR BIOL
   Sutnar A, 2007, TUMOR BIOL, V28, P247, DOI 10.1159/000110897
   Tang ZP, 2013, TUMOR BIOL, V34, P2835, DOI 10.1007/s13277-013-0843-7
   Yan Y, 2014, TUMOUR BIOL
NR 18
TC 85
Z9 87
U1 4
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2014
VL 35
IS 9
BP 8653
EP 8658
DI 10.1007/s13277-014-2131-6
PG 6
WC Oncology
SC Oncology
GA AR5ZQ
UT WOS:000343662000036
PM 24867100
DA 2018-12-27
ER

PT J
AU Wang, XR
   Cao, XC
AF Wang, Xiaoru
   Cao, Xiaocang
TI RETRACTED: Regulation of metastasis of pediatric multiple myeloma by
   MMP13 (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Multiple myeloma; FGFR4; MMP13; ERK/MAPK; PI3K; JNK
ID COLORECTAL-CANCER; FIBROBLAST; MMP-13; FGFR4; COMPLEX
AB The molecular mechanism underlying metastasis of pediatric multiple myeloma (MM) remains elusive. Here, we showed that the levels of MMP13 are significantly higher in MM from young patients than those from adult patients. Moreover, a strong correlation of the MMP13 and phosphorylated fibroblast growth factor receptor 4 (FGFR4) levels was detected in MM from young patients. To prove a causal link between activation of fibroblast growth factor receptors (FGFR) signaling pathway and MMP13 expression, we used a human MM line, RPMI-8226 (8226), to study the underlying molecular basis. We found that FGF1-induced FGFR4 phosphorylation in 8,226 cells resulted in significant activation of MMP13, and consequently, an increase in cancer invasiveness. FGFR4 inhibition in 8,226 cells abolished FGF1-stimulated MMP13 expression, suggesting that activation of FGFR signaling pathway in MM may promote cancer metastasis by inducing MMP13 expression. To define the signaling cascades downstream of FGFR4 activation for MMP13 activation, we applied specific inhibitors for PI3K, Jun N-terminal kinase (JNK), and ERK/MAPK, respectively, to the FGF1-stimulated 8,226 cells. We found that only inhibition of ERK1/2 significantly decreased the activation of MMP13 in response to FGF stimulation, suggesting that activation of FGFR signaling may activate ERK/MAPK, rather than JNK or PI3K pathway to activate MMP13 expression in 8,226 cells. Our study thus highlights FGFR4 signaling pathway and MMP13 as novel therapeutic targets for MM.
C1 [Wang, Xiaoru] Shandong Univ, Dept Pediat, Prov Hosp, Jinan 250021, Shandong, Peoples R China.
   [Cao, Xiaocang] Tianjin Med Univ, Tianjin Med Univ Gen Hosp, Dept Gastroenterol & Hepatol, Tianjin, Peoples R China.
RP Wang, XR (reprint author), Shandong Univ, Dept Pediat, Prov Hosp, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.
EM xiaoru_wang14@163.com
CR Balbin M, 1999, APMIS, V107, P45, DOI 10.1111/j.1699-0463.1999.tb01525.x
   Bange J, 2002, CANCER RES, V62, P840
   Dolloff NG, 2013, ADV EXP MED BIOL, V779, P197, DOI 10.1007/978-1-4614-6176-0_9
   Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748
   Fujimoto J, 1996, TUMOR BIOL, V17, P226, DOI 10.1159/000217984
   JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y
   Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947
   Kuslak SL, 2007, DIFFERENTIATION, V75, P638, DOI 10.1111/j.1432-0436.2006.00161.x
   Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008-5472.CAN-12-4718
   Smith D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3863
   Soundararajan P, 2010, J NEUROSCI, V30, P6595, DOI 10.1523/JNEUROSCI.4932-09.2010
   Takaishi H, 2008, CURR PHARM BIOTECHNO, V9, P47, DOI 10.2174/138920108783497659
   Turkington RC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.10
   Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401
   Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc>M409035200
NR 15
TC 10
Z9 11
U1 4
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2014
VL 35
IS 9
BP 8715
EP 8720
DI 10.1007/s13277-014-2147-y
PG 6
WC Oncology
SC Oncology
GA AR5ZQ
UT WOS:000343662000045
PM 24870599
DA 2018-12-27
ER

PT J
AU Chen, YZ
   Fan, ZH
   Zhao, YX
   Bai, L
   Zhou, BS
   Zhang, HB
   Liu, D
AF Chen, Yan-Zhi
   Fan, Zeng-Hui
   Zhao, Yu-Xia
   Bai, Lu
   Zhou, Bao-Shen
   Zhang, Hai-Bo
   Liu, Dan
TI RETRACTED: Single-nucleotide polymorphisms of LIG1 associated with risk
   of lung cancer (Retracted article. See vol. 36, pg. 7313, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Lung cancer; Single-nucleotide polymorphism; LIG1
ID RECEPTOR SUBUNIT GENES; SUSCEPTIBILITY LOCUS; CELL; EXPRESSION
AB To investigate the association of LIG1 with the risk of lung cancer, all subjects of unrelated ethnic Han Chinese in Liaoning Province were involved in a hospital-based case-control study. The case group consisted of 370 histologically diagnosed lung cancer patients; 314 controls were selected from cancer-free patients during Dec. 2009 to Dec. 2011. LIG1 rs1050298SNP were analyzed by TaqMan real-time PCR method. All statistical analyses were performed with Statistical Product and Service Solution sv13.0 (SPSS). The genotype distribution frequency of LIG1 rs1050298 SNP displayed significant difference between the case and the control group. Individuals carrying the LIG1 rs1050298 T genotype had higher risks of lung cancer, especially those with squamous cell carcinoma.
C1 [Chen, Yan-Zhi; Zhao, Yu-Xia; Liu, Dan] China Med Univ, Affiliated Hosp 4, Dept Radiat Oncol, Shenyang 110032, Peoples R China.
   [Fan, Zeng-Hui] Chinese Med Hosp Linyi City, Dept Radiat Oncol, Lanshan Dist 276000, Linyi, Peoples R China.
   [Bai, Lu] China Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Shenyang 110032, Peoples R China.
   [Zhou, Bao-Shen] Shenyang Mil Reg, Gen Hosp, Dept Radiat Oncol, Shenyang 110032, Peoples R China.
   [Zhang, Hai-Bo] China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110032, Peoples R China.
RP Zhao, YX (reprint author), China Med Univ, Affiliated Hosp 4, Dept Radiat Oncol, Chongshan East St 4, Shenyang 110032, Peoples R China.
EM cmu4h_zyx@yeah.net
FU Scientific Research Fund of Liaoning Province Education Department
   [L2010627]
FX This work was supported by Scientific Research Fund of Liaoning Province
   Education Department (No. L2010627). We would like to acknowledge the
   reviewers for their helpful comments on this paper.
CR Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109
   Buch SC, 2012, MOL CARCINOGEN, V51, pE11, DOI 10.1002/mc.20858
   Chang JS, 2008, INT J CANCER, V123, P2095, DOI 10.1002/ijc.23801
   Ho YS, 2005, TOXICOL APPL PHARM, V205, P133, DOI 10.1016/j.taap.2004.09.019
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Lam DCL, 2007, CANCER RES, V67, P4638, DOI 10.1158/0008-5472.CAN-06-4628
   Lee YCA, 2008, INT J CANCER, V122, P1630, DOI 10.1002/ijc.23274
   LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343
   Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492
   Ramos W, 1997, NUCLEIC ACIDS RES, V25, P1485, DOI 10.1093/nar/25.8.1485
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273
   Wu XF, 2004, ONCOGENE, V23, P6500, DOI 10.1038/sj.onc.1207811
   Zienolddiny S, 2004, INT J CANCER, V109, P353, DOI 10.1002/ijc.11695
NR 14
TC 6
Z9 6
U1 3
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2014
VL 35
IS 9
BP 9229
EP 9232
DI 10.1007/s13277-014-2199-z
PG 4
WC Oncology
SC Oncology
GA AR5ZQ
UT WOS:000343662000106
PM 24929328
DA 2018-12-27
ER

PT J
AU Zhou, X
   Qi, Y
AF Zhou, Xu
   Qi, Ying
TI RETRACTED: PLGF inhibition impairs metastasis of larynx carcinoma
   through MMP3 downregulation (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Placental growth factor; Matrix metalloproteinases 3; ERK/MAPK signaling
   pathway; Larynx carcinoma; Metastasis
ID ENDOTHELIAL GROWTH-FACTOR; GASTRIC-CANCER; ANGIOGENESIS; TARGET; CELLS;
   VEGF
AB Cancer neovascularization plays a key role in the metastasis of larynx carcinoma. However, the molecular mechanism for the neovascularization control in larynx carcinoma is poorly understood. Since placental growth factor (PLGF) has been reported to be involved in pathological angiogenesis, and since matrix metalloproteinases (MMPs) are essential for extracellular matrix degradation during neovascularization, here we were prompted to examine whether PLGF and MMPs may play a coordinate role in the metastasis of larynx carcinoma. Our data showed that the expression of PLGF and MMP3 strongly correlated in the larynx carcinoma in the patients, and significant higher levels of PLGF and MMP3 were detected in the larynx carcinoma from the patients with metastasis of the primary cancer. Thus, we used a human larynx carcinoma cell line, Hep-2, to examine whether expression of PLGF and MMP3 may affect each other. We found that overexpression of PLGF in Hep-2 cells increased expression of MMP3, while inhibition of PLGF in Hep-2 cells decreased expression of MMP3. However, neither overexpression, nor inhibition of MMP3 in Hep-2 cells affected the expression level of PLGF. These data suggest that PLGF may function upstream of MMP3 in larynx carcinoma cells. We then analyzed how PLGF affected MMP3. Application of a specific ERK1/2 inhibitor to PLGF-overexpressing Hep-2 cells substantially abolished the effect of PLGF on MMP3 activation, suggesting that PLGF may increase expression of MMP3 via ERK/MAPK signaling pathway. Since anti-PLGF was recently applied in clinical trials to inhibit cancer-related angiogenesis, here our data further demonstrate that inhibition of cancer neovascularization by anti-PLGF is mediated not only by direct effect on endothelial growth and capillary permeability, but also by indirect effect via MMP3 on the extracellular matrix degradation in larynx carcinoma.
C1 [Zhou, Xu; Qi, Ying] Fu Dan Univ, Zhongshan Hosp, Dept Otorhinolaryngol, Shanghai 200032, Peoples R China.
RP Zhou, X (reprint author), Fu Dan Univ, Zhongshan Hosp, Dept Otorhinolaryngol, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM xu_zhou14@163.com
CR Bagri A, 2010, TRENDS MOL MED, V16, P122, DOI 10.1016/j.molmed.2010.01.004
   Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Davidson B., 2002, Arkhiv Patologii, V64, P47
   Dufour A, 2013, TRENDS PHARMACOL SCI, V34, P233, DOI 10.1016/j.tips.2013.02.004
   Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Ilson DH, 2014, LANCET, V383, P4, DOI 10.1016/S0140-6736(13)61892-9
   Kim JG, 2013, KOREAN J INTERN MED, V28, P149, DOI 10.3904/kjim.2013.28.2.149
   Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585-005-8115-6
   Rhee JS, 2002, TRENDS CELL BIOL, V12, P209, DOI 10.1016/S0962-8924(02)02280-8
   Scartozzi M, 2013, PHARMACOGENOMICS, V14, P1991, DOI [10.2217/PGS.13.185, 10.2217/pgs.13.185]
   Xiao XW, 2014, DIABETOLOGIA, V57, P991, DOI 10.1007/s00125-014-3179-y
   Xiao XW, 2013, J BIOL CHEM, V288, P8636, DOI 10.1074/jbc.M112.422949
   Zhang CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062023
   Zhao XN, 2013, FRONT BIOSCI-LANDMRK, V18, P803, DOI 10.2741/4144
NR 16
TC 22
Z9 22
U1 4
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2014
VL 35
IS 9
BP 9381
EP 9386
DI 10.1007/s13277-014-2232-2
PG 6
WC Oncology
SC Oncology
GA AR5ZQ
UT WOS:000343662000123
PM 24946722
DA 2018-12-27
ER

PT J
AU Gu, X
   Xue, JQ
   Zhu, X
   Ye, MS
   Zhang, WH
AF Gu, Xi
   Xue, Jin-Qi
   Zhu, Xi
   Ye, Ming-Shi
   Zhang, Wen-Hai
TI RETRACTED: Aberrant promoter methylation of the CHD1 gene may contribute
   to the pathogenesis of breast cancer: a meta-analysis (Retracted
   article. See vol. 36, pg. 7315, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE CHD1; Promoter methylation; Breast cancer; Meta-analysis
ID E-CADHERIN EXPRESSION; HYPERMETHYLATION; CDH1; STATISTICS; TISSUE;
   WOMEN; DNA
AB Cadherin-1 (CHD1), as an invasion suppressor gene, could suppress tumor cell invasion and metastasis in various tumors, but reduced CHD1 levels, resulting from epigenetic silencing, are common in poorly differentiated, advanced stage carcinomas. This meta-analysis was performed to evaluate the relationships between promoter methylation of CHD1 and breast cancer. Relevant studies were retrieved from the Web of Science (1945 similar to 2013), the Cochrane Library (Issue 12, 2013), PubMed (1966 similar to 2013), EMBASE (1980 similar to 2013), CINAHL (1982 similar to 2013), and the Chinese Biomedical Database (CBM) (1982 similar to 2013) using a systematic literature search. Results were summarized by meta-analyses, conducted using the STATA software (version 12.0, Stata Corporation, College Station, TX, USA). Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were calculated. In the present meta-analysis, 9 cohort studies with a total of 425 patients with breast cancer were included. Our meta-analysis results demonstrated that the frequency of CHD1 promoter methylation in cancer tissues was significantly higher than that in normal tissues, adjacent tissues, and benign tissues (cancer tissue vs. normal tissue OR = 30.87, 95 % CI = 16.76 similar to 56.86, P < 0.001; cancer tissue vs. adjacent tissue OR = 23.30, 95 % CI = 12.85 similar to 42.26, P < 0.001; cancer tissue vs. benign tissue OR = 2.94, 95 % CI = 1.60 similar to 5.40, P < 0.001; respectively). Ethnicity-stratified analysis indicated that aberrant CHD1 promoter methylation was strongly correlated with breast cancer among both Asians and Caucasians in the majority of subgroups. Our results suggest that aberrant promoter methylation of the CHD1 gene may have a high frequency in breast cancer tissues. Thus, CHD1 methylation could be correlated with the pathogenesis of breast cancer.
C1 [Gu, Xi] China Med Univ, Dept Breast Surg, Shengjing Hosp, Shenyang 110004, Peoples R China.
   [Xue, Jin-Qi; Zhu, Xi; Ye, Ming-Shi; Zhang, Wen-Hai] China Med Univ, Shengjing Hosp, Dept Breast Surg, Shenyang 110022, Peoples R China.
RP Zhang, WH (reprint author), China Med Univ, Shengjing Hosp, Dept Breast Surg, Huaxiang Rd 39, Shenyang 110022, Peoples R China.
EM zhangwenhai401@126.com
FU Science and Technology Research Project of Liaoning Province
   [2012225016]
FX This study was supported by the Science and Technology Research Project
   of Liaoning Province (No. 2012225016). We would like to acknowledge the
   helpful comments on this paper received from our reviewers.
CR Baranwal S, 2009, BIOCHEM BIOPH RES CO, V384, P6, DOI 10.1016/j.bbrc.2009.04.051
   Benson JR, 2012, FUTURE ONCOL, V8, P697, DOI [10.2217/FON.12.61, 10.2217/fon.12.61]
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Burkhardt L, 2013, CANCER RES, V73, P2795, DOI 10.1158/0008-5472.CAN-12-1342
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Cavusoglu AC, 2010, NEOPLASMA, V57, P465, DOI 10.4149/neo_2010_05_465
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Dal Maso L, 2008, INT J CANCER, V123, P2188, DOI 10.1002/ijc.23747
   Dong LL, 2012, ACTA PHARMACOL SIN, V33, P817, DOI 10.1038/aps.2012.30
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hu XC, 2002, LIFE SCI, V71, P1397, DOI 10.1016/S0024-3205(02)01843-X
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kim MS, 2011, HISTOPATHOLOGY, V58, P660, DOI 10.1111/j.1365-2559.2011.03819.x
   Liu P, 2010, ACTA ACAD MED WEIFAN, V32, P94
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Mavaddat N, 2010, MOL ONCOL, V4, P174, DOI 10.1016/j.molonc.2010.04.011
   Nelson HD, 2012, ANN INTERN MED, V156, P635, DOI 10.7326/0003-4819-156-9-201205010-00006
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Pontoriero GF, 2009, DEV BIOL, V326, P403, DOI 10.1016/j.ydbio.2008.10.011
   Prasad CP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-325
   Sebova K, 2011, CANCER BIOMARK, V10, P13, DOI 10.3233/CBM-2012-0230
   Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Toyooka KO, 2002, AM J PATHOL, V161, P629, DOI 10.1016/S0002-9440(10)64218-6
   [王静萱 Wang Jingxuan], 2012, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V39, P1169
   Xue F, 2011, ARCH INTERN MED, V171, P125, DOI 10.1001/archinternmed.2010.503
   Zhang Jing-Jie, 2007, Zhonghua Zhongliu Zazhi, V29, P609
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   Zou DH, 2009, J PATHOL, V218, P265, DOI 10.1002/path.2541
NR 32
TC 2
Z9 2
U1 3
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2014
VL 35
IS 9
BP 9395
EP 9404
DI 10.1007/s13277-014-2235-z
PG 10
WC Oncology
SC Oncology
GA AR5ZQ
UT WOS:000343662000125
PM 24952891
DA 2018-12-27
ER

PT J
AU Qu, YL
   Yu, H
   Chen, YZ
   Zhao, YX
   Chen, GJ
   Bai, L
   Liu, D
   Su, HX
   Wang, HT
AF Qu, Yan-Li
   Yu, Hong
   Chen, Yan-Zhi
   Zhao, Yu-Xia
   Chen, Guang-Jun
   Bai, Lu
   Liu, Dan
   Su, Hong-Xin
   Wang, He-Tong
TI RETRACTED: Relationships between genetic polymorphisms in
   inflammation-related factor gene and the pathogenesis of nasopharyngeal
   cancer (Retracted article. See vol. 36, pg. 7311, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Genetic polymorphism; Inflammation; Nasopharyngeal cancer; Single
   nucleotide polymorphisms
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; EPITHELIAL-MESENCHYMAL TRANSITION;
   INTENSITY-MODULATED RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA;
   BREAST-CANCER; INTERLEUKIN-6 GENE; LUNG-CANCER; PROMOTER POLYMORPHISMS;
   CHINESE POPULATION; RISK
AB Our study aims to discuss the association between inflammation-related factors such as single nucleotide polymorphisms (SNPs) with susceptibility and recurrence in nasopharyngeal carcinoma. We used Taqman real-time polymerase chain reaction (PCR) to characterize the genetic variation of five SNPs in 194 nasopharyngeal carcinoma patients and 231 healthy subjects. All statistical analysis is performed with statistical product and service solutions v13.0; odds ratio (OR) value and 95 % confidence interval (CI) were calculated. There is no relationship between TGF beta 1 -869 T/C, IL-6 -634C/G, TGF beta 1 -509C/T, IL1 -511C/T and nasopharyngeal carcinoma susceptibility. Both single factor and multiple factors analysis showed that IL1a -889 T/T genotype is significantly associated with nasopharyngeal carcinoma in decreasing the risk of nasopharyngeal carcinoma. A highly significant association was found between IL1a -889 T/T genotype and protective genotype as defined by various pathological types. This is more obvious in the protective genotype of the non-keratin-type squamous carcinoma undifferentiated type. We also discovered that genotype G/G and C/G + G/G of IL6 -634 gene are associated with reduced recurrence of nasopharyngeal carcinoma. IL1a -889 gene polymorphism and susceptibility is related to nasopharyngeal carcinoma and can potentially decrease the risk of nasopharyngeal carcinoma in the Han Chinese population in north China. IL1-889 TT genotype is protective genotype for nasopharyngeal carcinoma. We have provided evidence that the GG genotype of the IL6 -634 gene is associated with recurrent risk of nasopharyngeal carcinoma. The G allele is the protective gene of nasopharyngeal carcinoma recurrence.
C1 [Qu, Yan-Li; Chen, Yan-Zhi; Zhao, Yu-Xia; Liu, Dan; Su, Hong-Xin; Wang, He-Tong] China Med Univ, Affiliated Hosp 4, Dept Radiat Oncol, Shenyang 110032, Peoples R China.
   [Qu, Yan-Li; Yu, Hong] Liaoning Canc Hosp & Inst, Dept Radiat Oncol, Liaoning, Peoples R China.
   [Chen, Guang-Jun] Clin Border Control Bur Liaoning Prov, Liaoning, Peoples R China.
   [Bai, Lu] China Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Shenyang, Peoples R China.
RP Zhao, YX (reprint author), China Med Univ, Affiliated Hosp 4, Dept Radiat Oncol, Chongshan Earth St 4, Shenyang 110032, Peoples R China.
EM cmu4h_zyx@yeah.net
FU grant of scientific and technological breakthrough project (Shenyang
   City, P.R. China) [1091149-9-00]; grant of science and technology
   project (Liaoning, P.R. China) [2011225019]
FX The authors thank all the participants from Department of Radiation
   Oncology, Fourth Affiliated Hospital of China Medical University. The
   authors also thank Drs. Yu-Xia Zhao and Hong Yu and Yan-Zhi Chen for
   helpful discussions and manuscript edits. This work was supported by the
   grant of scientific and technological breakthrough project (Shenyang
   City, P.R. China, No. 1091149-9-00) and the grant of science and
   technology project (Liaoning, P.R. China, No. 2011225019).
CR AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5
   Bai L, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0414-6
   Balasubramanian SP, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-188
   Bao SX, 2008, J HUAZHONG U SCI-MED, V28, P693, DOI 10.1007/s11596-008-0618-3
   Basso F, 2002, ARTERIOSCL THROM VAS, V22, P599, DOI 10.1161/01.ATV.00000132783.84306.lA
   Bennermo M, 2004, ATHEROSCLEROSIS, V174, P157, DOI 10.1016/j.atherosclerosis.2004.01.019
   Brull DJ, 2001, ARTERIOSCL THROM VAS, V21, P1458, DOI 10.1161/hq0901.094280
   Crivello A, 2006, ANN NY ACAD SCI, V1089, P98, DOI 10.1196/annals.1386.002
   Duffy SA, 2008, CANCER-AM CANCER SOC, V113, P750, DOI 10.1002/cncr.23615
   Eshghyar N, 2012, J ORAL PATHOL MED, V41, P697, DOI 10.1111/j.1600-0714.2012.01162.x
   Hefler LA, 2005, CLIN CANCER RES, V11, P5718, DOI 10.1158/1078-0432.CCR-05-0001
   HSU SM, 1993, HUM PATHOL, V24, P1040, DOI 10.1016/0046-8177(93)90183-H
   Hsu WL, 2009, CANCER EPIDEM BIOMAR, V18, P1218, DOI 10.1158/1055-9965.EPI-08-1175
   Hurme M, 1998, SCAND J IMMUNOL, V48, P219
   Jang Y, 2008, TRANSL RES, V151, P154, DOI 10.1016/j.trsi.2007.11.004
   Jin GF, 2008, J CANCER RES CLIN, V134, P345, DOI 10.1007/s00432-007-0290-1
   Kitamura A, 2002, DIABETIC MED, V19, P1000, DOI 10.1046/j.1464-5491.2002.00844.x
   Landeck L, 2013, J EUR ACAD DERMATOL, V27, P1040, DOI 10.1111/j.1468-3083.2012.04474.x
   Lee N, 2009, J CLIN ONCOL, V27, P3684, DOI 10.1200/JCO.2008.19.9109
   Liao WC, 2008, CLIN CANCER RES, V14, P428, DOI 10.1158/1078-0432.CCR-07-1032
   Lim WY, 2011, CARCINOGENESIS, V32, P522, DOI 10.1093/carcin/bgr006
   Luo WR, 2012, INT J CANCER, V131, P1863, DOI 10.1002/ijc.27467
   Ma N, 2008, INT J CANCER, V122, P2517, DOI 10.1002/ijc.23415
   Malarstig A, 2007, THROMB RES, V119, P467, DOI 10.1016/j.thromres.2006.05.001
   Matsuo K, 2001, HAEMATOLOGICA, V86, P602
   Oh K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3034
   Pan M, 2011, J INVEST MED, V59, P272, DOI 10.231/JIM.0b013e318206ffad
   Park KH, 2006, CANCER GENET CYTOGEN, V169, P39, DOI 10.1016/j.cancergencyto.2006.03.012
   Pharoah P, 2006, JNCI-J NATL CANCER I, V98, P1382, DOI 10.1093/jnci/djj374
   Riedel F, 2005, ANTICANCER RES, V25, P2761
   Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880
   Shibata N, 2002, AM J MED GENET, V114, P436, DOI 10.1002/ajmg.10417
   Shirodaria S, 2000, J DENT RES, V79, P1864, DOI 10.1177/00220345000790110801
   Singer C F, 2006, Int J Gynecol Cancer, V16 Suppl 2, P556, DOI 10.1111/j.1525-1438.2006.00695.x
   Singer CF, 2003, CLIN CANCER RES, V9, P4877
   Snoussi K, 2005, EUR CYTOKINE NETW, V16, P253
   Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989
   Tan EL, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-227
   Taylor SL, 2002, GENOMICS, V79, P726, DOI 10.1006/geno.2002.6752
   Tham IWK, 2009, INT J RADIAT ONCOL, V75, P1481, DOI 10.1016/j.ijrobp.2009.01.018
   Wang J, 2009, RADIOTHER ONCOL, V90, P221, DOI 10.1016/j.radonc.2008.08.017
   Wei YS, 2007, CLIN CHIM ACTA, V380, P165, DOI 10.1016/j.cca.2007.02.008
   Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271
   Yang EV, 2009, BRAIN BEHAV IMMUN, V23, P267, DOI 10.1016/j.bbi.2008.10.005
   Zhang DL, 2008, ANN CLIN LAB SCI, V38, P113
   Zhang LM, 2010, CARCINOGENESIS, V31, P559, DOI 10.1093/carcin/bgp335
   Zhang P, 2008, JPN J CLIN ONCOL, V38, P861, DOI 10.1093/jjco/hyn111
   Zhu YH, 2008, CLIN ONCOL-UK, V20, P207, DOI 10.1016/j.clon.2008.01.003
   Zienolddiny S, 2004, INT J CANCER, V109, P353, DOI 10.1002/ijc.11695
NR 49
TC 5
Z9 5
U1 2
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2014
VL 35
IS 9
BP 9411
EP 9418
DI 10.1007/s13277-014-2123-6
PG 8
WC Oncology
SC Oncology
GA AR5ZQ
UT WOS:000343662000127
PM 24952889
DA 2018-12-27
ER

PT J
AU Blake, DF
   Young, DA
   Brown, LH
AF Blake, Denise F.
   Young, Derelle A.
   Brown, Lawrence H.
TI RETRACTED: Transcutaneous oximetry: normal values for the lower limb
   (Retracted article. See vol. 46, pg. 54, 2016)
SO DIVING AND HYPERBARIC MEDICINE
LA English
DT Article; Retracted Publication
DE Transcutaneous oximetry; hyperbaric oxygen therapy; wounds; patient
   monitoring; standards
ID CUTANEOUS OXYGEN-TENSION; NONDIABETIC PATIENTS; PRESSURE; DISEASE
AB Introduction: Current guidelines for transcutaneous oximetry measurement (TCOM) for the lower limb define tissue hypoxia as a transcutaneous oxygen partial pressure < 40 mmHg. Values obtained with some newer machines and current research bring these reference values into question.
   Aim: To determine 'normal' TCOM values for the lower limb in healthy, non-smoking adults using the TCM400 oximeter with tc Sensor E5250.
   Method: Thirty-two healthy, non-smoking volunteers had TCOM performed at six positions on the lower leg and foot. Measurements were taken with subjects lying supine breathing air, then with leg elevated and whilst breathing 100% oxygen.
   Results: Room-air TCOM values (mean mmHg, 95% confidence interval (CI)) were: lateral leg 41.3, CI 37.8 to 44.7; lateral malleolus 38.6, CI 34.1 to 43.1; medial malleolus 43.9, CI 40.2 to 47.6; dorsum, between first and second toe 39.3, CI 35.9 to 42.7; dorsum, proximal to fifth metatarsal-phalangeal joint 46.4, CI 43.4 to 49.3; plantar 52.3, CI 49.6 to 55.1. Using the currently accepted value of less than 40 mmHg for tissue hypoxia, 24 of our 32 'healthy' subjects had at least one air sensor reading that would have been classified as hypoxic. Seventeen subjects had TCOM values less than 100 mmHg when breathing 100% normobaric oxygen.
   Conclusion: Normal lower limb TCOM readings using the TCOM400 with tc Sensor E5250 may be lower than 40 mmHg, used to define tissue hypoxia, but consistent with the wide range of values found in the literature. Because of the wide variability in TCOM at the different sensor sites we cannot recommend one TCOM value as indicative of tissue hypoxia. A thorough clinical assessment of the patient is essential to establish appropriateness for hyperbaric oxygen treatment, with TCOM used as an aid to help guide this decision, but not as an absolute diagnostic tool.
C1 [Blake, Denise F.] Townsville Hosp, Emergency Dept, Douglas, Qld 4814, Australia.
   [Blake, Denise F.] James Cook Univ, Sch Marine & Trop Biol, Townsville, Qld 4811, Australia.
   [Young, Derelle A.] Townsville Hosp, Hyperbar Med Unit, Townsville, Qld, Australia.
   [Brown, Lawrence H.] James Cook Univ, Fac Med Hlth & Mol Sci, Mt Isa Ctr Rural & Remote Hlth, Townsville, Qld 4811, Australia.
RP Blake, DF (reprint author), Townsville Hosp, Emergency Dept, IMB 23, 100 Angus Smith Dr, Douglas, Qld 4814, Australia.
EM drsblakeinoz@bigpond.com
FU Townsville Hospital and Health Service Private Practice Research and
   Education Trust Fund
FX The authors gratefully acknowledge the financial assistance received
   from the Townsville Hospital and Health Service Private Practice
   Research and Education Trust Fund, and thank our subjects for their
   participation.
CR [Anonymous], 2009, PROD LIN TRANSC MON
   BACHARACH JM, 1992, J VASC SURG, V15, P558, DOI 10.1016/0741-5214(92)90196-F
   Biotteau E, 2009, INT ANGIOL, V28, P479
   CLARKE D, 1997, TRANSCUTANEOUS MONIT
   COLEMAN LS, 1986, CLIN PHYS PHYSIOL M, V7, P259, DOI 10.1088/0143-0815/7/3/006
   de Meijer VE, 2008, J VASC SURG, V48, P382, DOI 10.1016/j.jvs.2008.03.010
   Dooley J, 1997, UNDERSEA HYPERBAR M, V24, P235
   DOWD GSE, 1983, CLIN PHYS PHYSIOL M, V4, P65, DOI 10.1088/0143-0815/4/1/006
   DOWD GSE, 1983, J BONE JOINT SURG BR, V65, P79
   Fife CE, 2009, UNDERSEA HYPERBAR M, V36, P43
   HAUSER CJ, 1983, ANN SURG, V197, P337, DOI 10.1097/00000658-198303000-00014
   HAUSER CJ, 1984, SURGERY, V95, P689
   Hunt R, 1981, CRIT CARE MED, V9, P694
   OLERUD JE, 1987, SCAND J CLIN LAB INV, V47, P535
   Radiometer Medical ApS, 2004, TCPO2 HDB
   Radiometer Medical ApS, 2005, TCM400 TRANSC PO2 MO
   Rich K, 2001, J Vasc Nurs, V19, P55, DOI 10.1067/mvn.2001.115782
   Rooke TW, 1998, BLOOD GAS NEWS, V7, P21
   Rugangsetakit C, 2010, J WOUND CARE, V19, P202
   Shah JB, 2008, UNDERSEA HYPERBAR M, V35, P41
   Sheffield PJ, 1998, UNDERSEA HYPERBAR M, V25, P179
   Sheffield PJ., 1998, BLOOD GAS NEWS, V7, P10
   Smart DR, 2006, DIVING HYPERB MED, V36, P72
   Ueno H, 2010, J ATHEROSCLER THROMB, V17, P858, DOI 10.5551/jat.3723
   Young DA, 2012, DIVING HYPERB MED, V42, P208
NR 25
TC 4
Z9 4
U1 2
U2 7
PU SOUTH PACIFIC UNDERWATER MED SOC
PI MELBOURNE
PA C/O AUSTRALIAN & NEW ZEALAND COLL ANAESTHETISTS, 630 ST KILDA RD,
   MELBOURNE, VIC 3004, AUSTRALIA
SN 1833-3516
J9 DIVING HYPERB MED
JI Diving Hyperb. Med.
PD SEP
PY 2014
VL 44
IS 3
BP 146
EP 153
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ6EN
UT WOS:000342902700008
PM 25311321
DA 2018-12-27
ER

PT J
AU Azami, M
   Anvarinejad, M
   Ghalesefidi, MJ
AF Azami, M.
   Anvarinejad, M.
   Ghalesefidi, M. Jamshidian
TI RETRACTED: The important role of matrix metalloproteinases in nematode
   parasites (Retracted article. See vol. 52, pg. 166, 2015)
SO HELMINTHOLOGIA
LA English
DT Review; Retracted Publication
DE matrix metalloproteinase; endopeptidases; nematode parasites
ID ANGIOSTRONGYLUS-CANTONENSIS; EOSINOPHILIC MENINGITIS; INFECTIVE LARVAE;
   MATRIX-METALLOPROTEINASE-9; IDENTIFICATION; GENE; ACTIVATION;
   INHIBITORS; INDUCTION; FAMILY
AB Matrix metalloproteinases (MMPs) represent a large family of over twenty different secreted or membrane-bound endopeptidases, involved in many physiological (embryogenesis, precursor or stem cell mobilization, tissue remodeling during wound healing, etc.), as well as pathological (inflammation, tumor progression and metastasis in cancer, vascular pathology, etc.) conditions. For a long time, MMPs were considered only for the ability to degrade extracellular matrix (ECM) molecules (e.g., collagen, laminin, fibronectin) and to release hidden epitopes from the ECM. However, expressions of many MMPs have been associated with several pathological conditions. It has been established that the MMPs are conserved throughout the animal kingdom and studies of invertebrate have demonstrated that primarily they are involved in various developing functions in hydra, Drosophila, sea urchin and nematodes. The syntheses of these proteolytic enzymes and their release as excretory and secretory products have been reported in various parasitic nematodes. Host invasion and tissue migration of several nematodes have been linked to the expression and release of parasite-derived proteases. Studies with enzyme inhibitors suggest that the enzyme may be a metalloproteinase. Moreover, substrate impregnated zymographic analysis of extracts and excretory and secretory products of different nematode parasites have revealed the multiple enzyme activities of MMPs with various molecular weights. More research on MMP degradome in nematode parasites can provide valuable information for intense evaluation of pathogenesis caused by these parasites.
C1 [Azami, M.] Isfahan Univ Med Sci, Skin Dis & Leishmaniasis Res Ctr, Esfahan, Iran.
   [Anvarinejad, M.] Shiraz Univ Med Sci, Sch Med, Nemazee Teaching Hosp, Prof Alborzi Clin Microbiol Res Ctr, Shiraz, Iran.
   [Ghalesefidi, M. Jamshidian] Isfahan Univ Med Sci, Moddares Hosp, Esfahan, Iran.
RP Azami, M (reprint author), Isfahan Univ Med Sci, Skin Dis & Leishmaniasis Res Ctr, Esfahan, Iran.
EM anvarinejad@yahoo.com
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
   Anderson R. C., 2000, NEMATODE PARASITES V
   Babu S, 2012, MED CLIN IMMUNOLOGY, P367
   Clark IM, 2001, METHODS MOL BIOL
   Gallego SG, 2005, PARASITOL INT, V54, P123, DOI 10.1016/j.parint.2005.02.002
   Greaves D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4610
   HAWDON JM, 1995, EXP PARASITOL, V80, P205, DOI 10.1006/expr.1995.1025
   HEALER J, 1991, PARASITOLOGY, V103, P305, DOI 10.1017/S0031182000059588
   Hijova E, 2005, Bratisl Lek Listy, V106, P127
   HILL DE, 1993, EXP PARASITOL, V77, P170, DOI 10.1006/expr.1993.1074
   HOTEZ P, 1990, INFECT IMMUN, V58, P3883
   Hotez PJ, 2004, NEW ENGL J MED, V351, P799, DOI 10.1056/NEJMra032492
   Lai SC, 2005, PARASITOL RES, V97, P466, DOI 10.1007/s00436-005-1484-6
   Lai SC, 2005, PARASITOL RES, V95, P193, DOI 10.1007/s00436-004-1271-9
   Lai SC, 2004, ANN TROP MED PARASIT, V98, P715, DOI 10.1179/000349804225021479
   Lee HH, 2004, PARASITOL RES, V94, P321, DOI 10.1007/s00436-004-1196-3
   Mannello F., 2005, ISJ, V2, P69
   Massova I, 1998, FASEB J, V12, P1075
   MCDONNELL S., 1992, BIOCHEM SOC T, V27, P734
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Parks WC, 2001, RESPIR RES, V2, P10, DOI 10.1186/rr33
   PETRALANDA I, 1986, MOL BIOCHEM PARASIT, V19, P51, DOI 10.1016/0166-6851(86)90065-4
   Salter JP, 2002, J BIOL CHEM, V277, P24618, DOI 10.1074/jbc.M202364200
   Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5
   TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013
   Tort J, 1999, ADV PARASIT, V43, P161, DOI 10.1016/S0065-308X(08)60243-2
   Ugalde AP, 2010, METHODS MOL BIOL, V622, P3, DOI 10.1007/978-1-60327-299-5_1
   Uparanukraw P, 2001, PARASITOL RES, V87, P751, DOI 10.1007/s004360100440
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Wang XH, 2001, MOL PLANT MICROBE IN, V14, P536, DOI 10.1094/MPMI.2001.14.4.536
   Yatsuda AP, 2006, INFECT IMMUN, V74, P1989, DOI 10.1128/IAI.74.3.1989-1993.2006
   Yoshizaki T, 2002, ONCOL REP, V9, P607
NR 32
TC 1
Z9 1
U1 1
U2 16
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0440-6605
EI 1336-9083
J9 HELMINTHOLOGIA
JI Helminthologia
PD SEP
PY 2014
VL 51
IS 3
BP 167
EP 170
DI 10.2478/s11687-014-0225-8
PG 4
WC Parasitology; Zoology
SC Parasitology; Zoology
GA AP6TR
UT WOS:000342211200001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Diao, LW
   Zheng, J
   Pan, XD
   Zhang, W
   Wang, LF
   Sun, LZ
AF Diao, Li-Wei
   Zheng, Jun
   Pan, Xu-Dong
   Zhang, Wei
   Wang, Long-Fei
   Sun, Li-Zhong
TI RETRACTED: Application of piezoelectric nanogenerator in medicine:
   bio-experiment and theoretical exploration (Retracted article. See vol.
   7, pg. E65, 2015)
SO JOURNAL OF THORACIC DISEASE
LA English
DT Article; Retracted Publication
DE Implantable medical electronic device; wearable medical electronic
   device; piezoelectric nanogenerator; body mechanical energy;
   biomechanical energy harvester; new power source
ID ENERGY; GENERATOR; CONTRACTION; VENTRICLE; PRESSURE; DESIGN; HEART
AB Background: A large number of wearable and implantable electronic medical devices are widely used in clinic and playing an increasingly important role in diagnosis and treatment, but the limited battery capacity restricts their service life and function expansion. Piezoelectric nanogenerators can convert mechanical energy into electrical energy. Our experiment tries to find out if the piezoelectric nanogenerator fixed to the surface of the heart can convert the natural contractions and relaxations of the heart into stable electric energy for electronic medical devices such as pacemakers.
   Methods: We used Chinese miniature pig and prepared with standard open chest procedure. Then we fixed two opposite edges of the rectangular nanogenerator at the following three positions of the heart respectively to detect the electric voltage output: Position A, right ventricular surface, near the atrioventricular groove, parallel to the long axis of the heart; Position B, right ventricular surface, parallel to the atrioventricular groove; and Position C, left ventricular surface, near cardiac apex, parallel to the left anterior descending branch. Then we selected the place which has the highest voltage output to fix both ends of the nanogenerator and closed the chest of pig. We recorded the voltage output of nanogenerator under closed chest condition (natural condition) and compared the result with open chest condition. Finally we used Dopamine (positive inotropic agents) and Esmolol (negative inotropic agents) respectively to detect the relation between voltage output of nanogenerator and myocardial contractility.
   Results: With its both ends fixed on the surface of the heart, the piezoelectric nanogenerator produced stable voltage output from the mechanical contractions of the heart. Piezoelectric nanogenerator which was fixed at Position A produced the highest voltage output (3.1 V), compared with those fixed at Position B or Position C. The voltage is enough for the pacemaker's operation. The voltage output of piezoelectric nanogenerator at the natural condition (closed chest) was the same as the open chest condition and made a light emitting diode (LED) light continue to shine, which further confirmed its clinical application value. The voltage output of piezoelectric nanogenerator is positively correlated with the myocardial contractile force. The voltage output increased after we used positive inotropic agents and decreased after we used negative inotropic agents.
   Conclusions: Piezoelectric nanogenerators can convert the kinetic energy of the heart during the contractions and relaxations of the muscles to electric energy. The output voltage was stable in three positions on the surface of the heart. The highest voltage appeared on the surface of right ventricle, near atrioventricular groove, parallel to the long axis direction of the heart, which can be the potential new energy source for pacemakers. Piezoelectric nanogenerator can be used as cardiac function monitor in the future for its voltage output is positively correlated with myocardial contractile force.
C1 [Diao, Li-Wei; Zheng, Jun; Pan, Xu-Dong; Zhang, Wei; Wang, Long-Fei; Sun, Li-Zhong] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiac Surg, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing 100029, Peoples R China.
RP Sun, LZ (reprint author), Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiac Surg, Anzhen Rd 2, Beijing 100029, Peoples R China.
EM doctor_dlw@126.com
FU BSTC [2012DFA31110]; Research Special Fund for Public Welfare Industry
   of Health [201402009]
FX Piezoelectric nanogenerator was provided by Professor Xue Feng and
   Bing-Wei Lu from Engineering Mechanics and Materials of Tsinghua
   University. The project was supported by "International Science &
   Technology Cooperation Program of China" from BSTC (2012DFA31110) and
   "The Standard Diagnosis and Treatment and Key Technology Research of
   Aortic Dissection" from The Research Special Fund for Public Welfare
   Industry of Health (201402009).
CR Anton SR, 2007, SMART MATER STRUCT, V16, pR1, DOI 10.1088/0964-1726/16/3/R01
   ANZOLA J, 1956, AM J PHYSIOL, V184, P567
   Chen X, 2010, NANO LETT, V10, P2133, DOI 10.1021/nl100812k
   Dagdeviren C, 2014, P NATL ACAD SCI USA, V111, P1927, DOI 10.1073/pnas.1317233111
   Dagdeviren C, 2013, SMALL, V9, P3398, DOI 10.1002/smll.201300146
   Fan FR, 2012, NANO LETT, V12, P3109, DOI 10.1021/nl300988z
   Feng X, 2011, ACS NANO, V5, P3326, DOI 10.1021/nn200477q
   Fritz J, 2005, J COMPUT ASSIST TOMO, V29, P725, DOI 10.1097/01.rct.0000179596.86221.38
   Hu YF, 2012, ADV MATER, V24, P110, DOI 10.1002/adma.201103727
   Koutentakis M, 2014, J THORAC DIS, V6, pS173, DOI 10.3978/j.issn.2072-1439.2013.10.23
   Li Z, 2010, ADV MATER, V22, P2534, DOI 10.1002/adma.200904355
   Pfenniger A, 2014, ARTIF ORGANS, V38, pE68, DOI 10.1111/aor.12279
   Pfenniger A, 2013, ANN BIOMED ENG, V41, P2248, DOI 10.1007/s10439-013-0887-2
   Pfenniger A, 2013, MED ENG PHYS, V35, P1256, DOI 10.1016/j.medengphy.2013.01.001
   Pfenniger A, 2013, MED BIOL ENG COMPUT, V51, P741, DOI 10.1007/s11517-012-0989-2
   RUSHMER RF, 1955, CIRC RES, V3, P639, DOI 10.1161/01.RES.3.6.639
   Wang ZL, 2012, ANGEW CHEM INT EDIT, V51, P11700, DOI 10.1002/anie.201201656
   Wang ZL, 2006, SCIENCE, V312, P242, DOI 10.1126/science.1124005
   Zhu GA, 2010, NANO LETT, V10, P3151, DOI 10.1021/nl101973h
   Zurbuchen A, 2013, ANN BIOMED ENG, V41, P131, DOI 10.1007/s10439-012-0623-3
NR 20
TC 4
Z9 5
U1 3
U2 26
PU PIONEER BIOSCIENCE PUBL CO
PI HONG KONG
PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG,
   00000, PEOPLES R CHINA
SN 2072-1439
EI 2077-6624
J9 J THORAC DIS
JI J. Thorac. Dis.
PD SEP
PY 2014
VL 6
IS 9
BP 1300
EP 1306
DI 10.3978/j.issn.2072-1439.2014.09.03
PG 7
WC Respiratory System
SC Respiratory System
GA AP8PL
UT WOS:000342340800038
PM 25276373
DA 2018-12-27
ER

PT J
AU Sahoo, PK
   Mishra, B
AF Sahoo, P. K.
   Mishra, B.
TI RETRACTED: Kaluza-Klein dark energy model in the form of wet dark fluid
   in f(R, T) gravity (Retracted article. See vol. 92, 2014)
SO CANADIAN JOURNAL OF PHYSICS
LA English
DT Article; Retracted Publication
ID HUBBLE-SPACE-TELESCOPE; HIGH-REDSHIFT SUPERNOVAE; PROBE WMAP
   OBSERVATIONS; COSMOLOGICAL MODEL; GENERAL-RELATIVITY; EXTRA DIMENSIONS;
   QUANTUM-THEORY; UNIVERSE; CONSTRAINTS; WDF
AB In this paper, we have investigated the five-dimensional Kaluza-Klein space time with wet dark fluid (WDF), which is a candidate for dark energy (DE), in the framework of f(R, T) gravity. R and T denote the Ricci scalar and the trace of the energy-momentum tensor, respectively (Harko et al. Phys. Rev. D, 84, 024020 (2011)). We have used equation of state in the form of WDF for the DE component of the universe. It is modeled on the equation of state p = omega(rho-rho*). With the help of the power law and exponential law of volumetric expansion, we have derived the exact solutions of the corresponding field equations. The geometrical and physical parameters for both the models are studied. The model obtained here may represent the inflationary era in the early universe and very late time of the universe. It is concluded that the model obtained here shows that even in the presence of WDF, the universe indicates accelerated expansion of the universe.
C1 [Sahoo, P. K.; Mishra, B.] Birla Inst Technol & Sci Pilani, Dept Math, Hyderabad 500078, Andhra Pradesh, India.
RP Sahoo, PK (reprint author), Birla Inst Technol & Sci Pilani, Dept Math, Hyderabad Campus, Hyderabad 500078, Andhra Pradesh, India.
EM sahoomaku@rediffmail.com
OI SAHOO, PRADYUMN KUMAR/0000-0003-2130-8832; Mishra,
   Bivudutta/0000-0001-5527-3565
CR Adhav KS, 2012, ASTROPHYS SPACE SCI, V339, P365, DOI 10.1007/s10509-011-0963-8
   Adhav KS, 2011, INT J THEOR PHYS, V50, P339, DOI 10.1007/s10773-010-0530-z
   Adhav KS, 2011, INT J THEOR PHYS, V50, P164, DOI 10.1007/s10773-010-0504-1
   Ahmed N, 2014, INT J THEOR PHYS, V53, P289, DOI 10.1007/s10773-013-1809-7
   Akarsu O, 2010, GEN RELAT GRAVIT, V42, P763, DOI 10.1007/s10714-009-0878-7
   Allen SW, 2004, MON NOT R ASTRON SOC, V353, P457, DOI 10.1111/j.1365-2966.2004.08080.x
   ALVAREZ E, 1983, PHYS REV LETT, V51, P931, DOI 10.1103/PhysRevLett.51.931
   APPELQUIST T, 1983, PHYS REV LETT, V50, P141, DOI 10.1103/PhysRevLett.50.141
   Babicbev E, 2005, CLASSICAL QUANT GRAV, V22, P143, DOI 10.1088/0264-9381/22/1/010
   Bamba K., 2014, ARXIV14044255V1
   Bamba K, 2012, ASTROPHYS SPACE SCI, V342, P155, DOI 10.1007/s10509-012-1181-8
   Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253
   Capozziello S, 2006, PHYS LETT B, V639, P135, DOI 10.1016/j.physletb.2006.06.034
   Carroll SM, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.043528
   Chaubey R, 2013, ASTROPHYS SPACE SCI, V343, P415, DOI 10.1007/s10509-012-1204-5
   CHODOS A, 1980, PHYS REV D, V21, P2167, DOI 10.1103/PhysRevD.21.2818
   Clocchiatti A, 2006, ASTROPHYS J, V642, P1, DOI 10.1086/498491
   FORGACS P, 1979, GEN RELAT GRAVIT, V11, P205, DOI 10.1007/BF00762129
   FREUND PGO, 1982, NUCL PHYS B, V209, P146, DOI 10.1016/0550-3213(82)90106-7
   Garcia NM, 2011, J PHYS CONF SER, V314, DOI 10.1088/1742-6596/314/1/012056
   GROSS DJ, 1983, NUCL PHYS B, V226, P29, DOI 10.1016/0550-3213(83)90462-5
   GUTH AH, 1981, PHYS REV D, V23, P347, DOI 10.1103/PhysRevD.23.347
   Harko T, 2011, PHYS REV D, V84, DOI 10.1103/PhysRevD.84.024020
   Jain P, 2012, INT J THEOR PHYS, V51, P2546, DOI 10.1007/s10773-012-1134-6
   Jamil M, 2012, EUR PHYS J C, V72, DOI 10.1140/epjc/s10052-012-2137-4
   Jamil M, 2012, CENT EUR J PHYS, V10, P1065, DOI 10.2478/s11534-012-0103-2
   Kaluza T., 1921, BERLIN PHYS MATH, V966, pK1
   Klein O, 1926, NATURE, V118, P516, DOI 10.1038/118516a0
   Klein O, 1926, Z PHYS, V37, P895, DOI 10.1007/BF01397481
   Knop RA, 2003, ASTROPHYS J, V598, P102, DOI 10.1086/378560
   Mishra B, 2014, ASTROPHYS SPACE SCI, V349, P491, DOI 10.1007/s10509-013-1652-6
   Nojiri S, 2005, PHYS LETT B, V631, P1, DOI 10.1016/j.physletb.2005.10.010
   Nojiri S, 2008, PROG THEOR PHYS SUPP, P81, DOI 10.1143/PTPS.172.81
   Nojiri S, 2006, PHYS REV D, V74, DOI 10.1103/PhysRevD.74.046004
   Nojiri S, 2011, PHYS REP, V505, P59, DOI 10.1016/j.physrep.2011.04.001
   Paul BC, 2009, PHYS REV D, V79, DOI 10.1103/PhysRevD.79.083534
   Perlmutter S, 1998, NATURE, V391, P51, DOI 10.1038/34124
   Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221
   Ram S, 2013, ASTROPHYS SPACE SCI, V347, P389, DOI 10.1007/s10509-013-1517-z
   RANDJBARDAEMI S, 1984, PHYS LETT B, V135, P388, DOI 10.1016/0370-2693(84)90300-9
   Rao VUM, 2013, EUR PHYS J PLUS, V128, DOI 10.1140/epjp/i2013-13035-y
   Reddy DRK, 2013, ASTROPHYS SPACE SCI, V344, P253, DOI 10.1007/s10509-012-1304-2
   Reddy DRK, 2013, INT J THEOR PHYS, V52, P239, DOI 10.1007/s10773-012-1325-1
   Reddy DRK, 2012, INT J THEOR PHYS, V51, P3222, DOI 10.1007/s10773-012-1203-x
   Reddy DRK, 2012, ASTROPHYS SPACE SCI, V342, P249, DOI 10.1007/s10509-012-1158-7
   Riess AG, 2004, ASTROPHYS J, V607, P665, DOI 10.1086/383612
   Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499
   SAHDEV D, 1984, PHYS LETT B, V137, P155, DOI 10.1016/0370-2693(84)90220-X
   Sahoo PK, 2014, EUR PHYS J PLUS, V129, DOI 10.1140/epjp/i2014-14049-7
   Samanta GC, 2014, EUR PHYS J PLUS, V129, DOI 10.1140/epjp/i2014-14048-8
   Samanta GC, 2013, INT J THEOR PHYS, V52, P2303, DOI 10.1007/s10773-013-1513-7
   Seljak U, 2005, PHYS REV D, V71, DOI 10.1103/PhysRevD.71.103515
   SHAFI Q, 1983, PHYS LETT B, V129, P387, DOI 10.1016/0370-2693(83)90125-9
   Shamir MF, 2010, ASTROPHYS SPACE SCI, V330, P183, DOI 10.1007/s10509-010-0371-5
   Sharif M, 2012, ASTROPHYS SPACE SCI, V342, P237, DOI 10.1007/s10509-012-1150-2
   Sharif M, 2010, MOD PHYS LETT A, V25, P1281, DOI 10.1142/S0217732310032536
   Sharif M, 2009, CLASSICAL QUANT GRAV, V26, DOI 10.1088/0264-9381/26/23/235020
   Singh T, 2008, PRAMANA-J PHYS, V71, P447, DOI 10.1007/s12043-008-0124-y
   Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226
   Tegmark M, 2004, ASTROPHYS J, V606, P702, DOI 10.1086/382125
   Tonry JL, 2003, ASTROPHYS J, V594, P1, DOI 10.1086/376865
NR 61
TC 12
Z9 12
U1 3
U2 14
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-4204
EI 1208-6045
J9 CAN J PHYS
JI Can. J. Phys.
PD SEP
PY 2014
VL 92
IS 9
BP 1062
EP 1067
DI 10.1139/cjp-2014-0411
PG 6
WC Physics, Multidisciplinary
SC Physics
GA AP0AW
UT WOS:000341723900019
DA 2018-12-27
ER

PT J
AU Govindaraju, RS
   McCuen, RH
   Hantush, MM
AF Govindaraju, R. S.
   McCuen, R. H.
   Hantush, M. M.
TI RETRACTED: Publishing in the Journal of Hydrologic Engineering
   (Retracted article. See vol. 20, 08215002, 2015)
SO JOURNAL OF HYDROLOGIC ENGINEERING
LA English
DT Editorial Material; Retracted Publication
C1 [Govindaraju, R. S.] Purdue Univ, Sch Civil Engn, W Lafayette, IN 47907 USA.
   [McCuen, R. H.] Univ Maryland, Dept Civil & Environm Engn, College Pk, MD 20742 USA.
   [Hantush, M. M.] US EPA, USEPA Natl Risk Management Lab, Cincinnati, OH 45268 USA.
RP McCuen, RH (reprint author), Univ Maryland, Dept Civil & Environm Engn, College Pk, MD 20742 USA.
EM rhmccuen@eng.umd.edu
NR 0
TC 1
Z9 1
U1 4
U2 13
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 1084-0699
EI 1943-5584
J9 J HYDROL ENG
JI J. Hydrol. Eng.
PD SEP
PY 2014
VL 19
IS 9
AR 01814001
DI 10.1061/(ASCE)HE.1943-5584.0001031
PG 1
WC Engineering, Civil; Environmental Sciences; Water Resources
SC Engineering; Environmental Sciences & Ecology; Water Resources
GA AP7AC
UT WOS:000342228800001
DA 2018-12-27
ER

PT J
AU Huang, JW
   Liu, B
   Hu, BS
   Li, Y
   He, X
   Zhao, W
   Zheng, YB
   Lu, LG
AF Huang, Jian-wen
   Liu, Bing
   Hu, Bao-shan
   Li, Yong
   He, Xu
   Zhao, Wei
   Zheng, You-bing
   Lu, Li-gong
TI RETRACTED: Clinical value of circulating tumor cells for the prognosis
   of postoperative transarterial chemoembolization therapy (Retracted
   article. See vol. 31, 277, 2014)
SO MEDICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE Circulating tumor cells; Transarterial chemoembolization; Hepatocellular
   carcinoma; Recurrence; Epithelial cell adhesion molecule
ID HEPATOCELLULAR-CARCINOMA HCC; ARTERIAL CHEMOEMBOLIZATION;
   GLOBAL-PERSPECTIVE; RESECTION; HEPATECTOMY; RECURRENCE; SURVIVAL
AB The aim of this study was to clarify circulating tumor cells (CTCs) count could reflect the effect of postoperative transarterial chemoembolization therapy. A single-blind, two-parallel group, randomized trial was conducted in Guangdong General Hospital, Guangzhou, China, with patients: (1) with biopsy-confirmed hepatocellular carcinoma (HCC) and (2) undergoing partial resection. Patients in transarterial chemoembolization (TACE) group received TACE 1 month after resection, while control group received no managements. The time points for blood collection to count CTCs were as follows: (1) 1 month after resection (also 1 day before TACE); (2) 1 month after TACE; (3) 2 months after TACE; (4) 3 months after TACE; (5) 6 months after TACE; and (6) 1 year after TACE. A diagnosis of recurrence was based on computed tomography scans, magnetic resonance imaging, or digital subtraction angiography. We compared recurrence rate (RR) and CTC counts between groups. Between July 2010 and July 2012, 171 patients (TACE group: n = 81; control group: n = 90) were recruited. After TACE, mean CTC count in TACE group was 1.32 (CI 2.59-3.34), compared with 3.65 (CI 3.43-3.88) in control group (F = 200.89, P<0.05). CTCs counts were statistically significantly between groups at post-TACE time points. In addition, RR of TACE group was 25.9 % (21/81), while the numberwas 56.7 % (51/90) in control group. RR was statistically significantly between groups (P = 0.031). CTCs count was an important prognostic parameter for postoperative TACE on HCC recurrence.
C1 [Huang, Jian-wen; Hu, Bao-shan; Li, Yong; He, Xu; Zhao, Wei; Zheng, You-bing; Lu, Li-gong] Guangdong Acad Med Sci, Dept Intervent Radiol, Ctr Canc, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China.
   [Liu, Bing] Guangdong Acad Med Sci, Dept Intervent Radiol, Ctr Canc, Guangdong Gen Hosp,Guangdong Cardiovasc Inst, Guangzhou, Guangdong, Peoples R China.
RP Lu, LG (reprint author), Guangdong Acad Med Sci, Dept Intervent Radiol, Ctr Canc, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China.
EM luligong1969@163.com
FU Science and Technology Foundation of Guangdong Province, China
   [2011A030400009]; Natural Science Foundation of Guangdong Province,
   China [S2012010010569]
FX This research was funded by Science and Technology Foundation of
   Guangdong Province, China (Grant No. 2011A030400009); and Natural
   Science Foundation of Guangdong Province, China (Grant No.
   S2012010010569).
CR Arii S, 1998, J Hepatobiliary Pancreat Surg, V5, P86, DOI 10.1007/PL00009956
   Cao G, 2012, WORLD J GASTROENTERO, V18, P6134, DOI 10.3748/wjg.v18.i42.6134
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Fan ST, 2011, ANN SURG, V254, P569, DOI 10.1097/SLA.0b013e3182300a1d
   Ferenci P, 2010, J GASTROINTEST LIVER, V19, P311
   Ferenci P, 2010, J CLIN GASTROENTEROL, V44, P239, DOI 10.1097/MCG.0b013e3181d46ef2
   Fong YM, 1999, ANN SURG, V229, P790, DOI 10.1097/00000658-199906000-00005
   Kaiser J, 2010, SCIENCE, V327, P1072, DOI 10.1126/science.327.5969.1074
   LI JQ, 1995, J CANCER RES CLIN, V121, P364, DOI 10.1007/BF01225689
   Minagawa M, 2003, ANN SURG, V238, P703, DOI 10.1097/01.sla.0000094549.11754.e6
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Poon RTP, 2002, J CLIN ONCOL, V20, P1775, DOI 10.1200/JCO.2002.07.089
   Poon RTP, 2001, ANN SURG, V234, P63, DOI 10.1097/00000658-200107000-00010
   Ren ZG, 2004, WORLD J GASTROENTERO, V10, P2791
   Sun YF, 2013, HEPATOLOGY, V57, P1458, DOI 10.1002/hep.26151
   van de Stolpe A, 2011, CANCER RES, V71, P5955, DOI 10.1158/0008-5472.CAN-11-1254
   Vogl TJ, 2012, ACAD RADIOL, V19, P434, DOI 10.1016/j.acra.2011.12.009
   Wu LJ, 2012, CANCER LETT, V326, P17, DOI 10.1016/j.canlet.2012.07.024
   Xu W, 2011, CLIN CANCER RES, V17, P3783, DOI 10.1158/1078-0432.CCR-10-0498
NR 19
TC 2
Z9 3
U1 3
U2 19
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD SEP
PY 2014
VL 31
IS 9
AR 175
DI 10.1007/s12032-014-0175-5
PG 5
WC Oncology
SC Oncology
GA AP1MW
UT WOS:000341835700046
PM 25134918
DA 2018-12-27
ER

PT J
AU Ruhullah, M
   Singh, HR
   Shah, S
   Shrestha, D
AF Ruhullah, Mohammad
   Singh, Hare Ram
   Shah, Sanjay
   Shrestha, Dipak
TI RETRACTED: Hip spica versus Rush pins for management of femoral
   diaphyseal fractures in children(Retracted article.See
   vol.50,pg.579,2016)
SO INDIAN JOURNAL OF ORTHOPAEDICS
LA English
DT Article; Retracted Publication
DE Femoral fractures; hip spica; Rush pins; diaphyseal fractures MeSH
   terms: Femoral fracture; intramedullary nailing; pediatric
ID PEDIATRIC FEMUR FRACTURES; SHAFT FRACTURES; STAINLESS-STEEL; NAIL
   FIXATION; BIOMECHANICAL ANALYSIS; TITANIUM NAILS; CAST TREATMENT;
   COMPLICATIONS
AB Background: Femoral fractures are common in children between 2 and 12 years of age and 75% of the lesions affect the femoral shaft. Traction followed by a plaster cast is universally accepted as conservative treatment. We compared primary hip spica with closed reduction and fixation with retrogradely passed crossed Rush pins for diaphyseal femur fracture in children. The hypothesis was that Rush pin might provide better treatment with good clinical results in comparison with primary hip spica. Materials and Methods: Fifty children with femoral fractures were evaluated; 25 of them underwent conservative treatment using immediate hip spica (group A) and 25 were treated with crossed retrograde Rush pins (group B). The patients ages ranged from 3 to 13 years (mean of 9 years). Results: Mean duration of fracture union was 15 weeks in group A and 12 weeks in group B. Mean duration of weight bearing 14 weeks in group and 7 weeks in group B. Mean hospital stay was 4 days in group A and 8 days in group B. Mean followup period in group A was 16 months and group B was 17 months. Complications such as angulation, shortening, infection were compared. Conclusions: Closed reduction and internal fixation with crossed Rush pins was superior in terms of early weight bearing and restoration of normal anatomy.
C1 [Ruhullah, Mohammad] Natl Med Coll Teaching Hosp, Dept Orthopaed, Birgunj, Nepal.
   [Singh, Hare Ram; Shah, Sanjay] Natl Med Coll, Birgunj, Nepal.
   [Shrestha, Dipak] Dhulikhel Hosp, Dhulikhel, Nepal.
RP Ruhullah, M (reprint author), Natl Med Coll Teaching Hosp, Dept Orthopaed, Birgunj, Nepal.
EM drruhullah@yahoo.com
FU National Medical College; KU Teaching Hospital
FX Source of Support: National Medical College and KU Teaching Hospital,
   Conflict of Interest: None.
CR Bopst L, 2007, J PEDIATR ORTHOPED, V27, P299, DOI 10.1097/BPO.0b013e3180326713
   Cramer KE, 2000, CLIN ORTHOP RELAT R
   Flynn JM, 2004, J AM ACAD ORTHOP SUR, V12, P347, DOI 10.5435/00124635-200409000-00009
   Flynn JM, 2001, J PEDIATR ORTHOPED, V21, P4, DOI 10.1097/01241398-200101000-00003
   Fricka KB, 2004, J PEDIATR ORTHOPED, V24, P167, DOI 10.1097/01241398-200403000-00006
   HEINRICH SD, 1994, J PEDIATR ORTHOPED, V14, P501, DOI 10.1097/01241398-199407000-00016
   HUGHES BF, 1995, J PEDIATR ORTHOPED, V15, P457, DOI 10.1097/01241398-199507000-00009
   Kasser JR, 2001, ROCKWOOD WILKINS FRA, P948
   KIRBY RM, 1981, J PEDIATR ORTHOPED, V1, P193, DOI 10.1097/01241398-198110000-00010
   Lee SS, 2001, J PEDIATR ORTHOPED, V21, P442, DOI 10.1097/00004694-200107000-00005
   Lee Zhon-Liau, 2005, Chang Gung Med J, V28, P9
   LIGIER JN, 1988, J BONE JOINT SURG BR, V70, P74
   Mahar AT, 2004, J PEDIATR ORTHOPED, V24, P638, DOI 10.1097/01241398-200411000-00008
   MANN DC, 1986, J PEDIATR ORTHOPED, V6, P651, DOI 10.1097/01241398-198611000-00002
   Nascimento FP, 2010, J CHILD ORTHOP, V4, P53, DOI 10.1007/s11832-009-0227-0
   Rathjen KE, 2007, J PEDIATR ORTHOPED, V27, P432, DOI 10.1097/01.bpb.0000271322.48987.46
   Simanovsky N, 2006, J PEDIATR ORTHOP B, V15, P293, DOI 10.1097/01202412-200607000-00012
   Staheli LT, 1977, CLIN ORTHOP RELAT R, V126, P162
   Vrsansky P, 2000, J PEDIATR ORTHOPED, V20, P23, DOI 10.1097/00004694-200001000-00006
   Wall EJ, 2008, J BONE JOINT SURG AM, V90A, P1305, DOI 10.2106/JBJS.G.00328
NR 20
TC 3
Z9 4
U1 1
U2 5
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0019-5413
EI 1998-3727
J9 INDIAN J ORTHOP
JI Indian J. Orthop.
PD SEP-OCT
PY 2014
VL 48
IS 5
BP 488
EP 494
DI 10.4103/0019-5413.139860
PG 7
WC Orthopedics
SC Orthopedics
GA AP1RH
UT WOS:000341848300009
PM 25298556
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yang, YH
   Yarka, C
   Cao, J
   Ehmann, K
AF Yang, Yunho
   Yarka, Christopher
   Cao, Jian
   Ehmann, Kornel
TI RETRACTED: Feasibility of using Copper(II)Oxide for additive
   manufacturing (Retracted article. See vol. 16, pg. 2607, 2015)
SO INTERNATIONAL JOURNAL OF PRECISION ENGINEERING AND MANUFACTURING
LA English
DT Article; Retracted Publication
DE Furnace sintering; 3D printing; FDM; Copper(II) oxide; Debinding;
   Chemical reduction
AB Additive manufacturing, in spite of its ever wider application range, is still plagued by issues ranging from accuracy to surface finish. In this study, to address the latter issue, the feasibility of using Copper(II)Oxide powder with a polymer binder deposited through a Fused Deposition Modeling (FDM) 3D printing technique is explored. In particular, the post processing of the green components through a newly developed furnace sintering process is investigated. The properties of the generated test samples were assessed by using Scanning Electron Microscope (SEM), surface roughness and optical analysis methods in addition to properties of the sintered samples through Energy Dispersive X-Ray Spectrometry (EDS).
C1 [Yang, Yunho; Yarka, Christopher; Cao, Jian; Ehmann, Kornel] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA.
RP Yang, YH (reprint author), Northwestern Univ, Dept Mech Engn, 2145 Sheridan Rd, Evanston, IL 60208 USA.
EM yunho.yang1@gmail.com
RI Cao, Jian/B-7544-2009; Ehmann, Kornel/B-7593-2009
OI Cao, Jian/0000-0003-1023-5244
FU Advanced Manufacturing Processes Laboratory (AMPL) at Northwestern
   University
FX Parts of this research were supported by the Advanced Manufacturing
   Processes Laboratory (AMPL) at Northwestern University.
CR Ahn SH, 2002, RAPID PROTOTYPING J, V8, P248, DOI 10.1108/13552540210441166
   Cochran J. K., 2001, P 4 C AER MAT PROC E
   Dezso G., 2012, ANN FACULTY ENG HUNE, V2, P181
   Quadbeck P., 2010, WORLD PM, V2, P239
   Ramos AIC, 2012, METALS-BASEL, V2, P265, DOI 10.3390/met2030265
   Rivera T., 2011, SYNTHESIS THERMOLUMI, P127
   SACHS E, 1992, J ENG IND-T ASME, V114, P481
   Sachs E., 1994, P SOL FREEF FABR S, P56
   THUMMLER F, 1967, METALL REV, V12, P69
   Wang AJ, 2005, MECH ADV MATER STRUC, V12, P185, DOI 10.1080/15376490590928534
NR 10
TC 3
Z9 3
U1 3
U2 38
PU KOREAN SOC PRECISION ENG
PI SEOUL
PA RM 306, KWANGMYUNG BLDG, 5-4 NONHYUN-DONG, KANGNAM-GU, SEOUL, 135-010,
   SOUTH KOREA
SN 2234-7593
EI 2005-4602
J9 INT J PRECIS ENG MAN
JI Int. J. Precis. Eng. Manuf.
PD SEP
PY 2014
VL 15
IS 9
BP 1961
EP 1965
DI 10.1007/s12541-014-0551-2
PG 5
WC Engineering, Manufacturing; Engineering, Mechanical
SC Engineering
GA AP1LD
UT WOS:000341830500023
DA 2018-12-27
ER

PT J
AU Caro-Tarrago, A
   Olona-Casas, C
   Olona-Cabases, M
   Guillen, VV
AF Caro-Tarrago, Aleidis
   Olona-Casas, Carles
   Olona-Cabases, Montserrat
   Vicente Guillen, Vicente
TI RETRACTED: Impact on Quality of Life of Using an Onlay Mesh to Prevent
   Incisional Hernia in Midline Laparotomy: A Randomized Clinical Trial
   (Retracted article. See vol. 220, pg. 126, 2015)
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article; Retracted Publication
ID SF-36 HEALTH SURVEY; HIGH-RISK PATIENTS; SPANISH VERSION; ABDOMINAL
   INCISIONS; REFERENCE VALUES; BODY-IMAGE; CLOSURE; SURGERY; REPAIR;
   COHORT
AB BACKGROUND: Recent studies have demonstrated the effectiveness of using prophylactic meshes to achieve abdominal wall closure, decreasing the risk of incisional hernia. However, the effect of prophylactic mesh placement on a patient's quality of life has not yet been evaluated.
   STUDY DESIGN: A controlled, prospective, randomized, and blind study was carried out. The patients in group A (mesh) were fitted with a polypropylene mesh to reinforce the standard abdominal wall closure. The patients in group B (nonmesh) were given a standard abdominal wall closure and were not fitted with the mesh. All patients were administered the 36-Item Short-Form generic health questionnaire during their preoperation visit and during their 1-month, 6-month, and 1-year follow-up appointments. The scores of the questionnaires have been compared with those recorded when the questionnaire was administered before surgery.
   RESULTS: The Kaplan-Meier survival curves show that the likelihood of incisional hernia at 12 months is 1.5% in mesh group compared with 35.9% in nonmesh group (p > 0.0001), which means that the differences are statistically significant. Patients with mesh placement had greater improvement in general health and bodily pain than patients in nonmesh group at 1-month and 6-month post operation. One year after operation, patients in the mesh group had statistically significant better quality of life than patients in the nonmesh group in the physical functioning, general health perceptions, vitality, social role functioning, mental health, physical component summary and mental component summary dimensions.
   CONCLUSIONS: Fitting a prophylactic supra-aponeurotic mesh prevents incisional hernia. (C) 2014 by the American College of Surgeons
C1 [Caro-Tarrago, Aleidis] Parc Tauli Univ Hosp, Gen & Digest Surg Dept, Barcelona 08208, Spain.
   [Olona-Casas, Carles; Vicente Guillen, Vicente] Univ Hosp Joan XXIII, Gen & Digest Surg Dept, Tarragona, Spain.
   [Olona-Cabases, Montserrat] Univ Hosp Joan XXIII, Dept Prevent Med, Tarragona, Spain.
RP Caro-Tarrago, A (reprint author), Parc Tauli Univ Hosp, Gen & Digest Surg Serv, Parc Tauli S-N, Barcelona 08208, Spain.
EM dra5028@gmail.com
CR ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771
   Alonso J, 1998, MED CLIN-BARCELONA, V111, P410
   Pereira JA, 2013, CIR ESPAN, V91, P44, DOI 10.1016/j.ciresp.2012.05.004
   Apolone G, 1998, ANN ONCOL, V9, P549, DOI 10.1023/A:1008264412398
   Bellon JM, 2006, J AM COLL SURGEONS, V203, P490, DOI 10.1016/j.jamcollsurg.2006.06.023
   Bellon JM, 2009, CIR ESPAN, V85, P268, DOI 10.1016/j.ciresp.2009.01.012
   Bevis PM, 2010, BRIT J SURG, V97, P1497, DOI 10.1002/bjs.7137
   Bringman S, 2010, HERNIA, V14, P81, DOI 10.1007/s10029-009-0587-x
   Caro A, 2012, COLORECTAL DIS, V14, pE470, DOI 10.1111/j.1463-1318.2012.03011.x
   Caro A, 2014, WORLD J SURG
   Dilege E, 2010, J INVEST SURG, V23, P262, DOI 10.3109/08941939.2010.481008
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Eisen GM, 1999, AM J GASTROENTEROL, V94, P2017
   El-Khadrawy OH, 2009, HERNIA, V13, P267, DOI 10.1007/s10029-009-0484-3
   Gutierrez de la Pena C, 2003, Hernia, V7, P134
   Heniford BT, 2008, J AM COLL SURGEONS, V206, P638, DOI 10.1016/j.jamcollsurg.2007.11.025
   Jenkins TNP, 1976, BRIT J SURG, V63, P837
   Karnosfsky DA, 1947, EVALUATION CHEMOTHER, P37
   Khan LR, 2010, HERNIA, V14, P39, DOI 10.1007/s10029-009-0558-2
   Klinge U, 2000, EUR SURG RES, V32, P43, DOI 10.1159/000008740
   Lainez MJA, 2007, AN MED INTERN, V24, P3
   Llaguna OH, 2011, WORLD J SURG, V35, P1651, DOI 10.1007/s00268-011-1131-6
   Lopez-Cano M, 2013, J SURG RES, V181, P160, DOI 10.1016/j.jss.2012.05.041
   Lopez-Garcia E, 2003, MED CLIN-BARCELONA, V120, P568, DOI 10.1157/13046436
   Mones J, 2004, CIR ESPAN, V76, P71
   Nieuwenhuizen J, 2007, SCAND J SURG, V96, P293, DOI 10.1177/145749690709600406
   Sajid MS, 2012, BRIT J SURG, V99, P29, DOI 10.1002/bjs.7718
   Schumpelick Volker, 2006, J Minim Access Surg, V2, P117
   Strzelczyk JM, 2006, BRIT J SURG, V93, P1347, DOI 10.1002/bjs.5512
   Sun YF, 2011, HEPATO-GASTROENTEROL, V58, P669
   Urbach DR, 2006, QUAL LIFE RES, V15, P1053, DOI 10.1007/s11136-006-0047-3
   van Ramshorst GH, 2013, J GASTROINTEST SURG, V17, P1477, DOI 10.1007/s11605-013-2233-2
   van Ramshorst GH, 2012, AM J SURG, V204, P144, DOI 10.1016/j.amjsurg.2012.01.012
   van't Riet M, 2002, BRIT J SURG, V89, P1350, DOI 10.1046/j.1365-2168.2002.02258.x
   Vilagut Gemma, 2005, Gac Sanit, V19, P135, DOI 10.1157/13074370
   Vilagut G, 2008, MED CLIN-BARCELONA, V130, P726, DOI 10.1157/13121076
   Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008
   Welty G, 2001, Hernia, V5, P142
   Wormer BA, 2013, J SURG RES, V184, P169, DOI 10.1016/j.jss.2013.04.034
NR 39
TC 3
Z9 5
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD SEP
PY 2014
VL 219
IS 3
BP 470
EP 479
DI 10.1016/j.jamcollsurg.2014.03.053
PG 10
WC Surgery
SC Surgery
GA AO5VW
UT WOS:000341415100019
PM 25087939
DA 2018-12-27
ER

PT J
AU Ma, HY
   Zhou, HM
   Li, P
   Song, XB
   Miao, XY
   Li, YP
   Jia, L
AF Ma, Hongye
   Zhou, Huimin
   Li, Peng
   Song, Xiaobo
   Miao, Xiaoyan
   Li, Yanping
   Jia, Li
TI RETRACTED: Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and
   multidrug resistance in human acute myeloid leukemia (Retracted article.
   See vol. 1842, pg. 2532, 2014)
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article; Retracted Publication
DE MDR; FUT7; ST3GAL4; sLe X; Acute myeloid leukemia cells
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; SIGNALING PATHWAY; P-GLYCOPROTEIN;
   BREAST-CANCER; CELL-LINES; IN-VITRO; EXPRESSION; ACTIVATION; INHIBITION;
   PROTEIN-1
AB Sialyl Lewis X (sLe X, CD15s) is a key antigen produced on tumor cell surfaces during multidrug resistance (MDR) development. The present study investigated the effect of alpha 1, 3 fucosyltransferase VII (FucT VII) and alpha 2, 3 sialyltransferase IV (ST3Gal IV) on sLe X oligosaccharides synthesis as well as their impact on MDR development in acute myeloid leukemia cells (AML). FUT7 and ST3GAL4 were overexpressed in three AML MDR cells and bone marrow mononuclear cells (BMMC) of AML patients with MDR by real-time polymerase chain reaction (PCR). A close association was found between the expression levels of FUT7 and ST3GAL4 and the amount of sLe X oligosaccharides, as well as the phenotypic variation of MDR of HL60 and HL60/ADR cells both in vitro and in vivo. Manipulation of these two genes' expression modulated the activity of phosphoinositide-3 kinase (PI3K)/Akt signaling pathway, thereby regulating the proportionally mutative expression of P-glycoprotein (P-gp) and multidrug resistance related protein I (MRP1), both of which are known to be involved in MDR. Blocking the PI3K/Akt pathway by its specific inhibitor LY294002 or Akt short hairpin RNA (shRNA) resulted in the reduced MDR of HL60/ADR cells. This study indicated that sLe X involved in the development of MDR of AML cells probably through FUT7 and ST3GAL4 regulating the activity of PI3K/Akt signaling pathway and the expression of P-gp and MRP1. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Ma, Hongye; Miao, Xiaoyan; Li, Yanping; Jia, Li] Dalian Med Univ, Coll Lab Med, Dalian 116044, Liaoning Provin, Peoples R China.
   [Zhou, Huimin] Dalian Med Univ, Dept Microbiol, Dalian 116044, Liaoning Provin, Peoples R China.
   [Li, Peng] Dalian Med Univ, Affiliated Hosp 2, Dept Bone Surg, Dalian 116044, Liaoning Provin, Peoples R China.
   [Song, Xiaobo] Univ Tromso, Fac Hlth Sci, Dept Med Biol, Tromso, Norway.
RP Jia, L (reprint author), Dalian Med Univ, Coll Lab Med, 9 Lvshunnan Rd Xiduan, Dalian 116044, Liaoning Provin, Peoples R China.
EM jiali@dlmedu.edu.cn
FU National Natural Science Foundation of China [81271910]; National Key
   Basic Research and Development Program of China (973 program)
   [2012CB822100]; Project for Liaoning BaiQianWan Talents Program
   [2012921014]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81271910), the National Key Basic Research and
   Development Program of China (973 program) (no. 2012CB822100), and the
   Project for Liaoning BaiQianWan Talents Program (2012921014).
CR Abdul-Ghani R, 2006, ONCOGENE, V25, P1743, DOI 10.1038/sj.onc.1209201
   Amado M, 1998, GASTROENTEROLOGY, V114, P462, DOI 10.1016/S0016-5085(98)70529-3
   Baldus SE, 1998, TUMOR BIOL, V19, P445, DOI 10.1159/000030036
   Bao RD, 2009, MOL CANCER THER, V8, P3296, DOI 10.1158/1535-7163.MCT-09-0538
   Barancik M, 2006, EUR J PHARM SCI, V29, P426, DOI 10.1016/j.ejps.2006.08.006
   Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(04)94002-X
   Berrie CP, 2001, EXPERT OPIN INV DRUG, V10, P1085, DOI 10.1517/13543784.10.6.1085
   Billottet C, 2009, CANCER RES, V69, P1027, DOI 10.1158/0008-5472.CAN-08-2608
   Cazet A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2577
   de Vries T, 2001, GLYCOBIOLOGY, V11, p119R, DOI 10.1093/glycob/11.10.119R
   Deschler B, 2006, CANCER-AM CANCER SOC, V107, P2099, DOI 10.1002/cncr.22233
   DEVRIES T, 2001, GLYCOBIOLOGY, V11, P119
   Dimitroff CJ, 2004, CANCER RES, V64, P5261, DOI 10.1158/0008-5472.CAN-04-0691
   Garcia MG, 2009, LEUKEMIA RES, V33, P288, DOI 10.1016/j.leukres.2008.06.010
   Gomes C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066737
   Grabowski P, 2000, INT J CANCER, V88, P281, DOI 10.1002/1097-0215(20001015)88:2<281::AID-IJC21>3.3.CO;2-U
   Harduin-Lepers A, 2005, GLYCOBIOLOGY, V15, P805, DOI 10.1093/glycob/cwi063
   Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3
   Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469
   Kourti M, 2007, INT J HEMATOL, V86, P166, DOI 10.1532/IJH97.E0624
   Li L, 2010, ONCOGENE, V29, P5785, DOI 10.1038/onc.2010.303
   Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108
   Ma B, 2006, GLYCOBIOLOGY, V16, p158R, DOI 10.1093/glycob/cwl040
   Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245
   Morishita N, 2012, PEDIATR BLOOD CANCER, V59, P83, DOI 10.1002/pbc.24034
   Nakamura M, 1999, GLYCOBIOLOGY, V9, P1, DOI 10.1093/glycob/9.1.1
   Nakano M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009001
   Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479
   Parasrampuria Ridhi, 2011, Drug Metab Lett, V5, P64, DOI 10.2174/187231211794455244
   Potapenko IO, 2010, MOL ONCOL, V4, P98, DOI 10.1016/j.molonc.2009.12.001
   Qi HL, 2003, EUR J BIOCHEM, V270, P3795, DOI 10.1046/j.1432-1033.2003.03767.x
   Radhakrishnan P, 2007, BIOCHEM BIOPH RES CO, V359, P457, DOI 10.1016/j.bbrc.2007.05.165
   Reis CA, 2010, J CLIN PATHOL, V63, P322, DOI 10.1136/jcp.2009.071035
   ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780
   Russo RIC, 2008, INT J CANCER, V122, P1012, DOI 10.1002/ijc.23122
   SASAKI K, 1993, J BIOL CHEM, V268, P22782
   Shimodaira K, 1997, CANCER RES, V57, P5201
   Su H., 2009, MOL CELL BIOCHEM, V331, P81
   Tazzari PL, 2007, LEUKEMIA, V21, P427, DOI 10.1038/sj.leu.2404523
   Van Der Kolk DM, 2002, LEUKEMIA LYMPHOMA, V43, P685, DOI 10.1080/10428190290016773
   Varki A, 2009, PROTEOMICS, V9, P5398, DOI 10.1002/pmic.200900708
   Wu Q, 2009, J HUAZHONG U SCI-MED, V29, P451, DOI 10.1007/s11596-009-0412-x
   Zhang ZH, 2012, INT J BIOCHEM CELL B, V44, P1244, DOI 10.1016/j.biocel.2012.04.026
   Zhou H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.186
NR 44
TC 3
Z9 3
U1 2
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 0006-3002
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD SEP
PY 2014
VL 1842
IS 9
BP 1681
EP 1692
DI 10.1016/j.bbadis.2014.06.014
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA AO0BZ
UT WOS:000340975400040
PM 24953795
OA Bronze
DA 2018-12-27
ER

PT J
AU Babaei, A
   Mashhadi, MM
AF Babaei, A.
   Mashhadi, M. M.
TI RETRACTED: Characterization of ultrafine-grained aluminum tubes
   processed by Tube Cyclic Extrusion-Compression (TCEC) (Retracted
   article. See vol. 130, pg. 312, 2017)
SO MATERIALS CHARACTERIZATION
LA English
DT Article; Retracted Publication
DE Tube Cyclic Extrusion-Compression; Severe plastic deformation; Ultrafine
   grained; Microhardness; Mechanical properties
ID SEVERE PLASTIC-DEFORMATION; ANGULAR PRESSING TCAP; HIGH-PRESSURE
   TORSION; MECHANICAL-PROPERTIES; MICROSTRUCTURAL EVOLUTION;
   NANOSTRUCTURED TUBES; CYLINDRICAL-TUBES; SHRINKING RTES; SPD METHOD;
   REFINEMENT
AB Tube Cyclic Extrusion-Compression as a novel severe plastic deformation technique for tubes was utilized for processing ultrafine grained 1050 aluminum alloy for the first time. In this method, aluminum tube is fully constrained and deformed between mandrel and chamber with a small neck zone. The material deformation during Tube Cyclic Extrusion-Compression processing analyzed and the grain refinement mechanism were described. The capability of Tube Cyclic Extrusion-Compression in grain refinement of the aluminum alloy was demonstrated by transmission electron microscopy observations and X-ray diffraction line profile analysis. The micrographs of the evolved microstructure show grain size of 850 nm and 550 nm after the first and second processing cycles of Tube Cyclic Extrusion-Compression, respectively. Mechanical properties of the initial and processed specimens were extracted from ring-hoop tensile tests. The documented results confirm grain refinement by showing remarkable increase in the yield and ultimate strengths. The main increase in strength and decrease in elongation take place after the first cycle. The microhardness assessments illustrate increase from the initial value of 29 Hv to 44 and 49 Hv respectively after the first and second cycles of Tube Cyclic Extrusion-Compression. There is a good homogeneity in peripheral microhardness and microhardness across the tube thickness. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Babaei, A.; Mashhadi, M. M.] Univ Tehran, Univ Coll Engn, Dept Mech Engn, Tehran, Iran.
RP Babaei, A (reprint author), Univ Tehran, Dept Mech Engn, Coll Engn, POB 515-14395, Tehran, Iran.
EM A_babaei@ut.ac.ir
CR Arzaghi M, 2012, ACTA MATER, V60, P4393, DOI 10.1016/j.actamat.2012.04.035
   Avitzur B, 1979, METALS FORMING PROCE
   Azimi A, 2012, MATER DESIGN, V42, P388, DOI 10.1016/j.matdes.2012.06.035
   Babaei A, 2014, MAT SCI ENG A-STRUCT, V598, P1, DOI 10.1016/j.msea.2014.01.025
   Beyerlein IJ, 2009, PROG MATER SCI, V54, P427, DOI 10.1016/j.pmatsci.2009.01.001
   Edalati K, 2008, MAT SCI ENG A-STRUCT, V497, P168, DOI 10.1016/j.msea.2008.06.039
   El-Danaf EA, 2007, MAT SCI ENG A-STRUCT, V458, P226, DOI 10.1016/j.msea.2006.12.077
   El-Danaf EA, 2012, MATER DESIGN, V34, P793, DOI 10.1016/j.matdes.2011.07.006
   El-Danaf EA, 2011, MATER DESIGN, V32, P3838, DOI 10.1016/j.matdes.2011.03.006
   Faraji G, 2012, MATER LETT, V77, P82, DOI 10.1016/j.matlet.2012.03.007
   Faraji G, 2011, MATER LETT, V65, P3009, DOI 10.1016/j.matlet.2011.06.039
   Gholinia A, 2000, ACTA MATER, V48, P1115, DOI 10.1016/S1359-6454(99)00388-2
   Han BQ, 2004, METALL MATER TRANS A, V35A, P1343, DOI 10.1007/s11661-004-0309-z
   Hosseini E, 2009, MAT SCI ENG A-STRUCT, V526, P219, DOI 10.1016/j.msea.2009.07.028
   Hughes DA, 1997, ACTA MATER, V45, P3871, DOI 10.1016/S1359-6454(97)00027-X
   Humphreys F. J., 2004, RECRYSTALLIZATION RE
   Jafarzadeh H, 2014, MAT SCI ENG A-STRUCT, V609, P65, DOI 10.1016/j.msea.2014.04.096
   Jafarzadeh H, 2014, MAT SCI ENG A-STRUCT, V596, P194, DOI 10.1016/j.msea.2013.12.037
   Kvackaja T, 2012, MICRON, V43
   Kwon YJ, 2003, SCRIPTA MATER, V49, P785, DOI 10.1016/S1359-6462(03)00407-X
   Langdon TG, 2007, MAT SCI ENG A-STRUCT, V462, P3, DOI 10.1016/j.msea.2006.02.473
   Mckenzie PWJ, 2007, ACTA MATER, V55, P2985, DOI 10.1016/j.actamat.2006.12.038
   Mesbah M, 2014, MAT SCI ENG A-STRUCT, V590, P289, DOI 10.1016/j.msea.2013.10.036
   Mishra A, 2005, MAT SCI ENG A-STRUCT, V410, P290, DOI 10.1016/j.msea.2005.08.201
   Mohebbi MS, 2010, MAT SCI ENG A-STRUCT, V528, P180, DOI 10.1016/j.msea.2010.08.081
   Morattab S, 2011, MAT SCI ENG A-STRUCT, V528, P6912, DOI 10.1016/j.msea.2011.05.074
   Reihanian M, 2008, MAT SCI ENG A-STRUCT, V473, P189, DOI 10.1016/j.msea.2007.04.075
   Richert J., 1986, ALUMINIUM, V62, P604
   Richert M, 2003, MATER CHEM PHYS, V81, P528, DOI 10.1016/S0254-0584(03)00066-X
   Richert M, 2003, MAT SCI ENG A-STRUCT, V355, P180, DOI 10.1016/S0921-5093(03)00046-7
   Richert M, 1999, MAT SCI ENG A-STRUCT, V260, P275, DOI 10.1016/S0921-5093(98)00988-5
   Richert M, 1998, CAN METALL QUART, V37, P449, DOI 10.1016/S0008-4433(98)00030-5
   Saito Y, 1998, SCRIPTA MATER, V39, P1221, DOI 10.1016/S1359-6462(98)00302-9
   Sakai T, 2014, PROG MATER SCI, V60, P130, DOI 10.1016/j.pmatsci.2013.09.002
   Saxl I, 2009, MATER CHARACT, V60, P1163, DOI 10.1016/j.matchar.2009.03.010
   SEGAL VM, 1995, MAT SCI ENG A-STRUCT, V197, P157, DOI 10.1016/0921-5093(95)09705-8
   Topic I, 2008, J MATER SCI, V43, P7320, DOI 10.1007/s10853-008-2754-3
   Toth LS, 2009, SCRIPTA MATER, V60, P175, DOI 10.1016/j.scriptamat.2008.09.029
   Valiev R. Z., 2000, PROG MAT SCI, V45
   Valiev RZ, 2006, PROG MATER SCI, V51, P881, DOI 10.1016/j.pmatsci.2006.02.003
   Verhoeven J.D., 1975, FUNDAMENTALS PHYS ME
   Wang H, 2002, J TEST EVAL, V30, P382
   Wang JT, 2012, SCRIPTA MATER, V67, P810, DOI 10.1016/j.scriptamat.2012.07.028
   WILLIAMSON GK, 1953, ACTA METALL MATER, V1, P22, DOI 10.1016/0001-6160(53)90006-6
   Xue Q, 2007, ACTA MATER, V55, P655, DOI 10.1016/j.actamat.2006.08.049
   Zangiabadi A, 2011, MAT SCI ENG A-STRUCT, V528, P5066, DOI 10.1016/j.msea.2011.03.012
   Zhang J, 2007, MATER SCI FORUM, V546-549, P2293, DOI 10.4028/www.scientific.net/MSF.546-549.2293
   Zhang Z, 2003, METALL MATER TRANS A, V34A, P1349, DOI 10.1007/s11661-003-0246-2
   Zhilyaev AP, 2008, PROG MATER SCI, V53, P893, DOI 10.1016/j.pmatsci.2008.03.002
   Zhu CF, 2013, MAT DES, V52
NR 50
TC 6
Z9 6
U1 3
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1044-5803
EI 1873-4189
J9 MATER CHARACT
JI Mater. Charact.
PD SEP
PY 2014
VL 95
BP 118
EP 128
DI 10.1016/j.matchar.2014.06.013
PG 11
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering; Materials Science, Characterization & Testing
SC Materials Science; Metallurgy & Metallurgical Engineering
GA AO0HO
UT WOS:000340989900013
DA 2018-12-27
ER

PT J
AU Chen, J
   Wang, L
   Shen, YH
   Yu, J
   Ye, TJ
   Zhuang, CY
   Zhang, WB
AF Chen, Jie
   Wang, Lei
   Shen, Yuhui
   Yu, Jian
   Ye, Tingjun
   Zhuang, Chengyu
   Zhang, Weibin
TI RETRACTED: Key genes associated with osteoporosis revealed by genome
   wide gene expression analysis (Retracted article. See vol. 42, pg. 1471,
   2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Osteoporosis; Peak bone mass; Differentially expressed genes; Functional
   enrichment analysis; Protein-protein interaction network
ID PEAK BONE MASS; CALCIUM-ABSORPTION; VITAMIN-D; CYTOSCAPE; OSTEOCLASTS;
   NETWORKS; ONTOLOGY; TRPV6
AB Gene expression profiles of circulating monocytes were analyzed to identify key genes associated with osteoporosis. Raw microarray data were downloaded from gene expression omnibus under accession number GSE7158, including 8 microarray dataset for patients with high peak bone mass (PBM) and 8 for low PBM. Package linear models for microarray data of R was adopted to screen out differentially expressed genes (DEGs). Gene ontology enrichment analysis and Kyoto encyclopedia of genes and genomes pathway analysis were performed with plug-ins of cytoscape. Protein-protein interaction network was constructed using FunCoup. A total of 283 DEGs were identified in low-PBM group, including 135 up- and 148 down-regulated genes. A considerable part of DEGs were localized in plasma membrane. Several ion transport-related pathways were revealed, such as mineral absorption and carbohydrate digestion and absorption. A range of DEGs were identified and some of them were related to calcium transport as well as osteoporosis. These findings are helpful in disclosing the pathogenetic mechanisms of osteoporosis.
C1 [Chen, Jie; Wang, Lei; Shen, Yuhui; Yu, Jian; Ye, Tingjun; Zhuang, Chengyu; Zhang, Weibin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Traumatol & Orthoped, Dept Orthoped,Ruijin Hosp, Shanghai 200025, Peoples R China.
RP Shen, YH (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Traumatol & Orthoped, Dept Orthoped,Ruijin Hosp, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.
EM yuhuiss@163.com; zhangweiibin@hotmail.com
FU Shanghai Municipal Education Commission [12YZ039]; Shanghai Municipal
   Commission of Health and Family Planning [20134224]
FX This study was supported by Shanghai Municipal Education Commission
   (Grant no. 12YZ039) and Shanghai Municipal Commission of Health and
   Family Planning (20134224).
CR Alexeyenko A, 2012, NUCLEIC ACIDS RES, V40, pD821, DOI 10.1093/nar/gkr1062
   Balesaria S, 2009, AM J PHYSIOL-GASTR L, V297, pG1193, DOI 10.1152/ajpgi.00237.2009
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170
   Bonjour JP, 2009, SALUD PUBLICA MEXICO, V51, pS5
   Chen XD, 2010, J BONE MINER RES, V25, P339, DOI 10.1359/jbmr.090724
   Czerwinski Edward, 2007, Ortop Traumatol Rehabil, V9, P337
   de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078
   Deng FY, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.011700
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gokhale NA, 2013, BIOCHEM J, V453, P413, DOI 10.1042/BJ20121528
   Heaney RP, 2000, OSTEOPOROSIS INT, V11, P985, DOI 10.1007/s001980070020
   Kang H, 2013, J BIOL CHEM, V288, P12187, DOI 10.1074/jbc.M112.430389
   Kellett GL, 2011, NUTR REV, V69, P347, DOI 10.1111/j.1753-4887.2011.00395.x
   Kotake S, 2013, CELL BIOL INT, V37, P65, DOI 10.1002/cbin.10013
   Lee GS, 2008, BRIT J NUTR, V100, P1011, DOI 10.1017/S0007114508959195
   Leung R, 2011, BLOOD, V117, P2044, DOI 10.1182/blood-2010-05-282574
   Lieben L, 2010, BONE, V47, P301, DOI 10.1016/j.bone.2010.04.595
   Lips P, 2011, BEST PRACT RES CL EN, V25, P585, DOI 10.1016/j.beem.2011.05.002
   Lopes CT, 2010, BIOINFORMATICS, V26, P2347, DOI 10.1093/bioinformatics/btq430
   Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
   Morgan JM, 2011, J CELL BIOCHEM, V112, P3354, DOI 10.1002/jcb.23265
   Osako MK, 2010, CIRC RES, V107, P466, DOI 10.1161/CIRCRESAHA.110.216846
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Razick S, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-405
   Ruiz- Heiland G, 2013, ANN RHEUM DIS
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Van der Eerden BCJ, 2012, J CELL PHYSIOL, V227, P1951, DOI 10.1002/jcp.22923
   Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034641
NR 33
TC 1
Z9 1
U1 2
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD SEP
PY 2014
VL 41
IS 9
BP 5971
EP 5977
DI 10.1007/s11033-014-3474-1
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AO1QX
UT WOS:000341089400045
PM 24993113
DA 2018-12-27
ER

PT J
AU Yu, XL
   Zhao, F
   Zhang, J
   Pan, XM
AF Yu, Xiao-Ling
   Zhao, Fei
   Zhang, Jun
   Pan, Xiao-Ming
TI RETRACTED: IL-18 genetic polymorphisms may contribute to the
   pathogenesis of tuberculosis among Asians: a meta-analysis of
   case-control studies (Retracted article. See vol. 42, pg. 1473, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Tuberculosis; IL-18; Polymorphism; Meta-analysis
ID MYCOBACTERIUM-TUBERCULOSIS; T-CELLS; PULMONARY TUBERCULOSIS; PROMOTER
   POLYMORPHISM; INTERLEUKIN-18; POPULATION; IMMUNITY
AB This current meta-analysis of case-control studies was continued to investigate whether the genetic polymorphisms of IL-18 gene contribute to the occurrence and progression of tuberculosis (TB). We searched certain English and Chinese databases for relevant studies without language restrictions. Meta-analysis for the moment was performed with the adoption of the STATA statistical software. Crude OR and its corresponding 95 % confidence interval (95 % CI) were calculated as estimates of relative risk for UC under different genetic models. Seven case-control studies (TB patients = 1,325, healthy subjects = 1,778) were included for the following analysis. We evaluated two functional polymorphisms (rs1946518 C > A and rs187238 G > C). Pooled OR within the progression of statistical analysis indicated that the specific polymorphism of IL-18 rs1946518 C > A showed a closely relationship with the elevated susceptibility to TB under those three genetic models (allele model: OR 1.24, 95 % CI 1.11-1.38, P < 0.001; dominant model: OR 1.41, 95 % CI 1.21-1.65, P < 0.001; homozygous model: OR 1.46, 95 % CI 1.15-1.86, P = 0.002; respectively). However, we observed no statistical associations of the IL-18 rs187238 G > C polymorphism with the susceptibility to TB under any of the genetic models (all P > 0.05). Country-stratified analysis results detected that the variants of IL-18 may be strongly enrolled in the risk of TB among populations in China (allele model: OR 1.19, 95 % CI 1.06-1.33, P = 0.003; recessive model: OR 1.54, 95 % CI 1.00-2.36, P = 0.048; homozygous model: OR 1.59, 95 % CI 1.09-2.33, P = 0.016; respectively), but not among populations in Iran, Korea and India (all P > 0.05). Current results provide strong evidence that IL-18 mutations may be evidently related to the occurrence and development of TB, especially for the rs1946518 C > A polymorphism among populations in China.
C1 [Yu, Xiao-Ling; Zhao, Fei; Zhang, Jun; Pan, Xiao-Ming] China Med Univ, Affiliated Hosp 4, Dept Resp Med, Shenyang 110005, Peoples R China.
RP Yu, XL (reprint author), China Med Univ, Affiliated Hosp 4, Dept Resp Med, South Seven Rd 102, Shenyang 110005, Peoples R China.
EM yuxiaoling1220@163.com
CR Biet F, 2002, J MOL MED-JMM, V80, P147, DOI 10.1007/s00109-001-0307-1
   Ceballos-Olvera I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002452
   Click ES, 2012, CLIN INFECT DIS, V54, P211, DOI 10.1093/cid/cir788
   Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703
   Das R, 2013, P NATL ACAD SCI USA, V110, pE2997, DOI 10.1073/pnas.1301128110
   Han M, 2011, MICROBIOL IMMUNOL, V55, P388, DOI 10.1111/j.1348-0421.2011.00332.x
   Harishankar M, 2007, INT J IMMUNOGENET, V34, P317, DOI 10.1111/j.1744-313X.2007.00714.x
   Kalina U, 2000, SCAND J IMMUNOL, V52, P525, DOI 10.1046/j.1365-3083.2000.00836.x
   Kleinnijenhuis J, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/405310
   Lee HM, 2006, INT J PEDIATR OTORHI, V70, P1085, DOI 10.1016/j.ijporl.2005.11.006
   Lee SH, 2011, INT J TUBERC LUNG D, V15, P1246, DOI 10.5588/ijtld.11.0031
   Li DD, 2013, CHINESE MED J-PEKING, V126, P3360, DOI 10.3760/cma.j.issn.0366-6999.20130550
   Liang ZH, 2009, J PRACT MED, V25, P2939
   Lin PL, 2010, J IMMUNOL, V185, P15, DOI 10.4049/jimmunol.0903856
   Moller M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-154
   Murray M, 2011, Int J Tuberc Lung Dis, V15 Suppl 2, P64, DOI 10.5588/ijtld.10.0535
   Narasimhan P, 2013, PULM MED, DOI 10.1155/2013/828939
   Oxlade O, 2009, INT J TUBERC LUNG D, V13, P1238
   Palladino I, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-206
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Schneider BE, 2010, EUR J IMMUNOL, V40, P396, DOI 10.1002/eji.200939583
   SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Taheri M, 2012, Prague Med Rep, V113, P16
   Vitoria M, 2009, AM J CLIN PATHOL, V131, P844, DOI 10.1309/AJCP5XHDB1PNAEYT
   Wong JL, 2011, J IMMUNOTHER, V34, P270, DOI 10.1097/CJI.0b013e31820b370b
   Yamada G, 2000, AM J RESP CRIT CARE, V161, P1786, DOI 10.1164/ajrccm.161.6.9911054
   Yoshimoto T, 1998, J IMMUNOL, V161, P3400
   Zhou C, 2008, J CHONGQING MED U, V33, p[1029, 1037]
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   赖远波, 2013, [广东医学, Guangdong Medical Journal], V34, P2553
NR 31
TC 5
Z9 5
U1 2
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD SEP
PY 2014
VL 41
IS 9
BP 6013
EP 6023
DI 10.1007/s11033-014-3479-9
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AO1QX
UT WOS:000341089400050
PM 24969483
DA 2018-12-27
ER

PT J
AU Wu, XJ
   Dong, ZQ
   Lu, QH
AF Wu, Xiang-Jun
   Dong, Zhao-Qiang
   Lu, Qing-Hua
TI RETRACTED: The role of cystatin C in vascular remodeling of
   balloon-injured abdominal aorta of rabbits (Retracted article. See vol.
   42, pg. 1475, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Cystatin C; Balloon dilatation; Abdominal aorta; Vascular remodeling
ID CARDIOVASCULAR-DISEASE; CYSTEINE PROTEASES; ATHEROSCLEROSIS; ADVENTITIA;
   CELLS; WALL; MYOFIBROBLAST; STENOSIS; STRESS; MODEL
AB This study aimed to evaluate the role of cystatin C (CysC) in the vascular remodeling of balloon-injured abdominal aorta of rabbits. Forty-eight New Zealand white rabbits were randomly divided into three groups: the balloon-injured injury group (n = 16), the CysC monoclonal antibody group (n = 16), and the sham-operative group (n = 16). Serum CysC levels were detected by enzyme linked immunosorbent assay. Changes in adventitial area, adventitial thickness, lumen area (LA), neointimal area (IA), internal elastic lamina area (IELA), external elastic lamina area (EELA), vascular remodeling index (VRI) and residual stenosis (RS) were measured by the Leica image analysis system. Immunohistochemical analysis of alpha-smooth muscle actin (alpha-SMA) and proliferating cell nuclear antigen (PCNA) were performed. Serum CysC levels of rabbits in the balloon-injured injury group were significantly higher than those in the CysC monoclonal antibody group and the sham-operative group (both P < 0.05). At 6 weeks after balloon injury, the adventitial area and thickness, LA, IA, IELA and EELA in the balloon-injured injury group were also higher than those in the CysC monoclonal antibody and sham-operative groups (all P < 0.05). In addition, the balloon-injured injury group showed higher VRI and RS than those of the CysC monoclonal antibody group (both P < 0.05). The positive expression of alpha-SMA in the vascular adventitia and media in the balloon-injured group were higher than that of the CysC monoclonal antibody and sham-operative groups. The balloon-injured group also showed a stronger expression of alpha-SMA in the neointima than that of the CysC monoclonal antibody group. There was a strong positive expression of PCNA in the vascular adventitia and neointima in the balloon-injured and CysC monoclonal antibody groups. However, the number of PCNA-positive cells in the balloon-injured group was higher than that of the CysC monoclonal antibody group (25.45 +/- A 4.21 vs. 6.75 +/- A 1.11, P = 0.003). Our findings provide empirical evidence that serum CysC levels may play an important role in the vascular remodeling of balloon-injured abdominal aorta of rabbits.
C1 [Wu, Xiang-Jun; Dong, Zhao-Qiang; Lu, Qing-Hua] Shandong Univ, Hosp 2, Dept Cardiovasc Med, Jinan 250033, Peoples R China.
   [Wu, Xiang-Jun] Binzhou City Peoples Hosp Shandong Prov, Dept Cardiovasc Med, Binzhou 256600, Peoples R China.
RP Lu, QH (reprint author), Shandong Univ, Hosp 2, Dept Cardiovasc Med, Beiyuan St 247, Jinan 250033, Peoples R China.
EM luqinghua1202@126.com
CR Angelidis C, 2013, CURR TOP MED CHEM, V13, P164, DOI 10.2174/1568026611313020006
   Bengtsson E, 2005, ARTERIOSCL THROM VAS, V25, P2151, DOI 10.1161/01.ATV.0000179600.34086.7d
   Coen M, 2011, ARTERIOSCL THROM VAS, V31, P2391, DOI 10.1161/ATVBAHA.111.231548
   Forte A, 2010, CARDIOVASC RES, V88, P395, DOI 10.1093/cvr/cvq224
   Gregory EK, 2011, AM J SURG, V202, P536, DOI 10.1016/j.amjsurg.2011.06.018
   Hoke M, 2010, STROKE, V41, P674, DOI 10.1161/STROKEAHA.109.573162
   Humphrey JD, 2008, HYPERTENSION, V52, P195, DOI 10.1161/HYPERTENSIONAHA.107.103440
   Jin X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023558
   Kwon ST, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4003134
   Lafarge JC, 2010, BIOCHIMIE, V92, P1580, DOI 10.1016/j.biochi.2010.04.011
   Lee T, 2011, NEPHROL DIAL TRANSPL, V26, P2264, DOI 10.1093/ndt/gfq733
   Leung FP, 2008, SPORTS MED, V38, P1009, DOI 10.2165/00007256-200838120-00005
   Liu JA, 2004, ARTERIOSCL THROM VAS, V24, P1359, DOI 10.1161/01.ATV.0000134530.27208.41
   Lutgens SPM, 2007, FASEB J, V21, P3029, DOI 10.1096/fj.06-7924com
   Maiellaro K, 2007, CARDIOVASC RES, V75, P640, DOI 10.1016/j.cardiores.2007.06.023
   Niccoli G, 2008, ATHEROSCLEROSIS, V198, P373, DOI 10.1016/j.atherosclerosis.2007.09.022
   Nugent HM, 2012, J VASC SURG, V56, P1078, DOI 10.1016/j.jvs.2012.03.002
   Otranto M, 2012, CELL ADHES MIGR, V6, P203, DOI 10.4161/cam.20377
   Remuzzi A, 2013, CLIN J AM SOC NEPHRO, V8, P2186, DOI 10.2215/CJN.03450413
   Saito T, 2009, GEN THORAC CARDIOVAS, V57, P406, DOI 10.1007/s11748-009-0413-5
   Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709
   Shlipak MG, 2006, ANN INTERN MED, V145, P237, DOI 10.7326/0003-4819-145-4-200608150-00003
   Smetana K, 2002, EUR J HISTOCHEM, V46, P125
   Song JW, 2004, J INTERV RADIOL, V13, P446, DOI [10.3969/j.issn.1008-794X.2004.05.022, DOI 10.3969/J.ISSN.1008-794X.2004.05.022]
   Stenmark KR, 2013, ANNU REV PHYSIOL, V75, P23, DOI 10.1146/annurev-physiol-030212-183802
   Taglieri N, 2009, CLIN CHEM, V55, P1932, DOI 10.1373/clinchem.2009.128397
   Wu XJ, 2013, EXP THER MED, V5, P1671, DOI 10.3892/etm.2013.1059
   Yamamoto T, 2013, CIRC J, V77, P2751, DOI 10.1253/circj.CJ-13-0179
NR 28
TC 2
Z9 2
U1 8
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD SEP
PY 2014
VL 41
IS 9
BP 6225
EP 6231
DI 10.1007/s11033-014-3502-1
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AO1QX
UT WOS:000341089400072
PM 24981928
DA 2018-12-27
ER

PT J
AU Li, P
   Bu, SH
   Lu, XT
   Li, LX
   Xu, AJ
   Tang, YN
   Zhang, J
AF Li, Ping
   Bu, Shu-Hong
   Lu, Xiao-Tong
   Li, Li-Xia
   Xu, A-Jing
   Tang, Yue-Nian
   Zhang, Jian
TI RETRACTED: Relationships between PON1 Q192R polymorphism and clinical
   outcome of antiplatelet treatment after percutaneous coronary
   intervention: a meta-analysis (Retracted article. See vol. 42, pg. 1477,
   2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE PON1; Antiplatelet treatment; Percutaneous coronary intervention;
   Meta-analysis
ID MYOCARDIAL-INFARCTION; CLOPIDOGREL; PARAOXONASE-1; EFFICACY; THERAPY;
   PHARMACODYNAMICS; ASSOCIATION; THROMBOSIS; GENOTYPES; VARIANTS
AB This meta-analysis was performed to assess the relationships between the PON1 Q192R (rs662 T > C) polymorphism and the clinical outcome of antiplatelet treatment after percutaneous coronary intervention (PCI). A range of electronic databases were searched: Web of Science (1945-2013), the Cochrane Library Database (Issue 12, 2013), PubMed (1966-2013), EMBASE (1980-2013), CINAHL (1982-2013) and the Chinese Biomedical Database (CBM) (1982-2013) without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. The crude odds ratio (OR) with their 95 % confidence interval (CI) were calculated. Six clinical cohort studies with a total number of 5,189 patients undergoing PCI for coronary heart disease were included. Our meta-analysis revealed that the PON1 Q192R polymorphism was correlated with an increased risk of major adverse cardiovascular events (MACE) in patients receiving antiplatelet treatment after PCI (C allele vs. T allele: OR = 1.22, 95 % CI 1.04-1.43, P = 0.014; CT+CC vs. TT: OR = 1.38, 95 % CI 1.03-1.86, P = 0.029; CC vs. TT: OR = 1.45, 95 % CI 1.05-1.99, P = 0.024; respectively), especially among Asians. Furthermore, we found significantly positive correlations between the PON1 Q192R polymorphism and the incidence of stent thrombosis in patients receiving antiplatelet treatment after PCI (C allele vs. T allele: OR = 1.42, 95 % CI 1.08-1.87, P = 0.011; CT+CC vs. TT: OR = 1.93, 95 % CI 1.01-3.67, P = 0.046; CC vs. TT: OR = 2.18, 95 % CI 1.09-4.35, P = 0.027; respectively). Our meta-analysis of clinical cohort studies provides evidence that the PON1 Q192R polymorphism may increase the risk of MACE and stent thrombosis in patients receiving antiplatelet treatment after PCI.
C1 [Li, Ping; Bu, Shu-Hong; Lu, Xiao-Tong; Li, Li-Xia; Xu, A-Jing; Tang, Yue-Nian; Zhang, Jian] Shanghai Jiao Tong Univ, Affiliated Xinhua Hosp, Dept Pharm, Shanghai 200082, Peoples R China.
RP Zhang, J (reprint author), Shanghai Jiao Tong Univ, Affiliated Xinhua Hosp, Dept Pharm, Kongjiang Rd 1665, Shanghai 200082, Peoples R China.
EM zhangjianzj116@126.com
FU Natural Science Foundation of China (NSFC) [81202598]; Shanghai
   Municipal Public Health Bureau [2009068]
FX We would like to acknowledge the reviewers for their helpful comments on
   this paper. This work was supported by Natural Science Foundation of
   China (NSFC) (grant #81202598), Shanghai Municipal Public Health Bureau
   (grant #2009068).
CR Bouman HJ, 2011, NAT MED, V17, P110, DOI 10.1038/nm.2281
   Caggegi A, 2011, AM J CARDIOL, V108, P355, DOI 10.1016/j.amjcard.2011.03.050
   Campo G, 2011, J THROMB HAEMOST, V9, P2106, DOI 10.1111/j.1538-7836.2011.04457.x
   Camps J, 2011, NAT MED, V17, P1041, DOI 10.1038/nm.2386
   Chen DY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039178
   Chhatriwalla AK, 2008, CIRC-CARDIOVASC INTE, V1, P217, DOI 10.1161/CIRCINTERVENTIONS.108.811380
   Costa LG, 2005, CLIN CHIM ACTA, V352, P37, DOI 10.1016/j.cccn.2004.09.019
   Getz GS, 2004, CURR OPIN LIPIDOL, V15, P261, DOI 10.1097/01.mol.0000130092.54381.6b
   Hulot JS, 2011, CIRC-CARDIOVASC INTE, V4, P422, DOI 10.1161/CIRCINTERVENTIONS.111.963025
   Lewis JP, 2011, CLIN PHARMACOL THER, V90, P568, DOI 10.1038/clpt.2011.194
   Lhermusier T, 2011, PLATELETS, V22, P479, DOI 10.3109/09537104.2011.567423
   Li WF, 2000, PHARMACOGENETICS, V10, P767, DOI 10.1097/00008571-200012000-00002
   Mause SF, 2010, CIRCULATION, V122, P495, DOI 10.1161/CIRCULATIONAHA.109.909473
   Park KW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052779
   Pereillo JM, 2002, DRUG METAB DISPOS, V30, P1288, DOI 10.1124/dmd.30.11.1288
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Plosker GL, 2007, DRUGS, V67, P613, DOI 10.2165/00003495-200767040-00013
   Price MJ, 2012, J AM COLL CARDIOL, V59, P1928, DOI 10.1016/j.jacc.2011.11.068
   Sibbing D, 2011, EUR HEART J, V32, P1605, DOI 10.1093/eurheartj/ehr155
   Simon T, 2011, CLIN PHARMACOL THER, V90, P561, DOI 10.1038/clpt.2011.193
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411
   Tang XF, 2013, EUR J CLIN PHARMACOL, V69, P1103, DOI 10.1007/s00228-012-1446-8
   Tousoulis D, 2010, PHARMACOL THERAPEUT, V127, P108, DOI 10.1016/j.pharmthera.2010.05.001
   Trenk D, 2011, CIRC-CARDIOVASC GENE, V4, P429, DOI 10.1161/CIRCGENETICS.111.960112
   Verschuren JJW, 2013, INT J CARDIOL, V167, P2882, DOI 10.1016/j.ijcard.2012.07.020
   Wang XL, 2003, ARTERIOSCL THROM VAS, V23, P328, DOI 10.1161/01.ATV.0000051702.38086.C1
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 28
TC 3
Z9 5
U1 3
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD SEP
PY 2014
VL 41
IS 9
BP 6263
EP 6273
DI 10.1007/s11033-014-3509-7
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AO1QX
UT WOS:000341089400077
PM 24981930
DA 2018-12-27
ER

PT J
AU Tao, SF
   He, HF
   Chen, Q
AF Tao, Sifeng
   He, Haifei
   Chen, Qiang
TI RETRACTED: ChIP-seq analysis of androgen receptor in LNCaP cell line
   (Retracted article. See vol. 42, pg. 1479, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Prostate cancer; Androgen receptor; Target gene; GO enrichment analysis;
   Transcription regulation factor
ID REFRACTORY PROSTATE-CANCER; BINDING PROTEINS; PROGRESSION; BIOLOGY;
   CYP3A4; GENES
AB The aim of this study was to screen target genes and gene functions of androgen receptor (AR) in LNCaP cell line by ChIP-seq data analysis. We downloaded the gene expression profile GSE14092 from Gene Expression Omnibus database and selected ChIP-seq data (GSM353644) of AR stimulated by androgen R1881 (R1881 stimulation group) and the ChIP-seq data (GSM353643) of AR without R1881 stimulation (control group). MACS peak calling software was used to identify the AR binding cites. After target genes selection and function analysis, motif finding analysis was utilized to predict the AR co-located transcription regulation factors, and we analyzed their functions through GO enrichment analysis. Total 27202 and 2730 AR binding sites were detected in the R1881 stimulation group and the control group, respectively and 398 and 58 target genes were identified in R1881 stimulation group and control group, respectively. Based on GO enrichment analysis, 20 biological processes which AR regulated in the LNCaP cells were enriched, including xenobiotic metabolic process, positive regulation of interleukin-2 production and cellular response to sterol etc. We finally identified 99 transcription factors with high motif enrichment significant levels, and the enrichment of AR co-located transcription factors was significantly enriched in the biological process of regulation of cell proliferation in which 13 transcription factors were involved (FOXJ1, FOXM1, NF1, SOX2, HOXD13, FOXO1, FOXP3, FOXO4, SOX9, PGR, DBP, JUN and TLX1). The analysis of AR target genes and gene functions help us to elucidate the mechanism of the prostate cancer on a molecular level. In addition, it will pave the way to effective therapies for prostatic cancer. However, further experiments are still needed to confirm our results.
C1 [Tao, Sifeng; He, Haifei; Chen, Qiang] Zhejiang Univ, Sch Med, Dept Surg Oncol, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
RP Tao, SF (reprint author), Zhejiang Univ, Sch Med, Dept Surg Oncol, Affiliated Hosp 2, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM ttsieng@hotmail.com
CR Antonaki A, 2011, J BIOL CHEM, V286, P38768, DOI 10.1074/jbc.M111.234161
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Centenera MM, 2008, MOL ENDOCRINOL, V22, P2373, DOI 10.1210/me.2008-0017
   Chen QH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015288
   Chowdhury S, 2013, PRACTITIONER, V257, P12
   Chowdhury Simon, 2013, Practitioner, V257, P15
   Conley AB, 2010, METHODS MOL BIOL, V674, P225, DOI 10.1007/978-1-60761-854-6_14
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008-5472.CAN-07-0199
   Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2
   Ewert R, 2008, COMPUT FLUIDS, V37, P369, DOI 10.1016/j.compfluid.2007.02.003
   Feng J, 2011, CURR PROT BIOINFORM
   Freeman MR, 2013, ASIAN J ANDROL, V15, P447, DOI 10.1038/aja.2013.62
   Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795
   Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019
   Heemers HV, 2009, CANCER CELL, V15, P245, DOI 10.1016/j.ccr.2009.03.009
   Hudson RS, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-13
   Jenster G, 1999, SEMIN ONCOL, V26, P407
   Jiang Jingting, 2010, Mol Cell Pharmacol, V2, P1, DOI 10.2174/1874467210902010001
   Keshava C, 2004, AM J EPIDEMIOL, V160, P825, DOI 10.1093/aje/kwh294
   Kharchenko PV, 2008, NAT BIOTECHNOL, V26, P1351, DOI 10.1038/nbt.1508
   Kim D, 2013, INT J MOL MED, V31, P386, DOI 10.3892/ijmm.2012.1196
   Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002
   Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li J, 2013, ASIAN PAC J CANCER P, V14, P5281, DOI 10.7314/APJCP.2013.14.9.5281
   Martin SK, 2012, ONCOL REP, V28, P409, DOI 10.3892/or.2012.1832
   Papatsoris AG, 2005, CURR MED CHEM, V12, P277, DOI 10.2174/0929867053363306
   Puig O, 2011, ANTIOXID REDOX SIGN, V14, P635, DOI 10.1089/ars.2010.3407
   Ravindranathan P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2912
   Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777
   Singh Madhu S., 2009, V472, P243, DOI 10.1007/978-1-60327-492-0_10
   Singh PK, 2012, J STEROID BIOCHEM, V136, P258
   Sutcliffe S, 2013, NAT REV CANCER, V13, P208, DOI 10.1038/nrc3434
   Tarazona S, 2012, EMBNET J, V17, P18, DOI DOI 10.14806/EJ.17.B.265
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   van der Vos KE, 2011, ANTIOXID REDOX SIGN, V14, P579, DOI 10.1089/ars.2010.3419
   Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2
   Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056
   Xie G, 2010, BRIT J PHARMACOL, V159, P689, DOI 10.1111/j.1476-5381.2009.00577.x
   Ye T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1287
   Zeigler-Johnson C, 2004, CANCER RES, V64, P8461, DOI 10.1158/0008-5472.CAN-04-1651
   Zhang L, 2011, ASIAN J ANDROL, V13, P574, DOI 10.1038/aja.2010.126
   Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237
NR 45
TC 5
Z9 5
U1 2
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD SEP
PY 2014
VL 41
IS 9
BP 6291
EP 6296
DI 10.1007/s11033-014-3511-0
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AO1QX
UT WOS:000341089400079
PM 24985976
DA 2018-12-27
ER

PT J
AU Zhang, XQ
   Hu, XB
   Mu, SJ
   Zhan, YH
   An, QX
   Liu, ZX
   Huang, XF
AF Zhang, Xianqing
   Hu, Xingbin
   Mu, Shijie
   Zhan, Yonghua
   An, Qunxing
   Liu, Zhixin
   Huang, Xiaofeng
TI RETRACTED: Apogossypolone inhibits the proliferation of LNCaP cells in
   vitro and in vivo (Retracted article. See vol. 17, pg. 6927, 2018)
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article; Retracted Publication
DE apogossypolone; autophagy; apoptosis; LNCaP cell; nude mouse
ID SUPPRESSES TUMOR-GROWTH; BCL-2 FAMILY PROTEINS; HUMAN-PROSTATE-CANCER;
   HEPATOCELLULAR-CARCINOMA; COLON-CARCINOMA; APOPTOSIS; AUTOPHAGY;
   (-)-GOSSYPOL; GOSSYPOL; RADIATION
AB The aim of the present study was to investigate the anti-tumor effect of apogossypolone (ApoG2) on human LNCaP cells in vitro and in vivo. Cell viability was evaluated using an MTT assay. Cell autophagy and apoptosis-were detected by flow cytometry and using a terminal deoxynucleotidyl transferase dUTP nick end labeling assay, respectively. Morphological autophagy alterations were observed by transmission electron microscopy. The formation of acidic vesicular organelles was assessed by acridine orange staining and fluorescence microscopy. Quantitative polymerase chain reaction (qPCR) was conducted to detect the expression levels of apoptosis-associated protein B-cell lymphoma 2 (Bcl-2) and Bak. The models of transplantation tumors in nude mice were established via subcutaneous injection of LNCaP cells. Growth of LNCaP cells was inhibited by ApoG2 treatment. Flow cytometry demonstrated that ApoG2 induced apoptosis in LNCaP cells. The Bcl-2 expression was decreased while Bak expression was increased. In addition, activation of cysteine aspartate protease (caspase)-3 and -8 was observed and 3-methyladenine (3-MA) enhanced apoptosis of LNCaP cells. Furthermore, nude mice treated with ApoG2 demonstrated a significant decrease in tumor volume and a significant increase in cell viability. Immunohistochemical analysis of tumor tissues demonstrated that ApoG2 enhanced caspase-3, -8, LC-3B and beclin-1 expression and reduced the expression of Bcl-2. ApoG2 was able to effectively suppress the growth of LNCaP cells through the induction of autophagy and apoptosis.
C1 [Zhang, Xianqing; Hu, Xingbin; Mu, Shijie; An, Qunxing; Liu, Zhixin] Fourth Mil Med Univ, Xijing Hosp, Dept Blood Transfus, Xian 710032, Shaanxi, Peoples R China.
   [Zhan, Yonghua] Xidian Univ, Sch Life Sci & Technol, Engn Res Ctr Mol & Neuroimaging, Xian 710071, Shaanxi, Peoples R China.
   [Huang, Xiaofeng] Fourth Mil Med Univ, Sch Basic Med, Cent Lab, Xian 710032, Shaanxi, Peoples R China.
RP Huang, XF (reprint author), Fourth Mil Med Univ, Sch Basic Med, Cent Lab, 17 West Changle Rd, Xian 710032, Shaanxi, Peoples R China.
EM xiaofenghuang2012@126.com
FU National Nature Science Foundation of China [81101100]; Natural Science
   Basic Research Plan in Shanxi Province of China [2012JQ4015];
   Fundamental Research Funds for the Central Universities [K50510100002,
   K50510100004]
FX This study was supported by the National Nature Science Foundation of
   China (no. 81101100), the Natural Science Basic Research Plan in Shanxi
   Province of China under Grant (no. 2012JQ4015) and the Fundamental
   Research Funds for the Central Universities (nos. K50510100002 and
   K50510100004).
CR ALESSANDRI G, 1987, CANCER RES, V47, P4243
   ARNOLD A, 2008, ECOLOGIST, V38, P7
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Burton JL, 2000, BJU INT, V85, P87, DOI 10.1046/j.1464-410x.2000.00422.x
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Deng R, 2010, INT J CANCER, V127, P220, DOI 10.1002/ijc.25032
   Diaz Michael, 2004, Cancer Control, V11, P364
   Gioeli D, 2005, CLIN SCI, V108, P293, DOI 10.1042/CS20040329
   Hu ZY, 2008, INT J CANCER, V123, P2418, DOI 10.1002/ijc.23752
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   MAINS RE, 1988, J BIOL CHEM, V263, P7887
   Mi JX, 2008, ACTA PHARMACOL SIN, V29, P1467, DOI 10.1111/j.1745-7254.2008.00901.x
   Mohammad RM, 2005, MOL CANCER THER, V4, P13
   Oliver CL, 2004, CLIN CANCER RES, V10, P7757, DOI 10.1158/1078-0432.CCR-04-0551
   Paglin S, 2001, CANCER RES, V61, P439
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   ROMIJN JC, 1988, PROSTATE, V12, P99, DOI 10.1002/pros.2990120112
   Sun J, 2008, ANTI-CANCER DRUG, V19, P967, DOI 10.1097/CAD.0b013e32831087e8
   TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185
   TUSZYNSKI GP, 1984, CANCER RES, V44, P768
   Wang L, 2007, APOPTOSIS, V12, P1489, DOI 10.1007/s10495-007-0073-9
   Wang XH, 2000, LIFE SCI, V67, P2663, DOI 10.1016/S0024-3205(00)00857-2
   WU DF, 1989, DRUGS, V38, P333, DOI 10.2165/00003495-198938030-00001
   Xu L, 2005, MOL CANCER THER, V4, P197
   Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780
   Zhang XQ, 2010, ASIAN J ANDROL, V12, P390, DOI 10.1038/aja.2009.87
NR 28
TC 2
Z9 2
U1 2
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2014
VL 10
IS 3
BP 1184
EP 1194
DI 10.3892/mmr.2014.2379
PG 11
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA AN8LA
UT WOS:000340854500002
PM 25060748
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Badi, H
   Hussein, SH
   Kareem, SA
AF Badi, Haitham
   Hussein, Sabah Hasan
   Kareem, Sameem Abdul
TI RETRACTED: Feature extraction and ML techniques for static gesture
   recognition(Retracted article. See vol. 28, pg.851, 2017)
SO NEURAL COMPUTING & APPLICATIONS
LA English
DT Article; Retracted Publication
DE Gesture recognition; Human-computer interaction; Representations;
   Recognition; Natural interfaces
ID HAND
AB The main objective of this study is to explore the utility of a neural network-based approach in hand gesture recognition. The proposed system presents two recognition algorithms to recognize a set of six specific static hand gestures, namely open, close, cut, paste, maximize, and minimize. The hand gesture image is passed through three stages: preprocessing, feature extraction, and classification. In the first method, the hand contour is used as a feature that treats scaling and translation of problems (in some cases). However, the complex moment algorithm is used to describe the hand gesture and to treat the rotation problem in addition to scaling and translation. The back-propagation learning algorithm is employed in the multilayer neural network classifier. The second method proposed in this article achieves better recognition rate than the first method.
C1 [Badi, Haitham; Kareem, Sameem Abdul] Univ Malaya, Fac Comp Sci & Informat Technol, Kuala Lumpur 50603, Malaysia.
   [Hussein, Sabah Hasan] Al Yarmouk Univ Coll, Baghdad, Iraq.
RP Badi, H (reprint author), Univ Malaya, Fac Comp Sci & Informat Technol, Kuala Lumpur 50603, Malaysia.
EM haitham875@yahoo.com
CR Dadgostar F, 2005, RES LETT INFORM MATH, V7, P127
   Dong G., 1998, P INT C CONTR AUT CO, P151
   Fei-Fei L., 2007, COMP VIS IMG UNDER, V106, P59, DOI DOI 10.1016/J.CVIU.2005.09.012
   Francke H, 2007, LECT NOTES COMPUT SC, V4872, P533
   Freeman W. T., 1995, IEEE INT WORKSH AUT
   Fu C, 2003, IMAGE VISION COMPUT, V21, P245
   Hasan H, 2013, NEURAL COMPUT APPL, V23, P1605, DOI 10.1007/s00521-012-1113-0
   Hasan H, 2014, ARTIF INTELL REV, V41, P147, DOI 10.1007/s10462-011-9303-1
   Ionescu B, 2005, EURASIP J APPL SIG P, V2005, P2101, DOI 10.1155/ASP.2005.2101
   Ishibuchi H, 1999, IEEE T SYST MAN CY B, V29, P601, DOI 10.1109/3477.790443
   Jia J, 2008, INT WORKSH CONT BAS, P353
   Just A, 2006, THESIS
   Kanan C., 2010, IEEE C COMP VIS PATT
   Kim TK, 2007, GESTURE RECOGNITION, P3335
   Lamar MV, 2001, THESIS NAGOYA I TECH
   Li X., 2005, VISION BASED GESTURE
   Manresa C, 2000, REAL TIME HAND TRACK
   Parvini Farid, 2007, Int J Bioinform Res Appl, V3, P4, DOI 10.1504/IJBRA.2007.011832
   Symeonidis K, 1996, NEURAL NETWORKS, V13, P1
   Vieriu RL, 2011, 10 INT S SIGN CIRC S, P1
   Winnemoller H, 1990, PRACTICAL GESTURE RE
   Wu Y, 1999, INT GEST WORKSH FRAN
NR 22
TC 9
Z9 9
U1 5
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-0643
EI 1433-3058
J9 NEURAL COMPUT APPL
JI Neural Comput. Appl.
PD SEP
PY 2014
VL 25
IS 3-4
BP 733
EP 741
DI 10.1007/s00521-013-1540-6
PG 9
WC Computer Science, Artificial Intelligence
SC Computer Science
GA AN4UT
UT WOS:000340584700021
DA 2018-12-27
ER

PT J
AU Zhen, HY
   Li, K
AF Zhen, Hongyu
   Li, Kan
TI RETRACTED: A surfactant-free co-assembly route to fabricate 2D TiO2-WO3
   composite inverse opal films for photochromic applications (Retracted
   article. See vol. 39, pg. 9031, 2015)
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article; Retracted Publication
ID PHOTONIC CRYSTALS; GENERAL-APPROACH; THIN-FILMS; CONFINEMENT; ARRAYS;
   OXIDE
AB 2D TiO2-WO3 composite inverse opal (IO) films on ITO substrates were prepared by using a surfactant-free co-assembly route using a template of polystyrene (PS) spheres with a diameter of 900 nm. Thus obtained TiO2-WO3 composite IO films were dye sensitized for the construction of photochromic devices which exhibited good photochromic properties.
C1 [Zhen, Hongyu; Li, Kan] Zhejiang Univ, State Key Lab Modern Opt Instrumentat, Hangzhou 310027, Zhejiang, Peoples R China.
RP Zhen, HY (reprint author), Zhejiang Univ, State Key Lab Modern Opt Instrumentat, Hangzhou 310027, Zhejiang, Peoples R China.
EM hongyuzhen@zju.edu.cn
RI Zhejiang University, Dep. Optical Eng./G-9022-2011
FU National Natural Science Foundation of China [61007056]
FX The financial support from the National Natural Science Foundation of
   China (grant No. 61007056) is gratefully acknowledged.
CR Aguirre CI, 2010, ADV FUNCT MATER, V20, P2565, DOI 10.1002/adfm.201000143
   Balaji S, 2006, J RAMAN SPECTROSC, V37, P1416, DOI 10.1002/jrs.1566
   Baserga A, 2007, THIN SOLID FILMS, V515, P6465, DOI 10.1016/j.tsf.2006.11.067
   Cassagneau T, 2002, ADV MATER, V14, P1629, DOI 10.1002/1521-4095(20021118)14:22<1629::AID-ADMA1629>3.0.CO;2-2
   Cheng CW, 2012, SMALL, V8, P37, DOI 10.1002/smll.201101660
   Deleuze C, 2011, PHYS CHEM CHEM PHYS, V13, P10681, DOI 10.1039/c0cp02517h
   Djaoued Y, 2012, J NANOMATER, DOI 10.1155/2012/674168
   Djaoued Y, 2013, J SOL-GEL SCI TECHN, V65, P374, DOI 10.1007/s10971-012-2948-7
   Freymann GV, 2013, CHEM SOC REV, V42, P2528
   Fu M, 2006, ADV MATER, V18, P1001, DOI 10.1002/adma.200502658
   Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538
   Hyun WJ, 2011, ADV MATER, V23, P1846, DOI 10.1002/adma.201004660
   Jiang P, 2001, SCIENCE, V291, P453, DOI 10.1126/science.291.5503.453
   Krasovec UO, 2004, SOL ENERG MAT SOL C, V84, P369, DOI 10.1016/j.solmat.2004.01.043
   Lee YL, 2009, ADV FUNCT MATER, V19, P604, DOI 10.1002/adfm.200800940
   Li B, 2003, J AM CERAM SOC, V86, P867, DOI 10.1111/j.1151-2916.2003.tb03389.x
   Li C, 2010, CHEM MATER, V22, P476, DOI 10.1021/cm9031946
   Li H, 2014, CHEM COMMUN, V50, P2184, DOI 10.1039/c3cc48558g
   Liu B, 2007, MACROMOL RAPID COMM, V28, P322, DOI 10.1002/marc.200600647
   Marlow F, 2009, ANGEW CHEM INT EDIT, V48, P6212, DOI 10.1002/anie.200900210
   NONAKA K, 1993, J MATER SCI LETT, V12, P274, DOI 10.1007/BF01910075
   Seo YG, 2011, ADV FUNCT MATER, V21, P3094, DOI 10.1002/adfm.201002489
   Stein A, 2013, CHEM SOC REV, V42, P2763, DOI 10.1039/c2cs35317b
   Sun FQ, 2004, ADV FUNCT MATER, V14, P283, DOI 10.1002/adfm.200305055
   Wang JY, 2007, ADV MATER, V19, P3865, DOI 10.1002/adma.200602884
   Xia YN, 2000, ADV MATER, V12, P693, DOI 10.1002/(SICI)1521-4095(200005)12:10<693::AID-ADMA693>3.0.CO;2-J
   Yuan YF, 2011, ELECTROCHIM ACTA, V56, P1208, DOI 10.1016/j.electacta.2010.10.097
   Zhang J, 2013, ELECTROCHIM ACTA, V99, P1, DOI 10.1016/j.electacta.2013.03.099
   Zhang WF, 2000, J PHYS D APPL PHYS, V33, P912, DOI 10.1088/0022-3727/33/8/305
   Zhou Q, 2008, J PHYS CHEM C, V112, P2378, DOI 10.1021/jp077149i
NR 30
TC 7
Z9 7
U1 3
U2 82
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
EI 1369-9261
J9 NEW J CHEM
JI New J. Chem.
PD SEP
PY 2014
VL 38
IS 9
BP 4041
EP 4044
DI 10.1039/c4nj00768a
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA AO1IM
UT WOS:000341065800003
DA 2018-12-27
ER

PT J
AU Kil, WH
   Lee, JE
   Nam, SJ
AF Kil, Won Ho
   Lee, Jeong Eon
   Nam, Seok Jin
TI RETRACTED: Clinical Significance of the Axillary Arch in Sentinel Lymph
   Node Biopsy (Retracted article. See vol. 18, pg. 101, 2015)
SO JOURNAL OF BREAST CANCER
LA English
DT Article; Retracted Publication
DE Axillary arch; Breast neoplasms; Sentinel lymph node biopsy
ID BREAST-CANCER; LYMPHADENECTOMY; LOCALIZATION; DISSECTION; ANATOMY;
   TENDON; MUSCLE
AB Purpose: The axillary arch is an anomalous muscle that is not infrequently encountered during axillary sentinel lymph node biopsy (SLNB) of breast cancer patients. In this study, we aimed to investigate how often the axillary arch is found during SLNB and whether it affects the intraoperative sentinel lymph node (SLN) identification rate. Methods: We retrospectively analyzed the correlation between the presence of the axillary arch and the SLN sampling failure rate during SLNB in 1,069 patients who underwent axillary SLNB for invasive breast cancer. Results: Of 1,069 patients who underwent SLNB, 79 patients (7.4%) had the axillary arch present. The SLNB failure rate was high when the patient's body mass index was 25 (p=0.026), when a single SLN mapping technique was used (p=0.012), and when the axillary arch was present (p<0.001). These three factors were also found to be statistically significant by multivariate analysis, and of these three factors, presence of the axillary arch most significantly increased the SLNB failure rate (hazard ratio, 10.96; 95% confidence interval, 4.42-27.21; p<0.001). Additionally, if the axillary arch was present, the mean operative time of SLNB was 20.8 minutes, compared to 12.5 minutes when the axillary arch was not present (p<0.001). If the axillary arch was present, the SLN was often located in a high axillary region (67%) rather than in a general low axillary location. Conclusion: The axillary arch was found to be a significant factor affecting intraoperative SLN failure rate. It is necessary to keep in mind that carefully checking the high axillar region during SLNB in breast cancer patients with the axillary arch is important for reducing SLN sampling failure.
C1 [Kil, Won Ho; Lee, Jeong Eon; Nam, Seok Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea.
RP Kil, WH (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, 81 Irwon Ro, Seoul 135710, South Korea.
EM gilbak73@gmail.com
CR Ando J, 2010, BREAST CANCER-TOKYO, V17, P3, DOI 10.1007/s12282-009-0138-4
   BERGMAN RA, 1991, ANAT ANZEIGER, V173, P23
   Besana-Ciani I, 2005, SURG-J R COLL SURG E, V3, P325, DOI 10.1016/S1479-666X(05)80111-8
   Chene G, 2007, GYNECOL OBSTET FERTI, V35, P25, DOI 10.1016/j.gyobfe.2006.10.031
   Cox Charles E, 2002, Breast J, V8, P88, DOI 10.1046/j.1524-4741.2002.08203.x
   Daniels IR, 2000, BREAST CANCER RES TR, V59, P77, DOI 10.1023/A:1006367904056
   Del Sol M, 2005, CLIN ANAT, V18, P112, DOI 10.1002/ca.20071
   Derossis AM, 2001, J AM COLL SURGEONS, V193, P473, DOI 10.1016/S1072-7515(01)01038-9
   Georgiev GP, 2007, CLIN ANAT, V20, P286, DOI 10.1002/ca.20369
   Goyal A, 2006, BREAST CANCER RES TR, V99, P203, DOI 10.1007/s10549-006-9192-1
   Guy Matthew S, 2011, AJR Am J Roentgenol, V196, pW52, DOI 10.2214/AJR.10.4380
   Karanlik H, 2013, BREAST CARE, V8, P424, DOI 10.1159/000357307
   Keshtgar MRS, 1999, BREAST, V8, P152, DOI 10.1054/brst.1999.0029
   Lo C, 2014, ASIAN J SURG, V37, P125, DOI 10.1016/j.asjsur.2014.01.006
   Natsis K, 2010, BREAST CANCER RES TR, V120, P77, DOI 10.1007/s10549-009-0374-5
   PETREK JA, 1995, CURR PROB SURG, V32, P261
   Ridgway PF, 2011, SURG RADIOL ANAT, V33, P147, DOI 10.1007/s00276-010-0724-3
   SERPELL JW, 1991, AUST NZ J SURG, V61, P310, DOI 10.1111/j.1445-2197.1991.tb00218.x
   Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0
NR 19
TC 2
Z9 2
U1 0
U2 0
PU KOREAN BREAST CANCER SOC
PI SEOUL
PA 163 SINMUNRO 1-GA JONGRO-GU, OFFICIA  BUILDING, SUITE 2024, SEOUL,
   110-999, SOUTH KOREA
SN 1738-6756
EI 2092-9900
J9 J BREAST CANCER
JI J. Breast Canc.
PD SEP
PY 2014
VL 17
IS 3
BP 244
EP 249
DI 10.4048/jbc.2014.17.3.244
PG 6
WC Oncology
SC Oncology
GA AQ5OW
UT WOS:000342859500007
PM 25320622
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Xiong, J
   Lai, SJ
   Zhang, PY
   Li, Q
   Wei, YL
   Yang, Y
   Wang, T
   Liu, L
   Ma, XY
   Chen, DF
AF Xiong, Ji
   Lai, Shujie
   Zhang, Piyun
   Li, Qing
   Wei, Yanling
   Yang, Yang
   Wang, Tao
   Liu, Lei
   Ma, Xiangyu
   Chen, Dongfeng
TI RETRACTED: Rebamipide Plus Proton Pump Inhibitor Versus Proton Pump
   Inhibitor Alone in the Treatment of Endoscopic Submucosal
   Dissection-Induced Gastric Ulcer (Retracted article. See vol. 93, 399,
   2014)
SO MEDICINE
LA English
DT Article; Retracted Publication
ID RANDOMIZED CONTROLLED-TRIAL; HELICOBACTER-PYLORI; CANCER; RESECTION;
   THERAPY; COMBINATION
AB Proton pump inhibitor (PPI) was the main prescription for gastric ulcer after endoscopic submucosal dissection (ESD). Some randomized controlled trials showed that a combination of rebamipide and PPI appears to be more efficient than PPI alone for the treatment of ESD-induced gastric ulcer. However, the sample sizes in these trials were limited and the conclusions were underpowered.
   This meta-analysis was conducted with 5 randomized controlled trials using the combination of rebamipide and PPI for healing ESD-induced ulcer compared with PPI monotherapy. Relevant studies were searched via MEDLINE, PubMed, Embase, and Cochrane Library databases by using terms such as "rebamipide," "proton pump inhibitor," "endoscopic submucosal dissection," "drug therapy," and "gastric ulcer or artificial ulcer."
   Five studies were included in this meta-analysis. The number of total patients was 626, with 317 patients in the combination group and 309 patients in the PPI alone group. The heterogeneity among these 5 studies was low (I-2 22%, P = 0.28). All 5 studies considered scarring stage 1 rate as a primary endpoint, and the scarring stage 1 rate in combination group (115/317) was higher than that in PPI alone group (63/309) (odds ratio 2.61, 95% confidence interval [CI] 1.76-3.88). The mean difference of initial ulcer size between 2 groups was -4.46 (95% CI -266.61 to -257.69, P = 0.97), but it enlarged to 68.38 (95% CI 35.72-101.05, P < 0.00001) in the 4th week.
   This meta-analysis demonstrates that combination therapy is more efficient than PPI monotherapy in healing ESD-induced gastric ulcer.
C1 [Xiong, Ji; Lai, Shujie; Zhang, Piyun; Li, Qing; Wei, Yanling; Yang, Yang; Wang, Tao; Liu, Lei; Chen, Dongfeng] Third Mil Med Univ, Daping Hosp, Dept Gastroenterol, Inst Surg Res, Chongqing 400042, Peoples R China.
   [Ma, Xiangyu] Third Mil Med Univ, Dept Epidemiol, Coll Prevent Med, Chongqing 400042, Peoples R China.
   [Ma, Xiangyu] Third Mil Med Univ, Ctr Clin Epidemiol & Evidence Based Med, Chongqing 400042, Peoples R China.
RP Chen, DF (reprint author), Third Mil Med Univ, Daping Hosp, Dept Gastroenterol, Inst Surg Res, Chongqing 400042, Peoples R China.
EM chendf1981@126.com
CR Abe N, 2013, DIGEST ENDOSC, V25, P64, DOI 10.1111/j.1443-1661.2012.01387.x
   Araki H, 2012, J CLIN BIOCHEM NUTR, V51, P185, DOI 10.3164/jcbn.12-14
   Fujiwara S, 2011, J GASTROENTEROL, V46, P595, DOI 10.1007/s00535-011-0372-3
   Furuta Takahisa, 2005, Drug Metab Pharmacokinet, V20, P153, DOI 10.2133/dmpk.20.153
   Gotoda T, 2007, GASTRIC CANCER, V10, P1, DOI 10.1007/s10120-006-0408-1
   Huang Y, 2011, ENDOSCOPY, V43, P236, DOI 10.1055/s-0030-1255927
   Kakushima N, 2006, ENDOSCOPY, V38, P412, DOI 10.1055/s-2006-925166
   Kakushima N, 2008, WORLD J GASTROENTERO, V14, P2962, DOI 10.3748/wjg.14.2962
   Kakushima N, 2006, J GASTROEN HEPATOL, V21, P1586, DOI 10.1111/j.1440-1746.2006.04321.x
   Kato T, 2010, J GASTROENTEROL, V45, P285, DOI 10.1007/s00535-009-0157-0
   Kawano S, 2011, DIGESTION, V84, P46, DOI 10.1159/000321660
   Kim HK, 2007, DIGEST DIS SCI, V52, P1776, DOI 10.1007/s10620-006-9367-y
   Kim SH, 2011, WORLD J GASTROENTERO, V17, P3575, DOI 10.3748/wjg.v17.i31.3575
   KLEINE A, 1993, DIGEST DIS SCI, V38, P1441, DOI 10.1007/BF01308601
   Kobayashi M, 2012, DIGEST DIS SCI, V57, P119, DOI 10.1007/s10620-011-1850-4
   Lee SH, 2012, DIGEST DIS SCI, V57, P429, DOI 10.1007/s10620-011-1941-2
   Lian JJ, 2012, GASTROINTEST ENDOSC, V76, P763, DOI 10.1016/j.gie.2012.06.014
   Nebiki H, 1998, DIGEST DIS SCI, V43, p203S
   Oh TH, 2009, DIGEST DIS SCI, V54, P1494, DOI 10.1007/s10620-008-0506-5
   Sakita T, 1971, ULCER STOMACH DUODEN, P198
   Shin WG, 2012, GASTROINTEST ENDOSC, V75, P739, DOI 10.1016/j.gie.2011.11.004
   TADA M, 1993, ENDOSCOPY, V25, P445, DOI 10.1055/s-2007-1010365
   Tarnawski AS, 2004, DIGEST DIS SCI, V49, P202, DOI 10.1023/B:DDAS.0000017439.60943.5c
   Terano A, 2007, J GASTROENTEROL, V42, P690, DOI 10.1007/s00535-007-2076-2
   Thong-Ngam Duangporn, 2009, Journal of the Medical Association of Thailand, V92, P1207
   Uedo N, 2007, AM J GASTROENTEROL, V102, P1610, DOI 10.1111/j.1572-0241.2007.01197.x
NR 26
TC 2
Z9 2
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP
PY 2014
VL 93
IS 12
AR e64
DI 10.1097/MD.0000000000000064
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA AP1SO
UT WOS:000341851800002
PM 25211045
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Liu, WP
   Guo, HL
   Li, H
   Li, Y
AF Liu, Wenping
   Guo, Hongling
   Li, Heng
   Li, Yan
TI RETRACTED: Using BIM to Improve the Design and Construction of Bridge
   Projects: A Case Study of a Long-span Steel-box Arch Bridge Project
   (Retracted article. See vol. 12, 96, 2015)
SO INTERNATIONAL JOURNAL OF ADVANCED ROBOTIC SYSTEMS
LA English
DT Article; Retracted Publication
DE Bridge projects; Design; Construction; BIM
ID VIRTUAL PROTOTYPING TECHNOLOGY; OF-THE-ART; IKEA MODEL; MANAGEMENT;
   INFORMATION; 3D
AB More and more mega-complex bridge projects are being or will be built worldwide. At the same time, the design and construction of such projects involve more and more challenges, e. g., complex structural designs, complicated construction environments, etc. This research study aims to apply BIM (Building Information Modelling) to bridge projects to improve the efficiency and effectiveness of design and construction. Through the analysis of the characteristics of bridge projects and relevant, associated problems, a BIM-based solution to improving design and construction is developed, including conceptual design optimization, detailed design optimization, the optimization of construction sequences, construction scheduling, construction management, and construction process monitoring. Furthermore, a real-life bridge project is presented to demonstrate the feasibility and validity of the BIM-aided approach to design and construction. It is shown that BIM has the potential to improve the design and construction of bridge projects. It is expected that this research could contribute to the extensive application of BIM in mega-complex bridge projects to aid in design and construction in the future.
C1 [Liu, Wenping; Guo, Hongling] Tsinghua Univ, Dept Construct Management, Beijing 100084, Peoples R China.
   [Li, Heng] Hong Kong Polytech Univ, Dept Bldg & Real Estate, Hong Kong, Hong Kong, Peoples R China.
   [Li, Yan] Ctr Assessment & Dev Real Estate, Shenzhen, Peoples R China.
RP Guo, HL (reprint author), Tsinghua Univ, Dept Construct Management, Beijing 100084, Peoples R China.
EM hlguo@tsinghua.edu.cn
FU National Natural Science Foundation of China [51208282]; Tsinghua-Glodon
   BIM Research Center
FX We would like to thank the National Natural Science Foundation of China
   (grant no. 51208282) and Tsinghua-Glodon BIM Research Center for
   supporting this research. We also wish to thank China State Construction
   Engineering Corporation Limited for providing the real-life case for
   this research.
CR Chen SS, 2006, TRANSPORT RES REC, P3
   Chiu C. T., 2011, P 28 ISARC, P560
   Ding W. P., 2004, OPTIMIZATION CAPITAL, V25, P1
   Feng C. W., 2011, BIM BASED INFORM INT, P1
   Golparvar-Fard M, 2009, J COMPUT CIVIL ENG, V23, P391, DOI 10.1061/(ASCE)0887-3801(2009)23:6(391)
   Guo HL, 2010, J MANAGE ENG, V26, P41, DOI 10.1061/(ASCE)0742-597X(2010)26:1(41)
   Guo HL, 2012, ACCIDENT ANAL PREV, V48, P204, DOI 10.1016/j.aap.2011.06.002
   Hartmann T, 2008, J CONSTR ENG M ASCE, V134, P776, DOI 10.1016/(ASCE)0733-9364(2008)134:10(776)
   Hu ZZ, 2011, AUTOMAT CONSTR, V20, P167, DOI 10.1016/j.autcon.2010.09.014
   Huang T, 2007, AUTOMAT CONSTR, V16, P576, DOI 10.1016/j.autcon.2006.09.007
   Hwang S., 2010, CONSTR RES C, P509
   Kang JH, 2007, J CONSTR ENG M, V133, P447, DOI 10.1061/(ASCE)0733-9364(2007)133:6(447)
   Kim C, 2011, J COMPUT CIVIL ENG, V25, P98, DOI 10.1061/(ASCE)CP.1943-5487.0000074
   Lee KM, 2012, STRUCT INFRASTRUCT E, V8, P687, DOI 10.1080/15732471003727977
   Li H., 2010, J ENG MANAGEMENT, V5, P525
   Li H, 2008, AUTOMAT CONSTR, V17, P915, DOI 10.1016/j.autcon.2008.02.016
   Li H, 2012, AUTOMAT CONSTR, V27, P1, DOI 10.1016/j.autcon.2012.04.009
   Li H, 2011, CONSTR MANAG ECON, V29, P233, DOI 10.1080/01446193.2010.545994
   Li H, 2008, CONSTR MANAG ECON, V26, P991, DOI 10.1080/01446190802290477
   Park T, 2009, J CONSTR ENG M, V135, P1261, DOI 10.1061/(ASCE)CO.1943-7862.0000101
   Shim CS, 2011, PROCEDIA ENGINEER, V14, DOI 10.1016/j.proeng.2011.07.010
   Shin HM, 2011, PROCEDIA ENGINEER, V14, DOI 10.1016/j.proeng.2011.07.271
   Shirole AM, 2009, BRIDG STRUCT, V5, P173, DOI 10.1080/15732480903143003
   Tang W. B., 2009, TECHNOLOGICAL DEV EN, V28, P127
   Wu IC, 2010, ADV ENG INFORM, V24, P379, DOI 10.1016/j.aei.2010.07.002
   Zhang JP, 2011, AUTOMAT CONSTR, V20, P155, DOI 10.1016/j.autcon2010.09.013
   Zhang J. P., 2005, ENG MECH, V22, P220
   [张正峰 Zhang Zhengfeng], 2006, [中国工程科学, Engineering science], V8, P63
   Zhou C.H., 2009, GEOHUNAN INT C, P138, DOI 10.1061/41042(349)18
NR 29
TC 7
Z9 7
U1 9
U2 106
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1729-8814
J9 INT J ADV ROBOT SYST
JI Int. J. Adv. Robot. Syst.
PD AUG 22
PY 2014
VL 11
AR 125
DI 10.5772/58442
PG 11
WC Robotics
SC Robotics
GA AO5FU
UT WOS:000341370100001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Huo, TX
   Qiao, L
   Wang, T
   Li, FS
AF Huo Tian-Xu
   Qiao Liang
   Wang Tao
   Li Fa-Shen
TI RETRACTED: High-frequency magnetic properties of planar anisotropy
   carbonyl-iron particles (Retracted Article)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
DE carbonyl-iron particles; Gaussian distribution; orientation degree;
   high-frequency magnetic properties
ID COMPLEX PERMEABILITY; MICROWAVE; FILMS; COMPOSITES
AB The effect of orientation degree on high-frequency magnetic properties of planar anisotropy carbonyl-iron particles is studied. We build the samples for planar carbonyl-iron particles, whose magnetic moments obey Gaussian distribution. Meanwhile, we obtain a new method about complex permeability by utilizing Landau-Lifshitz-Gilbert equation. Then the frequency-dependent complex permeability of sample is calculated using our method. The result shows that with the increase of orientation angle <theta >, the standard deviation of Gaussian distribution sigma decreases and the orientation degree f increases. Furthermore, the real part of initial permeability of the planar carbonyl-iron sample becomes higher with the increase of orientation degree f. For comparison, we measured the orientation degree and complex permeability of the sample by Mossbauer spectroscopy and vector network analyzer respectively. It is found that our experimental data accord well with the simulation results.
C1 [Huo Tian-Xu; Qiao Liang; Wang Tao; Li Fa-Shen] Lanzhou Univ, Minist Educ, Key Lab Magnetism & Magnet Mat, Lanzhou 730000, Peoples R China.
RP Qiao, L (reprint author), Lanzhou Univ, Minist Educ, Key Lab Magnetism & Magnet Mat, Lanzhou 730000, Peoples R China.
EM qiaoliang@lzu.edu.cn
FU State Key Development Program for Basic Research of China
   [2012CB933101]; National Natural Science Foundation of China [51102124];
   Fundamental Scientific Research Foundation for the Central Universities
   of China [lzujbky-2013-179]
FX Project supported by the State Key Development Program for Basic
   Research of China (Grant No. 2012CB933101), the National Natural Science
   Foundation of China (Grant No. 51102124), and the Fundamental Scientific
   Research Foundation for the Central Universities of China (Grant No.
   lzujbky-2013-179).
CR Chechenin NG, 2006, J MAGN MAGN MATER, V300, P198, DOI 10.1016/j.mmm.2005.10.062
   Chechenin NG, 2004, PHYS SOLID STATE+, V46, P479, DOI 10.1134/1.1687865
   Chechenin NG, 2002, IEEE T MAGN, V38, P3027, DOI 10.1109/TMAG.2002.802123
   Ding J, 2002, J MAGN MAGN MATER, V247, P249, DOI 10.1016/S0304-8853(02)00173-7
   [韩瑞 Han Rui], 2010, [科学通报, Chinese Science Bulletin], V55, P2570, DOI 10.1360/972009-1716
   He SL, 2005, ACTA PHYS SIN-CH ED, V54, P3408
   Liao S B, 1987, FERROMAGNETIC PHYS, V2, P43
   Liu JR, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2170402
   Qiao L, 2008, J APPL PHYS, V103, DOI 10.1063/1.2891671
   ROUSSELLE D, 1993, J APPL PHYS, V74, P475, DOI 10.1063/1.355256
   S Y Zhu, 2007, THESIS U SCI TECHN C
   Smit J., 1959, FERRITES, P279
   Soohoo R. F., 1985, MICROWAVE MAGNETICS
   VIAU G, 1995, J MAGN MAGN MATER, V140, P377, DOI 10.1016/0304-8853(94)00792-6
   Walser RM, 1998, IEEE T MAGN, V34, P1144, DOI 10.1109/20.706419
   Wen FS, 2008, CHINESE PHYS B, V17, P2263, DOI 10.1088/1674-1056/17/6/054
   Wen FS, 2008, CHINESE PHYS LETT, V25, P751, DOI 10.1088/0256-307X/25/2/108
   Xia Y F, 1984, MOSSBAUER EFFECT APP, P97
   Xue DS, 2008, CHINESE PHYS LETT, V25, P4120, DOI 10.1088/0256-307X/25/11/077
   Zhang B F, 1991, STUDY MOSSBAUER SPEC, P215
   Zhang BS, 2006, IEEE T MAGN, V42, P1778, DOI 10.1109/TMAG.2006.874188
   Zou GG, 2000, RARE METAL MAT ENG, V29, P149
NR 22
TC 0
Z9 0
U1 6
U2 15
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD AUG 20
PY 2014
VL 63
IS 16
AR 167503
DI 10.7498/aps.63.167503
PG 8
WC Physics, Multidisciplinary
SC Physics
GA AO5ZR
UT WOS:000341427000047
DA 2018-12-27
ER

PT J
AU Xu, RH
   Gao, W
   Wang, C
   Guo, DK
   Tang, L
   Zhang, H
   Wang, CJ
AF Xu, Rong-Hua
   Gao, Wei
   Wang, Chao
   Guo, De-Kai
   Tang, Lin
   Zhang, Hui
   Wang, Cong-Jun
TI RETRACTED: Systematic evaluation of percutaneous radiofrequency ablation
   versus percutaneous ethanol injection for the treatment of small
   hepatocellular carcinoma: a meta-analysis (Retracted article. See vol.
   20, 41, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE percutaneous radiofrequency ablation; percutaneous ethanol injection;
   small hepatocellular carcinoma; system evaluation; meta-analysis
ID RANDOMIZED CONTROLLED-TRIAL; THERMAL ABLATION; CIRRHOTIC-PATIENTS;
   SURVIVAL; RESECTION; CANCER; RECURRENCE; THERAPY
AB Background: Radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) have been used for patients with hepatocellular carcinoma (HCC). However, which therapy is superior remains to be further elucidated. We aimed to conduct a systematic review to assess survival and local tumor recurrence rate with RFA compared with PEI therapy for HCC.
   Methods: We conducted systematic review and meta-analysis of randomized controlled trials (RCTs) published up to 2014 in PubMed, MEDLINE, EMBASE, EBSCO, Springer, Ovid and the Cochrane library. Only RCTs that evaluated survival rate and occurrence of HCC between RFA and PEI therapy were included. The OR (odds ratio) with a 95% confidence interval (CI) was calculated by the Revman 5.0 software.
   Results: A total of six studies including 983 HCC patients were eligible for this analysis. The survival rate showed a significant benefit under RFA therapy over PEI at 1-year (P = 0.02, OR = 1.88, 95% CI: 1.09 to 3.22), 2-years (P = 0.0003, OR = 2.06, 95% CI: 1.39 to 3.05) and 3-years (P = 0.0007, OR = 1.68, 95% CI: 1.25 to 2.27). Likewise, RFA achieved significantly lower rates of local tumor recurrence over PEI at 1-year (P = 0.002, OR = 0.43, 95% CI: 0.26 to 0.73), 2-year (P = 0.03, OR = 0.33, 95% CI: 0.12 to 0.88) and 3-year (P = 0.003, OR = 0.61, 95% CI: 0.43 to 0.84).
   Conclusions: The current evidence suggests that RFA is superior to PEI in better survival and local disease control for small HCCs < 5 cm in diameter and that RFA is worthy of promotion in clinical applications.
C1 [Xu, Rong-Hua] Hainan Med Coll, Affiliated Hosp, Dept Surg Oncol, Haikou 570102, Hainan, Peoples R China.
   [Gao, Wei; Wang, Chao; Guo, De-Kai; Tang, Lin; Zhang, Hui; Wang, Cong-Jun] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Hepatobiliary & Pancreat Dis, Shanghai 200120, Peoples R China.
   [Xu, Rong-Hua; Gao, Wei; Wang, Chao; Guo, De-Kai; Tang, Lin; Zhang, Hui; Wang, Cong-Jun] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48105 USA.
   [Xu, Rong-Hua; Gao, Wei; Wang, Chao; Guo, De-Kai; Tang, Lin; Zhang, Hui; Wang, Cong-Jun] Univ Michigan, Sch Med, Translat Oncol Program, Ann Arbor, MI 48109 USA.
RP Zhang, H (reprint author), Tongji Univ, Sch Med, Shanghai East Hosp, Dept Hepatobiliary & Pancreat Dis, 150 Jimo Rd, Shanghai 200120, Peoples R China.
EM zhangh468@sohu.com; wcongjun@umich.edu
FU National Natural Science Foundation of China [30872510, 81272534,
   81260349]; Natural Science Foundation of Hubei Province [2008CDB127];
   Natural Science Foundation of Shanghai [064119620, 10411968400]
FX This project is supported by Grants from the National Natural Science
   Foundation of China (No. 30872510, 81272534, 81260349); the Natural
   Science Foundation of Hubei Province (No. 2008CDB127), and the Natural
   Science Foundation of Shanghai (No. 064119620; 10411968400).
CR Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011
   Bouza C, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-31
   Brunello F, 2008, SCAND J GASTROENTERO, V43, P727, DOI 10.1080/00365520701885481
   Cho YK, 2009, HEPATOLOGY, V49, P453, DOI 10.1002/hep.22648
   Crocetti L, 2008, CANCER IMAGING, V8, P19, DOI 10.1102/1470-7330.2008.0004
   Curley SA, 1999, ANN SURG, V230, P1, DOI 10.1097/00000658-199907000-00001
   El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001
   Giorgio A, 2011, ANTICANCER RES, V31, P2291
   Goldberg S N, 2001, Eur J Ultrasound, V13, P129, DOI 10.1016/S0929-8266(01)00126-4
   Grazi GL, 2003, ALIMENT PHARM THERAP, V17, P119, DOI 10.1046/j.1365-2036.17.s2.9.x
   Huang GT, 2005, ANN SURG, V242, P36, DOI 10.1097/01.sla.0000167925.90380.fe
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kurokohchi K, 2005, WORLD J GASTROENTERO, V11, P1426
   Lencioni RA, 2003, RADIOLOGY, V228, P235, DOI 10.1148/radiol.2281020718
   Lin SM, 2005, GUT, V54, P1151, DOI 10.1136/gut.2004.045203
   Lin SM, 2004, GASTROENTEROLOGY, V127, P1714, DOI 10.1053/j.gastro.2004.09.003
   Livraghi T, 2008, HEPATOLOGY, V47, P82, DOI 10.1002/hep.21933
   Lu DSK, 2005, HEPATOLOGY, V41, P1130, DOI 10.1002/hep.20688
   McCarthy M, 2008, ALLERGY, V8, P169
   Ng KK, 2008, J GASTROINTEST SURG, V12, P183, DOI 10.1007/s11605-007-0276-y
   Sangiovanni A, 2004, GASTROENTEROLOGY, V126, P1005, DOI 10.1053/j.gastro.2003.12.049
   Shen A, 2013, J GASTROEN HEPATOL, V28, P793, DOI 10.1111/jgh.12162
   Shiina S, 2005, GASTROENTEROLOGY, V129, P122, DOI 10.1053/j.gastro.2005.04.009
   Shuster JJ, 2011, REV COCHRANE HDB SYS
   Takahashi S, 2007, ONCOLOGY-BASEL, V72, P98, DOI 10.1159/000111714
   Wong SL, 2010, J CLIN ONCOL, V28, P493, DOI 10.1200/JCO.2009.23.4450
NR 26
TC 6
Z9 6
U1 1
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD AUG 20
PY 2014
VL 19
AR 39
DI 10.1186/2047-783X-19-39
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AO5QD
UT WOS:000341399000001
PM 25141776
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Xu, X
   Li, X
   Liu, L
   Wu, W
AF Xu, Xian
   Li, Xu
   Liu, Lin
   Wu, Wei
TI RETRACTED: A meta-analysis of external fixator versus intramedullary
   nails for open tibial fracture fixation (Retracted article. See vol. 10,
   41, 2015)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE Tibial fractures; Intramedullary nails; External fixator; Meta-analysis
ID SHAFT FRACTURES; INSERTION; IIIA
AB Background: To compare the clinical outcomes of external fixator (EF) and intramedullary nails (IN) in the treatment of open tibial fractures.
   Methods: We searched seven electronic databases (PubMed, MEDLINE, EMBASE, OVID, Cochrane library, CNKI, and CBM) for trials of tibial fracture fixation published from 1980 to 2013. The indicators including postoperative infection, malunion, nonunion, soft tissue injury, delayed healing, and healing time were used for quantitative outcome assessments.
   Results: A total of nine trials involving 532 patients (EF, n = 253; IN, n = 279) with open tibia fractures were included in this meta-analysis. The results indicated that the patients undergoing IN had lower incidence of postoperative infection (risk radio [RR] = 3.85; 95% confidence intervals [CI], 2.67-5.54; P < 0.0001), malunion (RR = 2.31; 95% CI, 1.40-3.81; P = 0.001), nonunion (RR = 1.41; 95% CI, 1.06-1.88; P = 0.02) and less healing time (weighted mean difference [WMD] = 6.19; 95% CI, 1.42-10.96; P = 0.01) compared with EF. However, regarding to the soft tissue injury (RR = 0.74; 95% CI, 0.34-1.62; P = 0.45) and delayed healing (RR = 1.38; 95% CI, 0.79-2.43; P = 0.26), there is no significantly difference between EF and IN approach.
   Conclusion: In conclusion, the use of IN is more effective than EF and may be considered as first-line approach in fixation of open tibial fractures.
C1 [Xu, Xian; Li, Xu; Liu, Lin; Wu, Wei] East Hosp, Dept Traumat Orthoped, Shanghai 200120, Peoples R China.
RP Wu, W (reprint author), East Hosp, Dept Traumat Orthoped, 150 Jimo Rd, Shanghai 200120, Peoples R China.
EM weiwuortho@hotmail.com
CR Abdelaal MA, 2014, OPEN J ORTHOP, V4, P60
   Aktekin CN, 2008, J PEDIATR ORTHOP B, V17, P171, DOI 10.1097/BPB.0b013e3283046530
   [Anonymous], 2008, J BONE JOINT SURG AM, V90, P2567
   AntichAdrover P, 1997, J BONE JOINT SURG BR, V79B, P433, DOI 10.1302/0301-620X.79B3.7394
   Behairy YM, 2006, SAUDI MED J, V27, P745
   Bhandari M, 2001, J BONE JOINT SURG BR, V83B, P62, DOI 10.1302/0301-620X.83B1.10986
   BLICK SS, 1989, CLIN ORTHOP RELAT R, P21
   Braten M, 2005, ARCH ORTHOP TRAUM SU, V125, P21, DOI 10.1007/s00402-004-0768-0
   CAUDLE RJ, 1987, J BONE JOINT SURG AM, V69A, P801, DOI 10.2106/00004623-198769060-00002
   COURTBROWN CM, 1990, J BONE JOINT SURG BR, V72, P801
   Cozma T, 2000, Rev Med Chir Soc Med Nat Iasi, V104, P77
   Cui Z, 2013, J NOV PHYSIOTHER, V3, P2
   Duan X, 2011, ARCH ORTHOP TRAUM SU, V131, P1445, DOI 10.1007/s00402-011-1311-8
   El-Sayed M, 2012, INT ORTHOP, V36, P2133, DOI 10.1007/s00264-012-1620-8
   EMAMI A, 1995, INJURY, V26, P299, DOI 10.1016/0020-1383(95)00037-A
   Giannoudis PV, 2006, J BONE JOINT SURG BR, V88B, P281, DOI 10.1302/0301-620X.88B3.16465
   Helland P, 1996, CLIN ORTHOP RELAT R, P209
   Henley MB, 1998, J ORTHOP TRAUMA, V12, P1, DOI 10.1097/00005131-199801000-00001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HOLBROOK JL, 1989, J BONE JOINT SURG AM, V71A, P1231, DOI 10.2106/00004623-198971080-00017
   Inan M, 2007, ARCH ORTHOP TRAUM SU, V127, P617, DOI 10.1007/s00402-007-0332-9
   Jadad A.R., 1998, RANDOMISED CONTROLLE
   Kakar S, 2007, J ORTHOP TRAUMA, V21, P153, DOI 10.1097/BOT.0b013e3180336923
   Krettek C, 1997, J BIOMECH, V30, P391, DOI 10.1016/S0021-9290(96)00160-1
   Mohseni Mohammad Ali, 2011, Pak J Biol Sci, V14, P490
   Nork SE, 2005, J BONE JOINT SURG AM, V87A, P1213, DOI 10.2106/JBJS.C.01135
   Noumi T, 2005, INJURY, V36, P1085, DOI 10.1016/j.injury.2004.09.012
   PUNO RM, 1986, CLIN ORTHOP RELAT R, P113
   Shannon FJ, 2002, J TRAUMA, V52, P650, DOI 10.1097/00005373-200204000-00006
   TORNETTA P, 1994, J BONE JOINT SURG BR, V76B, P13
   TU YK, 1995, J TRAUMA, V39, P361, DOI 10.1097/00005373-199508000-00029
   VANCLOOSTER P, 1988, ACTA CHIR BELG, V88, P21
NR 32
TC 4
Z9 5
U1 2
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD AUG 16
PY 2014
VL 9
AR 75
DI 10.1186/s13018-014-0075-6
PG 7
WC Orthopedics
SC Orthopedics
GA AO8RT
UT WOS:000341622600001
PM 25124047
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ferrandi, M
   Molinari, I
   Matafora, V
   Zerbini, G
   Trevisani, F
   Rastaldi, MP
   Simonini, M
   Giardino, L
   Ferrari, P
   Manunta, P
AF Ferrandi, M.
   Molinari, I.
   Matafora, V.
   Zerbini, G.
   Trevisani, F.
   Rastaldi, M. P.
   Simonini, M.
   Giardino, L.
   Ferrari, P.
   Manunta, P.
TI RETRACTED: SIK1 localizes with nephrin in glomerular podocytes and its
   polymorphism predicts kidney injury(Retracted article. See vol. 26, pg.
   660, 2017)
SO HUMAN MOLECULAR GENETICS
LA English
DT Article; Retracted Publication
ID ANTIHYPERTENSIVE COMPOUND; ENDOGENOUS OUABAIN; SODIUM-TRANSPORT; SLIT
   DIAPHRAGM; BLOOD-PRESSURE; HYPERTENSION; NETWORK; PHOSPHORYLATION; SALT;
   REABSORPTION
AB Mutant alpha-adducin and endogenous ouabain levels exert a causal role in hypertension by affecting renal Na-K ATPase. In addition, mutant beta-adducin is involved in glomerular damage through nephrin down-regulation. Recently, the salt-inducible kinase 1 (SIK1) has been shown to exert a permissive role on mutant alpha-adducin effects on renal Na-K ATPase activity involved in blood pressure (BP) regulation and a SIK1 rs3746951 polymorphism has been associated with changes in vascular Na-K ATPase activity and BP. Here, we addressed the role of SIK1 on nephrin and glomerular functional modifications induced by mutant beta-adducin and ouabain, by using congenic substrains of the Milan rats expressing either mutant alpha- or beta-adducin, alone or in combination, ouabain hypertensive rats (OHR) and hypertensive patients. SIK1 co-localized and co-immunoprecipitated with nephrin from glomerular podocytes and associated with caveolar nephrin signaling. In cultured podocytes, nephrin-gene silencing decreased SIK1 expression. In mutant beta-adducin congenic rats and in OHR, the podocyte damage was associated with decreased nephrin and SIK1 expression. Conversely, when the effects of beta-adducin on podocytes were blocked by the presence of mutant alpha-adducin, nephrin and SIK1 expressions were restored. Ouabain effects were also reproduced in cultured podocytes. In hypertensive patients, nephrinuria, but not albuminuria, was higher in carriers of mutant SIK1 rs3746951 than in wild-type, implying a more direct effect of SIK1 on glomerular damage. These results demonstrate that, through nephrin, SIK1 is involved in the glomerular effects of mutant adducin and ouabain and a direct effect of SIK1 is also likely to occur in humans.
C1 [Ferrandi, M.; Molinari, I.; Ferrari, P.] Prassis Sigma Tau Res Inst, Milan, Italy.
   [Ferrandi, M.; Molinari, I.; Manunta, P.] Ist Sci San Raffaele, Genom Renal Dis & Hypertens Unit, Div Genet & Cell Biol, I-20132 Milan, Italy.
   [Matafora, V.] Ist Sci San Raffaele, Div Genet & Cell Biol, Biomol Mass Spectrometry Unit, I-20132 Milan, Italy.
   [Zerbini, G.] Ist Sci San Raffaele, Div Metab & Cardiovasc Sci, I-20132 Milan, Italy.
   [Trevisani, F.; Simonini, M.] Ist Sci San Raffaele, Dept Internal & Specialist Med, I-20132 Milan, Italy.
   [Rastaldi, M. P.; Giardino, L.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Renal Res Lab, Milan, Italy.
   [Rastaldi, M. P.; Giardino, L.] Fdn DAmico Ric Malattie Renali, Milan, Italy.
   [Ferrari, P.] CVie Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Manunta, P.] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Milan, Italy.
RP Ferrandi, M (reprint author), Ist Sci San Raffaele, Genom Renal Dis & Hypertens Unit, Div Genet & Cell Biol, Via Olgettina 60, I-20132 Milan, Italy.
EM mara.ferrandi@gmail.com
CR Bianchi G, 2005, AM J PHYSIOL-REG I, V289, pR1536, DOI 10.1152/ajpregu.00441.2005
   Bignami E, 2013, CRIT CARE MED, V41, P744, DOI 10.1097/CCM.0b013e3182741599
   Briet M, 2010, NAT REV NEPHROL, V6, P261, DOI 10.1038/nrneph.2010.30
   Citterio L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019620
   Ferrandi M, 2004, J BIOL CHEM, V279, P33306, DOI 10.1074/jbc.M402187200
   Ferrandi M, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001815
   Ferrandi M, 2010, J MOL MED, V88, P203, DOI 10.1007/s00109-009-0549-x
   Ferrari P, 1999, J PHARMACOL EXP THER, V288, P1074
   Ferrari P, 1998, J PHARMACOL EXP THER, V285, P83
   Jim B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036041
   Lahdenpera J, 2003, KIDNEY INT, V64, P404, DOI 10.1046/j.1523-1755.2003.00097.x
   Lanzani C, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001814
   Liu BA, 2012, FEBS LETT, V586, P2597, DOI 10.1016/j.febslet.2012.04.054
   Manunta P, 1999, HYPERTENSION, V33, P694, DOI 10.1161/01.HYP.33.2.694
   Manunta P, 2011, J HYPERTENS, V29, P349, DOI 10.1097/HJH.0b013e32833ea821
   Manunta P, 2009, J HYPERTENS, V27, P9, DOI 10.1097/HJH.0b013e32831cf2c6
   Patari A, 2003, DIABETES, V52, P2969, DOI 10.2337/diabetes.52.12.2969
   Pawson T, 2008, FEBS LETT, V582, P1266, DOI 10.1016/j.febslet.2008.02.011
   Popov S, 2011, J HYPERTENS, V29, P2395, DOI 10.1097/HJH.0b013e32834d3d55
   PUGLIESE F, 1986, J HYPERTENS, V4, pS391
   SALVATI P, 1990, KIDNEY INT, V38, P447, DOI 10.1038/ki.1990.225
   Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849
   Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8
   Sjostrom M, 2007, P NATL ACAD SCI USA, V104, P16922, DOI 10.1073/pnas.0706838104
   Stenstrom K, 2009, J HYPERTENS, V27, P2452, DOI 10.1097/HJH.0b013e328330cf15
   Tripodi G, 2004, BIOCHEM BIOPH RES CO, V324, P562, DOI 10.1016/j.bbrc.2004.09.079
   Verma R, 2006, J CLIN INVEST, V116, P1346, DOI 10.1172/JCI27414
   Welling PA, 2010, KIDNEY INT, V77, P1063, DOI 10.1038/ki.2010.103
NR 28
TC 3
Z9 3
U1 3
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2014
VL 23
IS 16
BP 4371
EP 4382
DI 10.1093/hmg/ddu154
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AM7SX
UT WOS:000340070100014
PM 24698975
OA Bronze
DA 2018-12-27
ER

PT J
AU Tulio, AZ
   Jablonski, JE
   Jackson, LS
   Chang, C
   Edirisinghe, I
   Burton-Freeman, B
AF Tulio, Artemio Z., Jr.
   Jablonski, Joseph E.
   Jackson, Lauren S.
   Chang, Claire
   Edirisinghe, Indika
   Burton-Freeman, Britt
TI RETRACTED: Phenolic composition, antioxidant properties, and endothelial
   cell function of red and white cranberry fruits (Retracted article. See
   vol. 166, pg. 514, 2015)
SO FOOD CHEMISTRY
LA English
DT Article; Retracted Publication
DE Cranberry; Phenolic compounds; Antioxidants; Anthocyanins;
   Proanthocyanidins; Flavonols; Phenolic acids; Endothelial cell function;
   p-Akt; Cell migration; Tube formation
ID FIMBRIATED ESCHERICHIA-COLI; DEPENDENT RELAXATION;
   VACCINIUM-MACROCARPON; INHIBIT ADHERENCE; CAPACITY; EXTRACT;
   PROANTHOCYANIDINS; ANTHOCYANINS; PROCYANIDINS; VALIDATION
AB The effects of phenolic constituents in red cranberry extracts (RCE) and white cranberry extracts (WCE) on the endothelial cell function were investigated. Peonidin-3-O-galactoside, cyanidin-3-O-arabinoside, and cyanidin-3-O-galactoside were the predominant anthocyanins characterized, whereas a procyanidin tetramer was the predominant proanthocyanidin identified. The antioxidant properties of RCE and WCE were not significantly different regardless of antioxidant assays (DPPH, FRAP, and TEAC) used. Both RCE and WCE induced the phosphorylation of Akt in vitro in human umbilical endothelial cells (HUVEC), resulting in the phosphorylation of endothelial nitric oxide synthase, cell migration, and tube formation. The enhanced phosphorylation of PI3/Akt kinase in HUVEC, endothelial cell wound healing, and tube formation elicited by RCE and WCE suggest that overall phenolic constituents rather than individual phenolic compounds within the cranberry matrix may be responsible for these biological effects. Published by Elsevier Ltd.
C1 [Tulio, Artemio Z., Jr.; Jablonski, Joseph E.; Jackson, Lauren S.; Chang, Claire] US FDA, Ctr Food Safety & Appl Nutr, Bedford Pk, IL 60501 USA.
   [Chang, Claire] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37830 USA.
   [Edirisinghe, Indika; Burton-Freeman, Britt] IIT, Inst Food Safety & Hlth, Bedford Pk, IL 60501 USA.
RP Tulio, AZ (reprint author), US FDA, Ctr Food Safety & Appl Nutr, 6502 South Archer Rd, Bedford Pk, IL 60501 USA.
EM artemio.tulio@fda.hhs.gov
CR Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292
   BILYK A, 1986, J AGR FOOD CHEM, V34, P585, DOI 10.1021/jf00070a001
   BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25
   Brown PN, 2011, J AOAC INT, V94, P459
   Celik H, 2008, SCI HORTIC-AMSTERDAM, V117, P345, DOI 10.1016/j.scienta.2008.05.005
   Edirisinghe I, 2008, CLIN SCI, V114, P331, DOI 10.1042/CS20070264
   Edirisinghe I, 2007, FASEB J, V21, pA1232
   Ediristnghe I, 2008, J AGR FOOD CHEM, V56, P9383, DOI 10.1021/jf801864t
   Fitzpatrick DF, 2002, ANN NY ACAD SCI, V957, P78, DOI 10.1111/j.1749-6632.2002.tb02907.x
   Foo LY, 2000, J NAT PROD, V63, P1225, DOI [10.1021/np000128u, 10.1021/np00012Su]
   Foo LY, 2000, PHYTOCHEMISTRY, V54, P173, DOI 10.1016/S0031-9422(99)00573-7
   Giusti M., 2005, HDB FOOD ANAL CHEM F, VF1, P19
   Hakkinen SH, 1999, J AGR FOOD CHEM, V47, P2274, DOI 10.1021/jf9811065
   Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2
   Mazza G., 1993, ANTHOCYANINS FRUITS
   Mckay DL, 2007, NUTR REV, V65, P490, DOI 10.1301/nr.2007.nov.490-502
   Meyers KJ, 2003, J AGR FOOD CHEM, V51, P6887, DOI 10.1021/jf034506n
   Mullen W, 2002, J AGR FOOD CHEM, V50, P5191, DOI 10.1021/jf020140n
   Neto CC, 2011, J SCI FOOD AGR, V91, P2303, DOI 10.1002/jsfa.4621
   Ozgen M, 2006, J AGR FOOD CHEM, V54, P1151, DOI 10.1021/jf051960d
   Prior RL, 2001, J AGR FOOD CHEM, V49, P1270, DOI 10.1021/jf001211q
   Prior RL, 2010, J SCI FOOD AGR, V90, P1473, DOI 10.1002/jsfa.3966
   Reed J, 2002, CRIT REV FOOD SCI, V42, P301, DOI 10.1080/10408390209351919
   Seeram NP, 2001, PHYTOMEDICINE, V8, P362, DOI 10.1078/0944-7113-00053
   SLINKARD K, 1977, AM J ENOL VITICULT, V28, P49
   Sun J, 2002, J AGR FOOD CHEM, V50, P7449, DOI 10.1021/jf0207530
   Timberlake C. F., 1988, NATCOL Q B, V1, P4
   Tulio AZ, 2012, J AGR FOOD CHEM, V60, P5803, DOI 10.1021/jf3001636
   Vvedenskaya IO, 2004, PLANT SCI, V167, P1043, DOI 10.1016/j.plantsci.2004.06.001
NR 29
TC 7
Z9 7
U1 2
U2 87
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-8146
EI 1873-7072
J9 FOOD CHEM
JI Food Chem.
PD AUG 15
PY 2014
VL 157
BP 540
EP 552
DI 10.1016/j.foodchem.2014.02.047
PG 13
WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics
SC Chemistry; Food Science & Technology; Nutrition & Dietetics
GA AF8NT
UT WOS:000334973600073
PM 24679816
DA 2018-12-27
ER

PT J
AU Lu, YY
   An, LJ
   Wang, SQ
   Wang, ZG
AF Lu, Yuyuan
   An, Lijia
   Wang, Shi-Qing
   Wang, Zhen-Gang
TI RETRACTED: Coupled Effect of Orientation, Stretching and Retraction on
   the Dimension of Entangled Polymer Chains during Startup Shear(Retracted
   article. See vol. 50, pg. 2601, 2017)
SO MACROMOLECULES
LA English
DT Editorial Material; Retracted Publication
ID IMPROVED THEORETICAL DESCRIPTION; MOLECULAR-DYNAMICS SIMULATION;
   NONLINEAR RHEOLOGY; STEADY SHEAR; STEP SHEAR; LIQUIDS; DEFORMATION;
   MELTS; FLOW
C1 [Lu, Yuyuan; An, Lijia; Wang, Zhen-Gang] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China.
   [Wang, Shi-Qing] Univ Akron, Dept Polymer Sci, Akron, OH 44325 USA.
   [Wang, Zhen-Gang] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.
RP An, LJ (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China.
EM ljan@ciac.ac.cn; swang@uakron.edu; zgw@caltech.edu
CR Adams JM, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.219802
   Adams JM, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.067801
   Archer LA, 1999, J RHEOL, V43, P1555, DOI 10.1122/1.551060
   Baig C, 2010, MACROMOLECULES, V43, P6886, DOI 10.1021/ma100826u
   Bent J, 2003, SCIENCE, V301, P1691, DOI 10.1126/science.1086952
   Dealy J. M., 2006, STRUCTURE RHEOLOGY M
   DEGENNES PG, 1971, J CHEM PHYS, V55, P572, DOI 10.1063/1.1675789
   Doi M, 1986, THEORY POLYM DYNAMIC
   Graham RS, 2013, MACROMOLECULES, V46, P9849, DOI 10.1021/ma401183w
   Graham RS, 2003, J RHEOL, V47, P1171, DOI 10.1122/1.1595099
   Inoue T, 2002, MACROMOLECULES, V35, P4718, DOI 10.1021/ma012149g
   KREMER K, 1990, J CHEM PHYS, V92, P5057, DOI 10.1063/1.458541
   Kumar S, 2001, J CHEM PHYS, V114, P6937, DOI 10.1063/1.1358860
   LEES AW, 1972, J PHYS PART C SOLID, V5, P1921, DOI 10.1088/0022-3719/5/15/006
   Lu YY, 2014, ACS MACRO LETT, V3, P569, DOI 10.1021/mz500260h
   Lu YY, 2013, ACS MACRO LETT, V2, P561, DOI 10.1021/mz400145m
   Ravindranath S, 2008, MACROMOLECULES, V41, P2663, DOI 10.1021/ma7027352
   Ravindranath S, 2007, MACROMOLECULES, V40, P8031, DOI 10.1021/ma071495g
   Rubinstein M., 2003, POLYM PHYS
   Sanchez-Reyes J, 2002, MACROMOLECULES, V35, P5194, DOI 10.1021/ma020321q
   Tapadia P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.016001
   Wang SQ, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2753156
   Wang SQ, 2013, MACROMOLECULES, V46, P3147, DOI 10.1021/ma300398x
   Wang SQ, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.219801
   Wang SQ, 2008, J POLYM SCI POL PHYS, V46, P2660, DOI 10.1002/polb.21588
   Wang YY, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.237801
NR 26
TC 19
Z9 19
U1 6
U2 91
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0024-9297
EI 1520-5835
J9 MACROMOLECULES
JI Macromolecules
PD AUG 12
PY 2014
VL 47
IS 15
BP 5432
EP 5435
DI 10.1021/ma500131f
PG 4
WC Polymer Science
SC Polymer Science
GA AN1NK
UT WOS:000340350400064
DA 2018-12-27
ER

PT J
AU de Souza, FM
   Dias, APB
   Babeto, B
   Pelisson, S
   Lazarin, AM
   Sernaglia, RL
   Andreotti, EIS
   Airoldi, C
AF de Souza, Fernando M.
   Dias, Ana Paula B.
   Babeto, Beatriz
   Pelisson, Scarlet
   Lazarin, Angelica M.
   Sernaglia, Rosana L.
   Andreotti, E. I. S.
   Airoldi, Claudio
TI RETRACTED: Thermodynamics of the nickel, cobalt and zinc removal from
   ethanolic solution by p-aminobenzoic acid intercalated on layered
   calcium phosphate (Retracted article. See vol. 627, pg. 91, 2016)
SO THERMOCHIMICA ACTA
LA English
DT Article; Retracted Publication
DE Inorganic compounds; p-Aminobenzoic acid; Adsorption; Thermodynamic
   properties
ID ALPHA-TITANIUM HYDROGENPHOSPHATE; ZIRCONIUM-PHOSPHATE; THERMOCHEMICAL
   DATA; AQUEOUS-SOLUTION; CATION REMOVAL; HEAVY-METALS; SILICA-GEL;
   ADSORPTION; PHENYLPHOSPHONATE; PRECONCENTRATION
AB Crystalline lamellar calcium phosphate retained p-aminobenzoic acid inside its cavity without leaching. The adsorption isotherms from ethanol gave the maximum adsorption capacities of 6.44, 3.34 and 1.62 mmol g(-1) for nickel, cobalt and zinc, respectively. The energetic effects caused by metallic cation interactions were determined through calorimetric titration at the solid/liquid interface and gave a net thermal effect that enabled enthalpy and equilibrium constant calculations. Complete thermodynamic data composed of exothermic enthalpy, negative free Gibbs energy and positive entropy conformed to a set of favorable cation/basic center interactions, to indicate that these materials could be useful tools to eliminate undesirable cations from ethanolic systems. (C) 2014 Elsevier B.V. All rights reserved.
C1 [de Souza, Fernando M.; Dias, Ana Paula B.; Babeto, Beatriz; Pelisson, Scarlet; Lazarin, Angelica M.; Sernaglia, Rosana L.; Andreotti, E. I. S.] Univ Estadual Maringa, Dept Quim, BR-87020900 Maringa, Parana, Brazil.
   [Airoldi, Claudio] Univ Estadual Campinas, Inst Quim, BR-13084971 Campinas, SP, Brazil.
RP Lazarin, AM (reprint author), Univ Estadual Maringa, Dept Quim, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM amlazarin2@uem.br
FU CNPq
FX The authors are indebted to CNPq for the financial support and Josue A.
   da Silva for manuscript revision.
CR Airoldi C, 1996, J MATER CHEM, V6, P1963, DOI 10.1039/jm9960601963
   AIROLDI C, 1991, STRUCT CHEM, V2, P41, DOI 10.1007/BF00673488
   Al-Asheh S, 1999, WATER AIR SOIL POLL, V114, P251, DOI 10.1023/A:1005093821620
   Alberti G., 1996, COMPREHENSIVE SUPRAM
   Bem-Naim A., 1987, SOLVATION THERMODYNA
   Cabreza A., 1996, ACTA CRYSTALLOGR B, V52, P982
   Capkova P, 2003, J INCL PHENOM MACRO, V47, P1, DOI 10.1023/B:JIPH.0000003826.01697.42
   Clearfield A, 1998, PROG INORG CHEM, V47, P371
   CLEARFIELD A, 1982, INORGANIC ION EXCHAN
   da Silva OG, 2007, COLLOID SURFACE A, V301, P376, DOI 10.1016/j.colsurfa.2006.12.072
   Fonseca MG, 2000, THERMOCHIM ACTA, V359, P1, DOI 10.1016/S0040-6031(00)00490-1
   FONSECA MG, 1999, J CHEM SOC DA, V42, P3687
   Jacobson A.J., 1992, SOLID STATE CHEM COM
   Karadag D, 2007, J HAZARD MATER, V144, P432, DOI 10.1016/j.jhazmat.2006.10.055
   Kim HN, 1997, CHEM MATER, V9, P1414, DOI 10.1021/cm970027q
   Lazarin AM, 2006, CHEM MATER, V18, P2226, DOI 10.1021/cm0519333
   Lerf A., 2000, HDB NANOSTRUCTURED M, V5
   Lima CBA, 2004, SOLID STATE SCI, V6, P1245, DOI 10.1016/j.solidstatesciences.2004.06.009
   Guerra DL, 2008, APPL SURF SCI, V254, P5157, DOI 10.1016/j.apsusc.2008.02.017
   Marcus Y, 1985, ION SALVATION
   Monteiro OAC, 2005, J COLLOID INTERF SCI, V282, P32, DOI 10.1016/j.jcis.2004.08.165
   MURAKAMI Y, 1992, NIPPON SERAM KYO GAK, V100, P439
   NADHU N, 2003, THERMOCHIM ACTA, V400, P29
   Nunes LM, 2005, THERMOCHIM ACTA, V435, P118, DOI 10.1016/j.tca.2004.06.019
   OGAWA M, 1995, CHEM REV, V95, P399, DOI 10.1021/cr00034a005
   OGAWA M, 1998, ANN REP C, V94, P209, DOI DOI 10.1039/PC094209
   Padilha PD, 1997, TALANTA, V45, P317, DOI 10.1016/S0039-9140(97)00134-3
   Patrucelli G.C., 2006, THERMOCHIM ACTA, V450, P16
   Pessoa CA, 1997, ELECTROANAL, V9, P800, DOI 10.1002/elan.1140091014
   POOJARY DM, 1995, ANGEW CHEM INT EDIT, V34, P1508, DOI 10.1002/anie.199515081
   Prado AGS, 2001, ANAL CHIM ACTA, V432, P201, DOI 10.1016/S0003-2670(00)01372-6
   Ruiz VSO, 2006, J MATER CHEM, V16, P2338, DOI 10.1039/b515676a
   Ruiz VSO, 2004, THERMOCHIM ACTA, V420, P73, DOI 10.1016/j.tca.2003.10.029
   Sales JAA, 2005, THERMOCHIM ACTA, V427, P77, DOI 10.1016/j.tca.2004.08.015
   Vaghetti JCP, 2008, BIOCHEM ENG J, V42, P67, DOI 10.1016/j.bej.2008.05.021
   Yang X.-B., 2011, CHEM PAP, V65, P676
   Yang XB, 2010, CHEM PAP, V64, P118, DOI 10.2478/s11696-009-0091-x
NR 37
TC 1
Z9 1
U1 3
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0040-6031
EI 1872-762X
J9 THERMOCHIM ACTA
JI Thermochim. Acta
PD AUG 10
PY 2014
VL 589
BP 107
EP 113
DI 10.1016/j.tca.2014.05.017
PG 7
WC Thermodynamics; Chemistry, Analytical; Chemistry, Physical
SC Thermodynamics; Chemistry
GA AN1CN
UT WOS:000340320400015
DA 2018-12-27
ER

PT J
AU Nelson, OL
   Jansen, HT
   Galbreath, E
   Morgenstern, K
   Gehring, JL
   Rigano, KS
   Lee, J
   Gong, JH
   Shaywitz, AJ
   Vella, CA
   Robbins, CT
   Corbit, KC
AF Nelson, O. Lynne
   Jansen, Heiko T.
   Galbreath, Elizabeth
   Morgenstern, Kurt
   Gehring, Jamie Lauren
   Rigano, Kimberly Scott
   Lee, Jae
   Gong, Jianhua
   Shaywitz, Adam J.
   Vella, Chantal A.
   Robbins, Charles T.
   Corbit, Kevin C.
TI RETRACTED: Grizzly Bears Exhibit Augmented Insulin Sensitivity while
   Obese Prior to a Reversible Insulin Resistance during Hibernation
   (Retracted article. See vol. 22, pg. 532, 2015)
SO CELL METABOLISM
LA English
DT Article; Retracted Publication
ID NAKED MOLE-RAT; ADIPOSE-TISSUE; METABOLIC SYNDROME; LIPOTOXICITY;
   INFLAMMATION; GLUCOSE; MUSCLE; ADULTS; SIZE
AB The confluence of obesity and diabetes as a worldwide epidemic necessitates the discovery of new therapies. Success in this endeavor requires translatable preclinical studies, which traditionally employ rodent models. As an alternative approach, we explored hibernation where obesity is a natural adaptation to survive months of fasting. Here we report that grizzly bears exhibit seasonal tripartite insulin responsiveness such that obese animals augment insulin sensitivity but only weeks later enter hibernation-specific insulin resistance (IR) and subsequently reinitiate responsiveness upon awakening. Preparation for hibernation is characterized by adiposity coupled to increased insulin sensitivity via modified PTEN/AKT signaling specifically in adipose tissue, suggesting a state of "healthy'' obesity analogous to humans with PTEN haploinsufficiency. Collectively, we show that bears reversibly cope with homeostatic perturbations considered detrimental to humans and describe a mechanism whereby IR functions not as a late-stage metabolic adaptation to obesity, but rather a gatekeeper of the fed-fasting transition.
C1 [Nelson, O. Lynne] Washington State Univ, Coll Vet Med, Pullman, WA 99164 USA.
   [Nelson, O. Lynne] Washington State Univ, Dept Vet Clin Sci, Pullman, WA 99164 USA.
   [Jansen, Heiko T.] Washington State Univ, Dept Integrat Physiol & Neurosci, Pullman, WA 99164 USA.
   [Galbreath, Elizabeth] Amgen Inc, Dept Pathol, Thousand Oaks, CA 91360 USA.
   [Morgenstern, Kurt] Amgen Inc, Mol Struct & Characterizat, Thousand Oaks, CA 91360 USA.
   [Gehring, Jamie Lauren; Rigano, Kimberly Scott; Robbins, Charles T.] Washington State Univ, Sch Environm, Pullman, WA 99164 USA.
   [Gehring, Jamie Lauren; Rigano, Kimberly Scott; Robbins, Charles T.] Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA.
   [Lee, Jae; Gong, Jianhua; Corbit, Kevin C.] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91360 USA.
   [Shaywitz, Adam J.] Amgen Inc, Div Med Sci, Thousand Oaks, CA 91360 USA.
   [Vella, Chantal A.] Univ Idaho, Dept Movement Sci, Moscow, ID 83844 USA.
RP Corbit, KC (reprint author), Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91360 USA.
EM kcorbit@amgen.com
FU Interagency Grizzly Bear Committee; US Fish and Wildlife Service; Raili
   Korkka Brown Bear Endowment; Bear Research and Conservation Endowment;
   Nutritional Ecology Endowment at Washington State University
FX We would like to thank Larry Ross, Kenneth Ganley, and other members of
   the Amgen Clinical Pathology Laboratory for the expert technical
   assistance. We are indebted to the talented and dedicated graduate,
   undergraduate, and veterinary students and staff at the Washington State
   University Bear Center. Funding and bears were provided by the
   Interagency Grizzly Bear Committee, US Fish and Wildlife Service (Chris
   Servheen), the Raili Korkka Brown Bear Endowment, the Bear Research and
   Conservation Endowment, and the Nutritional Ecology Endowment at
   Washington State University. E.G., K.M., J.G., J.L., and K.C.C. are
   employees and stock holders of Amgen, Inc.
CR Alemzadeh R, 1998, J CLIN ENDOCR METAB, V83, P1911, DOI 10.1210/jc.83.6.1911
   Barbour LA, 2007, DIABETES CARE, V30, pS112, DOI 10.2337/dc07-s202
   Buffenstein R, 2009, MOL CELL ENDOCRINOL, V299, P101, DOI 10.1016/j.mce.2008.04.021
   Cahill G F Jr, 1970, N Engl J Med, V282, P668
   de Rycke LMJH, 1999, VET RADIOL ULTRASOUN, V40, P294, DOI 10.1111/j.1740-8261.1999.tb00364.x
   Dimitriadis G, 2011, DIABETES RES CLIN PR, V93, pS52, DOI 10.1016/S0168-8227(11)70014-6
   FARLEY SD, 1994, CAN J ZOOL, V72, P220, DOI 10.1139/z94-029
   Fauci AS, 2008, HARRISONS PRINCIPLES
   Fayard E, 2010, CURR TOP MICROBIOL, V346, P31, DOI 10.1007/82_2010_58
   FLORANT GL, 1985, AM J PHYSIOL, V249, pR159
   Girousse A, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001485
   Hilderbrand GV, 1999, CAN J ZOOL, V77, P132, DOI 10.1139/cjz-77-1-132
   Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126
   Kamine A, 2012, JPN J VET RES, V60, P5
   Karpe F, 2005, BIOCHEM SOC T, V33, P1045, DOI 10.1042/BST0331045
   Kralisch S, 2013, DIABETOLOGIA, V56, P10, DOI 10.1007/s00125-012-2737-4
   Lustig RH, 2006, INT J OBESITY, V30, P331, DOI 10.1038/sj.ijo.0803074
   Medina-Gomez G, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030064
   Mehran AE, 2012, CELL METAB, V16, P723, DOI 10.1016/j.cmet.2012.10.019
   Nelson OL, 2010, J COMP PHYSIOL B, V180, P465, DOI 10.1007/s00360-009-0421-x
   NELSON RA, 1973, MAYO CLIN PROC, V48, P733
   Rowe AH, 2013, SCIENCE, V342, P441, DOI 10.1126/science.1236451
   Saloranta C, 1996, DIABETES METAB REV, V12, P15
   Seifert AW, 2012, NATURE, V489, P561, DOI 10.1038/nature11499
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Smith ESJ, 2011, SCIENCE, V334, P1557, DOI 10.1126/science.1213760
   Tian X, 2013, NATURE, V499, P346, DOI 10.1038/nature12234
   Toien O, 2011, SCIENCE, V331, P906, DOI 10.1126/science.1199435
   Tomas E, 2002, ANN NY ACAD SCI, V967, P43
   Unger RH, 2010, TRENDS ENDOCRIN MET, V21, P345, DOI 10.1016/j.tem.2010.01.009
   van Greevenbroek MMJ, 2013, NETH J MED, V71, P174
   Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000
   Vickers SP, 2011, BRIT J PHARMACOL, V164, P1248, DOI 10.1111/j.1476-5381.2011.01245.x
   Wei YZ, 2008, AM J PHYSIOL-REG I, V294, pR673, DOI 10.1152/ajpregu.00561.2007
   Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560
   Yanovski SZ, 2014, JAMA-J AM MED ASSOC, V311, P74, DOI 10.1001/jama.2013.281361
   Zechner R, 2009, J LIPID RES, V50, P3, DOI 10.1194/jlr.R800031-JLR200
NR 37
TC 20
Z9 21
U1 2
U2 44
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD AUG 5
PY 2014
VL 20
IS 2
BP 376
EP 382
DI 10.1016/j.cmet.2014.07.008
PG 7
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA AO5RJ
UT WOS:000341402500022
PM 25100064
OA Bronze
DA 2018-12-27
ER

PT J
AU Liu, L
   Zou, J
   Wang, Q
   Yin, FQ
   Zhang, W
   Li, L
AF Liu, Ling
   Zou, Jing
   Wang, Qi
   Yin, Fu-Qiang
   Zhang, Wei
   Li, Li
TI RETRACTED: Novel microRNAs expression of patients with chemotherapy
   drug-resistant and chemotherapy-sensitive epithelial ovarian cancer
   (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Epithelial ovarian cancer; Drug-resistant tissues and drug-sensitive
   tissues; MicroRNA microarray chip; Real-time PCR
ID CELL-PROLIFERATION; PACLITAXEL; CARCINOMA; BURDEN
AB The aim of this study is to examine the microRNA (miRNA) expression of epithelial ovarian cancer (EOC) in both drug-resistant and drug-sensitive tissues and to explore the pathogenic characteristics of drug-resistant miRNAs in EOC. The samples with 10 cases of drug-resistant and drug-sensitive EOC tissue were obtained from undergoing surgical resection of ovarian cancer (OC). Total miRNAs were extracted and isolated, respectively. Hybridization was carried out on miRNA microarray chip. Real-time polymerase chain reaction (RT-PCR) was performed to confirm the difference of miRNA expression. Bioinformatic software was used to predict the possible target genes of each miRNA which expressed differently. The results indicated that four miRNAs related drug-resistance been identified, and the expression of hsa-miR-152 and hsa-miR-381 in drug-resistant OC tissue was significantly higher compared with those in drug-sensitive tissue (P < 0.01). However, expression of hsa-miR-200a-3p and hsa-miR-429 were downregulated in drug-resistant tissues (P < 0.01). The results obtained by miRNA microarrays of differential expression with hsa-miR-106b-3p, hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 were confirmed by real-time PCR. There were 62 significantly different miRNAs, including 42 significant upregulated miRNAs and 20 significant downregulated miRNAs in the drug-resistant tissue. Five databases, including Target Scan, miRanda, miRDB, PicTar5, and RNA22, were used for bioinformatics prediction. In conclusion, miRNA microarray analysis has become a fast and efficient molecular biological technology for the study of biological information. hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 may participate in the formation of drug resistance in EOC through the target genes predicted.
C1 [Liu, Ling; Zou, Jing; Wang, Qi; Zhang, Wei; Li, Li] Guangxi Med Univ, Dept Gynecol Oncol, Affiliated Tumor Hosp, Nanning 530021, Guangxi, Peoples R China.
   [Yin, Fu-Qiang] Guangxi Med Univ, Med Sci Res Ctr, Nanning 530021, Guangxi, Peoples R China.
RP Li, L (reprint author), Guangxi Med Univ, Dept Gynecol Oncol, Affiliated Tumor Hosp, Nanning 530021, Guangxi, Peoples R China.
EM liliguangxidr@yeah.net
FU National High Technology Research and Development Program of China
   [012AA02A507]; Research Fund for the Doctoral Program of Higher
   Education of China [20134503110009]
FX This study was supported by National High Technology Research and
   Development Program of China (No. 012AA02A507), and the Research Fund
   for the Doctoral Program of Higher Education of China (No.
   20134503110009).
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Boren T, 2009, GYNECOL ONCOL, V113, P249, DOI 10.1016/j.ygyno.2009.01.014
   BURCHENAL JH, 1950, SCIENCE, V111, P116, DOI 10.1126/science.111.2875.116
   Cittelly DM, 2012, MOL CANCER THER, V11, P2556, DOI 10.1158/1535-7163.MCT-12-0463
   Hassan MK, 2011, TUMOR BIOL, V32, P1031, DOI 10.1007/s13277-011-0207-0
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Kim YW, 2014, DRUG DES DEV THER, V8, P293, DOI 10.2147/DDDT.S51969
   Li H, 2014, ONCOL LETT, V7, P183
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsuo K, 2010, GYNECOL ONCOL, V116, P61, DOI 10.1016/j.ygyno.2009.09.018
   Raza U, 2014, CLIN CANCER RES, V20, P1990
   Samrao D, 2012, TRANSL ONCOL, V5, P469, DOI 10.1593/tlo.12265
   Sankaranarayanan R, 2006, BEST PRACT RES CL OB, V20, P207, DOI 10.1016/j.bpobgyn.2005.10.007
   Sorrentino A, 2008, GYNECOL ONCOL, V111, P478, DOI 10.1016/j.ygyno.2008.08.017
   Sun CY, 2013, ONCOL LETT, V6, P507, DOI 10.3892/ol.2013.1393
   Ying HC, 2013, TUMOR BIOL, V34, P3219, DOI 10.1007/s13277-013-0892-y
   Yu XT, 2013, TUMOR BIOL, V34, P3501, DOI 10.1007/s13277-013-0928-3
   Zimmerman AL, 2011, CANCER LETT, V300, P10, DOI 10.1016/j.canlet.2010.09.019
NR 19
TC 16
Z9 19
U1 4
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2014
VL 35
IS 8
BP 7713
EP 7717
DI 10.1007/s13277-014-1970-5
PG 5
WC Oncology
SC Oncology
GA AP2DU
UT WOS:000341883500058
PM 24805828
DA 2018-12-27
ER

PT J
AU Wu, HY
   Ding, LY
AF Wu, Hai-ying
   Ding, Ling-yu
TI RETRACTED: Comprehensive assessment of the association between XPD
   rs13181 polymorphism and lung cancer risk (retracted article)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Xeroderma pigmentosumgroupD; Lung cancer; Risk; Polymorphism
ID DNA-REPAIR GENES; EXCISION-REPAIR; CHINESE POPULATION; LYS751GLN
   POLYMORPHISM; CIGARETTE-SMOKING; SUSCEPTIBILITY; METAANALYSIS; XRCC1;
   ADENOCARCINOMA; CAPACITY
AB Xeroderma pigmentosum group D (XPD) rs13181 may reduce DNA repair capacity (DRC) through modifying XPD protein product. Reduced DRC is reportedly related to an increase in the risk of lung cancer. To precisely estimate the association between XPD rs13181 and lung cancer risk, we carried out the current meta-analysis. We searched multiple databases (up to 31 October 2013) for studies investigating the association of XPD rs13181 and lung cancer. Odds ratio (OR) was estimated with the fixed effect model to assess the association. Heterogeneity between studies was measured using Q test. Subgroup analyses were conducted by ethnicity, histological type, and sample size. Meta-analysis of 30 studies suggested that individuals carrying Gln/Gln genotype were more likely than the individuals with Lys/Lys or Lys/Gln + Lys/Lys genotypes (homozygous model, OR 1.18, 95 % confidence interval (CI) 1.07-1.31; recessive model, OR 1.17, 95 % CI 1.06-1.29) to develop lung cancer, without any substantial heterogeneity. This significantly increased risk was also revealed in the individuals harboring Gln/Gln + Lys/Gln genotypes (dominant model, OR 1.07, 95 % CI 1.01-1.12). Further stratification by histological type, ethnicity, and sample size yielded statistically significant estimates in subgroup of Caucasian subjects, non-small cell lung cancer, and relatively large studies, but borderline association in Asians. Our analyses demonstrate that XPD rs13181 may be associated with an increase in the risk of lung cancer among Caucasian populations.
C1 [Wu, Hai-ying; Ding, Ling-yu] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Guangzhou 510060, Guangdong, Peoples R China.
RP Wu, HY (reprint author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
EM wu_haiying@sogou.com
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Andrew AS, 2006, CARCINOGENESIS, V27, P1030, DOI 10.1093/carcin/bgi284
   Au WW, 2003, ENVIRON HEALTH PERSP, V111, P1843, DOI 10.1289/ehp.6632
   Baccarelli A, 2004, BRIT J CANCER, V90, P497, DOI 10.1038/sj.bjc.6601385
   Benhamou S, 2005, AM J EPIDEMIOL, V161, P1, DOI 10.1093/aje/kwi018
   Chang JS, 2008, INT J CANCER, V123, P2095, DOI 10.1002/ijc.23801
   Chen SQ, 2002, CARCINOGENESIS, V23, P1321, DOI 10.1093/CARCIN/23.8.1321
   CHYOU PH, 1992, AM J PUBLIC HEALTH, V82, P37, DOI 10.2105/AJPH.82.1.37
   Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491
   David-Beabes GL, 2001, CANCER EPIDEM BIOMAR, V10, P911
   De Ruyck K, 2007, MUTAT RES-GEN TOX EN, V631, P101, DOI 10.1016/j.mrgentox.2007.03.010
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feng Z, 2012, MOL BIOL REP, V39, P57, DOI 10.1007/s11033-011-0710-9
   Hansen RD, 2007, MUTAT RES-FUND MOL M, V619, P68, DOI 10.1016/j.mrfmmm.2007.02.002
   Harms C, 2004, ENVIRON MOL MUTAGEN, V44, P74, DOI 10.1002/em.20031
   Hou SM, 2002, CARCINOGENESIS, V23, P599, DOI 10.1093/carcin/23.4.599
   Hu Z, 2004, LUNG CANCER, V46, P1, DOI 10.1016/j.lungcan.2004.03.016
   Hu ZB, 2006, CANCER EPIDEM BIOMAR, V15, P1336, DOI 10.1158/1055-9965.EPI-06-0194
   Jia Zhifang, 2009, Zhongguo Fei Ai Za Zhi, V12, P1079, DOI 10.3779/j.issn.1009-3419.2009.10.05
   Kiyohara Chikako, 2007, Int J Med Sci, V4, P59
   Kiyohara C, 2012, J THORAC ONCOL, V7, P954, DOI 10.1097/JTO.0b013e31824de30f
   Kiyohara C, 2010, J NUCLEIC ACIDS, DOI 10.4061/2010/701760
   Kong FJ, 2008, PRAC J MED PHARM, V10, P1161
   Letkova L, 2013, MOL BIOL REP, V40, P5261, DOI 10.1007/s11033-013-2626-z
   Liang G, 2003, INT J CANCER, V105, P669, DOI 10.1002/ijc.11136
   Lopez-Cima MF, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-162
   Lunn RM, 2000, CARCINOGENESIS, V21, P551, DOI 10.1093/carcin/21.4.551
   Matullo G, 2006, CARCINOGENESIS, V27, P997, DOI 10.1093/carcin/bgi280
   Mei CR, 2011, CHINESE J CANCER RES, V23, P79, DOI 10.1007/s11670-011-0079-2
   Misra RR, 2003, CANCER LETT, V191, P171, DOI 10.1016/S0304-3835(02)00638-9
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   *NAT CANC I, 2007, SURV EP END RES SEER
   Ouyang FD, 2013, TUMOR BIOL, V34, P2843, DOI 10.1007/s13277-013-0844-6
   Park JY, 2002, LUNG CANCER-J IASLC, V36, P15, DOI 10.1016/S0169-5002(01)00447-0
   PETITTI DB, 1994, METAANALYSIS DECISIO
   Popanda O, 2004, CARCINOGENESIS, V25, P2433, DOI 10.1093/carcin/bgh264
   Qian BY, 2011, LUNG CANCER, V73, P138, DOI 10.1016/j.lungcan.2010.11.018
   Raaschou-Nielsen O, 2008, LUNG CANCER, V59, P171, DOI 10.1016/j.lungcan.2007.08.018
   Sakoda LC, 2012, INT J MOL EPIDEMIOL, V3, P1
   Shen HB, 2003, INT J CANCER, V107, P84, DOI 10.1002/ijc.11346
   Shen M, 2005, INT J CANCER, V116, P768, DOI 10.1002/ijc.21117
   Spitz MR, 2001, CANCER RES, V61, P1354
   Sreeja L, 2008, J CANCER RES CLIN, V134, P645, DOI 10.1007/s00432-007-0328-4
   Terry MB, 2004, CANCER EPIDEM BIOMAR, V13, P2053
   Wei QY, 1996, CANCER RES, V56, P4103
   Wei QY, 2000, J NATL CANCER I, V92, P1764
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Xi T, 2004, GENOMICS, V83, P970, DOI 10.1016/j.ygeno.2003.12.016
   Xing DY, 2002, LUNG CANCER-J IASLC, V38, P123, DOI 10.1016/S0169-5002(02)00184-8
   Ye WM, 2006, CARCINOGENESIS, V27, P1835, DOI 10.1093/carcin/bgl017
   Yin JY, 2008, MUTAT RES-FUND MOL M, V641, P12, DOI 10.1016/j.mrfmmm.2008.02.004
   Yin ZH, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-153
   Yu Z, 1999, ENVIRON MOL MUTAGEN, V33, P3, DOI 10.1002/(SICI)1098-2280(1999)33:1<3::AID-EM2>3.0.CO;2-L
   Zhan P, 2010, J THORAC ONCOL, V5, P1337, DOI 10.1097/JTO.0b013e3181e7fe2a
   Zhang J, 2010, EUR J CANCER, V46, P2479, DOI 10.1016/j.ejca.2010.05.008
   Zhou M, 2012, ONCOL LETT, V4, P247, DOI 10.3892/ol.2012.716
   Zhou W, 2002, CANCER RES, V62, P1377
   Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232
NR 58
TC 2
Z9 3
U1 2
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2014
VL 35
IS 8
BP 8125
EP 8132
DI 10.1007/s13277-014-1948-3
PG 8
WC Oncology
SC Oncology
GA AP2DU
UT WOS:000341883500105
PM 24845027
DA 2018-12-27
ER

PT J
AU Huang, JC
   Sun, CC
   Zhang, T
   Pan, L
   Wang, SQ
   He, QQ
   Li, DJ
AF Huang, Junchao
   Sun, Chengchao
   Zhang, Ting
   Pan, Lei
   Wang, Suqing
   He, Qiqiang
   Li, Dejia
TI RETRACTED: Potent antitumor activity of HSP90 inhibitor AUY922 in
   adrenocortical carcinoma (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Adrenocortical carcinoma; Heat shock protein 90; AUY922; Targeted
   therapy
ID TUMOR-CELL SURVIVAL; MULTIPLE-MYELOMA; BREAST-CANCER; PHASE-II;
   NVP-AUY922; EXPRESSION; FEATURES; ANGIOGENESIS; MALIGNANCY; MARKERS
AB The objective of this study is to investigate the expression of HSP90 and the effect of HSP90 inhibitor AUY922 in ACC. The expression of HSP90 was measured in tissue samples from 36 human sporadic adrenocortical tumors by immunohistochemistry, Western blotting, and real-time PCR. The effect of AUY922 was tested on SW13 and H295R cells by evaluating cell viability and apoptosis in vitro. Transwell assay was performed to evaluate the migration of SW13 cells after different concentrations of AUY922. Western blot, real-time PCR, and immunohistochemistry revealed that both HSP90 mRNA and protein were obviously expressed in a higher degree in ACC tissues than ACA tissues and normal adrenal tissues (P < 0.01). Positive staining for HSP90 was found in 15 of 20 ACCs (75.00 %) and in 3 of 16 (18.75 %) ACAs. There existed the significant statistical difference (P < 0.001). AUY922 inhibited the proliferation of ACC cells in a time- and concentration-dependent manner, and increasing apoptosis was observed in tumor cells treated with the HSP90 inhibitor. Finally, migration of SW13 cells was distinctly suppressed after undergoing treatment with AUY922. Our data suggest that the specific HSP90 inhibitor AUY922 can play a therapeutic role in treatment of ACC and, thus, HSP90 could qualify as a promising new target in ACC.
C1 [Huang, Junchao] Hubei Univ Sci & Technol, Hubei Prov Key Lab Cardiovasc Cerebrovasc & Metab, Sch Nucl Technol & Chem & Biol, Xianning 437100, Peoples R China.
   [Sun, Chengchao; Zhang, Ting; Pan, Lei; Wang, Suqing; He, Qiqiang; Li, Dejia] Wuhan Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430071, Peoples R China.
RP Li, DJ (reprint author), Wuhan Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, 115 Donghu Rd, Wuhan 430071, Peoples R China.
EM lidjwuhan@163.com
CR Abiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730
   Berruti A, 2010, J CLIN ONCOL, V28, pE401, DOI 10.1200/JCO.2009.27.5958
   Bovio S, 2006, J ENDOCRINOL INVEST, V29, P298, DOI 10.1007/BF03344099
   Chatterjee M, 2007, BLOOD, V109, P720, DOI 10.1182/blood-2006-05-024372
   Chatterjee M, 2013, HAEMATOLOGICA, V98, P1132, DOI 10.3324/haematol.2012.066175
   de Fraipont F, 2005, J CLIN ENDOCR METAB, V90, P1819, DOI 10.1210/jc.2004-1075
   de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678
   Eccles SA, 2008, CANCER RES, V68, P2850, DOI 10.1158/0008-5472.CAN-07-5256
   Fassnacht M, 2012, NEW ENGL J MED, V366, P2189, DOI 10.1056/NEJMoa1200966
   Fassnacht M, 2011, NAT REV ENDOCRINOL, V7, P323, DOI 10.1038/nrendo.2010.235
   Fassnacht M, 2010, CLIN ENDOCRINOL, V73, P561, DOI 10.1111/j.1365-2265.2010.03867.x
   Gartner EM, 2012, BREAST CANCER RES TR, V131, P933, DOI 10.1007/s10549-011-1866-7
   Jensen MR, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1996
   Kirschner LS, 2012, TRENDS ENDOCRIN MET, V23, P343, DOI 10.1016/j.tem.2012.04.001
   Kouyama R, 2011, ENDOCR J, V58, P527, DOI 10.1507/endocrj.K11E-026
   Moser C, 2012, ANTICANCER RES, V32, P2551
   Pacey S, 2012, INVEST NEW DRUG, V30, P341, DOI 10.1007/s10637-010-9493-4
   Powers MV, 2006, ENDOCR-RELAT CANCER, V13, pS125, DOI 10.1677/erc.1.01324
   Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201
   Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887
   Ueno T, 2012, LUNG CANCER, V76, P26, DOI 10.1016/j.lungcan.2011.09.011
   Veytsman I, 2009, J CLIN ONCOL, V27, P4619, DOI 10.1200/JCO.2008.17.2775
   WEISS LM, 1989, AM J SURG PATHOL, V13, P202, DOI 10.1097/00000478-198903000-00004
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
NR 24
TC 4
Z9 4
U1 3
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2014
VL 35
IS 8
BP 8193
EP 8199
DI 10.1007/s13277-014-2063-1
PG 7
WC Oncology
SC Oncology
GA AP2DU
UT WOS:000341883500112
PM 24850175
DA 2018-12-27
ER

PT J
AU Mao, D
   Zhang, Y
   Lu, H
   Zhang, H
AF Mao, Dong
   Zhang, Yun
   Lu, Hang
   Zhang, Hong
TI RETRACTED: Molecular basis underlying inhibition of metastasis of
   gastric cancer by anti-VEGFa treatment (Retracted article. See April,
   2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Vascular endothelial growth factor a; Matrix metalloproteinases 2; PI3
   kinase; Akt; Gastric cancer; Cancer invasiveness; Cancer metastasis
ID ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS; TARGET; CELLS
AB Neovascularization plays a substantial role in the invasiveness and metastasis of gastric cancer. However, the molecular mechanism underlying the control of neovascularization of gastric cancer remains undefined. Both vascular endothelial growth factor a (VEGFa) and matrix metalloproteinases 2 (MMP2) are essential for neovascularization by promoting endothelial mitogenesis and permeability and by promoting extracellular matrix degradation, respectively. Therefore, we were prompted to examine whether VEGFa and MMP2 may affect expression of each other to coordinate the neovascularization process. We found strong positive correlation of VEGFa and MMP2 levels in the gastric patients. Moreover, patients with metastasis of the original cancer had significantly higher levels of VEGFa and MMP2. Thus, we used a human gastric cancer cell line, SNU-5, to examine whether expression of VEGFa and MMP2 may affect each other. We found that overexpression of VEGFa in SNU-5 cells increased expression of MMP2, while inhibition of VEGFa in SNU-5 cells decreased expression of MMP2. On the other hand, overexpression of MMP2 in SNU-5 cells increased expression of VEGFa, while inhibition of MMP2 in SNU-5 cells decreased expression of VEGFa. These data suggest that expression of VEGFa and MMP2 may activate each other to reinforce a promoting effect on neovascularization. We then analyzed how VEGFa expression affects MMP2 level. Application of a specific Akt inhibitor to VEGFa-overexpressing SNU-5 cells substantially abolished the effect of VEGFa on MMP2 activation, suggesting that VEGFa may increase expression of MMP2 via PI3K/Akt signaling pathway. Since anti-VEGFa is a well-established therapy for many cancers, our data suggest that anti-VEGFa may not only inhibit neovascularization by prohibiting VEGFa-dependent endothelial mitogenesis and permeability increase but also by downregulating MMP2 to abolish the extracellular matrix degradation in gastric cancer.
C1 [Mao, Dong; Lu, Hang] Liaoning Med Coll, Affiliated Hosp 1, Dept Gastrointestinal Surg, Jinzhou 121001, Peoples R China.
   [Zhang, Yun] Liaoning Med Coll, Affiliated Hosp 3, Dept Gynecol & Obstet, Jinzhou 121001, Peoples R China.
   [Zhang, Hong] Liaoning Med Coll, Affiliated Hosp 1, Dept Orthoped, Jinzhou 121001, Peoples R China.
RP Mao, D (reprint author), Liaoning Med Coll, Affiliated Hosp 1, Dept Gastrointestinal Surg, 5-2 People Rd, Jinzhou 121001, Peoples R China.
EM dong_mao14@163.com
RI mao, maodong/K-6333-2016
CR Bagri A, 2010, TRENDS MOL MED, V16, P122, DOI 10.1016/j.molmed.2010.01.004
   Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661
   Davidson B., 2002, Arkhiv Patologii, V64, P47
   Dufour A, 2013, TRENDS PHARMACOL SCI, V34, P233, DOI 10.1016/j.tips.2013.02.004
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Ilson DH, 2014, LANCET, V383, P4, DOI 10.1016/S0140-6736(13)61892-9
   Kim JG, 2013, KOREAN J INTERN MED, V28, P149, DOI 10.3904/kjim.2013.28.2.149
   Mitra Aparna, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P93
   Rhee JS, 2002, TRENDS CELL BIOL, V12, P209, DOI 10.1016/S0962-8924(02)02280-8
   Scartozzi M, 2013, PHARMACOGENOMICS, V14, P1991, DOI [10.2217/PGS.13.185, 10.2217/pgs.13.185]
   THOMPSON EW, 1994, BREAST CANCER RES TR, V31, P357, DOI 10.1007/BF00666168
   Xiao XW, 2014, DIABETOLOGIA, V57, P991, DOI 10.1007/s00125-014-3179-y
   Xiao XW, 2013, J BIOL CHEM, V288, P8636, DOI 10.1074/jbc.M112.422949
   Zhao XN, 2013, FRONT BIOSCI-LANDMRK, V18, P803, DOI 10.2741/4144
NR 17
TC 30
Z9 30
U1 3
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2014
VL 35
IS 8
BP 8217
EP 8223
DI 10.1007/s13277-014-2095-6
PG 7
WC Oncology
SC Oncology
GA AP2DU
UT WOS:000341883500115
PM 24850176
DA 2018-12-27
ER

PT J
AU Wang, F
   Yang, Y
AF Wang, Feng
   Yang, Yong
TI RETRACTED: Suppression of the xCT-CD44v antiporter system sensitizes
   triple-negative breast cancer cells to doxorubicin (Retracted article.
   See vol. 151, pg. 479, 2015)
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article; Retracted Publication
DE Triple-negative breast cancer; xCT-CD44v antiporter system; Reactive
   oxygen; Species; Chemotherapy
ID TARGETED THERAPY; TUMOR-CELLS; ROS; MECHANISMS; APOPTOSIS; INCREASE;
   OUTCOMES; GROWTH; DAMAGE
AB The xCT antiporter is known to be upregulated in 30 % of triple-negative breast cancer (TNBC) cell lines. The xCT-CD44 variant (CD44v) system regulates the levels of reactive oxygen species (ROS) in cancer cells and promotes tumor growth. Here, the role of this antiporter system in relation to chemotherapy was evaluated. MDA-MB-231 and MDA-MB-436 cells were transfected with lentiviral vectors expressing short hairpin RNA against xCT or CD44v. Following doxorubicin treatment, cellular proliferation was monitored, ROS were measured, and intracellular levels of cysteine and glutathione (GSH) were determined using liquid chromatography-mass spectrometry. A TNBC orthotopic tumor model was used to evaluate the impact of xCT-CD44v inhibition on doxorubicin efficacy in vivo. Doxorubicin treatment of TNBC cells caused increased expression of xCT through upregulation of CD44v. Consequently, the intracellular uptake of cystine increased, enabling rapid synthesis of GSH, and neutralization of doxorubicin-induced ROS. Suppression of xCT or CD44v impaired the defense against drug-induced oxidative stress, thereby sensitizing cells to doxorubicin. The importance of the xCT-CD44v in supporting tumor growth during doxorubicin treatment was also demonstrated in an in vivo tumor model of TNBC. These findings suggest that the antiporter system could serve as a target for increasing the anticancer efficacy of conventional therapy in patients with TNBC.
C1 [Wang, Feng] Shanghai,Tongji Univ, Peoples Hosp 10, Dept Gastroenterol, Shanghai 200072, Peoples R China.
   [Yang, Yong] Houston Methodist Res Inst, Dept Nanomed, Houston, TX 77030 USA.
RP Yang, Y (reprint author), Houston Methodist Res Inst, Dept Nanomed, Houston, TX 77030 USA.
EM yyang@houstonmethodist.org
FU Excellent Academic Backbone Program of Tenth People's Hospital of
   Shanghai [12XSGG102]
FX We thank Prof. Osamu Nagano for providing the CD44v antibody. The
   research was supported by funds from Excellent Academic Backbone Program
   of Tenth People's Hospital of Shanghai (No. 12XSGG102).
CR Bristol IJ, 2008, INT J RADIAT ONCOL, V72, P474, DOI 10.1016/j.ijrobp.2008.01.039
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408
   Duffy MJ, 2012, INT J CANCER, V131, P2471, DOI 10.1002/ijc.27632
   Engel RH, 2006, FRONT BIOSCI-LANDMRK, V11, P300, DOI 10.2741/1798
   Gelmon K, 2012, ANN ONCOL, V23, P2223, DOI 10.1093/annonc/mds067
   Gilliam LAA, 2012, AM J PHYSIOL-CELL PH, V302, pC195, DOI 10.1152/ajpcell.00217.2011
   Isakoff SJ, 2010, CANCER J, V16, P53, DOI 10.1097/PPO.0b013e3181d24ff7
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Kim SY, 2006, EXP MOL MED, V38, P535, DOI 10.1038/emm.2006.63
   Lo M, 2008, BRIT J CANCER, V99, P464, DOI 10.1038/sj.bjc.6604485
   Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743
   Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638
   OSHAUGHNESSY JA, 1994, SEMIN ONCOL, V21, P19
   Pastore A, 2001, CLIN CHEM, V47, P1467
   Ravid A, 1999, CANCER RES, V59, P862
   Shih AY, 2001, BIOCHEM BIOPH RES CO, V282, P1132, DOI 10.1006/bbrc.2001.4703
   Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795
   Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067
   Wang SW, 2004, J BIOL CHEM, V279, P25535, DOI 10.1074/jbc.M400944200
   Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166
   Yang Y, 2014, SMALL, V10, P1250, DOI 10.1002/smll.201302887
   Yang Y, 2013, FEBS LETT, V587, P3912, DOI 10.1016/j.febslet.2013.10.041
   Yoshikawa M, 2013, CANCER RES, V73, P1855, DOI 10.1158/0008-5472.CAN-12-3609-T
NR 26
TC 13
Z9 13
U1 3
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2014
VL 147
IS 1
BP 203
EP 210
DI 10.1007/s10549-014-3068-6
PG 8
WC Oncology
SC Oncology
GA AN4HH
UT WOS:000340547800020
PM 25085754
DA 2018-12-27
ER

PT J
AU Qu, J
   Zhou, Q
   Du, Y
   Zhang, W
   Bai, M
   Zhang, Z
   Xi, Y
   Li, ZY
   Miao, JT
AF Qu, Jie
   Zhou, Qiong
   Du, Ying
   Zhang, Wei
   Bai, Miao
   Zhang, Zhuo
   Xi, Ye
   Li, Zhuyi
   Miao, Jianting
TI RETRACTED: Rutin protects against cognitive deficits and brain damage in
   rats with chronic cerebral hypoperfusion (Retracted article. See vol.
   172, pg. 4601, 2015)
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID SPATIAL MEMORY IMPAIRMENT; CAROTID-ARTERY OCCLUSION; ALZHEIMERS-DISEASE;
   OXIDATIVE STRESS; CHOLINERGIC DYSFUNCTION; BLOOD-FLOW; VASCULAR
   DEMENTIA; APPSWE/PS1DE9 MICE; ARRIVE GUIDELINES; NEURONAL DAMAGE
AB BACKGROUND AND PURPOSE
   Chronic cerebral hypoperfusion is a critical causative factor for the development of cognitive decline and dementia in the elderly, which involves many pathophysiological processes. Consequently, inhibition of several pathophysiological pathways is an attractive therapeutic strategy for this disorder. Rutin, a biologically active flavonoid, protects the brain against several insults through its antioxidant and anti-inflammatory properties, but its effect on cognitive deficits and brain damage caused by chronic cerebral hypoperfusion remains unknown. Here, we investigated the neuroprotective effect of rutin on cognitive impairments and the potential mechanisms underlying its action in rats with chronic cerebral hypoperfusion.
   EXPERIMENTAL APPROACH
   We used Sprague-Dawley rats with permanent bilateral common carotid artery occlusion (BCCAO), a well-established model of chronic cerebral hypoperfusion. After rutin treatment for 12 weeks, the neuroprotective effect of rutin in rats was evaluated by behavioural tests, biochemical and histopathological analyses.
   KEY RESULTS
   BCCAO rats showed marked cognitive deficits, which were improved by rutin treatment. Moreover, BCCAO rats exhibited central cholinergic dysfunction, oxidative damage, inflammatory responses and neuronal damage in the cerebral cortex and hippocampus, compared with sham-operated rats. All these effects were significantly alleviated by treatment with rutin.
   CONCLUSION AND IMPLICATIONS
   Our results provide new insights into the pharmacological actions of rutin and suggest that rutin has multi-targeted therapeutical potential on cognitive deficits associated with conditions with chronic cerebral hypoperfusion such as vascular dementia and Alzheimer's disease.
C1 [Qu, Jie; Zhou, Qiong; Du, Ying; Zhang, Wei; Bai, Miao; Zhang, Zhuo; Xi, Ye; Li, Zhuyi; Miao, Jianting] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Shaanxi Provinc, Peoples R China.
   [Zhou, Qiong; Du, Ying; Zhang, Zhuo; Xi, Ye; Li, Zhuyi] Fourth Mil Med Univ, Tangdu Hosp, Inst Funct Brain Disorders, Xian 710038, Shaanxi Provinc, Peoples R China.
RP Miao, JT (reprint author), Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Shaanxi Provinc, Peoples R China.
EM lizhuyi@fmmu.edu.cn; jtmiao@fmmu.edu.cn
FU National Natural Science Foundation of China [81271193, 81371209,
   81300928]
FX This work was supported by the research grant from the National Natural
   Science Foundation of China (Nos. 81271193, 81371209 and 81300928). We
   are grateful to Dr Changsheng Chen (Professor, Department of Medical
   Statistics, Fourth Military Medical University, China) for the advice on
   statistical analyses.
CR Ahmad A, 2012, MOL CELL BIOCHEM, V367, P215, DOI 10.1007/s11010-012-1335-6
   Annahazi A, 2007, EUR J PHARMACOL, V571, P120, DOI 10.1016/j.ejphar.2007.05.048
   Annapurna A, 2013, EUR REV MED PHARMACO, V17, P491
   Baskys A, 2012, EXP GERONTOL, V47, P887, DOI 10.1016/j.exger.2012.07.002
   Bossu P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-101
   Cechetti F, 2012, BRAIN RES BULL, V87, P109, DOI 10.1016/j.brainresbull.2011.10.006
   Choi Bo-Ryoung, 2011, Exp Neurobiol, V20, P92, DOI 10.5607/en.2011.20.2.92
   Crichton GE, 2013, PLANT FOOD HUM NUTR, V68, P279, DOI 10.1007/s11130-013-0370-0
   de la Torre JC, 2012, J ALZHEIMERS DIS, V32, P553, DOI 10.3233/JAD-2012-120793
   Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003
   Gao YZ, 2013, CURR NEUROVASC RES, V10, P49, DOI 10.2174/156720213804806016
   Rodrigues AMG, 2013, BRAIN RES, V1503, P53, DOI 10.1016/j.brainres.2013.01.039
   Hanyu H, 2010, J NEUROL SCI, V290, P96, DOI 10.1016/j.jns.2009.10.022
   Ishrat T, 2009, EUR NEUROPSYCHOPHARM, V19, P636, DOI 10.1016/j.euroneuro.2009.02.002
   Javed H, 2012, NEUROSCIENCE, V210, P340, DOI 10.1016/j.neuroscience.2012.02.046
   Jeon WK, 2012, EVID-BASED COMPL ALT, V2012
   Kamalakkannan N, 2006, MOL CELL BIOCHEM, V293, P211, DOI 10.1007/s11010-006-9244-1
   Khan MM, 2012, NEUROTOX RES, V22, P1, DOI 10.1007/s12640-011-9295-2
   Khan MM, 2009, BRAIN RES, V1292, P123, DOI 10.1016/j.brainres.2009.07.026
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x
   Koda T, 2008, NUTR RES, V28, P629, DOI 10.1016/j.nutres.2008.06.004
   Koda T, 2009, CELL MOL NEUROBIOL, V29, P523, DOI 10.1007/s10571-008-9344-4
   Kumaran D, 2008, NEUROSCIENCE, V155, P626, DOI 10.1016/j.neuroscience.2008.06.023
   Kume K, 2011, J NEUROL, V258, P1295, DOI 10.1007/s00415-011-5927-y
   Levine DA, 2011, NEUROTHERAPEUTICS, V8, P361, DOI 10.1007/s13311-011-0047-z
   Li E, 2011, ENDOCR J, V58, P257, DOI 10.1507/endocrj.K11E-006
   Li YX, 2012, BIOL TRACE ELEM RES, V150, P242, DOI 10.1007/s12011-012-9455-0
   Magalingam KB, 2013, INT J MOL MED, V32, P235, DOI 10.3892/ijmm.2013.1375
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Meunier J, 2006, BRIT J PHARMACOL, V149, P998, DOI 10.1038/sj.bjp.0706927
   Mizoguchi K, 2009, NEUROSCIENCE, V162, P1192, DOI 10.1016/j.neuroscience.2009.05.023
   Nassiri-Asl M, 2010, EPILEPSY BEHAV, V18, P50, DOI 10.1016/j.yebeh.2010.03.005
   Nobili F, 2009, J ALZHEIMERS DIS, V17, P761, DOI 10.3233/JAD-2009-1091
   Peng Y, 2007, J PHARMACOL EXP THER, V321, P902, DOI 10.1124/jpet.106.118760
   Pu FL, 2007, J PHARMACOL SCI, V104, P329, DOI 10.1254/jphs.FP0070247
   Pyrzanowska J, 2012, PHARMACOL REP, V64, P808, DOI 10.1016/S1734-1140(12)70876-9
   Richetti SK, 2011, BEHAV BRAIN RES, V217, P10, DOI 10.1016/j.bbr.2010.09.027
   Ruan CJ, 2010, BRAIN RES BULL, V82, P251, DOI 10.1016/j.brainresbull.2010.04.016
   Ruitenberg A, 2005, ANN NEUROL, V57, P789, DOI 10.1002/ana.20493
   Sarkaki A, 2013, MALAYS J MED SCI, V20, P25
   Sarti C, 2002, BEHAV BRAIN RES, V136, P13, DOI 10.1016/S0166-4328(02)00090-6
   Schuff N, 2009, ALZHEIMERS DEMENT, V5, P454, DOI 10.1016/j.jalz.2009.04.1233
   Sharma S, 2013, EXPERT OPIN INV DRUG, V22, P1063, DOI 10.1517/13543784.2013.805744
   Staffen W, 2006, J NEURAL TRANSM, V113, P195, DOI 10.1007/s00702-005-0321-5
   Tanaka K, 1996, BRAIN RES, V729, P55, DOI 10.1016/S0006-8993(96)00400-3
   Tanaka M, 2002, J NEUROIMAGING, V12, P112, DOI 10.1111/j.1552-6569.2002.tb00106.x
   Tongjaroenbuangam W, 2011, NEUROCHEM INT, V59, P677, DOI 10.1016/j.neuint.2011.06.014
   Vicente E, 2009, BRAIN RES, V1251, P204, DOI 10.1016/j.brainres.2008.11.032
   Wang SW, 2012, NEUROTOXICOLOGY, V33, P482, DOI 10.1016/j.neuro.2012.03.003
   Xi Y, 2014, NEUROBIOL LEARN MEM, V109, P7, DOI 10.1016/j.nlm.2013.11.016
   Yamamoto Y, 2009, BRAIN RES, V1295, P218, DOI 10.1016/j.brainres.2009.07.081
   Zhang GL, 2011, BEHAV PHARMACOL, V22, P633, DOI 10.1097/FBP.0b013e32834afef9
   Zhang W, 2012, NEUROBIOL AGING, V33, P2661, DOI 10.1016/j.neurobiolaging.2011.12.023
   Zhang W, 2012, FREE RADICAL BIO MED, V52, P1443, DOI 10.1016/j.freeradbiomed.2012.01.023
NR 54
TC 19
Z9 21
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD AUG
PY 2014
VL 171
IS 15
BP 3702
EP 3715
DI 10.1111/bph.12725
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AM7ZL
UT WOS:000340087500011
PM 24758388
OA Green Published
DA 2018-12-27
ER

PT J
AU Chen, YZ
   Li, J
   Zhao, YX
   Liu, D
   Wang, HT
   Gao, Y
   Chen, Y
AF Chen, Yan-Zhi
   Li, Jing
   Zhao, Yu-Xia
   Liu, Dan
   Wang, He-Tong
   Gao, Ya
   Chen, Ying
TI RETRACTED: Genetic polymorphisms in the CYP1A1 and CYP1B1 genes and
   susceptibility to bladder cancer: a meta-analysis (Retracted article.
   See vol. 42, pg. 1465, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Bladder cancer; CYP1A1; CYP1B1; Polymorphism; Meta-analysis
ID MICROSOMAL EPOXIDE HYDROLASE; TRANSITIONAL-CELL CARCINOMA;
   CYTOCHROME-P450 ENZYMES; TURKISH POPULATION; IN-SILICO; RISK; GSTM1;
   1A1; ASSOCIATION; METABOLISM
AB The current meta-analysis of case-control studies was conducted to evaluated the relationships of genetic polymorphisms in the CYP1A1 and CYP1B1 genes with the susceptibility to bladder cancer, aiming at determine whether these polymorphisms may contribute to the pathogenesis of bladder cancer. Related articles were determined via searching the following electronic databases without any language restrictions: PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases for relevant articles published before November 1st, 2013. STATA 12.0 software was also selected to deal with statistical data. The relationships were evaluated using the pooled odds ratios (ORs) and their 95 % confidence intervals (CI). Eleven case-control studies with a total of 2,609 bladder cancer patients and 2,634 healthy subjects met the inclusion criteria. The results of our meta-analysis demonstrated that CYP1A1 genetic polymorphisms were associated with increased risks of bladder cancer (allele model: RR = 1.18, 95 % CI 1.07-1.30, P = 0.001; dominant model: RR = 1.15, 95 % CI 1.05-1.27, P = 0.003; respectively), especially among 11599G > C, 2455A > G, 3810T > C, and 113T > C polymorphisms. A subgroup analysis by ethnicity was conducted to investigate its effect on susceptibility to bladder cancer. The subgroup analysis results revealed positive significant correlations between CYP1A1 genetic polymorphisms and bladder cancer risk among Asians (allele model: RR = 1.26, 95 % CI 1.10-1.44, P = 0.001; dominant model: RR = 1.22, 95 % CI 1.08-1.38, P = 0.001), but not among Caucasians (all P < 0.05). Nevertheless, we observed no significant correlations between CYP1B1 genetic polymorphisms and bladder cancer risk (all P > 0.05). Our meta-analysis indicates that CYP1A1 genetic polymorphisms may be involved in the pathogenesis of bladder cancer, especially among 11599G > C, 2455A > G, 3810T > C, and 113T > C polymorphisms. However, CYP1B1 genetic polymorphisms may not be important determinants of bladder cancer susceptibility.
C1 [Chen, Yan-Zhi; Zhao, Yu-Xia; Liu, Dan; Wang, He-Tong; Gao, Ya; Chen, Ying] China Med Univ, Affiliated Hosp 4, Dept Radiotherapy, Shenyang 110032, Peoples R China.
   [Li, Jing] Dalian Med Univ, Dept Radiotherapy, Affiliated Hosp 1, Shenyang 116011, Peoples R China.
RP Zhao, YX (reprint author), China Med Univ, Affiliated Hosp 4, Dept Radiotherapy, Chongshan East Rd 4, Shenyang 110032, Peoples R China.
EM cmu4h_zyx@yeah.net
CR Ahmad ST, 2013, UROL ONCOL-SEMIN ORI, V31, P1350, DOI 10.1016/j.urolonc.2011.12.009
   Androutsopoulos VP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-187
   Azoulay L, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3645
   Beedanagari SR, 2009, TOXICOL SCI, V110, P61, DOI 10.1093/toxsci/kfp079
   Berber U, 2013, ASIAN PAC J CANCER P, V14, P3925, DOI 10.7314/APJCP.2013.14.6.3925
   Brockmoller J, 1996, CANCER RES, V56, P3915
   Cash HL, 2012, INT J CANCER, V130, P1151, DOI 10.1002/ijc.26098
   Chen Chun-mei, 2012, Zhonghua Yixue Yichuanxue Zazhi, V29, P23, DOI 10.3760/cma.j.issn.1003-9406.2012.01.007
   Chu Haiyan, 2013, J Biomed Res, V27, P170, DOI 10.7555/JBR.27.20130026
   Delescluse C, 2000, TOXICOLOGY, V153, P73, DOI 10.1016/S0300-483X(00)00305-X
   Durocher F, 1998, PHARMACOGENETICS, V8, P49, DOI 10.1097/00008571-199802000-00007
   Feng CC, 2011, J HUAZHONG U SCI-MED, V31, P21, DOI 10.1007/s11596-011-0144-6
   Fontana L, 2009, ANTICANCER RES, V29, P1631
   Fu Jing CB-c, 2013, CHIN J CANC PREV TRE, V20, P10
   Gajjar K, 2012, TOXICOLOGY, V302, P157, DOI 10.1016/j.tox.2012.09.009
   Giri SK, 2013, BIOCHEM GENET, V51, P853, DOI 10.1007/s10528-013-9612-y
   Gregoraszczuk E L, 2011, Endocr Regul, V45, P125
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Huang MS, 2007, CANCER EPIDEM BIOMAR, V16, P84, DOI 10.1158/1055-9965.EPI-06-0712
   Hung RJ, 2004, INT J CANCER, V110, P598, DOI 10.1002/ijc.20157
   Li X, 2007, CHINA PRACTIC MED, V2, P3
   Masek V, 2011, DRUG METAB DISPOS, V39, P1704, DOI 10.1124/dmd.110.037986
   Nandekar PP, 2012, EXPERT OPIN DRUG DIS, V7, P771, DOI 10.1517/17460441.2012.698260
   Ozturk T, 2011, IN VIVO, V25, P663
   Pavanello S, 2010, EUR J EPIDEMIOL, V25, P491, DOI 10.1007/s10654-010-9479-8
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Rendic S, 2012, CHEM RES TOXICOL, V25, P1316, DOI 10.1021/tx300132k
   Salinas-Sanchez AS, 2012, J UROLOGY, V187, P700, DOI 10.1016/j.juro.2011.10.063
   Grando JPS, 2009, CLIN EXP MED, V9, P21, DOI 10.1007/s10238-008-0015-z
   Sridhar J, 2010, CHEM RES TOXICOL, V23, P600, DOI 10.1021/tx900348v
   Srivastava DS, 2008, ARCH TOXICOL, V82, P633, DOI 10.1007/s00204-007-0276-4
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stejskalova L, 2011, CURR PHARM BIOTECHNO, V12, P715, DOI 10.2174/138920111795470994
   Stoilov I, 1997, HUM MOL GENET, V6, P641, DOI 10.1093/hmg/6.4.641
   Sutherland M, 2013, MOL CANCER THER, V12, P27, DOI 10.1158/1535-7163.MCT-12-0405
   Turesky RJ, 2011, CHEM RES TOXICOL, V24, P1169, DOI 10.1021/tx200135s
   Villanueva CM, 2009, CANCER CAUSE CONTROL, V20, P121, DOI 10.1007/s10552-008-9226-6
   Volanisa D, 2010, TOXICOL LETT, V193, P131, DOI 10.1016/j.toxlet.2009.12.018
   Vondracek J, 2009, CHEM-BIOL INTERACT, V180, P226, DOI 10.1016/j.cbi.2009.03.011
   Wu XF, 2006, AM J HUM GENET, V78, P464, DOI 10.1086/500848
   Young CH, 2010, MOL VIS, V16, P1054
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 42
TC 3
Z9 3
U1 2
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD AUG
PY 2014
VL 41
IS 8
BP 4929
EP 4940
DI 10.1007/s11033-014-3359-3
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AM5OY
UT WOS:000339910900010
PM 24718782
DA 2018-12-27
ER

PT J
AU Hou, JM
   Wu, M
   Lin, QM
   Lin, F
   Xue, Y
   Lan, XH
   Chen, EY
   Wang, ML
   Yang, HY
   Wang, FX
AF Hou, Jian-ming
   Wu, Man
   Lin, Qing-ming
   Lin, Fan
   Xue, Ying
   Lan, Xu-hua
   Chen, En-yu
   Wang, Mei-li
   Yang, Hai-yan
   Wang, Feng-xiong
TI RETRACTED: Lactoferrin promote primary rat osteoblast proliferation and
   differentiation via up-regulation of insulin-like growth factor-1
   expression (Retracted article. See vol. 42, pg. 1467, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Primary rat osteoblast; Lactoferrin; Insulin-like growth factor 1
   (IGF-1); IGF binding protein 2 (IGFBP2); Small hairpin RNA (shRNA);
   Proliferation; Differentiation
ID FACTOR BINDING-PROTEINS; BOVINE LACTOFERRIN; BONE-FORMATION;
   OVARIECTOMIZED RATS; SIGNALING PATHWAYS; BIOLOGICAL ACTIONS; STEM-CELLS;
   IGF-I; RECEPTOR; KINASE
AB The aim of this study was to explore the effect of lactoferrin (LF) in primary fetal rat osteoblasts proliferation and differentiation and investigate the underlying molecular mechanisms. Primary rat osteoblasts were obtained from the calvarias of neonatal rats. Osteoblasts were treated with LF (0.1-1000 mu g/mL), or OSI-906 [a selective inhibitor of insulin-like growth factor 1 (IGF-1) receptor and insulin receptor]. The IGF-1 was then knocked down by small hairpin RNA (shRNA) technology and then was treated with recombinant human IGF-1 or LF. Cell proliferation and differentiation were measured by MTT assay and alkaline phosphatase (ALP) assay, respectively. The expression of IGF-1 and IGF binding protein 2 (IGFBP2) mRNA were analyzed using real-time PCR. LF promotes the proliferation and differentiation of osteoblasts in a certain range (1-100 mu g/mL) in time- and dose-dependent manner. The mRNA level of IGF-1 was significantly increased, while the expression of IGFBP2 was suppressed by LF treatment. Knockdown of IGF-1 by shRNA in primary rat osteoblast dramatically decreased the abilities of proliferation and differentiation of osteoblasts and blocked the proliferation and differentiation effect of LF in osteoblasts. OSI906 (5 mu M) blocked the mitogenic and differentiation of LF in osteoblasts. Proliferation and differentiation of primary rat osteoblasts in response to LF are mediated in part by stimulating of IGF-1 gene expression and alterations in the gene expression of IGFBP2.
C1 [Hou, Jian-ming; Lan, Xu-hua] Fujian Prov Hosp, Dept Endocrinol, Fuzhou 350001, Peoples R China.
   [Hou, Jian-ming; Wu, Man; Lin, Qing-ming; Chen, En-yu; Wang, Mei-li; Yang, Hai-yan; Wang, Feng-xiong] Fujian Med Univ, Prov Clin Med Coll, Fuzhou 350004, Peoples R China.
   [Lin, Fan; Xue, Ying] Fujian Prov Hosp, Cadre Clin Dept 1, Fuzhou 350001, Peoples R China.
RP Hou, JM (reprint author), Fujian Prov Hosp, Dept Endocrinol, 134 Dong Jie Rd, Fuzhou 350001, Peoples R China.
EM hjm996@126.com
OI Lin, Fan/0000-0002-9435-5181
FU National Natural Science Foundation of China [81270968]
FX This study was supported by the National Natural Science Foundation of
   China 81270968.
CR Amini AA, 2011, CURR MED CHEM, V18, P1220
   Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967
   Bharadwaj S, 2009, OSTEOPOROSIS INT, V20, P1603, DOI 10.1007/s00198-009-0839-8
   Bikle D, 2001, J BONE MINER RES, V16, P2320, DOI 10.1359/jbmr.2001.16.12.2320
   Bikle Daniel D, 2012, Curr Mol Pharmacol, V5, P135
   Blais A, 2009, AM J PHYSIOL-ENDOC M, V296, pE1281, DOI 10.1152/ajpendo.90938.2008
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   CANALIS E, 1992, J BONE MINER RES, V7, P1085
   Cao JJ, 2007, J BONE MINER RES, V22, P1271, DOI 10.1359/JBMR.070506
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Collett-Solberg PF, 2000, ENDOCRINE, V12, P121, DOI 10.1385/ENDO:12:2:121
   Cornish J, 2004, BIOMETALS, V17, P331, DOI 10.1023/B:BIOM.0000027713.18694.91
   Cornish J, 2004, ENDOCRINOLOGY, V145, P4366, DOI 10.1210/en.2003-1307
   Cornish J, 2010, BIOMETALS, V23, P425, DOI 10.1007/s10534-010-9320-6
   Cortot AB, 2013, CANCER RES, V73, P834, DOI 10.1158/0008-5472.CAN-12-2066
   Dinauer MC, 2000, INHERITED NEUTROPHIL, V1, P303
   ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081
   Ferry RJ, 1999, HORM METAB RES, V31, P192, DOI 10.1055/s-2007-978719
   Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295
   Frydecka I, 2002, ANTICANCER RES, V22, P1897
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007-0036
   Govoni KE, 2005, PEDIATR NEPHROL, V20, P261, DOI 10.1007/s00467-004-1658-y
   Grey A, 2006, MOL CELL ENDOCRINOL, V251, P96, DOI 10.1016/j.mce.2006.03.002
   Grey A, 2004, MOL ENDOCRINOL, V18, P2268, DOI 10.1210/me.2003-0456
   Grey A, 2003, ENDOCRINOLOGY, V144, P4886, DOI 10.1210/en.2003-0350
   Guo HY, 2009, J NUTR, V139, P958, DOI 10.3945/jn.108.100586
   Hansen BH, 2008, AQUAT TOXICOL, V86, P157, DOI 10.1016/j.aquatox.2007.10.009
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254
   Hou JM, 2012, ACTA PHARMACOL SIN, V33, P1277, DOI 10.1038/aps.2012.83
   Ieni A, 2011, PATHOL ONCOL RES, V17, P287, DOI 10.1007/s12253-010-9311-5
   Ieni A, 2009, J BONE MINER METAB, V27, P364, DOI 10.1007/s00774-009-0044-z
   JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3
   Jurgens WJFM, 2008, CELL TISSUE RES, V332, P415, DOI 10.1007/s00441-007-0555-7
   Kream BE, 1997, J BONE MINER RES, V12, P889, DOI 10.1359/jbmr.1997.12.6.889
   LeRoith Derek, 2008, Pediatr Endocrinol Rev, V5 Suppl 2, P739
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LONNERDAL B, 1995, ANNU REV NUTR, V15, P93, DOI 10.1146/annurev.nutr.15.1.93
   Lorget F, 2002, BIOCHEM BIOPH RES CO, V296, P261, DOI 10.1016/S0006-291X(02)00849-5
   METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x
   Mohan S, 1996, HORM RES, V45, P59, DOI 10.1159/000184833
   Mohan S, 2012, CURR OSTEOPOROS REP, V10, P178, DOI 10.1007/s11914-012-0100-9
   Nakajima K, 2011, BIOMETALS, V24, P847, DOI 10.1007/s10534-011-9439-0
   Naot D, 2005, CLIN MED RES, V3, P93, DOI 10.3121/cmr.3.2.93
   Naot D, 2011, BONE, V49, P217, DOI 10.1016/j.bone.2011.04.002
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   Rosen CJ, 1998, P SOC EXP BIOL MED, V219, P1
   SCHARLA SH, 1991, ENDOCRINOLOGY, V129, P3139, DOI 10.1210/endo-129-6-3139
   Spagnoli A, 2001, J BIOL CHEM, V276, P5533, DOI 10.1074/jbc.M005088200
   Takayama Y, 2008, BIOSCI BIOTECH BIOCH, V72, P226, DOI 10.1271/bbb.70465
   Takayama Y, 2009, J BIOSCI BIOENG, V107, P191, DOI 10.1016/j.jbiosc.2008.09.018
   Weinberg ED, 2001, J PHARM PHARMACOL, V53, P1303, DOI 10.1211/0022357011777792
   Wetterau LA, 1999, MOL GENET METAB, V68, P161, DOI 10.1006/mgme.1999.2920
   Yakar S, 2003, EXP BIOL MED, V228, P245
   Yakar S, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.234
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   ZAPF J, 1986, HORM RES, V24, P121, DOI 10.1159/000180551
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674
NR 58
TC 8
Z9 10
U1 2
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD AUG
PY 2014
VL 41
IS 8
BP 5019
EP 5030
DI 10.1007/s11033-014-3368-2
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AM5OY
UT WOS:000339910900018
PM 24792235
DA 2018-12-27
ER

PT J
AU Zuo, HN
   Wang, ZL
   Cui, DR
   Xin, DJ
AF Zuo, Hai-Ning
   Wang, Zhi-Long
   Cui, Dao-Ran
   Xin, Da-Jiang
TI RETRACTED: Genetic variations in the KIR gene family may contribute to
   susceptibility to ankylosing spondylitis: a meta-analysis (Retracted
   article. See vol. 42, pg. 1469, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Killer cell immunoglobulin-like receptor; Ankylosing spondylitis;
   Susceptibility; Meta-analysis
ID IMMUNOGLOBULIN-LIKE RECEPTORS; HLA-C ALLELES; POSSIBLE ASSOCIATION;
   POLYMORPHISMS; DISEASE; POPULATION; KIR3DL1; CELLS
AB The present meta-analysis of relevant case-control studies was conducted to investigate the possible relationships between genetic variations in the killer cell immunoglobulin-like receptor (KIR) gene clusters of the human KIR gene family and susceptibility to ankylosing spondylitis (AS). The following electronic databases were searched for relevant articles without language restrictions: the Web of Science, the Cochrane Library Database, PubMed, EMBASE, CINAHL, the Chinese Biomedical Database (CBM) and Chinese National Knowledge Infrastructure (CNKI) databases, covering all papers published until 2013. STATA statistical software was adopted in this meta-analysis as well. We also calculated the crude odds ratios (OR) and its 95 % confidence intervals (95 % CI). Seven case-control studies with 1,004 patients diagnosed with AS and 2,138 healthy cases were implicated in our meta-analysis, and 15 genes in the KIR gene family were also evaluated. The results of our meta-analysis show statistical significance between the genetic variations in the KIR2DL1, KIR2DS4, KIR2DS5 and KIR3DS1 genes and an increased susceptibility to AS (KIR2DL1: OR 7.82, 95 % CI 3.87-15.81, P < 0.001; KIR2DS4: OR 1.91, 95 % CI 1.16-3.13, P = 0.010; KIR2DS5: OR1.51, 95 % CI 1.14-2.01, P = 0.004; KIR3DS1: OR 1.58, 95 % CI 1.34-1.86, P < 0.001; respectively). However, we failed to found positive correlations between other genes and susceptibility to AS (all P > 0.05). The current meta-analysis provides reliable evidence that genetic variations in the KIR gene family may contribute to susceptibility to AS, especially for the KIR2DL1, KIR2DS4, KIR2DS5 and KIR3DS1 genes.
C1 [Zuo, Hai-Ning] Yantai Hill Hosp Yantai, Dept Trauma Surg 1, Yantai 264000, Peoples R China.
   [Wang, Zhi-Long] Yantai Hill Hosp Yantai, Dept Hand Surg, Yantai 264000, Peoples R China.
   [Cui, Dao-Ran] First Peoples Hosp Nantong, Dept Orthoped, Nantong 226000, Peoples R China.
   [Xin, Da-Jiang] Yantai Hill Hosp Yantai, Dept Trauma Surg 3, Yantai 264000, Peoples R China.
RP Xin, DJ (reprint author), Yantai Hill Hosp Yantai, Dept Trauma Surg 3, Jiefang Rd 91, Yantai 264000, Peoples R China.
EM xindajiang118@163.com
CR Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140-6736(07)60635-7
   Campbell KS, 2011, IMMUNOLOGY, V132, P315, DOI 10.1111/j.1365-2567.2010.03398.x
   Chung SD, 2013, INT J IMPOT RES, V25, P229, DOI 10.1038/ijir.2013.14
   Dean LE, 2014, RHEUMATOLOGY, V53, P650, DOI 10.1093/rheumatology/ket387
   Diaz-Pena R, 2008, HUM IMMUNOL, V69, P437, DOI 10.1016/j.humimm.2008.04.012
   Diaz-Pena R, 2010, ARTHRITIS RHEUM-US, V62, P1000, DOI 10.1002/art.27332
   Dupont B, 1997, TISSUE ANTIGENS, V49, P557, DOI 10.1111/j.1399-0039.1997.tb02802.x
   Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873
   Fauriat C, 2010, BLOOD, V115, P1166, DOI 10.1182/blood-2009-09-245746
   Harvey D, 2009, ANN RHEUM DIS, V68, P595, DOI 10.1136/ard.2008.095927
   Jiao YL, 2008, J CLIN IMMUNOL, V28, P343, DOI 10.1007/s10875-008-9183-6
   Jiao YL, 2010, J CLIN IMMUNOL, V30, P840, DOI 10.1007/s10875-010-9444-z
   McCappin J, 2010, TISSUE ANTIGENS, V75, P68, DOI 10.1111/j.1399-0039.2009.01392.x
   Moon SJ, 2013, OCUL IMMUNOL INFLAMM, V21, P135, DOI 10.3109/09273948.2012.754905
   Mousavi T, 2010, IRAN J IMMUNOL, V7, P88, DOI IJIv7i2A4
   Nowak I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012381
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Qin HJ, 2011, P NATL ACAD SCI USA, V108, P2016, DOI 10.1073/pnas.1019082108
   Sivori S, 2010, TRENDS IMMUNOL, V31, P289, DOI 10.1016/j.it.2010.05.007
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tajik N, 2011, INT J IMMUNOGENET, V38, P403, DOI 10.1111/j.1744-313X.2011.01024.x
   Tam LS, 2010, NAT REV RHEUMATOL, V6, P399, DOI 10.1038/nrrheum.2010.79
   Yan H, 2012, SHANXI MED J, V41, P281
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   Zvyagin IV, 2010, CELL MOL IMMUNOL, V7, P471, DOI 10.1038/cmi.2010.42
NR 25
TC 4
Z9 4
U1 3
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD AUG
PY 2014
VL 41
IS 8
BP 5311
EP 5319
DI 10.1007/s11033-014-3402-4
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AM5OY
UT WOS:000339910900046
PM 24880650
DA 2018-12-27
ER

PT J
AU Lai, Z
   Shi, SY
   Fei, J
   Wei, W
AF Lai, Zhen
   Shi, ShiYuan
   Fei, Jun
   Wei, Wei
TI RETRACTED: Total knee arthroplasty performed with either a
   mini-subvastus or a standard approach: a prospective randomized
   controlled study with a minimum follow-up of 2 years (Retracted article.
   See vol. 135, pg. 745, 2015)
SO ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY
LA English
DT Article; Retracted Publication
DE Total knee arthroplasty; Minimal invasive surgery; Mini-subvastus
   approach; Randomized controlled trial
ID CLINICAL-EXPERIENCE; PATELLAR TILT; REPLACEMENT; COMPLICATIONS;
   PROSTHESIS; TRIAL
AB There is currently a trend toward minimally invasive total knee arthroplasty (TKA) to decrease the morbidity related to the standard approach. The aim of our study was to clarify whether the mini-subvastus surgical had an advantage over the standard in term of pain level, blood loss, and postoperative recovery, whether the mini-subvastus surgical was prone to radiographic malalignment, prolonged operative time, and increased complications.
   In a prospective randomized study, we compared the clinical and radiological results of primary TKA using a mini-subvastus approach or a standard approach in 68 patients. The mini-subvastus approach was used on 35 patients (group I) and the standard approach on 33 patients (group II).
   The mean follow-up was 28 months (range 24-36 months). Patients in group I had less blood loss and better visual analogue scale score at 1 day postoperatively. They achieved active straight leg raise earlier and underwent less lateral retinacular releases. The mean Knee Society function score, Oxford knee score, and range of movement were significantly better in group I up to 9 months after surgery (all, p < 0.05). However, there were no significant differences in these parameters between the groups at final follow-up. Reduced access and visibility in group I prolonged tourniquet time by an average of 22 min and resulted in five technical errors on radiographic evaluation.
   Patients can receive marked but temporary benefits from the mini-subvastus technique, with a definite cost: that of component malposition and prolongation of operative time.
C1 [Lai, Zhen; Shi, ShiYuan; Fei, Jun; Wei, Wei] Red Cross Hosp Hangzhou, Dept Orthopaed Surg, Hangzhou 310003, Zhejiang, Peoples R China.
RP Lai, Z (reprint author), Red Cross Hosp Hangzhou, Dept Orthopaed Surg, 208 East Ring Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM laizhen76@163.com; hzhhyiyuanguke@163.com
CR Aglietti P, 2006, CLIN ORTHOP RELAT R, P106, DOI 10.1097/01.blo.0000238789.51972.16
   Benjamin J, 2006, J ARTHROPLASTY, V21, P121, DOI 10.1016/j.arth.2006.05.001
   Bindelglass DF, 1996, J ARTHROPLASTY, V11, P507, DOI 10.1016/S0883-5403(96)80101-X
   Buechel FF, 2002, CLIN ORTHOP RELAT R, P40, DOI 10.1097/01.blo.0000036529.46246.88
   Bullens PHJ, 2001, J ARTHROPLASTY, V16, P740, DOI 10.1054/arth.2001.23922
   Chen AF, 2006, J BONE JOINT SURG BR, V88B, P1448, DOI 10.1302/0301-620X.88B11.18052
   COLIZZA WA, 1995, J BONE JOINT SURG AM, V77A, P1713, DOI 10.2106/00004623-199511000-00011
   Dalury DF, 2005, CLIN ORTHOP RELAT R, P77, DOI 10.1097/01.blo.0000185757.17401.7b
   EWALD FC, 1989, CLIN ORTHOP RELAT R, P9
   Haas SB, 2004, CLIN ORTHOP RELAT R, P68, DOI 10.1097/01.blo.0000147649.82883.ca
   Haas SB, 2006, CLIN ORTHOP RELAT R, P112, DOI 10.1097/01.blo.0000238820.33154.18
   HOFMANN AA, 1991, CLIN ORTHOP RELAT R, P70
   Holt G, 2008, J ARTHROPLASTY, V23, P600, DOI 10.1016/j.arth.2007.05.053
   INSALL JN, 1989, CLIN ORTHOP RELAT R, P13
   Karachalios T, 2008, J BONE JOINT SURG BR, V90B, P584, DOI 10.1302/0301-620X.90B5.20122
   Kashyap SN, 2008, KNEE SURG SPORT TR A, V16, P544, DOI 10.1007/s00167-008-0523-0
   Kim JG, 2011, KNEE, V18, P443, DOI 10.1016/j.knee.2010.08.008
   Kim YH, 2007, J BONE JOINT SURG BR, V89B, P467, DOI 10.1302/0301-620X.89B4.18663
   King J, 2007, J BONE JOINT SURG AM, V89A, P1497, DOI 10.2106/JBJS.F.00867
   Laskin RS, 2004, CLIN ORTHOP RELAT R, P74, DOI 10.1097/01.blo.0000148582.86102.47
   Liebensteiner MC, 2012, CLIN ORTHOP RELAT R, V470, P3233, DOI 10.1007/s11999-012-2545-7
   Pagnano MW, 2006, CLIN ORTHOP RELAT R, P102, DOI 10.1097/01.blo.0000238788.44349.0f
   RANAWAT CS, 1993, CLIN ORTHOP RELAT R, P94
   Schroer WC, 2008, J ARTHROPLASTY, V23, P19, DOI 10.1016/j.arth.2006.12.100
   Schroer WC, 2007, J BONE JOINT SURG AM, V89A, P76, DOI 10.2106/JBJS.G.00606
   Scuderi GR, 2004, CLIN ORTHOP RELAT R, P61, DOI 10.1097/01.blo.0000148574.79874.d0
   STERN SH, 1992, J BONE JOINT SURG AM, V74A, P980, DOI 10.2106/00004623-199274070-00004
   Tenholder M, 2005, CLIN ORTHOP RELAT R, P67, DOI 10.1097/01.blo.0000185450.89364.10
   Tria AJ, 2003, CLIN ORTHOP RELAT R, P185, DOI 10.1097/01.blo.0000093030.56370.d9
   Walton NP, 2005, KNEE, V12, P103, DOI 10.1016/j.knee.2004.06.004
NR 30
TC 5
Z9 5
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0936-8051
EI 1434-3916
J9 ARCH ORTHOP TRAUM SU
JI Arch. Orthop. Trauma Surg.
PD AUG
PY 2014
VL 134
IS 8
BP 1155
EP 1162
DI 10.1007/s00402-014-1963-2
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA AM5BR
UT WOS:000339871100014
PM 24595613
DA 2018-12-27
ER

PT J
AU Hoque, MA
   Islam, MN
   Islam, MS
   Kato, T
   Nishino, N
   Ito, A
   Yoshida, M
AF Hoque, Md. Ashraful
   Islam, Md. Nurul
   Islam, Md. Shahidul
   Kato, Tamaki
   Nishino, Norikazu
   Ito, Akihiro
   Yoshida, Minoru
TI RETRACTED: Design and synthesis of CHAP31, trapoxin B and HC-toxin based
   bicyclic tetrapeptides disulfide as potent histone deacetylase
   inhibitors (Retracted article. See vol. 23, pg. 5078, 2015)
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article; Retracted Publication
DE Histone deacetylase inhibitors; Depsipeptide; FK228; Sulfhydryl group;
   Bicyclic tetrapeptides
ID HOST-SPECIFIC TOXIN; CYLINDROCLADIUM-SCOPARIUM;
   HELMINTHOSPORIUM-CARBONUM; CYCLIC TETRAPEPTIDES; BIOLOGICAL-ACTIVITY;
   CHLAMYDOCIN; CYL-2; DEPSIPEPTIDE; METABOLITE; ANALOGS
AB The naturally occurring cyclic depsipeptide, FK228 inhibits histone deacetylase (HDAC) enzymes after reductive cleavage of intra-molecular disulfide bond. One of the sulfhydryl groups produced in the reduction interacts with zinc atom that involved in the catalytic mechanism of type 1 and 2 HDACs such as HDAC1, HDAC4, and HDAC6. In the present study, we describe the development of CHAP31, trapoxin B and HC-toxin based cyclic tetrapeptides with intra-molecular disulfide bond as HDAC inhibitors. The bicyclic tetrapeptides disulfide showed potent HDAC1 and HDAC4 inhibition and p21 promoting activity. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Hoque, Md. Ashraful; Islam, Md. Nurul; Islam, Md. Shahidul; Kato, Tamaki; Nishino, Norikazu] Kyushu Inst Technol, Grad Sch Life Sci & Syst Engn, Kitakyushu, Fukuoka 8080196, Japan.
   [Hoque, Md. Ashraful] Rajshahi Univ, Dept Biochem & Mol Biol, Fac Sci, Rajshahi 6205, Bangladesh.
   [Islam, Md. Nurul; Islam, Md. Shahidul] Rajshahi Univ, Dept Chem, Fac Sci, Rajshahi 6205, Bangladesh.
   [Ito, Akihiro; Yoshida, Minoru] RIKEN Adv Sci Inst, Chem Genom Res Grp, Chem Genet Lab, Saitama 3510198, Japan.
RP Hoque, MA (reprint author), Kyushu Inst Technol, Grad Sch Life Sci & Syst Engn, Kitakyushu, Fukuoka 8080196, Japan.
EM ashraf_bio2003@yahoo.com
FU Kitakyushu Foundation for the Advancement of Industry, Science and
   Technology (FAIS)
FX This study was supported by Kitakyushu Foundation for the Advancement of
   Industry, Science and Technology (FAIS).
CR Bhuiyan MPI, 2006, BIOORGAN MED CHEM, V14, P3438, DOI 10.1016/j.bmc.2005.12.063
   CLOSSE A, 1974, HELV CHIM ACTA, V57, P533, DOI 10.1002/hlca.19740570306
   Dickinson M, 2012, DERMATOLOGY, V5, P21, DOI [DOI 10.4137/CMD.S7252, 10.4137/CMD.S7252]
   Furumai R, 2002, CANCER RES, V62, P4916
   Greshock TJ, 2008, ORG LETT, V10, P613, DOI 10.1021/ol702957z
   HIROTA A, 1973, AGR BIOL CHEM TOKYO, V37, P955, DOI 10.1080/00021369.1973.10860775
   HIROTA A, 1973, AGR BIOL CHEM TOKYO, V37, P1185, DOI 10.1080/00021369.1973.10860788
   HIROTA A, 1973, AGR BIOL CHEM TOKYO, V37, P643, DOI 10.1080/00021369.1973.10860699
   Hogue M. A., 2012, BIOORG MED CHEM LETT, V22, P6770
   Islam NM, 2010, BIOORG MED CHEM LETT, V20, P997, DOI 10.1016/j.bmcl.2009.12.054
   Kijima M., 1993, J BIOL CHEM, V268, P2249
   KIM SD, 1985, TETRAHEDRON LETT, V26, P969, DOI 10.1016/S0040-4039(00)98488-0
   LIESCH JM, 1982, TETRAHEDRON, V38, P45, DOI 10.1016/0040-4020(82)85043-6
   Narita K, 2009, CHEM-EUR J, V15, P11174, DOI 10.1002/chem.200901552
   Nielsen TK, 2005, J MOL BIOL, V354, P107, DOI 10.1016/j.jmb.2005.09.065
   Nishino N, 2003, ORG LETT, V5, P5079, DOI 10.1021/ol036098e
   Nishino N, 2008, BIOORGAN MED CHEM, V16, P437, DOI 10.1016/j.bmc.2007.09.021
   Shivashimpi GM, 2007, BIOORGAN MED CHEM, V15, P7830, DOI 10.1016/j.bmc.2007.08.041
   Suzuki T, 2004, BIOORG MED CHEM LETT, V14, P3313, DOI 10.1016/j.bmcl.2004.03.063
   Suzuki T, 2006, J MED CHEM, V49, P4809, DOI 10.1021/jm060554y
   TANIS SP, 1986, HETEROCYCLES, V24, P3423
   Taori K, 2008, J AM CHEM SOC, V130, P1806, DOI 10.1021/ja710064S0002-7863(71)01006-0
   UMEHARA K, 1983, J ANTIBIOT, V36, P478, DOI 10.7164/antibiotics.36.478
   Watanabe LA, 2004, TETRAHEDRON LETT, V45, P491, DOI 10.1016/j.tetlet.2003.11.007
   Zain J, 2010, EXPERT REV HEMATOL, V3, P187, DOI 10.1586/EHM.10.9
NR 25
TC 3
Z9 3
U1 2
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG 1
PY 2014
VL 22
IS 15
BP 3850
EP 3855
DI 10.1016/j.bmc.2014.06.029
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA AM4XO
UT WOS:000339859700006
PM 24997578
DA 2018-12-27
ER

PT J
AU Gray, J
   Shankar, S
AF Gray, J.
   Shankar, S.
TI RETRACTED: Epidural anaesthesia and analgesia for liver resection
   (Retracted article. See vol. 69, pg. 939, 2014)
SO ANAESTHESIA
LA English
DT Letter; Retracted Publication
C1 [Gray, J.; Shankar, S.] Hampshire Hosp Fdn Trust, Basingstoke, Hants, England.
RP Gray, J (reprint author), Hampshire Hosp Fdn Trust, Basingstoke, Hants, England.
EM jjgray@doctors.org.uk
CR Basu S, 2004, HPB (Oxford), V6, P186, DOI 10.1080/13651820410030844
   Kelliher L, 2013, ANAESTHESIA, V68, P975, DOI 10.1111/anae.12364
   Tzimas P, 2013, ANAESTHESIA, V68, P628, DOI 10.1111/anae.12191
   Wong-Lun-Hing E M, 2013, J INT HEPATO PANCREA, V16, P601
NR 4
TC 0
Z9 0
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD AUG
PY 2014
VL 69
IS 8
BP 933
EP 933
DI 10.1111/anae.12801
PG 1
WC Anesthesiology
SC Anesthesiology
GA AM0PD
UT WOS:000339546600024
PM 25039952
OA Bronze
DA 2018-12-27
ER

PT J
AU Attoui, B
   Kherici, N
   Kherici-Bousnoubra, H
AF Attoui, Badra
   Kherici, Nacer
   Kherici-Bousnoubra, Houria
TI RETRACTED: Use of a new method for determining the vulnerability and
   risk of pollution of major groundwater reservoirs in the region of
   Annaba-Bouteldja (NE Algeria)(Retracted article. See vol. 73, pg. 6721,
   2015)
SO ENVIRONMENTAL EARTH SCIENCES
LA English
DT Article; Retracted Publication
DE Unsaturated zone; Self-purification; Vulnerability to pollution; Risk of
   pollution
ID AQUIFER
AB Scientists are deeply concerned by the state of vulnerability of groundwater reservoirs. It is a complex task because of the difficulties in determining the degree of pollution of the groundwater. Many methods have been adopted like (DRASTIC, GOD, SI, SINTACSaEuro broken vertical bar). Another method (Kherici et al. in Geogr Tech 1-14, 2010) is added to identify the vulnerability of groundwater reservoirs and control the evolution of pollutants. The present article targets the determination of the vulnerability and risks of pollution of groundwater reservoirs of a climatic Mediterranean region (Annaba-Bouteldja region). The device used is based on the combination of two criteria: natural factors (thickness of the unsaturated zone, geological facies and degree of self-purification) and the causes of vulnerability and the pollution risks entropic factors (caused by man). The application of Kherici's method has revealed a distinction between the different degrees of pollution and has allowed a neat classification of the different reservoirs in the study. The results lead to a vulnerability map and the risks of pollution of Annaba-Bouteldja different aquifers. It has also led to the installation of protection areas; sustained by an efficient general evacuation plan of the sewerage net and the construction of treatment station of the sewage effluents in the urbanized areas.
C1 [Attoui, Badra; Kherici, Nacer; Kherici-Bousnoubra, Houria] Univ Annaba, Fac Earth Sci, Geol Lab, El Hadjar, Annaba, Algeria.
RP Attoui, B (reprint author), Univ Annaba, Fac Earth Sci, Geol Lab, BO 12, El Hadjar, Annaba, Algeria.
EM att.badra@yahoo.fr; nacer.kherici@univ-annaba.org;
   houria.kherici@univ-annaba.org
CR Attoui B, 2010, STATE VULNERABILITY, P1
   Baghvand A, 2010, DESALINATION, V260, P264, DOI 10.1016/j.desal.2010.02.038
   Boufekane A, 2010, INT J MANAG NETW CON, V1, P267
   Bousnoubra H, 2002, WATER RESOURCES SKIK, P150
   Debieche H, 2002, THESIS U FRANCHE COM, P199
   Detay M, 1997, GESTION ACTIVE AQUIF
   Ettienne E, 2009, EUR J SCI RES, V31, P157
   Gaud B, 1976, HYDROGEOLOGICA UNPUB, V2
   Hammor D, 1992, THESIS USTLANGUEDOC, P205
   Hamzaoui W, 2007, CHARACTERIZATION WAT
   Hani AD, 2003, THESIS, P18
   Kherici N, 1993, THESIS, P28
   Kherici N, 2010, GEOGRAPHIA TECHNICA, P1
   Lake IR, 2003, J ENVIRON MANAGE, V68, P315, DOI 10.1016/S0301-4797(03)00095-1
   Mohamed HH, 2007, GEOSCIENCES, V339, P493
   Rouabhia K, 2004, DROUGHT, V15, P347
   Schijven JF, 2010, WATER RES, V44, P1170, DOI 10.1016/j.watres.2010.01.002
   Worrall F, 2004, J HYDROL, V293, P191, DOI 10.1016/j.jhydrol.2004.01.013
NR 18
TC 4
Z9 4
U1 6
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1866-6280
EI 1866-6299
J9 ENVIRON EARTH SCI
JI Environ. Earth Sci.
PD AUG
PY 2014
VL 72
IS 3
BP 891
EP 903
DI 10.1007/s12665-013-3012-9
PG 13
WC Environmental Sciences; Geosciences, Multidisciplinary; Water Resources
SC Environmental Sciences & Ecology; Geology; Water Resources
GA AL8GN
UT WOS:000339376300023
DA 2018-12-27
ER

PT J
AU Hasan, H
   Abdul-Kareem, S
AF Hasan, Haitham
   Abdul-Kareem, Sameem
TI RETRACTED: Human-computer interaction using vision-based hand gesture
   recognition systems: a survey(Retracted article. See vol. 28, pg.849,
   2017)
SO NEURAL COMPUTING & APPLICATIONS
LA English
DT Review; Retracted Publication
DE Human-computer interaction; Gesture recognition; Representations;
   Recognition; Natural interfaces
ID ALGORITHM
AB Considerable effort has been put toward the development of intelligent and natural interfaces between users and computer systems. In line with this endeavor, several modes of information (e.g., visual, audio, and pen) that are used either individually or in combination have been proposed. The use of gestures to convey information is an important part of human communication. Hand gesture recognition is widely used in many applications, such as in computer games, machinery control (e.g., crane), and thorough mouse replacement. Computer recognition of hand gestures may provide a natural computer interface that allows people to point at or to rotate a computer-aided design model by rotating their hands. Hand gestures can be classified into two categories: static and dynamic. The use of hand gestures as a natural interface serves as a motivating force for research on gesture taxonomy, its representations, and recognition techniques. This paper summarizes the surveys carried out in human--computer interaction (HCI) studies and focuses on different application domains that use hand gestures for efficient interaction. This exploratory survey aims to provide a progress report on static and dynamic hand gesture recognition (i.e., gesture taxonomies, representations, and recognition techniques) in HCI and to identify future directions on this topic.
C1 [Hasan, Haitham; Abdul-Kareem, Sameem] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Artificial Intelligence, Kuala Lumpur 50603, Malaysia.
RP Hasan, H (reprint author), Univ Malaya, Fac Comp Sci & Informat Technol, Dept Artificial Intelligence, Kuala Lumpur 50603, Malaysia.
EM haitham@siswa.um.edu.my
CR [Anonymous], 2 INT C SIGN PROC SY
   Bao J, 2011, IEEE INT C EL INF CO, P338
   Bergh M, 2011, IEEE WORKSH APPL COM, P66
   Birdal A., 2008, 16 INT C CENTR EUR C, P17
   Boulay B., 2007, THESIS U NICE SOPHIA
   Bourke AK, 2007, GAIT POSTURE, V26, P194, DOI 10.1016/j.gaitpost.2006.09.012
   Bretzner L, 2002, 5 IEEE INT C AUT FAC, P405, DOI [10.1109/AFGR.2002.1004190, DOI 10.1109/AFGR.2002.1004190]
   Burgess C, 1998, AIP CONF PROC, V452, P1
   Chaudhary A, 2011, INT J COMPUT SCI ENG, V2, P122, DOI DOI 10.5121/IJCSES.2011.2109
   Cheng J, 2012, PATTERN RECOGN LETT, V33, P476, DOI 10.1016/j.patrec.2010.12.009
   Corera S, 2011, P CHI SPARKS 2011 HC
   Tran C, 2012, IEEE T IND INFORM, V8, P178, DOI 10.1109/TII.2011.2172450
   Derpanis K.G., 2004, REV VISION BASED HAN
   Derpanis KG, 2005, LECT NOTES
   Du H, 2011, INT C MULT TECHN ICM, P416
   Gorce MDL, 2011, 8 INT JOINT C COMP S, V33, P1793
   Hackenberg G, 2011, P IEEE VIRT REAL ANN, P19, DOI 10.1109/VR.2011.5759431
   Hall E. T., 1973, SILENT LANGUAGE
   Hasan H, 2013, NEURAL COMPUT APPL, V23, P1605, DOI 10.1007/s00521-012-1113-0
   Hasan H, 2014, ARTIF INTELL REV, V41, P147, DOI 10.1007/s10462-011-9303-1
   Haykin S. S., 2009, NEURAL NETWORKS LEAR
   He GF, 2011, EEE INT S VIRT REAL, P187
   Henia O. B., 2011, Proceedings of the 2011 Workshop on Digital Media and Digital Content Management (DMDCM 2011), P72, DOI 10.1109/DMDCM.2011.65
   Holzmann G., 1991, DESIGN VALIDATION CO
   Hsieh Chen-Chiung, 2010, 2 INT C SIGN PROC SY, P394
   Huang D, 2011, 6 IEEE INT S APPL CO, P737
   Ionescu B, 2005, EURASIP J APPL SIG P, V2005, P2101, DOI 10.1155/ASP.2005.2101
   Ionescu D, 2011, WORKSH APPL COMP VIS, P159
   Ionescu D, 2011, 7 INT C NAT COMP, P1
   Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819
   Ju SX, 1997, TECHNICAL REPORT
   Just A, 2006, 0673 IDIAP
   Kanniche MB, 2009, THESIS U NICE
   Karam M., 2006, THESIS U SOUTHAMPTON
   Kevin NYY, 2004, TENCON 2004 IEEE REG
   Lindsay J., 2009, K MEANS CLASSIFIER T
   Luo QS, 2010, MACH VISION APPL, V21, P377, DOI 10.1007/s00138-008-0168-5
   McNeill D., 1992, HAND MIND WHAT GESTU
   Mitra S, 2007, IEEE T SYST MAN CY C, V37, P311, DOI 10.1109/TSMCC.2007.893280
   Moeslund TB, 2001, COMPUT VIS IMAGE UND, V81, P231, DOI 10.1006/cviu.2000.0897
   Noury N, 2003, P ANN INT IEEE EMBS, V25, P3286, DOI 10.1109/IEMBS.2003.1280846
   Radkowski R, 2012, ACHI 2012 5 INT C AD, P303
   Ramage D, 2007, LECT NOTES
   Rautaray SS, 2011, 3DTV C TRUE VIS CAP, P292
   Rautaray SS, 2012, INT J UBICOMP, V3, P21
   Reale MJ, 2011, IEEE T MULTIMEDIA, V13, P474, DOI 10.1109/TMM.2011.2120600
   Sajjawiso T, 2011, WORKSH DIG MED DIG C, P177
   Sangineto E, 2012, IMAGE VISION COMPUT, V30, P26, DOI 10.1016/j.imavis.2011.11.004
   SCHLOMER T, 2008, TEI 08, P11, DOI DOI 10.1145/1347390.1347395.URL
   Senin P., 2008, TECHNICAL REPORT
   Symeonidis K, 1996, NEURAL NETWORKS, V13, P1
   Tan T, 2011, EXPERT SYST APPL, P311
   Thirumuruganathan S, 2010, DETAILED INTRO K NEA
   Visser M, 2011, 2 INT C SOFTW ENG SE, P1
   Vsrkonyi-Kczy AR, 2011, IEEE T PATTERN ANAL, V60, P1505
   Wachs JP, 2011, COMMUN ACM, V54, P60, DOI 10.1145/1897816.1897838
   Wang GW, 2012, MATH PROBL ENG, DOI 10.1155/2012/346951
   Webel S, 2008, VRST 08 P 2008 ACM S, P263
   Wohler C, 1999, IEEE T NEURAL NETWOR, V10, P1531, DOI 10.1109/72.809100
   Yang J, 2011, 6 INT C IM GRAPH, P1588
NR 60
TC 27
Z9 30
U1 4
U2 97
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-0643
EI 1433-3058
J9 NEURAL COMPUT APPL
JI Neural Comput. Appl.
PD AUG
PY 2014
VL 25
IS 2
BP 251
EP 261
DI 10.1007/s00521-013-1481-0
PG 11
WC Computer Science, Artificial Intelligence
SC Computer Science
GA AL8KO
UT WOS:000339387600001
DA 2018-12-27
ER

PT J
AU Leung, CK
   Hasegawa, K
   Wang, Y
   Deonarine, A
   Tang, L
   Miwa, J
   Choe, KP
AF Leung, Chi K.
   Hasegawa, Koichi
   Wang, Ying
   Deonarine, Andrew
   Tang, Lanlan
   Miwa, Johji
   Choe, Keith P.
TI RETRACTED: Direct Interaction between the WD40 Repeat Protein WDR-23 and
   SKN-1/Nrf Inhibits Binding to Target DNA (Retracted article. See vol.
   35, pg. 3255, 2015)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID OXIDATIVE-STRESS-RESPONSE; FACTOR E2-RELATED FACTOR-1; TRANSCRIPTION
   FACTOR SKN-1; SWISS-MODEL WORKSPACE; CAENORHABDITIS-ELEGANS; C-ELEGANS;
   UBIQUITIN LIGASE; LONGEVITY; NRF2; ACTIVATION
AB SKN-1/Nrf transcription factors activate cytoprotective genes in response to reactive small molecules and strongly influence stress resistance, longevity, and development. The molecular mechanisms of SKN-1/Nrf regulation are poorly defined. We previously identified the WD40 repeat protein WDR-23 as a repressor of Caenorhabditis elegans SKN-1 that functions with a ubiquitin ligase to presumably target the factor for degradation. However, SKN-1 activity and nuclear accumulation are not always correlated, suggesting that there could be additional regulatory mechanisms. Here, we integrate forward genetics and biochemistry to gain insights into how WDR-23 interacts with and regulates SKN-1. We provide evidence that WDR-23 preferentially regulates one of three SKN-1 variants through a direct interaction that is required for normal stress resistance and development. Homology modeling predicts that WDR-23 folds into a beta-propeller, and we identify the top of this structure and four motifs at the termini of SKN-1c as essential for the interaction. Two of these SKN-1 motifs are highly conserved in human Nrf1 and Nrf2 and two directly interact with target DNA. Lastly, we demonstrate that WDR-23 can block the ability of SKN-1c to interact with DNA sequences of target promoters identifying a new mechanism of regulation that is independent of the ubiquitin proteasome system, which can become occupied with damaged proteins during stress.
C1 [Leung, Chi K.; Wang, Ying; Deonarine, Andrew; Tang, Lanlan; Choe, Keith P.] Univ Florida, Dept Biol, Gainesville, FL 32611 USA.
   [Leung, Chi K.; Wang, Ying; Deonarine, Andrew; Tang, Lanlan; Choe, Keith P.] Univ Florida, Genet Inst, Gainesville, FL USA.
   [Hasegawa, Koichi; Miwa, Johji] Chubu Univ, Coll Biosci & Biotechnol, Dept Environm Biol, Kasugai, Aichi 487, Japan.
   [Miwa, Johji] Chubu Univ, Acad Arts & Sci, Kasugai, Aichi 487, Japan.
RP Choe, KP (reprint author), Univ Florida, Dept Biol, Gainesville, FL 32611 USA.
EM kchoe@ufl.edu
FU NSF [IOS-1120130]; MEXT
FX This study was funded by NSF grant IOS-1120130 to K.P.C. and a
   Grant-in-Aid for Scientific Research of MEXT to J.M.
CR Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Aiken CT, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006924
   Aithal KB, 2012, INTEGR CANCER THER, V11, P68, DOI 10.1177/1534735411403477
   An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803
   An JH, 2005, P NATL ACAD SCI USA, V102, P16275, DOI 10.1073/pnas.0508105102
   Angers S, 2006, NATURE, V443, P590, DOI 10.1038/nature05175
   Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904
   Biswas M, 2011, J BIOL CHEM, V286, P39282, DOI 10.1074/jbc.M111.253807
   BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715
   Bordoli Lorenza, 2012, Methods Mol Biol, V857, P107, DOI 10.1007/978-1-61779-588-6_5
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q
   BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H
   BRENNER S, 1974, GENETICS, V77, P71
   Brouette C, 2002, PROMEGA NOTES, V80, P10
   Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016
   Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779
   Chen LY, 2003, MOL CELL BIOL, V23, P4673, DOI 10.1128/MCB.23.13.4673-4686.2003
   Choe KP, 2012, DRUG METAB REV, V44, P209, DOI 10.3109/03602532.2012.684799
   Choe KP, 2009, MOL CELL BIOL, V29, P2704, DOI 10.1128/MCB.01811-08
   Curran SP, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030056
   Glover-Cutter KM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003701
   Hall DH, 2008, CAENORHABDITIS ELEGA
   Han WN, 2012, J BIOL CHEM, V287, P18788, DOI 10.1074/jbc.M112.363614
   Hasegawa K, 2010, ANN REPORT RES I BIO, V10, P72
   Hasegawa K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011194
   Hasegawa K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009267
   Inoue H, 2005, GENE DEV, V19, P2278, DOI 10.1101/gad.1324805
   Kahn NW, 2008, BIOCHEM J, V409, P205, DOI 10.1042/BJ20070521
   Kell A, 2007, FREE RADICAL BIO MED, V43, P1560, DOI 10.1016/j.freeradbiomed.2007.08.025
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Kiefer F, 2009, NUCLEIC ACIDS RES, V37, pD387, DOI 10.1093/nar/gkn750
   Kundu JK, 2010, PHARM RES-DORDR, V27, P999, DOI 10.1007/s11095-010-0096-8
   Lee CS, 2011, P NATL ACAD SCI USA, V108, P8408, DOI 10.1073/pnas.1019209108
   Lee JH, 2008, PLANT CELL, V20, P152, DOI 10.1105/tpc.107.055418
   Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042
   Lee OH, 2007, J BIOL CHEM, V282, P36412, DOI 10.1074/jbc.M706517200
   Leung CK, 2013, MOL CELL BIOL, V33, P3524, DOI 10.1128/MCB.00245-13
   Leung CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062166
   Leung CK, 2012, FREE RADICAL BIO MED, V52, P937, DOI 10.1016/j.freeradbiomed.2011.12.009
   McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200
   Migliori V, 2012, EPIGENETICS-US, V7, P815, DOI 10.4161/epi.21140
   Okuyama T, 2010, J BIOL CHEM, V285, P30274, DOI 10.1074/jbc.M110.146274
   Oliveira RP, 2009, AGING CELL, V8, P524, DOI 10.1111/j.1474-9726.2009.00501.x
   Paek J, 2012, CELL METAB, V16, P526, DOI 10.1016/j.cmet.2012.09.007
   Robida-Stubbs S, 2012, CELL METAB, V15, P713, DOI 10.1016/j.cmet.2012.04.007
   Rodriguez CE, 2004, TOXICOLOGY, V201, P185, DOI 10.1016/j.tox.2004.04.016
   Rupert PB, 1998, NAT STRUCT BIOL, V5, P484, DOI 10.1038/nsb0698-484
   Satoh T, 2006, P NATL ACAD SCI USA, V103, P768, DOI 10.1073/pnas.0505723102
   Staab TA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003354
   Stirnimann CU, 2010, TRENDS BIOCHEM SCI, V35, P565, DOI 10.1016/j.tibs.2010.04.003
   Suganuma T, 2010, J MOL CELL BIOL, V2, P81, DOI 10.1093/jmcb/mjp046
   Sykiotis GP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3112re3
   Tops BBJ, 2005, NUCLEIC ACIDS RES, V33, P347, DOI 10.1093/nar/gki183
   Tsuchiya Y, 2011, MOL CELL BIOL, V31, P4500, DOI 10.1128/MCB.05663-11
   Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   Walker AK, 2000, J BIOL CHEM, V275, P22166, DOI 10.1074/jbc.M001746200
   Wang JG, 2010, MAGNETIC FRINGE FIELDS AND INTERFERENCE IN HIGH INTENSITY ACCELERATORS, P1
   Wu XH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043005
NR 61
TC 9
Z9 10
U1 3
U2 17
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 2014
VL 34
IS 16
BP 3156
EP 3167
DI 10.1128/MCB.00114-14
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AL8IE
UT WOS:000339381000017
PM 24912676
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Abkhezr, M
   Dryer, SE
AF Abkhezr, Mousa
   Dryer, Stuart E.
TI RETRACTED: Angiotensin II and Canonical Transient Receptor Potential-6
   Activation Stimulate Release of a Signal Transducer and Activator of
   Transcription 3-Activating Factor from Mouse Podocytes (Retracted
   article. See vol. 90, pg. 160, 2016)
SO MOLECULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID HIV-ASSOCIATED NEPHROPATHY; BASEMENT-MEMBRANE GLOMERULONEPHRITIS; FOCAL
   SEGMENTAL GLOMERULOSCLEROSIS; NECROSIS-FACTOR-ALPHA; TRPC6 CHANNELS;
   GLOMERULAR PODOCYTES; JAK-STAT; COLLAPSING GLOMERULOPATHY;
   CELL-PROLIFERATION; OXIDATIVE STRESS
AB Previous studies have shown that the transcription factor signal transducer and activator of transcription-3 (STAT3) in podocytes plays an important role in progression of HIV nephropathy and in collapsing forms of glomerulonephritis. Here, we have observed that application of 100 nM angiotensin II (Ang II) to cultured podocytes for 6-24 hours causes a marked increase in the phosphorylation of STAT3 on tyrosine Y705 but has no effect on phosphorylation at serine S727. By contrast, Ang II treatment of short periods (20-60 minutes) caused a small but consistent suppression of tyrosine phosphylation of STAT3. A similar biphasic effect was seen after treatment with the diacylglycerol analog 1-oleoyl-2-acetyl-sn-glycerol (OAG), an agent that causes activation of Ca2+-permeable canonical transient receptor potential-6 (TRPC6) channels in podocytes. The stimulatory effects of Ang II on STAT3 phosphorylation were abolished by small-interfering RNA knockdown of TRPC6 and also by inhibitors of the Ca2+-dependent downstream enzymes calcineurin and Ca2+-calmodulin-dependent protein kinase II. The stimulatory effects of Ang II appear to be mediated by secretion and accumulation of an unknown factor into the surrounding medium, as they are no longer detected when medium is replaced every 2 hours even if Ang II is continuously present. By contrast, the inhibitory effect of Ang II on STAT3 phosphorylation persists with frequent medium changes. Experiments with neutralizing and inhibitory antibodies suggest that the STAT3 stimulatory factor secreted from podocytes is not interleukin-6, but also suggest that this factor exerts its actions through a receptor system that requires glycoprotein 130.
C1 [Abkhezr, Mousa; Dryer, Stuart E.] Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.
   [Dryer, Stuart E.] Baylor Coll Med, Div Nephrol, Houston, TX 77030 USA.
RP Dryer, SE (reprint author), Univ Houston, Dept Biol & Biochem, 4800 Calhoun, Houston, TX 77204 USA.
EM sdryer@uh.edu
FU American Society of Nephrology
FX This work was supported in part by an M. James Scherbenske award from
   the American Society of Nephrology (to S. E. D.), and by a contract from
   Pfizer, Inc. (to S. E. D.). The corresponding author had full control
   over the conduct of these experiments and controlled the decision to
   publish.
CR Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545
   Aki K, 2010, AM J PHYSIOL-RENAL, V298, pF870, DOI 10.1152/ajprenal.00374.2009
   Anderson M, 2014, J CELL PHYSIOL, V229, P434, DOI 10.1002/jcp.24461
   Anderson M, 2013, AM J PHYSIOL-CELL PH, V305, pC276, DOI 10.1152/ajpcell.00095.2013
   Arakawa T, 2008, NEPHROL DIAL TRANSPL, V23, P3418, DOI 10.1093/ndt/gfn314
   Bariety J, 1998, KIDNEY INT, V53, P918, DOI 10.1111/j.1523-1755.1998.00845.x
   Barisoni L, 1999, J AM SOC NEPHROL, V10, P51
   BOST KL, 1995, J IMMUNOL, V155, P285
   BRENNER BM, 1978, YALE J BIOL MED, V51, P301
   Dai Y, 2013, KIDNEY INT, V84, P950, DOI 10.1038/ki.2013.197
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   Dryer SE, 2010, AM J PHYSIOL-RENAL, V299, pF689, DOI 10.1152/ajprenal.00298.2010
   Eckel J, 2011, J AM SOC NEPHROL, V22, P526, DOI 10.1681/ASN.2010050522
   Endlich N, 2006, EUR J CELL BIOL, V85, P229, DOI 10.1016/j.ejcb.2005.09.006
   Feng XB, 2009, J AM SOC NEPHROL, V20, P2138, DOI 10.1681/ASN.2008080879
   Fitzgerald JS, 2008, HUM REPROD UPDATE, V14, P335, DOI 10.1093/humupd/dmn010
   Fornoni A, 2008, CURR DIABETES REV, V4, P10, DOI 10.2174/157339908783502361
   Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4
   Gu LY, 2013, AIDS, V27, P1091, DOI 10.1097/QAD.0b013e32835f1ea1
   He JCJ, 2004, J CLIN INVEST, V114, P643, DOI 10.1172/JCI200421004
   Hiramatsu N, 2007, J AM SOC NEPHROL, V18, P515, DOI 10.1681/ASN.2006030217
   Ideura H, 2007, AM J PHYSIOL-RENAL, V293, pF1214, DOI 10.1152/ajprenal.00162.2007
   Kim DI, 2013, BIOCHEM BIOPH RES CO, V435, P702, DOI 10.1016/j.bbrc.2013.05.046
   Kim EY, 2008, AM J PHYSIOL-RENAL, V295, pF235, DOI 10.1152/ajprenal.00140.2008
   Kim EY, 2013, AM J PHYSIOL-CELL PH, V305, pC960, DOI 10.1152/ajpcell.00191.2013
   Kim EY, 2012, MOL PHARMACOL, V82, P728, DOI 10.1124/mol.112.079376
   Kim EY, 2012, AM J PHYSIOL-RENAL, V302, pF298, DOI 10.1152/ajprenal.00423.2011
   Kim EY, 2009, MOL PHARMACOL, V75, P466, DOI 10.1124/mol.108.051912
   Kinoshita Y, 2011, TRANSL RES, V158, P235, DOI 10.1016/j.trsl.2011.05.003
   Korgaonkar SN, 2008, J AM SOC NEPHROL, V19, P877, DOI 10.1681/ASN2007050629
   Krall P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012859
   Kuhns D, 1998, J IMMUNOL, V161, P4332
   Le Gall SM, 2009, MOL BIOL CELL, V20, P1785, DOI 10.1091/mbc.E08-11-1135
   Lee SJ, 2012, NEPHRON EXP NEPHROL, V121, pE86, DOI 10.1159/000345151
   Liu BC, 2013, BBA-MOL CELL RES, V1833, P1434, DOI 10.1016/j.bbamcr.2013.02.031
   MADDOX DA, 1975, J CLIN INVEST, V55, P305, DOI 10.1172/JCI107934
   MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503
   Matsui F, 2012, J SURG RES, V178, P339, DOI 10.1016/j.jss.2012.06.050
   Migliorini A, 2013, AM J PATHOL, V183, P431, DOI 10.1016/j.ajpath.2013.04.017
   Mii A, 2009, LAB INVEST, V89, P164, DOI 10.1038/labinvest.2008.128
   Moeller CC, 2007, J AM SOC NEPHROL, V18, P29, DOI 10.1681/ASN.2006091010
   Nijenhuis T, 2011, AM J PATHOL, V179, P1719, DOI 10.1016/j.ajpath.2011.06.033
   Rao S, 2013, J BIOL CHEM, V288, P12448, DOI 10.1074/jbc.M113.454405
   Rastaldi MP, 2006, FASEB J, V20, P976, DOI 10.1096/fj.05-4962fje
   Rastaldi MP, 2003, AM J PATHOL, V163, P889, DOI 10.1016/S0002-9440(10)63449-9
   Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592
   Roshanravan H, 2014, AM J PHYSIOL-RENAL, V306, pF1088, DOI 10.1152/ajprenal.00661.2013
   Ruster C, 2006, J AM SOC NEPHROL, V17, P2985, DOI 10.1681/ASN.2006040356
   Sanchez-Miranda E, 2010, BIOCHEM BIOPH RES CO, V391, P1714, DOI 10.1016/j.bbrc.2009.12.139
   Sano M, 2000, BIOCHEM BIOPH RES CO, V269, P798, DOI 10.1006/bbrc.2000.2364
   SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201
   Schlondorff J, 2009, AM J PHYSIOL-CELL PH, V296, pC558, DOI 10.1152/ajpcell.00077.2008
   Schwimmer JA, 2003, SEMIN NEPHROL, V23, P209, DOI 10.1053/snep.2003.50019
   Skurk T, 2004, ARTERIOSCL THROM VAS, V24, P1199, DOI 10.1161/01.ATV.0000131266.38312.2e
   Stow JL, 2009, IMMUNOBIOLOGY, V214, P601, DOI 10.1016/j.imbio.2008.11.005
   Suzuki Y, 1998, KIDNEY INT, V54, P1166, DOI 10.1046/j.1523-1755.1998.00108.x
   Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797
   Tian DQ, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001200
   WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276
   Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
NR 62
TC 11
Z9 11
U1 2
U2 8
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD AUG
PY 2014
VL 86
IS 2
BP 150
EP 158
DI 10.1124/mol.114.092536
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AL6UD
UT WOS:000339267500003
PM 24850910
OA Bronze
DA 2018-12-27
ER

PT J
AU Ghoddoosinejad, J
   Jannati, A
   Gholipour, K
   Baghestan, EB
AF Ghoddoosinejad, Javad
   Jannati, Ali
   Gholipour, Kamal
   Baghestan, Elham Baghban
TI RETRACTED: Households encountering with catastrophic health expenditures
   in Ferdows, Iran (Retracted article. See vol. 91, pg. 100, 2016)
SO JOURNAL OF THE EGYPTIAN PUBLIC HEALTH ASSOCIATION
LA English
DT Article; Retracted Publication
DE catastrophic health expenditures; Ferdows; households; out-of-pocket
   payments
AB Background
   Out-of-pocket payments are the main sources of healthcare financing in most developing countries. Healthcare services can impose a massive cost burden on households, especially in developing countries. The purpose of this study was to calculate households encountered with catastrophic healthcare expenditures in Ferdows, Iran.
   Materials and methods
   The sample included 100 households representing 20% of all households in Ferdows, Iran. The data were collected using self-administered questionnaire. The ability to pay of households was calculated, and then if costs of household health were at least 40% of their ability to pay, it was considered as catastrophic expenditures.
   Results
   Rate of households encountered to catastrophic health expenditures was estimated to be 24%, of which dentistry services had the highest part in catastrophic health expenditures.
   Conclusion
   Low ability to pay of households should be supported against these expenditures. More equitable health system would solve the problem, although more financial aid should be provided for households encountered to catastrophic costs.
C1 [Ghoddoosinejad, Javad] Tabriz Univ Med Sci, Fac Management & Med Informat, Student Res Comm, Iranian Ctr Excellence Hlth Management,Dept Hlth, Tabriz, Iran.
   [Ghoddoosinejad, Javad; Jannati, Ali; Gholipour, Kamal] Tabriz Univ Med Sci, Fac Management & Med Informat, Iranian Ctr Excellence Hlth Management, Tabriz Hlth Serv Management Res Ctr,Dept Hlth Ser, Attar Nishabouri Rd, Tabriz 5166614711, Iran.
   [Baghestan, Elham Baghban] Islamic Azad Univ, Sch Human Sci, Birjand, Iran.
RP Jannati, A (reprint author), Tabriz Univ Med Sci, Fac Management & Med Informat, Iranian Ctr Excellence Hlth Management, Tabriz Hlth Serv Management Res Ctr,Dept Hlth Ser, Attar Nishabouri Rd, Tabriz 5166614711, Iran.
EM janati1382@gmail.com
OI gholipour, kamal/0000-0002-6595-4150
CR [Anonymous], DAC GUID REF SER POV
   Barros AJD, 2011, CAD SAUDE PUBLICA, V27, pS254, DOI 10.1590/S0102-311X2011001400012
   Filmer D, 2002, WORLD BANK RES OBSER, V17, P47, DOI 10.1093/wbro/17.1.47
   Garg CC, 2009, HEALTH POLICY PLANN, V24, P116, DOI 10.1093/heapol/czn046
   Gotsadze G, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-69
   Haines A, 2000, BRIT MED J, V320, P1, DOI 10.1136/bmj.320.7226.1
   Heijink R, VALIDITY COMPARABILI
   Jowett M., THEORETICAL INSIGHTS
   Karami M, 2009, J RES HEALTH SCI, V9, P36
   Kavosi Z, 2009, HAKIM RES J, V12, P38
   Knaul FM, 2006, LANCET, V368, P1828, DOI 10.1016/S0140-6736(06)69565-2
   Naga RH, 2011, CATASTROPHIC HLTH EX
   ODonnell O, ANAL HLTH EQUITY USI
   Statistical Center of Iran, 2012, SEL FIND SURV EN CAR
   Van Doorslaer E, 2007, HEALTH ECON, V16, P1159, DOI 10.1002/hec.1209
   Wagstaff A, 2003, HEALTH ECON, V12, P921, DOI 10.1002/hec.776
   WIIO. World Health Organization, 2000, WORLD HLTH REP 2000
   World Health Organization, MACR HLTH INV HLTH E
   [World Health Organization Organization WH], WORLD HLTH REP 2008
   World Health Organization (WHO), WORLD HLTH REP 2006
   Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5
   Xu K, 2007, HEALTH AFFAIR, V26, P972, DOI 10.1377/hlthaff.26.4.972
NR 22
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2090-262X
J9 J EGYPT PUBLIC HEAL
JI J. Egypt Public Health Assoc.
PD AUG
PY 2014
VL 89
IS 2
BP 81
EP 84
DI 10.1097/01.EPX.0000451789.21421.61
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V3G6W
UT WOS:000218239300006
PM 25162739
OA Bronze
DA 2018-12-27
ER

PT J
AU Mohamad, ADM
   Rabia, MK
   Ismail, NM
   Mahmoud, AA
AF Mohamad, Ahmad Desoky M.
   Rabia, Mostafa K.
   Ismail, Nabawia M.
   Mahmoud, Ali Abdo
TI RETRACTED: Acid-Catalyzed Aquation of Ni(II)-Hydrazone Complexes:
   Kinetics and Solvent Effect (Retracted article. See vol. 46, pg. 768,
   2014)
SO INTERNATIONAL JOURNAL OF CHEMICAL KINETICS
LA English
DT Article; Retracted Publication
ID BIOLOGICAL-ACTIVITY; METAL-COMPLEXES; SCHIFF-BASES; ANTIBACTERIAL
   ACTIVITY; COPPER(II) COMPLEXES; ISATIN-HYDRAZONES; ORGANIC SOLVENTS;
   MANNICH-BASES; DERIVATIVES; LIGANDS
AB Complexes of the type [Ni(L)(H2O)]Cl-2 center dot nH(2)O, where L= 2-pyridyl-3-isatinbishydrazone ligands, have been synthesized and characterized on the bases of elemental analysis, molar conductance, IR, electronic spectra, and thermal analysis (TGA and DTA). Acid-catalyzed aquation of the Ni(II) isatin-bishydrazone complexes was followed spectrophotometrically in various water-methanol and water-acetone mixtures at temperature 298K. Kinetic behavior of the acid aquation is a linear rate law, indicating that the acid-catalyzed aquation of these complexes in water-methanol and water-acetone mixtures follows a rate law with k(obs) = k(2)[H+]. The effect of the mole fraction of the ganic solvent, i.e., methanol and acetone, on the acid aquation has been analyzed; the decrease in the rate constant values with increasing of the methanol or acetone ratios is attributable to the effect of the co-organic solvent on the initial states of the acid aquation by the destabilization of the H+ ion.
C1 [Mohamad, Ahmad Desoky M.; Rabia, Mostafa K.; Ismail, Nabawia M.; Mahmoud, Ali Abdo] Sohag Univ, Dept Chem, Fac Sci, Sohag 82534, Egypt.
RP Mahmoud, AA (reprint author), Sohag Univ, Dept Chem, Fac Sci, Sohag 82534, Egypt.
EM alyabdo8081@yahoo.com
CR ABUELREASH GM, 1991, INDIAN J CHEM A, V30, P286
   BLANDAMER MJ, 1986, J CHEM SOC FARAD T 1, V82, P1471, DOI 10.1039/f19868201471
   Boon R, 1997, ANTIVIR CHEM CHEMOTH, V8, P5, DOI 10.1177/09563202970080S603
   Cerchiaro G, 2005, J INORG BIOCHEM, V99, P1433, DOI 10.1016/j.jinorgbio.2005.03.013
   Cerchiaro G, 2004, TRANSIT METAL CHEM, V29, P495, DOI 10.1023/B:TMCH.0000037515.77851.12
   Chew KB, 2004, POLYHEDRON, V23, P1385, DOI 10.1016/j.poly.2004.02.018
   DAISLEY RW, 1984, J PHARM SCI, V73, P407, DOI 10.1002/jps.2600730333
   FERRARI MB, 1994, J INORG BIOCHEM, V53, P13, DOI 10.1016/0162-0134(94)80017-0
   GARG BS, 1991, INDIAN J CHEM A, V30, P979
   GEARY WJ, 1971, COORDIN CHEM REV, V7, P81, DOI 10.1016/S0010-8545(00)80009-0
   GOLCHOUBIAN H, 2011, J CHIN CHEM SOC, V58
   Hatzidimitriou A, 1998, POLYHEDRON, V17, P1779, DOI 10.1016/S0277-5387(97)00438-5
   Kilic A, 2007, POLYHEDRON, V26, P4009, DOI 10.1016/j.poly.2007.05.013
   MAHMOUD MR, 1986, J SOLUTION CHEM, V15, P765, DOI 10.1007/BF00646717
   Marcus Y, 2007, CHEM REV, V107, P3880, DOI 10.1021/cr068045r
   Mohamed GG, 2006, SPECTROCHIM ACTA A, V64, P188, DOI 10.1016/j.saa.2005.05.044
   Murukan B, 2007, J COORD CHEM, V60, P1607, DOI 10.1080/00958970601099167
   NAKAMOTO K, 1970, INFRARED SPECTRA INO
   Neena S., 1992, SYNTH REACT INORG M, V22, P1283, DOI DOI 10.1080/15533179208017841
   Pandeya S. N., 1998, Indian Journal of Pharmaceutical Sciences, V60, P207
   PANDEYA SN, 1993, PHARMAZIE, V48, P659
   Pandeya SN, 1999, EUR J PHARM SCI, V9, P25, DOI 10.1016/S0928-0987(99)00038-X
   Phaniband MA, 2007, TRANSIT METAL CHEM, V32, P1117, DOI 10.1007/s11243-007-0295-2
   Rabia MK, 2014, J IRAN CHEM SOC, V11, P1147, DOI 10.1007/s13738-013-0383-5
   Rabia MK, 2013, RUSS J GEN CHEM+, V83, P2502, DOI 10.1134/S1070363213120487
   Rabia MK, 2013, RUSS J GEN CHEM+, V83, P2406, DOI 10.1134/S1070363213120360
   Rodriguez-Arguelles MC, 2004, J INORG BIOCHEM, V98, P313, DOI 10.1016/j.jinorgbio.2003.10.006
   Shi L, 2009, J COORD CHEM, V62, P3471, DOI 10.1080/00958970903093694
   Thompson K. H., 2006, J CHEM SOC DA, P761
NR 29
TC 1
Z9 1
U1 5
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0538-8066
EI 1097-4601
J9 INT J CHEM KINET
JI Int. J. Chem. Kinet.
PD AUG
PY 2014
VL 46
IS 8
BP 451
EP 461
DI 10.1002/kin.20861
PG 11
WC Chemistry, Physical
SC Chemistry
GA AJ9EC
UT WOS:000338008900004
DA 2018-12-27
ER

PT J
AU Khan, MA
   Khan, MZ
   Zaman, K
   Irfan, D
   Khatab, H
AF Khan, Muhammad Azhar
   Khan, Muhammad Zahir
   Zaman, Khalid
   Irfan, Danish
   Khatab, Humera
TI RETRACTED: Questing the three key growth determinants: Energy
   consumption, foreign direct investment and financial development in
   South Asia (Retracted article. See vol. 76, pg. 806, 2015)
SO RENEWABLE ENERGY
LA English
DT Article; Retracted Publication
DE Energy consumption; Economic growth; FDI; Financial development; South
   Asia
ID ECONOMIC-GROWTH; DEVELOPING-COUNTRIES; ELECTRICITY CONSUMPTION;
   COINTEGRATION VECTORS; PANEL-DATA; NEXUS; CAUSALITY; DEMAND; PRICES; GDP
AB The relationship between energy led growth, foreign direct investment (FDI) led growth and financial development led growth hypothesis has been widely debated inside the academic circles. There is a general consensus that these factors are a major cause of growth and vice versa. The objective of this study is to analyze the causal relationship among energy consumption, economic growth, relative price, financial development (FD) and foreign direct investment (FDI) in South Asia using a bivariate and multivariate framework. This study covers a sample from 1975 to 2011. The results of cointegration suggests that variables are cointegrated at their first order i.e, I(1) variables and there has been long-run relationship exist between them. The study finds that both energy consumption and economic growth Granger causes each other in the short and long run. The study supported five growth hypotheses in the context of South Asia and these hypotheses have important policy implications in the South Asian region i.e., a) energy led growth hypothesis, b) energy led financial development, c) FDI led growth hypothesis, d) finance led growth hypothesis and e) FDI led relative prices are supported by the findings from this study. The finding of bidirectional Granger causality between energy consumption and economic growth implies that South Asia is an energy dependent country. Energy is a prominent resource for financial sector development in South Asia, further developed financial sector need more energy resources, and this result indicates that energy consumption Granger cause FD and FD Granger cause energy consumption in South Asian region. Moreover, there is a bidirectional link between FDI & economic growth; and between FDI 8/ relative prices of energy in South Asia which explains that FDI increases energy prices in the host countries, whereas brighter growth prospects in the host countries attract an increased flow of FDI in this region. Finally, existing energy infrastructure fails to comply with speedy FDI and thus put strain on the energy channels which leads to higher energy prices. This quest supports the FDI led relative price hypothesis in South Asian region. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Khan, Muhammad Azhar] Univ Haripur, Dept Econ, Khyber Pakhtoonkhawa, Haripur, Pakistan.
   [Khan, Muhammad Zahir] Islamia Univ Bahawalpur, Bahawalpur, Pakistan.
   [Zaman, Khalid; Khatab, Humera] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Irfan, Danish] COMSATS Inst Informat Technol, Dept Comp Sci, Abbottabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM azhar.phd100@iiu.edu.pk; zahirpanian@yahoo.com; khalidzaman@ciit.net.pk;
   danish@ciit.net.pk; humeraaqeel@ciit.net.pk
CR ADB, 2010, ADB EC WORK PAP SER, V233
   ADB, 2008, FOR DIR INV S AS
   Akkemik KA, 2012, ENERG ECON, V34, P865, DOI 10.1016/j.eneco.2012.04.002
   Al-mulali U, 2012, ENERGY, V46, P156, DOI 10.1016/j.energy.2012.08.043
   Ang JB, 2009, APPL ECON, V41, P1595, DOI 10.1080/00036840701222553
   [Anonymous], 2012, WORLD INV REP
   Asafu-Adjaye J, 2000, ENERG ECON, V22, P615, DOI 10.1016/S0140-9883(00)00050-5
   ASTAE, 2010, AS SUST ALT EN PROGR
   Asteriou D, 2012, APPL ECONOMETRICS MO
   AusAID, 2011, S AS REG INFR GROWTH
   Azam M., 2012, TRANSITION STUD REV, V19, P59
   Bano S, 2011, FOREIGN DIRECT INVES
   Barros CP, 2013, CESA WORKING PAPER S
   Basu P, 2003, ECON INQ, V41, P510, DOI 10.1093/ei/cbg024
   Belke A, 2011, ENERG ECON, V33, P782, DOI 10.1016/j.eneco.2011.02.005
   Blanford GJ, 2012, ENERG ECON, V34, pS284, DOI 10.1016/j.eneco.2012.08.006
   Brew-Hammond A, 2012, ENV POLICY, V54, P35
   Butt M. S., 2001, ASIA PACIFIC DEV J, V8, P101
   Calderon C, 2003, J DEV ECON, V72, P321, DOI 10.1016/S0304-3878(03)00079-8
   Chu HP, 2012, ENERG POLICY, V48, P762, DOI 10.1016/j.enpol.2012.06.013
   Coban S, 2013, ENERG ECON, V39, P81, DOI 10.1016/j.eneco.2013.04.001
   Elliott RJR, 2012, GROWTH FDI ENERGY IN
   ENGLE RF, 1987, ECONOMETRICA, V55, P251, DOI 10.2307/1913236
   ESMAP, 2008, POT PROSP REG EN TRA
   FISMAN R, 2004, 3319 WORLD BANK
   Goyal A, 2012, ASIA PACIFIC DEV J, V19, P63
   Hannesson R, 2009, INT J ENERGY SECT MA, V3, P157, DOI 10.1108/17506220910970560
   Hossain MS, 2012, EUR SCI J, V8, P347
   Hye QMA, 2010, EUR J SOC SCI, V15, P217
   IMF, 2012, AS PAC REG EC OUTL O
   Jaswal P., 2006, ENERGY DEMANDS SUSTA
   JOHANSEN S, 1990, OXFORD B ECON STAT, V52, P169, DOI 10.1111/j.1468-0084.1990.mp52002003.x
   JOHANSEN S, 1991, ECONOMETRICA, V59, P1551, DOI 10.2307/2938278
   JOHANSEN S, 1988, J ECON DYN CONTROL, V12, P231, DOI 10.1016/0165-1889(88)90041-3
   Khan M.A., 2007, PAKISTAN DEV REV, V46, P481
   Khan MA, 2014, RENEW SUST ENERG REV, V29, P63, DOI 10.1016/j.rser.2013.08.088
   Kirkpatrick C, 2006, TRANSNATIONAL CORPOR, V15, P143
   Koljonen T, 2012, ENERG ECON, V34, pS410, DOI 10.1016/j.eneco.2012.05.003
   Kumar A, 2010, 201044 UN DEV PROGR
   Lee CC, 2005, ENERG ECON, V27, P415, DOI 10.1016/j.eneco.2005.03.003
   Lee CC, 2008, RESOUR ENERGY ECON, V30, P50, DOI 10.1016/j.reseneeco.2007.03.003
   Liu H, 2007, ASIA PACIFIC CONSULT
   Mahadevan R, 2007, ENERG POLICY, V35, P2481, DOI 10.1016/j.enpol.2006.08.019
   Majid H, 2012, LOSING TRADING POWER
   Mumtaz R, 2014, RENEW ENERG, V63, P353, DOI 10.1016/j.renene.2013.09.033
   Nabi I, 2010, DEV POLICY RES CTR M
   Narayan PK, 2005, ECON MODEL, V22, P423, DOI 10.1016/j.econmod.2004.06.004
   Narula K, 2012, ENERG POLICY, V47, P345, DOI 10.1016/j.enpol.2012.04.075
   Nasir ZM, 2011, 27 ANN GEN M C PSDE
   Noor S., 2010, INT J HUM SOC SCI, V5, P921
   Ozturk I, 2010, ENERG POLICY, V38, P340, DOI 10.1016/j.enpol.2009.09.024
   Payne JE, 2010, APPL ENERG, V87, P723, DOI 10.1016/j.apenergy.2009.06.034
   Pesaran MH, 2001, J APPL ECONOM, V16, P289, DOI 10.1002/jae.616
   Sadorsky P, 2012, ENERG POLICY, V48, P130, DOI 10.1016/j.enpol.2012.04.064
   Sahoo P., 2006, 56 ADB I
   Sahoo P, 2012, J WORLD INVEST TRADE, V13, P256, DOI 10.1163/221190012X627638
   Sahoo P, 2012, J INT TRADE ECON DEV, V21, P217, DOI 10.1080/09638191003596994
   Shahbaz M, 2011, DYNAMICS ELECT CONSU
   Tang C.F., 2012, QUAL QUANT
   The World Bank, 2012, WORLD DEV IND
   Ting Y., 2011, ENERGY PROCEDIA, V5, P100
   Tugcu CT, 2012, ENERG ECON, V34, P1942, DOI 10.1016/j.eneco.2012.08.021
   UNIDO, 2009, 022009 UNIDO
   United Nations, 2012, WORLD EC SIT PROSP 2
   Weforum, 2011, FIN DEV REP 2011
NR 65
TC 13
Z9 14
U1 1
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-1481
J9 RENEW ENERG
JI Renew. Energy
PD AUG
PY 2014
VL 68
BP 203
EP 215
DI 10.1016/j.renene.2014.02.021
PG 13
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA AG8ZG
UT WOS:000335706800023
DA 2018-12-27
ER

PT J
AU Ye, XX
   Tang, GY
   Song, GL
   Kuang, J
AF Ye, Xiaoxin
   Tang, Guoyi
   Song, Guolin
   Kuang, Jie
TI RETRACTED: Effect of electropulsing treatment on the microstructure,
   texture, and mechanical properties of cold-rolled Ti-6Al-4V alloy
   (Retracted article. See vol. 33, pg. 1699, 2018)
SO JOURNAL OF MATERIALS RESEARCH
LA English
DT Article; Retracted Publication
ID HOT DEFORMATION-BEHAVIOR; DYNAMIC RECRYSTALLIZATION;
   PHASE-TRANSFORMATIONS; STAINLESS-STEEL; STATE; TITANIUM; EVOLUTION;
   KINETICS; TENSILE; STRESS
AB Electropulsing treatment (EPT) provided a promising technology to improve the microstructure and plasticity of the cold-rolled Ti-6Al-4V noticeably while only affecting the strength mildly. Thus, titanium alloy of high plasticity and good comprehensive property can be obtained by this high efficient processing method. The research found that the tensile ductility could be improved largely with the increasing frequency. In the low frequency, the maximum ductility (32.5%) could be obtained at 293 Hz-EPT. Under high-frequency EPT, plasticity has a slight decrease but the tensile strength increases in the contrary. With the help of multi-characterization, abstracting phenomena are explained and therefore the conclusion has been drawn that the whole process of increasing frequency EPT can be divided roughly into two periods: (a) recrystallization period in the low frequency, at this period athermal effect of the EPT played a leading role and (b) phase change period in the high frequency, at this period the other important factor of the EPT thermal effect was predominant. As a comparison, furnace heat treatment is conducted to prove the preferential phase transition instead of complete recrystallization under the single heating effect. The mechanism of the results can be discussed by the competitive mechanism of recrystallization process and phase change in the EPT processing.
C1 [Ye, Xiaoxin; Tang, Guoyi; Song, Guolin; Kuang, Jie] Tsinghua Univ, Grad Sch Shenzhen, Adv Mat Inst, Shenzhen 518055, Peoples R China.
   [Ye, Xiaoxin; Tang, Guoyi] Tsinghua Univ, Dept Mat Sci & Engn, Minist Educ, Key Lab Adv Mat, Beijing 100084, Peoples R China.
RP Tang, GY (reprint author), Tsinghua Univ, Grad Sch Shenzhen, Adv Mat Inst, Shenzhen 518055, Peoples R China.
EM tanggy@mail.sz.tsinghua.edu.cn
FU National Natural Science Foundation of China [50571048]; Shenzhen
   science and technology research funding project of China
   [SGLH20121008144756946]
FX The work is supported by National Natural Science Foundation of China
   (No. 50571048) and Shenzhen science and technology research funding
   project of China (No. SGLH20121008144756946).
CR Boivineau M, 2006, INT J THERMOPHYS, V27, P507, DOI 10.1007/s10765-005-0001-6
   Chen F, 2011, MAT SCI ENG A-STRUCT, V528, P5073, DOI 10.1016/j.msea.2011.03.008
   Conrad H, 2000, MAT SCI ENG A-STRUCT, V287, P227, DOI 10.1016/S0921-5093(00)00780-2
   Correa ECS, 2003, J MATER PROCESS TECH, V142, P282, DOI 10.1016/S0924-0136(03)00575-2
   Demir E, 2010, ACTA MATER, V58, P1876, DOI 10.1016/j.actamat.2009.11.031
   Doherty RD, 1997, MAT SCI ENG A-STRUCT, V238, P219, DOI 10.1016/S0921-5093(97)00424-3
   Gil FJ, 2000, MAT SCI ENG A-STRUCT, V283, P17, DOI 10.1016/S0921-5093(00)00731-0
   Gromov VE, 2013, J SURF INVEST-X-RAY+, V7, P94, DOI 10.1134/S1027451013010114
   Gromov VE, 2011, J SURF INVEST-X-RAY+, V5, P974, DOI 10.1134/S1027451011100107
   Gromov V. E., 1991, Soviet Physics Journal, V34, P813, DOI 10.1007/BF00896719
   Gromov VE, 2010, MAT SCI ENG A-STRUCT, V527, P858, DOI 10.1016/j.msea.2009.10.045
   GROMOV VE, 1993, PHYS STATUS SOLIDI A, V139, P77, DOI 10.1002/pssa.2211390104
   Guan L, 2009, J ALLOY COMPD, V487, P309, DOI 10.1016/j.jallcom.2009.07.114
   Guan L, 2009, J MATER RES, V24, P3674, DOI 10.1557/JMR.2009.0436
   Gurrappa I, 2003, MATER CHARACT, V51, P131, DOI 10.1016/j.matchar.2003.10.006
   Jiang YB, 2008, J MATER RES, V23, P2685, DOI 10.1557/JMR.2008.0328
   Jiang YB, 2009, ACTA MATER, V57, P4797, DOI 10.1016/j.actamat.2009.06.044
   Jiang YB, 2009, J MATER RES, V24, P1810, DOI 10.1557/JMR.2009.0197
   Khan MA, 1999, BIOMATERIALS, V20, P631, DOI 10.1016/S0142-9612(98)00217-8
   Kim JH, 2012, MAT SCI ENG A-STRUCT, V543, P50, DOI 10.1016/j.msea.2012.02.044
   Lin YC, 2014, MAT SCI ENG A-STRUCT, V598, P251, DOI 10.1016/j.msea.2014.01.029
   Liu R, 2014, MAT SCI ENG A-STRUCT, V594, P352, DOI 10.1016/j.msea.2013.11.071
   Mataya MC, 2003, METALL MATER TRANS A, V34A, P3021, DOI 10.1007/s11661-003-0201-2
   McQueen HJ, 2004, J ALLOY COMPD, V378, P35, DOI 10.1016/j.jallcom.2003.10.067
   OKAZAKI K, 1979, SCRIPTA METALL MATER, V13, P473, DOI 10.1016/0036-9748(79)90072-3
   OKAZAKI K, 1978, SCRIPTA METALL MATER, V12, P1063, DOI 10.1016/0036-9748(78)90026-1
   OXTOBY DW, 1992, J PHYS-CONDENS MAT, V4, P7627, DOI 10.1088/0953-8984/4/38/001
   Potapova AA, 2013, MAT SCI ENG A-STRUCT, V579, P114, DOI 10.1016/j.msea.2013.05.003
   Renard K, 2012, SCRIPTA MATER, V66, P966, DOI 10.1016/j.scriptamat.2012.01.063
   TROITSKII OA, 1963, DOKL AKAD NAUK SSSR+, V148, P332
   Wang MH, 2013, MATER DESIGN, V45, P384, DOI 10.1016/j.matdes.2012.08.041
   Wang X.L., 2006, APPL PHYS LETT, V6, P619
   Xiao ML, 2012, MATER DESIGN, V34, P112, DOI 10.1016/j.matdes.2011.07.065
   Zhang D, 2012, METALL MATER TRANS A, V43A, P1341, DOI 10.1007/s11661-011-0955-x
   Zhang L, 2011, MAT SCI ENG A-STRUCT, V528, P1641, DOI 10.1016/j.msea.2010.10.103
   Zhu RF, 2012, J ALLOY COMPD, V544, P203, DOI 10.1016/j.jallcom.2012.07.150
   Zhu YH, 2009, MAT SCI ENG A-STRUCT, V501, P125, DOI 10.1016/j.msea.2008.09.080
   Zhu YH, 2009, J MATER RES, V24, P2661, DOI 10.1557/JMR.2009.0300
NR 38
TC 22
Z9 22
U1 15
U2 44
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0884-2914
EI 2044-5326
J9 J MATER RES
JI J. Mater. Res.
PD JUL 28
PY 2014
VL 29
IS 14
BP 1500
EP 1512
DI 10.1557/jmr.2014.171
PG 13
WC Materials Science, Multidisciplinary
SC Materials Science
GA AN4MJ
UT WOS:000340561700002
DA 2018-12-27
ER

PT J
AU Ramozzi, R
   Cheron, N
   El Kaim, L
   Grimaud, L
   Fleurat-Lessard, P
AF Ramozzi, Romain
   Cheron, Nicolas
   El Kaim, Laurent
   Grimaud, Laurence
   Fleurat-Lessard, Paul
TI RETRACTED: Predicting New Ugi-Smiles Couplings: A Combined Experimental
   and Theoretical Study(Retracted article. See vol. 23, pg.9094, 2017)
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article; Retracted Publication
DE density functional calculations; multicomponent reactions;
   nitrosophenols; prediction; Ugi-Smiles coupling
ID MULTICOMPONENT REACTIONS; DENSITY FUNCTIONALS; CHEMISTRY; SUBSTITUTION;
   ISOCYANIDES; REARRANGEMENTS; SOLUTE
AB Following our previous mechanistic studies of multicomponent Ugi-type reactions, theoretical calculations have been performed to predict the efficiency of new substrates in Ugi-Smiles couplings. First, as predicted, 2,4,6-trichlorophenol experimentally gave the corresponding aryl-imidate. Theoretical predictions of nitrosophenols as good acidic partners were then successfully confirmed by experiments. In the latter case, the reaction offers a new access to benzimidazoles.
C1 [Ramozzi, Romain; Cheron, Nicolas; Fleurat-Lessard, Paul] Univ Lyon, Ecole Normale Super Lyon, UMR 5182, Lab Chim, F-69364 Lyon 07, France.
   [Ramozzi, Romain; Cheron, Nicolas; El Kaim, Laurent] Ecole Natl Super Tech Avancees ParisTech, UMR 7652, DCSO, Lab Chim & Proc, F-91762 Palaiseau, France.
   [Ramozzi, Romain; Grimaud, Laurence] Ecole Normale Super, UMR 8640, Dept Chim, F-75231 Paris 05, France.
RP El Kaim, L (reprint author), Ecole Natl Super Tech Avancees ParisTech, UMR 7652, DCSO, Lab Chim & Proc, 828 Blvd Marechaux, F-91762 Palaiseau, France.
EM laurent.elkaim@ensta-paristech.fr; laurence.grimaud@ens.fr;
   paul-fleurat-lessard@ens-lyon.fr
RI Cheron, Nicolas/C-1324-2011; El Kaim, laurent/N-1831-2014
OI Cheron, Nicolas/0000-0002-4090-5897; El Kaim,
   laurent/0000-0001-5729-8010
FU ENS de Lyon; ENSTA; CNRS; ENS de Cachan;  [ANR-08-CP2D-15-02]
FX The authors thank ANR-08-CP2D-15-02, ENS de Lyon, ENSTA, and CNRS for
   financial support. This work was granted access to the HPC resources of
   IDRIS under the allocations 2012-080609 and 2013-080609 made by GENCI
   (Grand Equipement National de Calcul Intensif). This work has been
   achieved in part by resources from PSMN (Pole Scientifique de
   Modelisation Numerique). R. R. thanks the ENS de Cachan and N.C. the ENS
   de Lyon for a fellowship.
CR Bienayme H, 2000, CHEM-EUR J, V6, P3321, DOI 10.1002/1521-3765(20000915)6:18<3321::AID-CHEM3321>3.0.CO;2-A
   BUNNETT JF, 1955, J AM CHEM SOC, V77, P5051, DOI 10.1021/ja01624a033
   CADOGAN JIG, 1972, ACCOUNTS CHEM RES, V5, P303, DOI 10.1021/ar50057a003
   Cheron N, 2013, J PHYS CHEM A, V117, P8035, DOI 10.1021/jp4052227
   Cheron N, 2012, J ORG CHEM, V77, P1361, DOI 10.1021/jo2021554
   Cheron N, 2011, CHEM-EUR J, V17, P14929, DOI 10.1002/chem.201102463
   COSSI M, 1994, CHEM PHYS LETT, V228, P165, DOI 10.1016/0009-2614(94)00909-0
   Domling A, 2006, CHEM REV, V106, P17, DOI 10.1021/cr0505728
   Domling A, 2000, ANGEW CHEM INT EDIT, V39, P3168, DOI 10.1002/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U
   Domling A., 2000, ANGEW CHEM, V112, P3300
   Domling A, 2012, CHEM REV, V112, P3083, DOI 10.1021/cr100233r
   El Kaim L, 2011, EUR J ORG CHEM, P6177, DOI 10.1002/ejoc.201100939
   El Kaim L, 2005, ANGEW CHEM INT EDIT, V44, P7961, DOI 10.1002/anie.200502636
   El Kaim L., 2013, SMILES REARRANGEMENT
   El Kaim L, 2007, J ORG CHEM, V72, P4169, DOI 10.1021/jo070202e
   El Kaim L, 2010, MOL DIVERS, V14, P855, DOI 10.1007/s11030-009-9175-3
   ELKAIM L, 2005, ANGEW CHEM, V117, P8175
   Fleurat-Lessard P., CHEM VIEW REACTION P
   Frisch M.J., 2009, GAUSSIAN 09 REVISION
   GREINER A, 1989, TETRAHEDRON LETT, V30, P931, DOI 10.1016/S0040-4039(00)95282-1
   Medeiros GA, 2014, CHEM COMMUN, V50, P338, DOI 10.1039/c3cc47156j
   Mennucci B, 1997, J PHYS CHEM B, V101, P10506, DOI 10.1021/jp971959k
   MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2
   Nenadjenko V., 2012, ISOCYANIDE CHEMISTRY
   Nguyen QNN, 2014, CHEM-ASIAN J, V9, P674, DOI 10.1002/asia.201301452
   Ren W., 2002, PHYS REV B, V66, DOI DOI 10.1103/PHYSREVB.66.052301
   Ruijter Eelco, 2013, Drug Discov Today Technol, V10, pe15, DOI 10.1016/j.ddtec.2012.10.012
   Ugi I, 2003, MOLECULES, V8, P53, DOI 10.3390/80100053
   UGI I, 1959, ANGEW CHEM INT EDIT, V71, P386
   UGI I, 1960, ANGEW CHEM INT EDIT, V72, P267, DOI 10.1002/ange.19600720709
   Yang H, 2010, SYNLETT, P483, DOI 10.1055/s-0029-1219190
   Zhao Y., 2008, THEOR CHEM ACC, V119, P525, DOI DOI 10.1007/S00214-007-0401-8
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214-007-0310-x
   Zhao Y, 2008, ACCOUNTS CHEM RES, V41, P157, DOI 10.1021/ar700111a
   Zhu J, 2005, MULTICOMPONENT REACTIONS, P1, DOI 10.1002/3527605118
NR 35
TC 5
Z9 5
U1 2
U2 32
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0947-6539
EI 1521-3765
J9 CHEM-EUR J
JI Chem.-Eur. J.
PD JUL 14
PY 2014
VL 20
IS 29
BP 9094
EP 9099
DI 10.1002/chem.201400336
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA AL8KG
UT WOS:000339386700040
PM 24903608
DA 2018-12-27
ER

PT J
AU Mahmood, K
   Swain, BS
   Han, GS
   Kim, BJ
   Jung, HS
AF Mahmood, Khalid
   Swain, Bhabani Sankar
   Han, Gill-Sang
   Kim, Byeong-Jo
   Jung, Hyun Suk
TI RETRACTED: Polyethylenimine-Assisted Growth of High-Aspect-Ratio
   Nitrogen-Doped ZnO (NZO) Nanorod Arrays and Their Effect on Performance
   of Dye-Sensitized Solar Cells (Retracted article. See vol. 8, pg. 1554,
   2016)
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article; Retracted Publication
DE zinc oxide; doping; aspect ratio; polyethylenimine; hydrothermal crystal
   growth; dye-sensitized solar cell
ID NANOWIRE ARRAYS; ROOM-TEMPERATURE; ULTRAVIOLET PHOTODETECTORS;
   DEPOSITION; TRANSPORT; SURFACE; SHELL; CORE; FILM
AB The realization of arrays of high-aspect-ratio nitrogen-doped ZnO (NZO) nanorod is critical to the development of high-quality nanostructure-based optoelectronic and electronic devices. In this study, we used a solution-based method to grow arrays of vertically aligned high-aspect-ratio NZO nanorods on ZnO seed layer covered fluorine-doped tin oxide substrates. We investigated whether the diameters and aspect ratios of the nanorods were affected by the addition of polyethylenimine (PEI) to the precursor solution used as well as by variations in the growth temperature and the concentration of the precursor solution. The performances of dye-sensitized solar cells (DSSCs) in which the synthesized high-aspect-ratio NZO nanorods were used as the photo-anode material were also studied. That the dopant, nitrogen, was introduced into the ZnO lattice was confirmed using X-ray photoelectron spectroscopy and energy-dispersive X-ray spectroscopy. It was seen that after the addition of PEI, the NZO and ZnO nanorod arrays increased in length and their diameters became smaller (i.e., their aspect ratios increased). This resulted in an increase in the amount of dye absorbed by them, leading to improvements in the DSSCs based on the nanorods. The structural, morphological, optical, and photovoltaic characteristics of ZnO and NZO nanorod arrays synthesized using different precursor concentrations and growth temperatures (160-190 degrees C) were also examined. We also investigated the effect of the use of PEI on these characteristics. The power conversion efficiency (PCE) of DSSCs fabricated using the NZO nanorod arrays was found to be significantly higher than that of DSSCs based on the pure ZnO nanorod arrays. This increase in efficiency could be attributed to the combined effects of the increase in the charge-carrier concentration, change in morphology, and increase in the Fermi energy levels of the nanorods, which resulted because of N doping. A PCE of 5.0% was obtained for a DSSC based on a film of arrays of NZO nanorods having an aspect ratio of similar to 47 and synthesized using PEI.
C1 [Mahmood, Khalid; Swain, Bhabani Sankar; Han, Gill-Sang; Kim, Byeong-Jo; Jung, Hyun Suk] Sungkyunkwan Univ, Sch Adv Mat Sci & Engn, Suwon 440746, South Korea.
RP Mahmood, K (reprint author), Sungkyunkwan Univ, Sch Adv Mat Sci & Engn, Suwon 440746, South Korea.
EM khalid@kaist.ac.kr
RI Han, Gill Sang/P-8395-2015
OI Han, Gill Sang/0000-0002-3974-2138; Jung, Hyun Suk/0000-0002-7803-6930
FU National Research Foundation (NRF) - Korean government (MEST)
   [2012M3A7B4049967, 2012M3A6A7054861, 2014R1A4A1008474]
FX This work was supported by grants from the National Research Foundation
   (NRF), which is funded by the Korean government (MEST)
   (2012M3A7B4049967, 2012M3A6A7054861 and 2014R1A4A1008474).
CR Bagnall DM, 1997, APPL PHYS LETT, V70, P2230, DOI 10.1063/1.118824
   Baxter JB, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1861510
   Chen LY, 2012, CRYST GROWTH DES, V12, P1055, DOI 10.1021/cg201316f
   Chen LC, 2008, J PHOTOCH PHOTOBIO A, V199, P170, DOI 10.1016/j.jphotochem.2008.05.022
   Cheng C. W., 2010, PHYS LETT, V96
   Choi HS, 2012, J SOLID STATE CHEM, V189, P25, DOI 10.1016/j.jssc.2011.12.008
   Diamant Y, 2003, J PHYS CHEM B, V107, P1977, DOI 10.1021/jp027827v
   Emanetoglu NW, 2004, APPL PHYS LETT, V85, P3702, DOI 10.1063/1.1811383
   Furube A, 2004, J PHYS CHEM B, V108, P12583, DOI 10.1021/jp0487713
   Galoppini E, 2006, J PHYS CHEM B, V110, P16159, DOI 10.1021/jp062865q
   Gao HM, 2008, MATER RES BULL, V43, P3345, DOI 10.1016/j.materresbull.2008.02.010
   Gao YF, 2007, CRYST GROWTH DES, V7, P2467, DOI 10.1021/cg060934k
   Gratzel M, 2003, J PHOTOCH PHOTOBIO C, V4, P145, DOI 10.1016/S1389-5567(03)00026-1
   Greene LE, 2003, ANGEW CHEM INT EDIT, V42, P3031, DOI 10.1002/anie.200351461
   Greene LE, 2006, INORG CHEM, V45, P7535, DOI 10.1021/ic0601900
   Heo YW, 2004, MAT SCI ENG R, V47, P1, DOI 10.1016/j.mser.2004.09.001
   Hua GM, 2009, CRYST GROWTH DES, V9, P4653, DOI 10.1021/cg900438c
   Huang MH, 2001, SCIENCE, V292, P1897, DOI 10.1126/science.1060367
   Huang QL, 2011, J ALLOY COMPD, V509, P9456, DOI 10.1016/j.jallcom.2011.07.029
   Hwang DK, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1940736
   Ku CH, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2778454
   Kuo TJ, 2007, CHEM MATER, V19, P5143, DOI 10.1021/cm071568a
   Law M, 2005, NAT MATER, V4, P455, DOI 10.1038/nmat1387
   Lee YM, 2011, J SOLID STATE CHEM, V184, P615, DOI 10.1016/j.jssc.2011.01.021
   Liang S, 2001, J CRYST GROWTH, V225, P110, DOI 10.1016/S0022-0248(01)00830-2
   Liao L, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2800812
   Lide D. R, 2000, CHEM RUBBER CO HDB C
   Liu B, 2009, J AM CHEM SOC, V131, P3985, DOI 10.1021/ja8078972
   Mahmood K, 2013, J MATER CHEM A, V1, P4826, DOI 10.1039/c3ta10587c
   Mahmood K, 2012, J CRYST GROWTH, V347, P104, DOI 10.1016/j.jcrysgro.2012.03.033
   Mahpeykar SM, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/16/165602
   Martinson ABF, 2008, CHEM-EUR J, V14, P4458, DOI 10.1002/chem.200701667
   Mor GK, 2006, NANO LETT, V6, P215, DOI 10.1021/nl052099j
   Nakahara K, 2001, APPL PHYS LETT, V79, P4139, DOI 10.1063/1.1424066
   Ozgur U, 2005, J APPL PHYS, V98, DOI 10.1063/1.1992666
   Park CH, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.073202
   Polsongkram D, 2008, PHYSICA B, V403, P3713, DOI 10.1016/j.physb.2008.06.020
   Pradhan B, 2007, SOL ENERG MAT SOL C, V91, P769, DOI 10.1016/j.solmat.2007.01.006
   Qiu JJ, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/15/155603
   Qurashi A, 2010, SUPERLATTICE MICROST, V48, P162, DOI 10.1016/j.spmi.2010.05.011
   Rensmo H, 1997, J PHYS CHEM B, V101, P2598, DOI 10.1021/jp962918b
   Richardson JJ, 2009, CRYST GROWTH DES, V9, P2576, DOI 10.1021/cg900083s
   Shih A, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/12/125201
   Tang ZK, 1998, APPL PHYS LETT, V72, P3270, DOI 10.1063/1.121620
   Tian JH, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/24/245601
   Vayssieres L, 2003, ADV MATER, V15, P464, DOI 10.1002/adma.200390108
   Wang LG, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.256401
   Wen LY, 2011, J MATER CHEM, V21, P7090, DOI 10.1039/c1jm10496a
   Wu JJ, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2742639
   Xu CK, 2012, J PHYS CHEM C, V116, P7236, DOI 10.1021/jp300960r
   Xu CK, 2010, J PHYS CHEM C, V114, P125, DOI 10.1021/jp9085415
   Xu CK, 2010, CHEM MATER, V22, P143, DOI 10.1021/cm9027513
   Yi SH, 2007, J COLLOID INTERF SCI, V313, P705, DOI 10.1016/j.jcis.2007.05.006
   Zeng HB, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2196051
   Zhang H, 2004, J PHYS CHEM B, V108, P3955, DOI 10.1021/jp036826f
   Zheng Y.-Z., MAT RES B
   Zhou Y, 2008, MATER RES BULL, V43, P2113, DOI 10.1016/j.materresbull.2007.09.024
   Zhu G, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/5/055604
   Zhu SB, 2013, J SOLID STATE CHEM, V197, P69, DOI 10.1016/j.jssc.2012.09.001
NR 59
TC 13
Z9 13
U1 8
U2 101
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JUL 9
PY 2014
VL 6
IS 13
BP 10028
EP 10043
DI 10.1021/am500105x
PG 16
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA AL2UB
UT WOS:000338979900017
PM 24940708
DA 2018-12-27
ER

PT J
AU Nayyar, AS
   Khan, M
   Bafna, UD
   Ahmed, S
   Chaluvaiah, GH
AF Nayyar, Abhishek Singh
   Khan, Mubeen
   Bafna, Uttam Dungarmal
   Ahmed, Siddique
   Chaluvaiah, Gayitri Holenarasipur
TI RETRACTED: Colposcopy in oral epithelial dysplasia: Seeing the unseen, a
   pilot study (Retracted article. See vol. 11, pg. 1049, 2015)
SO JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
LA English
DT Article; Retracted Publication
DE Colposcopy; epithelial dysplasia; histopathological; potentially
   malignant epithelial lesions; vascular pattern
ID DIRECTED BIOPSY; DIAGNOSTIC AIDS; CANCER; NEOPLASIA; ACCURACY; LESIONS
AB Context: The diagnosis of malignant and potentially malignant epithelial lesions of oral mucosa cannot be based solely on clinical findings. The histologic evaluation of a representative biopsy specimen thus becomes necessary. The site for biopsy, however, is always a subjective choice that sometimes raises doubts about its representativeness. So far, no simple and reliable method is available for the selection of the most appropriate area for biopsy. Colposcopy is helpful in the selection of these sites of epithelial dysplasia depending upon the vascular patterns. Aims: The study was planned to assess the role of colposcopic examination in the selection of biopsy site in patients with varying grades of oral epithelial dysplasia at various sites. Settings and Design: Fifty patients between the ages of 30-60 years clinically diagnosed with leukoplakia and carcinoma buccal mucosa were included in the study. Materials and Methods: For each of the subject, a thorough clinical examination followed by colposcopic assessment was carried out for the selection of biopsy site from the involved mucosa. The histopathological findings were then compared in the two cases and results analyzed. Statistical Analysis Used: The statistical analysis was done using paired t-test. Results: In our study, sensitivity and specificity for the selection of biopsy site by colposcopic examination came out to be higher for leukoplakia than carcinoma buccal mucosa patients. Conclusions: It was concluded that colposcopic examination was found more significant in the selection of biopsy site for leukoplakia patients while clinical criterion was found to be more appropriate for carcinoma buccal mucosa cases.
C1 [Nayyar, Abhishek Singh; Khan, Mubeen; Chaluvaiah, Gayitri Holenarasipur] Govt Dent Coll & Res Inst, Dept Oral Med & Radiol, Bangalore, Karnataka, India.
   [Bafna, Uttam Dungarmal] Kidwai Mem Inst Oncol, Dept Gynecol, Bangalore, Karnataka, India.
   [Ahmed, Siddique] Bowring & Lady Curzon Hosp, Dept Gen Pathol, Bangalore, Karnataka, India.
RP Nayyar, AS (reprint author), H 44,Behind Singla Nursing Home, Panipat 132103, Haryana, India.
EM singhabhishek.rims@gmail.com
CR Bagan J, 2010, ORAL ONCOL, V46, P414, DOI 10.1016/j.oraloncology.2010.03.009
   Burke L, 1991, COLPOSCOPY TXB ATLAS
   CINEL A, 1990, European Journal of Gynaecological Oncology, V11, P433
   COPPLESON M, 1986, COLPOSCOPY SCI PRACT
   Dresang LT, 2005, J AM BOARD FAM PRACT, V18, P383, DOI 10.3122/jabfm.18.5.383
   Fedele S, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-5
   Gynther GW, 2000, ORAL SURG ORAL MED O, V90, P164, DOI 10.1067/moe.2000.105334
   HELMERHORST TJM, 1987, EUR J OBSTET GYN R B, V24, P221, DOI 10.1016/0028-2243(87)90021-9
   Hopman EH, 2005, CME J GYNAECOLOGIC O, V10, P11
   KIRKUP W, 1980, BRIT J OBSTET GYNAEC, V87, P1, DOI 10.1111/j.1471-0528.1980.tb04416.x
   Kolstad P, 1982, ATLAS COLPOSCOPY, P21
   Kujan Omar, 2005, J Dent Educ, V69, P255
   LESTRANGE P, 1989, ORAL SURG ORAL MED O, V67, P282, DOI 10.1016/0030-4220(89)90355-1
   Lingen MW, 2008, ORAL ONCOL, V44, P10, DOI 10.1016/j.oraloncology.2007.06.011
   Neville BW, 2002, CA-CANCER J CLIN, V52, P195, DOI 10.3322/canjclin.52.4.195
   Onofre HA, 2001, ORAL SURG ORAL MED O, V91, P535, DOI 10.1067/moe.2001.112949
   Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P
   PAYMASTER JC, 1962, CANCER, V15, P578, DOI 10.1002/1097-0142(196205/06)15:3<578::AID-CNCR2820150318>3.0.CO;2-3
   REID R, 1985, AM J OBSTET GYNECOL, V153, P611, DOI 10.1016/S0002-9378(85)80244-1
   Rosin MP, 2007, ANN NY ACAD SCI, V1098, P167, DOI 10.1196/annals.1384.039
   Shetty DC, 2011, VASC HEALTH RISK MAN, V7, P41, DOI 10.2147/VHRM.S15384
   Silverman Jr S, 1990, DIAGNOSIS ORAL CANC, P41
   Silverman S, 2001, J AM DENT ASSOC, V132, p7S, DOI 10.14219/jada.archive.2001.0382
   SILVERMAN S, 2003, ORAL CANC
   Smith RA, 2002, CA-CANCER J CLIN, V52, P8, DOI 10.3322/canjclin.52.1.8
   Swango PA, 1996, J PUBLIC HEALTH DENT, V56, P309, DOI 10.1111/j.1752-7325.1996.tb02458.x
   Walker P, 2003, OBSTET GYNECOL, V101, P175, DOI 10.1016/S0029-7844(02)02581-4
   Wang CY, 1999, ORAL ONCOL, V35, P144, DOI 10.1016/S1368-8375(98)00107-9
NR 28
TC 1
Z9 1
U1 3
U2 6
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0973-1482
EI 1998-4138
J9 J CANCER RES THER
JI J. Canc. Res. Ther.
PD JUL-SEP
PY 2014
VL 10
IS 3
BP 563
EP 570
DI 10.4103/0973-1482.137957
PG 8
WC Oncology
SC Oncology
GA AX4GC
UT WOS:000346890600021
PM 25313740
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Chen, CW
   Panzeri, D
   Yeh, YH
   Kadota, Y
   Huang, PY
   Tao, CN
   Roux, M
   Chien, SC
   Chin, TC
   Chu, PW
   Zipfel, C
   Zimmerli, L
AF Chen, Ching-Wei
   Panzeri, Dario
   Yeh, Yu-Hung
   Kadota, Yasuhiro
   Huang, Pin-Yao
   Tao, Chia-Nan
   Roux, Milena
   Chien, Shiao-Chiao
   Chin, Tzu-Chuan
   Chu, Po-Wei
   Zipfel, Cyril
   Zimmerli, Laurent
TI RETRACTED: The Arabidopsis Malectin-Like Leucine-Rich Repeat
   Receptor-Like Kinase IOS1 Associates with the Pattern Recognition
   Receptors FLS2 and EFR and Is Critical for Priming of Pattern-Triggered
   Immunity (Retracted article. See vol. 27, pg. 1563, 2015)
SO PLANT CELL
LA English
DT Article; Retracted Publication
ID BETA-AMINOBUTYRIC ACID; PLANT INNATE IMMUNITY; SYSTEMIC
   ACQUIRED-RESISTANCE; NADPH OXIDASE RBOHD; PSEUDOMONAS-SYRINGAE; DEFENSE
   RESPONSES; BIOTROPHIC PATHOGENS; BACTERIAL EFFECTORS;
   MOLECULAR-PATTERNS; PROTEIN-KINASES
AB Plasma membrane-localized pattern recognition receptors such as FLAGELLIN SENSING2 (FLS2) and EF-TU RECEPTOR (EFR) recognize microbe-associated molecular patterns (MAMPs) to activate the first layer of plant immunity termed pattern-triggered immunity (PTI). A reverse genetics approach with genes responsive to the priming agent beta-aminobutyric acid (BABA) revealed IMPAIRED OOMYCETE SUSCEPTIBILITY1 (IOS1) as a critical PTI player. Arabidopsis thaliana ios1 mutants were hypersusceptible to Pseudomonas syringae bacteria. Accordingly, ios1 mutants demonstrated defective PTI responses, notably delayed upregulation of PTI marker genes, lower callose deposition, and mitogen-activated protein kinase activities upon bacterial infection or MAMP treatment. Moreover, Arabidopsis lines overexpressing IOS1 were more resistant to P. syringae and demonstrated a primed PTI response. In vitro pull-down, bimolecular fluorescence complementation, coimmunoprecipitation, and mass spectrometry analyses supported the existence of complexes between the membrane-localized IOS1 and FLS2 and EFR. IOS1 also associated with BRASSINOSTEROID INSENSITIVE1-ASSOCIATED KINASE1 (BAK1) in a ligand-independent manner and positively regulated FLS2/BAK1 complex formation upon MAMP treatment. Finally, ios1 mutants were defective in BABA-induced resistance and priming. This work reveals IOS1 as a regulatory protein of FLS2- and EFR-mediated signaling that primes PTI activation upon bacterial elicitation.
C1 [Chen, Ching-Wei; Panzeri, Dario; Yeh, Yu-Hung; Huang, Pin-Yao; Tao, Chia-Nan; Chien, Shiao-Chiao; Chin, Tzu-Chuan; Chu, Po-Wei; Zimmerli, Laurent] Natl Taiwan Univ, Dept Life Sci, Taipei 106, Taiwan.
   [Chen, Ching-Wei; Panzeri, Dario; Yeh, Yu-Hung; Huang, Pin-Yao; Tao, Chia-Nan; Chien, Shiao-Chiao; Chin, Tzu-Chuan; Chu, Po-Wei; Zimmerli, Laurent] Natl Taiwan Univ, Inst Plant Biol, Taipei 106, Taiwan.
   [Kadota, Yasuhiro; Roux, Milena; Zipfel, Cyril] Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.
RP Zimmerli, L (reprint author), Natl Taiwan Univ, Dept Life Sci, Taipei 106, Taiwan.
EM lauzim2@ntu.edu.tw
RI ZIPFEL, CYRIL/D-7103-2011; Kadota, Yasuhiro/A-9406-2011
OI ZIPFEL, CYRIL/0000-0003-4935-8583; Kadota, Yasuhiro/0000-0002-4782-1418
FU National Science Council of Taiwan [99-2628-B-002-053-MY3,
   102-2628-B-002-011-MY3]; National Taiwan University [99R70436]; European
   Research Council; Gatsby Charitable Foundation; KAKENHI [23580068];
   Excellent Young Researcher Overseas Visit Program; Uehara Memorial
   Foundation
FX We thank the ABRC for providing seeds and constructs. We thank B.N.
   Kunkel, J. Glazebrook, and C.Y. Chen for the pathogens. We also thank P.
   He for providing the BIK1 construct and bik1 mutant seeds, D. Chinchilla
   for FLS2 antibody, and Y.R. Chen for AtPep1. We appreciate the help from
   the staff of Technology Commons, College of Life Science, National
   Taiwan University, in microscopy and for qRT-PCR equipment. We thank the
   Proteomics Core Laboratory sponsored by the Institute of Plant and
   Microbial Biology and the Agricultural Biotechnology Research Center,
   Academia Sinica, for mass spectrometric protein identifications and
   analyses. We also thank A. Jones and J. Sklenar from TSL Proteomics for
   their excellent service. We thank Y.S. Cheng and I.F. Chang for their
   technical support in protein expression and analyses and B. Schulze, M.
   Desclos-Theveniau, and members of L.Z.'s laboratory for critical
   comments. This work was supported by the National Science Council of
   Taiwan (Grants 99-2628-B-002-053-MY3 and 102-2628-B-002-011-MY3 to
   L.Z.), the National Taiwan University (Frontier and Innovative Research
   Grant 99R70436 to L.Z.), and the European Research Council and the
   Gatsby Charitable Foundation (to C.Z.). Y.K. was supported by
   fellowships from KAKENHI (Grant 23580068), the Excellent Young
   Researcher Overseas Visit Program, and the Uehara Memorial Foundation.
   M.R. was part of the John Innes Centre/Sainsbury Laboratory rotation
   program.
CR Beckers GJM, 2009, PLANT CELL, V21, P944, DOI 10.1105/tpc.108.062158
   Boller T, 2009, ANNU REV PLANT BIOL, V60, P379, DOI 10.1146/annurev.arplant.57.032905.105346
   Boudsocq M, 2010, NATURE, V464, P418, DOI 10.1038/nature08794
   Brooks DM, 2004, MOL PLANT MICROBE IN, V17, P162, DOI 10.1094/MPMI.2004.17.2.162
   Bucherl CA, 2013, PLANT PHYSIOL, V162, P1911, DOI 10.1104/pp.113.220152
   Chen PW, 2013, MOL PLANT PATHOL, V14, P58, DOI 10.1111/j.1364-3703.2012.00827.x
   Chinchilla D, 2007, NATURE, V448, P497, DOI 10.1038/nature05999
   Cohen YR, 2002, PLANT DIS, V86, P448, DOI 10.1094/PDIS.2002.86.5.448
   Conrath U, 2006, MOL PLANT MICROBE IN, V19, P1062, DOI 10.1094/MPMI-19-1062
   Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116
   Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718
   Desclos-Theveniau M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002513
   Deslandes L, 2012, TRENDS PLANT SCI, V17, P644, DOI 10.1016/j.tplants.2012.06.011
   Durrant WE, 2004, ANNU REV PHYTOPATHOL, V42, P185, DOI 10.1146/annurev.phyto.42.040803.140421
   Feng F, 2012, CURR OPIN PLANT BIOL, V15, P469, DOI 10.1016/j.pbi.2012.03.004
   Feng F, 2012, NATURE, V485, P114, DOI 10.1038/nature10962
   Gassmann W, 2012, MOL PLANT MICROBE IN, V25, P862, DOI [10.1094/MPMI-01-12-0024-1A, 10.1094/MPMI-01-12-0024-IA]
   Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X
   Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8
   Gou XP, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-19
   Haweker H, 2010, J BIOL CHEM, V285, P4629, DOI 10.1074/jbc.M109.063073
   Halter T, 2014, CURR BIOL, V24, P134, DOI 10.1016/j.cub.2013.11.047
   He Ping, 2007, Methods Mol Biol, V354, P1
   Heese A, 2007, P NATL ACAD SCI USA, V104, P12217, DOI 10.1073/pnas.0705306104
   Hodge S, 2005, B ENTOMOL RES, V95, P449, DOI 10.1079/BER2005375
   Hok S, 2011, PLANT CELL ENVIRON, V34, P1944, DOI 10.1111/j.1365-3040.2011.02390.x
   Huang TY, 2013, PLANT BIOLOGY, V15, P832, DOI 10.1111/j.1438-8677.2012.00685.x
   Huffaker A, 2006, P NATL ACAD SCI USA, V103, P10098, DOI 10.1073/pnas.0603727103
   Jakab G, 2005, PLANT PHYSIOL, V139, P267, DOI 10.1104/pp.105.065698
   Jakab G, 2001, EUR J PLANT PATHOL, V107, P29, DOI 10.1023/A:1008730721037
   Jaskiewicz M, 2011, EMBO REP, V12, P50, DOI 10.1038/embor.2010.186
   Kadota Y, 2014, MOL CELL, V54, P43, DOI 10.1016/j.molcel.2014.02.021
   Kemmerling B, 2011, FRONT PLANT SCI, V2, DOI 10.3389/fpls.2011.00088
   Korasick DA, 2010, J BIOL CHEM, V285, P23340, DOI 10.1074/jbc.M109.090787
   Krol E, 2010, J BIOL CHEM, V285, P13471, DOI 10.1074/jbc.M109.097394
   Li L, 2014, CELL HOST MICROBE, V15, P329, DOI 10.1016/j.chom.2014.02.009
   Liebrand TWH, 2014, TRENDS PLANT SCI, V19, P123, DOI 10.1016/j.tplants.2013.10.003
   Liu TT, 2012, SCIENCE, V336, P1160, DOI 10.1126/science.1218867
   Lu DP, 2011, SCIENCE, V332, P1439, DOI 10.1126/science.1204903
   Lu DP, 2010, PLANT SIGNAL BEHAV, V5, P598, DOI 10.4161/psb.11500
   Lu DP, 2010, P NATL ACAD SCI USA, V107, P496, DOI 10.1073/pnas.0909705107
   Lu Q, 2010, PLANT J, V61, P259, DOI 10.1111/j.1365-313X.2009.04048.x
   Luna E, 2012, PLANT PHYSIOL, V158, P844, DOI 10.1104/pp.111.187468
   Maekawa T, 2011, NAT IMMUNOL, V12, P818, DOI 10.1038/ni.2083
   Melotto M, 2006, CELL, V126, P969, DOI 10.1016/j.cell.2006.06.054
   Miya A, 2007, P NATL ACAD SCI USA, V104, P19613, DOI 10.1073/pnas.0705147104
   Monaghan J, 2012, CURR OPIN PLANT BIOL, V15, P349, DOI 10.1016/j.pbi.2012.05.006
   Navarova H, 2012, PLANT CELL, V24, P5123, DOI 10.1105/tpc.112.103564
   Nelson BK, 2007, PLANT J, V51, P1126, DOI 10.1111/j.1365-313X.2007.03212.x
   Nicaise V, 2009, PLANT PHYSIOL, V150, P1638, DOI 10.1104/pp.109.139709
   Ntoukakis V, 2011, PLANT CELL, V23, P3871, DOI 10.1105/tpc.111.090779
   Ntoukakis V, 2009, SCIENCE, V324, P784, DOI 10.1126/science.1169430
   Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521
   Oka Y, 1999, PHYTOPATHOLOGY, V89, P1138, DOI 10.1094/PHYTO.1999.89.12.1138
   Postel S, 2010, EUR J CELL BIOL, V89, P169, DOI 10.1016/j.ejcb.2009.11.001
   Ranf S, 2011, PLANT J, V68, P100, DOI 10.1111/j.1365-313X.2011.04671.x
   Rasmann S, 2012, PLANT PHYSIOL, V158, P854, DOI 10.1104/pp.111.187831
   Robatzek S, 2006, GENE DEV, V20, P537, DOI 10.1101/gad.366506
   Roux M, 2011, PLANT CELL, V23, P2440, DOI 10.1105/tpc.111.084301
   Ryan CA, 2007, CELL MICROBIOL, V9, P1902, DOI 10.1111/j.1462-5822.2007.00991.x
   Schulze B, 2010, J BIOL CHEM, V285, P9444, DOI 10.1074/jbc.M109.096842
   Schwessinger B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002046
   Segonzac C, 2011, PLANT PHYSIOL, V156, P687, DOI 10.1104/pp.110.171249
   Shan LB, 2008, CELL HOST MICROBE, V4, P17, DOI 10.1016/j.chom.2008.05.017
   Shi H, 2013, PLANT CELL, V25, P1143, DOI 10.1105/tpc.112.107904
   Shimada TL, 2010, PLANT J, V61, P519, DOI 10.1111/j.1365-313X.2009.04060.x
   Singh P., 2013, PLANT SIGNAL BEHAV, V8, DOI 10.4161/psb.22611
   Singh P, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00124
   Singh P, 2012, PLANT CELL, V24, P1256, DOI 10.1105/tpc.112.095778
   Slaughter A, 2012, PLANT PHYSIOL, V158, P835, DOI 10.1104/pp.111.191593
   Sun WX, 2012, PLANT CELL, V24, P1096, DOI 10.1105/tpc.112.095919
   Sun YD, 2013, SCIENCE, V342, P624, DOI 10.1126/science.1243825
   Tena G, 2011, CURR OPIN PLANT BIOL, V14, P519, DOI 10.1016/j.pbi.2011.05.006
   Ton J, 2004, PLANT J, V38, P119, DOI 10.1111/j.1365-313X.2004.02028.x
   Tsai CH, 2011, PLANT J, V65, P469, DOI 10.1111/j.1365-313X.2010.04436.x
   Tsuda K, 2010, CURR OPIN PLANT BIOL, V13, P459, DOI 10.1016/j.pbi.2010.04.006
   Van Wees SCM, 2008, CURR OPIN PLANT BIOL, V11, P443, DOI 10.1016/j.pbi.2008.05.005
   Veronese P, 2006, PLANT CELL, V18, P257, DOI 10.1105/tpc.105.035576
   Walter M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x
   Wan JR, 2008, PLANT CELL, V20, P471, DOI 10.1105/tpc.107.056754
   Wan JR, 2012, PLANT PHYSIOL, V160, P396, DOI 10.1104/pp.112.201699
   Wu CC, 2010, J EXP BOT, V61, P995, DOI 10.1093/jxb/erp363
   Xiao FM, 2007, PLANT J, V52, P595, DOI 10.1111/j.1365-313X.2007.03259.x
   Xu J, 2014, PLANT J, V77, P222, DOI 10.1111/tpj.12382
   Xu P, 2014, MOL PLANT, V7, P441, DOI 10.1093/mp/sst105
   Yamaguchi Y, 2006, P NATL ACAD SCI USA, V103, P10104, DOI 10.1073/pnas.0603729103
   Yamaguchi Y, 2010, PLANT CELL, V22, P508, DOI 10.1105/tpc.109.068874
   Yoo SD, 2007, NAT PROTOC, V2, P1565, DOI 10.1038/nprot.2007.199
   Zeng WQ, 2010, CURR OPIN BIOTECH, V21, P599, DOI 10.1016/j.copbio.2010.05.006
   Zhang J, 2010, MOL PLANT, V3, P783, DOI 10.1093/mp/ssq035
   Zhang J, 2010, CELL HOST MICROBE, V7, P290, DOI 10.1016/j.chom.2010.03.007
   Zimmerli L, 2000, P NATL ACAD SCI USA, V97, P12920, DOI 10.1073/pnas.230416897
   Zimmerli L, 2001, PLANT PHYSIOL, V126, P517, DOI 10.1104/pp.126.2.517
   Zimmerli L, 2008, PLANT J, V53, P144, DOI 10.1111/j.1365-313X.2007.03343.x
   Zipfel C, 2006, CELL, V125, P749, DOI 10.1016/j.cell.2006.03.037
   Zipfel C, 2010, PLANT PHYSIOL, V154, P551, DOI 10.1104/pp.110.161547
NR 96
TC 11
Z9 11
U1 3
U2 65
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 1040-4651
EI 1532-298X
J9 PLANT CELL
JI Plant Cell
PD JUL
PY 2014
VL 26
IS 7
BP 3201
EP 3219
DI 10.1105/tpc.114.125682
PG 19
WC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
SC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
GA AP4VE
UT WOS:000342076200036
PM 25070640
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Bassiri-Jahromi, S
AF Bassiri-Jahromi, Shahindokht
TI RETRACTED: Cutaneous Paecilomyces lilacinus infections in
   immunocompromised and immunocompetent patients (Retracted article. See
   vol. 80, pg. 592, 2014)
SO INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
LA English
DT Article; Retracted Publication
DE Cutaneous infection; fungal infection; ketoconazole; Paecilomyces
   infection; treatment
ID TRANSPLANT PATIENT; MANIFESTATIONS; CELLULITIS
AB Paecilomyces is a genus of saprophytic fungus that has been associated, in rare instances, with human disease. We report two cases in which Paecilomyces lilacinus was isolated from cutaneous and subcutaneous lesions in an immunocompromised and an immunocompetent host. The first case was a subcutaneous infection due to P. lilacinus in a patient with a renal transplant and diabetes mellitus. The second case was an immunocompetent young woman who developed a cutaneous infection, with no identified predisposing factors. A biopsy from each patient provided an initial diagnosis of fungal elements in the tissues under examination and multiple positive fungal cultures were obtained from the tissue biopsy samples. Both microscopic and macroscopic examinations of the biopsy revealed the presence of P. lilacinus. Each of the two cases was successfully treated with oral ketoconazole (200 mg/day) and itraconazole. We also review previously reported cases in which the clinical history and response to therapy were noted.
C1 Pasteur Inst Iran, Dept Med Mycol, Tehran, Iran.
RP Bassiri-Jahromi, S (reprint author), Pasteur Inst Iran, Dept Med Mycol, Pasteur St 69, Tehran, Iran.
EM basiri@pasteur.ac.ir
RI bassri-Jahromi, Shahindokht/J-9500-2017
OI bassri-Jahromi, Shahindokht/0000-0003-0495-7902
FU Pasteur Institute of Iran
FX Source of Support: Pasteur Institute of Iran.
CR ALLEVATO PA, 1984, AM J CLIN PATHOL, V82, P247, DOI 10.1093/ajcp/82.2.247
   Carey J, 2003, EMERG INFECT DIS, V9, P1155
   Ezzedine K, 2012, ACTA DERM-VENEREOL, V92, P156, DOI 10.2340/00015555-1179
   Gucalp R, 1996, CLIN INFECT DIS, V23, P391, DOI 10.1093/clinids/23.2.391
   Hall VC, 2004, INT J DERMATOL, V43, P648, DOI 10.1111/j.1365-4632.2004.02175.x
   HARRIS LF, 1979, SOUTHERN MED J, V72, P897, DOI 10.1097/00007611-197907000-00046
   Huang CY, 2011, MYCOPATHOLOGIA, V172, P141, DOI 10.1007/s11046-011-9409-7
   Itin PH, 1998, J AM ACAD DERMATOL, V39, P401, DOI 10.1016/S0190-9622(98)70315-9
   Naldi L, 2000, BRIT J DERMATOL, V143, P647, DOI 10.1111/j.1365-2133.2000.03729.x
   Pastor FJ, 2006, CLIN MICROBIOL INFEC, V12, P948, DOI 10.1111/j.1469-0691.2006.01481.x
   Saberhagen C, 1997, CLIN INFECT DIS, V25, P1411, DOI 10.1086/516136
NR 11
TC 2
Z9 2
U1 1
U2 8
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0378-6323
EI 0973-3922
J9 INDIAN J DERMATOL VE
JI Indian J. Dermatol. Venereol. Leprol.
PD JUL-AUG
PY 2014
VL 80
IS 4
BP 331
EP 334
DI 10.4103/0378-6323.136903
PG 4
WC Dermatology
SC Dermatology
GA AN4VZ
UT WOS:000340588200012
PM 25035359
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Haghayeghi, R
   Kapranos, P
AF Haghayeghi, R.
   Kapranos, P.
TI RETRACTED: Comparison on grain refinement efficiency of peritectic and
   eutectic alloying elements on pure aluminium (Retracted article. See
   vol. 22, pg. 346, 2016)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE liquid; solidification; nucleation; grain refinement; microstructure
ID NUCLEANT PARTICLES; MODEL; MECHANISM; POTENCY; SIZE
AB The work investigated the grain refining efficiency of peritectic forming solutes as well as eutectic solutes on pure Al. Significant grain refinement for peritectic and small refinement for the eutectic elements were achieved and the mechanisms of refinement were studied. In order to investigate the grain structure and solidification phenomena for each set of alloys, a TP-1 test, as well as thermal analysis, was performed and back scattered images were used to analyze the phases that may contribute to the grain refinement. It appears that the significant grain refinement of peritectic elements is due to the formation of in-situ properitectic particles and their appropriate constitutional undercooling. The results suggest that the availability of potent nuclei and exogenous particles play major roles in the grain refinement efficiency. However, in the case of eutectic elements only segregation power contributes to refinement whilst the availability of potent nuclei is of paramount importance.
C1 [Haghayeghi, R.] Islamic Azad Univ, Tehran Sci & Res Branch, Dept Mat Engn, Tehran, Iran.
   [Kapranos, P.] Univ Sheffield, Dept Mat Sci & Engn, Sheffield S1 3JD, S Yorkshire, England.
RP Haghayeghi, R (reprint author), Islamic Azad Univ, Tehran Sci & Res Branch, Dept Mat Engn, Tehran, Iran.
EM Reza.Haghayeghi@brunel.ac.uk
CR BANERJI A, 1986, METALL TRANS A, V17, P2127, DOI 10.1007/BF02645911
   Cantor B, 1997, CURR OPIN SOLID ST M, V2, P318, DOI 10.1016/S1359-0286(97)80122-2
   CIBULA A, 1951, J I MET, V80, P1
   Easton M, 1999, METALL MATER TRANS A, V30, P1625, DOI 10.1007/s11661-999-0099-4
   Easton M, 2005, METALL MATER TRANS A, V36A, P1911, DOI 10.1007/s11661-005-0054-y
   Easton MA, 2001, ACTA MATER, V49, P1867, DOI 10.1016/S1359-6454(00)00368-2
   Fu HM, 2008, J ALLOY COMPD, V456, P390, DOI 10.1016/j.jallcom.2007.02.076
   Fu HM, 2009, J ALLOY COMPD, V478, P809, DOI 10.1016/j.jallcom.2008.12.029
   Greer AL, 2003, ADV ENG MATER, V5, P81, DOI 10.1002/adem.200390013
   MCCARTNEY DG, 1989, INT MATER REV, V34, P247, DOI 10.1179/imr.1989.34.1.247
   Mohanty P, 1996, ACTA MATER, V44, P3749, DOI 10.1016/1359-6454(96)00021-3
   Murty BS, 2002, INT MATER REV, V47, P3, DOI 10.1179/095066001225001049
   Quested TE, 2006, MATER SCI TECH-LOND, V22, P1126, DOI 10.1179/174328406X114234
   Quested TE, 2004, ACTA MATER, V52, P3859, DOI 10.1016/j.actamat.2004.04.035
   St John D. H., 2011, ACTA MAT, V59, P4907
   The Aluminum. Association Inc, 1990, STAND TEST PROC AL A
   Toropova L.S., 1998, ADV ALUMINIUM ALLOYS
   Zhang MX, 2005, ACTA MATER, V53, P1427, DOI 10.1016/j.actamat.2004.11.037
NR 18
TC 3
Z9 4
U1 4
U2 19
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD JUL
PY 2014
VL 20
IS 4
BP 713
EP 717
DI 10.1007/s12540-014-4016-z
PG 5
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA AM6FB
UT WOS:000339957700017
DA 2018-12-27
ER

PT J
AU Pei, J
   Lou, YQ
   Zhong, RB
   Han, BH
AF Pei, Jun
   Lou, Yuqing
   Zhong, Runbo
   Han, Baohui
TI RETRACTED: MMP9 activation triggered by epidermal growth factor induced
   FoxO1 nuclear exclusion in non-small cell lung cancer (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Epidermal growth factor; PI3 kinase; FoxO1; Non-small cell lung cancer;
   MMP9; Cancer invasiveness; Cancer metastasis
ID NSCLC; EXPRESSION; INVASION; EGFR; INHIBITORS; LINE
AB The molecular mechanism underlying activation of matrix metallopeptidase 9 (MMP9) in non-small cell lung cancer (NSCLC) cells, which controls cancer invasiveness and metastasis, remains elusive. Here, we reported a strong correlation of epidermal growth factor receptor (EGFR) and MMP9 levels in NSCLC patients. Thus, we used a human NSCLC line, A549, to examine whether there is a causal link between EGFR and MMP9 activation. We found that EGF-induced activation of EGFR in A549 cells activated MMP9, resulting in an increase in cancer invasiveness. An EGFR inhibitor efficiently blocked this EGF-induced activation of MMP9 and, consequently, increased cancer invasiveness. Moreover, an inhibitor for phosphatidylinositol 3-kinase (PI3K)/Akt, but not an inhibitor for mitogen-activated protein kinase, or an inhibitor for Jun N-terminal kinase, significantly inhibited the epidermal growth factor (EGF)-induced activation of MMP9, suggesting that PI3K/Akt signaling cascades may be responsible for EGF-activated MMP9. We further dissected the pathway and found that nuclear exclusion of a major Akt downstream target, FoxO1, occurred by EGF-induced Akt activation, which could be inhibited by either EGFR inhibitor or by PI3K/Akt inhibitor. In a loss of function, expression of a constitutive nuclear form of FoxO1 significantly inhibited MMP9 activation induced by EGF. Taken together, these findings suggest that EGF/EGFR signaling activates downstream PI3K/Akt to induce FoxO1 nuclear exclusion, which activates MMP9 to promote NSCLC invasiveness. Thus, Akt and FoxO1, in addition to the well-known EGFR, appear to be promising therapeutic targets for preventing the metastasis of NSCLC.
C1 [Pei, Jun; Lou, Yuqing; Zhong, Runbo; Han, Baohui] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai 200030, Peoples R China.
RP Han, BH (reprint author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, 241 West Huaihai Rd, Shanghai 200030, Peoples R China.
EM hanbao_hui@163.com
FU Shanghai Chest Hospital, Shanghai Jiao Tong University, China
FX This work was supported by the internal funding of the Shanghai Chest
   Hospital, Shanghai Jiao Tong University, China.
CR Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421
   Feng XJ, 2014, TUMOR BIOL, V35, P149, DOI 10.1007/s13277-013-1018-2
   Hirsch FR, 2013, J THORAC ONCOL, V8, P373, DOI 10.1097/JTO.0b013e31827ed0ff
   Jassem J, 2013, LANCET ONCOL, V14, P916, DOI 10.1016/S1470-2045(13)70352-8
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kim S, 2009, CELL SIGNAL, V21, P892, DOI 10.1016/j.cellsig.2009.01.034
   Kobayashi K, 2013, TARGET ONCOL, V8, P27, DOI 10.1007/s11523-013-0258-9
   Mitsudomi T, 2013, NAT REV CLIN ONCOL, V10, P235, DOI 10.1038/nrclinonc.2013.22
   Pallis AG, 2013, LUNG CANCER, V80, P120, DOI 10.1016/j.lungcan.2012.12.025
   Sasaki T, 2013, BIOMED RES INT, DOI 10.1155/2013/546318
   Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635
   Schutz A, 2002, TUMOR BIOL, V23, P179, DOI 10.1159/000064034
   Stella GM, 2013, J CANCER RES CLIN, V139, P1327, DOI 10.1007/s00432-013-1444-y
   Sun GG, 2014, TUMOR BIOL, V35, P3819, DOI 10.1007/s13277-013-1504-6
   Sutnar A, 2007, TUMOR BIOL, V28, P247, DOI 10.1159/000110897
   Tang ZP, 2013, TUMOR BIOL, V34, P2835, DOI 10.1007/s13277-013-0843-7
   Yan YL, 2014, TUMOR BIOL, V35, P3047, DOI 10.1007/s13277-013-1395-6
   Zarogoulidis K, 2013, J THORAC DIS, V5, pS389, DOI 10.3978/j.issn.2072-1439.2013.07.10
NR 18
TC 54
Z9 55
U1 4
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2014
VL 35
IS 7
BP 6673
EP 6678
DI 10.1007/s13277-014-1850-z
PG 6
WC Oncology
SC Oncology
GA AM3EU
UT WOS:000339736300064
PM 24705809
DA 2018-12-27
ER

PT J
AU Xiao, WZ
   Han, DH
   Wang, F
   Wang, YQ
   Zhu, YH
   Wu, YF
   Liu, NT
   Sun, JY
AF Xiao, Wei-Zhong
   Han, Dong-Hua
   Wang, Fei
   Wang, Yong-Qian
   Zhu, You-Hou
   Wu, Yi-Fang
   Liu, Ning-Tao
   Sun, Ji-Yong
TI RETRACTED: Relationships between PTEN gene mutations and prognosis in
   glioma: a meta-analysis (Retracted article. See vol. 36, pg. 7309, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE PTEN; Gene mutations; Glioma; Meta-analysis
ID HIGH-GRADE GLIOMA; MALIGNANT GLIOMAS; TUMOR SUPPRESSION;
   PROSTATE-CANCER; UNITED-STATES; ASSOCIATION; EXPRESSION; MIGRATION;
   PATHWAYS; BREAST
AB We conducted a meta-analysis in order to investigate the relationships between PTEN gene mutations and the prognosis in glioma. The following electronic databases were searched for relevant articles without any language restrictions: Web of Science (1945 similar to 2013), the Cochrane Library Database (Issue 12, 2013), PubMed (1966 similar to 2013), EMBASE (1980 similar to 2013), CINAHL (1982 similar to 2013), and the Chinese Biomedical Database (CBM) (1982 similar to 2013). Meta-analyses were conducted using the STATA software (Version 12.0, Stata Corporation, College Station, Texas USA). Hazard ratio (HR) with its corresponding 95 % confidence interval (95%CI) was calculated. Six independent cohort studies with a total of 357 glioma patients met our inclusion criteria. Our meta-analysis results indicated that glioma patients with PTEN gene mutations exhibited a significantly shorter overall survival (OS) than those without PTEN gene mutations (HR = 3.66, 95%CI = 2.02 similar to 5.30, P < 0.001). Ethnicity-stratified subgroup analysis demonstrated that PTEN gene mutations were closely linked to poor prognosis in glioma among Americans (HR = 3.72, 95%CI = 1.72 similar to 5.73, P < 0.001), while similar correlations were not observed among populations in Sweden, Italy, and Malaysia (all P > 0.05). Our meta-analysis provides direct and strong evidences for the speculation of PTEN gene mutations' correlation with poor prognosis of glioma patients.
C1 [Xiao, Wei-Zhong] Fudan Univ, Shanghai Pudong Hosp, Dept Neurol, Shanghai 201399, Peoples R China.
   [Han, Dong-Hua] Fudan Univ, Shanghai Pudong Hosp, Dept Neurosurg, Shanghai 201399, Peoples R China.
   [Wang, Fei; Zhu, You-Hou; Wu, Yi-Fang; Liu, Ning-Tao] Tongji Univ, Tongji Hosp, Dept Neurosurg, Shanghai 200065, Peoples R China.
   [Wang, Yong-Qian] Shanghai Univ Tradit Chinese Med, Dept Neurosurg, Longhua Hosp, Shanghai 201399, Peoples R China.
   [Sun, Ji-Yong] Nanjing Med Univ, Wuxi Hosp 2, Dept Neurosurg, Wuxi 214002, Peoples R China.
RP Wang, F (reprint author), Tongji Univ, Tongji Hosp, Dept Neurosurg, Xincun Rd 389, Shanghai 200065, Peoples R China.
EM wangfeiwf305@126.com
CR Abdullah JM, 2006, ASIAN J SURG, V29, P274, DOI 10.1016/S1015-9584(09)60102-0
   Abounader R, 2009, EXPERT REV ANTICANC, V9, P235, DOI 10.1586/14737140.9.2.235
   Aguissa-Toure AH, 2012, CELL MOL LIFE SCI, V69, P1475, DOI 10.1007/s00018-011-0878-0
   Alexiou GA, 2010, NEUROL NEUROCHIR POL, V44, P80
   Baglietto L, 2011, INT J CANCER, V128, P1929, DOI 10.1002/ijc.25770
   Benson VS, 2008, BRIT J CANCER, V99, P185, DOI 10.1038/sj.bjc.6604445
   Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008
   Chen C, 2011, EUR J NEUROL, V18, P387, DOI 10.1111/j.1468-1331.2010.03187.x
   Chu EC, 2004, MED SCI MONITOR, V10, pRA235
   D'Urso OF, 2009, CANCER, V115, P3749, DOI 10.1002/cncr.24435
   Dasari VR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010350
   Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182
   Georgescu Maria-Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325
   Goodenberger ML, 2012, CANCER GENET-NY, V205, P613, DOI 10.1016/j.cancergen.2012.10.009
   Hou P, 2008, CANCER, V113, P2440, DOI 10.1002/cncr.23869
   Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409
   Idbaih A, 2011, J NEURO-ONCOL, V103, P221, DOI 10.1007/s11060-010-0380-9
   James CD, 1999, INT J ONCOL, V15, P547
   Jansen M, 2010, LANCET NEUROL, V9, P717, DOI 10.1016/S1474-4422(10)70105-8
   Kwon CH, 2008, CANCER RES, V68, P3286, DOI 10.1158/0008-54/2.CAN-07-6867
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Little MP, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1147
   Liu YH, 2010, CURR OPIN GENET DEV, V20, P239, DOI 10.1016/j.gde.2010.02.001
   Marsit CJ, 2005, HUM PATHOL, V36, P768, DOI 10.1016/j.humpath.2005.05.006
   Melin B, 2011, CURR OPIN ONCOL, V23, P643, DOI 10.1097/CCO.0b013e32834a6f61
   Ohgaki H, 2009, CANCER SCI, V100, P2235, DOI 10.1111/j.1349-7006.2009.01308.x
   Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   Sasaki H, 2001, AM J PATHOL, V159, P359, DOI 10.1016/S0002-9440(10)61702-6
   Sizoo EM, 2010, NEURO-ONCOLOGY, V12, P1162, DOI 10.1093/neuonc/nop045
   Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854
   Yang YL, 2010, ANTICANCER RES, V30, P981
   Zhou LP, 2012, BREAST CANCER RES TR, V136, P885, DOI 10.1007/s10549-012-2300-5
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 38
TC 11
Z9 12
U1 3
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2014
VL 35
IS 7
BP 6687
EP 6693
DI 10.1007/s13277-014-1885-1
PG 7
WC Oncology
SC Oncology
GA AM3EU
UT WOS:000339736300066
PM 24705863
DA 2018-12-27
ER

PT J
AU Li, CJ
   Dai, Y
   Fu, YJ
   Tian, JM
   Li, JL
   Lu, HJ
   Duan, F
   Li, QW
AF Li, Chun-Jiang
   Dai, Yue
   Fu, Yan-Jun
   Tian, Jia-Ming
   Li, Jin-Lun
   Lu, Hong-Jun
   Duan, Feng
   Li, Qing-Wang
TI RETRACTED: Correlations of IFN-gamma genetic polymorphisms with
   susceptibility to breast cancer: a meta-analysis (Retracted article. See
   vol. 36, pg. 7307, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE IFN-gamma; Genetic polymorphism; Susceptibility; Breast cancer;
   Meta-analysis
ID EPSTEIN-BARR-VIRUS; INTERFERON-GAMMA; RISK; ASSOCIATION; WOMEN;
   INTERLEUKIN-10; INFECTION; SURVIVAL; SEARCH; EBV
AB The meta-analysis was conducted to evaluate the correlations between common genetic polymorphisms in the IFN-gamma gene and susceptibility to breast cancer. The following electronic databases were searched without language restrictions: MEDLINE (1966 similar to 2013), the Cochrane Library Database (issue 12, 2013), EMBASE (1980 similar to 2013), CINAHL (1982 similar to 2013), Web of Science (1945 similar to 2013), and the Chinese Biomedical Database (CBM) (1982 similar to 2013). Meta-analysis was performed with the use of the STATA statistical software. Odds ratios (OR) with their 95 % confidence intervals (95 % CIs) were calculated. Nine clinical case-control studies met all the inclusion criteria and were included in this meta-analysis. A total of 1,182 breast cancer patients and 1,525 healthy controls were involved in this meta-analysis. Three functional polymorphisms were assessed, including rs2069705 C > T, rs2430561 T > A, and CA repeats 2/X. Our meta-analysis results indicated that IFN-gamma genetic polymorphisms might be significantly associated with an increased risk of breast cancer (allele model: OR = 1.37, 95 % CI = 1.03 similar to 1.83, P = 0.031; dominant model: OR = 1.55, 95 % CI = 1.01 similar to 2.37, P = 0.046; homozygous model: OR = 2.23, 95 % CI = 1.30 similar to 3.82, P = 0.004; respectively), especially the rs2430561 T > A polymorphism. Subgroup analysis based on ethnicity suggested that genetic polymorphisms in the IFN-gamma gene were closely correlated with increased breast cancer risk among Asians (allele model: OR = 1.21, 95 % CI = 1.02 similar to 1.58, P = 0.017; dominant model: OR = 3.44, 95 % CI = 2.07 similar to 5.71, P < 0.001; recessive model: OR = 1.58, 95 % CI = 1.06 similar to 2.37, P = 0.025; homozygous model: OR = 1.83, 95 % CI = 1.19 similar to 2.80, P = 0.006; respectively), but not among Caucasians (all P > 0.05). Our meta-analysis supported the hypothesis that IFN-gamma genetic polymorphisms may contribute to an increased risk of breast cancer, especially the rs2430561 T > A polymorphism among Asians.
C1 [Li, Chun-Jiang; Li, Qing-Wang] Yanshan Univ, Coll Environm & Chem Engn, Qinhuangdao 066004, Peoples R China.
   [Li, Chun-Jiang; Dai, Yue] Jiamusi Univ, Coll Basic Med, Jiamusi 154007, Peoples R China.
   [Fu, Yan-Jun; Tian, Jia-Ming; Lu, Hong-Jun] Jiamusi Univ, Affiliated Hosp 1, Jiamusi 154007, Peoples R China.
   [Li, Jin-Lun; Duan, Feng] Jiamusi Univ, Affiliated Hosp 2, Jiamusi 154007, Peoples R China.
   [Li, Qing-Wang] Northwest A&F Univ, Coll Anim Sci, Yangling 712100, Peoples R China.
RP Li, QW (reprint author), Yanshan Univ, Coll Environm & Chem Engn, Hebei St 438, Qinhuangdao 066004, Peoples R China.
EM liqingwang124@163.com
FU Natural Science Foundation of Heilongjiang Province [D201166]
FX This work was supported by the Natural Science Foundation of
   Heilongjiang Province (No. D201166). We would like to acknowledge the
   reviewers for their helpful comments on this paper.
CR Bouchardy C, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13879
   Brinton LA, 2010, BREAST CANCER RES TR, V119, P185, DOI 10.1007/s10549-009-0379-0
   Chou SF, 2013, ANALYST, V138, P2620, DOI 10.1039/c3an36547f
   Erdei E, 2010, CYTOKINE, V51, P18, DOI 10.1016/j.cyto.2010.03.014
   Farrell RA, 2009, NEUROLOGY, V73, P32, DOI 10.1212/WNL.0b013e3181aa29fe
   Fontein DBY, 2013, CANCER TREAT REV, V39, P958, DOI 10.1016/j.ctrv.2013.03.008
   Gonullu G, 2007, SAUDI MED J, V28, P1728
   Guo LJ, 2012, INT J MOL MED, V30, P680, DOI 10.3892/ijmm.2012.1021
   He JR, 2012, J INFECT DIS, V205, P64, DOI 10.1093/infdis/jir710
   Horras CJ, 2011, CYTOKINE GROWTH F R, V22, P35, DOI 10.1016/j.cytogfr.2011.01.001
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Joshi D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008180
   Kamali-Sarvestani E, 2005, CANCER LETT, V223, P113, DOI 10.1016/j.canlet.2004.09.025
   Karakus N, 2011, DNA CELL BIOL, V30, P371, DOI 10.1089/dna.2010.1113
   Kim K, 2010, ANN RHEUM DIS, V69, P1247, DOI 10.1136/ard.2009.117572
   La Vecchia C, 2011, ONCOLOGIST, V16, P726, DOI 10.1634/theoncologist.2011-0050
   Mi YY, 2011, MOL BIOL REP, V38, P4461, DOI 10.1007/s11033-010-0575-3
   NAYLOR SL, 1984, SOMAT CELL MOLEC GEN, V10, P531, DOI 10.1007/BF01534857
   Nickels S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003284
   Park SK, 2011, J BREAST CANCER, V14, P79, DOI 10.4048/jbc.2011.14.2.79
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Pluddemann A, 2011, IMMUNOL REV, V240, P11, DOI 10.1111/j.1600-065X.2010.00989.x
   Reiner AS, 2013, J CLIN ONCOL, V31, P433, DOI 10.1200/JCO.2012.43.2013
   Saha A, 2005, IMMUNOGENETICS, V57, P165, DOI 10.1007/s00251-005-0783-5
   Skerrett DL, 2005, CANCER INVEST, V23, P208, DOI 10.1081/CNV-200055954
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Su Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037275
   Wingate PJ, 2009, J MED VIROL, V81, P870, DOI 10.1002/jmv.21445
   Wu GH, 2008, CANC RES PREV TREAT, V35
   Wu JM, 2005, BIOL BLOOD MARROW TR, V11, P455, DOI 10.1016/j.bbmt.2005.03.008
   Xue F, 2011, ARCH INTERN MED, V171, P125, DOI 10.1001/archinternmed.2010.503
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   zur Hausen H, 2009, VIROLOGY, V392, P1, DOI 10.1016/j.virol.2009.06.001
NR 33
TC 6
Z9 6
U1 3
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2014
VL 35
IS 7
BP 6867
EP 6877
DI 10.1007/s13277-014-1856-6
PG 11
WC Oncology
SC Oncology
GA AM3EU
UT WOS:000339736300089
PM 25051917
DA 2018-12-27
ER

PT J
AU Chen, J
   Huang, Q
   Wang, F
AF Chen, Jin
   Huang, Qin
   Wang, Feng
TI RETRACTED: Inhibition of FoxO1 nuclear exclusion prevents metastasis of
   Glioblastoma (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Glioblastoma; FoxO1; PI-3 K; Akt
ID EGF RECEPTOR INHIBITORS; BREAST-CANCER; CELL INVASION; EXPRESSION;
   GROWTH; MMP-9; TUMOR; PHOSPHORYLATION; POLYMORPHISM; LINES
AB Glioblastoma is the most aggressive malignant primary brain tumor in humans, with extremely poor patient survival. Although previous studies have demonstrated that expression of matrix metalloproteinase-9 (MMP9) in glioblastoma promotes cancer metastasis, the upstream molecular signaling cascades that control activation of MMP9 remain largely unknown. Here, we used a human glioblastoma line, A-172, to examine molecular signaling to activate MMP9. We found that epidermal growth factor (EGF)-induced activation of epidermal growth factor receptor (EGFR) in A-172 cells activated MMP9, resulting in an increase in cancer invasiveness. A specific inhibitor for EGFR efficiently blocked EGF-induced activation of MMP9 and then cancer invasiveness. Moreover, an inhibitor for phosphatidylinositol 3-kinase (PI-3 K)/protein kinase B (Akt) significantly inhibited the EGF-induced activation of MMP9. Furthermore, nuclear exclusion of a major Akt downstream target, Forkhead box protein O1 (FoxO1), was induced by Akt activation, which could be inhibited by either an EGFR inhibitor or by PI-3 K/Akt inhibitor. An expression of a constitutive nuclear form of FoxO1 significantly inhibited MMP9 activation induced by EGF. Taken together, these findings suggest that EGF/EGFR signaling activates downstream PI-3 K/Akt to induce FoxO1 nuclear exclusion, which activates MMP9 to promote glioblastoma invasiveness. Thus, FoxO1 appears to be a novel therapeutic target for inhibiting metastasis of glioblastoma.
C1 [Chen, Jin; Huang, Qin; Wang, Feng] Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, Chongqing 400010, Peoples R China.
RP Wang, F (reprint author), Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, 74 Linjiang Rd, Chongqing 400010, Peoples R China.
EM feng_wang14@163.com
CR Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421
   Carpentier C, 2006, NEUROLOGY, V67, P872, DOI 10.1212/01.wnl.0000229927.12007.37
   Cornez I, 2013, J NEURO-ONCOL, V112, P49, DOI 10.1007/s11060-012-1035-9
   Del Vecchio CA, 2013, CANC RES
   Fenton TR, 2012, P NATL ACAD SCI USA, V109, P14164, DOI 10.1073/pnas.1211962109
   Gadji M, 2009, EUR J PHARMACOL, V625, P23, DOI 10.1016/j.ejphar.2009.10.010
   GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417
   Hu JJ, 2011, P NATL ACAD SCI USA, V108, P15984, DOI 10.1073/pnas.1113416108
   Kim S, 2009, CELL SIGNAL, V21, P892, DOI 10.1016/j.cellsig.2009.01.034
   Lee CC, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-85
   Liu QL, 2010, J NEURO-ONCOL, V100, P165, DOI 10.1007/s11060-010-0158-0
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Ozer BH, 2010, ONCOGENE, V29, P855, DOI 10.1038/onc.2009.385
   Papi A, 2007, ONCOL REP, V18, P1015
   Prabhu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052265
   SCHLEGEL J, 1994, INT J CANCER, V56, P72
   Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635
   Schonberg DL, 2013, NAT GENET, V45, P1105, DOI 10.1038/ng.2775
   Schutz A, 2002, TUMOR BIOL, V23, P179, DOI 10.1159/000064034
   Shir A, 2006, PLOS MED, V3, P125, DOI 10.1371/journal.pmed.0030006
   Sjostrom S, 2010, NEURO-ONCOLOGY, V12, P815, DOI 10.1093/neuonc/noq018
   Stea B, 2003, CANCER LETT, V202, P43, DOI 10.1016/j.canlet.2003.07.006
   Stish BJ, 2008, J NEURO-ONCOL, V87, P51, DOI 10.1007/s11060-007-9499-8
   Sutnar A, 2007, TUMOR BIOL, V28, P247, DOI 10.1159/000110897
   Tang ZP, 2013, TUMOR BIOL, V34, P2835, DOI 10.1007/s13277-013-0843-7
   Tian XX, 1999, BRIT J CANCER, V81, P994, DOI 10.1038/sj.bjc.6690798
   Tsatas D, 2002, J CLIN NEUROSCI, V9, P282, DOI 10.1054/jocn.2001.1063
   Vauleon E, 2007, CANCER GENET CYTOGEN, V172, P33, DOI 10.1016/j.cancergencyto.2006.07.013
   Zheng YH, 2013, J BIOL CHEM, V288, P31488, DOI 10.1074/jbc.M113.499020
NR 29
TC 27
Z9 28
U1 5
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2014
VL 35
IS 7
BP 7195
EP 7200
DI 10.1007/s13277-014-1913-1
PG 6
WC Oncology
SC Oncology
GA AM3EU
UT WOS:000339736300126
PM 24771221
DA 2018-12-27
ER

PT J
AU Shi, JF
   Yin, XH
   Xu, R
   Wang, YC
   Jin, L
   Gao, WW
AF Shi, Jingfang
   Yin, Xiaohua
   Xu, Rong
   Wang, Yingchun
   Jin, Lin
   Gao, Weiwei
TI RETRACTED: Clinical application of contrast enhanced ultrasound to
   diagnose benign prostatic hyperplasia (Retracted article. See vol. 10,
   10, 2015)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Contrast enhanced ultrasound; Benign prostatic hyperplasia; Contrast
   agents
ID TRANSRECTAL ULTRASOUND; CANCER; AGENTS; ULTRASONOGRAPHY; ANGIOGENESIS;
   CARCINOMA; NODULES
AB Background: This study aimed to investigate the clinical significance of contrast enhanced ultrasound (CEUS) in diagnosis of benign prostatic hyperplasia (BPH) through comparing CEUS parameters between BPH and normal person.
   Methods: A retrospective study of sixty BPH patients (aged 73.5 +/- 20.5 years old) and thirty normal controls without prostate diseases (aged 75.3 +/- 19.7 years old) who had accepted CEUS detection were performed. Time-intensity curves were obtained for all tests in regions of interest. Images were processed using ACQ software and the following parameters were obtained: arrival time (AT), peak intensity (P), time to peak (TP), area under the curve (AUC), mean transit time (MTT) and extinction time (ET). Differences in inner and outer gland of prostate between BPH and the normal tissue were evaluated.
   Results: There was a clear boundary between the inner and outer gland of BPH prostate. AT, TP, MTT, ET and P in BPH outer gland were significantly higher than the control group. In inner gland, MTT, ET, AUC and P were also significantly higher than the controls. The accurate rate to diagnose BPH using CEUS was 95.6%, and the sensitivity and specificity were 95.0% and 96.7%, respectively.
   Conclusions: Among these significantly changed parameters, the increases of MTT, ET and AUC in inner gland and AT, TP in outer gland were most likely related to BPH. These parameters provide an objective visual assessment to diagnosis of BPH.
C1 [Shi, Jingfang; Xu, Rong; Wang, Yingchun; Jin, Lin; Gao, Weiwei] Jiading Ctr Hosp, Dept Ultrasound, Shanghai 201800, Peoples R China.
   [Yin, Xiaohua] Jiading Ctr Hosp, Dept Radiol, Shanghai 201800, Peoples R China.
RP Shi, JF (reprint author), Jiading Ctr Hosp, Dept Ultrasound, Shanghai 201800, Peoples R China.
EM shijingfangpia@hotmail.com; yinxiaohuahappy@hotmail.com
FU Jiading district Scientific research projects of China [(2009) JKK024]
FX This work was supported by Jiading district Scientific research projects
   of China (Grant No. (2009) JKK024).
CR Bertolotto M, 2009, RADIOL MED, V114, P1106, DOI 10.1007/s11547-009-0449-8
   Bueno G, 2013, DIAGN PATHOL, V8, pS24
   Correas JM, 2001, EUR RADIOL, V11, P1316, DOI 10.1007/s003300100940
   Cosgrove D, 2006, EUR J RADIOL, V60, P324, DOI 10.1016/j.ejrad.2006.06.022
   DEERING RE, 1995, PROSTATE, V26, P111, DOI 10.1002/pros.2990260302
   Frauscher F, 2005, RADIOLOGE, V45, P544, DOI 10.1007/s00117-005-1193-2
   Gerst S, 2011, AM J ROENTGENOL, V197, P897, DOI 10.2214/AJR.10.6330
   Halpern Ethan J, 2006, Rev Urol, V8 Suppl 1, pS29
   Ismail M, 2001, Curr Opin Urol, V11, P471, DOI 10.1097/00042307-200109000-00004
   Jiang J, 2012, BRIT J RADIOL, V85, pE979, DOI 10.1259/bjr/63794331
   Kitano M, 2004, GUT, V53, P854, DOI 10.1136/gut.2003.029934
   Lee CH, 2011, ENDOCRIN METAB CLIN, V40, P565, DOI 10.1016/j.ecl.2011.05.012
   Leen E, 2002, EUR J RADIOL, V41, P200, DOI 10.1016/S0720-048X(01)00457-0
   Ma F, 2012, NEPHROL DIAL TRANSPL, V27, P2891, DOI 10.1093/ndt/gfr789
   MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001
   Ren J, 2008, CLIN RADIOL, V63, P153, DOI 10.1016/j.crad.2007.07.023
   Salvatore V, 2012, CURR PHARM DESIGN, V18, P2236, DOI 10.2174/138161212800099892
   Strohmeyer D, 2000, PROSTATE, V45, P216, DOI 10.1002/1097-0045(20001101)45:3<216::AID-PROS3>3.0.CO;2-C
   Sugimoto K, 2012, EUR RADIOL, V22, P1205, DOI 10.1007/s00330-011-2372-3
   Tang J, 2008, CLIN RADIOL, V63, P1086, DOI 10.1016/j.crad.2007.11.026
   Tang Jie, 2007, Zhonghua Nan Ke Xue, V13, P584
   Tian YT, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-42
   Wei JT, 2004, UROLOGIC DIS AM, P43
   Weingartner K, 1998, J UROLOGY, V159, P465, DOI 10.1016/S0022-5347(01)63949-1
   Yang JC, 2008, ULTRASOUND MED BIOL, V34, P1758, DOI 10.1016/j.ultrasmedbio.2008.04.009
NR 25
TC 1
Z9 1
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUL 1
PY 2014
VL 9
AR 133
DI 10.1186/1746-1596-9-133
PG 5
WC Pathology
SC Pathology
GA AL5UL
UT WOS:000339198700001
PM 24986664
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Petkovic, D
   Shamshirband, S
   Anuar, NB
   Nasir, MHNM
   Pavlovic, NT
   Akib, S
AF Petkovic, Dalibor
   Shamshirband, Shahaboddin
   Anuar, Nor Badrul
   Nasir, Mohd Hairul Nizam Md
   Pavlovic, Nenad T.
   Akib, Shatirah
TI RETRACTED: Adaptive neuro-fuzzy prediction of modulation transfer
   function of optical lens system (Retracted article. See vol.87, pg.153,
   2017)
SO INFRARED PHYSICS & TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Modulation transfer function; Spatial frequency; Optical system;
   Neuro-fuzzy; ANFIS
ID FOCAL-PLANE ARRAYS; INFERENCE SYSTEM; HUMAN EYE; ANFIS; CONTROLLER;
   ALLOY; MTF
AB The quantitative assessment of image quality is an important consideration in any type of imaging system. The modulation transfer function (MTF) is a graphical description of the sharpness and contrast of an imaging system or of its individual components. The MTF is also known and spatial frequency response. The MTF curve has different meanings according to the corresponding frequency. The MTF of an optical system specifies the contrast transmitted by the system as a function of image size, and is determined by the inherent optical properties of the system. In this study, the adaptive neuro-fuzzy (ANFIS) estimator is designed and adapted to predict MTF value of the actual optical system. Neural network in ANFIS adjusts parameters of membership function in the fuzzy logic of the fuzzy inference system. The back propagation learning algorithm is used for training this network. This intelligent estimator is implemented using MATLAB/Simulink and the performances are investigated. The simulation results presented in this paper show the effectiveness of the developed method. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Petkovic, Dalibor; Pavlovic, Nenad T.] Univ Nis, Fac Mech Engn, Dept Mech & Control, Nish 18000, Serbia.
   [Shamshirband, Shahaboddin] Islamic Azad Univ, Dept Comp Sci, Chalous Branch, Chalous 46615397, Mazandaran, Iran.
   [Anuar, Nor Badrul; Nasir, Mohd Hairul Nizam Md] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Software Engn, Kuala Lumpur 50603, Malaysia.
   [Akib, Shatirah] Univ Malaya, Dept Civil Engn, Fac Engn, Kuala Lumpur 50603, Malaysia.
RP Petkovic, D (reprint author), Univ Nis, Fac Mech Engn, Dept Mech & Control, Aleksandra Medvedeva 14, Nish 18000, Serbia.
EM dalibortc@gmail.com
RI Shamshirband, Shahaboddin/K-2544-2013
OI Shamshirband, Shahaboddin/0000-0002-6605-498X; Md Nasir, Mohd Hairul
   Nizam/0000-0002-9598-430X; Anuar, Nor Badrul/0000-0003-4380-5303; Akib,
   Shatirah/0000-0002-6538-0716
FU Ministry of Education, Science and Technological Development, Republic
   of Serbia [TP35005]; University of Malaya, Malaysia [RG108-12ICT]
FX This paper is supported by Project Grant TP35005 "Research and
   development of new generation wind turbines of high-energy efficiency"
   (2011-2014) financed by Ministry of Education, Science and Technological
   Development, Republic of Serbia. This work is also funded by the
   University of Malaya, Malaysia, under Grant RG108-12ICT.
CR Akcayol MA, 2004, ADV ENG SOFTW, V35, P129, DOI 10.1016/j.advengsoft.2004.03.005
   Al-Ghandoor A, 2009, JORDAN J MECH IND EN, V3, P69
   Banu W., 2011, INT J MODELING OPTIM, V1, P24, DOI DOI 10.7763/IJM0.2011.V1.5
   Boothroyd CB, 2013, ULTRAMICROSCOPY, V129, P18, DOI 10.1016/j.ultramic.2013.03.001
   BURALLI DA, 1992, APPL OPTICS, V31, P4389, DOI 10.1364/AO.31.004389
   de la Barriere F, 2010, APPL OPTICS, V49, P2879, DOI 10.1364/AO.49.002879
   Ekici BB, 2011, EXPERT SYST APPL, V38, P5352, DOI 10.1016/j.eswa.2010.10.021
   Farman TT, 2005, ORAL SURG ORAL MED O, V99, P608, DOI 10.1016/j.tripleo.2004.08.013
   Grigorie TL, 2009, P I MECH ENG G-J AER, V223, P655, DOI 10.1243/09544100JAERO522
   Gul N, 2010, TURK J ELECTR ENG CO, V18, P71, DOI 10.3906/elk-0811-9
   Gunapala SD, 2013, INFRARED PHYS TECHN, V59, P64, DOI 10.1016/j.infrared.2012.12.016
   Han YF, 2011, COMP MATER SCI, V50, P2273, DOI 10.1016/j.commatsci.2011.03.004
   Hong SM, 2009, J KOREAN PHYS SOC, V54, P607, DOI 10.3938/jkps.54.607
   Hsieh ML, 1999, OPT COMMUN, V170, P221, DOI 10.1016/S0030-4018(99)00499-X
   Inal M, 2008, J MATER PROCESS TECH, V195, P34, DOI 10.1016/j.jmatprotec.2007.04.106
   JANG JSR, 1993, IEEE T SYST MAN CYB, V23, P665, DOI 10.1109/21.256541
   Karaagac B, 2012, MATER DESIGN, V35, P833, DOI 10.1016/j.matdes.2011.03.062
   Khajeh A, 2009, EXPERT SYST APPL, V36, P5728, DOI 10.1016/j.eswa.2008.06.051
   Khalifehzadeh R, 2007, COMP MATER SCI, V40, P359, DOI 10.1016/j.commatsci.2007.01.007
   Kim Q, 2000, P SOC PHOTO-OPT INS, V3950, P49, DOI 10.1117/12.382175
   Kurnaz S, 2010, EXPERT SYST APPL, V37, P1229, DOI 10.1016/j.eswa.2009.06.009
   Li HS, 2008, OPT LASER TECHNOL, V40, P415, DOI 10.1016/j.optlastec.2007.07.004
   Lo SP, 2005, J MATER PROCESS TECH, V168, P250, DOI 10.1016/j.jmatprotec.2005.01.010
   Madanipour K, 2007, OPT LASER ENG, V45, P64, DOI 10.1016/j.optlaseng.2006.06.004
   McLeod RA, 2013, ULTRAMICROSCOPY, V129, P42, DOI 10.1016/j.ultramic.2013.02.021
   NAVARRO R, 1993, J OPT SOC AM A, V10, P201, DOI 10.1364/JOSAA.10.000201
   Petkovic D, 2012, NEURAL COMPUT APPL, V21, P2065, DOI 10.1007/s00521-011-0629-z
   Petkovic D, 2012, EXPERT SYST APPL, V39, P13295, DOI 10.1016/j.eswa.2012.05.072
   Petkovic D, 2012, EXPERT SYST APPL, V39, P9477, DOI 10.1016/j.eswa.2012.02.111
   ROVAMO J, 1994, VISION RES, V34, P2493, DOI 10.1016/0042-6989(94)90234-8
   ROVAMO J, 1995, VISION RES, V35, P767, DOI 10.1016/0042-6989(94)00171-H
   Singh M.K., 2010, PROGR ELECTROMAGN B, V23, P71
   Singh R, 2012, APPL SOFT COMPUT, V12, P40, DOI 10.1016/j.asoc.2011.09.010
   Sturzu A., 2011, B TRANSILVANIA U B 1, V4, P33
   Supin AY, 1995, HEARING RES, V92, P38, DOI 10.1016/0378-5955(95)00194-8
   Tian LF, 2005, MECHATRONICS, V15, P1305, DOI 10.1016/j.mechatronics.2005.02.001
   Vairappan C, 2009, NEUROCOMPUTING, V72, P1870, DOI 10.1016/j.neucom.2008.05.010
   ZANEVELD JR, 1969, J OPT SOC AM, V59, P378, DOI 10.1364/JOSA.59.000378
   Zhang Z, 2003, COMPOS SCI TECHNOL, V63, P2029, DOI 10.1016/S0266-3538(03)00106-4
NR 39
TC 10
Z9 10
U1 2
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1350-4495
EI 1879-0275
J9 INFRARED PHYS TECHN
JI Infrared Phys. Technol.
PD JUL
PY 2014
VL 65
BP 54
EP 60
DI 10.1016/j.infrared.2014.03.011
PG 7
WC Instruments & Instrumentation; Optics; Physics, Applied
SC Instruments & Instrumentation; Optics; Physics
GA AK7MQ
UT WOS:000338612800010
DA 2018-12-27
ER

PT J
AU Petkovic, D
   Shamshirband, S
   Saboohi, H
   Ang, TF
   Anuar, NB
   Rahman, ZA
   Pavlovic, NT
AF Petkovic, Dalibor
   Shamshirband, Shahaboddin
   Saboohi, Hadi
   Ang, Tan Fong
   Anuar, Nor Badrul
   Rahman, Zulkanain Abdul
   Pavlovic, Nenad T.
TI RETRACTED: Evaluation of modulation transfer function of optical lens
   system by support vector regression methodologies - A comparative study
   (Retracted article. See vol. 88, pg. 265, 2018)
SO INFRARED PHYSICS & TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Modulation transfer function; Optical system; Image quality; Support
   vector regression; Soft computing
ID TIME-SERIES PREDICTION; WIND TURBINE; HUMAN EYE; FUZZY; MTF
AB The quantitative assessment of image quality is an important consideration in any type of imaging system. The modulation transfer function (MTF) is a graphical description of the sharpness and contrast of an imaging system or of its individual components. The MTF is also known and spatial frequency response. The MTF curve has different meanings according to the corresponding frequency. The MTF of an optical system specifies the contrast transmitted by the system as a function of image size, and is determined by the inherent optical properties of the system. In this study, the polynomial and radial basis function (RBF) are applied as the kernel function of Support Vector Regression (SVR) to estimate and predict estimate MTF value of the actual optical system according to experimental tests. Instead of minimizing the observed training error, SVR_poly and SVR_rbf attempt to minimize the generalization error bound so as to achieve generalized performance. The experimental results show that an improvement in predictive accuracy and capability of generalization can be achieved by the SVR_rbf approach in compare to SVR_poly soft computing methodology. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Petkovic, Dalibor; Pavlovic, Nenad T.] Univ Nis, Fac Mech Engn, Deparment Mech & Control, Nish 18000, Serbia.
   [Shamshirband, Shahaboddin] Islamic Azad Univ, Dept Comp Sci, Chalous Branch, Mazandaran, Iran.
   [Saboohi, Hadi] Univ Malaya, Dept Informat Syst, Fac Comp Sci & Informat, Kuala Lumpur 50603, Malaysia.
   [Ang, Tan Fong; Anuar, Nor Badrul] Univ Malaya, Dept Comp Syst & Technol, Fac Comp Sci & Informat, Kuala Lumpur 50603, Malaysia.
   [Rahman, Zulkanain Abdul] Univ Malaya, Dept Hist, Fac Arts & Social Sci Bldg, Kuala Lumpur 50603, Malaysia.
RP Petkovic, D (reprint author), Univ Nis, Fac Mech Engn, Deparment Mech & Control, Aleksandra Medvedeva 14, Nish 18000, Serbia.
EM dalibortc@gmail.com
RI Shamshirband, Shahaboddin/K-2544-2013
OI Shamshirband, Shahaboddin/0000-0002-6605-498X; Anuar, Nor
   Badrul/0000-0003-4380-5303
FU University of Malaya, Malaysia [CG043-2013]
FX This work is funded by the University of Malaya, Malaysia, under grant
   CG043-2013.
CR Balahur A, 2014, COMPUT SPEECH LANG, V28, P56, DOI 10.1016/j.csl.2013.03.004
   Boothroyd CB, 2013, ULTRAMICROSCOPY, V129, P18, DOI 10.1016/j.ultramic.2013.03.001
   BURALLI DA, 1992, APPL OPTICS, V31, P4389, DOI 10.1364/AO.31.004389
   Chakraborty S, 2011, STAT METHODOL, V8, P68, DOI 10.1016/j.stamet.2009.09.002
   de la Barriere F, 2010, APPL OPTICS, V49, P2879, DOI 10.1364/AO.49.002879
   Farman TT, 2005, ORAL SURG ORAL MED O, V99, P608, DOI 10.1016/j.tripleo.2004.08.013
   Gul N, 2010, TURK J ELECTR ENG CO, V18, P71, DOI 10.3906/elk-0811-9
   Hong SM, 2009, J KOREAN PHYS SOC, V54, P607, DOI 10.3938/jkps.54.607
   Hsieh ML, 1999, OPT COMMUN, V170, P221, DOI 10.1016/S0030-4018(99)00499-X
   Jain P, 2009, COMPUT BIOL CHEM, V33, P216, DOI 10.1016/j.compbiolchem.2009.04.004
   Kim Q, 2000, P SOC PHOTO-OPT INS, V3950, P49, DOI 10.1117/12.382175
   Leng Y, 2013, KNOWL-BASED SYST, V44, P121, DOI 10.1016/j.knosys.2013.01.032
   Li HS, 2008, OPT LASER TECHNOL, V40, P415, DOI 10.1016/j.optlastec.2007.07.004
   Lilai Tang, 2011, Proceedings 2011 International Conference on Information and Automation (ICIA 2011), P57, DOI 10.1109/ICINFA.2011.5948963
   Lu K, 2006, PATTERN RECOGN, V39, P717, DOI 10.1016/j.patcog.2005.11.009
   Madanipour K, 2007, OPT LASER ENG, V45, P64, DOI 10.1016/j.optlaseng.2006.06.004
   NAVARRO R, 1993, J OPT SOC AM A, V10, P201, DOI 10.1364/JOSAA.10.000201
   Ornella L, 2010, COMPUT ELECTRON AGR, V74, P250, DOI 10.1016/j.compag.2010.08.013
   Petkovic D, 2014, ENERGY, V64, P868, DOI 10.1016/j.energy.2013.10.094
   Petkovic D, 2014, OPT LASER ENG, V55, P84, DOI 10.1016/j.optlaseng.2013.10.018
   Petkovic D, 2013, RENEW SUST ENERG REV, V28, P191, DOI 10.1016/j.rser.2013.07.049
   Petkovic D, 2013, EXPERT SYST APPL, V40, P1265, DOI 10.1016/j.eswa.2012.08.064
   Rajasekaran S, 2008, OCEAN ENG, V35, P1578, DOI 10.1016/j.oceaneng.2008.08.004
   ROVAMO J, 1994, VISION RES, V34, P2493, DOI 10.1016/0042-6989(94)90234-8
   ROVAMO J, 1995, VISION RES, V35, P767, DOI 10.1016/0042-6989(94)00171-H
   Sayegh RR, 2010, INVEST OPHTH VIS SCI, V51, P857, DOI 10.1167/iovs.09-3372
   Shamshirband S, 2013, ENG APPL ARTIF INTEL, V26, P2105, DOI 10.1016/j.engappai.2013.04.010
   Shamshirband S, 2010, SCI RES ESSAYS, V5, P3840
   Singh M.K., 2010, PROGR ELECTROMAGN B, V23, P71
   Sturzu A., 2011, B TRANSILVANIA U B 1, V4, P33
   Supin AY, 1995, HEARING RES, V92, P38, DOI 10.1016/0378-5955(95)00194-8
   Wei Z, 2013, RELIAB ENG SYST SAFE, V119, P109, DOI 10.1016/j.ress.2013.05.021
   Wu S, 2013, NEUROCOMPUTING, V102, P163, DOI 10.1016/j.neucom.2011.12.051
   Yang HQ, 2009, NEUROCOMPUTING, V72, P2659, DOI 10.1016/j.neucom.2008.09.014
   ZANEVELD JR, 1969, J OPT SOC AM, V59, P378, DOI 10.1364/JOSA.59.000378
   Zhang L, 2013, NEUROCOMPUTING, V99, P411, DOI 10.1016/j.neucom.2012.06.030
NR 36
TC 9
Z9 9
U1 2
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1350-4495
EI 1879-0275
J9 INFRARED PHYS TECHN
JI Infrared Phys. Technol.
PD JUL
PY 2014
VL 65
BP 94
EP 102
DI 10.1016/j.infrared.2014.04.005
PG 9
WC Instruments & Instrumentation; Optics; Physics, Applied
SC Instruments & Instrumentation; Optics; Physics
GA AK7MQ
UT WOS:000338612800017
DA 2018-12-27
ER

PT J
AU Yan, HC
   Wang, W
   Dou, CW
   Tian, FM
   Qi, ST
AF Yan, Hai-Cheng
   Wang, Wei
   Dou, Chang-Wu
   Tian, Fu-Ming
   Qi, Song-Tao
TI RETRACTED: Relationships of LDLR genetic polymorphisms with cerebral
   infarction: a meta-analysis (Retracted article. See vol. 42, pg. 1581,
   2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE LDLR; Cerebral infarction; Polymorphisms; Meta-analysis
ID DENSITY-LIPOPROTEIN-RECEPTOR; APOLIPOPROTEIN-E; ISCHEMIC-STROKE;
   HYPERCHOLESTEROLEMIA; EPIDEMIOLOGY; ASSOCIATION; JAPANESE; DISEASE;
   CHINESE; RISK
AB This meta-analysis was undertaken to identify the relationships between genetic polymorphisms in the LDLR gene and the risk of cerebral infarction. The Web of Science (1945-2013), the Cochrane Library Database (Issue 12, 2013), PubMed (1966-2013), EMBASE (1980-2013), CINAHL (1982-2013) and the Chinese Biomedical Database (CBM) (1982-2013) were searched for relevant articles without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios (OR) with their corresponding 95 % confidence interval (CI) were calculated. Eight case-control studies with a total of 4,655 patients with cerebral infarction and 15,920 healthy control subjects were included in our meta-analysis. Five common polymorphisms in the LDLR gene were evaluated, including rs11669576 A > T, rs1433099 C > T, rs5925 C > T, rs688 C > T, rs1122608 T > G in the LDLR gene. The results of this meta-analysis revealed that cerebral infarction patients had a higher frequency of LDLR genetic polymorphisms than that of healthy controls (allele model: OR 1.17, 95 % CI 1.05-1.30, P = 0.004; dominant model: OR 1.18, 95 % CI 1.05-1.33, P = 0.007; homozygous model: OR 1.50, 95 % CI 1.03-2.16, P = 0.032; respectively), especially for the rs11669576 A > T, rs1433099 C > T and rs5925 C > T polymorphisms. Among different ethnic subgroups, the results demonstrated positive correlations between LDLR genetic polymorphisms and an increased risk of cerebral infarction among both Asians and Caucasians under the allele and dominant models (all P < 0.05). Our findings indicate that LDLR genetic polymorphisms may be strongly involved in the pathogenesis of cerebral infarction, especially the rs11669576 A > T, rs1433099 C > T, rs5925 C > T polymorphisms.
C1 [Yan, Hai-Cheng; Qi, Song-Tao] Southern Med Univ, Nanfang Hosp, Dept Neurosurg, Guangzhou 510515, Guangdong, Peoples R China.
   [Wang, Wei] Guangzhou Inst Resp Dis, Dept Resp Med, Guangzhou 510120, Guangdong, Peoples R China.
   [Dou, Chang-Wu; Tian, Fu-Ming] Inner Mongolia Med Univ, Affiliated Hosp, Dept Neurosurg, Hohhot 010050, Peoples R China.
RP Qi, ST (reprint author), Southern Med Univ, Nanfang Hosp, Dept Neurosurg, Ave North Rd 1838, Guangzhou 510515, Guangdong, Peoples R China.
EM qisongtao121@163.com
CR Asahina M, 2012, BIOCHEM BIOPH RES CO, V418, P553, DOI 10.1016/j.bbrc.2012.01.067
   Basak JM, 2012, J BIOL CHEM, V287, P13959, DOI 10.1074/jbc.M111.288746
   Broussalis E, 2012, DRUG DISCOV TODAY, V17, P296, DOI 10.1016/j.drudis.2011.11.005
   [邓颖 Deng Ying], 2002, [中国急救医学, Chinese Journal of Critical Care Medicine], V22, P507
   Feigin VL, 2005, LANCET, V365, P2160, DOI 10.1016/S0140-6736(05)66755-4
   Frikke-Schmidt R, 2004, EUR HEART J, V25, P943, DOI 10.1016/j.ehj.2004.03.020
   Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564
   Guo Yang, 2002, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V19, P209
   Hata J, 2011, CEREBROVASC DIS, V31, P477, DOI 10.1159/000324392
   Lee JD, 2012, CURR NEUROVASC RES, V9, P200, DOI 10.2174/156720212801618965
   Lee JD, 2010, NEUROL RES, V32, P535, DOI 10.1179/174313209X455682
   LINDGREN V, 1985, P NATL ACAD SCI USA, V82, P8567, DOI 10.1073/pnas.82.24.8567
   Lye SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060729
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Shawar SM, 2012, ATHEROSCLEROSIS, V220, P429, DOI 10.1016/j.atherosclerosis.2011.10.045
   Shimizu M, 2013, J CLIN NEUROSCI, V20, P851, DOI 10.1016/j.jocn.2012.06.011
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123
   Vermeer SE, 2007, LANCET NEUROL, V6, P611, DOI 10.1016/S1474-4422(07)70170-9
   Vieira JRS, 2006, ANN HUM GENET, V70, P697, DOI 10.1111/j.1469-1809.2006.00294.x
   Wang B, 2009, J NEUROL SCI, V276, P118, DOI 10.1016/j.jns.2008.09.013
   Xiong X, 2014, HUM GENET, V133, P499, DOI 10.1007/s00439-013-1389-x
   Xu XW, 2010, NEUROGENETICS, V11, P327, DOI 10.1007/s10048-010-0235-8
   Yang XC, 2010, THROMB RES, V126, P292, DOI 10.1016/j.thromres.2010.01.030
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 26
TC 2
Z9 2
U1 2
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUL
PY 2014
VL 41
IS 7
BP 4425
EP 4434
DI 10.1007/s11033-014-3313-4
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AK2XH
UT WOS:000338283000027
PM 24595448
DA 2018-12-27
ER

PT J
AU Gao, Z
   Fu, HJ
   Xue, JJ
   Wu, ZX
   Zhao, LB
AF Gao, Zhan
   Fu, Hong-Juan
   Xue, Ju-Jun
   Wu, Zhi-Xuan
   Zhao, Li-Bo
TI RETRACTED: Genetic polymorphisms in VDR, ESR1 and ESR2 genes may
   contribute to susceptibility to Parkinson's disease: a meta-analysis
   (Retracted article. See vol. 42, pg. 1457, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE VDR; ESR1; ESR2; Parkinson's disease; Meta-analysis
ID VITAMIN-D-RECEPTOR; CHINESE HAN POPULATION; ESTROGEN-RECEPTOR;
   NERVOUS-SYSTEM; ASSOCIATION; RISK; BETA; DEMENTIA; ALPHA
AB We conducted this meta-analysis of relevant case-control studies to investigate the relationships between genetic polymorphisms in VDR, ESR1 and ESR2 genes to the susceptibility of Parkinson's disease (PD). A search on electronic databases without any language restrictions was conducted: MEDLINE (1966-2013), the Cochrane Library Database (Issue 12, 2013), EMBASE (1980-2013), CINAHL (1982-2013), Web of Science (1945-2013) and the Chinese Biomedical Database (1982-2013). Meta-analysis was performed using the STATA statistical software. Crude odds ratio (OR) with their 95 % confidence interval (95 % CI) was calculated. Fourteen case-control studies with a total of 3,689 PD patients and 4,627 healthy subjects were included in our meta-analysis. The results of our meta-analysis demonstrated that the VDR genetic polymorphisms might be closely related to increased risks of PD (allele model: OR = 1.18, 95 % CI 1.09-1.29, P < 0.001; dominant model: OR = 1.37, 95 % CI 1.16-1.63, P < 0.001; respectively), especially for the polymorphisms rs7976091 and rs10735810. Our findings also illustrated that ESR1 genetic polymorphisms might increase the risk of PD (allele model: OR = 1.56, 95 % CI 1.17-2.07, P = 0.002; recessive model: OR = 1.93, 95 % CI 1.33-2.80, P < 0.001; homozygous model: OR = 1.35, 95 % CI 1.02-1.79, P = 0.038; heterozygous model: OR = 2.04, 95 % CI 1.36-3.07, P = 0.001; respectively), especially for the polymorphisms rs2234693 and rs9340799. Furthermore, we found significant correlations of ESR2 genetic polymorphisms with the risk of PD (allele model: OR = 1.78, 95 % CI 1.19-2.67, P = 0.005; recessive model: OR = 1.93, 95 % CI 1.15-3.27, P = 0.014; homozygous model: OR = 1.77, 95 % CI 1.09-2.89, P = 0.022; heterozygous model: OR = 1.88, 95 % CI 1.08-3.27, P = 0.025; respectively), especially for the rs1256049 polymorphism. Our meta-analysis suggests that genetic polymorphisms in VDR, ESR1 and ESR2 genes may contribute to increased risks for PD.
C1 [Gao, Zhan; Fu, Hong-Juan; Xue, Ju-Jun; Wu, Zhi-Xuan; Zhao, Li-Bo] Heilongjiang Hosp, Dept Elderly Neurol, Harbin 150000, Peoples R China.
RP Zhao, LB (reprint author), Heilongjiang Hosp, Dept Elderly Neurol, Zhongshan Rd 82, Harbin 150000, Peoples R China.
EM zhaolibo115@126.com
CR Al-Sweidi S, 2011, NEUROPHARMACOLOGY, V61, P583, DOI 10.1016/j.neuropharm.2011.04.031
   Alves G, 2008, J NEUROL, V255, P18, DOI 10.1007/s00415-008-5004-3
   Butler MW, 2011, ANN HUM GENET, V75, P201, DOI 10.1111/j.1469-1809.2010.00631.x
   Chen Rong-Jie, 2008, Zhonghua Yi Xue Za Zhi, V88, P1185
   Chung SJ, 2011, MOVEMENT DISORD, V26, P1234, DOI 10.1002/mds.23604
   Fang WL, 2009, IRAN J ALLERGY ASTHM, V8, P141, DOI 08.03/ijaai.141147
   Fiorito E, 2013, CHROMOSOMA, V122, P1, DOI 10.1007/s00412-012-0392-7
   Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1
   Hakansson A, 2005, AM J MED GENET B, V133B, P88, DOI 10.1002/ajmg.b.30136
   Han M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032383
   Han X, 2012, NEUROSCI LETT, V525, P29, DOI 10.1016/j.neulet.2012.07.033
   Isoe-Wada K, 1999, EUR J NEUROL, V6, P431, DOI 10.1046/j.1468-1331.1999.640431.x
   Kim JS, 2005, J KOREAN MED SCI, V20, P495, DOI 10.3346/jkms.2005.20.3.495
   Knekt P, 2010, ARCH NEUROL-CHICAGO, V67, P808, DOI 10.1001/archneurol.2010.120
   Lear TL, 1998, CYTOGENET CELL GENET, V82, P110, DOI 10.1159/000015079
   Li XL, 2009, BIOMED PHARMACOTHER, V63, P599, DOI 10.1016/j.biopha.2008.09.007
   Lin CH, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.10.094
   Liu Hong-xin, 2013, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V30, P13, DOI 10.3760/cma.j.issn.1003-9406.2013.01.004
   Liu NK, 2011, PHYSIOL GENOMICS, V43, P571, DOI 10.1152/physiolgenomics.00168.2010
   Lv ZY, 2013, INT J NEUROSCI, V123, P60, DOI 10.3109/00207454.2012.726669
   Maraganore DM, 2002, MOVEMENT DISORD, V17, P509, DOI 10.1002/mds.1253
   Marques Sueli, 2013, Subcell Biochem, V61, P507, DOI 10.1007/978-94-007-4525-4_22
   Martin-Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009-0354
   Mattila KM, 2002, ACTA NEUROL SCAND, V106, P128, DOI 10.1034/j.1600-0404.2002.01331.x
   MCDONNELL DP, 1988, J STEROID BIOCHEM, V30, P41, DOI 10.1016/0022-4731(88)90074-X
   Muangpaisan Weerasak, 2011, Journal of the Medical Association of Thailand, V94, P749
   Palacios N, 2010, PARKINSONISM RELAT D, V16, P370, DOI 10.1016/j.parkreldis.2010.02.012
   Pavao M, 2001, STEROIDS, V66, P1, DOI 10.1016/S0039-128X(00)00143-4
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   San Luciano M, 2012, NEUROSCI LETT, V506, P312, DOI 10.1016/j.neulet.2011.11.032
   Schapira AH, 2011, MOVEMENT DISORD, V26, P1049, DOI 10.1002/mds.23732
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Torok R, 2013, NEUROSCI LETT, V551, P70, DOI 10.1016/j.neulet.2013.07.014
   Velarde MC, 2013, PHYSIOL GENOMICS, V45, P106, DOI 10.1152/physiolgenomics.00155.2012
   Westberg L, 2004, PSYCHONEUROENDOCRINO, V29, P993, DOI 10.1016/j.psyneuen.2003.08.010
   Yang L, 2012, CELL IMMUNOL, V279, P160, DOI 10.1016/j.cellimm.2012.10.002
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 37
TC 5
Z9 5
U1 2
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUL
PY 2014
VL 41
IS 7
BP 4463
EP 4474
DI 10.1007/s11033-014-3317-0
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AK2XH
UT WOS:000338283000031
PM 24595449
DA 2018-12-27
ER

PT J
AU Wang, HL
   Zhou, PY
   Liu, P
   Zhang, Y
AF Wang, He-Ling
   Zhou, Ping-Yi
   Liu, Peng
   Zhang, Yu
TI RETRACTED: Role of p16 gene promoter methylation in gastric
   carcinogenesis: a meta-analysis (Retracted article. See vol. 42, pg.
   1459, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE p16; Promoter methylation; Gastric cancer; Gastric carcinogenesis;
   Meta-analysis
ID TUMOR-SUPPRESSOR GENE; CPG ISLAND METHYLATION; CANCER PATIENTS; DNA
   METHYLATION; MICROSATELLITE INSTABILITY; INTESTINAL METAPLASIA; ABERRANT
   METHYLATION; PROTEIN EXPRESSION; HYPERMETHYLATION; P16(INK4A)
AB This meta-analysis was performed to evaluate the relationships between promoter DNA methylation in tumor suppressor gene p16 and gastric carcinogenesis. The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library and CBM databases were searched for relevant articles published before November 1st, 2013 without any language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios (ORs) with 95 % confidence intervals (95 % CI) were calculated. Forty-seven clinical cohort studies that met all inclusion criteria were included in this meta-analysis. A total of 2,813 gastric cancer (GC) patients were assessed. Our meta-analysis results revealed that the frequencies of p16 promoter methylation in the GC tissues were higher than those of normal and adjacent tissues (Normal: OR = 23.04, 95 % CI = 13.55-39.15, P < 0.001; Adjacent: OR = 4.42, 95 % CI = 1.66-11.76, P = 0.003; respectively). Furthermore, we observed significant associations of p16 promoter methylation with TNM stage, histologic grade, invasive grade, lymph node metastasis of GC (TNM stage: OR = 3.60, 95 % CI: 2.17-5.98, P < 0.001; Histologic grade: OR = 2.63, 95 % CI: 1.55-4.45, P < 0.001; Invasive grade: OR = 3.44, 95 % CI: 1.68-7.06, P = 0.001; Lymph node metastasis: OR = 2.68, 95 % CI: 1.66-4.32, P < 0.001; respectively). However, there were no correlations of p16 promoter methylation with the TNM stage and Helicobacter pylori (HP) infection of GC (Tumor size: OR = 0.76, 95 % CI: 0.14-4.07, P = 0.746; HP infection: OR = 1.31, 95 % CI: 0.75-2.27, P = 0.342; respectively). Our findings provide empirical evidence that p16 promoter methylation may play an important role in gastric carcinogenesis. Thus, p16 promoter methylation may be a promising potential biomarker for the early diagnosis of GC.
C1 [Wang, He-Ling; Zhou, Ping-Yi; Liu, Peng; Zhang, Yu] China Med Univ, Dept Gen Surg, Shengjing Hosp, Shenyang 110022, Peoples R China.
RP Wang, HL (reprint author), China Med Univ, Dept Gen Surg, Shengjing Hosp, Huaxiang Rd, Shenyang 110022, Peoples R China.
EM wangheling1127@126.com
FU Research Foundation of Science and Technology Agency of Liaoning
   Province [2011408004]
FX This work was supported by the Research Foundation of Science and
   Technology Agency of Liaoning Province (No. 2011408004). We would like
   to acknowledge the reviewers for their helpful comments on this paper.
CR Abbaszadegan MR, 2008, WORLD J GASTROENTERO, V14, P2055, DOI 10.3748/wjg.14.2055
   Borges BD, 2013, TUMOR BIOL, V34, P2127, DOI 10.1007/s13277-013-0742-y
   [陈刚 Chen Gang], 2006, [临床与实验病理学杂志, Chinese Journal of Clinical and Experimental Pathology], V22, P567
   Chen Y, 2008, SHANDONG MED J, V48, P86, DOI [10.3969/j.issn.1002-266X.2008.37.046, DOI 10.3969/J.ISSN.1002-266X.2008.37.046]
   Dai W, 2013, CLIN CANCER RES, V19, P5788, DOI 10.1158/1078-0432.CCR-13-1217
   Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2
   Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558
   Hibi K, 2003, CLIN CANCER RES, V9, P1053
   House MG, 2003, J GASTROINTEST SURG, V7, P1004, DOI 10.1016/j.gassur.2003.08.002
   Huang DB, 2009, SHANDONG MED J, V49, P1, DOI [10.3969/j.issn.1002-266X.2009.01.001, DOI 10.3969/J.ISSN.1002-266X.2009.01.001]
   Huang Q, 2004, MODERN PATHOL, V17, P416, DOI 10.1038/modpathol.3800072
   Ichikawa D, 2004, ANTICANCER RES, V24, P2477
   Jang TJ, 2001, INT J CANCER, V93, P629, DOI 10.1002/ijc.1394
   Jeong YJ, 2013, ONCOL REP, V30, P2270, DOI 10.3892/or.2013.2668
   Jha AK, 2012, ONCOL LETT, V3, P1331, DOI 10.3892/ol.2012.655
   Jia AP, 2011, ACTA MED SINIA, V24, P254, DOI [10.3969/j.issn.1008-2409.2011.03.003, DOI 10.3969/J.ISSN.1008-2409.2011.03.003]
   Kang GH, 2001, CANCER RES, V61, P2847
   Kang GH, 2012, KOREAN J PATHOL, V46, P1, DOI 10.4132/KoreanJPathol.2012.46.1.1
   Kanyama Y, 2003, CANCER SCI, V94, P418, DOI 10.1111/j.1349-7006.2003.tb01457.x
   Kim H, 2003, J PATHOL, V200, P23, DOI 10.1002/path.1325
   Koike H, 2005, HEPATO-GASTROENTEROL, V52, P1293
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   Leung WK, 2005, BRIT J CANCER, V92, P2190, DOI 10.1038/sj.bjc.6602636
   Leung WK, 2001, CANCER, V91, P2294
   Li Q, 2007, ACTA ACAD MED NEIMON, V29, P33, DOI [10.3969/j.issn.1004-2113.2007.01.010, DOI 10.3969/J.ISSN.1004-2113.2007.01.010]
   Li TC, 2007, J PRACT MED, V23, P3812, DOI [10.3969/j.issn.1006-5725.2007.24.003, DOI 10.3969/J.ISSN.1006-5725.2007.24.003]
   Liao AJ, 2001, PRACT J CANC, V16, P284
   Liu WT, 2007, WORLD CHIN J DIGESTO, V15, P2839, DOI [10.3969/j.issn.1009-3079.2007.26.016, DOI 10.3969/J.ISSN.1009-3079.2007.26.016]
   Liu Ya-hang, 2005, Beijing Da Xue Xue Bao Yi Xue Ban, V37, P257
   Luo DY, 2006, LAB INVEST, V86, P591, DOI 10.1038/labinvest.3700415
   Lv P, 2013, J CHIN ONCOL, V19, P332
   Min KO, 2006, MODERN PATHOL, V19, P141, DOI 10.1038/modpathol.3800505
   Mino A, 2006, ONCOL REP, V15, P615
   Mokrowiecka A, 2012, ADV MED SCI-POLAND, V57, P71, DOI 10.2478/v10039-012-0003-0
   Ojima H, 2006, ANTICANCER RES, V26, P933
   Oue N, 2003, CANCER SCI, V94, P901, DOI 10.1111/j.1349-7006.2003.tb01373.x
   Oue N, 2006, CANCER, V106, P1250, DOI 10.1002/cncr.21754
   Oue N, 2002, J PATHOL, V198, P55, DOI 10.1002/path.1170
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P705, DOI 10.1067/mjd.2000.104687
   Pinto Rodrigo Pozza, 2009, Rev. Col. Bras. Cir., V36, P199, DOI 10.1590/S0100-69912009000300004
   Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316
   [舍雅莉 She Yali], 2010, [肿瘤, Tumor], V30, P1038
   Shi W, 2001, CHIN J DIG ENDOSC, V16, P400
   Shi-Jun LI, 2005, CHIN J MISDIAGNOSTIC, V5, P607
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Steevens J, 2010, GUT, V59, P39, DOI 10.1136/gut.2009.191080
   Sun Y, 2004, CLIN CANCER RES, V10, P5087, DOI 10.1158/1078-0432.CCR-03-0622
   Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z
   Takachi R, 2010, AM J CLIN NUTR, V91, P456, DOI 10.3945/ajcn.2009.28587
   Tamura G, 2004, HISTOL HISTOPATHOL, V19, P221, DOI 10.14670/HH-19.221
   Tang Shao-Hui, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P517
   To KF, 2002, INT J CANCER, V102, P623, DOI 10.1002/ijc.10783
   Tsujimoto H, 2002, PATHOL RES PRACT, V198, P785, DOI 10.1078/0344-0338-00337
   Ushijima Toshikazu, 2012, Nihon Rinsho, V70, P1705
   Vo QN, 2002, HUM PATHOL, V33, P1200, DOI 10.1053/hupa.2002.130108
   Wang Y, 2010, WORLD CHI J DIGESTOL, V18, P384, DOI [10.3969/j.issn.1009-3079.2010.04.013, DOI 10.3969/J.ISSN.1009-3079.2010.04.013]
   Wani M, 2012, ASIAN PAC J CANCER P, V13, P4177, DOI 10.7314/APJCP.2012.13.8.4177
   Wei GuoHua, 2011, Cancer Research on Prevention and Treatment, V38, P51
   Wu PY, 2012, WORLD J GASTROENTERO, V18, P70, DOI 10.3748/wjg.v18.i1.70
   Yamamoto E, 2011, DIGESTION, V83, P241, DOI 10.1159/000320453
   [闫秀娥 YAN Xiue], 2006, [中华消化杂志, Chinese Journal of Digestion], V26, P726
   Yang LT, 2012, SHANDONG MED, V52, P47, DOI [10.3969/j.issn.1002-266X.2012.31.018, DOI 10.3969/J.ISSN.1002-266X.2012.31.018]
   [杨宇霞 Yang Yuxia], 2002, [基础医学与临床, Basic Medical Sciences and Clinics], V22, P318
   Yasui Wataru, 2005, Gastric Cancer, V8, P86, DOI 10.1007/s10120-005-0320-0
   Yu SL, 2005, ACTA ACAD MED, V25, P289
   [张斌 ZHANG Bin], 2009, [中华消化杂志, Chinese Journal of Digestion], V29, P177
   Zhang Fan, 2004, Chin J Dig Dis, V5, P149, DOI 10.1111/j.1443-9573.2004.00172.x
   Zhao CH, 2006, WORLD CHIN J DIGESTO, V14, P1004, DOI [10.3969/j.issn.1009-3079.2006.10.015, DOI 10.3969/J.ISSN.1009-3079.2006.10.015]
   Zhao Q, 2010, TOXICOL LETT, V197, P201, DOI 10.1016/j.toxlet.2010.05.019
   Zhao Yingfang, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P382
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 72
TC 9
Z9 9
U1 3
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUL
PY 2014
VL 41
IS 7
BP 4481
EP 4492
DI 10.1007/s11033-014-3319-y
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AK2XH
UT WOS:000338283000033
PM 24610350
DA 2018-12-27
ER

PT J
AU Zhao, YJ
   Yang, X
   Ren, L
   Cai, AS
   Zhang, YF
AF Zhao, Yu-Juan
   Yang, Xia
   Ren, Li
   Cai, An-Sheng
   Zhang, Yan-Fen
TI RETRACTED: Correlations of SELE and SELP genetic polymorphisms with
   myocardial infarction risk: a meta-analysis and meta-regression
   (Retracted article. See vol. 42, pg. 1461, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE SELE; SELP; Myocardial infarction; Meta-analysis; Meta-regression
ID CORONARY-ARTERY-DISEASE; AMERICAN-HEART-ASSOCIATION; UNIVERSAL
   DEFINITION; PLATELET ACTIVATION; S128R POLYMORPHISM; ATHEROSCLEROSIS;
   INFLAMMATION; PREVENTION; COPENHAGEN; INFECTION
AB This meta-analysis was undertaken in an attempt to understand the relationships of functional polymorphisms in the SELE and SELP genes to myocardial infarction (MI) risk. The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched for relevant articles published before March 1st, 2013 without any language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios with 95 % confidence intervals were calculated. The effect of SELE and SELP genetic polymorphisms on the pathogenesis of MI was investigated in this meta-analysis with a total of ten case-control studies, including 2,696 MI patients and 4,724 healthy subjects. Eight single nucleotide polymorphisms were assessed, including polymorphisms 98G/T, 128S/R and 561A/C in the SELE gene, and polymorphisms 715T/P, 599V/L, 290S/N, 562N/D and 2123G/C in the SELP gene. The results of our meta-analysis suggested that SELE genetic polymorphisms might be correlated with an increased risk of MI, especially for 128S/R and 561A/C polymorphisms. A subgroup analysis by ethnicity was conducted to investigate its effects on susceptibility to MI. The results revealed positive significant correlations between SELE genetic polymorphisms and the risk of MI among Asians, but not among Caucasians (all P > 0.05). Nevertheless, no significantly correlations were found between SELP genetic polymorphisms and MI risk (all P > 0.05). In the subgroup analysis by ethnicity, we also did not observe significant associations between SELP genetic polymorphisms and MI risks among both Asians and Caucasians (all P > 0.05). The current meta-analysis suggests that SELE genetic polymorphisms may contribute to the development of MI, especially for the 128S/R and 561A/C polymorphisms among Asians. However, SELP genetic polymorphisms may not be important risk factors in MI.
C1 [Zhao, Yu-Juan; Yang, Xia; Ren, Li; Cai, An-Sheng; Zhang, Yan-Fen] Harbin Med Univ, Dept Cardiol, Affiliated Hosp 1, Harbin 150001, Peoples R China.
RP Zhao, YJ (reprint author), Harbin Med Univ, Dept Cardiol, Affiliated Hosp 1, Youzheng St 23, Harbin 150001, Peoples R China.
EM zhaoyujuan1223@126.com
FU National Natural Science Foundation of Heilongjiang Province [D2007-23];
   Education Department of Heilongjiang Province [11531210]; Postdoctoral
   Fund of Heilongjiang Province [LRB-06-288]; Postdoctoral Research
   Startup Fund of Heilongjiang Province [LBH-Q10045]; First Affiliated
   Hospital of Harbin Medical University Hospital Foundation
FX The work is funded by the National Natural Science Foundation of
   Heilongjiang Province (D2007-23), the Education Department of
   Heilongjiang Province (11531210), the Postdoctoral Fund of Heilongjiang
   Province (LRB-06-288), the Postdoctoral Research Startup Fund of
   Heilongjiang Province (No. LBH-Q10045) and the First Affiliated Hospital
   of Harbin Medical University Hospital Foundation. We would like to
   acknowledge the helpful comments on this paper received from our
   reviewers.
CR Abu-Amero KK, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-52
   Baldwin KM, 2010, EXERC SPORT SCI REV, V38, P42, DOI 10.1097/JES.0b013e3181d49644
   Barbaux SC, 2001, ARTERIOSCL THROM VAS, V21, P1668, DOI 10.1161/hq1001.097022
   Borst O, 2012, CIRC RES, V111, P1297, DOI 10.1161/CIRCRESAHA.112.276444
   Buse JB, 2007, CIRCULATION, V115, P114, DOI 10.1161/CIRCULATIONAHA.106.179294
   Elmas E, 2010, J CARDIOVASC ELECTR, V21, P1260, DOI 10.1111/j.1540-8167.2010.01833.x
   Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620
   Ghazouani L, 2011, MOL BIOL REP, V38, P495, DOI 10.1007/s11033-010-0133-z
   Ghazouani L, 2009, J THROMB THROMBOLYS, V28, P314, DOI 10.1007/s11239-008-0297-8
   Golias C, 2011, CELL COMMUN ADHES, V18, P19, DOI 10.3109/15419061.2011.606381
   Goracy J, 2011, MED SCI MONITOR, V17, pCR334, DOI 10.12659/MSM.881806
   Graham I, 2007, EUR HEART J, V28, P2375, DOI 10.1093/eurheartj/ehm316
   Herrmann SM, 1998, HUM MOL GENET, V7, P1277, DOI 10.1093/hmg/7.8.1277
   Houshmand B, 2009, J PERIODONTAL RES, V44, P88, DOI 10.1111/j.1600-0765.2008.01092.x
   JENSEN G, 1991, EUR HEART J, V12, P298, DOI 10.1093/oxfordjournals.eurheartj.a059894
   Jubeli E, 2012, J CONTROL RELEASE, V158, P194, DOI 10.1016/j.jconrel.2011.09.084
   Kee F, 2000, HEART, V84, P548, DOI 10.1136/heart.84.5.548
   Laubli H, 2010, SEMIN CANCER BIOL, V20, P169, DOI 10.1016/j.semcancer.2010.04.005
   Li Y, 2004, CHIN J LABOR MED, V27, P51
   Li Y, 2004, CHIN J GERIATR, V23, P4
   [廖驰林 LIAO ChiLin], 2011, [中国动脉硬化杂志, Chinese Journal of Arteriosclerosis], V19, P151
   Lievens D, 2011, THROMB HAEMOSTASIS, V106, P827, DOI 10.1160/TH11-08-0592
   Marian AJ, 1998, CURR OPIN CARDIOL, V13, P171
   Moe KT, 2010, ANN ACAD MED SINGAP, V39, P210
   Motawi T, 2012, MED SCI MONITOR, V18, pCR381, DOI 10.12659/MSM.882908
   Nabel EG, 2012, NEW ENGL J MED, V366, P54, DOI 10.1056/NEJMra1112570
   NYBOE J, 1989, EUR HEART J, V10, P910, DOI 10.1093/oxfordjournals.eurheartj.a059401
   Pasquali A, 2010, MOL CELL PROBE, V24, P161, DOI 10.1016/j.mcp.2009.11.006
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Podgoreanu MV, 2006, CIRCULATION, V114, pI275, DOI 10.1161/CIRCULATIONAHA.105.001032
   Rautou PE, 2011, CIRC RES, V108, P335, DOI 10.1161/CIRCRESAHA.110.237420
   Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998
   Rosner SA, 2005, HUM GENET, V118, P287, DOI 10.1007/s00439-005-0052-6
   Sakowicz A, 2010, ARCH MED SCI, V6, P160, DOI 10.5114/aoms.2010.13887
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Smolina K, 2012, BRIT MED J, V344, DOI 10.1136/bmj.d8059
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stepien E, 2011, ARCH MED RES, V42, P375, DOI 10.1016/j.arcmed.2011.07.007
   TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1
   Thomas R, 2010, J MOL HISTOL, V41, P277, DOI 10.1007/s10735-010-9289-z
   Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397
   Thygesen K, 2012, J AM COLL CARDIOL, V60, P1581, DOI 10.1016/j.jacc.2012.08.001
   Tripathi R, 2009, INDIAN J MED RES, V130, P423
   Wang JG, 2013, J AM COLL CARDIOL, V62, P1442, DOI 10.1016/j.jacc.2013.04.054
   Wei CD, 2013, INT J MED SCI, V10, P457, DOI 10.7150/ijms.5234
   Wei M, 2007, CHIN J EMERG MED, V16, P1251, DOI DOI 10.3760/J.ISSN:1671-0282.2007.12.005
   Yeh JJ, 2010, BLOOD, V115, P4247, DOI 10.1182/blood-2009-09-241166
   Yoshida M, 2003, ARTERIOSCL THROM VAS, V23, P783, DOI 10.1161/01.ATV.0000067427.40133.59
   Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5
   Zak I, 2008, HEART VESSELS, V23, P257, DOI 10.1007/s00380-008-1040-2
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 52
TC 3
Z9 3
U1 4
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUL
PY 2014
VL 41
IS 7
BP 4521
EP 4532
DI 10.1007/s11033-014-3323-2
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AK2XH
UT WOS:000338283000037
PM 24639176
DA 2018-12-27
ER

PT J
AU Zhao, LL
   Zhang, T
   Zhuang, LW
   Yan, BZ
   Wang, RF
   Liu, BR
AF Zhao, Li-Li
   Zhang, Tong
   Zhuang, Li-Wei
   Yan, Bing-Zhu
   Wang, Rui-Feng
   Liu, Bing-Rong
TI RETRACTED: Uncovering the pathogenesis and identifying novel targets of
   pancreatic cancer using bioinformatics approach (Retracted article. See
   vol. 42, pg. 1463, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Pancreatic cancer; Differentially expressed gene; Functional analysis;
   Protein-protein interaction network; Text mining
ID PROTEIN INTERACTION NETWORKS; SIGNALING PATHWAY; CELL-ADHESION;
   EXPRESSION; GENE; DYNAMICS; BIOLOGY; PATHOPHYSIOLOGY; VISUALIZATION;
   INTEGRATION
AB Pancreatic cancer is a uniformly lethal disease that can be difficult to diagnose at its early stage. Thus, our present study aimed to explore the underlying mechanism and identify new targets for this disease. The data GSE16515, including 36 tumor and 16 normal samples were available from Gene Expression Omnibus. Differentially expressed genes (DEGs) were screened out using Robust Multichip Averaging and LIMMA package. Moreover, gene ontology and pathway enrichment analyses were performed to DEGs. Followed with protein-protein interaction (PPI) network construction by STRING and Cytoscape, module analysis was conducted using ClusterONE. Finally, based on PubMed, text mining about these DEGs was carried out. Total 274 up-regulated and 93 down-regulated genes were identified as the common DEGs and these genes were discovered significantly enriched in cell adhesion and extracellular region terms, as well as ECM-receptor interaction pathway. In addition, five modules were screened out from the up-regulated PPI network with none in down-regulated network. Finally, the up-regulated genes, including MIA, MET and CEACAMS, and down-regulated genes, such as FGF, INS and LAPP, had the most references in text mining analysis. Our findings demonstrate that the up- and down-regulated genes play important roles in pancreatic cancer development and might be new targets for the therapy.
C1 [Zhao, Li-Li; Zhuang, Li-Wei; Wang, Rui-Feng] Harbin Med Univ, Affiliated Hosp 4, Dept Gastroenterol, Harbin 150001, Heilongjiang, Peoples R China.
   [Zhang, Tong] Harbin Med Univ, Affiliated Hosp 4, Dept Cardiol, Harbin 150001, Heilongjiang, Peoples R China.
   [Yan, Bing-Zhu] Harbin Med Univ, Affiliated Hosp 2, Dept Infect Dis, Harbin 150001, Heilongjiang, Peoples R China.
   [Liu, Bing-Rong] Harbin Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Harbin 150001, Heilongjiang, Peoples R China.
RP Liu, BR (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Gastroenterol, 148 Baojian St, Harbin 150001, Heilongjiang, Peoples R China.
EM bingrongliu7y@hotmail.com
FU Administration of Traditional Chinese Medicine of Heilongjiang Province
   [ZHY12-Z170]
FX This study was supported by the Administration of Traditional Chinese
   Medicine of Heilongjiang Province (project number ZHY12-Z170). We wish
   to express our warm thanks to Fenghe(Shanghai) Information Technology
   Co., Ltd. Their ideas and help gave a valuable added dimension to our
   research.
CR Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033
   Aoki-Kinoshita Kiyoko F., 2007, V396, P71
   Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949
   Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009
   Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   Buchsbaum DJ, 2014, JAMA-J AM MED ASSOC, V311, P363, DOI 10.1001/jama.2013.284665
   Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460
   Cui JJ, 2012, J MED CHEM, V55, P8091, DOI 10.1021/jm300967g
   Edghill EL, 2008, DIABETES, V57, P1034, DOI 10.2337/db07-1405
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Hong X, 2010, J SURG ONCOL, V101, P564, DOI 10.1002/jso.21538
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200
   Kuespert K, 2006, CURR OPIN CELL BIOL, V18, P565, DOI 10.1016/j.ceb.2006.08.008
   Lee HO, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-245
   Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8
   Li M, 2007, P NATL ACAD SCI USA, V104, P18636, DOI 10.1073/pnas.0709307104
   Maitra A, 2006, BEST PRACT RES CL GA, V20, P211, DOI 10.1016/j.bpg.2005.10.002
   Nepusz T, 2012, NAT METHODS, V9, P471, DOI [10.1038/nmeth.1938, 10.1038/NMETH.1938]
   Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957
   Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016
   Sarkar FH, 2007, TOXICOL APPL PHARM, V224, P326, DOI 10.1016/j.taap.2006.11.007
   Shintani Y, 2006, CANCER RES, V66, P11745, DOI 10.1158/0008-5472.CAN-06-2322
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Stoll R, 2003, PROTEIN SCI, V12, P510, DOI 10.1110/ps.0222603
   Team R. D. C., 2005, R LANG ENV STAT COMP
   Tsai RTH, 2009, BIOINFORMATICS, V25, P3031, DOI 10.1093/bioinformatics/btp475
   Xu ZK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-161
NR 35
TC 2
Z9 2
U1 2
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUL
PY 2014
VL 41
IS 7
BP 4697
EP 4704
DI 10.1007/s11033-014-3340-1
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AK2XH
UT WOS:000338283000054
PM 24728565
DA 2018-12-27
ER

PT J
AU Jung, IS
   Kim, HJ
   Jung, WY
   Kim, CW
AF Jung, In-Soo
   Kim, Hyun-Jung
   Jung, Won-Yong
   Kim, Chan-Wha
TI RETRACTED: Hydrogen Peroxide as an Effective Disinfectant for
   Pasteurella multocida (Retracted article. See vol. 57, pg. 274, 2016)
SO YONSEI MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE Pasteurella multocida; human pathogen; environmental isolate;
   disinfectant; 3% hydrogen peroxide
ID PSEUDOMONAS-AERUGINOSA; INFECTIONS; EFFICACY
AB Pasteurella multocida (P multocida) infections vary widely, from local infections resulting from animal bites and scratches to general infections. As of yet, no vaccine against P multocida has been developed, and the most effective way to prevent pathogenic transmission is to clean the host environment using disinfectants. In this study, we identified which disinfectants most effectively inhibited environmental isolates of P multocida. Three readily available disinfectants were compared: 3% hydrogen peroxide (HP), 70% isopropyl alcohol, and synthetic phenol. In suspension tests and zone inhibition tests, 3% BP was the most promising disinfectant against P multocida.
C1 [Jung, In-Soo; Kim, Hyun-Jung; Jung, Won-Yong; Kim, Chan-Wha] Korea Univ, Coll Life Sci & Biotechnol, Seoul 136701, South Korea.
RP Kim, CW (reprint author), Korea Univ, Coll Life Sci & Biotechnol, 145 Anam Ro, Seoul 136701, South Korea.
EM cwkim@korea.ac.kr
CR [Anonymous], 1983, DISINFECTION STERILI, P225
   Arashima Y, 1993, Kansenshogaku Zasshi, V67, P791
   Arashima Y, 1990, Kansenshogaku Zasshi, V64, P1200
   Block S, 1991, DISINFECTION STERILI, P167
   Brogden KA, 1998, VET RES, V29, P233
   윤지희, 2005, [Korean Journal of Microbiology, 미생물학회지], V41, P183
   Cozad A, 2003, AM J INFECT CONTROL, V31, P243, DOI 10.1067/mic.2003.49
   Hernandez A, 2000, J HOSP INFECT, V46, P203, DOI 10.1053/jhin.2000.0818
   Herruzo-Cabrera R, 2004, J HOSP INFECT, V57, P217, DOI 10.1016/j.jhin.2004.01.031
   HUBBERT WT, 1970, AM J PUBLIC HEALTH N, V60, P1109, DOI 10.2105/AJPH.60.6.1109
   Larson E. L, 1991, DISINFECTION STERILI, P191
   McDonnell G, 1999, CLIN MICROBIOL REV, V12, P147, DOI 10.1128/CMR.12.1.147
   Poole K, 2002, J APPL MICROBIOL, V92, p55S, DOI 10.1046/j.1365-2672.92.5s1.8.x
   Romao CMCPA, 2005, MEM I OSWALDO CRUZ, V100, P541, DOI 10.1590/S0074-02762005000500015
   WEBER DJ, 1984, MEDICINE, V63, P133, DOI 10.1097/00005792-198405000-00001
NR 15
TC 2
Z9 4
U1 2
U2 19
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD JUL 1
PY 2014
VL 55
IS 4
BP 1152
EP 1156
DI 10.3349/ymj.2014.55.4.1152
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA AK2ST
UT WOS:000338270500041
PM 24954350
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Amin, SM
AF Amin, Sabry Mohammad
TI RETRACTED: Evaluation of gabapentin and dexamethasone alone or in
   combination for pain control after adenotonsillectomy in children
   (Retracted article. See vol. 12, pg. 662, 2018)
SO SAUDI JOURNAL OF ANAESTHESIA
LA English
DT Article; Retracted Publication
DE Adenotonsillectomy; dexamethasone; gabapentin; post-operative pain;
   post-tonsillectomy bleeding
AB Background: Different methods and many drugs have been used to control the postoperative pain. In this study, we evaluate the role of gabapentin premedication and/or dexamethasone in management of post- operative pain following adenotonsillectomy in children. Materials and Methods: In a double- blind randomized study, 120 children were subjected for adenotonsillectomy classifi ed into three equal groups. Group G: Gabapentin 10 mg/kg was given orally 2 h before induction of anesthesia (Gabapentin syrup 250 mg/5 ml. Group D: Children in this group received placebo pre- operatively and received dexamethasone 0.15 mg/kg intravenously after induction of anesthesia, but before surgery. Group C: Children in this group received combination of oral gabapentin 10 mg/kg 2 h before induction of anesthesia and intra- operative 0.15 mg/kg dexamethasone intravenously. All children underwent general anesthesia. Pain score was assisted post- operatively 2 h, 4 h, 6 h, 8 h, 12 h and 18 h after recovery using face, legs, activity, cry, consolability scale. Results: Pain score in Group C and Group G was signifi cantly less at 4 h, 6 h and 8 h post- operatively than in Group D (P < 0.05). At 12 h, the pain score in Group C was signifi cantly less than Group G and Group D (P < 0.05). And no signifi cant changes were observed in pain score at 18 h post- operatively between all groups (P > 0.05). The time to fi rst analgesia was longer in the Group C than in Group G and Group D and the time to fi rst analgesia was signifi cantly longer in Group G than in Group D (P < 0.05). The total amount of pethidine was less in Group C and Group G than in Group D (P < 0.05). The incidence of post- operative nausea and vomiting was statically insignifi cant among all groups and no reported post- operative bleeding. Conclusion: Gabapentin 10 mg/kg premedication combined with intra- operative dexamethasone 0.15 mg/kg prolongs the post- operative analgesia following adenotonsillectomy in children and decreases the amount of pethidine used post- operatively with no reported adverse effects or increase in the incidence of post- operative bleeding.
C1 [Amin, Sabry Mohammad] Tanta Univ Hosp, Fac Med, Dept Anesthesia, Tanta 31527, Egypt.
RP Amin, SM (reprint author), Tanta Univ Hosp, Fac Med, Dept Anesthesia, Tanta 31527, Egypt.
EM sabry_amin@yahoo.com
CR Al-Shehri AM, 2004, ANN SAUDI MED, V24, P365, DOI 10.5144/0256-4947.2004.365
   Brigger MT, 2010, ARCH OTOLARYNGOL, V136, P766, DOI 10.1001/archoto.2010.133
   Carr AS, 2009, GUIDELINES PREVENTIO, P20
   Czarnetzki C, 2008, JAMA-J AM MED ASSOC, V300, P2621, DOI 10.1001/jama.2008.794
   Davies A, 2007, TRENDS PHARMACOL SCI, V28, P220, DOI 10.1016/j.tips.2007.03.005
   Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007
   Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1213/01.ANE.0000024206.70089.15
   Geva A, 2011, OTOLARYNG HEAD NECK, V144, P838, DOI 10.1177/0194599811399538
   Gilron I, 2005, PAIN, V113, P191, DOI 10.1016/j.pain.2004.10.008
   Haig GM, 2001, J CLIN PHARMACOL, V41, P507, DOI 10.1177/00912700122010384
   Jeon EJ, 2009, EUR ARCH OTO-RHINO-L, V266, P1605, DOI 10.1007/s00405-008-0897-0
   Joshi Girish P, 2005, Anesthesiol Clin North America, V23, P21, DOI 10.1016/j.atc.2004.11.013
   Kaan MN, 2006, INT J PEDIATR OTORHI, V70, P73, DOI 10.1016/j.ijporl.2005.05.013
   Kamal SA, 2006, EUR ARCH OTO-RHINO-L, V263, P449, DOI 10.1007/s00405-005-1022-2
   KEHLET H, 2003, DRUGS, V63, P15
   Koc S, 2007, ANESTH ANALG, V105, P1137, DOI 10.1213/01.ane.0000278869.00918.b7
   Kong VKF, 2007, BRIT J ANAESTH, V99, P775, DOI 10.1093/bja/aem316
   Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574
   Merkel S I, 1997, Pediatr Nurs, V23, P293
   Michaloliakou C, 1996, ANESTH ANALG, V82, P44, DOI 10.1097/00000539-199601000-00009
   Mikkelsen S, 2006, ACTA ANAESTH SCAND, V50, P809, DOI 10.1111/j.1399-6579.2006.01057.x
   Mohammadi SS, 2009, SAUDI J ANAESTH, V3, P25
   Page GG, 2003, ADV EXP MED BIOL, V521, P117
   Panarese A, 1999, J LARYNGOL OTOL, V113, P1089
   Rasmussen ML, 2010, EUR J ANAESTH, V27, P324, DOI 10.1097/EJA.0b013e328331c71d
   Schimmer BP, 1996, GOODMAN GILMANS PHAR, P1459
   Shakeel M, 2010, J OTOLARYNGOL-HEAD N, V39, P732, DOI 10.2310/7070.2010.090332
   Steward DL, 2001, LARYNGOSCOPE, V111, P1712, DOI 10.1097/00005537-200110000-00008
   Svensson CI, 2002, ANNU REV PHARMACOL, V42, P553, DOI 10.1146/annurev.pharmtox.42.092401.143905
   Turan A, 2004, ANESTH ANALG, V99, P375
   Windfuhr JP, 2008, HNO, V56, P43, DOI 10.1007/s00106-007-1550-8
   Windfuhr JP, 2011, BRAZ J OTORHINOLAR, V77, P373, DOI 10.1590/S1808-86942011000300017
NR 32
TC 8
Z9 10
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1658-354X
EI 0975-3125
J9 SAUDI J ANAESTH
JI Saudi J. Anaesth.
PD JUL-SEP
PY 2014
VL 8
IS 3
BP 317
EP 322
DI 10.4103/1658-354X.136417
PG 6
WC Anesthesiology
SC Anesthesiology
GA V4P2I
UT WOS:000219137500003
PM 25191179
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhang, ZF
   Bai, XF
   Zha, JW
   Li, WK
   Dang, ZM
AF Zhang, Zhong-Feng
   Bai, Xiao-Fei
   Zha, Jun-Wei
   Li, Wei-Kang
   Dang, Zhi-Min
TI RETRACTED: Preparation and dielectric properties of BaTiO3/epoxy
   nanocomposites for embedded capacitor application (Retracted article.
   See vol. 115, pg. 87, 2015)
SO COMPOSITES SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Nanoparticle; Nanocomposites; Polymer; Electrical properties
ID ORGANIC SUBSTRATE APPLICATIONS; POLYMER COMPOSITES; HIGH-PERMITTIVITY;
   BARIUM-TITANATE; ENERGY-STORAGE; FILMS ECFS; CONSTANT; MICROSTRUCTURE;
   STRENGTH; BEHAVIOR
AB Incorporating the inorganic particles into polymer have opened up novel opportunities to prepare the dielectric materials applied in embedded capacitors. In this work, the barium titanate (BaTiO3)/epoxy nanocomposites with excellent dielectric properties were fabricated. The embedded capacitors with three-layer sandwich structure containing the BaTiO3/epoxy nanocomposites as dielectric layer and copper foil as electrodes were prepared through lamination process. This method could ensure uniformity of capacitor paste in the structure, resulting in improved dielectric properties. The capacitors exhibit high dielectric permittivity (epsilon = 20), low dielectric loss (0.01) at 10(3) Hz from 40 degrees C to 100 degrees C and high breakdown strength (24 kV/mm). These results demonstrate that the BaTiO3/epoxy nanocomposites have potential for high-performance embedded capacitors in field of microelectronics. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Zhang, Zhong-Feng] Cent South Univ Forestry & Technol, Coll Furniture, Changsha 410004, Hunan, Peoples R China.
   [Bai, Xiao-Fei; Zha, Jun-Wei; Dang, Zhi-Min] Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Lab Dielect Polymer Mat & Devices, Beijing 100083, Peoples R China.
   [Zha, Jun-Wei; Li, Wei-Kang; Dang, Zhi-Min] Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.
RP Zha, JW (reprint author), Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Lab Dielect Polymer Mat & Devices, Beijing 100083, Peoples R China.
EM zhajw@ustb.edu.cn
FU NSF of China [51207009, 51377010]; Beijing Natural Science Foundation
   [2122040]; National Basic Research Program of China (973 Program)
   [2014CB239503]
FX This work was financially supported by NSF of China (Nos. 51207009 and
   51377010), Beijing Natural Science Foundation (No. 2122040), and the
   National Basic Research Program of China (973 Program, 2014CB239503).
CR Arbatti M, 2007, ADV MATER, V19, P1369, DOI 10.1002/adma.200601996
   Avila HA, 2013, ACS APPL MATER INTER, V5, P505, DOI 10.1021/am302646z
   Cheng KC, 2007, MATER LETT, V61, P757, DOI 10.1016/j.matlet.2006.05.061
   Cho SD, 2005, IEEE T ELECTRON PACK, V28, P297, DOI 10.1109/TEPM.2005.856535
   Cho SD, 2004, MAT SCI ENG B-SOLID, V110, P233, DOI 10.1016/j.mseb.2004.01.022
   Dang ZM, 2008, COMPOS SCI TECHNOL, V68, P171, DOI 10.1016/j.compscitech.2007.05.021
   Dang ZM, 2013, ADV MATER, V25, P6334, DOI 10.1002/adma.201301752
   Dang ZM, 2012, PROG MATER SCI, V57, P660, DOI 10.1016/j.pmatsci.2011.08.001
   Dang ZM, 2011, IEEE T DIELECT EL IN, V18, P1518, DOI 10.1109/TDEI.2011.6032820
   Dang ZM, 2009, ADV MATER, V21, P2077, DOI 10.1002/adma.200803427
   Dang ZM, 2003, ADV MATER, V15, P1625, DOI 10.1002/adma.200304911
   Devaraju NG, 2006, J APPL POLYM SCI, V99, P3018, DOI 10.1002/app.22856
   Huang XY, 2011, IEEE T DIELECT EL IN, V18, P375, DOI 10.1109/TDEI.2011.5739440
   Jang KW, 2008, J APPL POLYM SCI, V110, P798, DOI 10.1002/app.28515
   Kim P, 2007, ADV MATER, V19, P1001, DOI 10.1002/adma.200602422
   Lee S, 2007, IEEE T ADV PACKAGING, V30, P428, DOI 10.1109/TADVP.2007.898614
   Liu WD, 2007, POLYM ADVAN TECHNOL, V18, P522, DOI 10.1002/pat.910
   Ogitani S, 2000, IEEE TRANS ADV PACK, V23, P313, DOI 10.1109/6040.846650
   Park SH, 2010, ELEC COMP C, P2035, DOI 10.1109/ECTC.2010.5490663
   Patsidis AC, 2012, MATER CHEM PHYS, V135, P798, DOI 10.1016/j.matchemphys.2012.05.060
   Qi L, 2005, ADV MATER, V17, P1777, DOI 10.1002/adma.200401816
   Rao Y, 2004, J APPL POLYM SCI, V92, P2228, DOI 10.1002/app.13690
   Shen Y, 2007, ADV MATER, V19, P1418, DOI 10.1002/adma.200602097
   Song Y, 2012, J MATER CHEM, V22, P16491, DOI 10.1039/c2jm32579a
   Takahashi A, 2005, J PHOTOPOLYM SCI TEC, V18, P297, DOI 10.2494/photopolymer.18.297
   Ulrich R, 2004, IEEE T ADV PACKAGING, V27, P326, DOI 10.1109/TADVP.2004.828812
   Xie LY, 2011, J MATER CHEM, V21, P5897, DOI 10.1039/c0jm04574h
   Xu JW, 2006, IEEE T ADV PACKAGING, V29, P295, DOI 10.1109/TADVP.2006.874701
NR 28
TC 21
Z9 22
U1 5
U2 91
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0266-3538
EI 1879-1050
J9 COMPOS SCI TECHNOL
JI Compos. Sci. Technol.
PD JUN 16
PY 2014
VL 97
BP 100
EP 105
DI 10.1016/j.compscitech.2014.04.012
PG 6
WC Materials Science, Composites
SC Materials Science
GA AI4YD
UT WOS:000336871600014
DA 2018-12-27
ER

PT J
AU Li, CC
   Hou, YC
   Yeh, CL
   Yeh, SL
AF Li, Cheng-Chung
   Hou, Yu-Chen
   Yeh, Chiu-Li
   Yeh, Sung-Ling
TI RETRACTED: Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on
   Prostate Cancer Cell Migration and Invasion Induced by Tumor-Associated
   Macrophages (Retracted article. See vol. 12, e0173325, 2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ACTIVATED-RECEPTOR-GAMMA; NF-KAPPA-B; N-3 FATTY-ACIDS; BREAST-CANCER;
   PPAR-GAMMA; MATRIX METALLOPROTEINASES; IN-VIVO; MACROPHAGES;
   PROGRESSION; PATHWAY
AB Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the major n-3 polyunsaturated fatty acids (PUFAs) in fish oil that decrease the risk of prostate cancer. Tumor-associated macrophages (TAMs) are the main leukocytes of intratumoral infiltration, and increased TAMs correlates with poor prostate cancer prognosis. However, the mechanism of n-3 PUFAs on prostate cancer cell progression induced by TAMs is not well understood. In this study, we investigated the effects of EPA and DHA on modulating of migration and invasion of prostate cancer cells induced by TAMs-like M2-type macrophages. PC-3 prostate cancer cells were pretreated with EPA, DHA, or the peroxisome proliferator-activated receptor (PPAR)-gamma antagonist, GW9662, before exposure to conditioned medium (CM). CM was derived from M2-polarized THP-1 macrophages. The migratory and invasive abilities of PC-3 cells were evaluated using a coculture system of M2-type macrophages and PC-3 cells. EPA/DHA administration decreased migration and invasion of PC-3 cells. The PPAR-gamma DNA-binding activity and cytosolic inhibitory factor kappa B alpha (I kappa B alpha) protein expression increased while the nuclear factor (NF)-kappa B p65 transcriptional activity and nuclear NF-kappa B p65 protein level decreased in PC-3 cells incubated with CM in the presence of EPA/DHA. Further, EPA/DHA downregulated mRNA expressions of matrix metalloproteinase-9, cyclooxygenase-2, vascular endothelial growth factor, and macrophage colony-stimulating factor. Pretreatment with GW9662 abolished the favorable effects of EPA/DHA on PC-3 cells. These results indicate that EPA/DHA administration reduced migration, invasion and macrophage chemotaxis of PC-3 cells induced by TAM-like M2-type macrophages, which may partly be explained by activation of PPAR-gamma and decreased NF-kappa B p65 transcriptional activity.
C1 [Li, Cheng-Chung; Yeh, Sung-Ling] Taipei Med Univ, Sch Nutr & Hlth Sci, Coll Publ Hlth & Nutr, Taipei, Taiwan.
   [Hou, Yu-Chen] Natl Taiwan Univ, Dept Surg, Taipei 10764, Taiwan.
   [Yeh, Chiu-Li] Chinese Culture Univ, Dept Nutr & Hlth Sci, Taipei, Taiwan.
RP Yeh, SL (reprint author), Taipei Med Univ, Sch Nutr & Hlth Sci, Coll Publ Hlth & Nutr, Taipei, Taiwan.
EM sangling@tmu.edu.tw
FU National Science Council Taipei, Taiwan [NSC 100-2320-B-038-009]
FX This study was supported by the National Science Council grant NSC
   100-2320-B-038-009 Taipei, Taiwan. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004
   Allred CD, 2008, J NUTR, V138, P250
   Annicotte JS, 2006, MOL CELL BIOL, V26, P7561, DOI 10.1128/MCB.00605-06
   Augustsson K, 2003, CANCER EPIDEM BIOMAR, V12, P64
   Bocci G, 2004, CANCER RES, V64, P6616, DOI 10.1158/0008-5472.CAN-04-0401
   CHEN PS, 2011, PLOS ONE, V0006
   Colombo MP, 2005, CANCER RES, V65, P9113, DOI 10.1158/0008-5472.CAN-05-2714
   DeCicco KL, 2004, CARCINOGENESIS, V25, P1805, DOI 10.1093/carcin/bgh210
   DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649
   Edwards IJ, 2008, J BIOL CHEM, V283, P18441, DOI 10.1074/jbc.M802107200
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014
   Guyton K, 2003, SHOCK, V20, P56, DOI 10.1097/01.shk.0000070903.21762.f8
   Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197
   Hebert JR, 1998, JNCI-J NATL CANCER I, V90, P1637, DOI 10.1093/jnci/90.21.1637
   Hotchkiss KA, 2003, CANCER RES, V63, P527
   Huang FR, 2011, BRIT J NUTR, V105, P348, DOI 10.1017/S0007114510003703
   Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535
   Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jinga DC, 2006, J CELL MOL MED, V10, P499, DOI 10.1111/j.1582-4934.2006.tb00415.x
   Kaikkonen S, 2013, MOL ENDOCRINOL, V27, P212, DOI 10.1210/me.2012-1313
   Kim HK, 2006, J NUTR, V136, P2965
   Kobayashi M, 1999, JPN J CANCER RES, V90, P914, DOI 10.1111/j.1349-7006.1999.tb00835.x
   Kobayashi N, 2006, CLIN CANCER RES, V12, P4662, DOI 10.1158/1078-0432.CCR-06-0459
   Lehrer S, 2004, TECHNOL CANCER RES T, V3, P411, DOI 10.1177/153303460400300501
   Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000
   Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910
   Lichtinghagen R, 2002, EUR UROL, V42, P398, DOI 10.1016/S0302-2838(02)00324-X
   Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912
   Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727
   Lissbrant IF, 2000, INT J ONCOL, V17, P445
   Loberg RD, 2007, NEOPLASIA, V9, P556, DOI 10.1593/neo.07307
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988
   Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197
   Nagata Daisuke, 2008, Cancer Detect Prev, V32, P259, DOI 10.1016/j.cdp.2008.05.008
   Niederberger E, 2008, FASEB J, V22, P3432, DOI 10.1096/fj.08-109355
   Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041
   Park BH, 2011, J BIOL CHEM, V286, P20087, DOI 10.1074/jbc.M110.191718
   Philibert A, 2006, AM J CLIN NUTR, V84, P1299
   Pollard AJ, 2004, CELL MICROBIOL, V6, P638, DOI 10.1111/j.1462-5822.2004.00388.x
   Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528
   Pruthi RS, 2003, J UROLOGY, V169, P2352, DOI 10.1097/01.ju.0000047364.56051.74
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353
   Shen D, 2007, POSTGRAD MED J, V83, P414, DOI 10.1136/pmj.2006.052761
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385
   Sroka IC, 2011, MOL CANCER RES, V9, P1319, DOI 10.1158/1541-7786.MCR-11-0080
   Stewart DA, 2012, MOL CANCER RES, V10, P727, DOI 10.1158/1541-7786.MCR-11-0604
   Sun H, 2008, CANCER RES, V68, P2912, DOI 10.1158/0008-5472.CAN-07-2305
   Tjiu JW, 2009, J INVEST DERMATOL, V129, P1016, DOI 10.1038/jid.2008.310
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843
   Yang YJ, 1999, CLIN BIOCHEM, V32, P405, DOI 10.1016/S0009-9120(99)00036-3
   Zerbini LF, 2003, CANCER RES, V63, P2206
NR 58
TC 13
Z9 13
U1 2
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2014
VL 9
IS 6
AR e99630
DI 10.1371/journal.pone.0099630
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK8TP
UT WOS:000338701300082
PM 24925287
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Chang, RX
   Qin, JL
   Gao, JG
AF Chang, Ruixue
   Qin, Jianglei
   Gao, Jungang
TI RETRACTED: Fully biobased epoxy from isosorbide diglycidyl ether cured
   by biobased curing agents with enhanced properties (Retracted article.
   See vol. 22, pg. 52, 2015)
SO JOURNAL OF POLYMER RESEARCH
LA English
DT Article; Retracted Publication
DE Bio-based epoxy; Isosorbide; Curing kinetics; Sustainable development
ID RESIN; PERFORMANCE; THERMOSETS; ANHYDRIDE; NETWORKS; KINETICS; ESTERS;
   ROSIN; ACID
AB In this study, isosorbide diglycidyl ether (isosorbide epoxy) was cured by a variety of biobased curing agent of terpene maleic anhydride (TMA) and maleopimaric acid (MPA) to prepare fully biobased epoxy resins. The structures of isosorbide epoxy and biobased curing agents were synthesized and characterized by NMR. The non-isothermal curing kinetics of fully biobased epoxies were studied using differential scanning calorimetry (DSC). The bis-phenol A type epoxy and petroleum based curing agent methyl Nadic anhydride (MNA) bearing similar caged structure was also studied for comparison. The mechanical properties of the biobased epoxy resins were evaluated using dynamic mechanical analysis (DMA) and the thermal stability was characterized by thermogravimetric analysis (TGA), respectively. The fully biobased epoxies have comparable or even better mechanical properties and thermal stability than the biophenol A type epoxies cured by petroleum based curing agents, showing that the biobased isosorbide epoxies have great potential application as substitute for those petroleum based epoxies.
C1 [Chang, Ruixue; Qin, Jianglei; Gao, Jungang] Hebei Univ, Coll Chem & Environm Sci, Baoding 071002, Peoples R China.
RP Qin, JL (reprint author), Hebei Univ, Coll Chem & Environm Sci, Baoding 071002, Peoples R China.
EM qinhbu@iccas.ac.cn
FU Baoding Bureau of Science and Technology [13ZG037]; Plan of Science
   Technology Research and Development of Hebei Province [13211219]
FX This research was kindly supported by Baoding Bureau of Science and
   Technology (Grant No. 13ZG037), The Plan of Science Technology Research
   and Development of Hebei Province (Grant No. 13211219), Science
   Foundation of Hebei University (y2013272).
CR Bardasz EA, 1991, US patant, Patent No. 5066461
   Chen X, 2007, J POLYM RES, V18, P2229
   Chrysanthos M, 2011, POLYMER, V52, P3611, DOI 10.1016/j.polymer.2011.06.001
   Colladon M, 2006, J AM CHEM SOC, V128, P14006, DOI 10.1021/ja0647607
   Feng P, 2012, BIORESOURCES, V7, P2860
   Feng XH, 2011, POLYM ADVAN TECHNOL, V22, P139, DOI 10.1002/pat.1859
   Flint S, 2012, J ENVIRON MANAGE, V104, P19, DOI 10.1016/j.jenvman.2012.03.021
   Hasegawa Y, 2012, SEN-I GAKKAISHI, V68, P73, DOI 10.2115/fiber.68.73
   Holland JM, 2003, J ORG CHEM, V68, P747, DOI 10.1021/jo026456b
   Huo L, 2008, J APPL POLYM SCI, V110, P3671, DOI 10.1002/app.28973
   Jiao J, 2013, J POLYM RES, V20, DOI 10.1007/s10965-013-0202-9
   KISSINGER HE, 1957, ANAL CHEM, V29, P1702, DOI 10.1021/ac60131a045
   Koike T, 2012, POLYM ENG SCI, V52, P701, DOI 10.1002/pen.23119
   Leng F, 2011, CHEM IND PROD, V31, P65
   Liu XQ, 2012, EXPRESS POLYM LETT, V6, P293, DOI 10.3144/expresspolymlett.2012.32
   Liu XQ, 2010, POLYM INT, V59, P607, DOI 10.1002/pi.2781
   Liu XQ, 2010, BIORESOURCE TECHNOL, V101, P2520, DOI 10.1016/j.biortech.2009.11.028
   Lukaszczyk J, 2011, EUR POLYM J, V47, P1601, DOI 10.1016/j.eurpolymj.2011.05.009
   Ma SQ, 2013, GREEN CHEM, V15, P245, DOI 10.1039/c2gc36715g
   Pan X, 2011, BIOMACROMOLECULES, V12, P2416, DOI 10.1021/bm200549c
   Pan XA, 2011, GREEN CHEM, V13, P965, DOI 10.1039/c0gc00882f
   Punchaipetch P, 2001, POLYMER, V42, P2067, DOI 10.1016/S0032-3861(00)00505-X
   Qin JL, 2014, POLYM INT, V63, P760, DOI 10.1002/pi.4588
   Stemmelen M, 2011, J POLYM SCI POL CHEM, V49, P2434, DOI 10.1002/pola.24674
   Vassao DG, 2007, ARCH BIOCHEM BIOPHYS, V465, P209, DOI 10.1016/j.abb.2007.06.002
   Wang Z, 2012, MACROMOLECULES, V45, P9010, DOI 10.1021/ma301938a
NR 26
TC 10
Z9 10
U1 5
U2 94
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1022-9760
EI 1572-8935
J9 J POLYM RES
JI J. Polym. Res.
PD JUN 12
PY 2014
VL 21
IS 7
AR 501
DI 10.1007/s10965-014-0501-9
PG 7
WC Polymer Science
SC Polymer Science
GA AI9EJ
UT WOS:000337231900001
DA 2018-12-27
ER

PT J
AU Khatun, S
   Sutradhar, KB
AF Khatun, Sabera
   Sutradhar, Kumar B.
TI RETRACTED: Water hyacinth: a possible alternatve rate retarding natural
   polymer used in sustained release tablet design (Retracted article. See
   vol. 7, 141, 2016)
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE sustained release; metformin hydrochloride; water hyacinth; drug
   release; natural polymer
ID DOSAGE FORMS; DRUG-RELEASE
AB In recent years natural polymers have been widely used because of their effectiveness and availability over synthetic polymers. In this present investigation matrix tablets of Metformin hydrochloride were formulated using Water hyacinth powder and its rate retardant activity was studied. Tablets were prepared using wet granulation method with 8% starch as granulating agent and 5, 10, 15, 20, 25 and 30% of Water hyacinth powder to the drug. In preformulation study, angle of repose, Carr's Index and Hausner ratio were calculated. Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), and Scanning Electron Microscopy (SEM) studies were performed and no interactions were found between drug and excipients. Weight variation, friability, hardness, thickness, diameter, and in vitro release study were performed with the prepared matrix tablets. Dissolution studies were conducted using USP type II apparatus at a speed of 100 rpm at 37 degrees C +/- 0.5 temperature for 8h. Though all the formulations comply with both BP and USP requirements, formulation F-1 (5% of Water hyacinth) was the best fitted formula. The drug release patterns were explained in different kinetic models such as Zero order, First order, Higuchi, Hixson Crowell, and Korsmeyer-Peppas equations. The current investigation implies that Water hyacinth has the potential to be used as a rate-retarding agent in sustained release drug formulations.
C1 [Khatun, Sabera; Sutradhar, Kumar B.] Stamford Univ Bangladesh, Dept Pharm, Dhaka 1217, Bangladesh.
RP Sutradhar, KB (reprint author), Stamford Univ Bangladesh, Dept Pharm, 51 Siddeswari Rd, Dhaka 1217, Bangladesh.
EM kumarbishwajit.pharm@gmail.com
CR Abdel-Fattah AF, 2012, CARBOHYD POLYM, V87, P2109, DOI 10.1016/j.carbpol.2011.10.033
   Adeyeye M. C., 2008, PREFORMULATION SOLID, P17
   Banker G. S., 1987, THEORY PRACTICE IND, P336
   Chen M, 2008, CARBOHYD POLYM, V71, P411, DOI 10.1016/j.carbpol.2007.06.011
   CHUEH HR, 1995, DRUG DEV IND PHARM, V21, P1725, DOI 10.3109/03639049509069261
   COOLEY TN, 1979, CHEMOSPHERE, V8, P75, DOI 10.1016/0045-6535(79)90052-3
   Epstein P, 1998, LANCET, V351, P577, DOI 10.1016/S0140-6736(05)78570-6
   Fernandez O. A., 1990, AQUATIC WEEDS ECOLOG, P406
   GIBALDI M, 1967, J PHARM SCI, V56, P1238, DOI 10.1002/jps.2600561005
   Gopal B., 1987, WATER HYACINTH
   HIGUCHI T, 1961, J PHARM SCI, V50, P874, DOI 10.1002/jps.2600501018
   Hixson AW, 1931, IND ENG CHEM, V23, P923, DOI 10.1021/ie50260a018
   Huma Ali, 2009, Journal of Pharmacy Research, V2, P1365
   KORSMEYER RW, 1983, INT J PHARM, V15, P25, DOI 10.1016/0378-5173(83)90064-9
   Lalitha P., 2012, ASIAN J PHARM CLIN R, V5, P59
   Mailu A. M., 2001, ACIAR P, V102
   Malik A, 2007, ENVIRON INT, V33, P122, DOI 10.1016/j.envint.2006.08.004
   Mendham J, 2000, VOGELS TXB QUANTITAT
   Menon S., 2005, POLLUT RES, V24, P175
   Mironga J. M., 2004, Applied Ecology and Environmental Research, V2, P83
   MOCKEL JE, 1993, PHARMACEUT RES, V10, P1066, DOI 10.1023/A:1018931210396
   PEPPAS NA, 1985, PHARM ACTA HELV, V60, P110
   Reddy K. R., 1987, P AQ PLANTS WAT TREA, P337
   REDDY KR, 1982, J ENVIRON QUAL, V11, P591, DOI 10.2134/jeq1982.00472425001100040008x
   Rudnic E, 1990, REMINGTONS PHARM SCI, P1633
   Sinha AK, 2000, ENV ED INF, V19, P215
   Sutradhar K. B., 2011, J APPL PHARM SCI, V1, P155
   Tchobanoglous G., 1989, J WPCF, V61, P11
   Tripathi BD, 2003, WATER AIR SOIL POLL, V143, P377, DOI 10.1023/A:1022813125339
   TRIVEDY PK, 1987, WATER SCI TECHNOL, V19, P103
   *US PHARM CONV, 2007, US PHARM 30 NAT FORM
   WAGNER JG, 1969, J PHARM SCI, V58, P1253, DOI 10.1002/jps.2600581021
   Wang Z, 2012, CHEMOSPHERE, V89, P1255, DOI 10.1016/j.chemosphere.2012.08.001
   WHO Technical Report, 1989, 33 WHO JOINT FAOWHO
   WOLVERTON B C, 1981, Environmental Professional, V3, P99
   Wu F, 2008, AAPS PHARMSCITECH, V9, P1218, DOI 10.1208/s12249-008-9148-3
   Wu WB, 2014, TOXICOL IND HEALTH, V30, P426, DOI 10.1177/0748233712458138
   Wu WB, 2011, HUM EXP TOXICOL, V30, P1514, DOI 10.1177/0960327110392085
   Xia LM, 2004, BIORESOURCE TECHNOL, V91, P259, DOI 10.1016/S0960-8524(03)00195-0
   Xie HB, 2012, GREEN CHEM, V14, P1202, DOI 10.1039/c2gc00033d
NR 40
TC 3
Z9 3
U1 2
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 11
PY 2014
VL 5
AR 137
DI 10.3389/fphar.2014.00137
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AX7LZ
UT WOS:000347098700001
PM 24966835
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Manesh, JYY
   Shafiee, R
   Bahrami, AM
   Pourzaer, M
   Pourzaer, M
   Pedram, B
   Javanbakht, J
   Mokarizadeh, A
   Khadivar, F
AF Manesh, Javad Yaghoobi Yeganeh
   Shafiee, Radmehr
   Bahrami, Ali Mohammad
   Pourzaer, Mehdi
   Pourzaer, Maryam
   Pedram, Behnam
   Javanbakht, Javad
   Mokarizadeh, Aram
   Khadivar, Farshid
TI RETRACTED: Cyto-histopathological and outcome features of the prepuce
   squamous cell carcinoma of a mixed breed dog(Retracted article. See vol.
   11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Histopathology; Cytology; Dog; Prepuce; Tumour
ID AFFECTED HORSES; ANAL SAC; PAPILLOMAVIRUSES; NEOPLASIA; PENILE; TUMOR;
   DOG; DIAGNOSIS; SKIN
AB Background: Squamous cell carcinomas (SCCs) are uncommon, high-grade tumors, predominantly composed of round cells in the prepuce. The aim of this study is to better define the clinicopathologic features of this neoplasm.
   Case report: We conducted cyto histopathologic analysis on the manifestations of the prepuce SCC by H & E staining in a terrier mix dog. Grossly, tumor was large, multiple erythematous patch, and ulcerated masses frequently affecting the prepuce and deeply invading to distal prepuce out from the ventro-lateral of penis and the tumor covered by a necrotic discharge. Cytological evaluation of fine-needle aspirates from the cutaneous mass from the prepuce comprised of round nuclei, coarse chromatin pattern, distinct nucleoli and nuclear pleomorphism. Furthermore, the neoplastic cells were pleomorphic, round to caudate in shape, exhibiting prominent anisokaryosis and anisocytosis with rare mitotic features. Microscopically, the lesions were predominantly composed of atypical round cells disposed in interlacing fascicles. Frequent findings include keratin formation, horn pearls, mitoses and cellular atypia. The cells showed distinct borders, ranged from polygonal to round or elongate and had moderate amounts of eosinophilic cytoplasm.
   Conclusion: The histopathologic features coupled with the cytopathology findings led to a diagnosis of squamous cell carcinoma. To the authors' knowledge, this is the first time that multiple erythematous plaques have undergone malignant transformation in a terrier mix dog.
C1 [Manesh, Javad Yaghoobi Yeganeh] Shahrekord Univ, Islamic Azad Univ Shahrekord, Fac Vet Med, Shahrekord, Iran.
   [Shafiee, Radmehr; Khadivar, Farshid] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Bahrami, Ali Mohammad] Ilam Univ, Fac Vet Med, Ilam, Iran.
   [Pourzaer, Mehdi] Islamic Azad Univ, Karaj Branch, Fac Vet Sci, Alborz, Iran.
   [Pourzaer, Maryam] Islamic Azad Univ, Damghan Branch, Fac Basic Sci, Dept Biol, Damghan, Iran.
   [Pedram, Behnam] Islamic Azad Univ, Susangerd Branch, Dept Pathobiol, Susangerd, Iran.
   [Javanbakht, Javad] Univ Tehran, Dept Pathol, Fac Vet Med, Tehran, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Dept Immunol, Fac Med, Sanandaj, Iran.
RP Javanbakht, J (reprint author), Univ Tehran, Dept Pathol, Fac Vet Med, Tehran, Iran.
EM jjavanbakht60@yahoo.com; A.mokarizadeh@muk.ac.ir
OI Mokarizadeh, Aram/0000-0002-2630-8308
CR Afify A, 2012, CYTOJOURNAL, V9, DOI 10.4103/1742-6413.93280
   Antonsson A, 2000, J VIROL, V74, P11636, DOI 10.1128/JVI.74.24.11636-11641.2000
   Barnes L, 2005, PATHOLOGY GENETICS H
   Brinsko SP, 1998, VET CLIN N AM-EQUINE, V14, P517
   Chernock RD, 2009, HEAD NECK PATHOL, V3, P186, DOI 10.1007/s12105-009-0126-1
   Cheville NF, 2009, ULTRASTRUCT PATHOL, P343
   Deem S, 2011, BJU INT, V108, P1378, DOI 10.1111/j.1464-410X.2011.10647.x
   Elango KJ, 2011, ASIAN PAC J CANCER P, V12, P889
   Esplin DG, 2003, VET PATHOL, V40, P332, DOI 10.1354/vp.40-3-332
   Evans SM, 1988, J AM VET MED ASSOC, V192, P933
   GARMAAVINA A, 1994, J VET DIAGN INVEST, V6, P238, DOI 10.1177/104063879400600216
   Ginn PE, 2007, JUBB KENNEDY PALMERS, P748
   Goldschmidt MH, 2002, TUMORS DOMESTIC ANIM, P64, DOI DOI 10.1002/9780470376928.CH2
   Gross TL, 2005, SKIN DISEASES OF THE DOG AND CAT: CLINICAL AND HISTOPATHOLOGIC DIAGNOSIS, 2ND EDITION, P562
   Haeri Hayedeh, 2013, Acta Med Iran, V51, P242
   Hargis AM, 2007, PATHOLOGIC BASIS VET, P1177
   Henson K, 2001, ATLAS CANINE FELINE, P277
   HOFFMANN D, 1978, J COMP PATHOL, V88, P497, DOI 10.1016/0021-9975(78)90003-8
   HUANG X, 1986, Zhonghua Zhongliu Zazhi, V8, P310
   Javanbakht Javad, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P580, DOI [10.1016/S2221-1691(13)60117-3, 10.1016/S2221-1091(13)60117-3]
   Javanbakht Javad, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P74, DOI 10.1016/S2221-1691(13)60027-1
   JUBB KVF, 1970, PATHOLOGY DOMESTIC A, V1
   Kasraeian S, 2010, CLIN ORTHOP RELAT R, V468, P2992, DOI 10.1007/s11999-010-1401-x
   Keller H, 1986, EQUINE DIS
   Kennedy PC, 1998, HISTOLOGICAL CLASSIF
   Khaki F, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-33
   Lascelles BDX, 2000, VET REC, V147, P473, DOI 10.1136/vr.147.17.473
   Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004
   Maiolino P, 2002, J COMP PATHOL, V127, P114, DOI 10.1053/jcpa.2002.0568
   May KA, 2008, EQUINE VET EDUC, V20, P135, DOI 10.2746/095777308X282408
   Munday JS, 2010, J VET DIAGN INVEST, V22, P946, DOI 10.1177/104063871002200615
   Nicholls PK, 2000, VET IMMUNOL IMMUNOP, V73, P101, DOI 10.1016/S0165-2427(99)00165-8
   Nugent EK, 2011, J LOW GENIT TRACT DI, V15, P15, DOI 10.1097/LGT.0b013e3181ee2598
   Ohtani S, 2007, CANCER RES, V67, P6293, DOI 10.1158/0008-5472.CAN-06-3884
   PATNAIK AK, 1988, J AM ANIM HOSP ASSOC, V24, P403
   Pereira TC, 2011, APPL IMMUNOHISTO M M, V19, P10, DOI 10.1097/PAI.0b013e3181ecaf1c
   Radostits OM, 2000, VET MED TXB DIS CATT, P1244
   Regezi JA, 2002, ORAL SURG ORAL MED O, V94, P724, DOI 10.1067/moe.2002.129760
   Ryschich E, 2005, CLIN CANCER RES, V11, P498
   Schumacher J, 2012, J AM ANIM HOSP ASSOC, V44, P840
   Schumacher K, 2001, CANCER RES, V61, P3932
   Tavasoly A, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-86
   Thuret R, 2013, CANCER CAUSE CONTROL, V24, P71, DOI 10.1007/s10552-012-0091-y
   Valentine BA, 2006, J VET DIAGN INVEST, V18, P123, DOI 10.1177/104063870601800121
   van den Top JGB, 2008, EQUINE VET J, V40, P528, DOI 10.2746/042516408X281180
   van den Top JGB, 2008, EQUINE VET J, V40, P533, DOI 10.2746/042516408X281171
   Viswanath S, 1998, IND J VETY PATH, V22, P150
NR 47
TC 1
Z9 1
U1 2
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUN 6
PY 2014
VL 9
AR 110
DI 10.1186/1746-1596-9-110
PG 7
WC Pathology
SC Pathology
GA AK5JB
UT WOS:000338459600001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Bianco, A
   Thomas, E
   Pomara, F
   Tabacchi, G
   Karsten, B
   Paoli, A
   Palma, A
AF Bianco, Antonino
   Thomas, Ewan
   Pomara, Francesco
   Tabacchi, Garden
   Karsten, Bettina
   Paoli, Antonio
   Palma, Antonio
TI RETRACTED: Alcohol consumption and hormonal alterations related to
   muscle hypertrophy: a review (Retracted article. See vol. 11, 43, 2014)
SO NUTRITION & METABOLISM
LA English
DT Review; Retracted Publication
DE Alcohol; Muscle hypertrophy; Hormones; Protein synthesis
ID PITUITARY-ADRENAL AXIS; HUMAN SKELETAL-MUSCLE; HEPATIC
   PROTEIN-METABOLISM; PLASMA TESTOSTERONE LEVELS; LEYDIG-CELL ACTIVITY;
   POSTMENOPAUSAL WOMEN; GROWTH-HORMONE; LUTEINIZING-HORMONE; SIGNALING
   PATHWAYS; GONADOTROPIN STIMULATION
AB Detrimental effects of acute and chronic alcohol (ethanol) consumption on human physiology are well documented in the literature. These adversely influence neural, metabolic, cardiovascular, and thermoregulatory functions. However, the side effects of ethanol consumption on hormonal fluctuations and subsequent related skeletal muscle alterations have received less attention and as such are not entirely understood. The focus of this review is to identify the side effects of ethanol consumption on the major hormones related to muscle metabolism and clarify how the hormonal profiles are altered by such consumption.
C1 [Bianco, Antonino; Thomas, Ewan; Palma, Antonio] Univ Palermo, Sport & Exercise Sci Res Unit, I-90146 Palermo, Italy.
   [Pomara, Francesco] MEDEOR, Res Inst, I-90147 Palermo, Italy.
   [Tabacchi, Garden] Univ Palermo, Dept Sci Hlth Promot & Mother Child Care G DAless, I-90127 Palermo, Italy.
   [Karsten, Bettina] Univ Greenwich, Chatham ME4 4TB, Kent, England.
   [Paoli, Antonio] Univ Padua, Dept Biomed Sci DSB, I-35131 Padua, Italy.
RP Paoli, A (reprint author), Univ Padua, Dept Biomed Sci DSB, Via Marzolo 3, I-35131 Padua, Italy.
EM antonio.paoli@unipd.it
RI Paoli, Antonio/A-6151-2015
OI Paoli, Antonio/0000-0003-0474-4229; Thomas, Ewan/0000-0001-5991-8316;
   Bianco, Antonino/0000-0001-8334-6581; Palma, Antonio/0000-0002-5387-468X
CR Andersen JL, 2010, SCAND J MED SCI SPOR, V20, P32, DOI 10.1111/j.1600-0838.2010.01196.x
   Andersen JL, 2000, MUSCLE NERVE, V23, P1095
   ANDERSSON S, 1986, ALCOHOL CLIN EXP RES, V10, pS55, DOI 10.1111/j.1530-0277.1986.tb05181.x
   Banerjee A, 2012, CURR OPIN SUPPORT PA, V6, P451, DOI 10.1097/SPC.0b013e328359b681
   Barnes MJ, 2012, J SPORT SCI, V30, P295, DOI 10.1080/02640414.2011.637949
   Berneis K, 1997, METABOLISM, V46, P750, DOI 10.1016/S0026-0495(97)90118-9
   CICERO TJ, 1980, J PHARMACOL EXP THER, V213, P228
   DEFEO P, 1995, J CLIN INVEST, V95, P1472, DOI 10.1172/JCI117818
   Emanuele MA, 1998, ALCOHOL HEALTH RES W, V22, P195
   Farnfield MM, 2012, APPL PHYSIOL NUTR ME, V37, P21, DOI [10.1139/h11-132, 10.1139/H11-132]
   Fernandez-Sola J, 2011, ALCOHOL CLIN EXP RES, V35, P1220, DOI 10.1111/j.1530-0277.2011.01456.x
   Foster DA, 2010, CELL CYCLE, V9, P1291, DOI 10.4161/cc.9.7.11145
   Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003
   Frias J, 2002, ALCOHOL ALCOHOLISM, V37, P169, DOI 10.1093/alcalc/37.2.169
   Frias J, 2000, LIFE SCI, V67, P1081, DOI 10.1016/S0024-3205(00)00702-5
   GAVALER JS, 1993, J AM COLL NUTR, V12, P349, DOI 10.1080/07315724.1993.10718321
   Giannessi F, 2008, MED SCI MONITOR, V14, pBR237
   Gill J, 2000, ALCOHOL ALCOHOLISM, V35, P417, DOI 10.1093/alcalc/35.5.417
   Ginsburg ES, 1996, JAMA-J AM MED ASSOC, V276, P1747, DOI 10.1001/jama.276.21.1747
   Glass DJ, 2005, INT J BIOCHEM CELL B, V37, P1974, DOI 10.1016/j.biocel.2005.04.018
   Heikkonen E, 1996, ALCOHOL CLIN EXP RES, V20, P711, DOI 10.1111/j.1530-0277.1996.tb01676.x
   Heikkonen E, 1998, ALCOHOL CLIN EXP RES, V22, P437, DOI 10.1111/j.1530-0277.1998.tb03671.x
   Herman M, 2006, ALCOHOL CLIN EXP RES, V30, P1479, DOI 10.1111/j.1530-0277.2006.00179.x
   Hong-Brown LQ, 2001, ALCOHOL CLIN EXP RES, V25, P1373
   Hong-Brown LQ, 2006, ALCOHOL CLIN EXP RES, V30, P1297, DOI 10.1111/j.1530-0277.2006.00157.x
   Jenkinson C, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-67
   Joulia-Ekaza D, 2006, EXP CELL RES, V312, P3458, DOI 10.1016/j.yexcr.2006.07.010
   Kachaeva E. V., 2012, Uspekhi Fiziologicheskikh Nauk, V43, P3
   Koziris LP, 2000, J APPL PHYSIOL, V88, P165
   Kumar V, 2009, J APPL PHYSIOL, V106, P2026, DOI 10.1152/japplphysiol.91481.2008
   Lang CH, 2004, ALCOHOL CLIN EXP RES, V28, P1758, DOI 10.1097/01.ALC.0000145787.66405.59
   Lang CH, 2004, AM J PHYSIOL-ENDOC M, V286, pE916, DOI 10.1152/ajpendo.00554.2003
   LANG RM, 1985, ANN INTERN MED, V102, P742, DOI 10.7326/0003-4819-102-6-742
   Langer P, 1986, Bratisl Lek Listy, V86, P87
   LARON Z, 2004, NOVART FDN SYMP, V262, P77
   Laron Z, 2004, NOVART FDN SYMP, V262, P265
   Laron Zvi, 2004, Novartis Found Symp, V262, P56
   Lee S, 2000, MOL CELL NEUROSCI, V16, P515, DOI 10.1006/mcne.2000.0890
   Looney DP, 1985, J APPL PHYSIOL 1985, V115, P1461
   Mager A, 2004, SOC SCI MED, V59, P735, DOI 10.1016/j.socscimed.2003.12.005
   Martin CA, 1999, AM J ADDICTION, V8, P9
   Meissner JD, 2000, J PHYSIOL-LONDON, V523, P19, DOI 10.1111/j.1469-7793.2000.t01-1-00019.x
   MENDELSON JH, 1977, J PHARMACOL EXP THER, V202, P676
   Miguez Hugo A, 2003, Vertex, V14 Suppl 2, P19
   Murphy AP, 2013, J STRENGTH COND RES, V27, P1304, DOI 10.1519/JSC.0b013e318267a5e9
   Nader GA, 2005, INT J BIOCHEM CELL B, V37, P1985, DOI 10.1016/j.biocel.2005.02.026
   Nader GA, 2001, J APPL PHYSIOL, V90, P1936
   Nilwik R, 2013, EXP GERONTOL, V48, P492, DOI 10.1016/j.exger.2013.02.012
   Onland-Moret NC, 2005, J CLIN ENDOCR METAB, V90, P1414, DOI 10.1210/jc.2004-0614
   ORPANA AK, 1990, J STEROID BIOCHEM, V37, P273, DOI 10.1016/0960-0760(90)90338-L
   Pallafacchina G, 2013, NUTR METAB CARDIOVAS, V23, pS12, DOI 10.1016/j.numecd.2012.02.002
   Paoli A, 2009, J SPORT SCI LAW, V2, P154
   Parr EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088384
   Pasiakos SM, 2010, INT J SPORT NUTR EXE, V20, P282, DOI 10.1123/ijsnem.20.4.282
   PELOSIO C, 1954, Policlinico Prat, V61, P1332
   Petrulis A, 2013, HORM BEHAV, V63, P723, DOI 10.1016/j.yhbeh.2013.03.011
   PHIPPS WR, 1987, PSYCHONEUROENDOCRINO, V12, P459, DOI 10.1016/0306-4530(87)90080-1
   Preedy VR, 2001, EUR J NEUROL, V8, P677, DOI 10.1046/j.1468-1331.2001.00303.x
   PREEDY VR, 1992, ALCOHOL ALCOHOLISM, V27, P241
   PREEDY VR, 1994, J PATHOL, V173, P309, DOI 10.1002/path.1711730405
   Pretorius L, 2009, SOC WORK PUBLIC HLTH, V24, P89, DOI 10.1080/19371910802569575
   Pruznak AM, 2013, ALCOHOL ALCOHOLISM, V48, P138, DOI 10.1093/alcalc/ags113
   Purohit V, 1998, ALCOHOL CLIN EXP RES, V22, P994, DOI 10.1111/j.1530-0277.1998.tb03694.x
   Ramadoss J, 2008, ALCOHOL, V42, P199, DOI 10.1016/j.alcohol.2007.12.004
   REICHMAN ME, 1993, J NATL CANCER I, V85, P722, DOI 10.1093/jnci/85.9.722
   Rennie MJ, 2000, ANNU REV NUTR, V20, P457, DOI 10.1146/annurev.nutr.20.1.457
   Richter EA, 2001, J PHYSIOL-LONDON, V535, P313, DOI 10.1111/j.1469-7793.2001.t01-2-00313.x
   Riddle RC, 2014, J CLIN INVEST, V124, P1465, DOI 10.1172/JCI75554
   Rivier C, 1996, ALCOHOL CLIN EXP RES, V20, P240, DOI 10.1111/j.1530-0277.1996.tb01636.x
   Rivier C, 1999, ALCOHOL CLIN EXP RES, V23, P38, DOI 10.1111/j.1530-0277.1999.tb04021.x
   Rojdmark S, 2001, CLIN ENDOCRINOL, V55, P639, DOI 10.1046/j.1365-2265.2001.01401.x
   Sakamoto K, 2002, J APPL PHYSIOL, V93, P369, DOI 10.1152/japplphysiol.00167.2002
   Sandri M, 2013, BIOGERONTOLOGY, V14, P303, DOI 10.1007/s10522-013-9432-9
   Sarkola T, 2000, ALCOHOL ALCOHOLISM, V35, P84, DOI 10.1093/alcalc/35.1.84
   Sarkola T, 2003, ALCOHOL CLIN EXP RES, V27, P682, DOI 10.1097/01.ALC.0000060526.43976.68
   Schiaffino S, 2013, FEBS J, V280, P4294, DOI 10.1111/febs.12253
   SCHUCKIT MA, 1988, AM J PSYCHIAT, V145, P1391
   Sciascia Q, 2013, J DAIRY SCI, V96, P2327, DOI 10.3168/jds.2012-6267
   Selvage DJ, 2004, ALCOHOL CLIN EXP RES, V28, P480, DOI 10.1097/01.ALC.0000117839.69352.B3
   Sierksma A, 2004, ALCOHOL CLIN EXP RES, V28, P780, DOI 10.1097/01.ALC.0000125356.708245.81
   Siler SQ, 1998, AM J PHYSIOL-ENDOC M, V275, pE897, DOI 10.1152/ajpendo.1998.275.5.E897
   Smiarowska M, 2014, POSTEP HIG MED DOSW, V68, P162
   Smith LR, 2013, WIRES SYST BIOL MED, V5, P55, DOI 10.1002/wsbm.1197
   Sonenberg N, 2008, BIOCHEM CELL BIOL, V86, P178, DOI [10.1139/O08-034, 10.1139/008-034]
   Sun LL, 2013, MOL CELL BIOCHEM, V377, P151, DOI 10.1007/s11010-013-1581-2
   Suter PM, 2008, INT J OBESITY, V32, pS48, DOI 10.1038/ijo.2008.206
   Tentler JJ, 1997, J ENDOCRINOL, V152, P477, DOI 10.1677/joe.0.1520477
   Thomas GA, 2013, SPORTS MED, V43, P839, DOI 10.1007/s40279-013-0064-7
   Tipton KD, 2013, NESTLE NUTR WORKS SE, V76, P73, DOI 10.1159/000350259
   Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08
   Uygur R, 2014, ANDROLOGIA, V46, P356, DOI 10.1111/and.12085
   VALIMAKI M, 1990, ALCOHOL CLIN EXP RES, V14, P928, DOI 10.1111/j.1530-0277.1990.tb01840.x
   Valimaki M J, 1984, Alcohol, V1, P89, DOI 10.1016/0741-8329(84)90043-0
   Vary TC, 2005, AM J PHYSIOL-HEART C, V288, pH121, DOI 10.1152/ajpheart.00440.2004
   Vary Thomas C., 2008, V447, P343, DOI 10.1007/978-1-59745-242-7_22
   Vary TC, 2008, ALCOHOL CLIN EXP RES, V32, P43, DOI 10.1111/j.1530-0277.2007.00544.x
   Vatsalya V, 2012, ALCOHOL CLIN EXP RES, V36, P207, DOI 10.1111/j.1530-0277.2011.01600.x
   Vingren JL, 2013, MED SCI SPORT EXER, V45, P1825, DOI 10.1249/MSS.0b013e31828d3767
   Volpi E, 1998, J NUTR, V128, P198
   Watjen W, 2005, J NUTR, V135, P525
   WEINBERG J, 1987, ALCOHOL CLIN EXP RES, V11, P274, DOI 10.1111/j.1530-0277.1987.tb01307.x
   Widegren U, 2000, PFLUG ARCH EUR J PHY, V441, P317, DOI 10.1007/s004240000417
   WIDENIUS TV, 1989, ALCOHOL, V6, P241, DOI 10.1016/0741-8329(89)90025-6
   Wolszczak Blanka, 2014, Pol Merkur Lekarski, V36, P45
   Woolcott CG, 2013, BREAST CANCER RES TR, V139, P255, DOI 10.1007/s10549-013-2534-x
   YLIKAHRI R, 1974, J STEROID BIOCHEM, V5, P655, DOI 10.1016/0022-4731(74)90008-9
   YLIKAHRI RH, 1978, J CLIN ENDOCR METAB, V46, P715, DOI 10.1210/jcem-46-5-715
   Zi JC, 2011, J BIOSCI BIOENG, V112, P360, DOI 10.1016/j.jbiosc.2011.06.006
NR 108
TC 3
Z9 3
U1 2
U2 26
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-7075
J9 NUTR METAB
JI Nutr. Metab.
PD JUN 6
PY 2014
VL 11
AR 26
DI 10.1186/1743-7075-11-26
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AK2IA
UT WOS:000338241500001
PM 24932207
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhao, JJ
   Wang, SY
AF Zhao, Jingjun
   Wang, Shiying
TI RETRACTED: Jacobi spectral solution for weakly singular integral
   algebraic equations of index-1 (Retracted article. Artn 205, 2015)
SO ADVANCES IN DIFFERENCE EQUATIONS
LA English
DT Article; Retracted Publication
DE integral algebraic equations; Jacobi collocation method; system of
   weakly singular Volterra equations; index of IAEs; error analysis
ID COLLOCATION METHODS; KERNELS
AB This paper is concerned with obtaining the approximate solution of a class of semi-explicit Integral Algebraic equations (IAEs) of index-1 with weakly singular kernels. Some function transformations and variable transformations are used to change the equations into integral equations defined on the standard interval [-1, 1], so that the solution of the new system possesses better regularity and the Jacobi orthogonal polynomial theory can be applied conveniently. A Jacobi collocation method is proposed and its convergence analysis is provided, which theoretically justifies the spectral rate of convergence. The numerical results are given to verify our theoretical analysis.
C1 [Zhao, Jingjun; Wang, Shiying] Harbin Inst Technol, Dept Math, Harbin 150001, Peoples R China.
RP Zhao, JJ (reprint author), Harbin Inst Technol, Dept Math, Harbin 150001, Peoples R China.
EM hit_zjj@hit.edu.cn
FU National Natural Science Foundation of China [11101109, 11271102];
   Natural Science Foundation of Hei-long-jiang Province of China
   [A201107]; SRF for ROCS, SEM
FX The authors would like to acknowledge the anonymous referees for their
   careful reading of the manuscript and constructive comments. This work
   is supported by the National Natural Science Foundation of China
   (11101109, 11271102), Natural Science Foundation of Hei-long-jiang
   Province of China (A201107) and SRF for ROCS, SEM.
CR Atkinson K, 2009, TEXTS APPL MATH, V39, P1, DOI 10.1007/978-1-4419-0458-4_1
   Brunner H., 2004, COLLOCATION METHODS
   Brunner H., 1998, P 11 BAIK INT SCH SE, P64
   Bulatov MV, 2011, J COMPUT APPL MATH, V236, P132, DOI 10.1016/j.cam.2011.06.001
   Bulatov MV, 2012, 21 ASC VIENN TU
   Bulatov MV, 1997, PROPERTIES DIFFERENT
   Bulatov MV, 2002, COMP MATH MATH PHYS, V42, P315
   Cannon JR, 1984, ONE DIMENSIONAL HEAT
   Canuto C., 2006, SPECTRAL METHODS FUN
   Chen YP, 2010, MATH COMPUT, V79, P147, DOI 10.1090/S0025-5718-09-02269-8
   Chen YP, 2009, J COMPUT APPL MATH, V233, P938, DOI 10.1016/j.cam.2009.08.057
   DIOGO T, 1994, P ROY SOC EDINB A, V124, P199, DOI 10.1017/S0308210500028432
   GEAR CW, 1990, SIAM J NUMER ANAL, V27, P1527, DOI 10.1137/0727089
   Gol'dman N. L., 1997, MATH ITS APPL, V412
   Gomilko AM, 2003, J ENG MATH, V46, P253, DOI 10.1023/A:1025065714786
   Graham IG, 2002, NUMER MATH, V92, P289, DOI 10.1007/s002110100343
   Hadizadeh M, 2011, APPL NUMER MATH, V61, P131, DOI 10.1016/j.apnum.2010.08.009
   Li XJ, 2012, FRONT MATH CHINA, V7, P69, DOI 10.1007/s11464-012-0170-0
   Pishbin S, 2013, J COMPUT APPL MATH, V245, P121, DOI 10.1016/j.cam.2012.12.012
   Pishbin S, 2011, ELECTRON T NUMER ANA, V38, P327
   Slodicka M, 2005, COMPUT METHOD APPL M, V194, P491, DOI 10.1016/j.cma.2004.04.010
NR 21
TC 2
Z9 2
U1 4
U2 28
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1687-1847
J9 ADV DIFFER EQU-NY
JI Adv. Differ. Equ.
PD JUN 5
PY 2014
AR 165
DI 10.1186/1687-1847-2014-165
PG 15
WC Mathematics, Applied; Mathematics
SC Mathematics
GA AP4YL
UT WOS:000342086400001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Tavasoly, A
   Gholami, H
   Rostami, A
   Anissian, A
   Touni, SR
   Khaleghian, P
   Mokarizadeh, A
   Javanbakht, J
   Nasoori, A
AF Tavasoly, Abbas
   Gholami, Hossein
   Rostami, Amir
   Anissian, Ali
   Touni, Seyed Rashid
   Khaleghian, Pooyan
   Mokarizadeh, Aram
   Javanbakht, Javad
   Nasoori, Alireza
TI RETRACTED: Clinico-histopathologic and outcome features of cutaneous
   infundibular keratinizing acanthoma: a case report and literature
   review(Retracted article. See vol. 14, 2016)
SO WORLD JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE IKA; Keratin; Dog; Histopathology; Tumor
ID SQUAMOUS-CELL CARCINOMA; HEAT-SHOCK PROTEINS; SKIN; PREVALENCE;
   NEOPLASMS; TUMORS; MODEL; DOGS
AB The infundibular keratinizing acanthoma (IKA) is a rare epithelial benign keratin-containing neoplasm of hair follicles. The purpose of this study was to evaluate the defining histopathologic architecture of IKA. A typical IKA consisted of a keratin-filled crypt in the dermis and subcutis that opened to the skin surface. Most of this tumor occurred on the back, neck, head, and the shoulders. Microscopically, the dermal nodules were focally contiguous in both the dermis and subcutis. Furthermore, most histological lesions are consistent with a simple or multiloculated cyst filled with keratin and lined by a wall of stratified squamous epithelium; keratin appears as a concentric lamellar mass, with a keratotic pearly aspect. Histological examination of the cutaneous lesions revealed that the growths were comprised of IKA. IKA of man and dog were compared, and it was concluded that although they are similar in many respects, they are not identical entities. To the best of our knowledge, this is the first report on the prevalence of IKAs among the population of owned dogs in Iran.
C1 [Tavasoly, Abbas; Gholami, Hossein; Javanbakht, Javad] Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
   [Rostami, Amir] Univ Tehran, Fac Vet Med, Dept Clin Sci, Tehran, Iran.
   [Anissian, Ali] Islamic Azad Univ, Abhar Branch, Coll Agr, Dept Vet, Abhar, Iran.
   [Touni, Seyed Rashid] Urmia Univ, Fac Vet Med, Orumiyeh, Iran.
   [Khaleghian, Pooyan] Islamic Azad Univ, Garmsar Branch, Grad Fac Vet Med, Garmsar, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Fac Med, Dept Immunol, Sanandaj, Iran.
   [Nasoori, Alireza] Islamic Azad Univ, Karaj Branch, Fac Vet Med, Karaj, Alborz, Iran.
   [Javanbakht, Javad] Univ Tehran, Fac Vet Med, Dept Pathobiol, Tehran, Iran.
RP Javanbakht, J (reprint author), Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
EM javadjavanbakht@ut.ac.ir
OI Abdi, Mohammad/0000-0002-4766-0423; Mokarizadeh,
   Aram/0000-0002-2630-8308
CR Anudep R, 2003, THAI J VET MED, V33, P60
   Barati F, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-120
   Bongiovanni L, 2008, VET DERMATOL, V19, P271, DOI 10.1111/j.1365-3164.2008.00687.x
   DELASMULAS JM, 1995, VET PATHOL, V32, P692, DOI 10.1177/030098589503200611
   Della Salda L, 2002, EUR J HISTOCHEM, V46, P165
   Fajardo R, 2013, ARCH MED VET, V45, P305, DOI 10.4067/S0301-732X2013000300011
   GOLDSCHMIDT MH, 2002, TUMORS DOMESTIC ANIM, P44
   Hobbenaghi R, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-59
   Hosseini E, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-9
   Kaldrymidou H, 2002, J VET MED A, V49, P87, DOI 10.1046/j.1439-0442.2002.jv408.x
   Kanitakis J, 1998, EUR J DERMATOL, V8, P539
   Romanucci M, 2005, VET DERMATOL, V16, P108, DOI 10.1111/j.1365-3164.2005.00436.x
   STRAFUSS AC, 1985, VET CLIN N AM-SMALL, V15, P473, DOI 10.1016/S0195-5616(85)50051-0
   SULLIVAN JJ, 1980, AUSTRALAS J DERMATOL, V21, P16, DOI 10.1111/j.1440-0960.1980.tb00134.x
   Tavasoly A, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-86
   Valli VE, 2002, WHO INT CLASSIFICATI, V8, P28
   Walder EJ, 1992, VET DERMATIOPATHOLOG, P451
   Yager JA, 1993, PATHOLOGY DOMESTIC A, V1, P531
NR 18
TC 5
Z9 5
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7819
J9 WORLD J SURG ONCOL
JI World J. Surg. Oncol.
PD JUN 3
PY 2014
VL 12
AR 173
DI 10.1186/1477-7819-12-173
PG 4
WC Oncology; Surgery
SC Oncology; Surgery
GA AK2JH
UT WOS:000338244900001
PM 24890648
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ndiath, MO
   Mazenot, C
   Sokhna, C
   Trape, JF
AF Ndiath, Mamadou Ousmane
   Mazenot, Catherine
   Sokhna, Cheikh
   Trape, Jean-Francois
TI RETRACTED: How the Malaria Vector Anopheles gambiae Adapts to the Use of
   Insecticide-Treated Nets by African Populations (Retracted article. See
   vol. 11, e0156196, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID LINKED IMMUNOSORBENT-ASSAY; BED NETS; IMPREGNATED BEDNETS; HOLOENDEMIC
   AREA; RESISTANCE; IDENTIFICATION; TRANSMISSION; SENEGAL; KENYA; BEHAVIOR
AB Background: Insecticide treated bed nets have been recommended and proven efficient as a measure to protect African populations from malaria mosquito vector Anopheles spp. This study evaluates the consequences of bed nets use on vectors resistance to insecticides, their feeding behavior and malaria transmission in Dielmo village, Senegal, were LLINs were offered to all villagers in July 2008.
   Methods: Adult mosquitoes were collected monthly from January 2006 to December 2011 by human landing catches (HLC) and by pyrethroid spray catches (PCS). A randomly selected sub-sample of 15-20% of An. gambiae s.l. collected each month was used to investigate the molecular forms of the An. gambiae complex, kdr mutations, and Plasmodium falciparum circumsporozoite (CSP) rate. Malaria prevalence and gametocytaemia in Dielmo villagers were measured quarterly.
   Results: Insecticide susceptible mosquitoes (wild kdr genotype) presented a reduced lifespan after LLINs implementation but they rapidly adapted their feeding behavior, becoming more exophageous and zoophilic, and biting earlier during the night. In the meantime, insecticide-resistant specimens (kdr L1014F genotype) increased in frequency in the population, with an unchanged lifespan and feeding behaviour. P. falciparum prevalence and gametocyte rate in villagers decreased dramatically after LLINs deployment. Malaria infection rate tended to zero in susceptible mosquitoes whereas the infection rate increased markedly in the kdr homozygote mosquitoes.
   Conclusion: Dramatic changes in vector populations and their behavior occurred after the deployment of LLINs due to the extraordinary adaptative skills of An. gambiae s.l. mosquitoes. However, despite the increasing proportion of insecticide resistant mosquitoes and their almost exclusive responsibility in malaria transmission, the P. falciparum gametocyte reservoir continued to decrease three years after the deployment of LLINs.
C1 [Ndiath, Mamadou Ousmane] Inst Pasteur, Grp G4, Inst Pasteur Int Network, Entomol Unit, Bangui, Cent Afr Republ.
   [Mazenot, Catherine; Trape, Jean-Francois] Inst Rech Dev, Lab Paludol & Zool Med, Dakar, Senegal.
   [Sokhna, Cheikh] Univ Aix Marseille, Unite Rech Malad Infect & Trop Emergentes, IRD198, UM63,CNRS7278,INSERMU1095, Dakar, Senegal.
RP Ndiath, MO (reprint author), Inst Pasteur, Grp G4, Inst Pasteur Int Network, Entomol Unit, Bangui, Cent Afr Republ.
EM Ousmane.ndiath@gmail.com
FU French Ministry of Research; Department Support and Formation of the
   south communities of the Research Institute for the Development (IRD);
   G4 Bangui (CAR) fellowship, Institut Pasteur International Network
FX This work was supported by the French Ministry of Research and the
   Department Support and Formation of the south communities of the
   Research Institute for the Development (IRD). M. O. Ndiath was supported
   by a G4 Bangui (CAR) fellowship provided by Institut Pasteur
   International Network. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BEIER JC, 1988, J MED ENTOMOL, V25, P9, DOI 10.1093/jmedent/25.1.9
   BURKOT TR, 1984, AM J TROP MED HYG, V33, P227, DOI 10.4269/ajtmh.1984.33.227
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1
   Corbel V, 2012, LANCET INFECT DIS, V12, P617, DOI 10.1016/S1473-3099(12)70081-6
   Curtis C. F., 2003, Journal of Vector Borne Diseases, V40, P1
   Czeher C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-189
   Diabate A, 2002, AM J TROP MED HYG, V67, P617, DOI 10.4269/ajtmh.2002.67.617
   Donnelly MJ, 2009, TRENDS PARASITOL, V25, P213, DOI 10.1016/j.pt.2009.02.007
   Enayati A, 2010, ANNU REV ENTOMOL, V55, P569, DOI 10.1146/annurev-ento-112408-085423
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Fegan GW, 2007, LANCET, V370, P1035, DOI 10.1016/S0140-6736(07)61477-9
   Fontenille D, 1997, AM J TROP MED HYG, V56, P247, DOI 10.4269/ajtmh.1997.56.247
   Fornadel CM, 2010, AM J TROP MED HYG, V83, P848, DOI 10.4269/ajtmh.2010.10-0242
   Gillies M, 1968, PUBL S AFR I MED RES, V54, P343
   Hemingway J, 2002, SCIENCE, V298, P96, DOI 10.1126/science.1078052
   Lemasson JJ, 1997, J MED ENTOMOL, V34, P396, DOI 10.1093/jmedent/34.4.396
   Lengeler C, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000363.PUB2
   MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q
   Martinez-Torres D, 1998, INSECT MOL BIOL, V7, P179, DOI 10.1046/j.1365-2583.1998.72062.x
   Mutuku FM, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-356
   Ndiath MO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031943
   Ranson H, 2000, INSECT MOL BIOL, V9, P491, DOI 10.1046/j.1365-2583.2000.00209.x
   Ranson H, 2011, TRENDS PARASITOL, V27, P91, DOI 10.1016/j.pt.2010.08.004
   Reddy MR, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-184
   Russell TL, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-80
   Russell TL, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-187
   Shaukat AM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-122
   Sougoufara S, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-125
   Trape JF, 2012, J INFECT DIS, V205, P672, DOI 10.1093/infdis/jir805
   Trape JF, 2011, LANCET INFECT DIS, V11, P925, DOI 10.1016/S1473-3099(11)70194-3
   TRAPE JF, 1994, AM J TROP MED HYG, V51, P123, DOI 10.4269/ajtmh.1994.51.123
   Trape JF, 2014, LANCET INFECT DIS, V14, P70712
   VULULE JM, 1994, MED VET ENTOMOL, V8, P71, DOI 10.1111/j.1365-2915.1994.tb00389.x
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
NR 35
TC 18
Z9 18
U1 2
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2014
VL 9
IS 6
AR e97700
DI 10.1371/journal.pone.0097700
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI5ML
UT WOS:000336911400018
PM 24892677
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, Y
   Bai, B
   Wu, HY
   Zhuang, H
AF Li Ying
   Bai Bo
   Wu Huo-yan
   Zhuang Hong
TI RETRACTED: Evaluation of a Modified POSSUM Scoring System for Predicting
   the Morbidity in Patients Undergoing Lumbar Surgery (Retracted article.
   See vol. 52, pg. 445, 2018)
SO INDIAN JOURNAL OF SURGERY
LA English
DT Review; Retracted Publication
DE POSSUM scoring; Audit; Morbidity; Lumbar surgery
ID PERIOPERATIVE COMPLICATIONS; POSTOPERATIVE MORBIDITY; ORTHOPEDIC POSSUM;
   FRACTURED NECK; RISK; MORTALITY; FUSION; RESECTION; STENOSIS; CANCER
AB For most spine surgeons, operative intervention is common for the treatment of lumbar disc herniation, lumbar stenosis, lumbar fracture or lumbar spondylolisthesis. However, with the increase in lumbar surgery, the complication rate increases accordingly. Whereas the Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity (POSSUM) scoring system has been widely used to predict morbidity in various surgical fields, the application of this system in lumbar surgery has not been reported. From January 2008 to January 2010, we recruited 158 patients (85 males and 73 females) with operation for lumbar disc herniation, lumbar stenosis, lumbar fracture, or lumbar spondylolisthesis. All patients were analyzed to compare the morbidity by a modified POSSUM scoring system. According to the modified POSSUM, the expected morbidity was 51 cases (32.3 %), whereas the observed mortality was 42 cases (26.6 %). The overall observed-to-expected ratio was 0.82, and the chi-squared test indicated no statistically significant difference between the expected and observed morbidities (chi (2) = 1.23, P = 0.27), suggesting that the modified POSSUM can accurately estimate the outcome. The modified POSSUM scoring system we developed is a useful tool for predicting and evaluating morbidity in lumbar surgery. Further studies are required to investigate whether this scoring system can predict mortality.
C1 [Li Ying; Wu Huo-yan] Guangdong Hosp Integrated Tradit & Western Med, Dept Orthopaed, Foshan 528200, Guangdong, Peoples R China.
   [Bai Bo] Guangzhou Med Univ, Affiliated Hosp 1, Dept Orthopaed, Guangzhou 510120, Guangdong, Peoples R China.
   [Zhuang Hong] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthopaed, Guangzhou 510405, Guangdong, Peoples R China.
RP Li, Y (reprint author), Guangdong Hosp Integrated Tradit & Western Med, Dept Orthopaed, Foshan 528200, Guangdong, Peoples R China.
EM leewinly@163.com
CR Arvidsson S, 1996, ACTA ANAESTH SCAND, V40, P783, DOI 10.1111/j.1399-6576.1996.tb04533.x
   Brosens RP, 2006, DIS COLON RECTUM, V49, P825, DOI 10.1007/s10350-005-0284-5
   Cassinelli EH, 2007, SPINE, V32, P230, DOI 10.1097/01.brs.0000251918.19508.b3
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   COPELAND GP, 1991, BRIT J SURG, V78, P356
   Crea N, 2009, ANN ITAL CHIR, V80, P177
   DAVNE SH, 1992, SPINE, V17, pS184, DOI 10.1097/00007632-199206001-00021
   de Castro SMM, 2009, WORLD J SURG, V33, P1481, DOI 10.1007/s00268-009-0037-z
   Fu KMG, 2010, J NEUROSURG-SPINE, V12, P443, DOI 10.3171/2009.11.SPINE09531
   GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601
   Griffiths H, 2002, CLIN OTOLARYNGOL, V27, P517, DOI 10.1046/j.1365-2273.2002.00626.x
   Heary RF, 2006, NEUROSURG CLIN N AM, V17, P377, DOI 10.1016/j.nec.2006.04.012
   Hirose J, 2009, CLIN ORTHOP RELAT R, V467, P3327, DOI 10.1007/s11999-009-0915-6
   Jutte PC, 2002, EUR SPINE J, V11, P594, DOI 10.1007/s00586-002-0469-8
   Kalanithi PS, 2009, SPINE, V34, P1963, DOI 10.1097/BRS.0b013e3181ae2243
   Knight RQ, 2009, J SPINAL DISORD TECH, V22, P34, DOI 10.1097/BSD.0b013e3181679b8a
   Kurita M, 2009, WOUND REPAIR REGEN, V17, P312, DOI 10.1111/j.1524-475X.2009.00486.x
   Loc PTB, 2010, BRIT J SURG, V97, P396, DOI 10.1002/bjs.6903
   MAHONEY F I, 1965, Md State Med J, V14, P61
   Mohamed K, 2002, J BONE JOINT SURG BR, V84B, P735, DOI 10.1302/0301-620X.84B5.12626
   Otsuka Y, 2007, HEPATO-GASTROENTEROL, V54, P1142
   Pratt W, 2008, SURGERY, V143, P8, DOI 10.1016/j.surg.2007.07.035
   Ramanathan TS, 2005, BRIT J ANAESTH, V94, P430, DOI 10.1093/bja/aei064
   Stromqvist F, 2010, EUR SPINE J, V19, P439, DOI 10.1007/s00586-009-1236-x
   Valenti V, 2009, LANGENBECK ARCH SURG, V394, P55, DOI 10.1007/s00423-008-0314-6
   Whiteley MS, 1996, BRIT J SURG, V83, P812, DOI 10.1002/bjs.1800830628
   Wright DM, 2008, INJURY, V39, P430, DOI 10.1016/j.injury.2007.11.009
   Young William, 2006, N Z Med J, V119, pU1986
NR 28
TC 4
Z9 4
U1 1
U2 5
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0972-2068
EI 0973-9793
J9 INDIAN J SURG
JI Indian J. Surg
PD JUN
PY 2014
VL 76
IS 3
BP 212
EP 216
DI 10.1007/s12262-013-0840-5
PG 5
WC Surgery
SC Surgery
GA AO0JS
UT WOS:000340995500008
PM 25177119
OA Green Published
DA 2018-12-27
ER

PT J
AU Guven, SF
   Dursun, AB
   Ciftci, B
   Erkekol, FO
   Kurt, OK
AF Guven, Selma Firat
   Dursun, Adile Berna
   Ciftci, Bulent
   Erkekol, Ferda Oner
   Kurt, Ozlem Kar
TI RETRACTED: The prevalence of obstructive sleep apnea in patients with
   difficult-to-treat asthama (Retracted article. See vol. 33, pg. 349,
   2015)
SO ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE asthma; difficult-to-treat asthma; obstructive sleep apnea;
   polysomnography; sleep quality
ID QUALITY-OF-LIFE; SEVERE ASTHMA; DAYTIME SLEEPINESS; ADULTS;
   DISTURBANCES; ASSOCIATION; POPULATION; DEFINITION; SYMPTOMS; RISK
AB Objectives: Obstructive sleep apnea (OSA) occurs more commonly in asthma patients than in the general population and can complicate asthma management. The aim of this study was to evaluate the presence of OSA in patients with difficult-to-treat asthma (DTA) and to investigate the sleep quality in these patients.
   Methods: Patients with DTA were recruited from the adult allergy clinic of a tertiary care hospital. After completing the Sleep Questionnaire and Epworth Sleepiness Scale, all participants underwent overnight polysomnography. The demographic and asthma severity assessments included the following measures: the age at diagnosis, duration of illness, smoking and atopy status, results of pulmonary function tests, number of asthma control medications used, and number of hospitalizations and emergency room visits because of asthma and analgesic hypersensitivity according to apnea-hypopnea index (AHI) scores.
   Results: We analyzed 47 (M:9/F:38) DTA patients with a mean age of 48.74 +/- 9.45 years. The mean duration of asthma was 9.17 +/- 6.5 years. Twenty-four (51.1%) patients were atopic. The analgesic hypersensitivity rate was 27.7%. Fourteen patients (29.8%) were former smokers and 2 patients were current smokers. Sleep quality was impaired in all patients. Thirty-five patients (74.5%) had OSA, 11 of whom had mild OSA, and 24 patients had moderate-severe OSA. The presence of OSA was not statistically correlated with asthma characteristics.
   Conclusion: The study showed that there is a remarkably high prevalence of OSA in DTA. Although no statistically significant relationship between the presence of OSA and clinical asthma characteristics was identified, all DTA patients should be assessed for OSA.
C1 [Guven, Selma Firat; Ciftci, Bulent] Ataturk Chest Dis & Thorac Surg Training & Res Ho, Sleep Disorders Ctr, Ankara, Turkey.
   [Dursun, Adile Berna; Erkekol, Ferda Oner] Ataturk Chest Dis & Thorac Surg Training & Res Ho, Allergy Clin, Ankara, Turkey.
   [Kurt, Ozlem Kar] Ataturk Chest Dis & Thorac Surg Training & Res Ho, Dept Chest Dis, Ankara, Turkey.
RP Guven, SF (reprint author), Ataturk Chest Dis & Thorac Surg Training & Res Ho, Sleep Disorders Ctr, Ankara, Turkey.
EM selmafiratguven@yahoo.com
RI Kar Kurt, Ozlem/B-7142-2016
OI Kar Kurt, Ozlem/0000-0002-4641-2866
CR Alkhalil M, 2009, J CLIN SLEEP MED, V5, P71
   Auckley D, 2008, SLEEP MED, V9, P494, DOI 10.1016/j.sleep.2007.06.010
   Beebe DW, 2002, J SLEEP RES, V11, P1, DOI 10.1046/j.1365-2869.2002.00289.x
   Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019
   Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702
   Ciftci TU, 2005, RESP MED, V99, P529, DOI 10.1016/j.rmed.2004.10.011
   Ekici A, 2005, CHEST, V128, P3358, DOI 10.1378/chest.128.5.3358
   Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263
   FITZPATRICK MF, 1993, EUR RESPIR J, V6, P531
   Flemons WW, 1999, SLEEP, V22, P667
   Iber C, 2007, AASM MANUAL SCORING
   Janson C, 1996, EUR RESPIR J, V9, P2132, DOI 10.1183/09031936.96.09102132
   JANSON C, 1990, RESP MED, V84, P37, DOI 10.1016/S0954-6111(08)80092-3
   JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376
   Julien JY, 2009, J ALLERGY CLIN IMMUN, V124, P371, DOI 10.1016/j.jaci.2009.05.016
   Kalra M, 2006, ANN ALLERG ASTHMA IM, V97, P231, DOI 10.1016/S1081-1206(10)60019-1
   Kasasbeh A, 2007, SLEEP MED REV, V11, P47, DOI 10.1016/j.smrv.2006.05.001
   Kushida CA, 2005, SLEEP, V28, P499, DOI 10.1093/sleep/28.4.499
   Lafond C, 2007, EUR RESPIR J, V29, P307, DOI 10.1183/09031936.00059706
   Larsson LG, 2001, RESP MED, V95, P423, DOI 10.1053/rmed.2001.1054
   Luyster FS, 2012, SLEEP BREATH, V16, P1129, DOI 10.1007/s11325-011-0616-8
   *NIH, 1998, OBES RES S2, V6, pS51
   NIMBI/WHO Workshop Report, 1995, NIH PUBLICATION
   Patil SP, 2007, CHEST, V132, P325, DOI 10.1378/chest.07-0040
   REMMERS JE, 1978, J APPL PHYSIOL, V44, P931
   Shigemitsu H, 2007, CURR OPIN PULM MED, V13, P49, DOI 10.1097/MCP.0b013e328010a890
   Sumino K, 2011, EUR RESPIR MONOGR, P16, DOI 10.1183/1025448x.10000610
   Teodorescu M, 2006, SLEEP MED, V7, P607, DOI 10.1016/j.sleep.2006.02.001
   Teodorescu M, 2010, CHEST, V138, P543, DOI 10.1378/chest.09-3066
   Yigla M, 2003, J ASTHMA, V40, P865, DOI 10.1081/JAS-120023577
   YOUNG T, N ENGL J MED, V328, P1230
NR 31
TC 12
Z9 13
U1 7
U2 30
PU ALLERGY IMMUNOL SOC THAILAND,
PI BANGKOK
PA MAHIDOL UNIV, DEPT MICROBIOL IMMUNOL, FACULTY TROPICAL MED, BANGKOK
   10400, THAILAND
SN 0125-877X
EI 2228-8694
J9 ASIAN PAC J ALLERGY
JI Asian Pac. J. Allergy Immunol.
PD JUN
PY 2014
VL 32
IS 2
BP 153
EP 159
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA AL4FI
UT WOS:000339087900008
PM 25003729
DA 2018-12-27
ER

PT J
AU Hwang, CC
   Tour, JJ
   Kittrell, C
   Espinal, L
   Alemany, LB
   Tour, JM
AF Hwang, Chih-Chau
   Tour, Josiah J.
   Kittrell, Carter
   Espinal, Laura
   Alemany, Lawrence B.
   Tour, James M.
TI RETRACTED: Capturing carbon dioxide as a polymer from natural
   gas(Retracted article. See vol. 7, 2016)
SO NATURE COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID ADSORPTION; CO2; HYDROGEN; NANOTUBES; STORAGE
AB Natural gas is considered the cleanest and recently the most abundant fossil fuel source, yet when it is extracted from wells, it often contains 10-20 mol% carbon dioxide (20-40 wt%), which is generally vented to the atmosphere. Efforts are underway to contain this carbon dioxide at the well-head using inexpensive and non-corrosive methods. Here we report nucleophilic porous carbons are synthesized from simple and inexpensive carbon-sulphur and carbon-nitrogen precursors. Infrared, Raman and C-13 nuclear magnetic resonance signatures substantiate carbon dioxide fixation by polymerization in the carbon channels to form poly(CO2) under much lower pressures than previously required. This growing chemisorbed sulphur- or nitrogen-atom-initiated poly(CO2) chain further displaces physisorbed hydrocarbon, providing a continuous carbon dioxide selectivity. Once returned to ambient conditions, the poly(CO2) spontaneously depolymerizes, leading to a sorbent that can be easily regenerated without the thermal energy input that is required for traditional sorbents.
C1 [Hwang, Chih-Chau; Tour, Josiah J.; Alemany, Lawrence B.; Tour, James M.] Rice Univ, Dept Chem, 6100 Main St, Houston, TX 77005 USA.
   [Kittrell, Carter; Alemany, Lawrence B.; Tour, James M.] Rice Univ, Richard E Smalley Inst Nanoscale Sci & Technol, Houston, TX 77005 USA.
   [Espinal, Laura] NIST, Mat Measurement Lab, Gaithersburg, MD 20899 USA.
   [Alemany, Lawrence B.] Rice Univ, Shared Equipment Author, Houston, TX 77005 USA.
   [Tour, James M.] Rice Univ, Dept Mat Sci & NanoEngn, Houston, TX 77005 USA.
RP Tour, JM (reprint author), Rice Univ, Dept Chem, 6100 Main St, Houston, TX 77005 USA.
EM tour@rice.edu
FU Apache Corporation; NIST
FX We thank G. Ruan, C. Xiang and Z. Peng for imaging. The work at Rice
   University was funded by Apache Corporation. The work at NIST was funded
   by NIST. Certain commercial materials, equipment, or processes are
   identified in the paper only to facilitate understanding. In no case
   does identification imply recommendation by NIST nor does it imply that
   the material, equipment, or process identified is necessarily the best
   available for this purpose.
CR Alvarez RA, 2012, P NATL ACAD SCI USA, V109, P6435, DOI 10.1073/pnas.1202407109
   Blach TP, 2007, J ALLOY COMPD, V446, P692, DOI 10.1016/j.jallcom.2006.12.061
   D'Alessandro DM, 2010, ANGEW CHEM INT EDIT, V49, P6058, DOI 10.1002/anie.201000431
   Dresselhaus MS, 2010, NANO LETT, V10, P751, DOI 10.1021/nl904286r
   Espinal L, 2013, ENVIRON SCI TECHNOL, V47, P11960, DOI 10.1021/es402622q
   Ferrari AC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187401
   Golombok M., 2008, HARTS E P, V81, P73
   Hartzog DG, 1995, ADSORPTION, V1, P133, DOI 10.1007/BF00705001
   Iota V, 1999, SCIENCE, V283, P1510, DOI 10.1126/science.283.5407.1510
   Langer J, 2010, ORGANOMETALLICS, V29, P1642, DOI 10.1021/om900918t
   Li JR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2552
   Puxty G, 2009, ENVIRON SCI TECHNOL, V43, P6427, DOI 10.1021/es901376a
   Qajar A, 2012, INT J HYDROGEN ENERG, V37, P9123, DOI 10.1016/j.ijhydene.2012.03.002
   Sankaran M, 2006, CARBON, V44, P2816, DOI 10.1016/j.carbon.2006.03.025
   Sevilla M, 2012, MICROPOR MESOPOR MAT, V158, P318, DOI 10.1016/j.micromeso.2012.02.029
   Siriwardane RV, 2001, ENERG FUEL, V15, P279, DOI 10.1021/ef000241s
   US Dept. of Energy, 1999, ARG NAT LAB REP FULL
   Wang LF, 2011, J PHYS CHEM C, V115, P21264, DOI 10.1021/jp206976d
   Xia YD, 2012, CARBON, V50, P5543, DOI 10.1016/j.carbon.2012.07.044
   Xie Y., 2013, NAT COMMUN, V4, P1960, DOI DOI 10.1038/NC0MMS2960;
   Yang R. T., 2003, ADSORBENTS FUNDAMENT
   Yong Z, 2001, ADSORPTION, V7, P41, DOI 10.1023/A:1011220900415
   Zhou L, 2003, LANGMUIR, V19, P2683, DOI 10.1021/la020682z
   Zhou W, 2007, J PHYS CHEM C, V111, P16131, DOI 10.1021/jp074889i
NR 24
TC 31
Z9 31
U1 8
U2 84
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN
PY 2014
VL 5
AR 3961
DI 10.1038/ncomms4961
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL0RK
UT WOS:000338834200004
PM 24892923
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Rosell-Negre, P
   Bustamante, JC
   Fuentes-Claramonte, P
   Costumero, V
   Benabarre, S
   Barros-Loscertales, A
AF Rosell-Negre, Patricia
   Carlos Bustamante, Juan
   Fuentes-Claramonte, Paola
   Costumero, Victor
   Benabarre, Sergio
   Barros-Loscertales, Alfonso
TI RETRACTED: Reward anticipation enhances brain activation during response
   inhibition(Retracted article. See vol.16,pg.1164,2016)
SO COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE Reward; Response inhibition; Sensitivity to reward
ID STOP-SIGNAL TASK; ANTERIOR CINGULATE CORTEX; EVENT-RELATED FMRI;
   COGNITIVE CONTROL; INDIVIDUAL-DIFFERENCES; PREFRONTAL CORTEX;
   MOTIVATIONAL INFLUENCES; ERROR-DETECTION; GRAYS ANXIETY; GO/NO-GO
AB The chance to achieve a reward starts up the required neurobehavioral mechanisms to adapt our thoughts and actions in order to accomplish our objective. However, reward does not equally reinforce everybody but depends on interindividual motivational dispositions. Thus, immediate reward contingencies can modulate the cognitive process required for goal achievement, while individual differences in personality can affect this modulation. We aimed to test the interaction between inhibition-related brain response and motivational processing in a stop signal task by reward anticipation and whether individual differences in sensitivity to reward (SR) modulate such interaction. We analyzed the cognitive-motivational interaction between the brain pattern activation of the regions involved in correct and incorrect response inhibition and the association between such brain activations and SR scores. We also analyzed the behavioral effects of reward on both reaction times for the "go" trials before and after correct and incorrect inhibition in order to test error prediction performance and postinhibition adjustment. Our results show enhanced activation during response inhibition under reward contingencies in frontal, parietal, and subcortical areas. Moreover, activation of the right insula and the left putamen positively correlates with the SR scores. Finally, the possibility of reward outcome affects not only response inhibition performance (e.g., reducing stop signal reaction time), but also error prediction performance and postinhibition adjustment. Therefore, reward contingencies improve behavioral performance and enhance brain activation during response inhibition, and SR is related to brain activation. Our results suggest the conditions and factors that subserve cognitive control strategies in cognitive motivational interactions during response inhibition.
C1 [Rosell-Negre, Patricia; Carlos Bustamante, Juan; Fuentes-Claramonte, Paola; Costumero, Victor; Barros-Loscertales, Alfonso] Univ Jaume 1, Dept Psicol Basica Clin & Psicobiol, Castellon de La Plana 12071, Castello De La, Spain.
   [Benabarre, Sergio] IACS, Unidad Docente Med Familiar & Comunitaria, Zaragoza 50009, Spain.
RP Barros-Loscertales, A (reprint author), Univ Jaume 1, Dept Psicol Basica Clin & Psicobiol, Av Vicent Sos Baynat S-N, Castellon de La Plana 12071, Castello De La, Spain.
EM barros@uji.es
RI Bustamante, Juan Carlos/J-7534-2015; Barros-Loscertales,
   Alfonso/D-7069-2013
OI Bustamante, Juan Carlos/0000-0002-8201-0469; Fuentes-Claramonte,
   Paola/0000-0002-1428-7976
FU Spanish Ministry of Economy and Competitiveness [PSI2012-33054];
   Generalitat Valenciana [GV/2012/042]; Spanish National Drug Strategy
   [2011I040]
FX This research has been supported by Grants PSI2012-33054 from the
   Spanish Ministry of Economy and Competitiveness, GV/2012/042 from the
   Generalitat Valenciana, and 2011I040 from the Spanish National Drug
   Strategy.
CR Aarts E, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00163
   Aron A., 2006, CORTICAL SUBCORTICAL
   Aron AR, 2011, BIOL PSYCHIAT, V69, pE55, DOI 10.1016/j.biopsych.2010.07.024
   Avila C, 2008, NEUROTOX RES, V14, P191, DOI 10.1007/BF03033810
   Avila C, 2001, PERS INDIV DIFFER, V31, P975, DOI 10.1016/S0191-8869(00)00199-9
   Avila C, 2012, SOC COGN AFFECT NEUR, V7, P423, DOI 10.1093/scan/nsr028
   Beck S., 2010, PLOS ONE, V5, pe9252
   Bissett PG, 2011, J EXP PSYCHOL LEARN, V37, P392, DOI 10.1037/a0021800
   Boehler CN, 2009, CEREB CORTEX, V19, P134, DOI 10.1093/cercor/bhn063
   Boehler CN, 2014, COGN AFFECT BEHAV NE, V14, P593, DOI 10.3758/s13415-014-0251-5
   Boehler CN, 2012, COGNITION, V125, P498, DOI 10.1016/j.cognition.2012.07.018
   Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109
   Braem S, 2012, COGNITION, V125, P324, DOI 10.1016/j.cognition.2012.07.015
   Braver TS, 2012, TRENDS COGN SCI, V16, P106, DOI 10.1016/j.tics.2011.12.010
   Caseras X, 2003, PERS INDIV DIFFER, V34, P999, DOI 10.1016/S0191-8869(02)00084-3
   Chamberlain SR, 2009, BIOL PSYCHIAT, V65, P550, DOI 10.1016/j.biopsych.2008.10.014
   Chambers CD, 2009, NEUROSCI BIOBEHAV R, V33, P631, DOI 10.1016/j.neubiorev.2008.08.016
   Chao HHA, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-75
   Chevrier A, 2010, NEUROIMAGE, V53, P664, DOI 10.1016/j.neuroimage.2010.06.056
   Chevrier AD, 2007, HUM BRAIN MAPP, V28, P1347, DOI 10.1002/hbm.20355
   Chikazoe J, 2010, CURR OPIN PSYCHIATR, V23, P267, DOI 10.1097/YCO.0b013e3283387a9f
   Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755
   Duann JR, 2009, J NEUROSCI, V29, P10171, DOI 10.1523/JNEUROSCI.1300-09.2009
   Emeric EE, 2007, VISION RES, V47, P35, DOI 10.1016/j.visres.2006.08.032
   Engelmann J. B., 2009, FRONTIERS HUMAN NEUR, V3
   FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007
   Gilbert Alison M., 2004, Cognitive Affective & Behavioral Neuroscience, V4, P540, DOI 10.3758/CABN.4.4.540
   Gray J., 2000, NERUOPSYCHOLOGY ANXI
   Hagberg GE, 2001, NEUROIMAGE, V14, P1193, DOI 10.1006/nimg.2001.0880
   Hendrick OM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013155
   Ide JS, 2013, J NEUROSCI, V33, P2039, DOI 10.1523/JNEUROSCI.2201-12.2013
   Ide JS, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00025
   Ide JS, 2011, NEUROIMAGE, V54, P455, DOI 10.1016/j.neuroimage.2010.07.042
   Jahfari S, 2010, J COGNITIVE NEUROSCI, V22, P1479, DOI 10.1162/jocn.2009.21307
   Jimura K, 2010, CEREB CORTEX, V20, P1420, DOI 10.1093/cercor/bhp206
   Jimura K, 2010, P NATL ACAD SCI USA, V107, P8871, DOI 10.1073/pnas.1002007107
   Krebs RM, 2009, NEUROPSYCHOLOGIA, V47, P2272, DOI 10.1016/j.neuropsychologia.2009.01.015
   Leotti LA, 2010, J EXP PSYCHOL HUMAN, V36, P430, DOI 10.1037/a0016802
   Li CSR, 2008, NEUROSCIENCE, V155, P1142, DOI 10.1016/j.neuroscience.2008.06.062
   Li CSR, 2008, NEUROIMAGE, V41, P1352, DOI 10.1016/j.neuroimage.2008.04.023
   Li CSR, 2007, PERS INDIV DIFFER, V43, P475, DOI 10.1016/j.paid.2006.12.016
   Li CSR, 2009, CEREB CORTEX, V19, P839, DOI 10.1093/cercor/bhn132
   Liu TT, 2001, NEUROIMAGE, V13, P759, DOI 10.1006/nimg.2000.0728
   Locke HS, 2008, COGN AFFECT BEHAV NE, V8, P99, DOI 10.3758/CABN.8.1.99
   Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x
   LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037//0033-295X.91.3.295
   Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1
   Marco-Pallares J., 2008, J COGNITIVE NEUROSCI, V22, P1
   Padmala S, 2011, J COGNITIVE NEUROSCI, V23, P3419, DOI 10.1162/jocn_a_00011
   Padmala S, 2010, NEUROPSYCHOLOGIA, V48, P558, DOI 10.1016/j.neuropsychologia.2009.10.017
   Pessoa L, 2010, FRONT NEUROSCI-SWITZ, V4, DOI [10.3389/fnins.2010.00017, 10.3389/fnhum.2010.00064]
   Pessoa L, 2009, TRENDS COGN SCI, V13, P160, DOI 10.1016/j.tics.2009.01.006
   Pochon JB, 2002, P NATL ACAD SCI USA, V99, P5669, DOI 10.1073/pnas.082111099
   Rogers RD, 2004, BIOL PSYCHIAT, V55, P594, DOI 10.1016/j.biopsych.2003.11.012
   Rubia K, 2003, NEUROIMAGE, V20, P351, DOI 10.1016/S1053-8119(03)00275-1
   Rubia K, 2007, HUM BRAIN MAPP, V28, P1163, DOI 10.1002/hbm.20347
   Schachar RJ, 2004, J ABNORM CHILD PSYCH, V32, P285, DOI 10.1023/B:JACP.0000026142.11217.f2
   Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272
   Stoppel CM, 2011, BRAIN RES, V1383, P218, DOI 10.1016/j.brainres.2011.01.095
   Swick D, 2011, NEUROIMAGE, V56, P1655, DOI 10.1016/j.neuroimage.2011.02.070
   Torrubia R, 2001, PERS INDIV DIFFER, V31, P837, DOI 10.1016/S0191-8869(00)00183-5
   van Steenbergen H, 2009, PSYCHOL SCI, V20, P1473, DOI 10.1111/j.1467-9280.2009.02470.x
   Verbruggen F, 2008, TRENDS COGN SCI, V12, P418, DOI 10.1016/j.tics.2008.07.005
   Verbruggen F, 2008, J EXP PSYCHOL GEN, V137, P649, DOI 10.1037/a0013170
   Verbruggen F, 2013, PSYCHOL SCI, V24, P352, DOI 10.1177/0956797612457390
   Verbruggen F, 2009, J EXP PSYCHOL HUMAN, V35, P835, DOI 10.1037/a0012726
   Vink M, 2005, HUM BRAIN MAPP, V25, P336, DOI 10.1002/hbm.20111
   Winkler AD, 2013, INT J PSYCHOPHYSIOL, V87, P254, DOI 10.1016/j.ijpsycho.2012.08.010
   Xue G, 2008, CEREB CORTEX, V18, P1923, DOI 10.1093/cercor/bhm220
   Zandbelt B., 2008, NEUROSCIENCE
   Zhang S, 2012, HUM BRAIN MAPP, V33, P89, DOI 10.1002/hbm.21197
   Zink CF, 2004, NEURON, V42, P509, DOI 10.1016/S0896-6273(04)00183-7
NR 72
TC 7
Z9 7
U1 8
U2 27
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-7026
EI 1531-135X
J9 COGN AFFECT BEHAV NE
JI Cogn. Affect. Behav. Neurosci.
PD JUN
PY 2014
VL 14
IS 2
BP 621
EP 634
DI 10.3758/s13415-014-0292-9
PG 14
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA AK6CY
UT WOS:000338516800011
PM 24867712
DA 2018-12-27
ER

PT J
AU Jafarzadeh, H
   Babaei, A
AF Jafarzadeh, H.
   Babaei, A.
TI RETRACTED: Accumulative radial-forward extrusion (ARFE) processing as a
   novel severe plastic deformation technique (Retracted article. See vol.
   30, pg. 3887, 2016)
SO JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Accumulative; FEM; Grain; Microhardness; Microstructure; Strain
ID TWIST EXTRUSION; ECAP
AB A novel severe plastic deformation (SPD) technique entitled accumulative radial-forward extrusion (ARFE) is introduced for producing ultra-fine grained bulk materials. This method is based on radial-forward extrusion process because of inherent capabilities for imposing extremely high plastic strains on material. ARFE was applied to AA1050 and the ability of this process in significant grain refinement is determined even after single cycle. Transmission electron microscopy (TEM) examination showed ultra-fine grains (UFGs) with the average grain size of 450 nm after one cycle of ARFE. Furthermore, micro-hardness distribution through the part's section indicates the hardness increase to similar to 52 Hv from the initial value of similar to 28 Hv after one cycle of ARFE. In order to further investigate of the accumulated strains, ARFE process was also numerically modelled by finite element method.
C1 [Jafarzadeh, H.; Babaei, A.] Islamic Azad Univ, Tabriz Branch, Dept Mech Engn, Tabriz, Iran.
RP Jafarzadeh, H (reprint author), Islamic Azad Univ, Tabriz Branch, Dept Mech Engn, Tabriz, Iran.
EM h.jafarzadeh@iaut.ac.ir
FU Tabriz Branch, Islamic Azad University
FX The authors would like to thank Tabriz Branch, Islamic Azad University
   for the financial support of this research, which is based on a research
   project contract.
CR Azushima A, 2008, CIRP ANN-MANUF TECHN, V57, P716, DOI 10.1016/j.cirp.2008.09.005
   Beygelzimer Y, 2009, MAT SCI ENG A-STRUCT, V503, P14, DOI 10.1016/j.msea.2007.12.055
   Eizadjou M., 2008, J ALLOY COMPD, V474, P406
   Farhoumand A, 2009, MATER DESIGN, V30, P2152, DOI 10.1016/j.matdes.2008.08.025
   Fatemi-Varzaneh SM, 2009, MAT SCI ENG A-STRUCT, V504, P104, DOI 10.1016/j.msea.2008.10.027
   Iwahashi Y, 1996, SCRIPTA MATER, V35, P143, DOI 10.1016/1359-6462(96)00107-8
   Jafarzadeh H, 2011, MATER MANUF PROCESS, V26, P703, DOI 10.1080/10426914.2010.496124
   Jafarzadeh H, 2010, MATER MANUF PROCESS, V25, P857, DOI 10.1080/10426910903536741
   Jahedi M, 2011, MAT SCI ENG A-STRUCT, V528, P8742, DOI 10.1016/j.msea.2011.08.055
   Korbel A., 1981, P 2 RISO INT S MET M, P450
   Loucif A., 2010, MAT SCI ENG A-STRUCT, V532, P139
   Pardis N, 2009, MAT SCI ENG A-STRUCT, V527, P355, DOI 10.1016/j.msea.2009.08.051
   Reihanian M, 2008, MATER CHARACT, V59, P1312, DOI 10.1016/j.matchar.2007.11.006
   Shirdel A, 2010, MATER DESIGN, V31, P946, DOI 10.1016/j.matdes.2009.07.035
   Valder J, 2012, MATER MANUF PROCESS, V27, P986, DOI 10.1080/10426914.2011.610081
   Varyukhin V, 2006, MATER SCI FORUM, V503-504, P335, DOI 10.4028/www.scientific.net/MSF.503-504.335
   Zhang J, 2007, MATER SCI FORUM, V546-549, P2293, DOI 10.4028/www.scientific.net/MSF.546-549.2293
NR 17
TC 3
Z9 3
U1 2
U2 8
PU KOREAN SOC MECHANICAL ENGINEERS
PI SEOUL
PA KSTC NEW BLD. 7TH FLOOR, 635-4 YEOKSAM-DONG KANGNAM-KU, SEOUL 135-703,
   SOUTH KOREA
SN 1738-494X
EI 1976-3824
J9 J MECH SCI TECHNOL
JI J. Mech. Sci. Technol.
PD JUN
PY 2014
VL 28
IS 6
BP 2337
EP 2341
DI 10.1007/s12206-014-0524-5
PG 5
WC Engineering, Mechanical
SC Engineering
GA AK0QI
UT WOS:000338119100037
DA 2018-12-27
ER

PT J
AU Derosa, G
   Bonaventura, A
   Romano, D
   Bianchi, L
   Fogari, E
   D'Angelo, A
   Maffioli, P
AF Derosa, Giuseppe
   Bonaventura, Aldo
   Romano, Davide
   Bianchi, Lucio
   Fogari, Elena
   D'Angelo, Angela
   Maffioli, Pamela
TI RETRACTED: Enalapril/lercanidipine combination on markers of
   cardiovascular risk: a randomized study (Retracted article. See vol. 9,
   pg. 822, 2015)
SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
LA English
DT Article; Retracted Publication
DE Enalapril; hypertension; lercanidipine; risk factors
ID GLYCATION END-PRODUCTS; HYPERTENSIVE PATIENTS; SERUM-LIPOPROTEINS;
   PLASMA; RECEPTOR; DISEASE; CLONING; MYELOPEROXIDASE; CHOLESTEROL;
   METABOLISM
AB The aim of this study was to evaluate enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to enalapril 20 mg, lercanidipine 10 mg, or enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-alpha (TNF-alpha). We recorded a decrease of BP in all groups, with the enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not enalapril, improved Lp(a) levels compared with baseline, with enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if enalapril/lercanidipine combination was more effective than single monotherapies. TNF-alpha and Hs-CRP were greater reduced by enalapril/lercanidipine combination compared with enalapril (P < .05 for both). The enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients. (C) 2014 American Society of Hypertension. All rights reserved.
C1 [Derosa, Giuseppe; Bonaventura, Aldo; Romano, Davide; Bianchi, Lucio; Fogari, Elena; D'Angelo, Angela; Maffioli, Pamela] Univ Pavia, Dept Internal Med & Therapeut, I-1927100 Pavia, Italy.
   [Derosa, Giuseppe; Bonaventura, Aldo; Romano, Davide; Bianchi, Lucio; Fogari, Elena; D'Angelo, Angela; Maffioli, Pamela] Fdn IRCCS Policlin S Matteo, I-1927100 Pavia, Italy.
   [Derosa, Giuseppe] Univ Pavia, Ctr Study Endocrine Metab Pathophysiol & Clin Res, I-1927100 Pavia, Italy.
RP Derosa, G (reprint author), Univ Pavia, Ple Golgi, I-1927100 Pavia, Italy.
EM giuseppe.derosa@unipv.it
OI Derosa, Giuseppe/0000-0003-3573-4760
CR Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524
   Bakris GL, 2002, J HUM HYPERTENS, V16, P185, DOI 10.1038/sj/jhh/1001315
   Bhavani BA, 2003, INDIAN J HUM GENET, V9, P65
   BRETT J, 1993, AM J PATHOL, V143, P1699
   Brook R D, 2000, Curr Hypertens Rep, V2, P370, DOI 10.1007/s11906-000-0040-0
   Catalano M, 1998, J HUM HYPERTENS, V12, P83, DOI 10.1038/sj.jhh.1000540
   CHOBANIAN AV, 1990, CLIN CARDIOL, V13, P43
   Derosa G, 2012, CURR MED RES OPIN, V28, P1435, DOI 10.1185/03007995.2012.717527
   Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830
   Estacio RO, 1998, AM J CARDIOL, V2, pR1
   Falcone C, 2005, ARTERIOSCL THROM VAS, V25, P1032, DOI 10.1161/01.ATV.0000160342.20342.00
   FERRARI P, 1991, AM J CARDIOL, V67, pB26, DOI 10.1016/0002-9149(91)90817-5
   Ferroni Patrizia, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P194, DOI 10.2174/187152908785849125
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226
   Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   KASISKE BL, 1995, ANN INTERN MED, V122, P133, DOI 10.7326/0003-4819-122-2-199501150-00010
   KEANE WF, 1991, AM J KIDNEY DIS, V17, P38
   KLOSE S, 1978, J CLIN CHEM CLIN BIO, V15, P121
   Koyama H, 2005, ARTERIOSCL THROM VAS, V25, P2587, DOI 10.1161/01.ATV.0000190660.32863.cd
   Malherbe P, 1999, MOL BRAIN RES, V71, P159, DOI 10.1016/S0169-328X(99)00174-6
   MORISHITA K, 1987, J BIOL CHEM, V262, P3844
   Rifai N, 1999, CLIN CHEM, V45, P2136
   Scanu A M, 1991, Adv Intern Med, V36, P249
   SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326
   UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093
   WAHLEFELD AW, 1974, METHOD ENZYMAT AN, P18
   WEIDMANN P, 1993, J CARDIOVASC PHARM, V22, pS98
   Winer B. J., 1971, STAT PRINCIPLES EXPT
   Zhang M, 1988, CYTOKINE HDB
NR 31
TC 6
Z9 6
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1933-1711
EI 1878-7436
J9 J AM SOC HYPERTENS
JI J. Am. Soc. Hypertens.
PD JUN
PY 2014
VL 8
IS 6
BP 422
EP 428
DI 10.1016/j.jash.2014.03.329
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AK5PW
UT WOS:000338479300010
PM 24836352
DA 2018-12-27
ER

PT J
AU Lu, YY
   An, LJ
   Wang, SQ
   Wang, ZG
AF Lu, Yuyuan
   An, Lijia
   Wang, Shi-Qing
   Wang, Zhen-Gang
TI RETRACTED: Origin of Stress Overshoot during Startup Shear of Entangled
   Polymer Melts (Retracted article. See vol. 6, pg. 343, 2017)
SO ACS MACRO LETTERS
LA English
DT Article; Retracted Publication
ID MOLECULAR-DYNAMICS; HIGH-RATES; FLOW; SIMULATIONS; BEHAVIOR;
   POLYSTYRENE; COMPUTER; RHEOLOGY; SYSTEMS; PATH
AB Using Brownian dynamics simulation, we determine the chain orientation and stretching and their connection to stress overshoot in an entangled polymer melt undergoing startup shear at rates lower than the reciprocal of the Rouse time yet higher than the reciprocal of the reptation time. In this rate regime, the prevailing tube theory attributes the stress overshoot to alignment of the primitive chain. In contrast, our results reveal that there is substantial chain stretching that persists well beyond the Rouse time, and it contributes significantly to the initial stress growth. In particular, stress overshoot is found to be primarily due to chain retraction after considerable stretching rather than chain orientation.
C1 [Lu, Yuyuan; An, Lijia; Wang, Zhen-Gang] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China.
   [Wang, Shi-Qing] Univ Akron, Dept Polymer Sci, Akron, OH 44325 USA.
   [Wang, Zhen-Gang] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.
RP An, LJ (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China.
EM ljan@ciac.jl.cn; swang@uakron.edu; zgw@caltech.edu
FU National Natural Science Foundation of China [21120102037, 21334007,
   21304097]; Special Funds for National Basic Research Program of China
   [2012CB821500]
FX This work is supported, in part, by the National Natural Science
   Foundation of China (Nos. 21120102037, 21334007, and 21304097) and
   further subsidized by the Special Funds for National Basic Research
   Program of China (No. 2012CB821500).
CR Auhl D, 2008, J RHEOL, V52, P801, DOI 10.1122/1.2890780
   Auhl R, 2003, J CHEM PHYS, V119, P12718, DOI 10.1063/1.1628670
   Boukany PE, 2009, J RHEOL, V53, P617, DOI 10.1122/1.3086872
   Cao J, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.028302
   Collis MW, 2005, J RHEOL, V49, P501, DOI 10.1122/1.1849180
   Doi M, 1986, THEORY POLYM DYNAMIC
   Graham RS, 2003, J RHEOL, V47, P1171, DOI 10.1122/1.1595099
   Hemadez A. R., 2013, MACROMOLECULES, V46, P6287
   Huppler J. D., 1967, T SOC RHEOL, V11, P181
   KREMER K, 1990, J CHEM PHYS, V92, P5057, DOI 10.1063/1.458541
   Kroger M, 2005, COMPUT PHYS COMMUN, V168, P209, DOI 10.1016/j.cpc.2005.01.020
   KROGER M, 1993, J RHEOL, V37, P1057
   Kumar S, 2001, J CHEM PHYS, V114, P6937, DOI 10.1063/1.1358860
   LEES AW, 1972, J PHYS PART C SOLID, V5, P1921, DOI 10.1088/0022-3719/5/15/006
   Lu YY, 2013, ACS MACRO LETT, V2, P561, DOI 10.1021/mz400145m
   McLeish TCB, 2002, ADV PHYS, V51, P1379, DOI 10.1080/00018730210153216
   MENEZES EV, 1982, J POLYM SCI POL PHYS, V20, P1817, DOI 10.1002/pol.1982.180201006
   Osaki K, 2000, J POLYM SCI POL PHYS, V38, P1917, DOI 10.1002/1099-0488(20000715)38:14<1917::AID-POLB100>3.0.CO;2-6
   Osaki K, 2000, J POLYM SCI POL PHYS, V38, P2043, DOI 10.1002/1099-0488(20000801)38:15<2043::AID-POLB90>3.3.CO;2-6
   PEARSON DS, 1989, J RHEOL, V33, P517, DOI 10.1122/1.550026
   Ravindranath S, 2008, J RHEOL, V52, P681, DOI 10.1122/1.2899147
   SHAFFER JS, 1994, J CHEM PHYS, V101, P4205, DOI 10.1063/1.467470
   Snijkers F, 2013, ACS MACRO LETT, V2, P601, DOI 10.1021/mz400236z
   Snijkers F, 2011, J RHEOL, V55, P1167, DOI 10.1122/1.3625559
   Sukumaran SK, 2005, J POLYM SCI POL PHYS, V43, P917, DOI 10.1002/polb.20384
   Tzoumanekas C, 2006, MACROMOLECULES, V39, P4592, DOI 10.1021/ma0607057
   VINOGRADOV GV, 1965, J POLYM SCI PART A, V3, P917, DOI 10.1002/pol.1965.100030307
   Wang SQ, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2753156
   Wang SQ, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187801
   Wang SQ, 2013, MACROMOLECULES, V46, P3147, DOI 10.1021/ma300398x
   Zhou Q, 2005, MACROMOLECULES, V38, P5761, DOI 10.1021/ma050347s
   Zhou Q, 2006, MACROMOLECULES, V39, P6737, DOI 10.1021/ma060670a
NR 32
TC 35
Z9 36
U1 5
U2 85
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2161-1653
J9 ACS MACRO LETT
JI ACS Macro Lett.
PD JUN
PY 2014
VL 3
IS 6
BP 569
EP 573
DI 10.1021/mz500260h
PG 5
WC Polymer Science
SC Polymer Science
GA AJ4KG
UT WOS:000337644500016
DA 2018-12-27
ER

PT J
AU Imazato, T
   Shiokawa, A
   Kurose, Y
   Katou, Y
   Kishikawa, N
   Ohyama, K
   Ali, MFB
   Ueki, Y
   Maehata, E
   Kuroda, N
AF Imazato, Takahiro
   Shiokawa, Akina
   Kurose, Yuri
   Katou, Yasuha
   Kishikawa, Naoya
   Ohyama, Kaname
   Ali, Marwa Fathy Bakr
   Ueki, Yukitaka
   Maehata, Eisuke
   Kuroda, Naotaka
TI RETRACTED: Determination of 4-hydroxy-2-nonenal in serum by
   high-performance liquid chromatography with fluorescence detection after
   pre-column derivatization using
   4-(N,N-dimethylaminosulfonyl)-7-hydrazino-2, 1,3-benzoxadiazole
   (Retracted article. See vol. 28, pg. 1430, 2014)
SO BIOMEDICAL CHROMATOGRAPHY
LA English
DT Article; Retracted Publication
DE 4-hydroxy-2-nonenal (4HNE); fluorescent labeling; sub-zero temperature
   extraction; rheumatoid arthritis
ID LIPID-PEROXIDATION; RHEUMATOID-ARTHRITIS; ALDEHYDIC PRODUCTS; PLASMA;
   IDENTIFICATION; SEPARATION; SAMPLES
AB 4-Hydroxy-2-nonenal (4HNE) is a major aldehyde generated during lipid peroxidation. The clinical monitoring of 4HNE in biological fluids should be useful for the early diagnosis of several diseases involving lipid peroxidation, such as rheumatoid arthritis, Parkinson's disease and cancer. In this study, an HPLC with fluorescence detection method was developed for the determination of 4HNE in human serum. The proposed method involves the extraction of 4HNE from human serum by sub-zero temperature extraction and fluorescent labeling of 4HNE with 4-(N,N-dimethylaminosulfonyl)-7-hydrazino-2, 1,3-benzoxadiazole. The lower detection limit (signal-to-noise ratio = 3) of the method was 0.06 m in serum. The proposed method was successfully applied to the measurement of 4HNE in sera obtained from patients with rheumatoid arthritis. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Imazato, Takahiro; Shiokawa, Akina; Kurose, Yuri; Katou, Yasuha; Kishikawa, Naoya; Ohyama, Kaname; Ali, Marwa Fathy Bakr; Kuroda, Naotaka] Nagasaki Univ, Grad Sch Biomed Sci, Course Pharmaceut Sci, Nagasaki 8528521, Japan.
   [Imazato, Takahiro; Ueki, Yukitaka] Sasebo Chuo Hosp, Sasebo, Japan.
   [Maehata, Eisuke] Showa Univ, Fujigaoka Hosp, Yokohama, Kanagawa 227, Japan.
   [Ali, Marwa Fathy Bakr] Assiut Univ, Fac Pharm, Dept Pharmaceut Analyt Chem, Assiut, Egypt.
RP Kuroda, N (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Course Pharmaceut Sci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.
EM n-kuro@nagasaki-u.ac.jp
CR BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X
   BENEDETTI A, 1987, BIOELECTROCH BIOENER, V18, P187, DOI 10.1016/0302-4598(87)85021-3
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   ESTERBAUER H, 1982, BIOCHEM J, V208, P129, DOI 10.1042/bj2080129
   ESTERBAUER H, 1982, FREE RADICALS LIPID, P101
   ESTERBAUER H, 1990, MEMBRANE LIPID OXIDA, P239
   FAZIO VM, 1992, CANCER RES, V52, P4866
   Liu YM, 1996, J CHROMATOGR A, V719, P450, DOI 10.1016/0021-9673(95)00733-4
   Milic I, 2013, ANAL CHEM, V85, P156, DOI 10.1021/ac302356z
   POLI G, 1985, BIOCHEM J, V227, P629, DOI 10.1042/bj2270629
   SCHAUENS.E, 1967, J LIPID RES, V8, P417
   SELLEY ML, 1992, ANN RHEUM DIS, V51, P481, DOI 10.1136/ard.51.4.481
   Selley ML, 1997, J CHROMATOGR B, V691, P263, DOI 10.1016/S0378-4347(96)00446-X
   Selley ML, 1998, FREE RADICAL BIO MED, V25, P169, DOI 10.1016/S0891-5849(98)00021-5
   Shi Q, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4062
   Spies-Martin D, 2002, J CHROMATOGR B, V774, P231, DOI 10.1016/S1570-0232(02)00242-8
   STROHMAIER H, 1995, J LIPID MEDIAT CELL, V11, P51, DOI 10.1016/0929-7855(94)00027-A
   Tanaka R, 2013, J LIQ CHROMATOGR R T, V36, P881, DOI 10.1080/10826076.2012.678454
   UCHIDA K, 1995, BIOCHEM BIOPH RES CO, V212, P1068, DOI 10.1006/bbrc.1995.2078
   Yoshida M, 2004, ANAL CHEM, V76, P4672, DOI 10.1021/ac040065a
NR 20
TC 1
Z9 1
U1 3
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-3879
EI 1099-0801
J9 BIOMED CHROMATOGR
JI Biomed. Chromatogr.
PD JUN
PY 2014
VL 28
IS 6
SI SI
BP 858
EP 861
DI 10.1002/bmc.3166
PG 4
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA AJ2YR
UT WOS:000337531900020
PM 24861754
DA 2018-12-27
ER

PT J
AU Wang, CX
   Liu, XJ
   Wang, P
   Yang, PF
AF Wang, Chengxue
   Liu, Xiaojing
   Wang, Peng
   Yang, Pengfei
TI RETRACTED: Determination and Correlation of Liquid-Liquid Equilibrium
   Data for the Ternary Dichloromethane plus Water plus
   N,N-Dimethylacetamide System (Retracted article. See vol. 63, pg. 1847,
   2018)
SO JOURNAL OF CHEMICAL AND ENGINEERING DATA
LA English
DT Article; Retracted Publication
AB The liquid liquid equilibrium (LLE) data for the ternary system dichloromethane +water + N,N-dimethylacetamide were determined at (298.15 and 308.15) K and atmospheric pressure. The solubility data were obtained by using the cloud point titration method. The ternary phase diagrams could be drawn from the data of the tie-lines. The experimental data were correlated by using the nonrandom two-liquid (NRTL) model. The binary interaction parameters of the ternary system were regressed by nonlinear least-squares method, then the LLE data of the ternary system were calculated. The results indicated that the calculated LLE data by using NRTL model agreed well with the experimental data. The relative mean deviation and the average mean deviation were no more than 1.484 % and 0.513 %, respectively.
C1 [Wang, Chengxue; Liu, Xiaojing; Wang, Peng; Yang, Pengfei] Changchun Univ Technol, Sch Chem Engn, Changchun 130012, Jilin, Peoples R China.
RP Wang, CX (reprint author), Changchun Univ Technol, Sch Chem Engn, Changchun 130012, Jilin, Peoples R China.
EM wchxccut@126.com
CR China Sixth Design Institute of the Ministry of Petroleum Chemical Industry, 1976, CHEM ENG, V6, P32
   Gao G. H., 2007, CHEM ENG THERMODYNAM
   Gholam K., 2008, J CHEM ENG JPN, V41, P878
   [郭斌 Guo Bin], 2012, [高校化学工程学报, Journal of Chemical Engineering of Chinese Universities], V26, P698
   [林金清 LIN Jin-qing], 2009, [高校化学工程学报, Journal of Chemical Engineering of Chinese Universities], V23, P736
   [林泉 Lin Quan], 2002, [水处理技术, Technology of Water Treatment], V28, P196
   [刘利 Liu Li], 2010, [环境工程学报, Chinese Journal of Environmental Engineering], V4, P269
   Piao X. L., 2006, CHIN CHEM SOC 8 CHEM, P481
   Wang ZH, 2011, FLUID PHASE EQUILIBR, V311, P54, DOI 10.1016/j.fluid.2011.09.001
   [叶长燊 YE Chang-shen], 2009, [高校化学工程学报, Journal of Chemical Engineering of Chinese Universities], V23, P183
   Zou S. O., 1982, CHEM ENG CHINA, V5, P78
NR 11
TC 9
Z9 10
U1 1
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-9568
J9 J CHEM ENG DATA
JI J. Chem. Eng. Data
PD JUN
PY 2014
VL 59
IS 6
BP 1733
EP 1736
DI 10.1021/je401001z
PG 4
WC Thermodynamics; Chemistry, Multidisciplinary; Engineering, Chemical
SC Thermodynamics; Chemistry; Engineering
GA AJ0JL
UT WOS:000337336700001
DA 2018-12-27
ER

PT J
AU Cha, MH
   Heo, JY
   Lee, C
   Lo, YM
   Moon, B
AF Cha, Min-Ha
   Heo, Ji-Young
   Lee, Chan
   Lo, Y. Martin
   Moon, Bokyung
TI RETRACTED: Quality and Sensory Characterization of White Jelly Mushroom
   (Tremella fuciformis) as a Meat Substitute in Pork Patty Formulation
   (Retracted Article)
SO JOURNAL OF FOOD PROCESSING AND PRESERVATION
LA English
DT Article; Retracted Publication
ID GROUND-BEEF; FAT; FLOUR; EXERCISE; FOODS
AB White jelly mushroom (WJM; Tremella fuciformis) has been used for medicinal purposes because of its diverse physiological activities. This study evaluated the effect of WJM on the quality and sensory characteristics of pork patties. In cooked pork patties, moisture content of patties increased with the amount of WJM added, and pork patties formulated with WJM had significantly higher cooking yield than control sample. All treatments had a higher lightness (64.31 approximate to 67.23) and yellowness (14.39 approximate to 14.60) content than the control (61.73 and 14.20, respectively), because WJM has typically whiteness and lightness values. Control sample showed lowest score (3.8) in preference by oiliness and this value was lower than average (4.0) whereas preference by oiliness in samples with WJM increased (4.9 approximate to 5.8). Therefore, the oil-holding capacity of WJM has a positive effect on cooking yield of patty as well as sensory affection. Practical Application The demands of products containing significant amounts of fat are inevitable, especially when immediate supply of energy is desirable. Although many meals ready-to-eat (MRE) with high calories have been developed, the low sensory quality inherent from the greasiness of high-fat products results in an under-consuming problem with MRE. In this study, white jelly mushroom (WJM; Tremella fuciformis) is added to pork patties to decrease the greasiness of the cooked products. Based on the results in this study, the oil-holding capacity of WJM had a positive effect on cooking yield of patty as well as sensory affection.
C1 [Cha, Min-Ha; Heo, Ji-Young; Moon, Bokyung] Chung Ang Univ, Dept Food & Nutr, Anseoung, South Korea.
   [Lee, Chan] Chung Ang Univ, Dept Food Sci & Technol, Anseoung, South Korea.
   [Lo, Y. Martin] Univ Maryland, Dept Food & Nutr, College Pk, MD 20742 USA.
RP Moon, B (reprint author), Chung Ang Univ, Dept Food & Nutr, Anseoung, South Korea.
EM bkmoon@cau.ac.kr
FU GRRC program of Gyeonggi province [GRRC-CAU-2012-B01]
FX This work was supported by the GRRC program of Gyeonggi province.
   [GRRC-CAU-2012-B01]
CR ADACHI Y, 1994, BIOL PHARM BULL, V17, P1554
   AOAC, 1995, OFFICIAL METHODS ANA
   Ayo J, 2007, MEAT SCI, V77, P173, DOI 10.1016/j.meatsci.2007.02.026
   BEUCHAT LR, 1977, J AGR FOOD CHEM, V25, P258, DOI 10.1021/jf60210a044
   Booth CK, 2003, MIL MED, V168, P63
   Borchers AT, 1999, P SOC EXP BIOL MED, V221, P281, DOI 10.1046/j.1525-1373.1999.d01-86.x
   CARBALLO J, 1995, MEAT SCI, V41, P301, DOI 10.1016/0309-1740(95)00001-2
   Cheung PCK, 1996, NUTR RES, V16, P1721, DOI 10.1016/0271-5317(96)00191-1
   Colmenero FJ, 1996, TRENDS FOOD SCI TECH, V7, P41, DOI 10.1016/0924-2244(96)81327-6
   Desmond EM, 1998, J MUSCLE FOODS, V9, P221, DOI 10.1111/j.1745-4573.1998.tb00657.x
   EGBERT WR, 1991, FOOD TECHNOL-CHICAGO, V45, P64
   Gao QP, 1998, PLANTA MED, V64, P551, DOI 10.1055/s-2006-957512
   Gao QP, 1997, PLANTA MED, V63, P457, DOI 10.1055/s-2006-957733
   Gok V, 2011, MEAT SCI, V89, P400, DOI 10.1016/j.meatsci.2011.04.032
   INGLETT GE, 1994, CEREAL FOOD WORLD, V39, P755
   Ma HB, 2009, AFR J MICROBIOL RES, V3, P774
   Meiselman H. L., 1995, NOT EATING ENOUGH OV, P57
   MEISELMAN HL, 1988, FOOD ACCEPTABILITY, P77
   Modi VK, 2004, MEAT SCI, V66, P143, DOI 10.1016/S0309-1740(03)00078-0
   MURPHY EW, 1975, J AGR FOOD CHEM, V23, P1153, DOI 10.1021/jf60202a021
   Naveena BM, 2006, J MUSCLE FOODS, V17, P92, DOI 10.1111/j.1745-4573.2006.00039.x
   PSZCZOLA DE, 1991, FOOD TECHNOL-CHICAGO, V45, P60
   Reshetnikov S. V., 2000, International Journal of Medicinal Mushrooms, V2, P169
   Serdaroglu M, 2006, INT J FOOD SCI TECH, V41, P147, DOI 10.1111/j.1365-2621.2005.01041.x
   Serdaroglu M, 2005, MEAT SCI, V70, P99, DOI 10.1016/j.meatsci.2004.12.015
   Sheridan PS, 2002, J FOOD ENG, V51, P3, DOI 10.1016/S0260-8774(01)00029-2
   SLODKI ME, 1966, CAN J MICROBIOL, V12, P489, DOI 10.1139/m66-071
   Suman SP, 2003, MEAT SCI, V65, P973, DOI 10.1016/S0309-1740(02)00313-3
   Warner K, 1997, CEREAL FOOD WORLD, V42, P821
   Yetim H, 2006, MEAT SCI, V72, P206, DOI 10.1016/j.meatsci.2005.07.002
   YUI T, 1995, J CARBOHYD CHEM, V14, P255, DOI 10.1080/07328309508002068
NR 31
TC 3
Z9 4
U1 4
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-8892
EI 1745-4549
J9 J FOOD PROCESS PRES
JI J. Food Process Preserv.
PD JUN
PY 2014
VL 38
IS 3
BP 1018
EP 1023
DI 10.1111/jfpp.12058
PG 6
WC Food Science & Technology
SC Food Science & Technology
GA AJ4AZ
UT WOS:000337612900032
DA 2018-12-27
ER

PT J
AU Chen, YZ
   Liu, D
   Zhao, YX
   Wang, HT
   Gao, Y
   Chen, Y
AF Chen, Yan-Zhi
   Liu, Dan
   Zhao, Yu-Xia
   Wang, He-Tong
   Gao, Ya
   Chen, Ying
TI RETRACTED: Diagnostic Performance of Serum Macrophage Inhibitory
   Cytokine-1 in Pancreatic Cancer: A Meta-Analysis and Meta-Regression
   Analysis (Retracted article. See vol. 34, pg. 742, 2015)
SO DNA AND CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID HUMAN BREAST; PHASE-II; CELLS; GROWTH; DIFFERENTIATION; EPIDEMIOLOGY;
   INDUCTION; TISSUE; GDF15; SCALE
AB Many existing studies have demonstrated that the macrophage inhibitory cytokine-1 (MIC-1) might be a powerful diagnostic biomarker in patients with pancreatic cancer; but individually published results are inconclusive. This meta-analysis aimed to derive a more precise estimation of the diagnostic performance of serum MIC-1 in pancreatic cancer. We searched CISCOM, CINAHL, Web of Science, PubMed, Google Scholar, EBSCO, Cochrane Library, China BioMedicine (CBM), and China National Knowledge Infrastructure (CNKI) databases from their inception through August 1st, 2013. Meta-analysis was performed using Meta-Disc version 1.4 and STATA version 12.0 software. Crude standardized mean difference (SMD) and their 95% confidence intervals (CI) were estimated. Data from selected studies were pooled to yield summary sensitivity, specificity, positive and negative likelihood ratio (LR), diagnostic odds ratio (DOR), and receiver operating characteristic (SROC) curve. Ten case-control studies were included in this meta-analysis with a total of 1235 pancreatic cancer patients and 730 healthy subjects. Our meta-analysis results revealed that serum MIC-1 levels in pancreatic patients were higher than those of healthy subjects (SMD = 1.38, 95% CI = 1.15-1.62, p < 0.001). The area under the SROC curve was 0.92 (SE = 0.020); the pooled sensitivity was 0.79 (95% CI = 0.77-0.82); and the pooled specificity was 0.86 (95% CI = 0.84-0.88). The pooled positive LR was 6.20 (95% CI = 1.24-30.91); the pooled DOR was 35.73 (95% CI = 18.52-68.93). In conclusion, the present meta-analysis suggests that serum MIC-1 may be a useful diagnostic biomarker with high sensitivity and specificity for identifying pancreatic cancer.
C1 [Chen, Yan-Zhi; Liu, Dan; Zhao, Yu-Xia; Wang, He-Tong; Gao, Ya; Chen, Ying] China Med Univ, Affiliated Hosp 4, Dept Radiotherapy, Shenyang 110032, Peoples R China.
RP Zhao, YX (reprint author), China Med Univ, Affiliated Hosp 4, Dept Radiotherapy, Chongshan East 4, Shenyang 110032, Peoples R China.
EM cmu4h_zyx@yeah.net
FU Science and Technology Research Project of Liaoning Province
   [2011225019]; Social Scientific Research Project of Shenyang City
   [F12-193-9-40]
FX This study was supported by the Science and Technology Research Project
   of Liaoning Province (No. 2011225019) and the Social Scientific Research
   Project of Shenyang City (No. F12-193-9-40).
CR Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103
   Ballehaninna UK, 2013, TUMOR BIOL, V34, P3279, DOI 10.1007/s13277-013-1033-3
   Bauskin AR, 2006, CANCER RES, V66, P4983, DOI 10.1158/0008-5472.CAN-05-4067
   Boyle GM, 2009, J INVEST DERMATOL, V129, P383, DOI 10.1038/jid.2008.270
   Breit SN, 2011, GROWTH FACTORS, V29, P187, DOI 10.3109/08977194.2011.607137
   Brown DA, 2009, CLIN CANCER RES, V15, P6658, DOI 10.1158/1078-0432.CCR-08-3126
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   Fu C., 2011, ONCOL PROG, V9, P204
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Ichikawa T, 2008, ONCOGENE, V27, P409, DOI 10.1038/sj.onc.1210658
   Kaur S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055171
   Kim KK, 2008, CARCINOGENESIS, V29, P704, DOI 10.1093/carcin/bgn031
   Koopmann J, 2006, CLIN CANCER RES, V12, P442, DOI 10.1158/1078-0432.CCR-05-0564
   Koopmann J, 2004, CLIN CANCER RES, V10, P2386, DOI 10.1158/1078-0432.CCR-03-0165
   Lambert JR, 2006, J CELL PHYSIOL, V208, P566, DOI 10.1002/jcp.20692
   Landi S, 2009, MUTAT RES-REV MUTAT, V681, P299, DOI 10.1016/j.mrrev.2008.12.001
   Lee DH, 2003, CANCER RES, V63, P4648
   Lopez R, 2013, ANTICANCER RES, V33, P717
   Ma H.B., 2012, MOD PREVENT MED, V39, P2249
   Maisonneuve P, 2010, DIGEST DIS, V28, P645, DOI 10.1159/000320068
   Mimeault M, 2013, BRIT J CANCER, V108, P1079, DOI 10.1038/bjc.2012.484
   Mimeault M, 2010, J CELL PHYSIOL, V224, P626, DOI 10.1002/jcp.22196
   Ozkan H, 2011, PANCREATOLOGY, V11, P295, DOI 10.1159/000328963
   Park YJ, 2010, BMB REP, V43, P91, DOI 10.5483/BMBRep.2010.43.2.091
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Powers AD, 2012, J HEALTHC ENG, V3, P503, DOI 10.1260/2040-2295.3.4.503
   Raimondi S, 2009, NAT REV GASTRO HEPAT, V6, P699, DOI 10.1038/nrgastro.2009.177
   Schlittenhardt D, 2004, CELL TISSUE RES, V318, P325, DOI 10.1007/s00441-004-0986-3
   Senapati S, 2010, ONCOGENE, V29, P1293, DOI 10.1038/onc.2009.420
   Shao C.J., 2007, WORLD DIGESTOL, V15, P3644
   Shnaper S, 2009, INT J CANCER, V125, P2624, DOI 10.1002/ijc.24639
   Spano JP, 2008, LANCET, V371, P2101, DOI 10.1016/S0140-6736(08)60661-3
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tanno T, 2007, NAT MED, V13, P1096, DOI 10.1038/nm1629
   Wang X.B., 2011, ONCOL PROG, V9, P367
   Wang XY, 2013, BIOCHEM PHARMACOL, V85, P597, DOI 10.1016/j.bcp.2012.11.025
   Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100
   Yang H, 2009, BIOCHEM PHARMACOL, V78, P1205, DOI 10.1016/j.bcp.2009.06.012
   [曾林山 ZENG Linshan], 2011, [中国普通外科杂志, Chinese Journal of General Surgery], V20, P956
   Zhao LL, 2009, CANCER RES, V69, P7696, DOI 10.1158/0008-5472.CAN-08-4901
   Zhou Y.F., 2013, CHIN J PANCREATOL, V13, P91
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 42
TC 4
Z9 5
U1 4
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD JUN
PY 2014
VL 33
IS 6
BP 370
EP 377
DI 10.1089/dna.2013.2237
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA AI8LM
UT WOS:000337166900005
PM 24592997
DA 2018-12-27
ER

PT J
AU Momcilovic, B
   Prejac, J
   Visnjevic, V
   Skalnaya, MG
   Mimica, N
   Drmic, S
   Skalny, AV
AF Momcilovic, Berislav
   Prejac, Juraj
   Visnjevic, Vjeran
   Skalnaya, Margarita G.
   Mimica, Ninoslav
   Drmic, Stipe
   Skalny, Anatoly V.
TI RETRACTED: Hair Iodine for Human Iodine Status Assessment (Retracted
   article. See vol. 28, pg. 958, 2018)
SO THYROID
LA English
DT Article; Retracted Publication
AB Background: Today, human iodine deficiency is, after iron, the most common nutritional deficiency in developed European and underdeveloped third world countries. A current biological indicator of iodine status is urinary iodine, which reflects very recent iodine exposure; a long-term indicator of iodine status remains to be identified.
   Methods: We analyzed hair iodine in a prospective, observational, cross-sectional, and exploratory study involving 870 apparently healthy Croatians (270 men and 600 women). Hair iodine was analyzed with inductively coupled plasma mass spectrometry.
   Results: The hair iodine median was 0.499 mu g/g, and was 0.482 and 0.508 mu g/g for men and women respectively, suggesting no sex-related difference. We studied hair iodine uptake by analyzing the logistic sigmoid saturation curve of the median derivatives to assess iodine deficiency, adequacy, and excess. We estimated overt iodine deficiency to occur when hair iodine concentration was below 0.1-0.15 mu g/g. Then there was a saturation range interval of about 0.1-2.0 mu g/g where the deposition of iodine in the hair was linearly increasing (R-2 = 0.994). Eventually, the sigmoid curve became saturated at about 2.0 mu g/g and upward, suggesting excessive iodine exposure.
   Conclusion: Hair appears to be a valuable and robust biological indicator tissue for assessing long-term iodine status. We propose that an adequate iodine status corresponds with hair iodine uptake saturation of 0.565-0.739 mu g/g (55-65%).
C1 [Momcilovic, Berislav; Visnjevic, Vjeran] Inst Res & Dev Sustainable Ecosyst, Zagreb 10000, Croatia.
   [Prejac, Juraj] Univ Hosp Ctr Zagreb, Dept Oncol, Zagreb, Croatia.
   [Skalnaya, Margarita G.; Skalny, Anatoly V.] ANO Ctr Biot Med, Moscow, Russia.
   [Mimica, Ninoslav] Univ Zagreb, Sch Med, Univ Psychiat Hosp Vrapce, Zagreb 41001, Croatia.
   [Drmic, Stipe] Neuropsychiat Hosp Dr Ivan Barbot, Popovaca, Croatia.
RP Momcilovic, B (reprint author), Inst Res & Dev Sustainable Ecosyst, Srebrnjak 59, Zagreb 10000, Croatia.
EM berislav.momcilovic@gmail.com
RI Skalny, Anatoly/Q-7995-2016
OI Skalny, Anatoly/0000-0001-7838-1366; Skalny, Anatolij
   Viktorovich/0000-0002-4185-6783; Skalnaya, Margarita/0000-0003-1099-2560
FU Croatian Ministry of Science, Education, and Sport [292-0222412-2405]
FX This study was supported in part by the Croatian Ministry of Science,
   Education, and Sport, Grant No. 292-0222412-2405 (formerly No.
   022-0222412-2405). We thank Prof. G. I. Lykken for his helpful
   suggestions, and Ms. A. Ranisate, librarian, for her help with
   references (both are from the University of North Dakota, Grand Forks,
   ND). The generous philanthropic support of the Royal College of
   Midwives, Isle of Man, United Kingdom to B. M. is greatly appreciated.
CR Andersson M, 2007, 2007 IODINE DEFICIEN
   Andersson M, 2012, J NUTR, V142, P744, DOI 10.3945/jn.111.149393
   Ashby Ross, 1965, INTRO CYBERNETICS
   BARRETT S, 1985, JAMA-J AM MED ASSOC, V254, P1041, DOI 10.1001/jama.254.8.1041
   Bass D A, 2001, Altern Med Rev, V6, P472
   Beers MH, 1999, MERCK MANUAL DIAGNOS, P52
   Biesalski HK, 2005, POCKET ATLAS NUTR
   Bizhanova A, 2009, ENDOCRINOLOGY, V150, P1084, DOI 10.1210/en.2008-1437
   Brauer FHV, 2005, COMPREHENSIVE HDB IO, P411
   Brodsky RS, 1967, PHENOMENON FLUID MOT
   Brown M, 1948, NY TIMES
   Burges C, 2000, VALID ANAL METHODS P
   Campbell PN, 1994, BOCH ILLUSTRATED
   Cutler AH, 2004, HAIR TEST INTERPRETA
   de Benoist B, 2009, COMPREHENSIVE HANDBOOK OF IODINE: NUTRITIONAL, BIOCHEMICAL, PATHOLOGICAL AND THERAPEUTIC ASPECTS, P461
   Eastern Research Group, 2001, CHOOS BEST BIOL MARK
   Emsley J, 2001, NATURE BUILDING BLOC
   Glantz SA, 2005, PRIMER BIOSTATISTICS, P126
   Harpley F. W., 1973, INT ENCY PHARM THERA, V1
   Hetzel BS, 1991, TRACE ELEMENTS MAN A, V7, P71
   Iitaka M, 2004, JAPAN MED ASS J, V47, P371
   International Atomic Energy Agency (IAEA), 1980, 190 IAEATEC DOC
   Kempson IM, 2011, CHEM SOC REV, V40, P3915, DOI 10.1039/c1cs15021a
   Kusic Z, 2003, J ENDOCRINOL INVEST, V26, P738, DOI 10.1007/BF03347356
   Lingappa VR, 2000, PHYSL MED CLIN APPRO
   Momcilovic B, 2008, TRACE ELEM ELECTROLY, V25, P195
   Momcilovic B, 2008, TRACE ELEM MED MOSCO, V9, P5
   Momcilovic B, 2007, TRACE ELEM MED MOSCO, V8, P1
   Momcilovic B, 1988, TRACE ELEMENTS MAN A, P173
   Momcilovic B, 2012, TRACE ELEMENTS MED M, V13, P20
   Momcilovic B, 2012, PSYCHOLOGY, V3, P825
   Momcilovic B, 2009, TRACE ELEM MED MOSCO, V10, P33
   Momcilovic B, 2006, TRACE ELEMENTS MED M, V7, P33
   Momcilovic B, 2012, TOXICOL ENVIRON CHEM, V94, P1238, DOI 10.1080/02772248.2012.692556
   Momcilovic B, 2010, TRANSL NEUROSCI, V1, P322, DOI 10.2478/v10134-010-0039-2
   Oppenheim AN, 2004, QUESTIONNAIRE DESIGN
   Reilly C., 2002, METAL CONTAMINATION
   Rook A, 1982, DIS HAIR SCALP
   Smylevich I., 2012, PROBABILISTIC BOOLEA
   Soldin OP, 2009, COMPREHENSIVE HANDBOOK OF IODINE: NUTRITIONAL, BIOCHEMICAL, PATHOLOGICAL AND THERAPEUTIC ASPECTS, P1129, DOI 10.1016/B978-0-12-374135-6.00115-1
   Visser TJ, 2006, ENDOCRINOLOGY, V147, P2095, DOI 10.1210/en.2006-0203
   Wilson L, NUTR BALANCING HAIR
   World Health Organization  United Nations Children's Fund  International Council for the Control of Iodine Deficiency Disorders, 2007, GUID PROGR MAN
   Zimmermann M, 2013, ADV NUTR, V4, P262, DOI 10.3945/an.113.003665
NR 44
TC 10
Z9 11
U1 1
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD JUN
PY 2014
VL 24
IS 6
BP 1018
EP 1026
DI 10.1089/thy.2012.0499
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AI9CB
UT WOS:000337224000012
PM 24446669
OA Green Published
DA 2018-12-27
ER

PT J
AU Javanbakht, J
   Pedram, B
   Taheriyan, MR
   Khadivar, F
   Hosseini, SH
   Abdi, FS
   Hosseini, E
   Moloudizargari, M
   Aghajanshakeri, SH
   Javaherypour, S
   Shafiee, R
   Bidi, RE
AF Javanbakht, J.
   Pedram, B.
   Taheriyan, M. R.
   Khadivar, F.
   Hosseini, S. H.
   Abdi, F. S.
   Hosseini, E.
   Moloudizargari, M.
   Aghajanshakeri, S. H.
   Javaherypour, S.
   Shafiee, R.
   Bidi, R. Emrani
TI RETRACTED: Canine transmissible venereal tumor and seminoma: a
   cytohistopathology and chemotherapy study of tumors in the growth phase
   and during regression after chemotherapy (Retracted article. See vol.37,
   pg. 16417, 2016)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Chemotherapy; TVT; Seminoma; Cytology; Pathology; Canine
ID GERM-CELL TUMORS; TESTICULAR-TUMORS; DOGS; CYTOLOGY; CANCER; BITCH
AB In this study, 12 dogs affected by canine transmissible venereal tumor (CTVT) and testicular seminoma tumor were studied retrospectively. The cytological sample was smeared onto a glass slide and either air-dried for May-Grunwald-stain, and masses were surgically removed. The tumors were grossly examined, and sections of 4-mu m thick were obtained from each sample and stained with H&E. For chemotherapy, vincristine sulfate was administered weekly as an infusion over 3 min via the cephalic vein at a dose of 0.025 mg/kg after diluting with physiological saline to a total amount of 10 ml. If no remission was observed after 8 weeks, chemotherapy was continued with weekly doxorubicin infusion at a dose of 1 mg/kg. All the tumor samples were divided into four cytohistopathologic groups, namely: multilobular (six cases), papillary (two cases), pedunculated (two cases), and tubular (two cases of seminoma). The most frequently represented tumor type was multilobular (6/10, 60 %) followed by pedunculated (2/10, 20 %), papillary (2/10, 20 %), and tubular (two cases of seminoma, 100 %). Cytological smears from eight tumors in regression after chemotherapy were poorly cellular, and many cells were fragmented. In two progressive tumors, there was an average of 1,406 +/- 972 CTVT 200 cells/mu l or 96 center dot 71 % of total cells counted. Thus, tumor cells represented 96 center dot 71 % of total cells within the biopsy specimens and the leukocytes 4 center dot 29 % (leukocyte, tumor cell ratio = 0 center dot 062 A +/- 0 A center dot 031). In eight regressive tumors, there was an average of 1,245 A +/- 1,032 CTVT 200 cells/mu l or 97 A center dot 31 % of total cells counted. Thus, tumor cells represented 97 A center dot 31 % of total cells and leukocytes 2 A center dot 69 % (leukocyte, tumor cell ratio = 0 A center dot 071 A +/- 0 A center dot 174). Our data suggested that combination treatment with vincristine and doxorubicin in the future could be an excellent therapeutic alternative for the treatment of TVT for probably reducing the resistance to vincristine, and also, treatment success could easily be followed by the cytological changes.
C1 [Javanbakht, J.] Univ Tehran, Dept Pathol, Fac Vet Med, Tehran, Iran.
   [Pedram, B.] Islamic Azad Univ, Susangerd Branch, Dept Pathobiol, Susangerd, Iran.
   [Taheriyan, M. R.] Islamic Azad Univ, Kashmar Branch, Dept Anim Sci, Coll Agr, Kashmar, Iran.
   [Khadivar, F.; Shafiee, R.] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Hosseini, S. H.] Islamic Azad Univ Garmsar, Fac Vet Med, Garmsar, Iran.
   [Abdi, F. S.] Islamic Azad Univ, Sci & Res Branch Tehran, Tehran, Iran.
   [Hosseini, E.] Ilam Univ, Fac Para Vet Med, Ilam, Iran.
   [Moloudizargari, M.; Aghajanshakeri, S. H.; Javaherypour, S.] Urmia Univ, Fac Vet Med, Orumiyeh, Iran.
   [Bidi, R. Emrani] Univ Rennes 1, Dept Pharm, M2S Lab EA1274, Rennes, France.
RP Javanbakht, J (reprint author), Univ Tehran, Dept Pathol, Fac Vet Med, Tehran, Iran.
EM javadjavanbakht@ut.ac.ir
CR ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108
   ALLEN SW, 1986, VET PATHOL, V23, P649, DOI 10.1177/030098588602300601
   Amaral Anne S., 2004, Revista Portuguesa de Ciencias Veterinarias, V99, P167
   AMBER EI, 1990, J VET INTERN MED, V4, P144, DOI 10.1111/j.1939-1676.1990.tb00887.x
   Bancroft JD, 1996, THEORY PRACTICE HIST, P276
   Bastan A, 2008, TURK J VET ANIM SCI, V32, P65
   BENAZZI C, 1995, J COMP PATHOL, V112, P141, DOI 10.1016/S0021-9975(05)80057-X
   Boscos CM, 2011, P 29 WORLD SMALL AN
   Brandao C. V. S., 2002, Revista de Educacao Continuada do CRMV-SP, V5, P25
   Bush JM, 2011, INT J ANDROL, V34, pE288, DOI 10.1111/j.1365-2605.2011.01166.x
   CARAWAY NP, 1995, DIAGN CYTOPATHOL, V12, P327, DOI 10.1002/dc.2840120409
   Cheng L, 2004, CANCER, V101, P2006, DOI 10.1002/cncr.20566
   COHEN D, 1978, ISRAEL J MED SCI, V14, P14
   Cooley DM, 2001, TUMORS MALE REPROD S, P478
   DAS U, 1991, INDIAN VET J, V68, P249
   Das U, 2000, VET RES COMMUN, V24, P545, DOI 10.1023/A:1006491918910
   DEMAY RM, 1996, ART SCI CYTOPATHOLOG, V2
   Erunal-Maral N, 2000, DEUT TIERARZTL WOCH, V107, P175
   Feldman EC, 1987, CANINE FELINE ENDOCR, P475
   Galofaro V, 2008, REPROD DOMEST ANIM, V43, P121, DOI 10.1111/j.1439-0531.2007.00851.x
   Gurarii LL, 2002, UROLOGIA, V4, P10
   Henson KL., 2001, ATLAS CANINE FELINE
   KROGER D, 1991, CANINE PRACT, V16, P17
   Kunakornsawat S, 2010, P 48 KAS U ANN C VET, P191
   Ladds PW., 1993, PATHOLOGY DOMESTIC A, V3, P504
   MACLACHLAN NJ, 2002, TUMORS DOMESTIC ANIM, P563
   Maiolino P, 2004, VET PATHOL, V41, P608, DOI 10.1354/vp.41-6-608
   McGlynn KA, 2003, CANCER, V97, P63, DOI 10.1002/cncr.11054
   Mello Martins MI, 2005, RECENT ADV SMALL ANI
   MOSTOFI FK, 1998, WHO INT HISTOLOGICAL, P10
   Mozos E, 1996, VET PATHOL, V33, P257, DOI 10.1177/030098589603300301
   Nochomovitz LE, 1978, PATHOL ANNU, V1, P327
   Park MS, 2006, J VET DIAGN INVEST, V18, P130, DOI 10.1177/104063870601800123
   PEREZ J, 1994, CANINE PRACT, V19, P7
   Peters MAJ, 2000, J REPROD FERTIL, V120, P443, DOI 10.1530/reprod/120.2.443
   REIF JS, 1979, J AM VET MED ASSOC, V175, P719
   Rogers KS, 1998, J AM ANIM HOSP ASSOC, V34, P463, DOI 10.5326/15473317-34-6-463
   Schlotthauer CF, 1938, J UROLOGY, V40, P539, DOI 10.1016/S0022-5347(17)71796-X
   Shafiee R, 2013, CANCER CELL INT, V9, P79
   Singh J, 1996, VET RES COMMUN, V20, P71, DOI 10.1007/BF00346579
   Stockmann D., 2011, Brazilian Journal of Veterinary Pathology, V4, P67
   Zheng TZ, 1996, INT J CANCER, V65, P723, DOI 10.1002/(SICI)1097-0215(19960315)65:6<723::AID-IJC2>3.0.CO;2-0
NR 42
TC 5
Z9 6
U1 1
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2014
VL 35
IS 6
BP 5493
EP 5500
DI 10.1007/s13277-014-1723-5
PG 8
WC Oncology
SC Oncology
GA AI7RW
UT WOS:000337094900056
PM 24557542
DA 2018-12-27
ER

PT J
AU Chang, DF
   Xu, ZQ
   Sun, B
AF Chang, De-Feng
   Xu, Zhong-Qing
   Sun, Bin
TI RETRACTED: Relationship between VEGF protein expression and lymph node
   metastasis in papillary thyroid carcinoma among Asians: a meta-analysis
   (Retracted article. See vol. 36, pg. 7305, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Vascular endothelial growth factor; Papillary thyroid carcinoma; Lymph
   node metastasis; Meta-analysis
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR-C; TUMOR ANGIOGENESIS; CANCER;
   INHIBITOR; DISEASE; TISSUES; FAMILY
AB We carried out the current meta-analysis of relevant cohort studies in an attempt to investigate the relationships between vascular endothelial growth factor (VEGF) protein expression and lymph node (LN) metastasis in papillary thyroid carcinoma (PTC) among Asians. A range of electronic databases were searched, including Web of Science (1945 similar to 2013), the Cochrane Library Database (Issue 12, 2013), MEDLINE (1966 similar to 2013), EMBASE (1980 similar to 2013), CINAHL (1982 similar to 2013), and Chinese Biomedical Database (CBM) (1982 similar to 2013) with cross-referencing without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratio (OR) with their 95 % confidence interval (95 %CI) was calculated. Twelve clinical cohort studies with a total of 1,045 PTC patients were included in our meta-analysis, The results of our meta-analysis revealed that patients with VEGF-positive tumors had a 3.02-fold higher risk of LN metastasis than that of patients with VEGF-negative tumors (OR = 3.02, 95 %CI = 2.05 similar to 4.43, P < 0.001). Furthermore, subgroup analysis by country suggested that VEGF-positive expression was associated with an increased risk of LN metastasis in PTC patients among Chinese populations (OR = 3.33, 95 %CI = 2.30 similar to 4.83, P < 0.001), but not among Korean, Turkish, and Japanese populations (all P > 0.05). Our findings support the view that VEGF protein expression may be correlated with LN metastasis in PTC patients, especially among Chinese populations.
C1 [Chang, De-Feng; Xu, Zhong-Qing; Sun, Bin] Heilongjiang Hosp, Dept Gen Surg, Harbin 150000, Peoples R China.
RP Chang, DF (reprint author), Heilongjiang Hosp, Dept Gen Surg, Zhongshan Rd 82, Harbin 150000, Peoples R China.
EM changdefeng114@126.com
CR Bates DO, 2010, CARDIOVASC RES, V87, P262, DOI 10.1093/cvr/cvq105
   Chen AY, 2009, CANCER, V115, P3801, DOI 10.1002/cncr.24416
   Doi K, 2010, CURR VASC PHARMACOL, V8, P122, DOI 10.2174/157016110790226606
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Erdem H, 2011, EXP MOL PATHOL, V90, P312, DOI 10.1016/j.yexmp.2011.01.008
   Ferrara N, 2010, CYTOKINE GROWTH F R, V21, P21, DOI 10.1016/j.cytogfr.2009.11.003
   Freeman R, 2012, ANAL CHEM, V84, P6192, DOI 10.1021/ac3011473
   de Araujo VJF, 2009, THYROID, V19, P1233, DOI 10.1089/thy.2008.0179
   Hsueh C, 2011, J SURG ONCOL, V103, P395, DOI 10.1002/jso.21844
   Jebreel A, 2007, INT J EXP PATHOL, V88, P271, DOI 10.1111/j.1365-2613.2007.00533.x
   Jiang Han-Guo, 2005, Ai Zheng, V24, P1136
   Kabat GC, 2012, CANCER CAUSE CONTROL, V23, P2031, DOI 10.1007/s10552-012-0084-x
   Kamat A, 2011, ARCH OTOLARYNGOL, V137, P1146, DOI 10.1001/archoto.2011.194
   Karpanen T, 2001, CANCER RES, V61, P1786
   Kebebew E, 2008, SURGERY, V144, P940
   Kim BH, 2013, THYROID, V23, P1431, DOI 10.1089/thy.2012.0546
   Lee SH, 2012, CLIN EXP OTORHINOLAR, V5, P150, DOI 10.3342/ceo.2012.5.3.150
   Li J, 2013, ASIA-PAC J CLIN ONCO, V40, P455
   Liao SY, 2013, BMC ENDOCR DISORD, V13, DOI 10.1186/1472-6823-13-48
   LiVolsi VA, 2011, MODERN PATHOL, V24, pS1, DOI 10.1038/modpathol.2010.129
   Lukas J, 2013, BIOMED PAP, V157, P266, DOI 10.5507/bp.2012.086
   Luo Huajie, 2009, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V23, P531
   Mazzaferri EL, 2009, THYROID, V19, P683, DOI 10.1089/thy.2009.1578
   Miao Ailin, 2009, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V23, P881
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Pasquali D, 2011, THYROID, V21, P391, DOI 10.1089/thy.2010.0168
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Poh CK, 2010, BIOMATERIALS, V31, P1578, DOI 10.1016/j.biomaterials.2009.11.042
   Saharinen P, 2011, TRENDS MOL MED, V17, P347, DOI 10.1016/j.molmed.2011.01.015
   Salajegheh A, 2013, HUM PATHOL, V44, P2204, DOI 10.1016/j.humpath.2013.04.014
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Swierniak M, 2013, J CLIN ENDOCR METAB, V98, pE1401, DOI 10.1210/jc.2013-1214
   Tanaka K, 2002, SURG TODAY, V32, P761, DOI 10.1007/s005950200146
   Thangarajah H, 2009, P NATL ACAD SCI USA, V106, P13505, DOI 10.1073/pnas.0906670106
   Tian X, 2008, J INT MED RES, V36, P699, DOI 10.1177/147323000803600411
   Wang Ting, 2009, Chinese Journal of Pathology, V38, P824, DOI 10.3760/cma.j.issn.0529-5807.2009.12.009
   Wang Yaqiu, 2007, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V21, P204
   Wartofsky L, 2010, HORM-INT J ENDOCRINO, V9, P103, DOI 10.14310/horm.2002.1260
   Yasuoka H, 2005, MODERN PATHOL, V18, P1127, DOI 10.1038/modpathol.3800402
   Yu XM, 2008, SURGERY, V144, P934, DOI 10.1016/j.surg.2008.07.027
   Yu XM, 2005, CLIN CANCER RES, V11, P8063, DOI 10.1158/1078-0432.CCR-05-0646
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 42
TC 4
Z9 4
U1 5
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2014
VL 35
IS 6
BP 5511
EP 5518
DI 10.1007/s13277-014-1725-3
PG 8
WC Oncology
SC Oncology
GA AI7RW
UT WOS:000337094900058
PM 24557543
DA 2018-12-27
ER

PT J
AU Yao, CJ
   Lv, SZ
   Han, MZ
   Zhang, J
   Zhang, Y
   Zhang, L
   Yi, RY
   Zhuang, DX
   Wu, JS
AF Yao, Chengjun
   Lv, Shunzeng
   Han, Mingzhi
   Zhang, Jie
   Zhang, Ya
   Zhang, Li
   Yi, Ruiyang
   Zhuang, Dongxiao
   Wu, Jinsong
TI RETRACTED: The association of Crk-like adapter protein with poor
   prognosis in glioma patients (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE CrkL; Immunohistochemistry; Glioma; Prognosis
ID CELL-PROLIFERATION; LUNG-CANCER; CARCINOMA; OVEREXPRESSION; EXPRESSION
AB Glioma is the most common of brain tumors that greatly affects patient survival. In our precious study, Crk-like adapter protein (CrkL) was identified as a key regulator in glioblastoma development [1]. Here, we aimed to investigate the correlation of CrkL with patient prognosis as well as pathological indicators. Immunohistochemistry was available to evaluate CrkL expression in 49 gliomas of distinct malignancy grade, and positive stained sites were analyzed. CrkL protein was detected in cell lines by Western blot as well. We observed CrkL protein stained in 59.2 % (29 out of 49) of all glioma tissues, including 41.4 % of low-grade (I + II) gliomas, and 85.0 % of high-grade (III + IV) gliomas. Of four grades, grade IV exhibited the highest CrkL level. CrkL protein was also identified in cell lines NHA, U87, U251, T98G, and A172 by Western blot. On the other hand, CrkL expression was significantly associated with the patient's age and WHO grade, and patients with high CrkL expression had a significantly shorter median survival time (17 months) than those (median survival time 52 months) with low CrkL expression (p < 0.001). According to Cox regression, CrkL can be suggested as an independent prognostic factor. In conclusion, CrkL is differently expressed in different grades of gliomas, and correlated to WHO grade. CrkL also independently indicates poor prognosis in old glioma patients, which can further be recommended as an effective prognostic biomarker or therapeutic target.
C1 [Yao, Chengjun; Zhuang, Dongxiao; Wu, Jinsong] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Neurol Surg Dept,Glioma Surg Div, Shanghai 200040, Peoples R China.
   [Lv, Shunzeng; Han, Mingzhi; Zhang, Li] Shandong Univ, Dept Neurosurg, Qilu Hosp, Jinan 250100, Shandong, Peoples R China.
   [Lv, Shunzeng; Han, Mingzhi; Zhang, Li] Shandong Univ, Brain Sci Res Inst, Jinan 250100, Shandong, Peoples R China.
   [Zhang, Jie] Nanjing Med Univ, Clin Coll 1, Nanjing, Jiangsu, Peoples R China.
   [Lv, Shunzeng; Zhang, Jie; Zhang, Li] Chinese Acad Med Sci, Dept Neurosurg, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
   [Lv, Shunzeng; Zhang, Jie; Zhang, Li] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Zhang, Ya] Shandong Univ, Dept Hematol, Shandong Prov Hosp, Jinan 250100, Shandong, Peoples R China.
   [Yi, Ruiyang] Univ Chicago, Div Biol Sci, Chicago, IL 60637 USA.
RP Wu, JS (reprint author), Fudan Univ, Shanghai Med Coll, Huashan Hosp, Neurol Surg Dept,Glioma Surg Div, 12 WulumuqiZhong Rd, Shanghai 200040, Peoples R China.
EM cjyhuashan@163.com
FU National Key Basic Research Program of China [2013CB932502]; National
   Natural Science Foundation of China [81171295]
FX This study was supported by the National Key Basic Research Program of
   China (No. 2013CB932502), and the National Natural Science Foundation of
   China (No. 81171295). We greatly thank Ranran Shi in Sandy Lab for
   valuable suggestions.
CR Bell Emily S, 2012, Genes Cancer, V3, P341, DOI 10.1177/1947601912459951
   Birge RB, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-13
   Butowski Nicholas A, 2006, Clin Neurosurg, V53, P106
   Hernandez-Boluda JC, 2009, BEST PRACT RES CL HA, V22, P343, DOI 10.1016/j.beha.2009.04.005
   Cheung HW, 2011, CANCER DISCOV, V1, P608, DOI 10.1158/2159-8290.CD-11-0046
   Chiu ST, 2009, CARCINOGENESIS, V30, P1475, DOI 10.1093/carcin/bgp133
   Evren S, 2012, EXP HEMATOL, V40, P1055, DOI 10.1016/j.exphem.2012.08.007
   Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779
   Graf R, 2013, CELL ADHES MIGR, V7, P362, DOI 10.4161/cam.25284
   Kim YH, 2010, ONCOGENE, V29, P1421, DOI 10.1038/onc.2009.437
   Kleihues P, 2000, CANCER, V88, P2887, DOI 10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F
   Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241
   Liu CH, 2013, MOL CELL PROTEOMICS, V12, P1335, DOI 10.1074/mcp.O112.020404
   Lv SZ, 2013, J MOL NEUROSCI, V51, P1046, DOI 10.1007/s12031-013-0096-3
   Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y
   Singer CF, 2006, ONCOL REP, V15, P353
   Sriram Ganapathy, 2010, Genes Cancer, V1, P1132, DOI 10.1177/1947601910397188
   Wang J, 2011, MOL CARCINOGEN, V50, P506, DOI 10.1002/mc.20745
   Wang Y, 2013, MOL CARCINOGEN, V52, P890, DOI 10.1002/mc.21935
   Yanagi H, 2012, BIOCHEM BIOPH RES CO, V418, P104, DOI 10.1016/j.bbrc.2011.12.142
   Zhao TT, 2013, TUMOR BIOL, V34, P2891, DOI 10.1007/s13277-013-0851-7
NR 21
TC 5
Z9 5
U1 5
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2014
VL 35
IS 6
BP 5695
EP 5700
DI 10.1007/s13277-014-1754-y
PG 6
WC Oncology
SC Oncology
GA AI7RW
UT WOS:000337094900082
PM 24563280
DA 2018-12-27
ER

PT J
AU Li, FF
   Yang, Y
   Wang, XL
   Hong, YY
   Wang, NF
   Chen, ZD
AF Li, Fan-Fan
   Yang, Yang
   Wang, Xiao-Lei
   Hong, Yan-Yan
   Wang, Nian-Fei
   Chen, Zhen-Dong
TI RETRACTED: Promoter methylation of DAPK gene may contribute to the
   pathogenesis of nonsmall cell lung cancer: a meta-analysis (Retracted
   article. See vol. 36, pg. 7303, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE DAPK; Methylation; Nonsmall cell lung cancer; Meta-analysis
ID PROTEIN-KINASE DAPK; DNA METHYLATION; DEATH; EXPRESSION;
   HYPERMETHYLATION; TUMOR; APOPTOSIS; BETA
AB We performed a meta-analysis of cohort studies to determine whether promoter methylation of the death-associated protein kinase (DAPK) gene contributes to the pathogenesis of nonsmall cell lung cancer (NSCLC). A range of electronic databases were searched: MEDLINE (1966 similar to aEuro parts per thousand 2013), the Cochrane Library Database (Issue 12, 2013), EMBASE (1980 similar to aEuro parts per thousand 2013), CINAHL (1982 similar to aEuro parts per thousand 2013), Web of Science (1945 similar to aEuro parts per thousand 2013), and the Chinese Biomedical Database (CBM; 1982 similar to aEuro parts per thousand 2013) without any language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratio (OR) with 95 % confidence interval (95 % CI) was calculated. Our meta-analysis integrated results from 12 clinical cohort studies that met all inclusion criteria with a total of 1,027 NSCLC patients. We observed that the frequency of DAPK gene methylation in cancer tissues were significantly higher than that in the adjacent normal and benign tissues (cancer tissues vs. benign tissues: OR = 8.50, 95 % CI = 5.88 similar to aEuro parts per thousand 12.28, P < 0.001; cancer tissues vs. adjacent tissues: OR = 5.95, 95 % CI = 4.11 similar to aEuro parts per thousand 8.60, P < 0.001; cancer tissues vs. normal tissues: OR = 4.75, 95 % CI = 3.28 similar to aEuro parts per thousand 6.87, P < 0.001; respectively). Subgroup analysis by ethnicity demonstrated that DAPK gene methylation was closely associated with the development and progression of NSCLC among both Asians and Caucasians (all P < 0.05). Furthermore, we conducted a subgroup analysis based on sample source and discovered that DAPK gene methylation was implicated in the pathogenesis of NSCLC in both blood and tissue subgroups (all P < 0.05). Our results suggest that DAPK promoter methylation may be involved in NSCLC carcinogenesis. Thus, the detection of aberrant DAPK methylation may be helpful in the diagnosis and prognosis of NSCLC.
C1 [Li, Fan-Fan; Yang, Yang; Wang, Xiao-Lei; Hong, Yan-Yan; Wang, Nian-Fei; Chen, Zhen-Dong] Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Hefei 230601, Peoples R China.
RP Li, FF (reprint author), Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Furong Rd 678, Hefei 230601, Peoples R China.
EM lffdwp@sina.com.cn; chenzhendong1231@163.com
FU Foundation of the Natural Science of Anhui province [1408085QH165];
   Specialized Research Fund for the Doctoral Program of Higher Education
   [20133420120001]
FX The authors would like to thank their colleagues at the Department of
   Oncology, the Second Affiliated Hospital of Anhui Medical University.
   This was funded by the Foundation of the Natural Science of Anhui
   province (1408085QH165) and the Specialized Research Fund for the
   Doctoral Program of Higher Education (20133420120001).
CR Alberg AJ, 2013, AM J EPIDEMIOL, V177, P613, DOI 10.1093/aje/kws444
   Arslan S, 2008, LUNG INDIA, V25, P148, DOI 10.4103/0970-2113.45279
   Bai T, 2010, INT J ONCOL, V37, P203, DOI 10.3892/ijo_00000668
   Belinsky SA, 2007, BRIT J CANCER, V96, P1278, DOI 10.1038/sj.bjc.6603721
   Carvalho RH, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-9
   Cebrian A, 2014, CLIN TRANSL IN PRESS
   Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052
   Chen P, 2012, MED J QILU, V27, P380
   de Diego I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000552
   De Jong WK, 2009, ANTICANCER RES, V29, P363
   DG Lu, 2010, SHANDONG MED J, V50, P69
   Feng QH, 2008, CANCER EPIDEM BIOMAR, V17, P645, DOI 10.1158/1055-9965.EPI-07-2518
   Gade P, 2008, MOL CELL BIOL, V28, P2528, DOI 10.1128/MCB.00784-07
   Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024
   Inbal B, 1997, NATURE, V390, P180
   Kawaguchi K, 2004, HUM PATHOL, V35, P1266, DOI 10.1016/j.humpath.2004.07.007
   Kim YT, 2005, ANN THORAC SURG, V79, P1180, DOI 10.1016/j.athoracsur.2004.09.060
   Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651
   Lin Q, 2009, J CANCER RES CLIN, V135, P1675, DOI 10.1007/s00432-009-0614-4
   Lin Y, 2010, FEBS J, V277, P48, DOI 10.1111/j.1742-4658.2009.07411.x
   Michie AM, 2010, FEBS J, V277, P74, DOI 10.1111/j.1742-4658.2009.07414.x
   Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Qian J, 2009, EUR J HAEMATOL, V82, P119, DOI 10.1111/j.1600-0609.2008.01178.x
   [宋超 Song Chao], 2013, [肿瘤防治研究, Cancer Research on Prevention and Treatment], V40, P772
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Takeda K, 2010, J CLIN ONCOL, V28, P753, DOI 10.1200/JCO.2009.23.3445
   Toyooka S, 2003, CLIN CANCER RES, V9, P3034
   Wang Y, 2008, CANCER, V112, P1325, DOI 10.1002/cncr.23312
   Yanagawa N, 2007, LUNG CANCER, V58, P131, DOI 10.1016/j.lungcan.2007.05.011
   Zhang Chen-ye, 2011, Zhonghua Yixue Yichuanxue Zazhi, V28, P23, DOI 10.3760/cma.j.issn.1003-9406.2011.01.006
   Zhang YW, 2011, CANCER LETT, V303, P21, DOI 10.1016/j.canlet.2010.12.011
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   Zochbauer-Muller S, 2001, CANCER RES, V61, P249
   林勍, 2006, [中国老年学杂志, Chinese Journal of Gerontology], V26, P1304
NR 35
TC 8
Z9 8
U1 2
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2014
VL 35
IS 6
BP 6011
EP 6020
DI 10.1007/s13277-014-1796-1
PG 10
WC Oncology
SC Oncology
GA AI7RW
UT WOS:000337094900119
PM 24659425
DA 2018-12-27
ER

PT J
AU Barnett, RLE
AF Barnett, R. -L. Etienne
TI RETRACTED: Words in the drifts Displacement and Chevillard virulence
   (Retracted article. See vol. 42, pg. 359, 2015)
SO NEOHELICON
LA French
DT Article; Retracted Publication
DE Eric Chevillard; Monstrousness; Monster-speak; Linguistic Subversions;
   Narrative Instance; Verbal violence; Dynamics of displacement
AB The present study scrutinizes the multifocal manifestations and grotesque comportments of "monstrousness" in the narrative prose of A parts per thousand ric Chevillard (Scalps and D,molir Nisard). Focusing on and questioning "monstrous" instances and ghastly verbal episodes in the contemporary author's works and the compelling dynamic that drives such impulse (e.g., violence revealing a determinative performativity in the establishment of monstrous individuals), this text seeks to illuminate the problematics of displacement and subversion associated with linguistic virulence and "monster-speak" with which Chevillard imbues his narrative.
C1 [Barnett, R. -L. Etienne] Univ Atlanta GIT, Off Univ Provost, Atlanta, GA 30360 USA.
   [Barnett, R. -L. Etienne] Univ Atlanta GIT, Andrew W Mellon Fdn, Atlanta, GA 30360 USA.
   [Barnett, R. -L. Etienne] CNRS, F-70005 Paris, France.
RP Barnett, RLE (reprint author), Univ Atlanta GIT, Off Univ Provost, Atlanta, GA 30360 USA.
EM RL_Barnett@msn.com
CR Alain J.-L., 2007, REPRISES DEGRE ZERO
   Alain J.-L., 2006, ESSAI SUBVERSION LIT
   Audet R., 2008, ROMAN, V20-50, P23
   Austin J. L., 1962, DO THINGS WORDS
   Bailly J.-L., 2004, ARTS RECHERCHES CREA, V82, P38
   Ballantine M., 2010, REV LIT STUDIES, V24, P55
   Barnett R.-L. E., 2012, ETUDES LETT, V292, P60
   Barnett R.-L. E., 2011, ALTERNATIVE MODES WR, P102
   Barnett R.-L. E., 2013, STUDIES LANGUAGE LIT, V17, P240
   Barnett R.-L. E., 2009, LANGAGES, V26, P49
   Barthes R., 1993, OEUVRES COMPLETES, VI, P1260
   Barthes R., 1978, FRAGMENTS DISCOURS A
   Bhabha H., 2005, FOREWORD WRETCHED EA
   Bhabha Homi K, 1990, NATION NARRATION
   BLANCHOT Maurice, 1980, ECRITURE DESASTRE
   Chevillard E., 1995, FANTOME
   Chevillard E, 1990, PALAFOX
   Chevillard E, 1994, PREHISTOIRE
   Chevillard E, 2006, DEMOLIR NISARD
   Chevillard E., 1992, CAOUTCHOUC DECIDEMEN
   Chevillard E, 1993, NEBULEUSE CRABE
   CHEVILLARD Eric, 2004, SCALPS
   CHEVILLARD Eric, 2007, COMMENTAIRE AUTORISE
   Cioran E., 2009, CAHIER CIORAN
   Cotea L., 2008, STUDIES LUCETTE DESV, V18, P201
   DE MAN P., 1979, ALLEGORIES READING
   Ducrot O., 1995, NOUVEAU DICT ENCY SC
   Havercroft B., 2008, REV ETUDE ROMAN 20 S, V46, P77
   Larochelle M.-H., 2008, POETIQUE INVECTIVE R
   Leclerc Y., 1989, DALHOUSIE FRENCH STU, V17, P63
   Lyon-Caen B., 2005, LIEUX REALISME
   Marin L, 1978, RECIT EST PIEGE
   Marsondans Marc-Antoine, 1999, OEUVRE POSTHUME T PI
   Pamuk Orhan, 2010, NAIVE SENTIMENTAL NO
   Perec G., 1992, VIE MODE EMPLOI
   Riffaterre M., 1979, PRODUCTION TEXTE
   Roussel J., 1963, COMMENT JAI ECRIT CE
   Schoentjes P., 2004, DICT LIT, P320
   Sontag S., 1982, S SONTAG READER, P95
   Stump J, 1998, FR REV, V71, P820
   Xanthos N., 2009, TEMPS ZERO REV ETUDE, V2, P98
NR 41
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0324-4652
EI 1588-2810
J9 NEOHELICON
JI Neohelicon
PD JUN
PY 2014
VL 41
IS 1
BP 129
EP 143
DI 10.1007/s11059-013-0232-7
PG 15
WC Literature
SC Literature
GA AI7RK
UT WOS:000337093200011
DA 2018-12-27
ER

PT J
AU Antoniu, A
   Nakajima, T
   Kurita, H
   Mizuno, A
AF Antoniu, Angela
   Nakajima, Tomoko
   Kurita, Hirofumi
   Mizuno, Akira
TI RETRACTED: Safety evaluation of nonthermal atmospheric pressure plasma
   liquid treatment: Single DNA molecule-based method (Retracted article.
   See vol. 93, pg. 69, 2018)
SO JOURNAL OF ELECTROSTATICS
LA English
DT Article; Retracted Publication
DE Nonthermal plasma; Plasma jet; lambda DNA Escherichia coli; Double
   strand break; Safety evaluation; Plasma medicine
ID COLD-PLASMA; ARGON PLASMA; MEDICINE; WOUNDS; DAMAGE; MODEL
AB We evaluated the beneficial effect of biological decontamination versus the DNA double strand breakage for a range of plasma jet treatment durations. We confirmed the effectiveness of the experimental procedure using a mixture of Escherichia coli and lambda DNA in buffered solutions. We simultaneously obtained the DNA cutting rate, k, and the decimal reduction value of the viability, D, for safety evaluation of plasma treatment. The results indicate that the toxicity of injected radicals could be quantitatively evaluated by measuring the DNA cutting rate k. In addition, the evaluation could be performed fast without cell cultivation. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Antoniu, Angela; Nakajima, Tomoko; Kurita, Hirofumi; Mizuno, Akira] Toyohashi Univ Technol, Dept Environm & Life Sci, Toyohashi, Aichi 4418580, Japan.
RP Antoniu, A (reprint author), Toyohashi Univ Technol, Dept Environm & Life Sci, 1-1 Hibarigaoka,Tempaku Cho, Toyohashi, Aichi 4418580, Japan.
EM AA002@edu.tut.ac.jp; TN008@edu.tut.ac.jp; kurita@ens.tut.ac.jp;
   mizuno@ens.tut.ac.jp
FU Chubu Science and Technology Center Foundation, "Greater Nagoya
   Initiative", Japan
FX The work was supported by the Chubu Science and Technology Center
   Foundation, "Greater Nagoya Initiative", Japan, through a one-year
   (2011-2012) overseas grant in environmental research for Dr. A. Antoniu.
CR Daeschlein G, 2012, J DTSCH DERMATOL GES, V10, P509, DOI 10.1111/j.1610-0387.2012.07857.x
   Dobrynin D, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115020
   Ermolaeva SA, 2011, J MED MICROBIOL, V60, P75, DOI 10.1099/jmm.0.020263-0
   Fridman G, 2008, PLASMA PROCESS POLYM, V5, P503, DOI 10.1002/ppap.200700154
   Ikawa S, 2010, PLASMA PROCESS POLYM, V7, P33, DOI 10.1002/ppap.200900090
   Imlay JA, 2013, NAT REV MICROBIOL, V11, P443, DOI 10.1038/nrmicro3032
   Isbary G, 2013, CLIN PLASMA MED, V1, P19, DOI 10.1016/j.cpme.2012.11.001
   Isbary G, 2010, BRIT J DERMATOL, V163, P78, DOI 10.1111/j.1365-2133.2010.09744.x
   Kalghatgi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016270
   Kim GJ, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3292206
   Klampfl TG, 2012, APPL ENVIRON MICROB, V78, P5077, DOI 10.1128/AEM.00583-12
   Kurita H, 2010, CHEM PHYS LETT, V493, P165, DOI 10.1016/j.cplett.2010.05.028
   Kvam E, 2012, ANTIMICROB AGENTS CH, V56, P2028, DOI 10.1128/AAC.05642-11
   Laroussi M, 2007, PLASMA PROCESS POLYM, V4, P777, DOI 10.1002/ppap.200700066
   Laroussi M, 2009, IEEE T PLASMA SCI, V37, P714, DOI 10.1109/TPS.2009.2017267
   Li G, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2938692
   Locke BR, 2011, PLASMA SOURCES SCI T, V20, DOI 10.1088/0963-0252/20/3/034006
   McCombs G., 2012, PLASMA MED APPL LOW, P319
   Mizuno A., 2012, PLASMA BIODECONTAMIN
   Morfill GE, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115011
   O'Connell D, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3521502
   Oshige M, 2010, ANAL BIOCHEM, V400, P145, DOI 10.1016/j.ab.2010.01.021
   Poiata A, 2010, J ELECTROSTAT, V68, P128, DOI 10.1016/j.elstat.2009.11.008
   Ptasinska S, 2010, PHYS CHEM CHEM PHYS, V12, P7779, DOI [10.1039/e001188f, 10.1039/c001188f]
   Stypczynska A, 2010, CHEM PHYS LETT, V500, P313, DOI 10.1016/j.cplett.2010.10.016
   Walsh JL, 2012, PLASMA SOURCES SCI T, V21, DOI 10.1088/0963-0252/21/3/034008
   Yoshikawa Y, 2010, CHEM PHYS LETT, V501, P146, DOI 10.1016/j.cplett.2010.11.003
   Zimmermann JL, 2012, NEW J PHYS, V14, DOI 10.1088/1367-2630/14/7/073037
NR 28
TC 9
Z9 9
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3886
EI 1873-5738
J9 J ELECTROSTAT
JI J. Electrost.
PD JUN
PY 2014
VL 72
IS 3
BP 210
EP 217
DI 10.1016/j.elstat.2014.02.004
PG 8
WC Engineering, Electrical & Electronic
SC Engineering
GA AI3OK
UT WOS:000336771600006
DA 2018-12-27
ER

PT J
AU Choi, J
   Shim, JH
   Shin, YM
   Kim, KM
   Lim, YS
   Lee, HC
AF Choi, Jonggi
   Shim, Ju Hyun
   Shin, Yong Moon
   Kim, Kang Mo
   Lim, Young-Suk
   Lee, Han Chu
TI RETRACTED: Clinical significance of the best response during repeated
   transarterial chemoembolization in the treatment of hepatocellular
   carcinoma (Retracted article. See vol. 62, pg. 252, 2015)
SO JOURNAL OF HEPATOLOGY
LA English
DT Article; Retracted Publication
DE Hepatocellular carcinoma; Transarterial chemoembolization; Best
   response; Initial response; Survival
ID TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; LIVER-TRANSPLANTATION;
   PROGNOSTIC-FACTORS; SURVIVAL; CRITERIA; CIRRHOSIS; TRIAL
AB Background & Aims: We assessed the clinical implications of the best response compared with the initial response during repeated transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
   Methods: We evaluated 332 patients with intermediate-stage HCC and preserved liver function initially treated with repeated TACE. All had >= 1 lesion measuring >= 1 cm, and the response measured after each session was based on EASL and mRECIST criteria. We performed survival analyses according to response kinetics, and identified clinical factors associated with the need for repeated TACE to achieve the best response.
   Results: An objective response, either a complete response (CR) or a partial response (PR), after the first TACE was seen in about 50% of patients by both EASL and mRECIST. In terms of the best response during serial TACE, 250 patients (75.3%) by EASL and 278 (83.7%) by mRECIST were overall responders. The sizes of the largest and second largest tumors were the only parameters positively correlated with the number of TACE sessions required to achieve the best response (p <0.05). Multivariate Cox analysis showed that achieving a CR or PR as the best response was the best predictor of survival following TACE with a hazard ratio of 0.45 by EASL and 0.24 by mRECIST, and more than 0.69 and 0.71, respectively for initial responders (p <0.05).
   Conclusions: The best response observed during serial TACE, rather than the initial response, most strongly predicts the survival of patients with intermediate-stage HCC. The number of TACE sessions needed to achieve a best response is a function of tumor size. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.
C1 [Choi, Jonggi; Shim, Ju Hyun; Kim, Kang Mo; Lim, Young-Suk; Lee, Han Chu] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol,Asan Liver Ctr, Seoul 138736, South Korea.
   [Shin, Yong Moon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol,Asan Liver Ctr, Seoul 138736, South Korea.
RP Shim, JH (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, 86 Asanbyeongwon Gil, Seoul 138736, South Korea.
EM s5854@medimail.co.kr
CR Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Caturelli E, 2000, RADIOLOGY, V215, P123, DOI 10.1148/radiology.215.1.r00ap21123
   Georgiades C, 2012, RADIOLOGY, V265, P115, DOI 10.1148/radiol.12112264
   Golfieri R, 2013, J VASC INTERV RADIOL, V24, P509, DOI 10.1016/j.jvir.2012.12.013
   Herber SCA, 2008, AM J ROENTGENOL, V190, P1035, DOI 10.2214/AJR.07.2755
   Jung ES, 2013, J HEPATOL, V58, P1181, DOI 10.1016/j.jhep.2013.01.039
   Kim BK, 2013, EUR J CANCER, V49, P826, DOI 10.1016/j.ejca.2012.08.022
   Kim DY, 2012, ALIMENT PHARM THER, V35, P1343, DOI 10.1111/j.1365-2036.2012.05089.x
   Kim JH, 2010, RADIOLOGY, V255, P270, DOI 10.1148/radiol.09091076
   Lammer J, 2010, CARDIOVASC INTER RAD, V33, P41, DOI 10.1007/s00270-009-9711-7
   Lewandowski RJ, 2010, RADIOLOGY, V255, P955, DOI 10.1148/radiol.10091473
   Llado L, 2000, CANCER, V88, P50, DOI 10.1002/(SICI)1097-0142(20000101)88:1<50::AID-CNCR8>3.0.CO;2-I
   Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156
   MATSUI O, 1993, RADIOLOGY, V188, P79, DOI 10.1148/radiology.188.1.8390073
   Memon K, 2011, GASTROENTEROLOGY, V141, P526, DOI 10.1053/j.gastro.2011.04.054
   Peng ZW, 2013, J CLIN ONCOL, V31, P426, DOI 10.1200/JCO.2012.42.9936
   Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006
   Savastano S, 1999, J CLIN GASTROENTEROL, V28, P334, DOI 10.1097/00004836-199906000-00010
   Shim JH, 2013, J VASC INTERV RADIOL, V24, P316, DOI 10.1016/j.jvir.2012.10.022
   Shim JH, 2012, RADIOLOGY, V262, P708, DOI 10.1148/radiol.11110282
   Sieghart W, 2013, HEPATOLOGY, V57, P2261, DOI 10.1002/hep.26256
   Terzi E, 2012, J HEPATOL, V57, P1258, DOI 10.1016/j.jhep.2012.07.025
   Vogl TJ, 2000, RADIOLOGY, V214, P349, DOI 10.1148/radiology.214.2.r00fe06349
NR 23
TC 14
Z9 15
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD JUN
PY 2014
VL 60
IS 6
BP 1212
EP 1218
DI 10.1016/j.jhep.2014.01.014
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AH9BO
UT WOS:000336434300017
PM 24486088
DA 2018-12-27
ER

PT J
AU Wang, HL
   Zhang, Y
   Liu, P
   Zhou, PY
AF Wang, He-Ling
   Zhang, Yu
   Liu, Peng
   Zhou, Ping-Yi
TI RETRACTED: Aberrant promoter methylation of RASSF1A gene may be
   correlated with colorectal carcinogenesis: a meta-analysis (Retracted
   article. See vol. 42, pg. 1455, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE RASSF1A; Methylation; Colorectal cancer; Meta-analysis
ID K-RAS MUTATIONS; CANCER; HYPERMETHYLATION; CARCINOMA; RISK
AB We conducted a meta-analysis of cohort studies to evaluate the potential role of RASSF1A promoter methylation in colorectal carcinogenesis. A range of electronic databases were searched: PubMed (1966-2013), the Cochrane Library Database (Issue 12, 2013), EMBASE (1980-2013), CINAHL (1982-2013), Web of Science (1945-2013) and the Chinese Biomedical Database (CBM) (1982-2013) without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratio (OR) with 95 % confidence interval (95 % CI) was calculated. Eleven clinical cohort studies with a total of 1,505 colorectal cancer (CRC) patients that met all inclusion criteria were included in our meta-analysis. The results of our meta-analysis revealed that the frequency of RASSF1A promoter methylation was strongly correlated with clinical stage (OR = 1.69, 95 % CI 1.16-2.44, P = 0.006), histological grade (OR = 1.92, 95 % CI 1.22-3.04, P = 0.005) and distant metastasis (OR = 2.59, 95 % CI 1.46-4.60, P = 0.037) of CRC patients. However, we observed no positive correlations of RASSF1A promoter methylation with gender (OR = 1.04, 95 % CI 0.74-1.46, P = 0.842), age (OR = 1.70, 95 % CI 0.98-2.93, P = 0.057) and lymph node metastasis (OR = 1.65, 95 % CI 0.87-3.14, P = 0.127) of CRC patients. Further subgroup analysis by ethnicity demonstrated that RASSF1A promoter methylation was correlated with clinicopathological characteristics of CRC patients among Asians (clinical stage: OR = 2.55, 95 % CI 1.55-4.20, P < 0.001; histological grade: OR = 2.70, 95 % CI 1.44-5.06, P = 0.002; lymph node metastasis: OR = 4.09, 95 % CI 1.49-11.26, P = 0.006; distant metastasis: OR = 5.38, 95 % CI 1.73-16.70, P = 0.004), but not among Caucasians and Africans (all P > 0.05). Our meta-analysis has shown positive correlations between aberrant promoter methylation of RASSF1A gene and clinicopathological characteristics of CRC patients, especially among Asians.
C1 [Wang, He-Ling; Zhang, Yu; Liu, Peng; Zhou, Ping-Yi] China Med Univ, Shengjing Hosp, Dept Gen Surg, Shenyang 110022, Peoples R China.
RP Wang, HL (reprint author), China Med Univ, Shengjing Hosp, Dept Gen Surg, Huaxiang Rd 39, Shenyang 110022, Peoples R China.
EM wangheling1127@126.com
FU Research Foundation of Science and Technology Agency of Liaoning
   Province [2011408004]
FX This work was supported by the Research Foundation of Science and
   Technology Agency of Liaoning Province (No. 2011408004). We would like
   to acknowledge the reviewers for their helpful comments on this paper.
CR Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051
   Amin Karishma S, 2012, J Carcinog, V11, P3, DOI 10.4103/1477-3163.93000
   Chen SP, 2012, GENET TEST MOL BIOMA, V16, P1277, DOI 10.1089/gtmb.2012.0126
   Cleary SP, 2010, AM J EPIDEMIOL, V172, P1000, DOI 10.1093/aje/kwq245
   Cooper K, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI [10.3310/hta.14320, 10.3310/hta14320]
   Dammann R, 2000, NAT GENET, V25, P315
   Dunlop MG, 2013, GUT, V62, P871, DOI 10.1136/gutjnl-2011-300537
   Ellinger J, 2011, BJU INT, V107, P664, DOI 10.1111/j.1464-410X.2010.09468.x
   Fernandes MS, 2013, INT J CANCER, V132, P251, DOI 10.1002/ijc.27696
   [胡佳乐 Hu Jiale], 2010, [中国肿瘤生物治疗杂志, Chinese Journal of Cancer Biotherapy], V17, P444
   Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343
   Kang Ho-Jin, 2012, J Prev Med Public Health, V45, P251, DOI 10.3961/jpmph.2012.45.4.251
   Kimura N, 2009, CLIN BIOCHEM, V42, P1113, DOI 10.1016/j.clinbiochem.2009.03.017
   Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173
   Li C. J., 2011, SHANDONG MED J, V51, P87, DOI DOI 10.3969/J.ISSN.1002-266X.2011.42.052
   Miladi-Abdennadher I, 2010, TUMOR BIOL, V31, P503, DOI 10.1007/s13277-010-0063-3
   Miranda E, 2006, BRIT J CANCER, V95, P1101, DOI 10.1038/sj.bjc.6603337
   Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906
   Pan ZG, 2005, CANCER BIOL THER, V4, P1116, DOI 10.4161/cbt.4.10.2023
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Shin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023196
   Sinha R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060142
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tommasi S, 2011, J CELL PHYSIOL, V226, P1934, DOI 10.1002/jcp.22524
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj/onc/1205466
   Wahab AHA, 2011, TUMOR BIOL, V32, P845, DOI 10.1007/s13277-011-0156-7
   Wang X. D., 2011, CHIN J LABOR DIAGNOS, V15, P1538, DOI DOI 10.3969/J.ISSN.1007-4287.2011.09.040
   Yu Z. H., 2011, ONCOLOGY PROGR, V9, P555, DOI DOI 10.3969/J.ISSN.1672-1535.2011.05.019
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 29
TC 7
Z9 7
U1 3
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUN
PY 2014
VL 41
IS 6
BP 3991
EP 3999
DI 10.1007/s11033-014-3267-6
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AH8QY
UT WOS:000336404500049
PM 24566684
DA 2018-12-27
ER

PT J
AU Huang, SC
   Chen, J
   Luo, Z
AF Huang, Shucheng
   Chen, Jian
   Luo, Zhi
TI RETRACTED: Sparse tensor CCA for color face recognition (Retracted
   article. See vol. 25, pg. 2091, 2014)
SO NEURAL COMPUTING & APPLICATIONS
LA English
DT Article; Retracted Publication
DE Color images; Face recognition; Tensor subspace analysis; Sparse
   representation
ID CANONICAL CORRELATION-ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; EIGENFACES
AB This paper proposes a subspace learning method, named as sparse tensor canonical correlation analysis (ST-CCA), for color face recognition. A sample image is formalized as high-order tensors to preserve the inherent structure of the color face images. We utilize sparse canonical correlation analysis (SCCA) to choose gene. For each pair of tensors, SCCA generates the sparse loadings alternately, which is helpful for choosing significant variables to reduce dimensions and eliminate the redundancies of tensors. We use the elastic net as constraint condition to attack the collinearity problem by decorrelating and selecting the sufficient variables irrespective of the limited dimensions. Furthermore, ST-CCA gains stable recognition rates because the alternating least square solution converges. ST-CCA is convex with different initials of the projection matrices. Experimental results on AR face database and LFW face database show the superior performance of our method over the state-of-the-art ones.
C1 [Huang, Shucheng; Chen, Jian; Luo, Zhi] Jiangsu Univ Sci & Technol, Sch Comp Sci & Engn, Zhenjiang 212003, Peoples R China.
RP Huang, SC (reprint author), Jiangsu Univ Sci & Technol, Sch Comp Sci & Engn, Zhenjiang 212003, Peoples R China.
EM schuang6@126.com
CR Belhumeur PN, 1997, IEEE T PATTERN ANAL, V19, P711, DOI 10.1109/34.598228
   Branco JA, 2005, COMPUTATION STAT, V20, P203, DOI 10.1007/BF02789700
   Choi JY, 2009, IEEE T SYST MAN CY B, V39, P1217, DOI 10.1109/TSMCB.2009.2014245
   De Lathauwer L, 2000, SIAM J MATRIX ANAL A, V21, P1253, DOI 10.1137/S0895479896305696
   De Lathauwer L, 2000, SIAM J MATRIX ANAL A, V21, P1324, DOI 10.1137/S0895479898346995
   Efron B, 2004, ANN STAT, V32, P407
   Hardoon DR, 2011, MACH LEARN, V83, P331, DOI 10.1007/s10994-010-5222-7
   Hardoon DR, 2004, NEURAL COMPUT, V16, P2639, DOI 10.1162/0899766042321814
   He X., 2005, ADV NEURAL INFORM PR, V18
   He XF, 2004, ADV NEUR IN, V16, P153
   HOTELLING H, 1936, BIOMETRIKA, V28, P312
   Kolda TG, 2009, SIAM REV, V51, P455, DOI 10.1137/07070111X
   Lai P L, 2000, Int J Neural Syst, V10, P365, DOI 10.1142/S012906570000034X
   Lai PL, 2000, IEEE IJCNN, P614
   Li M, 2005, PATTERN RECOGN LETT, V26, P527, DOI 10.1016/j.patrec.2004.09.007
   Liu CJ, 2008, IEEE T INF FOREN SEC, V3, P213, DOI 10.1109/TIFS.2008.923824
   Lu HP, 2008, IEEE T NEURAL NETWOR, V19, P18, DOI 10.1109/TNN.2007.901277
   Lykou A, 2010, COMPUT STAT DATA AN, V54, P3144, DOI 10.1016/j.csda.2009.08.002
   Martinez A, CVC TECH REP 24
   Moghaddam B., 2006, ADV NEURAL INFORM PR, V18, P915
   Moghaddam B., 2006, P 23 INT C MACH LEAR, P641
   Parkhomenko E, STAT APPL GENET MOL, V8
   Qiao Z, INT J APPL MATH, V39
   TORRES L, 1999, P INT C SYST MAN CYB, V3, P627
   TURK M, 1991, J COGNITIVE NEUROSCI, V3, P71, DOI 10.1162/jocn.1991.3.1.71
   Vasilescu M.A.O., 2002, EUR C COMP VIS, V2350, P447
   Vasilescu MAO, 2005, PROC CVPR IEEE, P547
   Waaijenborg S, STAT APPL GENET MOL, V7
   Wang Changyuan, 2008, 19 INT C PATT REC IC, P1
   Wang SJ, 2012, INT C PATT RECOG, P2278
   Wang SJ, 2012, IEEE T NEUR NET LEAR, V23, P876, DOI 10.1109/TNNLS.2012.2191620
   Wang SJ, 2011, IEEE T IMAGE PROCESS, V20, P2490, DOI 10.1109/TIP.2011.2121084
   Yang J, 2004, IEEE T PATTERN ANAL, V26, P131, DOI 10.1109/TPAMI.2004.1261097
   Yang J, 2008, IEEE T NEURAL NETWOR, V19, P2088, DOI 10.1109/TNN.2008.2003187
   Ye JP, 2005, MACH LEARN, V61, P167, DOI 10.1007/s10994-005-3561-6
   Zou H, 2006, J COMPUT GRAPH STAT, V15, P265, DOI 10.1198/106186006X113430
   Zou H, 2005, J ROY STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
   Zou H, JR STATIST SOC B
NR 38
TC 6
Z9 7
U1 4
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-0643
EI 1433-3058
J9 NEURAL COMPUT APPL
JI Neural Comput. Appl.
PD JUN
PY 2014
VL 24
IS 7-8
BP 1647
EP 1658
DI 10.1007/s00521-013-1387-x
PG 12
WC Computer Science, Artificial Intelligence
SC Computer Science
GA AH8FV
UT WOS:000336371900016
DA 2018-12-27
ER

PT J
AU Li, YH
   Xu, WN
   Jiang, ZJ
   Gao, Y
   Pang, Y
   Li, L
   OuYang, L
   Zhang, LQ
   Liu, ZH
   Wang, Y
   Xiao, Y
   Huang, XJ
AF Li, Yonghua
   Xu, Wenning
   Jiang, Zujun
   Gao, Yang
   Pang, Yan
   Li, Li
   OuYang, Ling
   Zhang, Leqing
   Liu, Zenghui
   Wang, Yang
   Xiao, Yang
   Huang, Xiaojun
TI RETRACTED: Neutropenia and invasive fungal infection in patients with
   hematological malignancies treated with chemotherapy: a multicenter,
   prospective, non-interventional study in China(Retracted article. See
   vol. 35, pg. 11693, 2014)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Hematological malignancies; Chemotherapy; Neutropenia; Invasive fungal
   infection
ID CELL TRANSPLANT RECIPIENTS; CIGARETTE-SMOKING; RISK-STRATIFICATION;
   CANDIDA INFECTIONS; AMPHOTERICIN-B; EPIDEMIOLOGY; MANAGEMENT; DIAGNOSIS;
   LEUKEMIA; AUTOPSY
AB In this study, we explored the relationship between neutropenia (absolute neutrophil count (ANC) < 1,500/mm(3)) and invasive fungal infection (IFI) in Chinese patients who had hematological malignancies treated with chemotherapy. We conducted a multicenter, prospective, non-interventional study of consecutive patients with hematological malignancies undergoing chemotherapy in China and determined clinical characteristics of patients who developed neutropenia and IFI. The results indicated that for the 2,177 neutropenic patients, 88 (4.0 %) were diagnosed with IFI. We found that a high risk of IFI (P < 0.05) is associated with male gender, non-remission of the primary disease, use of two or more broad-spectrum antibiotics, treatment with parenteral nutrition, presence of cardiovascular disease, history of IFI, and neutropenia. When the ANC was less than 1,000, 1,000 similar to 500, 500 similar to 100, and < 100/mm(3), the incidence of IFI was 0.5, 5.2, 3.9, and 4.7 %, respectively (ANC > 1,000/mm(3) versus other groups, P < 0.001). When the ANC was less than 1,000, 500, or 100/mm(3) for 10 days or more, the incidence of IFI was 3.2 versus 6.1 % (P = 0.0052), 3.5 versus 7.1 % (P = 0.0021), and 3.1 versus 10.0 % (P < 0.001). When the ANC was less than 100/mm(3), taking antifungal prophylaxis reduced the incidence of IFI (P < 0.05). The IFI-attributable mortality rate was 11.7 %. In conclusion, Chinese patients with IFI, severe and prolonged neutropenia increases the incidence of IFI. The incidence of IFI associated with neutropenia was reduced when antifungal prophylaxis was given. IFI was associated with a significantly increased high mortality rate in hematological malignancy patients with neutropenia.
C1 [Li, Yonghua; Xu, Wenning; Jiang, Zujun; Gao, Yang; Pang, Yan; Li, Li; OuYang, Ling; Zhang, Leqing; Liu, Zenghui; Wang, Yang; Xiao, Yang] Guangzhou Mil Command, Dept Hematol, Guangzhou Gen Hosp, Guangzhou 510010, Guangdong, Peoples R China.
   [Huang, Xiaojun] Peking Univ, Inst Hematol, Beijing 100871, Peoples R China.
   [Huang, Xiaojun] Peoples Hosp, Beijing, Peoples R China.
RP Xiao, Y (reprint author), Guangzhou Mil Command, Dept Hematol, Guangzhou Gen Hosp, 111 Liuhua Rd, Guangzhou 510010, Guangdong, Peoples R China.
EM xiaoyangdoctor@yeah.net; jdxiao111@163.com
FU Guangzhou Pearl River Scientific and Technological New Star Capitals
   [2012 J2200008]
FX This work was partly supported by Guangzhou Pearl River Scientific and
   Technological New Star Capitals (grant no. 2012 J2200008). The authors
   would like to thank Cai Bojing and his colleagues (Merck and Co., Inc.,
   China) for their help with data collection and statistical analysis for
   this paper. We also need to thank the International Science Editing for
   providing professional English-language writing assistance for this
   article.
CR Appelberg R, 2007, TRENDS MICROBIOL, V15, P87, DOI 10.1016/j.tim.2006.11.009
   Au William W., 2012, Reviews on Environmental Health, V27, P43, DOI 10.1515/reveh-2012-0003
   Auberger J, 2008, INT J HEMATOL, V88, P508, DOI 10.1007/s12185-008-0184-2
   Barreto JN, 2013, AM J HEMATOL, V88, P283, DOI 10.1002/ajh.23388
   Brakhage AA, 2005, CURR DRUG TARGETS, V6, P875, DOI 10.2174/138945005774912717
   BURKE PJ, 1976, JOHNS HOPKINS MED J, V139, P1
   Chamilos G, 2006, HAEMATOL-HEMATOL J, V91, P986
   Cuenca-Estrella M, 2008, INT J ANTIMICROB AG, V32, pS143, DOI 10.1016/S0924-8579(08)70016-5
   De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660
   DIAMOND RD, 1982, INFECT IMMUN, V38, P292
   Donhuijsen K, 2008, DTSCH ARZTEBL INT, V105, P501, DOI 10.3238/arztebl.2008.0501
   Erjavec Z, 2009, CLIN MICROBIOL INFEC, V15, P625, DOI 10.1111/j.1469-0691.2009.02929.x
   Estey EH, 2012, AM J HEMATOL, V87, P90, DOI 10.1002/ajh.22246
   FINKLEA JF, 1971, AM REV RESPIR DIS, V104, P368, DOI 10.1164/arrd.1971.104.3.368
   Garcia-Manero G, 2012, AM J HEMATOL, V87, P692, DOI 10.1002/ajh.23264
   GRUCHOW HW, 1981, AM REV RESPIR DIS, V124, P411
   Hahn-Ast C, 2010, J ANTIMICROB CHEMOTH, V65, P761, DOI 10.1093/jac/dkp507
   HOI AB, 1985, J HOSP INFECT, V6, P333, DOI 10.1016/0195-6701(85)90039-8
   Jiang HH, 2010, CHIN J MYCOL, V5, P148
   Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399
   Kontoyiannis DP, 2010, CLIN INFECT DIS, V50, P1091, DOI 10.1086/651263
   Kurosawa M, 2012, INT J HEMATOL, V96, P748, DOI 10.1007/s12185-012-1210-y
   Lacerda JF, 2013, CLIN DRUG INVEST, V33, pS5, DOI 10.1007/s40261-012-0023-3
   Leroy O, 2009, CRIT CARE MED, V37, P1612, DOI 10.1097/CCM.0b013e31819efac0
   Lewis RE, 2013, MYCOSES, V56, P638, DOI 10.1111/myc.12081
   Maertens J, 2011, BONE MARROW TRANSPL, V46, P709, DOI 10.1038/bmt.2010.175
   Maertens J, 2007, EUR J HAEMATOL, V78, P275, DOI 10.1111/j.1600-0609.2006.00805.x
   Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024
   Marr KA, 2002, CLIN INFECT DIS, V34, P909, DOI 10.1086/339202
   Marr Kieren A, 2004, Oncology (Williston Park), V18, P9
   Martino R, 2002, ANN HEMATOL, V81, P233, DOI 10.1007/s00277-002-0466-3
   Maschmeyer G, 2013, EUR J CLIN MICROBIOL, V32, P679, DOI 10.1007/s10096-012-1794-4
   Michallet M, 2009, J CLIN ONCOL, V27, P3398, DOI 10.1200/JCO.2008.20.1178
   Peng J, 2013, TUMOR BIOL, V34, P953, DOI 10.1007/s13277-012-0631-9
   PENNINGTON JE, 1976, NEW ENGL J MED, V295, P426, DOI 10.1056/NEJM197608192950806
   Pfaller MA, 2010, CRIT REV MICROBIOL, V36, P1, DOI 10.3109/10408410903241444
   Portugal RD, 2009, J CLIN ONCOL, V27, P3849, DOI 10.1200/JCO.2008.21.0856
   Reuter S, 2009, SCAND J INFECT DIS, V41, P483, DOI 10.1080/00365540902856529
   REYNOLDS HY, 1988, MAYO CLIN PROC, V63, P161, DOI 10.1016/S0025-6196(12)64949-0
   Reynolds L, 2009, HEALTH POLICY, V90, P32, DOI 10.1016/j.healthpol.2008.09.002
   Ruhnke M, 2006, CURR DRUG TARGETS, V7, P495, DOI 10.2174/138945006776359421
   Scott LJ, 2007, DRUGS, V67, P269, DOI 10.2165/00003495-200767020-00009
   Sopori ML, 1998, PSYCHONEUROENDOCRINO, V23, P189, DOI 10.1016/S0306-4530(97)00076-0
   SOPORI ML, 1994, IMMUNOTOXICOLOGY IMM, P413
   STEIN RS, 1982, CANCER, V50, P2247, DOI 10.1002/1097-0142(19821201)50:11<2247::AID-CNCR2820501102>3.0.CO;2-7
   TOLLERUD DJ, 1989, AM REV RESPIR DIS, V139, P1446, DOI 10.1164/ajrccm/139.6.1446
   VERFAILLIE C, 1991, BONE MARROW TRANSPL, V8, P177
   WALSH T J, 1990, NCI (National Cancer Institute) Monographs, P43
   Warnock David W, 2007, Nihon Ishinkin Gakkai Zasshi, V48, P1, DOI 10.3314/jjmm.48.1
   Wingard JR, 2004, CLIN INFECT DIS, V39, pS38, DOI 10.1086/383052
   Yang L, 2012, TUMOR BIOL, V33, P1445, DOI 10.1007/s13277-012-0395-2
   Zhang WD, 2013, TUMOR BIOL, V34, P1729, DOI 10.1007/s13277-013-0710-6
NR 52
TC 31
Z9 33
U1 7
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2014
VL 35
IS 6
BP 5869
EP 5876
DI 10.1007/s13277-014-1777-4
PG 8
WC Oncology
SC Oncology
GA AI7RW
UT WOS:000337094900103
PM 24664582
DA 2018-12-27
ER

PT J
AU Deng, LX
   Xiang, ZF
   He, C
   Zhang, JZ
   Xie, HB
AF Deng Lixin
   Xiang Zhifeng
   He Cong
   Zhang Jinzhou
   Xie Hongbin
TI RETRACTED: Aneuploidy analysis of non-pronuclear embryos from IVF with
   use of array CGH: a case report (Retracted article. See vol. 47, pg.
   101, 2016)
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article; Retracted Publication
DE IVF; Array CGH; Non-pronuclear; Blastomere
ID CHROMOSOME INSTABILITY; BLASTOCYST TRANSFER; BIOPSY; DIAGNOSIS; TIME
AB By using array comparative genomic hybridization (array CGH), to analyze the aneuploidy of the single blastomeres from non-pronuclear embryos on cleavage-stage in IVF cycle. Four non-pronuclear embryos were got from an IVF cycle, and the each single cell was biopsied from the four cleavage-stage embryos on the third day after the insemination which was investigated by using array CGH. After the biopsy, all the embryos continued to cleave, and lately entered the morula stage on the fifth day, just one embryo 3 was developed to early blastocyst stage on the sixth day. The four blastomere 24 chromosomes showed one X monomer and three normal XY diploids; the autosome chromosomes of blastomeres were abnormally gained or lost at different chromosome from four embryos, such as Embryo 1 : 49,X (-1, -5, -11, -19, -20, -21, -Y, +3, +6, +7, +8, +10, +13, +14, +16, +17, +18); Embryo 2 : 44,XY (-12, -15); Embryo 3: 47,XY (-3, -8, -9, -21, +7, +17, +18, +19, +20); Embryo 4 : 54,XY (+4, +7, +10, +12, +13, +16, +17, +22). With the use of the array CGH, the aneuploidy analysis could review the abnormal chromosomes of single blastomere from the non-pronuclear embryos, which can harbor the risk of abnormal sex chromosome and autosome chromosomes.
C1 [Deng Lixin; He Cong] Henan Agr Univ, Anim Husb & Vet Inst, Zhengzhou 450002, Henan Province, Peoples R China.
   [Deng Lixin; Xiang Zhifeng; Zhang Jinzhou; Xie Hongbin] Henan Inst Sci & Technol, Coll Biol Sci, Xinxiang 453003, Henan Province, Peoples R China.
   [Xiang Zhifeng] Henan Inst Sci & Technol, Coll Anim Sci, Xinxiang 453003, Henan Province, Peoples R China.
RP Xiang, ZF (reprint author), Henan Inst Sci & Technol, Coll Anim Sci, Xinxiang 453003, Henan Province, Peoples R China.
EM zhifeng7809@qq.com
CR Burney RO, 2008, CLIN EXP OBSTET GYN, V35, P170
   Duncan FE, 2009, FERTIL STERIL, V91, P1462, DOI 10.1016/j.fertnstert.2008.07.1710
   Elder K, 2000, IN VITRO FERTILIZATI, P59
   Feenan Katie, 2006, Hum Fertil (Camb), V9, P157, DOI 10.1080/14647270600636269
   Forman EJ, 2012, SEMIN REPROD MED, V30, P236, DOI 10.1055/s-0032-1311526
   Geigl JB, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp526
   Gutierrez-Mateo C, 2011, FERTIL STERIL, V95, P953, DOI 10.1016/j.fertnstert.2010.09.010
   Johnson DS, 2010, HUM REPROD, V25, P1066, DOI 10.1093/humrep/dep452
   Kirkegaard K, 2012, HUM REPROD, V27, P97, DOI 10.1093/humrep/der382
   Li PF, 2012, GYNECOL ENDOCRINOL, V28, P25, DOI 10.3109/09513590.2011.588748
   Liao HQ, 2009, J ASSIST REPROD GEN, V26, P583, DOI 10.1007/s10815-009-9355-1
   Macas E, 2006, FERTIL STERIL, V85, P1753, DOI 10.1016/j.fertnstert.2005.11.062
   Magli MC, 2004, HUM REPROD, V19, P1163, DOI 10.1093/humrep/deh162
   Malcov M, 2009, FERTIL STERIL, V91, DOI 10.1016/j.fertnstert.2008.08.083
   Manor D, 1996, HUM REPROD, V11, P2502
   Martins WP, 2011, HUM REPROD UPDATE, V17, P438, DOI 10.1093/humupd/dmr012
   MUNNE S, 1993, HUM REPROD, V8, P2185, DOI 10.1093/oxfordjournals.humrep.a138001
   Munne S, 2007, FERTIL STERIL, V88, pS86, DOI 10.1016/j.fertnstert.2007.07.288
   Noyes N, 2008, REPROD BIOMED ONLINE, V17, P782, DOI 10.1016/S1472-6483(10)60405-1
   Staessen C, 2004, HUM REPROD, V19, P2849, DOI 10.1093/humrep/deh536
   Vanneste E, 2009, HUM REPROD, V24, P2679, DOI 10.1093/humrep/dep266
   Vanneste E, 2009, NAT MED, V15, P577, DOI 10.1038/nm.1924
NR 22
TC 0
Z9 0
U1 2
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567-2379
EI 1567-2387
J9 J MOL HISTOL
JI J. Mol. Histol.
PD JUN
PY 2014
VL 45
IS 3
BP 269
EP 274
DI 10.1007/s10735-013-9556-x
PG 6
WC Cell Biology
SC Cell Biology
GA AF0XY
UT WOS:000334439500003
DA 2018-12-27
ER

PT J
AU Baradaran, A
   Nasri, H
AF Baradaran, Azar
   Nasri, Hamid
TI RETRACTED: Significance of Immunostaining Data in IgA Nephropathy
   Patients; Current Knowledge and New Concepts (Retracted article. See
   vol. 14, pg. 231, 2015)
SO IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY
LA English
DT Letter; Retracted Publication
C1 [Baradaran, Azar] Isfahan Univ Med Sci, Dept Pathol, Esfahan, Iran.
   [Nasri, Hamid] Isfahan Univ Med Sci, Dept Nephrol, Esfahan, Iran.
RP Nasri, H (reprint author), Isfahan Univ Med Sci, Div Nephropathol, Esfahan, Iran.
EM hamidnasri@med.mui.ac.ir
RI baradaran, azar/V-6360-2017
OI baradaran, azar/0000-0001-7058-6367
CR Baradaran A, 2013, J RENAL INJ PREV, V2, P39, DOI 10.12861/jrip.2013.15
   Baradaran A, 2013, J RENAL INJ PREV, V2, P37, DOI 10.12861/jrip.2013.14
   Baradaran A, 2012, J RENAL INJ PREV, V1, P9, DOI 10.12861/jrip.2012.04
   Bellur SS, 2011, NEPHROL DIAL TRANSPL, V26, P2533, DOI 10.1093/ndt/gfq812
   Hernandez GT, 2014, J RENAL INJ PREV, V3, P3, DOI 10.12861/jrip.2014.02
   Lanewala A, 2014, J RENAL INJ PREV, V3, P1, DOI 10.12861/jrip.2014.01
   Maeng YI, 2013, INT J CLIN EXP PATHO, V6, P904
   Mubarak Muhammed, 2014, J Nephropathol, V3, P22, DOI 10.12860/jnp.2014.05
   Mubarak Muhammed, 2013, J Nephropathol, V2, P210, DOI 10.12860/JNP.2013.34
   Mubarak Muhammed, 2012, J Nephropathol, V1, P13, DOI 10.5812/jnp.4
   Nasri H, 2013, J RENAL INJ PREV, V2, P41, DOI 10.12861/jrip.2013.16
   Nasri H, 2012, J RENAL INJ PREV, V1, P1, DOI 10.12861/jrip.2012.01
   Nasri Hamid, 2013, J Nephropathol, V2, P190, DOI 10.12860/JNP.2013.30
   Nasri Hamid, 2012, J Nephropathol, V1, P31, DOI 10.5812/jnp.7
   Torbati PM, 2012, J RENAL INJ PREV, V1, P7, DOI 10.12861/jrip.2012.03
   Wyatt RJ, 2013, NEW ENGL J MED, V368, P2402, DOI 10.1056/NEJMra1206793
NR 16
TC 2
Z9 2
U1 2
U2 9
PU IRANIAN SCIENTIFIC SOCIETY MEDICAL ENTOMOLOGY
PI TEHRAN
PA SCHOOL PUBLIC HEALTH & INST HEALTH RESEARCH, TEHRAN UNIV MEDICAL
   SCIENCES, P O BOX  6446-14155, TEHRAN, 00000, IRAN
SN 1735-1502
EI 1735-5249
J9 IRAN J ALLERGY ASTHM
JI Iran. J. Allergy Asthma Immunol.
PD JUN
PY 2014
VL 13
IS 3
BP 218
EP 219
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA 300SF
UT WOS:000330483100010
PM 24659127
DA 2018-12-27
ER

PT J
AU Yuan, H
   Wu, B
   Ma, SL
   Yang, XY
   Yin, L
   Li, AJ
AF Yuan, Hang
   Wu, Bin
   Ma, Senlin
   Yang, Xiaoyu
   Yin, Lei
   Li, Aijun
TI RETRACTED: Reanalysis of the gene expression profile in chronic
   pancreatitis via bioinformatics methods (Retracted article. See vol. 20,
   36, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Chronic pancreatitis; Differentially expressed genes; Gene cluster;
   miRNA
ID POLY(ADP-RIBOSE) POLYMERASE; ESCHERICHIA-COLI; MULTIDRUG-RESISTANCE;
   DNA-DAMAGE; CANCER; INFLAMMATION; MICRORNAS; ADENOCARCINOMA;
   IDENTIFICATION; PROLIFERATION
AB Background: Diagnosis at an early stage of chronic pancreatitis (CP) is challenging. It has been reported that microRNAs (miRNAs) are increasingly found and applied as targets for the diagnosis and treatment of various cancers. However, to the best of our knowledge, few published papers have described the role of miRNAs in the diagnosis of CP.
   Method: We downloaded gene expression profile data from the Gene Expression Omnibus and identified differentially expressed genes (DEGs) between CP and normal samples of Harlan mice and Jackson Laboratory mice. Common DEGs were filtered out, and the semantic similarities of gene classes were calculated using the GOSemSim software package. The gene class with the highest functional consistency was selected, and then the Lists2Networks web-based system was used to analyse regulatory relationships between miRNAs and gene classes. The functional enrichment of the gene classes was assessed based on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway annotation terms.
   Results: A total of 405 common upregulated DEGs and 7 common downregulated DEGs were extracted from the two kinds of mice. Gene cluster D was selected from the common upregulated DEGs because it had the highest semantic similarity. miRNA 124a (miR-124a) was found to have a significant regulatory relationship with cluster D, and DEGs such as CHSY1 and ABCC4 were found to be regulated by miR-124a. The GO term of response to DNA damage stimulus and the pathway of Escherichia coli infection were significantly enriched in cluster D.
   Conclusion: DNA damage and E. coli infection might play important roles in CP pathogenesis. In addition, miR-124a might be a potential target for the diagnosis and treatment of CP.
C1 [Yuan, Hang; Wu, Bin; Ma, Senlin; Yang, Xiaoyu; Yin, Lei; Li, Aijun] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Special Treatment 2, Shanghai 200438, Peoples R China.
RP Li, AJ (reprint author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Special Treatment 2, 225 Changhai Rd, Shanghai 200438, Peoples R China.
EM ajli62@gmail.com
CR de la Lastra CA, 2007, CURR PHARM DESIGN, V13, P933
   Allocco DJ, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-18
   Baradkar VP, 2009, INDIAN J PATHOL MICR, V52, P573, DOI 10.4103/0377-4929.56162
   Baroukh N, 2007, J BIOL CHEM, V282, P19575, DOI 10.1074/jbc.M611841200
   Bartsch H, 2006, LANGENBECK ARCH SURG, V391, P499, DOI 10.1007/s00423-006-0073-1
   Benesty J, 2009, SPRINGER TOP SIGN PR, V2, P1, DOI 10.1007/978-3-642-00296-0_1
   Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901
   Boehler C, 2011, P NATL ACAD SCI USA, V108, P2783, DOI 10.1073/pnas.1016574108
   Cote GA, 2011, CLIN GASTROENTEROL H, V9, P266, DOI 10.1016/j.cgh.2010.10.015
   El-Sheikh AAK, 2007, J PHARMACOL EXP THER, V320, P229, DOI 10.1124/jpet.106.110379
   Gharaibeh RZ, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-452
   Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Hamby AM, 2007, STROKE, V38, P632, DOI 10.1161/01.STR.0000250742.61241.79
   Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126
   ISSEKUTZ AC, 1982, INFECT IMMUN, V36, P558
   Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718
   Kalathas D, 2011, MOL MED REP, V4, P363, DOI 10.3892/mmr.2011.431
   KARMALI MA, 1983, LANCET, V1, P619
   Kauppinen TM, 2009, J CEREBR BLOOD F MET, V29, P820, DOI 10.1038/jcbfm.2009.9
   Lachmann A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-87
   Lage H, 2008, CELL MOL LIFE SCI, V65, P3145, DOI 10.1007/s00018-008-8111-5
   Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6
   Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394
   Lindley Keith J., 2006, Indian Journal of Pediatrics, V73, P907, DOI 10.1007/BF02859284
   Luzi E, 2013, NONCODING RNA ENDOCR, V1, P9, DOI [10.2478/micrnado-2013-0003, DOI 10.2478/MICRNADO-2013-0003]
   Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7
   Nakamachi Y, 2009, ARTHRITIS RHEUM-US, V60, P1294, DOI 10.1002/art.24475
   Nana-Sinkam SP, 2010, ANN NY ACAD SCI, V1210, P25, DOI 10.1111/j.1749-6632.2010.05822.x
   Ramadani M, 2001, PANCREAS, V22, P383, DOI 10.1097/00006676-200105000-00008
   Ramoni MF, 2002, P NATL ACAD SCI USA, V99, P9121, DOI 10.1073/pnas.132656399
   Rius M, 2008, J PHARMACOL EXP THER, V324, P86, DOI 10.1124/jpet.107.131342
   Sanuki R, 2011, NAT NEUROSCI, V14, P1125, DOI 10.1038/nn.2897
   Sodhi RK, 2010, VASC PHARMACOL, V53, P77, DOI 10.1016/j.vph.2010.06.003
   Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228
   Szafranska AE, 2008, CLIN CHEM, V54, P1716, DOI 10.1373/clinchem.2008.109603
   Tarraga J, 2008, NUCLEIC ACIDS RES, V36, pW308, DOI 10.1093/nar/gkn303
   THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0
   Tian J, 2010, AM J HUM GENET, V87, P768, DOI 10.1016/j.ajhg.2010.11.005
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P10515
   Ulmasov B, 2013, AM J PATHOL, V183, P692, DOI 10.1016/j.ajpath.2013.05.020
   Wilson DG, 2012, DEV BIOL, V363, P413, DOI 10.1016/j.ydbio.2012.01.005
   Yu GC, 2010, BIOINFORMATICS, V26, P976, DOI 10.1093/bioinformatics/btq064
NR 43
TC 3
Z9 4
U1 1
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD MAY 29
PY 2014
VL 19
AR 31
DI 10.1186/2047-783X-19-31
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AL2IK
UT WOS:000338949000001
PM 24886751
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Anderson, DE
   Serences, JT
   Vogel, EK
   Awh, E
AF Anderson, David E.
   Serences, John T.
   Vogel, Edward K.
   Awh, Edward
TI RETRACTED: Induced Alpha Rhythms Track the Content and Quality of Visual
   Working Memory Representations with High Temporal Precision (Retracted
   article. See vol. 35, pg. 2838, 2015)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE attention; decoding; EEG; oscillatory activity; tuning function; working
   memory
ID SHORT-TERM-MEMORY; POPULATION RESPONSES; DISCRETE RESOURCE; PARIETAL
   CORTEX; OSCILLATIONS; ATTENTION; MODULATIONS; CAPACITY; DYNAMICS; BRAIN
AB Past work has suggested that neuronal oscillations coordinate the cellular assemblies that represent items in working memory (WM). In line with this hypothesis, we show that the spatial distribution of power in the alpha frequency band (8 -12 Hz) can be used to decode the content and quality of the representations stored in visual WM. We acquired EEG data during an orientation WM task, and used a forward encoding model of orientation selectivity to reconstruct orientation-specific response profiles (termed channel tuning functions, or CTFs) that tracked the orientation of the memorandum during both encoding and delay periods of the trial. Critically, these EEG-based CTFs were robust predictors of both between-and within-subject differences in mnemonic precision, showing that EEG-based CTFs provide a sensitive measure of the quality of sensory population codes. Experiments 2 and 3 established that these EEG-based CTFs are contingent on the voluntary storage goals of the observer. When observers were given a postsample cue to store or drop the memorandum, the resulting CTF was sustained in the "store" condition and rapidly eliminated following the "drop" cue. When observers were instructed to store one of two simultaneously presented stimuli, only the stored item was represented in a sustained fashion throughout the delay period. These findings suggest that the oscillatory activity in the alpha frequency band plays a central role in the active storage of information in visual WM, and demonstrate a powerful approach for tracking the precision of on-line memories with high temporal resolution.
C1 [Anderson, David E.; Vogel, Edward K.; Awh, Edward] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
   [Anderson, David E.; Vogel, Edward K.; Awh, Edward] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.
   [Serences, John T.] Univ Calif San Diego, Dept Psychol, San Diego, CA 92110 USA.
   [Serences, John T.] Univ Calif San Diego, Grad Program Neurosci, San Diego, CA 92110 USA.
RP Anderson, DE (reprint author), Univ Oregon, Dept Psychol, 1227 Univ Oregon, Eugene, OR 97403 USA.
EM danders3@uoregon.edu; awh@uoregon.edu
FU National Institute of Mental Health [R01-MH087214]
FX This work is supported by National Institute of Mental Health
   R01-MH087214 (E.A. and E.K.V.).
CR Anderson DE, 2013, J NEUROSCI, V33, P9273, DOI 10.1523/JNEUROSCI.0239-13.2013
   Anderson DE, 2013, J EXP PSYCHOL HUMAN, V39, P824, DOI 10.1037/a0030094
   Anderson DE, 2012, ATTEN PERCEPT PSYCHO, V74, P891, DOI 10.3758/s13414-012-0292-1
   Anderson DE, 2011, J NEUROSCI, V31, P1128, DOI 10.1523/JNEUROSCI.4125-10.2011
   Awh E, 2001, TRENDS COGN SCI, V5, P119, DOI 10.1016/S1364-6613(00)01593-X
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Brouwer GJ, 2011, J NEUROPHYSIOL, V106, P2108, DOI 10.1152/jn.00540.2011
   Brouwer GJ, 2009, J NEUROSCI, V29, P13992, DOI 10.1523/JNEUROSCI.3577-09.2009
   Christophel TB, 2012, J NEUROSCI, V32, P12983, DOI 10.1523/JNEUROSCI.0184-12.2012
   D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086
   Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009
   Emrich SM, 2013, J NEUROSCI, V33, P6516, DOI 10.1523/JNEUROSCI.5732-12.2013
   Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565
   Ester EF, 2013, J COGNITIVE NEUROSCI, V25, P754, DOI 10.1162/jocn_a_00357
   Ester EF, 2009, J NEUROSCI, V29, P15258, DOI 10.1523/JNEUROSCI.4388-09.2009
   Fries P, 2005, TRENDS COGN SCI, V9, P474, DOI 10.1016/j.tics.2005.08.011
   Garcia JO, 2013, CURR BIOL, V23, P515, DOI 10.1016/j.cub.2013.02.013
   Harrison SA, 2009, NATURE, V458, P632, DOI 10.1038/nature07832
   Heinen K, 2013, CEREB CORTEX, DOI 10.1093/cercor/bht157
   Jensen O, 2002, CEREB CORTEX, V12, P877, DOI 10.1093/cercor/12.8.877
   Jensen O, 2007, TRENDS COGN SCI, V11, P267, DOI 10.1016/j.tics.2007.05.003
   Jensen O, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00186
   Jonides J, 2005, CURR DIR PSYCHOL SCI, V14, P2, DOI 10.1111/j.0963-7214.2005.00323.x
   Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003
   LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473
   Martinez-Trujillo JC, 2004, CURR BIOL, V14, P744, DOI 10.1016/j.cub.2004.04.028
   Mazaheri A, 2008, J NEUROSCI, V28, P7781, DOI 10.1523/JNEUROSCI.1631-08.2008
   McCollough AW, 2007, CORTEX, V43, P77, DOI 10.1016/S0010-9452(08)70447-7
   Palva JM, 2010, P NATL ACAD SCI USA, V107, P7580, DOI 10.1073/pnas.0913113107
   Palva S, 2007, TRENDS NEUROSCI, V30, P150, DOI 10.1016/j.tins.2007.02.001
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005
   Raffone A, 2001, J COGNITIVE NEUROSCI, V13, P766, DOI 10.1162/08989290152541430
   Salinas E, 2001, NAT REV NEUROSCI, V2, P539, DOI 10.1038/35086012
   Sauseng P, 2009, CURR BIOL, V19, P1846, DOI 10.1016/j.cub.2009.08.062
   Scolari M, 2012, J NEUROSCI, V32, P7723, DOI 10.1523/JNEUROSCI.5558-11.2012
   Serences JT, 2007, CEREB CORTEX, V17, P284, DOI 10.1093/cercor/bhj146
   Serences JT, 2012, NEUROPSYCHOLOGIA, V50, P435, DOI 10.1016/j.neuropsychologia.2011.07.013
   Serences JT, 2009, PSYCHOL SCI, V20, P207, DOI 10.1111/j.1467-9280.2009.02276.x
   Serences JT, 2009, NEUROIMAGE, V44, P223, DOI 10.1016/j.neuroimage.2008.07.043
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   Siegel M, 2012, NAT REV NEUROSCI, V13, P121, DOI 10.1038/nrn3137
   SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011
   Singer W, 1999, CURR OPIN NEUROBIOL, V9, P189, DOI 10.1016/S0959-4388(99)80026-9
   Stam CJ, 1999, CLIN NEUROPHYSIOL, V110, P1801, DOI 10.1016/S1388-2457(99)00099-1
   Todd JJ, 2004, NATURE, V428, P751, DOI 10.1038/nature02466
   Treue S, 1999, NATURE, V399, P575, DOI 10.1038/21176
   van Dijk H, 2010, P NATL ACAD SCI USA, V107, P900, DOI 10.1073/pnas.0908821107
   Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550
   Vogel EK, 2004, NATURE, V428, P748, DOI 10.1038/nature02447
   Vogel EK, 1998, J EXP PSYCHOL HUMAN, V24, P1656, DOI 10.1037/0096-1523.24.6.1656
   Wilken P, 2004, J VISION, V4, P1120, DOI 10.1167/4.12.11
   Xu YD, 2006, NATURE, V440, P91, DOI 10.1038/nature04262
   Zhang WW, 2008, NATURE, V453, P233, DOI 10.1038/nature06860
NR 54
TC 14
Z9 15
U1 2
U2 27
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 28
PY 2014
VL 34
IS 22
BP 7587
EP 7599
DI 10.1523/JNEUROSCI.0293-14.2014
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA AI8CE
UT WOS:000337131800019
PM 24872563
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Wang, WG
   Wei, JJ
   Xu, ZW
   Zhuo, WK
   Zhang, Y
   Rong, H
   Cao, XC
   Wang, PS
AF Wang, Weiguo
   Wei, Junjie
   Xu, Zhanwang
   Zhuo, Wenkun
   Zhang, Yuan
   Rong, Hui
   Cao, Xuecheng
   Wang, Pingshan
TI RETRACTED: Open reduction and closed reduction internal fixation in
   treatment of femoral neck fractures: a meta-analysis (Retracted article.
   See vol. 16, pg. 70, 2015)
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article; Retracted Publication
DE Femoral neck fracture; Open reduction internal fixation; Closed
   reduction internal fixation
ID YOUNG-ADULTS; COMPLICATIONS; CHILDREN; FEMUR; HIP
AB Background: A meta-analysis was performed to assess the association between healing rate, avascular necrosis (AVN) of femoral head and two reductions-open reduction internal fixation (ORIF) and closed reduction internal fixation (CRIF) for femoral neck fracture.
   Methods: A literature-based search was conducted to identify all relevant studies published before September 10, 2013. The odd ratio (OR) and 95% confidence interval (CI) were used for estimating the effects of the two reduction methods. Data were independently extracted by two investigators who reached a consensus on all of the items. The heterogeneity between studies was examined by chi(2)-based Q statistic. Egger's regression analysis was used to evaluate publication bias. Statistical analysis was performed by Stata 10.0 software.
   Results: We examined 14 publications. The results of the present meta-analysis showed that AVN of femoral head were significant associated with the two reductions (CRIF vs. ORIF, OR = 1.746, 95% CI 1.159-2.628, p = 0.008), while the healing rate were not (CRIF vs. ORIF, OR = 0.853, 95% CI 0.573-1.270, p = 0.433).
   Conclusion: The present meta-analysis indicated the risk of AVN of femoral head was significant higher after CRIF fixation compared with ORIF, but no association between the healing rate and the two reductions for femoral neck fracture.
C1 [Wang, Weiguo; Zhuo, Wenkun; Zhang, Yuan; Rong, Hui; Cao, Xuecheng; Wang, Pingshan] Gen Hosp Jinan Mil Command, Dept Orthopaed Surg, Jinan 250031, Peoples R China.
   [Wang, Weiguo] Shandong Univ Tradit Chinese Med, TCM Orthopaed, Jinan 250014, Peoples R China.
   [Wei, Junjie] Gen Hosp Jinan Mil Command, Outpatient Dept, Jinan 250031, Peoples R China.
   [Xu, Zhanwang] Shandong Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Orthopaed, Jinan 250014, Peoples R China.
RP Xu, ZW (reprint author), Shandong Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Orthopaed, 16369 Jingshi Rd, Jinan 250014, Peoples R China.
EM zhanwangxu@hotmail.com
CR Bali K, 2011, CLIN ORTHOP SURG, V3, P302, DOI 10.4055/cios.2011.3.4.302
   Bimmel R, 2010, ACTA ORTHOP BELG, V76, P7
   Chaudhuri S, 2008, INDIAN J ORTHOP, V42, P33, DOI 10.4103/0019-5413.38578
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Gao X, 2008, J PRACT ORTHOP, V14, P265
   GARDEN R S, 1971, Journal of Bone and Joint Surgery British Volume, V53, P183
   Gautam VK, 1998, INJURY, V29, P215, DOI 10.1016/S0020-1383(97)00184-8
   Gjertsen JE, 2010, J BONE JOINT SURG AM, V92A, P619, DOI 10.2106/JBJS.H.01750
   Huang HK, 2010, ORTHOPEDICS, V33, DOI 10.3928/01477447-20101021-15
   Iorio R, 2006, J ARTHROPLASTY, V21, P1124, DOI 10.1016/j.arth.2005.12.008
   Javdan M, 2013, ADV BIOIMED RES, V2, P1
   Kan W, 2008, CHIN J ORTHOP TRAUMA, V13, P401
   Ko JY, 2010, BONE, V46, P584, DOI 10.1016/j.bone.2009.10.030
   Kurtinaitis I, 2012, MED LITH, V48, P145
   Kyle Richard F, 2009, Instr Course Lect, V58, P61
   LiN Z, 2012, CHINA J ORTHOP TRAUM, V25, P546
   Liu Z, 2003, CHINA J ORTHOP TRAUM, V16, P257
   Ly TV, 2008, J BONE JOINT SURG AM, V90A, P2254
   Mirdad T, 2002, INJURY, V33, P823, DOI 10.1016/S0020-1383(02)00013-X
   Miyata N, 2010, CLIN EXP HYPERTENS, V32, P511, DOI 10.3109/10641963.2010.496511
   Parker MJ, 2007, CLIN ORTHOP RELAT R, P175, DOI 10.1097/BLO.0b013e3180325a42
   PAUWELS F, 1935, SCHENKELHALSBRUCH ME
   Raaymakers ELFB, 2008, INDIAN J ORTHOP, V42, P13, DOI 10.4103/0019-5413.38575
   Razik F, 2012, INT ORTHOP, V36, P2127, DOI 10.1007/s00264-012-1619-1
   Ross JR, 2012, CURR REV MUSCULOSKE, V5, P199, DOI 10.1007/s12178-012-9129-8
   Schmidt AH, 2002, ORTHOP CLIN N AM, V33, P97, DOI 10.1016/S0030-5898(03)00074-9
   Song KS, 2010, J BONE JOINT SURG BR, V92B, P1148, DOI 10.1302/0301-620X.92B8.24482
   Upadhyay A, 2004, J BONE JOINT SURG BR, V86B, P1035, DOI 10.1302/0301-620X.86B7.15047
   Vandermeer JS, 2011, J BONE JOINT SURG AM, V93A, P905, DOI 10.2106/JBJS.J.00716
   Wang Y, 2005, CHIN GEN PRACT, V8, P1970
   Xia Y, 2013, MOD MED HLTH, V29, P247
   Ye Z, 2005, CHINA PRAC MED, V6, P54
   Zhang F, 2013, GUIDE CHINA MED, V11, P169
   Zhang M, 2011, CHINA HLTH IND, V8, P4
   Zhou F, 2012, J PRACT ORTHOP, V18, P835
NR 35
TC 7
Z9 12
U1 3
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAY 22
PY 2014
VL 15
AR 167
DI 10.1186/1471-2474-15-167
PG 5
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA AK0XC
UT WOS:000338138600002
PM 24885566
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhao, JJ
   Wang, SY
AF Zhao, Jingjun
   Wang, Shiying
TI RETRACTED: Jacobi spectral solution for integral algebraic equations of
   index 1 (Retracted article. See pg. 173, 2015)
SO JOURNAL OF INEQUALITIES AND APPLICATIONS
LA English
DT Article; Retracted Publication
DE integral algebraic equations; Jacobi collocation method; system of
   Volterra equations; index of IAEs; error analysis
ID CONVERGENCE ANALYSIS
AB This paper is concerned with obtaining the approximate solution of a class of semi-explicit integral algebraic equations (IAEs) of index 1. A Jacobi collocation method is proposed for the IAEs of index 1. A rigorous analysis of the error bound in weighted L-2-norm is also provided, which theoretically justifies the spectral rate of convergence while the kernels and the source functions are sufficiently smooth. The results of several numerical experiments are presented which support the theoretical results.
C1 [Zhao, Jingjun; Wang, Shiying] Harbin Inst Technol, Dept Math, Harbin 150001, Peoples R China.
RP Zhao, JJ (reprint author), Harbin Inst Technol, Dept Math, Harbin 150001, Peoples R China.
EM hit_zjj@hit.edu.cn
FU National Natural Science Foundation of China [11101109, 11271102];
   Natural Science Foundation of Hei-long-jiang Province of China
   [A201107]; SRF for ROCS, SEM
FX This work is supported by the National Natural Science Foundation of
   China (11101109, 11271102), the Natural Science Foundation of
   Hei-long-jiang Province of China (A201107) and SRF for ROCS, SEM. The
   authors would like to acknowledge two anonymous referees for their
   careful reading of the manuscript and constructive comments.
CR Brunner H., 2004, COLLOCATION METHODS
   Bulatov MV, 1997, PROPERTIES DIFFERENT
   Bulatov MV, 2009, SCI CADE09, P25
   Bulatov MV, 2002, COMP MATH MATH PHYS, V42, P315
   Cannon JR, 1984, ONE DIMENSIONAL HEAT
   Canuto C., 2006, SPECTRAL METHODS FUN
   Chen YP, 2010, MATH COMPUT, V79, P147, DOI 10.1090/S0025-5718-09-02269-8
   Chistyakov VF, 1986, LYAPUNOV FUNCTIONS T, P231
   GEAR CW, 1990, SIAM J NUMER ANAL, V27, P1527, DOI 10.1137/0727089
   Gomilko AM, 2003, J ENG MATH, V46, P253, DOI 10.1023/A:1025065714786
   Guo BY, 2001, ADV COMPUT MATH, V14, P227
   Hadizadeh M, 2011, APPL NUMER MATH, V61, P131, DOI 10.1016/j.apnum.2010.08.009
   Hairer E., 1996, SOLVING ORDINARY DIF
   Hesthaven J.S., 2007, SPECTRAL METHODS TIM, V21, DOI DOI 10.2277/ 0521792118
   Kafarov VV, 1999, CHEM ENG SCI, V54, P4669, DOI 10.1016/S0009-2509(99)00277-8
   Kauthen JP, 2000, MATH COMPUT, V236, P1503
   Pishbin S, 2011, ELECTRON T NUMER ANA, V38, P327
   QU CK, 1988, PAC J MATH, V135, P157, DOI 10.2140/pjm.1988.135.157
   Shen J., 2006, SPECTRAL HIGH ORDER
   Tang T, 2008, J COMPUT MATH, V26, P825
   Zenchuk AI, 2008, J NONLINEAR MATH PHY, V15, P437, DOI 10.2991/jnmp.2008.15.s3.42
NR 21
TC 1
Z9 1
U1 2
U2 15
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1029-242X
J9 J INEQUAL APPL
JI J. Inequal. Appl.
PD MAY 6
PY 2014
AR 156
DI 10.1186/1029-242X-2014-156
PG 12
WC Mathematics, Applied; Mathematics
SC Mathematics
GA AK2CW
UT WOS:000338227600001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Ghasemi, O
   Ghanbariadivi, H
   Ghasemi, V
AF Ghasemi, O.
   Ghanbariadivi, H.
   Ghasemi, V.
TI RETRACTED: Inhibition Effect of Hydroxybenzaldehyde Schiff Bases on the
   Corrosion of Mild Steel in Hydrochloric Acid Solution (Retracted
   article. See vol. 36, pg. 298, 2015)
SO JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Schiff base; Langmuir; inhibition; AFM; Adsorption
ID 1 M HCL; MODEL CHEMISTRY; TOTAL ENERGIES; SULFURIC-ACID; CARBON-STEEL;
   ADSORPTION; DENSITY; MEDIA; ATOMS
AB The corrosion inhibition of mild steel in 1M HCl by N, N'-bis(n-hydroxybenzaldehyde)-1,3-propandiimine (n-HBP) Schiff bases has been investigated using electrochemical techniques. The experimental results suggest that these compounds are excellent corrosion inhibitors for mild steel and the inhibition efficiency increases with the increase in inhibitors concentration. Polarization curves reveal that all studied inhibitors are mixed type. The effect of temperature was studied in the temperature range from 25 to 65 degrees C. The experimentally obtained adsorption isotherms follow the Langmuir equation. Activation and thermodynamic adsorption parameters were calculated. The morphology of mild steel surface was examined by atomic force microscopy images.
C1 [Ghasemi, O.] Petr Univ Technol, Abadan Fac Petr Engn, Abadan 6318714331, Iran.
   [Ghanbariadivi, H.] Amirkabir Univ Technol, Dept Met & Mat, Tehran, Iran.
   [Ghasemi, V.] Karaj Azad Univ, Dept Ind Management, Karaj, Iran.
RP Ghasemi, O (reprint author), Petr Univ Technol, Abadan Fac Petr Engn, North Boarde St, Abadan 6318714331, Iran.
EM omidghasemi506@yahoo.com
CR Ahamad I, 2010, MATER CHEM PHYS, V124, P1155, DOI 10.1016/j.matchemphys.2010.08.051
   Ahamad I, 2010, CORROS SCI, V52, P933, DOI 10.1016/j.corsci.2009.11.016
   Aljourani J, 2009, CORROS SCI, V51, P1836, DOI 10.1016/j.corsci.2009.05.011
   Badiea AM, 2009, CORROS SCI, V51, P2231, DOI 10.1016/j.corsci.2009.06.011
   Badr GE, 2009, CORROS SCI, V51, P2529, DOI 10.1016/j.corsci.2009.06.017
   Bayol E, 2008, MATER CHEM PHYS, V112, P624, DOI 10.1016/j.matchemphys.2008.06.012
   Danaee I, 2013, J MOL STRUCT, V1035, P247, DOI 10.1016/j.molstruc.2012.11.013
   Danaee I, 2011, INT J HYDROGEN ENERG, V36, P12102, DOI 10.1016/j.ijhydene.2011.06.106
   Danaee I, 2008, J PHYS CHEM B, V112, P15933, DOI 10.1021/jp8069173
   Danaee I., 2011, ELECTROANAL CHEM, V662, P415, DOI DOI 10.1016/J.JELECHEM.2011.09.012
   Emregul KC, 2006, CORROS SCI, V48, P3243, DOI 10.1016/j.corsci.2005.11.016
   FAIRHURST SA, 1995, J CHEM SOC DALTON, P321, DOI 10.1039/dt9950000321
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Ghasemi O, 2013, J MATER ENG PERFORM, V22, P1054, DOI 10.1007/s11665-012-0348-3
   Ghasemi O, 2013, J CENT SOUTH UNIV, V20, P301, DOI 10.1007/s11771-013-1488-9
   Hegazy MA, 2011, CORROS SCI, V53, P671, DOI 10.1016/j.corsci.2010.10.004
   Hegazy MA, 2009, CORROS SCI, V51, P2610, DOI 10.1016/j.corsci.2009.06.046
   herrag L., 2008, ELECTROCHIM ACTA, V26, P211
   Hossein SMA, 2008, MATER CORROS, V59, P41, DOI 10.1002/maco.200704101
   Issaadi S, 2011, CORROS SCI, V53, P1484, DOI 10.1016/j.corsci.2011.01.022
   Jacob KS, 2010, CORROS SCI, V52, P224, DOI 10.1016/j.corsci.2009.09.007
   Keles H, 2008, MATER CHEM PHYS, V112, P173, DOI 10.1016/j.matchemphys.2008.05.027
   Keles H, 2011, MATER CHEM PHYS, V130, P1317, DOI 10.1016/j.matchemphys.2011.09.022
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Li XH, 2005, APPL SURF SCI, V252, P1254, DOI 10.1016/j.apsusc.2005.02.118
   Lowmunkhong P, 2010, CORROS SCI, V52, P30, DOI 10.1016/j.corsci.2009.08.039
   MACDONALD JR, 1984, SOLID STATE IONICS, V13, P147
   Mallaiya K, 2011, ELECTROCHIM ACTA, V56, P3857, DOI 10.1016/j.electacta.2011.02.036
   Micahed MA, 2008, ELECTROCHIM ACTA, V53, P2877, DOI 10.1016/j.electacta.2007.10.070
   Negm NA, 2011, CORROS SCI, V53, P3566, DOI 10.1016/j.corsci.2011.06.029
   Negm NA, 2010, CORROS SCI, V52, P3523, DOI 10.1016/j.corsci.2010.07.001
   Obot IB, 2011, CURR APPL PHYS, V11, P382, DOI 10.1016/j.cap.2010.08.007
   PETERSSON GA, 1988, J CHEM PHYS, V89, P2193, DOI 10.1063/1.455064
   PETERSSON GA, 1991, J CHEM PHYS, V94, P6081, DOI 10.1063/1.460447
   Solmaz R, 2011, MATER CHEM PHYS, V125, P796, DOI 10.1016/j.matchemphys.2010.09.056
   Solmaz R, 2010, CORROS SCI, V52, P3321, DOI 10.1016/j.corsci.2010.06.001
   Zhang F, 2011, ELECTROCHIM ACTA, V56, P1636, DOI 10.1016/j.electacta.2010.10.033
NR 37
TC 2
Z9 2
U1 2
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0193-2691
EI 1532-2351
J9 J DISPER SCI TECHNOL
JI J. Dispersion Sci. Technol.
PD MAY 4
PY 2014
VL 35
IS 5
BP 706
EP 716
DI 10.1080/01932691.2013.807740
PG 11
WC Chemistry, Physical
SC Chemistry
GA AF8VL
UT WOS:000334993600011
DA 2018-12-27
ER

PT J
AU Kwon, BW
   Hu, SZ
   Marin-Flores, O
   Norton, MG
   Kim, J
   Scudiero, L
   Breit, J
   Ha, S
AF Kwon, Byeong W.
   Hu, Shuozhen
   Marin-Flores, Oscar
   Norton, M. Grant
   Kim, Jinsoo
   Scudiero, Louis
   Breit, Joe
   Ha, Su
TI RETRACTED: High-Performance Molybdenum Dioxide-Based Anode for
   Dodecane-Fueled Solid-Oxide Fuel Cells (SOFCs)(Retracted article. See
   vol. 5, pg. 768, 2017)
SO ENERGY TECHNOLOGY
LA English
DT Article; Retracted Publication
DE dodecane; solid-oxide fuel cells; liquid hydrocarbon fuels; molybdenum
   dioxide; porosity
ID LITHIUM-ION BATTERIES; PARTIAL OXIDATION; SOFC ANODES; SULFUR; MOO2;
   CAPACITY; CATALYST; COKING
AB For the solid-oxide fuel cells (SOFCs), nickel-yttrium-stabilized zirconia (Ni-YSZ) cermet anodes operating with complex liquid hydrocarbon fuels display severe carbon formation on the Ni surface and sulfur poisoning. In this present study, we fabricate molybdenum dioxide (MoO2)-based anodes with an optimum microporous structure that leads to a maximum power density over 3 Wcm(-2) at 750 degrees C under the direct feeding of n-dodecane fuel mixture. The cell resisted the carbon (coke) formation for over 24 h of continuous cell testing and was also resistant to deactivation with 500 ppm of sulfur in the fuel stream.
C1 [Kwon, Byeong W.; Hu, Shuozhen; Ha, Su] Washington State Univ, Voiland Sch Chem Engn & Bioengn, Pullman, WA 99164 USA.
   [Marin-Flores, Oscar; Norton, M. Grant] Washington State Univ, Sch Mech & Mat Engn, Pullman, WA 99164 USA.
   [Kim, Jinsoo; Ha, Su] Kyung Hee Univ, Dept Chem Engn, Yongin 449701, Kyunggi Do, South Korea.
   [Scudiero, Louis] Washington State Univ, Dept Chem, Pullman, WA 99164 USA.
   [Breit, Joe] Boeing Commercial Airplanes, Syst Concept Ctr, Everett, WA 98203 USA.
RP Norton, MG (reprint author), Washington State Univ, Sch Mech & Mat Engn, Pullman, WA 99164 USA.
EM norton@mme.wsu.edu; suha@wsu.edu
RI Kim, Jinsoo/G-6348-2012
OI Kim, Jinsoo/0000-0002-1376-9498
FU National Science Foundation GOALI Program [CBET-1034308]; Boeing
   Commercial Airplanes; USDA/NIFA through Hatch Project [WNP00807]
FX This work was supported financially by the National Science Foundation
   GOALI Program (Grant No. CBET-1034308) and by Boeing Commercial
   Airplanes. This work was also partially funded by USDA/NIFA through
   Hatch Project #WNP00807 titled: "Fundamental and Applied Chemical and
   Biological Catalysts to Minimize Climate Change, Create a Sustainable
   Energy Future, and Provide a Safer Food Supply".
CR Adams C., 2001, AVIONICS        1001
   Atkinson A, 2004, NAT MATER, V3, P17, DOI 10.1038/nmat1040
   Braun RJ, 2009, J FUEL CELL SCI TECH, V6, DOI 10.1115/1.3008037
   Cho W, 2012, J APPL ELECTROCHEM, V42, P909, DOI 10.1007/s10800-012-0470-9
   Cimenti M, 2009, ENERGIES, V2, P377, DOI 10.3390/en20200377
   Ellefson CA, 2012, J MATER SCI, V47, P2057, DOI 10.1007/s10853-011-5918-5
   Gorte RJ, 2003, J CATAL, V216, P477, DOI 10.1016/S0021-9517(02)00121-5
   Huang YH, 2006, SCIENCE, V312, P254, DOI 10.1126/science.1125877
   Ji XL, 2007, CHEM MATER, V19, P374, DOI 10.1021/cm060961y
   Kendall K, 2006, J POWER SOURCES, V157, P750, DOI 10.1016/j.jpowsour.2006.01.061
   Kim T, 2007, J POWER SOURCES, V164, P42, DOI 10.1016/j.jpowsour.2006.09.101
   Kishimoto H, 2005, J ELECTROCHEM SOC, V152, pA532, DOI 10.1149/1.1854092
   Kishimoto H., 2007, P 10 INT S SOL OX FU, V1, P1669
   Koh JH, 2002, SOLID STATE IONICS, V149, P157, DOI 10.1016/S0167-2738(02)00243-6
   Kwon BW, 2013, J POWER SOURCES, V243, P203, DOI 10.1016/j.jpowsour.2013.05.133
   Marin-Flores O G, 2009, APPL CATAL A-GEN, V352, P124
   Marin-Flores O, 2011, APPL CATAL B-ENVIRON, V105, P61, DOI 10.1016/j.apcatb.2011.03.035
   Marin-Flores O, 2010, APPL CATAL B-ENVIRON, V98, P186, DOI 10.1016/j.apcatb.2010.05.028
   Marin-Flores O, 2010, APPL CATAL A-GEN, V381, P18, DOI 10.1016/j.apcata.2010.03.032
   Marin-Flores O, 2009, SURF SCI, V603, P2327, DOI 10.1016/j.susc.2009.05.010
   O'Brien J. S., 2010, P S EL PROC REL FUEL, V28, P221
   Pillai M, 2010, J POWER SOURCES, V195, P271, DOI 10.1016/j.jpowsour.2009.05.032
   Ruiz-Morales JC, 2006, J MATER CHEM, V16, P540, DOI 10.1039/b515747a
   Shi YF, 2009, NANO LETT, V9, P4215, DOI 10.1021/nl902423a
   Suzuki T, 2009, SCIENCE, V325, P852, DOI 10.1126/science.1176404
   Vohs JM, 2009, ADV MATER, V21, P943, DOI 10.1002/adma.200802428
   Wachsman ED, 2012, ENERG ENVIRON SCI, V5, P5498, DOI 10.1039/c1ee02445k
   Yang CH, 2012, ADV MATER, V24, P1439, DOI 10.1002/adma.201104852
   Yang L, 2009, SCIENCE, V326, P126, DOI 10.1126/science.1174811
   Zhou L, 2011, ACS APPL MATER INTER, V3, P4853, DOI 10.1021/am201351z
   Zhou ZF, 2007, J POWER SOURCES, V171, P856, DOI 10.1016/j.jpowsour.2007.06.210
NR 31
TC 12
Z9 12
U1 3
U2 40
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2194-4288
EI 2194-4296
J9 ENERGY TECHNOL-GER
JI Energy Technol.
PD MAY
PY 2014
VL 2
IS 5
BP 425
EP 430
DI 10.1002/ente.201300165
PG 6
WC Energy & Fuels
SC Energy & Fuels
GA AK3VL
UT WOS:000338353000001
DA 2018-12-27
ER

PT J
AU Macri, SMC
   Masek-Hammerman, K
   Crowell, AM
   Fenn, MS
   Knight, HL
   Westmoreland, SV
   Miller, AD
AF Macri, S. M. Cummings
   Masek-Hammerman, K.
   Crowell, A. M.
   Fenn, M. S.
   Knight, H. L.
   Westmoreland, S. V.
   Miller, A. D.
TI RETRACTED: Polioencephalomalacia Secondary to Hypernatremia in Squirrel
   Monkeys (Saimiri sciureus)(Retracted article. See vol. 53, pg. 697,
   2016)
SO VETERINARY PATHOLOGY
LA English
DT Article; Retracted Publication
DE hypernatremia; laminar necrosis; polioencephalomalacia; Saimiri
   sciureus; squirrel monkey
ID EXTRAPONTINE MYELINOLYSIS; STATUS EPILEPTICUS; NEURONAL INJURY; BRAIN;
   DISORDERS; ISCHEMIA; PONTINE; VOLUME
AB Squirrel monkeys (Saimiri spp) are one of the most consistently used New World primates in biomedical research and are increasingly being used in neuroscience research, including models of drug abuse and addiction. Spontaneous neurologic disease in the squirrel monkey is uncommonly reported but includes various infectious diseases as well as cerebral amyloidosis. Hypernatremia is an extremely serious condition of hyperosmolarity that occurs as a result of water loss, adipsia, or excess sodium intake. Neurologic effects of hypernatremia reflect the cellular dehydration produced by the shift of water from the intracellular fluid space into the hypertonic extracellular fluid space. Severe hypernatremia may result in cerebrocortical laminar necrosis (polioencephalomalacia) in human patients as well as in a number of domestic species, including pigs, poultry, and ruminants. We report the clinical, histopathologic, and immunohistochemical findings of polioencephalomalacia in 13 squirrel monkeys. Polioencephalomalacia in these animals was associated with hypernatremia that was confirmed by serum levels of sodium greater than 180 mmol/L (reference range, 134.0-154.0 mmol/L [mEq/L]). All animals had concurrent diseases or experimental manipulation that predisposed to adipsia. Immunohistochemical investigation using antibodies to neuronal nuclei (NeuN), CNPase, Iba-1, and CD31 revealed necrosis of predominantly cerebral cortical layers 3, 4, and 5 characterized by neuronal degeneration and loss, oligodendrocytic loss, microglial proliferation, and vascular reactivity. The squirrel monkey is exquisitely sensitive to hyperosmolar metabolic disruption and it is associated with laminar cortical necrosis.
C1 [Macri, S. M. Cummings; Knight, H. L.; Westmoreland, S. V.] Harvard Univ, Sch Med, Dept Comparat Pathol, New England Primate Res Ctr, Southborough, MA 01772 USA.
   [Masek-Hammerman, K.] Pfizer Drug Safety Res & Dev, Cambridge, MA USA.
   [Crowell, A. M.] Univ Notre Dame, Notre Dame, IN 46556 USA.
   [Fenn, M. S.; Miller, A. D.] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA.
RP Miller, AD (reprint author), Cornell Univ, Coll Vet Med, T5-006A Vet Res Tower, Ithaca, NY 14853 USA.
EM adm10@cornell.edu
RI Bin, Alex100/B-2729-2016
FU National Institutes of Health [OD0111103, T32 OD011064]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research was funded, in part, by National Institutes of Health grants
   NEPRC Base grant OD0111103 and T32 OD011064.
CR Abee C R, 2000, ILAR J, V41, P2
   Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006
   ASSADI FK, 1989, PEDIATR NEPHROL, V3, P438, DOI 10.1007/BF00850223
   Brady A G, 2000, ILAR J, V41, P10
   Brown WD, 1999, J CHILD NEUROL, V14, P428, DOI 10.1177/088307389901400704
   Brown WD, 2000, CURR OPIN NEUROL, V13, P691, DOI 10.1097/00019052-200012000-00014
   Crowley RK, 2007, CLIN ENDOCRINOL, V66, P475, DOI 10.1111/j.1365-2265.2007.02754.x
   CSERR HF, 1991, J PHYSIOL-LONDON, V442, P277, DOI 10.1113/jphysiol.1991.sp018793
   CSERR HF, 1987, AM J PHYSIOL, V253, pF522
   DeGracia DJ, 2008, J NEUROCHEM, V106, P2288, DOI 10.1111/j.1471-4159.2008.05561.x
   Donaire A, 2006, J NEUROL NEUROSUR PS, V77, P104, DOI 10.1136/jnnp.2004.058701
   Elfenbein HA, 2007, HISTOL HISTOPATHOL, V22, P155, DOI 10.14670/HH-22.155
   Goff David A, 2009, Pediatr Rev, V30, P412, DOI 10.1542/pir.30-10-412
   GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.med.44.1.289
   Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1
   Heinrich A, 2007, ACTA NEUROL SCAND, V115, P425, DOI 10.1111/j.1600-0404.2006.00784.x
   JENKINS LW, 1981, ACTA NEUROPATHOL, V55, P205, DOI 10.1007/BF00691320
   King JD, 2010, AM J MED SCI, V339, P561, DOI 10.1097/MAJ.0b013e3181d3cd78
   Levin J, 2012, CLIN NEUROL NEUROSUR, V114, P1290, DOI 10.1016/j.clineuro.2012.03.011
   Liu XX, 2011, PSYCHOPHARMACOLOGY, V217, P367, DOI 10.1007/s00213-011-2292-6
   Lowenstine Linda J., 2003, Toxicologic Pathology, V31, P92, DOI 10.1080/01926230390177668
   Maggiore U, 2009, CRIT CARE, V13, DOI 10.1186/cc7953
   Roh JH, 2009, J NEUROIMAGING, V19, P185, DOI 10.1111/j.1552-6569.2008.00244.x
   Samuels MA, 2011, SEMIN NEUROL, V31, P135, DOI 10.1055/s-0031-1277983
   STILLS HF, 1981, VET PATHOL, V18, P38, DOI 10.1177/0300985881018s0604
   Summers B. A., 1995, VET NEUROPATHOLOGY
   White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5
   Zachary J. F., 2012, PATHOLOGIC BASIS VET
NR 28
TC 1
Z9 1
U1 3
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0300-9858
EI 1544-2217
J9 VET PATHOL
JI Vet. Pathol.
PD MAY
PY 2014
VL 51
IS 3
BP 651
EP 658
DI 10.1177/0300985813498782
PG 8
WC Pathology; Veterinary Sciences
SC Pathology; Veterinary Sciences
GA AJ5CB
UT WOS:000337697400015
PM 23899691
OA Bronze
DA 2018-12-27
ER

PT J
AU Yamada, I
   Yamashita, N
   Einishi, T
   Saito, M
   Fukumi, K
   Nishii, J
AF Yamada, Itsunari
   Yamashita, Naoto
   Einishi, Toshihiko
   Saito, Mitsunori
   Fukumi, Kouhei
   Nishii, Junji
TI RETRACTED: Modeling and imprint fabrication of an infrared wire-grid
   polarizer with an antireflection grating structure(Retracted article.
   See vol. 81, pg. 339, 2017)
SO INFRARED PHYSICS & TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Infrared wire-grid polarizer; Chalcogenide glass; Antireflection grating
   structure; Direct imprint lithography
ID SURFACE-RELIEF GRATINGS; COUPLED-WAVE ANALYSIS; CHALCOGENIDE GLASS;
   IMAGING POLARIMETRY; LITHOGRAPHY; NANOIMPRINT; PATTERN; ARRAY
AB An infrared wire-grid polarizer with an antireflection (AR) grating structure was fabricated using direct imprint lithography on both sides of a low toxicity chalcogenide glass (Sb-Ge-Sn-S system) simultaneously. The AR grating structure was designed using rigorous coupled-wave analysis theory. Silicon carbide with a grating period of 500 nm and glassy carbon with a grating period of 3 mu m were employed as molds. After imprinting, a wire-grid polarizer was made by depositing Al obliquely on the grating. The transverse magnetic (TM) transmittance of the fabricated polarizer was over 70% at 8.5-10.5 mu m wavelength, although the transmittance of the glass substrate is 62-66%, and the extinction ratio was over 20 dB at 11 mu m wavelength. The polarizer has a high TM transmittance and is cheaper and simpler to fabricate as compared with conventional infrared polarizers. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Yamada, Itsunari] Univ Shiga Prefecture, Sch Engn, Dept Elect Syst Engn, Hassaka Cho, Hikone, Shiga 5228533, Japan.
   [Yamashita, Naoto; Einishi, Toshihiko] Isuzu Glass Co Ltd, Izumisano, Osaka 5980048, Japan.
   [Saito, Mitsunori] Ryukoku Univ, Dept Elect & Informat, Otsu, Shiga 5202194, Japan.
   [Fukumi, Kouhei] Natl Inst Adv Ind Sci & Technol, Ikeda, Osaka 5638577, Japan.
   [Nishii, Junji] Hokkaido Univ, Res Inst Elect Sci, Sapporo, Hokkaido 0600812, Japan.
RP Yamada, I (reprint author), Univ Shiga Prefecture, Sch Engn, Dept Elect Syst Engn, Hassaka Cho, Hikone, Shiga 5228533, Japan.
EM yamada.i@e.usp.ac.jp
CR Ahn SW, 2005, NANOTECHNOLOGY, V16, P1874, DOI 10.1088/0957-4484/16/9/076
   BREMER J, 1992, APPL OPTICS, V31, P471, DOI 10.1364/AO.31.000471
   Chen L, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2472532
   Han T, 2010, OPT EXPRESS, V18, P19286, DOI 10.1364/OE.18.019286
   Hecht E, 1990, OPTICS
   Korte EH, 1998, ANALYST, V123, P647, DOI 10.1039/a707112d
   MOHARAM MG, 1986, J OPT SOC AM A, V3, P1780, DOI 10.1364/JOSAA.3.001780
   MOHARAM MG, 1983, J OPT SOC AM, V73, P451, DOI 10.1364/JOSA.73.000451
   Mori T, 2008, OPT LETT, V33, P428, DOI 10.1364/OL.33.000428
   Nordin GP, 1999, J OPT SOC AM A, V16, P1168, DOI 10.1364/JOSAA.16.001168
   ONO Y, 1987, APPL OPTICS, V26, P1142, DOI 10.1364/AO.26.001142
   SAITO M, 1994, INFRARED PHYS TECHN, V35, P709, DOI 10.1016/1350-4495(94)90063-9
   Solmaz M, 2008, J VAC SCI TECHNOL B, V26, P606, DOI 10.1116/1.2890699
   Takebe H, 2007, OPT LETT, V32, P2750, DOI 10.1364/OL.32.002750
   Toyota H, 2001, JPN J APPL PHYS 2, V40, pL747, DOI 10.1143/JJAP.40.L747
   Vandormael D, 2006, PROC SPIE, V6395, DOI 10.1117/12.692449
   Vollmer M., 2004, PROC, V5, P287
   Wang JJ, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2358813
   Wu Z, 2008, OPT LETT, V33, P1653, DOI 10.1364/OL.33.001653
   Yamada I, 2008, OPT LETT, V33, P258, DOI 10.1364/OL.33.000258
   Yamada I, 2012, APPL PHYS EXPRESS, V5, DOI 10.1143/APEX.5.072601
   Yamada I, 2012, APPL PHYS EXPRESS, V5, DOI 10.1143/APEX.5.082502
   Yamada I, 2012, JPN J APPL PHYS, V51, DOI 10.1143/JJAP.51.012201
   Yamada I, 2011, OPT LETT, V36, P3882, DOI 10.1364/OL.36.003882
   Yamada I, 2010, OPT LETT, V35, P3111, DOI 10.1364/OL.35.003111
   Yamada I, 2009, APPL OPTICS, V48, P316, DOI 10.1364/AO.48.000316
   Yamada K, 2009, APPL SURF SCI, V255, P4267, DOI 10.1016/j.apsusc.2008.11.020
NR 27
TC 9
Z9 10
U1 4
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1350-4495
EI 1879-0275
J9 INFRARED PHYS TECHN
JI Infrared Phys. Technol.
PD MAY
PY 2014
VL 64
BP 13
EP 17
DI 10.1016/j.infrared.2014.01.002
PG 5
WC Instruments & Instrumentation; Optics; Physics, Applied
SC Instruments & Instrumentation; Optics; Physics
GA AH9QH
UT WOS:000336476400003
DA 2018-12-27
ER

PT J
AU Duca, FA
   Sakar, Y
   Lepage, P
   Devime, F
   Langelier, B
   Dore, J
   Covasa, M
AF Duca, Frank A.
   Sakar, Yassine
   Lepage, Patricia
   Devime, Fabienne
   Langelier, Benedicte
   Dore, Joel
   Covasa, Mihai
TI RETRACTED: Replication of Obesity and Associated Signaling Pathways
   Through Transfer of Microbiota From Obese-Prone Rats (Retracted article.
   See vol. 65, pg. 1447, 2016)
SO DIABETES
LA English
DT Article; Retracted Publication
ID DIET-INDUCED OBESITY; ALTERED GUT MICROBIOTA; LEPTIN-RESISTANT MICE;
   WEIGHT-LOSS; FAT DIET; INFLAMMATION; ADOLESCENTS; METABOLISM; RECEPTOR;
   PROTEIN
AB Aberrations in gut microbiota are associated with metabolic disorders, including obesity. However, whether shifts in the microbiota profile during obesity are a characteristic of the phenotype or a consequence of obesogenic feeding remains elusive. Therefore, we aimed to determine differences in the gut microbiota of obese-prone (OP) and obese-resistant (OR) rats and examined the contribution of this microbiota to the behavioral and metabolic characteristics during obesity. We found that OP rats display a gut microbiota distinct from OR rats fed the same high-fat diet, with a higher Firmicutes-to-Bacteroidetes ratio and significant genera differences. Transfer of OP but not OR microbiota to germ-free (GF) mice replicated the characteristics of the OP phenotype, including reduced intestinal and hypothalamic satiation signaling, hyperphagia, increased weight gain and adiposity, and enhanced lipogenesis and adipogenesis. Furthermore, increased gut permeability through conventionalization resulted in inflammation by proinflammatory nuclear factor (NF)-B/inhibitor of NF-B kinase subunit signaling in adipose tissue, liver, and hypothalamus. OP donor and GF recipient animals harbored specific species from Oscillibacter and Clostridium clusters XIVa and IV that were completely absent from OR animals. In conclusion, susceptibility to obesity is characterized by an unfavorable microbiome predisposing the host to peripheral and central inflammation and promoting weight gain and adiposity during obesogenic feeding.
C1 [Duca, Frank A.; Sakar, Yassine; Lepage, Patricia; Devime, Fabienne; Langelier, Benedicte; Dore, Joel; Covasa, Mihai] INRA, Microbiol Alimentat Serv Sante UMR1913, Jouy En Josas, France.
   [Duca, Frank A.; Sakar, Yassine; Lepage, Patricia; Devime, Fabienne; Langelier, Benedicte; Dore, Joel; Covasa, Mihai] AgroParisTech, Microbiol Alimentat Serv Sante UMR1913, Jouy En Josas, France.
   [Duca, Frank A.] Univ Paris 06, Doctoral Sch Physiol & Pathophysiol, Paris, France.
   [Covasa, Mihai] Western Univ Hlth Sci, Dept Basic Med Sci, Coll Osteopath Med, Pomona, CA USA.
   [Covasa, Mihai] Univ Suceava, Dept Human Hlth & Dev, Suceava, Romania.
RP Covasa, M (reprint author), INRA, Microbiol Alimentat Serv Sante UMR1913, Jouy En Josas, France.
EM mcovasa@jouy.inra.fr
RI Suceava, USV/E-8611-2011
FU INRA; Romanian National Program [PN-II-ID-PCE-2012-4-0608,
   48/02.09.2013]
FX The study was supported by INRA through a scientific package awarded to
   M. C. and by the Romanian National Program PN-II-ID-PCE-2012-4-0608 No.
   48/02.09.2013, "Analysis of novel risk factors influencing control of
   food intake and regulation of body weight."
CR Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
   Bervoets L, 2013, GUT PATHOG, V5, DOI 10.1186/1757-4749-5-10
   Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108
   Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879
   Cryan JF, 2012, NAT REV NEUROSCI, V13, P701, DOI 10.1038/nrn3346
   Cutler DR, 2007, ECOLOGY, V88, P2783, DOI 10.1890/07-0539.1
   Ding SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012191
   Duca FA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039748
   Duncan SH, 2008, INT J OBESITY, V32, P1720, DOI 10.1038/ijo.2008.155
   Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110
   Everard A, 2011, DIABETES, V60, P2775, DOI 10.2337/db11-0227
   Ferrer M, 2013, ENVIRON MICROBIOL, V15, P211, DOI 10.1111/j.1462-2920.2012.02845.x
   Fredborg M, 2012, J ANIM SCI, V90, P10, DOI [10.2527/jas53792, 10.2527/jas.53792]
   Furet JP, 2010, DIABETES, V59, P3049, DOI 10.2337/db10-0253
   Gakis G, 2009, AUTON NEUROSCI-BASIC, V148, P63, DOI 10.1016/j.autneu.2009.03.004
   Gao J, 2002, BRAIN RES, V936, P87, DOI 10.1016/S0006-8993(02)02493-9
   Geurts L, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00149
   Hildebrandt MA, 2009, GASTROENTEROLOGY, V137, P1716, DOI 10.1053/j.gastro.2009.08.042
   Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168
   Holzer P, 2004, NEUROSCIENCE, V129, P439, DOI 10.1016/j.neuroscience.2004.07.040
   Kim KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047713
   Kleinridders A, 2009, CELL METAB, V10, P249, DOI 10.1016/j.cmet.2009.08.013
   Lam YY, 2011, OBESITY, V19, P2113, DOI 10.1038/oby.2011.68
   Lepage P, 2005, INFLAMM BOWEL DIS, V11, P473, DOI 10.1097/01.MIB.0000159662.62651.06
   Levin BE, 2010, FRONT NEUROENDOCRIN, V31, P270, DOI 10.1016/j.yfrne.2010.02.005
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/nature4441022a
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199
   Louis P, 2007, J APPL MICROBIOL, V102, P1197, DOI 10.1111/j.1365-2672.2007.03322.x
   Milanski M, 2009, J NEUROSCI, V29, P359, DOI 10.1523/JNEUROSCI.2760-08.2009
   Munukka E, 2012, OBESITY, V20, P1082, DOI 10.1038/oby.2012.8
   Murphy EF, 2010, GUT, V59, P1635, DOI 10.1136/gut.2010.215665
   Nadal I, 2009, INT J OBESITY, V33, P758, DOI 10.1038/ijo.2008.260
   Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846
   Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214
   Samuel BS, 2008, P NATL ACAD SCI USA, V105, P16767, DOI 10.1073/pnas.0808567105
   Santacruz A, 2009, OBESITY, V17, P1906, DOI 10.1038/oby.2009.112
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Thaler JP, 2012, J CLIN INVEST, V122, P153, DOI 10.1172/JCI59660
   Tian DR, 2004, PEPTIDES, V25, P2147, DOI 10.1016/j.peptides.2004.08.009
   Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552
   Tuovinen E, 2013, ANAEROBE, V19, P70, DOI 10.1016/j.anaerobe.2012.11.002
   Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Turner JR, 2006, AM J PATHOL, V169, P1901, DOI 10.2353/ajpath.2006.060681
   Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721
   Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043
NR 52
TC 65
Z9 74
U1 3
U2 59
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD MAY
PY 2014
VL 63
IS 5
BP 1624
EP 1636
DI 10.2337/db13-1526
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AF6AK
UT WOS:000334796600026
PM 24430437
OA Other Gold
DA 2018-12-27
ER

PT J
AU Cheng, C
   Chen, ZQ
   Shi, XT
AF Cheng, Chi
   Chen, Zhen-Qiang
   Shi, Xue-Tao
TI RETRACTED: MicroRNA-320 inhibits osteosarcoma cells proliferation by
   directly targeting fatty acid synthase (Retracted article. See April,
   2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Osteosarcoma; MicroRNA; miR-320; FASN
ID CANCER-CELLS; SUPPRESSES; MIGRATION; INVASION; METASTASIS
AB Increasing evidence has demonstrated that small noncoding microRNAs (miRNAs) could contribute to cancer development and progression. Besides, they are differentially expressed in human tumor tissues. In the current study, we found that miR-320 was significantly downregulated in human osteosarcoma tissues, compared with adjacent normal tissues. Introduction of miR-320 mimics into U2OS and MG63 cells inhibited cell proliferation, while cell apoptosis rate remained unaltered. Additionally, miR-320 overexpression could also suppress tumor growth in the nude mice. At the molecular level, our results further revealed that the expression of fatty acid synthase (FASN), a key enzyme for de novo biosynthesis of fatty acids, was negatively regulated by miR-320. Therefore, our results suggest that miR-320 may act as a tumor suppressor for osteosarcoma.
C1 [Cheng, Chi] Feicheng Peoples Hosp, Dept Osteol, Tai An 271600, Shandong, Peoples R China.
   [Chen, Zhen-Qiang] Liaocheng Peoples Hosp, Dept Osteol, Liaocheng 252000, Shandong, Peoples R China.
   [Shi, Xue-Tao] Shandong Canc Hosp, Surg Ward 7, Jinan 250117, Shandong, Peoples R China.
RP Shi, XT (reprint author), Shandong Canc Hosp, Surg Ward 7, Jiyan Rd 440, Jinan 250117, Shandong, Peoples R China.
EM xuetao_shi@yeah.net
CR Ando Kosei, 2013, Cancers (Basel), V5, P591, DOI 10.3390/cancers5020591
   Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396
   Chou J, 2013, CELL CYCLE, V12, P3262, DOI 10.4161/cc.26087
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Flavin R, 2011, J PATHOL, V223, P283, DOI 10.1002/path.2809
   Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI 10.2217/FON.10.11
   Hsieh IS, 2013, CARCINOGENESIS, V34, P530, DOI 10.1093/carcin/bgs371
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Li J, 2013, CANCER LETT, V337, P22, DOI 10.1016/j.canlet.2013.05.034
   Liu ZL, 2012, ONCOL LETT, V4, P878, DOI 10.3892/ol.2012.862
   Liu ZL, 2012, INDIAN J PATHOL MICR, V55, P163, DOI 10.4103/0377-4929.97849
   Long XH, 2013, EXP THER MED, V5, P1048, DOI 10.3892/etm.2013.959
   Mao JH, 2012, ONCOL LETT, V4, P1125, DOI 10.3892/ol.2012.863
   Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769
   Sandoval J, 2013, EXPERT REV MOL DIAGN, V13, P457, DOI [10.1586/erm.13.37, 10.1586/ERM.13.37]
   Schaar DG, 2009, EXP HEMATOL, V37, P245, DOI 10.1016/j.exphem.2008.10.002
   Sun KL, 2013, NAT REV GENET, V14, P535, DOI 10.1038/nrg3471
   Wu YY, 2013, ANGIOGENESIS
   Zaytseva YY, 2012, CANCER RES, V72, P1504, DOI 10.1158/0008-5472.CAN-11-4057
   Zhou WB, 2003, CANCER RES, V63, P7330
NR 22
TC 40
Z9 44
U1 4
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2014
VL 35
IS 5
BP 4177
EP 4183
DI 10.1007/s13277-013-1546-9
PG 7
WC Oncology
SC Oncology
GA AG9SL
UT WOS:000335759800027
PM 24390663
DA 2018-12-27
ER

PT J
AU He, GS
   Chen, GD
   Chen, WQ
   Zhang, W
   Cao, JM
   Ye, QF
AF He, Gengsheng
   Chen, Guodong
   Chen, Wenqi
   Zhang, Wei
   Cao, Jinmin
   Ye, Qifa
TI RETRACTED: Lack of association of XRCC1 rs1799782 genetic polymorphism
   with risk of pancreatic cancer: a meta-analysis (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Pancreatic cancer; XRCC1gene; rs1799782; Genetic polymorphism;
   Meta-analysis
ID DNA-REPAIR GENES; BODY-MASS INDEX; ADENOCARCINOMA; SURVIVAL; SMOKING;
   BIAS
AB Emerging evidence suggests that genetic polymorphisms in X-ray repair cross-complementation group 1 (XRCC1) gene could be associated with pancreatic cancer risk. However, previous published studies on the association between XRCC1 rs1799782 genetic polymorphism and pancreatic cancer risk reported inconsistent results. For better understanding of the effects of XRCC1 rs1799782 genetic polymorphism on pancreatic cancer risk, we conducted a meta-analysis of previous published studies by calculating the pooled odds ratio (OR) with a 95 % confidence interval (95 % CI). A total of five eligible studies with 1,144 pancreatic cancer cases and 2,925 controls were eventually enrolled. Overall, we found that the XRCC1 rs1799782 genetic polymorphism was not associated with pancreatic cancer risk in total population under all genetic models (TT vs. CC: OR = 1.11, 95 % CI 0.76-1.63, P = 0.583; CT vs. CC: OR = 1.39, 95 % CI 0.92-2.10, P = 0.118; TT/CT vs. CC: OR = 1.39, 95 % CI 0.92-2.10, P = 0.121; TT vs. CT/CC: OR = 1.07, 95 % CI 0.73-1.55, P = 0.743; T vs. C: OR = 1.31, 95 % CI 0.93-1.86, P = 0.125). In the subgroup analysis based on ethnicity, there was no statistically significant association between XRCC1 rs1799782 genetic polymorphism and pancreatic cancer risk in Asians/Caucasians under all genetic models (all P values > 0.05). No publication bias was detected in this study. Our meta-analysis suggests that the XRCC1 rs1799782 genetic polymorphism is not significantly associated with pancreatic cancer risk. Considering the limited sample size and ethnicity enrolled in this meta-analysis, further larger scaled studies are needed to provide a more precise estimation on the association.
C1 [He, Gengsheng; Ye, Qifa] Cent S Univ, Xiangya Hosp 3, Ctr Transplant Surg, Changsha 410013, Hunan, Peoples R China.
   [He, Gengsheng; Chen, Guodong; Zhang, Wei; Cao, Jinmin] Univ South China, Affiliated Hosp 1, Dept Gen Surg, Hengyang 421001, Hunan, Peoples R China.
   [Chen, Wenqi] Univ South China, Affiliated Hosp 1, Dept Oncol, Hengyang 421001, Hunan, Peoples R China.
RP Ye, QF (reprint author), Cent S Univ, Xiangya Hosp 3, Ctr Transplant Surg, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
EM qifa_ye@sina.com
FU Science and Technology Plan Projects of Hunan Province [2012FJ3105]
FX This work was supported by Science and Technology Plan Projects of Hunan
   Province (2012FJ3105).
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duell EJ, 2002, CANCER RES, V62, P4630
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hansel DE, 2003, ANNU REV GENOM HUM G, V4, P237, DOI 10.1146/annurev.genom.4.070802.110341
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jiang HL, 2013, TUMOR BIOL, V34, P3417, DOI 10.1007/s13277-013-0914-9
   Jiao L, 2006, CANCER DETECT PREV, V30, P284, DOI 10.1016/j.cdp.2006.05.002
   Larsson SC, 2007, INT J CANCER, V120, P1993, DOI 10.1002/ijc.22535
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li DH, 2006, J CLIN ONCOL, V24, P1720, DOI 10.1200/JCO.2005.04.4206
   Li DH, 2007, INT J CANCER, V120, P1748, DOI 10.1002/ijc.22301
   Lowenfels AB, 2006, BEST PRACT RES CL GA, V20, P197, DOI 10.1016/j.bpg.2005.10.001
   Luo JH, 2007, CANCER CAUSE CONTROL, V18, P603, DOI 10.1007/s10552-007-9002-z
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   McWilliams RR, 2008, CANCER RES, V68, P4928, DOI 10.1158/0008-5472.CAN-07-5539
   Nakao M, 2012, J EPIDEMIOL, V22, P477, DOI 10.2188/jea.JE20120010
   Shen WD, 2011, CHINESE J CANCER RES, V23, P165, DOI 10.1007/s11670-011-0165-5
   Tanaka M, 2011, CANCER-AM CANCER SOC, V117, P744, DOI 10.1002/cncr.25510
   Vaccaro V, 2012, CURR DRUG TARGETS, V13, P731, DOI 10.2174/138945012800564077
   Wang Li, 2006, Wei Sheng Yan Jiu, V35, P534
   Yan Dong, 2013, Zhonghua Zhong Liu Za Zhi, V35, P472
   Yan YL, 2014, TUMOR BIOL, V35, P2397, DOI 10.1007/s13277-013-1317-7
NR 26
TC 6
Z9 6
U1 5
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2014
VL 35
IS 5
BP 4545
EP 4550
DI 10.1007/s13277-013-1598-x
PG 6
WC Oncology
SC Oncology
GA AG9SL
UT WOS:000335759800070
PM 24435745
DA 2018-12-27
ER

PT J
AU Han, MZ
   Lv, SZ
   Zhang, Y
   Yi, RY
   Huang, B
   Fu, HH
   Bian, RX
   Li, XG
AF Han, Mingzhi
   Lv, Shunzeng
   Zhang, Ya
   Yi, Ruiyang
   Huang, Bin
   Fu, Hanhui
   Bian, Ruixiang
   Li, Xingang
TI RETRACTED: The prognosis and clinicopathology of CXCR4 in gastric cancer
   patients: a meta-analysis (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE CXCR4; Gastric cancer; Prognosis; Clinicopathology; Meta-analysis
ID CHEMOKINE RECEPTORS; EXPRESSION; METASTASIS; AXIS; SURVIVAL; BIAS
AB The chemokine receptor 4 (CXCR4) has been widely investigated in diagnosis and prognosis of gastric cancer (GC). However, the impact of CXCR4 on GC patients remains controversial; Here, we conducted a meta-analysis to obtain the precise role of CXCR4 in GC prognosis and clinicopathology. Thirteen published studies with a total of 1,936 patients were included. Original data included the hazard ratio (HR) of overall survival (OS) and odds ratio (OR) in GC patients. We combined HR/OR with 95 % confidence interval (CI) to estimate the hazard. In this study, OS was significantly related to CXCR4 expression, with the HR 2.63 (95 % CI 1.69-4.09; p < 0.0001), and a significant correlation was also revealed between CXCR4 expression and stage (I + II, +) (OR 0.52, 95 % CI 0.32-0.83; p = 0.007), depth of invasion (T1/T2, +) (OR 0.44, 95 % CI 0.27-0.73; p = 0.001), lymph node metastasis (LN, +) (OR 2.30, 95 % CI 1.57-3.36; p < 0.0001), as well as vascular invasion (vas.inv, +) (OR 0.72, 95 % CI 0.53-0.98; p = 0.04). Heterogeneity was observed among the included studies with OS (I (2) = 51 %), stage (I (2) = 78 %), depth of invasion (I (2) = 74 %), lymph node metastasis (I (2) = 64 %), and histology differentiation (I (2) = 79 %). No publication bias was observed. In conclusion, this meta-analysis showed CXCR4 expression indicates poor prognosis in GC patients with advanced stage or deep invasion in GC tissues, which also implied lymph node metastasis and vascular invasion. Thus, CXCR4 could help predict patient prognosis and guide clinical diagnosis and treatment.
C1 [Han, Mingzhi; Lv, Shunzeng; Huang, Bin; Fu, Hanhui; Li, Xingang] Shandong Univ, Dept Neurosurg, Qilu Hosp, Jinan 250100, Shandong, Peoples R China.
   [Han, Mingzhi; Lv, Shunzeng; Huang, Bin; Fu, Hanhui; Li, Xingang] Shandong Univ, Brain Sci Res Inst, Jinan 250100, Shandong, Peoples R China.
   [Lv, Shunzeng] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing 100730, Peoples R China.
   [Lv, Shunzeng] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Zhang, Ya] Shandong Univ, Shandong Prov Hosp, Dept Hematol, Jinan 250100, Shandong, Peoples R China.
   [Yi, Ruiyang] Univ Chicago, Div Biol Sci, Chicago, IL 60637 USA.
   [Bian, Ruixiang] Shandong Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250100, Shandong, Peoples R China.
RP Li, XG (reprint author), Shandong Univ, Dept Neurosurg, Qilu Hosp, 44 West Wenhua Rd, Jinan 250100, Shandong, Peoples R China.
EM lixg@sdu.edu.cn
FU China Scholarship Council; Shandong University Science Technology
   Innovation Fund [M2011e01, 2013349]; National Natural Science Foundation
   of China [81172404, 81372720]
FX This study was supported by China Scholarship Council, Shandong
   University Science Technology Innovation Fund (M2011e01, 2013349), and
   National Natural Science Foundation of China (81172404, 81372720). We
   were also very grateful to the help of Sandy Lab staff Huihui Kang et
   al. for their valuable advice.
CR Arigami T, 2009, INT J ONCOL, V35, P19, DOI 10.3892/ijo_00000308
   BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fulton AM, 2009, CURR ONCOL REP, V11, P125, DOI 10.1007/s11912-009-0019-1
   Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6
   He HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071864
   Ingold B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010087
   Kim J, 2006, ANN SURG, V244, P113, DOI 10.1097/01.sla.0000217690.65909.9c
   Kwak MK, 2005, TUMOR BIOL, V26, P65, DOI 10.1159/000085587
   Lee HJ, 2011, EXP THER MED, V2, P499, DOI 10.3892/etm.2011.228
   Lee HJ, 2009, INT J ONCOL, V34, P473, DOI 10.3892/ijo_00000172
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Oonakahara K, 2004, AM J RESP CELL MOL, V30, P671, DOI 10.1165/rcmb.2003-0340OC
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357
   Steels E, 2001, EUR RESPIR J, V18, P705, DOI 10.1183/09031936.01.00062201
   Sun TY, 2011, CHIN J OPER PROC GEN, V5, P182
   Taichman RS, 2002, CANCER RES, V62, P1832
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Tsuboi K, 2008, ONCOL REP, V20, P1117, DOI 10.3892/or_00000118
   Ying JE, 2012, MED ONCOL, V29, P1716, DOI 10.1007/s12032-011-9990-0
   Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634
   Zhao BC, 2011, WORLD J GASTROENTERO, V17, P2389, DOI 10.3748/wjg.v17.i19.2389
   [朱志强 Zhu Zhiqiang], 2012, [第二军医大学学报, Academic Journal of Second Military Medical University], V33, P43
   Zou P, 2012, J CLIN EXP PATHAL, V28, P265
NR 26
TC 17
Z9 19
U1 5
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2014
VL 35
IS 5
BP 4589
EP 4597
DI 10.1007/s13277-013-1603-4
PG 9
WC Oncology
SC Oncology
GA AG9SL
UT WOS:000335759800075
PM 24464926
DA 2018-12-27
ER

PT J
AU Xue, HP
   Lu, Y
   Xue, ZY
   Lin, B
   Chen, JX
   Tang, F
   Huang, G
AF Xue, Huiping
   Lu, Yan
   Xue, Zeyun
   Lin, Bing
   Chen, Jinxian
   Tang, Feng
   Huang, Gang
TI RETRACTED: The effect of CYP1A1 and CYP1A2 polymorphisms on gastric
   cancer risk among different ethnicities: a systematic review and
   meta-analysis (Retracted article)
SO TUMOR BIOLOGY
LA English
DT Review; Retracted Publication
DE Cytochrome P450s (CYPs); Gene; Polymorphism; Association; Gastric cancer
ID GENETIC POLYMORPHISMS; GSTM1 POLYMORPHISMS; METABOLIZING-ENZYMES;
   ALCOHOL-CONSUMPTION; TOBACCO-SMOKE; ASSOCIATION; SUSCEPTIBILITY;
   INTERLEUKIN-1-BETA; EXPRESSION; PROMOTER
AB Potential Cytochrome P450s (CYPs) 1A1 MspI, 1A1 Ile462Val, 1A2*1 F, and/or 1A2*1C polymorphisms have been implicated in gastric cancer risk among different ethnicities. We aimed to explore the effect of CYP 1A1 MspI, 1A1 Ile462Val, 1A2*1 F, and/or 1A2*1C polymorphisms on the susceptibility to gastric cancer among different ethnicities through a systematic review and meta-analysis. Each initially included article was scored for quality appraisal. Desirable data were extracted and registered into databases. A number of 11 studies were ultimately eligible for the meta-analysis of CYP1A1 MspI polymorphism, eight studies for the meta-analysis of 1A1 Ile462Val polymorphism, and two studies for the meta-analysis of 1A2*1 F polymorphism. None of genetic model was evidently suggested, and thus all the genetic models were presented. Potential sources of heterogeneity were sought out via subgroup and sensitivity analyses, and publication biases were estimated. In our meta-analysis, significant results could be found in mutational heterozygous CT genotype, compared with wild TT genotype, among large sample size subgroup for CYP1A1 MspI polymorphism. Regarding CYP1A1 Ile462Val polymorphism, no statistically significant results could be found. For CYP1A2*1 F polymorphism, mutational heterozygous AC genotype, compared with wild-type AA, has deleterious effects, whereas mutational homozygous CC genotype, compared with mutational heterozygous type AC, has protective effects but lacks statistically significant difference despite its a proximity to 0.05. Combined mutational homozygous CC genotype and wild-type homozygous AA, compared with mutational heterozygous AC genotype, has protective effects. Our meta-analysis suggests no associations between CYP1A1 Ile462Val polymorphism and gastric cancer, but possible associations between CYP1A1 MspI and CYP1A2*1 F polymorphisms and gastric cancer, which needs to be further reinforced or refuted among different ethnicities in well-designed large-scale high-quality studies.
C1 [Xue, Huiping] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Shanghai Inst Digest Dis, Renji Hosp,Sch Med, Shanghai 200030, Peoples R China.
   [Xue, Huiping] Shanghai Jiao Tong Univ, Minist Hlth, Key Lab Gastroenterol & Hepatol, Shanghai 200030, Peoples R China.
   [Lu, Yan; Huang, Gang] Shanghai Jiao Tong Univ, Int Peace Hosp Protect Mother & Child Hlth, Dept Med, Sch Med, Shanghai 200030, Peoples R China.
   [Xue, Zeyun] Shanghai High Sch, Shanghai, Peoples R China.
   [Lin, Bing] Fudan Univ, Sch Med, Zhongshan Hosp, Div Nutr, Shanghai 200433, Peoples R China.
   [Chen, Jinxian] Renji Hosp, Dept Gen Surg, Shanghai, Peoples R China.
   [Tang, Feng] Fudan Univ, Sch Med, Huashan Hosp, Div Pathol, Shanghai 200433, Peoples R China.
   [Huang, Gang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Nucl Med, Shanghai 200127, Peoples R China.
   [Huang, Gang] Shanghai Jiao Tong Univ, Inst Hlth Sci, Sch Med, Shanghai 200025, Peoples R China.
   [Huang, Gang] Chinese Acad Sci, SIBS, Shanghai 200025, Peoples R China.
RP Xue, HP (reprint author), Shanghai Jiao Tong Univ, Minist Hlth, Key Lab Gastroenterol & Hepatol, Shanghai 200030, Peoples R China.
EM xue_huiping@126.com; huanggang_sjumed@163.com
FU National Natural Science Foundation of China [30830038, 30970842,
   81071180]; "973" Project [2012CB932604]; New Drug Discovery Project
   [2012ZX09506-001-005]; Key Project of Science and Technology Commission
   of Shanghai Municipality [10JC1410000]; Shanghai Leading Academic
   Discipline Project [S30203]
FX The authors would to acknowledge their grant sponsors, namely, the
   National Natural Science Foundation of China (grants 30830038, 30970842,
   and 81071180), the "973" Project (2012CB932604), the New Drug Discovery
   Project (2012ZX09506-001-005), the Key Project of Science and Technology
   Commission of Shanghai Municipality (grants 10JC1410000), and the
   Shanghai Leading Academic Discipline Project (grant S30203).
CR Agudo A, 2006, CANCER EPIDEM BIOMAR, V15, P2427, DOI 10.1158/1055-9965.EPI-06-0072
   Al-Buheissi SZ, 2006, PROSTATE, V66, P876, DOI 10.1002/pros.20400
   Boccia S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-206
   Camargo MC, 2006, CANCER EPIDEM BIOMAR, V15, P1674, DOI 10.1158/1055-9965.EPI-06-0189
   Constable A, 1999, MUTAT RES-GEN TOX EN, V442, P79, DOI 10.1016/S1383-5718(99)00066-2
   Darazy M, 2011, GENET TEST MOL BIOMA, V15, P423, DOI 10.1089/gtmb.2010.0206
   Gonzalez A, 2004, REV BIOL TROP, V52, P591
   Gonzalez FJ, 1997, REPROD TOXICOL, V11, P397, DOI 10.1016/S0890-6238(96)00154-2
   Guo RY, 2012, TUMOR BIOL, V33, P1125, DOI 10.1007/s13277-012-0353-z
   Han FJ, 2012, MOL BIOL REP, V39, P8335, DOI 10.1007/s11033-012-1683-z
   Huang X, 2012, CHIN J MODERN MED, V22, P27
   Huang X, 2010, INT J DIG DIS, V30, P304
   Hwang IR, 2002, GASTROENTEROLOGY, V123, P1793, DOI 10.1053/gast.2002.37043
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Kobayashi M, 2009, GASTRIC CANCER, V12, P198, DOI 10.1007/s10120-009-0523-x
   Lee K, 2006, REV MED CHILE, V134, P1107, DOI 10.4067/S0034-98872006000900004
   Li H, 2005, WORLD J GASTROENTERO, V11, P5757, DOI 10.3748/wjg.v11.i37.5757
   Li HQ, 2002, CHINA CANC, V11, P25
   Luo YP, 2011, TUMOR BIOL, V32, P215, DOI 10.1007/s13277-010-0115-8
   Ma JX, 2006, CANCER LETT, V240, P253, DOI 10.1016/j.canlet.2005.09.020
   Malik Manzoor A, 2009, J Gastrointest Cancer, V40, P26, DOI 10.1007/s12029-009-9072-0
   MCMANUS ME, 1990, CANCER RES, V50, P3367
   Minelli C, 2008, INT J EPIDEMIOL, V37, P136, DOI 10.1093/ije/dym234
   Nan HM, 2005, WORLD J GASTROENTERO, V11, P3834
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pavanello S, 2000, MUTAT RES-REV MUTAT, V463, P285, DOI 10.1016/S1383-5742(00)00051-X
   Olivieri EHR, 2009, ORAL ONCOL, V45, pE73, DOI 10.1016/j.oraloncology.2009.03.004
   Roth MJ, 2004, CANCER CAUSE CONTROL, V15, P1077, DOI 10.1007/s10552-004-2233-3
   Sachse C, 2003, BRIT J CLIN PHARMACO, V55, P68, DOI 10.1046/j.1365-2125.2003.01733.x
   Shen HX, 2005, J DALIAN MED U, V27
   Shen J, 2001, CHIN J PREV MED, V35, P167
   Shen J, 2005, WORLD J GASTROENTERO, V11, P6056, DOI 10.3748/wjg.v11.i38.6056
   [沈靖 Shen Jing], 2002, [肿瘤, Tumor], V22, P9
   Suzuki S, 2004, J GASTROENTEROL, V39, P220, DOI 10.1007/s00535-003-1281-x
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Wideroff L, 2007, CANCER DETECT PREV, V31, P233, DOI 10.1016/j.cdp.2007.03.004
   Wright CM, 2010, EUR RESPIR J, V35, P152, DOI 10.1183/09031936.00120808
   Xue HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043431
   Xue HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039868
   Xue HP, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-102
   Xue HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028083
   Xue HP, 2011, AM J EPIDEMIOL, V173, P363, DOI 10.1093/aje/kwq378
   Xue HP, 2010, J GASTROEN HEPATOL, V25, P1604, DOI 10.1111/j.1440-1746.2010.06428.x
   Zhou Tao, 2007, Journal of Shandong University (Health Sciences), V45, P71
NR 44
TC 9
Z9 11
U1 2
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2014
VL 35
IS 5
BP 4741
EP 4756
DI 10.1007/s13277-014-1620-y
PG 16
WC Oncology
SC Oncology
GA AG9SL
UT WOS:000335759800091
PM 24443269
DA 2018-12-27
ER

PT J
AU Han, S
   Cai, Z
   Peng, L
   Li, Z
   Zhou, HB
   Li, XQ
   Fang, SZ
   Huang, ZH
   Cui, DX
AF Han, Shuai
   Cai, Zhai
   Peng, Liang
   Li, Zhou
   Zhou, Hua-Bin
   Li, Xiu-Qin
   Fang, Su-Zhen
   Huang, Zong-Hai
   Cui, Da-Xiang
TI RETRACTED: Polyamidoamine dendrimer liposome-mediated survivin antisense
   oligonucleotide inhibits hepatic cancer cell proliferation by inducing
   apoptosis (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Polyamidoamine dendrimer liposome; Hepatic cancer; Antisense
   oligonucleotide; Survivin
ID GENE DELIVERY-SYSTEM; IN-VITRO; NANOPARTICLES; THERAPY; VIVO
AB Polyamidoamine dendrimer (PAMAM) is a new nanometer material, which can transfer the target genes to cells with high efficiency and lower toxicity. This study aims to evaluate antitumor effects of survivin antisense oligonucleotide (survivin-asODN) (carried by polyamidoamine dendrimer liposome) on hepatic cancer in nude mice. Hepatic cancer model was established by injecting SMMC-7721 cells subcutaneously into flanks of nude mice. Polyamidoamine dendrimer and liposome were mixed with survivin-asODN, respectively. The shape and size of complex were observed by transmission electron microscope, and zeta potential was measured by an analytical tool. Encapsulation efficiency and DNA loading level were determined by an ultraviolet spectrophotometer in centrifuging method. Expression of survivin in transplant tumor was measured by Western blotting. No significant difference appeared for diameter and envelopment ratio between PAMAM liposome-survivin-asODN and PAMAM-survivin-asODN (P > 0.05). Both zeta potential and transfection efficiency in PAMAM liposome-survivin-asODN were higher than that in PAMAM-survivin-asODN complex (P < 0.05). Expression of survivin protein and weight of tumors in transplanted tumors in PAMAM liposome-survivin-asODN group was less than that in PAMAM-survivin-asODN group (P < 0.05). Cell apoptosis rate in PAMAM liposome-survivin-asODN group was higher than that of PAMAM-survivin-asODN group (P < 0.05). In conclusion, polyamidoamine dendrimer liposome can deliver survivin-asODN into hepatic transplanted tumor cells effectively. Ployamidoamine dendrimer liposome-mediated survivin-asODN can inhibit hepatic cell proliferation by inducing apoptosis.
C1 [Han, Shuai; Cai, Zhai; Peng, Liang; Li, Zhou; Zhou, Hua-Bin; Li, Xiu-Qin; Fang, Su-Zhen; Huang, Zong-Hai] Southern Med Univ, Zhujiang Hosp, Dept Gen Surg, Guangzhou 510282, Guangdong, Peoples R China.
   [Cui, Da-Xiang] Shanghai Jiao Tong Univ, Res Inst Micro Nanometer Sci & Technol, Shanghai 200030, Peoples R China.
RP Li, Z (reprint author), Southern Med Univ, Zhujiang Hosp, Dept Gen Surg, Guangzhou 510282, Guangdong, Peoples R China.
EM leezhou888@yeah.net; doctorrhuang@yeah.net
FU Natural Science Foundation of Guangdong Province [9151051501000071]
FX This research was supported by the Natural Science Foundation of
   Guangdong Province (no. 9151051501000071).
CR Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Ao LM, 2006, ANAL CHEM, V78, P1104, DOI 10.1021/ac051323m
   Bhattacharyya S, 2011, PHARM RES-DORDR, V28, P237, DOI 10.1007/s11095-010-0318-0
   Cui DX, 2011, J CONTROL RELEASE, V152, pE137, DOI 10.1016/j.jconrel.2011.08.047
   Hector S, 2012, GUT, V61, P725, DOI 10.1136/gutjnl-2011-300433
   Huang M, 2004, PHARM RES, V21, P344, DOI 10.1023/B:PHAM.0000016249.52831.a5
   Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305
   Li XQ, 2011, TUMOR BIOL, V32, P863, DOI 10.1007/s13277-011-0187-0
   Li Z, 2012, CHIN J CANC BIOTHER, V19, P409
   Millan A, 2009, J SURG RES, V151, P163, DOI 10.1016/j.jss.2007.05.020
   Navarro G, 2009, NANOMED-NANOTECHNOL, V5, P287, DOI 10.1016/j.nano.2008.12.007
   Pan BF, 2007, CANCER RES, V67, P8156, DOI 10.1158/0008-5472.CAN-06-4762
   Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378-5173(02)00315-0
   Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941
   Sun NF, 2014, TUMOR BIOL, V35, P1057, DOI 10.1007/s13277-013-1140-1
   Surendiran A, 2009, INDIAN J MED RES, V130, P689
   Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023
   Wang CH, 2013, TUMOR BIOL, V34, P1667, DOI 10.1007/s13277-013-0700-8
   Wong PE, 2010, J PHARM SCI-US, V99, P4642, DOI 10.1002/jps.22165
   Yuan LJ, 2013, TUMOR BIOL, V34, P3027, DOI 10.1007/s13277-013-0867-z
   Zhang YD, 2007, NANOMED-NANOTECHNOL, V3, P144, DOI 10.1016/j.nano.2007.01.004
NR 21
TC 10
Z9 11
U1 4
U2 36
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2014
VL 35
IS 5
BP 5013
EP 5019
DI 10.1007/s13277-014-1661-2
PG 7
WC Oncology
SC Oncology
GA AG9SL
UT WOS:000335759800125
PM 24488668
DA 2018-12-27
ER

PT J
AU Gonzalez-Mingueza, C
   Munoz-Gutierrez, F
AF Gonzalez-Mingueza, Carlos
   Munoz-Gutierrez, Francisco
TI RETRACTED: Wind prediction using Weather Research Forecasting model
   (WRF): A case study in Peru (Retracted article. See vol. 88, pg. 1076,
   2014)
SO ENERGY CONVERSION AND MANAGEMENT
LA English
DT Article; Retracted Publication
DE Wind speed prediction; WRF model; Wind energy; Prediction horizons
ID POWER-GENERATION; NEURAL-NETWORK; SPEED FORECASTS; TIME-SERIES; ENERGY;
   SIMULATION; RESOURCE; SYSTEMS; TURKEY
AB As the installed capacity of wind power in the SEIN (National Interconnected Electric System) of Peru increases (developing country), very useful predictors for developing certain wind resource are obtained to provide stability to the system. The performance of WRF (Weather Research and Forecasting - version 3.4) forecast winds was evaluated using different parameterization options in the department of Ica (Peru) to minimize the uncertainty of the prediction. The complexity of the terrain and the resolution of the selected domain aspects were considered in the model. The wind rose and the frequency histograms were used to evaluate the model and it was noted that the wind frequency for low and intermediate speeds was underestimated. The wind direction was simulated in a similar manner but specifically for dominant wind regimes. For low wind speeds, the characterization of wind direction is very subjective with large deviations obtained between the simulation alternatives. The best numerical configuration is one that does not exceed 24 h: but where the error increases with the complexity of the terrain leading to the lack of accurate data. The wind direction is simulated by the model especially with strong dominant sectors. In January, it was detected significant frequencies in low speeds (1-2 m/s). In these cases, the characterization was subjective and could be higher the deviation between observed and simulated results. In June, the simulated wind speeds are constant below 4 m/s and above 11 m/s, obtaining similar results in dominant wind sectors. Increasing the resolution of the simulation domain was not sufficient to improve the efficiency of the model. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Gonzalez-Mingueza, Carlos; Munoz-Gutierrez, Francisco] Univ Malaga, Dept Ingn Elect, E-29071 Malaga, Spain.
RP Gonzalez-Mingueza, C (reprint author), Univ Malaga, Dept Ingn Elect, Ampliac Campus Teatinos,C Dr Ortiz Ramos,S-N, E-29071 Malaga, Spain.
EM carlos.gonzalez@uma.es
CR [Anonymous], 1998, 6140012 IEC
   Ardakani FJ, 2014, ENERG CONVERS MANAGE, V78, P745, DOI 10.1016/j.enconman.2013.11.019
   Ardehali MM, 2004, ENERG CONVERS MANAGE, V45, P1981, DOI 10.1016/j.enconman.2003.11.003
   Bazmi AA, 2011, RENEW SUST ENERG REV, V15, P3480, DOI 10.1016/j.rser.2011.05.003
   Bhaskar K, 2008, J WIND ENG IND AEROD, V96, P2348
   Bivona S, 2011, ENERG CONVERS MANAGE, V52, P1157, DOI 10.1016/j.enconman.2010.09.010
   Blonbou R, 2011, ENERG CONVERS MANAGE, V52, P2412, DOI 10.1016/j.enconman.2011.01.013
   Bouzgou H, 2011, APPL ENERG, V88, P2463, DOI 10.1016/j.apenergy.2011.01.037
   Catalao JPS, 2011, ENERG CONVERS MANAGE, V52, P1061, DOI 10.1016/j.enconman.2010.08.035
   Celik AN, 2013, APPL ENERG, V101, P582, DOI 10.1016/j.apenergy.2012.06.040
   da Costa JCL, 2006, J WIND ENG IND AEROD, V94, P603, DOI 10.1016/j.jweia.2006.02.002
   De Giorgi MG, 2011, APPL ENERG, V88, P1298, DOI 10.1016/j.apenergy.2010.10.035
   Douak F, 2013, APPL ENERG, V103, P328, DOI 10.1016/j.apenergy.2012.09.055
   El Alimi S, 2012, RENEW SUST ENERG REV, V16, P5466, DOI 10.1016/j.rser.2012.05.004
   Fadare DA, 2010, APPL ENERG, V87, P934, DOI 10.1016/j.apenergy.2009.09.005
   Fernandez S, 2012, APPL ENERG, V89, P347
   Ferrer-Marti L, 2012, RENEW SUST ENERG REV, V16, P5379, DOI 10.1016/j.rser.2012.04.015
   Filippo A, 2012, OCEAN COAST MANAGE, V55, P101, DOI 10.1016/j.ocecoaman.2011.09.007
   Foley AM, 2012, RENEW ENERG, V37, P1, DOI 10.1016/j.renene.2011.05.033
   Gallego C, 2011, APPL ENERG, V88, P4087, DOI 10.1016/j.apenergy.2011.04.051
   Giebel G, 2012, EUR J OPER RES, V221, P148
   Giebel S, 2011, APPL MATH COMPUT, V218, P1003, DOI 10.1016/j.amc.2011.03.121
   Giorgi MD, 2011, ENERGY, V36, P3968
   Hepbasli A, 2004, RENEW SUST ENERG REV, V8, P257, DOI 10.1016/j.rser.2003.10.006
   International Renewable Energy Agency, 2012, REN EN TECHN COST AN, V1
   Kanellos FD, 2011, ELECTR POW SYST RES, V81, P707, DOI 10.1016/j.epsr.2010.10.035
   Kani SAP, 2011, ENERG CONVERS MANAGE, V52, P738, DOI 10.1016/j.enconman.2010.07.053
   Kwon SD, 2010, APPL ENERG, V87, P856, DOI 10.1016/j.apenergy.2009.08.038
   Li G, 2011, RENEW ENERG, V36, P352, DOI 10.1016/j.renene.2010.06.049
   Lin CM, 2006, APPL MATH COMPUT, V175, P1139, DOI 10.1016/j.amc.2005.08.031
   Louka P, 2008, J WIND ENG IND AEROD, V96, P2348, DOI 10.1016/j.jweia.2008.03.013
   Ma L, 2009, RENEW SUST ENERG REV, V13, P915, DOI 10.1016/j.rser.2008.02.002
   Mabel MC, 2011, RENEW SUST ENERG REV, V15, P1210, DOI 10.1016/j.rser.2010.09.044
   Migoya E, 2007, ENERGY, V32, P1871, DOI 10.1016/j.energy.2007.03.012
   Panapakidis IP, 2012, RENEW SUST ENERG REV, V16, P551, DOI 10.1016/j.rser.2011.08.021
   Peng HW, 2013, RENEW ENERG, V50, P590, DOI 10.1016/j.renene.2012.07.022
   Pinson P, 2009, APPL ENERG, V86, P1326, DOI 10.1016/j.apenergy.2008.10.009
   Pousinho HMI, 2011, ENERG CONVERS MANAGE, V52, P397, DOI 10.1016/j.enconman.2010.07.015
   Sahin B, 2005, J WIND ENG IND AEROD, V93, P171, DOI 10.1016/j.jweia.2004.11.005
   Sfetsos A, 2000, RENEW ENERG, V21, P23, DOI 10.1016/S0960-1481(99)00125-1
   Sheela G, 2012, PROCEDIA ENG, V30, P380
   Shi J, 2012, RENEW SUST ENERG REV, V16, P3471, DOI 10.1016/j.rser.2012.02.044
   Skamarock W. C., 2005, NCARTN475STR, DOI [10. 5065/D6DZ069T, DOI 10.5065/D68S4MVH, 10.5065/D6DZ069T]
   Suganthi L, 2012, RENEW SUST ENERG REV, V16, P1223, DOI 10.1016/j.rser.2011.08.014
   Walsh-Thomas JM, 2012, RENEW SUST ENERG REV, V16, P6432, DOI 10.1016/j.rser.2012.07.004
   Wang XC, 2011, ENRGY PROCED, V12, DOI 10.1016/j.egypro.2011.10.103
NR 46
TC 15
Z9 15
U1 5
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0196-8904
EI 1879-2227
J9 ENERG CONVERS MANAGE
JI Energy Conv. Manag.
PD MAY
PY 2014
VL 81
BP 363
EP 373
DI 10.1016/j.enconman.2014.02.024
PG 11
WC Thermodynamics; Energy & Fuels; Mechanics
SC Thermodynamics; Energy & Fuels; Mechanics
GA AG7SJ
UT WOS:000335618400036
DA 2018-12-27
ER

PT J
AU Zhao, LL
   Zhang, T
   Liu, BR
   Liu, TF
   Tao, N
   Zhuang, LW
AF Zhao, Li-Li
   Zhang, Tong
   Liu, Bing-Rong
   Liu, Tie-Fu
   Tao, Na
   Zhuang, Li-Wei
TI RETRACTED: Construction of pancreatic cancer double-factor regulatory
   network based on chip data on the transcriptional level (Retracted
   article. See vol. 42, pg. 1447, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Pancreatic cancer; Transcription factor (TF); MicroRNA (miRNA);
   Differentially expressed genes (DEGs)
ID EXPRESSION; MICRORNAS; CELLS; ADENOCARCINOMA; INDUCTION; CARCINOMA;
   APOPTOSIS; SURVIVAL; IRF-1; MIRNA
AB Transcription factor (TF) and microRNA (miRNA) have been discovered playing crucial roles in cancer development. However, the effect of TFs and miRNAs in pancreatic cancer pathogenesis remains vague. We attempted to reveal the possible mechanism of pancreatic cancer based on transcription level. Using GSE16515 datasets downloaded from gene expression omnibus database, we first identified the differentially expressed genes (DEGs) in pancreatic cancer by the limma package in R. Then the DEGs were mapped into DAVID to conduct the kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis. TFs and miRNAs that DEGs significantly enriched were identified by Fisher's test, and then the pancreatic cancer double-factor regulatory network was constructed. In our study, total 1117 DEGs were identified and they significantly enriched in 4 KEGG pathways. A double-factor regulatory network was established, including 29 DEGs, 24 TFs, 25 miRNAs. In the network, LAMC2, BRIP1 and miR155 were identified which may be involved in pancreatic cancer development. In conclusion, the double-factor regulatory network was found to play an important role in pancreatic cancer progression and our results shed new light on the molecular mechanism of pancreatic cancer.
C1 [Zhao, Li-Li; Liu, Tie-Fu; Tao, Na; Zhuang, Li-Wei] Harbin Med Univ, Dept Gastroenterol, Affiliated Hosp 4, Harbin 150001, Heilongjiang, Peoples R China.
   [Zhang, Tong] Harbin Med Univ, Dept Cardiol, Affiliated Hosp 4, Harbin 150001, Heilongjiang, Peoples R China.
   [Liu, Bing-Rong] Harbin Med Univ, Dept Gastroenterol, Affiliated Hosp 2, Harbin 150001, Heilongjiang, Peoples R China.
RP Zhuang, LW (reprint author), Harbin Med Univ, Dept Gastroenterol, Affiliated Hosp 4, 37 Yiyuan St, Harbin 150001, Heilongjiang, Peoples R China.
EM liweizhuang001@hotmail.com
FU Provincial Health Department of Heilongjiang Province [2011-171]
FX This work was supported by the Fund of the Provincial Health Department
   of Heilongjiang Province (No. 2011-171), and we wish to express our warm
   thanks to Fenghe (Shanghai) Information Technology Co., Ltd. Their ideas
   and help gave a valuable added dimension to our research.
CR Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113
   Higareda-Almaraz JC, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-96
   Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-60
   Connett JM, 2005, J INTERF CYTOK RES, V25, P587, DOI 10.1089/jir.2005.25.587
   De Nicolo A, 2008, CLIN CANCER RES, V14, P4672, DOI 10.1158/1078-0432.CCR-08-0087
   Dennis Jr G., 2003, GENOME BIOL, V4, P3, DOI [10.1186/gb-2003-4-5-p3;pmid:12734009, DOI 10.1186/GB-2003-4-5-P3]
   Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251
   Ding D, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003065
   Edwards LE, 1997, FOSSILS ROCKS TIME
   EKBOM A, 1993, NEW ENGL J MED, V329, P1502
   Fu BJ, 2008, CANCER BIOL THER, V7, P1593, DOI 10.4161/cbt.7.10.6565
   Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687
   Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129
   Kim JH, 2010, TUMOR BIOL, V31, P541, DOI 10.1007/s13277-010-0067-z
   Kosanam H, 2013, MOL CELL PROTEOMICS, V12, P2820, DOI 10.1074/mcp.M112.023507
   Krupp M, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-53
   Kwon OH, 2011, BIOCHEM BIOPH RES CO, V406, P539, DOI 10.1016/j.bbrc.2011.02.082
   Lee HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066267
   Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051
   Li ZY, 2013, GYNECOL ONCOL, V131, P191, DOI 10.1016/j.ygyno.2013.07.095
   Liao Q, 2003, SCAND J GASTROENTERO, V38, P207, DOI 10.1080/00365520310000717
   LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001
   Pai P, 2013, CURR DRUG TARGETS, V14, P1101, DOI 10.2174/13894501113149990181
   Papadopoulos GL, 2009, NUCLEIC ACIDS RES, V37, pD155, DOI 10.1093/nar/gkn809
   Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016
   Schoniger C, 2013, BIOORGAN MED CHEM, V21, P6115, DOI 10.1016/j.bmc.2013.03.040
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358
   Wu SF, 2013, ARCH GYNECOL OBSTET, V287, P771, DOI 10.1007/s00404-012-2608-8
   Xue Y, 2013, CANCER GENET-NY, V206, P217, DOI 10.1016/j.cancergen.2013.05.020
   Ying SY, 2008, MOL BIOTECHNOL, V38, P257, DOI 10.1007/s12033-007-9013-8
   Zgheib NB, 2012, INT J ONCOL, V41, P179, DOI 10.3892/ijo.2012.1451
NR 35
TC 2
Z9 2
U1 3
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAY
PY 2014
VL 41
IS 5
BP 2875
EP 2883
DI 10.1007/s11033-014-3143-4
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AG9JC
UT WOS:000335734400020
PM 24469724
DA 2018-12-27
ER

PT J
AU Dong, ZQ
   Wu, XJ
   Lu, QH
AF Dong, Zhao-Qiang
   Wu, Xiang-Jun
   Lu, Qing-Hua
TI RETRACTED: Correlations of SELE genetic polymorphisms with risk of
   coronary heart disease and myocardial infarction: a meta-analysis
   (Retracted article. See vol. 42, pg. 1449, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE E-selectin; SELE; Coronary heart disease; Myocardial infarction;
   Meta-analysis
ID ARTERY-DISEASE; S128R POLYMORPHISM; UNIVERSAL DEFINITION;
   ATHEROSCLEROSIS; INFLAMMATION; ADHESION; SURGERY; TYPE-2; FLOW; CAD
AB This meta-analysis of case-control studies was conducted to determine whether SELE genetic polymorphisms contribute to the pathogenesis of coronary heart disease (CHD) and myocardial infarction (MI). The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched for relevant articles published before November 1st, 2013 without any language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Twenty case-control studies met the inclusion criteria, with a total of 2,292 CHD patients, 901 MI patients and 3,233 healthy controls. Six common polymorphisms in the SELE gene were evaluated, including 554L/F, 98G/T, 128S/R, 2692G/A, 1901C/T, and 1856A/G. The results of our meta-analysis suggest that SELE genetic polymorphisms might be strongly correlated with an increased risk of CHD (allele model: OR 2.08, 95 % CI 1.67-2.58, P < 0.001; dominant model: OR 2.12, 95 % CI 1.68-2.68, P < 0.001; respectively), especially the SELE 554L/F, 98G/T and 128S/R polymorphisms. Furthermore, our findings indicated that SELE genetic polymorphisms were closely linked to the risk of CHD in Asians but not Caucasians. However, our findings reveal no positive correlations between SELE genetic polymorphisms and MI risk (allele model: OR 1.39, 95 % CI 1.00-1.94, P = 0.054; dominant model: OR 1.40, 95 % CI 0.96-2.04, P = 0.081; respectively). The current meta-analysis suggests that SELE genetic polymorphisms may contribute to an increased risk of CHD, especially the SELE 554L/F, 98G/T and 128S/R polymorphisms in Asians. However, SELE genetic polymorphisms may not be important determinants of susceptibility to MI.
C1 [Dong, Zhao-Qiang; Wu, Xiang-Jun; Lu, Qing-Hua] Shandong Univ, Hosp 2, Dept Cardiovasc Med, Jinan 250033, Peoples R China.
RP Lu, QH (reprint author), Shandong Univ, Hosp 2, Dept Cardiovasc Med, 247 Beiyuan St, Jinan 250033, Peoples R China.
EM luqinghua1202@126.com
CR Abu-Amero KK, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-52
   Abu-Amero KK, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-35
   Barbaux SC, 2001, ARTERIOSCL THROM VAS, V21, P1668, DOI 10.1161/hq1001.097022
   Bendas Gerd, 2012, Int J Cell Biol, V2012, P676731, DOI 10.1155/2012/676731
   Chen Ji, 2013, J Biomed Res, V27, P437, DOI 10.7555/JBR.27.20130150
   El-Mesallamy HO, 2011, MINERVA ENDOCRINOL, V36, P163
   Endler G, 2003, THROMB RES, V112, P47, DOI 10.1016/j.thromres.2003.10.018
   Goracy J, 2011, MED SCI MONITOR, V17, pCR334, DOI 10.12659/MSM.881806
   Goswami B, 2010, CARDIOVASC J AFR, V21, P41
   Hong YD, 2009, J GUANGZHOU U TRAD C, V26, P1, DOI DOI 10.3969/J.ISSN.1007-3213.2009.01.001
   Houshmand B, 2009, J PERIODONTAL RES, V44, P88, DOI 10.1111/j.1600-0765.2008.01092.x
   Hu HL, 2006, ACTA MED U SCI TECHN, V35, P115
   Huan TX, 2013, ARTERIOSCL THROM VAS, V33, P1427, DOI 10.1161/ATVBAHA.112.300112
   Jubeli E, 2012, J CONTROL RELEASE, V158, P194, DOI 10.1016/j.jconrel.2011.09.084
   Kee F, 2000, HEART, V84, P548, DOI 10.1136/heart.84.5.548
   Kivimaki M, 2012, LANCET, V380, P1491, DOI 10.1016/S0140-6736(12)60994-5
   Li XH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020620
   Li Y, 2004, CHIN J LABOR MED, V27, P51
   Li Y, 2004, CHIN J GERIATR, V23, P4
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Lin F, 2001, J FUJIAN MED U, V35, P342
   [林帆 Lin Fan], 2003, [临床心血管病杂志, Journal of Clinical Cardiology], V19, P531
   [罗晓颖 Luo Xiaoying], 2003, [上海第二医科大学学报, Acta Universitatis Medicinalis Secondae Shanghai], V23, P220
   MA H, 2008, HLTH VOCAT ED, V26, P135
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Podgoreanu MV, 2006, CIRCULATION, V114, pI275, DOI 10.1161/CIRCULATIONAHA.105.001032
   RAO D, 2007, CHIN HEART J, V19, P555, DOI DOI 10.3969/J.ISSN.1009-7236.2007.05.014
   Sakowicz A, 2010, ARCH MED SCI, V6, P160, DOI 10.5114/aoms.2010.13887
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Smadja DM, 2012, AM J PATHOL, V181, P2239, DOI 10.1016/j.ajpath.2012.08.030
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stepien E, 2011, ARCH MED RES, V42, P375, DOI 10.1016/j.arcmed.2011.07.007
   Swirski FK, 2013, SCIENCE, V339, P161, DOI 10.1126/science.1230719
   Tehrani DM, 2013, CLEV CLIN J MED, V80, P777, DOI 10.3949/ccjm.80a.12158
   Teo KK, 2006, LANCET, V368, P647, DOI 10.1016/S0140-6736(06)69249-0
   Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397
   Torpy Janet M, 2009, JAMA, V302, P2388, DOI 10.1001/jama.302.21.2388
   Tripathi R, 2009, INDIAN J MED RES, V130, P423
   Turhan H, 2006, INT J CARDIOL, V108, P224, DOI 10.1016/j.ijcard.2005.05.008
   Vinukonda G, 2009, CLIN CHIM ACTA, V405, P127, DOI 10.1016/j.cca.2009.04.015
   Visvanathan S, 2009, J RHEUMATOL, V36, P1371, DOI 10.3899/jrheum.080755
   Wei M, 2007, CHIN J EMERG MED, V16, P1251, DOI DOI 10.3760/J.ISSN:1671-0282.2007.12.005
   Wenzel K, 1997, J MOL MED-JMM, V75, P57, DOI 10.1007/s001090050087
   Yoshida M, 2003, ARTERIOSCL THROM VAS, V23, P783, DOI 10.1161/01.ATV.0000067427.40133.59
   Zak I, 2008, HEART VESSELS, V23, P257, DOI 10.1007/s00380-008-1040-2
   ZHANG YL, 2011, CHINA J MOD MED, V21, P3521
   [张蕴莉 Zhang Yunli], 2013, [中国现代医学杂志, China Journal of Modern Medicine], V23, P41
   [张蕴莉 Zhang Yunli], 2011, [中国现代医学杂志, China Journal of Modern Medicine], V21, P3515
   Zheng F, 2001, CLIN GENET, V59, P58, DOI 10.1034/j.1399-0004.2001.590110.x
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 50
TC 2
Z9 2
U1 3
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAY
PY 2014
VL 41
IS 5
BP 3021
EP 3031
DI 10.1007/s11033-014-3161-2
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AG9JC
UT WOS:000335734400035
PM 24458828
DA 2018-12-27
ER

PT J
AU Zhou, DH
   Wang, Y
   Hu, WN
   Wang, LJ
   Wang, Q
   Chi, M
   Jin, YZ
AF Zhou, Dong-Hui
   Wang, Yong
   Hu, Wei-Na
   Wang, Li-Jie
   Wang, Qi
   Chi, Miao
   Jin, Yuan-Zhe
TI RETRACTED: SELP genetic polymorphisms may contribute to the pathogenesis
   of coronary heart disease and myocardial infarction: a meta-analysis
   (Retracted article. See vol. 42, pg. 1451, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE P-selectin; Coronary heart disease; Myocardial infarction; Meta-analysis
ID SOLUBLE P-SELECTIN; UNIVERSAL DEFINITION; RISK; ATHEROSCLEROSIS; STROKE;
   WOMEN; MEN
AB We conducted a meta-analysis of case-control studies to determine whether SELP genetic polymorphisms contribute to the pathogenesis of coronary heart disease (CHD) and myocardial infarction (MI). A range of electronic databases were searched: MEDLINE (1966-2013), the Cochrane Library Database (Issue 12, 2013), EMBASE (1980-2013), CINAHL (1982-2013), Web of Science (1945-2013) and the Chinese biomedical database (1982-2013) without language restrictions. Meta-analysis was performed with the use of the STATA statistical software. Nine case-control studies with a total of 3,154 CHD patients, 1,608 MI patients and 17,304 healthy controls were involved in this meta-analysis. Six common polymorphisms in the SELE gene were assessed, including -1969G/A (rs1800805 G > A), -1817T/C (rs1800808 T > C), -2123C/G (rs1800807 C > G), Thr715Pro (rs6136 A > C), Leu599Val (rs6133 G > T), and Ser290Asn (rs6131 C > T). Our findings illustrated significantly positive associations of SELE genetic polymorphisms with the development of CHD and MI. The results of subgroup analysis by SNP type indicated that -1969G/A, -1817T/C, -2123C/G, Thr715Pro and Ser290Asn in the SELP gene might be strongly correlated with CHD and MI risk, but no similar results were found in SELP Leu599Val polymorphism. In the subgroup analysis by ethnicity, our results indicated significant relationships between SELE genetic polymorphisms and the pathogenesis of CHD and MI among Asians and Caucasians. However, we observed no significant associations between SELP genetic polymorphisms and the risk of CHD and MI among Africans. Our findings provide empirical evidence that SELE genetic polymorphisms may contribute to the pathogenesis of CHD and MI, especially among Asians and Caucasians. Thus, SELP genetic polymorphisms could be potential and practical biomarkers for early diagnosis of CHD and MI.
C1 [Zhou, Dong-Hui; Wang, Yong; Hu, Wei-Na; Wang, Li-Jie; Wang, Qi; Chi, Miao; Jin, Yuan-Zhe] China Med Univ, Dept Cardiol, Affiliated Hosp 4, Shenyang 110032, Peoples R China.
RP Jin, YZ (reprint author), China Med Univ, Dept Cardiol, Affiliated Hosp 4, Shenyang 110032, Peoples R China.
EM cmu4h_jyz@163.com
FU Department of Education Project of Liaoning Province [20072092]
FX This study was funded by the Department of Education Project of Liaoning
   Province (20072092). We would like to thank our colleagues at the
   Department of Cardiology, The Fourth Affiliated Hospital of China
   Medical University.
CR Anand SS, 2008, EUR HEART J, V29, P932, DOI 10.1093/eurheartj/ehn018
   Barbaux SC, 2001, ARTERIOSCL THROM VAS, V21, P1668, DOI 10.1161/hq1001.097022
   Brown JB, 2012, INFLAMM BOWEL DIS, V18, P323, DOI 10.1002/ibd.21779
   Carter AM, 2003, J THROMB HAEMOST, V1, P1718, DOI 10.1046/j.1538-7836.2003.00312.x
   Chen AY, 2012, J LEUKOCYTE BIOL, V92, P183, DOI 10.1189/jlb.0112010
   Elmas E, 2010, J CARDIOVASC ELECTR, V21, P1260, DOI 10.1111/j.1540-8167.2010.01833.x
   Gaziano TA, 2010, CURR PROB CARDIOLOGY, V35, P72, DOI [10.1016/j.cpcardio1.2009.10.002, 10.1016/j.cpcardiol.2009.10.002]
   Gerretsen SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012998
   Ghazouani L, 2011, MOL BIOL REP, V38, P495, DOI 10.1007/s11033-010-0133-z
   Ghazouani L, 2009, J THROMB THROMBOLYS, V28, P314, DOI 10.1007/s11239-008-0297-8
   Jaremo P, 2013, SCAND J CLIN LAB INV, V73, P170, DOI 10.3109/00365513.2013.764572
   Kee F, 2000, HEART, V84, P548, DOI 10.1136/heart.84.5.548
   Kisucka J, 2009, BLOOD, V113, P6015, DOI 10.1182/blood-2008-10-186650
   [廖驰林 LIAO ChiLin], 2011, [中国动脉硬化杂志, Chinese Journal of Arteriosclerosis], V19, P151
   LIAO CL, 2012, J GUANGXI MED U, V29, P598
   Motawi T, 2012, MED SCI MONITOR, V18, pCR381, DOI 10.12659/MSM.882908
   Pasquali A, 2010, MOL CELL PROBE, V24, P161, DOI 10.1016/j.mcp.2009.11.006
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Rosner SA, 2005, HUM GENET, V118, P287, DOI 10.1007/s00439-005-0052-6
   Sivapalaratnam S, 2011, CURR ATHEROSCLER REP, V13, P225, DOI 10.1007/s11883-011-0173-4
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stellos K, 2010, J THROMB HAEMOST, V8, P205, DOI 10.1111/j.1538-7836.2009.03659.x
   Tehrani DM, 2013, CLEV CLIN J MED, V80, P777, DOI 10.3949/ccjm.80a.12158
   Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397
   Torpy Janet M, 2009, JAMA, V302, P2388, DOI 10.1001/jama.302.21.2388
   Van der Zee PM, 2006, CLIN CHEM, V52, P657, DOI 10.1373/clinchem.2005.057414
   Volcik KA, 2006, ATHEROSCLEROSIS, V186, P74, DOI 10.1016/j.atherosclerosis.2005.07.010
   Woollard KJ, 2010, CURR PHARM DESIGN, V16, P4113
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 29
TC 6
Z9 7
U1 2
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAY
PY 2014
VL 41
IS 5
BP 3369
EP 3380
DI 10.1007/s11033-014-3199-1
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AG9JC
UT WOS:000335734400070
PM 24504449
DA 2018-12-27
ER

PT J
AU Lin, Y
   Jin, Y
   Lin, LJ
   Cao, Y
   Zhang, Y
   Chen, SF
   Zheng, CQ
AF Lin, Yan
   Jin, Yu
   Lin, Lian-Jie
   Cao, Yong
   Zhang, Ying
   Chen, Shao-Fu
   Zheng, Chang-Qing
TI RETRACTED: Candidate agents for pancreatic ductal adenocarcinoma
   identified by a sub-pathway based method (Retracted article. See vol.
   578, pg. 138, 2016)
SO GENE
LA English
DT Article; Retracted Publication
DE Pancreatic ductal adenocarcinoma; Sub-pathway; Small molecules
ID MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; MOLECULAR MARKERS;
   CANCER; EXPRESSION; CARCINOMA; FLUDROCORTISONE; BETA-1-INTEGRIN;
   GEMCITABINE; METASTASIS
AB Aim: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death worldwide. This study aims to explore the molecular mechanism of PDAC and identify biologically active small molecules capable of targeting the sub-pathways which were dysregulated in the development of PDAC.
   Methods: The gene expression profile of GSE28735 microarray data (including 45 matching pairs of pancreatic tumor and adjacent non-tumor tissues) was downloaded from GEO (Gene Expression Omnibus) database. Differentially expressed genes (DEGs) between pancreatic tumor tissues and non-tumor tissues were identified, and then the sub-pathway enrichment analysis was performed. Moreover, an approach based on targeting sub-pathways was used to reveal potential agents for PDAC.
   Results: A total of 5315 DEGs were identified between pancreatic tumor tissues and non-tumor tissues with a false discovery rate of 0.01. Genes of collagen family and integrin receptor family which were involved in pathways of focal adhesion and ECM-receptor interaction respectively were differentially expressed in the pancreatic tumor tissue. Besides, a total of 85 small molecules including fludrocortisone, latamoxef and metronidazole were revealed by bioinformatics analysis.
   Conclusion: This study proposed the use of an approach based on targeting sub-pathways to identify potential agents for PDAC. The sub-pathways and small molecules discovered in this study were not only related to PDAC but also play a role in perturbing the development of PDAC. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Lin, Yan; Jin, Yu; Lin, Lian-Jie; Cao, Yong; Zhang, Ying; Chen, Shao-Fu; Zheng, Chang-Qing] China Med Univ, Shengjing Hosp, Dept Gastroenterol, Shenyang 110001, Liaoning Provin, Peoples R China.
RP Zheng, CQ (reprint author), China Med Univ, Shengjing Hosp, Dept Gastroenterol, 39 Huaxiang Rd, Shenyang 110001, Liaoning Provin, Peoples R China.
EM changqingzheng2@hotmail.com
FU Science and technology project of Shenyang [F13-318-1-42]
FX This study was supported by the Science and technology project of
   Shenyang, no. F13-318-1-42.
CR Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   BROWN RB, 1986, ARCH INTERN MED, V146, P2159, DOI 10.1001/archinte.146.11.2159
   Campagna D, 2008, INT J CLIN EXP PATHO, V1, P32
   Chen XJ, 2011, BIOINFORMATICS, V27, P649, DOI 10.1093/bioinformatics/btq714
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7
   Freitas J, 2000, CLIN AUTON RES, V10, P293, DOI 10.1007/BF02281112
   Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002
   Goggins M, 2005, J CLIN ONCOL, V23, P4524, DOI 10.1200/JCO.2005.193=.711
   Goggins M, 2007, SEMIN ONCOL, V34, P303, DOI 10.1053/j.seminoncol.2007.05.003
   Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   IMAMURA T, 1995, PANCREAS, V11, P357, DOI 10.1097/00006676-199511000-00007
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   ISHIKAWA SE, 1987, ANN INTERN MED, V106, P187, DOI 10.7326/0003-4819-106-2-187
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609
   Kanehisa M, 2002, NOVART FDN SYMP, V247, P91
   Keleg Shereen, 2003, Mol Cancer, V2, P14, DOI 10.1186/1476-4598-2-14
   Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lee CY, 2011, J ONCOL, DOI 10.1155/2011/365651
   LEE CS, 1994, INT J EXP PATHOL, V75, P79
   Li CQ, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp667
   Linder S, 2001, HEPATO-GASTROENTEROL, V48, P1321
   Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147
   Matsunaga Akihiro, 2005, Hokkaido Igaku Zasshi, V80, P9
   Mihaljevic AL, 2010, LANGENBECK ARCH SURG, V395, P295, DOI 10.1007/s00423-010-0622-5
   MOLLENHAUER J, 1987, Pancreas, V2, P14, DOI 10.1097/00006676-198701000-00003
   Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059
   Ostman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003
   Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267
   Shakibaei M, 2008, ADV ANAT EMBRYOL CEL, V197, P1, DOI 10.1007/978-3-540-78771-6
   Tan ZJ, 2003, WORLD J GASTROENTERO, V9, P818, DOI 10.3748/wjg.v9.i4.818
   Taplin CE, 2006, PEDIATRICS, V118, pE1904, DOI 10.1542/peds.2006-0702
   Team RDC, 2011, R LANG ENV STAT COMP
   Wang RN, 2005, DIABETES, V54, P2080, DOI 10.2337/diabetes.54.7.2080
   WEINEL RJ, 1995, GASTROENTEROLOGY, V108, P523, DOI 10.1016/0016-5085(95)90082-9
   WEITEKAMP MR, 1983, JAMA-J AM MED ASSOC, V249, P69, DOI 10.1001/jama.249.1.69
   Yashpal NK, 2005, ENDOCRINOLOGY, V146, P1798, DOI 10.1210/en.2004-1292
   Zhang G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031507
NR 42
TC 2
Z9 2
U1 3
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAY 1
PY 2014
VL 540
IS 2
BP 232
EP 237
DI 10.1016/j.gene.2014.01.081
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA AG0JQ
UT WOS:000335102200014
PM 24561286
DA 2018-12-27
ER

PT J
AU Wang, HL
   Liu, P
   Zhou, PY
   Zhang, Y
AF Wang, He-Ling
   Liu, Peng
   Zhou, Ping-Yi
   Zhang, Yu
TI RETRACTED: Promoter Methylation of the RASSF1A Gene may Contribute to
   Colorectal Cancer Susceptibility: A Meta-Analysis of Cohort Studies
   (Retracted article. See vol. 80, pg. 246, 2016)
SO ANNALS OF HUMAN GENETICS
LA English
DT Article; Retracted Publication
DE colorectal cancer; susceptibility; promoter methylation; meta-analysis;
   RASSF1A
ID TUMOR-SUPPRESSOR GENE; K-RAS MUTATIONS; HYPERMETHYLATION; METAANALYSIS;
   RISK
AB This meta-analysis of published cohort studies was conducted to evaluate whether promoter methylation of the RASSF1A gene contributes to colorectal cancer (CRC) susceptibility. A range of electronic databases were searched without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude risk differences (RD) with their 95% confidence intervals (95%CI) were calculated. In this meta-analysis, 11 clinical cohort studies with a total of 630 CRC patients were included. The pooled results revealed that the frequency of RASSF1A gene methylation in cancer tissues was significantly higher than that in benign, adjacent, and normal tissues (cancer tissues vs. benign tissues: RD = 0.25, 95%CI = 0.13-0.38, P < 0.001; cancer tissues vs. adjacent tissues: RD = 0.32, 95%CI: 0.20-0.45, P < 0.001; cancer tissues vs. normal tissues: RD = 0.38, 95%CI: 0.26-0.50, P < 0.001; respectively). Subgroup analysis by ethnicity demonstrated that RASSF1A promoter methylation also exhibited a higher frequency in cancer tissues among both Asians and Caucasians (all P < 0.05). Our meta-analysis has shown positive correlations between RASSF1A promoter methylation and CRC susceptibility. Thus, detection of RASSF1A promoter methylation may be utilized as a valuable diagnostic marker for CRC.
C1 [Wang, He-Ling; Liu, Peng; Zhou, Ping-Yi; Zhang, Yu] China Med Univ, Shengjing Hosp, Dept Gen Surg, Shenyang 110022, Peoples R China.
RP Wang, HL (reprint author), China Med Univ, Shengjing Hosp, Dept Gen Surg, Huaxiangy Rd 39, Shenyang 110022, Peoples R China.
EM wangheling1127@126.com
FU Research Foundation of Science and Technology Agency of Liaoning
   Province [2011408004]
FX This work was supported by the Research Foundation of Science and
   Technology Agency of Liaoning Province (No. 2011408004). We would like
   to acknowledge the reviewers for their helpful comments on this paper.
CR Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051
   Amin Karishma S, 2012, J Carcinog, V11, P3, DOI 10.4103/1477-3163.93000
   Chen SP, 2012, GENET TEST MOL BIOMA, V16, P1277, DOI 10.1089/gtmb.2012.0126
   Cleary SP, 2010, AM J EPIDEMIOL, V172, P1000, DOI 10.1093/aje/kwq245
   Cooper K, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI [10.3310/hta.14320, 10.3310/hta14320]
   Dammann R, 2000, NAT GENET, V25, P315
   Dunlop MG, 2013, GUT, V62, P871, DOI 10.1136/gutjnl-2011-300537
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fernandes MS, 2013, INT J CANCER, V132, P251, DOI 10.1002/ijc.27696
   Fu Jing, 2010, Progress in Modern Biomedicine, V10, P4513
   [胡佳乐 Hu Jiale], 2010, [中国肿瘤生物治疗杂志, Chinese Journal of Cancer Biotherapy], V17, P444
   Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343
   Kang Ho-Jin, 2012, J Prev Med Public Health, V45, P251, DOI 10.3961/jpmph.2012.45.4.251
   Kimura N, 2009, CLIN BIOCHEM, V42, P1113, DOI 10.1016/j.clinbiochem.2009.03.017
   Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173
   Li C. J., 2011, SHANDONG MED J, V51, P87, DOI DOI 10.3969/J.ISSN.1002-266X.2011.42.052
   Miladi-Abdennadher I, 2010, TUMOR BIOL, V31, P503, DOI 10.1007/s13277-010-0063-3
   Miranda E, 2006, BRIT J CANCER, V95, P1101, DOI 10.1038/sj.bjc.6603337
   Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906
   Pan ZG, 2005, CANCER BIOL THER, V4, P1116, DOI 10.4161/cbt.4.10.2023
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Sakamoto N, 2004, ONCOGENE, V23, P8900, DOI 10.1038/sj.onc.1207993
   Sinha R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060142
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tommasi S, 2011, J CELL PHYSIOL, V226, P1934, DOI 10.1002/jcp.22524
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj/onc/1205466
   Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922
   Wahab AHA, 2011, TUMOR BIOL, V32, P845, DOI 10.1007/s13277-011-0156-7
   Wang X. D., 2011, CHIN J LABOR DIAGNOS, V15, P1538, DOI DOI 10.3969/J.ISSN.1007-4287.2011.09.040
   Yu Z. H., 2011, ONCOLOGY PROGR, V9, P555, DOI DOI 10.3969/J.ISSN.1672-1535.2011.05.019
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 31
TC 9
Z9 9
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4800
EI 1469-1809
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD MAY
PY 2014
VL 78
IS 3
BP 208
EP 216
DI 10.1111/ahg.12059
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA AE5LL
UT WOS:000334030400005
PM 24621386
OA Bronze
DA 2018-12-27
ER

PT J
AU Timsina, YN
   Biswas, S
   RajanBabu, TV
AF Timsina, Yam N.
   Biswas, Souvagya
   RajanBabu, T. V.
TI RETRACTED: Chemoselective Reactions of (E)-1,3-Dienes: Cobalt-Mediated
   Isomerization to (Z)-1,3-Dienes and Reactions with Ethylene (Retracted
   article. See vol. 140, pg. 2700, 2018)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID ASYMMETRIC HYDROVINYLATION; STEREOSELECTIVE SYNTHESIS; ALKENE
   ISOMERIZATION; METAL-CATALYSTS; 1,3-DIENES; BOND; COMPLEXES;
   ORGANOTITANIUM; HYDROGENATION; DIENYLATION
AB In the asymmetric hydrovinylation (HV) of an E/Z-mixture of a prototypical 1,3-diene with (S,S)(DIOP)CoCl2 or (S,S)-(BDPP)CoCl2 catalyst in the presence of Me3Al, the (E)-isomer reacts significantly faster, leaving behind the Z-isomer intact at the end of the reaction. The presumed [LCo-H](+)-intermediate, especially when L is a large-bite angle ligand, similar to DIOP and BDPP, promote an unusual isomerization of (E/Z)-mixtures of 1,3-dienes to isomerically pure Z-isomers. A mechanism that involves an intramolecular hydride addition via an [eta(4)-(diene)(LCo-H)](+) complex, followed by pi-sigma-pi isomerization of the intermediate Co(allyl) species, is proposed for this reaction.
C1 [Timsina, Yam N.; Biswas, Souvagya; RajanBabu, T. V.] Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA.
RP RajanBabu, TV (reprint author), Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA.
EM rajanbabu.1@osu.edu
FU US National Science Foundation [CHE-1057818]; National Institutes of
   Health [R01 GM075107]
FX Financial assistance for this research provided by US National Science
   Foundation (CHE-1057818) and National Institutes of Health (General
   Medical Sciences, R01 GM075107) is gratefully acknowledged. We are
   grateful to Mr. William Coldren and Professor Chris Hadad for help with
   the DFT calculations.
CR Bianchini C, 2007, ORGANOMETALLICS, V26, P1303, DOI 10.1021/om070003l
   Billard F, 2012, J ORG CHEM, V77, P6358, DOI 10.1021/jo300929a
   BOGDANOVIC B, 1973, ANGEW CHEM INT EDIT, V12, P954, DOI 10.1002/anie.197309541
   Britovsek GJP, 1999, J AM CHEM SOC, V121, P8728, DOI 10.1021/ja990449w
   Chen C, 2014, J AM CHEM SOC, V136, P945, DOI 10.1021/ja408238n
   Ciancanelli R, 2002, J AM CHEM SOC, V124, P2984, DOI 10.1021/ja0122804
   CONSIGLIO G, 1989, CHEM REV, V89, P257, DOI 10.1021/cr00091a007
   de Vicente J, 2006, ANGEW CHEM INT EDIT, V45, P7258, DOI 10.1002/anie.200602742
   Donohoe TJ, 2009, ANGEW CHEM INT EDIT, V48, P1014, DOI 10.1002/anie.200804617
   Grutters MMP, 2006, J AM CHEM SOC, V128, P7414, DOI 10.1021/ja058095y
   GUNASEKERA SP, 1990, J ORG CHEM, V55, P4912, DOI 10.1021/jo00303a029
   Hilt G, 2001, ANGEW CHEM INT EDIT, V40, P387, DOI 10.1002/1521-3773(20010119)40:2<387::AID-ANIE387>3.0.CO;2-7
   Hilt G., 2012, EUR J ORG CHEM, P4441
   Hilt G., 2002, SYNTHESIS, P609
   IKEDA Y, 1987, TETRAHEDRON, V43, P723, DOI 10.1016/S0040-4020(01)90006-7
   IKEDA Y, 1987, TETRAHEDRON, V43, P731, DOI 10.1016/S0040-4020(01)90007-9
   IWAMOTO M, 1968, B CHEM SOC JPN, V41, P150, DOI 10.1246/bcsj.41.150
   Kong JR, 2006, J AM CHEM SOC, V128, P16040, DOI 10.1021/ja0664786
   Larsen CR, 2012, J AM CHEM SOC, V134, P15604, DOI 10.1021/ja308091h
   Nelson SG, 2003, J AM CHEM SOC, V125, P13000, DOI 10.1021/ja037655v
   Obligacion JV, 2013, J AM CHEM SOC, V135, P19107, DOI 10.1021/ja4108148
   Page JP, 2012, J AM CHEM SOC, V134, P6556, DOI 10.1021/ja301640e
   Paterson I., 1995, SYNLETT, P498
   Pettit G. R., 1994, J CHEM SOC CHEM COMM, V1994, P1111
   Punner F, 2012, ANGEW CHEM INT EDIT, V51, P1270, DOI 10.1002/anie.201107512
   RajanBabu T. V., 2009, SYNLETT, P853
   RajanBabu TV, 2003, CHEM REV, V103, P2845, DOI 10.1021/cr020040g
   Saha B, 2008, J AM CHEM SOC, V130, P9000, DOI 10.1021/ja711475f
   Sharma RK, 2010, J AM CHEM SOC, V132, P3295, DOI 10.1021/ja1004703
   Skucas E, 2007, J AM CHEM SOC, V129, P7242, DOI 10.1021/ja0715896
   Tellmann KF, 2004, ORGANOMETALLICS, V23, P5503, DOI 10.1021/om049581h
   Tellmann KP, 2005, ORGANOMETALLICS, V24, P280, DOI 10.1021/om049297q
   TOLMAN CA, 1970, J AM CHEM SOC, V92, P6777, DOI 10.1021/ja00726a011
   TROST BM, 2000, CATALYTIC ASYMMETRIC, P593
   van Leeuwen PWNM, 2000, CHEM REV, V100, P2741, DOI 10.1021/cr9902704
   Wang S., 2002, SYNTHESIS, P99
   Wille A., 1998, SYNTHESIS, P305
   WITTENBERG D, 1964, ANGEW CHEM INT EDIT, V3, P153
   Zhang AB, 2006, J AM CHEM SOC, V128, P54, DOI 10.1021/ja0561338
   Zhang GQ, 2012, ANGEW CHEM INT EDIT, V51, P12102, DOI 10.1002/anie.201206051
NR 40
TC 22
Z9 22
U1 5
U2 47
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD APR 30
PY 2014
VL 136
IS 17
BP 6215
EP 6218
DI 10.1021/ja501979g
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA AG4DJ
UT WOS:000335369200017
PM 24712838
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Meng, DP
   Ye, TW
   Chen, AM
AF Meng, De-peng
   Ye, Tian-wen
   Chen, Ai-min
TI RETRACTED: An osteotomy anterolateral approach for lateral tibial
   plateau fractures merged with relatively simple and intact
   posterolateral corner displacement (Retracted article. See vol. 10, 47,
   2015)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE Lateral tibial plateau fractures; Posterolateral corner displacement;
   Anterolateral approach; Indication and techniques
ID ANTERIOR; OUTCOMES
AB Introduction: This study investigates the safety and efficacy of anterolateral (AL) osteotomy for the treatment of lateral tibial plateau fractures merged with relatively simple and intact posterolateral (PL) corner displacement and screens applicable patients.
   Methods: Totally, 11 patients with lateral tibial plateau fractures involving the PL corner were included in this study. Of them, seven patients sustained their injuries from motor vehicle accidents (MVAs), three from sports and one from fall from height. All of them received open reduction and internal fixation through the AL approach. Operation time, incision length, range of motion (ROM), Hospital for Special Surgery (HSS) knee score, time of union and complications were retrospectively reviewed. Tibial plateau angle (TPA), lateral posterior slope angle (PSA) and articular step-off reduction after surgery were examined by a radiograph technique.
   Results: Statistically, the means of operation time, incision length, ROM and follow-up period were 82 min, 11 cm, 97 degrees and 27 months, respectively. Three patients had slight complications: superficial infection, hardware irritation and secondary valgus deformity, without severe neural or vascular injuries, which revealed the safety and efficacy of the PL treatment. The average HSS knee score was 91.2 (range 86-96). Reduction (mean TPA 87.2 degrees and mean PSA 8.3 degrees) was satisfactory in 10 patients, except for one patient with a radiographic articular step-off of 5 mm (case 10).
   Conclusions: The AL approach is safe and effective for lateral tibial plateau fractures involving the PL corner, especially for fractures merged with simple and intact PL corner displacement (depression and/or split).
C1 [Meng, De-peng; Ye, Tian-wen; Chen, Ai-min] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Surg, Shanghai 200003, Peoples R China.
RP Chen, AM (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Surg, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
EM aiminchen@aliyun.com
CR Barei DP, 2006, J BONE JOINT SURG AM, V88A, P1713, DOI 10.2106/JBJS.E.00907
   Carlson DA, 2005, J ORTHOP TRAUMA, V19, P73, DOI 10.1097/00005131-200502000-00001
   Chang SM, 2009, ARCH ORTHOP TRAUM SU, V129, P955, DOI 10.1007/s00402-009-0829-5
   Chen WT, 2013, J ORTHOP TRAUMA, V27, pe228, DOI 10.1097/BOT.0b013e31829ff3e9
   DEBOECK H, 1995, CLIN ORTHOP RELAT R, P125
   Frosch KH, 2010, J ORTHOP TRAUMA, V24, P515, DOI 10.1097/BOT.0b013e3181e5e17d
   GEORGIADIS GM, 1994, J BONE JOINT SURG BR, V76B, P285
   He XF, 2013, ARCH ORTHOP TRAUM SU, V133, P23, DOI 10.1007/s00402-012-1632-2
   Hsieh Chih-Hsin, 2010, Int J Biomed Sci, V6, P316
   INSALL JN, 1976, J BONE JOINT SURG AM, V58, P754, DOI 10.2106/00004623-197658060-00003
   Khan R M, 2000, Clin Orthop Relat Res, P231, DOI 10.1097/00003086-200006000-00028
   Lobenhoffer P, 2011, J ORTHOP TRAUMA, V25, pE31, DOI 10.1097/BOT.0b013e31820b809a
   Marsh JL, 2007, J ORTHOP TRAUMA, V21, pS1, DOI 10.1097/00005131-200711101-00001
   Solomon LB, 2013, INJURY, V44, P1561, DOI 10.1016/j.injury.2013.04.024
   Tao J, 2008, KNEE, V15, P473, DOI 10.1016/j.knee.2008.07.004
   TSCHERNE H, 1993, CLIN ORTHOP RELAT R, P87
   WALDROP JI, 1988, AM J SPORT MED, V16, P492, DOI 10.1177/036354658801600511
   Yu BQ, 2010, KNEE, V17, P313, DOI 10.1016/j.knee.2010.01.002
   Zhang W, 2012, KNEE, V19, P94, DOI 10.1016/j.knee.2011.02.004
NR 19
TC 7
Z9 9
U1 2
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD APR 26
PY 2014
VL 9
AR 26
DI 10.1186/1749-799X-9-26
PG 8
WC Orthopedics
SC Orthopedics
GA AF9TT
UT WOS:000335058200001
PM 24735864
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Littlefield, P
   Moasser, MM
   Jura, N
AF Littlefield, Peter
   Moasser, Mark M.
   Jura, Natalia
TI RETRACTED: An ATP-Competitive Inhibitor Modulates the Allosteric
   Function of the HER3 Pseudokinase (Retracted article. See vol. 24, pg.
   917, 2017)
SO CHEMISTRY & BIOLOGY
LA English
DT Article; Retracted Publication
ID EGF RECEPTOR; KINASE DOMAIN; ACTIVATION; MECHANISM; SENSITIVITY;
   HEREGULIN; MEMBRANE; GROWTH; RAF
AB Human epidermal growth factor receptor 3 (HER3) is a receptor tyrosine kinase that lacks catalytic activity but is essential for cellular homeostasis due to its ability to allosterically activate EGFR and HER2. Although catalytically inactive, HER3 binds ATP tightly, hinting at a possible role of the nucleotide-binding pocket in modulating HER3 function. We report a structure of the HER3 pseudokinase bound to the ATP-competitive inhibitor bosutinib. Previously solved structures show that bosutinib can potently interact with multiple kinase domain conformations. In complex with HER3, bosutinib binds to yet another conformation, which is nearly identical to that observed in the HER3-ATP complex. Interestingly, occupation of the ATP-binding site by bosutinib improves the ability of HER3 to act as an allosteric activator of EGFR in vitro by increasing the affinity of the HER3-EGFR heterodimer in a membrane-dependent manner.
C1 [Littlefield, Peter; Jura, Natalia] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.
   [Jura, Natalia] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.
   [Moasser, Mark M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA.
   [Moasser, Mark M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA.
RP Jura, N (reprint author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.
EM natalia.jura@ucsf.edu
FU NIH [CAl22216, CA112970]; California Breast Cancer Research; American
   Heart Association [11BGIA7440051]
FX We thank D. Shaya and C. Kimberlin for their assistance in producing
   crystals, N. Levinson for thoughtful discussions regarding bosutinib
   binding experiments and mutagenesis, and M. Grabe, D.L. Minor, and K.
   Shokat for critical reading of the manuscript and discussions. M.M.M.
   was supported by NIH grants CAl22216 and CA112970 and the California
   Breast Cancer Research Program; N.J. was supported by American Heart
   Association Beginning-in-Aid grant 11BGIA7440051. We also thank the
   staff at the Advanced Light Source at the Lawrence Berkeley National
   Laboratory.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Amin DN, 2010, SEMIN CELL DEV BIOL, V21, P944, DOI 10.1016/j.semcdb.2010.08.007
   Arkhipov A, 2013, CELL, V152, P557, DOI 10.1016/j.cell.2012.12.030
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760
   Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029
   Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003
   Chao LH, 2011, CELL, V146, P732, DOI 10.1016/j.cell.2011.07.038
   Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Endres NF, 2013, CELL, V152, P543, DOI 10.1016/j.cell.2012.12.032
   Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102
   Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833
   Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106
   Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025
   Kani K, 2005, J BIOL CHEM, V280, P8238, DOI 10.1074/jbc.M410944200
   Korennykh AV, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-48
   Landgraf R, 2000, BIOCHEMISTRY-US, V39, P8503, DOI 10.1021/bi000953+
   Leslie AGW, 2007, NATO SCI SER II-MATH, V245, P41, DOI 10.1007/978-1-4020-6316-9_4
   Levinson NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029828
   Littlefield P, 2013, P NATL ACAD SCI USA, V110, P15169, DOI 10.1073/pnas.1314719110
   Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920
   Okuzumi T, 2009, NAT CHEM BIOL, V5, P484, DOI 10.1038/nchembio.183
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   Red Brewer M, 2013, P NATL ACAD SCI USA, V110, pE3595, DOI 10.1073/pnas.1220050110
   Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474
   Shan YB, 2012, CELL, V149, P860, DOI 10.1016/j.cell.2012.02.063
   Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107
   Zeqiraj E, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000126
   Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013
NR 29
TC 20
Z9 20
U1 2
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-5521
EI 1879-1301
J9 CHEM BIOL
JI Chem. Biol.
PD APR 24
PY 2014
VL 21
IS 4
BP 453
EP 458
DI 10.1016/j.chembiol.2014.02.011
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AG5AK
UT WOS:000335431300007
PM 24656791
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Huang, YJ
   Liu, XM
AF Huang, Yijun
   Liu, Xuemei
TI RETRACTED: Leisure-time physical activity and the risk of metabolic
   syndrome: meta-analysis (Retracted article. See vol. 20, 42, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Metabolic disorder; Quantitative review; Blood pressure; Insulin
   resistance; Glucose intolerance; Sensitivity analysis
ID CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; PUBLICATION BIAS; EXERCISE
AB Background: The purpose of this study was to assess the association between leisure-time physical activity (LPA) and the risk of metabolic syndrome (MS).
   Methods: Prospective cohort studies of the association between LPA and the risk of MS were retrieved from the PubMed and Embase databases up to 12 August 2013. The statistical analysis in this study was performed using Stata 11.0 software. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the effect of LPA on the risk of MS.
   Results: A total of five articles were included in this meta-analysis. The overall effect sizes indicated that people with moderate level LPA (OR = 0.89, 95% CI: 0.82 to 0.96, P = 0.003) or high level LPA (OR = 0.58, 95% CI: 0.38 to 0.89, P = 0.012) had lower risk of MS than people with low level LPA. The subgroup analysis by gender showed that high level LPA could reduce the risk of MS in populations of different genders (female, OR = 0.20, 95% CI: 0.08 to 0.49, P <0.001; male, OR = 0.59, 95% CI: 0.43 to 0.82, P = 0.002). However, compared with low level LPA, Americans with high level LPA did not significantly reduce the risk of MS (OR = 0.59, 95% CI: 0.43 to 0.82, P = 0.002), while a significant decrease of the risk of MS was found in Europeans with high level LPA (OR = 0.49, 95% CI 0.32 to 0.77, P= 0.002) in the subgroup analysis by region.
   Conclusions: The meta-analysis confirmed that a moderate and high level of LPA could reduce the risk of MS.
C1 [Huang, Yijun] Ludong Univ, Coll Phys Educ, Yantai 264025, Shandong, Peoples R China.
   [Liu, Xuemei] Yantai Yuhuangding Hosp, Reprod Med Ctr, Yantai 264000, Shandong, Peoples R China.
RP Huang, YJ (reprint author), Ludong Univ, Coll Phys Educ, Hongqi Middle Rd 186, Yantai 264025, Shandong, Peoples R China.
EM huangyijunhyj@hotmail.com
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Buemann B, 1996, SPORTS MED, V21, P191, DOI 10.2165/00007256-199621030-00004
   Cheriyath P, 2010, EUR J CARDIOV PREV R, V17, P309, DOI 10.1097/HJR.0b013e32833189b8
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Cornelissen VA, 2005, HYPERTENSION, V46, P667, DOI 10.1161/01.HYP.0000184225.05629.51
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Despres J P, 1997, Exerc Sport Sci Rev, V25, P271
   Durstine J Larry, 2002, J Cardiopulm Rehabil, V22, P385, DOI 10.1097/00008483-200211000-00002
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eriksson J, 1997, DIABETOLOGIA, V40, P125
   Esposito K, 2014, ENDOCRINE, V45, P28, DOI 10.1007/s12020-013-9973-3
   Ford ES, 2008, DIABETES CARE, V31, P1898, DOI 10.2337/dc08-0423
   Ford Earl S, 2006, Expert Rev Cardiovasc Ther, V4, P897, DOI 10.1586/14779072.4.6.897
   Galassi A, 2006, AM J MED, V119, P812, DOI 10.1016/j.amjmed.2006.02.031
   Gebel K, 2012, MODERN EPIDEMIC: EXPERT PERSPECTIVES ON OBESITY AND DIABETES, P275
   HARDMAN A, 2003, PHYS ACTIVITY HLTH E
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hills SA, 2004, DIABETOLOGIA, V47, P566, DOI 10.1007/s00125-004-1335-5
   Holme I, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-154
   Laaksonen DE, 2002, DIABETES CARE, V25, P1612, DOI 10.2337/diacare.25.9.1612
   Lakka TA, 2007, APPL PHYSIOL NUTR ME, V32, P76, DOI 10.1139/H06-113
   McCardle W, 2010, EXERCISE PHYSL NUTR
   McMurray Robert G, 2008, Dyn Med, V7, P5, DOI 10.1186/1476-5918-7-5
   Mendez-Hernandez P, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-276
   Miles L, 2007, NUTR BULL, V32, P314, DOI 10.1111/j.1467-3010.2007.00668.x
   Misra KB, 2005, ETHNIC DIS, V15, P627
   Nieman David C, 2003, Curr Sports Med Rep, V2, P239
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   Rennie KL, 2003, INT J EPIDEMIOL, V32, P600, DOI 10.1093/ije/dyg179
   Wells G, 2011, NEWCASTLE OTTAWA SCA
   World Health Organization [WHO], 2010, GLOB REC PHYS ACT HL
   Yang XL, 2008, MED SCI SPORT EXER, V40, P1424, DOI 10.1249/MSS.0b013e318172ced4
   Yu ZJ, 2009, CIRCULATION, V119, P2969, DOI 10.1161/CIRCULATIONAHA.108.833574
NR 35
TC 10
Z9 10
U1 2
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD APR 23
PY 2014
VL 19
AR 22
DI 10.1186/2047-783X-19-22
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AG4SF
UT WOS:000335409800002
PM 24758610
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Liu, XH
   Fu, PL
   Wang, SY
   Yang, YJ
   Lu, GD
AF Liu, Xiao-Han
   Fu, Pei-Liang
   Wang, Shi-Ying
   Yang, Ya-Juan
   Lu, Gen-Di
TI RETRACTED: The effect of drainage tube on bleeding and prognosis after
   total knee arthroplasty: a prospective cohort study (Retracted article.
   See vol. 10, 46, 2015)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE Total knee arthroplasty; Drainage tube; Bleeding; Prognosis
ID HIDDEN BLOOD-LOSS; FOLLOW-UP; TOTAL HIP; REPLACEMENT; NONDRAINAGE;
   MANAGEMENT; OUTCOMES; ACCOUNT
AB Background: To evaluate the effect of drainage tube on prognosis after total knee arthroplasty (TKA) and explore an effective treatment with favorable prognosis.
   Methods: In a prospective study, 18 patients with TKA for the first time were included and randomly divided into three groups, group A (no placement of drainage tube), group B (negative pressure drainage), and group C (4 h clamping drainage). Intraoperative and postoperative blood loss, operation time, and the drainage volume were recorded and analyzed. Arthrocele, ecchymosis, and range of motion (ROM) were examined postoperatively. The degree of pain was scored by Visual Analog Scale (VAS) after 6, 12, and 24 h of operation. The complications were examined and HSS (hospital for special surgery) knee score was taken during the follow-up period.
   Results: There was no significant difference in operation time, total blood loss, intraoperative blood loss, and VAS score among three groups. Meanwhile, the hidden blood loss in group B was significantly decreased compared with group A (P = 0.0015). The postoperative drainage volume of group B was significantly increased compared with group C (P = 0.0002). No drainage increased the rate of arthrocele and ecchymosis. Compared with group A, ROM after 3 days of operation in groups B and C was significantly increased (P = 0.0357, P = 0.0372, respectively). During follow-up study, no deep infection or deep venous thrombosis was found.
   Conclusion: After TKA, early clamping of the drainage tube reduced the bleeding loss without adverse effect on prognosis, which might be useful for clinical application in future.
C1 [Liu, Xiao-Han; Wang, Shi-Ying; Yang, Ya-Juan; Lu, Gen-Di] Second Mil Med Univ, Changzheng Hosp, Dept Nursing, Shanghai 200003, Peoples R China.
   [Fu, Pei-Liang] Second Mil Med Univ, Changzheng Hosp, Dept Joint Surg, Shanghai 200003, Peoples R China.
RP Lu, GD (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Nursing, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
EM lugd2006@sina.com
CR Bezwada HP, 2004, J ARTHROPLASTY, V19, P453, DOI 10.1016/j.arth.2003.12.078
   Callaghan JJ, 2000, J BONE JOINT SURG AM, V82A, P705, DOI 10.2106/00004623-200005000-00011
   Chandratreya A, 1998, J ROY COLL SURG EDIN, V43, P404
   DICKINSON GM, 1989, ANTIMICROB AGENTS CH, V33, P602, DOI 10.1128/AAC.33.5.602
   Esler CNA, 2003, J BONE JOINT SURG BR, V85B, P215, DOI 10.1302/0301-620X.85B2.13357
   Good L, 2003, BRIT J ANAESTH, V90, P596, DOI 10.1093/bja/aeg111
   Huang HT, 2005, J ARTHROPLASTY, V20, P674, DOI 10.1016/j.arth.2004.09.053
   Katz JN, 2004, J BONE JOINT SURG AM, V86A, P1909, DOI 10.2106/00004623-200409000-00008
   Kiely N, 2001, KNEE, V8, P325, DOI 10.1016/S0968-0160(01)00095-3
   Kim YH, 1998, J ARTHROPLASTY, V13, P156, DOI 10.1016/S0883-5403(98)90093-6
   Kumar GS, 2005, KNEE, V12, P307, DOI 10.1016/j.knee.2004.08.008
   Li B, 2009, INT ORTHOP, V33, P1263, DOI 10.1007/s00264-008-0647-3
   Mengal B, 2001, REV CHIR ORTHOP, V87, P29
   Mizner RL, 2011, J ARTHROPLASTY, V26, P728, DOI 10.1016/j.arth.2010.06.004
   Pal S, 2014, DESIGN ARTIFICIAL HU, P195
   Palmer S, 2008, TOTAL KNEE REPLACEME
   Paxton EW, 2010, J BONE JOINT SURG AM, V92A, P117, DOI 10.2106/JBJS.J.00807
   Pfeiffer M, 2005, GER MED SCI, V3
   Prasad N, 2005, ARCH ORTHOP TRAUM SU, V125, P381, DOI 10.1007/s00402-005-0813-7
   Prasad N, 2007, INT ORTHOP, V31, P39, DOI 10.1007/s00264-006-0096-9
   Roy Niloy, 2006, Acta Orthop Belg, V72, P34
   Sehat KR, 2004, J BONE JOINT SURG BR, V86B, P561, DOI 10.1302/0301-620X.86B4.14508
   Sehat KR, 2000, KNEE, V7, P151, DOI 10.1016/S0968-0160(00)00047-8
   Shen PC, 2005, J ARTHROPLASTY, V20, P909, DOI 10.1016/j.arth.2005.01.017
   Tai Ta-Wei, 2010, Orthopedics, V33, DOI 10.3928/01477447-20100129-11
   Tai TW, 2010, J ARTHROPLASTY, V25, P1240, DOI 10.1016/j.arth.2009.08.013
   Tsumara N, 2006, J BONE JOINT SURG BR, V88B, P49, DOI 10.1302/0301-620X.88B1.16653
   Yamada K, 2001, J ARTHROPLASTY, V16, P458, DOI 10.1054/arth.2001.23620
NR 28
TC 7
Z9 9
U1 4
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD APR 23
PY 2014
VL 9
AR 27
DI 10.1186/1749-799X-9-27
PG 5
WC Orthopedics
SC Orthopedics
GA AF9TX
UT WOS:000335058600001
PM 24755244
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Sun, SH
   Jiang, MS
   Ma, XC
   Li, CY
   Liang, LM
AF Sun, Shi-Hai
   Jiang, Mu-Sheng
   Ma, Xiang-Chun
   Li, Chun-Yan
   Liang, Lin-Mei
TI RETRACTED: Hacking on decoy-state quantum key distribution system with
   partial phase randomization (Retracted article. See vol. 8, artn. 46943,
   2018)
SO SCIENTIFIC REPORTS
LA English
DT Article; Retracted Publication
ID COHERENT STATES; CRYPTOGRAPHY; SECURITY
AB Quantum key distribution (QKD) provides means for unconditional secure key transmission between two distant parties. However, in practical implementations, it suffers from quantum hacking due to device imperfections. Here we propose a hybrid measurement attack, with only linear optics, homodyne detection, and single photon detection, to the widely used vacuum + weak decoy state QKD system when the phase of source is partially randomized. Our analysis shows that, in some parameter regimes, the proposed attack would result in an entanglement breaking channel but still be able to trick the legitimate users to believe they have transmitted secure keys. That is, the eavesdropper is able to steal all the key information without discovered by the users. Thus, our proposal reveals that partial phase randomization is not sufficient to guarantee the security of phase-encoding QKD systems with weak coherent states.
C1 [Sun, Shi-Hai; Jiang, Mu-Sheng; Ma, Xiang-Chun; Li, Chun-Yan; Liang, Lin-Mei] Natl Univ Def Technol, Dept Phys, Changsha 410073, Hunan, Peoples R China.
   [Liang, Lin-Mei] Natl Univ Def Technol, State Key Lab High Performance Comp, Changsha 410073, Peoples R China.
RP Sun, SH (reprint author), Natl Univ Def Technol, Dept Phys, Changsha 410073, Hunan, Peoples R China.
EM shsun1983@126.com
RI cy, li/F-3239-2011
OI cy, li/0000-0001-7738-8494
FU National Natural Science Foundation of China [61072071, 11304391]
FX This work is supported by the National Natural Science Foundation of
   China, Grant No. 61072071, and Grant No. 11304391.
CR Bennett Charles H, 1984, INT C COMP SYST SIGN, P175, DOI DOI 10.1016/J.TCS.2011.08.039.AVAILABLE
   Brassard G, 2000, PHYS REV LETT, V85, P1330, DOI 10.1103/PhysRevLett.85.1330
   Gerhardt I, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1348
   Gottesman D, 2004, QUANTUM INFORM COMPU, V4, P325
   HUTTNER B, 1995, PHYS REV A, V51, P1863, DOI 10.1103/PhysRevA.51.1863
   Hwang WY, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.057901
   Jain N, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.110501
   Liu Y, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.130502
   Liu Y, 2010, OPT EXPRESS, V18, P8587, DOI 10.1364/OE.18.008587
   Lo H. K., 2013, PHYS REV LETT, V108
   Lo HK, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.230504
   Lo HK, 2007, QUANTUM INF COMPUT, V7, P431
   Lydersen L, 2010, NAT PHOTONICS, V4, P686, DOI 10.1038/NPHOTON.2010.214
   Ma XF, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.012326
   Ma XF, 2012, PHYS REV A, V86, DOI 10.1103/PhysRevA.86.052305
   Namekata N, 2009, OPT EXPRESS, V17, P6275, DOI 10.1364/OE.17.006275
   Qi B, 2007, QUANTUM INF COMPUT, V7, P73
   Rubenok A, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.130501
   Shor PW, 2000, PHYS REV LETT, V85, P441, DOI 10.1103/PhysRevLett.85.441
   Sun SH, 2013, PHYS REV A, V87, DOI 10.1103/PhysRevA.87.052329
   Sun SH, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4746402
   Sun SH, 2012, PHYS REV A, V85, DOI 10.1103/PhysRevA.85.032304
   Sun SH, 2011, PHYS REV A, V83, DOI 10.1103/PhysRevA.83.062331
   Tang YL, 2013, PHYS REV A, V88, DOI 10.1103/PhysRevA.88.022308
   Wang S, 2012, OPT LETT, V37, P1008, DOI 10.1364/OL.37.001008
   Wang X. B., 2005, PHYS RVE LETT, V94
   Wang XB, 2013, PHYS REV A, V87, DOI 10.1103/PhysRevA.87.012320
   Xu FH, 2013, NEW J PHYS, V15, DOI 10.1088/1367-2630/15/11/113007
   Xu FH, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/11/113026
   Yuan ZL, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2931070
   Zhao Y, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2432296
NR 31
TC 3
Z9 3
U1 1
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 23
PY 2014
VL 4
AR 4759
DI 10.1038/srep04759
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AF6PH
UT WOS:000334836500006
PM 24755767
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, C
   Wang, C
   Meng, LX
   Xing, JW
   Wang, TY
   Yang, H
   Yao, YY
   Peng, HR
   Hu, ZR
   Sun, QX
   Ni, ZF
AF Li, Chuan
   Wang, Cheng
   Meng, Lingxue
   Xing, Jiewen
   Wang, Tianya
   Yang, Hua
   Yao, Yingyin
   Peng, Huiru
   Hu, Zhaorong
   Sun, Qixin
   Ni, Zhongfu
TI RETRACTED: Ectopic Expression of a Maize Hybrid Down-Regulated Gene
   ZmARF25 Decreases Organ Size by Affecting Cellular Proliferation in
   Arabidopsis (Retracted article. See vol. 11, e0155904, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ZEA-MAYS L; GENOME-WIDE IDENTIFICATION; AUXIN RESPONSE ELEMENTS;
   TRANSCRIPTION FACTOR; LEAF DEVELOPMENT; INBRED PARENTS; GROWTH-RATE;
   HETEROSIS; PLANT; THALIANA
AB Heterosis is associated with differential gene expression between hybrids and their parental lines, and the genes involved in cell proliferation played important roles. AtARF2 is a general cell proliferation repressor in Arabidopsis. In our previous study, two homologues (ZmARF10 and ZmARF25) of AtARF2 were identified in maize, but their relationship with heterosis was not elucidated. Here, the expression patterns of ZmARF10 and ZmARF25 in seedling leaves of maize hybrids and their parental lines were analyzed. The results of qRT-PCR exhibited that ZmARF25 was down-regulated in leaf basal region of hybrids. Moreover, overexpression of ZmARF25 led to reduced organ size in Arabidopsis, which was mainly due to the decrease in cell number, not cell size. In addition, the cell proliferation related genes AtANT, AtGIF1 and AtGRF5 were down-regulated in 35S:: ZmARF25 transgenic lines. Collectively, we proposed that the down-regulation of ZmARF25 in maize hybrid may accelerate cell proliferation and promote leaf development, which, in turn, contributes to the observed leaf size heterosis in maize.
C1 [Li, Chuan; Wang, Cheng; Meng, Lingxue; Xing, Jiewen; Wang, Tianya; Yang, Hua; Yao, Yingyin; Peng, Huiru; Hu, Zhaorong; Sun, Qixin; Ni, Zhongfu] China Agr Univ, Beijing Key Lab Crop Genet Improvement, State Key Lab Agrobiotechnol, Beijing 100094, Peoples R China.
   [Li, Chuan; Wang, Cheng; Meng, Lingxue; Xing, Jiewen; Wang, Tianya; Yang, Hua; Yao, Yingyin; Peng, Huiru; Hu, Zhaorong; Sun, Qixin; Ni, Zhongfu] China Agr Univ, Beijing Key Lab Crop Genet Improvement, Key Lab Crop Heterosis & Utilizat MOE, Beijing 100094, Peoples R China.
   [Li, Chuan; Wang, Cheng; Meng, Lingxue; Xing, Jiewen; Wang, Tianya; Yang, Hua; Yao, Yingyin; Peng, Huiru; Hu, Zhaorong; Sun, Qixin; Ni, Zhongfu] Natl Plant Gene Res Ctr Beijing, Beijing, Peoples R China.
RP Ni, ZF (reprint author), China Agr Univ, Beijing Key Lab Crop Genet Improvement, State Key Lab Agrobiotechnol, Beijing 100094, Peoples R China.
EM nizf@cau.edu.cn
FU ational Natural Science Foundation of China [31230054, 30925023];
   National Basic Research Program of China (973 Program) [2012CB910900];
   863 Project of China [2012AA10A305]
FX This work was financially supported by the National Natural Science
   Foundation of China (31230054 and
   30925023)(http://www.nsfc.gov.cn/Portal0/default152.htm), the National
   Basic Research Program of China (973 Program) (2012CB910900)
   (http://www.973.gov.cn/Default_3.aspx) and 863 Project of
   China(2012AA10A305)(http://www.863.gov.cn/#). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Birchler JA, 2003, PLANT CELL, V15, P2236, DOI 10.1105/tpc.151030
   Birchler JA, 2010, PLANT CELL, V22, P2105, DOI 10.1105/tpc.110.076133
   BUDAK H, 2002, KSU J SCI ENG, V5, P69
   Chen ZJ, 2010, TRENDS PLANT SCI, V15, P57, DOI 10.1016/j.tplants.2009.12.003
   Ha CV, 2013, DNA RES, V20, P511, DOI 10.1093/dnares/dst027
   Cho HT, 2000, P NATL ACAD SCI USA, V97, P9783, DOI 10.1073/pnas.160276997
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x
   Doebley J, 1998, PLANT CELL, V10, P1075
   East EM, 1936, GENETICS, V21, P375
   Esau Katherine, 1943, HILGARDIA, V15, P327
   Evert RF, 1996, INT J PLANT SCI, V157, P247, DOI 10.1086/297344
   Flint-Garcia SA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007433
   Guilfoyle TJ, 2007, CURR OPIN PLANT BIOL, V10, P453, DOI 10.1016/j.pbi.2007.08.014
   Guo BJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065867
   Guo M, 2014, J EXP BOT, V65, P249, DOI 10.1093/jxb/ert370
   Guo M, 2011, PLANT SCI, V181, P1, DOI 10.1016/j.plantsci.2011.03.010
   Guo M, 2010, PLANT CELL, V22, P1057, DOI 10.1105/tpc.109.073676
   Horiguchi G, 2005, PLANT J, V43, P68, DOI 10.1111/j.1365-313X.2005.02429.x
   Huang Y, 2006, PLANT MOL BIOL, V62, P579, DOI 10.1007/s11103-006-9040-z
   JOHNSON GR, 1973, CROP SCI, V13, P178, DOI 10.2135/cropsci1973.0011183X001300020009x
   KIESSELBACH TA, 1922, B AGR EXPT STATION N, P96
   Kim JH, 2004, P NATL ACAD SCI USA, V101, P13374, DOI 10.1073/pnas.0405450101
   Krizek BA, 1999, DEV GENET, V25, P224, DOI 10.1002/(SICI)1520-6408(1999)25:3<224::AID-DVG5>3.3.CO;2-P
   Krizek BA, 2009, CURR OPIN PLANT BIOL, V12, P17, DOI 10.1016/j.pbi.2008.09.006
   Li A, 2013, PLANT CELL PHYSIOL, V54, P1822, DOI 10.1093/pcp/pct124
   Li A, 2012, MOL BIOL REP, V39, P3773, DOI 10.1007/s11033-011-1154-y
   Li PH, 2010, NAT GENET, V42, P1060, DOI 10.1038/ng.703
   Lippman ZB, 2007, TRENDS GENET, V23, P60, DOI 10.1016/j.tig.2006.12.006
   Majeran W, 2010, PLANT CELL, V22, P3509, DOI 10.1105/tpc.110.079764
   Mizukami Y, 2000, P NATL ACAD SCI USA, V97, P942, DOI 10.1073/pnas.97.2.942
   Mizukami Y, 2001, CURR OPIN PLANT BIOL, V4, P533, DOI 10.1016/S1369-5266(00)00212-0
   Mun JH, 2012, MOL GENET GENOMICS, V287, P765, DOI 10.1007/s00438-012-0718-4
   Niklas K. J, 1994, PLANT ALLOMETRY SCAL
   Palmer SJ, 1996, J EXP BOT, V47, P339, DOI 10.1093/jxb/47.3.339
   Paschold A, 2012, GENOME RES, V22, P2445, DOI 10.1101/gr.138461.112
   Paschold A, 2010, THEOR APPL GENET, V120, P383, DOI 10.1007/s00122-009-1082-6
   PAVLIKOVA E, 1987, CAN J PLANT SCI, V67, P99, DOI 10.4141/cjps87-011
   ROMAGNOLI S, 1990, THEOR APPL GENET, V80, P769, DOI 10.1007/BF00224190
   SAGHAIMAROOF MA, 1984, P NATL ACAD SCI-BIOL, V81, P8014, DOI 10.1073/pnas.81.24.8014
   Sandeep KT, 2012, J PROGR AGR, V3, P152
   SCHNYDER H, 1990, PLANTA, V181, P423, DOI 10.1007/BF00195897
   Schruff MC, 2006, DEVELOPMENT, V133, P251, DOI 10.1242/dev.02194
   Sharman BC, 1942, ANN BOT-LONDON, V6, P245, DOI 10.1093/oxfordjournals.aob.a088407
   Shen CJ, 2010, J EXP BOT, V61, P3971, DOI 10.1093/jxb/erq208
   Springer NM, 2007, GENOME RES, V17, P264, DOI 10.1101/gr.5347007
   Sun QX, 2004, PLANT SCI, V166, P651, DOI 10.1016/j.plantsci.2003.10.033
   Swanson-Wagner RA, 2006, P NATL ACAD SCI USA, V103, P6805, DOI 10.1073/pnas.0510430103
   UCHIMIYA H, 1973, ANN BOT-LONDON, V37, P247, DOI 10.1093/oxfordjournals.aob.a084688
   Ulmasov T, 1999, PLANT J, V19, P309, DOI 10.1046/j.1365-313X.1999.00538.x
   Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865
   Ulmasov T, 1997, PLANT CELL, V9, P1963
   Wang YJ, 2012, MOL BIOL REP, V39, P2401, DOI 10.1007/s11033-011-0991-z
   Wei G, 2009, P NATL ACAD SCI USA, V106, P7695, DOI 10.1073/pnas.0902340106
   Wilmoth JC, 2005, PLANT J, V43, P118, DOI 10.1111/j.1365-313X.2005.02432.x
   Wu J, 2011, PLANT CELL REP, V30, P2059, DOI 10.1007/s00299-011-1113-z
   Xing HY, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-178
   Yao YY, 2009, J INTEGR PLANT BIOL, V51, P35, DOI 10.1111/j.1744-7909.2008.00792.x
   Zhang YH, 2006, PROG NAT SCI, V16, P712
NR 58
TC 7
Z9 7
U1 1
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2014
VL 9
IS 4
AR e94830
DI 10.1371/journal.pone.0094830
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG2IS
UT WOS:000335240300018
PM 24756087
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhu, YB
   Liu, DH
   Li, XF
   Liu, AJ
   Wang, Q
   Qiao, CH
   Zhang, J
   Liao, QM
   Zhang, YB
AF Zhu Yaobin
   Liu Donghai
   Li Xiaofeng
   Liu Aijun
   Wang Qiang
   Qiao Chenhui
   Zhang Jing
   Liao Qiuming
   Zhang Yanbo
TI RETRACTED: A novel, minimally invasive rat model of normothermic
   cardiopulmonary bypass model without blood priming (Retracted article.
   See vol. 127, pg. 2611, 2014)
SO CHINESE MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE rats; animal model; cardiopulmonary bypass model; lung injury
ID ACUTE LUNG INJURY; OLEIC-ACID; CARDIOPLEGIC ARREST; PIGLETS
AB Background Cardiopulmonary bypass (CPB) has been shown to be associated with systemic inflammatory response leading to postoperative organ dysfunction. Elucidating the underlying mechanisms and developing protective strategies for the pathophysiological consequences of CPB have been hampered due to the absence of a satisfactory recovery animal model. The purpose of this study was to establish a novel, minimally invasive rat model of normothermic CPB model without blood priming.
   Methods Twenty adult male Sprague-Dawley rats weighing 450-560 g were randomly divided into CPB group (n=10) and control group (n=10). All rats were anaesthetized and mechanically ventilated. The carotid artery and jugular vein were cannulated. The blood was drained from the right atrium via the right jugular and further transferred by a miniaturized roller pump to a hollow fiber oxygenator and back to the rat via the left carotid artery. The volume of the priming solution, composed of 6% HES130/0.4 and 125 IU heparin, was less than 12 ml. The surface of the hollow fiber oxygenator was 0.075 m(2). CPB was conducted for 60 minutes at a flow rat of 100-120 ml. kg(-1). min(-1) in CPB group. Oxygen flow/perfusion flow was 0.8 to 1.0, and the mean arterial pressure remained 60-80 mmHg.
   Results All CPB processes were successfully achieved. Blood gas analysis and hemodynamic parameters of each time point were in accordance with normal ranges. The vital signs of all rats were stable.
   Conclusions The establishment of CPB without blood priming in rats can be achieved successfully. The nontransthoracic model should facilitate the investigation of pathophysiological processes concerning CPB-related multiple organ dysfunction and possible protective interventions. This novel, recovery, and reproducible minimally invasive CPB model may open the field for various studies on the pathophysiological process of CPB and systemic ischemia-reperfusion injury in vivo.
C1 [Zhu Yaobin; Li Xiaofeng; Liu Aijun; Zhang Jing] Capital Med Univ, Beijing Anzhen Hosp, Dept Pediat Heart Ctr, Beijing 100029, Peoples R China.
   [Liu Donghai; Qiao Chenhui] Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.
   [Wang Qiang; Zhang Yanbo] Chinese Acad Med Sci, Dept Pediat Heart Ctr, State Key Lab Cardiovasc Dis, Fuwai Hosp,Natl Ctr Cardiovasc Dis, Beijing 100037, Peoples R China.
   [Wang Qiang; Zhang Yanbo] Peking Union Med Coll, Beijing 100037, Peoples R China.
   [Liao Qiuming] Lund Univ, Dept Cardiothorac Surg, S-22594 Lund, Sweden.
RP Qiao, CH (reprint author), Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.
EM qchenhui@hotmail.com; zhangjing@126.com; yanbozhang@126.com
FU Capital Medical University-Clinical Research Cooperation Fund [11JL50,
   13JL26]; National Natural Science Foundation of China [30670928,
   81070055]; Beijing Natural Science Foundation [7142137, 7122056];
   Beijing Health System High Level Health Technical Personnel Training
   Plan [2011-1-4]; Specialized Research Fund for the Doctoral Program of
   Higher Education (SRFDP) [20111107110006]
FX This study was supported by grants from the Capital Medical
   University-Clinical Research Cooperation Fund (No. 11JL50, No. 13JL26),
   the National Natural Science Foundation of China (No. 30670928, No.
   81070055), Beijing Natural Science Foundation (No. 7142137, No.
   7122056), Beijing Health System High Level Health Technical Personnel
   Training Plan (No. 2011-1-4), and Specialized Research Fund for the
   Doctoral Program of Higher Education (SRFDP, No. 20111107110006)
CR An Y, 2007, HEART SURG FORUM, V10, P47, DOI 10.1532/HSF98.20061146
   An Yong, 2007, Chin J Traumatol, V10, P218
   Ballaux PKEW, 1999, PERFUSION-UK, V14, P411, DOI 10.1177/026765919901400603
   de Lange F, 2008, J CARDIOTHORAC SURG, V3, DOI 10.1186/1749-8090-3-51
   Dong X, 2006, EUR J CARDIO-THORAC, V30, P77, DOI 10.1016/j.ejcts.2006.02.040
   Gourlay T, 2002, PERFUSION-UK, V17, P191, DOI 10.1191/0267659102pf567oa
   Gunzinger R, 2007, BASIC RES CARDIOL, V102, P508, DOI 10.1007/s00395-007-0668-x
   Liu AJ, 2013, CHINESE MED J-PEKING, V126, P2530, DOI 10.3760/cma.j.issn.0366-6999.20130223
   Liu AJ, 2011, CHINESE MED J-PEKING, V124, P3098, DOI 10.3760/cma.j.issn.0366-6999.2011.19.027
   Mackensen GB, 2001, ANESTHESIOLOGY, V95, P1485, DOI 10.1097/00000542-200112000-00031
   Modine T, 2006, PERFUSION-UK, V21, P87, DOI 10.1191/0267659106pf854oa
   Moehrlen Ueli, 2003, Interact Cardiovasc Thorac Surg, V2, P603, DOI 10.1016/S1569-9293(03)00174-9
   Shang Hong-wei, 2005, Chin J Traumatol, V8, P289
   Wu RP, 2012, CHINESE MED J-PEKING, V125, P3093, DOI 10.3760/cma.j.issn.0366-6999.2012.17.023
   Xu YL, 2012, CHINESE MED J-PEKING, V125, P2012, DOI 10.3760/cma.j.issn.0366-6999.2012.11.031
   Yang H, 2004, J CARDIOTHOR VASC AN, V18, P620, DOI 10.1053/j.jvca.2004.07.001
   You Xiao-Mang, 2005, J Extra Corpor Technol, V37, P60
   Zhu X, 2014, PERFUSION-UK, V29, P63, DOI 10.1177/0267659113495914
   Zhu YB, 2013, CHINESE MED J-PEKING, V126, P747, DOI 10.3760/cma.j.issn.0366-6999.20122435
   Zhu YB, 2011, CHINESE MED J-PEKING, V124, P4149, DOI 10.3760/cma.j.issn.0366-6999.2011.24.006
NR 20
TC 0
Z9 0
U1 3
U2 14
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD APR 20
PY 2014
VL 127
IS 8
BP 1541
EP 1544
DI 10.3760/cma.j.issn.0366-6999.20132144
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH2FK
UT WOS:000335936700028
PM 24762603
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Dudalov, DE
   Fomin, YD
   Tsiok, EN
   Ryzhov, VN
AF Dudalov, D. E.
   Fomin, Yu. D.
   Tsiok, E. N.
   Ryzhov, V. N.
TI RETRACTED: Anomalous Melting Scenario of the Two-Dimensional
   Core-Softened System (Retracted article. See vol. 113, 239901, 2014)
SO PHYSICAL REVIEW LETTERS
LA English
DT Article; Retracted Publication
ID HARD-DISK SYSTEM; 2 DIMENSIONS; ORIENTATIONAL ORDER; TRANSITION;
   1ST-ORDER; CRYSTALS
AB We present a computer simulation study of the phase behavior of two-dimensional (2D) classical particles repelling each other through an isotropic core-softened potential. As in the analogous three-dimensional (3D) case, a reentrant-melting transition occurs upon compression for not too high pressures, along with a spectrum of waterlike anomalies in the fluid phase. However, in two dimensions in the low density part of the phase diagram melting is a continuous two-stage transition, with an intermediate hexatic phase. All available evidence supports the Kosterlitz-Thouless-Halperin-Nelson-Young scenario for this melting transition. On the other hand, at the high density part of the phase diagram one first-order transition takes place.
C1 [Dudalov, D. E.; Fomin, Yu. D.; Tsiok, E. N.; Ryzhov, V. N.] RAS, Inst High Pressure Phys, Moscow 142190, Russia.
   [Fomin, Yu. D.; Ryzhov, V. N.] Moscow Inst Phys & Technol, Moscow 141700, Russia.
RP Dudalov, DE (reprint author), RAS, Inst High Pressure Phys, Kaluzhskoe Shosse 14, Moscow 142190, Russia.
OI Ryzhov, Valentin/0000-0002-1331-3984
FU Russian Foundation for Basic Research [14-02-00451, 13-02-12008,
   13-02-00579, 13-02-00913]; Ministry of Education and Science of Russian
   Federation [MK-2099.2013.2]
FX We are greateful to S. M. Stishov, V. V. Brazhkin, and E. E. Tareyeva
   for stimulating discussions. Yu. D. F. and E. N. T. also thank the
   Russian Scientific Center Kurchatov Institute and Joint Supercomputing
   Center of the Russian Academy of Science for computational facilities.
   The work was supported in part by the Russian Foundation for Basic
   Research (Grants No. 14-02-00451, No. 13-02-12008, No. 13-02-00579, and
   No. 13-02-00913) and the Ministry of Education and Science of Russian
   Federation (Project No. MK-2099.2013.2).
CR Alcoutlabi M, 2005, J PHYS-CONDENS MAT, V17, pR461, DOI 10.1088/0953-8984/17/15/R01
   Almudallal AM, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4735093
   Bagchi K, 1996, PHYS REV LETT, V76, P255, DOI 10.1103/PhysRevLett.76.255
   Bernard EP, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.155704
   Binder K, 2002, J PHYS-CONDENS MAT, V14, P2323, DOI 10.1088/0953-8984/14/9/321
   BLADON P, 1995, PHYS REV LETT, V74, P2519, DOI 10.1103/PhysRevLett.74.2519
   Buldyrev SV, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/50/504106
   CHUI ST, 1983, PHYS REV B, V28, P178, DOI 10.1103/PhysRevB.28.178
   Daan F., 2002, UNDERSTANDING MOL SI
   Fomin YD, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.042122
   Fomin YD, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3668313
   Fomin YD, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3530790
   Fomin YD, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2965880
   Gasser U, 2010, CHEMPHYSCHEM, V11, P963, DOI 10.1002/cphc.200900755
   Gribova NV, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.051202
   GRIMES CC, 1979, PHYS REV LETT, V42, P795, DOI 10.1103/PhysRevLett.42.795
   HALPERIN BI, 1978, PHYS REV LETT, V41, P121, DOI 10.1103/PhysRevLett.41.121
   JANKE W, 1990, PHYS REV B, V41, P6848, DOI 10.1103/PhysRevB.41.6848
   Jaster A, 1998, EUROPHYS LETT, V42, P277, DOI 10.1209/epl/i1998-00242-8
   Keim P, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.031402
   Kosterlitz M., 1973, J PHYS C SOLID STATE, V6, P1181
   Krott LB, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.012110
   Krott LB, 2013, J CHEM PHYS, V138, DOI 10.1063/1.4792639
   LEE JY, 1992, PHYS REV B, V46, P11190, DOI 10.1103/PhysRevB.46.11190
   Lee SI, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.041504
   Mak CH, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.065104
   NELSON DR, 1979, PHYS REV B, V19, P2457, DOI 10.1103/PhysRevB.19.2457
   Pomirchi LM, 2002, THEOR MATH PHYS+, V130, P101, DOI 10.1023/A:1013884616321
   Prestipino S, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4749260
   Prestipino S, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.235701
   Rice SA, 2009, CHEM PHYS LETT, V479, P1, DOI 10.1016/j.cplett.2009.07.059
   Ryltsev RE, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.025701
   Ryzhov V. N., 1991, Soviet Physics - JETP, V73, P899
   Ryzhov V. N., 1995, Journal of Experimental and Theoretical Physics, V81, P1115
   RYZHOV VN, 1995, PHYS REV B, V51, P8789, DOI 10.1103/PhysRevB.51.8789
   Ryzhov VN, 2002, PHYSICA A, V314, P396, DOI 10.1016/S0378-4371(02)01062-2
   RYZHOV VN, 1991, THEOR MATH PHYS+, V88, P990, DOI 10.1007/BF01027701
   STRANDBURG KJ, 1988, REV MOD PHYS, V60, P161, DOI 10.1103/RevModPhys.60.161
   Vilaseca P, 2011, J NON-CRYST SOLIDS, V357, P419, DOI 10.1016/j.jnoncrysol.2010.07.053
   WEBER H, 1995, PHYS REV B, V51, P14636, DOI 10.1103/PhysRevB.51.14636
   YOUNG AP, 1979, PHYS REV B, V19, P1855, DOI 10.1103/PhysRevB.19.1855
   Zahn K, 2000, PHYS REV LETT, V85, P3656, DOI 10.1103/PhysRevLett.85.3656
NR 42
TC 7
Z9 7
U1 3
U2 19
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 0031-9007
EI 1079-7114
J9 PHYS REV LETT
JI Phys. Rev. Lett.
PD APR 18
PY 2014
VL 112
IS 15
AR 157803
DI 10.1103/PhysRevLett.112.157803
PG 5
WC Physics, Multidisciplinary
SC Physics
GA AG2ED
UT WOS:000335228000011
PM 24785074
DA 2018-12-27
ER

PT J
AU Lu, ZX
   Mao, LL
   Lian, F
   He, J
   Zhang, WT
   Dai, CY
   Xue, S
   Lu, WG
   Zhu, HS
AF Lu, Zhe-xin
   Mao, Li-li
   Lian, Feng
   He, Jun
   Zhang, Wen-tian
   Dai, Chen-yang
   Xue, Song
   Lu, Wei-gen
   Zhu, Hong-sheng
TI RETRACTED: Cardioprotective activity of placental growth factor in a rat
   model of acute myocardial infarction: nanoparticle-based delivery versus
   direct myocardial injection (Retracted article. See vol. 15, 27, 2015)
SO BMC CARDIOVASCULAR DISORDERS
LA English
DT Article; Retracted Publication
DE Placental growth factor; Acute myocardial infarction; Cardiac function;
   Nanoparticles-mediated drug delivery; Vicious ventricular remodeling
ID DRUG-DELIVERY; PLGA NANOPARTICLES; MATRIX METALLOPROTEINASES; TISSUE
   INHIBITOR; STROMAL CELLS; EXPRESSION; EFFICACY; THERAPY
AB Background: To comparatively evaluate the cardioprotective activity of placental growth factor (PGF) delivered through direct injection and a nanoparticle-based system respectively and to study the underlying mechanisms in a rat model of acute myocardial infarction (AMI).
   Methods: Poly lactic-co-glycolic acid (PLGA)-based PGF-carrying nanoparticles (PGF-PLGA(NPs)) were created. The mean size and morphology of particles were analyzed with particle size analyzer and transmission electronic microscopy (TEM). Encapsulation efficiency and sustained-release dose curve were analyzed by ELISA. Sprague-Dawley rats were randomized into four groups (n = 10). While animals in the first group were left untreated as controls, those in the other 3 groups underwent surgical induction of AMI, followed by treatment with physiological saline, PGF, and PGF-PLGA(NPs), respectively. Cardiac function was evaluated by transthoracic echocardiography at 4 weeks after treatment. At 6 weeks, rats were sacrificed, infarction size was analyzed with Masson trichrome staining, and protein contents of TIMP-2, MT1-MMP and MMP-2 at the infarction border were determined by immunohistochemistry and western blotting analysis.
   Results: PGF was released for at least 15 days, showing successful preparation of PGF-PLGA(NPs). Coronary artery ligation successfully induced AMI. Compared to physiological saline control, PGF, injected to the myocardium either as a nude molecule or in a form of nanoparticles, significantly reduced infarction size, improved cardiac function, and elevated myocardial expression of TIMP-2, MT1-MMP, and MMP-2 (P < 0.05). The effect of PGF-PLGA(NPs) was more pronounced than that of non-encapsulated PGF (P < 0.05).
   Conclusion: Target PGF delivery to myocardium may improve cardiac function after AMI in rats. PLGA-based nanoparticles appear to be a better approach to delivery PGF. PGF exerts its cardioprotective effect at least partially through regulating metalloproteinase-mediated myocardial tissue remodeling.
C1 [Lu, Zhe-xin; Lian, Feng; Zhang, Wen-tian; Dai, Chen-yang; Xue, Song; Zhu, Hong-sheng] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Cardiovasc Surg, Shanghai 200127, Peoples R China.
   [Mao, Li-li; He, Jun; Lu, Wei-gen] China State Inst Pharmaceut Ind, Natl Pharmaceut Engn Res Ctr, Shanghai 200437, Peoples R China.
RP Lian, F (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Cardiovasc Surg, 160 Pu Jian Rd, Shanghai 200127, Peoples R China.
EM dr.lianfeng@hotmail.com; chinaynhe@163.com
FU Shanghai Education Commission [11YZ48, 13ZZ091]; Shanghai municipal
   Scientific & Technological Commission [12 nm0502100]; Shanghai Municipal
   Bureau of Health P.R. China [20114243]
FX Shanghai Education Commission (11YZ48), Shanghai Education Commission
   (13ZZ091), Shanghai municipal Scientific & Technological Commission (12
   nm0502100), Shanghai Municipal Bureau of Health P.R. China (No.
   20114243)
CR Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
   Binsalamah ZM, 2011, INT J NANOMED, V6, P2667, DOI 10.2147/IJN.S25175
   Bujak M, 2007, CARDIOVASC RES, V74, P184, DOI 10.1016/j.cardiores.2006.10.002
   Carnevale D, 2012, TRENDS CARDIOVAS MED, V22, P209, DOI 10.1016/j.tcm.2012.07.022
   Chen GY, 2010, ANN THORAC SURG, V90, P190, DOI 10.1016/j.athoracsur.2010.02.074
   Chi NH, 2013, CARBOHYD POLYM, V92, P591, DOI 10.1016/j.carbpol.2012.09.012
   Cianfarani F, 2006, AM J PATHOL, V169, P1167, DOI 10.2353/ajpath.2006.051314
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Dayan V, 2011, BASIC RES CARDIOL, V106, P1299, DOI 10.1007/s00395-011-0221-9
   DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233
   Gmeiner M, 2011, J THORAC CARDIOV SUR, V141, P1238, DOI 10.1016/j.jtcvs.2010.10.054
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/740
   Iwasaki H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024872
   Kandalam V, 2011, CIRCULATION, V124, P2094, DOI 10.1161/CIRCULATIONAHA.111.030338
   Kandalam V, 2010, CIRC RES, V106, P796, DOI 10.1161/CIRCRESAHA.109.209189
   Karra N, 2013, SMALL, V9, P4221, DOI 10.1002/smll.201301417
   Kim DH, 2006, BIOMATERIALS, V27, P3031, DOI 10.1016/j.biomaterials.2005.12.021
   Kudo T, 2007, CANCER SCI, V98, P563, DOI 10.1111/j.1349-7006.2007.00426.x
   Li PL, 2013, MAR DRUGS, V11, P1113, DOI 10.3390/md11041113
   Li TS, 2012, J AM COLL CARDIOL, V59, P942, DOI 10.1016/j.jacc.2011.11.029
   Nishida Y, 2008, CANCER RES, V68, P9096, DOI 10.1158/0008-5472.CAN-08-2522
   Pereira MJN, 2011, J CARDIOVASC TRANSL, V4, P616, DOI 10.1007/s12265-011-9299-6
   Pandey R, 2005, INT J PHARM, V301, P268, DOI 10.1016/j.ijpharm.2005.05.027
   Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004
   Schutz CA, 2013, NANOMEDICINE-UK, V8, P449, DOI [10.2217/nnm.13.8, 10.2217/NNM.13.8]
   Shriver LP, 2009, J NEUROIMMUNOL, V211, P66, DOI 10.1016/j.jneuroim.2009.03.015
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4
   Spinale FG, 2007, PHYSIOL REV, V87, P1285, DOI 10.1152/physrev.00012.2007
   Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981
   Takeda Y, 2009, CIRC J, V73, P1674, DOI 10.1253/circj.CJ-08-1067
   Viita H, 2008, CIRC RES, V102, P177, DOI 10.1161/CIRCRESAHA.107.155556
NR 31
TC 7
Z9 8
U1 4
U2 23
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2261
J9 BMC CARDIOVASC DISOR
JI BMC Cardiovasc. Disord.
PD APR 17
PY 2014
VL 14
AR 53
DI 10.1186/1471-2261-14-53
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AG6JK
UT WOS:000335524700001
PM 24742302
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ma, JH
   Li, X
   Yi, B
   Yao, H
   Zhao, H
   Zhang, YS
   Zhang, XC
   Liu, N
   Tian, ZQ
   Dai, YW
AF Ma, Jianhua
   Li, Xin
   Yi, Bo
   Yao, Hui
   Zhao, Hao
   Zhang, Yesen
   Zhang, Xiaochong
   Liu, Ning
   Tian, Zhongqiu
   Dai, Yiwu
TI RETRACTED: Transplanted iNSCs migrate through SDF-1/CXCR4 signaling to
   promote neural recovery in a rat model of spinal cord injury (Retracted
   article. See vol. 25, pg. 806, 2014)
SO NEUROREPORT
LA English
DT Article; Retracted Publication
DE spinal cord injury; CXCR4; stromal cell-derived factor-1; induced neural
   stem cells
ID STEM-CELL TRANSPLANTATION; BONE-MARROW; PROGENITOR CELLS; FUNCTIONAL
   RECOVERY; HEMATOPOIETIC STEM; FACTOR-I; CXCR4; ACTIVATION; EXPRESSION;
   CONTUSION
AB The ability of transplanted induced neural stem cells (iNSCs) to promote functional recovery after spinal cord injury and the mechanism by which iNSCs migrate to injured areas are poorly understood. Stromal cell-derived factor-1 (SDF-1) is a cytokine, whereas CXCR4 is its cognate receptor. The aim of this study was to determine whether SDF-1 regulates the migration of iNSCs and to explore the potential mechanism by which iNSCs promotes functional recovery. In-vitro experiments demonstrated that SDF-1 induces a concentration-dependent migration of iNSCs. Pretreatment with the CXCR4-specific antagonist AMD3100 significantly prevented the migration of iNSCs. We found that the expression of SDF-1 increased significantly in spinal cord lesions and was mainly associated with neurons and astrocytes. We also demonstrated that transplanted green fluorescent protein-labeled iNSCs were localized to regions where SDF-1 was highly expressed. In addition, iNSC-treated animals showed significantly improved functional recovery as assessed by BBB at 7 days after injection compared with controls. iNSCs also increased cell proliferation, enhanced vascularity, and reduced apoptosis. These results suggest that upregulated SDF-1 plays an important role in the migration of iNSCs to the injured region and that iNSCs are beneficial for functional recovery after spinal cord injury.
C1 [Ma, Jianhua; Li, Xin; Yi, Bo; Zhang, Yesen; Dai, Yiwu] Anhui Med Univ, Gen Hosp Beijing Mil Reg, Clin Coll, Hefei, Peoples R China.
   [Ma, Jianhua; Yi, Bo; Yao, Hui; Zhao, Hao; Zhang, Yesen; Liu, Ning; Tian, Zhongqiu; Dai, Yiwu] Gen Hosp Beijing Mil Reg, Affiliated Bayi Brain Hosp, Beijing 100700, Peoples R China.
   [Ma, Jianhua; Yi, Bo; Yao, Hui; Zhao, Hao; Zhang, Yesen; Liu, Ning; Tian, Zhongqiu; Dai, Yiwu] Neurosurg Inst Beijing Mil Reg, Beijing, Peoples R China.
   [Zhang, Xiaochong] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China.
RP Dai, YW (reprint author), Gen Hosp Beijing Mil Reg, Affiliated Bayi Brain Hosp, 5 Nan Men Cang, Beijing 100700, Peoples R China.
EM malixin1206@126.com
FU National Natural Science Foundation of China [81271391, 81100917]
FX This work was supported by the National Natural Science Foundation of
   China (81271391, 81100917).
CR Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x
   BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1
   Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385
   Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374
   Deda H, 2008, CYTOTHERAPY, V10, P565, DOI 10.1080/14653240802241797
   Gleichmann M, 2000, EUR J NEUROSCI, V12, P1857, DOI 10.1046/j.1460-9568.2000.00048.x
   Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3
   Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84
   Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102
   Kim J, 2011, P NATL ACAD SCI USA, V108, P7838, DOI 10.1073/pnas.1103113108
   Kucia M, 2004, J MOL HISTOL, V35, P233
   Lee KH, 2007, ACTA NEUROBIOL EXP, V67, P13
   Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448
   NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305
   Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341
   Ohtani Y, 1998, NEUROSCI LETT, V249, P163, DOI 10.1016/S0304-3940(98)00425-X
   Sharp J, 2010, STEM CELLS, V28, P152, DOI 10.1002/stem.245
   Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002
   Tabatabai G, 2005, BRAIN, V128, P2200, DOI 10.1093/brain/awh563
   Takeuchi H, 2007, NEUROSCI LETT, V426, P69, DOI 10.1016/j.neulet.2007.08.048
   Tong YH, 2011, PHYTOMEDICINE, V18, P443, DOI 10.1016/j.phymed.2010.10.009
   Tysseling VM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-16
   Valentin G, 2007, CURR BIOL, V17, P1026, DOI 10.1016/j.cub.2007.05.020
   Yamaoka G, 2012, NEUROREPORT, V23, P546, DOI 10.1097/WNR.0b013e328354256c
   Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336
   Zendedel A, 2012, BRAIN RES, V1473, P214, DOI 10.1016/j.brainres.2012.07.037
   Zhang YS, 2013, BIOTECHNOL LETT, V35, P1997, DOI 10.1007/s10529-013-1304-5
NR 27
TC 4
Z9 5
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4965
EI 1473-558X
J9 NEUROREPORT
JI Neuroreport
PD APR 16
PY 2014
VL 25
IS 6
BP 391
EP 397
DI 10.1097/WNR.0000000000000109
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA AE1EM
UT WOS:000333710300007
PM 24374507
DA 2018-12-27
ER

PT J
AU Dey, P
   Chakraborty, M
   Kamdar, MR
   Maiti, MK
AF Dey, Prabuddha
   Chakraborty, Monami
   Kamdar, Maulik R.
   Maiti, Mrinal K.
TI RETRACTED: Functional Characterization of Two Structurally Novel
   Diacylglycerol Acyltransferase2 Isozymes Responsible for the Enhanced
   Production of Stearate-Rich Storage Lipid in Candida tropicalis
   SY005(Retracted article. See vol.12,ARTN E0187146, 2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ACYL-COA; TRIACYLGLYCEROL BIOSYNTHESIS; OLEAGINOUS MICROORGANISMS; OIL
   CONTENT; ACCUMULATION; EXPRESSION; DGAT2; GENE; ARABIDOPSIS;
   IDENTIFICATION
AB Diacylglycerol acyltransferase (DGAT) activity is an essential enzymatic step in the formation of neutral lipid i.e., triacylglycerol in all living cells capable of accumulating storage lipid. Previously, we characterized an oleaginous yeast Candida tropicalis SY005 that yields storage lipid up to 58% under a specific nitrogen-stress condition, when the DGAT-specific transcript is drastically up-regulated. Here we report the identification, differential expression and function of two DGAT2 gene homologues-CtDGAT2a and CtDGAT2b of this C. tropicalis. Two protein isoforms are unique with respect to the presence of five additional stretches of amino acids, besides possessing three highly conserved motifs known in other reported DGAT2 enzymes. Moreover, the CtDGAT2a and CtDGAT2b are characteristically different in amino acid sequences and predicted protein structures. The CtDGAT2b isozyme was found to be catalytically 12.5% more efficient than CtDGAT2a for triacylglycerol production in a heterologous yeast system i.e., Saccharomyces cerevisiae quadruple mutant strain H1246 that is inherently defective in neutral lipid biosynthesis. The CtDGAT2b activity rescued the growth of transformed S. cerevisiae mutant cells, which are usually non-viable in the medium containing free fatty acids by incorporating them into triacylglycerol, and displayed preferential specificity towards saturated acyl species as substrate. Furthermore, we document that the efficiency of triacylglycerol production by CtDGAT2b is differentially affected by deletion, insertion or replacement of amino acids in five regions exclusively present in two CtDGAT2 isozymes. Taken together, our study characterizes two structurally novel DGAT2 isozymes, which are accountable for the enhanced production of storage lipid enriched with saturated fatty acids inherently in C. tropicalis SY005 strain as well as in transformed S. cerevisiae neutral lipid-deficient mutant cells. These two genes certainly will be useful for further investigation on the novel structure-function relationship of DGAT repertoire, and also in metabolic engineering for the enhanced production of lipid feedstock in other organisms.
C1 [Dey, Prabuddha; Chakraborty, Monami; Maiti, Mrinal K.] Indian Inst Technol, Adv Technol Dev Ctr, Adv Lab Plant Genet Engn, Kharagpur 721302, W Bengal, India.
   [Kamdar, Maulik R.; Maiti, Mrinal K.] Indian Inst Technol, Dept Biotechnol, Kharagpur 721302, W Bengal, India.
RP Maiti, MK (reprint author), Indian Inst Technol, Adv Technol Dev Ctr, Adv Lab Plant Genet Engn, Kharagpur 721302, W Bengal, India.
EM maitimk@hijli.iitkgp.ernet.in
OI Maiti, Mrinal/0000-0001-7803-4356
FU ISIRD-SRIC (IIT-Kharagpur)
FX Grant support from ISIRD-SRIC (IIT-Kharagpur) is acknowledged. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andrianov V, 2010, PLANT BIOTECHNOL J, V8, P277, DOI 10.1111/j.1467-7652.2009.00458.x
   Beopoulos A, 2011, APPL MICROBIOL BIOT, V90, P1193, DOI 10.1007/s00253-011-3212-8
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bouvier-Nave P, 2000, BIOCHEM SOC T, V28, P692, DOI 10.1042/0300-5127:0280692
   Boyle NR, 2012, J BIOL CHEM, V287, P15811, DOI 10.1074/jbc.M111.334052
   Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297
   Dey P, 2013, J APPL MICROBIOL, V114, P1357, DOI 10.1111/jam.12133
   Gatenby CM, 2003, J APPL PHYCOL, V15, P1, DOI 10.1023/A:1022929423011
   Guiheneuf F, 2011, FEBS J, V278, P3651, DOI 10.1111/j.1742-4658.2011.08284.x
   Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X
   Jako C, 2001, PLANT PHYSIOL, V126, P861, DOI 10.1104/pp.126.2.861
   Kalscheuer R, 2003, J BIOL CHEM, V278, P8075, DOI 10.1047/jbc.M210533200
   Kimura K, 2004, J MICROBIOL METH, V56, P331, DOI 10.1016/j.mimet.2003.10.018
   Kroon JTM, 2006, PHYTOCHEMISTRY, V67, P2541, DOI 10.1016/j.phytochem.2006.09.020
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200
   Li RZ, 2010, PLANT BIOTECHNOL J, V8, P184, DOI [10.1111/j.1467-7652.2009.00476.x, 10.1111/j.1467-4652.2009.0047b.x]
   Liu BS, 2013, CURR OPIN BIOTECH, V24, P300, DOI 10.1016/j.copbio.2012.08.008
   Liu J, 2010, BIORESOURCE TECHNOL, V101, P8658, DOI 10.1016/j.biortech.2010.05.082
   Liu Q, 2012, PROG LIPID RES, V51, P350, DOI 10.1016/j.plipres.2012.06.001
   Liu Q, 2011, J BIOL CHEM, V286, P13115, DOI 10.1074/jbc.M110.204412
   McFie PJ, 2011, J LIPID RES, V52, P1760, DOI 10.1194/jlr.D016626
   Meng X, 2009, RENEW ENERG, V34, P1, DOI 10.1016/j.renene.2008.04.014
   Mishra S, 2009, BIOINFORMATION, V3, P394, DOI 10.6026/97320630003394
   Peng FY, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-286
   Peng ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061363
   Rani SH, 2013, MICROBIOL-SGM, V159, P155, DOI 10.1099/mic.0.063156-0
   Ratledge C, 2002, BIOCHEM SOC T, V30, P1047, DOI 10.1042/bst0301047
   RATLEDGE C, 1991, ACTA BIOTECHNOL, V11, P429, DOI 10.1002/abio.370110506
   Saha S, 2006, PLANT PHYSIOL, V141, P1533, DOI 10.1104/pp.106.082198
   Shockey JM, 2006, PLANT CELL, V18, P2294, DOI 10.1105/tpc.106.043695
   Siloto RMP, 2009, LIPIDS, V44, P963, DOI 10.1007/s11745-009-3336-0
   Snyder CL, 2009, NEW BIOTECHNOL, V26, P11, DOI 10.1016/j.nbt.2009.05.005
   Stone SJ, 2006, J BIOL CHEM, V281, P40273, DOI 10.1074/jbc.M607986200
   Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200
   Turkish AR, 2005, J BIOL CHEM, V280, P14755, DOI 10.1074/jbc.M500025200
   Wagner M, 2010, PLANT PHYSIOL BIOCH, V48, P407, DOI 10.1016/j.plaphy.2010.03.008
   Wakimoto K, 2003, BIOCHEM BIOPH RES CO, V310, P296, DOI 10.1016/j.bbrc.2003.09.015
   Xu JY, 2008, PLANT BIOTECHNOL J, V6, P799, DOI 10.1111/j.1467-7652.2008.00358.x
   Yu ET, 2009, J APPL PHYCOL, V21, P669, DOI 10.1007/s10811-008-9400-y
   Zhang HX, 2012, YEAST, V29, P25, DOI 10.1002/yea.1914
   Zhang Q, 2003, J BIOL CHEM, V278, P47145, DOI 10.1074/jbc.M306998200
   Zou J, 2009, WIPO Patent Application, Patent No. [WO/ 2009 / 085169, 2009085169]
   Zou JT, 1999, PLANT J, V19, P645, DOI 10.1046/j.1365-313x.1999.00555.x
NR 44
TC 12
Z9 12
U1 3
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2014
VL 9
IS 4
AR e94472
DI 10.1371/journal.pone.0094472
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI6GP
UT WOS:000336970400041
PM 24732323
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Xu, JM
   Zhang, CQ
AF Xu, Jiaming
   Zhang, Changqing
TI RETRACTED: Mini-plate versus Kirschner wire internal fixation for
   treatment of metacarpal and phalangeal fractures in Chinese Han
   population: a meta-analysis (Retracted article. See vol. 10, 43, 2015)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE Mini-plate internal fixation; Kirschner wire; Chinese Han population;
   Metacarpal/phalangeal fracture; Meta-analysis
ID COMPLICATIONS
AB Objectives: This meta-analysis aimed to compare the therapeutic effect of mini-plate versus Kirschner wire (K-wire) internal fixation on the treatment of metacarpal and phalangeal fractures among Chinese Han population.
   Methods: Databases of China National Knowledge Infrastructure (CNKI), Wanfang, Chinese VIP, PubMed, and Embase were retrieved for studies on mini- plate (case group) versus K-wire (control group) internal fixation for the treatment of metacarpal and phalangeal fractures among Chinese Han population. The odds ratio (OR) and standardized mean difference (SMD) at 95% confidence interval (CI) were used for estimating the effects of dichotomous data and continuous data, respectively. All statistical analyses were performed by Review Manager 5.2 software.
   Results: A total of 18 studies involving 1,375 metacarpal or phalangeal fracture patients (709 cases and 666 controls) were included in the meta-analysis. There were significant differences in fracture healing time (SMD = - 1.28; 95% CI: - 1.81, - 0.76), postoperative infection rate (OR = 0.25; 95% CI: 0.16, 0.39), complication incidence (OR = 0.24; 95% CI: 0.15, 0.38), and surgery time (SMD = 1.57; 95% CI: 0.76, 2.37) between the case and the control group, while no significant difference was found in hospital stays between these two groups (SMD = 0.43; 95% CI: - 0.34, 1.20; P = 0.27).
   Conclusions: For the treatment of metacarpal or phalangeal fracture among Chinese Han population, mini- plate has advantages of shorter healing time and lower infection rate and complication incidence compared with K-wire internal fixation, while a longer surgery time than K-wire. In conclusion, mini- plate is prior than K-wire internal fixation for the treatment of metacarpal or phalangeal fracture among Chinese Han population.
C1 [Xu, Jiaming; Zhang, Changqing] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Orthoped, Shanghai 200233, Peoples R China.
RP Zhang, CQ (reprint author), Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Orthoped, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM zhangchangqii@hotmail.com
CR Bernstein ML, 2006, INJURY, V37, P1043, DOI 10.1016/j.injury.2006.07.020
   BLACK D, 1985, J HAND SURG-AM, V10A, P466, DOI 10.1016/S0363-5023(85)80067-8
   Chu ZF, 2008, CHINA PRAC MED, V3, P67
   Duan YZ, 2006, J XINXIANG MED COLL, V23, P177
   Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533
   Haughton Dn, 2012, Open Orthop J, V6, P43, DOI 10.2174/1874325001206010043
   Hsu LP, 2011, J HAND SURG-AM, V36A, P610, DOI 10.1016/j.jhsa.2011.01.023
   Huang CY, 2007, J YOUJIANG ETHNIC ME, V1, P345
   IJSSELSTEIN CB, 1992, J HAND SURG-AM, V17A, P952, DOI 10.1016/0363-5023(92)90476-6
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jin DF, 2012, J XINXIANG MED COLL, V29, P548
   Kamath JB, 2011, INDIAN J PLAST SURG, V44, P203, DOI 10.4103/0970-0358.85341
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li HF, 2012, CHINESE J AESTHET ME, V21, P122
   Li JT, 2013, CHINESE J NINGXIA ME, V35, P709
   Lin CX, 2008, CHIN J INTEGR MED, V14, P224
   Liu ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059421
   Lu LM, 2013, CHINESE J MED FRONT, V3, P34
   Ma HZ, 2012, CHINESE J JILIN MED, V33, P6292
   Mumtaz MU, 2010, ULUS TRAVMA ACIL CER, V16, P334
   Prabhu J, 2006, J ORTHOD, V33, P288, DOI 10.1179/146531205225021807
   Qiu JZ, 2009, SICHUAN MED J, V30, P895
   Tang SY, 2004, CHINA J ORTHOP TRAUM, V17, P68
   Walde TA, 2008, ARCH ORTHOP TRAUM SU, V128, P585, DOI 10.1007/s00402-008-0590-1
   Wallny T, 1997, INT ORTHOP, V21, P374
   Wang JL, 2011, CHINESE J SW NATL DE, V21, P379
   Wang MZ, 2011, CHINESE J CONT MED, V17, P149
   Waris E, 2003, CLIN ORTHOP RELAT R, P310, DOI 10.1097/01.blo.0000063789.32430.c6
   Wu H, 2012, CHINESE J JILIN MED, V33, P4113
   Xu HD, 2012, CHINESE J MED POSTGR, V25, P1045
   Yang JG, 2013, CHINESE J MED FRONT, V9, P150
   Yang JJ, 2011, CHINESE J HAINAN MED, V17, P101
   Zhou B, 2010, CHINA MED HERALD, V7, P47
NR 33
TC 4
Z9 6
U1 2
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD APR 11
PY 2014
VL 9
AR 24
DI 10.1186/1749-799X-9-24
PG 7
WC Orthopedics
SC Orthopedics
GA AF9TO
UT WOS:000335057700001
PM 24721182
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kitambi, SS
   Toledo, EM
   Usoskin, D
   Wee, SM
   Harisankar, A
   Svensson, R
   Sigmundsson, K
   Kalderen, C
   Niklasson, M
   Kundu, S
   Aranda, S
   Westermark, B
   Uhrbom, L
   Andang, M
   Damberg, P
   Nelander, S
   Arenas, E
   Artursson, P
   Walfridsson, J
   Nilsson, KF
   Hammarstrom, LGJ
   Ernfors, P
AF Kitambi, Satish Srinivas
   Toledo, Enrique M.
   Usoskin, Dmitry
   Wee, Shimei
   Harisankar, Aditya
   Svensson, Richard
   Sigmundsson, Kristmundur
   Kalderen, Christina
   Niklasson, Mia
   Kundu, Soumi
   Aranda, Sergi
   Westermark, Bengt
   Uhrbom, Lene
   Andang, Michael
   Damberg, Peter
   Nelander, Sven
   Arenas, Ernest
   Artursson, Per
   Walfridsson, Julian
   Nilsson, Karin Forsberg
   Hammarstrom, Lars G. J.
   Ernfors, Patrik
TI RETRACTED: Vulnerability of Glioblastoma Cells to Catastrophic
   Vacuolization and Death Induced by a Small Molecule (Retracted article.
   See vol. 170, pg. 407, 2017)
SO CELL
LA English
DT Article; Retracted Publication
ID INTEGRATED GENOMIC ANALYSIS; CENTRAL-NERVOUS-SYSTEM;
   MULTIDRUG-RESISTANCE; STEM-CELLS; GLIOMA-CELLS; BRAIN-TUMORS; CANCER;
   MACROPINOCYTOSIS; TEMOZOLOMIDE; MULTIFORME
AB Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer with marginal life expectancy. Based on the assumption that GBM cells gain functions not necessarily involved in the cancerous process, patient-derived glioblastoma cells (GCs) were screened to identify cellular processes amenable for development of targeted treatments. The quinine-derivative NSC13316 reliably and selectively compromised viability. Synthetic chemical expansion reveals delicate structure-activity relationship and analogs with increased potency, termed Vacquinols. Vacquinols stimulate death by membrane ruffling, cell rounding, massive macropinocytic vacuole accumulation, ATP depletion, and cytoplasmic membrane rupture of GCs. The MAP kinase MKK4, identified by a shRNA screen, represents a critical signaling node. Vacquinol-1 displays excellent in vivo pharmacokinetics and brain exposure, attenuates disease progression, and prolongs survival in a GBM animal model. These results identify a vulnerability to massive vacuolization that can be targeted by small molecules and point to the possible exploitation of this process in the design of anticancer therapies.
C1 [Kitambi, Satish Srinivas; Toledo, Enrique M.; Usoskin, Dmitry; Wee, Shimei; Aranda, Sergi; Andang, Michael; Arenas, Ernest; Ernfors, Patrik] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, S-17177 Stockholm, Sweden.
   [Sigmundsson, Kristmundur; Kalderen, Christina; Hammarstrom, Lars G. J.] Karolinska Inst, Dept Med Biochem & Biophys, Div Translat Med & Chem Biol, Sci Life Lab,Chem Biol Consortium Sweden, S-17177 Stockholm, Sweden.
   [Svensson, Richard; Artursson, Per] Uppsala Univ, Chem Biol Consortium Sweden, UDOPP, Dept Pharm, S-75105 Uppsala, Sweden.
   [Wee, Shimei; Andang, Michael] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden.
   [Harisankar, Aditya] Karolinska Inst, HERM, Dept Med, S-14186 Stockholm, Sweden.
   [Niklasson, Mia; Kundu, Soumi; Westermark, Bengt; Uhrbom, Lene; Nelander, Sven; Nilsson, Karin Forsberg] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, S-75185 Uppsala, Sweden.
   [Damberg, Peter] Karolinska Inst, Dept Clin Sci Intervent & Technol, S-14186 Stockholm, Sweden.
RP Ernfors, P (reprint author), Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, S-17177 Stockholm, Sweden.
EM patrik.ernfors@ki.se
RI Aranda, Sergi/K-1211-2015
OI Aranda, Sergi/0000-0003-3853-430X; Arenas, Ernest/0000-0003-0197-6577;
   Westermark, Bengt/0000-0001-7153-5545; Hammarstrom,
   Lars/0000-0002-3903-7746; Toledo, Enrique/0000-0002-1460-4708; Andang,
   Michael/0000-0002-2886-7891
FU Swedish Research Council for Medicine and Health; Swedish Cancer
   Society; Swedish strategic funds (DBRM, StratNeuro); Swedish Brain
   Foundation; Hallsten Foundation; Torsten Soderberg Professorship;
   Wallenberg Foundation (Wallenberg Scholar grant); ERC advanced grant
   [232675]; Chemical Biology Consortium Sweden (CBCS); Swedish Research
   Council
FX The authors thank Helena Samuelsson for technical help and Robert Harmel
   for help with the synthesis of compounds. We also thank Susan Warner and
   the team at Mice and Zebrafish Core facility for wonderful support
   during the course of experiments, the CLICK Imaging Facility supported
   by the Wallenberg Foundation, Erik Nilsson for setting up the spectral
   analysis, and the Core Facility AKM/Karolinska Experimental Research and
   Imaging Centre at Karolinska University Hospital for MRI. This work was
   supported by the Swedish Research Council for Medicine and Health, the
   Swedish Cancer Society, the Swedish strategic funds (DBRM, StratNeuro),
   the Swedish Brain Foundation, Hallsten Foundation, Torsten Soderberg
   Professorship, Wallenberg Foundation (Wallenberg Scholar grant), and ERC
   advanced grant (232675) to P.E. (who is a Wallenberg Scholar). The
   contributions of K.S., C.K., R.S., P.A., and L.G.J.H. to the project
   were supported by Chemical Biology Consortium Sweden (CBCS) and funded
   by the Swedish Research Council. K.F.N., L.U., and B.W. were supported
   by grants from the Swedish Research Council for Medicine and Health and
   the Swedish Cancer Society. S.S.K., L.G.J.H., and P.E. have applied for
   protection of intellectual property related to the results in the
   manuscript.
CR ALCANTARA LS, 2009, CANCER CELL, V15, P45, DOI DOI 10.1016/J.CCR.2008.12.006
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Barami K, 2009, J CLIN NEUROSCI, V16, P195, DOI 10.1016/j.jocn.2008.03.006
   Bhanot H, 2010, MOL CANCER RES, V8, P1358, DOI 10.1158/1541-7786.MCR-10-0090
   Bleau AM, 2009, M S-MED SCI, V25, P775, DOI 10.1051/medsci/20092510775
   Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Charras G, 2008, NAT REV MOL CELL BIO, V9, P730, DOI 10.1038/nrm2453
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Dent P, 2008, CANCER BIOL THER, V7, P1335, DOI 10.4161/cbt.7.9.6408
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Duan ZF, 2012, J MED CHEM, V55, P3113, DOI 10.1021/jm300117u
   Duan ZF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007415
   Fuhler GM, 2012, MOL MED, V18, P65, DOI 10.2119/molmed.2011.00178
   Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707
   Gallo M, 2013, CANCER RES, V73, P417, DOI 10.1158/0008-5472.CAN-12-1881
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Gold S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011360
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Grimmer S, 2002, J CELL SCI, V115, P2953
   Gunther W, 2003, BRIT J CANCER, V88, P463, DOI 10.1038/sj.bjc.6600711
   HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82
   Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100
   HYAFIL F, 1993, CANCER RES, V53, P4595
   Kaul A, 2007, CELL SIGNAL, V19, P1034, DOI 10.1016/j.cellsig.2006.11.010
   Kitambi Satish Srinivas, 2012, BMC Physiology, V12, P3, DOI 10.1186/1472-6793-12-3
   Leon B, 2013, ORG LETT, V15, P1234, DOI 10.1021/ol400150z
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Mercer J, 2012, CURR OPIN MICROBIOL, V15, P490, DOI 10.1016/j.mib.2012.05.016
   Morrison DK, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011254
   Overmeyer JH, 2008, MOL CANCER RES, V6, P965, DOI 10.1158/1541-7786.MCR-07-2036
   Overmeyer JH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-69
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   PINDER RM, 1968, J MED CHEM, V11, P267, DOI 10.1021/jm00308a017
   Polivka J, 2012, ANTICANCER RES, V32, P2935
   Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014
   RAPPORT MM, 1946, J AM CHEM SOC, V68, P2697, DOI 10.1021/ja01216a085
   Singh SK, 2003, CANCER RES, V63, P5821
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Swanson JA, 2008, NAT REV MOL CELL BIO, V9, P639, DOI 10.1038/nrm2447
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Whitmarsh AJ, 2007, ONCOGENE, V26, P3172, DOI 10.1038/sj.onc.1210410
   Zhang JH, 2010, ONCOLOGY-BASEL, V78, P103, DOI 10.1159/000306139
NR 47
TC 71
Z9 72
U1 3
U2 51
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 10
PY 2014
VL 157
IS 2
DI 10.1016/j.cell.2014.02.021
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AE9DK
UT WOS:000334304500007
PM 24656405
OA Bronze
DA 2018-12-27
ER

PT J
AU Das, RR
   Singh, M
AF Das, Rashmi Ranjan
   Singh, Meenu
TI RETRACTED: Oral Zinc for the Common Cold (Retracted Article. See vol
   316, pg 2678, 2016)
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material; Retracted Publication
ID CHILDREN
AB CLINICAL QUESTION: Is oral zinc associated with a shorter duration, decreased severity, and reduced incidence of the common cold compared with placebo?
   BOTTOM LINE: When initiated within 24 hours of symptom onset, oral zinc is associated with a shorter duration of the common cold in healthy people. However, there is no association between oral zinc and symptom severity, and the prevalence of adverse effects with zinc lozenges is high. Given the high heterogeneity of data, these results should be interpreted with caution. Used prophylactically, oral zinc is associated with a reduced cold incidence in children. Prophylactic use has not been studied in adults.
C1 [Das, Rashmi Ranjan] All India Inst Med Sci, Dept Pediat, Bhubaneswar, Orissa, India.
   [Singh, Meenu] Postgrad Inst Med Educ & Res, Dept Pediat, Chandigarh 160012, India.
RP Singh, M (reprint author), Postgrad Inst Med Educ & Res, Chandigarh 160012, India.
EM meenusingh4@gmail.com
CR Eby GA, 2010, MED HYPOTHESES, V74, P482, DOI 10.1016/j.mehy.2009.10.017
   Fashner J, 2012, AM FAM PHYSICIAN, V86, P153
   National Institutes of Health, ZINC FACT SHEET CONS
   Rerksuppaphol S, 2013, PAEDIATR INT CHILD H, V33, P145, DOI 10.1179/2046905513Y.0000000064
   Singh M, 2013, COCHRANE DB SYST REV, V6
   Whiteman SC, 2003, J BIOL CHEM, V278, P11954, DOI 10.1074/jbc.M205329200
NR 6
TC 8
Z9 8
U1 1
U2 22
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 9
PY 2014
VL 311
IS 14
BP 1440
EP 1441
DI 10.1001/jama.2014.1404
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AE4EP
UT WOS:000333935000021
PM 24715076
DA 2018-12-27
ER

PT J
AU Zhang, WH
   Zhang, YB
   Liu, DH
   Zhu, YB
   Qiao, CH
   Wang, JX
   Xu, YL
   Liu, Y
   Li, B
   Yang, Y
AF Zhang Weihua
   Zhang Yanbo
   Liu Donghai
   Zhu Yaobin
   Qiao Chenhui
   Wang Jiaxiang
   Xu Yulin
   Liu Yang
   Li Bin
   Yang Yao
TI RETRACTED: A novel rat model of cardiopulmonary bypass for deep
   hypothermic circulatory arrest without blood priming (Retracted article.
   See vol. 127, pg. 2611, 2014)
SO CHINESE MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE rats; animal model; cardiopulmonary bypass model; deep hypothermic
   circulatory arrest
ID ACUTE LUNG INJURY; OLEIC-ACID; CARDIOPLEGIC ARREST; RECOVERY MODEL;
   SURVIVAL
AB Background Large animal cardiopulmonary bypass (CPB) models are expensive, and prevent assessment of neurocognitive function, and difficulties with long-term recovery. The purpose of this study was to establish a novel rat model of cardiopulmonary bypass for deep hypothermic circulatory arrest without blood priming.
   Methods Twenty adult male Sprague-Dawley rats weighing 450-560 g were randomized to CPB with deep hypothermic circulatory arrest (DHCA) and control groups, with 10 rats each. The experimental protocols, including blood and crystalloid fluid administration, anesthesia, orotracheal intubation, ventilation, cannulation, and heparinization were identical in both groups. After inducing cardiac arrest, the circuit was turned off and rats were left in a DHCA state for 15 minutes. Rats were rewarmed to 34 degrees C to 35 degrees C over a period of 36 to 42 minutes using CPB-assisted rewarming, a heating blanket, and a heating lamp along with administration of 0.1 mEq of sodium bicarbonate and 0.14 mEq of calcium chloride. The remaining priming volume was reinfused and animals were weaned from CPB.
   Results All CPB with DHCA processes were successfully achieved. Blood gas analysis and hemodynamic parameters were in the normal range. The vital signs of all rats were stable.
   Conclusions Our CPB circuit has several novel features, including a small priming volume, active cooling/rewarming processes, vacuum-assisted venous drainage, peripheral cannulation without thoracotomy or sternotonny, and an accurate means of monitoring peripheral tissue oxygenation.
C1 [Zhang Weihua; Liu Donghai; Qiao Chenhui; Wang Jiaxiang] Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.
   [Zhang Yanbo] Chinese Acad Med Sci, Dept Pediat Heart Ctr, State Key Lab Cardiovasc Dis, Fuwai Hosp,Natl Ctr Cardiovasc Dis, Beijing 100037, Peoples R China.
   [Zhang Yanbo] Peking Union Med Coll, Beijing 100037, Peoples R China.
   [Zhang Yanbo; Xu Yulin; Liu Yang; Li Bin; Yang Yao] Capital Med Univ, Dept Pediat Heart Ctr, Beijing Anzhen Hosp, Beijing 100029, Peoples R China.
RP Zhu, YB (reprint author), Capital Med Univ, Dept Pediat Heart Ctr, Beijing Anzhen Hosp, Beijing 100029, Peoples R China.
EM yanbozhang@126.com; zhuyaobin@yeah.net
FU National Natural Science Foundation of China [81371443]; Beijing Natural
   Science Foundation [7142137, 7122056, 7142049]; Basic and Clinical
   Cooperation Project of Capital Medical University [13JL26]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81371443), Beijing Natural Science Foundation
   (No. 7142137, No. 7122056 and No. 7142049), Basic and Clinical
   Cooperation Project of Capital Medical University (No.13JL26).
CR An Y, 2007, HEART SURG FORUM, V10, P47, DOI 10.1532/HSF98.20061146
   Backer CL, 2006, ANN THORAC SURG, V82, P964, DOI 10.1016/j.athoracsur.2006.04.060
   Cresce GD, 2008, ASAIO J, V54, P514, DOI 10.1097/MAT.0b013e3181877a38
   de Lange F, 2008, J CARDIOTHORAC SURG, V3, DOI 10.1186/1749-8090-3-51
   Dong GH, 2005, J SURG RES, V123, P171, DOI 10.1016/j.jss.2004.08.007
   Dong X, 2006, EUR J CARDIO-THORAC, V30, P77, DOI 10.1016/j.ejcts.2006.02.040
   Fabre O, 2001, PERFUSION-UK, V16, P215, DOI 10.1177/026765910101600307
   Gunzinger R, 2007, BASIC RES CARDIOL, V102, P508, DOI 10.1007/s00395-007-0668-x
   Modine T, 2006, PERFUSION-UK, V21, P87, DOI 10.1191/0267659106pf854oa
   Waterbury T, 2011, J THORAC CARDIOV SUR, V141, P1549, DOI 10.1016/j.jtcvs.2011.01.062
   Xu YL, 2012, CHINESE MED J-PEKING, V125, P2012, DOI 10.3760/cma.j.issn.0366-6999.2012.11.031
   Yang W, 2009, J CEREBR BLOOD F MET, V29, P886, DOI 10.1038/jcbfm.2009.16
   You Xiao-Mang, 2005, J Extra Corpor Technol, V37, P60
   Zhu X, 2014, PERFUSION-UK, V29, P63, DOI 10.1177/0267659113495914
   Zhu YB, 2013, CHINESE MED J-PEKING, V126, P747, DOI 10.3760/cma.j.issn.0366-6999.20122435
   Zhu YB, 2012, CHINESE MED J-PEKING, V125, P123, DOI 10.3760/cma.j.issn.0366-6999.2012.01.023
NR 16
TC 0
Z9 0
U1 4
U2 10
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD APR 5
PY 2014
VL 127
IS 7
BP 1317
EP 1320
DI 10.3760/cma.j.issn.0366-6999.20133074
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA AE9JY
UT WOS:000334325300022
PM 24709187
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Amer, MS
   Rahman, TTA
   Aly, WW
   Ahmad, NG
AF Amer, Moatasem Salah
   Rahman, Tomader Taha Abdel
   Aly, Walaa Wessam
   Ahmad, Nesma Gamal
TI RETRACTED: Cardiopulmonary resuscitation: Outcome and its predictors
   among hospitalized elderly patients in Egypt (Retracted article. See
   vol. 15, pg. 1104, 2015)
SO GERIATRICS & GERONTOLOGY INTERNATIONAL
LA English
DT Article; Retracted Publication
DE cardiopulmonary resuscitation; elderly; Egypt; outcome; predictors
ID CARDIAC-ARREST; SURVIVAL; IRAN
AB AimOur aim was to study the outcome and the predictors of in-hospital cardiopulmonary resuscitation (CPR) among elderly patients admitted to Ain Shams University Hospitals, Egypt.
   MethodsWe carried out a cross-sectional study for all elderly patients (age 60 years) who underwent CPR after cardiac arrest at Ain Shams University Hospitals, Egypt, during a 1.5-year study period. We excluded patients who were declared dead on arrival.
   ResultsWe found 380 cases of elderly in-hospital cardiac arrest that underwent CPR. Asystole was the most common arrhythmia detected at the time of arrest (85.1%), followed by ventricular tachycardia (8.7%) and ventricular fibrillation (6.2%). Return of spontaneous circulation was achieved in 32.6% of patients and 8.4% survived to discharge from hospital. Multivariate logistic regression analysis identified three independent predictors of better outcome (survival >24h): response time 5min (OR 5.1, 95% CI 1.9-13.4), location of CPR in emergency department (OR 3.2, 95% CI 1.6-6.4) and pre-arrest morbidity (PAM) score 7 (OR 3.1, 95% CI 1.6-6.1).
   ConclusionOutcome of CPR after in-hospital cardiac arrest in our setting was poor. The response time 5min, CPR in the emergency department and PAM score 7 were independent predictors of good outcome. Geriatr Gerontol Int 2014; 14: 309-314.
C1 [Amer, Moatasem Salah; Rahman, Tomader Taha Abdel; Aly, Walaa Wessam; Ahmad, Nesma Gamal] Ain Shams Univ Hosp, Dept Geriatr, Cairo 11331, Egypt.
RP Rahman, TTA (reprint author), Ain Shams Univ Hosp, Dept Geriatr, Abbassea Sq, Cairo 11331, Egypt.
EM tomelhagyn@hotmail.com
RI Aly, Walaa/W-8448-2018
OI Aly, Walaa/0000-0002-1750-2539
CR Alabi T. O., 2009, EMERGE MED, V17, P34
   Bolandparvaz SH, 2009, IRAN RED CRESCENT ME, V11, P437
   Bolandparvaz S, 2008, IRAN RED CRESCENT ME, V10, P118
   Brindley PG, 2002, CAN MED ASSOC J, V167, P343
   Chang WH, 2009, INT J GERONTOL, V3, P16, DOI 10.1016/S1873-9598(09)70016-X
   Cooper S, 2006, RESUSCITATION, V68, P231, DOI 10.1016/j.resuscitation.2005.06.012
   Dumot JA, 2001, ARCH INTERN MED, V161, P1751, DOI 10.1001/archinte.161.14.1751
   Eftychiou Christos, 2009, Hellenic J Cardiol, V50, P264
   Elshove-Bolk J, 2007, RESUSCITATION, V74, P372, DOI 10.1016/j.resuscitation.2007.01.015
   Fairbanks RJ, 2007, RESUSCITATION, V72, P415, DOI 10.1016/j.resuscitation.2006.06.135
   GEORGE AL, 1989, AM J MED, V87, P28
   Hajbaghery MA, 2005, RESUSCITATION, V66, P317, DOI 10.1016/j.resuscitation.2005.04.004
   Herlitz J, 2003, RESUSCITATION, V58, P309, DOI 10.1016/S0300-9572(03)00155-2
   Herlitz J, 2001, RESUSCITATION, V48, P125, DOI 10.1016/S0300-9572(00)00249-5
   Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008
   Kanoupakis EM, 2012, HOSP CHRON, V7, P77
   Khan NU, 2008, INT J EMERG MED, V1, P27, DOI 10.1007/s12245-008-0016-4
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Kutsogiannis DJ, 2011, CAN MED ASSOC J, V183, P1589, DOI 10.1503/cmaj.100034
   MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199
   Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729
   Papastylianou A, 2001, EMERG MED INT, V20, P815
   Patel M.R., 2012, J AM COLL CARDIOL, V59, P1, DOI DOI 10.1016/J.JACC.2012.03.003
   Peberdy MA, 2008, JAMA-J AM MED ASSOC, V299, P785, DOI 10.1001/jama.299.7.785
   Pembeci K, 2006, RESUSCITATION, V68, P221, DOI 10.1016/j.resuscitation.2005.07.003
   Rakic D, 2005, CROAT MED J, V46, P907
   Reisfield GM, 2006, RESUSCITATION, V71, P152, DOI 10.1016/j.resuscitation.2006.02.022
   SO HY, 1994, ANAESTH INTENS CARE, V22, P647
   Suraseranivongse S, 2006, RESUSCITATION, V71, P188, DOI 10.1016/j.resuscitation.2006.04.004
   Tok D, 2004, TOHOKU J EXP MED, V202, P265, DOI 10.1620/tjem.202.265
NR 30
TC 5
Z9 5
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-1586
EI 1447-0594
J9 GERIATR GERONTOL INT
JI Geriatr. Gerontol. Int.
PD APR
PY 2014
VL 14
IS 2
BP 309
EP 314
DI 10.1111/ggi.12099
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AE1TS
UT WOS:000333753700010
PM 23750740
DA 2018-12-27
ER

PT J
AU Hanna, E
   Cardillo, M
AF Hanna, Emily
   Cardillo, Marcel
TI RETRACTED: Predation selectively culls medium-sized species from island
   mammal faunas(Retracted article. See vol.12,2016)
SO BIOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE extinction risk; mammals; predation; body size
ID EXTINCTION RISK; BODY-SIZE; CONSERVATION IMPLICATIONS; AUSTRALIAN
   MAMMALS; DECLINE
AB Globally, elevated extinction risk in mammals is strongly associated with large body size. However, in regions where introduced predators exert strong top-down pressure on mammal populations, the selectivity of extinctions may be skewed towards species of intermediate body size, leading to a hump-shaped relationship between size and extinction risk. The existence of this kind of extinction pattern, and its link to predation, has been contentious and difficult to demonstrate. Here, we test the hypothesis of a hump-shaped body size-extinction relationship, using a database of 927 island mammal populations. We show that the size-selectivity of extinctions on many islands has exceeded that expected under null models. On islands with introduced predators, extinctions are biased towards intermediate body sizes, but this bias does not occur on islands without predators. Hence, on islands with a large-bodied mammal fauna, predators are selectively culling species from the lower end of the size distribution, and on islands with a small-bodied fauna they are culling species from the upper end. These findings suggest that it will be difficult to use predictable generalizations about extinction patterns, such as a positive body size-extinction risk association, to anticipate future species declines and plan conservation strategies accordingly.
C1 [Hanna, Emily; Cardillo, Marcel] Australian Natl Univ, Macroevolut & Macroecol Grp, Res Sch Biol, Canberra, ACT 0200, Australia.
RP Cardillo, M (reprint author), Australian Natl Univ, Macroevolut & Macroecol Grp, Res Sch Biol, Bldg 116,Daley Rd, Canberra, ACT 0200, Australia.
EM marcel.cardillo@anu.edu.au
RI Cardillo, Marcel/C-9396-2009
FU Australian Postgraduate Scholarship
FX E.H. was supported by an Australian Postgraduate Scholarship.
CR Brook LA, 2011, RANGELAND J, V33, P79, DOI 10.1071/RJ10052
   BURBIDGE AA, 1989, BIOL CONSERV, V50, P143, DOI 10.1016/0006-3207(89)90009-8
   Cardillo M, 2005, SCIENCE, V309, P1239, DOI 10.1126/science.1116030
   Cardillo M, 2003, ANIM CONSERV, V6, P63, DOI 10.1017/S1367943003003093
   Cardillo M, 2001, CONSERV BIOL, V15, P1435, DOI 10.1046/j.1523-1739.2001.00286.x
   Chisholm RA, 2010, AUSTRAL ECOL, V35, P616, DOI 10.1111/j.1442-9993.2009.02065.x
   DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0
   Davidson AD, 2009, P NATL ACAD SCI USA, V106, P10702, DOI 10.1073/pnas.0901956106
   DIAMOND JM, 1989, PHILOS T ROY SOC B, V325, P469, DOI 10.1098/rstb.1989.0100
   FENCHEL T, 1974, OECOLOGIA, V14, P317, DOI 10.1007/BF00384576
   Fisher DO, 2014, GLOBAL ECOL BIOGEOGR, V23, P181, DOI 10.1111/geb.12088
   Hanna E, 2014, GLOBAL ECOL BIOGEOGR, V23, P395, DOI 10.1111/geb.12103
   Johnson CN, 2009, AUSTRAL ECOL, V34, P35, DOI 10.1111/j.1442-9993.2008.01878.x
   Kinnear JE, 2002, BIOL CONSERV, V108, P335, DOI 10.1016/S0006-3207(02)00116-7
   Lee TM, 2011, P ROY SOC B-BIOL SCI, V278, P1329, DOI 10.1098/rspb.2010.1877
   Morton S.R., 1990, Proceedings of the Ecological Society of Australia, V16, P201
   Purvis A, 2000, P ROY SOC B-BIOL SCI, V267, P1947, DOI 10.1098/rspb.2000.1234
   SHORT J, 1994, J MAMMAL, V75, P288, DOI 10.2307/1382547
   Van Dyck S, 2008, MAMMALS AUSTR
NR 19
TC 4
Z9 4
U1 2
U2 19
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1744-9561
EI 1744-957X
J9 BIOL LETTERS
JI Biol. Lett.
PD APR 1
PY 2014
VL 10
IS 4
DI 10.1098/rsbl.2013.1066
PG 4
WC Biology; Ecology; Evolutionary Biology
SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences &
   Ecology; Evolutionary Biology
GA AH0MD
UT WOS:000335813100005
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Khoriati, AA
AF Khoriati, Al-Achraf
TI RETRACTED: Total Hip Arthroplasty With Acetabular Fixation: An
   Unexpected Complication (Retracted article. See vol. 38, pg. 336, 2015)
SO ORTHOPEDICS
LA English
DT Article; Retracted Publication
ID FEMORAL-ARTERY; INJURIES; SURGERY
AB The incidence of vascular injuries associated with total hip arthroplasty (THA) is low. However, several vascular structures are at risk of injury within the pelvis. These include the external iliac, femoral, and obturator vessels. Both reaming of the acetabulum and drilling of the acetabular screw holes may place these structures at risk. If left untreated, injuries to these vessels may be associated with severe morbidity and mortality. In this report, an acute vascular complication that had an unusual presentation is highlighted. A 72-year-old woman presented to the emergency department following a road traffic accident in which she sustained a combined fracture of the right acetabulum and femoral head. Her treatment involved a combination of THA and pelvic open reduction and internal fixation. The immediate perioperative recovery period was uncomplicated. However, the patient developed a deep venous thrombus in her right calf 7 days after surgery. Further investigation revealed a second thrombus, occluding the right common femoral vein. Surgical exploration revealed that a screw placed during the initial surgery was pressing against the vessel and occluding it. The discrepancy in incidence between the development of deep venous thrombosis and vascular compression or injury means that the association between the 2 events is unlikely to be made. The author highlights this unusual presentation to improve early recognition and prompt management of similar cases. The importance of adequate preoperative planning and intraoperative imaging with a C-arm is also stressed.
C1 Princess Grace Hosp, Dept Orthopaed, London W1U 5NY, England.
RP Khoriati, AA (reprint author), Princess Grace Hosp, Dept Orthopaed, 42-52 Nottingham Pl, London W1U 5NY, England.
EM alkhoriati@doctors.org.uk
CR Alazzawi S, 2012, J BONE JOINT SURG BR, V94B, P1120, DOI 10.1302/0301-620X.94B8.29040
   Hussain W. M., 2011, J ARTHROPLASTY, V26
   Kawasaki Y, 2012, J ORTHOP SCI, V17, P397, DOI 10.1007/s00776-012-0227-7
   Lavernia CJ, 2007, J ARTHROPLASTY, V22, P124, DOI 10.1016/j.arth.2006.02.082
   Mehta V, 2005, J ARTHROPLASTY, V20, P811, DOI 10.1016/j.arth.2004.12.050
   Parvizi J, 2008, J ARTHROPLASTY, V23, P1115, DOI 10.1016/j.arth.2008.02.016
   Rickman M, 2012, EUR J TRAUMA EMERG S, V38, P511, DOI 10.1007/s00068-012-0231-9
   Riouallon G, 2009, ORTHOP TRAUMATOL-SUR, V95, P154, DOI 10.1016/j.otsr.2008.11.002
   Schmitz Hc, 2012, Open Orthop J, V6, P215, DOI 10.2174/1874325001206010215
   Wang HL, 2012, INDIAN J ORTHOP, V46, P413, DOI 10.4103/0019-5413.98830
   WASIELEWSKI RC, 1990, J BONE JOINT SURG AM, V72A, P501, DOI 10.2106/00004623-199072040-00005
NR 11
TC 3
Z9 4
U1 2
U2 10
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0147-7447
EI 1938-2367
J9 ORTHOPEDICS
JI Orthopedics
PD APR
PY 2014
VL 37
IS 4
BP E407
EP E409
DI 10.3928/01477447-20140401-66
PG 3
WC Orthopedics
SC Orthopedics
GA AH2KO
UT WOS:000335950200017
PM 24762850
DA 2018-12-27
ER

PT J
AU Crosse, MJ
   Lalor, EC
AF Crosse, Michael J.
   Lalor, Edmund C.
TI RETRACTED: The cortical representation of the speech envelope is earlier
   for audiovisual speech than audio speech (Retracted article. See vol.
   112, pg. 2667, 2014)
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article; Retracted Publication
DE multisensory integration; analysis-by-synthesis; latency; EEG; TRF
ID HUMAN AUDITORY-CORTEX; MULTISENSORY INTEGRATION; TEMPORAL ENVELOPE;
   PERCEPTION; RESPONSES; SYSTEM; SOUNDS; BRAIN; BASES
AB Visual speech can greatly enhance a listener's comprehension of auditory speech when they are presented simultaneously. Efforts to determine the neural underpinnings of this phenomenon have been hampered by the limited temporal resolution of hemodynamic imaging and the fact that EEG and magnetoencephalographic data are usually analyzed in response to simple, discrete stimuli. Recent research has shown that neuronal activity in human auditory cortex tracks the envelope of natural speech. Here, we exploit this finding by estimating a linear forward-mapping between the speech envelope and EEG data and show that the latency at which the envelope of natural speech is represented in cortex is shortened by > 10 ms when continuous audiovisual speech is presented compared with audio-only speech. In addition, we use a reverse-mapping approach to reconstruct an estimate of the speech stimulus from the EEG data and, by comparing the bimodal estimate with the sum of the unimodal estimates, find no evidence of any nonlinear additive effects in the audiovisual speech condition. These findings point to an underlying mechanism that could account for enhanced comprehension during audiovisual speech. Specifically, we hypothesize that low-level acoustic features that are temporally coherent with the preceding visual stream may be synthesized into a speech object at an earlier latency, which may provide an extended period of low-level processing before extraction of semantic information.
C1 [Crosse, Michael J.; Lalor, Edmund C.] Univ Dublin Trinity Coll, Sch Engn, Dublin 2, Ireland.
   [Crosse, Michael J.; Lalor, Edmund C.] Univ Dublin Trinity Coll, Trinity Ctr Bioengn, Dublin 2, Ireland.
   [Lalor, Edmund C.] Univ Dublin Trinity Coll, Trinity Coll Inst Neurosci, Dublin 2, Ireland.
RP Lalor, EC (reprint author), Univ Dublin Trinity Coll, Coll Green, Printing House, Dublin 2, Ireland.
EM edlalor@tcd.ie
OI Lalor, Edmund/0000-0002-2498-6631
FU Irish Higher Education Authority Graduate Research Education Programme
   in Engineering; Science Foundation Ireland [09-RFP-NES2382]
FX This work was supported by the Irish Higher Education Authority Graduate
   Research Education Programme in Engineering and by a grant from Science
   Foundation Ireland (09-RFP-NES2382).
CR Arnal LH, 2009, J NEUROSCI, V29, P13445, DOI 10.1523/JNEUROSCI.3194-09.2009
   Barjatya A., 2004, IEEE T EVOLUT COMPUT, V8, P225, DOI DOI 10.1109/TEVC.2004.826069
   Bartels A, 2008, CEREB CORTEX, V18, P705, DOI 10.1093/cercor/bhm107
   Beauchamp MS, 2004, NEURON, V41, P809, DOI 10.1016/S0896-6273(04)00070-4
   Besle J, 2004, EUR J NEUROSCI, V20, P2225, DOI 10.1111/j.1460-9568.2004.03670.x
   Brandwein AB, 2013, CEREB CORTEX, V23, P1329, DOI 10.1093/cercor/bhs109
   Campbell R, 2008, PHILOS T R SOC B, V363, P1001, DOI 10.1098/rstb.2007.2155
   Chandrasekaran C, 2013, P NATL ACAD SCI USA, V110, pE4668, DOI 10.1073/pnas.1312518110
   Chandrasekaran C, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000436
   Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009
   Di Russo F, 2005, NEUROIMAGE, V24, P874, DOI 10.1016/j.neuroimage.2004.09.029
   Ding N, 2013, NEUROIMAGE, DOI [10.1016/j.neuro.image.2013.10.054, DOI 10.1016/J.NEURO.IMAGE.2013.10.054]
   Golumbic EZ, 2013, J NEUROSCI, V33, P1417, DOI 10.1523/JNEUROSCI.3675-12.2013
   Hairston WD, 2005, EXP BRAIN RES, V166, P474, DOI 10.1007/s00221-005-2387-6
   Kayser C, 2008, CEREB CORTEX, V18, P1560, DOI 10.1093/cercor/bhm187
   Klucharev V, 2003, COGNITIVE BRAIN RES, V18, P65, DOI 10.1016/j.cogbrainres.2003.09.004
   Lalor EC, 2010, EUR J NEUROSCI, V31, P189, DOI 10.1111/j.1460-9568.2009.07055.x
   Lalor EC, 2009, J NEUROPHYSIOL, V102, P349, DOI 10.1152/jn.90896.2008
   Luck S, 2004, EVENT RELATED POTENT
   Luo H, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000445
   Mercier MR, 2013, NEUROIMAGE, V79, P19, DOI 10.1016/j.neuroimage.2013.04.060
   Mesgarani N, 2009, J NEUROPHYSIOL, V102, P3329, DOI 10.1152/jn.91128.2008
   Millman RE, 2013, NEUROIMAGE, V64, P185, DOI 10.1016/j.neuroimage.2012.09.017
   Molholm S, 2002, COGNITIVE BRAIN RES, V14, P115, DOI 10.1016/S0926-6410(02)00066-6
   Munhall KG, 2004, PSYCHOL SCI, V15, P133, DOI 10.1111/j.0963-7214.2004.01502010.x
   Munhall KG, 1998, HEARING EYE 2, P123
   Murray MM, 2008, BRAIN TOPOGR, V20, P249, DOI 10.1007/s10548-008-0054-5
   Nelken I, 2008, CURR OPIN NEUROBIOL, V18, P413, DOI 10.1016/j.conb.2008.08.014
   Nourski KV, 2009, J NEUROSCI, V29, P15564, DOI 10.1523/JNEUROSCI.3065-09.2009
   Pilling M, 2009, J SPEECH LANG HEAR R, V52, P1073, DOI [10.1044/1092-4388(2009/07-0276), 10.1044/1092-4388]
   Reisberg D., 1987, HEARING EYE PSYCHOL, P97
   Ross LA, 2007, CEREB CORTEX, V17, P1147, DOI 10.1093/cercor/bhl024
   Ross LA, 2007, SCHIZOPHR RES, V97, P173, DOI 10.1016/j.schres.2007.08.008
   Salmelin R, 2007, CLIN NEUROPHYSIOL, V118, P237, DOI 10.1016/j.clinph.2006.07.316
   Schroeder CE, 2008, TRENDS COGN SCI, V12, P106, DOI 10.1016/j.tics.2008.01.002
   Shamma SA, 2011, TRENDS NEUROSCI, V34, P114, DOI 10.1016/j.tins.2010.11.002
   Stekelenburg JJ, 2007, J COGNITIVE NEUROSCI, V19, P1964, DOI 10.1162/jocn.2007.19.12.1964
   SUMBY WH, 1954, J ACOUST SOC AM, V26, P212, DOI 10.1121/1.1907309
   Teki S, 2011, J NEUROSCI, V31, P164, DOI 10.1523/JNEUROSCI.3788-10.2011
   van Wassenhove V, 2005, P NATL ACAD SCI USA, V102, P1181, DOI 10.1073/pnas.0408949102
NR 40
TC 5
Z9 5
U1 2
U2 17
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
EI 1522-1598
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD APR
PY 2014
VL 111
IS 7
BP 1400
EP 1408
DI 10.1152/jn.00690.2013
PG 9
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA AG9YN
UT WOS:000335776200002
PM 24401714
OA Green Published
DA 2018-12-27
ER

PT J
AU Fang, QX
AF Fang, Qingxiang
TI RETRACTED: Synchronization and state feedback control of linearly
   coupled singular systems (Retracted article. See vol. 273, pg. 1276,
   2016)
SO APPLIED MATHEMATICS AND COMPUTATION
LA English
DT Article; Retracted Publication
DE Linearly coupled singular systems; Globally exponential synchronization;
   State feedback control; Linear matrix inequality
ID COMPLEX DYNAMICAL NETWORKS; TIME-VARYING DELAYS; CHAOTIC SYSTEMS;
   EXPONENTIAL SYNCHRONIZATION; ROBUST SYNCHRONIZATION; NONLINEAR
   PERTURBATION; ACTUATOR SATURATION; NEURAL-NETWORKS; SAMPLED-DATA;
   STABILITY
AB In this paper, the synchronization and state feedback control problem of the linearly coupled singular systems is investigated. The uncoupled dynamical behavior at each node is general and can be chaotic or otherwise; the coupling matrix is not assumed to be symmetrical. Some sufficient conditions for globally exponential synchronization are derived based on Lyapunov stability theory. These criteria, which are in terms of linear matrix inequality (LMI), indicate that the left and right eigenvector corresponding to eigenvalue zero of the coupling matrix play key roles in the stability analysis of the synchronization manifold. The state feedback controller is designed. Finally, a numerical example is provided to illustrate the effectiveness of the proposed conditions. (C) 2014 Elsevier Inc. All rights reserved.
C1 China Jiliang Univ, Coll Sci, Hangzhou 310018, Zhejiang, Peoples R China.
RP Fang, QX (reprint author), China Jiliang Univ, Coll Sci, Hangzhou 310018, Zhejiang, Peoples R China.
EM qingxiang.fang@gmail.com
FU Natural Science Foundation of Zhejiang Province [Y1110036]; Research
   Project of Zhejiang Province Education Department [Y201018827]
FX This work was supported by Natural Science Foundation of Zhejiang
   Province under Grant Y1110036 and Research Project of Zhejiang Province
   Education Department under Grant Y201018827.
CR APLEVICH J. D., 1991, IMPLICIT LINEAR SYST
   Cheng CJ, 2012, APPL MATH COMPUT, V219, P2698, DOI 10.1016/j.amc.2012.08.101
   DAI L, 1988, IEEE T AUTOMAT CONTR, V33, P187, DOI 10.1109/9.387
   Dhamala M, 2004, PHYS REV LETT, V92, DOI [10.1103/PhysRevLett.92.028101, 10.1103/PhysRevLett.92.074104]
   Fan CX, 2010, IEEE T CIRCUITS-I, V57, P2991, DOI 10.1109/TCSI.2010.2048774
   Grammel G, 2008, SYST CONTROL LETT, V57, P505, DOI 10.1016/j.sysconle.2007.11.009
   Guan ZH, 2010, IEEE T CIRCUITS-I, V57, P2182, DOI 10.1109/TCSI.2009.2037848
   Haidar A, 2009, AUTOMATICA, V45, P539, DOI 10.1016/j.automatica.2008.08.019
   HEAGY JF, 1994, PHYS REV E, V50, P1874, DOI 10.1103/PhysRevE.50.1874
   Hoppensteadt FC, 2000, IEEE T NEURAL NETWOR, V11, P734, DOI 10.1109/72.846744
   Huygens C., 1672, HOROLOQUIUM OSCILLAT
   Ji DH, 2010, J OPTIMIZ THEORY APP, V147, P298, DOI 10.1007/s10957-010-9723-0
   Khalil K.K., 2002, NONLINEAR SYSTEM
   Kim JH, 2010, AUTOMATICA, V46, P591, DOI 10.1016/j.automatica.2010.01.011
   Koo JH, 2010, APPL MATH COMPUT, V217, P3916, DOI 10.1016/j.amc.2010.09.055
   KRINSKY VI, 1991, PHYSICA D, V49, P247, DOI 10.1016/0167-2789(91)90213-S
   KUHNERT L, 1989, NATURE, V337, P244, DOI 10.1038/337244a0
   Kuzmina LK, 2009, NONLINEAR ANAL-THEOR, V71, pE2481, DOI 10.1016/j.na.2009.05.046
   Lan YY, 2010, APPL MATH COMPUT, V217, P2125, DOI 10.1016/j.amc.2010.07.011
   Lashmanan M., 1996, CHAOS NONLINEAR OSCI
   Lee TH, 2013, INT J CONTROL, V86, P107, DOI 10.1080/00207179.2012.720034
   Lee TH, 2012, NONLINEAR DYNAM, V69, P1081, DOI 10.1007/s11071-012-0328-z
   LEWIS FL, 1986, CIRC SYST SIGNAL PR, V5, P3, DOI 10.1007/BF01600184
   Li Q, 2009, IEEE T CIRCUITS-I, V56, P653, DOI 10.1109/TCSI.2008.2002663
   Liu C, 2009, AUTOMATICA, V45, P1879, DOI 10.1016/j.automatica.2009.04.004
   Liu H, 2010, PHYSICA A, V389, P1759, DOI 10.1016/j.physa.2009.12.035
   Liu XP, 2002, IEEE T AUTOMAT CONTR, V47, P335, DOI 10.1109/9.983376
   Lloyd AL, 2004, MATH BIOSCI, V188, P1, DOI 10.1016/j.mbs.2003.09.003
   Lu GP, 2006, IEEE T AUTOMAT CONTR, V51, P818, DOI 10.1109/TAC.2006.875017
   Lu GP, 2006, AUTOMATICA, V42, P309, DOI 10.1016/j.automatica.2005.09.010
   Lu JQ, 2010, IEEE T SYST MAN CY B, V40, P350, DOI 10.1109/TSMCB.2009.2023509
   Lu WL, 2006, PHYSICA D, V213, P214, DOI 10.1016/j.physd.2005.11.009
   Lu WL, 2004, IEEE T CIRCUITS-I, V51, P2491, DOI 10.1109/TCSI.2004.838308
   Lv L, 2008, SYST CONTROL LETT, V57, P904, DOI 10.1016/j.sysconle.2008.04.004
   Masubuchi I, 1997, AUTOMATICA, V33, P669, DOI 10.1016/S0005-1098(96)00193-8
   Meng B, 2006, IEEE T AUTOMAT CONTR, V51, P482, DOI 10.1109/TAC.2005.864196
   MIROLLO RE, 1990, SIAM J APPL MATH, V50, P1645, DOI 10.1137/0150098
   Pecora L, 2000, INT J BIFURCAT CHAOS, V10, P273, DOI 10.1142/S0218127400000189
   PECORA LM, 1990, PHYS REV LETT, V64, P821, DOI 10.1103/PhysRevLett.64.821
   PEREZMUNUZURI V, 1993, IEEE T CIRCUITS-I, V40, P174, DOI 10.1109/81.222798
   Shorten R, 2009, IEEE T AUTOMAT CONTR, V54, P2714, DOI 10.1109/TAC.2009.2031586
   Song B, 2012, APPL MATH COMPUT, V219, P3831, DOI 10.1016/j.amc.2012.10.012
   Uezato E., 1999, P 38 IEEE C DEC CONT, P4092
   VanWiggeren GD, 1998, SCIENCE, V279, P1198, DOI 10.1126/science.279.5354.1198
   Wang XF, 2002, IEEE T CIRCUITS-I, V49, P54, DOI 10.1109/81.974874
   Wang XF, 2002, INT J BIFURCAT CHAOS, V12, P187, DOI 10.1142/S0218127402004292
   Winfree AT, 1980, GEOMETRY BIOL TIME
   WU CW, 1995, IEEE T CIRCUITS-I, V42, P430, DOI 10.1109/81.404047
   Wu LG, 2009, AUTOMATICA, V45, P2120, DOI 10.1016/j.automatica.2009.05.014
   Wu ZG, 2012, IET CONTROL THEORY A, V6, P2308, DOI 10.1049/iet-cta.2012.0235
   Wu ZG, 2012, J FRANKLIN I, V349, P2735, DOI 10.1016/j.jfranklin.2012.09.002
   Wu ZG, 2010, INT J ROBUST NONLIN, V20, P1269, DOI 10.1002/rnc.1509
   Wu ZG, 2010, SIGNAL PROCESS, V90, P1815, DOI 10.1016/j.sigpro.2009.11.029
   Xiong WJ, 2008, PHYS LETT A, V372, P6633, DOI 10.1016/j.physleta.2008.09.030
   Xu SY, 2002, IEEE T AUTOMAT CONTR, V47, P1122, DOI 10.1109/TAC.2002.800651
   Xu SY, 2000, IEEE T AUTOMAT CONTR, V45, P1405
   Yang CC, 2013, APPL MATH COMPUT, V219, P5152, DOI 10.1016/j.amc.2012.11.003
   Yang M, 2012, COMMUN NONLINEAR SCI, V17, P4404, DOI 10.1016/j.cnsns.2012.03.021
   Zhang GM, 2008, AUTOMATICA, V44, P886, DOI 10.1016/j.automatica.2007.07.017
   Zhang LQ, 2003, IEEE T CIRCUITS-II, V50, P615, DOI 10.1109/TCSII.2003.816904
   Zhang Y., 2012, ABSTR APPL ANAL, V2012
   Zuo ZQ, 2010, AUTOMATICA, V46, P569, DOI 10.1016/j.automatica.2010.01.024
NR 62
TC 4
Z9 4
U1 5
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0096-3003
EI 1873-5649
J9 APPL MATH COMPUT
JI Appl. Math. Comput.
PD APR 1
PY 2014
VL 232
BP 381
EP 390
DI 10.1016/j.amc.2014.01.092
PG 10
WC Mathematics, Applied
SC Mathematics
GA AG1UM
UT WOS:000335201700038
DA 2018-12-27
ER

PT J
AU Elhosseini, MA
   Haikal, AY
AF Elhosseini, Mostafa A.
   Haikal, Amira Y.
TI RETRACTED: Modified hybrid algorithm for process optimization (Retracted
   article. See vol. 266, pg. 1177, 2015)
SO APPLIED MATHEMATICS AND COMPUTATION
LA English
DT Article; Retracted Publication
DE Culture algorithm; CSTR; Fed-batch fermentor; Genetic algorithm;
   Pressure vessel; Rastrigin
ID GENETIC ALGORITHM
AB The main weak points in using Al optimization techniques are the possibility of being trapped at local minima, being confined to the population space, difficulty to solve heavily nonlinear problems and to make full use of the historical information beside the lack of prediction about the search space. This paper is concerned with a hybrid optimization technique; namely cultural-based genetic algorithm MCBGA for solving multidimensional and nonlinear applications. The feature of proposed MCBGA technique is enhanced using biased initialization and dynamic parameters setting. Also elitism is carried out. The proposed approach has been carried out on pressure vessel design, fed-batch fermentor and continuous Stirred Tank Reactor CSTR test systems as well as Rastrigin, a well known standard workbench. The proposed MCBGA in terms of the diversity of the optimal solutions are obtained and compared to real coded genetic algorithm as well as other optimization techniques reported in the literature such as binary Genetic Algorithm (GA), Particle Swarm Optimization (PSO) and its variants. The results obtained using the proposed algorithm are more accurate and the fast convergence is obvious. (c) 2014 Elsevier Inc. All rights reserved.
C1 [Elhosseini, Mostafa A.; Haikal, Amira Y.] Mansoura Univ, Fac Engn, Comp Eng & Control Syst Dept, Mansoura, Egypt.
RP Haikal, AY (reprint author), Mansoura Univ, Fac Engn, Comp Eng & Control Syst Dept, Mansoura, Egypt.
EM melhosseini@gmail.com; amirayh@gmail.com
CR Amjady N, 2009, IEEE T POWER SYST, V24, P1489, DOI 10.1109/TPWRS.2009.2022998
   Balsa-Canto E, 2001, COMPUT CHEM ENG, V25, P539, DOI 10.1016/S0098-1354(01)00633-0
   Banga JR, 1996, NONCON OPTIM ITS APP, V7, P563
   Becerra RL, 2006, COMPUT METHOD APPL M, V195, P4303, DOI 10.1016/j.cma.2005.09.006
   Chambners L., 1995, PRACTICAL HDB GENETI
   Chen ZQ, 2011, INT J INNOV COMPUT I, V7, P4871
   Cheng R., 2000, GENETIC ALGORITHMS E
   Coelho L.S., 2006, IEEE C EV COMP, P1099
   Coello CAC, 2000, COMPUT IND, V41, P113, DOI 10.1016/S0166-3615(99)00046-9
   Gandelli A, 2005, P URSIGA
   Haupt R.L., 2004, PRACTICAL GENETIC AL, P47
   Haupt R. L., 2004, PRACTICAL GENETIC AL
   Hirmajer Tomas, 2007, AT P J PLUS2 PROCESS
   Hu X., 2003, PROCEEDINGS OF IEEE
   Janikow C. Z., 1991, P 4 INT C GEN ALG, P31
   Jiang YJ, 2012, IEEE T POWER SYST, V27, P612, DOI 10.1109/TPWRS.2011.2179951
   Juang CF, 2004, IEEE T SYST MAN CY B, V34, P997, DOI 10.1109/TSMCB.2003.818557
   Karr C. L., 1999, IND APPL GENETIC ALG
   Khalik MA, 2007, APPL MATH COMPUT, V187, P1495, DOI 10.1016/j.amc.2006.09.102
   Klepeis JL, 2003, COMPUT PHYS COMMUN, V151, P121, DOI 10.1016/S0010-4655(02)00735-X
   Kobti Z., 2006, AGENT BASED MODELING, P1111
   Kobti Z., AGENT BASED MODELING
   Liu ZG, 2012, INT J INNOV COMPUT I, V8, P8249
   Mekarapiruk W, 2001, CAN J CHEM ENG, V79, P777, DOI 10.1002/cjce.5450790512
   Mohamed Ehab R., 2010, INT J COMPUT SCI INF, V8, P37
   Ochoa A., 2008, 18 INT C EL COMM COM
   Skolpap W., 2005, SONGKLANAKARIN J SCI, V27, P1057
   Smith S, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON EVOLUTIONARY COMPUTATION, VOLS 1 AND 2, P418, DOI 10.1109/ICEC.1995.489184
   Sun DY, 2010, APPL MATH COMPUT, V216, P3343, DOI 10.1016/j.amc.2010.04.062
   WALTERS DC, 1993, IEEE T POWER SYST, V8, P1325, DOI 10.1109/59.260861
   Wu M, 2009, CONTROL ENG PRACT, V17, P280, DOI 10.1016/j.conengprac.2008.07.007
   Xidong Jin, 1999, Proceedings of the 1999 Congress on Evolutionary Computation-CEC99 (Cat. No. 99TH8406), P1672, DOI 10.1109/CEC.1999.785475
   Xue ZG, 2007, 2007 IEEE INTERNATIONAL CONFERENCE ON INTEGRATION TECHNOLOGY, PROCEEDINGS, P117, DOI 10.1109/ICITECHNOLOGY.2007.4290443
NR 33
TC 3
Z9 4
U1 3
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0096-3003
EI 1873-5649
J9 APPL MATH COMPUT
JI Appl. Math. Comput.
PD APR 1
PY 2014
VL 232
BP 1209
EP 1224
DI 10.1016/j.amc.2014.01.117
PG 16
WC Mathematics, Applied
SC Mathematics
GA AG1UM
UT WOS:000335201700113
DA 2018-12-27
ER

PT J
AU Sjoqvist, S
   Jungebluth, P
   Lim, ML
   Haag, JC
   Gustafsson, Y
   Lemon, G
   Baiguera, S
   Burguillos, MA
   Del Gaudio, C
   Rodriguez, AB
   Sotnichenko, A
   Kublickiene, K
   Ullman, H
   Kielstein, H
   Damberg, P
   Bianco, A
   Heuchel, R
   Zhao, Y
   Ribatti, D
   Ibarra, C
   Joseph, B
   Taylor, DA
   Macchiarini, P
AF Sjoqvist, Sebastian
   Jungebluth, Philipp
   Lim, Mei Ling
   Haag, Johannes C.
   Gustafsson, Ylva
   Lemon, Greg
   Baiguera, Silvia
   Burguillos, Miguel Angel
   Del Gaudio, Costantino
   Rodriguez, Antonio Beltran
   Sotnichenko, Alexander
   Kublickiene, Karolina
   Ullman, Henrik
   Kielstein, Heike
   Damberg, Peter
   Bianco, Alessandra
   Heuchel, Rainer
   Zhao, Ying
   Ribatti, Domenico
   Ibarra, Cristian
   Joseph, Bertrand
   Taylor, Doris A.
   Macchiarini, Paolo
TI RETRACTED: Experimental orthotopic transplantation of a
   tissue-engineered oesophagus in rats(Retracted article. See Vol.8, Artn
   No.15077, 2017)
SO NATURE COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID SMALL-INTESTINAL SUBMUCOSA; BARRIER FUNCTION; BIOLOGIC SCAFFOLD; FIBER
   TRACKING; CELL SHEETS; EX-VIVO; CANCER; DECELLULARIZATION; MATRIX; RAT
AB A tissue-engineered oesophageal scaffold could be very useful for the treatment of pediatric and adult patients with benign or malignant diseases such as carcinomas, trauma or congenital malformations. Here we decellularize rat oesophagi inside a perfusion bioreactor to create biocompatible biological rat scaffolds that mimic native architecture, resist mechanical stress and induce angiogenesis. Seeded allogeneic mesenchymal stromal cells spontaneously differentiate (proven by gene-, protein and functional evaluations) into epithelial-and muscle-like cells. The reseeded scaffolds are used to orthotopically replace the entire cervical oesophagus in immunocompetent rats. All animals survive the 14-day study period, with patent and functional grafts, and gain significantly more weight than sham-operated animals. Explanted grafts show regeneration of all the major cell and tissue components of the oesophagus including functional epithelium, muscle fibres, nerves and vasculature. We consider the presented tissue-engineered oesophageal scaffolds a significant step towards the clinical application of bioengineered oesophagi.
C1 [Sjoqvist, Sebastian; Jungebluth, Philipp; Lim, Mei Ling; Haag, Johannes C.; Gustafsson, Ylva; Lemon, Greg; Baiguera, Silvia; Rodriguez, Antonio Beltran; Macchiarini, Paolo] Karolinska Inst, Adv Ctr Translat Regenerat Med ACTREM, Dept Clin Sci Intervent & Technol CLINTEC, SE-14186 Stockholm, Sweden.
   [Sjoqvist, Sebastian; Jungebluth, Philipp; Lim, Mei Ling; Haag, Johannes C.; Gustafsson, Ylva; Rodriguez, Antonio Beltran; Macchiarini, Paolo] Karolinska Univ Hosp, Div Ear Nose & Throat, SE-14186 Stockholm, Sweden.
   [Burguillos, Miguel Angel; Joseph, Bertrand] Karolinska Inst, Canc Centrum Karolinska, SE-17177 Stockholm, Sweden.
   [Del Gaudio, Costantino; Bianco, Alessandra] Univ Rome, Dept Ind Engn, Res Unit Tor Vergata, Consortium Mat Sci & Technol INSTM, I-00133 Rome, Italy.
   [Sotnichenko, Alexander] Kuban State Med Univ, Int Sci Res Clin & Educ Ctr Regenerat Med, Krasnodar 350040, Russia.
   [Kublickiene, Karolina] Karolinska Inst, Ctr Gender Med, SE-14186 Stockholm, Sweden.
   [Kublickiene, Karolina] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Obstet & Gynecol, SE-14186 Stockholm, Sweden.
   [Ullman, Henrik] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden.
   [Kielstein, Heike] Univ Halle Wittenberg, Fac Med, Dept Anat & Cell Biol, D-06108 Halle, Saale, Germany.
   [Damberg, Peter] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Med Imaging & Technol, SE-17177 Stockholm, Sweden.
   [Heuchel, Rainer; Zhao, Ying] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, SE-14186 Stockholm, Sweden.
   [Heuchel, Rainer; Zhao, Ying] Karolinska Inst, Ctr Biosci, SE-14186 Stockholm, Sweden.
   [Ribatti, Domenico] Univ Bari, Sch Med, Natl Canc Inst Giovanni Paolo II, Dept Basic Med Sci Neurosci & Sensory Organs, I-70121 Bari, Italy.
   [Ibarra, Cristian] Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.
   [Taylor, Doris A.] Texas Heart Inst, Ctr Regenerat Med, Houston, TX 77030 USA.
RP Macchiarini, P (reprint author), Karolinska Inst, Adv Ctr Translat Regenerat Med ACTREM, Dept Clin Sci Intervent & Technol CLINTEC, SE-14186 Stockholm, Sweden.
EM paolo.macchiarini@ki.se
RI Lim, Mei Ling/N-8596-2014; Macchiarini, Paolo/E-6878-2013
OI Sotnichenko, Alexander/0000-0001-7322-0459
FU Swedish Research Council [K2012-99X-22333-01-5]; ALF Medicine
   [20120545]; European Union
FX We would like to thank Piet Boels and 3Ph_S Biomedical (www.3phs.eu) and
   Ilgar Badalov former visiting scientist at CLINTEC, Karolinska
   Institutet, Stockholm, Sweden for assisting with the functional studies
   and Kjell Hultenby at Electron Microscopy Unit (EMIL) at Karolinska
   University Hospital, Huddinge. This study was supported by Swedish
   Research Council, project number K2012-99X-22333-01-5 and ALF Medicine,
   project number 20120545. European Union Seventh Framework Programme
CR Almine JF, 2010, CHEM SOC REV, V39, P3371, DOI 10.1039/b919452p
   Andreollo NA, 2012, ABCD-ARQ BRAS CIR DI, V25, P49, DOI 10.1590/S0102-67202012000100011
   Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264
   Badylak SF, 2011, TISSUE ENG PT A, V17, P1643, DOI [10.1089/ten.TEA.2010.0739, 10.1089/ten.tea.2010.0739]
   Badylak SF, 2012, LANCET, V379, P943, DOI 10.1016/S0140-6736(12)60073-7
   Badylak SF, 2011, ANNU REV BIOMED ENG, V13, P27, DOI 10.1146/annurev-bioeng-071910-124743
   Bhrany AD, 2006, TISSUE ENG, V12, P319, DOI 10.1089/ten.2006.12.319
   Bloom DE, 2012, GLOBAL EC BURDEN NON
   Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891
   Cowles RA, 2010, PEDIATR SURG INT, V26, P1129, DOI 10.1007/s00383-010-2736-9
   Debats IBJG, 2009, NITRIC OXIDE-BIOL CH, V21, P175, DOI 10.1016/j.niox.2009.07.006
   Del Gaudio C, 2012, J BIOMED MATER RES B, V100B, P1883, DOI 10.1002/jbm.b.32756
   Doede T, 2009, ARTIF ORGANS, V33, P328, DOI 10.1111/j.1525-1594.2009.00727.x
   Friedrich LH, 2014, BIOMATERIALS, V35, P1907, DOI 10.1016/j.biomaterials.2013.11.053
   Gilbert TW, 2012, J CELL BIOCHEM, V113, P2217, DOI 10.1002/jcb.24130
   Go T, 2010, J THORAC CARDIOV SUR, V139, P437, DOI 10.1016/j.jtcvs.2009.10.002
   Goissis G, 2000, ARTIF ORGANS, V24, P217, DOI 10.1046/j.1525-1594.2000.06537.x
   Grikscheit T, 2003, J THORAC CARDIOV SUR, V126, P537, DOI 10.1016/S0022-5223(03)00032-1
   Guo CL, 2012, P NATL ACAD SCI USA, V109, P5576, DOI 10.1073/pnas.1114781109
   Gustafsson Y, 2012, BIOMATERIALS, V33, P8094, DOI 10.1016/j.biomaterials.2012.07.060
   Haag J, 2012, BIOMATERIALS, V33, P780, DOI 10.1016/j.biomaterials.2011.10.008
   Heemskerk AM, 2010, NMR BIOMED, V23, P294, DOI 10.1002/nbm.1463
   Hutcheon AEK, 2007, EXP EYE RES, V84, P32, DOI 10.1016/j.exer.2006.08.011
   Jansen PL, 2004, EUR SURG RES, V36, P104, DOI 10.1159/000076650
   Jonsson L, 2011, EUR SURG RES, V46, P169, DOI 10.1159/000324401
   Jungebluth P, 2009, J THORAC CARDIOV SUR, V138, P586, DOI 10.1016/j.jtcvs.2008.09.085
   Kaiitani M, 2001, ASAIO J, V47, P342, DOI 10.1097/00002480-200107000-00009
   Kanazawa S, 2013, J TISSUE ENG REGEN M, V7, P1, DOI 10.1002/term.458
   Kauffman AL, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00079
   Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035
   Keane TJ, 2012, BIOMATERIALS, V33, P1771, DOI 10.1016/j.biomaterials.2011.10.054
   Kuppan P, 2012, BIOTECHNOL ADV, V30, P1481, DOI 10.1016/j.biotechadv.2012.03.005
   Le Blanc K, 2006, CYTOTHERAPY, V8, P559, DOI 10.1080/14653240601045399
   Legrand C, 2012, ARCH DIS CHILD, V97, P808, DOI 10.1136/archdischild-2012-301730
   Lopes MF, 2006, DIS ESOPHAGUS, V19, P254, DOI 10.1111/j.1442-2050.2006.00574.x
   MACCHIARINI P, 1995, J THORAC CARDIOV SUR, V110, P1037, DOI 10.1016/S0022-5223(05)80172-2
   Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6
   Martin L, 2009, BRIT J SURG, V96, P1308, DOI 10.1002/bjs.6723
   MEEZAN E, 1975, LIFE SCI, V17, P1721, DOI 10.1016/0024-3205(75)90119-8
   Montoya CV, 2009, TISSUE ENG PART C-ME, V15, P191, DOI 10.1089/ten.tec.2008.0372
   Morelli T, 2011, J DENT RES, V90, P456, DOI 10.1177/0022034510389334
   Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781
   Munoz-Bongrand N, 2011, J VISC SURG, V148, pE327, DOI 10.1016/j.jviscsurg.2011.09.001
   Nakase Y, 2008, J THORAC CARDIOV SUR, V136, P850, DOI 10.1016/j.jtcvs.2008.05.027
   Nomi M, 2002, MOL ASPECTS MED, V23, P463, DOI 10.1016/S0098-2997(02)00008-0
   Ohki T, 2012, GASTROENTEROLOGY, V143, P582, DOI 10.1053/j.gastro.2012.04.050
   Ott HC, 2008, NAT MED, V14, P213, DOI 10.1038/nm1684
   Petersen TH, 2010, SCIENCE, V329, P538, DOI 10.1126/science.1189345
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shimazaki J, 2009, INVEST OPHTH VIS SCI, V50, P5672, DOI 10.1167/iovs.09-3820
   Smithers BM, 2007, ANN SURG, V245, P232, DOI 10.1097/01.sla.0000225093.58071.c6
   Song JJ, 2013, NAT MED, V19, P646, DOI 10.1038/nm.3154
   Sotocinal SG, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-55
   Stein HJ, 2005, ANN SURG, V242, P566, DOI 10.1097/01.sla.0000184211.75970.85
   STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0
   Swisher SG, 2000, J THORAC CARDIOV SUR, V119, P1126, DOI 10.1067/mtc.2000.105644
   Tan JY, 2012, BIOTECHNOL BIOENG, V109, P1, DOI 10.1002/bit.23323
   Teoh AYB, 2011, ANN SURG, V253, P1, DOI 10.1097/SLA.0b013e3181fcd991
   Uchiyama H, 2012, CLIN TRANSPLANT, V26, pE522, DOI 10.1111/ctr.12019
   Wheeler JB, 2012, SURG CLIN N AM, V92, P1077, DOI 10.1016/j.suc.2012.07.008
   Zheng MH, 2005, J BIOMED MATER RES B, V73B, P61, DOI 10.1002/jbm.b.30170
NR 61
TC 20
Z9 22
U1 4
U2 54
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR
PY 2014
VL 5
AR 3562
DI 10.1038/ncomms4562
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG2BK
UT WOS:000335220000004
PM 24736316
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Geng, S
   Wang, XY
   Xu, XY
   Zhang, HP
   Ma, Y
   Zhang, YQ
   Li, BX
   Bi, ZG
   Yang, CL
AF Geng, Shuo
   Wang, Xiaoyu
   Xu, Xiaoyan
   Zhang, Hepeng
   Ma, Yan
   Zhang, Yunqi
   Li, Baoxin
   Bi, Zhenggang
   Yang, Chenglin
TI RETRACTED: Steroid receptor co-activator-3 promotes osteosarcoma
   progression through up-regulation of FoxM1 (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Osteosarcoma; Transcription; SRC-3; FoxM1; C/EBP gamma
ID COACTIVATOR SRC FAMILY; FORKHEAD BOX M1; SRC-3/AIB1 COACTIVATOR; SYSTEMS
   BIOLOGY; CANCER; TRANSCRIPTION; E2F1; NETWORK; GENES
AB Increasing evidence suggests that the three homologous members of steroid receptor co-activator (SRC) family (SRC-1, SRC-2, and SRC-3) play key roles in enhancing cell proliferation in various human cancers, such as breast, prostate, and hepatocellular carcinoma. However, the function of SRC-3 in osteosarcoma remains largely unexplored. In the current study, we found that SRC-3, but not SRC-1 and SRC-2, was dramatically up-regulated in human osteosarcoma tissues, compared with adjacent normal tissues. To explore the functions of SRC-3 in osteosarcoma, in vitro studies were performed in MG63 and U2OS cells. SRC-3 overexpression promoted osteosarcoma cell proliferation, whereas knockdown of SRC-3 inhibits its proliferation. In support of these findings, we further demonstrated that SRC-3 up-regulated FoxM1 expression through co-activation of C/EBP gamma. Together our results show that SRC-3 drives osteosarcoma progression and imply it as a therapeutic target to abrogate osteosarcoma.
C1 [Geng, Shuo; Wang, Xiaoyu; Xu, Xiaoyan; Zhang, Hepeng; Ma, Yan; Zhang, Yunqi; Bi, Zhenggang; Yang, Chenglin] Harbin Med Univ, Dept Orthoped Surg, Affiliated Hosp 1, Harbin 150001, Heilongjiang, Peoples R China.
   [Li, Baoxin] Harbin Med Univ, Dept Pharmacol, Harbin 150081, Heilongjiang, Peoples R China.
RP Geng, S (reprint author), Harbin Med Univ, Dept Orthoped Surg, Affiliated Hosp 1, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.
EM Geng_Shuo@yeah.net; linYang_Cheng@126.com
FU National Natural Science Foundation of China [81271984]; Research Fund
   for the Doctoral Program of Higher Education of China [20122307120036];
   Natural Science Foundation for Returnees of Heilongjiang Province of
   China [LC2012C11]; Research Fund for Returnees of Education Department
   of Heilongjiang Province of China [1253HQ003]; Research Fund of the
   First Affiliated Hospital of Harbin Medical University [2013LX01]
FX This work was partially supported by National Natural Science Foundation
   of China (81271984), Research Fund for the Doctoral Program of Higher
   Education of China (20122307120036), Natural Science Foundation for
   Returnees of Heilongjiang Province of China (LC2012C11), Research Fund
   for Returnees of Education Department of Heilongjiang Province of China
   (1253HQ003), Research Fund of the First Affiliated Hospital of Harbin
   Medical University(2013LX01).
CR Agoulnik IU, 2008, ADV EXP MED BIOL, V617, P245, DOI 10.1007/978-0-387-69080-3_23
   Gojis O, 2010, NAT REV CLIN ONCOL, V7, P83, DOI 10.1038/nrclinonc.2009.219
   Jin RH, 2011, DNA REPAIR, V10, P926, DOI 10.1016/j.dnarep.2011.05.006
   Johnson AB, 2012, MOL CELL ENDOCRINOL, V348, P430, DOI 10.1016/j.mce.2011.04.021
   Li Q, 2009, CANCER RES, V69, P3501, DOI 10.1158/0008-5472.CAN-08-3045
   Li SS, 2007, CELL SIGNAL, V19, P1101, DOI 10.1016/j.cellsig.2007.02.002
   Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037
   Liontos M, 2009, AM J PATHOL, V175, P376, DOI 10.2353/ajpath.2009.081160
   Long WW, 2012, J CLIN INVEST, V122, P1869, DOI 10.1172/JCI61492
   Luo Y, 2013, ARCH MED SCI, V9, P569, DOI 10.5114/aoms.2012.30956
   McBryan J, 2012, CANCER RES, V72, P548, DOI 10.1158/0008-5472.CAN-11-2073
   Mussi P, 2006, MOL ENDOCRINOL, V20, P3105, DOI 10.1210/me.2005-0522
   Poos K, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003210
   Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576
   Teh MT, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-45
   Walsh CA, 2012, INT J BIOL SCI, V8, P470, DOI 10.7150/ijbs.4125
   Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200
   Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005
   Wang Y, 2011, MOL ENDOCRINOL, V25, P2041, DOI 10.1210/me.2011-1222
   Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039
   Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019
   Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695
   York B, 2010, J BIOL CHEM, V285, P38743, DOI 10.1074/jbc.R110.193367
   York B, 2010, P NATL ACAD SCI USA, V107, P11122, DOI 10.1073/pnas.1005262107
NR 24
TC 5
Z9 5
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2014
VL 35
IS 4
BP 3087
EP 3094
DI 10.1007/s13277-013-1406-7
PG 8
WC Oncology
SC Oncology
GA AF1TF
UT WOS:000334495900031
PM 24282087
DA 2018-12-27
ER

PT J
AU He, Y
   Coonar, A
   Gelvez-Zapata, S
   Sastry, P
   Page, A
AF He, Yong
   Coonar, Amans
   Gelvez-Zapata, Sabin
   Sastry, Post
   Page, Archer
TI RETRACTED: Evaluation of a robot-assisted video-assisted thoracoscopic
   surgery programme (Retracted article. See vol. 10, pg. 389, 2015)
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article; Retracted Publication
DE FreeHand; robot-assisted video-assisted thoracoscopic surgery;
   thoracoscopic camera holders
ID LAPAROSCOPIC RADICAL PROSTATECTOMY; VOICE-CONTROLLED ROBOT;
   QUALITY-OF-LIFE; LUNG-CANCER; THORACIC-SURGERY; CAMERA-HOLDER;
   LOBECTOMY; RESECTION; AESOP; PERFORMANCE
AB At present, there is increasing interest in surgical procedures using a robot-assisted device. The aim of this study was to investigate whether robot-assisted video-assisted thoracoscopic surgery (VATS) was more effective than conventional VATS. A total of 64 VATS lobectomies in Papworth Hospital (Cambridge, UK) were included in the study. In 34 cases the lobectomies were performed using conventional VATS (CV group), while in the remaining 30 cases the lobectomies were performed using robot-assisted VATS (Robotic group). In the robot-assisted VATS, FreeHand((R)), a thoracoscopic camera controller produced by Freehand 2010 Ltd. (Eastleigh, UK), was used. The duration of the thoracoscopic surgery in the Robotic group was 145.50 +/- 10.43 min, whereas in the CV group the duration was 162.79 +/- 9.40 min. The surgery duration in the Robotic group was 10.62% shorter than that in the CV group (P<0.05). The rates of bleeding, pulmonary infection, arrhythmia and prolonged air leak (>= 5 days) in the Robotic group were 0, 3.33, 26.67 and 13.33%, respectively, while the corresponding rates in the CV group were 2.94, 5.88, 20.59 and 17.65%, respectively. No significant differences were identified in the postoperative complication rates between the two groups (P >= 0.05). There was no perioperative mortality in the study. Compared with conventional VATS, FreeHand-assisted VATS provides a similar rate of postoperative complications and a reduced surgery duration, and may be beneficial for the recovery of the patients following VATS.
C1 [He, Yong] Fifth Hosp Dalian, Dept Thorac Surg, Dalian 116021, Liaoning, Peoples R China.
   [Coonar, Amans; Gelvez-Zapata, Sabin; Sastry, Post; Page, Archer] Cambridge Univ Partners, Papworth Hosp NHS Fdn Trust, Dept Thorac Surg, Cambridge CB23 3RE, England.
RP He, Y (reprint author), Fifth Hosp Dalian, Dept Thorac Surg, 890 Huanghe Rd, Dalian 116021, Liaoning, Peoples R China.
EM yonghecn@126.com; connarcn@163.com
CR Al-Mufarrej F, 2009, J LAPAROENDOSC ADV S, V19, P389, DOI 10.1089/lap.2008.0256
   Bodner J, 2010, MEMO-MAG EUR MED ONC, V3, P103, DOI 10.1007/s12254-010-0216-5
   Carballo M, 2002, J CARDIOTHORAC SURG, V4, P13
   D'Amico TA, 2006, J THORAC CARDIOV SUR, V131, P19, DOI 10.1016/j.jtcvs.2005.09.007
   Flores RM, 2008, ANN THORAC SURG, V85, pS710, DOI 10.1016/j.athoracsur.2007.09.055
   FUJITA H, 1995, ANN SURG, V222, P654, DOI 10.1097/00000658-199511000-00008
   Gharagozloo F, 2008, ANN THORAC SURG, V85, P1880, DOI 10.1016/j.athoracsur.2008.02.085
   Hartmann J, 2009, INT J MED ROBOT COMP, V5, P32, DOI 10.1002/rcs.228
   Iwasaki A, 2004, EUR J CARDIO-THORAC, V26, P158, DOI 10.1016/j.ejcts.2004.02.033
   Jaspers JEN, 2004, SURG LAPARO ENDO PER, V14, P145, DOI 10.1097/01.sle.0000129395.42501.5d
   KAVOUSSI LR, 1995, J UROLOGY, V154, P2134, DOI 10.1016/S0022-5347(01)66715-6
   Kunisaki C, 2004, SURG LAPARO ENDO PER, V14, P323, DOI 10.1097/01.sle.0000148468.74546.9a
   Nebot PB, 2003, SURG LAPARO ENDO PER, V13, P334
   Ohtsuka T, 2004, CHEST, V125, P1742, DOI 10.1378/chest.125.5.1742
   Okada S, 1998, LANCET, V351, P1249, DOI 10.1016/S0140-6736(98)24017-7
   Park BJ, 2006, J THORAC CARDIOV SUR, V131, P54, DOI 10.1016/j.jtcvs.2005.07.031
   Podgaetz E, 2009, INNOVATIONS, V4, P225, DOI 10.1097/IMI.0b013e3181a69bf0
   Rassweiler J, 2001, J UROLOGY, V166, P2101, DOI 10.1016/S0022-5347(05)65514-0
   Savitt MA, 2005, ANN THORAC SURG, V79, P450, DOI 10.1016/j/.athoracsur.2004.07.022
   Stolzenburg JU, 2011, BJU INT, V107, P970, DOI 10.1111/j.1464-410X.2010.09656.x
   Su LM, 2004, UROLOGY, V64, P123, DOI 10.1016/j.urology.2004.02.010
   Uchal M, 2009, SURG LAPARO ENDO PER, V19, P272, DOI 10.1097/SLE.0b013e3181a6da6c
   Wagner AA, 2006, UROLOGY, V68, P70, DOI 10.1016/j.urology.2006.02.003
   Way LW, 2003, ANN SURG, V237, P460, DOI 10.1097/00000658-200304000-00004
   Yamada K, 2008, GEN THORAC CARDIOVAS, V56, P292, DOI 10.1007/s11748-008-0240-0
NR 25
TC 4
Z9 5
U1 3
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD APR
PY 2014
VL 7
IS 4
BP 873
EP 876
DI 10.3892/etm.2014.1532
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AE9BP
UT WOS:000334299200020
PM 24669243
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Lu, N
   Gao, XY
   Zhang, S
AF Lu, Nan
   Gao, Xiaoyan
   Zhang, Shuang
TI RETRACTED: Attitudes on intimate touch during nursing care in China
   (Retracted article. See vol. 23, artn e12575, 2017)
SO INTERNATIONAL JOURNAL OF NURSING PRACTICE
LA English
DT Article; Retracted Publication
DE intimate touch; patient privacy; qualitative research
ID MALE NURSES; PRIVACY
AB Although intimate touch is essential to nursing practice, few studies have investigated patients' wishes and how nurses should perform in preserving patient privacy in China. A maximum-variation sample of 18 adults was selected, and semistructured interviews were conducted in two focus groups. Interviews were recorded and transcribed, and thematic analysis was performed. Five themes emerged from the interviews. These findings suggest that nurses should pay more attention to the patient's attitudes, needs and wishes.
C1 [Lu, Nan; Zhang, Shuang] Beijing Jishuitan Hosp, Dept Sports Med Serv, Beijing 100035, Peoples R China.
   [Gao, Xiaoyan] Beijing Jishuitan Hosp, Dept Nursing, Beijing 100035, Peoples R China.
RP Gao, XY (reprint author), Beijing Jishuitan Hosp, Dept Nursing, Beijing 100035, Peoples R China.
EM jstgxy@sina.com
CR Aronson J, 1994, QUALITATIVE REPORT, V2
   BATES AP, 1964, SOC FORCES, V42, P429, DOI 10.2307/2574986
   Black Roxie M, 2005, Work, V24, P409
   COHEN M, 1995, CAN MED ASSOC J, V153, P169
   Edwards SC, 1998, J ADV NURS, V28, P809
   ESTABROOKS CA, 1992, J ADV NURS, V17, P448, DOI 10.1111/j.1365-2648.1992.tb01929.x
   Evans JA, 2002, J ADV NURS, V40, P441, DOI 10.1046/j.1365-2648.2002.02392.x
   Glesson M, 2009, J PSYCHIATR MENT HLT, V16, P382, DOI 10.1111/j.1365-2850.2009.01389.x
   Harding Thomas, 2008, Res Theory Nurs Pract, V22, P88, DOI 10.1891/0889-7182.22.2.88
   Inoue M, 2006, J ADV NURS, V55, P559, DOI 10.1111/j.1365-2648.2006.03948.x
   Keogh Brian, 2006, Br J Nurs, V15, P1172
   Leino-Kilpi H, 2000, PATIENTS AUTONOMY PR
   Lodge N, 1997, J ADV NURS, V25, P893, DOI 10.1046/j.1365-2648.1997.1997025893.x
   MCCANN K, 1993, J ADV NURS, V18, P838, DOI 10.1046/j.1365-2648.1993.18050838.x
   Morin K H, 1999, Image J Nurs Sch, V31, P83
   O'Lynn CE, 2004, J NURS EDUC, V43, P229
   O'Lynn C, 2011, AM J NURS, V111, P24, DOI [10.1097/10.1097/01.NAJ.0000395237.83851.79, 10.1097/01.NAJ.0000395237.83851.79]
   Patton M.Q., 2002, QUALITATIVE RES EVAL
   PENNOCK JR, 1971, PRIVACY
   Pinch W J, 2000, Nurs Forum, V35, P5
   Routasalo P, 1996, NURS ETHICS, V3, P165, DOI 10.1177/096973309600300209
   Westin A. F., 1968, WASHINGTON LEE LAW R, V25, P166
   Woogara J, 2001, NURS ETHICS, V8, P234, DOI 10.1177/096973300100800308
NR 23
TC 2
Z9 2
U1 4
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1322-7114
EI 1440-172X
J9 INT J NURS PRACT
JI Int. J. Nurs. Pract.
PD APR
PY 2014
VL 20
IS 2
BP 221
EP 225
DI 10.1111/ijn.12129
PG 5
WC Nursing
SC Nursing
GA AE5QJ
UT WOS:000334043500014
PM 24713019
DA 2018-12-27
ER

PT J
AU Huang, CY
   Sheng, YY
AF Huang, Chunyun
   Sheng, Youyu
TI RETRACTED: Pimecrolimus Cream 1% in the Management of Atopic Dermatitis
   in Pediatric Patients: A Meta-Analysis (Retracted article. See vol. 9,
   e108566, 2014)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID LONG-TERM MANAGEMENT; RANDOMIZED CONTROLLED-TRIALS; ANTIINFLAMMATORY
   DRUG; TOPICAL PIMECROLIMUS; CLINICAL-TRIALS; CHILDREN; INFANTS;
   EFFICACY; ECZEMA; SAFETY
AB Objective: To evaluate the efficacy and safety of pimecrolimus cream 1% in the treatment of AD in the pediatric population.
   Methods: PubMed, EMBASE, Web of Science and Cochrane library databases were searched till July 2013. The randomized and nonrandomized blinded studies of pimecrolimus cream 1% applied twice daily with Jaded score >= 3 in pediatric patients with AD were included. The efficacy outcomes included investigator global assessment ( IGA), eczema area and severity index ( EASI) scores, pruritus and care giver's assessments and flares free period. Adverse events were reviewed to assess the safety.
   Results: Out of 81 studies, 7 were selected that enrolled 2,170 pediatric patients. The pooled analysis reported that pimecrolimus was no better to vehicle reducing eczema at day- 8, day- 26 and six weeks ( OR 4.95, 95% CI 2.79-8.80), ( OR 9.69, 95% CI 4.12- 22.83) and ( OR 3.83. 95% CI 1.94- 7.56), respectively in children. Similarly, pimecrolimus did not show beneficial effects when analyzed for mild or absent pruritus at day 4 ( OR 8.29, 95% CI 3.88- 17.72 favoring vehicle), day 43 ( OR 1.81 95% CI 1.13-2.89 favoring vehicle) and 1 week ( OR 2.29, 95% CI 1.45 to 3.60 favoring vehicle) as compared with vehicle. One study comparing pimecrolimus with tacrolimus found no significant difference in achieving mild or absent pruritus ( OR 0.94, 95% CI 0.44-1.99). More patients showed an improvement in overall disease in vehicle group at day 8 ( OR 3.30, 95% CI 2.03-5.35), day 29 ( OR 14.14, 95% CI 6.87- 29.13) and day 43 ( OR 4.11, 95% CI 2.59-6.52) as compared with pimecrolimus 1% group, as assessed by caregivers. No significant difference was seen between the total AEs in both groups ( pimecrolimus vs vehicle/ tacrolimus) ( OR 1.19, 95% CI 0.85, 1.65) Conclusion: The results of the present meta- analysis showed that pimecrolimus cream 1% was not significantly better to vehicle for AD in pediatrics population.
C1 [Huang, Chunyun; Sheng, Youyu] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Dermatol, Shanghai 200433, Peoples R China.
RP Sheng, YY (reprint author), Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Dermatol, Shanghai 200433, Peoples R China.
EM hspfsyy@163.com
FU Science and Technology Commission of Shanghai Municipality [12411951500]
FX The present work (No. 12411951500) was sponsored by Science and
   Technology Commission of Shanghai Municipality on the supply of data.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akdis CA, 2006, ALLERGY, V61, P969, DOI 10.1111/j.1398-9995.2006.01153.x
   Ashcroft DM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005500.pub2
   Ashcroft DM, 2005, BRIT MED J, V330, P516, DOI 10.1136/bmj.38376.439653.D3
   Breuer K, 2004, DERMATOLOGY, V209, P314, DOI 10.1159/000080855
   Chen SL, 2010, J DERMATOL TREAT, V21, P144, DOI 10.3109/09546630903401470
   Deckers IAG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039803
   Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187
   Eichenfield LF, 2005, INT J DERMATOL, V44, P70, DOI 10.1111/j.1365-4632.2004.02234.x
   Emerson RM, 2001, BRIT J DERMATOL, V144, P514, DOI 10.1046/j.1365-2133.2001.04077.x
   Gollnick H, 2008, BRIT J DERMATOL, V158, P1083, DOI 10.1111/j.1365-2133.2008.08484.x
   Graham-Brown RAC, 2003, INT J CLIN PRACT, V57, P319
   Grassberger M, 2004, EXP DERMATOL, V13, P721, DOI 10.1111/j.0906-6705.2004.00269.x
   Gupta AK, 2006, J EUR ACAD DERMATOL, V17, P493, DOI 10.1046/j.1468-3083.2003.00692.x
   Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x
   Hebert AA, 2006, CLIN THER, V28, P1972, DOI 10.1016/j.clinthera.2006.12.014
   Ho VC, 2003, J PEDIATR-US, V142, P155, DOI 10.1067/mpd.2003.65
   Hoare C, 2000, Health Technol Assess, V4, P1
   Hywel C, 1997, CHALLENGE DERMATOEPI
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kapp A, 2002, J ALLERGY CLIN IMMUN, V110, P277, DOI 10.1067/mai.2002.126500
   Kaufmann R, 2004, J ALLERGY CLIN IMMUN, V114, P1183, DOI 10.1016/j.jaci.2004.08.015
   KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4
   Kempers S, 2004, J AM ACAD DERMATOL, V51, P515, DOI 10.1016/j.jaad.2004.01.051
   Krakowski AC, 2008, PEDIATRICS, V122, P812, DOI 10.1542/peds.2007-2232
   LARSEN FS, 1993, MONOGR ALLERGY, V31, P9
   Luger T A, 2004, J Dermatolog Treat, V15, P169
   Meurer M, 2002, DERMATOLOGY, V205, P271, DOI 10.1159/000065863
   Meurer M, 2004, DERMATOLOGY, V208, P365, DOI 10.1159/000078462
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Papp KA, 2005, J AM ACAD DERMATOL, V52, P240, DOI 10.1016/j.jaaf.2004.09.016
   Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x
   Siegfried E, 2006, J DERMATOL TREAT, V17, P143, DOI 10.1080/09546630600647297
   Staab D, 2005, PEDIAT ALLERG IMM-UK, V16, P527, DOI 10.1111/j.1399-3038.2005.00306.x
   Stuetz A, 2001, SEMIN CUTAN MED SURG, V20, P233, DOI 10.1053/sder.2001.29066
   Su JC, 1997, ARCH DIS CHILD, V76, P159, DOI 10.1136/adc.76.2.159
   Wadonda-Kabondo N, 2003, BRIT J DERMATOL, V149, P1023, DOI 10.1111/j.1365-2133.2003.05605.x
   Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2
   Wellington K, 2004, AM J CLIN DERMATOL, V5, P479, DOI 10.2165/00128071-200405060-00013
   Williams H, 2002, BRIT MED J, V324, P1533, DOI 10.1136/bmj.324.7353.1533
   Xu F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036174
NR 40
TC 1
Z9 2
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 1
PY 2014
VL 9
IS 4
AR e93095
DI 10.1371/journal.pone.0093095
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE6KM
UT WOS:000334101100044
PM 24691404
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ouyang, TH
   Zhang, N
   Benjamin, T
   Wang, L
   Jiao, JT
   Zhao, YQ
   Chen, J
AF Ouyang, Taohui
   Zhang, Na
   Benjamin, Thomas
   Wang, Long
   Jiao, Jiantong
   Zhao, Yiqing
   Chen, Jian
TI RETRACTED: Subependymal giant cell astrocytoma: current concepts,
   management, and future directions (Retracted article. See vol. 32, pg.
   761, 2016)
SO CHILDS NERVOUS SYSTEM
LA English
DT Review; Retracted Publication
DE Subependymal giant cell astrocytoma; Tuberous sclerosis complex; mTOR
   inhibitors; Neurosurgery
ID TUBEROUS SCLEROSIS COMPLEX; CENTRAL-NERVOUS-SYSTEM; LOW-GRADE
   ASTROCYTOMAS; GAMMA-KNIFE SURGERY; CONSENSUS CONFERENCE;
   EARLY-DIAGNOSIS; TUMORS; EPILEPSY; RAPAMYCIN; EVEROLIMUS
AB Subependymal giant cell astrocytoma (SEGA) is the most common central nervous system tumor in patients with tuberous sclerosis complex (TSC). SEGAs are generally benign, non-infiltrative lesions, but they can lead to intracranial hypertension, obstructive hydrocephalus, focal neurologic deficits, and even sudden death.
   Surgical resection has been the standard treatment for SEGAs, and it is generally curative with complete resection. However, not all SEGAs are amenable to safe and complete resection. Gamma Knife stereotactic radiosurgery provides another treatment option as a primary or adjuvant treatment for SEGAs, but it has highly variable response effects with sporadic cases demonstrating its efficacy. Recently, biologically targeted pharmacotherapy with mammalian target of rapamycin (mTOR) inhibitors such as sirolimus and everolimus has provided a safe and efficacious treatment option for patients with SEGAs. However, SEGAs can recur few months after drug discontinuation, indicating that mTOR inhibitors may need to be continued to avoid recurrence. Further studies are needed to evaluate the advantages and adverse effects of long-term treatment with mTOR inhibitors. This review presents an overview of the current knowledge and particularly highlights the surgical and medical options of SEGAs in patients with TSC.
C1 [Ouyang, Taohui; Benjamin, Thomas; Wang, Long; Jiao, Jiantong; Zhao, Yiqing; Chen, Jian] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Neurosurg, Wuhan 430030, Peoples R China.
   [Zhang, Na] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Neurol, Wuhan 430030, Peoples R China.
RP Chen, J (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Neurosurg, Wuhan 430030, Peoples R China.
EM husttjchen110@163.com
CR Adriaensen MEAPM, 2009, EUR J NEUROL, V16, P691, DOI 10.1111/j.1468-1331.2009.02567.x
   Baskin HJ, 2008, PEDIATR RADIOL, V38, P936, DOI 10.1007/s00247-008-0832-y
   Beems T, 2001, MINIM INVAS NEUROSUR, V44, P58, DOI 10.1055/s-2001-13580
   Berhouma M, 2010, WORLD J PEDIATR, V6, P103, DOI 10.1007/s12519-010-0025-2
   Birca A, 2010, J NEUROSURG-PEDIATR, V6, P381, DOI 10.3171/2010.7.PEDS10221
   Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564
   BONNIN JM, 1984, J NEUROSURG, V60, P1121, DOI 10.3171/jns.1984.60.6.1121
   Boogaarts HD, 2011, NEUROSURGERY, V68, P179, DOI 10.1227/NEU.0b013e3181ffae71
   BROWN JM, 1975, MED J AUSTRALIA, V1, P811
   Buccoliero AM, 2009, NEUROPATHOLOGY, V29, P25, DOI 10.1111/j.1440-1789.2008.00934.x
   Byard RW, 2003, J FORENSIC SCI, V48, P172
   Cai RS, 2010, WORLD NEUROSURG, V73, P713, DOI 10.1016/j.wneu.2010.02.068
   Cappabianca P, 2008, NEUROSURGERY, V62, P575, DOI [10.1227/01.NEU.0000297107.42131.DF, 10.1227/01.neu.0000316262.74843.dd]
   Chan JA, 2004, J NEUROPATH EXP NEUR, V63, P1236, DOI 10.1093/jnen/63.12.1236
   Chu-Shore CJ, 2010, EPILEPSIA, V51, P1236, DOI 10.1111/j.1528-1167.2009.02474.x
   Cross JH, 2005, EPILEPSIA, V46, P17, DOI 10.1111/j.1528-1167.2005.00353.x
   Cuccia V, 2003, CHILD NERV SYST, V19, P232, DOI 10.1007/s00381-002-0700-2
   Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9
   de Ribaupierre S, 2007, NEUROSURGERY, V60, P83, DOI 10.1227/01.NEU.0000249216.19591.5D
   Debiec-Rychter M, 1999, CANCER GENET CYTOGEN, V109, P29, DOI 10.1016/S0165-4608(98)00140-X
   Ehninger D, 2008, NAT MED, V14, P843, DOI 10.1038/nm1788
   Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542
   Franz DN, 2009, ARCH DIS CHILD, V94, P75
   Franz DN, 2011, EXPERT REV ANTICANC, V11, P1181, DOI [10.1586/ERA.11.93, 10.1586/era.11.93]
   Franz DN, 2006, ANN NEUROL, V59, P490, DOI 10.1002/ana.20784
   Franz DN, 2012, LANCET
   FUJIWARA S, 1989, CHILD NERV SYST, V5, P43, DOI 10.1007/BF00706748
   Goh S, 2004, NEUROLOGY, V63, P1457
   Gomez MR, 1999, TUBEROUS SCLEROSIS C, P29
   Govindarajan B, 2003, CLIN CANCER RES, V9, P3469
   HAHN JS, 1991, NEUROLOGY, V41, P124, DOI 10.1212/WNL.41.1.124
   Henderson MA, 2009, STEREOT FUNCT NEUROS, V87, P161, DOI 10.1159/000209297
   Holmes GL, 2007, EPILEPSIA, V48, P617, DOI 10.1111/j.1528-1167.2007.01035.x
   Hyman MH, 2000, ARCH NEUROL-CHICAGO, V57, P662, DOI 10.1001/archneur.57.5.662
   Ichikawa T, 2005, J MOL DIAGN, V7, P544, DOI 10.1016/S1525-1578(10)60586-7
   JAMBAQUE I, 1991, DEV MED CHILD NEUROL, V33, P698
   Jansen FE, 2008, NEUROLOGY, V70, P908, DOI 10.1212/01.wnl.0000280578.99900.96
   Jiang T, 2011, CHILD NERV SYST, V27, P55, DOI 10.1007/s00381-010-1159-1
   Jozwiak J, 2008, LANCET ONCOL, V9, P73, DOI 10.1016/S1470-2045(07)70411-4
   Jozwiak J, 2007, NEUROMOL MED, V9, P117, DOI 10.1385/NMM:9:2:117
   Kim SK, 2001, J NEURO-ONCOL, V52, P217, DOI 10.1023/A:1010664311717
   Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481
   Koenig MK, 2008, J CHILD NEUROL, V23, P1238, DOI 10.1177/0883073808321764
   Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671
   Kwiatkowska J, 1999, NEW ENGL J MED, V340, P703, DOI 10.1056/NEJM199903043400905
   Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260
   Lam C, 2010, PEDIATR BLOOD CANCER, V54, P476, DOI 10.1002/pbc.22298
   Lin Y, 2011, FEBS J, V278, P354, DOI 10.1111/j.1742-4658.2010.07959.x
   Lopes MBS, 2007, WHO CLASSIFICATION T, V1, P218
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Matsumura H, 1998, NEUROL MED-CHIR, V38, P287, DOI 10.2176/nmc.38.287
   Medhkour A, 2002, PEDIATR NEUROSURG, V36, P271, DOI 10.1159/000058432
   MENOR F, 1992, PEDIATR RADIOL, V22, P485, DOI 10.1007/BF02012989
   Moavero R, 2011, CHILD NERV SYST, V27, P1203, DOI 10.1007/s00381-011-1406-0
   Nabbout R, 1999, J NEUROL NEUROSUR PS, V66, P370, DOI 10.1136/jnnp.66.3.370
   Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972
   O'Callaghan FJK, 2004, ARCH DIS CHILD, V89, P530, DOI 10.1136/adc.2003.026815
   OSBORNE J, 1993, DEV MED CHILD NEUROL, V35, P276
   Park KJ, 2011, J NEUROSURG, V114, P808, DOI 10.3171/2010.9.JNS10816
   Park YG, 1997, SURG NEUROL, V48, P488, DOI 10.1016/S0090-3019(97)00186-9
   Perek-Polnik M, 2012, EUR J PAEDIATR NEURO, V16, P83, DOI 10.1016/j.ejpn.2011.09.006
   Pullikuth AK, 2007, CELL SIGNAL, V19, P1621, DOI 10.1016/j.cellsig.2007.04.012
   Raab-Graham KF, 2006, SCIENCE, V314, P144, DOI 10.1126/science.1131693
   Raju GP, 2007, PEDIATR NEUROL, V36, P128, DOI 10.1016/j.pediatrneurol.2006.08.009
   Roach ES, 1999, J CHILD NEUROL, V14, P401, DOI 10.1177/088307389901400610
   Russell DS, 1959, PATHOLOGY TUMOURS NE, p[29, 105, 169]
   Sepp T, 1996, J MED GENET, V33, P962, DOI 10.1136/jmg.33.11.962
   Sharma MC, 2004, PATHOL ONCOL RES, V10, P219, DOI 10.1007/BF03033764
   SHEPHERD CW, 1991, MAYO CLIN PROC, V66, P792, DOI 10.1016/S0025-6196(12)61196-3
   SHEPHERD CW, 1991, NEUROSURGERY, V28, P864, DOI 10.1227/00006123-199106000-00013
   SHEPHERD CW, 1991, ANN NY ACAD SCI, V615, P375
   SINSON G, 1994, PEDIATR NEUROSURG, V20, P233, DOI 10.1159/000120796
   Souweidane MM, 2006, J NEUROSURG, V105, P271, DOI 10.3171/jns.2006.105.2.271
   Takata K, 2007, ARQ NEURO-PSIQUIAT, V65, P313, DOI 10.1590/S0004-282X2007000200023
   Torres OA, 1998, J CHILD NEUROL, V13, P173, DOI 10.1177/088307389801300405
   Torres VE, 2001, CONTRIB NEPHROL, V136, P33
   Tyburczy ME, 2010, AM J PATHOL, V176, P1878, DOI 10.2353/ajpath.2010.090950
   WAGA S, 1977, SURG NEUROL, V8, P99
   Wang LW, 2006, J NEUROSURG, V105, P127
   Wang YL, 2006, NEUROSCI LETT, V401, P35, DOI 10.1016/j.neulet.2006.03.011
   Wilfong A, 2011, AM EP SOC ANN M BALT
   Wong M, 2012, FUTUR NEUROL, V7, P537, DOI 10.2217/FNL.12.45
   Yalon M, 2011, CHILD NERV SYST, V27, P179, DOI 10.1007/s00381-010-1222-y
   You H, 2005, J NEURO-ONCOL, V74, P1, DOI 10.1007/s11060-004-2354-2
   Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222
NR 85
TC 13
Z9 13
U1 3
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0256-7040
EI 1433-0350
J9 CHILD NERV SYST
JI Childs Nerv. Syst.
PD APR
PY 2014
VL 30
IS 4
BP 561
EP 570
DI 10.1007/s00381-014-2383-x
PG 10
WC Clinical Neurology; Pediatrics; Surgery
SC Neurosciences & Neurology; Pediatrics; Surgery
GA AE5UT
UT WOS:000334055500004
PM 24549759
DA 2018-12-27
ER

PT J
AU Oliveira, HL
   Leonel, ED
AF Oliveira, Hugo Luiz
   Leonel, Edson Denner
TI RETRACTED: An alternative BEM formulation, based on dipoles of stresses
   and tangent operator technique, applied to cohesive crack growth
   modelling (Retracted article. See vol. 61, pg. 301, 2015)
SO ENGINEERING ANALYSIS WITH BOUNDARY ELEMENTS
LA English
DT Article; Retracted Publication
DE Dipoles of stresses; Tangent operator; Cohesive crack growth;
   Quasi-brittle fracture
ID BOUNDARY-ELEMENT METHOD; LINEAR ELASTIC FRACTURE;
   QUASI-BRITTLE-FRACTURE; PROPAGATION; CONCRETE; SIMULATION
AB Fracture mechanics has been widely studied by the scientific community in recent years because it can consistently explain the failure of structures. The simulation of the failure process of complex engineering structures requires numerical techniques coupled with robust theories. The boundary element method (BEM) has been widely used to solve such complex engineering problems, particularly those problems in which the BEM mesh dimension reduction provides modelling advantages. This paper presents an alternative BEM formulation applied to cohesive crack propagation analysis. In this type of problem, the process zone ahead of the crack tip is simulated using the fictitious crack model. Therefore, the residual resistance of the fracture process zone is represented by cohesive stresses. The proposed BEM formulation models the cohesive stresses using the domain term of the direct integral representation. This term is modified to be non-null only at the fictitious crack path. As a result of this domain term manipulation, a dipole of stresses appears that will govern the cohesive stresses. The nonlinear problem is solved using a tangent operator, which incorporates the nonlinear cohesive laws into the algebraic BEM equations. The results from the proposed formulation are compared with experimental and numerical results to validate and prove the formulation's robustness and accuracy. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Oliveira, Hugo Luiz; Leonel, Edson Denner] Univ Sao Paulo, Sch Engn Sao Carlos, Dept Struct Engn, BR-13566590 Sao Carlos, SP, Brazil.
RP Leonel, ED (reprint author), Univ Sao Paulo, Sch Engn Sao Carlos, Dept Struct Engn, Ave Trabalhador Sao Carlense,400 Ctr, BR-13566590 Sao Carlos, SP, Brazil.
EM edleonel@sc.usp.br
RI Oliveira, Hugo/K-1227-2014; Leonel, Edson/K-4774-2012
OI Oliveira, Hugo/0000-0002-0050-6904; Leonel, Edson/0000-0002-7842-0334
FU Sao Paulo State Foundation for Research (FAPESP) [2011/07771-7]
FX Sponsorship of this research project by the Sao Paulo State Foundation
   for Research (FAPESP), project number 2011/07771-7 is greatly
   appreciated.
CR Abbas S, 2010, INT J NUMER METHODS, V1
   Asferg JL, 2007, INT J NUMER METH ENG, V72, P464, DOI 10.1002/nme.2023
   Azadi H, 2011, INT J NUMER METH ENG, V85, P1017, DOI 10.1002/nme.3002
   Barenblatt G. I, 1962, ADV APPL MECH, V7, P55, DOI DOI 10.1016/S0065-2156(08)70121-2
   Belytschko T, 1999, INT J NUMER METH ENG, V45, P601, DOI 10.1002/(SICI)1097-0207(19990620)45:5<601::AID-NME598>3.0.CO;2-S
   Brebbia CA, 1992, BOUNDARY ELEMENTS IN
   Budyn E, 2004, INT J NUMER METH ENG, V61, P1741, DOI 10.1002/nme.1130
   CARPINTERI A, 1989, ENG FRACT MECH, V32, P265, DOI 10.1016/0013-7944(89)90299-3
   Cen Z, 1992, FRACT ENG MAT
   Cendon DA, 2000, INT J FRACTURE, V103, P293, DOI 10.1023/A:1007687025575
   Chen TZ, 1999, ENG FRACT MECH, V63, P591, DOI 10.1016/S0013-7944(99)00036-3
   Comi C, 2007, COMPUT METHOD APPL M, V196, P4013, DOI 10.1016/j.cma.2007.02.014
   DUGDALE DS, 1960, J MECH PHYS SOLIDS, V8, P100, DOI 10.1016/0022-5096(60)90013-2
   Ferreira MDC, 2010, ADV ENG SOFTW, V41, P1061, DOI 10.1016/j.advengsoft.2010.04.003
   Galvez JC, 1998, INT J FRACTURE, V94, P267, DOI 10.1023/A:1007578814070
   Hillerborg A., 1976, CEMENT CONCRETE RES, V6, P773, DOI [10.1016/0008-8846(76)90007-7, DOI 10.1016/0008-8846(76)90007-7]
   Leonel ED, 2012, ENG ANAL BOUND ELEM, V36, P944, DOI 10.1016/j.enganabound.2011.12.016
   Leonel ED, 2011, ENG ANAL BOUND ELEM, V35, P1237, DOI 10.1016/j.enganabound.2011.06.005
   Leonel ED, 2011, ENG FAIL ANAL, V18, P1538, DOI 10.1016/j.engfailanal.2011.05.014
   Leonel ED, 2011, ENG FRACT MECH, V78, P1077, DOI 10.1016/j.engfracmech.2010.11.012
   Leonel ED, 2010, ENG ANAL BOUND ELEM, V34, P1092, DOI 10.1016/j.enganabound.2010.06.014
   Leonel ED, 2010, ENG ANAL BOUND ELEM, V34, P122, DOI 10.1016/j.enganabound.2009.08.005
   MAIER G, 1993, COMPUT MECH, V13, P74
   Moes N, 1999, INT J NUMER METH ENG, V46, P131, DOI 10.1002/(SICI)1097-0207(19990910)46:1<131::AID-NME726>3.0.CO;2-J
   Moes N, 2002, ENG FRACT MECH, V69, P813, DOI 10.1016/S0013-7944(01)00128-X
   Mohammadnejad T, 2013, INT J NUMER ANAL MET, V37, P1247, DOI 10.1002/nag.2079
   Oliveira HL, 2013, KEY ENG MATER, V560, P99, DOI 10.4028/www.scientific.net/KEM.560.99
   Poon H, 1998, ENG ANAL BOUND ELEM, V22, P257, DOI 10.1016/S0955-7997(98)00030-7
   SALEH AL, 1995, ENG FRACT MECH, V51, P533, DOI 10.1016/0013-7944(94)00301-W
   Sukumar N, 2003, INT J NUMER METH ENG, V56, P2015, DOI 10.1002/nme.653
   Yan XQ, 2007, ENG FRACT MECH, V74, P2225, DOI 10.1016/j.engfracmech.2006.10.020
   Yang B, 1998, INT J FRACTURE, V93, P115, DOI 10.1023/A:1007535407986
NR 32
TC 17
Z9 17
U1 2
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0955-7997
EI 1873-197X
J9 ENG ANAL BOUND ELEM
JI Eng. Anal. Bound. Elem.
PD APR
PY 2014
VL 41
BP 74
EP 82
DI 10.1016/j.enganabound.2014.01.002
PG 9
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
   Applications
SC Engineering; Mathematics
GA AE2FG
UT WOS:000333788100008
DA 2018-12-27
ER

PT J
AU Ye, JT
   Zhang, YJ
   Yoshida, M
   Saito, Y
   Iwasa, Y
AF Ye, J. T.
   Zhang, Y. J.
   Yoshida, M.
   Saito, Y.
   Iwasa, Y.
TI RETRACTED: Field-Induced Superconductivity in MoS2 (Retracted article.
   See vol. 27, pg. 2645, 2014)
SO JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM
LA English
DT Article; Retracted Publication
ID TRANSITION-TEMPERATURE; INSULATOR; TRANSISTORS; MECHANISM; SYSTEMS
AB Semiconducting TMDs are nowadays attracting great interest after the invention of the so-called "Scotch-tape method" established in graphene research. Semiconducting TMDs are front-runners of "post graphene" materials for their finite band gap crucial for device applications. MoS2 is the most widely used TMD because of its application as a solid lubricant. Scientifically, it shows superconductivity after alkali or alkaline-earth doping with a highest T (c) of around 7 K. Recently, we succeeded in inducing superconductivity in the MoS2 transistor adopting electric double layer (EDL), a nanosized capacitor, as a gate dielectric. The field-induced superconducting transition of MoS2 was realized with a maximum T (c) around 11 K, the highest not only within a reported MoS2 compound, but also among TMDs. This highest T (c) lies in the carrier density region much smaller than a chemically doped compound; a low density region has never been successfully accessed by chemical methods. Combining a HfO2 (high-k) back gate, quasi-continuous control of carrier density, and thus quantum phase, was demonstrated to unveil the phase diagram; the T (c) exhibits strong carrier density dependence with a superconducting dome. Our result implies a common existence of the superconducting dome in 2D band insulators.
C1 [Ye, J. T.; Zhang, Y. J.; Yoshida, M.; Saito, Y.; Iwasa, Y.] Univ Tokyo, Quantum Phase Elect Ctr, Bunkyo Ku, Tokyo 1138656, Japan.
   [Ye, J. T.; Zhang, Y. J.; Yoshida, M.; Saito, Y.; Iwasa, Y.] Univ Tokyo, Dept Appl Phys, Bunkyo Ku, Tokyo 1138656, Japan.
   [Ye, J. T.] Univ Groningen, Zernike Inst Adv Mat, NL-9700 AE Groningen, Netherlands.
   [Iwasa, Y.] RIKEN, CERG, Wako, Saitama 3510198, Japan.
RP Ye, JT (reprint author), Univ Groningen, Zernike Inst Adv Mat, Nijenborgh 4, NL-9700 AE Groningen, Netherlands.
EM j.ye@rug.nl
RI Ye, Jianting/K-8194-2012
FU Japan and Strategic International Collaborative Research Program
   (SICORP), Japan Science and Technology Agency [21224009]; Japan Society
   for the Promotion of Science (JSPS) through its Funding Program for
   World-Leading Innovative R&D on Science and Technology (FIRST Program)
FX This work was supported by Grant-in-Aid for Scientific Research (S) (No.
   21224009) from Japan and Strategic International Collaborative Research
   Program (SICORP), Japan Science and Technology Agency. Y.I. was
   supported by the Japan Society for the Promotion of Science (JSPS)
   through its Funding Program for World-Leading Innovative R&D on Science
   and Technology (FIRST Program).
CR Abrahams E, 2001, REV MOD PHYS, V73, P251, DOI 10.1103/RevModPhys.73.251
   Ahn CH, 2006, REV MOD PHYS, V78, P1185, DOI 10.1103/RevModPhys.78.1185
   Ahn CH, 2003, NATURE, V424, P1015, DOI 10.1038/nature01878
   ALLENDER D, 1973, PHYS REV B, V7, P1020, DOI 10.1103/PhysRevB.7.1020
   Bao WZ, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4789365
   BRAZOVSKII S, 1985, SOLID STATE COMMUN, V55, P187, DOI 10.1016/0038-1098(85)90276-5
   Caviglia AD, 2008, NATURE, V456, P624, DOI 10.1038/nature07576
   Checkelsky JG, 2012, NAT PHYS, V8, P729, DOI [10.1038/NPHYS2388, 10.1038/nphys2388]
   FIVAZ R, 1967, PHYS REV, V163, P743, DOI 10.1103/PhysRev.163.743
   GLOVER RE, 1960, PHYS REV LETT, V5, P248, DOI 10.1103/PhysRevLett.5.248
   Klein T, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.165313
   Novoselov KS, 2005, P NATL ACAD SCI USA, V102, P10451, DOI 10.1073/pnas.0502848102
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   SCHOOLEY JF, 1965, PHYS REV LETT, V14, P305, DOI 10.1103/PhysRevLett.14.305
   SHANKS HR, 1974, SOLID STATE COMMUN, V15, P753, DOI 10.1016/0038-1098(74)90254-3
   SOMOANO RB, 1973, J CHEM PHYS, V58, P697, DOI 10.1063/1.1679256
   Taguchi Y, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.107001
   TAKADA Y, 1978, J PHYS SOC JPN, V45, P786, DOI 10.1143/JPSJ.45.786
   Ueno K, 2008, NAT MATER, V7, P855, DOI 10.1038/nmat2298
   Wang QH, 2012, NAT NANOTECHNOL, V7, P699, DOI [10.1038/nnano.2012.193, 10.1038/NNANO.2012.193]
   WOOLLAM JA, 1977, MATER SCI ENG, V31, P289, DOI 10.1016/0025-5416(77)90048-9
   Ye JT, 2012, SCIENCE, V338, P1193, DOI 10.1126/science.1228006
   Ye JT, 2010, PHYSICA C, V470, pS682, DOI 10.1016/j.physc.2009.10.140
   Ye JT, 2010, NAT MATER, V9, P125, DOI [10.1038/nmat2587, 10.1038/NMAT2587]
   Ye JT, 2011, P NATL ACAD SCI USA, V108, P13002, DOI 10.1073/pnas.1018388108
   Zhang YJ, 2012, NANO LETT, V12, P1136, DOI 10.1021/nl2021575
NR 26
TC 6
Z9 6
U1 5
U2 96
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1939
EI 1557-1947
J9 J SUPERCOND NOV MAGN
JI J. Supercond. Nov. Magn
PD APR
PY 2014
VL 27
IS 4
BP 981
EP 985
DI 10.1007/s10948-013-2422-y
PG 5
WC Physics, Applied; Physics, Condensed Matter
SC Physics
GA AD4HO
UT WOS:000333209600018
DA 2018-12-27
ER

PT J
AU Bustan, D
   Sani, SKH
   Pariz, N
AF Bustan, Danyal
   Sani, Seyyed Kamal Hosseini
   Pariz, Naser
TI RETRACTED: Immersion and Invariance based Fault Tolerant Adaptive
   Spacecraft Attitude Control(Retracted article. See vol. 15, pg. 965,
   2017)
SO INTERNATIONAL JOURNAL OF CONTROL AUTOMATION AND SYSTEMS
LA English
DT Article; Retracted Publication
DE Actuator fault; fault tolerant control; immersion and invariance;
   spacecraft attitude control
ID NONLINEAR-SYSTEMS; ATTITUDE TRACKING; CONTROLLER; OBSERVER;
   STABILIZATION
AB In this paper, an immersion and invariance (I&I) adaptive fault tolerant satellite attitude tracking control scheme is proposed. The proposed controller is capable of track the desired trajectory in the presence of unknown actuator multiplicative faults and unknown inertial matrix. Also based on Lyapunov direct method, all closed loop signals are proven to be globally asymptotically stable. The main advantage of this controller is improving closed loop performance while maintaining stability in the presence of unknown actuator faults. This method does not rely on certainty equivalence principle so it can be used to control the transient response of overall closed loop system by means of controlling the parameter estimation behavior which is not possible in traditional adaptive control. Numerical simulations are performed to demonstrate the effectiveness of proposed control scheme.
C1 [Bustan, Danyal; Sani, Seyyed Kamal Hosseini; Pariz, Naser] Ferdowsi Univ Mashhad, Fac Elect Engn, Mashhad, Iran.
RP Bustan, D (reprint author), Ferdowsi Univ Mashhad, Fac Elect Engn, Mashhad, Iran.
EM bustan.danyal@stu.um.ac.ir; k.hosseini@um.ac.ir; n-pariz@um.ac.ir
CR Alwi H, 2009, IEEE INT CONF CON AU, P878, DOI 10.1109/ICCA.2009.5410574
   Alwi H., 2007, P 46 IEEE C DEC CONT, P2639
   Astolfi A, 2003, IEEE T AUTOMAT CONTR, V48, P590, DOI 10.1109/TAC.2003.809820
   Astolfi A, 2008, COMMUN CONTROL ENG, P1
   Cai WC, 2008, J GUID CONTROL DYNAM, V31, P1456, DOI 10.2514/1.31158
   Costic BT, 2000, IEEE DECIS CONTR P, P2424, DOI 10.1109/CDC.2000.914164
   Fujimoto Keigo, 2010, IECON 2010 - 36th Annual Conference of IEEE Industrial Electronics, P144, DOI 10.1109/IECON.2010.5675184
   Han X., 2011, DISCRETE TIME SYSTEM
   Hu Q, 2011, IET CONTROL THEORY A, V5, P271, DOI 10.1049/iet-cta.2009.0628
   Ji YH, 2012, CHIN CONT DECIS CONF, P2025, DOI 10.1109/CCDC.2012.6244326
   Jin J, 2008, CONTROL ENG PRACT, V16, P1250, DOI 10.1016/j.conengprac.2008.02.001
   Lee H, 2010, IET CONTROL THEORY A, V4, P1436, DOI 10.1049/iet-cta.2009.0159
   Li S, 2012, ADV SPACE RES, V49, P49, DOI 10.1016/j.asr.2011.08.016
   Liu YJ, 2011, IEEE T NEURAL NETWOR, V22, P1328, DOI 10.1109/TNN.2011.2159865
   Liu YJ, 2010, IEEE T SYST MAN CY A, V40, P170, DOI 10.1109/TSMCA.2009.2030164
   Seo D. E., 2007, THESIS U TEXAS AUSTI
   Sidi M., 1997, SPACECRAFT DYNAMICS
   Sonneveldt L., 2010, P AIAA GUID NAV CONT
   THANAPALAN KKT, 2006, IEEE DECIS CONTR P, P1562
   Tong SC, 2009, FUZZY SET SYST, V160, P2755, DOI 10.1016/j.fss.2009.03.008
   Tong SC, 2009, FUZZY SET SYST, V160, P1749, DOI 10.1016/j.fss.2008.09.004
   Trigo G. F., 2011, THESIS DELFT U TECHN
   Xiao B., 2011, J DYNAMIC SYSTEMS ME, V133
   Zhang JM, 2011, 2011 9TH WORLD CONGRESS ON INTELLIGENT CONTROL AND AUTOMATION (WCICA 2011), P985, DOI 10.1109/WCICA.2011.5970663
   Zhou Q, 2011, IEEE T FUZZY SYST, V19, P972, DOI 10.1109/TFUZZ.2011.2158652
   Zou AM, 2011, CONTROL ENG PRACT, V19, P10, DOI 10.1016/j.conengprac.2010.08.005
NR 26
TC 10
Z9 11
U1 1
U2 25
PU INST CONTROL ROBOTICS & SYSTEMS, KOREAN INST ELECTRICAL ENGINEERS
PI BUCHEON
PA BUCHEON TECHNO PARK 401-1506, 193 YAKDAE-DONG WONMI-GU, BUCHEON,
   GYEONGGI-DO 420-734, SOUTH KOREA
SN 1598-6446
EI 2005-4092
J9 INT J CONTROL AUTOM
JI Int. J. Control Autom. Syst.
PD APR
PY 2014
VL 12
IS 2
BP 333
EP 339
DI 10.1007/s12555-012-0536-9
PG 7
WC Automation & Control Systems
SC Automation & Control Systems
GA AD7XF
UT WOS:000333480100014
DA 2018-12-27
ER

PT J
AU Bahrpaima, K
   Ebrahimi, M
   Madani, H
   Shekarriz, S
AF Bahrpaima, Kh.
   Ebrahimi, M.
   Madani, H.
   Shekarriz, S.
TI RETRACTED: Salting-out effect on the (liquid plus liquid) equilibrium
   for the ternary systems (water plus phosphoric acid plus dichloromethane
   or 1,2-dichloroethane) (Retracted article. See vol. 121, pg. 221, 2018)
SO JOURNAL OF CHEMICAL THERMODYNAMICS
LA English
DT Article; Retracted Publication
DE Salt effect; LLE; Dichloromethane; 1,2-Dichloroethane; NRTL; GMDH
ID PARTIALLY MISCIBLE SYSTEMS; N-BUTANOL WATER; PHASE-EQUILIBRIA;
   SODIUM-CHLORIDE; MIXTURES; 25-DEGREES-C; EXTRACTION; T=(298.2; SOLVENTS;
   METHANOL
AB (Liquid + liquid) equilibrium (LLE) data for the ternary systems of the (water + phosphoric acid + dichloromethane) and (water + phosphoric acid + 1,2-dichloroethane) systems at T = 298.2 K have been studied. The effect of inorganic salts (sodium chloride and calcium chloride) on the LLE data for these ternary systems has also been investigated. The NRTL and GMDH correlations are used to fit the tie line data of these ternary liquid systems. The results for the binary interaction parameters for the NRTL model have also been reported. In order to selecting a suitable salt for better separation, the distribution coefficients and the separation factors by adding the same percent of the salts (10 wt%) have been calculated and compared. The tie line data of the ternary systems were correlated using the Othmer-Tobias method. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Bahrpaima, Kh.; Madani, H.; Shekarriz, S.] Islamic Azad Univ, Firoozabad Branch, Dept Chem, Firoozabad 74715117, Fars, Iran.
   [Ebrahimi, M.] Islamic Azad Univ, Marvdasht Branch, Dept Chem, Marvdasht, Iran.
RP Bahrpaima, K (reprint author), Islamic Azad Univ, Firoozabad Branch, Dept Chem, Firoozabad 74715117, Fars, Iran.
EM Kh.bahrpyma@iauf.ac.ir
FU Research Council of Islamic Azad University, Firoozabad Branch
FX We gratefully acknowledge the financial support from the Research
   Council of Islamic Azad University, Firoozabad Branch.
CR BEVIA FR, 1993, FLUID PHASE EQUILIBR, V89, P387, DOI 10.1016/0378-3812(93)85096-5
   Chavarnakul T, 2008, EXPERT SYST APPL, V34, P1004, DOI 10.1016/j.eswa.2006.10.028
   Chen JT, 2008, FLUID PHASE EQUILIBR, V266, P1, DOI 10.1016/j.fluid.2008.01.008
   Chen XM, 2012, FLUID PHASE EQUILIBR, V313, P102, DOI 10.1016/j.fluid.2011.09.025
   Dhouib-Sahnoun R, 2002, J CHEM ENG DATA, V47, P861, DOI 10.1021/je010293r
   Farlow S.J., 1984, SELF ORG METHOD MODE
   Ghalami-Choobar B, 2011, CHINESE J CHEM ENG, V19, P565
   Ghanadzadeh H, 2010, J CHEM THERMODYN, V42, P695, DOI 10.1016/j.jct.2010.01.001
   Gilani HG, 2013, THERMOCHIM ACTA, V558, P36, DOI 10.1016/j.tca.2013.02.006
   Gilani HG, 2013, FLUID PHASE EQUILIBR, V337, P32, DOI 10.1016/j.fluid.2012.09.038
   Gilani HG, 2012, J CHEM THERMODYN, V53, P52, DOI 10.1016/j.jct.2012.04.011
   Gilani HG, 2012, FLUID PHASE EQUILIBR, V316, P109, DOI 10.1016/j.fluid.2011.12.016
   Gomez-Siurana A, 2001, IND ENG CHEM RES, V40, P892, DOI 10.1021/ie000065a
   Harrison CH, 2004, J CHEM ENG DATA, V49, P218, DOI 10.1021/je030158+
   Hasseine A, 2009, DESALINATION, V242, P264, DOI 10.1016/j.desal.2008.05.006
   Ivakhnenko A. G., 1968, SOVIET AUTOMATIC CON, V13, P43
   LI ZC, 1995, FLUID PHASE EQUILIBR, V103, P143, DOI 10.1016/0378-3812(94)02615-8
   Mohsen-Nia M, 2006, J CHEM ENG DATA, V51, P1316, DOI 10.1021/je060061y
   Olaya MM, 1999, FLUID PHASE EQUILIBR, V157, P197, DOI 10.1016/S0378-3812(99)00042-4
   Othmer DF, 1942, IND ENG CHEM, V34, P690, DOI 10.1021/ie50390a011
   Prausntiz J.M., 1999, MOL THERMODYNAMICS F
   RENON H, 1968, AICHE J, V14, P135, DOI 10.1002/aic.690140124
   Reyhani SZ, 2009, IND ENG CHEM RES, V48, P2129, DOI 10.1021/ie801082s
   Ruiz F, 1998, FLUID PHASE EQUILIBR, V146, P175, DOI 10.1016/S0378-3812(98)00219-2
   Salabat A, 2010, FLUID PHASE EQUILIBR, V288, P63, DOI 10.1016/j.fluid.2009.10.020
   Shaverdi M., 2012, APPL MATH SCI, V6, P319
   Solimo HN, 1997, FLUID PHASE EQUILIBR, V137, P163, DOI 10.1016/S0378-3812(97)00084-8
   TANG YP, 1995, FLUID PHASE EQUILIBR, V105, P241, DOI 10.1016/0378-3812(94)02616-9
   Vakili-Nezhaad GR, 2004, J CHEM THERMODYN, V36, P341, DOI 10.1016/j.jct.2003.11.011
NR 29
TC 4
Z9 4
U1 2
U2 28
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0021-9614
EI 1096-3626
J9 J CHEM THERMODYN
JI J. Chem. Thermodyn.
PD APR
PY 2014
VL 71
BP 118
EP 125
DI 10.1016/j.jct.2013.11.034
PG 8
WC Thermodynamics; Chemistry, Physical
SC Thermodynamics; Chemistry
GA 302BJ
UT WOS:000330576000015
DA 2018-12-27
ER

PT J
AU Nasri, H
AF Nasri, Hamid
TI RETRACTED: Current Concepts on Anti-Phospholipase A2 Receptor Antibody
   in Idiopathic Membranous Nephropathy (Retracted article. See vol. 14,
   pg. 231, 2015)
SO IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY
LA English
DT Letter; Retracted Publication
DE Membranous nephropathy; Nephrotic syndrome; Phospholipase A2 receptor
ID A(2) RECEPTOR; GLOMERULONEPHRITIS
C1 Isfahan Univ Med Sci, Dept Nephrol, Div Nephropathol, Esfahan, Iran.
RP Nasri, H (reprint author), Isfahan Univ Med Sci, Dept Nephrol, Div Nephropathol, Esfahan, Iran.
EM hamidnasri@med.mui.ac.ir
CR Ardalan Mohammadreza, 2013, J Nephropathol, V2, P241, DOI 10.12860/JNP.2013.38
   Beck LH, 2009, NEW ENGL J MED, V361, P11, DOI 10.1056/NEJMoa0810457
   Debiec H, 2011, AM J TRANSPLANT, V11, P2144, DOI 10.1111/j.1600-6143.2011.03643.x
   Glassock RJ, 2003, SEMIN NEPHROL, V23, P324, DOI 10.1016/S0270-9295(03)00049-4
   Hofstra JM, 2011, CLIN J AM SOC NEPHRO, V6, P1286, DOI 10.2215/CJN.07210810
   Kari Jameela, 2012, J Nephropathol, V1, P162, DOI 10.5812/nephropathol.8113
   Lv JC, 2013, J AM SOC NEPHROL, V24, P1323, DOI 10.1681/ASN.2012080771
   Malleshappa P, 2013, J RENAL INJ PREV, V2, P117, DOI 10.12861/jrip.2013.37
   Murtas C, 2011, NEPHROL DIAL TRANSPL, V26, P2428, DOI 10.1093/ndt/gfr336
   Nasri H, 2013, J RENAL INJ PREV, V2, P1, DOI 10.12861/jrip.2013.01
   Nasri H, 2013, J RENAL INJ PREV, V2, P105, DOI 10.12861/jrip.2013.33
   Nasri H, 2013, J RENAL INJ PREV, V2, P107, DOI 10.12861/jrip.2013.34
   Nasri H, 2012, J RENAL INJ PREV, V1, P39, DOI 10.12861/jrip.2012.14
   Nayer Ali, 2013, J Nephropathol, V2, P214, DOI 10.12860/JNP.2013.35
   Oh YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062151
   Qin WS, 2011, J AM SOC NEPHROL, V22, P1137, DOI 10.1681/ASN.2010090967
   Rolla Davide, 2013, J Nephropathol, V2, P144, DOI 10.12860/JNP.2013.24
   Seif El, 2013, J NEPHROPATHOLOGY, V2, P53
   Stone JH, 2013, KIDNEY INT, V83, P348, DOI 10.1038/ki.2012.454
NR 19
TC 1
Z9 1
U1 1
U2 10
PU IRANIAN SCIENTIFIC SOCIETY MEDICAL ENTOMOLOGY
PI TEHRAN
PA SCHOOL PUBLIC HEALTH & INST HEALTH RESEARCH, TEHRAN UNIV MEDICAL
   SCIENCES, P O BOX  6446-14155, TEHRAN, 00000, IRAN
SN 1735-1502
EI 1735-5249
J9 IRAN J ALLERGY ASTHM
JI Iran. J. Allergy Asthma Immunol.
PD APR
PY 2014
VL 13
IS 2
BP 144
EP 146
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA 267II
UT WOS:000328090300010
PM 24338261
DA 2018-12-27
ER

PT J
AU Janecka, IP
AF Janecka, Ivo P.
TI RETRACTED: Sensing risk, fearing uncertainty: systems science approach
   to change (Retracted article. See vol. 10, 19, 2016)
SO FRONTIERS IN COMPUTATIONAL NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE change; risk; uncertainty; systems science; chaos; entropy; cancer;
   neuro-degeneration
ID PARKINSON DISEASE; LIFE-STYLE; CANCER; INFLAMMATION; BRAIN; MOUSE;
   EPIGENETICS; PERCEPTION; EXPRESSION; OVERLOAD
AB Background: Medicine devotes its primary focus to understanding change, from cells to network relationships; observations of non-linearity are inescapable. Recent events provide extraordinary examples of major non-linear surprises within the societal system: human genome-from anticipated 100,000+ genes to only 20,000+; junk DNA-initially ignored but now proven to control genetic processes; economic reversals-bursting of bubbles in technology, housing, finance; foreign wars; relentless rise in obesity, neurodegenerative diseases. There are two attributes of systems science that are especially relevant to this research: One-it offers a method for creating a structural context with a guiding path to pragmatic knowledge; and, two-it gives pre-eminence to sensory input capable to register, evaluate, and react to change.
   Materials/Methods: Public domain records of change, during the last 50 years, have been studied in the context of systems science, the dynamic systems model, and various cycles.
   Results/Conclusions: Change is dynamic, ever-present, never isolated, and of variable impact; it reflects innumerable relationships among contextual systems; change can be perceived as risk or uncertainty depending upon how the assessment is made; risk is quantifiable by sensory input and generates a degree of rational optimism; uncertainty is not quantifiable and evokes fear; trust is key to sharing risk; the measurable financial credit can be a proxy for societal trust; expanding credit dilutes trust; when a credit bubble bursts, so will trust; absence of trust paralyzes systems' relationships leading to disorganized complexity which prevents value creation and heightens the probability of random events; disappearance of value, accompanied by chaos, threatens all systems. From personal health to economic sustainability and collective rationality, most examined components of the societal system were found not to be optimized and trust was not in evidence.
C1 [Janecka, Ivo P.] Fdn Syst Res & Educ, New York, NY USA.
RP Janecka, IP (reprint author), Hlth Res Int, 333 Westbrook Rd, St Helena Isl, SC 29920 USA.
EM janecka@post.harvard.edu
RI Johnson, Marilyn/E-7209-2011
CR Ahn J, 2013, JNCI-J NATL CANCER I, V105, P1907, DOI 10.1093/jnci/djt300
   AIGRAIN S, 2013, MAKING SENSE UNCERTA
   Alladi S, 2013, NEUROLOGY, V81, P1938, DOI 10.1212/01.wnl.0000436620.33155.a4
   *AM PUBL HLTH ASS, 2012, PRET LIT STRONG PRED
   Ames R., 1999, ANALECTS CONFUCIUS P
   [Anonymous], 2010, NY TIMES
   Appelbaum B, 2013, NY TIMES
   Armbruster M, 2011, NAT NEUROSCI, V14, P824, DOI 10.1038/nn.2828
   Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2
   Barres R, 2012, CELL METAB, V15, P405, DOI 10.1016/j.cmet.2012.01.001
   BARRETT BLB, 2012, MOL ECOL, V22, P249, DOI DOI 10.1111/MEC.12110
   Bauer Nina G., 2009, Journal of Biology (London), V8, P78, DOI 10.1186/jbiol169
   Berger CC, 2013, CURR BIOL, V23, P1367, DOI 10.1016/j.cub.2013.06.012
   Blackburn EH, 2012, NATURE, V490, P169, DOI 10.1038/490169a
   Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108
   Brody H, 2013, NATURE, V502, pS81, DOI 10.1038/502S81a
   CASTI JL, 2001, GODEL LIFE LOGIC
   Chanson L, 2011, P NATL ACAD SCI USA, V108, P3264, DOI 10.1073/pnas.1019556108
   CHAPMAN S, 2012, CHICAGO TRIBUNE
   CHASE WG, 1973, COGNITIVE PSYCHOL, V4, P55, DOI 10.1016/0010-0285(73)90004-2
   Chatzi C, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000609
   Churchland MM, 2012, NATURE, V487, P51, DOI 10.1038/nature11129
   Cohen S, 2012, P NATL ACAD SCI USA, V109, P5995, DOI 10.1073/pnas.1118355109
   Collins Gail, 2013, NY TIMES
   Cotillard A, 2013, NATURE, V500, P585, DOI 10.1038/nature12480
   Cross RA, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-107
   De Wall F., 2009, PRIMATES PHILOS MORA
   Dejosez M, 2013, SCIENCE, V341, P1511, DOI 10.1126/science.1241628
   Ding H, 2013, NEUROLOGY, V81, P1531, DOI 10.1212/WNL.0b013e3182a95818
   DOTY RL, 2013, SCIENTIST
   Emes RD, 2008, NAT NEUROSCI, V11, P799, DOI 10.1038/nn.2135
   Evans MD, 2004, BIOESSAYS, V26, P533, DOI 10.1002/bies.20027
   Ferguson Niall, 2013, GREAT DEGENERATION I
   Festinger L., 1957, THEORY COGNITIVE DIS
   Friedman T. L., 2009, NY TIMES
   Frost G, 2013, BRIT J CANCER, V109, P1965, DOI 10.1038/bjc.2013.514
   Funk JA, 2011, BRAIN BEHAV IMMUN, V25, P1063, DOI 10.1016/j.bbi.2011.03.012
   Gitschier J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003828
   Goleman Daniel, 2013, FOCUS HIDDEN DRIVER
   Gorka SM, 2013, PSYCHOPHARMACOLOGY, V229, P141, DOI 10.1007/s00213-013-3090-0
   GRANTHAM J, 2007, COMMUNICATION
   GROSS B, 2011, INVESTMENT OUTLOOK
   GUNTURKUN O, 2013, FRONT COMPUT NEUROSC, V7, P89, DOI DOI 10.3389/FNC0M.2013.00089
   Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414
   HAYEK F, 1974, INHERENT LIMITATIONS
   HEISENBERG W, 1949, PHYS PRINCIPLES QUAN, P50401
   HELENO B, 2013, BMJ-BRIT MED J, V347, DOI DOI 10.1136/BMJ.F5334
   Herbstman JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072824
   Herculano-Houzel S, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.031.2009
   Hills TT, 2013, PSYCHON B REV, V20, P1023, DOI 10.3758/s13423-013-0422-3
   Hino S, 2013, J HUM GENET, V58, P410, DOI 10.1038/jhg.2013.57
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   HUPPKE RW, 2012, CHICAGO TRIBUNE
   Huth AG, 2012, NEURON, V76, P1210, DOI 10.1016/j.neuron.2012.10.014
   Ingalhalikar M, 2014, P NATL ACAD SCI USA, V111, P823, DOI 10.1073/pnas.1316909110
   Isaacson W, 2008, EINSTEIN HIS LIFE UN
   Janecka Ivo P, 2007, Int J Med Sci, V4, P164
   Jha S, 2013, JAMA INTERN MED, V173, P1751, DOI 10.1001/jamainternmed.2013.8471
   JOST T, 2013, ENVIRON MICROBIOL, DOI DOI 10.1111/1462-2920.12238.[
   Junger M, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-22
   Kimmel M, 2010, BIOL DIRECT, V5, DOI 10.1186/1745-6150-5-29
   Kondratieff Nikolai D., 2010, LONG WAVES EC LIFE
   Kumar A, 2011, FRONT COMPUT NEUROSC, V5, DOI 10.3389/fncom.2011.00038
   Lacey S, 2012, BRAIN LANG, V120, P416, DOI 10.1016/j.bandl.2011.12.016
   LAOZI MS, 1900, TAO TE CHING
   Ledoux J., 2003, SYNAPTIC SELF
   Lieberman M. D., 2013, SOCIAL WHY OUR BRAIN
   Lim JX, 2013, FASEB J, V27, P4757, DOI 10.1096/fj.13-232702
   Lin FR, 2013, JAMA INTERN MED, V173, P293, DOI 10.1001/jamainternmed.2013.1868
   Linschooten JO, 2013, FASEB J, V27, P2873, DOI 10.1096/fj.13-227694
   Lister R, 2013, SCIENCE, V341, P629, DOI 10.1126/science.1237905
   Lokmane L, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-1
   London M, 2010, NATURE, V466, P123, DOI 10.1038/nature09086
   LOPATTO E, 2012, BLOOMBERG NEWS
   Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361
   MANDELBROT BB, 2004, MISBEHAVIOR MARKETS
   Marcott SA, 2013, SCIENCE, V339, P1198, DOI 10.1126/science.1228026
   Marshall WF, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-101
   MASCARELLI A, 2013, NATURE, DOI DOI 10.1038/NATURE.2013.13981
   Maslow A., 1954, MOTIVATION PERSONALI
   Maslow AH, 1943, PSYCHOL REV, V50, P370, DOI 10.1037/h0054346
   McGinty EE, 2012, PSYCHIAT SERV, V63, P714, DOI 10.1176/appi.ps.201100169
   McMillan DC, 2013, BRIT J CANCER, V109, P529, DOI 10.1038/bjc.2013.418
   Minerbi A, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000136
   Monaghan P, 2012, AGING-US, V4, P76, DOI 10.18632/aging.100437
   Musicco M, 2013, NEUROLOGY, V81, P322, DOI 10.1212/WNL.0b013e31829c5ec1
   Naidoo N, 2008, J NEUROSCI, V28, P6539, DOI 10.1523/JNEUROSCI.5685-07.2008
   Nestler EJ, 2012, NATURE, V490, P171, DOI 10.1038/490171a
   NOLTE D, 2001, MIND LIGHT SPEED
   *NOVA, 2013, EARTH SPACE
   Ornish D, 2013, LANCET ONCOL, V14, P1112, DOI 10.1016/S1470-2045(13)70366-8
   Oury F, 2013, CELL, V155, P228, DOI 10.1016/j.cell.2013.08.042
   Pack A, 2009, SCIENTIST, V23, P42
   Packer George, 2013, UNWINDING INNER HIST
   Padmanabhan N, 2013, CELL, V155, P81, DOI 10.1016/j.cell.2013.09.002
   Pagels H. R, 1989, DREAMS REASON COMPUT
   Parnell GP, 2013, SHOCK, V40, P166, DOI 10.1097/SHK.0b013e31829ee604
   Pera MF, 2013, NAT GENET, V45, P1412, DOI 10.1038/ng.2834
   Petersen AK, 2014, HUM MOL GENET, V23, P534, DOI 10.1093/hmg/ddt430
   Plun-Favreau H, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001257
   Puterman E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010837
   Qureshi IA, 2011, ARCH NEUROL-CHICAGO, V68, P294, DOI 10.1001/archneurol.2011.6
   Ramirez S, 2013, SCIENCE, V341, P387, DOI 10.1126/science.1239073
   Rattner S., 2013, NY TIMES
   Rendall D, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-108
   Rey G, 2013, TRENDS CELL BIOL, V23, P234, DOI 10.1016/j.tcb.2013.01.003
   Rich Frank, 2009, NY TIMES, P10
   Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214
   Roberts S, 2010, NY TIMES
   Rosenblum S, 2013, J NEUROL, V260, P2357, DOI 10.1007/s00415-013-6996-x
   Samuels DC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003929
   Schipanski A, 2013, GENETICS, V193, P865, DOI 10.1534/genetics.112.149088
   Seligman M. E. P, 2012, FLOURISH VISIONARY N
   Shen CC, 2013, NEUROLOGY, V81, P1538, DOI 10.1212/WNL.0b013e3182a956ad
   SHORT D, 2013, 21 CENTURY INDEPENDE
   Smith AK, 2013, NEW ENGL J MED, V369, P2476, DOI 10.1056/NEJMp1310684
   Smith E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073148
   Smith HA, 2013, CLIN CANCER RES, V19, P4547, DOI 10.1158/1078-0432.CCR-13-1524
   Strauss W., 1991, GENERATIONS
   Swindell WR, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-55
   Syed M., 2010, BOUNCE
   Tamaki M, 2013, J NEUROSCI, V33, P13894, DOI 10.1523/JNEUROSCI.1198-13.2013
   TETRAKIS S, 2012, PLOS GENET, V8, DOI DOI 10.1371/J0UR-NAL.PGEN.1002897
   Toffler A., 1990, POWERSHIFT
   Unsain N, 2013, CELL REP, V4, P751, DOI 10.1016/j.celrep.2013.07.015
   van Gigch JP, 2007, SYST RES BEHAV SCI, V24, P261, DOI 10.1002/sres.813
   Verhoeven JE, 2014, MOL PSYCHIATR, V19, P895, DOI 10.1038/mp.2013.151
   Von Bertalanffy L., 1969, GEN SYSTEM THEORY FD
   WADE L, 2010, DRUGS ALCOHOL PLURAL
   Weaver Janelle, 2011, PLoS Biol, V9, pe1001228, DOI 10.1371/journal.pbio.1001228
   Weinstein G, 2014, JAMA NEUROL, V71, P55, DOI 10.1001/jamaneurol.2013.4781
   Weisman Jonathan, 2013, NY TIMES
   Welch HG, 2013, JAMA INTERN MED, V173, P2088, DOI 10.1001/jamainternmed.2013.6759
   Werner C, 2009, CIRCULATION, V120, P2438, DOI 10.1161/CIRCULATIONAHA.109.861005
   WIKGREN M, 2011, BIOL PSYCHIAT, V71, P294, DOI DOI 10.1016/J.BI0PSYCH.2011.09.015
   Wirtz JJ, 2014, INTELL NATL SECUR, V29, P1, DOI 10.1080/02684527.2012.748371
   Woolf NJ, 2010, NEUROQUANTOLOGY, V8, P13
   Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224
   Yowtak J, 2013, PAIN, V154, P2469, DOI 10.1016/j.pain.2013.07.024
   Yu XF, 2013, SCIENCE, V342, P727, DOI 10.1126/science.1243884
   2013, BMJ-BRIT MED J, V347, pF7141, DOI DOI 10.1136/BMJ.F7141
NR 141
TC 1
Z9 1
U1 2
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-5188
J9 FRONT COMPUT NEUROSC
JI Front. Comput. Neurosci.
PD MAR 31
PY 2014
VL 8
AR 30
DI 10.3389/fncom.2014.00030
PG 20
WC Mathematical & Computational Biology; Neurosciences
SC Mathematical & Computational Biology; Neurosciences & Neurology
GA AE2PY
UT WOS:000333816600001
PM 24744723
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Puentes, G
   Gerhardt, I
   Katzschmann, F
   Silberhorn, C
   Wrachtrup, J
   Lewenstein, M
AF Puentes, Graciana
   Gerhardt, Ilja
   Katzschmann, Fabian
   Silberhorn, Christine
   Wrachtrup, Joerg
   Lewenstein, Maciej
TI RETRACTED: Observation of Topological Structures in Photonic Quantum
   Walks (Retracted article. See vol. 113, pg. 9901, 2014)
SO PHYSICAL REVIEW LETTERS
LA English
DT Article; Retracted Publication
ID INSULATOR; STATES; WELLS; PHASE
AB Phases of matter with nontrivial topological order are predicted to exhibit a variety of exotic phenomena, such as robust localized bound states in 1D systems, and edge states in 2D systems, which are expected to display spin helicity, immunity to backscattering, and weak antilocalization. In this Letter, we present an experimental observation of topological structures generated via the controlled implementation of two consecutive noncommuting rotations in photonic discrete-time quantum walks. The second rotation introduces valleylike Dirac points in the system, allowing us to create the nontrivial topological pattern. By choosing specific values for the rotations, it is possible to coherently drive the system between topological sectors characterized by different topological invariants. We probe the full topological landscape, demonstrating the emergence of localized bound states hosted at the topological boundaries, and the existence of extremely localized or delocalized non-Gaussian quantum states. Our results pave the way for the study of valley polarization and applications of topological mechanisms in robust optical-device engineering.
C1 [Puentes, Graciana; Gerhardt, Ilja; Wrachtrup, Joerg] Univ Stuttgart, Inst Phys 3, Res Ctr SCOPE, D-70569 Stuttgart, Germany.
   [Puentes, Graciana; Gerhardt, Ilja; Wrachtrup, Joerg] Univ Stuttgart, MPI Solid State Res, D-70569 Stuttgart, Germany.
   [Puentes, Graciana; Lewenstein, Maciej] ICFO Inst Ciencies Foton, E-08860 Barcelona, Spain.
   [Katzschmann, Fabian; Silberhorn, Christine] Univ Paderborn, Dept Phys, D-33098 Paderborn, Germany.
   [Lewenstein, Maciej] ICREA, E-08010 Barcelona, Spain.
RP Puentes, G (reprint author), Univ Stuttgart, Inst Phys 3, Res Ctr SCOPE, Pfaffenwaldring 57, D-70569 Stuttgart, Germany.
EM gracianapuentes@gmail.com
RI Lewenstein, Maciej/I-1337-2014
OI Lewenstein, Maciej/0000-0002-0210-7800; Silberhorn,
   Christine/0000-0002-2349-5443
FU Max-Planck-society; EU (Squtec); Darpa (Quasar); BMBF (CHIST-ERA); ERC
   (Quagatua, Osyris); Spanish Ministry TOQATA; Baden-Wurttemberg
   Foundation; ICREA
FX The authors gratefully acknowledge A. Schreiber, P. Neumann, F.
   Reinhard, Y. Shikano, J. Asboth, J. P. Torres, and S. Moulieras for
   useful discussions and technical support. We acknowledge financial
   support by the Max-Planck-society, EU (Squtec), Darpa (Quasar), BMBF
   (CHIST-ERA), ERC (Quagatua, Osyris), Spanish Ministry TOQATA, and
   contract research of the Baden-Wurttemberg Foundation.
CR AHARONOV Y, 1993, PHYS REV A, V48, P1687, DOI 10.1103/PhysRevA.48.1687
   Asboth JK, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.195414
   Bernevig BA, 2006, SCIENCE, V314, P1757, DOI 10.1126/science.1133734
   Bloch I, 2008, REV MOD PHYS, V80, P885, DOI 10.1103/RevModPhys.80.885
   Bose S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.207901
   Broome MA, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.153602
   Broome MA, 2013, SCIENCE, V339, P794, DOI 10.1126/science.1231440
   Carolan J., ARXIV13112913
   Chen YL, 2009, SCIENCE, V325, P178, DOI 10.1126/science.1173034
   Childs AM, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.180501
   Christandl M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.187902
   Crespi A, 2013, NAT PHOTONICS, V7, P545, DOI [10.1038/nphoton.2013.112, 10.1038/NPHOTON.2013.112]
   Crespi A, 2013, NAT PHOTONICS, V7, P322, DOI [10.1038/NPHOTON.2013.26, 10.1038/nphoton.2013.26]
   Genske M, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.190601
   Gunawan O, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.186404
   Hafezi M, 2013, NAT PHOTONICS, V7, P1001, DOI [10.1038/NPHOTON.2013.274, 10.1038/nphoton.2013.274]
   Hafezi M, 2011, NAT PHYS, V7, P907, DOI [10.1038/nphys2063, 10.1038/NPHYS2063]
   Hsieh D, 2008, NATURE, V452, P970, DOI 10.1038/nature06843
   Kane CL, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.146802
   Karski M, 2009, SCIENCE, V325, P174, DOI 10.1126/science.1174436
   Kitagawa T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1872
   Kitagawa T, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.033429
   Konig M, 2007, SCIENCE, V318, P766, DOI 10.1126/science.1148047
   LAUGHLIN RB, 1983, PHYS REV LETT, V50, P1395, DOI 10.1103/PhysRevLett.50.1395
   Lewenstein M, 2012, ULTRACOLD ATOMS IN OPTICAL LATTICES: SIMULATING QUANTUM MANY-BODY SYSTEMS, P1, DOI 10.1093/acprof:oso/9780199573127.001.0001
   Moulieras S, 2013, J PHYS B-AT MOL OPT, V46, DOI 10.1088/0953-4075/46/10/104005
   Nielsen MA, 2000, QUANTUM COMPUTATION
   Obuse H, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.195139
   Peruzzo A, 2010, SCIENCE, V329, P1500, DOI 10.1126/science.1193515
   Plenio MB, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/11/113019
   Poulios K., ARXIV13082554
   Qi XL, 2008, NAT PHYS, V4, P273, DOI 10.1038/nphys913
   Rycerz A, 2007, NAT PHYS, V3, P172, DOI 10.1038/nphys547
   Schreiber A, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.180403
   Schreiber A, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.050502
   Schreiber A, 2012, SCIENCE, V336, P55, DOI 10.1126/science.1218448
   Shikano Y, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.062129
   Spagnolo N., ARXIV13111622
   Spring JB, 2013, SCIENCE, V339, P798, DOI 10.1126/science.1231692
   Tarruell L, 2012, NATURE, V483, P302, DOI 10.1038/nature10871
   THOULESS DJ, 1982, PHYS REV LETT, V49, P405, DOI 10.1103/PhysRevLett.49.405
   Tillmann M, 2013, NAT PHOTONICS, V7, P540, DOI [10.1038/nphoton.2013.102, 10.1038/NPHOTON.2013.102]
   TSUI DC, 1982, PHYS REV LETT, V48, P1559, DOI 10.1103/PhysRevLett.48.1559
   VONKLITZING K, 1980, PHYS REV LETT, V45, P494
   Wojcik A, 2012, PHYS REV A, V85, DOI 10.1103/PhysRevA.85.012329
   Xia Y, 2009, NAT PHYS, V5, P398, DOI 10.1038/NPHYS1274
   Xiao D, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.196802
   Xiao D, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.236809
   Zahringer F, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.100503
NR 49
TC 7
Z9 7
U1 7
U2 48
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 0031-9007
EI 1079-7114
J9 PHYS REV LETT
JI Phys. Rev. Lett.
PD MAR 26
PY 2014
VL 112
IS 12
AR 120502
DI 10.1103/PhysRevLett.112.120502
PG 5
WC Physics, Multidisciplinary
SC Physics
GA AE4AP
UT WOS:000333920000008
PM 24724637
DA 2018-12-27
ER

PT J
AU Babaei, A
   Mashhadi, MM
   Jafarzadeh, H
AF Babaei, A.
   Mashhadi, M. M.
   Jafarzadeh, H.
TI RETRACTED: Tube Cyclic Extrusion-Compression (TCEC) as a novel severe
   plastic deformation method for cylindrical tubes (Retracted article. See
   vol. 651, pg. 1031, 2016)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Retracted Publication
DE Severe plastic deformation; Ultrafine grain; Microhardness; Mechanical
   properties; Tube Cyclic Extrusion-Compression; AZ91
ID CHANNEL; SHEAR; MICROSTRUCTURE
AB A severe plastic deformation (SPD) method entitled Tube Cyclic Extrusion-Compression (TCEC) is proposed. Cylindrical tubes are deformed through TCEC to large strains without dimensional and geometrical changes. In the TCEC method, tubular specimen is constrained in a space with constant volume and is deformed between mandrel and chamber in which a neck zone was devised. TCEC was applied to commercial AZ91 magnesium alloy leading to substantial grain refinement even after single cycle of TCEC. Mean grain size of 800 nm was achieved after two cycles of TCEC. Microhardness of the initial tube increased from 65 Hv to 92 Hv after two processing cycles of TCEC. Moreover, hardness assessment along tube thickness demonstrates good homogeneity of hardness distribution. After two processing cycles of TCEC, yield and ultimate strengths were increased by 3 and 2.7 times compared to those in as-cast condition. The elongation to failure was also increased from initial value of 1.6% to about 9%. In order to further investigate the accumulated strains, the TCEC process was also numerically modeled by FE code of ABAQUS/Explicit. The TCEC method seems a promising SPD process for industrial applications. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Babaei, A.; Mashhadi, M. M.; Jafarzadeh, H.] Univ Tehran, Coll Engn, Dept Mech Engn, Tehran, Iran.
RP Babaei, A (reprint author), Univ Tehran, Coll Engn, Dept Mech Engn, POB 515-14395, Tehran, Iran.
EM A_babaei@ut.ac.ir
CR [Anonymous], AB EXPL VERS 6 10 US
   Arzaghi M, 2012, ACTA MATER, V60, P4393, DOI 10.1016/j.actamat.2012.04.035
   Choi YC, 2009, MET MATER INT, V15, P733, DOI 10.1007/s12540-009-0733-5
   Faraji G, 2011, MAT SCI ENG A-STRUCT, V528, P4312, DOI 10.1016/j.msea.2011.02.075
   Faraji G, 2012, MATER LETT, V77, P82, DOI 10.1016/j.matlet.2012.03.007
   Faraji G, 2011, MATER LETT, V65, P3009, DOI 10.1016/j.matlet.2011.06.039
   Faraji G, 2011, MAT SCI ENG A-STRUCT, V528, P2431, DOI 10.1016/j.msea.2010.11.065
   Lee KM, 2010, MET MATER INT, V16, P851, DOI 10.1007/s12540-010-1025-4
   Lee WB, 2006, COMPOS SCI TECHNOL, V66, P1513, DOI 10.1016/j.compscitech.2005.11.023
   Mathis K, 2005, J ALLOY COMPD, V394, P194, DOI 10.1016/j.jallcom.2004.10.050
   Mohebbi MS, 2010, MAT SCI ENG A-STRUCT, V528, P180, DOI 10.1016/j.msea.2010.08.081
   Pardis N, 2009, MAT SCI ENG A-STRUCT, V527, P355, DOI 10.1016/j.msea.2009.08.051
   Richert J., 1998, INT J MAT, V1, P479
   Saito Y, 1998, SCRIPTA MATER, V39, P1221, DOI 10.1016/S1359-6462(98)00302-9
   SEGAL VM, 1995, MAT SCI ENG A-STRUCT, V197, P157, DOI 10.1016/0921-5093(95)09705-8
   Shin DH, 2002, MAT SCI ENG A-STRUCT, V334, P239, DOI 10.1016/S0921-5093(01)01813-5
   Valiev RZ, 2006, PROG MATER SCI, V51, P881, DOI 10.1016/j.pmatsci.2006.02.003
   Zangiabadi A, 2011, MAT SCI ENG A-STRUCT, V528, P5066, DOI 10.1016/j.msea.2011.03.012
   Zhilyaev AP, 2008, PROG MATER SCI, V53, P893, DOI 10.1016/j.pmatsci.2008.03.002
NR 19
TC 13
Z9 13
U1 2
U2 20
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD MAR 26
PY 2014
VL 598
BP 1
EP 6
DI 10.1016/j.msea.2014.01.025
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA AE1ZF
UT WOS:000333772400001
DA 2018-12-27
ER

PT J
AU Li, GL
   Xu, XH
   Wang, BA
   Yao, YM
   Qin, Y
   Bai, SR
   Rong, J
   Deng, T
   Hu, YH
AF Li, Gai-Li
   Xu, Xian-Hua
   Wang, Bing-Ang
   Yao, Yi-Min
   Qin, Yang
   Bai, Shu-Rong
   Rong, Jian
   Deng, Tao
   Hu, Yong-He
TI RETRACTED: Analysis of protein-protein interaction network and
   functional modules on primary osteoporosis (Retracted article. See vol.
   20, 33, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Primary osteoporosis; Protein-protein interaction network; Functional
   modules; Differentially expressed genes; Topological properties
ID I-LIKE RECEPTORS; OSTEOCLAST DIFFERENTIATION; GENE-EXPRESSION;
   ACTIVATION; VIEW; LRP5
AB Background: Primary osteoporosis is an age-related disease, and the main cause of this disease is the failure of bone homeostasis. Previous studies have shown that primary osteoporosis is associated with gene mutations. To explore the functional modules of the PPI (protein-protein interaction) network of differentially expressed genes (DEGs), and the related pathways participating in primary osteoporosis.
   Methods: The gene expression profile of primary osteoporosis GSE35956 was downloaded from the GEO (Gene Expression Omnibus) database and included five MSC (mesenchymal stem cell) specimens of normal osseous tissue and five MSC specimens of osteoporosis. The DEGs between the two types of MSC specimens were identified by the samr package in R language. In addition, the functions and pathways of DEGs were enriched. Then the DEGs were mapped to String to acquire PPI pairs and the PPI network was constructed with by these PPI pairs. Topological properties of the network were calculated by Network Analyzer, and modules in the network were screened by Cluster ONE software. Subsequently, the fronting five modules whose P-value was less than 1.0e-05 were identified and function analysis was conducted.
   Results: A total of 797 genes were filtered as DEGs from these ten specimens of GSE35956 with 660 up-regulated genes and 137 down-regulated genes. Meanwhile, up-regulated DEGs were mainly enriched in functions and pathways related to cell cycle and DNA replication. Furthermore, there were 4,135 PPI pairs and 377 nodes in the PPI network. Four modules were enriched in different pathways, including cell cycle and DNA replication pathway in module 2.
   Conclusions: In this paper, we explored the genes and pathways involved in primary osteoporosis based on gene expression profiles, and the present findings have the potential to be used clinically for the future treatment of primary osteoporosis.
C1 [Li, Gai-Li; Xu, Xian-Hua; Qin, Yang; Bai, Shu-Rong; Rong, Jian; Deng, Tao; Hu, Yong-He] Chengdu Mil Gen Hosp, Dept Geriatr, Chengdu 610083, Peoples R China.
   [Wang, Bing-Ang; Yao, Yi-Min] 452 Hosp Peoples Liberat Army, Dept Orthoped, Chengdu 610021, Peoples R China.
RP Wang, BA (reprint author), 452 Hosp Peoples Liberat Army, Dept Orthoped, Shunjiang Rd, Chengdu 610021, Peoples R China.
EM bingangwang@hotmail.com; yonghehufh@hotmail.com
FU Chengdu Military General Hospital
FX This study was by grants from Chengdu Military General Hospital. The
   authors would also like to thank Lin Jin and Ya-juan Zhang for active
   help with data analysis.
CR Anders J, 2010, ROLLE SERPENTIN REZE
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Estrada E, 2006, PROTEOMICS, V6, P35, DOI 10.1002/pmic.200500209
   Gabet Y, 2011, J CELL PHYSIOL, V226, P991, DOI 10.1002/jcp.22412
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760
   Kato H, 2011, IMMUNOL REV, V243, P91, DOI 10.1111/j.1600-065X.2011.01052.x
   Khalid O, 2008, ENDOCRINOLOGY, V149, P5984, DOI 10.1210/en.2008-0680
   Kojima-Shibata C, 2009, IMMUNOGENETICS, V61, P153, DOI 10.1007/s00251-008-0350-y
   Konishi K, 2009, AM J RESP CRIT CARE, V180, P167, DOI 10.1164/rccm.200810-1596OC
   Korvala J, 2012, EUR J MED GENET, V55, P515, DOI 10.1016/j.ejmg.2012.06.011
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X
   Lei SF, 2009, BONE, V44, P1010, DOI 10.1016/j.bone.2008.05.016
   Liu ZP, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S11
   Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003
   MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x
   Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13
   Osako MK, 2010, CIRC RES, V107, P466, DOI 10.1161/CIRCRESAHA.110.216846
   Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259
   Peck W, 1993, CONS DEV C DIAGN PRO
   Prantner D, 2010, J IMMUNOL, V184, P2551, DOI 10.4049/jimmunol.0903704
   Przulj N, 2007, BIOINFORMATICS, V23, pE177, DOI 10.1093/bioinformatics/btl301
   Rajski M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029743
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   TRD C, 2008, R LANG ENV STAT COMP, P1
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   van Meurs JBJ, 2008, JAMA-J AM MED ASSOC, V299, P1277, DOI 10.1001/jama.299.11.1277
   Wei SW, 2006, J LEUKOCYTE BIOL, V80, P1445, DOI 10.1189/jlb.0506304
NR 32
TC 3
Z9 3
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD MAR 21
PY 2014
VL 19
AR 15
DI 10.1186/2047-783X-19-15
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AF1KW
UT WOS:000334473800001
PM 24656062
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhu, MH
   Han, D
AF Zhu, Minhui
   Han, Di
TI RETRACTED: On the fourth power mean of the two-term exponential sums
   (Retracted article. See 344, 2014)
SO JOURNAL OF INEQUALITIES AND APPLICATIONS
LA English
DT Article; Retracted Publication
DE the two-term exponential sums; fourth power mean; Gauss sums; identity;
   asymptotic formula
AB The main purpose of this paper is using the analytic methods and the properties of Gauss sums to study the computational problem of one kind of fourth power mean of two-term exponential sums, and to give an interesting identity and asymptotic formula for it.
C1 [Zhu, Minhui] Xian Polytech Univ, Sch Sci, Xian, Shaanxi, Peoples R China.
   [Han, Di] NW Univ Xian, Dept Math, Xian 710069, Shaanxi, Peoples R China.
RP Han, D (reprint author), NW Univ Xian, Dept Math, Xian 710069, Shaanxi, Peoples R China.
EM handi515@163.com
FU P.S.F. of P.R. China [2013JZ001]; N.S.F. of P.R. China [11371291]; SF of
   Education of Shaanxi province [12JK0877]
FX The authors would like to thank the referee for his very helpful and
   detailed comments, which have significantly improved the presentation of
   this paper. This work is supported by the P.S.F. (2013JZ001) and N.S.F.
   (11371291) of P.R. China, and the SF of Education of Shaanxi province
   (12JK0877).
CR Apostol T. M., 1976, INTRO ANAL NUMBER TH
   Cochrane T, 2006, J NUMBER THEORY, V116, P270, DOI 10.1016/j.jnt.2005.04.001
   Cochrane T, 2005, ACTA ARITH, V116, P35, DOI 10.4064/aa116-1-4
   Cochrane T, 1999, ACTA ARITH, V91, P249
   Cochrane T, 2001, SCI CHINA SER A, V44, P1003, DOI 10.1007/BF02878976
   Cochrane T, 2000, ASIAN J MATH, V4, P757
NR 6
TC 2
Z9 2
U1 2
U2 14
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1029-242X
J9 J INEQUAL APPL
JI J. Inequal. Appl.
PD MAR 19
PY 2014
AR 116
DI 10.1186/1029-242X-2014-116
PG 7
WC Mathematics, Applied; Mathematics
SC Mathematics
GA AK1ZB
UT WOS:000338217000001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ran, B
   Zhang, GY
   Shen, F
   Chen, JY
   Wu, JB
   Zhao, FC
   Guo, KJ
   Qi, DY
   Zhou, B
   Chen, XY
   Zhang, XZ
   Qiao, YH
   Li, M
AF Ran, Bo
   Zhang, Guo-you
   Shen, Feng
   Chen, Jia-yu
   Wu, Ji-bin
   Zhao, Feng-chao
   Guo, Kai-jin
   Qi, Dun-yi
   Zhou, Bing
   Chen, Xiang-yang
   Zhang, Xin-zhu
   Qiao, Yue-hua
   Li, Ming
TI RETRACTED: Comparison of the sagittal profiles among thoracic idiopathic
   scoliosis patients with different Cobb angles and growth potentials
   (Retracted article. See vol. 10, 44, 2015)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE Sagittal profiles; Idiopathic scoliosis; Thoracic kyphosis; Lumbar
   lordosis
ID CURVE PROGRESSION; ALIGNMENT; GIRLS; SPINE
AB Background: Previous studies have demonstrated that pelvic incidence and sacral slope are significantly greater in idiopathic scoliosis patients compared with normal adolescents. However, whether these sagittal parameters are related to the progression of scoliosis remain unknown. The present was designed to determine the differences in the sagittal profiles among thoracic idiopathic scoliosis patients with different potentials for curve progression.
   Methods: Ninety-seven outpatient idiopathic scoliosis patients enrolled from June 2008 to June 2011 were divided to three groups according to different Cobb angles and growth potentials: (1) non-progression of thoracic curve group, Risser sign of 5 and Cobb's angle < 40 degrees; (2) moderate progression of thoracic curve group, Risser sign of 5 and Cobb's angle >= 40 degrees; and (3) severe progression of thoracic curve group, Risser sign <= 3 and Cobb's angle >= 40 degrees. All patients underwent whole spinal anteroposterior and lateral X-ray in standing position, and the sagittal parameters were measured, including thoracic kyphosis, lumbar lordosis, sacral slope, pelvic incidence, and pelvic tilt.
   Results: The average thoracic scoliosis Cobb's angle in the non-progression group was significantly less than that in the moderate progression group (P < 0.01) and severe progression group (P < 0.01), but there was no statistical difference in the average thoracic scoliosis Cobb's angle between the severe progression group and moderate progression group. The average thoracic kyphosis angle in the severe progression group (9 degrees +/- 4 degrees) was significantly smaller than that in the non-progression group (18 degrees +/- 6 degrees, P < 0.01) and moderate progression group (14 degrees +/- 5 degrees, P < 0.05). No statistical differences were present in the average lumbar lordosis, sacral slope, pelvic incidence, and pelvic tilt among the three groups.
   Conclusions: Thoracic hypokyphosis is strongly related with the curve progression in thoracic idiopathic scoliosis patients, but not pelvic sagittal profiles.
C1 [Ran, Bo; Wu, Ji-bin; Zhao, Feng-chao; Guo, Kai-jin; Zhou, Bing; Chen, Xiang-yang; Zhang, Xin-zhu] Xuzhou Med Coll, Affiliated Hosp, Dept Orthoped, Xuzhou 221006, Jiangsu, Peoples R China.
   [Zhang, Guo-you; Shen, Feng; Li, Ming] Second Mil Med Univ, Changhai Hosp, Dept Orthoped, Shanghai 200433, Peoples R China.
   [Chen, Jia-yu] Kunming Gen Hosp Chengdu Mil Command, Dept Orthoped, Kunming 650032, Peoples R China.
   [Qi, Dun-yi] Xuzhou Med Coll, Affiliated Hosp, Dept Anesthesiol, Xuzhou 221006, Jiangsu, Peoples R China.
   [Qiao, Yue-hua] Xuzhou Med Coll, Affiliated Hosp, Dept Otolaryngol, Xuzhou 221006, Jiangsu, Peoples R China.
   [Qiao, Yue-hua] Xuzhou Med Coll, Affiliated Hosp, Inst Audiol & Speech Sci, Xuzhou 221006, Jiangsu, Peoples R China.
RP Chen, XY (reprint author), Xuzhou Med Coll, Affiliated Hosp, Dept Orthoped, 99 Huaihai Rd, Xuzhou 221006, Jiangsu, Peoples R China.
EM pengpinwei@hotmail.com; zhangxzhu@126.com; ranbobobobo@hotmail.com
CR Burwell R G, 2003, Pediatr Rehabil, V6, P137
   Dede O, 2011, SCOLIOSIS SPINAL DIS, V6, DOI 10.1186/1748-7161-6-24
   Dolan L, 2012, SCOLIOSIS, V7, pO14
   Guo X, 2003, J BONE JOINT SURG BR, V85B, P1026, DOI 10.1302/0301-620X.85B7.14046
   Hayashi K, 2009, SPINE, V34, P792, DOI 10.1097/BRS.0b013e31818e2c36
   Kuklo TR, 2006, SPINE, V31, P1240, DOI 10.1097/01.brs.0000217774.13433.a7
   Lee CF, 2012, SPINE J, V12, P989, DOI 10.1016/j.spinee.2012.05.009
   Legaye J, 1998, Eur Spine J, V7, P99, DOI 10.1007/s005860050038
   Mac-Thiong JM, 2003, SPINE, V28, P1404, DOI 10.1097/01.BRS.0000067118.60199.D1
   Mao SH, 2011, EUR SPINE J, V20, P260, DOI 10.1007/s00586-010-1649-6
   Ogilvie J, 2010, CURR OPIN PEDIATR, V22, P67, DOI 10.1097/MOP.0b013e32833419ac
   Ogura Y, 2013, SPINE, V38, P571, DOI 10.1097/BRS.0b013e3182761535
   Rigo M, 2006, STUD HEALTH TECHNOL, V123, P90
   Upasani VV, 2007, SPINE, V32, P1355, DOI 10.1097/BRS.0b013e318059321d
   Weinstein SL, 1999, SPINE, V24, P2592, DOI 10.1097/00007632-199912150-00006
   Ylikoski M, 2005, J PEDIATR ORTHOP B, V14, P320, DOI 10.1097/01202412-200509000-00002
NR 16
TC 5
Z9 5
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD MAR 17
PY 2014
VL 9
AR 19
DI 10.1186/1749-799X-9-19
PG 5
WC Orthopedics
SC Orthopedics
GA AG5NK
UT WOS:000335465500001
PM 24635839
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hobbenaghi, R
   Mahboob, P
   Saifzadeh, S
   Javanbakht, J
   Manesh, JYY
   Mortezaee, R
   Touni, SR
   Hosseini, E
   Aghajanshakeri, S
   Moloudizargari, M
   Javaherypour, S
AF Hobbenaghi, Rahim
   Mahboob, Pariya
   Saifzadeh, Siamak
   Javanbakht, Javad
   Manesh, Javad Yaghoobi Yeganeh
   Mortezaee, Rasool
   Touni, Seyed Rashid
   Hosseini, Ehsan
   Aghajanshakeri, Shahin
   Moloudizargari, Milad
   Javaherypour, Soheil
TI RETRACTED: Histopathological features of bone regeneration in a canine
   segmental ulnar defect model(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Bone defect; Bone regeneration; Vascular bone grafting; Histopathology;
   Dog
ID GRAFT SUBSTITUTE; DISTRACTION OSTEOGENESIS; MORPHOGENETIC PROTEIN-2;
   TUMOR-DIAGNOSIS; GROWTH-FACTOR; REPAIR; MODEL; HYDROXYAPATITE;
   RECONSTRUCTION; ANGIOGENESIS
AB Background: Today, finding an ideal biomaterial to treat the large bone defects, delayed unions and non-unions remains a challenge for orthopaedic surgeions and researchers. Several studies have been carried out on the subject of bone regeneration, each having its own advantages. The present study has been designed in vivo to evaluate the effects of cellular auto-transplantation of tail vertebrae on healing of experimental critical bone defect in a dog model.
   Methods: Six indigenous breeds of dog with 32 +/- 3.6 kg average weight from both sexes (5 males and 1 female) received bilateral critical-sized ulnar segmental defects. After determining the health condition, divided to 2 groups: The Group I were kept as control I (n = 1) while in Group II (experimental group; n = 5) bioactive bone implants were inserted. The defects were implanted with either autogeneic coccygeal bone grafts in dogs with 3-4 cm diaphyseal defects in the ulna. Defects were stabilized with internal plate fixation, and the control defects were not stabilized. Animals were euthanized at 16 weeks and analyzed by histopathology.
   Results: Histological evaluation of this new bone at sixteen weeks postoperatively revealed primarily lamellar bone, with the formation of new cortices and normal-appearing marrow elements. And also reformation cortical compartment and reconstitution of marrow space were observed at the graft-host interface together with graft resorption and necrosis responses. Finally, our data were consistent with the osteoconducting function of the tail autograft.
   Conclusions: Our results suggested that the tail vertebrae autograft seemed to be a new source of autogenous cortical bone in order to supporting segmental long bone defects in dogs. Furthermore, cellular autotransplantation was found to be a successful replacement for the tail vertebrae allograft bone at 3-4 cm segmental defects in the canine mid-ulna. Clinical application using graft expanders or bone autotransplantation should be used carefully and requires further investigation.
C1 [Hobbenaghi, Rahim] Urmia Univ, Fac Vet Med, Dept Pathol, Orumiyeh, Iran.
   [Mahboob, Pariya] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Saifzadeh, Siamak] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Javanbakht, Javad] Univ Tehran, Fac Vet Med, Dept Pathobiol, Tehran, Iran.
   [Manesh, Javad Yaghoobi Yeganeh] Shahrekord Univ, Fac Vet Med, Gradute Islamic Azad Univ Shahrekord, Shahrekord, Iran.
   [Mortezaee, Rasool] Ferdowsi Univ Mashhad, Fac Vet Med, Ferdowsi Univ Mashhad, Mashahd, Iran.
   [Touni, Seyed Rashid] Urmia Univ, Fac Vet Med, Orumiyeh, Iran.
   [Hosseini, Ehsan] Ilam Univ, Fac Vet Med, Ilam, Iran.
   [Aghajanshakeri, Shahin; Moloudizargari, Milad; Javaherypour, Soheil] Urmia Univ, Fac Vet Med, Orumiyeh, Iran.
RP Javanbakht, J (reprint author), Univ Tehran, Fac Vet Med, Dept Pathobiol, Tehran, Iran.
EM javadpatho@gmail.com
RI Saifzadeh, Siamak/J-1240-2012
OI Saifzadeh, Siamak/0000-0002-0295-7477
CR Aerssens J, 1998, ENDOCRINOLOGY, V139, P663, DOI 10.1210/en.139.2.663
   Barati F, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-120
   BLACK L, 1967, VET REC, V80, P198, DOI 10.1136/vr.80.5.198
   Bojrab JM, 1993, DISEASEMECHANISM SMA, V663-667, P1009
   Brandi ML, 2006, J BONE MINER RES, V21, P183, DOI 10.1359/JBMR.050917
   Brighton CT, 1997, J ORTHOP TRAUMA, V11, P244, DOI 10.1097/00005131-199705000-00002
   Choupina M, 2004, BRIT J PLAST SURG, V57, P465, DOI 10.1016/j.bjps.2003.12.007
   DELLOYE C, 1992, CLIN ORTHOP RELAT R, P273
   Fossum TW, 2002, TXB SMALL ANIMAL SUR, P381
   Gao TJ, 1997, BIOMATERIALS, V18, P219, DOI 10.1016/S0142-9612(96)00133-0
   Gil-Albarova J, 2004, BIOMATERIALS, V25, P4639, DOI 10.1016/j.biomaterials.2003.12.009
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086-199810001-00010
   Gogolewski S, 2000, BIOMATERIALS, V21, P2513, DOI 10.1016/S0142-9612(00)00119-8
   GONG JK, 1964, ANAT REC, V149, P319, DOI 10.1002/ar.1091490302
   GRUNDEL RE, 1991, CLIN ORTHOP RELAT R, P244
   GUILLEMIN G, 1987, J BIOMED MATER RES, V21, P557, DOI 10.1002/jbm.820210503
   Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756-3282(01)00608-1
   HOLMES RE, 1986, J BONE JOINT SURG AM, V68A, P904, DOI 10.2106/00004623-198668060-00013
   Itoh T, 1998, J VET MED SCI, V60, P451, DOI 10.1292/jvms.60.451
   Jazrawi LM, 1998, J ORTHOP TRAUMA, V12, P111, DOI 10.1097/00005131-199802000-00008
   Kato T, 1998, J ORTHOP RES, V16, P654, DOI 10.1002/jor.1100160605
   Khaki F, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-98
   Kroese-Deutman HC, 2008, INT J ORAL MAX SURG, V37, P542, DOI 10.1016/j.ijom.2008.01.009
   Li G, 1999, J ORTHOP RES, V17, P362, DOI 10.1002/jor.1100170310
   Macedo Nelson Luiz de, 2004, J. Appl. Oral Sci., V12, P137, DOI 10.1590/S1678-77572004000200011
   Mackenzie DJ, 2001, PLAST RECONSTR SURG, V107, P989, DOI 10.1097/00006534-200104010-00013
   Matsuzaki H, 2007, CALCIFIED TISSUE INT, V80, P391, DOI 10.1007/s00223-007-9031-3
   Murakami N, 2002, J BIOMED MATER RES, V62, P169, DOI 10.1002/jbm.10236
   Ongpipattanakul B, 1997, J BIOMED MATER RES, V36, P295, DOI 10.1002/(SICI)1097-4636(19970905)36:3<295::AID-JBM4>3.0.CO;2-9
   Oonishi H, 1997, CLIN ORTHOP RELAT R, P316
   Petcu EB, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-78
   Reichert JC, 2009, BIOMATERIALS, V30, P2149, DOI 10.1016/j.biomaterials.2008.12.050
   Salkeld SL, 2001, J BONE JOINT SURG AM, V83A, P803, DOI 10.2106/00004623-200106000-00001
   Sheller MR, 2004, J ORTHOPAED RES, V22, P1094, DOI 10.1016/j.orthres.2004.03.009
   SHUKLA BP, 1989, THESIS INDIAN VET RE
   Singh S, 2000, INDIAN J ANIM SCI, V70, P276
   Slatter DH, 2002, TXB SMALL ANIMAL SUR, P1785
   Tavasoly A, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-86
   Tseng SS, 2008, J BONE JOINT SURG AM, V90A, P92, DOI 10.2106/JBJS.G.01192
   Vogelin E, 2005, J BONE JOINT SURG AM, V87A, P1323, DOI 10.2106/JBJS.C.00913
NR 40
TC 5
Z9 5
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD MAR 17
PY 2014
VL 9
AR 59
DI 10.1186/1746-1596-9-59
PG 7
WC Pathology
SC Pathology
GA AF3KY
UT WOS:000334612400001
PM 24636669
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Khaki, F
   Javanbakht, J
   Sharifzad, S
   Gharagozlou, MJ
   Khadivar, F
   Manesh, JYY
   Hosseini, SH
   Anissian, A
   Touni, SR
   Gilvari, A
   Abdi, FS
AF Khaki, Fariba
   Javanbakht, Javad
   Sharifzad, Samieh
   Gharagozlou, Mohammad Javad
   Khadivar, Farshid
   Manesh, Javad Yaghoobi Yeganeh
   Hosseini, Seyed Hojjat
   Anissian, Ali
   Touni, Seyed Rashid
   Gilvari, Alireza
   Abdi, Fatemeh Soghra
TI RETRACTED: Metastatic ovarian papillary cystadenocarcinoma to the small
   intestine serous surface: report of a case of high-grade histopathologic
   malignancy(Retracted article. See vol.9, pg.76, 2016)
SO JOURNAL OF OVARIAN RESEARCH
LA English
DT Article; Retracted Publication
DE Ovary tumor; Small intestinal; Immunohistochemistry; Histopatholohy;
   Markers
ID ABDOMINAL-WALL METASTASIS; HUMAN BREAST-CANCER; TUMOR-DIAGNOSIS; MODEL;
   NEOPLASMS; PATHOLOGY; GLAND; DEER; GRANULOSA; CARCINOMA
AB Ovarian cystadenocarcinoma is characterized by marked heterogeneity and may be composed of an admixture of histologic growth patterns, including acinar, papillary and solid. In the present study, a case of isolated small intestine metastasis of ovarian papillary cystadenocarcinoma was reported. A 7-year-old female mixed-breed dog presented with a mass in the left upper quadrant with progressive enlargement of the abdomen, periodic bloody discharge from the vulva and incontinence. The tumor was histologically characterized by the presence of cysts and proliferation of papillae, both lined by single-or multi-layered pleomorphic epithelial cells. Furthermore, the mass was composed by intense cellular and nuclear pleomorphism and numerous mitotic figures. These findings indicate a tumor of high-grade malignancy with infiterative tumor cells resembling the papillary ovarian tumor in the serosal surface of the small intestine along with an intact serosa. Immunohistochemically, tumor was positive for CK7 and negative immunoreactivity for CK20. The histopathologic features coupled with the CK7 immunoreactivity led to a diagnosis of high grade ovarian papillary cystadenocarcinoma. To the best of our knowledge, this is the first case of small intestine serousal surface metastasis from ovarian papillary cystadenocarcinoma.
C1 [Khaki, Fariba; Javanbakht, Javad; Gharagozlou, Mohammad Javad] Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
   [Sharifzad, Samieh] Univ Tehran, Dept Clin Sci, Fac Vet Med, Tehran, Iran.
   [Khadivar, Farshid] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Manesh, Javad Yaghoobi Yeganeh] Shahrekord Univ, Fac Vet Med, Shahrekord, Iran.
   [Hosseini, Seyed Hojjat] Fac Vet Med, Garmsar, Iran.
   [Anissian, Ali] Islamic Azad Univ, Abhar Branch, Coll Agr, Dept Vet, Abhar, Iran.
   [Touni, Seyed Rashid] Urmia Univ, Fac Vet Med, Orumiyeh, Iran.
   [Gilvari, Alireza] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Abdi, Fatemeh Soghra] Islamic Azad Univ, Sci & Res Branch Tehran, Tehran, Iran.
RP Javanbakht, J (reprint author), Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
EM jjavanbakht60@yahoo.com
CR Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255
   Baron MA, 2002, EUR J GYNAECOL ONCOL, V23, P561
   Berezowski K, 1996, MODERN PATHOL, V9, P426
   BOSSART GD, 1983, J ZOO ANIM MED, V14, P73, DOI 10.2307/20094643
   Cathro HP, 2002, AM J CLIN PATHOL, V117, P944, DOI 10.1309/2T1Y-7BB7-DAPE-PQ6L
   CZERNOBILSKY B, 1985, EUR J CELL BIOL, V37, P175
   DOW C, 1960, J Comp Pathol, V70, P59
   Dragan E, 2005, ARCH ONCOL, V13, P86
   Ellis GL, 1996, MALIGNANT EPITHELIAL, P155
   Foss RD, 1996, AM J SURG PATHOL, V20, P1440, DOI 10.1097/00000478-199612000-00002
   GELBERG HB, 1985, VET PATHOL, V22, P572, DOI 10.1177/030098588502200610
   Haughney RVM, 2001, EUR J GYNAECOL ONCOL, V22, P102
   HELD JP, 1982, J AM VET MED ASSOC, V181, P496
   Hofle U, 2004, NEW ZEAL VET J, V52, P44, DOI 10.1080/00480169.2004.36390
   Kaku Tsunehisa, 2003, Medical Electron Microscopy, V36, P9, DOI 10.1007/s007950300002
   Kennedy PC, 1993, PATHOLOGY DOMESTIC A, P349
   Kennedy PC, 1998, WHO INT HISTOLOGICAL, V4
   Khaki F, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-98
   Kobayashi I, 1999, J ORAL PATHOL MED, V28, P282
   Lakhani SR, 2004, CLIN CANCER RES, V10, P2473, DOI 10.1158/1078-0432.CCR-1029-3
   MacLachlan N. J., 2002, Tumors in domestic animals, P547, DOI 10.1002/9780470376928.ch11
   MACLACHLAN NJ, 1987, ENVIRON HEALTH PERSP, V73, P27, DOI 10.2307/3430595
   Mittal K, 2008, ARCH PATHOL LAB MED, V132, P402, DOI 10.1043/1543-2165(2008)132[402:AOITGP]2.0.CO;2
   Naoe M, 2004, INT J UROL, V11, P1036, DOI 10.1111/j.1442-2042.2004.00929.x
   NELSON LW, 1967, J AM VET MED ASSOC, V151, P1331
   PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413
   PATNAIK AK, 1987, VET PATHOL, V24, P509, DOI 10.1177/030098588702400607
   SCHLAFER DH, 2007, JUBB KENNEDY PALMERS, V3, P431
   Seidman JD, 2002, BLAUSTEINS PATHOLOGY
   Seifert G, 1991, HISTOLOGICAL CLASSIF, P1
   Shafiee R, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-136
   Shafiee R, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-79
   SUNDBERG JP, 1985, AM J VET RES, V46, P1145
   Tavasoly A, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-86
   WAUTERS CCAP, 1995, HUM PATHOL, V26, P852, DOI 10.1016/0046-8177(95)90006-3
   Yoon BI, 1999, J ZOO WILDLIFE MED, V30, P456
NR 36
TC 3
Z9 3
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757-2215
J9 J OVARIAN RES
JI J. Ovarian Res.
PD MAR 17
PY 2014
VL 7
AR 33
DI 10.1186/1757-2215-7-33
PG 5
WC Reproductive Biology
SC Reproductive Biology
GA AF7DB
UT WOS:000334872600001
PM 24636424
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Urbanek, T
   Kuczmik, W
   Basta-Kaim, A
   Gabryel, B
AF Urbanek, Tomasz
   Kuczmik, Waclaw
   Basta-Kaim, Agnieszka
   Gabryel, Bozena
TI RETRACTED: Rapamycin induces of protective autophagy in vascular
   endothelial cells exposed to oxygen-glucose deprivation (Retracted
   article. See vol. 1694, pg. 149, 2018)
SO BRAIN RESEARCH
LA English
DT Article; Retracted Publication
DE Rapamycin; Autophagy; mTOR; Ischemia; Endothelial cells
ID FOCAL CEREBRAL-ISCHEMIA; ENDOPLASMIC-RETICULUM STRESS; NEONATAL
   HYPOXIA-ISCHEMIA; NEUROVASCULAR UNIT; BRAIN-INJURY; PROTEIN-DEGRADATION;
   INDUCED DEATH; IN-VITRO; RAT; ACTIVATION
AB The protective potential of rapamycin has been reported in a few experimental models of brain ischemia, both in vivo and in vitro. Although the precise cellular processes underlying the neuroprotective effects of rapamycin in experimental models of stroke remain unknown, the current experimental data suggest that the mechanism of action of the drug may result from the mTOR-mediated autophagy induction. However, it is unclear whether the activation of autophagy acts as a pro-death or pro-survival factor in vascular endothelial cells in ischemic brain damage. It seems to be very important, since stroke affects not only neurons and astrocytes but also microvessels. In the present study, we used human umbilical vein endothelial cells (HUVEC) subjected to ischemia-simulating conditions (combined oxygen and glucose deprivation, OGD) for 6 h to determine potential effect of rapamycin-induced autophagy on HUVEC damage. The drug at concentrations of 100 and 1000 nM increased the expression of Beclin 1 and LC3-II together with a significant increase in the p62 degradation in ischemic HUVEC. Treatment with rapamycin in OGD significantly increased the cell viability, indicating that the drug exerts cytoprotective effect. The inhibition of Beclin 1 by siRNAs significantly attenuated the expression of autophagy-related proteins and reduced HUVEC viability following OGD and rapamycin treatment. Our findings demonstrated that toxicity of simulated ischemia conditions were enhanced in HUVEC when autophagy was blocked, and that rapamycin effectively prevented OGD-evoked damage by induction of protective autophagy via inhibition of the mTOR pathway. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Urbanek, Tomasz; Kuczmik, Waclaw] Med Univ Silesia, Dept Gen & Vasc Surg, PL-40635 Katowice, Poland.
   [Basta-Kaim, Agnieszka] Polish Acad Sci, Inst Pharmacol, Dept Expt Neuroendocrinol, PL-31343 Krakow, Poland.
   [Gabryel, Bozena] Med Univ Silesia, Dept Pharmacol, PL-40752 Katowice, Poland.
RP Gabryel, B (reprint author), Med Univ Silesia, Dept Pharmacol, Medykow 18, PL-40752 Katowice, Poland.
EM bgabryel@interia.pl
FU Polish Society of Phlebology
FX The work was supported by the scientific Grant from the Polish Society
   of Phlebology.
CR Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412
   Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066
   Alirezaei M, 2011, EUR J NEUROSCI, V33, P197, DOI 10.1111/j.1460-9568.2010.07500.x
   Bae D, 2008, J BIOL CHEM, V283, P28074, DOI 10.1074/jbc.M804203200
   BODIN P, 1995, EXPERIENTIA, V51, P256, DOI 10.1007/BF01931108
   BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Carloni S, 2012, NEUROSCIENCE, V203, P160, DOI 10.1016/j.neuroscience.2011.12.021
   Carloni S, 2010, AUTOPHAGY, V6, P366, DOI 10.4161/auto.6.3.11261
   Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022
   Chauhan A, 2011, BEHAV BRAIN RES, V225, P603, DOI 10.1016/j.bbr.2011.08.035
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Ciechomska IA, 2013, ONCOGENE, V32, P1518, DOI 10.1038/onc.2012.174
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Curin Y., 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P277, DOI 10.2174/187152506778520691
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003
   Ferguson CJ, 2009, HUM MOL GENET, V18, P4868, DOI 10.1093/hmg/ddp460
   Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023
   Gabryel B, 2012, PHARMACOL REP, V64, P1
   Gabryel B, 2011, PHARMACOL REP, V63, P392, DOI 10.1016/S1734-1140(11)70505-9
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Guo HL, 2013, CARDIOVASC DRUG THER, V27, P189, DOI 10.1007/s10557-013-6442-4
   Gupta YK, 2011, INDIAN J MED RES, V133, P15
   Gurusamy N, 2009, ANTIOXID REDOX SIGN, V11, P1975, DOI [10.1089/ars.2009.2524, 10.1089/ARS.2009.2524]
   Gurusamy N, 2010, CARDIOVASC RES, V86, P103, DOI 10.1093/cvr/cvp384
   Hamid R, 2004, TOXICOL IN VITRO, V18, P703, DOI 10.1016/j.tiv.2004.03.012
   Han HS, 2005, CURR NEUROVASC RES, V2, P409, DOI 10.2174/156720205774962647
   Han J, 2012, AUTOPHAGY, V8, P812, DOI 10.4161/auto.19471
   Harris Thurl E, 2003, Sci STKE, V2003, pre15
   Hayashi S, 2009, AM J PATHOL, V175, P2226, DOI 10.2353/ajpath.2009.090152
   Hoyer-Hansen M, 2007, AUTOPHAGY, V3, P381, DOI 10.4161/auto.4240
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kubota C, 2010, J BIOL CHEM, V285, P667, DOI 10.1074/jbc.M109.053058
   Lee JS, 2012, BIOTECHNOL BIOENG, V109, P3093, DOI 10.1002/bit.24567
   Lee SR, 2004, NEUROL RES, V26, P854, DOI 10.1179/016164101X3806
   Li L, 2013, CELL SIGNAL, V25, P50, DOI 10.1016/j.cellsig.2012.09.020
   Li WL, 2013, NEUROSCIENCE, V244, P16, DOI 10.1016/j.neuroscience.2013.03.045
   Liu CL, 2010, J NEUROCHEM, V115, P68, DOI 10.1111/j.1471-4159.2010.06905.x
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Meloni BP, 2011, J NEUROSCI METH, V195, P67, DOI 10.1016/j.jneumeth.2010.11.023
   Mizushima N, 2007, AUTOPHAGY, V3, P542
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Moroni F, 2009, FEBS J, V276, P36, DOI 10.1111/j.1742-4658.2008.06768.x
   Peracchio C, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-22
   Perycz Malgorzata, 2007, Postepy Biologii Komorki, V34, P511
   Qin AP, 2010, AUTOPHAGY, V6, P738, DOI 10.4161/auto.6.6.12573
   Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005
   Raught B., 2001, NATL ACAD SCI US, V98, P7037
   Sachdev U, 2012, J VASC SURG, V55, P180, DOI 10.1016/j.jvs.2011.07.072
   Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   SEGLEN PO, 1980, MOL PHARMACOL, V18, P468
   Shacka JJ, 2006, MOL PHARMACOL, V69, P1125, DOI 10.1124/mol.105.018408
   Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233
   Uchiyama Y, 2008, HISTOCHEM CELL BIOL, V129, P407, DOI 10.1007/s00418-008-0406-y
   Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113
   Wang JY, 2011, J NEUROPATH EXP NEUR, V70, P314, DOI 10.1097/NEN.0b013e31821352bd
   Wang L, 2010, AUTOPHAGY, V6, P1115, DOI 10.4161/auto.6.8.13508
   Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5
   Wei K, 2012, CNS NEUROSCI THER, V18, P879, DOI 10.1111/cns.12005
   Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xie R, 2012, BRAIN RES, V1482, P81, DOI 10.1016/j.brainres.2012.09.009
   Xie Y, 2011, MOL MED REP, V4, P459, DOI 10.3892/mmr.2011.460
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yan CH, 2006, TOXICON, V47, P521, DOI 10.1016/j.toxicon.2006.01.010
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
   Zhou XG, 2011, BIOCHEM BIOPH RES CO, V411, P271, DOI 10.1016/j.bbrc.2011.06.117
NR 74
TC 41
Z9 44
U1 1
U2 31
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD MAR 17
PY 2014
VL 1553
BP 1
EP 11
DI 10.1016/j.brainres.2014.01.017
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA AD8DR
UT WOS:000333497200001
PM 24462935
DA 2018-12-27
ER

PT J
AU Briones, TL
   Darwish, H
AF Briones, T. L.
   Darwish, H.
TI RETRACTED: DECREASE IN AGE-RELATED TAU HYPERPHOSPHORYLATION AND
   COGNITIVE IMPROVEMENT FOLLOWING VITAMIN D SUPPLEMENTATION ARE ASSOCIATED
   WITH MODULATION OF BRAIN ENERGY METABOLISM AND REDOX STATE (Retracted
   article. See vol. 298, pg. 475, 2015)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE water maze; superoxide dismutase; glutathione; cognitive aging
ID ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL DYSFUNCTION; ALZHEIMERS-DISEASE;
   OXIDATIVE STRESS; NEURODEGENERATION; PHOSPHORYLATION; MEMORY;
   HOMEOSTASIS; DEFICIENCY; EXPERIENCE
AB In the present study we examined whether vitamin D supplementation can reduce age-related tau hyperphosphorylation and cognitive impairment by enhancing brain energy homeostasis and protein phosphatase 2A (PP2A) activity, and modulating the redox state. Male F344 rats aged 20 months (aged) and 6 months (young) were randomly assigned to either vitamin D supplementation or no supplementation (control). Rats were housed in pairs and the supplementation group (n = 10 young and n = 10 aged) received subcutaneous injections of vitamin D (1, alpha 25-dihydroxyvitamin D3) for 21 days. Control animals (n = 10 young and n = 10 aged) received equal volume of normal saline and behavioral testing in the water maze started on day 14 after the initiation of vitamin D supplementation. Tau phosphorylation, markers of brain energy metabolism (ADP/ATP ratio and adenosine monophosphate-activated protein kinase) and redox state (levels of reactive oxygen species, activity of superoxide dismutase, and glutathione levels) as well as PP2A activity were measured in hippocampal tissues. Our results extended previous findings that: (1) tau phosphorylation significantly increased during aging; (2) markers of brain energy metabolism and redox state are significantly decreased in aging; and (3) aged rats demonstrated significant learning and memory impairment. More importantly, we found that age-related changes in brain energy metabolism, redox state, and cognitive function were attenuated by vitamin D supplementation. No significant differences were seen in tau hyperphosphorylation, markers of energy metabolism and redox state in the young animal groups. Our data suggest that vitamin D ameliorated the age-related tau hyperphosphorylation and cognitive decline by enhancing brain energy metabolism, redox state, and PP2A activity making it a potentially useful therapeutic option to alleviate the effects of aging. (C) 2014 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Briones, T. L.] Wayne State Univ, Dept Adult Hlth, Detroit, MI 48202 USA.
   [Darwish, H.] Amer Univ Beirut, Hariri Sch Nursing, Beirut, Lebanon.
RP Briones, TL (reprint author), Wayne State Univ, Dept Adult Hlth, 5557 Cass Ave,Cohn Bldg,Room 344, Detroit, MI 48202 USA.
EM tbriones@wayne.edu
FU National Institutes of Health [P30 NR000914]
FX This work was supported in part by the National Institutes of Health,
   P30 NR000914. We are grateful for the assistance of Maria Palu in tissue
   sectioning and imaging.
CR Annweiler C, 2010, NEUROLOGY, V75, P1810, DOI 10.1212/WNL.0b013e3181fd6352
   Annweiler C, 2012, EUR J NEUROL
   Annweiler C, 2013, J ALZHEIMERS DIS, V33, P659, DOI 10.3233/JAD-2012-121432
   Atamna H, 2007, MITOCHONDRION, V7, P297, DOI 10.1016/j.mito.2007.06.001
   Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Boveris A, 2008, IUBMB LIFE, V60, P308, DOI 10.1002/iub.46
   Briones TL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-244
   Briones TL, 2009, J NEUROTRAUM, V26, P613, DOI 10.1089/neu.2008.0707
   Briones TL, 2006, BEHAV BRAIN RES, V168, P261, DOI 10.1016/j.bbr.2005.11.015
   Brown J, 2003, NEUROSCI LETT, V343, P139, DOI 10.1016/S0304-3940(03)00303-3
   Buell JS, 2008, MOL ASPECTS MED, V29, P415, DOI 10.1016/j.mam.2008.05.001
   Calabrese V, 2010, METHODS MOL BIOL, V610, P285, DOI 10.1007/978-1-60327-029-8_17
   Chung JW, 2006, J DERMATOL, V33, P662, DOI 10.1111/j.1346-8138.2006.00156.x
   Coudray C, 2005, EUR J CLIN NUTR, V59, pS5, DOI 10.1038/sj.ejcn.1602304
   Cui B, 2012, EXP NEUROL, V238, P122, DOI 10.1016/j.expneurol.2012.08.028
   DeLuca GC, 2013, NEUROPATH APPL NEURO, V39, P458, DOI 10.1111/nan.12020
   Dringen R, 1998, DEV NEUROSCI-BASEL, V20, P401, DOI 10.1159/000017337
   Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059
   Dursun E, 2011, J ALZHEIMERS DIS, V23, P207, DOI 10.3233/JAD-2010-101377
   Dusso AS, 2013, CURR VASC PHARM
   Eyles D, 2007, J STEROID BIOCHEM, V103, P538, DOI 10.1016/j.jsbmb.2006.12.096
   Eyles D, 2003, NEUROSCIENCE, V118, P641, DOI 10.1016/S0306-4522(03)00040-X
   Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006
   Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030
   Flynn JM, 2013, FREE RADICAL BIO MED, V62, P4, DOI 10.1016/j.freeradbiomed.2013.05.027
   Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167
   Fukui H, 2008, TRENDS NEUROSCI, V31, P251, DOI 10.1016/j.tins.2008.02.008
   Fuster-Matanzo A, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00104
   Gibson GE, 2010, BBA-MOL BASIS DIS, V1802, P122, DOI 10.1016/j.bbadis.2009.08.010
   Gotz J, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00072
   Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535
   Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047
   HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S
   Hashiguchi M, 2013, INT REV CEL MOL BIO, V300, P121, DOI 10.1016/B978-0-12-405210-9.00004-7
   Hu D, 2009, ANTIOXID REDOX SIGN, V9, P201
   Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3
   Johnson WM, 2012, NUTRIENTS, V4, P1399, DOI 10.3390/nu4101399
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Kalueff AV, 2007, CURR OPIN CLIN NUTR, V10, P12, DOI 10.1097/MCO.0b013e328010ca18
   Kapogiannis D, 2011, LANCET NEUROL, V10, P187, DOI 10.1016/S1474-4422(10)70277-5
   Kleman AM, 2008, J NEUROSCI METH, V167, P292, DOI 10.1016/j.jneumeth.2007.08.028
   LaFrance R, 2005, AGING CELL, V4, P139, DOI 10.1111/j.1474-9726.2005.00156.x
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   Liu C, 2013, J ALZHEIMERS DIS, V37, P483, DOI 10.3233/JAD-130503
   Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x
   Liu Rong, 2009, Pathophysiology, V16, P273, DOI 10.1016/j.pathophys.2009.02.008
   MacLeod JE, 2007, BEHAV BRAIN RES, V181, P168, DOI 10.1016/j.bbr.2007.04.003
   MISRA HP, 1972, J BIOL CHEM, V247, P3170
   Morris RGM, 2003, PHILOS T ROY SOC B, V358, P643, DOI 10.1098/rstb.2002.1230
   Navarro A, 2008, AM J PHYSIOL-REG I, V294, pR501, DOI 10.1152/ajpregu.00492.2007
   Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006
   Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187
   Nunomura A, 2012, NEUROTOX RES, V22, P231, DOI 10.1007/s12640-012-9331-x
   Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007
   Ramcharitar J, 2013, J NEUROPATH EXP NEUR, V72, P824, DOI 10.1097/NEN.0b013e3182a0a39f
   Schmitt K, 2012, ANTIOXID REDOX SIGN, V16, P1456, DOI 10.1089/ars.2011.4400
   Shulman RG, 2004, TRENDS NEUROSCI, V27, P489, DOI 10.1016/j.tins.2004.06.005
   Spach KM, 2005, J IMMUNOL, V175, P4119, DOI 10.4049/jimmunol.175.6.4119
   Tuohimaa P, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS278, DOI 10.1016/j.psyneuen.2009.07.003
   Winocur G, 2004, NEUROBIOL AGING, V25, P1107, DOI 10.1016/j.neurobiolaging.2003.10.005
   Winocur G, 2006, PHARMACOL BIOCHEM BE, V85, P66, DOI 10.1016/j.pbb.2006.07.010
   Yap LP, 2009, ADV DRUG DELIVER REV, V61, P1283, DOI 10.1016/j.addr.2009.07.015
   Yin F, 2012, ANTIOXID REDOX SIGN, V1010, DOI [101089/ars.2012.4639., DOI 10.101089/ARS.2012.4639]
   Yin F, 2014, ANTIOXID REDOX SIGN, V20, P353, DOI 10.1089/ars.2012.4774
NR 65
TC 21
Z9 21
U1 3
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD MAR 14
PY 2014
VL 262
BP 143
EP 155
DI 10.1016/j.neuroscience.2013.12.064
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA AB2UP
UT WOS:000331647900013
PM 24412233
OA Other Gold, Green Accepted
DA 2018-12-27
ER

PT J
AU Houshmand, M
   Mebadi, A
   Zandi, MH
   Gorji, NE
AF Houshmand, Mohammad
   Mebadi, Ashkan
   Zandi, M. Hosein
   Gorji, Nima E.
TI RETRACTED: Simulation of carbon nanotubes/GaAs hybrid photovoltaic using
   AMPS-1D (Retracted Article)
SO JOURNAL OF MODERN OPTICS
LA English
DT Article; Retracted Publication
DE GaAs; hybrid solar cell; carbon nanotube; AMPS-1D modelling
ID GROWTH; GAAS
AB The performance and characteristics of a hybrid heterojunction single-walled carbon nanotube/GaAs solar cell were modelled and numerically simulated using the AMPS-1D device simulation tool. The device physics and performance parameters with different junction parameters were analysed. The results suggest that the open-circuit voltage changes very slightly by changing the work function, acceptor and donor density, while the other electrical parameters reach an optimum value. Increasing the concentration of a discrete defect density in the absorber layer decreases the electrical parameters. The current-voltage characteristics, quantum efficiency, band gap and thickness variation of the photovoltaic response will be quantitatively considered.
C1 [Houshmand, Mohammad; Mebadi, Ashkan; Zandi, M. Hosein] Shahid Bahonar Univ Kerman, Dept Sci, Kerman 767691, Iran.
   [Gorji, Nima E.] Univ Tabriz, Dept New Technol, Tabriz 51566, Iran.
RP Houshmand, M (reprint author), Shahid Bahonar Univ Kerman, Dept Sci, Kerman 767691, Iran.
EM mhmd.houshmand@gmail.com
FU Nanotechnology Council of Iranian
FX The authors gratefully acknowledge support via a Senior Research
   Fellowship provided by the Nanotechnology Council of Iranian. The
   authors also gratefully acknowledge Professor S. Fonash of the
   Pennsylvania State University (USA) and the Electric Power Research
   Institute for providing the AMPS-1D program used in the simulations.
CR Behnam A, 2008, J APPL PHYS, V103, DOI 10.1063/1.2938037
   Belfar A, 2012, THIN SOLID FILMS, V525, P167, DOI 10.1016/j.tsf.2012.10.060
   Cooray M. L. C., 2006, J APPL PHYS, V88
   Engel-Herbert R, 2007, MATER LETT, V61, P4631, DOI 10.1016/j.matlet.2007.02.063
   Ghosh P, 2009, APPL SURF SCI, V255, P4611, DOI 10.1016/j.apsusc.2008.12.005
   Gorji N. E., 2012, P 27 EUR PHOT SOL EN, P2856
   Gorji NE, 2013, PHYSICA E, V50, P122, DOI 10.1016/j.physe.2013.03.001
   Li H., 2010, J APPL PHYS, V96
   Liang CW, 2008, NANO LETT, V8, P1809, DOI 10.1021/nl0802178
   Tune D., 2013, NANO LETT, DOI [10.1002/aenm.201200949, DOI 10.1002/AENM.201200949]
NR 10
TC 0
Z9 0
U1 2
U2 23
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0950-0340
EI 1362-3044
J9 J MOD OPTIC
JI J. Mod. Opt.
PD MAR 12
PY 2014
VL 61
IS 5
BP 368
EP 372
DI 10.1080/09500340.2013.816385
PG 5
WC Optics
SC Optics
GA AE3NV
UT WOS:000333884100001
DA 2018-12-27
ER

PT J
AU Jiang, X
   Li, Y
   Liu, LJ
   Peng, MX
   Tang, XY
   Wang, DX
   Yang, XD
AF Jiang, Xin
   Li, Yuan
   Liu, Lijun
   Peng, MingXin
   Tang, XueYang
   Wang, DaoXi
   Yang, XiaoDong
TI RETRACTED: Pathological dislocation of the hip due to coxotuberculosis
   in children: a 29-case report (Retracted article. See vol. 10, 42, 2015)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE Pathological hip dislocation; Coxotuberculosis; Open reduction;
   Acetabular reconstruction
ID DEVELOPMENTAL DYSPLASIA; FEMORAL-HEAD; TUBERCULOSIS; OSTEOTOMY;
   ARTHROPLASTY; ARTHRITIS; BONE
AB Background: The aim of this study is to evaluate the clinical outcome of various surgery methods in children suffering pathological dislocation of the hip joint due to coxotuberculosis.
   Patients and methods: From January 2006 to January 2011, 29 children with coxotuberculosis hip dislocation were treated with open reduction (4 children) and acetabular reconstruction (25 children). According to degree of dislocation and age, acetabular reconstructions included Salter osteotomy (nine children), Pemberton operation (six children), Dega operation (seven children), the hip shelf arthroplasty (two children), and Chiari operation (one child). During acetabular reconstruction, 16 children underwent upper femoral rotational shortening osteotomies simultaneously, 6 children underwent the femoral head and neck reconstruction simultaneously, and 3 children were underwent corrective osteotomy. After operation, children were immobilized with plaster external fixation for 1-3 months and treated with routine anti-infective therapy for 3 days. During follow-up study (12-18 months), the hip stability was examined via X-ray. The recovery was evaluated via acetabular index (AI) and Harris hip score.
   Results: Postoperative X-ray films of 29 children showed concentric reduction of all hips. Total 25 children healed I incision surgery, while 4 children with skin antrum of incision were further treated leading to 1-3 months delay of healing. Total 24 children were followed up for 2-5 years. X-ray examination revealed no redislocation after 2 years postoperative. The postoperative AI was normal (15 degrees-20 degrees) in 22 children and increased to 25 degrees-30 degrees in 2 children. After 2 years postoperative, 8 children had normal function of hip joint, 13 children had mild limitation of flexion and rotation, and 3 children had fibrous ankylosis. The average of Harris hip score was 83 (ranged, 62-90).
   Conclusion: In our study, pathological hip dislocations of children attributed to coxotuberculosis were treated via open reduction and acetabular reconstruction and the outcomes were both excellent. Individual characteristic should be taken into consideration during treatment, and proper surgery approach should be adopted according to pathological changes of the hip.
C1 [Jiang, Xin; Li, Yuan; Liu, Lijun; Peng, MingXin; Tang, XueYang; Wang, DaoXi; Yang, XiaoDong] Sichuan Univ, West China Hosp, Dept Pediat Surg, Chengdu 610041, Sichuan, Peoples R China.
RP Li, Y (reprint author), Sichuan Univ, West China Hosp, Dept Pediat Surg, 37 Guoxue Rd, Chengdu 610041, Sichuan, Peoples R China.
EM yuanlilili@hotmail.com
FU Applied basic research programs funded projects in Sichuan province
   [2012JY0086]
FX Applied basic research programs funded projects in Sichuan province
   (2012JY0086): iatrogenic epiphyseal plate penetrating wound on the
   developmental effects of children's epiphyseal plate.
CR CAMPBELL JAB, 1995, J BONE JOINT SURG BR, V77B, P319
   Davidson PT, 1983, MONOGRAPH TUBERCULOS, P119
   Fabry G, 2010, EUR J PEDIATR, V169, P143, DOI 10.1007/s00431-009-1025-x
   HADDAD RJ, 1990, J BONE JOINT SURG BR, V72, P2
   HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012
   Johari AN, 2011, J PEDIATR ORTHOP B, V20, P413, DOI 10.1097/BPB.0b013e32834af5f0
   Kim M, 2010, CLIN ORTHOP RELAT R, V468, P1611, DOI 10.1007/s11999-010-1288-6
   Kleinberg S, 1936, ARCH SURG-CHICAGO, V32, P1049, DOI 10.1001/archsurg.1936.01180240137007
   Masonis JL, 2003, J ARTHROPLASTY, V18, P68, DOI 10.1054/arth.2003.50104
   MASOOD S, 1992, DIAGN CYTOPATHOL, V8, P451, DOI 10.1002/dc.2840080505
   MOON MS, 1984, CLIN ORTHOP RELAT R, P154
   Mousa HAL, 1997, J BONE JOINT SURG BR, V79B, P567, DOI 10.1302/0301-620X.79B4.7316
   MUBARAK SJ, 1992, J BONE JOINT SURG AM, V74A, P1347, DOI 10.2106/00004623-199274090-00008
   Pekmezci M, 2004, ACTA ORTHOP TRAUMATO, V41, P37
   Spangehl MJ, 2001, J BONE JOINT SURG AM, V83A, P1484, DOI 10.2106/00004623-200110000-00004
   Tahasildar N, 2012, J PEDIATR ORTHOP B, V21, P567, DOI 10.1097/BPB.0b013e328354da73
   UTTERBACK TD, 1974, CLIN ORTHOP RELAT R, P104
   Wang YQ, 2010, INT ORTHOP, V34, P1111, DOI 10.1007/s00264-009-0854-6
   WONGCHUNG J, 1990, J BONE JOINT SURG BR, V72, P563
   Zadeh HG, 2000, J BONE JOINT SURG BR, V82B, P17, DOI 10.1302/0301-620X.82B1.9618
NR 20
TC 1
Z9 2
U1 2
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD MAR 10
PY 2014
VL 9
AR 16
DI 10.1186/1749-799X-9-16
PG 5
WC Orthopedics
SC Orthopedics
GA AD6QS
UT WOS:000333386500001
PM 24606985
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Abdi, FS
   Jamshidi, S
   Moosakhani, F
   Sasani, F
AF Abdi, Fatemeh Soghra
   Jamshidi, Shahram
   Moosakhani, Farhad
   Sasani, Farhang
TI RETRACTED: Detection of Helicobacter spp. DNA in the colonic biopsies of
   stray dogs: molecular and histopathological investigations(Retracted
   article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Dog; Inflammatory lesions; Helicobacter; Single PCR; Colonic biopsies
ID UNIDENTIFIED CURVED BACILLI; INFLAMMATORY-BOWEL-DISEASE;
   TUMOR-DIAGNOSIS; IDENTIFICATION; BIZZOZERONII; MODEL; CATS;
   COLONIZATION; PATHOGENESIS; ORGANISMS
AB Background: In dogs, the gastric Helicobacter spp. have been well studied, but there is little information regarding the other parts of the alimentary system. The incidence of Helicobacter spp. infection in dogs is largely unknown and to our knowledge there are no data about their potential pathogenic role. In light of these considerations, the aims of this study were (i) to assess the prevalence of Helicobacter spp. in colonic biopsies of healthy and symptomatic stray dogs also (ii) we isolate and characterize helicobacters in canine colonic biopsies to compare the commonly used tests for the identification of Helicobacter spp. and to determine the occurrence of these species in dogs.
   Methods: Tissues from fifteen stray dogs (8 males and 7 females, age 6 months -10 years) were used in this study. From each stray dog, multiple colonic biopsies were taken for PCR. Biopsies for PCR of cecum and colon were immediately frozen and stored at -20 degrees C until DNA extraction. Samples for histological examination were fixed in 10% neutral buffered formalin and embedded in paraffin wax.
   Results: In the cecum and colon, Helicobacter spp. DNA was detected in all dogs. H.canis, H.bizzozeronii, H. bilis, H.felis, H.salomonis and H.pylori Identified by specific polymerase chain reaction. Histopathology demonstrated that Helicobacter organisms were localized within the surface mucus and the intestinal crypts. Dogs with heavy Helicobacter spp. colonization were significantly in younger as well as had a higher level of mucosal fibrosis/atrophy than dogs with uncolonized or poorly colonized biopsies (p < 0.05).
   Conclusions: We have indicated that the crypts of the cecum and colon of healthy and symptomatic dogs are heavily colonized by Helicobacter spp.. Combined molecular and histological approaches demonstrated that enterohepatic Helicobacter spp. infection is rather common in colonic biopsies of healthy and symptomatic stray dogs, with Helicobacter spp. specialy H. canis, H. bizzozeroni, H.billis, H.felis and H. salomonis identified as the most common species.
C1 [Abdi, Fatemeh Soghra] Islamic Azad Univ, Dept Small Anim Internal Med, Specialized Vet Sci, Sci & Res Branch, 14,Corner Parvaz 1,Payam Blvd, Tehran, Iran.
   [Jamshidi, Shahram] Univ Tehran, Fac Vet Med, Dept Clin Sci, Tehran, Iran.
   [Moosakhani, Farhad] Univ Karaj, Dept Microbiol, Fac Vet Med, Karaj, Iran.
   [Sasani, Farhang] Univ Tehran, Dept Pathol, Fac Vet Med, Tehran, Iran.
RP Abdi, FS (reprint author), Islamic Azad Univ, Dept Small Anim Internal Med, Specialized Vet Sci, Sci & Res Branch, 14,Corner Parvaz 1,Payam Blvd, Tehran, Iran.
EM fabdi1360@hotmail.com
CR Baele M, 2004, J CLIN MICROBIOL, V42, P1115, DOI 10.1128/JCM.42.3.1115-1122.2004
   Castiglioni V, 2012, VET MICROBIOL, V159, P107, DOI 10.1016/j.vetmic.2012.03.026
   Chan V, 2005, HELICOBACTER, V10, P114, DOI 10.1111/j.1523-5378.2005.00298.x
   Dewhirst FE, 2005, J BACTERIOL, V187, P6106, DOI 10.1128/JB.187.17.6106-6118.2005
   Feng YX, 2008, CANCER LETT, V270, P250, DOI 10.1016/j.canlet.2008.05.013
   Fink M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026210
   Fox JG, 2002, GUT, V50, P273, DOI 10.1136/gut.50.2.273
   Fox JG, 2001, J MED MICROBIOL, V50, P421, DOI 10.1099/0022-1317-50-5-421
   Hanninen ML, 1996, INT J SYST BACTERIOL, V46, P160, DOI 10.1099/00207713-46-1-160
   He K, 2002, JAMA-J AM MED ASSOC, V288, P3130, DOI 10.1001/jama.288.24.3130
   Hobbenaghi R, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-123
   Jalava K, 1997, INT J SYST BACTERIOL, V47, P975, DOI 10.1099/00207713-47-4-975
   Khaki F, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-98
   Kusters JG, 2006, CLIN MICROBIOL REV, V19, P449, DOI 10.1128/CMR.00054-05
   Leemann C, 2006, J CLIN MICROBIOL, V44, P4598, DOI 10.1128/JCM.01453-06
   MARSHALL BJ, 1984, LANCET, V1, P1311
   Mikkonen TP, 2004, INT J SYST EVOL MICR, V54, P753, DOI 10.1099/ijs.0.02839-0
   Muthupalani S, 2012, INFECT IMMUN, V80, P4388, DOI 10.1128/IAI.00530-12
   On SLW, 1996, CLIN MICROBIOL REV, V9, P405, DOI 10.1128/CMR.9.3.405
   OTTO G, 1994, J CLIN MICROBIOL, V32, P1043
   Recordati C, 2009, HELICOBACTER, V14, P180, DOI 10.1111/j.1523-5378.2009.00674.x
   Rieder F, 2009, NAT REV GASTRO HEPAT, V6, P228, DOI 10.1038/nrgastro.2009.31
   Riley LK, 1996, J CLIN MICROBIOL, V34, P942
   Riley LK, 1996, J MOL EVOL, V16, P111
   Rossi M, 2008, VET MICROBIOL, V129, P304, DOI 10.1016/j.vetmic.2007.11.014
   Solnick JV, 2001, CLIN MICROBIOL REV, V14, P59, DOI 10.1128/CMR.14.1.59-97.2001
   STANLEY J, 1993, J GEN MICROBIOL, V139, P2495, DOI 10.1099/00221287-139-10-2495
   Tabrizi AS, 2010, VET MICROBIOL, V140, P142, DOI 10.1016/j.vetmic.2009.07.019
   Tankovic J, 2011, INFLAMM BOWEL DIS, V17, P1830, DOI 10.1002/ibd.21610
   Tavasoly A, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-86
   THOMSON MA, 1994, LANCET, V343, P1605, DOI 10.1016/S0140-6736(94)93060-0
   WARREN JR, 1983, LANCET, V1, P1273
   Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X
   Zhang L, 2006, J CLIN MICROBIOL, V44, P2276, DOI 10.1128/JCM.02017-05
   Zhang L, 2006, DRUGS TODAY, V42, P605, DOI 10.1358/dot.2006.42.9.1025694
NR 35
TC 9
Z9 10
U1 3
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD MAR 6
PY 2014
VL 9
AR 50
DI 10.1186/1746-1596-9-50
PG 9
WC Pathology
SC Pathology
GA V42JG
UT WOS:000209609500001
PM 24602369
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Mavi, B
   Gurbuz, F
   Ciftci, H
   Akkurt, I
AF Mavi, B.
   Gurbuz, F.
   Ciftci, H.
   Akkurt, I.
TI RETRACTED: SHIELDING PROPERTY OF NATURAL BIOMASS AGAINST GAMMA RAYS
   (Retracted article. See vol. 17, pg. 787, 2015)
SO INTERNATIONAL JOURNAL OF PHYTOREMEDIATION
LA English
DT Article; Retracted Publication
DE Co-60; Linear Attenuation Coefficient; Biomass; Environmental
   Protection; NaI(Tl)
ID ULTRAVIOLET-B RADIATION; BLUE-GREEN-ALGAE; IONIZING-RADIATION;
   FRESH-WATER; UV PROTECTANTS; AMINO-ACIDS; CYANOBACTERIA; LEAD;
   DESICCATION; RESISTANCE
AB Algae and cyanobacteria are capable living under harsh conditions in the natural environments and can develop peculiar survival processes. In order to evaluate radiation shielding properties of green algae; Chlorella vulgaris, Scenedesmus obliquus, and cyanobacteria; Synechococcus sp., Planktothrix limnetica, Microcystis aeruginosa, Arthrospira maxima, Anabaena affinis, Phormidium articulatum, and Pseudoanabaena sp. were cultured in batch systems. Air dried biomass was tested for its high tolerance to gamma-radiations in terms of linear attenuation coefficients. In the present work, the linear and mass attenuation coefficients were measured at photon energies of 1173 and 1332keV. Protection capacity of some biomass was observed to be higher than a 1-cm thick lead standard for comparison. Gamma ray related protection depends not only to thickness but also to density (g/cm(3)). Hence the effect of biomass density also was tested and significantly found the tested biomass absorbed more of the incoming energy on a density basis than lead. This paper discusses the a new approach to environmental protection from gamma ray, The findings suggest that the test samples, especially cyanobacteria, have a potential for reducing gamma ray more significantly than lead and can be used as shielding materials.
C1 [Mavi, B.] Amasya Univ, Dept Phys, Amasya, Turkey.
   [Gurbuz, F.] Aksaray Univ, Dept Environm Engn, Aksaray, Turkey.
   [Ciftci, H.] Suleyman Demirel Univ, Mineral Proc Div, Dept Min Engn, TR-32200 Isparta, Turkey.
   [Akkurt, I.] Suleyman Demirel Univ, Dept Phys Sci, TR-32200 Isparta, Turkey.
RP Gurbuz, F (reprint author), Aksaray Univ, Aksaray, Turkey.
EM fatma_gurbuz@yahoo.com
RI Ciftci, Hasan/A-3151-2016
OI Ciftci, Hasan/0000-0002-3306-783X; Cetin, Betul/0000-0001-9129-2421
CR Agarwal R, 2008, J PHOTOCH PHOTOBIO B, V91, P9, DOI 10.1016/j.jphotobiol.2008.01.006
   Akkurt I, 2010, PROG NUCL ENERG, V52, P620, DOI 10.1016/j.pnucene.2010.04.006
   Akkurt I, 2009, INT J PHYS SCI, V4, P588
   Becker EW, 1994, MICROALGAE BIOTECHNO, P293
   Billi D, 2000, APPL ENVIRON MICROB, V66, P1489, DOI 10.1128/AEM.66.4.1489-1492.2000
   Ciffroy P, 2007, ECOL MODEL, V206, P360, DOI 10.1016/j.ecolmodel.2007.04.004
   CONTER A, 1984, RADIAT RES, V99, P651, DOI 10.2307/3576338
   Copplestone D, 2004, J ENVIRON RADIOACTIV, V74, P31, DOI 10.1016/j.jenvrad.2004.01.020
   Demir D, 2006, NUCL INSTRUM METH B, V245, P501, DOI 10.1016/j.nimb.2005.11.139
   Erdem M, 2010, RADIAT PHYS CHEM, V79, P917, DOI 10.1016/j.radphyschem.2010.04.009
   Evseeva T, 2010, CHEMOSPHERE, V81, P1320, DOI 10.1016/j.chemosphere.2010.08.028
   Fleming ED, 2007, ENVIRON MICROBIOL, V9, P1448, DOI 10.1111/j.1462-2920.2007.01261.x
   Fuma S, 2003, J ENVIRON RADIOACTIV, V67, P1, DOI 10.1016/S0265-931X(02)00143-1
   Fuma S, 2010, J ENVIRON RADIOACTIV, V101, P915, DOI 10.1016/j.jenvrad.2010.06.007
   GARCIAPICHEL F, 1993, APPL ENVIRON MICROB, V59, P163
   Gurbuz F., 2009, REMOVAL HAZARDOUS MA
   KARENTZ D, 1991, J PHYCOL, V27, P326, DOI 10.1111/j.0022-3646.1991.00326.x
   Knoll GF, 2000, RAD DETECTION MEASUR, P802
   Komarek J., 1987, ALGOL STUD, V45, P437
   KRAUS MP, 1969, RADIAT BOT, V9, P481, DOI 10.1016/S0033-7560(69)80054-2
   Mavi B, 2012, ANN NUCL ENERGY, V44, P22, DOI 10.1016/j.anucene.2012.01.009
   Nelson G., 1991, PASSIVE NONDESTRUCTI
   Oren A, 2007, FEMS MICROBIOL LETT, V269, P1, DOI 10.1111/j.1574-6968.2007.00650.x
   Paerl HW, 2000, ENVIRON MICROBIOL, V2, P11, DOI 10.1046/j.1462-2920.2000.00071.x
   Prasad SG, 1998, RADIAT PHYS CHEM, V53, P361, DOI 10.1016/S0969-806X(98)00130-3
   Rogoff Dana, 2005, Astrobiology, V5, P317
   Singh K, 2005, RADIAT PHYS CHEM, V72, P225, DOI 10.1016/j.radpyhschem.2003.11.010
   Singh K, 2006, NUCL SCI ENG, V154, P233, DOI 10.13182/NSE06-A2629
   Sinha RP, 2008, PLANT SCI, V174, P278, DOI 10.1016/j.plantsci.2007.12.004
   Sinha RP, 2001, J PHOTOCH PHOTOBIO B, V60, P129, DOI 10.1016/S1011-1344(01)00137-3
   STANIER RY, 1971, BACTERIOL REV, V35, P171
   VONSHAK A, 1986, CRC HDB MICROALGAL M
   Woods J., 1982, COMPUTATIONAL METHOD
   Xiong FS, 1996, J PLANT PHYSIOL, V148, P42, DOI 10.1016/S0176-1617(96)80292-6
NR 34
TC 2
Z9 2
U1 3
U2 117
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1522-6514
EI 1549-7879
J9 INT J PHYTOREMEDIAT
JI Int. J. Phytoremediat.
PD MAR 4
PY 2014
VL 16
IS 3
BP 247
EP 256
DI 10.1080/15226514.2013.773276
PG 10
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 224QV
UT WOS:000324904100003
PM 24912221
DA 2018-12-27
ER

PT J
AU Soetedjo, L
   Jin, H
AF Soetedjo, Livana
   Jin, Hua
TI RETRACTED: Agonist-Induced GPCR Shedding from the Ciliary Surface Is
   Dependent on ESCRT-III and VPS4 (Retracted article. See vol. 24, pg.
   1293, 2014)
SO CURRENT BIOLOGY
LA English
DT Article; Retracted Publication
ID CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTOR MESSENGER-RNA; EXTRACELLULAR
   VESICLES; SUPRACHIASMATIC NUCLEI; MEMBRANE TRAFFICKING; CIRCADIAN
   CHANGES; VPAC(2) RECEPTOR; MAMMALIAN-CELLS; PROTEIN; RAT
AB Background: Membrane trafficking of G protein-coupled receptors (GPCRs) is crucial for temporal and spatial control of cell-surface GPCR signaling. Receptor internalization is a well-documented method cells use for regulating a wide variety of GPCRs following their exposure to agonists.
   Results: We report that, upon agonist stimulation, a GPCR called vasoactive intestinal peptide receptor 2 (VPAC2) is shed, rather than being internalized, in vitro and in vivo, from the membrane of primary cilia-solitary hair-like organelles that project from the cell surface. VPAC2 is released into the extracellular milieu in the form of ciliary ectosomes that are devoid of exosome markers. The agonist-induced VPAC2 shedding is selective, as shown by the fact that other ciliary membrane proteins including two ciliary GPCRs are not shed with VPAC2. VPAC2 ectosome shedding is dependent on several components of endosomal sorting complexes required for transport (ESCRT), including a subset of ESCRT-III, VPS4, and LIP5. Agonist-stimulated VPAC2 is important for ciliary-ectosome generation because it allows VPS4 and LIP5 to transiently accumulate in primary cilia. Shedding of VPAC2 from the ciliary surface results in termination of intracellular VPAC2 signaling.
   Conclusions: Agonist-induced GPCR shedding from the ciliary surface may represent an additional mode of GPCR trafficking and signal regulation.
C1 [Soetedjo, Livana; Jin, Hua] Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA.
RP Jin, H (reprint author), Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA.
EM huajin@uic.edu
FU University of Illinois at Chicago
FX We thank De'Vona A. Glover for technical assistance and Yimei Chen at
   the University of Chicago for providing electron microscopy service.
   Furthermore, we thank the anonymous reviewers for their insightful
   comments. This work was supported by the University of Illinois at
   Chicago.
CR Agromayor M, 2013, TRENDS CELL BIOL, V23, P433, DOI 10.1016/j.tcb.2013.04.006
   Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005
   Cagampang FRA, 1998, MOL BRAIN RES, V54, P108, DOI 10.1016/S0169-328X(97)00327-6
   Cagampang FRA, 1998, BRAIN RES, V813, P218, DOI 10.1016/S0006-8993(98)01044-0
   Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003
   Dubreuil V, 2007, J CELL BIOL, V176, P483, DOI 10.1083/jcb.200608137
   Faure J, 2006, MOL CELL NEUROSCI, V31, P642, DOI 10.1016/j.mcn.2005.12.003
   Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213
   Garcia-Gonzalo FR, 2012, J CELL BIOL, V197, P697, DOI 10.1083/jcb.201111146
   Hannibal J, 2002, CELL TISSUE RES, V309, P73, DOI 10.1007/s00441-002-0574-3
   Hanyaloglu AC, 2008, ANNU REV PHARMACOL, V48, P537, DOI 10.1146/annurev.pharmtox.48.113006.094830
   Harmar AJ, 2002, CELL, V109, P497, DOI 10.1016/S0092-8674(02)00736-5
   Henne WM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016766
   Hogan MC, 2009, J AM SOC NEPHROL, V20, P278, DOI 10.1681/ASN.2008060564
   Hurley JH, 2010, NAT REV MOL CELL BIO, V11, P556, DOI 10.1038/nrm2937
   Kinhult J, 2003, CLIN EXP ALLERGY, V33, P942, DOI 10.1046/j.1365-2222.2003.01721.x
   Lambert C, 2007, J VIROL, V81, P9050, DOI 10.1128/JVI.00479-07
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Levinson DF, 2011, AM J PSYCHIAT, V168, P302, DOI 10.1176/appi.ajp.2010.10060876
   Marchese A, 2008, ANNU REV PHARMACOL, V48, P601, DOI 10.1146/annurev.pharmtox.48.113006.094646
   McCullough J, 2013, ANNU REV BIOCHEM, V82, P663, DOI 10.1146/annurev-biochem-072909-101058
   Metz VV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041823
   Morin LP, 2006, BRAIN RES REV, V51, P1, DOI 10.1016/j.brainresrev.2005.08.003
   Morita E, 2011, CELL HOST MICROBE, V9, P235, DOI 10.1016/j.chom.2011.02.004
   Mueller M, 2012, CURR BIOL, V22, pR603, DOI 10.1016/j.cub.2012.06.063
   Nabhan JF, 2012, P NATL ACAD SCI USA, V109, P4146, DOI 10.1073/pnas.1200448109
   Nachury MV, 2010, ANNU REV CELL DEV BI, V26, P59, DOI 10.1146/annurev.cellbio.042308.113337
   Nonaka N, 2012, PEPTIDES, V36, P168, DOI 10.1016/j.peptides.2012.05.021
   Pawliczek T, 2009, J VIROL, V83, P11254, DOI 10.1128/JVI.00574-09
   Perez-Gonzalez R, 2012, J BIOL CHEM, V287, P43108, DOI 10.1074/jbc.M112.404467
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Rat D, 2011, FASEB J, V25, P3208, DOI 10.1096/fj.10-180133
   Scheuring S, 2001, J MOL BIOL, V312, P469, DOI 10.1006/jmbi.2001.4917
   Shen SB, 2000, P NATL ACAD SCI USA, V97, P11575, DOI 10.1073/pnas.97.21.11575
   Soetedjo L, 2013, BIOL OPEN, V2, DOI 10.1242/bio.20134747
   SPEH JC, 1993, DEV BRAIN RES, V76, P171, DOI 10.1016/0165-3806(93)90205-O
   Tauro BJ, 2012, METHODS, V56, P293, DOI 10.1016/j.ymeth.2012.01.002
   Taylor Douglas D., 2013, Frontiers in Genetics, V4, P142, DOI 10.3389/fgene.2013.00142
   Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Vacic V, 2011, NATURE, V471, P499, DOI 10.1038/nature09884
   Wang WJ, 2013, NAT CELL BIOL, V15, P591, DOI 10.1038/ncb2739
   Wehman AM, 2011, CURR BIOL, V21, P1951, DOI 10.1016/j.cub.2011.10.040
   Wood CR, 2013, CURR BIOL, V23, P906, DOI 10.1016/j.cub.2013.04.019
NR 43
TC 2
Z9 2
U1 2
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD MAR 3
PY 2014
VL 24
IS 5
BP 509
EP 518
DI 10.1016/j.cub.2014.01.010
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AC3JB
UT WOS:000332412400017
PM 24530064
OA Bronze
DA 2018-12-27
ER

PT J
AU Belenli, C
   Arpaci, AH
AF Belenli, Ceyda
   Arpaci, Ayse Hande
TI RETRACTED: Anesthesiological approach to a case with FAHR syndrome
   (Retracted article. See vol. 19, pg. 286, 2014)
SO JOURNAL OF RESEARCH IN MEDICAL SCIENCES
LA English
DT Letter; Retracted Publication
C1 [Belenli, Ceyda; Arpaci, Ayse Hande] Cankiri State Hosp, Dept Anaesthesiol & Reanimat, Cankiri, Turkey.
RP Arpaci, AH (reprint author), Ankara Univ, Fac Dent, Dept Oral & Maxillofacial, TR-06100 Ankara, Turkey.
EM handarpaci@yahoo.com
CR Aguilera IM, 2000, ANAESTHESIA, V55, P779, DOI 10.1046/j.1365-2044.2000.01540.x
   Baba Y, 2005, MAYO CLIN PROC, V80, P641, DOI 10.4065/80.5.641
   Fahr T, 1930, ZBL ALLG PATH PATH A, V50, P129
   Joyce SP, 2007, HONG KONG MED J, V13, P75
   Shakibai SV, 2005, PSYCHOSOMATICS, V46, P569, DOI 10.1176/appi.psy.46.6.569
   Sogut O, 2010, GERMAN J PSYCHIAT, V13, P86
NR 6
TC 0
Z9 0
U1 3
U2 7
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 1735-1995
EI 1735-7136
J9 J RES MED SCI
JI J. Res. Med. Sci.
PD MAR
PY 2014
VL 19
IS 3
BP 286
EP 286
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA AQ4SK
UT WOS:000342789800019
PM 24949042
DA 2018-12-27
ER

PT J
AU Parker, RL
AF Parker, Robert L.
TI RETRACTED: Anomalous phases in TE-mode magnetotellurics (Retracted
   article. See vol. 80, pg. Y3, 2015)
SO GEOPHYSICS
LA English
DT Article; Retracted Publication
AB We examined the transverse electric mode of 2D magnetotelluric sounding for a simple system comprising a laterally variable thin sheet over an insulator terminated by a perfectly conducting base. We found, by asymptotic analysis and a numerical example, that the phase of the c response, or that of the corresponding entry in the impedance tensor, is completely unrestricted. This behavior is unlike that of 1D systems or transverse magnetic mode induction, where the phase is confined to a single quadrant.
C1 Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA.
RP Parker, RL (reprint author), Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA.
EM rlparker@ucsd.edu
CR Boyd J. P., 2001, CHEBYCHEV FOURIER SP
   Parker RL, 2010, GEOPHYS J INT, V181, P269, DOI 10.1111/j.1365-246X.2010.04512.x
   Porter D, 1990, INTEGRAL EQUATIONS
   Schmucker U., 1973, Physics of the Earth and Planetary Interiors, V7, P365, DOI 10.1016/0031-9201(73)90061-7
   Selway K, 2012, GEOPHYS J INT, V188, P945, DOI 10.1111/j.1365-246X.2011.05312.x
   Simpson F., 2005, PRACTICAL MAGNETOTEL
   Trefethen L. N., 2000, SPECTRAL METHODS MAT
   Weidelt P., 1972, Zeitschrift fur Geophysik, V38, P257
   WEIDELT P, 1994, GEOPHYS J INT, V117, P733, DOI 10.1111/j.1365-246X.1994.tb02466.x
NR 9
TC 1
Z9 1
U1 3
U2 17
PU SOC EXPLORATION GEOPHYSICISTS
PI TULSA
PA 8801 S YALE ST, TULSA, OK 74137 USA
SN 0016-8033
EI 1942-2156
J9 GEOPHYSICS
JI Geophysics
PD MAR-APR
PY 2014
VL 79
IS 2
BP E75
EP E79
DI 10.1190/GEO2013-0325.1
PG 5
WC Geochemistry & Geophysics
SC Geochemistry & Geophysics
GA AI5OO
UT WOS:000336918700019
DA 2018-12-27
ER

PT J
AU Yi, X
   Wang, PD
   Wang, Z
   Cai, J
   Hu, MY
   Zhong, GH
AF Yi, Xin
   Wang, PeiDan
   Wang, Zheng
   Cai, Jun
   Hu, MeiYing
   Zhong, GuoHua
TI RETRACTED: Involvement of a Specific Chemosensory Protein from
   Bactrocera dorsalis in Perceiving Host Plant Volatiles (Retracted
   article. See vol. 42, pg. 461, 2016)
SO JOURNAL OF CHEMICAL ECOLOGY
LA English
DT Article; Retracted Publication
DE Bactrocera dorsalis; Chemosensory protein; Binding assay; RNA
   interference; Electroantennogram recording
ID ODORANT-BINDING PROTEINS; LOCUSTA-MIGRATORIA ORTHOPTERA;
   BACTROCERA-DORSALIS; PHEROMONE-BINDING; IMMUNOCYTOCHEMICAL LOCALIZATION;
   MOLECULAR CHARACTERIZATION; OLFACTORY SENSILLA; BOMBYX-MORI; EXPRESSION;
   INSECT
AB Insects have evolved many physiological and behavioral adaptations to recognize external complex chemicals. Olfaction plays an important role in perceiving volatile chemicals, utilizing them to locate host sites, conspecifics, and enemies. Chemosensory proteins (CSPs) are present in high concentrations within the sensory sensilla of insects and are endowed with a heterogeneous range of functions. However, direct evidence for the involvement of CSPs in olfactory function is still lacking. In this study, a fluorescence-based ligand binding assay using Bdor-CSP2 illustrated its ability to bind the majority of the selected ligands of different shapes and chemical structures that are ecologically significant, host plant volatiles of Bactrocera dorsalis. RNAi-mediated silencing coupled with electrophysiological tests showed lower electrophysiological responses to (3Z)-hex-3-en-1-ol, trans-2-hexenal, 6-methylhept-5-en-2one, and 3-methylbutyl acetate in dsBdor CSP2 treated flies compared with the untreated controls. The reduced expression of Bdor-CSP2 by RNA interference was confirmed by semiquantitative PCR, real-time quantitative PCR and Western blot, which suggested the RNAi-treatment was responsible for the observed reduction of antennal responses in EAG recordings. These data suggest that the expression of BdorCSP2 is necessary for the recognition of antennal responses to some plant host volatiles by B. dorsalis.
C1 [Yi, Xin; Wang, PeiDan; Wang, Zheng; Cai, Jun; Hu, MeiYing] South China Agr Univ, Lab Insect Toxicol, Key Lab Pesticide & Chem Biol, Minist Educ, Guangzhou 510642, Guangdong, Peoples R China.
   [Zhong, GuoHua] South China Agr Univ, Coll Nat Resources & Environm, Key Lab Pesticide & Chem Biol, Minist Educ,PR China, Guangzhou 510642, Guangdong, Peoples R China.
RP Zhong, GH (reprint author), South China Agr Univ, Coll Nat Resources & Environm, Key Lab Pesticide & Chem Biol, Minist Educ,PR China, Guangzhou 510642, Guangdong, Peoples R China.
EM guohuazhong@scau.edu.cn
FU National Natural Science Foundation of China [31071713]; China
   Postdoctoral Science Foundation [2013M542185]
FX The work was supported by the National Natural Science Foundation of
   China for grant no. 31071713, and the China Postdoctoral Science
   Foundation (2013M542185). We thank Dr XiaoLin Dong for reviewing and
   providing useful comments regarding this manuscript.
CR Anfora G, 2013, PEST MANAG SCI
   Angeli S, 1999, EUR J BIOCHEM, V262, P745, DOI 10.1046/j.1432-1327.1999.00438.x
   Ban LP, 2002, BIOCHEM BIOPH RES CO, V293, P50, DOI 10.1016/S0006-291X(02)00185-7
   Biessmann H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009471
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Bruce TJA, 2005, TRENDS PLANT SCI, V10, P269, DOI 10.1016/j.tplants.2005.04.003
   Clarke AR, 2005, ANNU REV ENTOMOL, V50, P293, DOI 10.1146/annurev.ento.50.071803.130428
   Cui SY, 2006, PEPTIDES, V27, P1226, DOI 10.1016/j.peptides.2005.11.011
   Dani FR, 2011, CHEM SENSES, V36, P335, DOI 10.1093/chemse/bjq137
   Deng SS, 2012, CHEM SENSES, V37, P141, DOI 10.1093/chemse/bjr084
   Grosse-Wilde E, 2007, EUR J NEUROSCI, V25, P2364, DOI 10.1111/j.1460-9568.2007.05512.x
   Grosse-Wilde E, 2006, CHEM SENSES, V31, P547, DOI 10.1093/chemse/bjj059
   Gu SH, 2013, INSECT BIOCHEM MOLEC, V43, P237, DOI 10.1016/j.ibmb.2012.12.009
   Gu SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042871
   Guo W, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001291
   Immacolata Iovinella FB, 2013, CHEM SENSES, V4, P3
   Jayanthi PDK, 2012, J CHEM ECOL, V38, P361, DOI 10.1007/s10886-012-0093-y
   Leal WS, 2005, P NATL ACAD SCI USA, V102, P5386, DOI 10.1073/pnas.0501447102
   Li XR, 2011, INT J BIOL SCI, V7, P848, DOI 10.7150/ijbs.7.848
   Li XX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017788
   Liu R, 2012, INSECT MOL BIOL, V21, P41, DOI 10.1111/j.1365-2583.2011.01114.x
   Liu XL, 2010, J BIOCHEM, V148, P189, DOI 10.1093/jb/mvq050
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maleszka J, 2007, DEV GENES EVOL, V217, P189, DOI 10.1007/s00427-006-0127-y
   Maleszka R, 1997, GENE, V202, P39, DOI 10.1016/S0378-1119(97)00448-4
   Metcalf R. L, 1992, PLANT KAIROMONES INS
   Muller C, 2000, NATURWISSENSCHAFTEN, V87, P216, DOI 10.1007/s001140050706
   NOMURA A, 1992, INT J DEV BIOL, V36, P391
   Pelletier J, 2010, J CHEM ECOL, V36, P245, DOI 10.1007/s10886-010-9762-x
   Pelosi P, 2006, CELL MOL LIFE SCI, V63, P1658, DOI 10.1007/s00018-005-5607-0
   PELOSI P, 1994, CRIT REV BIOCHEM MOL, V29, P199, DOI 10.3109/10409239409086801
   Qiao HL, 2013, J INSECT PHYSIOL, V59, P667, DOI 10.1016/j.jinsphys.2013.04.004
   STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S
   Sun L, 2013, J CHEM ECOL, V39, P1221, DOI 10.1007/s10886-013-0333-9
   VET LEM, 1992, ANNU REV ENTOMOL, V37, P141, DOI 10.1146/annurev.en.37.010192.001041
   Vieira FG, 2011, GENOME BIOL EVOL, V3, P476, DOI 10.1093/gbe/evr033
   VISSER JH, 1986, ANNU REV ENTOMOL, V31, P121, DOI 10.1146/annurev.en.31.010186.001005
   VOGT RG, 1985, P NATL ACAD SCI USA, V82, P8827, DOI 10.1073/pnas.82.24.8827
   VOLLER A, 1980, P SOC EXP BIOL MED, V163, P402
   Vosshall LB, 2007, ANNU REV NEUROSCI, V30, P505, DOI 10.1146/annurev.neuro.30.051606.094306
   Yin XW, 2013, CELL MOL LIFE SCI, V70, P3029, DOI 10.1007/s00018-013-1308-2
   Zhang YB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047611
   Zhao N, 2010, PLANT PHYSIOL BIOCH, V48, P279, DOI 10.1016/j.plaphy.2010.01.023
   Zheng WW, 2012, J INSECT PHYSIOL, V58, P1122, DOI 10.1016/j.jinsphys.2012.05.011
   Zhou SH, 2008, J APPL ENTOMOL, V132, P439, DOI 10.1111/j.1439-0418.2007.01255.x
   Zhou SH, 2009, J MORPHOL, V270, P1356, DOI 10.1002/jmor.10763
NR 46
TC 14
Z9 16
U1 2
U2 69
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0098-0331
EI 1573-1561
J9 J CHEM ECOL
JI J. Chem. Ecol.
PD MAR
PY 2014
VL 40
IS 3
BP 267
EP 275
DI 10.1007/s10886-014-0406-4
PG 9
WC Biochemistry & Molecular Biology; Ecology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology
GA AG8GI
UT WOS:000335656400016
PM 24627092
DA 2018-12-27
ER

PT J
AU Li, JQ
   Cheng, M
   Tian, WC
   Zhang, J
AF Li, Jun-Quan
   Cheng, Ming
   Tian, Wei-Chen
   Zhang, Jian
TI RETRACTED: Generation of induced pluripotent stem cells using skin
   fibroblasts from patients with myocardial infarction under feeder- free
   conditions (Retracted article. See vol. 10, pg. 1170, 2014)
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article; Retracted Publication
DE induced pluripotent stem cells; myocardial infarction; reprogramming
ID CARDIOMYOCYTE DIFFERENTIATION; NUCLEAR TRANSFER; DOWN-SYNDROME; DISEASE;
   BLASTOCYSTS
AB Myocardial infarction (MI) is an increasing medical problem; however, its pathogenesis has yet to be elucidated and more effective treatment strategies are required. Induced pluripotent stem cells (iPSCs) were recently successfully generated using human somatic cells transfected with four transcription factors. The present study aimed to generate iPSCs from cells from patients with myocardial infarction. Six patients who had been diagnosed with myocardial infarction were enrolled in this study. The fibroblast cells from the biopsied skin were reprogrammed using octamer-binding transcription factor 4 (Oct-4), SRY-related HMG-box gene 2 (Sox-2), Kruppel-like factor 4 (Klf-4) and cellular myelocytomatosis oncogene (c-Myc) transcription factors. The generated cells were identified by karyotyping, in vitro and in vivo differentiation ability and staining for specific markers. These human MI-iPSCs expressed pluripotent genes and cell surface markers, and exhibited normal proliferation. The iPSCs also showed in vivo and in vitro differentiation ability, as indicated by teratoma and embryoid body formation, respectively. Moreover, the iPSCs differentiated into cardiomyocytes and neuronal cells. In conclusion, human iPSCs were successfully generated from skin fibroblasts from patients with MI under feeder-independent conditions, which increases their potential suitability for clinical applications. These results may encourage further study of MI pathogenesis and facilitate the development of safe downstream clinical applications of iPSC-based cell therapies.
C1 [Li, Jun-Quan; Cheng, Ming; Tian, Wei-Chen] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiac Surg, Harbin 150086, Heilongjiang, Peoples R China.
   [Zhang, Jian] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Surg, Qingdao 266003, Shandong, Peoples R China.
RP Zhang, J (reprint author), Qingdao Univ, Coll Med, Affiliated Hosp, Dept Surg, 16 Jiangsu Rd, Qingdao 266003, Shandong, Peoples R China.
EM tianweichendoctor@gmail.com; zhangjianmedmail@126.com
FU Technological Innovation Talent Special Foundation of Harbin, China
   [2009RFXXS018]; Youth Science Foundation of Heilongjiang Province
   [QC2013C116]; Medical Research Council [G0801418B]
FX This study was supported by the Technological Innovation Talent Special
   Foundation of Harbin, China (2009RFXXS018) and the Youth Science
   Foundation of Heilongjiang Province (QC2013C116).
CR Beltrao-Braga PCB, 2011, CELL TRANSPLANT, V20, P1707, DOI 10.3727/096368911X566235
   Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32
   Chun YS, 2010, INT J BIOL SCI, V6, P796
   French AJ, 2008, STEM CELLS, V26, P485, DOI 10.1634/stemcells.2007-0252
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Klimanskaya I, 2005, LANCET, V365, P1636, DOI 10.1016/S0140-6736(05)66473-2
   Li LB, 2012, CELL STEM CELL, V11, P615, DOI 10.1016/j.stem.2012.08.004
   Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109
   Liao J, 2009, CELL STEM CELL, V4, P11, DOI 10.1016/j.stem.2008.11.013
   Liu HS, 2008, CELL STEM CELL, V3, P587, DOI 10.1016/j.stem.2008.10.014
   Lu ZY, 2010, J ASSIST REPROD GEN, V27, P285, DOI 10.1007/s10815-010-9408-5
   Ludwig TE, 2006, NAT METHODS, V3, P637, DOI 10.1038/NMETH902
   Macarthur CC, 2012, STEM CELLS INT, V2012
   Maehr R, 2009, P NATL ACAD SCI USA, V106, P15768, DOI 10.1073/pnas.0906894106
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Mou XN, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt105
   Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041
   Passier R, 2005, STEM CELLS, V23, P772, DOI 10.1634/stemcells.20040184
   Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186
   Sun N, 2009, P NATL ACAD SCI USA, V106, P15720, DOI 10.1073/pnas.0908450106
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thatava T, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt89
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Valensi P, 2011, ARCH CARDIOVASC DIS, V104, P178, DOI 10.1016/j.acvd.2010.11.013
   Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971
   Ye ZH, 2009, BLOOD, V114, P5473, DOI 10.1182/blood-2009-04-217406
   Yu Y, 2009, HUM REPROD, V24, P649, DOI 10.1093/humrep/den407
   Zhang YS, 2012, J ASSIST REPROD GEN, V29, P735, DOI 10.1007/s10815-012-9802-2
   Zwi L, 2009, CIRCULATION, V120, P1513, DOI 10.1161/CIRCULATIONAHA.109.868885
NR 30
TC 2
Z9 2
U1 2
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2014
VL 9
IS 3
BP 837
EP 842
DI 10.3892/mmr.2014.1885
PG 6
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA AC7HO
UT WOS:000332699000010
PM 24398533
OA Bronze
DA 2018-12-27
ER

PT J
AU Liu, CB
   Yin, LH
   Chen, JQ
   Chen, JY
AF Liu, Chibo
   Yin, Lihui
   Chen, Jiaqi
   Chen, Jiayu
TI RETRACTED: The apoptotic effect of shikonin on human papillary thyroid
   carcinoma cells through mitochondrial pathway (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Shikonin; Papillary thyroid cancer; Cell apoptosis; Mitochondria signal
   pathway
ID IN-VITRO; ANTITUMOR-ACTIVITY; INDUCTION; DERIVATIVES; INHIBITION;
   MODULATION; RELEASE; FAMILY
AB This study aims to explore the apoptotic function of shikonin on the papillary thyroid cancer cells and the related mechanism. The papillary thyroid cancer cell lines K1 and W3 and thyroid follicular epithelial cells NTHY-ORI 3-1 were treated with different concentrations of shikonin. Cell proliferation was tested. Morphological changes of the apoptotic cells were observed by Hoechst 33342 staining. The apoptosis rate of the papillary thyroid cancer cells was measured with flow cytometry. Changes of the cell cycle were explored. The mitochondrial membrane potential changes were analyzed after JC-1 staining. Bcl-2 family proteins and caspase-3 expression with shikonin treatment was analyzed by real-time fluorescence polymerase chain reaction (PCR). Cell proliferation of K1 and W3 was inhibited by shikonin, and the inhibition was dose-time dependent. Papillary thyroid carcinoma cells treated by shikonin had no obvious cell cycle arrest but were observed with the higher apoptosis rate and the typical apoptotic morphological changes of the cell nucleus. JC-1 staining showed that shikonin reduced the mitochondrial membrane potential of papillary thyroid carcinoma cells. Real-time PCR results showed that shikonin significantly increased Bax and caspase-3 expression and upregulated Bcl-2 expression in a dose-dependent manner in papillary thyroid carcinoma cells. However, the NTHY-ORI 3-1 was almost not affected by shikonin treatment. Shikonin can inhibit K1 and W3 cell proliferation in a dose- and time-dependent manner, enhance Bax levels, reduce anti-apoptotic protein Bcl-2 levels, result in decreasing mitochondrial membrane potential and activating caspase-3 enzyme, and finally lead to apoptosis.
C1 [Liu, Chibo] Taizhou Municipal Hosp, Dept Clin Lab, Taizhou 317000, Zhejiang, Peoples R China.
   [Yin, Lihui] Blood Ctr Wisconsin, Milwaukee, WI USA.
   [Chen, Jiaqi] Jilin Univ, Coll Life Sci, Changchun 136000, Jilin, Peoples R China.
   [Chen, Jiaqi] Wenzhou Med Univ, Sch Lab Med, Wenzhou 325035, Zhejiang, Peoples R China.
   [Chen, Jiayu] Taizhou Univ, Sch Med, Taizhou City 325035, Zhejiang, Peoples R China.
RP Chen, JY (reprint author), Taizhou Univ, Sch Med, 1139 Shifu Rd, Taizhou City 325035, Zhejiang, Peoples R China.
EM chenyujia10@163.com
FU Zhejiang Natural Science Foundation [Y2100248]; Foundation of Department
   of Science and Technology of Zhejiang Province [2009C33155]; Foundation
   of Zhejiang Health Department [2009A218]; Taizhou Science and Technology
   Bureau [102KY15]; Zhejiang Province Chinese Medicine Study Foundation
   [2011ZA113]
FX This study was supported by the grants from the Zhejiang Natural Science
   Foundation (Y2100248), Foundation of Department of Science and
   Technology of Zhejiang Province (2009C33155), Foundation of Zhejiang
   Health Department (2009A218), Taizhou Science and Technology Bureau
   (102KY15), and Zhejiang Province Chinese Medicine Study Foundation
   (2011ZA113).
CR Andujar I, 2013, EUR J PHARM SCI, V49, P637, DOI 10.1016/j.ejps.2013.05.018
   Aschebrook-Kilfoy B, 2011, THYROID, V21, P125, DOI 10.1089/thy.2010.0021
   Chang IC, 2010, BIOL PHARM BULL, V33, P816, DOI 10.1248/bpb.33.816
   Elumalai P, 2012, TOXICOL LETT, V215, P131, DOI 10.1016/j.toxlet.2012.10.008
   Fan YY, 2012, INT J MOL SCI, V13, P9184, DOI 10.3390/ijms13079184
   Gao H, 2011, BIOL PHARM BULL, V34, P197, DOI 10.1248/bpb.34.197
   Gong K, 2011, FREE RADICAL BIO MED, V51, P2259, DOI 10.1016/j.freeradbiomed.2011.09.018
   Han WD, 2012, INT J MOL SCI, V13, P7212, DOI 10.3390/ijms13067212
   Hsu PC, 2004, J AGR FOOD CHEM, V52, P6330, DOI 10.1021/jf0495993
   Kontogiannopoulos KN, 2012, INT J PHARMACEUT, V422, P381, DOI 10.1016/j.ijpharm.2011.09.031
   Kretschmer N, 2012, J NAT PROD, V75, P865, DOI 10.1021/np2006499
   Leibowitz Brian, 2010, Cancer Biol Ther, V9, P417, DOI 10.4161/cbt.9.6.11392
   Lu L, 2011, EUR J PHARMACOL, V658, P242, DOI 10.1016/j.ejphar.2011.02.043
   Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8
   SANKAWA U, 1977, CHEM PHARM BULL, V25, P2392
   SANKAWA U, 1981, CHEM PHARM BULL, V29, P116
   Sasaki K, 2002, BIOL PHARM BULL, V25, P669, DOI 10.1248/bpb.25.669
   Sasi N, 2009, MOL CANCER THER, V8, P1421, DOI 10.1158/1535-7163.MCT-08-0895
   Yin SY, 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/262796
NR 19
TC 18
Z9 21
U1 4
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2014
VL 35
IS 3
BP 1791
EP 1798
DI 10.1007/s13277-013-1238-5
PG 8
WC Oncology
SC Oncology
GA AD8SQ
UT WOS:000333536300010
PM 24081676
DA 2018-12-27
ER

PT J
AU Shen, L
   Chen, XD
   Zhang, YH
AF Shen, Lei
   Chen, Xiao-Dong
   Zhang, Yao-Hui
TI RETRACTED: MicroRNA-128 promotes proliferation in osteosarcoma cells by
   downregulating PTEN (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Osteosarcoma; MicroRNA; Cell proliferation; miR-128; PTEN
ID ACUTE MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; POOR-PROGNOSIS;
   OVARIAN-CANCER; CYR61; EXPRESSION; GROWTH; METASTASIS; MIR-100
AB MicroRNAs are a class of small noncoding RNAs that function as critical gene regulators through targeting mRNAs for translational repression or degradation. Several studies have indicated that abnormal expression of miRNAs occurs frequently in human osteosarcoma. In the present study, we found that miR-128 expression was significantly increased in osteosarcoma tissues compared to adjacent normal tissues. Ectopic overexpression of miR-128 significantly promoted while suppression of miR-128 by its antisense inhibited the proliferation of MG63 and U2OS cells. At the molecular level, our results demonstrated that miR-128 overexpression could repress expression of PTEN by directly targeting PTEN 3'-untranslated region. Consistently, downstream AKT signaling was altered by miR-128 overexpression or knockdown. Therefore, our results suggest that miR-128 plays an important role in the proliferation of human osteosarcoma cells by directly regulation of PTEN/AKT signaling.
C1 [Shen, Lei; Chen, Xiao-Dong; Zhang, Yao-Hui] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Orthopaed Surg, Shanghai 200092, Peoples R China.
RP Chen, XD (reprint author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Orthopaed Surg, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.
EM chenxdmd@163.com; Zhang_Yao_Hui@126.com
FU National natural science foundation [81171705]
FX This work was partially supported by National natural science foundation
   81171705.
CR Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611
   Bai J, 2012, ONCOTARGETS THER, V5, P213, DOI 10.2147/OTT.S36017
   Cai CK, 2012, ONCOL REP, V28, P1764, DOI 10.3892/or.2012.1995
   Chen P, 2013, MOL CELL BI IN PRESS
   Fromigue O, 2011, J BONE MINER RES, V26, P1533, DOI 10.1002/jbmr.343
   Gebeshuber CA, 2013, ONCOGENE, V32, P3306, DOI 10.1038/onc.2012.372
   Goodwin CR, 2010, CANCER RES, V70, P2932, DOI 10.1158/0008-5472.CAN-09-3570
   Haque I, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-8
   Huang GX, 2012, CANCER RES, V72, P908, DOI 10.1158/0008-5472.CAN-11-1460
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3
   Leask A, 2011, J CELL COMMUN SIGNAL, V5, P123, DOI 10.1007/s12079-011-0127-1
   Lee KB, 2012, CANCER LETT, V315, P86, DOI 10.1016/j.canlet.2011.10.016
   Liang WQ, 2013, FRONT BIOSCI-LANDMRK, V18, P788, DOI 10.2741/4142
   Lin JPA, 2012, CANCER IMMUNOL IMMUN, V61, P677, DOI 10.1007/s00262-011-1135-y
   Liu J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-519
   Peng DX, 2012, ONCOL REP, V27, P1238, DOI 10.3892/or.2012.1625
   Petrelli A, 2012, ONCOGENE, V31, P4517, DOI 10.1038/onc.2011.631
   Sabile AA, 2012, J BONE MINER RES, V27, P58, DOI 10.1002/jbmr.535
   Sun KL, 2013, NAT REV GENET, V14, P535, DOI 10.1038/nrg3471
   Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj.onc.1205131
   Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2
   van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107
   Xie JJ, 2011, INT J MOL MED, V27, P429, DOI 10.3892/ijmm.2011.603
   Zheng YS, 2012, ONCOGENE, V31, P80, DOI 10.1038/onc.2011.208
NR 25
TC 53
Z9 58
U1 4
U2 20
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2014
VL 35
IS 3
BP 2069
EP 2074
DI 10.1007/s13277-013-1274-1
PG 6
WC Oncology
SC Oncology
GA AD8SQ
UT WOS:000333536300043
PM 24132591
DA 2018-12-27
ER

PT J
AU Ma, Z
   Guo, W
   Gong, TQ
   Niu, HJ
   Wang, RW
   Jiang, YG
AF Ma, Zheng
   Guo, Wei
   Gong, Taiqian
   Niu, Hui-Jun
   Wang, Ru-Wen
   Jiang, Yao-Guang
TI RETRACTED: CYP1A2 rs762551 polymorphism contributes to risk of lung
   cancer: A meta-analysis (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE CYP1A2; Lung cancer; Meta-analysis; Polymorphism
ID ENZYMES; SUSCEPTIBILITY; CARCINOGENESIS; POPULATION; HAPLOTYPES;
   INDUCTION; TOXICITY; SMOKING
AB Previous studies proposed that CYP1A2 rs762551 polymorphism might be associated with risk of lung cancer by influencing the function of CYP1A2. However, previous studies on the association between CYP1A2 rs762551 polymorphism and risk of lung cancer reported inconsistent findings. We performed a meta-analysis of the published case-control studies to assess the association between CYP1A2 rs762551 polymorphism and risk of lung cancer. PubMed and Embase were searched to identify relevant studies on the association between CYP1A2 rs762551 polymorphism and risk of lung cancer, and seven studies with a total of 3,320 subjects were finally included into the meta-analysis. The pooled odds ratio (OR) and 95 % confidence interval (95%CI) was calculated to evaluate the association. Meta-analysis of total studies showed that CYP1A2 rs762551 polymorphism contributed to risk of lung cancer under all four genetic models (C versus A: OR = 1.26, 95%CI 1.13 to 1.40, P < 0.001; CC versus AA: OR = 1.61, 95%CI 1.28 to 2.04, P < 0.001; CC versus AA/AC: OR = 1.52, 95%CI 1.11 to 2.09, P = 0.009; CC/AC versus AA: OR = 1.28, 95%CI 1.10 to 1.48, P = 0.001). Subgroup analysis based on ethnicity further suggested that CYP1A2 rs762551 polymorphism was associated with risk of lung cancer in Caucasians. These results from the meta-analysis suggest that CYP1A2 rs762551 polymorphism contributes to risk of lung cancer.
C1 [Ma, Zheng; Guo, Wei; Gong, Taiqian; Niu, Hui-Jun; Wang, Ru-Wen; Jiang, Yao-Guang] Third Millitary Med Univ, Daping Hosp, Dept Gen Thorac Surg, Chongqing 400042, Peoples R China.
   [Ma, Zheng; Guo, Wei; Gong, Taiqian; Niu, Hui-Jun; Wang, Ru-Wen; Jiang, Yao-Guang] Third Millitary Med Univ, Inst Surg Res, Chongqing 400042, Peoples R China.
RP Ma, Z (reprint author), Third Millitary Med Univ, Daping Hosp, Dept Gen Thorac Surg, 10 Changjiang Zhilu Rd, Chongqing 400042, Peoples R China.
EM mzcqdoc@163.com
CR Aldrich MC, 2009, CANCER RES, V69, P2340, DOI 10.1158/0008-5472.CAN-08-2576
   B'chir F, 2009, LIFE SCI, V84, P779, DOI 10.1016/j.lfs.2009.03.008
   Bozina N, 2009, ARH HIG RADA TOKSIKO, V60, P217, DOI 10.2478/10004-1254-60-2009-1885
   Brennan P, 2011, LANCET ONCOL, V12, P399, DOI 10.1016/S1470-2045(10)70126-1
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Gemignani F, 2007, CARCINOGENESIS, V28, P1287, DOI 10.1093/carcin/bgm021
   Gervasini G, 2013, ENVIRON MOL MUTAGEN, V54, P124, DOI 10.1002/em.21747
   Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kiyohara Chikako, 2007, Future Oncol, V3, P617, DOI 10.2217/14796694.3.6.617
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marshall AL, 2013, CARCINOGENESIS, V34, P487, DOI 10.1093/carcin/bgt016
   Nebert DW, 2006, NAT REV CANCER, V6, P947, DOI 10.1038/nrc2015
   Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200
   Nishikawa A, 2004, CURR DRUG METAB, V5, P363, DOI 10.2174/1389200043335441
   Osawa Y, 2007, ASIAN PAC J CANCER P, V8, P103
   Oyama Tsunehiro, 2012, Front Biosci (Schol Ed), V4, P1539
   Pavanello S, 2012, CANCER GENET-NY, V205, P278, DOI 10.1016/j.cancergen.2012.02.004
   Singh AP, 2010, CANCER BIOMARK, V8, P351, DOI 10.3233/CBM-2011-0224
   Tan XL, 2009, LUNG CANCER, V65, P129, DOI 10.1016/j.lungcan.2009.01.002
   Tian Z, 2013, GENE, V524, P168, DOI 10.1016/j.gene.2013.04.038
   Zhao Y, 2013, PLOS ONE, V8
NR 23
TC 8
Z9 8
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2014
VL 35
IS 3
BP 2253
EP 2257
DI 10.1007/s13277-013-1298-6
PG 5
WC Oncology
SC Oncology
GA AD8SQ
UT WOS:000333536300066
PM 24293373
DA 2018-12-27
ER

PT J
AU Zheng, JS
   Li, C
   Wu, X
   Yang, YZ
   Hao, MJ
   Sheng, SP
   Sun, Y
   Zhang, HH
   Long, J
   Hu, CX
AF Zheng, Jiasheng
   Li, Cong
   Wu, Xia
   Yang, Yingzhuo
   Hao, Meijun
   Sheng, Shoupeng
   Sun, Yu
   Zhang, Honghai
   Long, Jiang
   Hu, Caixia
TI RETRACTED: Astrocyte elevated gene-1 is a novel biomarker of
   epithelial-mesenchymal transition and progression of hepatocellular
   carcinoma in two China regions (Retracted article)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Hepatocellular carcinoma; Astrocyte elevated gene-1 (AEG-1); Vimentin;
   Epithelial-mesenchymal transition (EMT); Biomarker
ID BREAST-CANCER; LIVER-CANCER; AEG-1; EXPRESSION; METASTASIS; METADHERIN;
   ANGIOGENESIS; INDUCTION; PROTEIN; CLONING
AB Astrocyte elevated gene-1 (AEG-1) is involved in important biological processes including cell invasion, metastasis, and carcinogenesis. However, its clinical significance has remained largely unknown in hepatocellular carcinoma. Here, specimens from 144 patients with hepatocellular carcinomas in Beijing and Heilongjiang regions were investigated by immunohistochemical staining for AEG-1, vimentin, and E-cadherin expressions. A clinicopathological study revealed that AEG-1 expression level in tumor cells was significantly correlated with TNM stage (P = 0.001) and Edmonson grade (P < 0.0001). In addition, AEG-1, vimentin, and E-cadherin (epithelial-mesenchymal transition (EMT) biomarker) expressions were correlated with each other. These findings suggest that AEG-1 may be an epithelial-mesenchymal transition-associated biomarker in human hepatocellular carcinoma and play important roles in the progression of hepatocellular carcinoma. In addition, the AEG-1 gene is a potential target for elimination of hepatocellular carcinoma in the future.
C1 [Zheng, Jiasheng; Li, Cong; Hao, Meijun; Sheng, Shoupeng; Sun, Yu; Zhang, Honghai; Long, Jiang; Hu, Caixia] Capital Med Univ, Beijing Youan Hosp, Intervent Therapy Ctr Liver Dis, Beijing 100069, Peoples R China.
   [Zheng, Jiasheng; Li, Cong; Hao, Meijun; Sheng, Shoupeng; Sun, Yu; Zhang, Honghai; Long, Jiang; Hu, Caixia] Capital Med Univ, Beijing Inst Liver Dis, Beijing Youan Hosp, Beijing 100069, Peoples R China.
   [Wu, Xia; Yang, Yingzhuo] Harbin Med Univ, Dept Infect Dis, Affiliated Hosp 2, Harbin 150081, Peoples R China.
RP Zheng, JS (reprint author), Capital Med Univ, Beijing Inst Liver Dis, Beijing Youan Hosp, Beijing 100069, Peoples R China.
EM zhengjiasheng66@163.com
FU Twelve-fifth Key Science and Technology Five Year Plan of China
   [2012BAI15B08]
FX This paper was supported by the Twelve-fifth Key Science and Technology
   Five Year Plan of China (no. 2012BAI15B08).
CR Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0
   Emdad L, 2013, ADV CANCER RES, V120, P75, DOI 10.1016/B978-0-12-401676-7.00003-6
   Emdad L, 2009, P NATL ACAD SCI USA, V106, P21300, DOI 10.1073/pnas.0910936106
   Erdem H, 2013, NIGER J CLIN PRACT, V16, P418, DOI 10.4103/1119-3077.116873
   He XX, 2012, ONCOGENE, V31, P3357, DOI 10.1038/onc.2011.500
   Huang WB, 2013, DIGEST DIS SCI, V58, P2873, DOI 10.1007/s10620-013-2735-5
   Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]
   Kohles N, 2012, TUMOR BIOL, V33, P2401, DOI 10.1007/s13277-012-0504-2
   Lee HJ, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI DOI 10.1371/J0URNAL.P0NE.0034318
   Lee TK, 2006, CLIN CANCER RES, V12, P5369, DOI 10.1158/1078-0432.CCR-05-2722
   Li C, 2012, HISTOPATHOLOGY, V60, P953, DOI 10.1111/j.1365-2559.2012.04182.x
   Li C, 2011, J SURG ONCOL, V103, P184, DOI 10.1002/jso.21788
   Li C, 2011, INT J GYNECOL CANCER, V21, P602, DOI 10.1097/IGC.0b013e3182145561
   Li XA, 2011, CANCER SCI, V102, P1151, DOI 10.1111/j.1349-7006.2011.01919.x
   Liu KM, 2013, ANTI-CANCER DRUG, V24, P494, DOI 10.1097/CAD.0b013e328360093b
   Meng XB, 2012, J BIOL CHEM, V287, P4485, DOI 10.1074/jbc.C111.291518
   Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29
   Noch E, 2011, CANCER BIOL THER, V11, P32, DOI 10.4161/cbt.11.1.13835
   Noch EK, 2013, ADV CANCER RES, V120, P159, DOI 10.1016/B978-0-12-401676-7.00006-1
   Padhya KT, 2013, CURR OPIN GASTROEN, V29, P285, DOI 10.1097/MOG.0b013e32835ff1cf
   Sarkar D, 2013, ADV CANCER RES, V120, P193, DOI 10.1016/B978-0-12-401676-7.00007-3
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Song HT, 2010, INT J COLORECTAL DIS, V25, P1201, DOI 10.1007/s00384-010-1009-3
   Srivastava J, 2012, HEPATOLOGY, V56, P1782, DOI 10.1002/hep.25868
   Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj/onc/1205445
   Sun Y, 2013, CARBOHYD POLYM, V92, P577, DOI 10.1016/j.carbpol.2012.09.006
   Thirkettle HJ, 2009, ONCOGENE, V28, P3663, DOI 10.1038/onc.2009.223
   van Zijl F, 2009, FUTURE ONCOL, V5, P1169, DOI 10.2217/FON.09.91
   Wan LL, 2013, ADV CANCER RES, V120, P113, DOI 10.1016/B978-0-12-401676-7.00004-8
   Wei JL, 2013, CELL BIOL INT, V37, P1016, DOI 10.1002/cbin.10125
   Yao NH, 2012, TUMOR BIOL, V33, P1767, DOI 10.1007/s13277-012-0436-x
   Yoo BK, 2011, PHARMACOL THERAPEUT, V130, P1, DOI 10.1016/j.pharmthera.2011.01.008
   Zhu K, 2011, CLIN CANCER RES, V17, P7294, DOI 10.1158/1078-0432.CCR-11-1327
NR 33
TC 19
Z9 20
U1 2
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2014
VL 35
IS 3
BP 2265
EP 2269
DI 10.1007/s13277-013-1300-3
PG 5
WC Oncology
SC Oncology
GA AD8SQ
UT WOS:000333536300068
PM 24136747
DA 2018-12-27
ER

PT J
AU Costa-Martins, JM
   Pereira, M
   Martins, H
   Moura-Ramos, M
   Coelho, R
   Tavares, J
AF Costa-Martins, Jose Manuel
   Pereira, Marco
   Martins, Henriqueta
   Moura-Ramos, Mariana
   Coelho, Rui
   Tavares, Jorge
TI RETRACTED: Attachment Styles, Pain, and the Consumption of Analgesics
   During Labor: A Prospective Observational Study (Retracted article. See
   vol. 16, pg. 803, 2015)
SO JOURNAL OF PAIN
LA English
DT Article; Retracted Publication
DE Attachment styles; analgesic consumption; labor pain; patient-controlled
   epidural analgesia
ID CONTROLLED EPIDURAL ANALGESIA; ADULT ATTACHMENT; CONTINUOUS-INFUSION;
   PREDICTORS; DEPRESSION; EMOTION; HEALTH
AB Individuals with less secure attachment styles have been shown to experience more pain than people with more secure attachment styles; however, attachment styles have not yet been examined in the context of labor pain and analgesic consumption. The purpose of this prospective observational study was to assess the influence of the mother's attachment style on the perception of labor pain, as assessed by a visual analog scale and analgesic consumption. Eighty-one pregnant women with a mean age of 32 years (standard deviation = 5.1) were assessed during the third trimester of pregnancy and during labor. The physical predictors of labor pain were recorded, and the adult attachment style was assessed with the Adult Attachment Scale Revised. For labor analgesia, a low dose of patient-controlled epidural analgesia protocol (ropivacaine .6 mg/mL plus sufentanil .5 mu g/mL) was used. Women with a secure attachment style reported significantly less labor pain (P <. 001) and a significantly lower analgesic consumption during labor (P < .001) than insecurely attached women. These findings suggest that women's attachment style was associated with labor pain and analgesic consumption and support the relevance of the attachment theory as a promising conceptual framework for understanding labor pain.
   Perspective: This study showed that women with an insecure attachment style were more likely to report higher pain before patient-controlled epidural analgesia and higher analgesic consumption and to request supplemental analgesia during labor. The assessment of adult attachment has the potential to identify women at high risk of poorly coping with pain during childbirth. (C) 2014 by the American Pain Society.
C1 [Costa-Martins, Jose Manuel] Univ Porto, Dept Anaesthesiol, Matern Hosp Alfredo Da Costa, P-4100 Oporto, Portugal.
   [Pereira, Marco; Moura-Ramos, Mariana] Univ Coimbra, Fac Psychol & Educ Sci, P-3000 Coimbra, Portugal.
   [Martins, Henriqueta] Univ Inst, Inst Super Psicol Aplicada, Lisbon, Portugal.
   [Coelho, Rui] Univ Porto, Hosp Sao Joao, Dept Clin Neurosci & Mental Hlth, Fac Med, P-4100 Oporto, Portugal.
   [Tavares, Jorge] Univ Porto, Dept Anaesthesiol, Hosp Sao Joao, P-4100 Oporto, Portugal.
RP Costa-Martins, JM (reprint author), Rua Major Neutel Abreu,13,10 A, P-1500409 Lisbon, Portugal.
EM hcostamartins@gmail.com
OI Coelho, Rui/0000-0001-5790-8616
CR Angle P, 2010, CAN J ANAESTH, V57, P468, DOI 10.1007/s12630-010-9289-1
   BARTHOLOMEW K, 1991, J PERS SOC PSYCHOL, V61, P226, DOI 10.1037/0022-3514.61.2.226
   Boselli E, 2003, ANESTH ANALG, V96, P1173, DOI 10.1213/01.ANE.0000054168.36798.4A
   Bowlby J., 1982, ATTACHMENT LOSS
   Brennan K. A., 1998, ATTACHMENT THEORY CL, P46
   BROWN ST, 1989, PAIN, V38, P289, DOI 10.1016/0304-3959(89)90215-7
   Canavarro M. Cristina, 2006, Psicologia, V20, P155
   Chang Mei-Yueh, 2002, Kaohsiung Journal of Medical Sciences, V18, P604
   Ciechanowski P, 2003, PAIN, V104, P627, DOI 10.1016/S0304-3959(03)00120-9
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037//0033-2909.112.1.155
   Collins NL, 1996, J PERS SOC PSYCHOL, V71, P810, DOI 10.1037//0022-3514.71.4.810
   Davies KA, 2009, PAIN, V143, P200, DOI 10.1016/j.pain.2009.02.013
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Feeney J, 2003, PERS RELATIONSHIP, V10, P475, DOI 10.1046/j.1475-6811.2003.00061.x
   Feeney JA, 2000, CHILD CARE HLTH DEV, V26, P277, DOI 10.1046/j.1365-2214.2000.00146.x
   FRIDH G, 1988, RES NURS HEALTH, V11, P117, DOI 10.1002/nur.4770110207
   GAMBLING DR, 1988, CAN J ANAESTH, V35, P249, DOI 10.1007/BF03010618
   Gauthier LR, 2012, J PAIN, V13, P1258, DOI 10.1016/j.jpain.2012.10.001
   Halpern SH, 2009, ANESTH ANALG, V108, P921, DOI 10.1213/ane.0b013e3181951a7f
   Hess PE, 2001, ANESTH ANALG, V93, P414
   Hesse E., 2008, HDB ATTACHMENT THEOR, V2, P552
   Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a
   Lally JE, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-7
   Lang AJ, 2006, EUR J PAIN, V10, P263, DOI 10.1016/j.ejpain.2005.05.001
   Lopez FG, 2000, J COUNS PSYCHOL, V47, P283, DOI 10.1037//0022-0167.47.3.283
   Lowe NK, 2002, AM J OBSTET GYNECOL, V186, pS16, DOI 10.1067/mob.2002.121427
   McWilliams LA, 2000, CLIN J PAIN, V16, P360, DOI 10.1097/00002508-200012000-00014
   McWilliams LA, 2007, PAIN, V127, P27, DOI 10.1016/j.pain.2006.07.020
   MELZACK R, 1984, PAIN, V19, P321, DOI 10.1016/0304-3959(84)90079-4
   MELZACK R, 1984, CAN MED ASSOC J, V130, P579
   Meredith P, 2008, CLIN PSYCHOL REV, V28, P407, DOI 10.1016/j.cpr.2007.07.009
   Meredith PJ, 2007, EUR J PAIN, V11, P164, DOI 10.1016/j.ejpain.2006.01.004
   Meredith PJ, 2006, PAIN, V120, P44, DOI 10.1016/j.pain.2005.10.008
   MIKULINCER M, 1995, PERS SOC PSYCHOL B, V21, P406, DOI 10.1177/0146167295214011
   Nielsen CS, 2009, J PAIN, V10, P231, DOI 10.1016/j.jpain.2008.09.010
   Pan PH, 2009, OBSTET ANESTHESIA PR, P387
   Porter LS, 2007, PAIN, V128, P195, DOI 10.1016/j.pain.2007.02.001
   READING AE, 1985, PAIN, V22, P309, DOI 10.1016/0304-3959(85)90031-4
   Roberts L, 2010, J MIDWIFERY WOM HEAL, V55, P107, DOI 10.1016/j.jmwh.2009.11.002
   Saito Miwako, 2005, J Anesth, V19, P208, DOI 10.1007/s00540-005-0316-2
   Tremblay I, 2010, J PAIN, V11, P160, DOI 10.1016/j.jpain.2009.06.015
   van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217
NR 42
TC 9
Z9 10
U1 6
U2 33
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD MAR
PY 2014
VL 15
IS 3
BP 304
EP 311
DI 10.1016/j.jpain.2013.12.004
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AD7IQ
UT WOS:000333437800011
PM 24393700
DA 2018-12-27
ER

PT J
AU Gumley, A
   Braehler, C
   Macbeth, A
AF Gumley, Andrew
   Braehler, Christine
   Macbeth, Angus
TI RETRACTED: A meta-analysis and theoretical critique of oxytocin and
   psychosis: Prospects for attachment and compassion in promoting
   recovery(Retracted article. See vol. 56, pg. 212, 2017)
SO BRITISH JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE Compassion; Oxytocin; Psychosis; Schizophrenia; Attachment;
   meta-analysis
ID ADJUNCTIVE INTRANASAL OXYTOCIN; CEREBROSPINAL-FLUID;
   SCHIZOPHRENIC-PATIENTS; 1ST-EPISODE PSYCHOSIS; PLASMA OXYTOCIN; SOCIAL
   RECOGNITION; MATERNAL BRAIN; DOUBLE-BLIND; HUMANS; VASOPRESSIN
AB ObjectivesThere is now considerable evidence that affiliative processes are linked to oxytocin (OXT), which is linked to a range of social-cognition competences underpinning interpersonal functioning. There is evidence that OXT circuitry is involved in psychosis and emerging evidence for OXT in treatment. Therefore, this study explored studies investigating OXT and improvements in symptoms and social cognition among individuals diagnosed with psychosis.
   MethodWe conducted a systematic review of randomized controlled trials investigating OXT and psychosis. Specifically we asked, (1) what is the evidence that OXT is associated with improved overall, positive, negative and general symptoms and (2) what is the evidence that OXT is associated with improved social cognition?
   ResultsThere were seven randomized controlled trials that met the inclusion criteria for this review. We conducted an exploratory meta-analysis of data from four of these studies on a total sample size of n=105. For overall symptoms, using a random-effects model OXT versus placebo was associated with an effect size of d=0.52 (95% CI=0.34-0.70; z=5.66; p<.01). There was evidence of significant heterogeneity (Q=96.4, p<.001; I-2=96.5%). Similar patterns of findings were observed for positive, negative, and general symptoms. We found significant evidence of high risk of bias across all studies. We also identified that one particular study had an undue effect on overall effect size estimates. Finally, evidence regarding OXT was linked to improved social cognition was inconsistent.
   ConclusionsThere are significant problems in interpreting the current evidence base for OXT in psychosis. However, OXT may provide a useful biomarker for exploring mechanisms of change occurring in psychological therapies including compassion-focused therapy (CFT), which through its engagement of the attachment system may directly influence OXT.
C1 [Gumley, Andrew; Braehler, Christine] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland.
   [Macbeth, Angus] Univ Aberdeen, Inst Med Sci, Aberdeen AB9 1FX, Scotland.
RP Gumley, A (reprint author), Univ Glasgow, Gartnavel Royal Hosp, Inst Hlth & Wellbeing Mental Hlth & Wellbeing, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.
EM andrew.gumley@glasgow.ac.uk
OI MacBeth, Angus/0000-0002-0618-044X
CR Averbeck BB, 2012, PSYCHOL MED, V42, P259, DOI 10.1017/S0033291711001413
   Bakharev V D, 1986, Neurosci Behav Physiol, V16, P160, DOI 10.1007/BF01186517
   Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003
   Bartz J, 2011, SOC COGN AFFECT NEUR, V6, P556, DOI 10.1093/scan/nsq085
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   BECKMANN H, 1985, PSYCHONEUROENDOCRINO, V10, P187, DOI 10.1016/0306-4530(85)90056-3
   Birchwood M, 2000, PSYCHOL MED, V30, P337, DOI 10.1017/S0033291799001828
   Braehler C, 2013, COGNITIVE BEHAV THER, P236, DOI 10.1002/9781118330029
   Braehler C, 2013, BRIT J CLIN PSYCHOL, V52, P199, DOI 10.1111/bjc.12009
   Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002
   Buchheim A, 2009, PSYCHONEUROENDOCRINO, V34, P1417, DOI 10.1016/j.psyneuen.2009.04.002
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Chung Y. S., 2013, SCHIZOPHRENIA B, DOI 10.1093/schbul/sbt048
   Connor C, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00213
   Davis MC, 2013, SCHIZOPHR RES, V147, P393, DOI 10.1016/j.schres.2013.04.023
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Declerck CH, 2010, HORM BEHAV, V57, P368, DOI 10.1016/j.yhbeh.2010.01.006
   Dixon AK, 1998, BRIT J MED PSYCHOL, V71, P417, DOI 10.1111/j.2044-8341.1998.tb01001.x
   Feeney BC, 2010, J PERS SOC PSYCHOL, V98, P57, DOI 10.1037/a0016961
   Feifel D, 2012, SCHIZOPHR RES, V139, P207, DOI 10.1016/j.schres.2012.05.018
   Feifel D, 2012, NEUROPSYCHOPHARMACOL, V37, P304, DOI 10.1038/npp.2011.184
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Feldman R, 2010, HORM BEHAV, V58, P669, DOI 10.1016/j.yhbeh.2010.06.005
   Ferguson JN, 2002, FRONT NEUROENDOCRIN, V23, P200, DOI 10.1006/frne.2002.0229
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Fischer-Shofty M, 2013, SCHIZOPHR RES, V146, P357, DOI 10.1016/j.schres.2013.01.006
   Fonagy P, 2006, J PERS DISORD, V20, P544, DOI 10.1521/pedi.2006.20.6.544
   Gilbert P, 2001, PSYCHOL MED, V31, P1117
   Gilbert P, 1998, SHAME INTERPERSONAL
   Gilbert P, 2000, GENES COUCH EXPLORAT, P118
   Gilbert P., 2010, COMPASSION FOCUSED T
   GLOVINSKY D, 1994, SCHIZOPHR RES, V11, P273, DOI 10.1016/0920-9964(94)90021-3
   Goldman MB, 2007, J CLIN ENDOCR METAB, V92, P698, DOI 10.1210/jc.2006-1131
   Goldman MB, 2011, PSYCHOPHARMACOLOGY, V216, P101, DOI 10.1007/s00213-011-2193-8
   Gordon I, 2010, BIOL PSYCHIAT, V68, P377, DOI 10.1016/j.biopsych.2010.02.005
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Gumley A., 2013, ACTA PSYCHIAT SCANDI, DOI 10.1111/acps.12172
   Gumley A, 2010, INT J COGN THER, V3, P186, DOI 10.1521/ijct.2010.3.2.186
   Heim C, 2009, MOL PSYCHIATR, V14, P954, DOI 10.1038/mp.2008.112
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hutton P., 2012, PSYCHIAT RES, V30, P127, DOI 10.1016/j.psychres.2012.08.010
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579
   Iqbal Z, 2000, BRIT J PSYCHIAT, V177, P522
   Keri S, 2009, SOC NEUROSCI-UK, V4, P287, DOI 10.1080/17470910802319710
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kohler CG, 2010, SCHIZOPHRENIA BULL, V36, P1009, DOI 10.1093/schbul/sbn192
   Lardinois M, 2011, ACTA PSYCHIAT SCAND, V123, P28, DOI 10.1111/j.1600-0447.2010.01594.x
   Lataster J, 2012, ACTA PSYCHIAT SCAND, V125, P388, DOI 10.1111/j.1600-0447.2011.01805.x
   Lee J, 2013, SCHIZOPHRENIA BULL, V39, P640, DOI 10.1093/schbul/sbs063
   Lee MR, 2013, SCHIZOPHR RES, V145, P110, DOI 10.1016/j.schres.2013.01.001
   LEGROS JJ, 1992, PSYCHONEUROENDOCRINO, V17, P611, DOI 10.1016/0306-4530(92)90019-4
   Leucht S, 2013, EUR NEUROPSYCHOPHARM, V23, P956, DOI 10.1016/j.euroneuro.2012.11.004
   Leucht S, 2013, LANCET, V382, P951, DOI 10.1016/S0140-6736(13)60733-3
   Lincoln T. M., 2012, COGNITIVE THERAPY RE, V37, P1
   LINKOWSKI P, 1984, EUR ARCH PSY CLIN N, V234, P162, DOI 10.1007/BF00461555
   Liotti G, 2011, PSYCHOL PSYCHOTHER-T, V84, P9, DOI 10.1348/147608310X520094
   Lipsey M, 2001, PRACTICAL METAANALYS
   LUCAS A, 1980, BRIT MED J, V281, P834, DOI 10.1136/bmj.281.6244.834
   Lysaker PH, 2013, ACTA PSYCHIAT SCAND, V127, P239, DOI 10.1111/acps.12012
   MacBeth A, 2011, PSYCHOL PSYCHOTHER-T, V84, P42, DOI 10.1348/147608310X530246
   MacDonald K, 2012, ACTA NEUROPSYCHIATR, V24, P130, DOI 10.1111/j.1601-5215.2011.00634.x
   Matos M, 2013, CLIN PSYCHOL PSYCHOT, V20, P334, DOI 10.1002/cpp.1766
   Mayhew SL, 2008, CLIN PSYCHOL PSYCHOT, V15, P113, DOI 10.1002/cpp.566
   Michail M, 2009, BRIT J PSYCHIAT, V195, P234, DOI 10.1192/bjp.bp.108.053124
   Mikolajczak M, 2010, PSYCHOL SCI, V21, P1072, DOI 10.1177/0956797610377343
   Modabbernia A, 2013, CNS DRUGS, V27, P57, DOI 10.1007/s40263-012-0022-1
   Morris RW, 2009, CURR OPIN PSYCHIATR, V22, P140, DOI 10.1097/YCO.0b013e328324f895
   Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027
   Pereira TV, 2012, JAMA-J AM MED ASSOC, V308, P1676, DOI 10.1001/jama.2012.13444
   Pinto-Gouveia J., 2012, CLIN PSYCHOL PSYCHOT, DOI 10.1002/cpp.1818
   Rockliff H, 2011, EMOTION, V11, P1388, DOI 10.1037/a0023861
   Rosenfeld AJ, 2011, SCHIZOPHRENIA BULL, V37, P1077, DOI 10.1093/schbul/sbq015
   Rubin LH, 2013, SCHIZOPHR RES, V146, P138, DOI 10.1016/j.schres.2013.01.019
   Rubin LH, 2011, SCHIZOPHR RES, V130, P266, DOI 10.1016/j.schres.2011.06.002
   Ruble LH, 2010, SCHIZOPHR RES, V124, P13, DOI 10.1016/j.schres.2010.09.014
   Sasayama D, 2012, SCHIZOPHR RES, V139, P201, DOI 10.1016/j.schres.2012.06.016
   Souza RP, 2010, INT J NEUROPSYCHOPH, V13, P793, DOI 10.1017/S1461145710000167
   Strathearn L, 2011, J NEUROENDOCRINOL, V23, P1054, DOI 10.1111/j.1365-2826.2011.02228.x
   Strathearn L, 2008, PEDIATRICS, V122, P40, DOI 10.1542/peds.2007-1566
   Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103
   Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023
   Tremeau Fabien, 2006, Dialogues Clin Neurosci, V8, P59
   Turner M. H., 2012, BRIT J CLIN PSYCHOL, DOI 10.1111/bjc.12007
   UVNASMOBERG K, 1993, ACTA PHYSIOL SCAND, V149, P199, DOI 10.1111/j.1748-1716.1993.tb09612.x
   van Os J, 2010, NATURE, V468, P203, DOI 10.1038/nature09563
   Varese F, 2012, SCHIZOPHRENIA BULL, V38, P661, DOI 10.1093/schbul/sbs050
   Walss-Bass C, 2013, SCHIZOPHR RES, V147, P387, DOI 10.1016/j.schres.2013.04.003
   Whalen PJ, 2013, EMOT REV, V5, P78, DOI 10.1177/1754073912457231
   White R. G., 2013, PSYCHOSIS EMOTION RO, P177
NR 92
TC 24
Z9 24
U1 2
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0144-6657
EI 2044-8260
J9 BRIT J CLIN PSYCHOL
JI Br. J. Clin. Psychol.
PD MAR
PY 2014
VL 53
IS 1
BP 42
EP 61
DI 10.1111/bjc.12041
PG 20
WC Psychology, Clinical
SC Psychology
GA AB2IO
UT WOS:000331616600003
PM 24588761
DA 2018-12-27
ER

PT J
AU Chan, SW
   Chan, MF
   Lee, SY
   Henderson, A
AF Chan, S. W.
   Chan, M. F.
   Lee, S. -Y.
   Henderson, A.
TI RETRACTED: Nurses learning in the workplace: a comparison of workplace
   attributes in acute care settings in Australia and Singapore (Retracted
   article. See vol. 61, pg. 295, 2014)
SO INTERNATIONAL NURSING REVIEW
LA English
DT Article; Retracted Publication
DE Clinical; Context; Culture; Learning; Nursing; Organizational Culture;
   Workplace
ID PSYCHOLOGICAL SAFETY; NURSING-STUDENTS; ORGANIZATION; TEAMS
AB BackgroundWorkplaces need to foster teaching and learning interactions so staff collaborate and learn from each other. Internationally, many countries provide support to graduates and experienced staff to foster engagement necessary for learning and quality care. Workplace attributes can differ across countries depending on managerial, contextual, social and policy issues.
   AimThis study compared workplace attributes of two Australian hospitals with a Singaporean hospital.
   MethodsA representative sample of nurses in two acute care facilities in Australia (n=203) and a comparable facility in Singapore (n=154) during 2010 and 2011 responded to a survey requesting demographic data and responses about workplace attributes. Attributes were determined through validated tools that measure staff perception of support when facilitating others learning (Support Instrument for Nurses Facilitating the Learning of Others) and the clinical learning organizational culture (Clinical Learning Organizational Culture Survey).
   ResultsResults indicated Singaporean nurses rated perception of acknowledgement, workload management and teamwork support in facilitating learners in their hospital as significantly better than the Australian cohort despite similar provisions for support and development. There were no significant differences across the two sites in the clinical learning culture.
   LimitationsAnalysis across three health facilities only provides a snapshot. Targeting more facilities would assist in confirming the extent of reported trends.
   ConclusionsFindings indicate differences in nurses' perceptions of support when facilitating learners. Further exploration of Singaporean nurses' increased perceptions of support is worthy. Clinical learning organizational culture findings across Australian and Singaporean acute care facilities suggest common attributes within the nursing profession that transcend contextual factors, for example, a strong sense of task accomplishment.
   Implications for nursing and health policyNurses across both countries demonstrate strengths in accomplishing tasks but less so in recognizing nurses' contributions that may also impact nurses' influence in the practice context. As these attributes are common, nursing can collectively lobby and develop policy, thereby strengthening their cause to be recognized.
C1 [Chan, S. W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Alice Lee Ctr Nursing Studies, Singapore 117595, Singapore.
   [Chan, M. F.] Natl Univ Hlth Syst, Alice Lee Ctr Nursing Studies, Singapore, Singapore.
   [Lee, S. -Y.] Natl Univ Hlth Syst, Natl Univ Hosp, Singapore, Singapore.
   [Henderson, A.] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
   [Henderson, A.] Griffith Univ, Griffith Hlth, Sch Nursing & Midwifery, Gold Coast, Qld, Australia.
RP Henderson, A (reprint author), Princess Alexandra Hosp, Ipswich Rd, Woolloongabba, Qld 4102, Australia.
EM amanda_henderson@health.qld.gov.au
OI Henderson, Amanda/0000-0003-0564-3243
CR Barnett T, 2008, COLLEGIAN, V15, P55, DOI 10.1016/j.colegn.2008.02.002
   Bound H., 2011, FOSTERING CULTURE WO
   Clarke J, 2010, NURS EDUC TODAY, V30, P15, DOI 10.1016/j.nedt.2009.05.009
   Duddle M, 2007, J ADV NURS, V59, P29, DOI 10.1111/j.1365-2648.2007.04302.x
   Edmondson A, 1999, ADMIN SCI QUART, V44, P350, DOI 10.2307/2666999
   Egan T, 2009, HEALTH, V13, P107, DOI 10.1177/1363459308097363
   Elkin G, 2009, LEARN ORGAN, V16, P69, DOI 10.1108/09696470910927687
   Henderson A., J NURSING M IN PRESS, DOI 10.1111/jonm.12090
   Henderson A, 2012, INT J NURS STUD, V49, P1013, DOI 10.1016/j.ijnurstu.2012.02.013
   Henderson A, 2012, NURS EDUC TODAY, V32, P299, DOI 10.1016/j.nedt.2011.03.010
   Henderson A, 2010, NURS EDUC TODAY, V30, P598, DOI 10.1016/j.nedt.2009.12.006
   Institute of Medicine, 2007, LEARN HLTH CAR SYST
   International Council of Nurses, 2006, POS STAT CONT COMP P
   Kelly J, 2009, J CLIN NURS, V18, P910, DOI 10.1111/j.1365-2702.2008.02308.x
   Koh C., 2013, SINGAPORE NURSING J, V40, P38
   Kumar P., 2004, INT LIFELONG ED, V23, P559
   Lin C., 2008, J LEADERSH ORG STUD, V14, P303, DOI DOI 10.1177/1548051808315552
   Malouf N, 2011, NURS EDUC TODAY, V31, P488, DOI 10.1016/j.nedt.2010.10.002
   Nembhard IM, 2006, J ORGAN BEHAV, V27, P941, DOI 10.1002/job.413
   *NQUERY ADV, 2001, STAT SOL
   Polit D. F., 2010, ESSENTIALS NURSING R, P374
   Schalk DMJ, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-34
   State Government of Victoria, 2013, NURS VICT GRAD NURS
NR 23
TC 1
Z9 1
U1 5
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-8132
EI 1466-7657
J9 INT NURS REV
JI Int. Nurs. Rev.
PD MAR
PY 2014
VL 61
IS 1
BP 82
EP 89
DI 10.1111/inr.12062
PG 8
WC Nursing
SC Nursing
GA AA7GA
UT WOS:000331264300012
PM 24456256
DA 2018-12-27
ER

PT J
AU Xi, Y
   Wang, M
   Zhang, W
   Bai, M
   Du, Y
   Zhang, Z
   Li, ZY
   Miao, JT
AF Xi, Ye
   Wang, Man
   Zhang, Wei
   Bai, Miao
   Du, Ying
   Zhang, Zhuo
   Li, Zhuyi
   Miao, Jianting
TI RETRACTED: Neuronal damage, central cholinergic dysfunction and
   oxidative damage correlate with cognitive deficits in rats with chronic
   cerebral hypoperfusion (Retracted article. See vol. 126, pg. 87, 2015)
SO NEUROBIOLOGY OF LEARNING AND MEMORY
LA English
DT Article; Retracted Publication
DE Chronic cerebral hypoperfusion; Cognitive deficit; Oxidative stress;
   Cholinergic function; Vascular dementia; Alzheimer's disease
ID CHRONIC BRAIN HYPOPERFUSION; SPATIAL MEMORY IMPAIRMENT; CAROTID-ARTERY
   LIGATION; ALZHEIMERS-DISEASE; BLOOD-FLOW; VASCULAR DEMENTIA;
   WHITE-MATTER; WORKING-MEMORY; WISTAR RATS; HISTOPATHOLOGICAL CHANGES
AB Chronic cerebral hypoperfusion has been identified to be a risk factor for cognitive decline in aging, vascular dementia, and Alzheimer's disease. Substantial evidence has shown that chronic cerebral hypoperfusion may cause cognitive impairment, but the underlying neurobiological mechanism is poorly understood so far. In this study, we used a rat model of chronic cerebral hypoperfusion by permanent bilateral common carotid artery occlusion (BCCAO) to investigate the alterations of neuronal damage, glial activation oxidative stress and central cholinergic dysfunction, and their causal relationship with the cognitive deficits induced by chronic cerebral hypoperfusion. We found that BCCAO rats exhibited spatial learning and memory impairments and working memory dysfunction 12 weeks after BCCAO compared with sham-operated rats, simultaneously accompanied by significantly increased neuronal damage and glial cell activation in the cerebral cortex and hippocampus. Twelve weeks of BCCAO treatment in rats resulted in central cholinergic dysfunction and increased oxidative damage compared with sham-operated rats. Correlational analyses revealed that spatial learning and memory impairments and working memory dysfunction were significantly correlated with the measures of neuronal damage, central cholinergic dysfunction and oxidative damage in the cerebral cortex and hippocampus of rats with BCCAO. Moreover, the measures of neuronal damage and central cholinergic dysfunction were significantly correlated with the indexes of oxidative damage in rats with BCCAO. Collectively, this study provides novel evidence that neuronal damage and central cholinergic dysfunction is likely due to increased oxidative stress under the condition of chronic cerebral hypoperfusion. Furthermore, the results of the present study suggest that neuronal damage, central cholinergic dysfunction and oxidative damage in the brain following the reduction of cerebral blood flow could be involved in cognitive deficits induced by chronic cerebral hypoperfusion. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Xi, Ye; Wang, Man; Zhang, Wei; Bai, Miao; Du, Ying; Zhang, Zhuo; Li, Zhuyi; Miao, Jianting] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Shaanxi Provinc, Peoples R China.
   [Wang, Man; Bai, Miao; Du, Ying; Li, Zhuyi] Fourth Mil Med Univ, Tangdu Hosp, Inst Funct Brain Disorders, Xian 710038, Shaanxi Provinc, Peoples R China.
RP Li, ZY (reprint author), Fourth Mil Med Univ, Tangdu Hosp, Inst Funct Brain Disorders, Dept Neurol, Xian 710038, Shaanxi Provinc, Peoples R China.
EM lizhuyi@fmmu.edu.cn; jtmiao@fmmu.edu.cn
FU National Natural Science Foundation of China [81271193]
FX This work was supported by the research grant from National Natural
   Science Foundation of China (No. 81271193). We are very grateful to Dr.
   Changsheng Chen (Department of Medical Statistics, Fourth Military
   Medical University) for his expert technical assistance in statistical
   analyses.
CR Alegret M, 2010, J ALZHEIMERS DIS, V21, P557, DOI 10.3233/JAD-2010-091069
   Annahazi A, 2007, EUR J PHARMACOL, V571, P120, DOI 10.1016/j.ejphar.2007.05.048
   Austin BP, 2011, J ALZHEIMERS DIS, V26, P123, DOI 10.3233/JAD-2011-0010
   Avrova NF, 1998, NEUROCHEM RES, V23, P945, DOI 10.1023/A:1021076220411
   Bennett SAL, 1998, NEUROREPORT, V9, P161
   Bennett S, 2009, J ALZHEIMERS DIS, V17, P245, DOI 10.3233/JAD-2009-1041
   BIERER LM, 1995, J NEUROCHEM, V64, P749
   Borroni B, 2006, NEUROBIOL AGING, V27, P24, DOI 10.1016/j.neurobiolaging.2004.12.010
   Breteler MMB, 2000, NEUROBIOL AGING, V21, P153, DOI 10.1016/S0197-4580(99)00110-4
   Butterfield DA, 2007, FREE RADICAL BIO MED, V43, P658, DOI 10.1016/j.freeradbiomed.2007.05.037
   Cankurtaran M, 2008, ARCH GERONTOL GERIAT, V47, P25, DOI 10.1016/j.archger.2007.06.005
   Casado A, 2008, NEUROCHEM RES, V33, P450, DOI 10.1007/s11064-007-9453-3
   Cechetti F, 2012, LIFE SCI, V91, P29, DOI 10.1016/j.lfs.2012.05.013
   Cechetti F, 2012, BRAIN RES BULL, V87, P109, DOI 10.1016/j.brainresbull.2011.10.006
   Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002
   Choi BR, 2011, STROKE, V42, P2595, DOI 10.1161/STROKEAHA.111.620179
   Choy M, 2006, J CEREBR BLOOD F MET, V26, P1066, DOI 10.1038/sj.jcbfm.9600259
   Dash PK, 2007, LEARN MEMORY, V14, P554, DOI 10.1101/lm.558707
   De Jong GI, 1999, NEUROSCIENCE, V91, P203, DOI 10.1016/S0306-4522(98)00659-9
   de la Torre JC, 2005, J CEREBR BLOOD F MET, V25, P663, DOI 10.1038/sj.jcbfm.9600057
   de la Torre JC, 2004, NEUROL RES, V26, P517, DOI 10.1179/016164104225016254
   De La Torre JC, 2002, ANN NY ACAD SCI, V977, P196
   Deiana S, 2011, BEHAV BRAIN RES, V221, P389, DOI 10.1016/j.bbr.2010.11.036
   Dheen ST, 2007, CURR MED CHEM, V14, P1189
   Du J, 2013, NEUROSCIENCE, V231, P345, DOI 10.1016/j.neuroscience.2012.11.062
   Egashira T, 1996, JPN J PHARMACOL, V72, P57, DOI 10.1254/jjp.72.57
   Farkas E, 2004, ACTA NEUROPATHOL, V108, P57, DOI 10.1007/s00401-004-0864-9
   Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X
   Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003
   FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706
   Gackowski D, 2008, J NEUROL SCI, V266, P57, DOI 10.1016/j.jns.2007.08.041
   Garcia-Alloza M, 2011, BRAIN, V134, P3694, DOI 10.1093/brain/awr300
   Hanyu H, 2010, J NEUROL SCI, V290, P96, DOI 10.1016/j.jns.2009.10.022
   He XL, 2012, EUR J PHARMACOL, V680, P41, DOI 10.1016/j.ejphar.2012.01.025
   He XL, 2009, BRAIN RES, V1249, P212, DOI 10.1016/j.brainres.2008.10.005
   Hirao K, 2005, NEUROIMAGE, V28, P1014, DOI 10.1016/j.neuroimage.2005.06.066
   Huang L, 2008, CELL MOL NEUROBIOL, V28, P757, DOI 10.1007/s10571-007-9157-x
   Humpel C, 2005, CURR NEUROVASC RES, V2, P341, DOI 10.2174/156720205774322610
   JASPERS RMA, 1990, NEUROSCI LETT, V117, P149, DOI 10.1016/0304-3940(90)90135-V
   Jhoo JH, 2008, DEMENT GERIATR COGN, V26, P270, DOI 10.1159/000160960
   Jiwa NS, 2010, J NEUROCHEM, V115, P814, DOI 10.1111/j.1471-4159.2010.06958.x
   Kalaria RN, 2012, J NEUROL SCI, V322, P141, DOI 10.1016/j.jns.2012.07.032
   Kasparova S, 2005, NEUROCHEM INT, V46, P601, DOI 10.1016/j.neuint.2005.02.006
   Kato H, 2008, CEREBROVASC DIS, V26, P556, DOI 10.1159/000160213
   Keller JN, 2005, NEUROLOGY, V64, P1152, DOI 10.1212/01.WNL.0000156156.13641.BA
   Kim HA, 2012, N-S ARCH PHARMACOL, V385, P953, DOI 10.1007/s00210-012-0790-7
   Kovari E, 2007, NEUROLOGY, V68, P927, DOI 10.1212/01.wnl.0000257094.10655.9a
   Kume K, 2011, J NEUROL, V258, P1295, DOI 10.1007/s00415-011-5927-y
   Lai AY, 2006, CAN J PHYSIOL PHARM, V84, P49, DOI 10.1138/Y05-143
   Li YX, 2012, BIOL TRACE ELEM RES, V150, P242, DOI 10.1007/s12011-012-9455-0
   Liao Y, 2004, ACTA PHARMACOL SIN, V25, P1590
   Liu C, 2007, PHARMACOL BIOCHEM BE, V86, P423, DOI 10.1016/j.pbb.2006.11.005
   Liu H., 2012, NEUROBIOL AGING, V33, pe31
   Liu H, 2012, INT J NEUROSCI, V122, P494, DOI 10.3109/00207454.2012.686543
   Love S, 1999, BRAIN PATHOL, V9, P119
   Matsuda H, 2001, ANN NUCL MED, V15, P85, DOI 10.1007/BF02988596
   Mazza M, 2011, J ALZHEIMERS DIS, V23, P375, DOI 10.3233/JAD-2010-090700
   Micheau J, 2011, BEHAV BRAIN RES, V221, P424, DOI 10.1016/j.bbr.2010.11.052
   Mizoguchi K, 2009, NEUROSCIENCE, V162, P1192, DOI 10.1016/j.neuroscience.2009.05.023
   Moretti A, 2011, CNS NEUROL DISORD-DR, V10, P370, DOI 10.2174/187152711794653832
   Mracsko E, 2010, BRAIN RES, V1321, P13, DOI 10.1016/j.brainres.2009.11.080
   Murakami Y, 2005, PHARMACOL BIOCHEM BE, V81, P616, DOI 10.1016/j.pbb.2005.05.004
   Murakami Y, 1997, JPN J PHARMACOL, V75, P443, DOI 10.1254/jjp.75.443
   NUNN J, 1994, BEHAV BRAIN RES, V65, P1, DOI 10.1016/0166-4328(94)90069-8
   Okamoto Y, 2012, ACTA NEUROPATHOL, V123, P381, DOI 10.1007/s00401-011-0925-9
   OLSEN GM, 1994, BEHAV NEUROSCI, V108, P681, DOI 10.1037/0735-7044.108.4.681
   Otori T, 2003, CLIN EXP PHARMACOL P, V30, P266, DOI 10.1046/j.1440-1681.2003.03825.x
   Ozacmak VH, 2009, J PINEAL RES, V47, P156, DOI 10.1111/j.1600-079X.2009.00695.x
   Pappas BA, 1996, BRAIN RES, V708, P50, DOI 10.1016/0006-8993(95)01267-2
   Peng Y, 2007, J PHARMACOL EXP THER, V321, P902, DOI 10.1124/jpet.106.118760
   Perry E, 2005, NEUROLOGY, V64, P132, DOI 10.1212/01.WNL.0000148591.63727.80
   Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7
   Pimentel-Coelho PM, 2013, NEUROBIOL AGING, V34, P679, DOI 10.1016/j.neurobiolaging.2012.06.025
   Ruan CJ, 2010, BRAIN RES BULL, V82, P251, DOI 10.1016/j.brainresbull.2010.04.016
   SADOSHIMA S, 1995, J CEREBR BLOOD F MET, V15, P845, DOI 10.1038/jcbfm.1995.105
   Sarter M, 2004, NEUROBIOL AGING, V25, P1127, DOI 10.1016/j.neurobiolaging.2003.11.011
   Sayan-Ozacmak H, 2012, NEUROCHEM INT, V61, P287, DOI 10.1016/j.neuint.2012.05.011
   Sekita A, 2010, ACTA PSYCHIAT SCAND, V122, P319, DOI 10.1111/j.1600-0447.2010.01587.x
   Shim YS, 2006, J NEUROL SCI, V250, P85, DOI 10.1016/j.jns.2006.07.008
   Shinotoh H, 2000, ANN NEUROL, V48, P194, DOI 10.1002/1531-8249(200008)48:2<194::AID-ANA9>3.0.CO;2-X
   Sopala M, 2001, J NEURAL TRANSM, V108, P1445, DOI 10.1007/s007020100019
   Suter OC, 2002, STROKE, V33, P1986, DOI 10.1161/01.STR.0000024523.82300.77
   Tanaka K, 1996, BRAIN RES, V729, P55, DOI 10.1016/S0006-8993(96)00400-3
   Tanaka K, 1998, J NEUROSCI METH, V84, P63, DOI 10.1016/S0165-0270(98)00092-2
   Tomimoto H, 2003, ACTA NEUROPATHOL, V106, P527, DOI 10.1007/s00401-003-0749-3
   TSUCHIYA M, 1992, EXP BRAIN RES, V89, P87
   TSUCHIYA M, 1993, EXP BRAIN RES, V95, P1
   Ulrich PT, 1998, STROKE, V29, P2412, DOI 10.1161/01.STR.29.11.2412
   Vicente E, 2009, BRAIN RES, V1251, P204, DOI 10.1016/j.brainres.2008.11.032
   WAKITA H, 1994, ACTA NEUROPATHOL, V87, P484
   Wakita H, 2002, BRAIN RES, V924, P63, DOI 10.1016/S0006-8993(01)03223-1
   Wang J, 2010, J NEUROSCI RES, V88, P807, DOI 10.1002/jnr.22237
   Wang J, 2009, ACTA PHARMACOL SIN, V30, P879, DOI 10.1038/aps.2009.82
   Wang XJ, 2010, J ALZHEIMERS DIS, V21, P813, DOI 10.3233/JAD-2010-100216
   Watanabe T, 2006, STROKE, V37, P1539, DOI 10.1161/01.STR.0000221783.08037.a9
   Xing BZ, 2008, STROKE, V39, P2362, DOI 10.1161/STROKEAHA.107.507939
   Xiong L, 2011, CHIN J INTEGR MED, V17, P134, DOI 10.1007/s11655-011-0643-0
   Xu Y, 2010, J NUTR BIOCHEM, V21, P741, DOI 10.1016/j.jnutbio.2009.05.002
   Yang DW, 2002, J NEUROL SCI, V203, P199, DOI 10.1016/S0022-510X(02)00291-5
   Yao ZH, 2012, CURR NEUROVASC RES, V9, P176, DOI 10.2174/156720212801618974
   Yuen EY, 2009, P NATL ACAD SCI USA, V106, P14075, DOI 10.1073/pnas.0906791106
   Zhang GL, 2011, BEHAV PHARMACOL, V22, P633, DOI 10.1097/FBP.0b013e32834afef9
   Zhang W, 2012, FREE RADICAL BIO MED, V52, P1443, DOI 10.1016/j.freeradbiomed.2012.01.023
   Zhang W, 2011, BEHAV BRAIN RES, V222, P342, DOI 10.1016/j.bbr.2011.03.072
   Zhang WJ, 2012, PHARMACOL BIOCHEM BE, V100, P361, DOI 10.1016/j.pbb.2011.09.012
   Zhao Q, 2007, J PHARMACOL SCI, V103, P360, DOI 10.1254/jphs.FP0061457
   Zito G, 2013, REJUV RES, V16, P51, DOI 10.1089/rej.2012.1383
   Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114
NR 108
TC 45
Z9 50
U1 2
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1074-7427
EI 1095-9564
J9 NEUROBIOL LEARN MEM
JI Neurobiol. Learn. Mem.
PD MAR
PY 2014
VL 109
BP 7
EP 19
DI 10.1016/j.nlm.2013.11.016
PG 13
WC Behavioral Sciences; Neurosciences; Psychology; Psychology,
   Multidisciplinary
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA AC3PF
UT WOS:000332433000002
PM 24315928
DA 2018-12-27
ER

PT J
AU Chai, SJ
   Qian, YY
   Tang, JF
   Liang, ZY
   Zhang, M
   Si, JX
   Li, XZ
   Huang, WD
   Xu, RZ
   Wang, K
AF Chai, Shoujie
   Qian, Yingying
   Tang, Jingfen
   Liang, Zhuyu
   Zhang, Min
   Si, Jingxing
   Li, Xiuzhen
   Huang, Wengdong
   Xu, Rongzhen
   Wang, Kai
TI RETRACTED: Ca2+/calmodulin-dependent protein kinase II gamma, a critical
   mediator of the NF-kappa B network, is a novel therapeutic target in
   non-small cell lung cancer (Retracted article. See vol. 414, pg. 312,
   2018)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE CaMKII gamma; Non-small cell lung cancer; NF-kappa B; Therapeutic target
ID GROWTH-FACTOR RECEPTOR; MYELOID-LEUKEMIA; CRITICAL REGULATOR;
   OPEN-LABEL; GEFITINIB; CAMKII; MUTATIONS; EGFR; RESISTANCE; EML4-ALK
AB The molecular mechanism that triggers constitutive activation of nuclear factor-kappa B (NF-kappa B) in non-small cell lung cancer (NSCLC) remains elusive. In this present study, we demonstrated that Ca2+/calmodulin-dependent protein kinase II gamma (CaMKII gamma) is a critical molecular switch of continuous activation of NF-kappa B in NSCLC. We found that CaMKII gamma was aberrantly expressed in human NSCLC tissues and correlated well with the degree of malignancy. Functionally, CaMKII gamma promoted the growth and survival of NSCLC cells via direct activation of NF-kappa B and multiple oncogenic signaling pathways in NSCLC. Taken together, our findings described a previously uncharacterized role of CaMKII gamma in NSCLC, and suggest a novel potential therapeutic target for NSCLC treatment. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Chai, Shoujie; Qian, Yingying; Liang, Zhuyu; Zhang, Min; Si, Jingxing; Wang, Kai] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp Med, Hangzhou 310009, Zhejiang, Peoples R China.
   [Tang, Jingfen; Xu, Rongzhen] Zhejiang Univ, Sch Med, Key Lab Canc Prevent & Intervent, China Natl Minist Educ,Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
   [Tang, Jingfen; Xu, Rongzhen] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Inst Canc, Hangzhou 310009, Zhejiang, Peoples R China.
   [Tang, Jingfen; Xu, Rongzhen] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hematol, Hangzhou 310009, Zhejiang, Peoples R China.
   [Li, Xiuzhen] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Pathol, Hangzhou 310009, Zhejiang, Peoples R China.
   [Huang, Wengdong] City Hope Natl Med Ctr, Beckman Res Inst, Div Gene Regulat, Duarte, CA 91010 USA.
RP Wang, K (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp Med, Hangzhou 310009, Zhejiang, Peoples R China.
EM zrxyk10@zju.edu.cn; kaiw@zju.edu.cn
FU National Natural Science Foundation of China [81070420, 81170026,
   81270601]; Major Science and Technology Special Project of Zhejiang
   Province [2012C13022-1]; Zhejiang Provincial Natural Science Foundation
   of Distinguished Young Scientists [LR12H01001]; Science and Technology
   Department of Zhejiang Province [2012C23081, 2013C33130]; Health
   Department of Zhejiang Province [201232200]; Zhejiang Provincial Program
   for the Cultivation of High-level Innovative Health Talents
FX The authors thank Y. Zhu, J. Peng, Y. Fang, Q. Lu, and Q. Dong for their
   technical assistance. This work was supported by grants from the
   National Natural Science Foundation of China (Nos. 81070420, 81170026
   and 81270601), the Major Science and Technology Special Project of
   Zhejiang Province (No. 2012C13022-1), the Zhejiang Provincial Natural
   Science Foundation of Distinguished Young Scientists (No. LR12H01001),
   the Science and Technology Department of Zhejiang Province (Nos.
   2012C23081, 2013C33130), the Health Department of Zhejiang Province (No.
   201232200), and Zhejiang Provincial Program for the Cultivation of
   High-level Innovative Health Talents.
CR Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221
   Buontempo F, 2012, CELL CYCLE, V11, P2467, DOI 10.4161/cc.20859
   Chen G, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-28
   Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478
   Daniluk J, 2012, J CLIN INVEST, V122, P1519, DOI 10.1172/JCI59743
   Dougan M, 2011, J CLIN INVEST, V121, P2436, DOI 10.1172/JCI44796
   Erickson JR, 2011, PHYSIOL REV, V91, P889, DOI 10.1152/physrev.00018.2010
   Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235
   Garg R, 2012, J BIOL CHEM, V287, P37570, DOI 10.1074/jbc.M112.398925
   Gu Y, 2012, BLOOD, V120, P4829, DOI 10.1182/blood-2012-06-434894
   Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200
   Katayama R, 2011, P NATL ACAD SCI USA, V108, P7535, DOI 10.1073/pnas.1019559108
   Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753
   Ly PTT, 2011, J NEUROCHEM, V119, P673, DOI 10.1111/j.1471-4159.2011.07473.x
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   Meng ZP, 2013, MOL CANCER THER, V12, P2067, DOI 10.1158/1535-7163.MCT-13-0314
   Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Ou SHI, 2011, DRUG DES DEV THER, V5, P471, DOI 10.2147/DDDT.S19045
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947
   Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025
   Rushworth SA, 2012, BLOOD, V120, P5188, DOI 10.1182/blood-2012-04-422121
   Sfikas A, 2012, CELL SIGNAL, V24, P2007, DOI 10.1016/j.cellsig.2012.06.010
   Si JT, 2008, CANCER RES, V68, P3733, DOI 10.1158/0008-5472.CAN-07-2509
   Si JT, 2007, J CLIN INVEST, V117, P1412, DOI 10.1172/JCI30779
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   [徐菲 Xu Fei], 2013, [南方医科大学学报, Journal of Southern Medical University], V33, P649
   Zaynagetdinov R, 2012, ONCOGENE, V31, P3164, DOI 10.1038/onc.2011.480
   Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X
NR 33
TC 10
Z9 11
U1 1
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAR 1
PY 2014
VL 344
IS 1
BP 119
EP 128
DI 10.1016/j.canlet.2013.10.022
PG 10
WC Oncology
SC Oncology
GA AB3KC
UT WOS:000331688700014
PM 24189456
DA 2018-12-27
ER

PT J
AU Scheinfeld, NS
   Chernoff, K
   Ho, MKD
   Liu, YC
AF Scheinfeld, Noah S.
   Chernoff, Karen
   Ho, Man Kin Derek
   Liu, Yen Chen
TI RETRACTED: Drug-induced photoallergic and phototoxic reactions - an
   update (Retracted article. See vol. 13, pg. 1431, 2014)
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review; Retracted Publication
DE photoallergy and photoallergic; photosensitive; photosensitivity;
   phototoxic; phototoxicity
ID AMPIROXICAM-INDUCED PHOTOSENSITIVITY; CHRONIC ACTINIC DERMATITIS;
   CONTACT-DERMATITIS; INDUCED PSEUDOPORPHYRIA; CUTANEOUS PHOTOSENSITIVITY;
   PHOTOCONTACT DERMATITIS; LICHENOID REACTION; TETRACYCLINE-HYDROCHLORIDE;
   PHOTODYNAMIC THERAPY; TOPICAL KETOPROFEN
AB Introduction: Photoallergic and phototoxic medications continue to be an important concern for dermatologists. In the last 5 years, the list of phototoxic and photoallergic medications has expanded, as well as the testing tools used to screen for potential allergy. Currently available testing methods include the photoprick, photoscratch and illuminated intracutaneous tests. If the causative photosensitizer is not the test substance but a metabolite of the test substance, a systemic photoprovocation test can be utilized. Photodynamic therapy pro-photosensitizers have been shown to be sensitizers to visible light, while most other phototoxins respond to the UVA and/or UVB spectrum.
   Areas covered: This article reviews the findings of a PubMed search for the key words 'photosensitivity', 'photosensitive', 'phototoxicity', 'phototoxic', 'photoallergy' and 'photoallergic'. Articles published over the last 5 years were compared with those published earlier than this to find updated information on photo-reactions.
   Expert opinion: With the variety of new monoclonal antibodies, clinicians must remain up to date as to the drugs that can cause photo-reactions. There are new tests that can aid in assessing photo-reactions.
C1 [Scheinfeld, Noah S.; Chernoff, Karen; Liu, Yen Chen] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Dermatol, New York, NY 10021 USA.
   [Ho, Man Kin Derek] SUNY Downstate Coll Med, Brooklyn, NY 11203 USA.
RP Scheinfeld, NS (reprint author), New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Dermatol, New York, NY 10021 USA.
EM nss1scheinfeld@gmail.com
CR ADDO HA, 1987, BRIT J DERMATOL, V116, P749, DOI 10.1111/j.1365-2133.1987.tb04893.x
   Akay BN, 2010, JPN J CLIN ONCOL, V40, P989, DOI 10.1093/jjco/hyq085
   Al-Khenaizan S, 1999, J Cutan Med Surg, V3, P162
   Atarashi K, 2012, J PHOTOCH PHOTOBIO B, V113, P56, DOI 10.1016/j.jphotobiol.2012.05.002
   BALABANOVA MB, 1994, CONTACT DERMATITIS, V30, P303, DOI 10.1111/j.1600-0536.1994.tb00607.x
   BARAN R, 1990, ANN DERMATOL VENER, V117, P367
   BARAN R, 1987, J AM ACAD DERMATOL, V17, P1012, DOI 10.1016/S0190-9622(87)70291-6
   Baran R, 2002, PHOTODERMATOL PHOTO, V18, P202, DOI 10.1034/j.1600-0781.2002.00760.x
   BERGNER T, 1992, J AM ACAD DERMATOL, V26, P114, DOI 10.1016/0190-9622(92)70018-B
   BILSLAND D, 1990, BRIT J DERMATOL, V123, P547
   BJELLERUP M, 1994, BRIT J DERMATOL, V130, P356, DOI 10.1111/j.1365-2133.1994.tb02933.x
   Borgia F, 2000, BRIT J DERMATOL, V143, P674, DOI 10.1111/j.1365-2133.2000.03749.x
   Bourrain JL, 1997, PHOTODERMATOL PHOTO, V13, P159, DOI 10.1111/j.1600-0781.1997.tb00221.x
   Brazzelli V, 2013, J EUR ACAD DERMATOL, V27, P1471, DOI 10.1111/jdv.12172
   Brazzelli V, 2012, PHOTODERMATOL PHOTO, V28, P2, DOI 10.1111/j.1600-0781.2011.00621.x
   Breier F, 1998, DERMATOLOGY, V197, P271, DOI 10.1159/000018012
   BREZA TS, 1975, ARCH DERMATOL, V111, P1168, DOI 10.1001/archderm.111.9.1168
   BURRY JN, 1976, BRIT J DERMATOL, V94, P495, DOI 10.1111/j.1365-2133.1976.tb05136.x
   Canelas MM, 2010, CONTACT DERMATITIS, V63, P85, DOI 10.1111/j.1600-0536.2010.01707.x
   Caterina F, 2011, CONTACT DERMATITIS, V64, P181, DOI 10.1111/j.1600-0536.2010.01817.x
   Chang CH, 2009, J CLIN ONCOL, V27, pE114, DOI 10.1200/JCO.2009.21.8479
   Chishiki M, 1997, DERMATOLOGY, V195, P409, DOI 10.1159/000246002
   COOHILL TP, 1991, PHOTOCHEM PHOTOBIOL, V54, P859, DOI 10.1111/j.1751-1097.1991.tb02103.x
   Cooper SM, 2003, CLIN EXP DERMATOL, V28, P588, DOI 10.1046/j.1365-2230.2003.01408.x
   Cooper SM, 2001, BRIT J DERMATOL, V144, P641, DOI 10.1046/j.1365-2133.2001.04111.x
   Cron RQ, 2000, J RHEUMATOL, V27, P1817
   Cummins R, 2000, J RHEUMATOL, V27, P2938
   Dawe RS, 2005, DRUG AGING, V22, P201, DOI 10.2165/00002512-200522030-00002
   Dawson GA, 2009, ONCOLOGIST, V14, P303, DOI 10.1634/theoncologist.2008-0277
   Diaz RL, 2006, CONTACT DERMATITIS, V54, P239, DOI 10.1111/j.0105-1873.2006.00797.x
   Doffoel-Hantz V, 2009, CLIN EXP DERMATOL, V34, pE763, DOI 10.1111/j.1365-2230.2009.03484.x
   Dogra S, 2003, BRIT J DERMATOL, V148, P609, DOI 10.1046/j.1365-2133.2003.05209_17.x
   Drucker AM, 2011, DRUG SAFETY, V34, P821, DOI 10.2165/11592780-000000000-00000
   ELMETS CA, 1993, CLIN PHOTOMEDICINE, P207
   EMMETT EA, 1978, INT J DERMATOL, V17, P370, DOI 10.1111/ijd.1978.17.5.370
   EPSTEIN JH, 1976, ARCH DERMATOL, V112, P661, DOI 10.1001/archderm.112.5.661
   FALKSON G, 1962, BRIT J DERMATOL, V74, P229, DOI 10.1111/j.1365-2133.1962.tb13497.x
   FERGUSON J, 1985, BRIT J DERMATOL, V113, P537, DOI 10.1111/j.1365-2133.1985.tb02377.x
   FERGUSON J, 1982, BRIT J DERMATOL, V107, P429, DOI 10.1111/j.1365-2133.1982.tb00386.x
   FERGUSON J, 1989, PHARMACOL THERAPEUT, V40, P123, DOI 10.1016/0163-7258(89)90079-X
   Fernandez-Jorge B, 2008, CONTACT DERMATITIS, V58, P113, DOI 10.1111/j.1600-0536.2007.01183.x
   FITZPATRICK TB, 1959, J INVEST DERMATOL, V32, P229, DOI 10.1038/jid.1959.40
   Foering K, 2013, J AM ACAD DERMATOL, V69, P205, DOI 10.1016/j.jaad.2013.03.015
   Frye CB, 1998, PHARMACOTHERAPY, V18, P866
   GERBERICK GF, 1991, J INVEST DERMATOL, V97, P210, DOI 10.1111/1523-1747.ep12480149
   Gomez-Bernal S, 2010, PHOTODERMATOL PHOTO, V26, P213, DOI 10.1111/j.1600-0781.2010.00517.x
   Goncalo M, 2013, CONTACT DERMATITIS, V68, P239, DOI 10.1111/cod.12037
   GOULD JW, 1995, J AM ACAD DERMATOL, V33, P551, DOI 10.1016/0190-9622(95)91271-1
   Grabczynska SA, 2000, BRIT J DERMATOL, V142, P1255, DOI 10.1046/j.1365-2133.2000.03572.x
   Granados MTR, 2004, J EUR ACAD DERMATOL, V18, P389, DOI 10.1111/j.1468-3083.2004.00897.x
   Gregoriou S, 2008, J CLIN PSYCHOPHARM, V28, P219, DOI 10.1097/JCP.0b013e318166c50a
   Grossberg AL, 2013, CURR OPIN PEDIATR, V25, P474, DOI 10.1097/MOP.0b013e328362c2c3
   Gutierrez-Gonzalez E, 2011, PHOTODERMATOL PHOTO, V27, P338, DOI 10.1111/j.1600-0781.2011.00625.x
   Habif TP, 2006, NEW ENGL J MED, V355, P182, DOI 10.1056/NEJMicm050829
   Hague JS, 2007, CLIN EXP DERMATOL, V32, P102, DOI 10.1111/j.1365-2230.2006.02245.x
   HALSEY JP, 1982, BMJ-BRIT MED J, V284, P1365, DOI 10.1136/bmj.284.6326.1365
   Hansford JR, 2012, J ANTIMICROB CHEMOTH, V67, P1807, DOI 10.1093/jac/dks105
   Hanson M, 2008, J DRUGS DERMATOL, V7, P792
   HARBER LC, 1972, J INVEST DERMATOL, V58, P327, DOI 10.1111/1523-1747.ep12540517
   HARBER LC, 1985, ANN NY ACAD SCI, V453, P317, DOI 10.1111/j.1749-6632.1985.tb11820.x
   HARRIS L, 1983, CIRCULATION, V67, P45, DOI 10.1161/01.CIR.67.1.45
   HAWK JLM, 1980, CLIN EXP DERMATOL, V5, P321, DOI 10.1111/j.1365-2230.1980.tb01710.x
   Hivnor C, 2003, ARCH DERMATOL, V139, P1373, DOI 10.1001/archderm.139.10.1373
   HORIO T, 1979, ARCH DERMATOL, V115, P986, DOI 10.1001/archderm.115.8.986
   Hussain S, 2000, CANCER, V88, P2367, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2367::AID-CNCR22>3.0.CO;2-#
   Huygens S, 2001, CONTACT DERMATITIS, V44, P1, DOI 10.1034/j.1600-0536.2001.440101.x
   IBSEN HH, 1983, ACTA DERM-VENEREOL, V63, P555
   Ingrish G, 1996, ARCH DERMATOL, V132, P1519, DOI 10.1001/archderm.132.12.1519
   James W, 2006, PHOTOSENSITIVITY REA
   Johnston GA, 2002, CLIN EXP DERMATOL, V27, P670, DOI 10.1046/j.1365-2230.2002.01108.x
   KAIDBEY KH, 1977, ARCH DERMATOL, V113, P592, DOI 10.1001/archderm.113.5.592
   KESTEL JL, 1981, CUTIS, V28, P53
   Koulu LM, 2010, J INVEST DERMATOL, V130, P2578, DOI 10.1038/jid.2010.181
   Kowalzick L, 2006, CONTACT DERMATITIS, V54, P348, DOI 10.1111/j.0105-1873.2006.0645f.x
   Kurumaji Y, 1996, CONTACT DERMATITIS, V34, P298, DOI 10.1111/j.1600-0536.1996.tb02208.x
   LaDuca JR, 2002, J CUTAN MED SURG, V6, P320, DOI 10.1007/s10227-001-0051-8
   LAYTON AM, 1993, CLIN EXP DERMATOL, V18, P425, DOI 10.1111/j.1365-2230.1993.tb02242.x
   Le Coz CJ, 1998, CONTACT DERMATITIS, V38, P245
   LIM HW, 1994, ARCH DERMATOL, V130, P1284, DOI 10.1001/archderm.130.10.1284
   Lipsky BA, 1999, CLIN THER, V21, P675, DOI 10.1016/S0149-2918(00)88319-8
   LJUNGGREN B, 1991, CONTACT DERMATITIS, V24, P259, DOI 10.1111/j.1600-0536.1991.tb01719.x
   Llambrich A, 2004, PHOTODERMATOL PHOTO, V20, P108, DOI 10.1111/j.1600-0781.2004.00087.x
   LOVELL CR, 1986, CONTACT DERMATITIS, V14, P290, DOI 10.1111/j.1600-0536.1986.tb05278.x
   LUI H, 1993, DERMATOL CLIN, V11, P1
   LUTON EF, 1965, ARCH DERMATOL, V91, P362, DOI 10.1001/archderm.91.4.362
   Mahajan Vikram K, 2005, Australas J Dermatol, V46, P104, DOI 10.1111/j.1440-0960.2005.00153.x
   Martin-Lazaro J, 2004, CONTACT DERMATITIS, V50, P325, DOI 10.1111/j.0105-1873.2004.00341m.x
   MATSUO I, 1979, DERMATOLOGICA, V159, P46, DOI 10.1159/000250560
   Meola T, 1993, EVALUATION PHOTOSENS
   MIYAUCHI H, 1994, PHOTODERMATOL PHOTO, V10, P255
   Montoro J, 1997, CONTACT DERMATITIS, V37, P139, DOI 10.1111/j.1600-0536.1997.tb00332.x
   Moore DE, 2002, DRUG SAFETY, V25, P345, DOI 10.2165/00002018-200225050-00004
   Mote AV, 1998, PHOTODERMATOL PHOTO, V14, P132, DOI 10.1111/j.1600-0781.1998.tb00027.x
   Natkunarajah J, 2010, CLIN EXP DERMATOL, V35, pe83, DOI 10.1111/j.1365-2230.2009.03538.x
   Norrby S R, 1993, Drugs, V45 Suppl 3, P59
   ORTONNE JP, 1979, BRIT J DERMATOL, V101, P1, DOI 10.1111/j.1365-2133.1979.tb15285.x
   Passier A, 2004, BRIT MED J, V329, P265, DOI 10.1136/bmj.329.7460.265
   Petersen B, 2013, PHOTOCH PHOTOBIO SCI, V12, P190, DOI 10.1039/c2pp25127b
   PETERSEN C S, 1992, Ugeskrift for Laeger, V154, P1713
   Pruim B, 1999, Australas J Dermatol, V40, P79, DOI 10.1046/j.1440-0960.1999.00325.x
   RAFFLE EJ, 1975, ARCH DERMATOL, V111, P1364, DOI 10.1001/archderm.111.10.1364
   RIETSCHEL RL, 1978, CONTACT DERMATITIS, V4, P334, DOI 10.1111/j.1600-0536.1978.tb03845.x
   ROBINSON HN, 1985, ARCH DERMATOL, V121, P522, DOI 10.1001/archderm.121.4.522
   Rodriguez-Pazos L, 2013, ACTAS DERMO-SIFILOGR, V104, P645, DOI [10.1016/j.ad.2012.01.021, 10.1016/j.adengl.2012.01.024]
   Rodriguez-Serna M, 1999, CONTACT DERMATITIS, V41, P54, DOI 10.1111/j.1600-0536.1999.tb06220.x
   Saravolatz LD, 2003, CLIN INFECT DIS, V37, P1210, DOI 10.1086/378809
   SASSOLAS B, 1994, CLIN EXP DERMATOL, V19, P189, DOI 10.1111/j.1365-2230.1994.tb01162.x
   Selvaag E, 1997, PHOTODERMATOL PHOTO, V13, P21, DOI 10.1111/j.1600-0781.1997.tb00103.x
   SERRANO G, 1990, J AM ACAD DERMATOL, V23, P479, DOI 10.1016/0190-9622(90)70244-C
   SERRANO G, 1989, PHOTODERMATOLOGY, V6, P140
   Silver EA, 2003, ARCH DERMATOL, V139, P227, DOI 10.1001/archderm.139.2.227
   Slade HB, 2009, PHOTODERMATOL PHOTO, V25, P146, DOI 10.1111/j.1600-0781.2009.00433.x
   SONG PS, 1979, PHOTOCHEM PHOTOBIOL, V29, P1177, DOI 10.1111/j.1751-1097.1979.tb07838.x
   STERN RS, 1984, JAMA-J AM MED ASSOC, V252, P1433
   TAN SV, 1989, CLIN EXP DERMATOL, V14, P335, DOI 10.1111/j.1365-2230.1989.tb02006.x
   Tintle S, 2014, INT J DERMATOL, V53, P3, DOI 10.1111/ijd.12016
   TOBACK AC, 1986, DERMATOL CLIN, V4, P223, DOI 10.1016/S0733-8635(18)30825-8
   Tolland JP, 2007, PHOTODERMATOL PHOTO, V23, P29, DOI 10.1111/j.1600-0781.2007.00263.x
   Toyohara A, 1996, CONTACT DERMATITIS, V35, P101, DOI 10.1111/j.1600-0536.1996.tb02300.x
   Tremblay JF, 2003, J AM ACAD DERMATOL, V49, P1189, DOI 10.1016/S0190-9622(03)00893-4
   Usuki A, 1997, INT J DERMATOL, V36, P604
   Vaccaro M, 2007, BRIT J DERMATOL, V157, P822, DOI 10.1111/j.1365-2133.2007.08082.x
   VAILLANT L, 1988, ARCH DERMATOL, V124, P326, DOI 10.1001/archderm.124.3.326
   Vassileva SG, 1998, ARCH INTERN MED, V158, P1993, DOI 10.1001/archinte.158.18.1993
   Verrotti A, 2014, EUR J PAEDIATR NEURO, V18, P13, DOI 10.1016/j.ejpn.2013.06.006
   Wagner SN, 2000, CONTACT DERMATITIS, V43, P245
   Watanabe Y, 1999, J AM ACAD DERMATOL, V40, P832, DOI 10.1053/jd.1999.v40.a94737
   WILLIS I, 1968, J INVEST DERMATOL, V51, P378, DOI 10.1038/jid.1968.143
   WOLF R, 1987, DERMATOLOGICA, V174, P285, DOI 10.1159/000249200
   YASUDA S, 1988, PHOTODERMATOLOGY, V5, P206
   Yazici AC, 2004, INT J DERMATOL, V43, P459, DOI 10.1111/j.1365-4632.2004.02149.x
   Yones SS, 2005, CLIN EXP DERMATOL, V30, P500, DOI 10.1111/j.1365-2230.2005.01820.x
   ZACHARY CB, 1984, BRIT J DERMATOL, V110, P451, DOI 10.1111/j.1365-2133.1984.tb04660.x
   Zeitouni NC, 2003, MOL IMMUNOL, V39, P1133, DOI 10.1016/S0161-5890(03)00083-X
   ZENAROLA P, 1991, DERMATOLOGICA, V182, P196, DOI 10.1159/000247783
   ZINSSER HH, 1964, MED CLIN N AM, V48, P293, DOI 10.1016/S0025-7125(16)33463-0
NR 136
TC 6
Z9 7
U1 2
U2 32
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD MAR
PY 2014
VL 13
IS 3
BP 321
EP 340
DI 10.1517/14740338.2014.885948
PG 20
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AB6NW
UT WOS:000331907200007
PM 24547917
DA 2018-12-27
ER

PT J
AU Akhmat, G
   Zaman, K
   Shukui, T
   Ahmed, T
AF Akhmat, Ghulam
   Zaman, Khalid
   Shukui, Tan
   Ahmed, Tauseef
TI RETRACTED: Educational reforms and internationalization of universities:
   evidence from major regions of the world (Retracted article. See vol.
   108, pg. 999, 2016)
SO SCIENTOMETRICS
LA English
DT Article; Retracted Publication
DE Internationalization; Educational reforms; Growth factors; World regions
AB Internationalization of universities has become a worldwide phenomenon as global economic integration continues to make its way forcefully into the higher education. The objective of the study is to develop a model for internationalization of universities with the transformation of some promising macroeconomic variables i.e., educational reforms and economic growth in the seven largest regions of the world [namely, East Asia and Pacific (sample 25 countries); Europe and Central Asia (40 countries); Latin America and Caribbean (27 countries); Middle East and North Africa (17 countries); North America (22 countries); South Asia (7 countries) and Sub-Saharan Africa (21 countries)]. The data has been analyzed by panel fixed effect regression from the period of 1990-2011. In addition to transform inputs into output, the study employed eleven indicators of education and five indicators for growth, where the resulting vector is internationalization. The results show the dynamic linkages between educational indicators and economic factors in the selected regions of the World. In East Asia and Pacific region, tertiary and higher education expenditures per student increase the economic factors. Higher education is a powerful driver of long-term growth in Europe and Central Asia. Governments of the state should have to focus on higher education enrolment, as it does not have any significant contribution to increase GDP; gross capital formation and FDI in Latin America and Caribbean region. Higher education enrolment in MENA region significantly increases growth factors on the cost of increase gross national expenditures. Investment in general education and other generic human capital is of the utmost importance in creating an enabling environment for FDI in North America. It is imperative for South Asia to encourage the skill levels and education opportunities for females, in order to maximize the effects of FDI on the female human capital stock and therefore economic growth. Tertiary school enrolment and tertiary expenditures per student identified the importance of tertiary education in Sub-Saharan Africa. The results conclude that educational indicators improve the economic gains, which ultimately reap out the benefit of internationalization.
C1 [Akhmat, Ghulam; Shukui, Tan] Huazhong Univ Sci & Technol, Coll Publ Adm, Wuhan 430074, Peoples R China.
   [Zaman, Khalid; Ahmed, Tauseef] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
RP Shukui, T (reprint author), Huazhong Univ Sci & Technol, Coll Publ Adm, 1037 Luoyu Rd, Wuhan 430074, Peoples R China.
EM ahmad_choudary@hotmail.com; khalidzaman@ciit.net.pk; tansk@126.com
FU National 985 Project of Non-traditional Security at Huazhong University
   of Science and Technology, P. R. China
FX This work was financially supported by the National 985 Project of
   Non-traditional Security at Huazhong University of Science and
   Technology, P. R. China. Authors are thankful to the anonymous reviewers
   for their comments and suggestions. Any remaining errors are the authors
   own responsibility.
CR ADB, 2010, ADB EC WORK PAP SER, V236
   Altbach Philip G., 2007, J STUD INT EDUC, V11, P290, DOI DOI 10.1177/1028315307303542
   [Anonymous], 2009, MILL DEV GOALS REP 2
   Bergerhoff J., 2013, INT ED EC GROWTH
   Bhattacharya R., 2010, WP1030 IMF
   Bolden R., 2000, HIGHER ED EC GROWTH
   Byun K, 2013, HIGH EDUC, V65, P645, DOI 10.1007/s10734-012-9568-6
   Calderon A., 2012, U WORLD NEWS
   Calvo CC, 2006, GLOB EC POL 5 ANN PO
   Cho YH, 2013, HIGH EDUC, V65, P291, DOI 10.1007/s10734-012-9544-1
   Cooray A., 2011, 145 BWPI
   Dee, 2008, PRODUCTIVITY HIGHER
   Etzkowitz H, 2000, RES POLICY, V29, P313, DOI 10.1016/S0048-7333(99)00069-4
   EU, 2012, HIGH ED MOD AG NAV P
   Greens M. F., 2012, U WORLD NEWS
   Hanushek E., 2009, POOR STUDENT LEARNIN
   Hanushek EA, 2012, J DEV ECON, V99, P497, DOI 10.1016/j.jdeveco.2012.06.004
   Inglesi-Lotz R, 2013, SCIENTOMETRICS, V95, P129, DOI 10.1007/s11192-012-0817-3
   Jons H, 2013, GEOFORUM, V46, P45, DOI 10.1016/j.geoforum.2012.12.014
   MEXT, 2013, INT U THEIR LOC CONT
   Mok K. H., 2006, INT S OS U JAN 13 14
   Montanini M., 2013, SUPPORTING TERTIARY
   Morris B., 2009, J EMERGING KNOWLEDGE, V1, P143
   National Association of State Universities and Land Grant Colleges [NASULGC], 2007, NAT ACT AG INT HIGH
   OECD, 2002, FOR DIR INV DEV MAX
   OECD, 2004, OECD OBSERVER
   OECD, 2007, CROSS BORD TERT ED W
   OECD (Organization of Economic Co-operation and Development), 2010, HIGH COST LOW ED PER
   Olds K, 2007, WORLD DEV, V35, P959, DOI 10.1016/j.worlddev.2006.05.014
   PSU, 2009, U OFF INT PROGR STRA
   Sakellariou C., 2010, ACCESS EQUITY HIGHER
   UNESCO, 2008, OV IN WHY GOV MATT
   UNESCO, 2011, REG OV E AS PAC
   UNESCO, 2012, GOV ED SPEND SOURC M
   UNICEF, 2002, ED LIT
   Vinluan LR, 2012, SCIENTOMETRICS, V91, P277, DOI 10.1007/s11192-011-0496-5
   Waters M., 2012, U WORLD NEWS
   WES, 2012, 01 WES RES ADV SERV
   World Bank, 2009, DIR DEV, P1, DOI 10.1596/978-0-8213-7738-3
   World Bank, 2012, PUTT HIGH ED WORK SK
   World Bank, 2007, TERT ED AFR
   World Bank, 2008, ROAD NOT TRAV ED REF
   World Bank, 2012, WORLD DEV IND DAT BA
   World Penn Table, 2012, PENN WORLD TABL VERS
NR 44
TC 3
Z9 3
U1 5
U2 79
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0138-9130
EI 1588-2861
J9 SCIENTOMETRICS
JI Scientometrics
PD MAR
PY 2014
VL 98
IS 3
BP 2185
EP 2205
DI 10.1007/s11192-013-1130-5
PG 21
WC Computer Science, Interdisciplinary Applications; Information Science &
   Library Science
SC Computer Science; Information Science & Library Science
GA AB1NT
UT WOS:000331559800038
DA 2018-12-27
ER

PT J
AU Mumtaz, R
   Zaman, K
   Sajjad, F
   Lodhi, MS
   Irfan, M
   Khan, I
   Naseem, I
AF Mumtaz, Rehma
   Zaman, Khalid
   Sajjad, Faiza
   Lodhi, Muhammad Saeed
   Irfan, Muhammad
   Khan, Imran
   Naseem, Imran
TI RETRACTED: Modeling the causal relationship between energy and growth
   factors: Journey towards sustainable development (Retracted article. See
   vol. 76, pg. 805, 2015)
SO RENEWABLE ENERGY
LA English
DT Article; Retracted Publication
DE Energy; Trade; Education; Health; Environment; Pakistan
ID ECONOMIC-GROWTH; DEVELOPING-COUNTRIES; BIVARIATE COINTEGRATION; CARBON
   EMISSIONS; ERROR-CORRECTION; CONSUMPTION; PAKISTAN; PERSPECTIVE;
   ENVIRONMENT; SECTOR
AB The objective of the study was to find the direction of the causality between energy consumption and six broad categories of growth factors i.e., trade factors, education indicators, growth measures, environmental indicators, health variables and population growth in Pakistan over a period of 1975-2010. For this purpose, cointegration and Granger causality tests have been applied. In this study, energy consumption and growth factors are explicitly included in model. The result shows that trade in services, FDI and exports have a significant and positive contribution to increases energy consumption in Pakistan, however, the intensity of the relationship with the energy consumption is different in nature, as exports have around 2.049 percent increases energy consumption, if there is one percent increase in exports. Imports, on the other hand, have a negative relationship with energy consumption in Pakistan. The impact of education indicators (i.e., education expenditure, primary & secondary school enrollment and literacy rate) on energy consumption is positive, which confirms that education has a strategic role in improving energy efficiency. Sectoral growth (i.e., agriculture, industry, manufacturing, services sector and economic growth) have a positive contribution to increase energy consumption in Pakistan. As, agriculture and industry value added serves as an engine of energy, hence, as agriculture modernizes, energy demand increases. Carbon dioxide emission and natural resource depletion both increases energy consumption in Pakistan, however, arable land decreases energy consumption around 1.743 percent. The impact of health care indicators (i.e., health expenditure, life expectancy and mortality) increases the demand for energy. Energy progress has been seen as a factor of supply and demand which explains the growth of health care expenditures. Population indicators (i.e., population growth, urban population, rural population, unemployment and labor force) have a significant and positive association with the energy consumption in Pakistan. The results of Granger causality indicates that there has been a unidirectional causality running towards energy consumption to trade factors (i.e., trade in services, FDI and imports) but not vice versa. The result indicates that energy consumption is found to Granger cause imports, which means that any reductions in energy consumption, energy conservation polices would reduce imports and lessen the benefits of trade. Similarly, energy consumption Granger cause education factors (i.e., primary and secondary school enrollment); growth factors (i.e., agriculture, industry and manufacturing value added); environmental factor (i.e., carbon dioxide emissions); health factor (i.e., mortality) and population measures (i.e., population growth, urban and rural population) but not vice versa, however, the remaining sub-variables are independent in nature and there has been no causality found with the energy consumption in Pakistan. The overall result concludes that causality running towards energy consumption to macroeconomic factors in Pakistan but not other way around. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Mumtaz, Rehma; Zaman, Khalid; Sajjad, Faiza; Lodhi, Muhammad Saeed; Irfan, Muhammad; Khan, Imran; Naseem, Imran] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad 22060, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad 22060, Pakistan.
EM rehmajadoon@gmail.com; khalidzaman@ciit.net.pk; faiza@ciit.net.pk;
   saeedlodhi@ciit.net.pk; mirfan@ciit.net.pk; imrankjadoon@ciit.net.pk;
   drimran@ciit.net.pk
CR Andreoni V, 2012, ENERGY, V44, P682, DOI 10.1016/j.energy.2012.05.024
   Ang JB, 2007, ENERG POLICY, V35, P4772, DOI 10.1016/j.enpol.2007.03.032
   Apergis N, 2010, ENERG ECON, V31, P641
   Apergis N, 2012, ENERG ECON, V34, P733, DOI 10.1016/j.eneco.2011.04.007
   Asafu-Adjaye J, 2000, ENERG ECON, V22, P615, DOI 10.1016/S0140-9883(00)00050-5
   Bekhet H.A., 2011, INT J EC FINANCE, V3, P208
   Butt M. S., 2001, ASIA PACIFIC DEV J, V8, P101
   Demirbas MF, 2009, ENERG CONVERS MANAGE, V50, P1746, DOI 10.1016/j.enconman.2009.03.013
   DIESENDORF M, 2007, GREENHOUSE SOLUTIONS, P86
   Dincer I., 2002, ROLE THERMAL ENERGY
   Ebohon OJ, 1996, ENERG POLICY, V24, P447, DOI 10.1016/0301-4215(96)00027-4
   ENGLE RF, 1987, ECONOMETRICA, V55, P251, DOI 10.2307/1913236
   EPA, 2005, EV CHOIC OPP ENV STE
   Exxonmobil, OUTL EN VIEW 2040
   Ghani MO, 2010, BUSINESS MAGAZINE NE
   GoP. Government of Pakistan, 2011, EC SURV PAK FIN DIV
   GoP. Government of Pakistan, 2010, EC SURV PAK FIN DIV
   GRANGER CWJ, 1981, J ECONOMETRICS, V16, P121, DOI 10.1016/0304-4076(81)90079-8
   Grossman G., 1991, 3194 NBER
   Hamit-Haggar M, 2012, ENERG ECON, V34, P358, DOI 10.1016/j.eneco.2011.06.005
   Hossain S., 2012, LOW CARBON EC, V3, P92, DOI DOI 10.4236/1CE.2012.323013
   IAEA, 2005, EN IND SUST DEV GUID
   IISD, 2012, SUST DEV JOURN
   International Energy Outlook, 2012, INT EN OUTL
   JOHANSEN S, 1991, ECONOMETRICA, V59, P1551, DOI 10.2307/2938278
   Kahsai SM, 2012, ENERG ECON, V34, P739
   Kakar ZK, 2011, J INT ACAD RES, V11, P33
   Keser OF, 2003, ENERG SOURCE, V25, P123, DOI 10.1080/00908310390142181
   KRAFT J, 1978, J ENERGY DEV, V3, P401
   Lee CC, 2008, RESOUR ENERGY ECON, V30, P50, DOI 10.1016/j.reseneeco.2007.03.003
   MAHMUD F, 1990, ENERG ECON, V12, P251, DOI 10.1016/0140-9883(90)90015-8
   Mirza UK, 2007, RENEW SUST ENERG REV, V13, P927
   Mirza UK, 2008, RENEW SUST ENERG REV, V12, P1988, DOI 10.1016/j.rser.2007.04.001
   Nadia OS, 2012, ENERG ECON, V36, P637
   Nakicenovic N, 1996, DAEDALUS, V125, P95
   NCSD, 2004, BARB SUST DEV POL
   PHILLIPS PCB, 1990, ECONOMETRICA, V58, P165, DOI 10.2307/2938339
   Pirlogea C, 2012, RENEW SUST ENERG REV, V16, P5718, DOI 10.1016/j.rser.2012.06.010
   Ragheb M, 2012, SUSTAINABLE ENERGY R
   Sadorsky P, 2012, ENERG ECON, V34, P476, DOI 10.1016/j.eneco.2011.12.008
   Schreyer P., 2001, OECD EC STUDIES, V33, pII
   Shahbaz M, 2010, DEV RES PAPERS MONAS, V10/05
   Siddiqui R., 2004, PAK DEV REV, V43, P175
   Song CS, 2006, CATAL TODAY, V115, P2, DOI 10.1016/j.cattod.2006.02.029
   Soytas U, 2007, ECOL ECON, V62, P482, DOI 10.1016/j.ecolecon.2006.07.009
   Stern DI, 2011, 12011 CAMA
   Sun V., 1998, ECOL ECON, V25, P195, DOI DOI 10.1016/S0921-8009(97)00180-8
   Tang CF, 2014, QUAL QUANT, V48, P781, DOI 10.1007/s11135-012-9802-4
   The World Bank, 2012, WORLD DEV IND
   Ting Y., 2011, ENERGY PROCEDIA, V5, P100
   Toman M, 2002, 9 STANF U
   Toman MA, 2003, ENERGY J, V24, P93
   UNEP, 2008, REF EN SUBS OPP CONT
   United Nations, 2004, WORLD POP 2300
   Vaillancourt K, 2008, ENERG POLICY, V36, P2296, DOI 10.1016/j.enpol.2008.01.015
   Van Ruijven B, 2008, WORLD DEV, V36, P2801, DOI 10.1016/j.worlddev.2008.01.011
   World Health Organization, 2012, HLTH IND SUST EN CON
   Zabel G., 2009, ENERGY B
   Zaman K, 2012, INT J ECOLOGICAL EC, V25, P85
   Zaman K, 2012, RENEW SUST ENERG REV, V19, P107, DOI DOI 10.1016/J.RSER.2012.11.013
   Zaman K, 2012, ENERG POLICY, V50, P623, DOI 10.1016/j.enpol.2012.08.003
   Zaman K, 2012, ECON MODEL, V29, P1632, DOI 10.1016/j.econmod.2012.05.024
   Zaman K, 2012, ENERG POLICY, V44, P268, DOI 10.1016/j.enpol.2012.01.050
   Zaman K, 2011, INT J GREEN ENERGY, V8, P820, DOI 10.1080/15435075.2011.602157
   Zaman K, 2010, J ENVIRON PLANN MAN, V53, P977, DOI 10.1080/09640568.2010.495537
NR 65
TC 19
Z9 19
U1 3
U2 76
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-1481
J9 RENEW ENERG
JI Renew. Energy
PD MAR
PY 2014
VL 63
BP 353
EP 365
DI 10.1016/j.renene.2013.09.033
PG 13
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA 300TY
UT WOS:000330488100040
DA 2018-12-27
ER

PT J
AU Chen, D
   Fuller, D
AF Chen, Danzhu (Anna)
   Fuller, Daniel
TI RETRACTED: Analyzing road surface conditions, collision time, and road
   structural factors associated with bicycle collisions from 2000 to 2010
   in Saskatoon, Saskatchewan (Retracted article. See vol. 1, pg. 210,
   2014)
SO JOURNAL OF TRANSPORT & HEALTH
LA English
DT Article; Retracted Publication
DE Bicycle collision; Road surface conditions; Road structural factors;
   Logistic regression; Public health
ID INJURY; RISK; ACCIDENTS; CRASHES
AB Objective: The purpose of this study was to analyze the relationship between the likelihood of bicycle collisions and time of day, traffic volume, road surface conditions, legal speed limit, and weather.
   Method: Data from the Saskatchewan Traffic Accident Information System (TAIS) was used. Descriptive statistics, mapping and logistic regression analysis were conducted to examine factors associated with bicycle collisions.
   Results: Legal speed limits greater than 70 km/h were shown to be more dangerous when compared to legal speed limits less than 50 km/h, which showed an 84% reduced probability of collisions (OR= 0.26, CI: 0.11 to 0.54). Compared to morning cycling, night time cycling was associated with 2.13 times the risk of collision (95% CI: 1.28 to 3.82). Hazardous road surface conditions, such as snow and ice, increased the likelihood of a collision by 12.13 times (95% CI: 8.13 to 19.98). Contrary to previous research, our analysis showed that collisions do not occur more frequently at intersections.
   Conclusion: The results from this study demonstrated that road conditions and time of day play an important role in cycling collisions. Transportation and public health policies such as regular maintenance of roadways for cyclists and more bicycle scale street lights could address these factors at relatively low cost. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Chen, Danzhu (Anna)] Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK S7N 0W0, Canada.
   [Fuller, Daniel] Univ Saskatchewan, Dept Community Hlth & Epidemiol, Saskatoon, SK S7N 0W0, Canada.
RP Chen, D (reprint author), 1106 40 Carabob Court, Scarborough, ON M1T 3N3, Canada.
EM dac091@maiLusask.ca
CR Allen-Munley C, 2005, TRANSPORT RES REC, P107
   [Anonymous], 2011, SASK TRAFF ACC FACTS, P1
   Georgina A.L., 1999, ACCIDENT ANAL PREV, V31, P675
   Geus B., 2012, ACCIDENT ANAL PREV, V45, P683
   Government of Canada, 2013, CAN CLIM NORM 1971 2
   Harris M, 2009, ENV HLTH, V8
   Hogue M. M., 2002, ACCIDENT ANAL PREV, V10, P1
   Johnston I, 2004, INJURY PREV, V10, P257, DOI 10.1136/ip.2004.006486
   Kim JK, 2007, ACCIDENT ANAL PREV, V39, P238, DOI 10.1016/j.aap.2006.07.002
   Klop Jeremy, 1999, TRANSPORT RES REC, V11, P1
   Lusk AC, 2011, INJURY PREV, V17, P131, DOI 10.1136/ip.2010.028696
   Mir L. F., 2011, ACCIDENT ANAL PREV, V43, P1624
   Public Health Agency of Canada, 2008, INJ ASS BIC 2006 AG
   Pucher J, 2003, AM J PUBLIC HEALTH, V93, P1509, DOI 10.2105/AJPH.93.9.1509
   ROWE BH, 1995, CAN MED ASSOC J, V152, P45
   Schepers JP, 2011, ACCIDENT ANAL PREV, V43, P853, DOI 10.1016/j.aap.2010.11.005
   Stone M, 2003, ACCIDENT ANAL PREV, V35, P549, DOI 10.1016/S0001-4575(02)00032-5
   Teschke K, 2012, AM J PUBLIC HEALTH, V102, P2336, DOI 10.2105/AJPH.2012.300762
   Transport Canada, 2007, INT REL CRASH CAN DR, P131
   Wang YH, 2004, ACCIDENT ANAL PREV, V36, P313, DOI 10.1016/S0001-4575(03)00009-5
   Wanvik P. O., 2009, ACCIDENT ANAL PREV, V41, P123, DOI DOI 10.1016/J
   Winters M, 2007, AM J PREV MED, V32, P52, DOI 10.1016/j.amepre.2006.08.027
   Works & Department E. S, 2003, CIT TOR, P1
   Yan XP, 2011, ACCIDENT ANAL PREV, V43, P1751, DOI 10.1016/j.aap.2011.04.006
   Zolnik EJ, 2007, TRANSP RES RECORD, P1, DOI 10.3141/2031-01
NR 25
TC 2
Z9 2
U1 2
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-1405
J9 J TRANSP HEALTH
JI J. Transp. Health
PD MAR
PY 2014
VL 1
IS 1
BP 40
EP 44
DI 10.1016/j.jth.2013.12.001
PG 5
WC Public, Environmental & Occupational Health; Transportation
SC Public, Environmental & Occupational Health; Transportation
GA CB3ZQ
UT WOS:000349568400009
DA 2018-12-27
ER

PT J
AU Sedaghat, A
   Taheri-Nassaj, E
   Soraru, GD
   Ebadzadeh, T
AF Sedaghat, A.
   Taheri-Nassaj, E.
   Soraru, G. D.
   Ebadzadeh, T.
TI RETRACTED: Microstructure development and phase evolution of
   alumina-mullite nanocomposite (Retracted article. See vol. 40, pg.
   16841, 2014)
SO CERAMICS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Sintering; Microstructure-final; Al2O3; Mullite
ID THERMAL-SHOCK RESISTANCE; MECHANICAL-PROPERTIES; REFRACTORY MATERIALS;
   BEHAVIOR; ADDITIONS
AB In this work, the alumina-mullite composite was prepared using sol-gel derived alumina composite nanopowders. Results revealed the intragranular mullite was embedded in the alumina grain and the intergranular mullite was embedded on the grain boundary. Accordingly, the intragranular mullites (average grain size, 0.3 mu m) were smaller than the intergranular mullites (average grain size, 0.5 mu m). Moreover, the alumina grains (average grain size, 1.0 mu m) are larger than the mullites. Meanwhile, the mullites showed positive results in the prevention of the alumina grains growth, known as the Zener law behavior, and the retardation of densification. The relative density of alumina-mullite that was sintered at 1650 degrees C for 2 h was obtained as 98.7%. After sintering at 1750 degrees C for 2 h, the mullite was decomposed. (C) 2013 Elsevier Ltd and Techna Group S.r.l. All rights reserved.
C1 [Sedaghat, A.; Taheri-Nassaj, E.] Tarbiat Modares Univ, Dept Mat Sci & Engn, Tehran, Iran.
   [Soraru, G. D.] Univ Trento, Dept Mat Engn & Ind Technol, I-38050 Trento, Italy.
   [Ebadzadeh, T.] Mat & Energy Res Ctr, Tehran, Iran.
RP Taheri-Nassaj, E (reprint author), Tarbiat Modares Univ, Dept Mat Sci & Engn, POB 14115-143, Tehran, Iran.
EM taheri@modares.ac.ir
CR Aksel C, 2003, CERAM INT, V29, P183, DOI 10.1016/S0272-8842(02)00103-7
   Aksel C, 2002, MATER LETT, V57, P708, DOI 10.1016/S0167-577X(02)00858-3
   [Anonymous], 2005, ASTM STAND, V15.02
   [Anonymous], POWD DIFFR FIL
   Fang JX, 1997, J AM CERAM SOC, V80, P2005
   Lutterotti L, 1998, MATER SCI FORUM, V278-2, P87, DOI 10.4028/www.scientific.net/MSF.278-281.87
   Medvedovski E, 2006, CERAM INT, V32, P369, DOI 10.1016/j.ceramint.2005.04.001
   Mezquita S, 2001, BRIT CERAM T, V100, P246, DOI 10.1179/096797801681503
   Moreno R, 2001, BRIT CERAM T, V100, P241, DOI 10.1179/096797801681495
   Rahaman M.N., 2003, CERAMIC PROCESSING S, P574
   Richerson D.W., 1992, MODERN CERAMIC ENG, P808
   Schehl M, 2002, ACTA MATER, V50, P1125, DOI 10.1016/S1359-6454(01)00413-X
   Schneider H, 2008, J EUR CERAM SOC, V28, P329, DOI 10.1016/j.jeurceramsoc.2007.03.017
   Schneider H, 2005, MULLITE, P1, DOI 10.1002/3527607358
   Sedaghat A, 2006, J NON-CRYST SOLIDS, V352, P2818, DOI 10.1016/j.jnoncrysol.2006.02.068
   Thompson AM, 1997, J AM CERAM SOC, V80, P373
   Won CW, 1998, COLLOID SURFACE A, V131, P161, DOI 10.1016/S0927-7757(97)00149-0
   Zhang FC, 2007, J MATER SCI, V42, P6798, DOI 10.1007/s10853-006-1402-z
NR 18
TC 6
Z9 6
U1 2
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0272-8842
EI 1873-3956
J9 CERAM INT
JI Ceram. Int.
PD MAR
PY 2014
VL 40
IS 2
BP 2605
EP 2611
DI 10.1016/j.ceramint.2013.10.071
PG 7
WC Materials Science, Ceramics
SC Materials Science
GA 292DJ
UT WOS:000329882100008
DA 2018-12-27
ER

PT J
AU Calvo-Guirado, JL
   Boquete-Castro, A
   Negri, B
   Ruiz, RD
   Gomez-Moreno, G
   Iezzi, G
AF Calvo-Guirado, Jose L.
   Boquete-Castro, Ana
   Negri, Bruno
   Delgado Ruiz, Rafael
   Gomez-Moreno, Gerardo
   Iezzi, Giovanna
TI RETRACTED: Crestal bone reactions to immediate implants placed at
   different levels in relation to crestal bone. A pilot study in Foxhound
   dogs (Retracted article. See vol. 29, pg. 814, 2018)
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article; Retracted Publication
DE bone - to - implant contact; crestal; immediate implant; subcrestal
ID FRESH EXTRACTION SOCKETS; TISSUE FORMATION ADJACENT; RIDGE ALTERATIONS;
   MICROGAP LOCATION; NONSUBMERGED IMPLANTS; TITANIUM IMPLANTS; TOOTH
   EXTRACTION; CONFIGURATION; HARD; DEFECTS
AB ObjectivesThe aim of the present study was to evaluate bone-to-implant contact (BIC) and bone remodeling dynamics after immediate implant placement at different levels in relation to the crestal bone.
   Materials and methodsThe mandibular second, third, and fourth premolars of six Foxhound dogs were extracted bilaterally. Randomly, three implants were immediately placed in the hemi-arches of each dog, crestally or 2mm subcrestally. Three dogs were allowed an 8-week submerged healing period, and the other three at 12-week submerged healing period. The animals were sacrificed at 12weeks and samples were obtained. Biopsies were processed for ground sectioning. Histomorphometric analysis was carried out to compare BIC, bone neoformation, and bone remodeling.
   ResultsAll implants osseointegrated clinically and histologically. Healing patterns examined microscopically at eight and twelve weeks for both groups (crestal and subcrestal) yielded similar qualitative bone findings. The Total BIC mean value for the crestal group 44.52% at 8weeks and 39.50% at 12weeks, and for the subcrestal group was 47.33% at 8weeks and 53.85% at 12weeks%. There was less bone resorption in the subcrestal group (test) than in crestal group (control).
   ConclusionsWithin the limitations of this study, our findings suggest that apical positioning of the top of the implant does not jeopardize bone crest and peri-implant tissue remodeling. However, less resorption of the lingual crest may be expected when implants are placed 2mm subcrestally. Moreover, higher BIC values were found in implants placed subcrestally.
C1 [Calvo-Guirado, Jose L.; Negri, Bruno; Delgado Ruiz, Rafael; Gomez-Moreno, Gerardo] Univ Murcia, Fac Med & Dent, Dept Gen & Implant Dent, Murcia 30007, Spain.
   [Boquete-Castro, Ana] Univ Granada, Sch Dent, Dept Pharmacol Interact Dent, Granada, Spain.
   [Iezzi, Giovanna] Univ G dAnnunzio, Dept Oral Med, Chieti, Italy.
RP Calvo-Guirado, JL (reprint author), Univ Murcia, Hosp Morales Meseguer, Fac Med & Dent, 2 Planta Clin Odontol Calle Marques de los Velez, Murcia 30007, Spain.
EM joseluis.calvo@um.es
RI Gomez-Moreno, Gerardo/L-8123-2014
OI Gomez-Moreno, Gerardo/0000-0001-9094-4985; Delgado-Ruiz,
   Rafael/0000-0003-1721-0509; Delgado-Ruiz, Rafael/0000-0003-0322-7166
FU Department of General Dentistry (C.O.I.A); Faculty of Medicine and
   Dentistry, University of Murcia, Spain
FX The authors declare that they have no conflict of interests. The study
   was initiated and self-funded by the Department of General Dentistry
   (C.O.I.A) and Master of Implant Dentistry, Faculty of Medicine and
   Dentistry, University of Murcia, Spain. The study materials were kindly
   provided by Sweden and Martina. The authors gratefully acknowledge the
   assistance of Stefania Lepore (University of Chieti, Italy) in the
   statistical analysis, the CTS-654 group "Pharmacological research in
   dentistry" (Junta de Andalucia, Spain) and Nuria Garcia Carrillo
   (Veterinary of the University of Murcia).
CR Abrahamsson I, 1996, CLIN ORAL IMPLAN RES, V7, P212, DOI 10.1034/j.1600-0501.1996.070303.x
   ADELL R, 1981, INT J ORAL MAXILLOF, V10, P387, DOI 10.1016/S0300-9785(81)80077-4
   Araujo MG, 2006, CLIN ORAL IMPLAN RES, V17, P615, DOI 10.1111/j.1600-0501.2006.01317.x
   Araujo MG, 2006, CLIN ORAL IMPLAN RES, V17, P606, DOI 10.1111/j.1600-0501.2006.01315.x
   Araujo MG, 2011, CLIN ORAL IMPLAN RES, V22, P1, DOI 10.1111/j.1600-0501.2010.01920.x
   Araujo MG, 2005, J CLIN PERIODONTOL, V32, P212, DOI 10.1111/j.1600-051X.2005.00642.x
   Araujo MG, 2005, J CLIN PERIODONTOL, V32, P645, DOI 10.1111/j.1600-051X.2005.00726.x
   Barros R. R. M., 2009, TITANIUM, V1, P45
   Barros RRM, 2010, CLIN ORAL IMPLAN RES, V21, P371, DOI 10.1111/j.1600-0501.2009.01860.x
   Berglundh T, 2003, CLIN ORAL IMPLAN RES, V14, P251, DOI 10.1034/j.1600-0501.2003.00972.x
   Bornstein MM, 2008, CLIN ORAL IMPLAN RES, V19, P233, DOI 10.1111/j.1600-0501.2007.01473.x
   Bornstein MM, 2003, INT J ORAL MAX IMPL, V18, P659
   Bornstein MM, 2005, CLIN ORAL IMPLAN RES, V16, P631, DOI 10.1111/j.1600-0501.2005.01209.x
   Botticelli D, 2004, J CLIN PERIODONTOL, V31, P820, DOI 10.1111/j.1600-051X.2004.00565.x
   Botticelli D, 2005, J CLIN PERIODONTOL, V32, P448, DOI 10.1111/j.1600-051X.2005.00693.x
   Botticelli D, 2004, CLIN ORAL IMPLAN RES, V15, P285, DOI 10.1046/j.1600-0501.2003.01008.x
   Botticelli D, 2004, J CLIN PERIODONTOL, V31, P309, DOI 10.1111/j.1600-051X.2004.00502.x
   Botticelli D, 2006, CLIN ORAL IMPLAN RES, V17, P351, DOI 10.1111/j.1600-0501.2006.01270.x
   Buser D, 2007, ITI TREATMENT GUIDE, V1, P26
   Calvo-Guirado JL, 2010, CLIN ORAL IMPLAN RES, V21, P308, DOI 10.1111/j.1600-0501.2009.01841.x
   Caneva M, 2010, CLIN ORAL IMPLAN RES, V21, P885, DOI 10.1111/j.1600-0501.2010.01931.x
   Caneva M, 2010, CLIN ORAL IMPLAN RES, V21, P43, DOI 10.1111/j.1600-0501.2009.01842.x
   Cardaropoli G, 2006, CLIN ORAL IMPLAN RES, V17, P165, DOI 10.1111/j.1600-0501.2005.01210.x
   Degidi M, 2012, CLIN ORAL INVEST, V16, P857, DOI 10.1007/s00784-011-0574-3
   Degidi M, 2011, CLIN ORAL IMPLAN RES, V22, P1303, DOI 10.1111/j.1600-0501.2010.02111.x
   Pontes AEF, 2008, CLIN ORAL IMPLAN RES, V19, P483, DOI 10.1111/j.1600-0501.2007.01506.x
   Ferrus J, 2010, CLIN ORAL IMPLAN RES, V21, P22, DOI 10.1111/j.1600-0501.2009.01825.x
   Fick S, 2010, INT J ORAL MAX IMPL, V25, P577
   Hammerle CHF, 1996, CLIN ORAL IMPLAN RES, V7, P111, DOI 10.1034/j.1600-0501.1996.070204.x
   Negri B, 2012, CLIN ORAL IMPLAN RES, V23, P236, DOI 10.1111/j.1600-0501.2011.02290.x
   Negri B, 2012, CLIN ORAL IMPLAN RES, V23, P228, DOI 10.1111/j.1600-0501.2011.02158.x
   Nemcovsky CE, 2002, CLIN ORAL IMPLAN RES, V13, P410, DOI 10.1034/j.1600-0501.2002.130410.x
   Orsini E, 2009, Minerva Stomatol, V58, P263
   Paolantonio M, 2001, J PERIODONTOL, V72, P1560, DOI 10.1902/jop.2001.72.11.1560
   Rodriguez-Ciurana X, 2009, INT J PERIODONT REST, V29, P141
   Sanz M, 2010, CLIN ORAL IMPLAN RES, V21, P13, DOI 10.1111/j.1600-0501.2009.01824.x
   SCHROEDER A, 1986, DEUT MED WOCHENSCHR, V111, P1427, DOI 10.1055/s-2008-1068645
   Schropp L, 2003, INT J PERIODONT REST, V23, P313
   Spray J R, 2000, Ann Periodontol, V5, P119, DOI 10.1902/annals.2000.5.1.119
   Tomasi C, 2010, CLIN ORAL IMPLAN RES, V21, P30, DOI 10.1111/j.1600-0501.2009.01848.x
   Tran BLT, 2010, CLIN ORAL IMPLAN RES, V21, P794, DOI 10.1111/j.1600-0501.2010.01911.x
   Trisi P, 2003, J PERIODONTOL, V74, P945, DOI 10.1902/jop.2003.74.7.945
   Trisi P, 2002, INT J PERIODONT REST, V22, P535
   Vela-Nebot Xavier, 2006, Implant Dent, V15, P313, DOI 10.1097/01.id.0000226788.19742.32
   Vignoletti F, 2009, J CLIN PERIODONTOL, V36, P688, DOI 10.1111/j.1600-051X.2009.01439.x
   Vignoletti F, 2009, J CLIN PERIODONTOL, V36, P265, DOI 10.1111/j.1600-051X.2008.01363.x
   Welander M, 2009, J PERIODONTOL, V80, P324, DOI [10.1902/jop.2009.080375, 10.1902/jop.2009.080375 ]
   Weng D, 2011, INT J ORAL MAX IMPL, V26, P941
   Weng D, 2011, INT J PROSTHODONT, V24, P445
   Weng D, 2010, INT J ORAL MAX IMPL, V25, P540
NR 50
TC 15
Z9 15
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7161
EI 1600-0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD MAR
PY 2014
VL 25
IS 3
BP 344
EP 351
DI 10.1111/clr.12110
PG 8
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA 293UM
UT WOS:000329999200009
PM 23346955
DA 2018-12-27
ER

PT J
AU Godhani, DR
   Dobariya, PB
   Sanghani, AM
   Jogel, AA
   Mehta, JP
AF Godhani, Dinesh R.
   Dobariya, Purvesh B.
   Sanghani, Anil M.
   Jogel, Anand A.
   Mehta, Jignasu P.
TI RETRACTED: Thermo-acoustical studies of 1,3,4-oxadiazole as binary
   mixture at three different temperatures (Retracted article. See vol.
   102, pg. 451, 2016)
SO JOURNAL OF CHEMICAL THERMODYNAMICS
LA English
DT Article; Retracted Publication
DE Acoustical parameter; Density; Molecular interaction; 1,3,4-Oxadiazole;
   Ultrasonic sound velocity; Viscosity; Kinematic viscosity
ID ULTRASONIC VELOCITY; 308.15 K; DERIVATIVES; WATER;
   N,N-DIMETHYLFORMAMIDE; NITROBENZENE; 1,4-DIOXANE; VISCOSITIES;
   PARAMETERS; SOLVENTS
AB Thermo-acoustical parameters of solutions of 2-((4-acetyl-5-(4-chlorophenyl)-5-methyl-4,5-dihydro-1,3,4-oxadiazol-2-yl)methylthio)-3-o-tolylquinazolin-4(3H)-one (PDI-B) in chloroform (CF) and N,N-dimethylformamide (DMF) were elucidated. Thus, density (rho), viscosity (eta) and ultrasonic sound velocity (U), kinematic viscosity (nu) and thereby various acoustical and thermodynamic parameters have been determined at temperatures (303, 308 and 313) K and at atmospheric pressure. Moreover, a comparison between experimental results for the pure solvents and solutions of compound PDI-B studied has been carried out to analyze carefully how the structural modifications affect the values of Gibbs free energy of activation (Delta G*), enthalpy of activation (Delta H*) and entropy of activation (Delta S*) in CF and DMF. A good to excellent correlation between a given parameter and concentration is observed at all temperatures and solvent systems studied. Linear or non-linear increases or decreases of acoustical parameters with concentration and temperature indicated the existence of strong molecular interactions. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Godhani, Dinesh R.; Dobariya, Purvesh B.; Sanghani, Anil M.; Jogel, Anand A.; Mehta, Jignasu P.] Maharaja Krishankumarsinhji Bhavnagar Univ, Div Phys Chem, Dept Chem DST FIST Sponsored Mahatma Gandhi Campu, Bhavnagar 364022, Gujarat, India.
RP Godhani, DR (reprint author), Maharaja Krishankumarsinhji Bhavnagar Univ, Div Phys Chem, Dept Chem DST FIST Sponsored Mahatma Gandhi Campu, Bhavnagar 364022, Gujarat, India.
EM drgodhani@yahoo.com
CR Akramova M., 1971, PRIMENENIE ULTRAAKUS, V25, P154
   Albar HA, 1996, INDIAN J CHEM B, V35, P23
   Amrutia RR, 2006, J SCI IND RES INDIA, V65, P905
   ANDREAE JH, 1965, ACUSTICA, V15, P74
   BAGCHI S, 1986, EUR POLYM J, V22, P851, DOI 10.1016/0014-3057(86)90029-7
   Baluja S, 2004, ACTA PHYS-CHIM SIN, V20, P1104, DOI 10.3866/PKU.WHXB20040909
   Baluja S, 2003, FLUID PHASE EQUILIBR, V208, P83, DOI 10.1016/S0378-3812(02)00327-8
   Belinskii B.A., 1965, Akusticheskii Zhurnal, V11, P243
   Bhardwaj M. C., 1998, P AM CERAM SOC, V89
   Bhuva BD, 2011, J SOLUTION CHEM, V40, P719, DOI 10.1007/s10953-011-9669-3
   Callen H. B., 1985, THERMODYNAMICS INTRO
   CHEN GS, 1995, J CHEM ENG DATA, V40, P1005, DOI 10.1021/je00020a062
   Deshmukh C. C., 2003, ACTA CIENC INDICA, V29, P5
   Enriquez-Sarano M., 2008, CARD SURG ADULT, V3, P315
   Faidallah HM, 2002, PHOSPHORUS SULFUR, V177, P685, DOI 10.1080/10426500210275
   Godhani D. R., 2001, Journal of Pure and Applied Ultrasonics, V23, P58
   Godhani DR, 2012, INDIAN J HETEROCY CH, V21, P259
   Godhani DR, 2012, J MOL LIQ, V168, P28, DOI 10.1016/j.molliq.2012.01.020
   Godhani DR, 2002, J INDIAN CHEM SOC, V79, P620
   HIRAI N, 1958, J APPL PHYS, V29, P810, DOI 10.1063/1.1723290
   JACOBSON B, 1954, NATURE, V173, P772, DOI 10.1038/173772a0
   JOSHI SS, 1990, J CHEM ENG DATA, V35, P185, DOI 10.1021/je00060a027
   Katoh R, 1998, ULTRASON SONOCHEM, V5, P69, DOI 10.1016/S1350-4177(98)00014-5
   Khan V. H., 1974, TECHNOLOGY, V21, P82
   Kruger O, 1999, ULTRASON SONOCHEM, V6, P123, DOI 10.1016/S1350-4177(98)00031-5
   Kulshrestha A., 2010, ADV APPL SCI RES, V1, P229
   Levina M, 2000, J PHARM SCI, V89, P705, DOI 10.1002/(SICI)1520-6017(200006)89:6<705::AID-JPS2>3.0.CO;2-D
   Meciarova M, 2005, ULTRASON SONOCHEM, V12, P401, DOI 10.1016/j.ultsonch.2004.03.003
   Mecozzi M, 2002, ULTRASON SONOCHEM, V9, P11, DOI 10.1016/S1350-4177(01)00098-0
   MURTHY NM, 1982, ACUSTICA, V50, P226
   Nelson LJ, 2008, INSIGHT, V50, P78, DOI 10.1784/insi.2008.50.2.78
   NIKAM PS, 1995, INDIAN J PURE AP PHY, V33, P398
   PAL A, 1995, J CHEM ENG DATA, V40, P818, DOI 10.1021/je00020a018
   PRICE GJ, 1992, CURRENT TRENDS SONOC
   Rajkotia KM, 1997, EUR POLYM J, V33, P1005, DOI 10.1016/S0014-3057(96)00302-3
   Rao K. S., 1958, J SCI IND RES INDIA, V17, P444
   Regmi S., 2007, J SCI ENG TECH, V1, P1
   Riddick J. A., 1986, ORGANIC SOLVENTS PHY
   Sherlock CE, 2009, VET RADIOL ULTRASOUN, V50, P13, DOI 10.1111/j.1740-8261.2008.01484.x
   SINGH DP, 1984, ACUSTICA, V56, P290
   Soitkar V. S., 1984, Acoustics Letters, V7, P191
   SRIVASTAVA SP, 1970, Z PHYS CHEM NEUE FOL, V70, P219, DOI 10.1524/zpch.1970.70.3_6.219
   Surayanarayana C.V., 1976, J ACOUST SOC IND, V4, P75
   Suryanarayana C.V., 1979, J ACOUST SOC IND, V7, P131
   Vasantharani P, 2008, Journal of Applied Sciences, V8, P2329, DOI 10.3923/jas.2008.2329.2332
   Vigoureux P., 1952, ULTRASONIC CHAPMANN
   Wallace J.W., 1983, PHARM TECH, V7, P94
   Woland M., 1988, Z PHYS CHEM, V268, P628
   YALE HL, 1953, J AM CHEM SOC, V75, P1933, DOI 10.1021/ja01104a046
   Zhao Y, 2004, MATER CHEM PHYS, V87, P149, DOI 10.1016/j.matchemphys.2004.05.026
NR 50
TC 5
Z9 5
U1 2
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0021-9614
EI 1096-3626
J9 J CHEM THERMODYN
JI J. Chem. Thermodyn.
PD MAR
PY 2014
VL 70
BP 73
EP 80
DI 10.1016/j.jct.2013.10.008
PG 8
WC Thermodynamics; Chemistry, Physical
SC Thermodynamics; Chemistry
GA 276FK
UT WOS:000328733700007
DA 2018-12-27
ER

PT J
AU Li, RG
   Yang, SS
   Tang, L
   Yang, YQ
   Chen, H
   Guan, SF
   Han, WZ
   Liu, H
   Dai, JJ
   Gan, Q
   Fang, WY
   Qu, XK
AF Li, Ruogu
   Yang, Shuansuo
   Tang, Lei
   Yang, Yiqing
   Chen, Hui
   Guan, Shaofeng
   Han, Wenzheng
   Liu, Hua
   Dai, Jinjie
   Gan, Qian
   Fang, Weiyi
   Qu, Xinkai
TI RETRACTED: Meta-analysis of the effect of percutaneous coronary
   intervention on chronic total coronary occlusions (Retracted article.
   See vol. 10, 43, 2015)
SO JOURNAL OF CARDIOTHORACIC SURGERY
LA English
DT Article; Retracted Publication
DE Coronary artery chronic total occlusion; Percutaneous coronary
   intervention; Meta-analysis
ID LEFT-VENTRICULAR FUNCTION; PRIMARY SUCCESS; ANGIOPLASTY; RECANALIZATION;
   EXPERIENCE; SURVIVAL; OUTCOMES; ARTERY; REVASCULARIZATION; PRINCIPLES
AB Background and purpose: Coronary chronic total occlusion (CTO) is the last stage of coronary artery atherosclerosis. Percutaneous coronary intervention (PCI) is a therapeutic procedure used to recanalize vessels with total occlusion. However, successful recanalization of CTO is still not optimal, and the key influence factors are still uncertainty. Therefore, a scientific evaluation on the effective of PCI for CTO treatment is necessary.
   Methods: Relevant studies of PCI treatment for CTO were examined. Data were extracted and assessed by two independent clinical experts. Embase, PubMed and Medline et al. were used as database. The main research key words include "CTO", "PCI", "Stent", "Reopen", "long-term", "follow-up" and "outcome". Quality assessment was carried out according to the Cochrane Handbook. The selected data were pooled and analyzed using fixed-effect model and random-effect model. Heterogeneity was assessed using the I-2 test, Q test, L'abbe and Galbraith. Comprehensive Meta-Analysis 2.0 and Metanalysis 1.0 were used for statistics analysis in this research.
   Results: A total of 16 articles involving 6695 cases in successful CTO recanalization (CTO success group) and 2370 cases in failed CTO recanalization(CTO failure group) were included in this research. Low CTO success was associated with elder age, previous coronary artery bypass graft surgery (CABG) history, multi-vessel diseases and right coronary artery disease lesion. Six follow-up variables including major adverse cardiac events (MACE), recurrent myocardial infarction (MI), all-cause death, incidence of angina, subsequent CABG and cumulative survival rate were found significantly reduced associated with CTO success.
   Conclusions: Clinical baseline characteristics such as age, previous CABG history and lesion baseline characteristics such as lesion length, multi-vessel diseases might be important factors influencing the successful rate of CTO recanalization. Compared to CTO failure patients, all six follow-up variables showed advantage for CTO success patients.
C1 [Li, Ruogu; Chen, Hui; Guan, Shaofeng; Han, Wenzheng; Liu, Hua; Dai, Jinjie; Gan, Qian; Fang, Weiyi; Qu, Xinkai] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Cardiol, Shanghai 200030, Peoples R China.
   [Yang, Shuansuo] Cent Hosp, Dept Cardiol, Shanghai 201400, Peoples R China.
   [Tang, Lei] Shanghai Jiao Tong Univ, Sch Med Grad, Shanghai 200025, Peoples R China.
   [Yang, Yiqing] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Cardiovasc Res, Shanghai 200030, Peoples R China.
RP Yang, SS (reprint author), Cent Hosp, Dept Cardiol, Shanghai 201400, Peoples R China.
EM shuansuoyang11@163.com
CR Aziz S, 2007, CATHETER CARDIO INTE, V70, P15, DOI 10.1002/ccd.21092
   Binwei L, 2008, THESIS JILIN U CHANG
   Chen SL, 2009, CHINESE MED J-PEKING, V122, P2278, DOI 10.3760/cma.j.issn.0366-6999.2009.19.017
   Christofferson RD, 2005, AM J CARDIOL, V95, P1088, DOI 10.1016/j.amjcard.2004.12.065
   Chung CM, 2003, CATHETER CARDIO INTE, V60, P368, DOI 10.1002/ccd.10641
   Claessen BEPM, 2009, JACC-CARDIOVASC INTE, V2, P1128, DOI 10.1016/j.jcin.2009.08.024
   de Labriolle A, 2008, AM J CARDIOL, V102, P1175, DOI 10.1016/j.amjcard.2008.06.059
   Drozd Jakub, 2006, Kardiol Pol, V64, P667
   Ermis C, 2005, CAN J CARDIOL, V21, P275
   FINCI L, 1990, AM J CARDIOL, V66, P660, DOI 10.1016/0002-9149(90)91125-P
   Gasowski J, 2002, J HYPERTENS, V20, P145, DOI 10.1097/00004872-200201000-00021
   Grantham JA, 2009, JACC-CARDIOVASC INTE, V2, P479, DOI 10.1016/j.jcin.2009.02.008
   Higgins JP, 2008, COCHRANE HDB SYSTEMA
   Hoye A, 2005, EUR HEART J, V26, P2630, DOI 10.1093/eurheartj/ehi498
   Hoye A, 2012, HEART, V98, P822, DOI 10.1136/heartjnl-2011-300616
   IVANHOE RJ, 1992, CIRCULATION, V85, P106, DOI 10.1161/01.CIR.85.1.106
   MAINLAND D, 1948, CAN J RES E, V26, P1, DOI 10.1139/cjr48e-001
   Noguchi T, 2000, CATHETER CARDIO INTE, V49, P258, DOI 10.1002/(SICI)1522-726X(200003)49:3<258::AID-CCD7>3.3.CO;2-C
   Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.3.CO;2-G
   Olivari Z, 2003, J AM COLL CARDIOL, V41, P1672, DOI 10.1016/S0735-1097(03)00312-7
   Piscione F, 2005, HEART, V91, P646, DOI 10.1136/hrt.2004.041152
   Prasad A, 2007, J AM COLL CARDIOL, V49, P1611, DOI 10.1016/j.jacc.2006.12.040
   Saito S, 2003, CATHETER CARDIO INTE, V59, P305, DOI 10.1002/ccd.10505
   Serruys PW, 2000, EUR HEART J, V21, P1797, DOI 10.1053/euhj.2000.2263
   Shrier I, 2007, AM J EPIDEMIOL, V166, P1203, DOI 10.1093/aje/kwm189
   Sirnes PA, 1998, EUR HEART J, V19, P273, DOI 10.1053/euhj.1997.0617
   Suero JA, 2001, J AM COLL CARDIOL, V38, P409, DOI 10.1016/S0735-1097(01)01349-3
   Surmely Jean-Francois, 2006, J Cardiol, V48, P95
   Takagi K, 2012, J AM COLL CARDIOL, V60, pB21, DOI 10.1016/j.jacc.2012.08.078
   Takimura H, 2012, J INVASIVE CARDIOL, V24, pE5
   Talukder S, 2012, AM J CARDIOL, V109, p93S, DOI 10.1016/j.amjcard.2012.01.214
   Valenti R, 2008, EUR HEART J, V29, P2336, DOI 10.1093/eurheartj/ehn357
   WARREN RJ, 1990, AM HEART J, V120, P270, DOI 10.1016/0002-8703(90)90069-A
   Weisz G, 2010, CATHETER CARDIO INTE, V75, pS21, DOI 10.1002/ccd.22382
   Whitlow PL, 2011, JACC-CARDIOVASC INTE, V4, P962, DOI 10.1016/j.jcin.2011.05.023
   Xianhua Y, 2008, THESIS DALIAN MED U
   Yamaguchi T, 2012, AM J CARDIOL, V109, p125S, DOI 10.1016/j.amjcard.2012.01.296
   Yamane M, 2012, REV ESP CARDIOL, V65, P265, DOI [10.1016/j.recesp.2011.10.026, 10.1016/j.rec.2011.12.001]
   Yu L, 2012, ANN SAUDI MED, V32, P156, DOI 10.5144/0256-4947.2012.156
   Zhu Y-B, 2008, J CLIN REHABILITATIV, P12
NR 40
TC 10
Z9 10
U1 1
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-8090
J9 J CARDIOTHORAC SURG
JI J. Cardiothorac. Surg.
PD FEB 28
PY 2014
VL 9
AR 41
DI 10.1186/1749-8090-9-41
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AD6SP
UT WOS:000333391500001
PM 24580774
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhang, ZN
   Lv, JR
   Lei, XM
   Li, SY
   Zhang, Y
   Meng, LH
   Xue, RL
   Li, ZF
AF Zhang, Zhenni
   Lv, Jianrui
   Lei, Xiaoming
   Li, Siyuan
   Zhang, Yong
   Meng, Lihua
   Xue, Rongliang
   Li, Zongfang
TI RETRACTED: Baicalein Reduces the Invasion of Glioma Cells via Reducing
   the Activity of p38 Signaling Pathway (Retracted article. See vol. 11,
   e0160194, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID RANDOMIZED PHASE-III; MATRIX METALLOPROTEINASES; ADJUVANT TEMOZOLOMIDE;
   MALIGNANT GLIOMA; ORAL-CANCER; MAPK; GLIOBLASTOMA; SURVIVAL;
   RADIOTHERAPY; PROGRESSION
AB Baicalein, one of the major flavonids in Scutellaria baicalensis, has historically been used in anti-inflammatory and anticancer therapies. However, the anti-metastatic effect and related mechanism(s) in glioma are still unclear. In this study, we thus utilized glioma cell lines U87MG and U251MG to explore the effect of baicalein. We found that administration of baicalein significantly inhibited migration and invasion of glioma cells. In addition, after treating with baicalein for 24 h, there was a decrease in the levels of matrix metalloproteinase-2 (MMP-2) and MMP-9 expression as well as proteinase activity in glioma cells. Conversely, the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 was increased in a dose-dependent manner. Moreover, baicalein treatment significantly decreased the phosphorylated level of p38, but not ERK1/2, JNK1/2 and PI3K/Akt. Combined treatment with a p38 inhibitor (SB203580) and baicalein resulted in the synergistic reduction of MMP-2 and MMP-9 expression and then increase of TIMP-1 and TIMP-2 expression; and the invasive capabilities of U87MG cells were also inhibited. However, p38 chemical activator (anisomycin) could block these effects produced by baicalein, suggesting baicalein directly downregulate the p38 signaling pathway. In conclusion, baicalein inhibits glioma cells invasion and metastasis by reducing cell motility and migration via suppression of p38 signaling pathway, suggesting that baicalein is a potential therapeutic agent for glioma.
C1 [Zhang, Zhenni; Lv, Jianrui; Lei, Xiaoming; Li, Siyuan; Zhang, Yong; Meng, Lihua; Xue, Rongliang] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Dept Anesthesia, Xian 710049, Peoples R China.
   [Li, Zongfang] Xi An Jiao Tong Univ, Natl Local Joint Engn Res Ctr Biodiagnost & Bioth, Xian 710049, Peoples R China.
   [Li, Zongfang] Xi An Jiao Tong Univ, Sch Med, Educ Minist, Key Lab Environm & Genes Related Dis, Xian 710049, Peoples R China.
   [Li, Zongfang] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Gen Surgeon Dept Cadres Ward, Xian 710049, Peoples R China.
RP Li, ZF (reprint author), Xi An Jiao Tong Univ, Natl Local Joint Engn Res Ctr Biodiagnost & Bioth, Xian 710049, Peoples R China.
EM lzf2568@gmail.com
FU Program for Changjiang Scholars and Innovative Research Team in
   University [PCSIRT: 1171]; Fundamental Research Funds for the Central
   Universities [XJJ2008020]
FX This research was supported by Program for Changjiang Scholars and
   Innovative Research Team in University (PCSIRT: 1171) and by the
   Fundamental Research Funds for the Central Universities (XJJ2008020).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Acha O, 2003, REV CLIN ESP, V203, P189, DOI 10.1157/13045539
   Ahmed AU, 2013, EXPERT REV NEUROTHER, V13, P545, DOI [10.1586/ern.13.42, 10.1586/ERN.13.42]
   Ahn HC, 2001, MOL CELLS, V12, P127
   Bradham C, 2006, CELL CYCLE, V5, P824, DOI 10.4161/cc.5.8.2685
   Chandrashekar N, 2012, TOXICOL APPL PHARM, V261, P10, DOI 10.1016/j.taap.2012.02.004
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen KL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072927
   Cohen M, 2006, MOL HUM REPROD, V12, P225, DOI 10.1093/molehr/ga1023
   Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711
   Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x
   Huang WH, 2005, J PHARM PHARMACOL, V57, P219, DOI 10.1211/0022357055371
   Hwang JM, 2005, J BIOMED SCI, V12, P389, DOI 10.1007/s11373-005-1572-8
   Iguchi K, 2012, YAKUGAKU ZASSHI, V132, P1025, DOI 10.1248/yakushi.132.1025
   Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   Kim SM, 2008, NEUROSCI LETT, V440, P289, DOI 10.1016/j.neulet.2008.05.064
   Kumar A, 2010, INVEST OPHTH VIS SCI, V51, P2664, DOI 10.1167/iovs.09-4195
   Liu B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021416
   Ma YY, 2010, CANCER-AM CANCER SOC, V116, P3294, DOI 10.1002/cncr.25059
   Mondal S, 2012, ANTI-CANCER AGENT ME, V12, P49, DOI 10.2174/187152012798764697
   Murphy G, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-233
   Okada A, 1999, Gan To Kagaku Ryoho, V26, P2247
   Posser T, 2007, ARCH TOXICOL, V81, P407, DOI 10.1007/s00204-007-0177-6
   Ricard D, 2012, LANCET, V379, P1984, DOI 10.1016/S0140-6736(11)61346-9
   Rock K, 2012, BRIT J RADIOL, V85, pE729, DOI 10.1259/bjr/83796755
   ROTA R, 2012, PLOS ONE, V7
   Rubaci AH, 2012, J ORAL PATHOL MED, V41, P689, DOI 10.1111/j.1600-0714.2012.01160.x
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Sun CY, 2013, NEUROSCI BULL, V29, P83, DOI 10.1007/s12264-012-1296-5
   Wang ZD, 2010, ONCOL REP, V23, P413, DOI 10.3892/or_00000650
   WANG ZS, 2013, CELLULAR MOL NEUROBI
   Wei J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/285246
   Weng CJ, 2008, CARCINOGENESIS, V29, P147, DOI 10.1093/carcin/bgm261
   Wisniewski P, 2010, CELL SIGNAL, V22, P212, DOI 10.1016/j.cellsig.2009.09.016
   Woo JS, 2013, BIOCHEM BIOPH RES CO, V431, P354, DOI 10.1016/j.bbrc.2012.11.134
   Wu B, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-527
   WU Y, 2013, J CELLULAR PHYSL
   Yang SF, 2008, ARCH ORAL BIOL, V53, P287, DOI 10.1016/j.archoralbio.2007.09.001
   Yang SF, 2010, FOOD CHEM TOXICOL, V48, P1052, DOI 10.1016/j.fct.2010.01.019
   Yoshino Y, 2006, INT J ONCOL, V29, P981
NR 41
TC 29
Z9 32
U1 1
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2014
VL 9
IS 2
AR e90318
DI 10.1371/journal.pone.0090318
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC3DW
UT WOS:000332396200167
PM 24587321
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jafarzadeh, H
   Abrinia, K
   Babaei, A
AF Jafarzadeh, H.
   Abrinia, K.
   Babaei, A.
TI RETRACTED: Repetitive tube expansion and shrinking (RTES) as a novel SPD
   method for fabrication of nanostructured tubes (Retracted article. See
   vol. 621, pg. 287, 2015)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Retracted Publication
DE Severe plastic deformation; Ultrafine grain; Micro-hardness; Repetitive
   tube expansion and shrinking; AZ91
ID SEVERE PLASTIC-DEFORMATION; ARB PROCESS; MICROSTRUCTURE; REFINEMENT;
   EXTRUSION; METALS; GRAINS; ALLOY
AB A novel severe plastic deformation (SPD) technique entitled repetitive tube expansion and shrinking (RTES) is introduced for producing ultra-fine grained tubular parts. This method includes two different half-cycles and is based on pressing a tubular part through an angular channel die with two shear zones. Because of inherent capabilities, this method imposes extremely high plastic strains in parts without any geometrical change. RTES was applied to commercial AZ91 alloy and the ability of this process in significant grain refinement of tubular samples is determined even after single cycle. At room temperature the yield and ultimate tensile strength of the RTES processed specimens is higher than that of the as-cast state due to the grain refinement during RTES. Furthermore, microhardness distribution through tube thickness is proposed the hardness increasing to similar to 80Hv from the initial value of similar to 50Hv after one cycle of RTES. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Jafarzadeh, H.; Abrinia, K.; Babaei, A.] Univ Tehran, Dept Mech Engn, Coll Engn, Tehran, Iran.
RP Jafarzadeh, H (reprint author), Univ Tehran, Dept Mech Engn, Coll Engn, POB 11155-4563, Tehran, Iran.
EM h.jafarzadeh@ut.ac.ir
CR del Valle JA, 2003, MATER TRANS, V44, P2625
   Eizadjou M, 2009, J ALLOY COMPD, V474, P406, DOI 10.1016/j.jallcom.2008.06.161
   Faraji G., 2011, MAT LETT, V65, P4
   Faraji G, 2012, MATER LETT, V77, P82, DOI 10.1016/j.matlet.2012.03.007
   Furukawa M, 2001, J MATER SCI, V36, P2835, DOI 10.1023/A:1017932417043
   Hasnaoui A, 2003, SCIENCE, V300, P1550, DOI 10.1126/science.1084284
   Inoue T, 2002, MATER SCI TECH-LOND, V18, P1007, DOI 10.1179/026708302225005855
   LANGUILLAUME J, 1993, ACTA METALL MATER, V41, P2953, DOI 10.1016/0956-7151(93)90110-E
   Lin JB, 2009, J ALLOY COMPD, V476, P441, DOI 10.1016/j.jallcom.2008.09.031
   Mathis K, 2005, J ALLOY COMPD, V394, P194, DOI 10.1016/j.jallcom.2004.10.050
   Meshinchi Asl K., 2011, MAGNESIUM ALLOYS DES
   Mohebbi MS, 2010, MAT SCI ENG A-STRUCT, V528, P180, DOI 10.1016/j.msea.2010.08.081
   Pardis N, 2009, MAT SCI ENG A-STRUCT, V527, P355, DOI 10.1016/j.msea.2009.08.051
   Saito Y, 1999, ACTA MATER, V47, P579, DOI 10.1016/S1359-6454(98)00365-6
   Sakai T., 2011, MAGNESIUM ALLOYS DES
   Toth LS, 2009, SCRIPTA MATER, V60, P175, DOI 10.1016/j.scriptamat.2008.09.029
   Varyukhin V, 2006, MATER SCI FORUM, V503-504, P335, DOI 10.4028/www.scientific.net/MSF.503-504.335
   Zangiabadi A, 2011, MAT SCI ENG A-STRUCT, V528, P5066, DOI 10.1016/j.msea.2011.03.012
   Zhang J, 2007, MATER SCI FORUM, V546-549, P2293, DOI 10.4028/www.scientific.net/MSF.546-549.2293
NR 19
TC 6
Z9 6
U1 2
U2 16
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD FEB 24
PY 2014
VL 596
BP 194
EP 199
DI 10.1016/j.msea.2013.12.037
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA AC0OB
UT WOS:000332193500025
DA 2018-12-27
ER

PT J
AU Yang, PL
   He, XJ
   Li, HP
   Zang, QJ
   Yang, BH
AF Yang, Pinglin
   He, Xijing
   Li, Haopeng
   Zang, Quanjin
   Yang, Baohui
TI RETRACTED: Clinical efficacy of posterior versus anterior
   instrumentation for the treatment of spinal tuberculosis in adults: a
   meta-analysis (Retracted article. See vol. 10, 40, 2015)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE Adult spinal tuberculosis; Thoracic and lumbar; Meta-analysis
ID RETROSPECTIVE ANALYSIS; SURGICAL-TREATMENT; INTERBODY FUSION; LUMBAR
   SPINE; DEBRIDEMENT; DECOMPRESSION; SPONDYLITIS; MANAGEMENT; OUTCOMES;
   SURGERY
AB Background: The aim of our study was to evaluate the clinical efficacy of posterior vs. anterior instrumentation for the treatment of spinal tuberculosis in adults.
   Methods: The electronic databases such as PubMed, MEDLINE, Springer, EMBASE, Google scholar, and Cochrane library were searched to select the potentially relevant reports that compared the efficacy of posterior instrumentation group (group A) with anterior instrumentation group (group B) in the treatment of spinal tuberculosis. Outcome assessments were correction of angle, loss of correction, fusion rate of the grafting bone, and complications after surgery.
   Results: This meta-analysis included four trials published between 2006 and 2012, involving 291 adult patients (group A, 154; group B, 137) with spinal tuberculosis. The overall meta-analysis showed that there were no significant differences (P > 0.01) between group A and group B in correction of angle and loss of correction at final follow-up after operation The pooled WMD (weighted mean difference) of group A and group B was 2.85 (95% CI (confidence interval) = -1.25 similar to 6.94) and 1.14 (95% CI = -3.07 similar to 5.34), respectively. Besides, no significant differences (P > 0.01) were observed in fusion rate of the grafting bone and complications after operation between group A and group B, and the pooled ORs (odds ratio) were 0.65 (95% CI = -0.23 similar to 1.85) and (95% CI = -0.19 similar to 1.50), respectively.
   Conclusions: Our results suggested that the posterior instrumentation appeared to have the same clinical outcome with the anterior instrumentation in the treatment of the adult patients with spinal tuberculosis.
C1 [Yang, Pinglin; He, Xijing; Li, Haopeng; Zang, Quanjin; Yang, Baohui] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped 2, Xian 710004, Shaanxi, Peoples R China.
RP He, XJ (reprint author), Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped 2, 157 West Fifth Rd, Xian 710004, Shaanxi, Peoples R China.
EM xijing_h@vip.tom.com
CR Albee FH, 2007, CLIN ORTHOP RELAT R, P14, DOI 10.1097/BLO.0b013e3180686a0f
   Chen WJ, 2002, CLIN ORTHOP RELAT R, P50
   Deeks J. J., 2001, SYSTEMATIC REV HLTH, V2, P285, DOI DOI 10.1002/9780470693926.CH15
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   El-Sharkawi MM, 2012, INT ORTHOP, V36, P315, DOI 10.1007/s00264-011-1401-9
   Garg B, 2012, INDIAN J ORTHOP, V46, P165, DOI 10.4103/0019-5413.93682
   Guzey FK, 2005, J NEUROSURG-SPINE, V3, P450, DOI 10.3171/spi.2005.3.6.0450
   Hibbs RA, 2007, CLIN ORTHOP RELAT R, P17, DOI 10.1097/BLO.0b013e3180686b30
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jain AK, 2008, J BONE JOINT SURG BR, V90B, P1477, DOI 10.1302/0301-620X.90B11.20972
   Jin DD, 2004, EUR SPINE J, V13, P114, DOI 10.1007/s00586-003-0661-5
   Karaeminogullari O, 2007, ORTHOPEDICS, V30, P55
   Lee SH, 2006, J SPINAL DISORD TECH, V19, P595, DOI 10.1097/01.bsd.0000211241.06588.7b
   Ma YZ, 2012, INT ORTHOP, V36, P299, DOI 10.1007/s00264-011-1390-8
   Mantel N, 2004, CHALLENGE EPIDEMIOLO, V1, P533
   Mehta JS, 2001, J BONE JOINT SURG BR, V83B, P859, DOI 10.1302/0301-620X.83B6.11142
   MOON MS, 1995, SPINE, V20, P1910, DOI 10.1097/00007632-199509000-00013
   Moreno SG, 2012, STAT MED, V31, P1407, DOI 10.1002/sim.4488
   Munafo MR, 2004, TRENDS GENET, V20, P439, DOI 10.1016/j.tig.2004.06.014
   Palle Lalitha, 2010, Indian J Radiol Imaging, V20, P279, DOI 10.4103/0971-3026.73544
   Pang XY, 2013, ARCH ORTHOP TRAUM SU, V133, P765, DOI 10.1007/s00402-013-1722-9
   Pu XB, 2012, INT ORTHOP, V36, P307, DOI 10.1007/s00264-011-1329-0
   Ramachandran S, 2005, INT J TUBERC LUNG D, V9, P541
   Sahoo MM, 2012, J SPINAL DISORD TECH, V25, pE217, DOI 10.1097/BSD.0b013e31826a088e
   Sundararaj GD, 2003, J BONE JOINT SURG BR, V85B, P100, DOI 10.1302/0301-620X.85B1.13300
   Talu U, 2006, J SPINAL DISORD TECH, V19, P554, DOI 10.1097/01.bsd.0000211202.93125.c7
   Zhao J, 2007, INT ORTHOP, V31, P859, DOI 10.1007/s00264-006-0253-1
NR 27
TC 13
Z9 16
U1 3
U2 22
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD FEB 21
PY 2014
VL 9
AR 10
DI 10.1186/1749-799X-9-10
PG 6
WC Orthopedics
SC Orthopedics
GA AD6QH
UT WOS:000333385400001
PM 24555672
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Chen, L
   Zhang, XW
AF Chen, Liang
   Zhang, Xiao-Wei
TI RETRACTED: Which lamp will be optimum to eye? Incandescent, fluorescent
   or LED etc (Retracted article. See vol. 8, pg. 314, 2015)
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review; Retracted Publication
DE low frequency flicker; high frequency flicker; strong light; infrared;
   ultraviolet; electromagnetic radiation; ripple flicker; dimming flicker
ID ULTRAVIOLET-RADIATION; MACULAR DEGENERATION; LIGHT PROMOTES; MYOPIC
   SHIFT; DAMAGE; LENS
AB Low frequency flicker, high frequency flicker, strong light, strong blue light, infrared, ultraviolet, electromagnetic radiation, ripple flicker and dimming flicker produced by different lamps have negative impact on vision, eyes and health. Negative impact on eyes resulting in myopia or cataract etc. the solution is to remove all the negative factors by applying upright lighting technology and that is optimum to vision, eyes and health.
C1 [Chen, Liang] Upright Lighting LLC, Dept Lighting, Allen, TX 75013 USA.
   [Zhang, Xiao-Wei] Childrens Med Ctr, Dept Ophthalmol, Dallas, TX 75235 USA.
RP Chen, L (reprint author), Upright Lighting LLC, POB 1804, Allen, TX 75013 USA.
EM uprltcom@gmail.com
CR Albert DM, 2010, ARCH OPHTHALMOL-CHIC, V128, P212, DOI 10.1001/archophthalmol.2009.395
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Crewther SG, 2006, EXP EYE RES, V83, P322, DOI 10.1016/j.exer.2005.12.016
   Edwards KH, 2010, CLIN EXP OPTOM, V93, P390, DOI 10.1111/j.1444-0938.2010.00538.x
   Hornbeak DM, 2009, CURR OPIN OPHTHALMOL, V20, P356, DOI 10.1097/ICU.0b013e32832f8040
   LEHMAN B, 2011, EN CONV C EXP ECCE 2, P2865
   Long Q, 2009, CUTAN OCUL TOXICOL, V28, P176, DOI 10.3109/15569520903178364
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Roberts JE, 2011, EYE CONTACT LENS, V37, P246, DOI 10.1097/ICL.0b013e31821cbcc9
   Soderberg PG, 2011, PROG BIOPHYS MOL BIO, V107, P389, DOI 10.1016/j.pbiomolbio.2011.09.009
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Vincelette RL, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2978066
   Walker DP, 2012, J AM ACAD DERMATOL, V66, P130, DOI 10.1016/j.jaad.2010.11.040
   Walline JJ, 2011, COCHRANE DB SYST REV, V7
   Wang F, 2011, CURR EYE RES, V36, P103, DOI 10.3109/02713683.2010.526750
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wilkins A, 2010, EN CONV C EXP ECCE 2, P173
   Wilkins Arnold, 2010, P1789 IEEE
   Xhauflaire G, 2005, Rev Med Liege, V60 Suppl 1, P99
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   Yu Y, 2011, OPHTHALMIC RES, V46, P80, DOI 10.1159/000323179
   Zuclich JA, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1990163
NR 23
TC 4
Z9 4
U1 1
U2 28
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2014
VL 7
IS 1
BP 163
EP 168
DI 10.3980/j.issn.2222-3959.2014.01.30
PG 6
WC Ophthalmology
SC Ophthalmology
GA AB0QS
UT WOS:000331497800030
PM 24634884
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Niu, DP
   Li, M
   Wang, FL
AF Niu, Dapeng
   Li, Ming
   Wang, Fuli
TI RETRACTED: Optimization of fluidized bed spray granulation process based
   on a multiphase hybrid model (Retracted article. See vol. 143, pg. 152,
   2015)
SO CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS
LA English
DT Article; Retracted Publication
DE Fluidized bed spray granulation; Optimization; Population balance
   equation; RBF neural network; Differential evolution algorithm
ID FED-BATCH FERMENTATION; POPULATION BALANCE; NEURAL-NETWORKS; PROCESS
   PARAMETERS; CROSS-VALIDATION; MELT GRANULATION; WET GRANULATION; SIZE;
   AGGREGATION; ALGORITHMS
AB An optimization strategy is presented to improve the granule quality of fluidized bed spray granulation in this paper. An accurate description of the relationship between the granule quality and the manipulated variables is first established as a prerequisite for optimization. Considering the characteristics of the fluidized bed spray granulation process and its multiphase features, a multiphase hybrid model is built with the population balance equations as the basic model, in combination with the use of black box models to obtain the unknown parameters. RBF neural network is adopted as the black modeling method in this work to describe the relationship between the parameters and the manipulated variables. Batch experiments of fluidized bed spray granulation are then used for hybrid model validation. The results show that the model has high accuracy and good generalization ability, and it can effectively reflect the characteristics of each phase of the granulation process. Based on the established multiphase hybrid model, an optimization problem and its corresponding online optimization strategy are proposed for fluidized bed spray granulation process. An improved differential evolution algorithm is used to solve the problem for online optimization and adjustment of the granulation process. Experimental results illustrate that both the hybrid model and the improved DE algorithm are effective when used in optimization of batch fluidized bed spray granulation process. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Niu, Dapeng; Wang, Fuli] Northeastern Univ, Coll Informat Sci & Engn, Shenyang 110819, Peoples R China.
   [Li, Ming] De Montfort Univ, Sch Pharm, Leicester LE1 9BH, Leics, England.
RP Niu, DP (reprint author), Northeastern Univ, Coll Informat Sci & Engn, Shenyang 110819, Peoples R China.
EM niudapeng@ise.neu.edu.cn
FU National Natural Science Foundation of China [61304121]; National
   High-tech R&D Program of China (863 Program) [2011AA060204]; Fundamental
   Research Funds for the Central Universities [N110304009]
FX This work was supported by the National Natural Science Foundation of
   China under Grant No. 61304121, the National High-tech R&D Program of
   China (863 Program) under Grant No. 2011AA060204, and the Fundamental
   Research Funds for the Central Universities under Grant No. N110304009.
CR Bengio Y, 2004, J MACH LEARN RES, V5, P1089
   Bogomolov A, 2011, CHEMOMETR INTELL LAB, V108, P49, DOI 10.1016/j.chemolab.2011.02.005
   Browne MW, 2000, J MATH PSYCHOL, V44, P108, DOI 10.1006/jmps.1999.1279
   CHEN S, 1992, INT J CONTROL, V56, P319, DOI 10.1080/00207179208934317
   Cheng SF, 2012, EXPERT SYST APPL, V39, P8467, DOI 10.1016/j.eswa.2012.01.172
   Chiou JP, 1999, COMPUT CHEM ENG, V23, P1277, DOI 10.1016/S0098-1354(99)00290-2
   Christofides PD, 2008, CHEM ENG SCI, V63, P1156, DOI 10.1016/j.ces.2007.07.017
   Deb K, 2000, COMPUT METHOD APPL M, V186, P311, DOI 10.1016/S0045-7825(99)00389-8
   FUNAHASHI K, 1989, NEURAL NETWORKS, V2, P183, DOI 10.1016/0893-6080(89)90003-8
   Hounslow MJ, 2001, AICHE J, V47, P1984, DOI 10.1002/aic.690470910
   HOUNSLOW MJ, 1988, AICHE J, V34, P1821, DOI 10.1002/aic.690341108
   Iveson SM, 2001, POWDER TECHNOL, V117, P3, DOI 10.1016/S0032-5910(01)00313-8
   James S, 2002, J PROCESS CONTR, V12, P113, DOI 10.1016/S0959-1524(00)00065-2
   Kittisupakorn P, 2009, J PROCESS CONTR, V19, P579, DOI 10.1016/j.jprocont.2008.09.003
   LITSTER JD, 1995, AICHE J, V41, P591
   Long CE, 2005, P AMER CONTR CONF, P949, DOI 10.1109/ACC.2005.1470082
   Marchisio DL, 2003, J COLLOID INTERF SCI, V258, P322, DOI 10.1016/S0021-9797(02)00054-1
   Matero S, 2009, CHEMOMETR INTELL LAB, V97, P75, DOI 10.1016/j.chemolab.2008.11.001
   Nagy ZK, 2007, CHEM ENG J, V127, P95, DOI 10.1016/j.cej.2006.10.015
   Narvanen T, 2008, INT J PHARMACEUT, V357, P132, DOI 10.1016/j.ijpharm.2008.01.060
   Nieuwmeyer FJS, 2007, PHARM RES, V24, P1854, DOI 10.1007/s11095-007-9305-5
   Pomerantsev AL, 2011, ANALYST, V136, P4830, DOI 10.1039/c0an01033b
   Poutiainen S, 2012, POWDER TECHNOL, V228, P149, DOI 10.1016/j.powtec.2012.05.010
   Rajniak P, 2009, POWDER TECHNOL, V189, P190, DOI 10.1016/j.powtec.2008.04.027
   Rambali B, 2001, DRUG DEV IND PHARM, V27, P47, DOI 10.1081/DDC-100000127
   Smith M, 1998, CHEM ENG SCI, V53, P1777, DOI 10.1016/S0009-2509(98)00045-1
   Tan HS, 2006, CHEM ENG SCI, V61, P1585, DOI 10.1016/j.ces.2005.09.012
   Vreman AW, 2009, CHEM ENG SCI, V64, P4389, DOI 10.1016/j.ces.2009.07.010
   Walker GM, 2006, POWDER TECHNOL, V165, P161, DOI 10.1016/j.powtec.2006.03.024
NR 29
TC 2
Z9 2
U1 5
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-7439
EI 1873-3239
J9 CHEMOMETR INTELL LAB
JI Chemometrics Intell. Lab. Syst.
PD FEB 15
PY 2014
VL 131
BP 7
EP 15
DI 10.1016/j.chemolab.2013.11.007
PG 9
WC Automation & Control Systems; Chemistry, Analytical; Computer Science,
   Artificial Intelligence; Instruments & Instrumentation; Mathematics,
   Interdisciplinary Applications; Statistics & Probability
SC Automation & Control Systems; Chemistry; Computer Science; Instruments &
   Instrumentation; Mathematics
GA AB3JQ
UT WOS:000331687500002
DA 2018-12-27
ER

PT J
AU Mahendran, G
   Thamotharan, G
   Sengottuvelu, S
   Bai, VN
AF Mahendran, G.
   Thamotharan, G.
   Sengottuvelu, S.
   Bai, V. Narmatha
TI RETRACTED: Anti-diabetic activity of Swertia corymbosa (Griseb.) Wight
   ex CB Clarke aerial parts extract in streptozotocin induced diabetic
   rats (Retracted article. See vol. 207, pg. 271, 2017)
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Swertia corymbosa; Lipid profile; Biochemical estimation; Anti-diabetic;
   Antioxidant activity
ID BIOASSAY GUIDED ISOLATION; PANCREATIC BETA-CELLS; ALPHA-GLUCOSIDASE;
   HYPOGLYCEMIC ACTIVITY; LIPID-PEROXIDATION; CHIRAYITA; HYPERGLYCEMIA;
   BELLIDIFOLIN; ANTIOXIDANTS; INVOLVEMENT
AB Ethnopharmacologicals relevance: Swertia corymbosa locally called as Shirattakuchi have a long history of use in Ayurveda herbal preparations in Indian traditional system of medicine. It has been used in folklore medicine for the treatment of diabetes.
   Aim of the study: The present study aimed to investigate the effect of the methanolic extract of Swertia corymbosa (SC) in diabetic and to analyze its chemical composition by HPLC-ESI/MS that may correlate with their pharmacological activities.
   Materials and methods: The in vitro anti-diabetic activity of the extracts was measured by using alpha-glucosidase and alpha-amylase enzyme inhibitory activity. The methanolic extract of Swertia corymbosa were administered orally (125, 250 and 500 mg/kg, for 28 days) to streptozotocin-induced diabetic rats. Hypoglycemic effects, oral glucose tolerance test, change in body weight and lipid profile, biochemical analysis and histopathological examination were assessed. High-performance liquid chromatography-electrospray ionization/mass spectrometry (HPLC-ESI/MS) method was also developed to analyze the chemical composition.
   Results: In vitro anti-dabetic study, the methanol extract of SC is found to be a potent inhibitor of alpha-glucosidase and alpha-amylase activity. Oral administration of SC and standard drug for 28 days caused a significant decrease in the concentrations of blood glucose level, total cholesterol (TC), serum triglycerides (TGs), low-density lipoprotein-cholesterol (LDL-C), malondialdehyde (MDA) and significant increase in the concentrations of high density lipoprotein-cholesterol (HDL-C), serum insulin and body weight. Furthermore, activities of antioxidative enzymes, including SOD, GPx, GSH and CAT were enhanced dosed dependently with SC. Histopathological studies of the pancreas showed the regeneration of the beta-cells by extract which were earlier necrosed by streptozotocin. Ten major compounds such as loganic acid (1), swertiamarin (2), sweroside (3), gentiopicroside (4), isovitexin (5), amoroswertin (6), amarogentin (7), gentiacaulein (8), decussatin (9) and swertianin (10) were analyzed by HPLC-ESI/MS system.
   Conclusions: These results demonstrate that SC aerial parts of methanolic extract is an effective anti-diabetic and antioxidant activities which provides the scientific proof for the folklore medicine. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Mahendran, G.; Bai, V. Narmatha] Bharathiar Univ, Sch Life Sci, Dept Bot, Coimbatore 641046, Tamil Nadu, India.
   [Thamotharan, G.; Sengottuvelu, S.] Nandha Coll Pharm & Res Inst, Dept Pharmacol, Erode 638052, India.
RP Mahendran, G (reprint author), Bharathiar Univ, Sch Life Sci, Dept Bot, Coimbatore 641046, Tamil Nadu, India.
EM mahendran0007@gmail.com
CR Abraham Z., 1981, GLIMPSES INDIAN ETHN, P26
   Ananthan R, 2003, Exp Diabesity Res, V4, P183, DOI 10.1155/EDR.2003.183
   ANDERSON T, 1974, J CLIN INVEST, V54, P672, DOI 10.1172/JCI107805
   Bagri P, 2009, FOOD CHEM TOXICOL, V47, P50, DOI 10.1016/j.fct.2008.09.058
   BAJPAI MB, 1991, PLANTA MED, V57, P102, DOI 10.1055/s-2006-960041
   BASNET P, 1995, PLANTA MED, V61, P402, DOI 10.1055/s-2006-958124
   BASNET P, 1994, PLANTA MED, V60, P507, DOI 10.1055/s-2006-959560
   Chan JCN, 2001, DIABETES RES CLIN PR, V54, pS19
   CHANDRASEKAR B, 1990, INDIAN J EXP BIOL, V28, P616
   Eliza J, 2009, CHEM-BIOL INTERACT, V182, P67, DOI 10.1016/j.cbi.2009.08.012
   Feng J, 2011, PHYTOCHEMISTRY, V72, P242, DOI 10.1016/j.phytochem.2010.11.025
   Fouotsa H, 2012, PHYTOCHEM LETT, V5, P236, DOI 10.1016/j.phytol.2012.01.002
   JACKSON RL, 1979, DIABETES CARE, V2, P391, DOI 10.2337/diacare.2.5.391
   Jain S, 2010, J ETHNOPHARMACOL, V127, P325, DOI 10.1016/j.jep.2009.10.038
   Jasmine R., 2007, International Journal of Biological Chemistry, V1, P117
   Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398
   Kar A, 2003, J ETHNOPHARMACOL, V84, P105, DOI 10.1016/S0378-8741(02)00144-7
   Kasetti RB, 2010, FOOD CHEM TOXICOL, V48, P1078, DOI 10.1016/j.fct.2010.01.029
   Kim YM, 2004, CARBOHYD RES, V339, P715, DOI 10.1016/j.carres.2003.11.005
   KIND PRN, 1954, J CLIN PATHOL, V7, P322, DOI 10.1136/jcp.7.4.322
   Kirtikar KR, 1984, INDIAN MED PLANTS, V3, P1664
   Kumar D, 2013, J FUNCT FOODS, V5, P211, DOI 10.1016/j.jff.2012.10.007
   Kumar D, 2012, NAT PROD COMMUN, V7, P989
   Kuzuya T, 2002, DIABETES RES CLIN PR, V55, P65, DOI 10.1016/S0168-8227(01)00365-5
   Latha RCR, 2011, CHEM-BIOL INTERACT, V189, P112, DOI 10.1016/j.cbi.2010.11.005
   Liu YT, 2013, FOOD CHEM TOXICOL, V57, P39, DOI 10.1016/j.fct.2013.03.001
   Mahendran G, 2014, ACTA PHYSIOL PLANT, V36, P589, DOI 10.1007/s11738-013-1435-2
   Mahendran G., 2013, INT J PHARM PHARM SC, V5, P551
   Mahendran G., 2013, INT J PHARM PHARM SC, V5, P459
   MARKLUND S, 1974, EUR J BIOCHEM, V47, P469
   MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7
   Muruganandan S, 2005, J ETHNOPHARMACOL, V97, P497, DOI 10.1016/j.jep.2004.12.010
   NIEHAUS WG, 1968, EUR J BIOCHEM, V6, P126, DOI 10.1111/j.1432-1033.1968.tb00428.x
   OECD, 2001, OECD GUID TEST CHEM
   Ohaeri OC, 2001, BIOSCIENCE REP, V21, P19, DOI 10.1023/A:1010425932561
   Oudhia P., 2012, INDIGENOUS MED RICE
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Papaccio G, 2000, J CELL BIOCHEM, V77, P82, DOI 10.1002/(SICI)1097-4644(20000401)77:1<82::AID-JCB9>3.3.CO;2-M
   Pen F., 2003, CHIN J TRADIT MED SC, V10, P96
   REITMAN S, 1957, AM J CLIN PATHOL, V28, P56
   Renu A., 2011, INT RES J PHARM, V2, P230
   ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588
   Ryu HW, 2011, PHYTOCHEMISTRY, V72, P2148, DOI 10.1016/j.phytochem.2011.08.007
   Saraswathy A., 2011, International Journal of Pharmacy and Life Sciences (IJPLS), V2, P976
   Saxena A. M., 2007, Flora and Fauna (Jhansi), V13, P415
   SAXENA AM, 1992, J MICROBIAL BIOTECH, V7, P27
   Saxena Anand Murari, 1993, Indian Journal of Experimental Biology, V31, P178
   Scartezzini P, 2000, J ETHNOPHARMACOL, V71, P23, DOI 10.1016/S0378-8741(00)00213-0
   Selvameena P., 2011, S ASIAN J BIOL SCI, V1, P21
   Selvameena P., 2010, INT RES J PHARM, V1, P392
   SINHA AK, 1972, ANAL BIOCHEM, V47, P389, DOI 10.1016/0003-2697(72)90132-7
   Szkudelski T, 2001, PHYSIOL RES, V50, P537
   Tian LY, 2010, PHYTOMEDICINE, V17, P533, DOI 10.1016/j.phymed.2009.10.007
   Wan LS, 2013, J ETHNOPHARMACOL, V147, P622, DOI 10.1016/j.jep.2013.03.052
   Wang YL, 2013, J ETHNOPHARMACOL, V150, P536, DOI 10.1016/j.jep.2013.08.053
   Wang YF, 2010, INT J BIOL MACROMOL, V46, P270, DOI 10.1016/j.ijbiomac.2009.12.007
   *WHO, 2003, TRAD MED
   Wu CC, 2012, TOXICOL LETT, V208, P275, DOI 10.1016/j.toxlet.2011.10.022
NR 58
TC 27
Z9 29
U1 3
U2 37
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD FEB 12
PY 2014
VL 151
IS 3
BP 1175
EP 1183
DI 10.1016/j.jep.2013.12.032
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA AB0KP
UT WOS:000331481000017
PM 24378350
DA 2018-12-27
ER

PT J
AU Oh, MH
   Wang, XJ
   Kim, SY
   Wu, X
   Clouse, SD
   Huber, SC
AF Oh, Man-Ho
   Wang, Xuejun
   Kim, Sang Yeol
   Wu, Xia
   Clouse, Steven D.
   Huber, Steven C.
TI RETRACTED: The Carboxy-terminus of BAK1 regulates kinase activity and is
   required for normal growth of Arabidopsis (Retracted article. See vol.
   7, 960, 2016)
SO FRONTIERS IN PLANT SCIENCE
LA English
DT Article; Retracted Publication
DE brassinosteroid; RAKI; BRI1; domain; phosphotyrosine; protein peptide
   interaction
ID RECEPTOR-LIKE KINASES; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION;
   IN-VITRO; BRI1; ACTIVATION; DEFENSE; BRASSINOSTEROIDS; IDENTIFICATION;
   PERCEPTION
AB Binding of brassinolide to the brassinosteroid-insenstive 1(BRI1) receptor kinase promotes interaction with its co-receptor, BRI1-associated receptor kinase 1 (BAK1). Juxtaposition of the kinase domains that occurs then allows reciprocal transphosphorylation and activation of both kinases, but details of that process are not entirely clear. In the present study we show that the carboxy (C)-terminal polypeptide of BAK1 may play a role. First, we demonstrate that the C-terminal domain is a strong inhibitor of the transphosphorylation activity of the recombinant BAK1 cytoplasmic domain protein. However, recombinant BAK1 lacking the C-terminal domain is unable to transactivate the peptide kinase activity of BRI1 in vitro. Thus, the C-terminal domain may play both a positive and negative role. Interestingly, a synthetic peptide corresponding to the full C-terminal domain (residues 576-615 of BAK1) interacted with recombinant BRI1 in vitro, and that interaction was enhanced by phosphorylation at the Tyr-610 site. Expression of a BAK1 C-terminal domain truncation (designated BAK1-Delta CT-Flag) in transgenic Arabidopsis plants lacking endogenous bak1 and its functional paralog, bkk1, produced plants that were wild type in appearance but much smaller than plants expressing full-length BAK1-Flag. The reduction in growth may be attributed to a partial inhibition of BR signaling in vivo as reflected in root growth assays but other factors are likely involved as well. Our working model is that in vivo, the inhibitory action of the C-terminal domain of BAK1 is relieved by binding to BRI1. However, that interaction is not essential for BR signaling, but other aspects of cellular signaling are impacted when the C-terminal domain is truncated and result in inhibition of growth. These results increase the molecular understanding of the C-terminal domain of BAK1 as a regulator of kinase activity that may serve as a model for other receptor kinases.
C1 [Oh, Man-Ho; Wang, Xuejun; Kim, Sang Yeol; Wu, Xia; Huber, Steven C.] Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA.
   [Oh, Man-Ho] Chungnam Natl Univ, Dept Biol Sci, Coll Biol Sci & Biotechnol, Taejon, South Korea.
   [Wu, Xia] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
   [Clouse, Steven D.] N Carolina State Univ, Dept Hort Sci, Raleigh, NC 27695 USA.
   [Huber, Steven C.] ARS, USDA, Urbana, IL USA.
RP Huber, SC (reprint author), Univ Illinois, Dept Plant Biol, 1201 West Gregory Dr,197 ERML, Urbana, IL 61801 USA.
EM schuber1@illinois.edu
RI Wu, Xia/J-8690-2014
OI Wu, Xia/0000-0002-0024-4481; Oh, Man-Ho/0000-0002-6524-3252
FU National Science Foundation [IOS-1022177, MCB-1021363]; US Department of
   Agriculture (USDA)-Agricultural Research Service (ARS)
FX This work was supported in part by the National Science Foundation
   (IOS-1022177and MCB-1021363) and the US Department of Agriculture
   (USDA)-Agricultural Research Service (ARS). The authors thank Dr. Cyril
   Zipfel for the generous gift of BAK1-CT antibodies.
CR ADAMS JA, 1993, PROTEIN SCI, V2, P2177, DOI 10.1002/pro.5560021217
   Bastidas AC, 2013, J AM CHEM SOC, V135, P4788, DOI 10.1021/ja312237q
   Chinchilla D, 2007, NATURE, V448, P497, DOI 10.1038/nature05999
   Chou MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052747
   Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671
   Clouse SD, 1998, ANNU REV PLANT PHYS, V49, P427, DOI 10.1146/annurev.arplant.49.1.427
   Clouse SD, 2011, PLANT CELL, V23, P1219, DOI 10.1105/tpc.111.084475
   He K, 2007, CURR BIOL, V17, P1109, DOI 10.1016/j.cub.2007.05.036
   Hothorn M, 2011, NATURE, V474, P467, DOI 10.1038/nature10153
   Karlova R, 2009, PROTEOMICS, V9, P368, DOI 10.1002/pmic.200701059
   Kinoshita T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227
   Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7
   Li JM, 2001, PLANT PHYSIOL, V127, P14, DOI 10.1104/pp.127.1.14
   Ntoukakis V, 2011, PLANT CELL, V23, P3871, DOI 10.1105/tpc.111.090779
   Oh MH, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00175
   Oh MH, 2011, PLANT SIGNAL BEHAV, V6, P400, DOI 10.4161/psb.6.3.14337
   Oh MH, 2010, P NATL ACAD SCI USA, V107, P17827, DOI 10.1073/pnas.0915064107
   Oh MH, 2009, PLANT SIGNAL BEHAV, V4, P1182, DOI 10.4161/psb.4.12.10046
   Oh MH, 2009, P NATL ACAD SCI USA, V106, P658, DOI 10.1073/pnas.0810249106
   Oh MH, 2000, PLANT PHYSIOL, V124, P751, DOI 10.1104/pp.124.2.751
   Robatzek S, 2006, GENE DEV, V20, P537, DOI 10.1101/gad.366506
   Santiago J, 2013, SCIENCE, V341, P889, DOI 10.1126/science.1242468
   She J, 2011, NATURE, V474, P472, DOI 10.1038/nature10178
   Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598
   Vert G, 2005, ANNU REV CELL DEV BI, V21, P177, DOI 10.1146/annurev.cellbio.21.090704.151241
   Wang XF, 2005, PLANT CELL, V17, P1685, DOI 10.1105/tpc.105.031393
   Wang XF, 2008, DEV CELL, V15, P220, DOI 10.1016/j.devcel.2008.06.011
   Wang XL, 2005, DEV CELL, V8, P855, DOI 10.1016/j.devcel.2005.05.001
   Wu X, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00262
   Zhu Y, 2013, PLANT PHYSIOL, V161, P2005, DOI 10.1104/pp.112.213363
NR 30
TC 12
Z9 12
U1 1
U2 21
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-462X
J9 FRONT PLANT SCI
JI Front. Plant Sci.
PD FEB 4
PY 2014
VL 5
AR 16
DI 10.3389/fpls.2014.00016
PG 9
WC Plant Sciences
SC Plant Sciences
GA AB1EH
UT WOS:000331533800001
PM 24550926
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Messer, WB
   de Alwis, R
   Yount, BL
   Royal, SR
   Huynh, JP
   Smith, SA
   Crowe, JE
   Doranz, BJ
   Kahle, KM
   Pfaff, JM
   White, LJ
   Sariol, CA
   de Silva, AM
   Baric, RS
AF Messer, William B.
   de Alwis, Ruklanthi
   Yount, Boyd L.
   Royal, Scott R.
   Huynh, Jeremy P.
   Smith, Scott A.
   Crowe, James E., Jr.
   Doranz, Benjamin J.
   Kahle, Kristen M.
   Pfaff, Jennifer M.
   White, Laura J.
   Sariol, Carlos A.
   de Silva, Aravinda M.
   Baric, Ralph S.
TI RETRACTED: Dengue virus envelope protein domain I/II hinge determines
   long-lived serotype-specific dengue immunity (Retracted article. See
   vol. 112, pg. E2738, 2015)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE infectious clone; neutralizing antibody
ID HUMAN MONOCLONAL-ANTIBODIES; WEST NILE VIRUS; SEQUENCE ALIGNMENT;
   INFECTION; NEUTRALIZATION; GLYCOPROTEIN; VACCINE; ENHANCEMENT;
   RESPONSES; MACAQUES
AB The four dengue virus (DENV) serotypes, DENV-1, -2, -3, and -4, are endemic throughout tropical and subtropical regions of the world, with an estimated 390 million acute infections annually. Infection confers long-term protective immunity against the infecting serotype, but secondary infection with a different serotype carries a greater risk of potentially fatal severe dengue disease, including dengue hemorrhagic fever and dengue shock syndrome. The single most effective measure to control this threat to global health is a tetravalent DENV vaccine. To date, attempts to develop a protective vaccine have progressed slowly, partly because the targets of type-specific human neutralizing antibodies (NAbs), which are critical for long-term protection, remain poorly defined, impeding our understanding of natural immunity and hindering effective vaccine development. Here, we show that the envelope glycoprotein domain I/II hinge of DENV-3 and DENV-4 is the primary target of the long-term type-specific NAb response in humans. Transplantation of a DENV-4 hinge into a recombinant DENV-3 virus showed that the hinge determines the serotype-specific neutralizing potency of primary human and nonhuman primate DENV immune sera and that the hinge region both induces NAbs and is targeted by protective NAbs in rhesus macaques. These results suggest that the success of live dengue vaccines may depend on their ability to stimulate NAbs that target the envelope glycoprotein domain I/II hinge region. More broadly, this study shows that complex conformational antibody epitopes can be transplanted between live viruses, opening up similar possibilities for improving the breadth and specificity of vaccines for influenza, HIV, hepatitis C virus, and other clinically important viral pathogens.
C1 [Messer, William B.; Huynh, Jeremy P.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
   [Messer, William B.] Oregon Hlth & Sci Univ, Div Infect Dis, Dept Med, Portland, OR 97239 USA.
   [de Alwis, Ruklanthi; de Silva, Aravinda M.; Baric, Ralph S.] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Yount, Boyd L.; Royal, Scott R.; Huynh, Jeremy P.; Baric, Ralph S.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Smith, Scott A.] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Vanderbilt Vaccine Ctr, Nashville, TN 37232 USA.
   [Doranz, Benjamin J.; Kahle, Kristen M.; Pfaff, Jennifer M.] Integral Mol, Philadelphia, PA 19104 USA.
   [White, Laura J.] Global Vaccines Inc, Res Triangle Pk, NC 27709 USA.
   [Sariol, Carlos A.] Univ Puerto Rico, Caribbean Primate Res Ctr, San Juan, PR 00936 USA.
   [Sariol, Carlos A.] Univ Puerto Rico, Dept Microbiol & Med Zool, San Juan, PR 00936 USA.
   [Sariol, Carlos A.] Univ Puerto Rico, Dept Internal Med, San Juan, PR 00936 USA.
RP de Silva, AM (reprint author), Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
EM aravinda_desilva@med.unc.edu; rbaric@email.unc.edu
RI Crowe, James/B-5549-2009
OI Crowe, James/0000-0002-0049-1079
FU National Institutes of Health National Institute of Allergy and
   Infectious Diseases from the Southeast Region Center of Excellence for
   Emerging Infections and Biodefense [U54 AI057157]; National Institute of
   Allergy and Infectious Diseases [HHSN272200900055C]; National Institutes
   of Health National Institute of Allergy and Infectious Diseases
   [OD012217, U24 OD010421, U42OD011128, 1 R56 AI097560-01, 1 RO1 AI
   107731-01]
FX We thank Dr. Fred Sparling for his long-term support and leadership that
   brought these studies to fruition. We thank Anne Broad-water, Nurgun
   Kose, Frances House, Teresa Arana Santiago, and Petraleigh Pantoja for
   excellent technical support. We also thank Dr. Idia V. Rodriguez for
   excellent veterinarian support of the nonhuman primate studies. This
   research was supported by National Institutes of Health National
   Institute of Allergy and Infectious Diseases Grant U54 AI057157 from the
   Southeast Region Center of Excellence for Emerging Infections and
   Biodefense (to W.B.M., S.A.S., J.E.C., A.M.d.S., and R.S.B.), National
   Institute of Allergy and Infectious Diseases Contract HHSN272200900055C
   (to B.J.D.), and National Institutes of Health National Institute of
   Allergy and Infectious Diseases Grants P40 OD012217 (to C.A.S.), U24
   OD010421 (to C.A.S.), U42OD011128 (to C.A.S.), 1 R56 AI097560-01 (to
   A.M.d.S., R.S.B., and J.E.C.), and 1 RO1 AI 107731-01 (to A.M. d.S.,
   R.S.B., and J.E.C.).
CR [Anonymous], 2009, DENG GUID DIAGN TREA
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bond CS, 2009, ACTA CRYSTALLOGR D, V65, P510, DOI 10.1107/S0907444909007835
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500
   Christian EA, 2013, P NATL ACAD SCI USA, V110, P18662, DOI 10.1073/pnas.1310962110
   de Alwis R, 2012, P NATL ACAD SCI USA, V109, P7439, DOI 10.1073/pnas.1200566109
   Dowd KA, 2011, VIROLOGY, V411, P306, DOI 10.1016/j.virol.2010.12.020
   Durbin AP, 2011, VIRUSES-BASEL, V3, P1800, DOI 10.3390/v3101800
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   HALSTEAD SB, 1973, AM J TROP MED HYG, V22, P365, DOI 10.4269/ajtmh.1973.22.365
   HALSTEAD SB, 1973, NATURE-NEW BIOL, V243, P24
   Julien JP, 2013, P NATL ACAD SCI USA, V110, P4351, DOI 10.1073/pnas.1217537110
   Kaufmann B, 2010, P NATL ACAD SCI USA, V107, P18950, DOI 10.1073/pnas.1011036107
   Keck ZY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002653
   Koraka P, 2007, MICROBES INFECT, V9, P940, DOI 10.1016/j.micinf.2007.03.012
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Messer WB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001486
   Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100
   Modis Y, 2005, J VIROL, V79, P1223, DOI 10.1128/JVI.79.2.1223-1231.2005
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Paes C, 2013, J AM CHEM SOC, V131, P6952
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Smith SA, 2013, J INFECT DIS, V207, P1898, DOI 10.1093/infdis/jit119
   Smith SA, 2012, J VIROL, V86, P2665, DOI 10.1128/JVI.06335-11
   Teoh E.P., 2012, SCI TRANSL MED, V4
   Tsibane T, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003067
   Vogt MR, 2009, J VIROL, V83, P6494, DOI 10.1128/JVI.00286-09
   Wahala WMPB, 2009, VIROLOGY, V392, P103, DOI 10.1016/j.virol.2009.06.037
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   White LJ, 2013, J VIROL, V87, P3409, DOI 10.1128/JVI.02298-12
   Zhang Y, 2004, STRUCTURE, V12, P1607, DOI 10.1016/j.str.2004.06.019
NR 33
TC 41
Z9 41
U1 2
U2 22
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 4
PY 2014
VL 111
IS 5
BP 1939
EP 1944
DI 10.1073/pnas.1317350111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 302FL
UT WOS:000330587600068
PM 24385585
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Nandyala, SV
   Marquez-Lara, A
   Fineberg, SJ
   Pelton, M
   Singh, K
AF Nandyala, Sreeharsha V.
   Marquez-Lara, Alejandro
   Fineberg, Steven J.
   Pelton, Miguel
   Singh, Kern
TI RETRACTED: Prospective, Randomized, Controlled Trial of
   Silicate-Substituted Calcium Phosphate Versus rhBMP-2 in a Minimally
   Invasive Transforaminal Lumbar Interbody Fusion (Retracted article. See
   vol. 41, pg. 553, 2016)
SO SPINE
LA English
DT Article; Retracted Publication
DE MISTLIF; arthrodesis; pseudarthrosis; rhBMP-2; ceramics; Actifuse
ID BONE MORPHOGENETIC PROTEIN-2; SPINAL-FUSION; GRAFT SUBSTITUTES;
   METAANALYSIS; ACCESS
AB Study Design. Prospective, randomized, controlled trial.
   Objective. To compare arthrodesis rates between patients undergoing a primary single-level minimally invasive transforaminal lumbar interbody fusion (MIS TLIF) with either Actifuse or recombinant human bone morphogenetic protein-2 (rhBMP-2).
   Summary of Background Data. Preclinical animal studies suggest that silicate-substituted calcium phosphate(Actifuse) bone graft substitute offers equivalent or an increased fusion rate compared with other graft enhancers/extenders and rhBMP-2. Methods. Fifty-two patients undergoing a single-level unilateral MIS TLIF were evenly randomized into 2 cohorts as follows: the Actifuse cohort received Actifuse combined with 5 mL of bone marrow aspirate(n = 26; 50%), whereas the rhBMP cohort received 4.2 mg of rhBMP-2 (n = 26; 50%). A pre hoc G* Power analysis yielded a sample size of n = 26 that was determined through a 2-tailed distribution calculation. Computed tomographic analysis was performed at 6 months and 1 year postoperatively. Pre- and postoperative visual analogue scale scores were obtained to assess the clinical outcomes. Arthrodesis was determined by 2 separate, blinded orthopedic surgeons and a board certified radiologist.
   Results. At 1-year follow-up, 65%(17/26) of the Actifuse cohort and 92% (24/26) of the rhBMP-2 cohort demonstrated a radiographical arthrodesis(P = 0.01). In both study cohorts, the 1-year postoperative visual analogue scale scores significantly improved (P < 0.001). Pseudarthrosis rates at 1 year were 35.0% (9/ 26) and 7.7% (2/ 26) for the Actifuse and rhBMP-2 groups, respectively (P = 0.01, OR = 6.35, 95% CI = 1.22-33.1). A greater reoperation rate was noted in the Actifuse cohort (35.0%, 9/ 26) compared with the BMP-2 cohort (7.7%, 2/ 26; P = 0.01). One patient with BMP-2 also experienced symptomatic neuroforaminal bone growth (3.8%, n = 1/ 26).
   Conclusion. Silicate-substituted calcium phosphate was associated with a signifi cantly lower rate of arthrodesis than rhBMP-2 in a MIS TLIF. The patients with pseudarthrosis in both cohorts were all clinically symptomatic with an unimproved visual analogue scale score. Additional analysis of Actifuse and other graft enhancers/ extenders are needed prior to the utilization for an MIS TLIF.
C1 [Nandyala, Sreeharsha V.; Marquez-Lara, Alejandro; Fineberg, Steven J.; Pelton, Miguel; Singh, Kern] Rush Univ, Med Ctr, Dept Orthopaed Surg, Chicago, IL 60612 USA.
RP Singh, K (reprint author), Rush Univ, Med Ctr, Dept Orthopaed Surg, 1611 W Harrison St,Ste 400, Chicago, IL 60612 USA.
EM Kern.singh@rushortho.com
CR Aubin M, 2010, SPINE J, P317
   Cahill KS, 2009, JAMA-J AM MED ASSOC, V302, P58, DOI 10.1001/jama.2009.956
   Campion CR, 2011, J BIOMED MATER RES B, V97B, P245, DOI 10.1002/jbm.b.31807
   Hing KA, 2007, SPINE J, V7, P475, DOI 10.1016/j.spinee.2006.07.017
   Hofstetter C, 2010, FUNDAMENTALS OPERATI, P883
   Joseph V, 2007, SPINE, V32, P2885, DOI 10.1097/BRS.0b013e31815b7596
   KOZAK JA, 1994, CLIN ORTHOP RELAT R, P45
   Lee YP, 2009, CONT SPINE SURG, V10, P8
   LeGeros RZ, 2002, CLIN ORTHOP RELAT R, P81
   Miyazaki M, 2009, EUR SPINE J, V18, P783, DOI 10.1007/s00586-009-0924-x
   Oliveira L, 2010, SPINE, V35, pS331, DOI 10.1097/BRS.0b013e3182022db0
   Patel N, 2005, J MATER SCI-MATER M, V16, P429, DOI 10.1007/s10856-005-6983-6
   Peng Chan Wearn Benedict, 2009, Spine (Phila Pa 1976), V34, P1385, DOI 10.1097/BRS.0b013e3181a4e3be
   Pimenta Luiz, 2008, SAS J, V2, P62, DOI 10.1016/SASJ-2007-0122-RR
   Rouben D, 2011, J SPINAL DISORD TECH, V24, P288, DOI 10.1097/BSD.0b013e3181f9a60a
   Seebach C, 2010, INJURY, V41, P731, DOI 10.1016/j.injury.2010.02.017
   Sekhon L, 2009, SPINE J, V9, p32S
   Shepherd JH, 2011, JOM-US, V63, P83, DOI 10.1007/s11837-011-0063-9
   Simmonds MC, 2013, ANN INTERN MED, V158, P877, DOI 10.7326/0003-4819-158-12-201306180-00005
   Vaz Kenneth, 2010, SAS J, V4, P75, DOI 10.1016/j.esas.2010.01.004
   Wheeler DL, 2007, SPINE J, V7, P308, DOI 10.1016/j.spinee.2006.01.005
   Wong DA, 2008, SPINE J, V8, P1011, DOI 10.1016/j.spinee.2007.06.014
   Wu RH, 2010, SPINE, V35, P2273, DOI 10.1097/BRS.0b013e3181cd42cc
   Zimmermann G, 2011, INJURY, V42, pS16, DOI 10.1016/j.injury.2011.06.199
NR 24
TC 14
Z9 15
U1 4
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD FEB 1
PY 2014
VL 39
IS 3
BP 185
EP 191
DI 10.1097/BRS.0000000000000106
PG 7
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA AH5ZZ
UT WOS:000336211800015
PM 24253788
DA 2018-12-27
ER

PT J
AU Yang, ZH
   Zheng, R
   Gao, Y
   Zhang, Q
   Zhang, H
AF Yang, Z-H
   Zheng, R.
   Gao, Y.
   Zhang, Q.
   Zhang, H.
TI RETRACTED: Abnormal gene expression and gene fusion in lung
   adenocarcinoma with high-throughput RNA sequencing (Retracted article.
   See vol. 23, pg. 72, 2016)
SO CANCER GENE THERAPY
LA English
DT Article; Retracted Publication
DE lung adenocarcinoma; high-throughput mRNA sequencing; tumor suppressor
   genes; oncogenes; fusion gene
ID HOX GENES; SOMATIC MUTATIONS; PROSTATE-CANCER; SMALL-CELL; GENOME;
   WISP-1; OVEREXPRESSION; TRANSCRIPTS; CARCINOMA; RESOURCE
AB To explore the universal law of the abnormal gene expression and the structural variation of genes related to lung adenocarcinoma, the gene expression profile of GSE37765 were downloaded from Gene Expression Omnibus database. The differentially expressed genes (DEGs) were analyzed with t-test and NOISeq tool, and the core DEGs were screened out by combining with another RNA-seq data containing totally 77 pairs of samples in 77 patients with lung adenocarcinoma. Moreover, the functional annotation of the core DEGs was performed by using the Database for Annotation Visualization and Integrated Discovery following selection of oncogene and tumor suppressor by combining with tumor suppressor genes and Cancer Genes database, and motif-finding of core DEGs was performed with motif-finding algorithm Seqpos. We also Used Tophat-fusion tool to further explore the fusion genes. In total, 850 downregulated DEGs and 206 upregulated DEGs were screened out in lung adenocarcinoma tissues. Next, we selected 543 core DEGs, including 401 downregulated and 142 upregulated genes, and vasculature development (P = 1.89E - 06) was significantly enriched among downregulated core genes, as well as mitosis (P=6.26E-04) enriched among upregulated core genes. On the basis of the cellular localization analysis of core genes, wnt-1-induced secreted protein 1 (WISP1) and receptor (G protein-coupled) activity modifying protein 1 (RAMP1) identified mainly located in extracellular region and extracellular space. We also screened one oncogene, v-myb avian myeloblastosis viral oncogene homolog-like 2 (MYBL2). Moreover, transcription factor GATA2 was mined by motif-finding analysis. Finally, four fusion genes belonged to the human leukocyte antigen (HLA) family. WISP1, RAMP1, MYBL2 and GATA2 could be potential targets of treatment for lung adenocarcinoma and the fusion of HLA family genes might have important roles in lung adenocarcinoma.
C1 [Yang, Z-H; Zheng, R.; Gao, Y.; Zhang, Q.; Zhang, H.] China Med Univ, Shengjing Hosp, Dept Resp Med, Shenyang 110004, Peoples R China.
RP Zheng, R (reprint author), China Med Univ, Shengjing Hosp, Dept Resp Med, 36 Sanhao St, Shenyang 110004, Peoples R China.
EM zhengruizrzr@hotmail.com
CR Abe M, 2006, ONCOL REP, V15, P797
   Beane J, 2011, CANCER PREV RES, V4, P803, DOI 10.1158/1940-6207.CAPR-11-0212
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   Bohm M, 2009, ONCOGENE, V28, P3847, DOI 10.1038/onc.2009.243
   Chen GA, 2002, CLIN CANCER RES, V8, P2298
   Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534
   Cheung ALM, 2008, FRONT BIOSCI-LANDMRK, V13, P2075, DOI 10.2741/2825
   Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   El-Rifai W, 2000, CANCER RES, V60, P3899
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710
   Higgins ME, 2007, NUCLEIC ACIDS RES, V35, pD721, DOI 10.1093/nar/gkl811
   Hosgood HD, 2008, CARCINOGENESIS, V29, P1938, DOI 10.1093/carcin/bgn178
   Jiang HY, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-81
   Juergens Rosalyn A, 2006, J Natl Compr Canc Netw, V4, P595
   Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72
   Kim SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055596
   Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504
   Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059
   Li CH, 2012, FISH SHELLFISH IMMUN, V33, P436, DOI 10.1016/j.fsi.2012.04.013
   Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83
   Logan M, 2013, AM J PATHOL, V183, P951, DOI 10.1016/j.ajpath.2013.05.021
   Margalit O, 2003, BRIT J CANCER, V89, P314, DOI 10.1038/sj.bjc.6600977
   Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108
   Meissner M, 2005, CLIN CANCER RES, V11, P2552, DOI 10.1158/1078-0432.CCR-04-2146
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857
   Schiller JH, 2001, ONCOLOGY-BASEL, V61, P3, DOI 10.1159/000055386
   Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112
   Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200
   Tang FC, 2009, NAT METHODS, V6, P377, DOI [10.1038/NMETH.1315, 10.1038/nmeth.1315]
   Tanner MM, 2000, CLIN CANCER RES, V6, P1833
   Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Urosevic M, 2001, AM J PATHOL, V159, P817, DOI 10.1016/S0002-9440(10)61756-7
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Zhao M, 2013, NUCLEIC ACIDS RES, V41, pD970, DOI 10.1093/nar/gks937
   Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223
   Zudaire E, 2003, REGUL PEPTIDES, V112, P175, DOI 10.1016/S0167-0115(03)00037-5
NR 46
TC 11
Z9 11
U1 3
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
EI 1476-5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD FEB
PY 2014
VL 21
IS 2
BP 74
EP 82
DI 10.1038/cgt.2013.86
PG 9
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA AB3IN
UT WOS:000331684600006
PM 24503571
DA 2018-12-27
ER

PT J
AU Lv, SZ
   Turlova, E
   Zhao, SG
   Kang, HH
   Han, MZ
   Sun, HS
AF Lv, Shunzeng
   Turlova, Ekaterina
   Zhao, Shigang
   Kang, Huihui
   Han, Mingzhi
   Sun, Hong-Shuo
TI RETRACTED: Prognostic and clinicopathological significance of survivin
   expression in bladder cancer patients: a meta-analysis (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Survivin; Bladder cancer; Prognosis; Clinicopathology; Meta-analysis
ID UROTHELIAL CARCINOMA; RADICAL CYSTECTOMY; PUBLICATION BIAS;
   CELL-CARCINOMA; RECURRENCE; NUCLEAR; MARKER; STATISTICS; MORTALITY;
   THERAPY
AB Survivin has been widely reported to play a role in diagnosis and prognosis of bladder cancer patients. However, published data on this subject are heterogeneous. Here, we conducted a meta-analysis to obtain a complete evaluation of the association between survivin and recurrence-free survival (RFS), disease-specific survival (DSS), overall survival (OS), and odds ratio (OR) in bladder cancer patients. Published studies on this subject were selected for further assessment by online articles in PubMed, MEDLINE, EMBASE, and OVID databases. Pooled hazard ratios (HR) with 95 % confidence interval (95 % CI) were estimated. Funnel plots were used to evaluate the publication bias. As well, heterogeneity and sensitivity were analyzed. In this meta-analysis, we included 13 studies with the total number of 1,963 patients. Positive survivin expression in bladder cancer was associated with a poor RFS (HR, 1.831; 95 % CI, 1.344-2.49), DSS (HR, 1.721; 95 % CI, 1.477-2.004), or OS (HR, 1.753; 95 % CI, 1.092-2.816) in patients. In addition, a significant association between expression of survivin and age (OR, 0.641; 95 % CI, 0.416-0.987) as well as stage (OR, 0.37; 95 % CI, 0.190-0.750) was revealed. Heterogeneity was observed among the included studies with RFS (x (2) = 29.58, p = 0.009, I (2) = 52.7 %), OS (x (2) = 15.67, p = 0.008, I (2) = 68.1 %), and stage (x (2) = 11.97, p = 0.035, I (2) = 58.2 %). There was no publication bias according to Begg's and Egger's tests except for studies with gender. Furthermore, sensitivity analysis obtained the source of heterogeneity and confirmed opposite results of some studies. This study suggests that expression of survivin indicates poor prognosis in older patients and muscle invasive or advanced stage in bladder cancer. Survivin expression could be used in identifying a subgroup of patients with potential to benefit from a targeted therapy against survivin.
C1 [Lv, Shunzeng; Turlova, Ekaterina; Sun, Hong-Shuo] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [Zhao, Shigang] Shanghai Jiao Tong Univ, Dept Med, Shanghai 200030, Peoples R China.
   [Kang, Huihui; Han, Mingzhi] Shandong Univ, Dept Med, Jinan 250100, Shandong, Peoples R China.
RP Sun, HS (reprint author), Univ Toronto, Dept Surg, Toronto, ON, Canada.
EM hss.sun@utoronto.ca
FU China Scholarship Council
FX This study was supported by China Scholarship Council. We were also very
   thankful to the support of Sun lab staff for their valuable advice.
CR Als AB, 2007, CLIN CANCER RES, V13, P4407, DOI 10.1158/1078-0432.CCR-07-0109
   Athanassiadou AM, 2011, FOLIA HISTOCHEM CYTO, V49, P26, DOI 10.5603/FHC.2011.0005
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gradilone A, 2010, BJU INT, V106, P710, DOI 10.1111/j.1464-410X.2009.09130.x
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Karam JA, 2007, UROLOGY, V70, P482, DOI 10.1016/j.urology.2007.05.009
   Karam JA, 2007, LANCET ONCOL, V8, P128, DOI 10.1016/S1470-2045(07)70002-5
   Li CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044764
   Li Y, 2010, HEPATO-GASTROENTEROL, V57, P1435
   Margulis V, 2008, BJU INT, V102, P15, DOI 10.1111/j.1464-410X.2008.07594.x
   Nakanishi K, 2002, VIRCHOWS ARCH, V441, P559, DOI 10.1007/s00428-002-0712-z
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Pennati M, 2008, EXPERT OPIN THER TAR, V12, P463, DOI 10.1517/14728222.12.4.463 
   Pina-Cabral L, 2007, CLIN TRANSL ONCOL, V9, P731, DOI 10.1007/s12094-007-0130-4
   Rodel F, 2012, CURR MED CHEM, V19, P3679, DOI 10.2174/092986712801661040
   Sah NK, 2006, CANCER LETT, V244, P164, DOI 10.1016/j.canlet.2006.03.007
   Shariat SF, 2008, CURR OPIN UROL, V18, P1, DOI 10.1097/MOU.0b013e3282f1c5c1
   Shariat SF, 2007, CANCER-AM CANCER SOC, V109, P1106, DOI 10.1002/cncr.22521
   Shariat SF, 2009, CLIN CANCER RES, V15, P7012, DOI 10.1158/1078-0432.CCR-08-2554
   Shariat SF, 2009, J UROLOGY, V182, P78, DOI 10.1016/j.juro.2009.02.125
   Skagias L, 2009, ANTICANCER RES, V29, P4163
   Stauber RH, 2007, CANCER RES, V67, P5999, DOI 10.1158/0008-5472.CAN-07-0494
   Steels E, 2001, EUR RESPIR J, V18, P705, DOI 10.1183/09031936.01.00062201
   Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Weiss C, 2009, INT J RADIAT ONCOL, V74, P1455, DOI 10.1016/j.ijrobp.2008.10.063
   Xi RC, 2013, J SURG ONCOL, V107, P550, DOI 10.1002/jso.23272
   Yamamoto Tetsuhisa, 2001, Medical Electron Microscopy, V34, P207, DOI 10.1007/s007950100017
   Yin W, 2006, MODERN PATHOL, V19, P1487, DOI 10.1038/modpathol.3800675
   Zhang L, 2012, J ENG FIBER FABR, V7, P7
NR 32
TC 16
Z9 17
U1 3
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2014
VL 35
IS 2
BP 1565
EP 1574
DI 10.1007/s13277-013-1216-y
PG 10
WC Oncology
SC Oncology
GA AB8FT
UT WOS:000332026300091
PM 24101190
DA 2018-12-27
ER

PT J
AU Liu, Y
   Song, H
   Pan, J
   Zhao, J
AF Liu, Yi
   Song, Hua
   Pan, Jing
   Zhao, Jing
TI RETRACTED: Comprehensive gene expression analysis reveals multiple
   signal pathways associated with prostate cancer (Retracted article. See
   vol. 56, pg. 557, 2015)
SO JOURNAL OF APPLIED GENETICS
LA English
DT Article; Retracted Publication
DE Differentially expressed genes; Hormone stimulus; Pathway enrichment
   analysis; Prostate cancer; Protein-protein interaction
ID PROTEIN REFERENCE DATABASE; GROWTH-FACTOR-BETA; DISCOVERY; CELLS;
   3-KINASES; NETWORKS; SYSTEM; NKX3.1; RISK
AB Prostate cancer (PC) depends on androgenic signaling for growth and survival. To data, the exact molecular mechanism of hormone controlling proliferation and tumorigenesis in the PC remains unclear. Therefore, in this study, we explored the differentially expressed genes (DEGs) and identified featured genes related to hormone stimulus from PC. Two sets of gene expression data, including PC and normal control sample, were downloaded from Gene Expression Omnibus (GEO) database. The t-test was used to identify DEGs between PC and controls. Gene ontology (GO) functional annotation was applied to analyze the function of DEGs and screen hormone-related DEGs. Then these hormone-related DEGs were further analyzed in constructed cancer network and Human Protein Reference Database to screen important signaling pathways they participated in. A total of 912 DEGs were obtained which included 326 up-regulated genes and 586 down-regulated genes. GO functional enrichment analysis identified 50 hormone-related DEGs associated with PC. After pathway and PPI network analysis, we found these hormone-related DEGs participated in several important signaling pathways including TGF-beta (TGFB2, TGFB3 and TGFBR2), MAPK (TGFB2, TGFB3 and TGFBR2), insulin (PIK3R3, SHC1 and EIF4EBP1), and p53 signaling pathways (CCND2 and CDKN1A). In addition, a total of five hormone-related DEGs (SHC1, CAV1, RXRA, CDKN1A and SRF) were located in the center of PPI network and 12 hormone-related DEGs formed six protein modules. These important signal pathways and hormone-related DEGs may provide potential therapeutic targets for PC.
C1 [Liu, Yi; Song, Hua] Gen Hosp Jinan Mil Command, Dept Urol, Jinan 250031, Peoples R China.
   [Pan, Jing] Jinan Municipal Ctr Dis Control & Prevent, Jinan 250021, Peoples R China.
   [Zhao, Jing] Shandong Univ, Jinan Cent Hosp, Dept Eurol, Jinan 250013, Peoples R China.
RP Song, H (reprint author), Gen Hosp Jinan Mil Command, Dept Urol, 25 Shifan Rd, Jinan 250031, Peoples R China.
EM songhua1937@hotmail.com
CR Adamcsek B, 2006, BIOINFORMATICS, V22, P1021, DOI 10.1093/bioinformatics/btl039
   Allen NE, 2007, CANCER EPIDEM BIOMAR, V16, P1121, DOI 10.1158/-1055-9965.EPI-06-1062
   Bakin RE, 2003, CANCER RES, V63, P1981
   BALK SP, 2008, NUCL RECEPT SIGNAL, V6
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723
   Boormans JL, 2008, INT J CANCER, V123, P2725, DOI 10.1002/ijc.23787
   Brown RA, 2001, BIOCHEM SOC T, V29, P535, DOI 10.1042/BST0290535
   Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008
   Chan June M, 2004, J Urol, V172, pS13, DOI 10.1097/01.ju.0000142068.66876.53
   Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64
   Chandran UR, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-45
   Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480
   Comstock CES, 2011, J BIOL CHEM, V286, P8117, DOI 10.1074/jbc.M110.170720
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0
   Eide T, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-4
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Goel R, 2011, MOL BIOTECHNOL, V48, P87, DOI 10.1007/s12033-010-9336-8
   Gordon KJ, 2008, BBA-MOL BASIS DIS, V1782, P197, DOI 10.1016/j.bbadis.2008.01.006
   Gurel B, 2010, AM J SURG PATHOL, V34, P1097, DOI 10.1097/PAS.0b013e3181e6cbf3
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Hulsegge Ina, 2009, BMC Proc, V3 Suppl 4, pS10, DOI 10.1186/1753-6561-3-S4-S10
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928
   Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002
   Koutros S, 2010, CANCER RES, V70, P2389, DOI 10.1158/0008-5472.CAN-09-3575
   LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9
   Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001
   Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Palla G, 2005, NATURE, V435, P814, DOI 10.1038/nature03607
   Pechlivanis S, 2007, ENDOCR-RELAT CANCER, V14, P733, DOI 10.1677/ERC-07-0107
   Peri S, 2004, NUCLEIC ACIDS RES, V32, pD497, DOI 10.1093/nar/gkh070
   Petrylak Daniel P, 2007, Rev Urol, V9 Suppl 2, pS3
   Petrylak DP, 2005, UROLOGY, V65, P3, DOI 10.1016/j.urology.2005.03.053
   Prasad TSK, 2009, METHODS MOL BIOL, V577, P67, DOI 10.1007/978-1-60761-232-2_6
   Prescott JL, 1998, PROSTATE, V35, P71, DOI 10.1002/(SICI)1097-0045(19980401)35:1<71::AID-PROS10>3.0.CO;2-H
   Santibanez JF, 2011, CLIN SCI, V121, P233, DOI 10.1042/CS20110086
   Shen M, 2008, COLD SPRING HARBOR S
   Soulitzis N, 2006, INT J ONCOL, V29, P305
   Wang Y, 2005, ASIAN J ANDROL, V7, P375, DOI 10.1111/j.1745-7262.2005.00031.x
   [项荣 Xiang Rong], 2012, [肿瘤, Tumor], V32, P1035
   Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158
   Zhu B, 2005, CANC TREAT, V126, P157, DOI 10.1007/0-387-24361-5_7
NR 47
TC 5
Z9 5
U1 3
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1234-1983
EI 2190-3883
J9 J APPL GENET
JI J. Appl. Genetics
PD FEB
PY 2014
VL 55
IS 1
BP 117
EP 124
DI 10.1007/s13353-013-0174-9
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AA6GX
UT WOS:000331197900011
PM 24154878
DA 2018-12-27
ER

PT J
AU Li, XJ
   Guo, CJ
   Gu, JT
   Duan, WW
   Zhao, M
   Ma, CY
   Du, XM
   Lu, WJ
   Xiao, K
AF Li, Xiaojuan
   Guo, Chengjin
   Gu, Juntao
   Duan, Weiwei
   Zhao, Miao
   Ma, Chunying
   Du, Xiaoming
   Lu, Wenjing
   Xiao, Kai
TI RETRACTED: Overexpression of VP, a vacuolar H-pyrophosphatase gene in
   wheat (Triticum aestivum L.), improves tobacco plant growth under Pi and
   N deprivation, high salinity, and drought (Retracted article. See vol.
   67, pg. 2913, 2016)
SO JOURNAL OF EXPERIMENTAL BOTANY
LA English
DT Article; Retracted Publication
DE Abiotic stresses; gene expression; physiological and biochemical
   property; plant growth; transgene analysis; vacuolar H-pyrophosphatase
ID PHOSPHATE TRANSPORTER GENE; NITRATE TRANSPORTER; SALT TOLERANCE;
   ARABIDOPSIS-THALIANA; WATER-STRESS; MOLECULAR CHARACTERIZATION;
   FUNCTIONAL-ANALYSIS; LIPID-PEROXIDATION; ROOT-GROWTH; MAJOR ROLE
AB Establishing crop cultivars with strong tolerance to P and N deprivation, high salinity, and drought is an effective way to improve crop yield and promote sustainable agriculture worldwide. A vacuolar H-pyrophosphatase (V-H-PPase) gene in wheat (TaVP) was functionally characterized in this study. TaVP cDNA is 2586-bp long and encodes a 775-amino-acid polypeptide that contains 10 conserved membrane-spanning domains. Transcription of TaVP was upregulated by inorganic phosphate (Pi) and N deprivation, high salinity, and drought. Transgene analysis revealed that TaVP overexpression improved plant growth under normal conditions and specifically under Pi and N deprivation stresses, high salinity, and drought. The improvement of growth of the transgenic plants was found to be closely related to elevated V-H-PPase activities in their tonoplasts and enlarged root systems, which possibly resulted from elevated expression of auxin transport-associated genes. TaVP-overexpressing plants showed high dry mass, photosynthetic efficiencies, antioxidant enzyme activities, and P, N, and soluble carbohydrate concentrations under various growth conditions, particularly under the stress conditions. The transcription of phosphate and nitrate transporter genes was not altered in TaVP-overexpressing plants compared with the wild type, suggesting that high P and N concentrations regulated by TaVP were caused by increased root absorption area instead of alteration of Pi and NO3 acquisition kinetics. TaVP is important in the tolerance of multiple stresses and can serve as a useful genetic resource to improve plant P- and N-use efficiencies and to increase tolerance to high salinity and drought.
C1 [Li, Xiaojuan; Guo, Chengjin; Duan, Weiwei; Ma, Chunying; Xiao, Kai] Agr Univ Hebei, Coll Agron, Baoding 071001, Peoples R China.
   [Gu, Juntao; Lu, Wenjing] Agr Univ Hebei, Coll Life Sci, Baoding 071001, Peoples R China.
   [Zhao, Miao] North China Elect Power Univ, Coll Sci & Technol, Baoding 071051, Peoples R China.
RP Lu, WJ (reprint author), Agr Univ Hebei, Coll Life Sci, Baoding 071001, Peoples R China.
EM luwenjing@sohu.com; xiaokai@hebau.edu.cn
FU National Natural Science Foundation of China [31371618, 31201674];
   National Transgenic Major Program [2011ZX08008]; Key Laboratory of Crop
   Growth Regulation of Hebei Province
FX This work was supported by the National Natural Science Foundation of
   China (grant nos. 31371618 and 31201674), the National Transgenic Major
   Program (grant no. 2011ZX08008), and the Key Laboratory of Crop Growth
   Regulation of Hebei Province. The authors thank two anonymous reviewers
   whose detailed comments helped to improve the manuscript.
CR Ai PH, 2009, PLANT J, V57, P798, DOI 10.1111/j.1365-313X.2008.03726.x
   Amiour N, 2012, J EXP BOT, V63, P5017, DOI 10.1093/jxb/ers186
   Atkinson NJ, 2013, PLANT PHYSIOL, V162, P2028, DOI 10.1104/pp.113.222372
   Bartels D, 2005, CRIT REV PLANT SCI, V24, P23, DOI 10.1080/07352680590910410
   BOHNERT HJ, 1995, PLANT CELL, V7, P1099, DOI 10.1105/tpc.7.7.1099
   Bray EA, 2000, BIOCH MOL BIOL PLANT, P1159
   Brini F, 2007, J EXP BOT, V58, P301, DOI 10.1093/jxb/erl251
   Chaves MM, 2002, ANN BOT-LONDON, V89, P907, DOI 10.1093/aob/mcf105
   Chen AQ, 2007, NEW PHYTOL, V173, P817, DOI 10.1111/j.1469-8137.2006.01962.x
   Corpas FJ, 1999, FREE RADICAL RES, V31, pS235
   Dechorgnat J, 2011, J EXP BOT, V62, P1349, DOI 10.1093/jxb/erq409
   DEMICHELIS MI, 1986, PLANT PHYSIOL, V81, P542, DOI 10.1104/pp.81.2.542
   Filleur S, 2001, FEBS LETT, V489, P220, DOI 10.1016/S0014-5793(01)02096-8
   Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480
   Gaxiola RA, 2001, P NATL ACAD SCI USA, V98, P11444, DOI 10.1073/pnas.191389398
   Gaxiola RA, 2012, PLANT PHYSIOL, V159, P3, DOI 10.1104/pp.112.195701
   Golldack D, 2001, PLANT PHYSIOL, V125, P1643, DOI 10.1104/pp.125.4.1643
   Guo CJ, 2013, PLANTA, V237, P1163, DOI 10.1007/s00425-012-1836-2
   Guo ChengJin, 2011, Frontiers of Agriculture in China, V5, P253, DOI 10.1007/s11703-011-1069-3
   Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463
   Hernandez JA, 2000, PLANT CELL ENVIRON, V23, P853, DOI 10.1046/j.1365-3040.2000.00602.x
   Huang NC, 1999, PLANT CELL, V11, P1381, DOI 10.1105/tpc.11.8.1381
   Huang XS, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-230
   Kim J, 2012, J EXP BOT, V63, P6335, DOI 10.1093/jxb/ers285
   Li B, 2008, PLANT BIOTECHNOL J, V6, P146, DOI 10.1111/j.1467-7652.2007.00301.x
   Li JS, 2005, SCIENCE, V310, P121, DOI 10.1126/science.1115711
   Li RJ, 2012, J INTEGR AGR, V11, P1217, DOI 10.1016/S2095-3119(12)60118-X
   Li WB, 2007, PLANT PHYSIOL, V143, P425, DOI 10.1104/pp.106.091223
   Liang YC, 2003, J PLANT PHYSIOL, V160, P1157, DOI 10.1078/0176-1617-01065
   LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6
   Liu F, 2010, PLANT J, V62, P508, DOI 10.1111/j.1365-313X.2010.04170.x
   Liu XM, 2013, FUNCT PLANT BIOL, V40, P329, DOI 10.1071/FP12242
   Luttge U, 1997, ADV BOT RES, V25, P253, DOI 10.1016/S0065-2296(08)60155-X
   Lv SL, 2009, PLANTA, V229, P899, DOI 10.1007/s00425-008-0880-4
   Lv S, 2008, PLANT CELL PHYSIOL, V49, P1150, DOI 10.1093/pcp/pcn090
   Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9
   Marty F, 1999, PLANT CELL, V11, P587
   McNeil SD, 1999, PLANT PHYSIOL, V120, P945, DOI 10.1104/pp.120.4.945
   Misson J, 2004, PLANT MOL BIOL, V55, P727, DOI 10.1007/s11103-004-1965-5
   MUSICK G. J., 1965, CROP SCI, V5, P601
   Nussaume L, 2011, FRONT PLANT SCI, V2, DOI 10.3389/fpls.2011.00083
   Ober ES, 2003, J EXP BOT, V54, P813, DOI 10.1093/jxb/erg060
   Oropeza-Aburto A, 2012, J EXP BOT, V63, P2189, DOI 10.1093/jxb/err446
   Orsel M, 2004, PLANTA, V219, P714, DOI 10.1007/s00425-004-1266-x
   OTTER T, 1994, PLANT CELL PHYSIOL, V35, P1231, DOI 10.1093/oxfordjournals.pcp.a078717
   Park S, 2005, P NATL ACAD SCI USA, V102, P18830, DOI 10.1073/pnas.0509512102
   PEEVER TL, 1989, PLANT PHYSIOL, V90, P867, DOI 10.1104/pp.90.3.867
   Pei LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043501
   Pinheiro HA, 2005, ANN BOT-LONDON, V96, P101, DOI 10.1093/aob/mci154
   SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775
   Scandalios J.G., 1997, OXIDATIVE STRESS MOL, P527
   Shalata A, 2001, PHYSIOL PLANTARUM, V112, P487, DOI 10.1034/j.1399-3054.2001.1120405.x
   Sharp RE, 2004, J EXP BOT, V55, P2343, DOI 10.1093/jxb/erh276
   Sharp RE, 2002, J EXP BOT, V53, P33, DOI 10.1093/jexbot/53.366.33
   Shavrukov Y, 2013, J EXP BOT, V64, P119, DOI 10.1093/jxb/ers316
   Shi J, 2010, TREE PHYSIOL, V30, P914, DOI 10.1093/treephys/tpq030
   Shin H, 2004, PLANT J, V39, P629, DOI 10.1111/j.1365-313X.2004.02161.x
   Silva FCE, 2004, TREE PHYSIOL, V24, P1165, DOI 10.1093/treephys/24.10.1165
   Smart LB, 1998, PLANT PHYSIOL, V116, P1539, DOI 10.1104/pp.116.4.1539
   SONNEWALD U, 1992, PLANT J, V2, P571
   Sun ZH, 2012, J INTEGR AGR, V11, P31, DOI 10.1016/S1671-2927(12)60780-9
   Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677
   TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B
   Tschaplinski TJ, 1998, TREE PHYSIOL, V18, P653
   Wang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065120
   Wang HH, 2007, PLANT MOL BIOL, V65, P799, DOI 10.1007/s11103-007-9244-x
   Wang RC, 1998, P NATL ACAD SCI USA, V95, P15134, DOI 10.1073/pnas.95.25.15134
   Xiang Y, 2007, PLANT PHYSIOL, V144, P1416, DOI 10.1104/pp.107.101295
   Xie YJ, 2013, J EXP BOT, V64, P3045, DOI 10.1093/jxb/ert149
   Yang H, 2007, PLANT BIOTECHNOL J, V5, P735, DOI 10.1111/j.1467-7652.2007.00281.x
   Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621
   Yu XQ, 2013, J EXP BOT, V64, P1537, DOI 10.1093/jxb/ert018
   Zhang H, 2011, PLANT SIGNAL BEHAV, V6, P861, DOI 10.4161/psb.6.6.15223
   Zhen RG, 1997, ADV BOT RES, V25, P298
NR 74
TC 34
Z9 41
U1 3
U2 64
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-0957
EI 1460-2431
J9 J EXP BOT
JI J. Exp. Bot.
PD FEB
PY 2014
VL 65
IS 2
BP 683
EP 696
DI 10.1093/jxb/ert442
PG 14
WC Plant Sciences
SC Plant Sciences
GA AA5EQ
UT WOS:000331119300025
PM 24474810
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Bao, H
   Wang, JM
   Zhou, D
   Han, ZY
   Su, L
   Zhang, Y
   Ye, X
   Xu, CY
   Wang, YP
   Li, QH
AF Bao, Hong
   Wang, Jiaman
   Zhou, Ding
   Han, Zhaoyong
   Su, Ling
   Zhang, Yuan
   Ye, Xiong
   Xu, Chunyan
   Wang, Yuping
   Li, Qinghua
TI RETRACTED: Protein-Protein Interaction Network Analysis in Chronic
   Obstructive Pulmonary Disease (Retracted article. See vol. 193, pg. 869,
   2015)
SO LUNG
LA English
DT Article; Retracted Publication
DE Differentially expressed genes (DEGs); Protein-protein interaction;
   Connectivity map; COPD
ID HISTONE DEACETYLASE ACTIVITY; CANCER CELL-GROWTH; INTERFERON-ALPHA;
   SMALL MOLECULES; COPD PATIENTS; OLDER-ADULTS; EXPRESSION; GENES; GAMMA;
   DISULFIRAM
AB The aim of this study was to investigate the gene expression profile of chronic obstructive pulmonary disease (COPD) patients and non-COPD patients.
   Microarray raw data (GSE29133) was downloaded from Gene Expression Omnibus, including three COPD samples and three normal controls. Gene expression profiling was performed using Affymetrix human genome u133 plus 2.0 GeneChip. Differentially expressed genes were identified by Student's t test and genes with p < 0.05 were considered significantly changed. Up- and downregulated genes were submitted to the molecular signatures database (MSigDB) to search for a possible association with other previously published gene expression signatures. Furthermore, we constructed a COPD protein-protein interaction (PPI) network and used the connectivity map (cMap) to query for potential drugs for COPD.
   A total of 680 upregulated genes and 530 downregulated genes in COPD were identified. The MSigDB investigation found that upregulated genes were highly similar to gene signatures that respond to interferon and downregulated genes were similar to erythroid progenitor cells from fetal livers of E13.5 embryos with KLF1 knocked out. A PPI network consisting of 814 gene/proteins and 2,613 interactions was identified by Search Tool for the Retrieval of Interacting Genes. The cMap predicted helveticoside, disulfiram, and lanatoside C as the top three possible drugs that could perhaps treat COPD.
   Comprehensive analysis of the gene expression profile for COPD versus control reveals helveticoside, disulfiram, and lanatoside C as potential molecular targets in COPD. This evidence provides a new breakthrough in the medical treatment of patients with COPD.
C1 [Bao, Hong; Wang, Jiaman; Zhou, Ding; Han, Zhaoyong; Su, Ling; Zhang, Yuan; Ye, Xiong; Xu, Chunyan; Wang, Yuping; Li, Qinghua] Fudan Univ, Shanghai Pudong Hosp, Pudong Med Ctr, Dept Resp Med, Shanghai 201399, Peoples R China.
RP Li, QH (reprint author), Fudan Univ, Shanghai Pudong Hosp, Pudong Med Ctr, Dept Resp Med, 2800 Gongwei Rd, Shanghai 201399, Peoples R China.
EM liqinghua123456@hotmail.com
CR Abramson M, 2002, RESPIROLOGY, V7, P325, DOI 10.1046/j.1440-1843.2002.00408.x
   Badr CE, 2011, NEURO-ONCOLOGY, V13, P1213, DOI 10.1093/neuonc/nor067
   Bakke PS, 2011, EUR RESPIR J, V37, P255, DOI 10.1183/09031936.00091709
   Barnes PJ, 2009, ANNU REV PHYSIOL, V71, P451, DOI 10.1146/annurev.physiol.010908.163257
   Barnes PJ, 2002, NAT REV DRUG DISCOV, V1, P437, DOI 10.1038/nrd820
   Berndt A, 2012, EMBO MOL MED, V4, P1144, DOI 10.1002/emmm.201100627
   Cantu E, 2013, J HEART LUNG TRANSPL, V32, pS41, DOI 10.1016/j.healun.2013.01.908
   Chen Y, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-10
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623
   Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575
   Fujino N, 2012, BMJ OPEN, DOI [10.1136/bmjopen-2012-001553, DOI 10.1136/BMJ0PEN-2012-001553]
   Gaajetaan GR, 2013, J INFECTION, V66, P163, DOI 10.1016/j.jinf.2012.11.008
   Gan WQ, 2004, THORAX, V59, P574, DOI 10.1136/thx.2003.019588
   Hammond T, 2012, CHRONIC OBSTRUCTIVE
   Holownia A, 2013, ADV EXP MED BIOL, V788, P1, DOI [10.1007/978-94-007-4549-0_2, 10.1007/978-94-007-6627-3_1]
   Iljin K, 2009, CLIN CANCER RES, V15, P6070, DOI 10.1158/1078-0432.CCR-09-1035
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lee YJ, 2013, ARCH PHARM RES, V36, P536, DOI 10.1007/s12272-013-0066-x
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Lin JQ, 2011, PROSTATE, V71, P333, DOI 10.1002/pros.21247
   MacNee William, 2005, Proc Am Thorac Soc, V2, P258, DOI 10.1513/pats.200504-045SR
   Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
   Mallia P, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-116
   Murphy TF, 2002, DRUG AGING, V19, P761, DOI 10.2165/00002512-200219100-00005
   Nazir SA, 2009, DRUG AGING, V26, P813, DOI 10.2165/11316760-000000000-00000
   Ning W, 2004, P NATL ACAD SCI USA, V101, P14895, DOI 10.1073/pnas.0401168101
   Petty Thomas L, 2003, Clin Cornerstone, V5, P1, DOI 10.1016/S1098-3597(03)90003-2
   Pilon AM, 2008, MOL CELL BIOL, V28, P7394, DOI 10.1128/MCB.01087-08
   Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO
   Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388
   Richens TR, 2009, AM J RESP CRIT CARE, V179, P1011, DOI 10.1164/rccm.200807-1148OC
   Sana TR, 2005, CYTOKINE, V29, P256, DOI 10.1016/j.cyto.2004.11.003
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Southworth T, 2012, BRIT J PHARMACOL, V166, P2070, DOI 10.1111/j.1476-5381.2012.01907.x
   Storck EM, 2013, VASC PHARMACOL, V58, P202, DOI 10.1016/j.vph.2012.09.004
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Wang Q, 2009, J IMMUNOL, V183, P6989, DOI 10.4049/jimmunol.0901386
NR 40
TC 5
Z9 5
U1 5
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
EI 1432-1750
J9 LUNG
JI Lung
PD FEB
PY 2014
VL 192
IS 1
BP 87
EP 93
DI 10.1007/s00408-013-9509-x
PG 7
WC Respiratory System
SC Respiratory System
GA AA2XR
UT WOS:000330958000027
PM 24241792
DA 2018-12-27
ER

PT J
AU Yang, XH
   Uddin, A
AF Yang, Xiaohan
   Uddin, Ashraf
TI RETRACTED: Effect of thermal annealing on P3HT:PCBM bulk-heterojunction
   organic solar cells: A critical review (Retracted article. See vol. 43,
   pg. 1468, 2015)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE Organic solar cell; Thermal annealing; Physical film property;
   Electronic performance; Balancing
ID OPEN-CIRCUIT VOLTAGE; TO-ROLL FABRICATION; POLYMER PHOTOVOLTAIC CELLS;
   HIGH-EFFICIENCY; IMPEDANCE SPECTROSCOPY; CONVERSION EFFICIENCY;
   SELF-ORGANIZATION; CHARGE-TRANSPORT; BANDGAP POLYMER; FULLERENE
AB The main focus of this review article is to introduce the reader to the advantage and limitation of organic solar cells and to understand how the thermal annealing process could improve performance of organic solar cells. The article explores the operation principles of organic photovoltaic (OPV) device and reviews the effects of thermal annealing on bulk-heterojunction organic solar cells based on a thin film blend of poly (3-hexylthiophene-2,5 diyl) (P3HT) and [6,6]-phenyl-C-61 butyric acid methyl ester (PCBM). It focuses on changes in the physical film properties, the electronic performance of devices, as well as the link between film structure and electronic performance during a thermal annealing process. Analysis of film and electrical characteristics, as a function of thermal annealing parameters, indicates that a balancing is established. The balancing between charge conduction and excitonic dissociation leads to the establishment of optimal annealing conditions for maximized electronic performance. Additionally, the report highlights research areas that require attention for future development of this technology. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Yang, Xiaohan; Uddin, Ashraf] Univ New S Wales, Sch Photovolta & Renewable Energy Engn, Sydney, NSW 2052, Australia.
RP Yang, XH (reprint author), Univ New S Wales, Sch Photovolta & Renewable Energy Engn, Sydney, NSW 2052, Australia.
EM xiaohan.yang@unsw.edu.au
FU Australian Government through the Australian Renewable Energy Agency
   (ARENA)
FX This program has been supported by the Australian Government through the
   Australian Renewable Energy Agency (ARENA). Responsibility for the
   views, information or advice expressed herein is not accepted by the
   Australian Government. The authors would like to thank the Australian
   Centre for Advanced Photovoltaics, UNSW staff and technicians for their
   support. We are also grateful to all of our OPV group members for useful
   discussions and support during this work.
CR Agostinelli T, 2011, ADV FUNCT MATER, V21, P1701, DOI 10.1002/adfm.201002076
   Ahmad J, 2013, RENEW SUST ENERG REV, V27, P104, DOI 10.1016/j.rser.2013.06.027
   Ameri T, 2013, ADV MATER, V25, P4245, DOI 10.1002/adma.201300623
   Ameri T, 2013, ENERG ENVIRON SCI, V6, P2390, DOI 10.1039/c3ee40388b
   Arlauskas A, 2010, J NANOSCI NANOTECHNO, V10, P1376
   Bavel S. S. v., 2008, NANO LETT, V9, P507
   Bertho S, 2007, SOL ENERG MAT SOL C, V91, P385, DOI 10.1016/j.solmat.2006.10.008
   Brabec CJ, 2010, ADV MATER, V22, P3839, DOI 10.1002/adma.200903697
   Brabec CJ, 2002, APPL PHYS LETT, V80, P1288, DOI 10.1063/1.1446988
   Brabec CJ, 2001, ADV FUNCT MATER, V11, P374, DOI 10.1002/1616-3028(200110)11:5<374::AID-ADFM374>3.0.CO;2-W
   Brabec CJ, 2004, SOL ENERG MAT SOL C, V83, P273, DOI 10.1016/j.solmat.2004.02.030
   Bull TA, 2009, ACS NANO, V3, P627, DOI 10.1021/nn800878c
   Bundgaard E, 2007, SOL ENERG MAT SOL C, V91, P1631, DOI 10.1016/j.solmat.2007.05.013
   Bundgaard E, 2007, SOL ENERG MAT SOL C, V91, P954, DOI 10.1016/j.solmat.2007.01.015
   Cai WZ, 2010, SOL ENERG MAT SOL C, V94, P114, DOI 10.1016/j.solmat.2009.10.005
   Campoy-Quiles M, 2008, NAT MATER, V7, P158, DOI 10.1038/nmat2102
   Chang LL, 2011, ADV FUNCT MATER, V21, P1779, DOI 10.1002/adfm.201002372
   Chen FC, 2010, SOL ENERG MAT SOL C, V94, P2426, DOI 10.1016/j.solmat.2010.09.004
   Chen HY, 2009, NAT PHOTONICS, V3, P649, DOI 10.1038/NPHOTON.2009.192
   Chen J, 2007, APPL PHYS LETT, V90
   Chirvase D, 2004, NANOTECHNOLOGY, V15, P1317, DOI 10.1088/0957-4484/15/9/035
   Dante M, 2008, J PHYS CHEM C, V112, P7241, DOI 10.1021/jp712086q
   Dennler G, 2009, ADV MATER, V21, P1323, DOI 10.1002/adma.200801283
   Dou LT, 2012, NAT PHOTONICS, V6, P180, DOI [10.1038/NPHOTON.2011.356, 10.1038/nphoton.2011.356]
   Erb T, 2005, ADV FUNCT MATER, V15, P1193, DOI 10.1002/adfm.200400521
   Espinosa N, 2013, J MATER CHEM A, V1, P7037, DOI 10.1039/c3ta01611k
   Facchetti A., 2010, CHEM MATER, V23, P733
   Garcia-Belmonte G, 2008, ORG ELECTRON, V9, P847, DOI 10.1016/j.orgel.2008.06.007
   Green MA, 2013, PROG PHOTOVOLTAICS, V21, P827, DOI 10.1002/pip.2404
   Green MA, 2012, PROG PHOTOVOLTAICS, V20, P12, DOI 10.1002/pip.2163
   Gregg BA, 2003, J APPL PHYS, V93, P3605, DOI 10.1063/1.1544413
   Guo TF, 2008, THIN SOLID FILMS, V516, P3138, DOI 10.1016/j.tsf.2007.08.066
   Gupta D, 2010, SOL ENERG MAT SOL C, V94, P1309, DOI 10.1016/j.solmat.2008.06.001
   He ZC, 2012, NAT PHOTONICS, V6, P591, DOI [10.1038/NPHOTON.2012.190, 10.1038/nphoton.2012.190]
   Hou JH, 2009, J AM CHEM SOC, V131, P15586, DOI 10.1021/ja9064975
   Hou JH, 2009, J PHYS CHEM C, V113, P1601, DOI 10.1021/jp808255b
   HUMMELEN JC, 1995, J ORG CHEM, V60, P532, DOI 10.1021/jo00108a012
   Jorgensen M, 2012, ADV MATER, V24, P580, DOI 10.1002/adma.201104187
   Kim H, 2007, SOL ENERG MAT SOL C, V91, P581, DOI 10.1016/j.solmat.2006.11.010
   Kim H, 2009, J PHYS CHEM C, V113, P1620, DOI 10.1021/jp809589n
   Kim JS, 2011, ADV FUNCT MATER, V21, P480, DOI 10.1002/adfm.201000971
   Kim JY, 2013, J NANOSCI NANOTECHNO, V13, P3360, DOI 10.1166/jnn.2013.7262
   KIM K, 2007, APPL PHYS LETT, V90
   Kim MH, 2010, J NANOSCI NANOTECHNO, V10, P279, DOI 10.1166/jnn.2010.1489
   Kim SO, 2011, SOL ENERG MAT SOL C, V95, P432, DOI 10.1016/j.solmat.2010.08.009
   Kim Y, 2006, NAT MATER, V5, P197, DOI 10.1038/nmat1574
   Kim Y, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1861123
   Kim Y, 2009, ORG ELECTRON, V10, P205, DOI 10.1016/j.orgel.2008.10.003
   Kirchartz T, 2009, J PHYS CHEM C, V113, P17958, DOI 10.1021/jp906292h
   Kong H, 2009, APPL PHYS LETT, V95
   Krebs FC, 2011, ENERG ENVIRON SCI, V4, P4116, DOI 10.1039/c1ee01891d
   Krebs FC, 2010, NANOSCALE, V2, P873, DOI 10.1039/b9nr00430k
   Krebs FC, 2010, ENERG ENVIRON SCI, V3, P512, DOI 10.1039/b918441d
   Krebs FC, 2009, SOL ENERG MAT SOL C, V93, P1636, DOI 10.1016/j.solmat.2009.04.020
   Krebs FC, 2009, SOL ENERG MAT SOL C, V93, P422, DOI 10.1016/j.solmat.2008.12.001
   Krebs FC, 2009, SOL ENERG MAT SOL C, V93, P394, DOI 10.1016/j.solmat.2008.10.004
   Krishnamoorthy T, 2011, ENERG ENVIRON SCI, V4, P2807, DOI 10.1039/c1ee01315g
   Li G, 2005, NAT MATER, V4, P864, DOI 10.1038/nmat1500
   Li G, 2012, NAT PHOTONICS, V6, P153, DOI [10.1038/nphoton.2012.11, 10.1038/NPHOTON.2012.11]
   Li WW, 2013, ADV MATER, V25, P3182, DOI 10.1002/adma.201300017
   Ma WL, 2005, ADV FUNCT MATER, V15, P1617, DOI 10.1002/adfm.200500211
   Marks TJ, 2009, APPL PHYS LETT, V95
   Mihailetchi VD, 2006, ADV FUNCT MATER, V16, P699, DOI 10.1002/adfm.200500420
   Mor GK, 2007, APPL PHYS LETT, V91
   Motaung DE, 2009, SOL ENERG MAT SOL C, V93, P1674, DOI 10.1016/j.solmat.2009.05.016
   Moule AJ, 2008, ADV MATER, V20, P240, DOI 10.1002/adma.200701519
   Norrman K, 2010, J AM CHEM SOC, V132, P16883, DOI 10.1021/ja106299g
   Oklobia O, 2013, SOL ENERG MAT SOL C, V117, P1, DOI 10.1016/j.solmat.2013.05.011
   Oklobia O, 2013, SOLID STATE ELECTRON, V87, P64, DOI 10.1016/j.sse.2013.05.005
   Padinger F, 2003, ADV FUNCT MATER, V13, P85, DOI 10.1002/adfm.200390011
   Park SH, 2009, NAT PHOTONICS, V3, P297, DOI 10.1038/NPHOTON.2009.69
   Pearson AJ, 2012, MACROMOLECULES, V45, P1499, DOI 10.1021/ma202063k
   Potscavage WJ, 2009, ACCOUNTS CHEM RES, V42, P1758, DOI 10.1021/ar900139v
   Reyes-Reyes M, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2006986
   Rohr S, 2013, HELIATEK CONSOLIDATE
   Ryu MS, 2010, CURR APPL PHYS, V10, pS206, DOI 10.1016/j.cap.2009.11.070
   SARICIFTCI NS, 1992, SCIENCE, V258, P1474, DOI 10.1126/science.258.5087.1474
   Saunders BR, 2011, J COLLOID INTERF SCI, V369, P1
   Scharber MC, 2006, ADV MATER, V18, P789, DOI 10.1002/adma.200501717
   Schilinsky P, 2005, CHEM MATER, V17, P2175, DOI 10.1021/cm047811c
   Schumann S, 2011, J MATER CHEM, V21, P2381, DOI 10.1039/c0jm03048a
   Sondergaard R, 2012, MATER TODAY, V15, P36, DOI 10.1016/S1369-7021(12)70019-6
   Sondergaard RR, 2013, J POLYM SCI POL PHYS, V51, P16, DOI 10.1002/polb.23192
   TANG CW, 1987, APPL PHYS LETT, V51, P913, DOI 10.1063/1.98799
   TANG CW, 1986, APPL PHYS LETT, V48, P183, DOI 10.1063/1.96937
   Wang T, 2011, ADV FUNCT MATER, V21, P1383, DOI 10.1002/adfm.201002300
   Wienk MM, 2003, ANGEW CHEM INT EDIT, V42, P3371, DOI 10.1002/anie.200351647
   Wright M, 2012, SOL ENERG MAT SOL C, V107, P87, DOI 10.1016/j.solmat.2012.07.006
   YABLONOVITCH E, 1982, J OPT SOC AM, V72, P899, DOI 10.1364/JOSA.72.000899
   Yamanari T, 2009, SOL ENERG MAT SOL C, V93, P759, DOI 10.1016/j.solmat.2008.09.022
   Yang XN, 2005, NANO LETT, V5, P579, DOI 10.1021/nl048120i
   Yin B, 2010, J NANOSCI NANOTECHNO, V10, P1934, DOI 10.1166/jnn.2010.2107
   Yip HL, 2012, ENERG ENVIRON SCI, V5, P5994, DOI 10.1039/c2ee02806a
   YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789
   Zeng LC, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3474654
   Zhang CF, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3093831
   Zhao JH, 1999, PROG PHOTOVOLTAICS, V7, P471, DOI 10.1002/(SICI)1099-159X(199911/12)7:6<471::AID-PIP298>3.0.CO;2-7
   Zhokhavets U, 2006, CHEM PHYS LETT, V418, P347, DOI 10.1016/j.cplett.2005.11.020
   Zhou N, 2013, NAT PHOTONICS
   Zuo LJ, 2011, SOL ENERG MAT SOL C, V95, P2664, DOI 10.1016/j.solmat.2011.05.038
NR 100
TC 46
Z9 47
U1 7
U2 229
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD FEB
PY 2014
VL 30
BP 324
EP 336
DI 10.1016/j.rser.2013.10.025
PG 13
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA AA9OC
UT WOS:000331421800025
DA 2018-12-27
ER

PT J
AU Chernecky, CC
   Macklin, D
   Jarvis, WR
   Joshua, TV
AF Chernecky, Cynthia C.
   Macklin, Denise
   Jarvis, William R.
   Joshua, Thomas V.
TI RETRACTED: Comparison of central line-associated bloodstream infection
   rates when changing to a zero fluid displacement intravenous needleless
   connector in acute care settings (Retracted article. See vol. 44, 2016)
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article; Retracted Publication
DE CLABSI; Positive pressure; Negative pressure; Neutral; Split septum;
   Comparative effectiveness; Mechanical valve
ID VALVE
AB Thiswas a multicenter, quasiexperimental, 140-month, acute care study comparing central line-associated bloodstream infection rates associated with positive or negative intravenous connectors to a zero fluid displacement connector. A decrease in central line-associated bloodstream infections was found after changing from either negative or positive intravenous connectors to the zero fluid displacement connector (P = .004) with total cost savings of over $3 million. Copyright (C) 2014 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Chernecky, Cynthia C.; Joshua, Thomas V.] Georgia Regents Univ, Augusta, GA 30912 USA.
   [Macklin, Denise] Nurse Consultant, Marietta, GA USA.
   [Jarvis, William R.] Jason & Jarvis Associates LLC, Hilton Head Isl, SC USA.
RP Chernecky, CC (reprint author), Georgia Regents Univ, 987 St Sebastian Way,EC 5440, Augusta, GA 30912 USA.
EM cchernecky@gru.edu
CR Chernecky C, 2013, J ASS VASCULAR ACCES, V18, P169
   Chernecky C, 2011, J ADV NURS, V67, P1601, DOI 10.1111/j.1365-2648.2010.05598.x
   Jarvis W, 2010, INFECT CONTROL TODAY, V14, P30
   Jarvis WR, 2009, CLIN INFECT DIS, V49, P1821, DOI 10.1086/648418
   Maragakis LL, 2006, INFECT CONT HOSP EP, V27, P67, DOI 10.1086/499166
   Mermel LA, 2009, INFECT CONT HOSP EP, V30, P403, DOI 10.1086/597203
   O'Grady NP, 2011, GUIDELINES PREVENTIO
   Rupp ME, 2007, CLIN INFECT DIS, V44, P1408, DOI 10.1086/517538
   Salgado CD, 2007, INFECT CONT HOSP EP, V28, P684, DOI 10.1086/516800
NR 9
TC 6
Z9 6
U1 2
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD FEB
PY 2014
VL 42
IS 2
BP 200
EP 202
DI 10.1016/j.ajic.2013.05.023
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AA2VO
UT WOS:000330952500027
PM 23973422
DA 2018-12-27
ER

PT J
AU Derosa, G
   Cicero, AFG
   Carbone, A
   Querci, F
   Fogari, E
   D'Angelo, A
   Maffioli, P
AF Derosa, Giuseppe
   Cicero, Arrigo F. G.
   Carbone, Anna
   Querci, Fabrizio
   Fogari, Elena
   D'Angelo, Angela
   Maffioli, Pamela
TI RETRACTED: Different Aspects of Sartan plus Calcium Antagonist
   Association Compared to the Single Therapy on Inflammation and Metabolic
   Parameters in Hypertensive Patients (Retracted article. See vol. 39, pg.
   502, 2016)
SO INFLAMMATION
LA English
DT Article; Retracted Publication
DE adiponectin; amlodipine; high sensitivity C-reactive protein; monocyte
   chemoattractant protein-1; olmesartan
ID AMERICAN-HEART-ASSOCIATION; TYPE-2 DIABETES-MELLITUS; REDUCING
   BLOOD-PRESSURE; COMBINATION THERAPY; INSULIN-RESISTANCE; ANKLE EDEMA;
   AMLODIPINE/HYDROCHLOROTHIAZIDE COMBINATION;
   OLMESARTAN/HYDROCHLOROTHIAZIDE COMBINATION; OLMESARTAN ADDITION;
   AMLODIPINE
AB This study aims to evaluate the effects of an angiotensin receptor blocker (ARB)/calcium channel blocker combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation markers. We randomized 276 hypertensive patients to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing an olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following: body weight, systolic and diastolic blood pressure, fasting plasma glucose, fasting plasma insulin (FPI), M value, lipid profile, adiponectin (ADN), high sensitivity C-reactive protein (Hs-CRP), monocyte chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor-1 beta (MIP-1 beta). Olmesartan/amlodipine combination better reduced blood pressure, FPI, homeostasis model assessment index, and increased M value and ADN compared to olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly decreased Hs-CRP, MCP-1, and MIP-1 beta. In this multicenter, randomized, double-blind, clinical study, ARB/calcium antagonist combination resulted to be more effective than single monotherapies in reducing blood pressure, in improving insulin sensitivity, and in reducing inflammation parameters in patients with stage I essential hypertension.
C1 [Derosa, Giuseppe; Fogari, Elena; D'Angelo, Angela; Maffioli, Pamela] Univ Pavia, Dept Internal Med & Therapeut, Fdn IRCCS Policlin S Matteo, I-27100 Pavia, Italy.
   [Derosa, Giuseppe] Univ Pavia, Ctr Study Endocrine Metab Pathophysiol & Clin Res, I-27100 Pavia, Italy.
   [Cicero, Arrigo F. G.] Univ Bologna, G Descovich Atherosclerosis Study Ctr, Bologna, Italy.
   [Carbone, Anna] Hosp Ctr Diabet, Lodi, Italy.
   [Querci, Fabrizio] Osped Pesenti Fenaroli, Bergamo, Italy.
RP Derosa, G (reprint author), Univ Pavia, Dept Internal Med & Therapeut, Fdn IRCCS Policlin S Matteo, Ple C Golgi 2, I-27100 Pavia, Italy.
EM giuseppe.derosa@unipv.it
OI Cicero, Arrigo/0000-0002-4367-3884; Derosa, Giuseppe/0000-0003-3573-4760
CR Aguilar M, 1999, DIABETIC MED, V16, P716
   Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0
   Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992
   Botti C, 2012, J BIOL REG HOMEOS AG, V26, P67
   Bouskila M, 2005, INT J OBESITY, V29, pS17, DOI 10.1038/sj.ijo.0802908
   Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17
   Chrysant SG, 2008, CLIN THER, V30, P587, DOI 10.1016/j.clinthera.2008.04.002
   de la Sierra A, 2013, J HYPERTENS, V31, pS13, DOI 10.1097/HJH.0b013e32835d2b05
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
   Derosa G, 2011, EXPERT OPIN DRUG SAF, V10, P795, DOI 10.1517/14740338.2011.585966
   Derosa G, 2010, HYPERTENS RES, V33, P790, DOI 10.1038/hr.2010.85
   Epstein BJ, 2007, DRUGS, V67, P1309, DOI 10.2165/00003495-200767090-00005
   FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605
   Fogari R, 2006, ADV THER, V23, P680, DOI 10.1007/BF02850307
   Fogari R, 2012, DIABETIC MED, V29, P24, DOI 10.1111/j.1464-5491.2011.03383.x
   Fogari R, 2008, INTERNAL MED, V47, P361, DOI 10.2169/internalmedicine.47.0449
   Fogari R, 2008, HYPERTENS RES, V31, P43, DOI 10.1291/hypres.31.43
   Fogari R, 2012, EXPERT OPIN PHARMACO, V13, P1091, DOI 10.1517/14656566.2012.683175
   Fogari R, 2012, EXPERT OPIN PHARMACO, V13, P629, DOI 10.1517/14656566.2012.667077
   Fogari R, 2012, EUR J GASTROEN HEPAT, V24, P164, DOI 10.1097/MEG.0b013e32834ba188
   Fogari R, 2011, EXPERT OPIN PHARMACO, V12, P2441, DOI 10.1517/14656566.2011.623698
   Fogari R, 2011, EXPERT OPIN PHARMACO, V12, P1351, DOI 10.1517/14656566.2011.580276
   Fogari R, 2010, ADV THER, V27, P48, DOI 10.1007/s12325-010-0002-0
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gerszten RE, 1999, NATURE, V398, P718
   Gradman AH, 2010, J AM SOC HYPERTENS, V4, P90, DOI 10.1016/j.jash.2010.03.001
   Gradman AH, 2010, J AM SOC HYPERTENS, V4, P42, DOI 10.1016/j.jash.2010.02.005
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Hasegawa M, 1999, CLIN EXP IMMUNOL, V117, P159
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569
   Jackson MB, 2006, CLIN SCI, V110, P143, DOI 10.1042/CS20050243
   KLOSE S, 1978, J CLIN CHEM CLIN BIO, V15, P121
   Lichtenstein AH, 2006, ARTERIOSCL THROM VAS, V26, P2186, DOI 10.1161/01.ATV.0000238352.25222.5e
   Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667
   Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Nesbitt SD, 2013, J HUM HYPERTENS, V27, P445, DOI 10.1038/jhh.2012.65
   Oparil S, 2009, POSTGRAD MED, V121, P25, DOI 10.3810/pgm.2009.03.1974
   Rifai N, 1999, CLIN CHEM, V45, P2136
   SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821
   TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0
   WAHLEFELD AW, 1974, METHOD ENZYMAT AN, P18
   Wald DS, 2009, AM J MED, V122, P290, DOI 10.1016/j.amjmed.2008.09.038
   Winer B. J., 1971, STAT PRINCIPLES EXPT
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Zwaka TP, 2001, CIRCULATION, V103, P1194
NR 47
TC 7
Z9 7
U1 2
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD FEB
PY 2014
VL 37
IS 1
BP 154
EP 162
DI 10.1007/s10753-013-9724-x
PG 9
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA AA1IK
UT WOS:000330849600020
PM 24018781
DA 2018-12-27
ER

PT J
AU Jung, HS
   Kim, K
   Ko, JH
AF Jung, Ho-Sup
   Kim, Keesung
   Ko, Jin Hwan
TI RETRACTED: Effect of a marine bacterial biofilm on adhesion and
   retention of pseudo barnacle to silicone coating surface (Retracted
   article. See vol. 31, pg. 540, 2014)
SO KOREAN JOURNAL OF CHEMICAL ENGINEERING
LA English
DT Article; Retracted Publication
DE Biofilm; Biofouling; Silicone Coating; Pseudobarnacle; Adhesion
ID RELEASE COATINGS; FOULING-RELEASE; ELASTIC-MODULUS; PERFORMANCE;
   ATTACHMENT; SETTLEMENT; THICKNESS; TENSION; LARVAE; PLATE
AB The effect of a marine bacterial Cytophaga lytica (C. lytica) biofilm on the adhesion and retention of a pseudobarnacle (epoxy adhesive) to platinum-cured silicone coatings was investigated at varying coating thickness (100-800 mu m), modulus (E=0.08-1.3 MPa), and shear rate (2-22 mu m/s). The initial adhesion of C. lytica biofilm on the silicone coating surfaces was increased as the coating modulus was increased. Nonetheless, the adhesion strength of the pseudobarnacle was not significantly influenced by the attached biofilms, with its strength decreasing with increasing the coating modulus. Thus, these results suggest that the pseudobarnacle adhesion strength would be primarily determined by physico-mechanical properties of the silicone coatings. Also, the adhesion/detachment tests demonstrated that the retention of the pseudobarnacle after water jetting was minimal for the soft silicone coating (VP1), which showed better performance than the widely acceptable silicone resin of DC 3140.
C1 [Jung, Ho-Sup; Kim, Keesung] Seoul Natl Univ, Sch Mech & Aerosp Engn, Seoul 151742, South Korea.
   [Jung, Ho-Sup; Kim, Keesung] Seoul Natl Univ, IAMD, Seoul 151742, South Korea.
   [Ko, Jin Hwan] Korea Inst Ocean Sci & Technol, Coastal Engn & Ocean Energy Res Dept, Ansan 426744, South Korea.
RP Ko, JH (reprint author), Korea Inst Ocean Sci & Technol, Coastal Engn & Ocean Energy Res Dept, 1270 Sa Dong, Ansan 426744, South Korea.
EM jhko@kiost.ac
FU Ministry of Oceans and Fisheries, Korea [20110171]; Priority Research
   Centers Program through the National Research Foundation of Korea (NRF);
   Ministry of Education, Science and Technology [2012-041247]
FX This research was a part of the project titled "Development of
   active-controlled tidal stream generation technology" funded by the
   Ministry of Oceans and Fisheries, Korea (20110171) and was partially
   supported by Priority Research Centers Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education,
   Science and Technology (2012-041247).
CR ABARZUA S, 1995, MAR ECOL PROG SER, V123, P301, DOI 10.3354/meps123301
   Baier R. E., 1980, ADSORPTION MICROORGA, V58
   Bakker DP, 2003, COLLOID SURFACE B, V32, P179, DOI 10.1016/S0927-7765(03)00159-0
   Brady RF, 2001, PROG ORG COAT, V43, P188, DOI 10.1016/S0300-9440(01)00180-1
   Brady RF, 2000, BIOFOULING, V15, P73, DOI 10.1080/08927010009386299
   Callow M. E., 1994, INT BIODETERIOR, V24, P333
   Chaudhury MK, 2005, BIOFOULING, V21, P41, DOI 10.1080/08927010500044377
   Chung JY, 2005, J ADHESION, V81, P1119, DOI 10.1080/00218460500310887
   DEXTER SC, 1979, J COLLOID INTERF SCI, V70, P346, DOI 10.1016/0021-9797(79)90038-9
   DEXTER SC, 1975, APPL MICROBIOL, V30, P298
   Grasland B, 2003, BIOFOULING, V19, P307, DOI 10.1080/0892701031000121041
   Gray NL, 2002, BIOFOULING, V18, P269, DOI 10.1080/0892701021000034373
   Han MS, 2009, MACROMOL RES, V17, P44, DOI 10.1007/BF03218600
   Huang SY, 2003, MAR ECOL PROG SER, V260, P161, DOI 10.3354/meps260161
   Kim J, 2007, BIOFOULING, V23, P113, DOI 10.1080/08927010701189708
   LOEB GI, 1975, ADV CHEM SER, P319
   MAKI JS, 1985, B MAR SCI, V37, P675
   Omae M, 2003, CHEM REV, V103, P3431, DOI 10.1021/cr030669z
   OWENS DK, 1969, J APPL POLYM SCI, V13, P1741, DOI 10.1002/app.1969.070130815
   Perbrey R. S., 1999, APPL ENVIRON MICROB, V65, P2877
   Singer IL, 2000, BIOFOULING, V16, P301, DOI 10.1080/08927010009378453
   Sperling L. H., 1992, INTRO PHYS POLYM SCI, P428
   Stafslien S, 2007, BIOFOULING, V23, P45, DOI 10.1080/08927010601137856
   Stafslien SJ, 2006, J COMB CHEM, V8, P156, DOI 10.1021/cc050047m
   Stein J, 2003, BIOFOULING, V19, P71, DOI 10.1080/0892701031000089525
   Sun YJ, 2004, BIOFOULING, V20, P279, DOI 10.1080/08927010400026383
   Truby K, 2000, BIOFOULING, V15, P141, DOI 10.1080/08927010009386305
   WAHL M, 1989, MAR ECOL PROG SER, V58, P175, DOI 10.3354/meps058175
   Yebra DM, 2006, BIOFOULING, V22, P33, DOI 10.1080/08927010500519097
NR 29
TC 1
Z9 1
U1 2
U2 32
PU KOREAN INSTITUTE CHEMICAL  ENGINEERS
PI SEOUL
PA F.5, 119, ANAM-RO, SEONGBUK-GU, SEOUL 136-075, SOUTH KOREA
SN 0256-1115
EI 1975-7220
J9 KOREAN J CHEM ENG
JI Korean J. Chem. Eng.
PD FEB
PY 2014
VL 31
IS 2
BP 262
EP 267
DI 10.1007/s11814-013-0218-1
PG 6
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA AA3ED
UT WOS:000330974800012
DA 2018-12-27
ER

PT J
AU Cha, ZS
   Zang, Y
   Guo, HJ
   Gu, HH
   Tu, XH
   Song, HH
   Qian, BH
AF Cha, Zhanshan
   Zang, Yan
   Guo, Huijun
   Gu, Haihui
   Tu, Xiaohua
   Song, Haihan
   Qian, Baohua
TI RETRACTED: Fibroblast growth factor receptor 4 polymorphisms and the
   prognosis of non-Hodgkin lymphoma (Retracted article. See vol. 43, pg.
   753, 2016)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Fibroblast growth factor receptor 4; Polymorphism; Prognosis;
   Non-Hodgkin lymphoma
ID RENAL-CELL CARCINOMA; FGF RECEPTOR; CANCER; ANGIOGENESIS; ARTERY;
   SUSCEPTIBILITY; OSTEOSARCOMA; EXPRESSION; BREAST; RISK
AB Fibroblast growth factors and their receptors (FGFRs) play important roles in blood system. FGFR4 rs351855 (Gly388Arg) polymorphism has shown to be a risk factor for many diseases. The aim of this study was to investigate the association between FGFR4 polymorphisms and the susceptibility to non-Hodgkin lymphoma (NHL) in the Chinese population. We identified two polymorphisms in the FGFR4 gene, rs351855G/A (Gly388Arg), and rs147603016G/A, by polymerase chain reaction-restriction fragment length polymorphism in 412 NHL cases and 476 healthy controls. Results showed that frequencies of AA genotype and A allele in rs351855 (Gly388Arg) polymorphism were significantly higher in patients than in controls (odds ratio (OR) 2.12, 95 % confidence intervals (CI) 1.99-3.48, P < 0.0001; OR 1.45, 95 % CI 1.21-1.88, P < 0.0001, respectively; data were adjusted for age and sex). The rs147603016G/A polymorphism did not show any correlation with NHL. When analyzing the survival time of NHL patients with FGFR4 rs351855G/A polymorphism, cases with AA genotype had significantly shorter survival time compared to the patients with GG and GA genotypes (P = 0.002). These results suggested polymorphism in FGFR4 gene was associated with increased susceptibility to NHL and could be used as a prognostic marker for this malignancy.
C1 [Cha, Zhanshan; Zang, Yan; Guo, Huijun; Gu, Haihui; Tu, Xiaohua; Qian, Baohua] Second Mil Med Univ, Changhai Hosp, Dept Transfus, Shanghai 200433, Peoples R China.
   [Song, Haihan] Tongji Univ, Shanghai East Hosp, Emergency Ctr, Dept Internal Med, Shanghai 200120, Peoples R China.
RP Qian, BH (reprint author), Second Mil Med Univ, Changhai Hosp, Dept Transfus, 168 Changhai Rd, Shanghai 200433, Peoples R China.
EM haihansong@126.com; qianbh1963@163.com
FU Public Health Project of the Shanghai Health Bureau [12GWZX0202];
   Changhai Hospital 1255 Project [CH125541100]
FX This study was supported by the Public Health Project of the Shanghai
   Health Bureau (NO. 12GWZX0202), and Changhai Hospital 1255 Project (NO.
   CH125541100).
CR Bellamy WT, 1999, CANCER RES, V59, P728
   BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651
   Boyle P, 2008, WORLD CANC REPORT 20, P468
   CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159
   CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979
   CUEVAS P, 1991, CIRC RES, V69, P360, DOI 10.1161/01.RES.69.2.360
   Delahunt B, 1997, BRIT J UROL, V80, P401, DOI 10.1046/j.1464-410X.1997.00374.x
   EISEMANN A, 1991, ONCOGENE, V6, P1195
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Frullanti E, 2011, EUR J CANCER PREV, V20, P340, DOI 10.1097/CEJ.0b013e3283457274
   JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305
   LEHTOLA L, 1992, INT J CANCER, V50, P598, DOI 10.1002/ijc.2910500419
   LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515
   LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106
   Liu Y, 2011, DNA CELL BIOL, V30, P1051, DOI 10.1089/dna.2011.1269
   Ma L, 2011, DNA CELL BIOL, V30, P1033, DOI 10.1089/dna.2011.1261
   MatsumotoYoshitomi S, 1997, INT J CANCER, V71, P442
   MIKAWA T, 1995, ANN NY ACAD SCI, V752, P506, DOI 10.1111/j.1749-6632.1995.tb17459.x
   Muller AMS, 2005, ANN HEMATOL, V84, P1, DOI 10.1007/s00277-004-0939-7
   NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0
   REIDY MA, 1991, ANN NY ACAD SCI, V638, P290, DOI 10.1111/j.1749-6632.1991.tb49039.x
   REILLY JT, 1985, J CLIN PATHOL, V38, P849, DOI 10.1136/jcp.38.8.849
   Ribatti D, 1996, EUR J HAEMATOL, V56, P45
   SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518
   Takahashi A, 1999, BIOCHEM BIOPH RES CO, V257, P855, DOI 10.1006/bbrc.1999.0465
   TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N
   Wang JH, 2008, NEOPLASIA, V10, P847, DOI 10.1593/neo.08450
   Wang W, 2011, DNA CELL BIOL, V30, P925, DOI 10.1089/dna.2011.1211
   WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82
   WOLF JE, 1975, BRIT J DERMATOL, V92, P273, DOI 10.1111/j.1365-2133.1975.tb03076.x
   Yang Y, 2012, MOL CARCINOGEN, V51, P515, DOI 10.1002/mc.20805
   Zhu Q, 2012, MOL BIOL REP, V39, P8679, DOI 10.1007/s11033-012-1723-8
NR 32
TC 5
Z9 5
U1 3
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD FEB
PY 2014
VL 41
IS 2
BP 1165
EP 1170
DI 10.1007/s11033-013-2963-y
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AA1MR
UT WOS:000330860900066
PM 24381107
DA 2018-12-27
ER

PT J
AU Hasan, H
   Abdul-Kareem, S
AF Hasan, Haitham
   Abdul-Kareem, S.
TI RETRACTED: Static hand gesture recognition using neural networks
   (Retracted article. See vol.47,pg.561,2017)
SO ARTIFICIAL INTELLIGENCE REVIEW
LA English
DT Article; Retracted Publication
DE Gesture recognition; Hand gestures; Artificial neural network;
   Human-computer interaction; Computer vision
AB This paper presents a novel technique for hand gesture recognition through human-computer interaction based on shape analysis. The main objective of this effort is to explore the utility of a neural network-based approach to the recognition of the hand gestures. A unique multi-layer perception of neural network is built for classification by using back-propagation learning algorithm. The goal of static hand gesture recognition is to classify the given hand gesture data represented by some features into some predefined finite number of gesture classes. The proposed system presents a recognition algorithm to recognize a set of six specific static hand gestures, namely: Open, Close, Cut, Paste, Maximize, and Minimize. The hand gesture image is passed through three stages, preprocessing, feature extraction, and classification. In preprocessing stage some operations are applied to extract the hand gesture from its background and prepare the hand gesture image for the feature extraction stage. In the first method, the hand contour is used as a feature which treats scaling and translation of problems (in some cases). The complex moment algorithm is, however, used to describe the hand gesture and treat the rotation problem in addition to the scaling and translation. The algorithm used in a multi-layer neural network classifier which uses back-propagation learning algorithm. The results show that the first method has a performance of 70.83% recognition, while the second method, proposed in this article, has a better performance of 86.38% recognition rate.
C1 [Hasan, Haitham; Abdul-Kareem, S.] Univ Malaya, Fac Comp Sci & Informat Technol, Kuala Lumpur 50603, Malaysia.
RP Hasan, H (reprint author), Univ Malaya, Fac Comp Sci & Informat Technol, Kuala Lumpur 50603, Malaysia.
EM haitham@siswa.um.edu.my; sameem@um.edu.my.com
CR Abd Alrazak R, 2004, THESIS U TECHNOLOGY
   ABUMOSTAFA YS, 1984, IEEE T PATTERN ANAL, V6, P698, DOI 10.1109/TPAMI.1984.4767594
   Aditya A, 2003, J PATTERN RECOGN SOC, V36, P12
   AWCOCK GJ, 1995, APPL IMAGE PROCESSIN
   Boussaid K, 1999, CONTOUR DETECTION ME
   Chang CC, 2006, J INF SCI ENG, V22, P1047
   Dadgostar F, 2005, RES LETT INF MATH SC, V7, P29
   Dadgostar F, 2005, RES LETT INFORM MATH, V7, P127
   Fausett L., 1994, FUNDAMENTALS NEURAL
   Freeman W. T., 1995, IEEE INT WORKSH AUT
   Gonzalez R., 2001, DIGITAL IMAGE PROCES
   Guiar P, 2002, GESTURE RECOGNITION
   Guo D, 1998, 5 INT C CONTR AUT RO, V1
   Haykin S., 1994, NEURAL NETWORKS COMP
   Hu C, 2003, C INT ROB SYST LAS V
   Huang J, 1998, THESIS CORNELL U
   Ionescu B, 2005, EURASIP J APPL SIG P, V2005, P2101, DOI 10.1155/ASP.2005.2101
   Joshi G, 2004, SIMPLE SCHEME CONTOU
   Just A, 2006, THESIS
   Kim TK, 2007, LECT NOTES COMPUT SC, V4843, P335
   Kinnebrock W, 1995, NEURAL NETWORKS FUND
   Kjrlfdrn FCM, 1997, THESIS COLUMBIA U NE
   Lamar MV, 2001, THESIS NAGOYA I TECH
   Licsar A, 2002, 2 INT WORKSH PATT RE, P95
   Manresa C, 2000, REAL TIME HAND TRACK
   Musa AK, 1998, THESIS U BAGHDAD
   Naidoo S, 1998, VISION BASED STATIC
   Nehaniv CI, 2005, IEEE INT WORKSH ROB
   Parvini F, 2007, INT J BIOINFORM RES, V3
   PHILIPS D, 1994, IMAGE PROCESSING
   Picton P., 2000, NEURAL NETWORKS
   Pitas I, 1998, THESIS CORNELL U
   Shet VD, 2003, THESIS U MARYLAND CO
   Symonidis K, 2000, HAND GESTURE RECOGNI, V68, P5
   TRIESCH J, 1996, P 2 INT C AUT FAC GE
   UMBAUGH SE, 1998, COMPUTER VISION IMAG
   Winnemoller H, 1999, PRACTICAL GESTURE RE
   Wu Y, 1999, INT GEST WORKSH FRAN
NR 38
TC 39
Z9 40
U1 2
U2 66
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0269-2821
EI 1573-7462
J9 ARTIF INTELL REV
JI Artif. Intell. Rev.
PD FEB
PY 2014
VL 41
IS 2
BP 147
EP 181
DI 10.1007/s10462-011-9303-1
PG 35
WC Computer Science, Artificial Intelligence
SC Computer Science
GA 304ED
UT WOS:000330728800001
DA 2018-12-27
ER

PT J
AU Hu, SSJ
   Ho, YC
   Chiou, LC
AF Hu, Sherry Shu-Jung
   Ho, Yu-Cheng
   Chiou, Lih-Chu
TI RETRACTED: No more pain upon G(q)-protein-coupled receptor activation:
   role of endocannabinoids (Retracted article. See vol. 43, pg. 991, 2016)
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Review; Retracted Publication
DE endocannabinoids; metabotropic glutamate receptors; neuropeptides; pain;
   periaqueductal gray
ID ACID AMIDE HYDROLASE; METABOTROPIC GLUTAMATE RECEPTORS; PERIAQUEDUCTAL
   GRAY-MATTER; CANNABINOID CB1 RECEPTOR; STRESS-INDUCED ANALGESIA; RAT
   SPINAL-CORD; PROTEIN-LIKE IMMUNOREACTIVITY; STIMULUS-EVOKED ACTIVITY;
   VANILLOID VR1 RECEPTORS; CENTRAL-NERVOUS-SYSTEM
AB Marijuana has been used to relieve pain for centuries. The analgesic mechanism of its constituents, the cannabinoids, was only revealed after the discovery of cannabinoid receptors (CB1 and CB2) two decades ago. The subsequent identification of the endocannabinoids, anandamide and 2-arachidonoylglycerol (2-AG), and their biosynthetic and degradation enzymes discloses the therapeutic potential of compounds targeting the endocannabinoid system for pain control. Inhibitors of the anandamide and 2-AG degradation enzymes, fatty acid amide hydrolase and monoacylglycerol lipase, respectively, may be superior to direct cannabinoid receptor ligands as endocannabinoids are synthesized on demand and rapidly degraded, focusing action at generating sites. Recently, a promising strategy for pain relief was revealed in the periaqueductal gray (PAG). It is initiated by G(q)-protein-coupled receptor (G(q)PCR) activation of the phospholipase C-diacylglycerol lipase enzymatic cascade, generating 2-AG that produces inhibition of GABAergic transmission (disinhibition) in the PAG, thereby leading to analgesia. Here, we introduce the antinociceptive properties of exogenous cannabinoids and endocannabinoids, involving their biosynthesis and degradation processes, particularly in the PAG. We also review recent studies disclosing the G(q)PCR-phospholipase C-diacylglycerol lipase-2-AG retrograde disinhibition mechanism in the PAG, induced by activating several G(q)PCRs, including metabotropic glutamatergic (type 5 metabotropic glutamate receptor), muscarinic acetylcholine (M1/M3), and orexin 1 receptors. Disinhibition mediated by type 5 metabotropic glutamate receptor can be initiated by glutamate transporter inhibitors or indirectly by substance P, neurotensin, cholecystokinin and capsaicin. Finally, the putative role of 2-AG generated after activating the above neurotransmitter receptors in stress-induced analgesia is discussed.
C1 [Hu, Sherry Shu-Jung] Natl Cheng Kung Univ, Dept Psychol, Tainan 70101, Taiwan.
   [Ho, Yu-Cheng; Chiou, Lih-Chu] Natl Taiwan Univ, Grad Inst Pharmacol, Coll Med, Taipei 10764, Taiwan.
   [Chiou, Lih-Chu] Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 10764, Taiwan.
   [Chiou, Lih-Chu] Coll Med, Grad Inst Brain & Mind Sci, Taipei, Taiwan.
   [Chiou, Lih-Chu] Natl Taiwan Univ, Neurobiol & Cognit Sci Ctr, Taipei 10764, Taiwan.
RP Chiou, LC (reprint author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 10764, Taiwan.
EM lcchiou@ntu.edu.tw
RI Latyshev, Nikolay/D-1464-2014
FU National Science Council, Taiwan [NSC101-2325-B002-048,
   NSC101-2321-B002-081, NSC100-2410-H-006-085-MY2, NSC101-2320-B-006-007,
   NSC102-2410-H-006-016-MY2]; National Health Research Institutes, Taiwan
   [NHRI-EX102-10251NI]; NCKU Aiming for the Top University; Elite Research
   Center Development Plan (MoE ATU Plan)
FX The authors declare no competing financial interests. This work was
   supported by the grants to L.-C. C. from the National Science Council,
   Taiwan (NSC101-2325-B002-048 and NSC101-2321-B002-081) and National
   Health Research Institutes, Taiwan (NHRI-EX102-10251NI) and the grants
   to S.S.-J.H. from the National Science Council, Taiwan
   (NSC100-2410-H-006-085-MY2, NSC101-2320-B-006-007, and
   NSC102-2410-H-006-016-MY2) and NCKU Aiming for the Top University and
   Elite Research Center Development Plan (MoE ATU Plan).
CR Agarwal N, 2007, NAT NEUROSCI, V10, P870, DOI 10.1038/nn1916
   Ahn K, 2011, J PHARMACOL EXP THER, V338, P114, DOI 10.1124/jpet.111.180257
   Ahn K, 2009, CHEM BIOL, V16, P411, DOI 10.1016/j.chembiol.2009.02.013
   AKIL H, 1986, ANN NY ACAD SCI, V467, P140, DOI 10.1111/j.1749-6632.1986.tb14625.x
   Albutaihi IAM, 2004, NEUROSIGNALS, V13, P207, DOI 10.1159/000079336
   Alexander JP, 2006, J AM CHEM SOC, V128, P9699, DOI 10.1021/ja062999h
   Alvarez-Jaimes LJ, 2011, CURR PHARM BIOTECHNO, V12, P1644
   AMIT Z, 1986, PHYSIOL REV, V66, P1091
   Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x
   BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7
   Beaulieu P, 2000, EUR J PHARMACOL, V396, P85, DOI 10.1016/S0014-2999(00)00226-0
   Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094
   Benedetti F, 2013, PAIN, V154, P361, DOI 10.1016/j.pain.2012.11.007
   Bequet F, 2007, EUR J NEUROSCI, V26, P3458, DOI 10.1111/j.1460-9568.2007.05900.x
   Berquin P, 2000, BRAIN RES, V857, P30, DOI 10.1016/S0006-8993(99)02304-5
   Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129
   Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006
   BLOOM AS, 1977, J PHARMACOL EXP THER, V200, P263
   Booker L, 2012, BRIT J PHARMACOL, V165, P2485, DOI 10.1111/j.1476-5381.2011.01445.x
   Busquets-Garcia A, 2011, BIOL PSYCHIAT, V70, P479, DOI 10.1016/j.biopsych.2011.04.022
   Butler RK, 2012, J PSYCHOPHARMACOL, V26, P83, DOI 10.1177/0269881111413823
   Caille S, 2007, J NEUROSCI, V27, P3695, DOI 10.1523/JNEUROSCI.4403-06.2007
   Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393
   Chanda PK, 2010, MOL PHARMACOL, V78, P996, DOI 10.1124/mol.110.068304
   Chapman V, 1999, BRIT J PHARMACOL, V127, P1765, DOI 10.1038/sj.bjp.0702758
   Chen XH, 1998, NEUROPHARMACOLOGY, V37, P751, DOI 10.1016/S0028-3908(98)00028-8
   Chiou L. C., 2010, NEUROSCIENCE, V2010
   Chiou LC, 2010, CURR PHARM DESIGN, V16, P3089, DOI 10.2174/138161210793292483
   Clayton N, 2002, PAIN, V96, P253, DOI 10.1016/S0304-3959(01)00454-7
   Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205
   Costa B, 1999, ACTA PHARMACOL SIN, V20, P1103
   Cravatt BF, 2004, J NEUROBIOL, V61, P149, DOI 10.1002/neu.20080
   Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698
   Cravatt BF, 2004, P NATL ACAD SCI USA, V101, P10821, DOI 10.1073/pnas.0401292101
   DAmico M, 1996, PAIN, V65, P205, DOI 10.1016/0304-3959(95)00178-6
   De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322
   de Novellis V, 2003, EUR J PHARMACOL, V462, P73, DOI 10.1016/S0014-2999(03)01342-6
   De Petrocellis L, 2001, J BIOL CHEM, V276, P12856, DOI 10.1074/jbc.M008555200
   DEPAULIS A, 1987, BRAIN RES, V436, P223, DOI 10.1016/0006-8993(87)91665-9
   Desroches J, 2008, BRIT J PHARMACOL, V155, P913, DOI 10.1038/bjp.2008.322
   DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919
   Di Marzo V, 2008, REV PHYSIOL BIOCH P, V160, P1, DOI 10.1007/112_0505
   Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495
   Di Marzo V, 2005, NAT NEUROSCI, V8, P585, DOI 10.1038/nn1457
   Di Marzo V, 1998, BIOCHEM J, V331, P15
   Di Marzo V, 2001, TRENDS PHARMACOL SCI, V22, P346, DOI 10.1016/S0165-6147(00)01712-0
   Di Marzo V, 2012, PAIN, V153, P1785, DOI 10.1016/j.pain.2012.06.016
   DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0
   Dinh TP, 2004, MOL PHARMACOL, V66, P1260, DOI 10.1124/mol.104.002071
   Dinh TP, 2002, CHEM PHYS LIPIDS, V121, P149, DOI 10.1016/S0009-3084(02)00150-0
   Dogrul A, 2002, PAIN, V100, P203, DOI 10.1016/S0304-3959(02)00302-0
   Drew GM, 2008, J NEUROSCI, V28, P808, DOI 10.1523/JNEUROSCI.4876-07.2008
   Drew GM, 2009, J NEUROSCI, V29, P7220, DOI 10.1523/JNEUROSCI.4362-08.2009
   Drew GM, 2004, NEUROPHARMACOLOGY, V46, P927, DOI 10.1016/j.neuropharm.2004.01.015
   Egertova M, 2003, NEUROSCIENCE, V119, P481, DOI 10.1016/S0306-4522(03)00145-3
   Egertova M, 1998, P ROY SOC B-BIOL SCI, V265, P2081, DOI 10.1098/rspb.1998.0543
   Egertova M, 2004, J CHEM NEUROANAT, V28, P171, DOI 10.1016/j.jchemneu.2004.07.001
   Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625
   Filaretov A A, 1996, Neurosci Behav Physiol, V26, P572, DOI 10.1007/BF02359502
   Finn DP, 2004, EUR J NEUROSCI, V20, P848, DOI 10.1111/j.1460-9568.2004.03509.x
   Flor H, 2002, EUR J PAIN-LONDON, V6, P395, DOI 10.1016/S1090-3801(02)00043-5
   Fowler CJ, 2013, FEBS J, V280, P1895, DOI 10.1111/febs.12212
   Freund TF, 2003, NEURON, V38, P362, DOI 10.1016/S0896-6273(03)00262-9
   GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x
   Gao Y, 2010, J NEUROSCI, V30, P2017, DOI 10.1523/JNEUROSCI.5693-09.2010
   GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046
   GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129
   Gertsch J, 2008, P NATL ACAD SCI USA, V105, P9099, DOI 10.1073/pnas.0803601105
   Ghosh S, 2013, LIFE SCI, V92, P498, DOI 10.1016/j.lfs.2012.06.020
   Glaser ST, 2005, LIFE SCI, V77, P1584, DOI 10.1016/j.lfs.2005.05.007
   Gonsiorek W, 2000, MOL PHARMACOL, V57, P1045
   Goparaju SK, 1999, BIOCHEM PHARMACOL, V57, P417, DOI 10.1016/S0006-2952(98)00314-1
   Greenbaum L, 2012, EUR J PAIN, V16, P1243, DOI 10.1002/j.1532-2149.2012.00134.x
   Gregg LC, 2012, J NEUROSCI, V32, P9457, DOI 10.1523/JNEUROSCI.0013-12.2012
   Gui X, 2004, NEUROSCIENCE, V126, P1023, DOI 10.1016/j.neuroscience.2004.04.034
   Guimaraes APC, 2000, BRAIN RES BULL, V51, P471, DOI 10.1016/S0361-9230(99)00266-X
   Guindon J, 2013, PHARMACOL RES, V67, P94, DOI 10.1016/j.phrs.2012.10.013
   Guindon J, 2011, BRIT J PHARMACOL, V163, P1464, DOI 10.1111/j.1476-5381.2010.01192.x
   Gyombolai P, 2012, MOL CELL ENDOCRINOL, V353, P29, DOI 10.1016/j.mce.2011.10.011
   Haj-Dahmane S, 2005, J NEUROSCI, V25, P896, DOI 10.1523/JNEUROSCI.3258-04.2005
   Haller VL, 2008, EUR J PHARMACOL, V600, P50, DOI 10.1016/j.ejphar.2008.08.005
   Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898
   Hasanein P, 2008, EUR J PHARMACOL, V591, P132, DOI 10.1016/j.ejphar.2008.06.061
   Hashimotodani Y, 2005, NEURON, V45, P257, DOI 10.1016/j.neuron.2005.01.004
   Hashimotodani Y, 2007, CURR OPIN NEUROBIOL, V17, P360, DOI 10.1016/j.conb.2007.03.012
   Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009
   HERKENHAM M, 1991, J NEUROSCI, V11, P563
   Ho YC, 2011, J NEUROSCI, V31, P14600, DOI 10.1523/JNEUROSCI.2671-11.2011
   HOHMANN AG, 1995, LIFE SCI, V56, P2111, DOI 10.1016/0024-3205(95)00196-D
   Hohmann AG, 1999, J NEUROPHYSIOL, V81, P575
   Hohmann AG, 1999, ACTA PHARMACOL SIN, V20, P1132
   Hohmann AG, 2005, NATURE, V435, P1108, DOI 10.1038/nature03658
   Holden JE, 2009, NEUROSCI LETT, V453, P115, DOI 10.1016/j.neulet.2009.01.083
   Horvath TL, 1999, J NEUROSCI, V19, P1072
   Horvath TL, 1999, J COMP NEUROL, V415, P145
   Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161
   Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030
   Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999
   Huggins JP, 2012, PAIN, V153, P1837, DOI 10.1016/j.pain.2012.04.020
   Ibrahim MM, 2003, P NATL ACAD SCI USA, V100, P10529, DOI 10.1073/pnas.1834309100
   Ibrahim MM, 2006, PAIN, V122, P36, DOI 10.1016/j.pain.2005.12.018
   Ignatowska-Jankowska B. M., 2013, BRIT J PHARM, DOI 10.1111/bph.12298
   INUI K, 1994, J PHYSIOL-LONDON, V477, P89, DOI 10.1113/jphysiol.1994.sp020174
   Iwamura H, 2001, J PHARMACOL EXP THER, V296, P420
   Jarrahian A, 2000, J NEUROCHEM, V74, P2597, DOI 10.1046/j.1471-4159.2000.0742597.x
   Johnson DS, 2011, ACS MED CHEM LETT, V2, P91, DOI 10.1021/ml100190t
   KALIVAS PW, 1982, J COMP NEUROL, V210, P225, DOI 10.1002/cne.902100303
   Kano M, 2009, PHYSIOL REV, V89, P309, DOI 10.1152/physrev.00019.2008
   Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803
   Katona I, 1999, J NEUROSCI, V19, P4544
   Kawahara H, 2011, BRIT J PHARMACOL, V163, P1214, DOI 10.1111/j.1476-5381.2010.01157.x
   Khasabova IA, 2011, PHARMACOL RES, V64, P60, DOI 10.1016/j.phrs.2011.03.007
   Kinsey SG, 2009, J PHARMACOL EXP THER, V330, P902, DOI 10.1124/jpet.109.155465
   Kinsey SG, 2013, J PHARMACOL EXP THER, V345, P492, DOI 10.1124/jpet.112.201426
   Kinsey SG, 2010, J PAIN, V11, P1420, DOI 10.1016/j.jpain.2010.04.001
   Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6
   Lau BK, 2008, MOL PHARMACOL, V74, P1392, DOI 10.1124/mol.108.045872
   Lauckner JE, 2005, P NATL ACAD SCI USA, V102, P19144, DOI 10.1073/pnas.0509588102
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi0601631
   LEWIS VA, 1977, BRAIN RES, V124, P283, DOI 10.1016/0006-8993(77)90886-1
   Liao HT, 2011, BRIT J PHARMACOL, V163, P330, DOI 10.1111/j.1476-5381.2011.01214.x
   Lichtman AH, 2002, J PHARMACOL EXP THER, V302, P73, DOI 10.1124/jpet.302.1.73
   Lichtman AH, 2004, PAIN, V109, P319, DOI 10.1016/j.pain.2004.01.022
   Lichtman AH, 2004, J PHARMACOL EXP THER, V311, P441, DOI 10.1124/jpet.104.069401
   Lichtman AH, 1996, J PHARMACOL EXP THER, V276, P585
   Liu J, 2008, NEUROPHARMACOLOGY, V54, P1, DOI 10.1016/j.neuropharm.2007.05.020
   Lotsch J, 2011, BRIT J PHARMACOL, V163, P447, DOI 10.1111/j.1476-5381.2010.01074.x
   Long JZ, 2009, P NATL ACAD SCI USA, V106, P20270, DOI 10.1073/pnas.0909411106
   Long JZ, 2009, CHEM BIOL, V16, P744, DOI 10.1016/j.chembiol.2009.05.009
   MACKIE K, 1995, J NEUROSCI, V15, P6552
   Maione S, 2006, J PHARMACOL EXP THER, V316, P969, DOI 10.1124/jpet.105.093286
   Maione S, 2000, PAIN, V85, P183, DOI 10.1016/S0304-3959(99)00269-9
   Maione S, 1998, NEUROPHARMACOLOGY, V37, P1475, DOI 10.1016/S0028-3908(98)00126-9
   Malan TP, 2001, PAIN, V93, P239, DOI 10.1016/S0304-3959(01)00321-9
   Marabese I, 2007, J NEUROPHYSIOL, V98, P43, DOI 10.1152/jn.00356.2007
   Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x
   Marrs WR, 2010, NAT NEUROSCI, V13, P951, DOI 10.1038/nn.2601
   Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839
   Martin WJ, 1996, J NEUROSCI, V16, P6601
   MARTIN WJ, 1995, LIFE SCI, V56, P2103, DOI 10.1016/0024-3205(95)00195-C
   MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0
   Matyas F, 2008, NEUROPHARMACOLOGY, V54, P95, DOI 10.1016/j.neuropharm.2007.05.028
   MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D
   Meng ID, 1998, NATURE, V395, P381, DOI 10.1038/26481
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Mitchell VA, 2009, J PHYSIOL-LONDON, V587, P2511, DOI 10.1113/jphysiol.2008.167429
   Mitchell VA, 2011, NEUROPSYCHOPHARMACOL, V36, P1801, DOI 10.1038/npp.2011.59
   Monassi CR, 1997, PHYSIOL BEHAV, V62, P53, DOI 10.1016/S0031-9384(97)00134-0
   Morgan MM, 1998, BRAIN RES, V804, P159, DOI 10.1016/S0006-8993(98)00669-6
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Nackley AG, 2003, NEUROSCIENCE, V119, P747, DOI 10.1016/S0306-4522(03)00126-X
   Nackley AG, 2003, NEUROSCIENCE, V117, P659, DOI 10.1016/S0306-4522(02)00870-9
   NUSSER Z, 1994, NEUROSCIENCE, V61, P421, DOI 10.1016/0306-4522(94)90421-9
   Nyilas R, 2008, J NEUROSCI, V28, P1058, DOI 10.1523/JNEUROSCI.5102-07.2008
   Nyilas R, 2009, EUR J NEUROSCI, V29, P1964, DOI 10.1111/j.1460-9568.2009.06751.x
   OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402
   Okamoto Y, 2007, CHEM BIODIVERS, V4, P1842, DOI 10.1002/cbdv.200790155
   Olango WM, 2012, BRIT J PHARMACOL, V165, P2549, DOI 10.1111/j.1476-5381.2011.01478.x
   Oliva P, 2006, EUR J PHARMACOL, V530, P40, DOI 10.1016/j.ejphar.2005.11.025
   Palazzo E, 2002, EUR J PHARMACOL, V439, P69, DOI 10.1016/S0014-2999(02)01367-5
   Palazzo E, 2001, NEUROPHARMACOLOGY, V40, P319, DOI 10.1016/S0028-3908(00)00160-X
   Palazzo E, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-82
   Pamplona FA, 2012, P NATL ACAD SCI USA, V109, P21134, DOI 10.1073/pnas.1202906109
   Panula P, 1999, BRAIN RES, V848, P191, DOI 10.1016/S0006-8993(99)02044-2
   Pecina M., 2013, MOL PSYCHIAT, DOI 10.1038/mp.2013.124
   Peng YL, 2010, PEPTIDES, V31, P1878, DOI 10.1016/j.peptides.2010.06.027
   Pernia-Andrade AJ, 2009, SCIENCE, V325, P760, DOI 10.1126/science.1171870
   PERT A, 1980, BRAIN RES, V193, P209, DOI 10.1016/0006-8993(80)90958-0
   Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442
   Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004
   Pertwee R. G., 2013, P NUTR SOC, V18, P1
   Pertwee RG, 2005, LIFE SCI, V76, P1307, DOI 10.1016/j.lfs.2004.10.025
   Pertwee RG, 2008, ADDICT BIOL, V13, P147, DOI 10.1111/j.1369-1600.2008.00108.x
   Pertwee Roger G, 2012, Proc Natl Acad Sci U S A, V109, P20781, DOI 10.1073/pnas.1218529110
   Peyron C, 1998, J NEUROSCI, V18, P9996
   PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G
   Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6
   Porter AC, 2002, J PHARMACOL EXP THER, V301, P1020, DOI 10.1124/jpet.301.3.1020
   Puighermanal E, 2012, PHILOS T R SOC B, V367, P3254, DOI 10.1098/rstb.2011.0384
   Racz I, 2008, J NEUROSCI, V28, P12125, DOI 10.1523/JNEUROSCI.3400-08.2008
   Racz I, 2008, J NEUROSCI, V28, P12136, DOI 10.1523/JNEUROSCI.3402-08.2008
   REYNOLDS DV, 1969, SCIENCE, V164, P444, DOI 10.1126/science.164.3878.444
   Rhee MH, 1998, J NEUROCHEM, V71, P1525
   Richardson JD, 1998, PAIN, V75, P111, DOI 10.1016/S0304-3959(97)00213-3
   Richardson JD, 1998, J NEUROSCI, V18, P451
   Richardson JD, 1997, EUR J PHARMACOL, V319, pR3, DOI 10.1016/S0014-2999(96)00952-1
   Riedel G, 1996, TRENDS NEUROSCI, V19, P219
   RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X
   Rosen A, 2004, BRAIN RES, V1001, P87, DOI 10.1016/j.brainres.2003.11.060
   Ruehle S, 2013, J NEUROSCI, V33, P10264, DOI 10.1523/JNEUROSCI.4171-12.2013
   Russo R, 2007, J PHARMACOL EXP THER, V322, P236, DOI 10.1124/jpet.107.119941
   Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6
   Sasso O, 2012, PHARMACOL RES, V65, P553, DOI 10.1016/j.phrs.2012.02.012
   Savinainen JR, 2001, BRIT J PHARMACOL, V134, P664, DOI 10.1038/sj.bjp.0704297
   Schindler M, 1998, BRAIN RES, V798, P25, DOI 10.1016/S0006-8993(98)00361-8
   Schlosburg JE, 2010, NAT NEUROSCI, V13, P1113, DOI 10.1038/nn.2616
   SCHMID PC, 1983, J BIOL CHEM, V258, P9302
   Scott CW, 2011, EUR J PHARMACOL, V667, P74, DOI 10.1016/j.ejphar.2011.05.052
   Serrano A, 2011, PHARMACOL THERAPEUT, V132, P215, DOI 10.1016/j.pharmthera.2011.06.005
   Shen MX, 1996, J NEUROSCI, V16, P4322
   Sigel E, 2011, P NATL ACAD SCI USA, V108, P18150, DOI 10.1073/pnas.1113444108
   Simon GM, 2006, J BIOL CHEM, V281, P26465, DOI 10.1074/jbc.M604660200
   Simon GM, 2010, MOL BIOSYST, V6, P1411, DOI 10.1039/c000237b
   Sink KS, 2008, NEUROPSYCHOPHARMACOL, V33, P946, DOI 10.1038/sj.npp.1301476
   Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799
   Sit S., 2002, BISARYLIMIDAZOLYL FA
   Sit S., 2003, (Oxime) carbamoyl fatty acid amide hydrolase inhibitors, Patent No. 2003065989
   Starowicz K, 2007, J NEUROSCI, V27, P13739, DOI 10.1523/JNEUROSCI.3258-07.2007
   Strangman NM, 1998, BRAIN RES, V813, P323, DOI 10.1016/S0006-8993(98)01031-2
   Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605
   SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437
   Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356
   Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031
   Tallent M, 1996, NEUROSCIENCE, V71, P1073, DOI 10.1016/0306-4522(95)00510-2
   Tamaru Y, 2001, NEUROSCIENCE, V106, P481, DOI 10.1016/S0306-4522(01)00305-0
   THOBURN KK, 1994, PAIN, V58, P29, DOI 10.1016/0304-3959(94)90182-1
   Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3
   Tsou K, 1996, NEUROSCIENCE, V70, P791, DOI 10.1016/S0306-4522(96)83015-6
   Tsou K, 1998, NEUROSCI LETT, V254, P137, DOI 10.1016/S0304-3940(98)00700-9
   Tsujino N, 2009, PHARMACOL REV, V61, P162, DOI 10.1124/pr.109.001321
   Turu G, 2009, J BIOL CHEM, V284, P16914, DOI 10.1074/jbc.M109.003681
   Valverde O, 2000, EUR J NEUROSCI, V12, P533, DOI 10.1046/j.1460-9568.2000.00929.x
   van den Pol AN, 1999, J NEUROSCI, V19, P3171
   Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740
   Vandevoorde S, 2005, BRIT J PHARMACOL, V145, P885, DOI 10.1038/sj.bjp.0706253
   Vaughan CW, 2000, MOL PHARMACOL, V57, P288
   Walczak JS, 2006, J NEUROSCI RES, V83, P1310, DOI 10.1002/jnr.20821
   Walker J M, 2001, Pain Res Manag, V6, P74
   Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200
   Wang JZ, 2000, BRAIN RES, V859, P361, DOI 10.1016/S0006-8993(99)02408-7
   Wang JZ, 2001, BRAIN RES, V893, P264, DOI 10.1016/S0006-8993(00)03279-0
   Watanabe S, 2005, NEUROREPORT, V16, P5, DOI 10.1097/00001756-200501190-00002
   Wei BQQ, 2006, J BIOL CHEM, V281, P36569, DOI 10.1074/jbc.M606646200
   Wei H, 1998, NEUROSCIENCE, V86, P311, DOI 10.1016/S0306-4522(98)00027-X
   Whiteside GT, 2005, EUR J PHARMACOL, V528, P65, DOI 10.1016/j.ejphar.2005.10.043
   Wilson-Poe AR, 2013, NEUROPHARMACOLOGY, V66, P348, DOI 10.1016/j.neuropharm.2012.06.057
   Woodhams SG, 2012, BRIT J PHARMACOL, V167, P1609, DOI 10.1111/j.1476-5381.2012.02179.x
   WOOLF NJ, 1990, BRAIN RES, V520, P55, DOI 10.1016/0006-8993(90)91691-9
   Wotherspoon G, 2005, NEUROSCIENCE, V135, P235, DOI 10.1016/j.neuroscience.2005.06.009
   Xiao Z, 2010, BRAIN RES, V1330, P31, DOI 10.1016/j.brainres.2010.03.030
   Xie XM, 2008, J CLIN INVEST, V118, P2471, DOI 10.1172/JCI35115
   Xing JH, 2008, BRAIN RES, V1208, P46, DOI 10.1016/j.brainres.2008.02.083
   Xing JH, 2007, J NEUROPHYSIOL, V97, P503, DOI 10.1152/jn.01023.2006
   Yang J, 2011, REGUL PEPTIDES, V169, P39, DOI 10.1016/j.regpep.2011.04.007
   Zarmehri HA, 2011, J PAIN, V12, P280, DOI 10.1016/j.jpain.2010.09.006
   Zhang J, 2003, EUR J NEUROSCI, V17, P2750, DOI 10.1046/j.1460-9568.2003.02704.x
   Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780
   Zygmunt PM, 1999, NATURE, V400, P452
NR 249
TC 9
Z9 9
U1 3
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD FEB
PY 2014
VL 39
IS 3
SI SI
BP 467
EP 484
DI 10.1111/ejn.12475
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA 301UT
UT WOS:000330558300014
PM 24494686
DA 2018-12-27
ER

PT J
AU Xu, XO
   Shuen, WH
   Chen, C
   Goudevenou, K
   Jones, P
   Sablitzky, F
AF Xu, Xiaoou
   Shuen, Wai Ho
   Chen, Chen
   Goudevenou, Katerina
   Jones, Peter
   Sablitzky, Fred
TI RETRACTED: Swap70b is required for convergent and extension cell
   movement during zebrafish gastrulation linking Wnt11 signalling and RhoA
   effector function (Retracted article. See vol. 410, pg. 131, 2016)
SO DEVELOPMENTAL BIOLOGY
LA English
DT Article; Retracted Publication
DE Swap70; Guanine nucleotide exchange factor; Convergent and extension
   cell movement; Gastrulation; Wnt11; Non-canonical Wnt signalling
   pathway; Def6
ID NUCLEOTIDE-EXCHANGE FACTOR; VERTEBRATE GASTRULATION; ACTS DOWNSTREAM;
   TAIL FORMATION; DANIO-RERIO; PH DOMAIN; SWAP-70; MUTATIONS; MEMBRANE;
   MORPHOGENESIS
AB Swap70 functions as a guanine nucleotide exchange factor for Rac and RhoA regulating F-actin cytoskeletal rearrangements and playing a crucial role in mammalian cell activation, migration, adhesion and invasion. Here we show that the zebrafish orthologue, Swap70b, is required for convergent and extension cell movement during gastrulation. Swap70b morphants exhibited broader and shorter body axis but cell fate specification appeared normal. While ectopic Swap70b expression robustly rescued Wnt11 morphants, RhoA overexpression was sufficient to rescue Swap70b morphants, establishing Swap70b as a novel member of the non-canonical Wnt/PCP pathway downstream of Wnt11 and upstream of RhoA. This is distinct from the related Def6a protein that acts downstream of Wnt5b. Def6a/Swap70b morphants resemble Ppt/Slb double mutant embryos suggesting that Swap70b and Def6a delineate Wnt11 and Wnt5b signalling pathways. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
C1 [Xu, Xiaoou; Shuen, Wai Ho; Chen, Chen; Goudevenou, Katerina; Jones, Peter; Sablitzky, Fred] Univ Nottingham, Sch Life Sci, Nottingham NG7 2UH, England.
RP Sablitzky, F (reprint author), Univ Nottingham, Sch Life Sci, Queens Med Ctr, Nottingham NG7 2UH, England.
EM fred.sablitzky@nottingham.ac.uk
RI Sablitzky, Fred/A-2276-2011
OI Sablitzky, Fred/0000-0001-9718-1546
CR Becart S., 2008, IMMUNITY, V29, P1
   Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025
   Borggrefe T, 2001, EUR J IMMUNOL, V31, P2467, DOI 10.1002/1521-4141(200108)31:8<2467::AID-IMMU2467>3.0.CO;2-P
   Carreira-Barbosa F, 2003, DEVELOPMENT, V130, P4037, DOI 10.1242/dev.00567
   Concha ML, 1998, DEVELOPMENT, V125, P983
   Djiane A, 2000, DEVELOPMENT, V127, P3091
   Driever W, 1996, DEVELOPMENT, V123, P37
   Fukui Y, 2007, IUBMB LIFE, V59, P99, DOI 10.1080/15216540701222880
   Goudevenou K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026548
   Gray RS, 2011, DEV CELL, V21, P120, DOI 10.1016/j.devcel.2011.06.011
   Gupta S, 2003, J BIOL CHEM, V278, P43541, DOI 10.1074/jbc.M308960200
   Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6
   Haffter P, 1996, DEVELOPMENT, V123, P1
   Hammerschmidt M, 1996, DEVELOPMENT, V123, P143
   Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068
   Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511
   Hey F, 2012, J BIOL CHEM, V287, P31073, DOI 10.1074/jbc.M112.346767
   Hotfilder M, 1999, BRIT J HAEMATOL, V106, P335, DOI 10.1046/j.1365-2141.1999.01551.x
   Ihara S, 2006, J CELL SCI, V119, P500, DOI 10.1242/jcs.02767
   Jopling C, 2005, EMBO REP, V6, P426, DOI 10.1038/sj.embor.7400386
   Kai M, 2008, DEVELOPMENT, V135, P3043, DOI 10.1242/dev.020396
   Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478
   Kilian B, 2003, MECH DEVELOP, V120, P467, DOI 10.1016/S0925-4773(03)00004-2
   Lele Z, 2001, GENESIS, V30, P190, DOI 10.1002/gene.1063
   Marlow F, 2002, CURR BIOL, V12, P876, DOI 10.1016/S0960-9822(02)00864-3
   Mavrakis KJ, 2004, EXP CELL RES, V294, P335, DOI 10.1016/j.yexcr.2003.12.004
   Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1
   Ocana-Morgner C, 2011, J IMMUNOL, V186, P5345, DOI 10.4049/jimmunol.1003461
   Pearce G, 2006, NAT IMMUNOL, V7, P827, DOI 10.1038/ni1365
   Pearce G, 2011, BLOOD, V117, P1574, DOI 10.1182/blood-2010-07-295659
   Rauch GJ, 1997, COLD SPRING HARB SYM, V62, P227
   Roszko I, 2009, SEMIN CELL DEV BIOL, V20, P986, DOI 10.1016/j.semcdb.2009.09.004
   Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a
   Sivalenka RR, 2004, MOL CELL BIOL, V24, P10277, DOI 10.1128/MCB.24.23.10277.10288.2004
   Solnica-Krezel L, 2003, DEVELOPMENT, V130, P4229, DOI 10.1242/dev.00693
   SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67
   Stoick-Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123
   Tada M., 2009, ZEBRAFISH, V6, P29039
   Takada N, 2011, MOL CELL NEUROSCI, V48, P225, DOI 10.1016/j.mcn.2011.08.003
   Tanegashima K, 2008, EMBO J, V27, P606, DOI 10.1038/emboj.2008.9
   Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514
   Tybulewicz Henderson, 2009, IYMPHOCYTES S, P1
   Wakamatsu I, 2006, MOL CELL BIOCHEM, V293, P137, DOI 10.1007/s11010-006-9236-1
   Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1
   WARGA RM, 1990, DEVELOPMENT, V108, P569
   Westerfield M, 2000, ZEBRAFISH BOOK GUIDE
   Witzel S, 2006, J CELL BIOL, V175, P791, DOI 10.1083/jcb.200606017
   Zhu SZ, 2006, CELL SIGNAL, V18, P359, DOI 10.1016/j.cellsig.2005.05.019
NR 48
TC 5
Z9 5
U1 5
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0012-1606
EI 1095-564X
J9 DEV BIOL
JI Dev. Biol.
PD FEB 1
PY 2014
VL 386
IS 1
BP 191
EP 203
DI 10.1016/j.ydbio.2013.10.020
PG 13
WC Developmental Biology
SC Developmental Biology
GA 297LX
UT WOS:000330258000017
PM 24177263
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Chatterjee, S
   Sarkar, K
AF Chatterjee, Saptarshi
   Sarkar, Keka
TI RETRACTED: Surface-functionalized gold nanoparticles mediate bacterial
   transformation: a nanobiotechnological approach (Retracted article. See
   vol. 37, pg. 1527, 2015)
SO BIOTECHNOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE Cytotoxicity; Glutathione-functionalized gold nanoparticles;
   Nanobiotechnology; Nanoparticles; Transformation
ID ESCHERICHIA-COLI; MAMMALIAN-CELLS; DELIVERY; DNA
AB Transformation of bacteria is an important step in molecular biology. Viral and non-virus-based gene delivery techniques, including chemical/biological and physical approaches, have been applied to bacterial, mammalian and plant cells. E. coli is not competent to take up DNA; hence, different methods are used to incorporate plasmid DNA. A novel method has been developed using glutathione-functionalized gold nanoparticles to mediate transformation of plasmid DNA (pUC19) into E. coli DH5 alpha that does not require the preparation of competent cells. The glutathione-functionalized gold nanoparticles acted as a vector and facilitated the entry of DNA into the host cell. The method also gave a higher transformation efficiency (4.2 x 10(7)/mu g DNA) compared to 2.3 x 10(5)/mu g DNA using the conventional CaCl2-mediated method. It was also non-toxic to the bacterium making it suitable for biotechnological applications.
C1 [Chatterjee, Saptarshi; Sarkar, Keka] Univ Kalyani, Dept Microbiol, Kolkata, W Bengal, India.
RP Sarkar, K (reprint author), Univ Kalyani, Dept Microbiol, Kolkata, W Bengal, India.
EM saptarshi_gcc07@yahoo.co.in; keka.micro@gmail.com
FU Department of Science & Technology, Government of India
   [SR/NM/NS-48/2009]; University of Kalyani, Nadia, West Bengal
FX This research work has been carried out with the financial support of
   Department of Science & Technology, Government of India
   (Project-Nanomission: SR/NM/NS-48/2009) and University of Kalyani,
   Nadia, West Bengal.
CR Cai WB, 2008, NANOTECHNOL SCI APPL, V1, P17, DOI 10.2147/NSA.S3788
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chatterjee S, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-34
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P
   Kim EY, 2012, GENE THER, V19, P347, DOI 10.1038/gt.2011.95
   LEDERBERG EM, 1974, J BACTERIOL, V119, P1072
   MICHOD RE, 1988, GENETICS, V118, P31
   NISHIMURA A, 1990, NUCLEIC ACIDS RES, V18, P6169, DOI 10.1093/nar/18.20.6169
   Pinto-Alphandary H, 2000, INT J ANTIMICROB AG, V13, P155, DOI 10.1016/S0924-8579(99)00121-1
   Prakash GD, 2011, ANAL BIOCHEM, V419, P292, DOI 10.1016/j.ab.2011.08.038
   Sandhu KK, 2002, BIOCONJUGATE CHEM, V13, P3, DOI 10.1021/bc015545c
   Schaaff TG, 2000, J PHYS CHEM B, V104, P2630, DOI 10.1021/jp993691y
   Song Y, 2007, NUCLEIC ACIDS RES, V35, P19
   TANG XR, 1994, NUCLEIC ACIDS RES, V22, P2857, DOI 10.1093/nar/22.14.2857
   WIRTH R, 1989, MOL GEN GENET, V216, P175, DOI 10.1007/BF00332248
NR 18
TC 1
Z9 1
U1 3
U2 38
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-5492
EI 1573-6776
J9 BIOTECHNOL LETT
JI Biotechnol. Lett.
PD FEB
PY 2014
VL 36
IS 2
BP 265
EP 271
DI 10.1007/s10529-013-1360-x
PG 7
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 293RE
UT WOS:000329990600009
PM 24101244
DA 2018-12-27
ER

PT J
AU Bendjaballah, M
   Saidi, H
AF Bendjaballah, Malek
   Saidi, Hacina
TI RETRACTED: CLOUD POINT BEHAVIOUR MODELLING OF POLYOXYETHYLENE NONIONIC
   SURFACTANTS (Retracted article. See vol. 93, pg. 2316, 2015)
SO CANADIAN JOURNAL OF CHEMICAL ENGINEERING
LA English
DT Article; Retracted Publication
DE nonionic surfactants; cloud point; Flory-Huggins theory; pseudo-phase
   modelling
ID ADDITIVES; MIXTURES
AB The cloud point temperature, T-c, of commercial nonionic surfactants: poly(oxyethylene) alkyl ethers CncHne (case: dodecan-1ol polyethoxylate, with the middle chemical structure n-C12E6) was predicted by applying the Flory-Huggins theory for polymer solutions, adapted to alcohol ethoxylates aqueous solutions by Rupert and using the pseudo-phase model original developed for micro-emulsions diagrams composition. The variations of interaction enthalpy as a function of carbon chain length and number of ethylene oxide units are also modelled. The expression of T-c as the function of the composition was derived assuming the regular solution for mixed micelles. The experimental results of the cloud point obtained for mixtures of n-C12E6 was better reproduced by the pseudo-phase model, which requires more specific surfactant data (the critical micelles concentration, cmc; critical temperature T-C), and a minimum of experimental data.
C1 [Bendjaballah, Malek] 8 Mai 1945 Guelma Univ Algeria, Ind Anal & Mat Engn Lab LAIGM, Guelma 24000, Algeria.
   [Saidi, Hacina] Badji Mokhtar Univ, Environm & Ecol Lab, Annaba 23000, Algeria.
RP Bendjaballah, M (reprint author), 8 Mai 1945 Guelma Univ Algeria, Ind Anal & Mat Engn Lab LAIGM, PO 401, Guelma 24000, Algeria.
EM mbendjaballah@hotmail.com
OI Malek, BENDJABALLAH/0000-0003-0483-4785
FU Algerian Government (Ministry of Higher Education and Scientific
   Research)
FX The authors are grateful to the Algerian Government (Ministry of Higher
   Education and Scientific Research) for financial this work and a
   particular thanks are due to Dr. J. P. Canselier from the Laboratory of
   Chemical Engineering L.G.C/INP/UMR 5503, Toulouse France for suggestions
   and advice about the analysis and use this type of nonionic surfactants
   and his valuable scientific discussion.
CR Adamsom A. W., 1990, PHYS CHEM SURFACES
   Alibrahim M, 2005, TENSIDE SURFACT DET, V42, P295, DOI 10.3139/113.100271
   Attwood D, 1983, SURFACTANT SYSTEMS T
   Bai DS, 2001, ENVIRON SCI TECHNOL, V35, P3936, DOI 10.1021/es0108335
   BARRY BW, 1972, J COLLOID INTERF SCI, V40, P174, DOI 10.1016/0021-9797(72)90007-0
   Degiorgio V., 1985, PHYSICS AMPHIPHILES, P303
   Denver G. H., 1987, NONIONIC SURFACTANTS, V23, P281
   Duarte LJN, 2005, TENSIDE SURFACT DET, V42, P299, DOI 10.3139/113.100272
   EVANS H, 1987, J CHEM SOC FARAD T 2, V83, P1525, DOI 10.1039/f29878301525
   Flory P. J., 1953, PRINCIPLES POLYM CHE
   GOLDFARB J, 1969, J COLLOID INTERF SCI, V31, P454, DOI 10.1016/0021-9797(69)90046-0
   Hadou B., 2003, THESIS INP TOULOUSE
   HINZE WL, 1993, CRIT REV ANAL CHEM, V24, P133, DOI 10.1080/10408349308048821
   Leng C. A., 1984, J SOC F2, V2, P145
   LINDMAN B, 1991, J PHYS CHEM-US, V95, P6053, DOI 10.1021/j100168a063
   Nakagawa T., 1966, NONIONIC SURFACTANTS
   Prigogine I., 1950, THERMODYNAMIQUE CHIM
   RUPERT LAM, 1992, J COLLOID INTERF SCI, V153, P92, DOI 10.1016/0021-9797(92)90300-B
   Schick MJ, 1987, NONIONIC SURFACTANTS
   Tohru I., 2003, J COLLOID INTERF SCI, V258, P374
   Unda C., 2002, CAHIERS FORMULATION, V9, P139
   WIDOM B, 1970, J CHEM PHYS, V52, P1670, DOI 10.1063/1.1673203
NR 22
TC 3
Z9 3
U1 2
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-4034
EI 1939-019X
J9 CAN J CHEM ENG
JI Can. J. Chem. Eng.
PD FEB
PY 2014
VL 92
IS 2
BP 288
EP 295
DI 10.1002/cjce.21943
PG 8
WC Engineering, Chemical
SC Engineering
GA 290TG
UT WOS:000329780600009
DA 2018-12-27
ER

PT J
AU Hagihara, A
AF Hagihara, Akio
TI RETRACTED: Deriving the mean mass-density trajectory by reconciling the
   competition-density effect law with the self-thinning law in even-aged
   pure stands (Retracted Article. See vol. 21, pg 259, 2016)
SO JOURNAL OF FOREST RESEARCH
LA English
DT Article; Retracted Publication
DE Density-independent mortality; General logistic equation; rho - rho(i)
   model; Survivorship curve; The law of constant final yield
ID SIMULATED PLANT-POPULATIONS; MATHEMATICAL CONSIDERATIONS; GROWTH
   ANALYSIS; BIRCH STANDS; RULE; MODEL; YIELD; MONOCULTURES; SYMMETRY; DEAD
AB The competition-density (C-D) effect law refers to the relationship between mean mass w and density rho at a particular moment among a set of tree populations grown at a wide range of densities. The self-thinning law refers to the time trajectory of w and rho in overcrowded stands. Because these two laws have not yet been theoretically harmonised, the aim of this paper is to achieve the unification of the two laws. Under the assumption that the reciprocal equation of the C-D effect in self-thinning stands and the self-thinning equation both hold, the slope of the reciprocal equation becomes the same as that of the self-thinning equation on logarithmic scales as the growth stage progresses. Finally, the reciprocal equation is converted to the w-rho trajectory, eliminating the biological time from the reciprocal equation. The w-rho trajectory of stands starting with any initial density has thus been explicitly formulated. Larger values of the relative mortality rate play an important role in relieving the C-D effect and cause the w-rho trajectory to approach the self-thinning line at an earlier stage of growth. Stands exponentially decreasing in number obey the self-thinning law after a sufficient lapse of biological time, irrespective of their initial densities. Unknown functions, such as the survivorship curve and the ceiling biomass, have been explicitly represented as a function of biological time. The approximate expression for the w-rho trajectory suitably mimics the time trajectory of mean stem and density in an eastern pine plantation.
C1 Univ Ryukyus, Fac Sci, Okinawa 9030213, Japan.
RP Hagihara, A (reprint author), Univ Ryukyus, Fac Sci, Okinawa 9030213, Japan.
EM amyh@sci.u-ryukyu.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [23380094]
FX I gratefully appreciate the valuable suggestions and criticisms offered
   by Emeritus Professor Kazuo Hozumi, Nagoya University, and Emeritus
   Professor Takuo Yamakura, Osaka City University during the development
   of this paper. I thank Dr. Sahadev Sharma and Mr. Md. Kamruzzaman for
   their artwork. This study was financed in part by a Grant-in-Aid for
   Scientific Research (No. 23380094) from the Ministry of Education,
   Culture, Sports, Science and Technology, Japan.
CR AIKMAN DP, 1980, ANN BOT-LONDON, V45, P419, DOI 10.1093/oxfordjournals.aob.a085840
   Analuddin K, 2009, J PLANT RES, V122, P53, DOI 10.1007/s10265-008-0190-8
   Ando T, 1968, B GOV FOR EXP STN TO, V210, P1
   ANDO TAKASHL, 1962, BULL GOVT FOREST EXPT STA, V147, P45
   Begon M., 2006, ECOLOGY INDIVIDUALS
   Chu CJ, 2010, ANN BOT-LONDON, V106, P647, DOI 10.1093/aob/mcq145
   DREW TJ, 1977, FOREST SCI, V23, P517
   Enquist BJ, 1998, NATURE, V395, P163, DOI 10.1038/25977
   FIRBANK LG, 1985, J THEOR BIOL, V116, P291, DOI 10.1016/S0022-5193(85)80269-1
   Hagihara A., 1998, Journal of Forest Planning, V4, P65
   Hagihara A, 1999, RES POPUL ECOL, V41, P151, DOI 10.1007/s101440050017
   Hagihara A, 1996, B NAGOYA U FOR, V15, P51
   Hagihara A, 2000, B FAC SCI U RYUKYUS, V70, P99
   HAMILTON NRS, 1995, ANN BOT-LONDON, V76, P569, DOI 10.1006/anbo.1995.1134
   HARA T, 1984, ANN BOT-LONDON, V53, P181, DOI 10.1093/oxfordjournals.aob.a086679
   HARPER J. L., 1977, POPULATION BIOL PLAN
   HOZUMI K, 1977, BOT MAG TOKYO, V90, P165, DOI 10.1007/BF02488355
   HOZUMI K, 1980, BOT MAG TOKYO, V93, P149, DOI 10.1007/BF02489121
   HOZUMI K, 1983, BOT MAG TOKYO, V96, P171, DOI 10.1007/BF02498999
   HOZUMI KAZUO, 1956, JOUR INST POLYTECH OSAKA CITY UNIV SER D BIOL, V7, P15
   KAYS S, 1974, J ECOL, V62, P97, DOI 10.2307/2258882
   KIRA TATUO, 1956, JOUR INST POLYTECH OSAKA CITY UNIV SER D BIOL, V7, P1
   KIRA TATUO, 1953, JOUR INST POLYTECH [OSAKA CITY UNIV] SER D BIOL, V4, P1
   LONSDALE WM, 1990, ECOLOGY, V71, P1373, DOI 10.2307/1938275
   Minowa M., 1982, Journal of the Japanese Forestry Society, V64, P461
   Naito K, 1992, B UTSUNOMIYA U FOR, V28, P1
   NORBERG RA, 1988, AM NAT, V131, P220, DOI 10.1086/284787
   Ogawa K, 2005, FOREST ECOL MANAG, V214, P104, DOI 10.1016/j.foreco.2005.03.067
   Ogawa K, 2001, FOREST ECOL MANAG, V142, P291, DOI 10.1016/S0378-1127(00)00358-3
   OSAWA A, 1989, ECOLOGY, V70, P279, DOI 10.2307/1938435
   Osawa A, 2004, TREES-STRUCT FUNCT, V18, P327, DOI 10.1007/s00468-003-0310-y
   Reynolds JH, 2005, J ECOL, V93, P362, DOI 10.1111/j.1365-2745.2005.00976.x
   Shibuya M., 1997, Research Bulletin of the Hokkaido University Forests, V54, P202
   Shibuya M, 1994, ECOL RES, V9, P325, DOI 10.1007/BF02348419
   Shinozaki K, 1953, J OSAKA CITY MED SCH, V2, P265
   Shinozaki K., 1953, J OSAKA CITY MED SCH, V2, P143
   Shinozaki K, 1962, THESIS KYOTO U
   SHINOZAKI KICHIRO, 1956, JOUR INST POLYTECH OSAKA CITY UNIV SER D BIOL, V7, P35
   Silvertown J., 2001, INTRO PLANT POPULATI
   SMITH NJ, 1986, CAN J FOREST RES, V16, P330, DOI 10.1139/x86-056
   SPURR STEPHEN H., 1957, JOUR FOREST, V55, P7
   Stankova T, 2003, FOREST ECOL MANAG, V186, P7, DOI 10.1016/S0378-1127(03)00260-3
   Tadaki Y, 1979, B FOR FOR PROD RES I, V305, P125
   TADAKI YOSHIYA, 1959, JOUR JAPANESE FOREST SOC, V41, P341
   TANG SZ, 1994, FOREST ECOL MANAG, V70, P67, DOI 10.1016/0378-1127(94)90075-2
   THORANISORN S, 1990, BOT MAG TOKYO, V103, P283, DOI 10.1007/BF02488640
   WATKINSON AR, 1984, ANN BOT-LONDON, V53, P469, DOI 10.1093/oxfordjournals.aob.a086711
   WATKINSON AR, 1980, J THEOR BIOL, V83, P345, DOI 10.1016/0022-5193(80)90297-0
   Watkinson AR, 1997, PLANT ECOL, P349
   Weiner J, 2001, AM NAT, V158, P438, DOI 10.1086/321988
   Weiner J, 2010, ANNU REV ECOL EVOL S, V41, P173, DOI 10.1146/annurev-ecolsys-102209-144642
   WELLER DE, 1991, ECOLOGY, V72, P747, DOI 10.2307/2937216
   WELLER DE, 1990, ECOLOGY, V71, P1204, DOI 10.2307/1937389
   WESTOBY M, 1984, ADV ECOL RES, V14, P167, DOI 10.1016/S0065-2504(08)60171-3
   WHITE J, 1981, J THEOR BIOL, V89, P475, DOI 10.1016/0022-5193(81)90363-5
   WHITE J, 1985, STUDIES PLANT DEMOGR, P291
   Xue L, 1998, ECOL RES, V13, P183, DOI 10.1046/j.1440-1703.1998.00256.x
   Xue L, 2010, EUR J FOREST RES, V129, P1027, DOI 10.1007/s10342-010-0387-y
   Yamakura T, 2008, J JPN SOC HORTIC SCI, V77, P17, DOI 10.2503/jjshs1.77.17
   YODA KYOJI, 1963, J BIOL OSAKA CITY UNIV, V14, P107
   ZEIDE B, 1987, FOREST SCI, V33, P517
NR 61
TC 1
Z9 1
U1 3
U2 26
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 1341-6979
EI 1610-7403
J9 J FOREST RES-JPN
JI J. For. Res.
PD FEB
PY 2014
VL 19
IS 1
BP 125
EP 133
DI 10.1007/s10310-013-0393-2
PG 9
WC Forestry
SC Forestry
GA 285OY
UT WOS:000329404600014
DA 2018-12-27
ER

PT J
AU Norman, AB
   Tabet, MR
   Norman, MK
   Tsibulsky, VL
AF Norman, Andrew B.
   Tabet, Michael R.
   Norman, Mantana K.
   Tsibulsky, Vladimir L.
TI RETRACTED: Maintained Cocaine Self-Administration Is Determined by
   Quantal Responses: Implications for the Measurement of Antagonist
   Potency (Retracted article. See vol. 358, pg. 241, 2016)
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article; Retracted Publication
ID RATS; AMPHETAMINE
AB The change in frequency of cocaine self-administration as a function of the unit dose is widely assumed to represent a graded pharmacodynamic response. Alternatively, a pharmacological theory states that during maintained self-administration, a quantal response occurs at a minimum maintained cocaine concentration (satiety threshold). Rats self-administered cocaine at unit doses spanning an 8-fold range from 0.75 to 6 mu mol/kg. Despite an approximately 7-fold difference in the interinjection intervals, there were no differences in the plasma cocaine concentration at the time of lever press across this range of unit doses, consistent with the satiety threshold representing an equiactive cocaine concentration. Because self-administration always occurs when cocaine concentrations decline back to the satiety threshold, this behavior represents a process of automatic back titration of equiactive agonist concentrations. Therefore, the lower frequency of self-administration at higher unit doses is caused by an increase in the duration of the cocaine-induced satiety response, and the graded dose-frequency relationship is due to cocaine pharmacokinetics. After the interinjection intervals at a particular unit dose were stable, rats were injected with the competitive D-1-like dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390; 15 nmol/kg intravenously) and the session continued. At all cocaine unit doses, SCH23390 accelerated self-administration with a concomitant increase in the calculated satiety threshold, and these equiactive cocaine concentration ratios were independent of the cocaine unit dose. Therefore, the measurement of antagonist potency requires only a single unit dose of cocaine, selected on the basis of convenience, and using multiple cocaine unit doses is redundant.
C1 [Norman, Andrew B.; Tabet, Michael R.; Norman, Mantana K.; Tsibulsky, Vladimir L.] Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA.
RP Norman, AB (reprint author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.
EM andrew.norman@uc.edu
OI Tsibulsky, Vladimir/0000-0002-7163-2684
FU National Institutes of Health National Institute on Drug Abuse
   [DP1-DA031386]
FX This research was supported by the National Institutes of Health
   National Institute on Drug Abuse [Grant DP1-DA031386].
CR Colquhoun D, 2007, TRENDS PHARMACOL SCI, V28, P608, DOI 10.1016/j.tips.2007.09.011
   KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4
   Norman AB, 2006, BRAIN RES, V1116, P143, DOI 10.1016/j.brainres.2006.07.092
   Norman AB, 2011, SYNAPSE, V65, P404, DOI 10.1002/syn.20858
   Norman AB, 2011, J NEUROSCI METH, V194, P252, DOI 10.1016/j.jneumeth.2010.10.017
   Norman AB, 2007, J PHARMACOL EXP THER, V320, P145, DOI 10.1124/jpet.106.111781
   PICKENS R, 1968, J PHARMACOL EXP THER, V161, P122
   SCHILD HO, 1957, PHARMACOL REV, V9, P242
   SCHILD HO, 1947, BRIT J PHARM CHEMOTH, V2, P189, DOI 10.1111/j.1476-5381.1947.tb00336.x
   Tsibulsky VL, 2005, BRAIN RES PROTOC, V15, P38, DOI 10.1016/j.brainresprot.2005.03.003
   Tsibulsky VL, 1999, BRAIN RES, V839, P85, DOI 10.1016/S0006-8993(99)01717-5
   Tsibulsky VL, 2012, SPR SER COMPUT NEURO, V10, P3, DOI 10.1007/978-1-4614-0751-5_1
   WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140
   YOKEL RA, 1975, SCIENCE, V187, P547, DOI 10.1126/science.1114313
   YOKEL RA, 1974, PSYCHOPHARMACOLOGIA, V34, P255, DOI 10.1007/BF00421966
NR 15
TC 2
Z9 2
U1 2
U2 6
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD FEB
PY 2014
VL 348
IS 2
BP 311
EP 315
DI 10.1124/jpet.113.210690
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 292OO
UT WOS:000329911800010
PM 24307200
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Obokata, H
   Wakayama, T
   Sasai, Y
   Kojima, K
   Vacanti, MP
   Niwa, H
   Yamato, M
   Vacanti, CA
AF Obokata, Haruko
   Wakayama, Teruhiko
   Sasai, Yoshiki
   Kojima, Koji
   Vacanti, Martin P.
   Niwa, Hitoshi
   Yamato, Masayuki
   Vacanti, Charles A.
TI RETRACTED: Stimulus-triggered fate conversion of somatic cells into
   pluripotency (Retracted article. See vol. 511, pg. 112, 2014)
SO NATURE
LA English
DT Article; Retracted Publication
ID EMBRYONIC STEM-CELLS; HEMATOPOIETIC STEM; ES CELLS; MOUSE; CULTURE;
   MARROW; MICE; DIFFERENTIATION; MORPHOGENESIS; POPULATION
AB Here we report a unique cellular reprogramming phenomenon, called stimulus-triggered acquisition of pluripotency (STAP), which requires neither nuclear transfer nor the introduction of transcription factors. In STAP, strong external stimuli such as a transient low-pH stressor reprogrammed mammalian somatic cells, resulting in the generation of pluripotent cells. Through real-time imaging of STAP cells derived from purified lymphocytes, as well as gene rearrangement analysis, we found that committed somatic cells give rise to STAP cells by reprogramming rather than selection. STAP cells showed a substantial decrease in DNA methylation in the regulatory regions of pluripotency marker genes. Blastocyst injection showed that STAP cells efficiently contribute to chimaeric embryos and to offspring via germline transmission. We also demonstrate the derivation of robustly expandable pluripotent cell lines from STAP cells. Thus, our findings indicate that epigenetic fate determination of mammalian cells can be markedly converted in a context-dependent manner by strong environmental cues.
C1 [Obokata, Haruko; Kojima, Koji; Vacanti, Martin P.; Vacanti, Charles A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Lab Tissue Engn & Regenerat Med, Boston, MA 02115 USA.
   [Obokata, Haruko] RIKEN Ctr Dev Biol, Lab Cellular Reprogramming, Kobe, Hyogo 6500047, Japan.
   [Obokata, Haruko; Wakayama, Teruhiko] RIKEN Ctr Dev Biol, Lab Genom Reprogramming, Kobe, Hyogo 6500047, Japan.
   [Sasai, Yoshiki] RIKEN Ctr Dev Biol, Lab Organogenesis & Neurogenesis, Kobe, Hyogo 6500047, Japan.
   [Vacanti, Martin P.] Irwin Army Community Hosp, Dept Pathol, Ft Riley, KS 66442 USA.
   [Niwa, Hitoshi] RIKEN Ctr Dev Biol, Lab Pluripotent Stem Cell Studies, Kobe, Hyogo 6500047, Japan.
   [Yamato, Masayuki] Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Tokyo 1628666, Japan.
RP Obokata, H (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Lab Tissue Engn & Regenerat Med, Boston, MA 02115 USA.
EM obokata@cdb.riken.jp; cvacanti@partners.org
FU RIKEN; Network Project for Realization of Regenerative Medicine;
   Department of Anesthesiology, Perioperative and Pain Medicine at Brigham
   and Women's Hospital;  [20062015]
FX We thank S. Nishikawa for discussion and J. D. Ross, N. Takata, M.
   Eiraku, M. Ohgushi, S. Itoh, S. Yonemura, S. Ohtsuka and K. Kakiguchi
   for help with experiments and analyses. We thank A. Penvose and K.
   Westerman for comments on the manuscript. H.O. is grateful to T. Okano,
   S. Tsuneda and K. Kuroda for support and encouragement. Financial
   support for this research was provided by Intramural RIKEN Research
   Budget (H.O., T.W. and Y.S.), a Scientific Research in Priority Areas
   (20062015) to T.W., the Network Project for Realization of Regenerative
   Medicine to Y.S., and Department of Anesthesiology, Perioperative and
   Pain Medicine at Brigham and Women's Hospital to C.A.V.
CR Berg JS, 2007, CELL STEM CELL, V1, P359, DOI 10.1016/j.stem.2007.09.007
   Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950
   Byrnes WM, 2009, MOL REPROD DEV, V76, P912, DOI 10.1002/mrd.21081
   D'Ippolito G, 2004, J CELL SCI, V117, P2971, DOI 10.1242/jcs.01103
   Eakin GS, 2005, DEV BIOL, V288, P150, DOI 10.1016/j.ydbio.2005.09.028
   Eilken M. H., 2009, NATURE, V457, P896
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Gerhart J, 1996, DEV DYNAM, V205, P245, DOI 10.1002/(SICI)1097-0177(199603)205:3<245::AID-AJA5>3.0.CO;2-I
   Gouon-Evans V, 2006, NAT BIOTECHNOL, V24, P1402, DOI 10.1038/nbt1258
   Gratama JW, 2001, SEMIN HEMATOL, V38, P139, DOI 10.1053/shem.2001.21925
   GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622
   Hanna J, 2008, CELL, V133, P250, DOI 10.1016/j.cell.2008.03.028
   HOLTFRETER J, 1947, J EXP ZOOL, V106, P197, DOI 10.1002/jez.1401060205
   Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235
   Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278
   Hurtado C, 2007, DEV BIOL, V307, P282, DOI 10.1016/j.ydbio.2007.04.049
   Inoue K, 2006, J CELL SCI, V119, P1985, DOI 10.1242/jcs.02913
   Jentsch I, 2003, CYTOGENET GENOME RES, V103, P84, DOI 10.1159/000076294
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0
   Kucia M, 2006, LEUKEMIA, V20, P857, DOI 10.1038/sj.leu.2404171
   Kuroda Y, 2013, NAT PROTOC, V8, P1391, DOI 10.1038/nprot.2013.076
   Kuroda Y, 2010, P NATL ACAD SCI USA, V107, P8639, DOI 10.1073/pnas.0911647107
   Lengner CJ, 2008, CELL CYCLE, V7, P725, DOI 10.4161/cc.7.6.5573
   Murakami K, 2011, DEVELOPMENT, V138, P197, DOI 10.1242/dev.056606
   NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424
   Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787
   Obokata H, 2011, TISSUE ENG PT A, V17, P607, DOI [10.1089/ten.tea.2010.0385, 10.1089/ten.TEA.2010.0385]
   Ogawa K, 2004, GENES CELLS, V9, P471, DOI 10.1111/j.1365-9597.2004.00736.x
   Ohbo K, 2003, DEV BIOL, V258, P209, DOI 10.1016/S0012-1606(03)00111-8
   Ohgushi M, 2011, TRENDS CELL BIOL, V21, P274, DOI 10.1016/j.tcb.2011.02.004
   Ohgushi M, 2010, CELL STEM CELL, V7, P225, DOI 10.1016/j.stem.2010.06.018
   Pera MF, 2010, NATURE, V465, P713, DOI 10.1038/nature09228
   SURANI MAH, 1983, SCIENCE, V222, P1034, DOI 10.1126/science.6648518
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972
   Thorpe TA, 2007, MOL BIOTECHNOL, V37, P169, DOI 10.1007/s12033-007-0031-3
   Wakayama S, 2013, CELL STEM CELL, V12, P293, DOI 10.1016/j.stem.2013.01.005
   Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615
   Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402
   Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968
NR 41
TC 148
Z9 157
U1 20
U2 775
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JAN 30
PY 2014
VL 505
IS 7485
BP 641
EP +
DI 10.1038/nature12968
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 298JV
UT WOS:000330321000032
PM 24476887
DA 2018-12-27
ER

PT J
AU Obokata, H
   Sasai, Y
   Niwa, H
   Kadota, M
   Andrabi, M
   Takata, N
   Tokoro, M
   Terashita, Y
   Yonemura, S
   Vacanti, CA
   Wakayama, T
AF Obokata, Haruko
   Sasai, Yoshiki
   Niwa, Hitoshi
   Kadota, Mitsutaka
   Andrabi, Munazah
   Takata, Nozomu
   Tokoro, Mikiko
   Terashita, Yukari
   Yonemura, Shigenobu
   Vacanti, Charles A.
   Wakayama, Teruhiko
TI RETRACTED: Bidirectional developmental potential in reprogrammed cells
   with acquired pluripotency (Retracted article. See vol. 511, pg. 112,
   2014)
SO NATURE
LA English
DT Article; Retracted Publication
ID EMBRYONIC STEM-CELLS; SELF-RENEWAL; GROUND-STATE; EXPRESSION; NUCLEI;
   GENES; MICE
AB We recently discovered an unexpected phenomenon of somatic cell reprogramming into pluripotent cells by exposure to sublethal stimuli, which we call stimulus-triggered acquisition of pluripotency (STAP)(1). This reprogramming does not require nuclear transfer(2,3) or genetic manipulation(4). Here we report that reprogrammed STAP cells, unlike embryonic stem (ES) cells, can contribute to both embryonic and placental tissues, as seen in a blastocyst injection assay. Mouse STAP cells lose the ability to contribute to the placenta as well as trophoblast marker expression on converting into ES-like stem cells by treatment with adrenocorticotropic hormone (ACTH) and leukaemia inhibitory factor (LIF). In contrast, when cultured with Fgf4, STAP cells give rise to proliferative stem cells with enhanced trophoblastic characteristics. Notably, unlike conventional trophoblast stem cells, the Fgf4-induced stem cells from STAP cells contribute to both embryonic and placental tissues in vivo and transform into ES-like cells when cultured with LIF-containing medium. Taken together, the developmental potential of STAP cells, shown by chimaera formation and in vitro cell conversion, indicates that they represent a unique state of pluripotency.
C1 [Obokata, Haruko; Terashita, Yukari] RIKEN Ctr Dev Biol, Lab Cellular Reprogramming, Kobe, Hyogo 6500047, Japan.
   [Obokata, Haruko; Tokoro, Mikiko; Terashita, Yukari; Wakayama, Teruhiko] RIKEN Ctr Dev Biol, Lab Genom Reprogramming, Kobe, Hyogo 6500047, Japan.
   [Obokata, Haruko; Vacanti, Charles A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Lab Tissue Engn & Regenerat Med, Boston, MA 02115 USA.
   [Sasai, Yoshiki; Takata, Nozomu] RIKEN Ctr Dev Biol, Lab Organogenesis & Neurogenesis, Kobe, Hyogo 6500047, Japan.
   [Niwa, Hitoshi] RIKEN Ctr Dev Biol, Lab Pluripotent Stem Cell Studies, Kobe, Hyogo 6500047, Japan.
   [Kadota, Mitsutaka; Andrabi, Munazah] RIKEN Ctr Dev Biol, Genome Resource & Anal Unit, Kobe, Hyogo 6500047, Japan.
   [Yonemura, Shigenobu] RIKEN Ctr Dev Biol, Electron Microscopy Lab, Kobe, Hyogo 6500047, Japan.
   [Wakayama, Teruhiko] Univ Yamanashi, Fac Life & Environm Sci, Yamanashi 4008510, Japan.
RP Obokata, H (reprint author), RIKEN Ctr Dev Biol, Lab Cellular Reprogramming, Kobe, Hyogo 6500047, Japan.
EM obokata@cdb.riken.jp; yoshikisasai@cdb.riken.jp; teru@cdb.riken.jp
FU RIKEN; Network Project for Realization of Regenerative Medicine;
   Department of Anesthesiology, Perioperative and Pain Medicine at Brigham
   and Women's Hospital;  [20062015]
FX We thank S. Nishikawa and N. Love for discussion and M. Ohgushi, S.
   Kuraku, M. Eiraku, S. Ohtsuka and K. Kakiguchi for help with
   experimental planning, material preparation and analyses. Financial
   support for this research was provided by Intramural RIKEN Research
   Budget (H.O., T.W. and Y.S.), a Scientific Research in Priority Areas
   (20062015) to T.W., the Network Project for Realization of Regenerative
   Medicine to Y.S., and Department of Anesthesiology, Perioperative and
   Pain Medicine at Brigham and Women's Hospital to C.A.V.
CR Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Chen YY, 2013, STEM CELL REP, V1, P209, DOI 10.1016/j.stemcr.2013.07.003
   Debeb BG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007216
   GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622
   Klaffky E, 2001, DEV BIOL, V239, P161, DOI 10.1006/dbio.2001.0404
   Macfarlan TS, 2012, NATURE, V487, P57, DOI 10.1038/nature11244
   Meek S, 2013, STEM CELLS, V31, P2104, DOI 10.1002/stem.1466
   Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056
   NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424
   Niwa H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040
   Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787
   Obokata H, 2014, NATURE, V505, P641, DOI 10.1038/nature12968
   Quinn J, 2006, METH MOLEC MED, V121, P125
   Russ AP, 2000, NATURE, V404, P95, DOI 10.1038/35003601
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072
   Tanaka TS, 2002, GENOME RES, V12, P1921, DOI 10.1101/gr.670002
   van Oosten AL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1822
   Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615
   Yang JA, 2010, CELL STEM CELL, V7, P319, DOI 10.1016/j.stem.2010.06.022
   Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968
NR 23
TC 75
Z9 80
U1 5
U2 373
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JAN 30
PY 2014
VL 505
IS 7485
BP 676
EP +
DI 10.1038/nature12969
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 298JV
UT WOS:000330321000040
PM 24476891
DA 2018-12-27
ER

PT J
AU Briones, TL
   Woods, J
   Wadowska, M
AF Briones, Teresita L.
   Woods, Julie
   Wadowska, Magdalena
TI RETRACTED: Chronic neuroinflammation and cognitive impairment following
   transient global cerebral ischemia: role of fractalkine/CX3CR1 signaling
   (Retracted article. See vol. 12, 220, 2015)
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article; Retracted Publication
DE siRNA; Learning and memory; Microglia; Cytokines
ID MICROGLIAL ACTIVATION; GENE-EXPRESSION; BRAIN; DEFICIENCY; RECEPTOR;
   INFLAMMATION; PLASTICITY; INJURY; MOUSE; NEUROTOXICITY
AB Although neuroinflammation has been studied extensively in animal models of cerebral ischemia, their contrasting functions are still not completely understood. A major participant in neuroinflammation is microglia and microglial activation usually regulated by the chemokine CX3CL1 (fractalkine) and its receptor, CX3CR1. Here, we examined the involvement of CX3CR1 on ischemia-induced chronic neuroinflammation and cognitive function using small interfering RNA (siRNA). Forty adult male Wistar rats were included in the study and received either ischemia or sham surgery then were randomized to receive either CX3CR1 siRNA or scrambled RNA as control starting at 7 days after reperfusion. Behavioral testing commenced 28 days after siRNA delivery and all rats were euthanized after behavioral testing. Our data showed that: (i) transient global cerebral ischemia significantly decreased fractalkine/CX3CR1 signaling in the hippocampus; (ii) inhibition of CX3CR1 function exacerbated the ischemia-induced chronic increase in microglial activation and pro-inflammatory cytokine levels; (iii) inhibition of CX3CR1 function worsened ischemia-induced chronic cognitive impairment; (iv) inhibition of CX3CR1 function in sham rats resulted in increased IL-1 beta expression and impaired behavioral performance. However, no significant effect of CX3CR1 on ischemia-induced neurodegeneration was seen. The present study provides important insight to understanding the involvement of CX3CR1 in chronic neuroinflammation and cognitive impairment.
C1 [Briones, Teresita L.] Wayne State Univ, Dept Adult Hlth, Detroit, MI 48202 USA.
   [Woods, Julie; Wadowska, Magdalena] Univ Illinois, Dept Biobehav Hlth Sci, Chicago, IL 60612 USA.
RP Briones, TL (reprint author), Wayne State Univ, Dept Adult Hlth, 5557 Cass Ave Cohn Bldg,Rm 344, Detroit, MI 48202 USA.
EM tbriones@wayne.edu
FU National Institutes of Health, NINR [RO1 NR005260]; Wayne State
   University Faville Endowment Fund
FX This work was supported in part by the National Institutes of Health,
   NINR grant # RO1 NR005260 and the Wayne State University Faville
   Endowment Fund. We are grateful for the assistance of Mai Nguyen in
   imaging and data analysis.
CR Briones TL, 2011, J NEUROTRAUM, V28, P2485, DOI 10.1089/neu.2011.1842
   Briones TL, 2004, BRAIN RES, V997, P137, DOI 10.1016/j.brainres.2003.10.030
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Cho SH, 2011, J BIOL CHEM, V286, P32713, DOI 10.1074/jbc.M111.254268
   Cipriani R, 2011, J NEUROSCI, V31, P16327, DOI 10.1523/JNEUROSCI.3611-11.2011
   Denes A, 2008, J CEREBR BLOOD F MET, V28, P1707, DOI 10.1038/jcbfm.2008.64
   Desforges Nicole M, 2012, Int J Alzheimers Dis, V2012, P345472, DOI 10.1155/2012/345472
   Eggen BJL, 2013, J NEUROIMMUNE PHARM, V8, P807, DOI 10.1007/s11481-013-9490-4
   Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474
   Gaikwad Sadanand M, 2013, Methods Mol Biol, V1041, P185, DOI 10.1007/978-1-62703-520-0_18
   Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896
   Hassani Z, 2005, J GENE MED, V7, P198, DOI 10.1002/jgm.659
   ladecola C, 2011, NAT MED, V17, P796, DOI DOI 10.1038/NM.2399
   Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lourbopoulos A, 2011, LAB ANIM, V44, P71
   Maggi L, 2011, FRONT CELL NEUROSCI, V5, DOI 10.3389/fncel.2011.00022
   McColl BW, 2007, BIOCHEM SOC T, V35, P1163, DOI 10.1042/BST0351163
   Morris RGM, 2003, PHILOS T ROY SOC B, V358, P643, DOI 10.1098/rstb.2002.1230
   Muir KW, 2007, CURR OPIN NEUROL, V20, P334, DOI 10.1097/WCO.0b013e32813ba151
   Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008
   Pabon MM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-9
   Paxinos G, 1997, RAT BRAIN STEREOTAXI
   Pluta R, 2012, ROM J MORPHOL EMBRYO, V53, P461
   Ransohoff RM, 2007, INT REV NEUROBIOL, V82, P187, DOI 10.1016/S0074-7742(07)82010-1
   Rogers JT, 2011, J NEUROSCI, V31, P16241, DOI 10.1523/JNEUROSCI.3667-11.2011
   Selakovic V, 2009, DIS MARKERS, V26, P65, DOI 10.3233/DMA-2009-0608
   Sioud M, 2005, METH MOL B, V309, P237
   Soriano SG, 2002, J NEUROIMMUNOL, V125, P59, DOI 10.1016/S0165-5728(02)00033-4
   Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x
   Wang JP, 2013, INT J MOL MED, V31, P172, DOI 10.3892/ijmm.2012.1179
   Weinstein JR, 2010, FUTUR NEUROL, V5, P227, DOI 10.2217/FNL.10.1
   Winocur G, 2004, NEUROBIOL AGING
   Wu J, 2013, NEUROBIOL AGING, V34, P2843, DOI 10.1016/j.neurobiolaging.2013.06.003
NR 34
TC 18
Z9 21
U1 2
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JAN 22
PY 2014
VL 11
AR 13
DI 10.1186/1742-2094-11-13
PG 13
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA AD4II
UT WOS:000333212000001
PM 24447880
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ying, HC
   Lyu, J
   Ying, TS
   Li, J
   Jin, SS
   Shao, JR
   Wang, LL
   Xu, HY
AF Ying, Huanchun
   Lyu, Jing
   Ying, Tianshu
   Li, Jun
   Jin, Shanshan
   Shao, Jingru
   Wang, Lili
   Xu, Hongying
TI RETRACTED: Risk miRNA screening of ovarian cancer based on miRNA
   functional synergistic network (Retracted article. See vol. 8, 17, 2015)
SO JOURNAL OF OVARIAN RESEARCH
LA English
DT Article; Retracted Publication
DE miRNA expression profile; Ovarian cancer; miRNA functional synergistic
   network; Co-regulating; Functional module
ID MICRORNA EXPRESSION PROFILES; GENE-EXPRESSION; LUNG; CARCINOMA;
   PROSTATE; PLATFORM; TARGETS; SAMPLES; CELLS; CREB
AB Background: miRNAs are proved to have causal roles in tumorgenesis involving various types of human cancers, but the mechanism is not clear. We aimed to explore the effect of miRNAs on the development of ovarian cancer and the underlying mechanism.
   Methods: The miRNA expression profile GSE31801 was downloaded from GEO (Gene Expression Omnibus) database. Firstly, the differentially expressed miRNAs were screened. Target genes of the miRNAs were collected from TargetScan, PicTar, miRanda, and DIANA-microT database, then the miRNA-miRNA co-regulating network was constructed using miRNA pairs with common regulated target genes. Next, the functional modules in the network were studied, the miRNA pairs regulated at least one modules were enriched to form the miRNA functional synergistic network (MFSN).
   Results: Risk miRNA were selected in MFSN according to the topological structure. Transcript factors (TFs) in MFSN were identified, followed by the miRNA-transcript factor networks construction. Totally, 42 up-and 61 down-regulated differentially expressed miRNAs were identified, of which 68 formed 2292 miRNA pairs in the miRNA-miRNA co-regulating network. GO: 0007268 (synaptic transmission) and GO: 0019226 (transmission of nerve impulse) were the two common functions of miRNAs in MFSN, and hsa-miR-579 (36), hsa-miR-942 (31), hsa-miR-105 (31), hsa-miR-150 (34), and hsa-miR-27a* (32) were selected as the hub nodes in MFSN.
   Conclusions: In all, 17 TFs, including CREM, ERG, and CREB1 were screened as the cancer related TFs in MFSN. Other TFs, such as BIN1, FOXN3, FOXK1, FOXP2, and ESRRG with high degrees may be inhibited in ovarian cancer. MFSN gave us a new shed light on the mechanism studies in ovarian cancer.
C1 [Ying, Huanchun; Ying, Tianshu; Li, Jun; Jin, Shanshan; Shao, Jingru; Wang, Lili] China Med Univ, Shengjing Hosp, Dept Gynecol & Obstet, Shenyang 110004, Liaoning Provin, Peoples R China.
   [Lyu, Jing] Fifth Hosp Shenyang, Dept Oncol, Shenyang 110023, Peoples R China.
   [Xu, Hongying] Ninth Hosp Shenyang, Dept Gynecol & Obstet, Shenyang 110024, Peoples R China.
RP Ying, HC (reprint author), China Med Univ, Shengjing Hosp, Dept Gynecol & Obstet, 36 Sanhao St, Shenyang 110004, Liaoning Provin, Peoples R China.
EM huanchunying2@hotmail.com
FU Liaoning Province Doctor Startup Fund of Natural Science Foundation
   [20071047]; Scientific Research Project of Higher Education Program of
   Liaoning Provincial Department of Education [2009A724]; Liaoning Science
   and Technology Project [2010225032]; National Natural Science Foundation
   of China [81372486]
FX This study was supported by Liaoning Province Doctor Startup Fund of
   Natural Science Foundation (20071047), The Scientific Research Project
   of Higher Education Program of Liaoning Provincial Department of
   Education (2009A724), Liaoning Science and Technology Project
   (2010225032) and the National Natural Science Foundation of China (Grant
   No. 81372486).
CR Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
   Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370
   Csardi G, 2006, INTERJOURNAL, P1695, DOI DOI 10.1093/NAR/
   Davis JW, 2007, J AM STAT ASS, V102
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gubbay O, 2006, J ENDOCRINOL, V191, P275, DOI 10.1677/joe.1.06928
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704
   Kontorovich T, 2010, INT J CANCER, V127, P589, DOI 10.1002/ijc.25065
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Lin MS, 2011, ONCOL REP, V25, P739, DOI 10.3892/or.2010.1112
   MASQUILIER D, 1993, CELL GROWTH DIFFER, V4, P931
   Mollet G. A., 2008, J UNDERGRAD NEUROSCI, V6, pR3
   Novotny GW, 2012, ENDOCR-RELAT CANCER, V19, P365, DOI 10.1530/ERC-11-0271
   Pejovic T, 2011, J MINIM INVAS GYN, V18, P823, DOI 10.1016/j.jmig.2011.07.013
   Pritchard CC, 2012, CANCER PREV RES, V5, P492, DOI 10.1158/1940-6207.CAPR-11-0370
   Rao YL, 2008, STAT APPL GENET MOL, V7, DOI 10.2202/1544-6115.1287
   Rentoft M, 2011, INT J ONCOL, V38, P61, DOI 10.3892/ijo_00000824
   Resnick KE, 2009, GYNECOL ONCOL, V112, P55, DOI 10.1016/j.ygyno.2008.08.036
   Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen J, 2012, CARCINOGENESIS, V33, P604, DOI 10.1093/carcin/bgs008
   Shigehara K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023584
   Tantipaiboonwong P, 2005, PROTEOMICS, V5, P1140, DOI 10.1002/pmic.200401143
   Xu J, 2013, MOL BIOSYST, V9, P217, DOI 10.1039/c2mb25360g
   Xu JA, 2011, NUCLEIC ACIDS RES, V39, P825, DOI 10.1093/nar/gkq832
   Xu LL, 2013, ANTI-CANCER AGENT ME, V13, P1126, DOI 10.2174/18715206113139990006
   Yan W, 2012, NEURO-ONCOLOGY, V14, P1432, DOI 10.1093/neuonc/nos263
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang Z, 2013, INT J MOL SCI, V14, P1105, DOI 10.3390/ijms14011105
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105
   Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010
   Zhao F, 2005, NUCLEIC ACIDS RES, V33, pD103, DOI 10.1093/nar/gki004
NR 36
TC 7
Z9 7
U1 2
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757-2215
J9 J OVARIAN RES
JI J. Ovarian Res.
PD JAN 21
PY 2014
VL 7
AR 9
DI 10.1186/1757-2215-7-9
PG 9
WC Reproductive Biology
SC Reproductive Biology
GA 295TK
UT WOS:000330138200001
PM 24444095
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Akhtar, J
   Wang, Z
   Yu, C
   Li, CS
   Shi, YL
   Liu, HJ
AF Akhtar, Javed
   Wang, Zhou
   Yu, Che
   Li, Chen-Sheng
   Shi, Yu-Long
   Liu, Hong-Jun
TI RETRACTED: STMN-1 is a potential marker of lymph node metastasis in
   distal esophageal adenocarcinomas and silencing its expression can
   reverse malignant phenotype of tumor cells (Retracted article. See vol.
   15, 187, 2015)
SO BMC CANCER
LA English
DT Article; Retracted Publication
DE Stathmin1; Distal esophageal adenocarcinoma; Short hairpin RNA;
   Multivariate logistic regression
ID CANCER STATISTICS; POOR-PROGNOSIS; BREAST-CANCER; STATHMIN; PROTEIN;
   OVEREXPRESSION; PHOSPHOPROTEIN; CARCINOMA; APOPTOSIS; THERAPY
AB Background: Distal esophageal adenocarcinoma is a highly aggressive neoplasm. Despite advances in diagnosis and therapy, the prognosis is still poor. Stathmin (STMN-1) is a ubiquitously expressed microtubule destabilizing phosphoprotein. It promotes the disassembly of microtubules and prevents assembly. STMN-1 can cause uncontrolled cell proliferation when mutated and not functioning properly. Recently, found to be overexpressed in many types of human cancers. However, its clinical significance remains elusive in distal esophageal adenocarcinoma. Here, we reported for the first time that STMN-1 is highly overexpressed in adenocarcinomas of the distal esophagus and strongly associated with lymph node metastasis.
   Methods: STMN-1 expression in 63 cases of distal esophageal adenocarcinoma was analyzed by immunoblotting, while expression in esophageal adenocarcinoma cells was determined by immunocytochemistry, immunofluorescence, qRT-PCR and western blotting. Lentivirus-mediated RNAi was employed to knock-down STMN-1 expression in Human esophageal adenocarcinoma cells. The relationship between STMN-1 expression and lymph node metastasis in distal esophageal adenocarcinoma was determined by univariate and multivariate analyses.
   Results: STMN-1 was detected in 31 (49.21%) of the 63 cases. STMN-1 was highly overexpressed in specimens with lymph node metastasis pN (+), but its expression was almost undetected in pN (-) status. Multivarian regression analysis demonstrated that STMN-1 overexpression is an independent factor for lymph node metastasis in distal esophageal adenocarcinoma. STMN-1 shRNA effectively reduced STMN-1 expression in esophageal adenocarcinoma cells (P < 0.05), which significantly suppressed proliferation (P < 0.05), increased migration (P < 0.05) and invasion ability (P < 0.05) and G1 phase arrest (P < 0.05) which lead to induction of apoptosis in esophageal adenocarcinoma cells in vitro. To verify the in vitro data, we conducted in vivo tumor xenograft studies. Esophageal adenocarcinoma cells stably transfected with STMN-1 shRNA significantly reduced tumor xenografts volume in vivo.
   Conclusions: STMN-1 overexpression is associated with lymph node metastasis and increase malignancy in distal esophageal adenocarcinoma. In vivo and in vitro laboratory findings, suggests that STMN-1 may be a suitable target for future therapeutic strategies in distal esophageal adenocarcinoma.
C1 [Akhtar, Javed; Wang, Zhou] Shandong Univ, Prov Hosp, Dept Thorac Surg, Jinan 250021, Shandong, Peoples R China.
   [Akhtar, Javed; Li, Chen-Sheng; Shi, Yu-Long; Liu, Hong-Jun] Shandong Univ, Prov Hosp, Div Gastrointestinal Surg, Jinan 250021, Shandong, Peoples R China.
   [Yu, Che] Shandong Univ, Prov Hosp, Dept Nephrol, Jinan 250021, Shandong, Peoples R China.
RP Shi, YL (reprint author), Shandong Univ, Prov Hosp, Div Gastrointestinal Surg, Jinan 250021, Shandong, Peoples R China.
EM shiyl9889@126.com; liuhongjun502@hotmail.com
FU Natural Science Foundation of Shandong Province of China [Y2007C102];
   Medical Science and Technology Development Foundation of Shandong
   Province of China [2007H2071]; Key research Project from Shandong
   Science Technology Commission [25006GG2202025]
FX We are grateful to Renee Lovett for English language editing of our
   manuscript. This study was supported by a grant from the Natural Science
   Foundation of Shandong Province of China (Y2007C102), the Medical
   Science and Technology Development Foundation of Shandong Province of
   China (2007H2071), Key research Project from Shandong Science Technology
   Commission (25006GG2202025).
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903
   [Anonymous], 2010, AJCC CANC STAG HDB F, P129
   Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025
   Belletti B, 2011, EXPERT OPIN THER TAR, V15, P1249, DOI 10.1517/14728222.2011.620951
   Brattsand G, 2000, BRIT J CANCER, V83, P311, DOI 10.1054/bjoc.2000.1264
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736
   Gewirtz AM, 2007, J CLIN INVEST, V117, P3612, DOI 10.1172/JCI34274
   Golouh R, 2008, BREAST CANCER RES TR, V110, P317, DOI 10.1007/s10549-007-9724-3
   Grimm D, 2009, ADV DRUG DELIVER REV, V61, P672, DOI 10.1016/j.addr.2009.05.002
   Iancu-Rubin C, 2005, TRENDS CELL BIOL, V15, P346, DOI 10.1016/j.tcb.2005.05.008
   Jeha S, 1996, CANCER RES, V56, P1445
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Kachroo S, 2009, EUR J CANCER CARE, V18, P18, DOI 10.1111/j.1365-2354.2008.00985.x
   Kouzu Y, 2006, BRIT J CANCER, V94, P717, DOI 10.1038/sj.bjc.6602991
   Kuo MF, 2009, J NEUROSURG-PEDIATR, V4, P74, DOI 10.3171/2009.2.PEDS08287
   Lin WC, 2009, UROLOGY, V74, P1264, DOI 10.1016/j.urology.2009.04.088
   Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023
   Mistry SJ, 2002, MT SINAI J MED, V69, P299
   Rana S, 2008, EXPERT REV ANTICANC, V8, P1461, DOI 10.1586/14737140.8.9.1461
   Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104
   Sherbet G. V., 2005, Cancer Genomics & Proteomics, V2, P227
   Singer S, 2007, HEPATOLOGY, V46, P759, DOI 10.1002/hep.21736
   SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D
   Su D, 2009, CANCER-AM CANCER SOC, V115, P2453, DOI 10.1002/cncr.24282
   Wittekind C., 2009, TNM CLASSIFICATION M
NR 28
TC 16
Z9 17
U1 3
U2 18
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 16
PY 2014
VL 14
AR 28
DI 10.1186/1471-2407-14-28
PG 13
WC Oncology
SC Oncology
GA 294ME
UT WOS:000330049900001
PM 24433541
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Pan, ZC
   Luo, JM
   Tian, XL
   Wu, SK
   Chen, C
   Deng, JF
   Xiao, CM
   Hu, GH
   Wei, ZG
AF Pan, Zhanchang
   Luo, Junming
   Tian, Xinlong
   Wu, Shoukun
   Chen, Chun
   Deng, Jianfeng
   Xiao, Chumin
   Hu, Guanghui
   Wei, Zhigang
TI RETRACTED: Highly transparent and conductive Sn/F and Al co-doped ZnO
   thin films prepared by sol-gel method (Retracted article. See vol. 746,
   pg. 742, 2018)
SO JOURNAL OF ALLOYS AND COMPOUNDS
LA English
DT Article; Retracted Publication
DE Al doped ZnO; Al-Sn co-doped ZnO; Al-F co-doped ZnO; XPS; Sol-gel method
ID OPTICAL-PROPERTIES; HYDROTHERMAL METHOD; ZINC-OXIDE; NANORODS;
   PHOTOLUMINESCENCE; MORPHOLOGY; FLUORINE; MICROSTRUCTURES;
   NANOSTRUCTURES; DEPOSITION
AB Al doped ZnO, Al-Sn co-doped ZnO and Al-F co-doped ZnO nanocrystals were successfully synthesized onto glass substrates by the sol-gel method. The structure and morphology of the films are characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM) and high resolution transmission electron microscopy (HRTEM). The results indicated that all the films were polycrystalline with a hexagonal wurtzite structure and exhibited a c-axis preferred orientation. The electrical and optical properties were also investigated by 4-point probe device and Uv-vis spectroscopy, room temperature photoluminescence (PL) and Raman spectrum (Raman), respectively. The PL and Raman results suggested that the co-doped films with a very low defect concentration and exhibit a better crystallinity than AZO thin films. The XPS study confirmed the incorporation of Al, Sn and F ions in the ZnO lattice. (C) 2013 Elsevier B. V. All rights reserved.
C1 [Pan, Zhanchang; Luo, Junming; Tian, Xinlong; Xiao, Chumin; Hu, Guanghui; Wei, Zhigang] Guangdong Univ Technol, Sch Chem Engn & Light Ind, Guangzhou 510006, Guangdong, Peoples R China.
   [Wu, Shoukun; Chen, Chun; Deng, Jianfeng] Huizhou King Brother Elect Technol Co Ltd, Huizhou 516083, Peoples R China.
RP Pan, ZC (reprint author), Guangdong Univ Technol, Sch Chem Engn & Light Ind, Guangzhou 510006, Guangdong, Peoples R China.
EM panzhanchang@163.com; tianxinlong2010@163.com; qhxy123@126.com
FU National Natural Science Foundation of China [20803014]; Scientific and
   technological projects in Guangdong Province [2012B010200035]; Huizhou
   Daya Bay technological projects [20110111]; 211 funding program of
   Guangdong Province
FX This research was financially supported by the National Natural Science
   Foundation of China (20803014), Scientific and technological projects in
   Guangdong Province (No. 2012B010200035), Huizhou Daya Bay technological
   projects (20110111) and the 211 funding program of Guangdong Province.
CR Aksoy S, 2012, J ALLOY COMPD, V512, P171, DOI 10.1016/j.jallcom.2011.09.058
   Al-Salman HS, 2013, J ALLOY COMPD, V547, P132, DOI 10.1016/j.jallcom.2012.08.119
   Amornpitoksuk P, 2012, SUPERLATTICE MICROST, V51, P103, DOI 10.1016/j.spmi.2011.11.002
   Barick KC, 2010, J COLLOID INTERF SCI, V349, P19, DOI 10.1016/j.jcis.2010.05.036
   Bowen A, 2011, THIN SOLID FILMS, V519, P1809, DOI 10.1016/j.tsf.2010.10.019
   Caglar Y, 2009, SUPERLATTICE MICROST, V46, P469, DOI 10.1016/j.spmi.2009.05.005
   Cao L, 2011, SOL ENERG MAT SOL C, V95, P894, DOI 10.1016/j.solmat.2010.11.012
   Cheng BC, 2004, ADV FUNCT MATER, V14, P913, DOI 10.1002/adfm.200305097
   Cunha DM, 2013, J ALLOY COMPD, V577, P158, DOI 10.1016/j.jallcom.2013.04.126
   Gordon RG, 2000, MRS BULL, V25, P52, DOI 10.1557/mrs2000.151
   Gupta J, 2011, J ALLOY COMPD, V509, P6725, DOI 10.1016/j.jallcom.2011.03.157
   Houng B, 2012, CERAM INT, V38, P801, DOI 10.1016/j.ceramint.2011.08.007
   Ilican S, 2013, J ALLOY COMPD, V553, P225, DOI 10.1016/j.jallcom.2012.11.081
   Jung M, 2011, OPT MATER, V33, P280, DOI 10.1016/j.optmat.2010.08.029
   Kar JP, 2009, MATER LETT, V63, P2327, DOI 10.1016/j.matlet.2009.08.002
   Kim J, 2011, MATER LETT, V65, P786, DOI 10.1016/j.matlet.2010.11.065
   Kim YS, 2007, APPL SURF SCI, V253, P4911, DOI 10.1016/j.apsusc.2006.10.068
   Kirby SD, 2009, THIN SOLID FILMS, V517, P1958, DOI 10.1016/j.tsf.2008.10.066
   Lana C., 2013, J ALLOY COMPD, V575, P24
   Lee W, 2012, CURR APPL PHYS, V12, P628, DOI 10.1016/j.cap.2011.09.008
   Lupan O, 2010, APPL SURF SCI, V256, P1895, DOI 10.1016/j.apsusc.2009.10.032
   Ma LG, 2011, APPL SURF SCI, V257, P10036, DOI 10.1016/j.apsusc.2011.06.134
   Mahmoud WE, 2011, J CRYST GROWTH, V327, P52, DOI 10.1016/j.jcrysgro.2011.05.003
   Noirfalise X, 2011, ACTA MATER, V59, P7521, DOI 10.1016/j.actamat.2011.07.068
   Pan ZC, 2013, J ALLOY COMPD, V576, P31, DOI 10.1016/j.jallcom.2013.04.132
   Pan ZC, 2013, SUPERLATTICE MICROST, V54, P107, DOI 10.1016/j.spmi.2012.11.003
   Pan ZC, 2013, APPL SURF SCI, V265, P870, DOI 10.1016/j.apsusc.2012.11.139
   Ri KH, 2011, APPL SURF SCI, V258, P1283, DOI 10.1016/j.apsusc.2011.07.022
   Sengupta J, 2012, MATER LETT, V83, P84, DOI 10.1016/j.matlet.2012.05.130
   Shao JZ, 2010, THIN SOLID FILMS, V518, P5288, DOI 10.1016/j.tsf.2010.04.068
   Shi SB, 2013, J ALLOY COMPD, V576, P59, DOI 10.1016/j.jallcom.2013.04.011
   Suzuki S, 2003, THIN SOLID FILMS, V434, P14, DOI 10.1016/S0040-6090(03)00463-2
   Tian XL, 2013, MATER LETT, V97, P71, DOI 10.1016/j.matlet.2013.01.116
   Vimalkumar TV, 2011, APPL SURF SCI, V257, P8334, DOI 10.1016/j.apsusc.2011.03.118
   Vinodkumar R, 2010, APPL SURF SCI, V257, P708, DOI 10.1016/j.apsusc.2010.07.044
   Xia QX, 2012, MATER LETT, V78, P180, DOI 10.1016/j.matlet.2012.03.066
   Yang JH, 2008, APPL SURF SCI, V255, P2646, DOI 10.1016/j.apsusc.2008.08.001
   Yoon HS, 2008, SOL ENERG MAT SOL C, V92, P1366, DOI 10.1016/j.solmat.2008.05.010
   Yousefi R, 2013, CERAM INT, V39, P1371, DOI 10.1016/j.ceramint.2012.07.076
   Yousefi R, 2012, CERAM INT, V38, P6295, DOI 10.1016/j.ceramint.2012.04.085
   Yousefi R, 2009, J ALLOY COMPD, V479, pL11, DOI 10.1016/j.jallcom.2008.12.147
   Zhang DH, 2011, J ALLOY COMPD, V509, P4972, DOI 10.1016/j.jallcom.2011.01.145
NR 42
TC 18
Z9 18
U1 5
U2 202
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-8388
EI 1873-4669
J9 J ALLOY COMPD
JI J. Alloy. Compd.
PD JAN 15
PY 2014
VL 583
BP 32
EP 38
DI 10.1016/j.jallcom.2013.06.192
PG 7
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering
GA 239OM
UT WOS:000326035200005
DA 2018-12-27
ER

PT J
AU Fang, AB
   Mi, YL
AF Fang, Angbo
   Mi, Yongli
TI RETRACTED: Drainage of a Thin Liquid Film between Hydrophobic Spheres:
   Boundary Curvature Effects (Retracted article. See vol. 30, pg. 10977,
   2014)
SO LANGMUIR
LA English
DT Article; Retracted Publication
ID SURFACES; SLIP; FLOW
AB We investigate theoretically the drainage of a thin liquid film confined between two hydrophobic spheres. Such a problem has been considered in Vinogradova's seminal work, emphasizing the role of slippage. However, it does not include the boundary curvature effects, which may become especially important when the slip lengths are comparable to the sphere radii. We present a reformulation of the hydrodynamic boundary conditions, with the boundary curvature effects fully taken into account. It is shown that such effects not only renormalize the effective slip lengths but also give new contributions to the pressure and drag force, neglected so far. We focus on the symmetric case of two identical spheres with the same radii and slip lengths and obtain analytical expressions for the pressure as well as the drag force. The boundary curvature corrections to the drag force are analyzed and found to be more important for more hydrophobic spheres. The implications of our results are discussed for the coagulation processes of colloids and measurements of surface forces or slip lengths with the drainage technique.
C1 [Fang, Angbo; Mi, Yongli] Tongji Univ, Dept Chem, Shanghai 200092, Peoples R China.
   [Mi, Yongli] Hong Kong Univ Sci & Technol, Dept Chem & Biomol Engn, Kowloon, Hong Kong, Peoples R China.
RP Fang, AB (reprint author), Tongji Univ, Dept Chem, 1239 Siping Rd, Shanghai 200092, Peoples R China.
EM afang1@gmail.com; keymix@ust.hk
FU China 1000 Talent Scholar Grant
FX The research grant to Yongli Mi by the China 1000 Talent Scholar Grant
   is greatly appreciated for the support of this work.
CR Bocquet L, 2007, SOFT MATTER, V3, P685, DOI 10.1039/b616490k
   CHAN DYC, 1985, J CHEM PHYS, V83, P5311, DOI 10.1063/1.449693
   Cottin-Bizonne C, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.056102
   EINZEL D, 1990, PHYS REV LETT, V64, P2269, DOI 10.1103/PhysRevLett.64.2269
   Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1
   Lauga E., 2005, CONDENS MATTER
   Neto C, 2005, REP PROG PHYS, V68, P2859, DOI 10.1088/0034-4885/68/12/R05
   Potanin A. A., 1988, KOLLOID ZH, V50, P493
   Vinogradova OI, 1998, LANGMUIR, V14, P2827, DOI 10.1021/la970332q
   VINOGRADOVA OI, 1995, LANGMUIR, V11, P2213, DOI 10.1021/la00006a059
   Zhu LW, 2012, LANGMUIR, V28, P7768, DOI 10.1021/la301040d
NR 11
TC 2
Z9 2
U1 6
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD JAN 14
PY 2014
VL 30
IS 1
BP 83
EP 89
DI 10.1021/la404125u
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 293VK
UT WOS:000330001600011
PM 24325397
DA 2018-12-27
ER

PT J
AU Kumar, MS
   Armenteros-Monterroso, E
   East, P
   Chakravorty, P
   Matthews, N
   Winslow, MM
   Downward, J
AF Kumar, Madhu S.
   Armenteros-Monterroso, Elena
   East, Philip
   Chakravorty, Probir
   Matthews, Nik
   Winslow, Monte M.
   Downward, Julian
TI RETRACTED: HMGA2 functions as a competing endogenous RNA to promote lung
   cancer progression (Retracted article. See vol. 523, 2015)
SO NATURE
LA English
DT Article; Retracted Publication
ID TGF-BETA; MESSENGER-RNAS; EXPRESSION DATA; GENE; ADENOCARCINOMA;
   BINDING; LET-7; OVEREXPRESSION; TRANSFORMATION; INHIBITOR
AB Non-small-cell lung cancer (NSCLC) is the most prevalent histological cancer subtype worldwide(1). As the majority of patients present with invasive, metastatic disease(2), it is vital to understand the basis for lung cancer progression. Hmga2 is highly expressed in metastatic lung adenocarcinoma, in which it contributes to cancer progression and metastasis(3-6). Here we show that Hmga2 promotes lung cancer progression in mouse and human cells by operating as a competing endogenous RNA (ceRNA)(7-11) for the let-7 microRNA (miRNA) family. Hmga2 can promote the transformation of lung cancer cells independent of protein-coding function but dependent upon the presence of let-7 sites; this occurs without changes in the levels of let-7 isoforms, suggesting that Hmga2 affects let-7 activity by altering miRNA targeting. These effects are also observed in vivo, where Hmga2 ceRNA activity drives lung cancer growth, invasion and dissemination. Integrated analysis of miRNA target prediction algorithms and metastatic lung cancer gene expression data reveals the TGF-beta co-receptor Tgfbr3 (ref. 12) as a putative target of Hmga2 ceRNA function. Tgfbr3 expression is regulated by the Hmga2 ceRNA through differential recruitment to Argonaute 2 (Ago2), and TGF-beta signalling driven by Tgfbr3 is important for Hmga2 to promote lung cancer progression. Finally, analysis of NSCLC-patient gene-expression data reveals that HMGA2 and TGFBR3 are coordinately regulated in NSCLC-patient material, a vital corollary to ceRNA function. Taken together, these results suggest that Hmga2 promotes lung carcinogenesis both as a protein-coding gene and as a non-coding RNA; such dual-function regulation of gene-expression networks reflects a novel means by which oncogenes promote disease progression.
C1 [Kumar, Madhu S.; Armenteros-Monterroso, Elena; Downward, Julian] Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3LY, England.
   [East, Philip; Chakravorty, Probir] Canc Res UK London Res Inst, Bioinformat & Biostat Grp, London WC2A 3LY, England.
   [Matthews, Nik] Canc Res UK London Res Inst, Adv Sequencing Facil, London WC2A 3LY, England.
   [Winslow, Monte M.] Stanford Univ, Sch Med, Stanford Canc Inst, Dept Genet,Dept Pathol, Stanford, CA 94305 USA.
   [Downward, Julian] Inst Canc Res, Div Canc Biol, Lung Canc Grp, London SW3 6JB, England.
RP Downward, J (reprint author), Canc Res UK London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.
EM julian.downward@cancer.org.uk
FU Cancer Research UK; European Commission [259770]; Worldwide Cancer
   Research [13-0142]
FX We thank the laboratory of T. Jacks for providing the 482N1 and 368T1
   lung cancer cell lines and the laboratories of P. A. Sharp and P.
   Chambon for providing the KPD sarcoma cell lines. We thank the LRI FACS
   Facility for the BrdU analyses and the LRI Biological Resources Unit for
   assistance with the animal studies. We thank M. S. Ebert and E. De Bruin
   for critical review of the manuscript. M. S. K. is a Long-Term Fellow of
   the Human Frontier Science Program and the European Molecular Biology
   Organization. This work was funded by Cancer Research UK and by the
   European Commission's Seventh Framework Programme (FP7/2007-2013) under
   the grant agreement Lungtarget (project no. 259770).
CR Brants JR, 2004, FEBS LETT, V569, P277, DOI 10.1016/j.febslet.2004.05.075
   Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091
   Di Cello F, 2008, MOL CANCER RES, V6, P743, DOI 10.1158/1541-7786.MCR-07-0095
   Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kaelin WG, 2012, SCIENCE, V337, P421, DOI 10.1126/science.1225787
   Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059
   Liau SS, 2007, BRIT J CANCER, V96, P993, DOI 10.1038/sj.bjc.6603654
   Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999
   Meyer B, 2007, MOL CARCINOGEN, V46, P503, DOI 10.1002/mc.20235
   Oida T, 2010, J IMMUNOL METHODS, V362, P195, DOI 10.1016/j.jim.2010.09.008
   Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Ravi A, 2012, CANCER CELL, V21, P848, DOI 10.1016/j.ccr.2012.04.037
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Sarhadi V, 2006, J PATHOL, V209, P206, DOI 10.1002/path.1960
   Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790
   Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029
   Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200
   Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450
   van Dongen S, 2008, NAT METHODS, V5, P1023, DOI 10.1038/nmeth.1267
   WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9
   Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881
   Xie J, 2012, NAT METHODS, V9, P403, DOI [10.1038/NMETH.1903, 10.1038/nmeth.1903]
NR 34
TC 149
Z9 161
U1 6
U2 101
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JAN 9
PY 2014
VL 505
IS 7482
BP 212
EP +
DI 10.1038/nature12785
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 286CG
UT WOS:000329441500038
PM 24305048
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Markos, C
AF Markos, Christos
TI RETRACTED: Photo-induced changes in a hybrid amorphous
   chalcogenide/silica photonic crystal fiber (Retracted article. See vol.
   104, 109901, 2014)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID POLYMER OPTICAL-FIBER; GLASS; FILMS
AB Photostructural changes in a hybrid photonic crystal fiber with chalcogenide nanofilms inside the inner surface of the cladding holes are experimentally demonstrated. The deposition of the amorphous chalcogenide glass films inside the silica capillaries of the fiber was made by infiltrating the nanocolloidal solution-based As25S75, while the photoinduced changes were performed by side illuminating the fiber near the bandgap edge of the formed glass nanofilms. The photoinduced effect of the chalcogenide glass directly red-shifts the transmission bandgap position of the fiber as high as similar to 20.6nm at around 1600 nm wavelength, while the maximum bandgap intensity change at similar to 1270nm was -3dB. (C)2014 AIP Publishing LLC.
C1 Tech Univ Denmark, Dept Photon Engn, DTU Foton, DK-2800 Lyngby, Denmark.
RP Markos, C (reprint author), Tech Univ Denmark, Dept Photon Engn, DTU Foton, DK-2800 Lyngby, Denmark.
EM chmar@fotonik.dtu.dk
OI Markos, Christos/0000-0002-9989-5275
FU Hans Christian Orsted post-doc program
FX C.M. would like to acknowledge the Hans Christian Orsted post-doc
   program for the financial support.
CR Birks TA, 1997, OPT LETT, V22, P961, DOI 10.1364/OL.22.000961
   Brilland L, 2006, OPT EXPRESS, V14, P1280, DOI 10.1364/OE.14.001280
   Calvez L, 2010, J PHYS D APPL PHYS, V43, DOI 10.1088/0022-3727/43/44/445401
   Da N, 2010, J NON-CRYST SOLIDS, V356, P1829, DOI 10.1016/j.jnoncrysol.2010.07.002
   Domachuk P, 2004, APPL PHYS LETT, V84, P1838, DOI 10.1063/1.1667592
   Eggleton BJ, 2011, NAT PHOTONICS, V5, P141, DOI [10.1038/nphoton.2011.309, 10.1038/NPHOTON.2011.309]
   Granzow N, 2013, OPT EXPRESS, V21, P10969, DOI 10.1364/OE.21.010969
   Granzow N, 2011, OPT LETT, V36, P2432, DOI 10.1364/OL.36.002432
   Guiton T. A., 1989, CHEM MATER, V1, P558
   Litchinitser NM, 2002, OPT LETT, V27, P1592, DOI 10.1364/OL.27.001592
   Luan F, 2011, OPT LETT, V36, P4761, DOI 10.1364/OL.36.004761
   Markos C, 2013, OPT EXPRESS, V21, P4758, DOI 10.1364/OE.21.004758
   Markos C, 2012, OPT MATER EXPRESS, V2, P929, DOI 10.1364/OME.2.000929
   Markos C, 2012, OPT EXPRESS, V20, P14814, DOI 10.1364/OE.20.014814
   Nielsen K, 2005, J OPT A-PURE APPL OP, V7, pL13, DOI [10.1088/1464-4258/7/8/L02, 10.1088/1464-4268/7/8/L02]
   Sanghera JS, 1999, J NON-CRYST SOLIDS, V256, P6, DOI 10.1016/S0022-3093(99)00484-6
   SEDDON AB, 1995, J NON-CRYST SOLIDS, V184, P44, DOI 10.1016/0022-3093(94)00686-5
   Song SS, 2010, OPT EXPRESS, V18, P5472, DOI 10.1364/OE.18.005472
   van Eijkelenborg MA, 2001, OPT EXPRESS, V9, P319, DOI 10.1364/OE.9.000319
   Wei L, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3455105
   YANG CY, 1987, PHYS REV B, V36, P9160, DOI 10.1103/PhysRevB.36.9160
   Yannopoulos SN, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.064206
   Yuan W, 2009, OPT EXPRESS, V17, P19356, DOI 10.1364/OE.17.019356
   Zito G, 2013, OPT LETT, V38, P3253, DOI 10.1364/OL.38.003253
   Zou LE, 2009, APPL OPTICS, V48, P6442, DOI 10.1364/AO.48.006442
NR 25
TC 4
Z9 4
U1 2
U2 22
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0003-6951
EI 1077-3118
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD JAN 6
PY 2014
VL 104
IS 1
AR 011114
DI 10.1063/1.4861374
PG 4
WC Physics, Applied
SC Physics
GA 291OT
UT WOS:000329838800014
OA Green Published
DA 2018-12-27
ER

PT J
AU Barros, JAO
   Lourenco, LAP
   Soltanzadeh, F
   Taheri, M
AF Barros, Joaquim A. O.
   Lourenco, Lucio A. P.
   Soltanzadeh, Fatemeh
   Taheri, Mahsa
TI RETRACTED: Steel-fibre reinforced concrete for elements failing in
   bending and in shear (Retracted article. See vol. 22, pg. 137, 2018)
SO EUROPEAN JOURNAL OF ENVIRONMENTAL AND CIVIL ENGINEERING
LA English
DT Article; Retracted Publication
DE shallow structures; fibre-reinforced concrete; moment-curvature
   relationship; shear reinforcement; crack shear softening diagram;
   material nonlinear analysis; FEM
ID SELF-COMPACTING CONCRETE; BEHAVIOR; FRACTURE; BEAMS
AB Discrete steel fibres can increase significantly the bending and the shear resistance of concrete structural elements when Steel Fibre Reinforced Concrete (SFRC) is designed in such a way that fibre-reinforcing mechanisms are optimised. To assess the fibre reinforcement effectiveness in shallow structural elements failing in bending and in shear, experimental and numerical research were performed. Uniaxial compression and bending tests were executed to derive the constitutive laws of the developed SFRC. Using a cross-section-layered model and the material constitutive laws, the deformational behaviour of structural elements failing in bending was predicted from the moment-curvature relationship of the representative cross sections. To evaluate the influence of the percentage of fibres on the shear resistance of shallow structures, three point bending tests with shallow beams were performed. The applicability of the formulation proposed by RILEM TC 162-TDF for the prediction of the shear resistance of SFRC elements was evaluated. Inverse analysis was adopted to determine indirectly the values of the fracture mode I parameters of the developed SFRC. With these values, and using a softening diagram for modelling the crack shear softening behaviour, the response of the SFRC beams failing in shear was predicted.
C1 [Barros, Joaquim A. O.; Lourenco, Lucio A. P.; Soltanzadeh, Fatemeh; Taheri, Mahsa] Univ Minho, ISISE, Dept Civil Engn, Guimaraes, Portugal.
RP Barros, JAO (reprint author), Univ Minho, ISISE, Dept Civil Engn, Guimaraes, Portugal.
EM barros@civil.uminho.pt
RI Barros, Joaquim/M-4091-2013; Soltanzadeh, Fatemeh/O-9081-2017
OI Barros, Joaquim/0000-0003-1528-757X; Soltanzadeh,
   Fatemeh/0000-0003-3453-699X
CR ACI: 318, 2008, 318 ACI
   [Anonymous], 2000, EN19712000, P52
   [Anonymous], 2002, 199211 PREN
   Baant Z. P., 1983, MATERIALS STRUCTURES, V16, P155, DOI DOI 10.1007/BF02486267
   Barragan B. E., 2002, THESIS U POLITECNICA
   Barros J., 2003, RILEM TC 162 TDF WOR, P77
   Barros J. A. O., 2004, P 6 INT RILEM S FIBR, V1, P711
   Barros J. A. O., 2009, C NUM METH ENG BARC
   Barros J. A. O., 1995, THESIS PORTO U, P502
   Barros JAO, 1998, MECH COHES-FRICT MAT, V3, P277, DOI 10.1002/(SICI)1099-1484(199807)3:3<277::AID-CFM52>3.0.CO;2-N
   Barros JAO, 1999, J MATER CIVIL ENG, V11, P331, DOI 10.1061/(ASCE)0899-1561(1999)11:4(331)
   Barros JAO, 2005, MATER STRUCT, V38, P47, DOI 10.1617/14058
   Barros JAO, 2005, CEMENT CONCRETE COMP, V27, P471, DOI 10.1016/j.cemconcomp.2004.07.004
   Barros J, 2007, J MATER CIVIL ENG, V19, P295, DOI 10.1061/(ASCE)0899-1561(2007)19:4(295)
   Brite Euram/Swedish Cement and Concrete Research Institute, 2002, BRPRCT960366
   Casanova P, 1997, ACI MATER J, V94, P341
   Casanova P., 1995, THESIS ECOLE NATL PO
   CEB-FIP Model Code, 1993, BULLETIN, V213/214
   Chiaia B, 2009, MATER STRUCT, V42, P339, DOI 10.1617/s11527-008-9385-7
   de Borst R, 2002, ENG FRACT MECH, V69, P95, DOI 10.1016/S0013-7944(01)00082-0
   Di Prisco M., 2004, P 6 RILEM S FIBR REI
   DIVAKAR MP, 1987, J STRUCT ENG-ASCE, V113, P1046, DOI 10.1061/(ASCE)0733-9445(1987)113:5(1046)
   EFNARC, 2002, SPEC GUID SELF COMP
   EFNARC, 1996, EUR FED PROD APPL SP
   Eurocode 2, 2004, EN1992112004E
   Gettu R., 2004, P 6 RILEM S FIBR REI
   Meda A, 2005, MATER STRUCT, V38, P343, DOI 10.1617/14112
   Naaman A.E., 2005, P 3 INT C CONSTR MAT, P458
   Nooru M. B.-M., 1992, THESIS DELFT U TECHN
   OKAMURA T., 1997, CONCRETE INT, V19, P50
   Pereira E. B., 2010, P FRAMCOS 7 JEJ KOR
   Pereira E. N. B., 2006, THESIS U MINHO, P188
   Pereira ENB, 2008, J STRUCT ENG-ASCE, V134, P1310, DOI 10.1061/(ASCE)0733-9445(2008)134:8(1310)
   Roshani D., 1996, THESIS GOTEBORG U
   ROTS JG, 1987, J ENG MECH-ASCE, V113, P1739, DOI 10.1061/(ASCE)0733-9399(1987)113:11(1739)
   Schellekens J. C. J., 1990, 25290517 DELFT U TEC, P82
   Sena Cruz J. M., 2004, THESIS U MINHO
   Sena-Cruz J. M., 2004, 9 PORT C FRACT ESTSE, P395
   Soranakom C., 2008, THESIS ARIZONA STATE
   Soranakom C, 2008, CEMENT CONCRETE COMP, V30, P465, DOI 10.1016/j.cemconcomp.2008.01.007
   SWAMY RN, 1981, J AM CONCRETE I, V78, P395
   Taheri M., 2010, 10DECE06 U MINH SCH
   Vandewalle L, 2003, MATER STRUCT, V36, P560
   Vandewalle L., 2000, J MAT STRUCTURES, V33, P339
NR 44
TC 6
Z9 6
U1 1
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1964-8189
EI 2116-7214
J9 EUR J ENVIRON CIV EN
JI Eur. J. Environ. Civ. Eng.
PD JAN 2
PY 2014
VL 18
IS 1
BP 33
EP 65
DI 10.1080/19648189.2013.842937
PG 33
WC Engineering, Civil; Engineering, Geological
SC Engineering
GA 275IX
UT WOS:000328670600003
DA 2018-12-27
ER

PT J
AU Zhang, H
   Liu, W
   Hu, JJ
   Liu, RZ
AF Zhang, Hui
   Liu, Wei
   Hu, Jin-Ju
   Liu, Rui-Zhi
TI RETRACTED: Evaluation of elite table tennis players' technique
   effectiveness(Retracted article. See vol. 35, pg. 1326, 2017)
SO JOURNAL OF SPORTS SCIENCES
LA English
DT Article; Retracted Publication
DE table tennis; technique effectiveness evaluation; competition
   performance
AB This study constructed a technique effectiveness evaluation formula for table tennis players based on the relationship between the scoring rate and usage rate of techniques and established evaluation criteria through the examination of 224 matches of the world's top 35 players. It also built a competition performance formula with the score difference theory for the exploration of the correlation between player technique effectiveness and competition performance. The results showed the three indices - the technique effectiveness of the first and third strokes (TE1,3), the second and fourth strokes (TE2,4) and the after fourth strokes (TE>4) - could help better evaluate the technique effectiveness of elite players. The comparative analysis of Chinese elite table tennis players and players from other countries and regions revealed that Chinese players as a whole were excellent' in all the examined techniques except in the male's first and third strokes'; while players from other countries and regions were overall general'. The case analysis of two of the world's top players further indicated that correlation analysis of technique effectiveness and competition performance could help identify the technique indices highly correlated with player competition performance.
C1 [Zhang, Hui; Liu, Rui-Zhi] Shanghai Univ Sport, China Table Tennis Coll, Shanghai 200438, Peoples R China.
   [Liu, Wei] Shanghai Univ Sport, Sch Econ & Management, Shanghai 200438, Peoples R China.
   [Hu, Jin-Ju] Shanghai Univ Sport, Sch Sport Journalism & Foreign Studies, Shanghai 200438, Peoples R China.
RP Zhang, H (reprint author), Shanghai Univ Sport, China Table Tennis Coll, Qing Yuan Huan Rd 650, Shanghai 200438, Peoples R China.
EM huizhang@sus.edu.cn
FU Shanghai Key Lab of Human Performance (Shanghai University of Sport)
   [11DZ2261100]; Shanghai Science and Technology Commission [10490503700]
FX This work was supported by the grants from Shanghai Key Lab of Human
   Performance (Shanghai University of Sport) (No. 11DZ2261100) and
   Shanghai Science and Technology Commission (No. 10490503700).
CR LI Jinliang, 2004, J BEIJING SPORT U, V27, P830
   Li Jinliang, 1998, J BEIJING U PHYS ED, V21, P71
   Li Z., 2009, J BEIJING SPORT U, V10, P26
   Li Z., 1989, CHINA SPORTS SCI TEC, V3, P15
   Li Z., 1991, J BEIJING I PHYS ED, V2, P95
   Li Z., 1997, J TIANJIN I PHYS ED, V12, P70
   LI Zhenbiao, 2008, J TUS, V23, P428
   Meng Xian-ming, 2010, Computer Engineering, V36, P28
   Meng Xian-ming, 2009, Computer Engineering and Applications, V45, P8, DOI 10.3778/j.issn.1002-8331.2009.36.003
   Wang H., 2010, THESIS BEIJING SPORT
   Wang J., 2010, THESIS SHANGHAI U SP
   WANG Jie, 2009, J SHANGHAI U SPORT, V33, P87
   Wang L., 2008, METHODS APPL SPORTS, P89
   Wang Y., 2007, P 8 CHIN NAT CONV SP, P107
   Wu H., 1989, J NATL RES I SPORTS, V1, P32
   Xiao Y., 2008, SPORT SCI RES, V6, P19
   Yu L., 2008, J SHANGHAI U SPORT, V32, P39
   Yu L., 2008, CHINA SPORT SCI, V10, P41
   YU Li-juan, 2009, CHINA SPORT SCI TECH, V6, P8
   Zhai H., 2011, J SHANDONG I PHYS ED, V2, P78
   Zhang H., 2008, SPORT SCI RES, V6, P6
   Zhang X., 2004, THESIS BEIJING SPORT
   Zhang X., 2002, J BEIJING U PHYS ED, V3, P396
   Zhang X., 2000, J TIANJIN I PHYS ED, V3, P65
   Zhang Y., 2006, CHINA SPORT SCI TECH, V1, P99
   ZHAO Yang-qing, 2008, J SHANGHAI U SPORT, V32, P83
NR 26
TC 18
Z9 18
U1 7
U2 30
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0264-0414
EI 1466-447X
J9 J SPORT SCI
JI J. Sports Sci.
PD JAN 2
PY 2014
VL 32
IS 1
BP 70
EP 77
DI 10.1080/02640414.2013.805885
PG 8
WC Sport Sciences
SC Sport Sciences
GA AB2CU
UT WOS:000331601400010
PM 23687933
DA 2018-12-27
ER

PT J
AU Zhang, TW
   Tang, MF
   Lu, Y
   Dong, DY
AF Zhang, Tengwen
   Tang, Mingfeng
   Lu, Yong
   Dong, Dayong
TI RETRACTED: Trust Building in Online Peer-to-Peer Lending(Retracted
   article. See vol.19,pg.216,2016)
SO JOURNAL OF GLOBAL INFORMATION TECHNOLOGY MANAGEMENT
LA English
DT Article; Retracted Publication
DE Online Peer-to-Peer Lending; Social Capital; Trust; Willingness to Lend
ID INTERPERSONAL-TRUST; ELECTRONIC COMMERCE; INFORMATION; MODEL
AB Online peer-to-peer lending is a new type of financial market where individual borrowers and lenders interact directly without collateral or financial institution as an intermediary. We develop a trust model to understand the critical factors that influence a lender's trust-building process. The results confirm that trust in borrowers positively affects the lender's willingness to lend; however, we find that trust in the intermediary does not affect the lender's willingness to lend, which is different from traditional consumer-to-consumer e-commerce. We also discuss the relationship between trust building and the Chinese culture-Guanxi.
C1 [Zhang, Tengwen] Southwestern Univ Finance & Econ, Sch Secur & Futures, Chengdu 610074, Peoples R China.
   [Tang, Mingfeng] Southwestern Univ Finance & Econ, Sch Business Adm, Chengdu 610074, Peoples R China.
   [Lu, Yong] Southwestern Univ Finance & Econ, Inst Chinese Financial Studies, Collaborat Innovat Ctr Financial Secur, Chengdu 610074, Peoples R China.
   [Dong, Dayong] Southwest Jiaotong Univ, Sch Econ & Management, Chengdu, Peoples R China.
RP Tang, MF (reprint author), Southwestern Univ Finance & Econ, Sch Business Adm, 55 Guanghua Cun St, Chengdu 610074, Peoples R China.
EM tang@swufe.edu.cn
CR ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037//0033-2909.103.3.411
   Ba SL, 2001, DECIS SUPPORT SYST, V31, P323, DOI 10.1016/S0167-9236(00)00144-5
   Berkovich E, 2011, ANN FINANC, V7, P389, DOI 10.1007/s10436-011-0178-6
   BRADACH JL, 1989, ANNU REV SOCIOL, V15, P97, DOI 10.1146/annurev.so.15.080189.000525
   Collier B, 2010, 2010 ACM CONFERENCE ON COMPUTER SUPPORTED COOPERATIVE WORK, P197
   Fukuyama Francis, 1995, TRUST SOCIAL VIRTUES
   Gefen D, 2008, J MANAGE INFORM SYST, V24, P275, DOI 10.2753/MIS0742-1222240411
   Gefen D, 2005, COMMUN ASSOC INF SYS, V16, P91
   Hair J. F., 2006, MULTIVARIATE ANAL
   Kim C, 2010, ELECTRON COMMER R A, V9, P84, DOI 10.1016/j.elerap.2009.04.014
   Kim DJ, 2008, DECIS SUPPORT SYST, V44, P544, DOI 10.1016/j.dss.2007.07.001
   Kipnis Andrew, 1997, PRODUCING GUANXI
   Lin MF, 2013, MANAGE SCI, V59, P17, DOI 10.1287/mnsc.1120.1560
   Lu YB, 2010, ELECTRON COMMER R A, V9, P346, DOI 10.1016/j.elerap.2009.07.003
   MAYER RC, 1995, ACAD MANAGE REV, V20, P709, DOI 10.2307/258792
   McKnight DH, 2002, INFORM SYST RES, V13, P334, DOI 10.1287/isre.13.3.334.81
   Moore GC, 1991, INFORM SYST RES, V2, P192, DOI 10.1287/isre.2.3.192
   Nahapiet J, 1998, ACAD MANAGE REV, V23, P242, DOI 10.2307/259373
   PARASURAMAN A, 1985, J MARKETING, V49, P41, DOI 10.2307/1251430
   Pavlou PA, 2006, MIS QUART, V30, P115
   Pavlou PA, 2004, INFORM SYST RES, V15, P37, DOI 10.1287/isre.1040.0015
   ROTTER JB, 1967, J PERS, V35, P651, DOI 10.1111/j.1467-6494.1967.tb01454.x
   ROTTER JB, 1971, AM PSYCHOL, V26, P443, DOI 10.1037/h0031464
   Schierz PG, 2010, ELECTRON COMMER R A, V9, P209, DOI 10.1016/j.elerap.2009.07.005
   Tang XF, 2012, J GLOB INF TECH MAN, V15, P5, DOI 10.1080/1097198X.2012.10845616
   Teo TSH, 2008, J MANAGE INFORM SYST, V25, P99, DOI 10.2753/MIS0742-1222250303
   Watson RT, 1998, MIS QUART, V22, P61, DOI 10.2307/249678
NR 27
TC 3
Z9 3
U1 4
U2 65
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1097-198X
EI 2333-6846
J9 J GLOB INF TECH MAN
JI J. Glob. Inf. Technol. Manag.
PY 2014
VL 17
IS 4
BP 250
EP 266
DI 10.1080/1097198X.2014.978624
PG 17
WC Information Science & Library Science
SC Information Science & Library Science
GA CB4YA
UT WOS:000349633200003
DA 2018-12-27
ER

PT J
AU Sohrab, SS
   Karim, S
   Varma, A
   Azhar, EI
   Abuzenadah, AM
   Mandal, B
AF Sohrab, Sayed Sartaj
   Karim, Sajjad
   Varma, Anupam
   Azhar, Esam I.
   Abuzenadah, Adel M.
   Mandal, Bikash
TI RETRACTED: Sap transmission of Tomato leaf curl New Delhi virus
   infecting sponge gourd in northern India (Retracted Article)
SO JOURNAL OF PLANT INTERACTIONS
LA English
DT Correction; Retracted Publication
RI SOHRAB, SAYED/H-9613-2012
NR 0
TC 1
Z9 1
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1742-9145
EI 1742-9153
J9 J PLANT INTERACT
JI J. Plant Interact.
PY 2014
VL 9
IS 1
BP 241
EP 248
DI 10.1080/17429145.2013.819943
PG 8
WC Plant Sciences; Ecology
SC Plant Sciences; Environmental Sciences & Ecology
GA AX3QD
UT WOS:000346853000039
DA 2018-12-27
ER

PT J
AU Zhou, FH
   Liu, HT
   Zhang, X
   Shen, YY
   Zheng, DF
   Zhang, AJ
   Lai, YM
   Li, HY
AF Zhou, Fanhan
   Liu, Hongtao
   Zhang, Xiang
   Shen, Yuanyuan
   Zheng, Daofeng
   Zhang, Aijie
   Lai, Yanmei
   Li, Hongyuan
TI RETRACTED: Proline-rich protein 11 regulates epithelial-to-mesenchymal
   transition to promote breast cancer cell invasion (Retracted article.
   See vol. 9, pg. 407, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE PRR11; EMT; breast cancer; migration; invasion
ID EXPRESSION; SNAIL; TRANSCRIPTION; MIGRATION; ACTIVATOR; DISEASE; TWIST
AB Breast cancer is the leading cause of cancer death in women world wide which is closely related to metastasis. Recent studies argue that breast cancer cells that have undergone epithelial-to-mesenchymal transition (EMT) acquire aggressive malignant properties, but the molecular mechanisms underlying this transition are poorly understood. In this study, we found that increased expression of proline-rich protein 11 (PRR11) was associated with the progression of breast cancer and that PRR11 protein levels were significantly elevated in breast cancer. High PRR11 levels also predict shorter overall survival of breast cancer patients. Moreover, we found that the forced expression of PRR11 decreased the expression of the epithelial marker E-cadherin but increased the mesenchymal markers in breast cancer cells. In contrast, silencing PRR11 in metastatic breast tumor cells promoted a shift toward an epithelial morphology concomitant with increased expression of E-cadherin and decreased expression of mesenchymal markers. PRR11 silencing also reduced the expression of EMT-inducing transcription factors (Snail, Slug, ZEB1 and ZEB2).
C1 [Zhou, Fanhan; Liu, Hongtao; Zhang, Xiang; Shen, Yuanyuan; Zheng, Daofeng; Zhang, Aijie; Lai, Yanmei; Li, Hongyuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing 400016, Peoples R China.
RP Li, HY (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM hongY_Li@hotmail.com
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Nieto MA, 2009, INT J DEV BIOL, V53, P1541, DOI 10.1387/ijdb.072410mn
   Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990
   Bosco EE, 2010, BLOOD, V115, P3320, DOI 10.1182/blood-2009-02-202440
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chen QZ, 2009, J LEUKOCYTE BIOL, V85, P539, DOI 10.1189/jlb.0308219
   Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2
   Li HY, 2015, CELL SIGNAL, V27, P82, DOI 10.1016/j.cellsig.2014.09.018
   Li HY, 2014, INT J CLIN EXP PATHO, V7, P3057
   Liao XH, 2014, CELL SIGNAL, V26, P2370, DOI 10.1016/j.cellsig.2014.07.023
   Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575
   Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207
   Qiao YY, 2011, CANCER RES, V71, P3076, DOI 10.1158/0008-5472.CAN-10-2787
   Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035
   Rosano L, 2005, CANCER RES, V65, P11649, DOI 10.1158/0008-5472.CAN-05-2123
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Yoshida J, 2009, MED MOL MORPHOL, V42, P82, DOI 10.1007/s00795-008-0436-5
NR 18
TC 12
Z9 12
U1 1
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2014
VL 7
IS 12
BP 8692
EP 8699
PG 8
WC Oncology; Pathology
SC Oncology; Pathology
GA AZ6RG
UT WOS:000348345900038
PM 25674234
DA 2018-12-27
ER

PT J
AU Wu, H
   Yao, L
   Mei, JZ
   Li, F
AF Wu, Hong
   Yao, Li
   Mei, Jiazhuan
   Li, Feng
TI RETRACTED: Development of synthetic of peptide-functionalized liposome
   for enhanced targeted ovarian carcinoma therapy (Retracted article. See
   vol. 10, pg. 10152, 2017)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Ovarian carcinoma; transferrin receptor; liposome; tumor targeting
ID GYNECOLOGIC-ONCOLOGY-GROUP; METASTATIC NASOPHARYNGEAL CARCINOMA;
   TAT-MODIFIED CHOLESTEROL; BRAIN DELIVERY; DRUG-DELIVERY; PHASE-II;
   PACLITAXEL; CISPLATIN; CANCER; CERVIX
AB In this study, we report an active targeting liposomal formulation directed by a novel peptide (T7) that specifically binds to the transferrin receptor (TfR) overexpressed on ovarian carcinoma cells. The objectives of this study were to evaluate the in vitro and in vivo tumor drug targeting delivery of T7-anchored liposomes on A2780 cells. T7 conjugated to the distal end of DSPE-PEG2000-maleimide was incorporated into the liposomes via a post-insertion method, the liposome could keep stability in 50% FBS for more than 24 h. The uptake efficiency of T7-LP was 3.7 times higher than that of LP on A2780 cells. The anti-proliferative activity of T7-LP-PTX against A2780 cells was much stronger compared to that of LP-PTX and free PTX, respectively. The homing specificity and anticancer efficacy of T7-LP-PTX were also evaluated on the tumor spheroids, which revealed that T7-LP-PTX was more efficaciously internalized into tumor cells than LP. Compared to LP, T7-LP-PTX showed the highest accumulation capability into tumor spheroids, and the greatest tumor growth inhibitory effect in vitro. In the in vivo study, the T7-LP-PTX showed the best inhibition effect of the tumor growth for the A2780-bearing mice and tumor accumulation. In brief, the T7-LP may be an efficient targeting drug delivery system for ovarian carcinoma.
C1 [Wu, Hong; Yao, Li; Li, Feng] Zhengzhou Peoples Hosp, Dept Gynecol, Zhengzhou 450003, Peoples R China.
   [Mei, Jiazhuan] Zhengzhou Peoples Hosp, Dept Oncol, Zhengzhou 450003, Peoples R China.
RP Yao, L (reprint author), Zhengzhou Peoples Hosp, Dept Gynecol, 33 Huanghe Rd, Zhengzhou 450003, Peoples R China.
EM yaolizz-rmyy@163.com
CR Bidros DS, 2009, NEUROTHERAPEUTICS, V6, P539, DOI 10.1016/j.nurt.2009.04.004
   Chao HT, 2012, CANC LETT, V2, P29
   Chua DTT, 2005, ORAL ONCOL, V41, P589, DOI 10.1016/j.oraloncology.2005.01.008
   Curtin JP, 2001, J CLIN ONCOL, V19, P1275, DOI 10.1200/JCO.2001.19.5.1275
   Despierre E, 2010, GYNECOL ONCOL, V117, P358, DOI 10.1016/j.ygyno.2010.02.012
   Du WW, 2013, BIOMATERIALS, V34, P794, DOI 10.1016/j.biomaterials.2012.10.003
   Gao HL, 2014, BIOMATERIALS, V35, P2374, DOI 10.1016/j.biomaterials.2013.11.076
   Gao HL, 2012, BIOMATERIALS, V33, P5115, DOI 10.1016/j.biomaterials.2012.03.058
   Gao HL, 2011, BIOMATERIALS, V32, P8669, DOI 10.1016/j.biomaterials.2011.07.069
   Gould N, 2012, GYNECOL ONCOL, V125, P54, DOI 10.1016/j.ygyno.2011.12.417
   Horwitz S. B., 1994, ANN ONCOL, V5, pS3
   LIEBMANN J, 1993, LANCET, V342, P1428, DOI 10.1016/0140-6736(93)92789-V
   McCarthy JS, 2002, ORAL ONCOL, V38, P686, DOI 10.1016/S1368-8375(01)00134-8
   McGuire WP, 1996, J CLIN ONCOL, V14, P792, DOI 10.1200/JCO.1996.14.3.792
   Miyata S, 2011, NEUROSURGERY, V68, P1380, DOI 10.1227/NEU.0b013e31820b52aa
   Pillai JJ, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-25
   Qin Y, 2011, INT J PHARMACEUT, V420, P304, DOI 10.1016/j.ijpharm.2011.09.008
   Qin Y, 2011, INT J PHARMACEUT, V419, P85, DOI 10.1016/j.ijpharm.2011.07.021
   Rose PG, 1999, J CLIN ONCOL, V17, P2676, DOI 10.1200/JCO.1999.17.9.2676
   Shahzad MK, 2012, CANC LETT, V18, P76
   Yin YJ, 2013, PHARM RES-DORDR, V30, P2050, DOI 10.1007/s11095-013-1058-8
NR 21
TC 1
Z9 2
U1 3
U2 12
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2014
VL 7
IS 12
BP 4809
EP 4818
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AZ6BP
UT WOS:000348303600021
PM 25663977
DA 2018-12-27
ER

PT J
AU Chen, G
   Tang, Y
   Wu, JH
   Liu, FH
AF Chen, Gang
   Tang, Yong
   Wu, Jiang-Hua
   Liu, Feng-Hua
TI RETRACTED: Role of microRNAs in diagnosis and treatment of the
   pathogenesis of gastric cancer (Retracted article. See vol. 8, pg.
   11862, 2015)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE microRNAs; gastric cancer; SGC-7901; diagnosis biomarker
ID CELL-PROLIFERATION; EXPRESSION; PATHWAY; OVEREXPRESSION; TUMORIGENESIS;
   CONTRIBUTES; POPULATION; BIOMARKERS; MOTILITY; INVASION
AB We aim to detect the miRNAs that are correlated with the gastric cancer cell line SGC-7901 to provide theoretical basis for clinical application. We first analyzed miRNA expression profiles of gastric cancer patients compared with normal controls by microarray analysis and validated the results by real-time qPCR. We also determined the absolute copy numbers of these three miRNAs in normal adults. The results showed that three miRNAs (miR-150, miR-23a, and miR-130a) were identified to significantly decrease in expanded 38 gastric cancer patients compared with 90 normal controls. Molecular and statistical analysis showed that the decreased miRNAs were significant in clinical analysis. Generally speaking, this finding suggest vital roles of these miRNAs in human gastric cancer genesis and as potential biomarkers in gastric cancer diagnosis.
C1 [Chen, Gang; Tang, Yong] Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, Wuhan 430072, Peoples R China.
   [Wu, Jiang-Hua; Liu, Feng-Hua] Tianjin Med Univ, Canc Inst & Hosp, Dept Gynecol Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.
RP Liu, FH (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Dept Gynecol Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.
EM pananyang1234@163.com
CR Cao WG, 2014, TUMOR BIOL, V35, P1287, DOI 10.1007/s13277-013-1171-7
   Du YT, 2014, ANAT REC, V297, P2273, DOI 10.1002/ar.23003
   Duan JH, 2014, TUMOR BIOL, V35, P11013, DOI 10.1007/s13277-014-2342-x
   Eto K, 2014, ANN SURG ONCOL, V21, P343, DOI 10.1245/s10434-013-3325-7
   Fang Y, 2013, ACTA BIOCH BIOPH SIN, V45, P963, DOI 10.1093/abbs/gmt106
   Fei BJ, 2012, ONCOL RES, V20, P557, DOI 10.3727/096504013X13775486749254
   Fu ZC, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0164-8
   Gong JA, 2014, CARCINOGENESIS, V35, P497, DOI 10.1093/carcin/bgt337
   Guo SL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3544
   Iwaya T, 2013, CLIN CANCER RES, V19, P6438, DOI 10.1158/1078-0432.CCR-12-3186
   Jiang HB, 2014, EUR REV MED PHARMACO, V18, P2109
   Kim HP, 2014, ONCOGENE, V33, P5434, DOI 10.1038/onc.2013.490
   Kim O, 2014, J CELL PHYSIOL, V229, P762, DOI 10.1002/jcp.24496
   Li B.S., 2014, ONCOGENE
   Li RX, 2014, MOL CELL BIOCHEM, V396, P295, DOI 10.1007/s11010-014-2164-6
   Lim JY, 2013, WORLD J GASTROENTERO, V19, P7078, DOI 10.3748/wjg.v19.i41.7078
   Marquitz AR, 2014, J VIROL, V88, P1389, DOI 10.1128/JVI.02662-13
   McLean M. H., 2014, NAT REV GASTROENTERO
   Naito Y, 2014, ONCOL REP, V32, P1720, DOI 10.3892/or.2014.3333
   Noto JM, 2013, AM J PHYSIOL-GASTR L, V305, pG786, DOI 10.1152/ajpgi.00279.2013
   Park D, 2014, PATHOL INT, V64, P309, DOI 10.1111/pin.12178
   Qi YJ, 2013, J CANCER RES THER, V9, P410, DOI 10.4103/0973-1482.119319
   Shang H, 2014, MOL MED REP, V10, P1839, DOI 10.3892/mmr.2014.2441
   Shen JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104510
   Shin VY, 2014, WORLD J GASTROENTERO, V20, P10432, DOI 10.3748/wjg.v20.i30.10432
   Shiotani A, 2013, BRIT J CANCER, V109, P2323, DOI 10.1038/bjc.2013.596
   Toiyama Y, 2014, BIOCH BIOPHYS RES CO
   Tong FY, 2014, DIGEST DIS SCI, V59, P24, DOI 10.1007/s10620-013-2887-3
   Wu K, 2014, ASIAN PAC J CANCER P, V15, P5583, DOI 10.7314/APJCP.2014.15.14.5583
   Wu XJ, 2013, ONKOLOGIE, V36, P573, DOI 10.1159/000355518
   Xia T, 2014, SCI REP-UK, V4, DOI 10.1038/srep06088
   Xu XH, 2013, ONCOL LETT, V6, P631, DOI 10.3892/ol.2013.1428
   Xu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099516
   Yoon JH, 2013, BIOCHEM BIOPH RES CO, V440, P689, DOI 10.1016/j.bbrc.2013.09.123
   Zhai RL, 2014, TUMOR BIOL, V35, P11367, DOI 10.1007/s13277-014-2471-2
   Zhang XT, 2013, ONCOL LETT, V6, P1427, DOI 10.3892/ol.2013.1534
   Zhang Z, 2014, CANCER GENE THER, V21, P305, DOI 10.1038/cgt.2014.37
   Zhao HY, 2014, MOL CELL BIOCHEM, V385, P207, DOI 10.1007/s11010-013-1829-x
   Zhao X, 2014, CELL DEATH DIFFER, V21, P1900, DOI 10.1038/cdd.2014.109
   Zhu M, 2014, PATHOL RES PRACT, V210, P909, DOI 10.1016/j.prp.2014.07.008
NR 40
TC 12
Z9 12
U1 1
U2 10
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2014
VL 7
IS 12
BP 5947
EP 5957
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AZ6BP
UT WOS:000348303600184
PM 25664140
DA 2018-12-27
ER

PT J
AU Xie, C
   Han, YW
   Liu, Y
   Han, L
   Liu, J
AF Xie, Chao
   Han, Yunwei
   Liu, Yi
   Han, Lei
   Liu, Jie
TI RETRACTED: miRNA-124 down-regulates SOX8 expression and suppresses cell
   proliferation in non-small cell lung cancer (Retracted article. See vol.
   9, pg. 2756, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE NSCLC; miRNA-124; Sox8; IHC; lung cancer; survival analysis; cell
   proliferation
ID EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA;
   TUMOR-SUPPRESSOR; PROSTATE-CANCER; BREAST-CANCER; MICRORNA; MIR-124;
   GROWTH; METASTASIS; GENES
AB Non-small lung cell carcinoma (NSCLC) is a leading lethal disease and a global health burden. The function of the Sex determining region Y (SRY)-related high mobility group box (SOX) family gene in cancer has attracted the attention of more and more scientists recently, yet there are few reports regarding the role of SOX in NSCLC. Our study aimed to investigate the expression of SOX8, a protein belonging to the E group of the SOX family, as well as SOX9, in non-small cell lung cancer (NSCLC) and the relationship of gene expression to clinicopathological factors and prognosis in patients. Immunohistochemical analysis was used to measure the expression of SOX8 in 80 NSCLC and 7 adjacent normal tissues. SOX8 expression was detected as elevated in tumor samples and correlated to tumor size (P < 0.001), lymph node metastasis (P = 0.001), differentiation classification (P = 0.015), and clinical stage (P = 0.013) significantly. Moreover, Kaplan-Meier survival analysis demonstrated that shorter survival time for patients who had higher SOX8 expression (P < 0.001). In addition, our experiments indicate that miRNA-124 functions as a tumor suppressor in NSCLC. We also demonstrate miRNA-124 directly targeted and decreased SOX8 in NSCLC cell lines, suggesting smiRNA-124 may regulate NSCLC cell proliferation via decreasing SOX8 (oncogenicity of biomarker in NSCLC).
C1 [Xie, Chao] Shandong Univ, Qilu Hosp, Dept Oncol, Jinan 250000, Shandong, Peoples R China.
   [Han, Yunwei] Luzhou Med Coll, Affiliated Hosp, Dept Oncol, Luzhou 646000, Sichuan, Peoples R China.
   [Liu, Yi] Shangdong Ctr Dis Control & Prevent, Dept Radiat Protect, Jinan 250000, Shandong, Peoples R China.
   [Han, Lei] Jining Med Coll, Affiliated Hosp, Dept Oncol, Jining 272000, Shandong, Peoples R China.
   [Liu, Jie] Shandong Acad Med Sci, Shandong Canc Hosp, Dept Oncol, Jinan 250117, Peoples R China.
RP Liu, J (reprint author), Shandong Acad Med Sci, Shandong Canc Hosp, Dept Oncol, 440 Jiyan Rd, Jinan 250117, Peoples R China.
EM liujielab@163.com
CR Bader AG, 2011, GENE THER, V18, P1121, DOI 10.1038/gt.2011.79
   Boeri M, 2012, CANCER J, V18, P268, DOI 10.1097/PPO.0b013e318258b743
   Castillo SD, 2012, EXPERT OPIN THER TAR, V16, P903, DOI 10.1517/14728222.2012.709239
   Cheng LC, 2009, NAT NEUROSCI, V12, P399, DOI 10.1038/nn.2294
   Cheng YC, 2001, MOL BRAIN RES, V92, P193, DOI 10.1016/S0169-328X(01)00147-4
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Han ZB, 2013, CELL PHYSIOL BIOCHEM, V31, P823, DOI 10.1159/000350100
   Herlofsen SR, 2014, STEM CELLS, V32, P1629, DOI 10.1002/stem.1642
   Hunt S, 2011, FEBS LETT, V585, P187, DOI 10.1016/j.febslet.2010.11.038
   Jiang SS, 2010, CLIN CANCER RES, V16, P4363, DOI 10.1158/1078-0432.CCR-10-0138
   Kang J, 2012, EXP THER MED, V3, P149, DOI 10.3892/etm.2011.366
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383
   Liu KJ, 2013, BIOMED RES INT, DOI 10.1155/2013/867537
   Lu YX, 2013, BIOCHEM BIOPH RES CO, V441, P873, DOI 10.1016/j.bbrc.2013.10.157
   Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015
   Mishima T, 2007, BRAIN RES, V1131, P37, DOI 10.1016/j.brainres.2006.11.035
   O'Bryan MK, 2008, DEV BIOL, V316, P359, DOI 10.1016/j.ydbio.2008.01.042
   Qin GQ, 2014, ONCOTARGETS THER, V7, P137, DOI 10.2147/OTT.S55432
   Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007
   Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X
   Schepers GE, 2000, NUCLEIC ACIDS RES, V28, P1473, DOI 10.1093/nar/28.6.1473
   Schlierf B, 2007, NEUROPATH APPL NEURO, V33, P621, DOI 10.1111/j.1365-2990.2007.00881.x
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394
   Takada S, 2004, DEV DYNAM, V231, P387, DOI 10.1002/dvdy.20132
   Waldman SA, 2009, CTS-CLIN TRANSL SCI, V2, P248, DOI 10.1111/j.1752-8062.2009.00110.x
   Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654
   Wang MJ, 2013, INT J COLORECTAL DIS, V28, P183, DOI 10.1007/s00384-012-1550-3
   Wu KJ, 2013, CELL SIGNAL, V25, P2625, DOI 10.1016/j.cellsig.2013.08.028
   Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627
   Xie LM, 2014, MOL CELL BIOCHEM, V392, P153, DOI 10.1007/s11010-014-2028-0
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-276
   Yu CY, 2014, CANCER LETT, V343, P258, DOI 10.1016/j.canlet.2013.09.033
   Zhang SQ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0918-3
   Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145
   Zhou CH, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-18
NR 37
TC 13
Z9 15
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2014
VL 7
IS 11
BP 7518
EP 7526
PG 9
WC Oncology; Pathology
SC Oncology; Pathology
GA AZ6RB
UT WOS:000348345200021
PM 25550787
DA 2018-12-27
ER

PT J
AU Belhouchet, H
   Makri, H
   Hamidouche, M
   Bouaouadja, N
   Garnier, V
   Fantozzi, G
AF Belhouchet, H.
   Makri, H.
   Hamidouche, M.
   Bouaouadja, N.
   Garnier, V.
   Fantozzi, G.
TI RETRACTED: Multiphase Composites Obtained by Sintering Reaction of
   Boehmite and Zircon Part I: Development and Microstructural
   Characterization (Retracted article. See vol. 47, pg. 115, 2015)
SO SCIENCE OF SINTERING
LA English
DT Article; Retracted Publication
DE Multiphase composites; Reactive sintering; Development; Alumina; Zircon;
   Mullite; Zirconia
ID ALUMINA-MULLITE-ZIRCONIA; THERMAL-SHOCK BEHAVIOR; MECHANICAL-PROPERTIES;
   THERMOMECHANICAL BEHAVIOR
AB In this work, different composites (zircon-mullite, zirconia-mullite-zirconia, mullite-zirconia and alumina-zirconia-mullite) were developed by reactive sintering of a powder mixture of boehmite (AlOOH)) and zircon (ZrSiO4). These powder mixtures were mixed and ground by ball milling and then pressed in cylindrical form. Finally, the green specimens were sintered in air during 2 hours between 1400 degrees C and 1600 degrees C, with a heating and cooling rate of 5 degrees C/min.
   The dilatometric curves show that there are several microstructural transformations in these mixtures. X-rays diffraction spectra showed formation of several composites depending on the initial conditions (% of boehmite and zircon and sintering temperature). The micrographic observations of the samples confirmed the presence of various phases.
C1 [Belhouchet, H.; Bouaouadja, N.] Univ Ferhat Abbas Setif 1, Inst Opt & Mecan Precis, Lab Mat Non Metall, Setif 19000, Algeria.
   [Makri, H.] Univ Med Boudiaf, Fac Sci Ingn, Dept Genie Mecan, Msila 28000, Algeria.
   [Hamidouche, M.] Univ Ferhat Abbas Setif 1, Unite Rech Mat Emergents, Setif 19000, Algeria.
   [Garnier, V.; Fantozzi, G.] Univ Lyon, INSA Lyon, MATEIS UMR CNRS 5510, F-69621 Villeurbanne, France.
RP Belhouchet, H (reprint author), Univ Ferhat Abbas Setif 1, Inst Opt & Mecan Precis, Lab Mat Non Metall, Setif 19000, Algeria.
EM hbelhou@yahoo.com
CR Aksel C, 2003, CERAM INT, V29, P311, DOI 10.1016/S0272-8842(02)00139-6
   Anjali MC, 2012, SCI SINTER, V44, P323, DOI 10.2298/SOS1203323A
   ANSEAU MR, 1976, J MATER SCI, V11, P578, DOI 10.1007/BF00540943
   Badiee SH, 2012, SCI SINTER, V44, P341, DOI 10.2298/SOS1203341B
   Belhouchet H, 2011, VERRES CERAMIQUES CO, V1, P16
   Belhouchet H, 2007, ANN CHIM-SCI MAT, V32, P605, DOI 10.3166/acsm.32.605-614
   BUDNIKOV PP, 1956, DOKL AKAD NAUK SSSR+, V106, P267
   Carbonneau X., 1997, THESIS INSA DE LYON
   Chraska T, 2009, J EUR CERAM SOC, V29, P3159, DOI 10.1016/j.jeurceramsoc.2009.05.020
   CLAUSSEN N, 1980, J AM CERAM SOC, V63, P228, DOI 10.1111/j.1151-2916.1980.tb10700.x
   Hamidouche M, 2007, CERAM INT, V33, P655, DOI 10.1016/j.ceramint.2005.12.002
   Hamidouche M, 2003, CERAM INT, V29, P599, DOI 10.1016/S0272-8842(02)00207-9
   Hamidouche M, 1996, J EUR CERAM SOC, V16, P441, DOI 10.1016/0955-2219(95)00110-7
   Kato K., 1982, YOGYO KYOKAISHI, V90, P1
   Khor KA, 1998, MAT SCI ENG A-STRUCT, V256, P271, DOI 10.1016/S0921-5093(98)00807-7
   Koyama T, 1996, J EUR CERAM SOC, V16, P231, DOI 10.1016/0955-2219(95)00142-5
   Mazzei AC, 2000, J MATER SCI, V35, P2807, DOI 10.1023/A:1004743001686
   Prestidge CA, 1999, COLLOID SURFACE A, V157, P137, DOI 10.1016/S0927-7757(98)00774-2
   Rendtorff NM, 2010, CERAM INT, V36, P781, DOI 10.1016/j.ceramint.2009.11.010
   Rendtorff NM, 2008, MAT SCI ENG A-STRUCT, V498, P208, DOI 10.1016/j.msea.2008.08.036
NR 20
TC 2
Z9 2
U1 1
U2 8
PU INT INST SCIENCE SINTERING (I I S S)
PI BELGRADE
PA C/O ITN SANU, KNEZ MIHAILOVA 35/IV, PO BOX 315, 11000 BELGRADE,
   YUGOSLAVIA
SN 0350-820X
J9 SCI SINTER
JI Sci. Sinter.
PY 2014
VL 46
IS 3
BP 291
EP 306
DI 10.2298/SOS1403291B
PG 16
WC Materials Science, Ceramics; Metallurgy & Metallurgical Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA CA0HX
UT WOS:000348599200003
OA DOAJ Gold
DA 2018-12-27
ER

PT S
AU Merie, VV
   Pustan, MS
   Birleanu, C
   Negrea, G
AF Merie, V. V.
   Pustan, M. S.
   Birleanu, C.
   Negrea, G.
GP IOP
TI RETRACTED: Nanocharacterization of titanium nitride thin films obtained
   by reactive magnetron sputtering (Retracted article. See vol 69, pg
   1455, 2017)
SO 2ND INTERNATIONAL CONFERENCE ON STRUCTURAL NANO COMPOSITES (NANOSTRUC
   2014)
SE IOP Conference Series-Materials Science and Engineering
LA English
DT Proceedings Paper; Retracted Publication
CT 2nd International Conference on Structural Nano Composites (NANOSTRUC)
CY MAY 20-21, 2014
CL Madrid, SPAIN
ID ATOMIC-FORCE MICROSCOPY; DEPOSITION
AB Titanium nitride thin films are used in applications such as tribological layers for cutting tools, coating of some medical devices (scalpel blades, prosthesis, implants etc.), sensors, electrodes for bioelectronics, microelectronics, diffusion barrier, bio-microelectromechanical systems (Bio-MEMS) and so on. This work is a comparative study concerning the influence of substrate temperature on some mechanical and tribological characteristics of titanium nitride thin films. The researched thin films were obtained by reactive magnetron sputtering method. The experiments employed two kinds of substrates: a steel substrate and a silicon one. The elaboration of titanium nitride thin films was done at two temperatures. First, the obtaining was realized when the substrates were at room temperature, and second, the obtaining was realized when the substrates were previously heated at 250 degrees C. The elaborated samples were then investigated by atomic force microscopy in order to establish their mechanical and tribological properties. The nanohardness, roughness, friction force are some of the determined characteristics. The results marked out that the substrate which was previously heated at 250 degrees C led to the obtaining of more adherent titanium nitride thin films than the substrate used at room temperature.
C1 [Merie, V. V.; Pustan, M. S.; Birleanu, C.] Tech Univ Cluj Napoca, Fac Machines Bldg, Dept Mech Syst Engn, 103-105 Muncii Ave, Cluj Napoca, Romania.
   [Negrea, G.] Tech Univ Cluj Napoca, Fac Mat & Environm Engn, Dept Mat Sci & Engn, Cluj Napoca, Romania.
RP Merie, VV (reprint author), Tech Univ Cluj Napoca, Fac Machines Bldg, Dept Mech Syst Engn, 103-105 Muncii Ave, Cluj Napoca, Romania.
EM Violeta.Merie@stm.utcluj.ro
OI Marius, PUSTAN/0000-0002-1683-8663
CR Bavadi R, 2012, MATER PHYS MECH, V15, P167
   Borah SM, 2008, APPL SURF SCI, V254, P5760, DOI 10.1016/j.apsusc.2008.03.047
   Cui XL, 2009, SURF COAT TECH, V204, P418, DOI 10.1016/j.surfcoat.2009.07.039
   Hsieh CF, 2006, MICROELECTRON J, V37, P867, DOI 10.1016/j.mejo.2006.03.003
   Hussain T, 2009, NUCL INSTRUM METH B, V267, P768, DOI 10.1016/j.nimb.2009.01.008
   Jeyachandran YL, 2007, MAT SCI ENG A-STRUCT, V445, P223, DOI 10.1016/j.msea.2006.09.021
   Karagkiozaki V, 2009, NANOMED-NANOTECHNOL, V5, P64, DOI 10.1016/j.nano.2008.07.005
   Kim SH, 2009, J CERAM PROCESS RES, V10, P49
   Lawand NS, 2012, PROCEDIA ENGINEER, V47, P726, DOI 10.1016/j.proeng.2012.09.250
   Machunze R, 2009, THIN SOLID FILMS, V517, P5888, DOI 10.1016/j.tsf.2009.04.020
   Merie V, 2013, ACTA TECH NAPOCENSIS, V56, P709
   Pustan M, 2010, ECNF 1 EUR C NAN LIE
   Sanchez O, 2006, THIN SOLID FILMS, V495, P149, DOI 10.1016/j.tsf.2005.08.203
   Serban VA, 2013, APPL SURF SCI, V265, P245, DOI 10.1016/j.apsusc.2012.10.187
   Su PJ, 2013, THIN SOLID FILMS, V529, P317, DOI 10.1016/j.tsf.2012.07.066
   Subramanian B, 2008, APPL SURF SCI, V255, P2133, DOI 10.1016/j.apsusc.2008.07.083
   Vasu K, 2011, THIN SOLID FILMS, V519, P7702, DOI 10.1016/j.tsf.2011.05.052
   Yazdani A, 2011, VACUUM, V86, P131, DOI 10.1016/j.vacuum.2011.04.020
NR 18
TC 0
Z9 0
U1 3
U2 12
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 1757-8981
J9 IOP CONF SER-MAT SCI
PY 2014
VL 64
AR UNSP 012025
DI 10.1088/1757-899X/64/1/012025
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Materials Science, Composites
SC Science & Technology - Other Topics; Materials Science
GA BB8JQ
UT WOS:000346741500026
OA Other Gold
DA 2018-12-27
ER

PT J
AU Mirjalili, A
   Yazdanpanah, MM
   Moradi, Z
AF Mirjalili, A.
   Yazdanpanah, M. M.
   Moradi, Z.
TI RETRACTED: Extracting the QCD Cutoff Parameter Using the Bernstein
   Polynomials and the Truncated Moments (Retracted article. See 975023,
   2015)
SO ADVANCES IN HIGH ENERGY PHYSICS
LA English
DT Article; Retracted Publication
ID INELASTIC EP SCATTERING; PARTON DISTRIBUTIONS; PERTURBATION-THEORY;
   EVOLUTION-EQUATIONS; CORGI APPROACH; NEUTRINO; ANNIHILATION; DEUTERIUM;
   PROTON; NNLO
AB Since there are not experimental data over the whole range of x-Bjorken variable, that is, 0 < x < 1, we are inevitable in practice to do the integration for Mellin moments over the available range of experimental data. Among the methods of analysing DIS data, there are the methods based on application of Mellin moments. We use the truncated Mellin moments rather than the usual moments to analyse the EMC collaboration data formuon-nucleon and WA25 data for neutrino-deuterium DIS scattering. How to connect the truncated Mellin moments to usual ones is discussed. Following that we combine the truncated Mellin moments with the Bernstein polynomials. As a result, Bernstein averages which are related to different orders of the truncated Mellin moment are obtained. These averaged quantities can be considered as the constructed experimental data. By accessing the sufficient experimental data we can do the fitting more precisely. We do the fitting at leading order and next-to-leading order approximations to extract the QCD cutoff parameter. The results are in good agreement with what is being expected.
C1 [Mirjalili, A.; Moradi, Z.] Yazd Univ, Dept Phys, Yazd, Iran.
   [Yazdanpanah, M. M.] Shahid Bahonar Univ Kerman, Fac Phys, Kerman, Iran.
RP Mirjalili, A (reprint author), Yazd Univ, Dept Phys, POB 89195-741, Yazd, Iran.
EM mirjalili@ipm.ir
CR ALLASIA D, 1984, PHYS LETT B, V135, P231, DOI 10.1016/0370-2693(84)90488-X
   ALTARELLI G, 1977, NUCL PHYS B, V126, P298, DOI 10.1016/0550-3213(77)90384-4
   AUBERT JJ, 1987, NUCL PHYS B, V293, P740, DOI 10.1016/0550-3213(87)90090-3
   BERNREUTHER W, 1982, NUCL PHYS B, V197, P228, DOI 10.1016/0550-3213(82)90288-7
   Bernreuther W, 1998, NUCL PHYS B, V513, P758, DOI 10.1016/S0550-3213(97)00811-0
   Cafarella A, 2006, NUCL PHYS B, V748, P253, DOI 10.1016/j.nuclphysb.2006.05.010
   DOKSHITSER YL, 1977, ZH EKSP TEOR FIZ+, V73, P1216
   Dokshitzer Yu. L., 1977, SOV PHYS JETP, V46, P641, DOI DOI 10.1016/0550-3213(77)90384-4
   Forte S, 2001, NUCL PHYS B, V594, P46, DOI 10.1016/S0550-3213(00)00670-2
   Forte S, 1999, PHYS LETT B, V448, P295, DOI 10.1016/S0370-2693(99)00065-9
   GLUCK M, 1995, Z PHYS C PART FIELDS, V67, P433, DOI 10.1007/BF01624586
   Gribov V. N., 1972, Yadernaya Fizika, V15, P781
   Gribov V. N., 1972, Yadernaya Fizika, V15, P1218
   GRIBOV VN, 1972, SOV J NUCL PHYS+, V15, P675
   GRIBOV VN, 1972, SOV J NUCL PHYS+, V15, P438
   Kataev A. L., GEN BLM EXP IN PRESS
   Kataev AL, 1998, PHYS LETT B, V417, P374, DOI 10.1016/S0370-2693(97)01239-2
   Khorramian A. N., 2004, JHEP-Journal of High Energy Physics, V2004, DOI 10.1088/1126-6708/2004/10/062
   Kotlorz D, 2014, J HIGH ENERGY PHYS, DOI 10.1007/JHEP06(2014)065
   Kotlorz D, 2007, PHYS LETT B, V644, P284, DOI 10.1016/j.physletb.2006.11.054
   Kotlorz D, 2009, ACTA PHYS POL B, V40, P1661
   Maxwell CJ, 2002, NUCL PHYS B, V645, P298, DOI 10.1016/S0550-3213(02)00838-6
   Mirjalili A, 2007, INT J MOD PHYS A, V22, P4519, DOI 10.1142/S0217751X07037056
   Santiago J, 2001, NUCL PHYS B, V611, P447, DOI 10.1016/S0550-3213(01)00328-5
   Wang SQ, 2014, PHYS REV D, V90, DOI 10.1103/PhysRevD.90.037503
   YNDURAIN FJ, 1978, PHYS LETT B, V74, P68, DOI 10.1016/0370-2693(78)90062-X
NR 26
TC 0
Z9 0
U1 3
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-7357
EI 1687-7365
J9 ADV HIGH ENERGY PHYS
JI Adv. High. Energy Phys.
PY 2014
AR 304369
DI 10.1155/2014/304369
PG 7
WC Physics, Particles & Fields
SC Physics
GA AX2CE
UT WOS:000346749800001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Momenzadeh, D
   Rahmanzadeh, S
   Rezaei-Tavirani, M
   Baradaran-Rafii, A
   Ghasemvand, F
   Heidari-Keshel, S
AF Momenzadeh, D.
   Rahmanzadeh, S.
   Rezaei-Tavirani, M.
   Baradaran-Rafii, A.
   Ghasemvand, F.
   Heidari-Keshel, S.
TI RETRACTED: ZNF797 plays an oncogenic role in gastric cancer (Retracted
   article. See vol. 14, pg. 788, 2015)
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article; Retracted Publication
DE Gastric cancer; SALL4 expression; 5' Nuclease assay
ID EMBRYONIC STEM-CELLS; OKIHIRO-SYNDROME; GENE SPALT; SALL4; EXPRESSION;
   PLURIPOTENCY; MARKER; TUMORS; MORTALITY; LINEAGES
AB Human cancer cells resemble stem cells in expression signatures leading them to share some features, most notably, self-renewal. A complex network of transcription factors and signaling molecules are required for continuation of this trait. ZNF797 (SALL4) is a zinc finger transcriptional activator crucial for maintenance of self-renewal in stem cells; however, its expression level has not yet been elucidated in gastric tumor cells. Its expression was analyzed to determine this level and probable clinicopathological consequences. SALL4 expression in fresh tumor and distant tumor-free tissues from 46 colorectal samples was compared by real-time polymerase chain reaction. Greater than a 2-fold increase in SALL4 expression was detected in 89.5% of tumors vs normal related tissues. SALL4 expression was significantly correlated with tumor cell metastasis to lymph nodes, especially in moderately differentiated tumor samples (P < 0.05). Furthermore, higher levels of SALL4 mRNA expression were significantly associated with younger patients with tumor cells in stages I and II (P < 0.05). These results indicate a relationship between SALL4 expression and tumor cell metastasis to lymph nodes and consequent progression of tumors to advanced stages III and IV. Along with the promising evidence of its role in self-renewal in various cancers, SALL4 is introduced as a potentially interesting therapeutic target to reverse a number of aberrations that promote gastric tumor development and maintenance. This result may lead to new approaches for cancer therapy.
C1 [Momenzadeh, D.; Rahmanzadeh, S.; Rezaei-Tavirani, M.; Ghasemvand, F.; Heidari-Keshel, S.] Shahid Beheshti Univ Med Sci, Prote Res Ctr, Tehran, Iran.
   [Baradaran-Rafii, A.] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran.
RP Heidari-Keshel, S (reprint author), Shahid Beheshti Univ Med Sci, Prote Res Ctr, Tehran, Iran.
EM saeed_heidari@spu.ir
RI Rezaei Tavirani, Mostafa/I-2407-2017
OI Heidari keshel, Saeed/0000-0003-2637-2825; Rezaei-Tavirani,
   Mostafa/0000-0003-1767-7475
CR Cao DF, 2009, AM J SURG PATHOL, V33, P1065, DOI 10.1097/PAS.0b013e3181a13eef
   Cao DF, 2009, CANCER-AM CANCER SOC, V115, P2640, DOI 10.1002/cncr.24308
   Cao DF, 2009, AM J SURG PATHOL, V33, P894, DOI 10.1097/PAS.0b013e318198177d
   Cenitagoya GF, 1998, DIGEST SURG, V15, P317, DOI 10.1159/000018645
   Cui W, 2006, MODERN PATHOL, V19, P1585, DOI 10.1038/modpathol.3800694
   Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103
   Forte A, 2009, MOL MED, V15, P392, DOI 10.2119/molmed.2009.00068
   FREI E, 1988, EMBO J, V7, P197, DOI 10.1002/j.1460-2075.1988.tb02800.x
   Huang Zheng-Jie, 2012, Sichuan Da Xue Xue Bao Yi Xue Ban, V43, P812
   Kohlhase J, 2002, HUM MOL GENET, V11, P2979, DOI 10.1093/hmg/11.23.2979
   Kohlhase J, 2002, CYTOGENET GENOME RES, V98, P274, DOI 10.1159/000071048
   Kohlhase J, 1996, GENOMICS, V38, P291, DOI 10.1006/geno.1996.0631
   Kuhnlein RP, 1996, DEVELOPMENT, V122, P2215
   Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736
   Lim CY, 2008, CELL STEM CELL, V3, P543, DOI 10.1016/j.stem.2008.08.004
   Liu AJ, 2010, AM J SURG PATHOL, V34, P697, DOI 10.1097/PAS.0b013e3181db84aa
   Lu H, 2012, ASIAN PAC J CANCER P, V13, P3437, DOI 10.7314/APJCP.2012.13.7.3437
   Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577
   Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594
   Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.3.CO;2-D
   Rajasekhar VK, 2007, STEM CELLS, V25, P2498, DOI 10.1634/stemcells.2006-0608
   Shuai X, 2009, CANCER GENET CYTOGEN, V194, P119, DOI 10.1016/j.cancergencyto.2009.06.006
   Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200
   Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104
   Yang JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010766
   Yang JC, 2008, P NATL ACAD SCI USA, V105, P19756, DOI 10.1073/pnas.0809321105
   Yuri S, 2009, STEM CELLS, V27, P796, DOI 10.1002/stem.14
   Zhang JY, 2010, ONCOL LETT, V1, P457, DOI 10.3892/ol_00000081
   Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481
NR 29
TC 4
Z9 4
U1 1
U2 5
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2014
VL 13
IS 4
BP 8421
EP 8427
DI 10.4238/2014.October.20.18
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AT7LY
UT WOS:000345119800036
PM 25366736
OA Bronze
DA 2018-12-27
ER

PT J
AU Tao, DY
   Pan, YH
   Lu, HS
   Zheng, S
   Lin, H
   Fang, HY
   Cao, FL
AF Tao, Deyou
   Pan, Yihong
   Lu, Hongsheng
   Zheng, Song
   Lin, Hui
   Fang, Hongyan
   Cao, Feilin
TI RETRACTED: B-myb is a gene implicated in cell cycle and proliferation of
   breast cancer (Retracted article. See vol. 9, pg. 2754, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE B-myb; cell cycle; proliferation; migration; invasion; breast cancer
ID TRANSCRIPTION FACTOR; ACTIVATION; TRANSITION
AB B-myb belongs to the myb family of transcription factors that include A-myb and c-myb. While A-myb and c-myb are tissue-specific, B-myb is broadly expressed in rapidly dividing cells of developing adult mammals. Results of our study showed that increased B-myb expression of was associated with the progression of breast cancer and that B-myb protein levels were significantly elevated in matched metastases. High B-myb levels also predict shorter overall survival of breast cancer patients. Moreover, B-myb stimulated transcription of target genes that promoted entry into the S and M-phases of the cell cycle, cell proliferation, migration and invasion in breast cancer. Taken together, our results strongly demonstrated that B-myb had a critical role in both cell cycle progression and tumorigenesis, and might serve as a novel potential target in the diagnosis and/or treatment of human breast cancer.
C1 [Tao, Deyou; Fang, Hongyan] Luqiao Hosp, Taizhou Enze Med Grp, Dept Surg Oncol, Luqiao, Zhejiang, Peoples R China.
   [Pan, Yihong] Luqiao Hosp, Taizhou Enze Med Grp, Dept Gynecol, Luqiao, Zhejiang, Peoples R China.
   [Lu, Hongsheng] Taizhou Cent Hosp, Taizhou Enze Med Group, Dept Pathol, Taizhou, Peoples R China.
   [Zheng, Song] First Peoples Hosp Hangzhou, Hangzhou Canc Hosp, Dept Oncol, Hangzhou, Zhejiang, Peoples R China.
   [Lin, Hui; Cao, Feilin] Taizhou Hosp, Taizhou Enze Med Grp, Dept Surg Oncol, Linhai, Peoples R China.
RP Pan, YH (reprint author), Taizhou Cent Hosp, Dept Gynecol, 999 Donghai Rd, Taizhou 318000, Zhejiang, Peoples R China.
EM yhpantz@163.com
FU Taizhou science and technology program [102KY13]
FX This study was supported by the grants from Taizhou science and
   technology program (102KY13).
CR ARSURA M, 1992, BLOOD, V79, P2708
   Bar-Shira A, 2002, CANCER RES, V62, P6803
   Bu YQ, 2010, BIOCHEM BIOPH RES CO, V397, P157, DOI 10.1016/j.bbrc.2010.05.063
   Cesi V, 2002, CELL DEATH DIFFER, V9, P1232, DOI 10.1038/sj.cdd.4401103
   Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618
   Gualdrini F, 2010, ONCOTARGET, V1, P278
   Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302
   Joaquin M, 2003, J BIOL CHEM, V278, P44255, DOI 10.1074/jbc.M308953200
   Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4
   LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8
   LAM EWF, 1992, ONCOGENE, V7, P1885
   Li HY, 2014, INT J CLIN EXP PATHO, V7, P3057
   NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075
   Sala A, 2005, EUR J CANCER, V41, P2479, DOI 10.1016/j.ejca.2005.08.004
   Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532
   Sala A, 1999, J CELL PHYSIOL, V179, P245
   Thorner AR, 2009, ONCOGENE, V28, P742, DOI 10.1038/onc.2008.430
   Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459
   Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7
NR 19
TC 8
Z9 8
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2014
VL 7
IS 9
BP 5819
EP 5827
PG 9
WC Oncology; Pathology
SC Oncology; Pathology
GA AT7PH
UT WOS:000345129400042
PM 25337223
DA 2018-12-27
ER

PT J
AU Ibrahim, MY
   Hashim, NM
   Mohan, S
   Abdulla, MA
   Abdelwahab, SI
   Kamalidehghan, B
   Ghaderian, M
   Dehghan, F
   Ali, LZ
   Karimian, H
   Yahayu, M
   Ee, GCL
   Farjam, AS
   Ali, HM
AF Ibrahim, Mohamed Yousif
   Hashim, Najihah Mohd
   Mohan, Syam
   Abdulla, Mahmood Ameen
   Abdelwahab, Siddig Ibrahim
   Kamalidehghan, Behnam
   Ghaderian, Mostafa
   Dehghan, Firouzeh
   Ali, Landa Zeenelabdin
   Karimian, Hamed
   Yahayu, Maizatulakmal
   Ee, Gwendoline Cheng Lian
   Farjam, Abdoreza Soleimani
   Ali, Hapipah Mohd
TI RETRACTED: Involvement of NF-kappa B and HSP70 signaling pathways in the
   apoptosis of MDA-MB-231 cells induced by a prenylated xanthone compound,
   alpha-mangostin, from Cratoxylum arborescens (Retracted article. See
   vol. 12, pg. 533, 2018)
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article; Retracted Publication
DE mitochondria; protein array; caspase-3/7
ID BREAST-CANCER CELLS; HUMAN COLON-CANCER; CYTOCHROME-C RELEASE;
   GARCINIA-MANGOSTANA; CYCLE ARREST; ANTITUMOR-ACTIVITY; DOWN-REGULATION;
   TUMOR-GROWTH; RISK-FACTORS; A549 CELLS
AB Background: Cratoxylum arborescens has been used traditionally in Malaysia for the treatment of various ailments. Methods: alpha-Mangostin (AM) was isolated from C. arborescens and its cell death mechanism was investigated. AM-induced cytotoxicity was observed with the 3-(4,5-dimethylthiazol-2-yl)2,5- diphenyltetrazolium bromide (MTT) assay. Acridine orange/propidium iodide staining and annexin V were used to detect cells in early phases of apoptosis. High-content screening was used to observe the nuclear condensation, cell permeability, mitochondrial membrane potential, and cytochrome c release. The role of caspases-3/7, -8, and -9, reactive oxygen species, Bcl-2 and Bax expression, and cell cycle arrest were also investigated. To determine the role of the central apoptosis-related proteins, a protein array followed by immunoblot analysis was conducted. Moreover, the involvement of nuclear factor-kappa B (NF-kappa B) was also analyzed.
   Results: Apoptosis was confirmed by the apoptotic cells stained with annexin V and increase in chromatin condensation in nucleus. Treatment of cells with AM promoted cell death-transducing signals that reduced MMP by downregulation of Bcl-2 and upregulation of Bax, triggering cytochrome c release from the mitochondria to the cytosol. The released cytochrome c triggered the activation of caspase-9 followed by the executioner caspase-3/7 and then cleaved the PARP protein. Increase of caspase-8 showed the involvement of extrinsic pathway. AM treatment significantly arrested the cells at the S phase (P<0.05) concomitant with an increase in reactive oxygen species. The protein array and Western blotting demonstrated the expression of HSP70. Moreover, AM significantly blocked the induced translocation of NF-kappa B from cytoplasm to nucleus.
   Conclusion: Together, the results demonstrate that the AM isolated from C. arborescens inhibited the proliferation of MDA-MB-231 cells, leading to cell cycle arrest and programmed cell death, which was suggested to occur through both the extrinsic and intrinsic apoptosis pathways with involvement of the NF-kappa B and HSP70 signaling pathways.
C1 [Ibrahim, Mohamed Yousif; Hashim, Najihah Mohd; Kamalidehghan, Behnam; Ghaderian, Mostafa; Dehghan, Firouzeh; Ali, Landa Zeenelabdin; Karimian, Hamed] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur 50603, Malaysia.
   [Mohan, Syam; Abdelwahab, Siddig Ibrahim] Jazan Univ, Med Res Ctr, Jazan, Saudi Arabia.
   [Abdulla, Mahmood Ameen] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur 50603, Malaysia.
   [Ghaderian, Mostafa] Univ Malaya, Fac Sci, Inst Biol Sci, Epigenet Lab, Kuala Lumpur 50603, Malaysia.
   [Dehghan, Firouzeh] Univ Malaya, Fac Med, Dept Physiol, Kuala Lumpur 50603, Malaysia.
   [Yahayu, Maizatulakmal] Univ Teknol Malaysia, IBD, Dept Bioprod Res & Innovat, Utm Johor Bahru, Johor, Malaysia.
   [Ee, Gwendoline Cheng Lian] Univ Putra Malaysia, Fac Sci, Dept Chem, Serdang, Selangor, Malaysia.
   [Farjam, Abdoreza Soleimani] Univ Putra Malaysia, Inst Trop Agr, Serdang, Selangor, Malaysia.
   [Ali, Hapipah Mohd] Univ Malaya, Dept Chem, Kuala Lumpur 50603, Malaysia.
RP Hashim, NM (reprint author), Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur 50603, Malaysia.
EM al_omdah2003@hotmail.com; najihahmh@um.edu.my
RI Karimian, Hamed/A-2324-2014; Yahayu, Maizatulakmal/F-1761-2015; Mohd
   Hashim, Najihah/J-5508-2015; Mohan, Syam/A-1231-2011
OI Karimian, Hamed/0000-0002-8501-9864; Mohd Hashim,
   Najihah/0000-0003-1133-7998; soleimani farjam,
   abdoreza/0000-0002-7637-0556
FU University of Malaya through the Postgraduate Research Fund (PPP) [PG
   141-2012B]; University Malaya Research Grant [RP001C-13BIO]; High Impact
   Research Grant from the Ministry of Higher Education Malaysia [UM-MOHE
   M.C/625/1/HIR/MOHE//SC/09]
FX This study was financially supported by the University of Malaya through
   the Postgraduate Research Fund (PPP) grant PG 141-2012B, University
   Malaya Research Grant RP001C-13BIO, and High Impact Research Grant
   UM-MOHE M.C/625/1/HIR/MOHE//SC/09 from the Ministry of Higher Education
   Malaysia.
CR Abbasalipourkabir R, 2010, AFR J BIOTECHNOL, V9, P7337
   Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Anatole PC, 2013, ENVIRON TOXICOL PHAR, V36, P865, DOI 10.1016/j.etap.2013.07.015
   Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3
   Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711
   Campisi G, 2005, ORAL ONCOL, V41, P994, DOI 10.1016/j.oraloncology.2005.05.014
   Chai JJ, 2000, NATURE, V406, P855
   Charalambous C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-238
   Cheng XX, 2012, J ETHNOPHARMACOL, V143, P49, DOI 10.1016/j.jep.2012.05.054
   Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008
   Cui YH, 2007, EUR J CANCER, V43, P2590, DOI 10.1016/j.ejca.2007.08.015
   Devalaraja S, 2011, FOOD RES INT, V44, P1856, DOI 10.1016/j.foodres.2011.04.008
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x
   Ferenc P, 2010, J PHOTOCH PHOTOBIO B, V98, P25, DOI 10.1016/j.jphotobiol.2009.10.004
   Giorgi C, 2008, CURR MOL MED, V8, P119
   Gu Q, 2005, CARCINOGENESIS, V26, P541, DOI 10.1093/carcin/bgh345
   Ham YM, 2012, J FUNCT FOODS, V4, P253, DOI 10.1016/j.jff.2011.12.001
   Hortobagyi Gabriel N, 2005, Clin Breast Cancer, V6, P391, DOI 10.3816/CBC.2005.n.043
   Hsieh SCY, 2013, MONIE MARK FINANC E, V3, P1
   Isa NM, 2013, J FUNCT FOODS, V5, P87, DOI 10.1016/j.jff.2012.08.008
   Jia ZL, 2012, J MOL HISTOL, V43, P115, DOI 10.1007/s10735-011-9371-1
   Jin S, 2010, ANN ONCOL, V21, P263, DOI 10.1093/annonc/mdp499
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Kaomongkolgit R, 2011, ARCH ORAL BIOL, V56, P483, DOI 10.1016/j.archoralbio.2010.10.023
   Kaomongkolgit Ruchadaporn, 2009, J Oral Sci, V51, P401
   Khan MA, 2013, MOL CELLS, V35, P219, DOI 10.1007/s10059-013-2259-z
   Kijjoa A, 1998, PHYTOCHEMISTRY, V49, P2159, DOI 10.1016/S0031-9422(98)00381-1
   Koh JJ, 2013, BBA-BIOMEMBRANES, V1828, P834, DOI 10.1016/j.bbamem.2012.09.004
   Krajarng A, 2012, RES VET SCI, V93, P788, DOI 10.1016/j.rvsc.2012.01.015
   Krajarng A, 2011, J AGR FOOD CHEM, V59, P5746, DOI 10.1021/jf200620n
   Kumar RB, 2010, PHARMACOGN RES, V2, P247, DOI 10.4103/0974-8490.69126
   Kumazaki M, 2013, J NUTR BIOCHEM, V24, P1849, DOI 10.1016/j.jnutbio.2013.04.006
   Kuo JR, 2012, NEUROCHEM INT, V60, P105, DOI 10.1016/j.neuint.2011.11.014
   Kurose H, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/672428
   Lancon A, 2013, J SCI FOOD AGR, V93, P3155, DOI 10.1002/jsfa.6228
   Lee JS, 2012, INT J TOXICOL, V31, P70, DOI 10.1177/1091581811423845
   Li Z, 2010, CELL, V141, P859, DOI 10.1016/j.cell.2010.03.053
   Looi CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056643
   Mohan S, 2012, PHYTOMEDICINE, V19, P1007, DOI 10.1016/j.phymed.2012.05.012
   Mohan S, 2010, J ETHNOPHARMACOL, V131, P592, DOI 10.1016/j.jep.2010.07.043
   Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000
   Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020
   Nelli GB, 2013, SYST BIOL REPROD MED, V59, P319, DOI 10.3109/19396368.2013.820369
   Ngawhirunpat T, 2010, PHARM BIOL, V48, P55, DOI 10.3109/13880200903046138
   Obolskiy D, 2009, PHYTOTHER RES, V23, P1047, DOI 10.1002/ptr.2730
   Olguin-Martinez M, 2013, FREE RADICAL BIO MED, V65, P1090, DOI 10.1016/j.freeradbiomed.2013.08.176
   Otterbach F, 2010, BREAST CANCER RES TR, V120, P67, DOI 10.1007/s10549-009-0370-9
   Pacifico S, 2013, FOOD CHEM TOXICOL, V62, P628, DOI 10.1016/j.fct.2013.09.029
   Pan M-H, 2013, FOOD SCI HUMAN WELLN, V2, P12, DOI DOI 10.1016/J.FSHW.2013.03.004
   Park HS, 2012, FOOD CHEM TOXICOL, V50, P2407, DOI 10.1016/j.fct.2012.04.034
   Pawar P, 2009, CLIN CANCER RES, V15, P1288, DOI 10.1158/1078-0432.CCR-08-1150
   Pedraza-Chaverri J, 2008, FOOD CHEM TOXICOL, V46, P3227, DOI 10.1016/j.fct.2008.07.024
   Perez-Rojas JM, 2009, FREE RADICAL RES, V43, P1122, DOI 10.1080/10715760903214447
   Plastina P, 2012, J ETHNOPHARMACOL, V140, P325, DOI 10.1016/j.jep.2012.01.022
   Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0
   Saleem M, 2009, CANCER LETT, V285, P109, DOI 10.1016/j.canlet.2009.04.033
   Sampath PD, 2009, DRUG CHEM TOXICOL, V32, P344, DOI 10.1080/01480540903159210
   Sanchez-Perez Y, 2010, CHEM-BIOL INTERACT, V188, P144, DOI 10.1016/j.cbi.2010.06.014
   Schottenfeld D, 2013, ANNU REV PUBL HEALTH, V34, P97, DOI 10.1146/annurev-publhealth-031912-114350
   Shibata MA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-69
   Shier W.T., 1991, MAMMALIAN CELL CULTU, P64
   Shih YW, 2010, CELL BIOCHEM BIOPHYS, V58, P31, DOI 10.1007/s12013-010-9091-2
   Shukla Y, 2011, ANN NY ACAD SCI, V1229, P162, DOI 10.1111/j.1749-6632.2011.06104.x
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125
   Srithi K, 2009, J ETHNOPHARMACOL, V123, P335, DOI 10.1016/j.jep.2009.02.035
   Tanaka T., 2013, Journal of Experimental and Clinical Medicine, V5, P89, DOI 10.1016/j.jecm.2013.04.001
   Tang J, 2009, J ETHNOPHARMACOL, V126, P5, DOI 10.1016/j.jep.2009.08.009
   Turk B, 2007, FEBS LETT, V581, P2761, DOI 10.1016/j.febslet.2007.05.038
   van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R
   Varghese JS, 2012, CANCER EPIDEM BIOMAR, V21, P2167, DOI 10.1158/1055-9965.EPI-12-0789
   Verfaillie T, 2013, CANCER LETT, V332, P249, DOI 10.1016/j.canlet.2010.07.016
   Wang JJ, 2012, ANTICANCER RES, V32, P3805
   Watanapokasin R, 2011, WORLD J GASTROENTERO, V17, P2086, DOI 10.3748/wjg.v17.i16.2086
   Wen SM, 2014, CANCER TREAT REV, V40, P31, DOI 10.1016/j.ctrv.2013.07.008
   Xiao D, 2005, ONCOGENE, V24, P6256, DOI 10.1038/sj.onc.1208759
   Yang F, 2013, PARASITOL RES, V112, P1261, DOI 10.1007/s00436-012-3260-8
   Yang S, 2011, FOOD CHEM TOXICOL, V49, P527, DOI 10.1016/j.fct.2010.11.044
   Yang W, 2012, J CONTROL RELEASE, V160, P239, DOI 10.1016/j.jconrel.2011.12.031
   Yoon JS, 2013, J NAT MED-TOKYO, V67, P519, DOI 10.1007/s11418-012-0709-0
   Yu XY, 2010, TOXICOL APPL PHARM, V245, P83, DOI 10.1016/j.taap.2010.02.005
   Zhang GJ, 1999, CLIN CANCER RES, V5, P2971
   Zhang XN, 2013, TOXICOL APPL PHARM, V270, P122, DOI 10.1016/j.taap.2013.04.011
   Zhu AK, 2013, BRAZ J MED BIOL RES, V46, P670, DOI 10.1590/1414-431X20133050
NR 87
TC 11
Z9 11
U1 1
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2014
VL 8
BP 2193
EP 2211
DI 10.2147/DDDT.S66574
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AT4PK
UT WOS:000344922400001
PM 25395836
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Manaa, A
   Mimouni, H
   Wasti, S
   Gharbi, E
   Terras, A
   Ben Ahmed, H
AF Manaa, Arafet
   Mimouni, Hajer
   Wasti, Salma
   Gharbi, Emna
   Terras, Amel
   Ben Ahmed, Hela
TI RETRACTED: Characterization of transgenic Arabidopsis and tomato plants
   antisensed for the ethylene receptor gene CcEIN4 under NaCl stress
   (Retracted article. See vol. 12, pg. 254, 2017)
SO JOURNAL OF PLANT INTERACTIONS
LA English
DT Article; Retracted Publication
DE Arabidopsis; ethylene receptor; NaCl; tomato; transgenic plants
ID SALT-STRESS; TOLERANCE; RESPONSES; EXPRESSION; THALIANA; FAMILY; GROWTH;
   ROOTS; GERMINATION; TRANSPORT
AB The plant hormone ethylene (C2H4) plays important roles in plant growth and development. Here, we report physiological response of transgenic Arabidopsis and tomato plants, antisensed for the ethylene receptor gene CcEIN4 from coffee trees (Coffea canephora), under salinity stress. Results showed that the germination rate was higher in seeds collected from transgenic plants than that seeds from wild plants under salt stress condition. Growth of transgenic Arabidopsis and tomato plants was less sensitive to salt stress than wild type. Some transgenic plants showed a stimulation of radicle length and root system growth. The better salt tolerance observed in transgenic tomatoes lines can be explained by: ability to control the accumulation of Na+ and Cl-in shoots and better K+ and Ca2+ uptake, resulting in higher K+: Na+ and Ca2+: Na+ ratios. These results suggest that ethylene perception is involved in the plant response to saline stress and plays a pivotal role in the plant salt tolerance.
C1 [Manaa, Arafet; Mimouni, Hajer; Wasti, Salma; Terras, Amel; Ben Ahmed, Hela] Univ Tunis El Manar, Unite Ecophysiol & Nutr Plantes, Dept Biol, Fac Sci Tunis, Tunis 2092, Tunisia.
   [Gharbi, Emna] Catholic Univ Louvain, GRPV, ELI A, B-1348 Louvain La Neuve, Belgium.
RP Manaa, A (reprint author), CBBC, Lab Plantes Extremophiles, BP 901, Hammam Lif 2050, Tunisia.
EM manaaarafet@gmail.com
OI Arafet, Manaa/0000-0001-5657-6007
FU Ministry of Higher Education and Scientific Research of Tunisia
FX The authors acknowledge the Ministry of Higher Education and Scientific
   Research of Tunisia for financial support. Many thanks to Mr. Fadhel BEN
   AICH and karine LEYRE for technical assistance and taking care of the
   plants. We thank Pr. Alexandre de Kochko for help and critical reading
   of the manuscript and Dr Abdellah CHALH for statistical analysis.
CR Abeles F. B., 1992, ETHYLENE PLANT BIOL, P182
   Achard P, 2006, SCIENCE, V311, P91, DOI 10.1126/science.1118642
   Arrillaga I, 1998, PLANT SCI, V136, P219, DOI 10.1016/S0168-9452(98)00122-8
   BERNATZKY R, 1986, GENETICS, V112, P887
   Borsani O, 2003, PLANT CELL TISS ORG, V73, P101, DOI 10.1023/A:1022849200433
   Borsani O, 2001, PLANT PHYSIOL, V126, P1024, DOI 10.1104/pp.126.3.1024
   Bustamante J, 2007, ADV PLANT ETHYLENE R, V1, P53
   Cao WH, 2007, PLANT PHYSIOL, V143, P707, DOI 10.1104/pp.106.094292
   Cao WH, 2006, PLANT CELL ENVIRON, V29, P1210, DOI 10.1111/j.1365-3040.2006.01501.x
   Cao YR, 2008, PLANT SIGNAL BEHAV, V3, P761, DOI 10.4161/psb.3.10.5934
   CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181
   Chang CS, 2010, J PLANT PHYSIOL, V167, P1152, DOI 10.1016/j.jplph.2010.03.018
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x
   Datta Swapan K., 2000, Agricultural Chemistry and Biotechnology, V43, P197
   El-Iklil Y, 2000, AGRONOMIE, V20, P399, DOI 10.1051/agro:2000136
   Flowers TJ, 2004, J EXP BOT, V55, P307, DOI 10.1093/jxb/erh003
   Fu J. R., 1983, Journal of Plant Growth Regulation, V2, P185, DOI 10.1007/BF02042247
   GALBRAITH DW, 1983, SCIENCE, V220, P1049, DOI 10.1126/science.220.4601.1049
   Gamble RL, 1998, P NATL ACAD SCI USA, V95, P7825, DOI 10.1073/pnas.95.13.7825
   Geisler-Lee J, 2010, J EXP BOT, V61, P857, DOI 10.1093/jxb/erp362
   Gisbert C, 2000, PLANT PHYSIOL, V123, P393, DOI 10.1104/pp.123.1.393
   Guo M, 2013, J PLANT INTERACT, P1
   He XJ, 2005, PLANT J, V44, P903, DOI 10.1111/j.1365-313X.2005.02575.x
   Hua J, 1998, PLANT CELL, V10, P1321, DOI 10.1105/tpc.10.8.1321
   Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7
   HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898
   Jiang CF, 2013, PLANT CELL, V25, P3535, DOI 10.1105/tpc.113.115659
   Jiang CF, 2012, EMBO J, V31, P4359, DOI 10.1038/emboj.2012.273
   Juan M, 2005, ENVIRON EXP BOT, V54, P193, DOI 10.1016/j.envexpbot.2004.07.004
   Lin ZF, 2009, J EXP BOT, V60, P3311, DOI 10.1093/jxb/erp204
   Mattoo AK, 1991, PLANT HORMONE ETHYLE, P21
   Moghaieb REA, 2000, SOIL SCI PLANT NUTR, V46, P873, DOI 10.1080/00380768.2000.10409153
   Morgan PW, 1997, PHYSIOL PLANTARUM, V100, P620, DOI 10.1034/j.1399-3054.1997.1000325.x
   Moussatche P, 2004, J BIOL CHEM, V279, P48734, DOI 10.1074/jbc.M403100200
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   Negi S, 2008, PLANT J, V55, P175, DOI 10.1111/j.1365-313X.2008.03495.x
   O'Donnell PJ, 2003, PLANT PHYSIOL, V133, P1181, DOI 10.1104/pp.103.030379
   Penninckx IAMA, 1998, PLANT CELL, V10, P2103, DOI 10.1105/tpc.10.12.2103
   Plett JM, 2010, NEW PHYTOL, V185, P868, DOI 10.1111/j.1469-8137.2009.03171.x
   Plett JM, 2009, PHYSIOL MOL PLANT P, V74, P18, DOI 10.1016/j.pmpp.2009.08.004
   Poncet V, 2006, MOL GENET GENOMICS, V276, P436, DOI 10.1007/s00438-006-0153-5
   Rus A, 2001, P NATL ACAD SCI USA, V98, P14150, DOI 10.1073/pnas.241501798
   Ruzicka K, 2007, PLANT CELL, V19, P2197, DOI 10.1105/tpc.107.052126
   Saadallah K, 2001, AGRONOMIE, V21, P627
   Sairam RK, 2002, PLANT SCI, V163, P1037, DOI 10.1016/S0168-9452(02)00278-9
   Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812
   Shaheen S, 2013, J PLANT INTERACT, V8, P85, DOI 10.1080/17429145.2012.718376
   Siddiqui MH, 2009, J PLANT INTERACT, V4, P67, DOI 10.1080/17429140802227992
   Siriwitayawan G, 2003, SEED SCI RES, V13, P303, DOI 10.1079/SSR2003147
   WOLF B, 1982, COMMUN SOIL SCI PLAN, V13, P1035, DOI 10.1080/00103628209367332
   Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9
   Zhang HX, 2001, NAT BIOTECHNOL, V19, P765, DOI 10.1038/90824
   Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329
NR 53
TC 1
Z9 1
U1 4
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-9145
EI 1742-9153
J9 J PLANT INTERACT
JI J. Plant Interact.
PY 2014
VL 9
IS 1
BP 539
EP 549
DI 10.1080/17429145.2013.865796
PG 11
WC Plant Sciences; Ecology
SC Plant Sciences; Environmental Sciences & Ecology
GA AT7YN
UT WOS:000345150700032
DA 2018-12-27
ER

PT J
AU Khan, M
   Broadbent, K
   Morris, M
   Ewins, D
   Joseph, F
AF Khan, Muhammad
   Broadbent, Keith
   Morris, Mike
   Ewins, David
   Joseph, Franklin
TI RETRACTED: System Accuracy Evaluation of the GlucoRx Nexus Voice TD-4280
   Blood Glucose Monitoring System (Retracted article. See 496928, 2015)
SO DISEASE MARKERS
LA English
DT Article; Retracted Publication
ID DIABETES-MELLITUS; EPIDEMIC; PREVENT
AB Use of blood glucose (BG) meters in the self-monitoring of blood glucose (SMBG) significantly lowers the risk of diabetic complications. With several BG meters now commercially available, the International Organization for Standardization (ISO) ensures that each BG meter conforms to a set degree of accuracy. Although adherence to ISO guidelines is a prerequisite for commercialization in Europe, several BG meters claim to meet the ISO guidelines yet fail to do so on internal validation. We conducted a study to determine whether the accuracy of the GlucoRx Nexus TD-4280 meter, utilized by our department for its cost-effectiveness, complied with ISO guidelines. 105 patients requiring laboratory blood glucose analysis were randomly selected and reference measurements were determined by the UniCel DxC 800 clinical system. Overall the BG meter failed to adhere to the >= 95% accuracy criterion required by both the 15197:2003 (overall accuracy 92.4%) and 15197:2013 protocol (overall accuracy 86.7%). Inaccurate meters have an inherent risk of over-and/or underestimating the true BG concentration, thereby risking patients to incorrect therapeutic interventions. Our study demonstrates the importance of internally validating the accuracy of BG meters to ensure that its accuracy is accepted by standardized guidelines.
C1 [Khan, Muhammad; Broadbent, Keith; Ewins, David; Joseph, Franklin] Countess Chester Hosp NHS Fdn Trust, Dept Endocrinol & Diabet, Chester CH2 1UL, Cheshire, England.
   [Morris, Mike] Univ Chester, Dept Clin Sci & Nutr, Chester CH1 4BJ, Cheshire, England.
RP Khan, M (reprint author), Countess Chester Hosp NHS Fdn Trust, Dept Endocrinol & Diabet, Chester CH2 1UL, Cheshire, England.
EM md0u930b@liverpool.ac.uk
CR Austin MM, 2006, DIABETES EDUCATOR, V32, P835, DOI 10.1177/0145721706295873
   Bergenstal RM, 2013, DIABETES CARE, V36, pE107, DOI [10.2337/dc13-0295, 10.2337/dc12-2625]
   BLAND JM, 1986, LANCET, V1, P307
   Blonde L, 2005, AM J MED, V118, p20S, DOI 10.1016/j.amjmed.2005.07.053
   Chen L, 2012, NAT REV ENDOCRINOL, V8, P228, DOI 10.1038/nrendo.2011.183
   Frank Joy, 2011, J Diabetes Sci Technol, V5, P198
   Freckmann Guido, 2012, J Diabetes Sci Technol, V6, P1060
   Freckmann G, 2010, DIABETES TECHNOL THE, V12, P221, DOI 10.1089/dia.2009.0128
   Ginsberg Barry H, 2009, J Diabetes Sci Technol, V3, P903
   Goldstein David E, 2003, Diabetes Care, V26 Suppl 1, pS106
   Heinemann Lutz, 2012, J Diabetes Sci Technol, V6, P435
   Hex N, 2012, DIABETIC MED, V29, P855, DOI 10.1111/j.1464-5491.2012.03698.x
   International Diabetes Federation, 2013, IDF DIABETES ATLAS
   ISO, 2013, 15197 ISO
   Klonoff DC, 2004, DIABETES CARE, V27, P834, DOI 10.2337/diacare.27.3.834
   Kuo CY, 2011, DIABETES TECHNOL THE, V13, P596, DOI 10.1089/dia.2010.0223
   Li R, 2010, DIABETES CARE, V33, P1872, DOI 10.2337/dc10-0843
   London School of Economics, 2012, DIAB EXP BURD DIS MA
   *NAT I HLTH CLIN E, 2009, TYP 2 DIAB MAN TYP 2
   Parkes JL, 2000, DIABETES CARE, V23, P1143, DOI 10.2337/diacare.23.8.1143
   Pfutzner A, 2012, CURR MED RES OPIN, V28, P525, DOI 10.1185/03007995.2012.673479
   Pfutzner Andreas, 2013, J Diabetes Sci Technol, V7, P1275
   Polonsky WH, 2011, DIABETES CARE, V34, P262, DOI 10.2337/dc10-1732
   Rebel Annette, 2012, J Diabetes Sci Technol, V6, P396
   Robertson RP, 2010, NAT REV ENDOCRINOL, V6, P128, DOI 10.1038/nrendo.2010.2
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977
   Smyth S, 2006, NAT MED, V12, P75, DOI 10.1038/nm0106-75
   Tack C, 2012, DIABETES TECHNOL THE, V14, P330, DOI 10.1089/dia.2011.0170
   Turner RC, 1998, LANCET, V352, P837
   World Health Organization, 2011, GLOB STAT REP NONC D
   Ziegler R, 2011, PEDIATR DIABETES, V12, P11, DOI 10.1111/j.1399-5448.2010.00650.x
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
   Zimmet PZ, 2014, LANCET DIABETES ENDO, V2, P56, DOI 10.1016/S2213-8587(13)70112-8
NR 33
TC 0
Z9 0
U1 1
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278-0240
EI 1875-8630
J9 DIS MARKERS
JI Dis. Markers
PY 2014
AR 602586
DI 10.1155/2014/602586
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental; Pathology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine; Pathology
GA AS3AJ
UT WOS:000344147200001
PM 25374434
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zeng, K
   Li, YZ
   Liang, M
   Gao, YG
   Cai, HD
   Lin, CZ
AF Zeng, Kai
   Li, Yanzhen
   Liang, Min
   Gao, Youguang
   Cai, Hongda
   Lin, Caizhu
TI RETRACTED: The influence of goal-directed fluid therapy on the prognosis
   of elderly patients with hypertension and gastric cancer surgery
   (Retracted article. See vol. 11, pg. 2675, 2017)
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article; Retracted Publication
DE stroke volume variation; gastric cancer; the elderly
ID BLOOD LACTATE LEVELS; RANDOMIZED CONTROLLED-TRIAL; VENOUS
   OXYGEN-SATURATION; OF-THE-LITERATURE; POSTERIOR LEUKOENCEPHALOPATHY;
   MANAGEMENT; RESPONSIVENESS; METAANALYSIS; VARIABLES; IMPROVES
AB Purpose: We aimed to investigate the influence of perioperative goal-directed fluid therapy (GDFT) on the prognosis of elderly patients with gastric cancer and hypertension.
   Methods: Sixty elderly patients (>60 years old) with primary hypertension who received gastric cancer radical surgery and who were American Society of Anesthesiologists (ASA) class II or III were enrolled in the current study. Selected patients were divided randomly into two arms, comprising a conventional intraoperative fluid management arm (arm C, n=30) and a GDFT arm (arm G, n=30). Patients in arm C were infused with crystalloids or colloids according to the methods of Miller's Anesthesia (6th edition), while those in arm G were infused with 200 mL hydroxyethyl starch over 15 minutes under the FloTrac/Vigileo monitoring system, with stroke volume variation between 8% and 13%. Hemodynamics and tissue perfusion laboratory indicators in patients were recorded continuously from 30 minutes before the operation to 24 hours after the operation.
   Results: Compared with arm C, the average intraoperative intravenous infusion quantity in arm G was significantly reduced (2,732 +/- 488 mL versus 3,135 +/- 346 mL, P<0.05), whereas average colloid fluid volume was significantly increased (1,235 +/- 360 mL versus 760 +/- 280 mL, P<0.05). In addition, there were more patients exhibiting intraoperatively and postoperatively stable hemodynamics and less patients with low blood pressure in arm G. Postoperative complications were less frequent, and the time of postoperative hospital stay shorter, in arm G. No significant differences were observed in mortality between the two arms.
   Conclusion: Our research showed that GDFT stabilized perioperative hemodynamics and reduced the occurrence of postoperative complications in elderly patients who underwent gastric cancer surgery.
C1 [Zeng, Kai; Li, Yanzhen; Liang, Min; Gao, Youguang; Cai, Hongda; Lin, Caizhu] Fujian Med Univ, Affiliated Hosp 1, Dept Anesthesia, 20 Chazhong Rd, Fuzhou 350005, Peoples R China.
RP Lin, CZ (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Anesthesia, 20 Chazhong Rd, Fuzhou 350005, Peoples R China.
EM lincaizhu2013@yeah.net
FU Joint Research Fund of Fujian Medical University [2013B002]
FX This study was supported by the Joint Research Fund of Fujian Medical
   University, grant number 2013B002.
CR BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956
   Bienkowski P, 2006, J TRAUMA, V61, P1458, DOI 10.1097/01.ta.0000200937.12453.fb
   Bundgaard-Nielsen M, 2009, ACTA ANAESTH SCAND, V53, P843, DOI 10.1111/j.1399-6576.2009.02029.x
   Chambers KA, 2004, ANN EMERG MED, V43, P243, DOI 10.1016/mem.2004.382
   Chappell D, 2008, ANESTHESIOLOGY, V109, P723, DOI 10.1097/ALN.0b013e3181863117
   Chua TC, 2011, AM J SURG, V201, P149, DOI 10.1016/j.amjsurg.2010.02.012
   Chytra I, 2007, CRIT CARE, V11, DOI 10.1186/cc5703
   Dueck MH, 2005, ANESTHESIOLOGY, V103, P249, DOI 10.1097/00000542-200508000-00007
   Goodrich Cindy, 2006, Crit Care Nurs Clin North Am, V18, P203, DOI 10.1016/j.ccell.2006.01.005
   HamiltonDavies C, 1997, INTENS CARE MED, V23, P276, DOI 10.1007/s001340050328
   Hiltebrand LB, 2009, CRIT CARE, V13, DOI 10.1186/cc7761
   Joshi GP, 2005, ANESTH ANALG, V101, P601, DOI 10.1213/01.ANE.0000159171.26521.31
   Kimberger O, 2009, ANESTHESIOLOGY, V110, P496, DOI 10.1097/ALN.0b013e31819841f6
   Klatte T, 2014, J UROLOGY, V191, P1209, DOI 10.1016/j.juro.2013.11.006
   L'Hermite J, 2013, Ann Fr Anesth Reanim, V32, pe121, DOI 10.1016/j.annfar.2013.05.006
   Ladakis C, 2001, RESPIRATION, V68, P279, DOI 10.1159/000050511
   Li L, 2013, J OBSTET GYNAECOL RE, V39, P932, DOI 10.1111/jog.12001
   LINDINGER MI, 1990, AM J PHYSIOL, V258, pR1486
   Long TR, 2007, J CLIN ANESTH, V19, P145, DOI 10.1016/j.jclinane.2006.07.004
   Lopes MR, 2007, CRIT CARE, V11, DOI 10.1186/cc6117
   Marik PE, 2008, CHEST, V134, P172, DOI 10.1378/chest.07-2331
   Marik PE, 2009, CRIT CARE MED, V37, P2642, DOI 10.1097/CCM.0b013e3181a590da
   Marx G, 2006, CURR OPIN CRIT CARE, V12, P263, DOI 10.1097/01.ccx.0000224872.09077.dc
   Ming BSY, 2010, CHINESE HYPERTENSION
   Munoz R, 2000, J THORAC CARDIOV SUR, V119, P155, DOI 10.1016/S0022-5223(00)70231-5
   Nagy K, 2001, Magy Seb, V54, P138
   Ni Qin-yun, 2013, Zhonghua Yi Xue Za Zhi, V93, P693
   Pearse RM, 2004, CRIT CARE, V8, P503, DOI 10.1186/cc2922
   Pizon AF, 2005, J EMERG MED, V29, P163, DOI 10.1016/j.jemermed.2005.02.006
   Reinhart K, 2005, CURR OPIN CRIT CARE, V11, P259, DOI 10.1097/01.ccx.0000158092.64795.cf
   Rivers E P, 2001, Curr Opin Crit Care, V7, P204, DOI 10.1097/00075198-200106000-00011
   Sax H, 2011, ANN SURG, V253, P365, DOI 10.1097/SLA.0b013e318202fda9
   Shafer S. L., 2008, V182, P409, DOI 10.1007/978-3-540-74806-9_19
   SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176
   Singhal AB, 2004, ARCH NEUROL-CHICAGO, V61, P411, DOI 10.1001/archneur.61.3.411
   Srinivasa S, 2013, BRIT J SURG, V100, P66, DOI 10.1002/bjs.8940
NR 36
TC 19
Z9 21
U1 3
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2014
VL 8
BP 2113
EP 2119
DI 10.2147/DDDT.S66724
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AS0NC
UT WOS:000343973200001
PM 25378913
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ehrlich, GD
   Hu, FZ
   Sotereanos, N
   Sewicke, J
   Parvizi, J
   Nara, PL
   Arciola, CR
AF Ehrlich, Garth D.
   Hu, Fen Z.
   Sotereanos, Nicholas
   Sewicke, Jeffrey
   Parvizi, Javad
   Nara, Peter L.
   Arciola, Carla Renata
TI RETRACTED: What role do periodontal pathogens play in osteoarthritis and
   periprosthetic joint infections of the knee? (Retracted article. See
   vol. 15, pg. E423, 2017)
SO JOURNAL OF APPLIED BIOMATERIALS & FUNCTIONAL MATERIALS
LA English
DT Article; Retracted Publication
DE Molecular diagnostics; Bacteria; Osteoarthritis; Periprosthetic joint
   infections; Periodontal pathogens
ID ORTHOPEDIC BIOFILM INFECTIONS; FLIGHT-MASS-SPECTROMETRY; BACTERIAL
   BIOFILM; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; ANTIBIOTIC
   TOLERANCE; VIRULENCE FACTORS; IN-SITU; CULTURE; IDENTIFICATION
AB Through the use of polymerase chain reaction (PCR)-electron spray ionization (ESI)-time of flight (TOF)-mass spectrometry (MS), we identified multiple periodontal pathogens within joint tissues of individuals undergoing replacement arthroplasties of the knee. The most prevalent of the periodontal pathogens were Treponema denticola and Enterococcus faecalis, the latter of which is commonly associated with apical periodontitis. These findings were unique to periprosthetic joint infections (PJI) of the knee and were never observed for PJIs of other lower extremity joints (hip and ankle) or upper extremity joints (shoulder and elbow). These data were confirmed by multiple independent methodologies including fluorescent in situ hybridization (FISH) which showed the bacteria deeply penetrated inside the diseased tissues, and 454-based deep 16S rDNA sequencing. The site-specificity, the tissue investment, and the identical findings by multiple nucleic-acid-based techniques strongly suggests the presence of infecting bacteria within these diseased anatomic sites. Subsequently, as part of a control program using PCR-ESI-TOF-MS, we again detected these same periodontal pathogens in aspirates from patients with osteoarthritis who were undergoing primary arthroplasty of the knee and thus who had no history of orthopedic implants. This latter finding raises the question of whether hematogenic spread of periodontal pathogens to the knee play a primary or secondary-exacerbatory role in osteoarthritis.
C1 [Ehrlich, Garth D.; Hu, Fen Z.] Drexel Univ, Coll Med, Inst Mol Med & Infect Dis, Ctr Genom Sci, Philadelphia, PA 19102 USA.
   [Ehrlich, Garth D.; Hu, Fen Z.] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19102 USA.
   [Ehrlich, Garth D.; Hu, Fen Z.] Drexel Univ, Coll Med, Dept Otolaryngol, Philadelphia, PA 19102 USA.
   [Sotereanos, Nicholas; Sewicke, Jeffrey] Allegheny Gen Hosp, Dept Orthoped Surg, Pittsburgh, PA 15212 USA.
   [Parvizi, Javad] Thomas Jefferson Univ, Rothman Inst, Philadelphia, PA 19107 USA.
   [Nara, Peter L.] Biol Mimet Inc, Frederick, MD USA.
   [Arciola, Carla Renata] Rizzoli Orthoped Inst, Res Unit Implant Infect, I-40136 Bologna, Italy.
   [Arciola, Carla Renata] Univ Bologna, DIMES, Bologna, Italy.
RP Ehrlich, GD (reprint author), Drexel Univ, Coll Med, Dept Microbiol & Immunol, Ctr Genom Sci, 245 S 15th St,14th Floor, Philadelphia, PA 19102 USA.
EM Garth.Ehrlich@DrexelMed.edu; carlarenata.arciola@ior.it
OI Ehrlich, Garth/0000-0003-1140-6594
FU Allegheny General Hospital's Department of Orthopedic Surgery; Allegheny
   Singer Research Institute; Pittsburgh Foundation; Abbott Molecular
FX This work was funded in part by Allegheny General Hospital's Department
   of Orthopedic Surgery, the Allegheny Singer Research Institute, and
   grants from the Pittsburgh Foundation (GDE), and Abbott Molecular (FZH).
   Contribution from the "5 per mille" grant for Health Research to the
   Rizzoli Orthopaedic Institute is also acknowledged.
CR Arciola CR, 2012, BIOMATERIALS, V33, P5967, DOI 10.1016/j.biomaterials.2012.05.031
   Arciola CR, 2011, INT J ARTIF ORGANS, V34, P727, DOI 10.5301/IJAO.2011.8784
   Artini M, 2012, BIOORGAN MED CHEM, V20, P920, DOI 10.1016/j.bmc.2011.11.052
   Artini M, 2011, J CLIN MICROBIOL, V49, P423, DOI 10.1128/JCM.01836-10
   Bjarnsholt Thomas, 2008, Curr Infect Dis Rep, V10, P22, DOI 10.1007/s11908-008-0006-y
   Boase S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-210
   Borriello G, 2006, ANTIMICROB AGENTS CH, V50, P382, DOI 10.1128/AAC.50.1.382-384.2006
   Borriello G, 2004, ANTIMICROB AGENTS CH, V48, P2659, DOI 10.1128/AAC.48.7.2659-2664.2004
   Brady RA, 2008, FEMS IMMUNOL MED MIC, V52, P13, DOI 10.1111/j.1574-695X.2007.00357.x
   Choi HR, 2013, J ARTHROPLASTY, V28, P899, DOI 10.1016/j.arth.2012.10.022
   Costerton JW, 2011, FEMS IMMUNOL MED MIC, V61, P133, DOI 10.1111/j.1574-695X.2010.00766.x
   COSTERTON JW, 1978, SCI AM, V238, P86, DOI 10.1038/scientificamerican0178-86
   Costerton W, 2003, J CLIN INVEST, V112, P1466, DOI 10.1172/JCI20365
   Dandekar AA, 2012, SCIENCE, V338, P264, DOI 10.1126/science.1227289
   Nguyen D, 2011, SCIENCE, V334, P982, DOI 10.1126/science.1211037
   Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295
   Ecker DJ, 2008, NAT REV MICROBIOL, V6, P553, DOI 10.1038/nrmicro1918
   Ehrlich GD, 2012, INT J ARTIF ORGANS, V35, P695, DOI 10.5301/ijao.5000169
   Ehrlich GD, 2010, FEMS IMMUNOL MED MIC, V59, P269, DOI 10.1111/j.1574-695X.2010.00704.x
   Ehrlich GD, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-225
   Ehrlich GD, 2005, CLIN ORTHOP RELAT R, P59, DOI 10.1097/01.blo.0000175125.60214.a4
   Ehrlich GD, 2005, CLIN ORTHOP RELAT R, P20, DOI 10.1097/01.blo.0000175124.52590.c0
   Ehrlich GD, 2004, MICROBIAL BIOFILMS, P332
   Ehrlich GD, 2004, ASM NEWS, V70, P127
   Ehrlich GD, 2012, SERIES BIOFILMS
   Ehrlich GD, 1996, MOL DIAGN, V1, P83
   Ehrlich GD, 1994, NEED PCR BASED PANEL
   Fux CA, 2006, CLIN MICROBIOL INFEC, V12, P331, DOI 10.1111/j.1469-0691.2006.01361.x
   Gallo PH, 2011, J BONE JOINT SURG AM, V93A, DOI 10.2106/JBJS.J.01181
   Givskov M, 1996, J BACTERIOL, V178, P6618, DOI 10.1128/jb.178.22.6618-6622.1996
   Harro JM, 2010, FEMS IMMUNOL MED MIC, V59, P306, DOI 10.1111/j.1574-695X.2010.00708.x
   Hiller NL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001108
   Hoiby N, 2011, INT J ORAL SCI, V3, P55, DOI 10.4248/IJOS11026
   Howe TS, 2013, OSTEOPOROSIS INT, V24, P1765, DOI 10.1007/s00198-012-2222-4
   Hu FZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047983
   Hu FZ, 2008, FUTURE MICROBIOL, V3, P31, DOI 10.2217/17460913.3.1.31
   Jacovides CL, 2012, J BONE JOINT SURG AM, V94A, P2247, DOI 10.2106/JBJS.L.00210
   Kathju Sandeep, 2010, BMC Res Notes, V3, P259, DOI 10.1186/1756-0500-3-259
   Kathju S, 2009, SURG INFECT, V10, P457, DOI 10.1089/sur.2008.062
   Nistico L, 2011, J CLIN MICROBIOL, V49, P1411, DOI 10.1128/JCM.00756-10
   Nistico Laura, 2009, V493, P191, DOI 10.1007/978-1-59745-523-7_12
   Nucci C, 2005, GRAEF ARCH CLIN EXP, V243, P951, DOI 10.1007/s00417-004-1110-9
   Palmer MP, 2013, J ORTHOP TRAUMA
   Papa R, 2013, MICROB PATHOGENESIS, V63, P44, DOI 10.1016/j.micpath.2013.05.003
   Papa R, 2013, RES MICROBIOL, V164, P450, DOI 10.1016/j.resmic.2013.01.010
   Parsek MR, 2004, J BACTERIOL, V186, P4427, DOI 10.1128/JB.186.14.4427-4440.2004
   Percival SL, 2011, BIOFILMS VET MED HEI
   Sampath R, 2007, ANN NY ACAD SCI, V1102, P109, DOI 10.1196/annals.1408.008
   Sotereanos N, 2012, SERIES BIOFILMS
   Stewart S, 2012, J BONE JOINT SURG AM, V94A, P1406, DOI 10.2106/JBJS.K.00886
   Stoodley P, 2005, CLIN ORTHOP RELAT R, P31, DOI 10.1097/01.blo.0000175129.83084.d5
   Stoodley P, 2011, CURR ORTHOP PRACT, V22, P558, DOI 10.1097/BCO.0b013e318230efcf
   Stoodley P, 2011, FEMS IMMUNOL MED MIC, V62, P66, DOI 10.1111/j.1574-695X.2011.00793.x
   Swords WE, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00100
   Tan SY, 2013, ANTIMICROB AGENTS CH
   Yun HC, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-252
NR 56
TC 10
Z9 10
U1 1
U2 8
PU WICHTIG PUBLISHING
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 2280-8000
J9 J APPL BIOMATER FUNC
JI J. Appl. Biomater. Funct. Mater.
PY 2014
VL 12
IS 1
BP 13
EP 20
DI 10.5301/jabfm.5000203
PG 8
WC Biophysics; Engineering, Biomedical; Materials Science, Biomaterials
SC Biophysics; Engineering; Materials Science
GA AP7LC
UT WOS:000342257800002
PM 24921460
DA 2018-12-27
ER

PT J
AU DeOcesano-Pereira, C
   Amaral, MS
   Parreira, KS
   Ayupe, AC
   Jacysyn, JF
   Amarante-Mendes, GP
   Reis, EM
   Verjovski-Almeida, S
AF DeOcesano-Pereira, Carlos
   Amaral, Murilo S.
   Parreira, Kleber S.
   Ayupe, Ana C.
   Jacysyn, Jacqueline F.
   Amarante-Mendes, Gustavo P.
   Reis, Eduardo M.
   Verjovski-Almeida, Sergio
TI RETRACTED: Long non-coding RNA INXS is a critical mediator of BCL-XS
   induced apoptosis (Retracted article. See vol. 44, pg. 9518, 2016)
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article; Retracted Publication
ID PRE-MESSENGER-RNA; BINDING PROTEIN SAM68; CELL-DEATH; 5'-SPLICE-SITE
   SELECTION; GENE-EXPRESSION; MELANOMA-CELLS; BREAST-CANCER;
   TRANSCRIPTION; IDENTIFICATION; BCL-X(S)
AB BCL-X mRNA alternative splicing generates pro-apoptotic BCL-XS or anti-apoptotic BCL-XL gene products and the mechanism that regulates splice shifting is incompletely understood. We identified and characterized a long non-coding RNA (IncRNA) named INXS, transcribed from the opposite genomic strand of BCL-X, that was 5- to 9-fold less abundant in tumor cell lines from kidney, liver, breast and prostate and in kidney tumor tissues compared with non-tumors. INXS is an unspliced 1903 nt-long RNA, is transcribed by RNA polymerase II, 5'-capped, nuclear enriched and binds Sam68 splicing-modulator. Three apoptosis-inducing agents increased INXS lncRNA endogenous expression in the 786-O kidney tumor cell line, increased BCL-XS/BCL-XL mRNA ratio and activated caspases 3, 7 and 9. These effects were abrogated in the presence of INXS knockdown. Similarly, ectopic INXS overexpression caused a shift in splicing toward BCL-XS and activation of caspases, thus leading to apoptosis. BCL-XS protein accumulation was detected upon INXS overexpression. In a mouse xenograft model, intra-tumor injections of an INXS-expressing plasmid caused a marked reduction in tumor weight, and an increase in BCL-XS isoform, as determined in the excised tumors. We revealed an endogenous lncRNA that induces apoptosis, suggesting that INXS is a possible target to be explored in cancer therapies.
C1 [DeOcesano-Pereira, Carlos; Amaral, Murilo S.; Parreira, Kleber S.; Ayupe, Ana C.; Reis, Eduardo M.; Verjovski-Almeida, Sergio] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.
   [Jacysyn, Jacqueline F.; Amarante-Mendes, Gustavo P.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508900 Sao Paulo, Brazil.
   [Amarante-Mendes, Gustavo P.] Univ Sao Paulo, Inst Nacl Ciencia & Tecnol Invest Imunol, BR-05508900 Sao Paulo, Brazil.
   [Reis, Eduardo M.; Verjovski-Almeida, Sergio] Univ Sao Paulo, Inst Nacl Ciencia & Tecnol Oncogen, BR-05508900 Sao Paulo, Brazil.
RP Verjovski-Almeida, S (reprint author), Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.
EM verjo@iq.usp.br
RI DeOcesano-Pereira, Carlos/O-2022-2015; Amaral, Murilo/G-5769-2013;
   Amarante Mendes, Gustavo/C-8187-2012; Verjovski-Almeida,
   Sergio/E-4082-2012; Reis, Eduardo/H-2008-2011
OI Amarante Mendes, Gustavo/0000-0002-7851-6205; Verjovski-Almeida,
   Sergio/0000-0002-6356-2401; Reis, Eduardo/0000-0002-9556-3070
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); FAPESP;
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   through the Instituto Nacional de Ciencia e Tecnologia em Oncogenomica;
   CNPq
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [to S.V.A.
   and to E.M.R.]; FAPESP and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) through the Instituto Nacional de
   Ciencia e Tecnologia em Oncogenomica. C.D.P., M.S.A., K.S.P. and A.C.A.
   received fellowships from FAPESP, and M.S.A. received a fellowship from
   CNPq prior to the one from FAPESP. S.V.A. and E.M.R. received
   investigator fellowship awards from CNPq. Fundingfor open access charge:
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) and
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   through the Instituto Nacional de Ciencia e Tecnologia em Oncogenomica.
CR Bauman JA, 2010, NUCLEIC ACIDS RES, V38, P8348, DOI 10.1093/nar/gkq731
   Beckedorff FC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003705
   Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708
   Bielli P, 2014, EMBO REP, V15, P419, DOI 10.1002/embr.201338241
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N
   BURGE CB, 1999, RNA WORLD, P525
   Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Garneau D, 2005, J BIOL CHEM, V280, P22641, DOI 10.1074/jbc.M501070200
   Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887
   Hossini AM, 2003, FEBS LETT, V553, P250, DOI 10.1016/S0014-5793(03)01017-2
   Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17
   Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391
   KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180
   Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704
   Lee J, 2012, BIOCHEM BIOPH RES CO, V420, P467, DOI 10.1016/j.bbrc.2012.03.029
   Louro R, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-4
   Massiello A, 2004, J BIOL CHEM, V279, P15799, DOI 10.1074/jbc.M313950200
   Massiello A, 2006, FASEB J, V20, P1680, DOI 10.1096/fj.05-5021fje
   Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200
   Michelle L, 2012, MOL CELL BIOL, V32, P954, DOI 10.1128/MCB.06130-11
   Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306
   Montes M, 2012, MOL CELL BIOL, V32, P751, DOI 10.1128/MCB.06255-11
   Moore MJ, 2010, CELL, V142, P625, DOI 10.1016/j.cell.2010.07.019
   Morrissy AS, 2011, GENOME RES, V21, P1203, DOI 10.1101/gr.113431.110
   Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373
   Nakaya HI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-r43
   Nie L, 2012, AM J TRANSL RES, V4, P127
   Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022
   Paronetto MP, 2007, J CELL BIOL, V176, P929, DOI 10.1083/jcb.200701005
   Paronetto MP, 2010, CANCER RES, V70, P229, DOI 10.1158/0008-5472.CAN-09-2788
   Plati J, 2011, INTEGR BIOL-UK, V3, P279, DOI 10.1039/c0ib00144a
   Plotz M, 2012, CELL DEATH DIFFER, V19, P1928, DOI 10.1038/cdd.2012.71
   Revil T, 2009, J BIOL CHEM, V284, P21458, DOI 10.1074/jbc.M109.019711
   Shkreta L, 2008, MOL CANCER THER, V7, P1398, DOI 10.1158/1535-7163.MCT-08-0192
   Spitali P, 2012, CELL, V148, P1085, DOI 10.1016/j.cell.2012.02.014
   SUMANTRAN VN, 1995, CANCER RES, V55, P2507
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097
   Tripathi V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003368
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Valacca C, 2010, J CELL BIOL, V191, P87, DOI 10.1083/jcb.201001073
   Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992
   Yan MD, 2005, HUM MOL GENET, V14, P1465, DOI 10.1093/hmg/ddi156
   Yeh CT, 2005, CARCINOGENESIS, V26, P2138, DOI 10.1093/carcin/bgi185
   Zhang X, 2010, ENDOCRINOLOGY, V151, P939, DOI 10.1210/en.2009-0657
   Zhou A, 2008, MOL CELL BIOL, V28, P5924, DOI 10.1128/MCB.00560-08
NR 55
TC 34
Z9 39
U1 3
U2 29
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PY 2014
VL 42
IS 13
BP 8343
EP 8355
DI 10.1093/nar/gku561
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AO7ER
UT WOS:000341515400021
PM 24992962
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wang, QX
   Wu, XZ
   Wang, LJ
   Chen, ZW
   Wang, SL
AF Wang, Qingxiu
   Wu, Xianzheng
   Wang, Lijun
   Chen, Zhiwen
   Wang, Shilong
TI RETRACTED: Graphene-SnO2 nanocomposites decorated with quantum tunneling
   junctions: preparation strategies, microstructures and formation
   mechanism (Retracted article. See vol. 19, pg. 25223, 2017)
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID LITHIUM-ION BATTERIES; IN-SITU SYNTHESIS; ANODE MATERIAL; STORAGE
   CAPACITY; SNO2/GRAPHENE COMPOSITE; RECHARGEABLE BATTERIES; HYDROTHERMAL
   SYNTHESIS; CYCLING PERFORMANCE; ROOM-TEMPERATURE; TIN OXIDE
AB Tin dioxide (SnO2) and graphene are versatile materials that are vitally important for creating new functional and smart materials. A facile, simple and efficient ultrasonic-assisted hydrothermal synthesis approach has been developed to prepare graphene-SnO2 nanocomposites (GSNCs), including three samples with graphene/Sn weight ratios = 1 : 2 (GSNC-2), 1 : 1 (GSNC-1), and graphene oxide/Sn weight ratio = 1 : 1 (GOSNC-1). Low-magnification electron microscopy analysis indicated that graphene was exfoliated and adorned with SnO2 nanoparticles, which were dispersed uniformly on both the sides of the graphene nanosheets. High-magnification electron microscopy analysis confirmed that the graphene-SnO2 nanocomposites presented network tunneling frameworks, which were decorated with the SnO2 quantum tunneling junctions. The size distribution of SnO2 nanoparticles was estimated to range from 3 to 5.5 nm. Comparing GSNC-2, GSNC-1, and GOSNC-1, GOSNC-1 was found to exhibit a significantly better the homogeneous distribution and a considerably smaller size distribution of SnO2 nanoparticles, which indicated that it was better to use graphene oxide as a supporting material and SnCl4 center dot 5H(2)O as a precursor to synthesize hybrid graphene-SnO2 nanocomposites. Experimental results suggest that the graphene-SnO2 nanocomposites with interesting SnO2 quantum tunneling junctions may be a promising material to facilitate the improvement of the future design of micro/nanodevices.
C1 [Wang, Qingxiu; Wang, Shilong] Tongji Univ, East Hosp, Dept Anesthesiol, Shanghai 200092, Peoples R China.
   [Wang, Qingxiu; Wang, Shilong] Tongji Univ, East Hosp, Res Ctr Translat Med, Shanghai 200092, Peoples R China.
   [Wu, Xianzheng] Shanghai Tongji Hosp, Dept Emergency, Shanghai, Peoples R China.
   [Wang, Lijun; Chen, Zhiwen] Shanghai Univ, Sch Environm & Chem Engn, Shanghai, Peoples R China.
RP Wu, XZ (reprint author), Shanghai Tongji Hosp, Dept Emergency, Shanghai, Peoples R China.
EM wuxianzheng1962@163.com; wsl@tongji.edu.cn
RI Chen, Zhiwen/S-7256-2016
OI Chen, Zhiwen/0000-0001-9625-8556
FU National Natural Science Foundation of China [11375111, 11074161];
   Research Fund for the Doctoral Program of Higher Education of China
   [20133108110021]; Key Innovation Fund of Shanghai Municipal Education
   Commission [14ZZ098, 10ZZ64]; Science and Technology Commission of
   Shanghai Municipality [14JC1402000, 10JC1405400]; Shanghai Pujiang
   Program [10PJ1404100]; Program for Innovative Research Team in
   University [IRT13078]
FX This work was financially supported by the National Natural Science
   Foundation of China (Project numbers: 11375111 and 11074161), the
   Research Fund for the Doctoral Program of Higher Education of China
   (Project number: 20133108110021), the Key Innovation Fund of Shanghai
   Municipal Education Commission (Project numbers: 14ZZ098 and 10ZZ64),
   the Science and Technology Commission of Shanghai Municipality (Project
   numbers: 14JC1402000 and 10JC1405400), the Shanghai Pujiang Program
   (Project number: 10PJ1404100), and the Program for Innovative Research
   Team in University (Project number: IRT13078).
CR Abergel DSL, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.155430
   Berger C, 2004, J PHYS CHEM B, V108, P19912, DOI 10.1021/jp040650f
   Chen C, 2013, LANGMUIR, V29, P4111, DOI 10.1021/la304753x
   Chen F, 2009, ACCOUNTS CHEM RES, V42, P429, DOI 10.1021/ar800199a
   Chen S, 2011, J SOLID STATE CHEM, V184, P1393, DOI 10.1016/j.jssc.2011.03.054
   Chen SQ, 2010, J MATER CHEM, V20, P9735, DOI 10.1039/c0jm01573c
   Chen ZW, 2010, ACS NANO, V4, P1202, DOI 10.1021/nn901635f
   Dikin DA, 2007, NATURE, V448, P457, DOI 10.1038/nature06016
   Ding SJ, 2011, CHEM COMMUN, V47, P5780, DOI 10.1039/c1cc10687b
   Dresselhaus MS, 2002, ADV PHYS, V51, P1, DOI 10.1080/00018730110113644
   Du ZF, 2010, MATER LETT, V64, P2076, DOI 10.1016/j.matlet.2010.06.039
   Dvininov E, 2010, J HAZARD MATER, V177, P150, DOI 10.1016/j.jhazmat.2009.12.011
   HARRISON PG, 1988, NATURE, V332, P337, DOI 10.1038/332337a0
   Hirata M, 2004, CARBON, V42, P2929, DOI 10.1016/j.carbon.2004.07.003
   Huang XD, 2011, CHEMPHYSCHEM, V12, P278, DOI 10.1002/cphc.201000376
   Kim H, 2011, CARBON, V49, P326, DOI 10.1016/j.carbon.2010.09.033
   Kim H, 2010, NANO RES, V3, P813, DOI 10.1007/s12274-010-0050-4
   Lee JW, 2012, CHEM MATER, V24, P1158, DOI 10.1021/cm203697w
   Li BJ, 2011, J MATER CHEM, V21, P5069, DOI 10.1039/c0jm03717f
   Li BJ, 2011, INORG CHEM, V50, P1628, DOI 10.1021/ic1023086
   Li L, 2012, J MATER CHEM, V22, P3600, DOI 10.1039/c2jm15075a
   Lian PC, 2010, ELECTROCHIM ACTA, V56, P834, DOI 10.1016/j.electacta.2010.09.086
   Liang JF, 2012, ACS APPL MATER INTER, V4, P454, DOI 10.1021/am201541s
   Liang Y, 2007, MATER LETT, V61, P4370, DOI 10.1016/j.matlet.2007.02.008
   Lim HN, 2012, CERAM INT, V38, P4209, DOI 10.1016/j.ceramint.2012.02.004
   Lin QQ, 2012, SENSOR ACTUAT B-CHEM, V173, P139, DOI 10.1016/j.snb.2012.06.055
   Liu HD, 2012, PHYSICA E, V44, P1931, DOI 10.1016/j.physe.2012.05.023
   Nair RR, 2008, SCIENCE, V320, P1308, DOI 10.1126/science.1156965
   Ning JJ, 2009, LANGMUIR, V25, P1818, DOI 10.1021/la8037473
   Noerochim L, 2010, ELECTROCHIM ACTA, V56, P314, DOI 10.1016/j.electacta.2010.08.078
   Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   OREL B, 1994, J ELECTROCHEM SOC, V141, pL127, DOI 10.1149/1.2055177
   Paek SM, 2009, NANO LETT, V9, P72, DOI 10.1021/nl802484w
   Peng CX, 2012, ACS NANO, V6, P1074, DOI 10.1021/nn202888d
   Pumera M, 2009, CHEM-EUR J, V15, P4970, DOI 10.1002/chem.200900421
   Qiu YC, 2010, ACS NANO, V4, P6515, DOI 10.1021/nn101603g
   Russo PA, 2012, ANGEW CHEM INT EDIT, V51, P11053, DOI 10.1002/anie.201204373
   Stankovich S, 2006, NATURE, V442, P282, DOI 10.1038/nature04969
   Wang B, 2010, J MATER CHEM, V20, P10661, DOI 10.1039/c0jm01941k
   Wang C, 2010, J AM CHEM SOC, V132, P46, DOI 10.1021/ja909321d
   Wang DN, 2012, J PHYS CHEM C, V116, P22149, DOI 10.1021/jp306041y
   Wang F, 2008, SCIENCE, V320, P206, DOI 10.1126/science.1152793
   Wang HL, 2010, J AM CHEM SOC, V132, P13978, DOI 10.1021/ja105296a
   Wang XY, 2011, CARBON, V49, P133, DOI 10.1016/j.carbon.2010.08.052
   Wang Y, 2006, ADV MATER, V18, P645, DOI 10.1002/adma.200501883
   Wang YL, 2003, J AM CHEM SOC, V125, P16176, DOI 10.1021/ja037743f
   Wang ZY, 2010, NANO RES, V3, P748, DOI 10.1007/s12274-010-0041-5
   Wu ZS, 2010, ACS NANO, V4, P3187, DOI 10.1021/nn100740x
   Xu C, 2009, J SOLID STATE CHEM, V182, P2486, DOI 10.1016/j.jssc.2009.07.001
   Yao J, 2009, ELECTROCHEM COMMUN, V11, P1849, DOI 10.1016/j.elecom.2009.07.035
   Zhang LS, 2010, J MATER CHEM, V20, P5462, DOI 10.1039/c0jm00672f
   Zhang M, 2011, J MATER CHEM, V21, P1673, DOI 10.1039/c0jm03410j
   Zhang SL, 2010, J PHYS CHEM C, V114, P19284, DOI 10.1021/jp107780q
   Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235
   Zhou XZ, 2009, J PHYS CHEM C, V113, P10842, DOI 10.1021/jp903821n
   Zhu JX, 2011, J PHYS CHEM C, V115, P8400, DOI 10.1021/jp2002113
   Zhu XJ, 2011, ACS NANO, V5, P3333, DOI 10.1021/nn200493r
   Zou YQ, 2011, NANOSCALE, V3, P2615, DOI 10.1039/c1nr10070j
NR 59
TC 10
Z9 10
U1 6
U2 65
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2014
VL 16
IS 36
BP 19351
EP 19357
DI 10.1039/c4cp02615b
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA AO4IA
UT WOS:000341299500034
PM 25099195
DA 2018-12-27
ER

PT J
AU Zhan, Y
   Wan, ZH
AF Zhan, Ying
   Wan, Zhi Hong
TI RETRACTED: Dynamic nature of washback on individual learners: the role
   of possible selves (Retracted article. See vol. 40, pg. 329, 2015)
SO ASSESSMENT & EVALUATION IN HIGHER EDUCATION
LA English
DT Article; Retracted Publication
DE washback; possible self; out-of-class English learning; College English
   Test Band 4; Chinese non-English major undergraduates
ID CHINA; SELF
AB This study examines how the revised College English Test Band 4 (CET-4) influenced Chinese non-English major undergraduates' out-of-class English learning practices over time, by following two informants in one university from the day they began their college English learning to the day they knew their results in the target examination. In total, 96 diary entries and 20 post-diary interview recordings were collected in the study. The data analysis shows that the washback effects from the CET-4 on the two informants' out-of-class English learning practices seemed to vary across time, and tended to increase as the target examination approached. Furthermore, such dynamic washback effects appeared to be mediated by the two informants' possible selves concerning the CET-4. The study identified the dynamic nature of washback on individual learners and interpreted the underlying mechanism by gaining insights from possible selftheories.
C1 [Zhan, Ying] Guangdong Univ Foreign Studies, Fac English & Educ, Guangzhou, Guangdong, Peoples R China.
   [Wan, Zhi Hong] Hong Kong Inst Educ, Dept Curriculum & Instruct, Hong Kong, Hong Kong, Peoples R China.
RP Zhan, Y (reprint author), Guangdong Univ Foreign Studies, Fac English & Educ, Guangzhou, Guangdong, Peoples R China.
EM 201010006@oamail.gdufs.edu.cn
CR Andrews S., 2002, SYSTEM, V30, P207, DOI DOI 10.1016/S0346-251X(02)00005-2
   Andrews S., 2012, LANG TEST, V30, P49, DOI DOI 10.1177/0265532212442634
   Bailey K. M., 1996, LANG TEST, P257, DOI DOI 10.1177/026553229601300303
   Cheng LY, 2008, ENCYCLOPEDIA OF LANGUAGE AND EDUCATION, VOL 7: LANGUAGE TESTING AND ASSESSMENT, P349
   Cheng LY, 2011, LANG TEST, V28, P221, DOI 10.1177/0265532210384253
   Cheng LY, 2008, LANG TEST, V25, P15, DOI 10.1177/0265532207083743
   Curtis A., 2004, WASHBACK LANGUAGE TE, P190
   Curtis A., 2010, ENGLISH LANGUAGE ASS, P3
   Curtis A., 2009, CUE J, V3, P67
   Dai M., 2004, FOREIGN LANGUAGE TEA, V35, P352
   Dornyei Z, 2009, SECOND LANG ACQUIS, P9
   Dunkel CS, 2006, POSSIBLE SELVES: THEORY, RESEARCH AND APPLICATIONS, P187
   Ellis R., 2005, ANAL LEARNER LANGUAG
   Gosa C. M. C., 2004, THESIS LANCASTER U
   Green A, 2007, ASSESS EDUC, V14, P75, DOI 10.1080/09695940701272880
   Gu X. D., 2005, THESIS SHANGHAI JIAO
   Higgins ET, 1998, ADV EXP SOC PSYCHOL, V30, P1, DOI 10.1016/S0065-2601(08)60381-0
   HIGGINS ET, 1987, PSYCHOL REV, V94, P319, DOI 10.1037/0033-295X.94.3.319
   Higgins ET, 1996, J PERS SOC PSYCHOL, V71, P1062, DOI 10.1037/0022-3514.71.6.1062
   HU CT, 1984, COMP EDUC, V20, P7, DOI 10.1080/0305006840200103
   Jin Y., 2006, FOREIGN LANGUAGE WOR, V6, P65
   LI XJ, 1990, J MULTILING MULTICUL, V11, P393
   Litter A., 1994, ASSESSMENT ED, V1, P201
   MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037//0003-066X.41.9.954
   Mickan P., 2009, LELTS RES REPORT, V10, P223
   Norton B., 2001, LEARNER CONTRIBUTION, P159
   Pan Y., 2009, INT J ED PSYCHOL ASS, V2, P74
   Prodromou L, 1995, ELT J, V49, P13
   Shih CM, 2007, CAN MOD LANG REV, V64, P135, DOI 10.3138/cmlr.64.1.135
   Shohamy E, 1996, LANG TEST, V13, P298, DOI DOI 10.1177/026553229601300305
   Spolsky B, 1995, MEASURED WORDS
   Spratt M., 2005, LANG TEACH RES, V9, P5, DOI [DOI 10.1191/1362168805LR152OA, DOI 10.1191/1362168805LR1520A]
   Stoneman B. W., 2006, THESIS HONG KONG POL
   Tsagari D., 2009, COMPLEXITY TEST WASH
   Ushioda E, 2001, MOTIVATION 2 LANGUAG, P91
   Wall D., 1993, LANG TEST, V10, DOI [10.1177/026553229301000103, DOI 10.1177/026553229301000103]
   Wall D., 2000, SYSTEM, V28, P499, DOI DOI 10.1016/S0346-251X(00)00035-X
   Wenger E, 1998, COMMUNITIES PRACTICE
   Williams M., 1997, PSYCHOL LANGUAGE TEA
NR 39
TC 2
Z9 2
U1 5
U2 12
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0260-2938
EI 1469-297X
J9 ASSESS EVAL HIGH EDU
JI Assess. Eval. High. Educ.
PY 2014
VL 39
IS 7
BP 821
EP 839
DI 10.1080/02602938.2013.872769
PG 19
WC Education & Educational Research
SC Education & Educational Research
GA AN2KQ
UT WOS:000340414500004
DA 2018-12-27
ER

PT J
AU Beznosko, D
   Batyrkhanov, A
   Duspayev, A
   Iakovlev, A
   Yessenov, M
AF Beznosko, D.
   Batyrkhanov, A.
   Duspayev, A.
   Iakovlev, A.
   Yessenov, M.
TI RETRACTED: Performance of Water-Based Liquid Scintillator: An
   Independent Analysis (Retracted article. See 893920, 2015)
SO ADVANCES IN HIGH ENERGY PHYSICS
LA English
DT Article; Retracted Publication
AB The water-based liquid scintillator (WbLS) is a new material currently under development. It is based on the idea of dissolving the organic scintillator in water using special surfactants. This material strives to achieve the novel detection techniques by combining theCerenkov rings and scintillation light, aswell as the total cost reduction compared to pure liquid scintillator (LS). The independent light yieldmeasurement analysis for the light yield measurements using three different proton beamenergies (210MeV, 475MeV, and 2000MeV) for water, two different WbLS formulations (0.4% and 0.99%), and pure LS conducted at Brookhaven National Laboratory, USA, is presented. The results show that a goal of similar to 100 optical photons/MeV, indicated by the simulation to be an optimal light yield for observing both the Cerenkov ring and the scintillation light from the proton decay in a large water detector, has been achieved.
C1 [Beznosko, D.; Batyrkhanov, A.; Duspayev, A.; Iakovlev, A.; Yessenov, M.] Nazarbayev Univ, Dept Phys, Astana 010000, Kazakhstan.
RP Beznosko, D (reprint author), Nazarbayev Univ, Dept Phys, Astana 010000, Kazakhstan.
EM dima@hitecht.us
CR Aberle C., 2014, J INSTRUMENTATION, V9
   Brookhaven National Lab, PO BOX 5000
   Fechner M, 2009, PHYS REV D, V79, DOI 10.1103/PhysRevD.79.112010
   Jaffe D., 2013, 2 OP M HYP KAMI PROJ
   Phillips Scientific, 31 IND AVE
   Yeh M, 2011, NUCL INSTRUM METH A, V660, P51, DOI 10.1016/j.nima.2011.08.040
   Zhang C., 2013, P AM PHYS SOC M APR
NR 7
TC 1
Z9 1
U1 3
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-7357
EI 1687-7365
J9 ADV HIGH ENERGY PHYS
JI Adv. High. Energy Phys.
PY 2014
AR 250646
DI 10.1155/2014/250646
PG 8
WC Physics, Particles & Fields
SC Physics
GA AM8FR
UT WOS:000340108200001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Fakharyan, M
   Omidvar, S
   Khodadadian, MR
   Jalilvand, MR
   Vosta, LN
AF Fakharyan, Meysam
   Omidvar, Sadaf
   Khodadadian, Mohammad Reza
   Jalilvand, Mohammad Reza
   Vosta, Leila Nasrolahi
TI RETRACTED: EXAMINING THE EFFECT OF CUSTOMER-TO-CUSTOMER INTERACTIONS ON
   SATISFACTION, LOYALTY, AND WORD-OF-MOUTH BEHAVIORS IN THE HOSPITALITY
   INDUSTRY: THE MEDIATING ROLE OF PERSONAL INTERACTION QUALITY AND SERVICE
   ATMOSPHERICS (Retracted article. See vol. 35, pg. 394, 2018)
SO JOURNAL OF TRAVEL & TOURISM MARKETING
LA English
DT Article; Retracted Publication
DE Customer-to-customer interactions; satisfaction; loyalty; word of mouth;
   personal interaction quality; service atmospherics
ID ENCOUNTER; IMPACT; CONSUMERS; PERFORMANCE; RESTAURANTS; EXPERIENCES;
   ENVIRONMENT; INTENTIONS; STRANGERS; EMOTIONS
AB Few empirical studies have been conducted to explore how customer-to-customer interactions (CCI) affect satisfaction, loyalty, and word-of-mouth (WOM) behaviors in the hospitality industry. The purpose of this paper is to address this knowledge gap. Then, the paper examines the mediating role of personal interaction quality (PIQ) and service atmospherics on CCI, satisfaction, and loyalty behaviors. The study proposes a structural model of the relationships among CCI, satisfaction, loyalty, WOM, PIQ, and service atmospherics in the context of the hospitality industry. The hypothesized relationships are then tested in an empirical study with a sample of 200 guests of Laleh Hotels in the area of Tehran. The subjects were asked to complete a self-administrated questionnaire using a convenience-sampling approach. Exploratory factor analysis, confirmatory factor analysis, one sample t-test, and structural equation modeling were employed to analyze guests' perceptions of the research constructs. The results show that: 1) service atmospherics has a significant impact on CCI and hotel satisfaction, 2) personal interaction quality has a significant impact on hotel satisfaction and hotel loyalty, 3) hotel satisfaction has a significant impact on hotel loyalty and hotel WOM, and 4) CCI is significantly associated with hotel loyalty and hotel WOM.
C1 [Fakharyan, Meysam] Islamic Azad Univ, Young Researchers Club, Firozkoh Branch, Firozkoh, Iran.
   [Omidvar, Sadaf; Khodadadian, Mohammad Reza] Islamic Azad Univ, Dept Management, Firozkoh, Iran.
   [Jalilvand, Mohammad Reza] Univ Tehran, Fac New Sci & Technol, Tehran, Iran.
   [Jalilvand, Mohammad Reza] Inst Planning & Econ Res, Tehran, Iran.
   [Vosta, Leila Nasrolahi] Univ Tehran, Fac Social Sci, Tehran, Iran.
RP Jalilvand, MR (reprint author), Univ Tehran, Fac New Sci & Technol, Tehran, Iran.
EM meysam.fakharyan@yahoo.com; sadaf.omidvar@yahoo.com;
   mrjd.reza2006@gmail.com; rezajalilvand@ut.ac.ir;
   leila.nasrolahi@ut.ac.ir
CR Anderson E. W., 1998, J SERV RES-US, V1, P5, DOI DOI 10.1177/109467059800100102
   ANDERSON EW, 1993, MARKET SCI, V12, P125, DOI 10.1287/mksc.12.2.125
   ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037//0033-2909.103.3.411
   ARNOULD EJ, 1993, J CONSUM RES, V20, P24, DOI 10.1086/209331
   BAGOZZI RP, 1992, SOC PSYCHOL QUART, V55, P178, DOI 10.2307/2786945
   Baker J., 1994, J ACAD MARKET SCI, V22, P328, DOI DOI 10.1177/0092070394224002
   Baron S., 2007, P QUIS 10 C ORL FL
   Baron S., 1996, EUR J MARKETING, V30, P75, DOI DOI 10.1108/03090569610130052
   Baron S, 2007, SERV BUS, V1, P211, DOI 10.1007/s11628-007-0031-1
   Beatty SE, 1996, J RETAILING, V72, P223, DOI 10.1016/S0022-4359(96)90028-7
   BELLIZZI JA, 1983, J RETAILING, V59, P21
   BITNER MJ, 1990, J MARKETING, V54, P69, DOI 10.2307/1251871
   BITNER MJ, 1992, J MARKETING, V56, P57, DOI 10.2307/1252042
   Bo Edvardsson, 2005, MANAG SERV QUAL, V15, P127, DOI DOI 10.1108/09604520510585316
   Brady M. K., 2001, J INT MANAG, V7, P129, DOI DOI 10.1016/S1075-4253(00)00041-7
   Carmines E., 1979, RELIABILITY VALIDITY
   Caro L. M., 2006, 0618 BRADF U
   Chang K., 2000, J PROFESSIONAL SERVI, V21, P75, DOI DOI 10.1300/J090V21N02_06
   Chebat J., 2007, J BUS RES, V60, P59
   Chen CM, 2013, ASIA PAC J TOUR RES, V18, P262, DOI 10.1080/10941665.2011.647041
   Clark T., 1994, METHODS APPL RELATIO, P1
   COWELL DW, 1984, MARKETING SERVICES
   CZEPIEL JA, 1990, J BUS RES, V20, P13, DOI 10.1016/0148-2963(90)90038-F
   Darley J. M., 1985, HDB SOCIAL PSYCHOL, P949
   Fowler K, 2012, MANAG SERV QUAL, V22, P165, DOI 10.1108/09604521211218972
   Grove SJ, 1998, SERV IND J, V18, P116, DOI 10.1080/02642069800000035
   Grove SJ, 1997, J RETAILING, V73, P63, DOI 10.1016/S0022-4359(97)90015-4
   Guenzi P, 2004, INT J SERV IND MANAG, V15, P365, DOI 10.1108/09564230410552059
   GUMMESSON E, 1993, QUALITY MANAGEMENT S
   Hair Jr J. F., 1998, MULTIVARIATE DATA AN
   HARRELL GD, 1980, J MARKETING RES, V17, P45, DOI 10.2307/3151115
   Harris K., 1995, J SERV MARK, V9, P64
   HARRIS K, 2000, J MARKETING MANAGEME, V16, P111, DOI DOI 10.1362/026725700785100505
   Harris K., 2004, J SERV RES-US, V6, P287, DOI DOI 10.1177/1094670503260132
   HARRIS K, 1997, INT REV RETAIL DISTR, V7, P173, DOI DOI 10.1080/095939697342987
   Haytko D. L., 2009, MANAGEMENT RES NEWS, V32, P337
   Hoare R. J., 2008, International Journal of Contemporary Hospitality Management, V20, P156, DOI 10.1108/09596110810852140
   Howat G., 1996, MANAGING LEISURE INT, V1, P77, DOI DOI 10.1080/136067196376456
   Jang SC, 2009, J BUS RES, V62, P451, DOI 10.1016/j.jbusres.2008.01.038
   Jones MA, 2006, J BUS RES, V59, P974, DOI 10.1016/j.jbusres.2006.03.006
   Kassim N, 2010, ASIA PAC J MARKET LO, V22, P351, DOI 10.1108/13555851011062269
   Khong K. W., 2003, MANAG SERV QUAL, V13, P54, DOI DOI 10.1108/09604520310456717
   Kincaid C, 2010, INT J CONTEMP HOSP M, V22, P209, DOI 10.1108/09596111011018197
   KOTLER P, 1974, J RETAILING, V49, P48
   Kozak M, 2001, ANN TOURISM RES, V28, P784, DOI 10.1016/S0160-7383(00)00078-5
   Kozak M., 2000, Journal of Travel Research, V38, P260
   Kumar N, 1998, J MARKETING RES, V35, P225, DOI 10.2307/3151850
   Langeard E., 1977, MARKETING CONSUMER S, P83
   LeBlanc G., 1992, Journal of Travel Research, V30, P10, DOI 10.1177/004728759203000402
   Liljander V, 1995, MANAG SERV QUAL, P45
   Lloyd AE, 2011, J SERV MARK, V25, P176, DOI 10.1108/08876041111129164
   Martin C. L., 1997, BOWLINGS TEAM CONCEP
   Martin C. L., 1995, J CONSUMER STUDIES H, V19, P299
   Martin C. L., 1996, NETWORKS MARKETING, P342
   Martin CL, 1996, J CONSUM AFF, V30, P146, DOI 10.1111/j.1745-6606.1996.tb00729.x
   Mcdougall G. H. G., 1994, J PROFESSIONAL SERVI, V11, P189, DOI DOI 10.1080/15332969.1994.9985149
   MCGRATH MA, 1995, J BUS RES, V32, P261, DOI 10.1016/0148-2963(94)00051-F
   Meyer A., 1994, QUIS 3 QUAL SERV C P, P301
   Moore R., 2005, J SERV MARK, V19, P482, DOI DOI 10.1108/08876040510625981
   Namkung Young, 2008, International Journal of Contemporary Hospitality Management, V20, P142, DOI 10.1108/09596110810852131
   Nicholls R., 2007, SEARCH VALUE SELECTE, P79
   Nicholls R., 2008, SERVICE MANAGEMENT, V3, P97
   Nicholls R. F., 2005, INTERACTIONS SERVICE
   Nicholls R, 2011, INT J CONTEMP HOSP M, V23, P209, DOI 10.1108/09596111111119338
   Nunnally JC, 1994, PSYCHOMETRIC THEORY
   O'Leary S., 2005, Journal of Travel Research, V43, P247, DOI 10.1177/0047287504272025
   Oliver RL, 1999, J MARKETING, V63, P33, DOI 10.2307/1252099
   Oppermann M., 2000, Journal of Travel Research, V39, P78
   PARKER C, 2000, EUR J MARKETING, V34, P341, DOI DOI 10.1108/03090560010311894
   Pearce P. L, 2005, TOURIST BEHAV THEMES
   Raajpoot N. A., 2006, J SERV MARK, V20, P324, DOI DOI 10.1108/08876040610679936
   Ramani G, 2008, J MARKETING, V72, P27, DOI 10.1509/jmkg.72.1.27
   Ranaweera C, 2003, INT J SERV IND MANAG, V14, P374, DOI 10.1108/09564230310489231
   Reichheld F., 2006, ULTIMATE QUESTION
   Richardson S., 2000, J INTELLECTUAL CAPIT, V1, P85, DOI DOI 10.1108/14691930010324188
   Rosenbaum MS, 2007, J SERV RES-US, V9, P257, DOI 10.1177/1094670506295851
   Rowley J. E., 1995, LIB REV, V44, P7
   Ryu K, 2008, SERV IND J, V28, P1151, DOI 10.1080/02642060802188023
   Sanders N. R., 2005, Journal of Business Logistics, V26, P1
   Schmidt R., 1995, INT J RETAIL DISTRIB, V23, P34, DOI DOI 10.1108/09590559510083984
   Sherman E, 1997, PSYCHOL MARKET, V14, P361, DOI 10.1002/(SICI)1520-6793(199707)14:4<361::AID-MAR4>3.0.CO;2-7
   Stokols D, 1987, HDB ENV PSYCHOL
   SWAN JE, 1989, J RETAILING, V65, P516
   Thakor MV, 2008, J RETAILING, V84, P137, DOI 10.1016/j.jretai.2008.01.002
   vom Lehn D, 2006, EUR J MARKETING, V40, P1340, DOI 10.1108/03090560610702849
   Wakefield KL, 1996, J SPORT MANAGE, V10, P15, DOI 10.1123/jsm.10.1.15
   Wakefield KL, 1998, J RETAILING, V74, P515, DOI 10.1016/S0022-4359(99)80106-7
   Walter U, 2010, MANAG SERV QUAL, V20, P236, DOI 10.1108/09604521011041961
   Wu CHJ, 2007, TOURISM MANAGE, V28, P1518, DOI 10.1016/j.tourman.2007.02.002
   Yang C. M., 2007, THESIS NATL SUN YAT
   Yoon Y, 2005, TOURISM MANAGE, V26, P45, DOI 10.1016/j.tourman.2003.08.016
NR 91
TC 20
Z9 21
U1 2
U2 53
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1054-8408
EI 1540-7306
J9 J TRAVEL TOUR MARK
JI J. Travel Tour. Mark.
PY 2014
VL 31
IS 5
BP 610
EP 626
DI 10.1080/10548408.2014.884964
PG 17
WC Hospitality, Leisure, Sport & Tourism
SC Social Sciences - Other Topics
GA AM8II
UT WOS:000340116600004
DA 2018-12-27
ER

PT J
AU Bayat, N
   Mokhtari, MM
   Rezaei-Tavirani, M
   Baradaran-Rafii, A
   Zadeh, SR
   Heidari-Keshel, S
   Ghasemvand, F
AF Bayat, N.
   Mokhtari, M. M.
   Rezaei-Tavirani, M.
   Baradaran-rafii, A.
   Zadeh, S. Rahman
   Heidari-Keshel, S.
   Ghasemvand, F.
TI RETRACTED: Absolute quantification of free tumor cells in the peripheral
   blood of gastric cancer patients (Retracted article. See vol. 14, pg.
   789, 2015)
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article; Retracted Publication
DE Gastric Cancer; Tumor markers; TEM-8; Real-time PCR; CEA
ID POLYMERASE-CHAIN-REACTION; COLORECTAL-CANCER; MOLECULAR-DETECTION;
   RT-PCR; COLON-CANCER; RNA; METASTASIS; MARKERS; RISK
AB Gastric cancer remains the third most common cancer in the world. Metastatic disease is a major cause of death in about half of the patients; therefore, early diagnosis is crucial for successful outcome. This study applied a sensitive method for the detection of circulating tumor cells using specific tumor markers for early detection. A total of 80 blood samples from 40 patients and 40 age-matched healthy controls were collected for the study. Circulating mRNA levels of two tumor markers, tumor endothelial marker 8 (TEM-8) and carcinoembryogenic antigen (CEA) were evaluated using absolute quantitative real-time PCR assay in the Stratagene Mx-3000P real-time PCR system. GAPDH was used to normalize the data. TEM-8 and CEA were detected in patients' blood more than in controls, 22/40 vs 9/40, P = 0.005, and 30/40 vs 11/40, P = 0.008, respectively. The mRNA level of these markers in patients was significantly higher in comparison to normal controls (P = 0.018, 0.01). This panel showed an overall sensitivity of 64% and specificity of 73%. Statistical analysis for demographic variants did not show any significant differences. Both markers were detected more frequently and in significantly higher levels in blood samples of patients compared to samples from normal individuals. Copy number of CEA and TEM-8 mRNA, as detected by real-time quantitative PCR, appears to be a promising marker to evaluate the risk of tumor spread.
C1 [Bayat, N.; Mokhtari, M. M.; Rezaei-Tavirani, M.; Zadeh, S. Rahman; Heidari-Keshel, S.; Ghasemvand, F.] Shahid Beheshti Univ Med Sci, Fac Paramed Sci, Prote Res Ctr, Tehran, Iran.
   [Baradaran-rafii, A.] Shahid Beheshti Univ Med Sci, Ophtalm Res Ctr, Tehran, Iran.
RP Heidari-Keshel, S (reprint author), Shahid Beheshti Univ Med Sci, Fac Paramed Sci, Prote Res Ctr, Tehran, Iran.
EM saeed_heidari@spu.ir
RI Rezaei Tavirani, Mostafa/I-2407-2017
OI Rezaei-Tavirani, Mostafa/0000-0003-1767-7475; Heidari keshel,
   Saeed/0000-0003-2637-2825; Mokhtari, Majid/0000-0001-5980-1003
FU Beheshti University [UN125]
FX Research supported by the Beheshti University (#UN125). The authors
   kindly thank all the colleagues who contributed to this study. This
   project is part of the master's thesis of Neda Bayat.
CR BURT RW, 1995, ANNU REV MED, V46, P371
   Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169
   Conzelmann M, 2005, INT J COLORECTAL DIS, V20, P137, DOI 10.1007/s00384-004-0640-2
   Gerard CJ, 1998, CANCER RES, V58, P3957
   Ghossein RA, 1999, CLIN CANCER RES, V5, P1950
   HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276
   Lloyd JM, 2006, CLIN CANCER RES, V12, P417, DOI 10.1158/1078-0432.CCR-05-1473
   Nanda A, 2004, CURR OPIN ONCOL, V16, P44, DOI 10.1097/00001622-200401000-00009
   Ohlsson L, 2006, BRIT J CANCER, V95, P218, DOI 10.1038/sj.bjc.6603206
   Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.3.CO;2-D
   Rmali KA, 2005, BIOCHEM BIOPH RES CO, V334, P231, DOI 10.1016/j.bbrc.2005.06.085
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738
   Shen CX, 2008, JPN J CLIN ONCOL, V38, P770, DOI 10.1093/jjco/hyn105
   Silva JM, 2002, GUT, V50, P530, DOI 10.1136/gut.50.4.530
   Turner RR, 2001, WORLD J SURG, V25, P798, DOI 10.1007/s00268-001-0008-5
   Wang JY, 2006, WORLD J SURG, V30, P1007, DOI 10.1007/s00268-005-0485-z
   Xu Dong, 2006, J Zhejiang Univ Sci B, V7, P445, DOI 10.1631/jzus.2006.B0445
   Yeh CS, 2006, INT J ONCOL, V28, P411
   Zieglschmid V, 2005, CRIT REV CL LAB SCI, V42, P155, DOI 10.1080/10408360590913696
NR 20
TC 2
Z9 2
U1 2
U2 8
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2014
VL 13
IS 2
BP 4425
EP 4432
DI 10.4238/2014.June.16.1
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AM5DM
UT WOS:000339876200028
PM 25036347
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhou, JM
   Liu, F
   Lu, QY
AF Zhou Jianming
   Liu Fan
   Lu Qiuyuan
TI RETRACTED: Data Fusion Based on Node Trust Evaluation in Wireless Sensor
   Networks(Retracted article. See pg.2815039,2016)
SO JOURNAL OF SENSORS
LA English
DT Article; Retracted Publication
ID TARGET LOCALIZATION; TRACKING; SYSTEM
AB Abnormal behavior detection and trust evaluation mode of traditional sensor node have a single function without considering all the factors, and the trust value algorithm is relatively complicated. To avoid these above disadvantages, a trust evaluation model based on the autonomous behavior of sensor node is proposed in this paper. Each sensor node has the monitoring privilege and obligation. Neighboring sensor nodes can monitor each other. Their direct and indirect trust values can be achieved by using a relatively simple calculation method, the synthesis trust value of which could be got according to the composition rule of D-S evidence theory. Firstly, the cluster head assigns different weighted value for the data from each sensor node, then the weight vector is set according to the synthesis trust value, the data fusion processing is executed, and finally the cluster head sensor node transmits the fused result to the base station. Simulation experiment results demonstrate that the trust evaluation model can rapidly, exactly, and effectively recognize malicious sensor node and avoid malicious sensor node becoming cluster head sensor node. The proposed algorithm can greatly increase the safety and accuracy of data fusion, improve communication efficiency, save energy of sensor node, suit different application fields, and deploy environments.
C1 [Zhou Jianming; Liu Fan; Lu Qiuyuan] Beijing Inst Technol, Sch Informat & Elect, Beijing 100081, Peoples R China.
RP Zhou, JM (reprint author), Beijing Inst Technol, Sch Informat & Elect, Beijing 100081, Peoples R China.
EM zhoujm@bit.edu.cn
CR Cevher V., 2008, P 16 EUR SIGN PROC C
   Le D., 2010, P 2 INT C ADV COMP C, V1, P465
   Verellen D, 2003, RADIOTHER ONCOL, V67, P129, DOI 10.1016/S0167-8140(02)00385-7
   Willoughby TR, 2006, INT J RADIAT ONCOL, V65, P528, DOI 10.1016/j.ijrobp.2006.01.050
   Xia K., 2013, J NETWORKS, V8, P1632, DOI DOI 10.4304/JNW.8.7.1632-1639
   Xia K., 2012, J CONVERGENCE INFORM, V7, P114
   Xia K.-J., 2010, P 2 INT C COMP AUT E, V1
   Yao Y., 2009, P 15 INT C PAR DISTR, P799
   Zhong S., 2010, P 2 IEEE INT C INF M, P480
   Zou Y., 2004, ACM T EMBED COMPUT S, V3, P61, DOI DOI 10.1145/972627.972631
NR 10
TC 0
Z9 0
U1 2
U2 61
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA
SN 1687-725X
EI 1687-7268
J9 J SENSORS
JI J. Sens.
PY 2014
AR 391401
DI 10.1155/2014/391401
PG 7
WC Engineering, Electrical & Electronic; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA AM3QK
UT WOS:000339767400001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Lv, FF
   Liu, X
   Wang, BY
   Guo, HY
   Li, J
   Shen, L
   Jin, ML
AF Lv, Fangfang
   Liu, Xin
   Wang, Biyun
   Guo, Haiyi
   Li, Jin
   Shen, Lin
   Jin, Maolin
TI RETRACTED: S-1 monotherapy as second line chemotherapy in advanced
   gastric cancer patients previously treated with cisplatin/infusional
   fluorouracil (Retracted article. See vol. 9, pg. 2755, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE S-1 monotherapy; chemotherapy; cisplatin/infusional fluorouracil;
   gastric cancer
ID PHASE-II; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT; 5-FLUOROURACIL;
   FLUOROPYRIMIDINE; CARCINOMA; PLATINUM; EFFICACY
AB The treatment choice of advanced gastric carcinoma after failure from first-line therapy is quite limited. To evaluate the efficacy and toxicity of S-1 monotherapy in patients with advanced gastric cancer after failure of first line cisplatin and fluorouracil combination (CF). S-1 monotherapy as a second line treatment was given to the patients who had failed to CF combination in SC-101 study. The efficacy and toxicity of S-1 monotherapy were evaluated exploratory. The results indicated that forty-one patients received S-1 as a second line therapy after disease progression. The overall response rate and disease control rate were 14.6% and 41.5%, respectively. The median progression free survival (PFS) was 5.1 months (range: 2.9 similar to 6.2 month). The median overall survival time was 6.4 months. The survival rates at 6 month and 1 year were 56% and 7.3%, respectively. Grade 3/ 4 adverse events were uncommonly occurred, including anemia (2.4%), neutropenia (2.4%), thrombocytopenia (4.9%) and rash (2.4%). There were no unexpected or life-threatening toxicities. Only one patient experienced dose reduction due to grade 3 rash. In conclusion, S-1 monotherapy provided a mild response rate and overall survival, and a favorable toxicity profile in the second line setting after the first line failure to cisplatin and fluorouracil combination.
C1 [Lv, Fangfang; Liu, Xin; Wang, Biyun; Guo, Haiyi; Li, Jin] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai 200032, Peoples R China.
   [Lv, Fangfang; Liu, Xin; Wang, Biyun; Guo, Haiyi; Li, Jin] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
   [Shen, Lin; Jin, Maolin] Beijing Canc Hosp, Dept Digest Oncol, Beijing 100036, Peoples R China.
RP Li, J (reprint author), Fudan Univ, Canc Hosp, Dept Med Oncol, 270 Dong An Rd, Shanghai 200032, Peoples R China.
EM lijindoctor@yeah.net; maolinjin213@yeah.net
CR Chen MC, 2013, NEOPLASMA, V60, P561, DOI 10.4149/neo_2013_073
   Chou I, 2004, J CLIN ONCOL, V22, P2395, DOI 10.1200/JCO.2004.08.154
   Fiala O, 2013, NEOPLASMA, V60, P129, DOI 10.4149/neo_2013_017
   Guo Y, 2013, NEOPLASMA, V60, P605, DOI 10.4149/neo_2013_078
   Hartmann JT, 2007, ONKOLOGIE, V30, P235, DOI 10.1159/000100828
   Hironaka Shuichi, 2006, Gastric Cancer, V9, P14, DOI 10.1007/s10120-005-0351-6
   Jo JC, 2007, JPN J CLIN ONCOL, V37, P936, DOI 10.1093/jjco/hym123
   Koizumi W, 2000, ONCOLOGY-BASEL, V58, P191, DOI 10.1159/000012099
   Nguyen Suzanne, 2006, Bull Cancer, V93, pE1
   Park SH, 2008, ANTI-CANCER DRUG, V19, P303, DOI 10.1097/CAD.0b013e3282f46ad8
   PYRHONEN S, 1995, BRIT J CANCER, V71, P587, DOI 10.1038/bjc.1995.114
   Sakata Y, 1998, EUR J CANCER, V34, P1715, DOI 10.1016/S0959-8049(98)00211-1
   Seo MD, 2008, JPN J CLIN ONCOL, V38, P589, DOI 10.1093/jjco/hyn078
   SHIRASAKA T, 1993, CANCER RES, V53, P4004
   Ueda Shinya, 2006, Gastric Cancer, V9, P203, DOI 10.1007/s10120-006-0379-2
   Usakova V, 2013, NEOPLASMA, V60, P83, DOI 10.4149/neo_2013_012
NR 16
TC 0
Z9 0
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2014
VL 7
IS 6
BP 3293
EP 3298
PG 6
WC Oncology; Pathology
SC Oncology; Pathology
GA AK9TQ
UT WOS:000338770500059
PM 25031751
DA 2018-12-27
ER

PT J
AU Kundu, D
   Hazra, C
   Chatterjee, A
   Chaudhari, A
   Mishra, S
AF Kundu, Debasree
   Hazra, Chinmay
   Chatterjee, Aniruddha
   Chaudhari, Ambalal
   Mishra, Satyendra
TI RETRACTED: Sonochemical synthesis of poly(methyl methacrylate)
   core-surfactin shell nanoparticles for recyclable removal of heavy metal
   ions and its cytotoxicity (Retracted article. See vol. 4, pg. 52949,
   2014)
SO RSC ADVANCES
LA English
DT Article; Retracted Publication
ID ULTRASOUND ASSISTED SYNTHESIS; LOW-COST ADSORBENT; BAGASSE-FLY-ASH;
   AQUEOUS-SOLUTION; POLYSTYRENE NANOPARTICLES; METHYLENE-BLUE;
   MECHANICAL-PROPERTIES; SORPTION EQUILIBRIUM; POLYPROPYLENE PP; BRILLIANT
   GREEN
AB This work deals with the use of intensified processes based on the combined use of acoustic cavitation and biosurfactants for enhancing the latex yield and colloid characteristics in the acoustic atomized microemulsion polymerization of methyl methacrylate (MMA). It was compared with an oil/water (o/w) modified atomized microemulsion process in a conventional mechanically agitated reactor. The synthesized nanoparticles were further applied for selective removal of Pb2+, Cd2+, Cu2+ and Fe2+ ions from water. Batch adsorption equilibrium was reached in 30 min and maximum uptakes for Pb2+, Cd2+, Cu2+ and Fe2+ in non-competitive adsorption mode were 86, 52, 80, and 71 mg g(-1), respectively at 30 degrees C. Adsorption data were fitted well to the Langmuir isotherm and pseudo-second-order models for kinetic study. The heavy metals loaded on these nanoparticles could be desorbed in acid or EDTA solution and the adsorption capacity of the regenerated adsorbent did not significantly decline after five cycles of adsorption-desorption cycles. Negative values of Gibb's free energy change (Delta G degrees) showed that the adsorption was feasible and spontaneous and negative values of enthalpy change (Delta H degrees) confirmed exothermic adsorption. A cell viability study indicated that the nanoparticle is non-cytotoxic in nature. Lastly, a continuous filtering-type water purification device was designed and constructed to successfully attain the World Health Organization standard for drinking water.
C1 [Kundu, Debasree; Hazra, Chinmay; Chaudhari, Ambalal] North Maharashtra Univ, Sch Life Sci, Jalgaon, Maharashtra, India.
   [Chatterjee, Aniruddha; Mishra, Satyendra] North Maharashtra Univ, Univ Inst Chem Technol, Jalgaon, Maharashtra, India.
RP Chatterjee, A (reprint author), North Maharashtra Univ, Univ Inst Chem Technol, Jalgaon, Maharashtra, India.
EM aniruddha_chatterjee2006@yahoo.co.in
FU University Grants Commission (U.G.C), New Delhi [41-375/2012 (SR)]
FX This work was financially supported by University Grants Commission
   (U.G.C), New Delhi [F. no. 41-375/2012 (SR), dated July 16, 2012].
   Department of Science and Technology (D.S.T), New Delhi and Council for
   Scientific and Industrial Research (C.S.I.R), New Delhi are earnestly
   acknowledged for providing INSPIRE-SRF and CSIR-SRF to Chinmay Hazra and
   Debasree Kundu, respectively.
CR Abdel-Halim ES, 2014, REACT FUNCT POLYM, V75, P1, DOI 10.1016/j.reactfunctpolym.2013.12.003
   Aguado J, 2009, J HAZARD MATER, V163, P213, DOI 10.1016/j.jhazmat.2008.06.080
   Anirudhan TS, 2012, J ENVIRON RADIOACTIV, V106, P8, DOI 10.1016/j.jenvrad.2011.10.013
   Arunbabu D, 2011, J COLLOID INTERF SCI, V361, P534, DOI 10.1016/j.jcis.2011.06.005
   Bhanvase BA, 2012, ULTRASON SONOCHEM, V19, P97, DOI 10.1016/j.ultsonch.2011.05.016
   Bhaumik M, 2012, CHEM ENG J, V181, P323, DOI 10.1016/j.cej.2011.11.088
   Bradley M, 2002, J COLLOID INTERF SCI, V251, P78, DOI 10.1006/jcis.2002.8383
   Camli ST, 2010, J COLLOID INTERF SCI, V344, P528, DOI 10.1016/j.jcis.2010.01.041
   Chatterjee A, 2012, MACROMOL RES, V20, P780, DOI 10.1007/s13233-012-0108-0
   Chen W, 2010, COLLOID SURFACE A, V364, P145, DOI 10.1016/j.colsurfa.2010.05.010
   Colombo C, 2013, MACROMOL SYMP, V324, P134, DOI 10.1002/masy.201200078
   Dobie CG, 2010, CHEM ENG PROCESS, V49, P901, DOI 10.1016/j.cep.2010.08.005
   Emik S, 2014, REACT FUNCT POLYM, V75, P63, DOI 10.1016/j.reactfunctpolym.2013.12.006
   Fu FL, 2011, J ENVIRON MANAGE, V92, P407, DOI 10.1016/j.jenvman.2010.11.011
   Hameed BH, 2008, J HAZARD MATER, V158, P499, DOI 10.1016/j.jhazmat.2008.01.098
   Hameed BH, 2009, J HAZARD MATER, V162, P344, DOI 10.1016/j.jhazmat.2008.05.045
   Hazra C, 2014, COLLOID SURFACE A, V449, P96, DOI 10.1016/j.colsurfa.2014.02.051
   Hazra C, 2013, J CHEM TECHNOL BIOT, V88, P1551, DOI 10.1002/jctb.4003
   Jana S, 2011, CHEM ENG J, V170, P209, DOI 10.1016/j.cej.2011.03.056
   Korkut I, 2014, ULTRASON SONOCHEM, V21, P1592, DOI 10.1016/j.ultsonch.2013.12.028
   Kurniawan A, 2011, CHEM ENG J, V172, P158, DOI 10.1016/j.cej.2011.05.083
   Kushwaha AK, 2017, ARAB J CHEM, V10, pS1645, DOI 10.1016/j.arabjc.2013.06.007
   Li ZK, 2013, ENVIRON SCI POLLUT R, V20, P1511, DOI 10.1007/s11356-012-0973-2
   Liu X, 2007, PROTEIN PEPTIDE LETT, V14, P766
   Low LW, 2014, SEP SCI TECHNOL, V49, P1104, DOI 10.1080/01496395.2013.872148
   Low LW, 2013, SEP SCI TECHNOL, V48, P1688, DOI 10.1080/01496395.2012.756912
   Low LW, 2011, WATER AIR SOIL POLL, V218, P293, DOI 10.1007/s11270-010-0642-3
   Low LW, 2011, WATER AIR SOIL POLL, V214, P185, DOI 10.1007/s11270-010-0414-0
   Mall ID, 2006, DYES PIGMENTS, V69, P210, DOI 10.1016/j.dyepig.2005.03.013
   Mane VS, 2007, DYES PIGMENTS, V73, P269, DOI 10.1016/j.dyepig.2005.12.006
   Mishra S., 2013, Indian Patent Application, Patent No. 254969
   Mishra S, 2011, POLYM ADVAN TECHNOL, V22, P1593, DOI 10.1002/pat.1646
   Mishra S, 2011, POLYM ADVAN TECHNOL, V22, P1547, DOI 10.1002/pat.1637
   Mishra S, 2010, POLYM-PLAST TECHNOL, V49, P791, DOI 10.1080/03602551003749593
   Mishra S, 2011, POLYM ADVAN TECHNOL, V22, P1802, DOI 10.1002/pat.1674
   Modrzejewska Z, 2013, REACT FUNCT POLYM, V73, P719, DOI 10.1016/j.reactfunctpolym.2013.02.014
   Molochnikov LS, 2003, POLYMER, V44, P4805, DOI 10.1016/S0032-3861(03)00500-7
   Moradi O, 2009, J HAZARD MATER, V170, P673, DOI 10.1016/j.jhazmat.2009.05.012
   Namir H., 2008, PROTEIN PEPTIDE LETT, V15, P265
   Pan BJ, 2009, CHEM ENG J, V151, P19, DOI 10.1016/j.cej.2009.02.036
   Prasad K, 2013, CHEM ENG J, V219, P254, DOI 10.1016/j.cej.2013.01.012
   Ratanajanchai M, 2014, MAT SCI ENG C-MATER, V34, P377, DOI 10.1016/j.msec.2013.09.037
   Saber-Samandari S, 2013, REACT FUNCT POLYM, V73, P1523, DOI 10.1016/j.reactfunctpolym.2013.07.007
   Santos AM, 2005, POLYMER, V46, P1181, DOI 10.1016/j.polymer.2004.11.069
   Shahadat M, 2012, RSC ADV, V2, P7207, DOI 10.1039/c2ra20589k
   Shirsath SR, 2013, ULTRASON SONOCHEM, V20, P277, DOI 10.1016/j.ultsonch.2012.05.015
   Shirsath SR, 2013, ULTRASON SONOCHEM, V20, P914, DOI 10.1016/j.ultsonch.2012.11.010
   Sinna M. M., 2004, PURE APPL CHEM, V41, P1187
   Su CXH, 2014, WATER AIR SOIL POLL, V225, DOI 10.1007/s11270-014-1941-x
   Tan IAW, 2007, CHEM ENG J, V127, P111, DOI [10.1016/j.cej.2006.09.010, 10.1016/j.cej.200609.010]
   Tang YL, 2012, COLLOID SURFACE A, V406, P61, DOI 10.1016/j.colsurfa.2012.04.050
   Tekin K, 2011, REACT FUNCT POLYM, V71, P985, DOI 10.1016/j.reactfunctpolym.2011.06.005
   Teo BM, 2008, ULTRASON SONOCHEM, V15, P89, DOI 10.1016/j.ultsonch.2007.01.009
   Turkmen D, 2009, MAT SCI ENG C-MATER, V29, P2072, DOI 10.1016/j.msec.2009.04.005
   Uyar T, 2010, J MEMBRANE SCI, V365, P409, DOI 10.1016/j.memsci.2010.09.037
   Uzun L, 2008, COLLOID SURFACE A, V330, P161, DOI 10.1016/j.colsurfa.2008.07.045
   Vieira RS, 2011, COLLOID SURFACE A, V374, P108, DOI 10.1016/j.colsurfa.2010.11.022
   Wang JH, 2010, J COLLOID INTERF SCI, V349, P293, DOI 10.1016/j.jcis.2010.05.010
   Wu AH, 2011, COLLOID SURFACE A, V384, P180, DOI 10.1016/j.colsurfa.2011.03.060
   Wu N, 2012, ENVIRON SCI TECHNOL, V46, P419, DOI 10.1021/es202043u
   Yuan Q, 2013, J HAZARD MATER, V254, P157, DOI 10.1016/j.jhazmat.2013.03.035
NR 61
TC 3
Z9 3
U1 5
U2 35
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2014
VL 4
IS 48
BP 24991
EP 25004
DI 10.1039/c4ra03008g
PG 14
WC Chemistry, Multidisciplinary
SC Chemistry
GA AJ9PJ
UT WOS:000338044500006
DA 2018-12-27
ER

PT J
AU Zhang, DY
   Joy, M
   Cosma, G
   Boyatt, R
   Sinclair, J
   Yau, J
AF Zhang, Dongyang
   Joy, Mike
   Cosma, Georgina
   Boyatt, Russell
   Sinclair, Jane
   Yau, Jane
TI RETRACTED: Source-code plagiarism in universities: a comparative study
   of student perspectives in China and the UK (Retracted article. See vol.
   40, pg. 330, 2015)
SO ASSESSMENT & EVALUATION IN HIGHER EDUCATION
LA English
DT Article; Retracted Publication
DE source-code; plagiarism; UK; China
AB There has been much research and discussion relating to variations in plagiaristic activity observed in students from different demographic backgrounds. Differences in behaviour have been noted in many studies, although the underlying reasons are still a matter of debate. Existing work focuses mainly on textual plagiarism, and most often derives results by studying (small) groups of overseas students studying in a Western context. This study investigates understanding of source-code plagiarism (i.e. plagiarism of computer programmes) amongst university students in China. The survey instrument was a Chinese translation of a survey previously administered in English in the UK. This paper reports the results of the exploratory survey conducted in China, and compares these results to those from a parallel survey conducted in the UK. The results show that there is a significant difference in understanding between the respondents from the two surveys, and suggest topics which a future and more comprehensive study may focus on.
C1 [Zhang, Dongyang] Henan Agr Univ, Coll Informat & Management Sci, Zhengzhou, Peoples R China.
   [Joy, Mike; Boyatt, Russell; Sinclair, Jane] Univ Warwick, Dept Comp Sci, Coventry CV4 7AL, W Midlands, England.
   [Cosma, Georgina] Nottingham Trent Univ, Sch Sci & Technol, Nottingham, England.
   [Yau, Jane] Malmo Univ, Dept Comp Sci, Malmo, Sweden.
RP Joy, M (reprint author), Univ Warwick, Dept Comp Sci, Coventry CV4 7AL, W Midlands, England.
EM m.s.joy@warwick.ac.uk
OI Joy, Mike/0000-0001-9826-5928; Cosma, Georgina/0000-0002-4663-6907
CR Bista K., 2011, IMPROVE ACAD RESOURC, V30, P159
   Bowyer K., 1999, P 29 ASEE IEEE FRONT, P18
   Bradley C, 2011, CHANDOS INF PROF SER, P1
   Chuda D, 2012, IEEE T EDUC, V55, P22, DOI 10.1109/TE.2011.2112768
   Cohen J, 1988, STAT POWER ANAL BEHA
   Eaton N., 2009, MICROSOFT BLOG  0416
   Gullifer JM, 2014, STUD HIGH EDUC, V39, P1202, DOI 10.1080/03075079.2013.777412
   Hayes N, 2005, ETHICS BEHAV, V15, P213, DOI 10.1207/s15327019eb1503_2
   Heitman E, 2011, UROL ONCOL-SEMIN ORI, V29, P104, DOI 10.1016/j.urolonc.2010.09.014
   Hu GW, 2012, LANG LEARN, V62, P813, DOI 10.1111/j.1467-9922.2011.00650.x
   Joy M, 1999, IEEE T EDUC, V42, P129, DOI 10.1109/13.762946
   Joy M, 2011, IEEE T EDUC, V54, P125, DOI 10.1109/TE.2010.2046664
   Leask B, 2006, ASSESS EVAL HIGH EDU, V31, P183, DOI 10.1080/02602930500262486
   Ledwith A., 2011, ASSESS EVAL HIGH EDU, V2, P34
   Liu D., 2005, ELT J, V59.3, P234, DOI DOI 10.1093/ELT/CCI043
   Mann S., 2006, P 8 AUSTR COMP ED C, V52, P143
   Ministry of Education, 2013, PROJ 211 LIST SCH
   Ministry of Education, 2006, 985 PROJ SCH LIST
   Ministry of Education, 2013, ED TECHNOLOGY LETT, P26
   Park C., 2003, ASSESS EVAL HIGH EDU, V28.5, P471, DOI DOI 10.1080/02602930301677
   Patel N, 2005, WISCONSIN INT LAW J, V23, P781
   Pennycook A, 1996, TESOL QUART, V30, P201, DOI 10.2307/3588141
   Prechelt L, 2002, J UNIVERS COMPUT SCI, V8, P1016
   Qi S, 2008, THESIS SF AUSTIN STA
   Sergiou K., 2005, INVESTIGATIONS U TEA, V2
   Sowden C., 2005, ELT J, V59.3, P226, DOI DOI 10.1093/ELT/CCI042
   Sraka D, 2009, ITI, P461, DOI 10.1109/ITI.2009.5196127
   Stone C. R., 2008, MARQUETTE LAW REV, V92, P199
   TWOMEY T, 2009, PEDAGOGY NOT POLICIN
   Yakovchuk N., 2008, CURRENT DEV ENGLISH, P39
NR 30
TC 7
Z9 7
U1 4
U2 18
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0260-2938
EI 1469-297X
J9 ASSESS EVAL HIGH EDU
JI Assess. Eval. High. Educ.
PY 2014
VL 39
IS 6
BP 743
EP 758
DI 10.1080/02602938.2013.870122
PG 16
WC Education & Educational Research
SC Education & Educational Research
GA AJ9EU
UT WOS:000338011000007
DA 2018-12-27
ER

PT J
AU Li, PC
   Zhang, JL
AF Li, Peng-Cheng
   Zhang, Jian-Liang
TI RETRACTED: Representation of Reaction Ability for Structural Units in
   Fe-Al Binary Melts (Retracted article. See vol. 54, pg. 2663, 2014)
SO ISIJ INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Fe-Al binary melts; activity of aluminum; activity of iron; mass action
   concentration; reaction ability; thermodynamic model; structural units;
   atom and molecule coexistence theory (AMCT)
ID MOLECULE COEXISTENCE THEORY; CAO-SIO2-MGO-AL2O3 IRONMAKING SLAGS;
   QUASI-CHEMICAL MODEL; METAL-SULFUR SYSTEMS; THERMODYNAMIC PROPERTIES;
   PHASE-RELATIONSHIPS; LIQUID ALLOYS; IRON-ALUMINUM; ION
AB A thermodynamic model for calculating the mass action concentrations of structural units in Fe-Al binary melts based on the atom-molecule coexistence theory, i.e., AMCT-N-i model, has been developed and verified through comparing with the reported activities of both Al and Fe in Fe-Al binary melts in a temperature from 1 573 K to 1 873 K by different researchers. The calculated mass action concentration N-Al of Al or N-Fe of Fe can be applied to ideally substitute the measured activity a(R, Al) of Al or a(R, Fe) of Fe relative to pure liquid AI(I) or Fe(I) as standard state in Fe-Al binary melts. The following equations were derived for the activity coefficient of Al in natural logarithmic form In gamma(Al) and the calculated activity coefficient of Fe in natural logarithmic form In gamma(Fe) in the temperature range from 1 573 K to 1 873 K.
   In gamma(Al)= -3.810+4.476x(Al) 0 < x(Al) <= 0.005, T = 1573 K
   In gamma(Al)= -3.397+4.248x(Al) 0 < x(Al) <= 0.005, T = 1673 K
   In gamma(Al)= -3.056+4.011x(Al) 0 < x(Al) <= 0.005, T = 1773 K
   In gamma(Al)= -2.537+3.599x(Al) 0 < x(Al) <= 0.005, T = 1873 K
   In gamma(Fe)= -3.837+6.701x(Fe) 0 < x(Fe) <= 0.005, T = 1573 K
   In gamma(Fe)= -3.753+7.627x(Fe) 0 < x(Fe) <= 0.005, T = 1673 K
   In gamma(Fe)= -3.701+8.066x(Fe) 0 < x(Fe) <= 0.005, T = 1773 K
   In gamma(Fe)= -3.686+8.176x(Fe) 0 < x(Fe) <= 0.005, T = 1873 K
   Temperature dependences of the activity coefficient of Al in natural logarithmic form In gamma(0)(Al), and the calculated activity coefficient of Fe in natural logarithmic form In gamma(0)(Fe) were given
C1 [Li, Peng-Cheng; Zhang, Jian-Liang] Univ Sci & Technol Beijing, State Key Lab Adv Met, Beijing 100083, Peoples R China.
   [Li, Peng-Cheng; Zhang, Jian-Liang] Univ Sci & Technol Beijing, Sch Met & Ecol Engn, Beijing 100083, Peoples R China.
   [Li, Peng-Cheng] Chinese Acad Sci, State Key Lab Multiphase Complex Syst, Inst Proc Engn, Beijing 100190, Peoples R China.
RP Li, PC (reprint author), Univ Sci & Technol Beijing, State Key Lab Adv Met, Beijing 100083, Peoples R China.
EM lipengcheng000@126.com
CR BELTON GR, 1969, T METALL SOC AIME, V245, P113
   Chartrand P, 2001, METALL MATER TRANS A, V32, P1397, DOI 10.1007/s11661-001-0229-0
   CHIPMAN J, 1955, ACTA METALL MATER, V3, P456, DOI 10.1016/0001-6160(55)90135-8
   CHUANG YY, 1985, METALL TRANS B, V16, P277, DOI 10.1007/BF02679718
   COSKUN A, 1968, T METALL SOC AIME, V242, P253
   DESAI PD, 1987, J PHYS CHEM REF DATA, V16, P109, DOI 10.1063/1.555788
   Hildebrand JH, 1915, J AM CHEM SOC, V37, P2452, DOI 10.1021/ja02176a002
   HOFFMAN DW, 1972, METALL TRANS, V3, P3231, DOI 10.1007/BF02661338
   Ichise E., 1977, TETSU TO HAGANE, V63, P417
   JACOBSON NS, 1993, METALL TRANS B, V24, P481, DOI 10.1007/BF02666431
   Kim WY, 2007, ISIJ INT, V47, P945, DOI 10.2355/isijinternational.47.945
   Le Bouteiller M., 1977, METALL MATER TRANS B, V1B, P339
   Lee YE, 1998, METALL MATER TRANS B, V29, P397, DOI 10.1007/s11663-998-0116-9
   MISRA AK, 1990, METALL TRANS A, V21, P441, DOI 10.1007/BF02782424
   Pelton AD, 2000, METALL MATER TRANS B, V31, P651, DOI 10.1007/s11663-000-0103-2
   SHARMA RC, 1979, METALL TRANS B, V10, P103, DOI 10.1007/BF02653979
   Shi CB, 2010, ISIJ INT, V50, P1362, DOI 10.2355/isijinternational.50.1362
   SOMMER F, 1982, Z METALLKD, V73, P72
   WILDER TC, 1960, J ELECTROCHEM SOC, V107, P628, DOI 10.1149/1.2427788
   WOOLLEY F, 1967, T METALL SOC AIME, V239, P1872
   Yang XM, 2013, STEEL RES INT, V84, P784, DOI 10.1002/srin.201200181
   Yang XM, 2012, METALL MATER TRANS B, V43, P1358, DOI 10.1007/s11663-012-9707-6
   Yang XM, 2009, ISIJ INT, V49, P1828, DOI 10.2355/isijinternational.49.1828
   Zaitsev AI, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/11/114121
   Zhang J, 2005, J IRON STEEL RES INT, V12, P11
   Zhang J., 2007, COMPUTATIONAL THERMO, P40
NR 26
TC 1
Z9 1
U1 3
U2 12
PU IRON STEEL INST JAPAN KEIDANREN KAIKAN
PI TOKYO
PA TEKKO KAIKAN-5F, 3-2-10, NIHONBASHI-KAYABACHO, TOKYO, CHUO-KU 103-0025,
   JAPAN
SN 0915-1559
EI 1347-5460
J9 ISIJ INT
JI ISIJ Int.
PY 2014
VL 54
IS 6
BP 1185
EP 1194
DI 10.2355/isijinternational.54.1185
PG 10
WC Metallurgy & Metallurgical Engineering
SC Metallurgy & Metallurgical Engineering
GA AJ8US
UT WOS:000337984000002
OA Bronze
DA 2018-12-27
ER

PT J
AU Talukdar, D
   Talukdar, T
AF Talukdar, Dibyendu
   Talukdar, Tulika
TI RETRACTED: Leaf Rolling and Stem Fasciation in Grass Pea (Lathyrus
   sativus L.) Mutant Are Mediated through Glutathione-Dependent Cellular
   and Metabolic Changes and Associated with a Metabolic Diversion through
   Cysteine during Phenotypic Reversal (Retracted article. See 4938464,
   2016)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID ARABIDOPSIS-THALIANA; CTENANTHE-SETOSA; HYDROGEN-SULFIDE; SERINE
   ACETYLTRANSFERASE; PLANT-CELLS; ASCORBATE; DEATH; PROLIFERATION;
   TRANSFERASES; HOMEOSTASIS
AB A Lathyrus sativus L. mutant isolated in ethylmethane sulfonate-treated M-2 progeny of mother variety BioL-212 and designated as rlfL-1 was characterized by inwardly rolled-leaf and stem and bud fasciations. The mutant exhibited karyomorphological peculiarities in both mitosis and meiosis with origin of aneuploidy. The mitosis was vigorous with high frequency of divisional cells and their quick turnover presumably steered cell proliferations. Significant transcriptional upregulations of cysteine and glutathione synthesis and concomitant stimulations of glutathione-mediated antioxidant defense helped rlfL-1 mutant to maintain balanced reactive oxygen species (ROS) metabolisms, as deduced by ROS-imaging study. Glutathione synthesis was shut down in buthionine sulfoximine- (BSO-) treated mother plant and mutant, and leaf-rolling and stems/buds fasciations in the mutant were reversed, accompanied by normalization of mitotic cell division process. Antioxidant defense was downregulated under low glutathioneredox but cysteine-desulfurations and photorespiratory glycolate oxidase transcripts were markedly overexpressed, preventing cysteine overaccumulation but resulted in excess H2O2 in BSO-treated mutant. This led to oxidative damage in proliferating cells, manifested by severe necrosis in rolled-leaf and fasciated stems. Results indicated vital role of glutathione in maintaining abnormal proliferations in plant organs, and its deficiency triggered phenotypic reversal through metabolic diversions of cysteine and concomitant cellular and metabolic modulations.
C1 [Talukdar, Dibyendu] Univ Calcutta, RPM Coll, Dept Bot, Hooghly 712258, W Bengal, India.
   [Talukdar, Tulika] Univ N Bengal, Acharya Prafulla Chandra Roy Govt Coll, Dept Bot, Darjeeling 734010, W Bengal, India.
RP Talukdar, D (reprint author), Univ Calcutta, RPM Coll, Dept Bot, Hooghly 712258, W Bengal, India.
EM dibyendutalukdar9@gmail.com
CR Aksoy E., 2008, THESIS MIDDLE E TU A
   Alvarez C, 2010, PLANT PHYSIOL, V152, P656, DOI 10.1104/pp.109.147975
   Baker AL, 1966, METHOD ENZYMOL, V8, P338
   Beemster GTS, 1998, PLANT PHYSIOL, V116, P1515, DOI 10.1104/pp.116.4.1515
   BEYER WF, 1987, ANAL BIOCHEM, V161, P559, DOI 10.1016/0003-2697(87)90489-1
   Blaszczyk A, 2002, PLANT SCI, V162, P589, DOI 10.1016/S0168-9452(01)00598-2
   Bloem E, 2004, J EXP BOT, V55, P2305, DOI 10.1093/jxb/erh236
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CARLBERG I, 1985, METHOD ENZYMOL, V113, P484
   Cetin B, 2010, CELL, V143, P27, DOI 10.1016/j.cell.2010.09.030
   Chen J, 2011, J EXP BOT, V62, P4481, DOI 10.1093/jxb/err145
   Vivancos PD, 2010, PLANT J, V64, P825, DOI 10.1111/j.1365-313X.2010.04371.x
   Dixon DP, 2009, J BIOL CHEM, V284, P21249, DOI 10.1074/jbc.M109.020107
   Edwards R, 1996, PHYSIOL PLANTARUM, V98, P594
   Foyer CH, 2011, PLANT PHYSIOL, V155, P2, DOI 10.1104/pp.110.167569
   GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627
   Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001
   GRIFFITH OW, 1985, METHOD ENZYMAT AN, V8, P521
   Han SJ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-179
   Hasler J, 2003, BIOL CELL, V95, P357, DOI 10.1016/S0248-4900(03)00077-7
   Kadioglu A, 2007, BOT REV, V73, P290, DOI 10.1663/0006-8101(2007)73[290:ADAMLR]2.0.CO;2
   Komatsu K, 2010, MOL PLANT MICROBE IN, V23, P283, DOI 10.1094/MPMI-23-3-0283
   Kopriva S., 2012, FRONT PLANT SCI, V3, P1
   Krueger S, 2009, PLANT CELL ENVIRON, V32, P349, DOI [10.1111/j.1365-3040.2009.01928.x, 10.1111/j.1365-3040.2008.01928.x]
   Kuta DD, 2005, AFR J BIOTECHNOL, V4, P752
   Laborde E, 2010, CELL DEATH DIFFER, V17, P1373, DOI 10.1038/cdd.2010.80
   Lee CW, 2009, PLANT CELL, V21, P2948, DOI 10.1105/tpc.108.064576
   LI ZS, 1995, PLANT PHYSIOL, V109, P177, DOI 10.1104/pp.109.1.177
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lucas MR, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00095
   Matias AMA, 2011, SCI DILIMAN, V23, P43
   NAKANO Y, 1981, PLANT CELL PHYSIOL, V22, P867
   Neill SJ, 2002, J EXP BOT, V53, P1237, DOI 10.1093/jexbot/53.372.1237
   Niizeki M., 2003, B FACULTY AGR LIFE S, P1
   Noctor G, 2013, PLANT PHYSIOL, V163, P665, DOI 10.1104/pp.113.223545
   Park S, 2003, J BACTERIOL, V185, P1942, DOI 10.1128/JB.185.6.1942-1950.2003
   Patto MCV, 2006, EUPHYTICA, V147, P133, DOI 10.1007/s10681-006-3607-2
   Rahantaniaina MS, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00477
   Saglam A, 2008, RUSS J PLANT PHYSL+, V55, P48, DOI 10.1007/s11183-008-1005-4
   SAITO K, 1994, PLANT PHYSIOL, V106, P887, DOI 10.1104/pp.106.3.887
   Sarieva GE, 2010, RUSS J PLANT PHYSL+, V57, P28, DOI 10.1134/S1021443710010048
   Saruhan N, 2009, BIOL RES, V42, P315, DOI [10.4067/S0716-97602009000300006, /S0716-97602009000300006]
   SEELIG GF, 1984, J BIOL CHEM, V259, P3534
   SEKIYA J, 1982, PLANT PHYSIOL, V70, P430, DOI 10.1104/pp.70.2.430
   Sheltzer JM, 2012, P NATL ACAD SCI USA, V109, P12644, DOI 10.1073/pnas.1209227109
   Srinivasan S, 2008, PLANT BREEDING, V127, P319, DOI 10.1111/j.1439-0523.2007.01447.x
   Taguchi-Shiobara F, 2001, GENE DEV, V15, P2755, DOI 10.1101/gad.208501
   Takahashi H, 2011, ANNU REV PLANT BIOL, V62, P157, DOI 10.1146/annurev-arplant-042110-103921
   Talukdar D, 2012, BIOL PLANTARUM, V56, P675, DOI 10.1007/s10535-012-0245-5
   Talukdar D., 2013, J CROP SCI BIOTECHNO, V15, P325
   Talukdar D., 2013, BIOCH MOL BIOL, V1, P34
   Talukdar D., 2014, PROTOPLASMA
   Talukdar D., 2008, CARYOLOGIA, V61, P402
   Talukdar Dibyendu, 2007, Cytologia (Tokyo), V72, P385, DOI 10.1508/cytologia.72.385
   Talukdar D, 2013, BIOMED RES INT, DOI 10.1155/2013/782450
   Talukdar D, 2013, RUSS J PLANT PHYSL+, V60, P652, DOI 10.1134/S1021443713050130
   Talukdar D, 2013, PHYSIOL MOL BIOL PLA, V19, P69, DOI 10.1007/s12298-012-0140-8
   Talukdar D, 2012, SCI WORLD J, P1, DOI 10.1100/2012/345983
   Talukdar Dibyendu, 2010, Chromosome Science, V13, P3
   Talukdar D, 2009, AFR J AGR RES, V4, P1549
   Toker C., MUTATION BREEDING, P209
   Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038
   Traverso JA, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00465
   Traverso N., 2013, OXID MED CELL LONGEV, V2013, DOI DOI 10.1155/2013/972913
   Turgut R, 1998, BIOL PLANTARUM, V41, P629, DOI 10.1023/A:1001817105685
   Vernoux T, 2000, PLANT CELL, V12, P97, DOI 10.1105/tpc.12.1.97
   Waghmare V. N., 2001, Indian Journal of Genetics and Plant Breeding, V61, P155
   Wang CQ, 2007, PLANT SCI, V172, P1, DOI 10.1016/j.plantsci.2006.06.015
   Williams L, 2005, CURR OPIN PLANT BIOL, V8, P582, DOI 10.1016/j.pbi.2005.09.010
   Xie YJ, 2014, J PLANT PHYSIOL, V171, P53, DOI 10.1016/j.jplph.2013.09.018
   Yamamoto E, 2000, BBA-GENE STRUCT EXPR, V1491, P333, DOI 10.1016/S0167-4781(00)00061-0
   Zou LP, 2011, PLANT PHYSIOL, V156, P1589, DOI 10.1104/pp.111.176016
NR 72
TC 5
Z9 5
U1 2
U2 5
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
AR 479180
DI 10.1155/2014/479180
PG 21
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AJ1RM
UT WOS:000337433400001
PM 24987684
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ghasemi, O
   Ghadimi, MR
   Ghasemi, V
AF Ghasemi, O.
   Ghadimi, M. R.
   Ghasemi, V.
TI RETRACTED: Adsorption and Inhibition Effect of Benzaldehyde Schiff Bases
   on Mild Steel Corrosion in 1 M HCl Medium (Retracted article. See vol.
   36, pg. 298, 2015)
SO JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Adsorption; AFM; corrosion inhibitor; Langmuir; Schiff base
ID HYDROCHLORIC-ACID SOLUTION; MODEL CHEMISTRY; TOTAL ENERGIES;
   SULFURIC-ACID; CARBON-STEEL; DENSITY; ATOMS
AB The corrosion inhibition of mild steel in 1 M HCl by N,N'-bis(n-hydroxybenzaldehyde)-1,3-propandiimine (n-HBP) and N,N'-bis(2-hydroxy, 3-methoxy benzaldehyde)-1,3-propandiimine (H2L2) Schiff bases has been investigated using potentiodynamic polarization, electrochemical impedance spectroscopy, and chronoamperometry measurements. The experimental results suggest that these compounds are excellent corrosion inhibitors for mild steel, and the inhibition efficiency increases with the increase in inhibitors concentration. Polarization curves reveal that all studied inhibitors are mixed type. The effect of temperature was studied in the range of 25 degrees C to 65 degrees C. The experimentally obtained adsorption isotherms follow the Langmuir equation. Activation and thermodynamic adsorption parameters were calculated. The morphology of mild steel surface was examined by AFM images.
C1 [Ghasemi, O.; Ghadimi, M. R.] Iranian Offshore Oil Co, Natl Iranian Oil Co, Tehran P1966664791, Iran.
   [Ghasemi, V.] Karaj Azad Univ, Ind Management Dept, Karaj, Iran.
RP Ghasemi, O (reprint author), Iranian Offshore Oil Co, Natl Iranian Oil Co, Valiasr St,Touraj St 3, Tehran P1966664791, Iran.
EM omidghasemi506@yahoo.com
CR Ahamad I, 2010, MATER CHEM PHYS, V124, P1155, DOI 10.1016/j.matchemphys.2010.08.051
   Ahamad I, 2010, CORROS SCI, V52, P933, DOI 10.1016/j.corsci.2009.11.016
   Aljourani J, 2009, CORROS SCI, V51, P1836, DOI 10.1016/j.corsci.2009.05.011
   Badiea AM, 2009, CORROS SCI, V51, P2231, DOI 10.1016/j.corsci.2009.06.011
   Bayol E, 2008, MATER CHEM PHYS, V112, P624, DOI 10.1016/j.matchemphys.2008.06.012
   Danaee I, 2013, J MOL STRUCT, V1035, P247, DOI 10.1016/j.molstruc.2012.11.013
   Danaee I, 2011, INT J HYDROGEN ENERG, V36, P12102, DOI 10.1016/j.ijhydene.2011.06.106
   Danaee I, 2008, J PHYS CHEM B, V112, P15933, DOI 10.1021/jp8069173
   Danaee I., 2011, ELECTROANAL CHEM, V662, P415, DOI DOI 10.1016/J.JELECHEM.2011.09.012
   Emregul KC, 2006, CORROS SCI, V48, P3243, DOI 10.1016/j.corsci.2005.11.016
   FAIRHURST SA, 1995, J CHEM SOC DALTON, P321, DOI 10.1039/dt9950000321
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Ghasemi O, 2013, J DISPER SCI TECHNOL, V34, P985, DOI 10.1080/01932691.2012.712006
   Ghasemi O, 2013, J MATER ENG PERFORM, V22, P1054, DOI 10.1007/s11665-012-0348-3
   Ghasemi O, 2013, J CENT SOUTH UNIV, V20, P301, DOI 10.1007/s11771-013-1488-9
   Hegazy MA, 2011, CORROS SCI, V53, P671, DOI 10.1016/j.corsci.2010.10.004
   Hegazy MA, 2009, CORROS SCI, V51, P2610, DOI 10.1016/j.corsci.2009.06.046
   herrag L., 2008, ELECTROCHIM ACTA, V26, P211
   Hossein SMA, 2008, MATER CORROS, V59, P41, DOI 10.1002/maco.200704101
   Issaadi S, 2011, CORROS SCI, V53, P1484, DOI 10.1016/j.corsci.2011.01.022
   Jacob KS, 2010, CORROS SCI, V52, P224, DOI 10.1016/j.corsci.2009.09.007
   Keles H, 2008, MATER CHEM PHYS, V112, P173, DOI 10.1016/j.matchemphys.2008.05.027
   Keles H, 2011, MATER CHEM PHYS, V130, P1317, DOI 10.1016/j.matchemphys.2011.09.022
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Li XH, 2005, APPL SURF SCI, V252, P1254, DOI 10.1016/j.apsusc.2005.02.118
   Lowmunkhong P, 2010, CORROS SCI, V52, P30, DOI 10.1016/j.corsci.2009.08.039
   MACDONALD JR, 1984, SOLID STATE IONICS, V13, P147
   Mallaiya K, 2011, ELECTROCHIM ACTA, V56, P3857, DOI 10.1016/j.electacta.2011.02.036
   Micahed MA, 2008, ELECTROCHIM ACTA, V53, P2877, DOI 10.1016/j.electacta.2007.10.070
   Negm NA, 2011, CORROS SCI, V53, P3566, DOI 10.1016/j.corsci.2011.06.029
   Negm NA, 2010, CORROS SCI, V52, P3523, DOI 10.1016/j.corsci.2010.07.001
   Obot IB, 2011, CURR APPL PHYS, V11, P382, DOI 10.1016/j.cap.2010.08.007
   PETERSSON GA, 1988, J CHEM PHYS, V89, P2193, DOI 10.1063/1.455064
   PETERSSON GA, 1991, J CHEM PHYS, V94, P6081, DOI 10.1063/1.460447
   Rayati S, 2010, CATAL COMMUN, V11, P792, DOI 10.1016/j.catcom.2010.02.017
   Solmaz R, 2011, MATER CHEM PHYS, V125, P796, DOI 10.1016/j.matchemphys.2010.09.056
   Solmaz R, 2010, CORROS SCI, V52, P3321, DOI 10.1016/j.corsci.2010.06.001
   Zhang F, 2011, ELECTROCHIM ACTA, V56, P1636, DOI 10.1016/j.electacta.2010.10.033
NR 38
TC 5
Z9 5
U1 2
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0193-2691
EI 1532-2351
J9 J DISPER SCI TECHNOL
JI J. Dispersion Sci. Technol.
PY 2014
VL 35
IS 8
BP 1143
EP 1154
DI 10.1080/01932691.2013.834263
PG 12
WC Chemistry, Physical
SC Chemistry
GA AJ4GS
UT WOS:000337632100010
DA 2018-12-27
ER

PT J
AU Oliveira, NRC
   Marques, SO
   Luciano, TF
   Pauli, JR
   Moura, LP
   Caperuto, E
   Pieri, BLS
   Engelmann, J
   Scaini, G
   Streck, EL
   Lira, FS
   Pinho, RA
   Ropelle, ER
   Silva, ASR
   De Souza, CT
AF Oliveira, Nara R. C.
   Marques, Scherolin O.
   Luciano, Thais F.
   Pauli, Jose R.
   Moura, Leandro P.
   Caperuto, Erico
   Pieri, Bruno L. S.
   Engelmann, Julia
   Scaini, Gisele
   Streck, Emilio L.
   Lira, Fabio S.
   Pinho, Ricardo A.
   Ropelle, Eduardo R.
   Silva, Adelino S. R.
   De Souza, Claudio T.
TI RETRACTED: Treadmill Training Increases SIRT-1 and PGC-1 alpha Protein
   Levels and AMPK Phosphorylation in Quadriceps of Middle-Aged Rats in an
   Intensity-Dependent Manner(Retracted article. See vol 0, artn no
   8287646, 2017)
SO MEDIATORS OF INFLAMMATION
LA English
DT Article; Retracted Publication
ID HUMAN SKELETAL-MUSCLE; MITOCHONDRIAL BIOGENESIS; CHRONIC ACTIVATION;
   OXIDATIVE STRESS; KINASE; EXERCISE; METABOLISM
AB The present study investigated the effects of running at 0.8 or 1.2 km/h on inflammatory proteins (i.e., protein levels of TNF-alpha, IL-1 beta, and NF-kappa B) and metabolic proteins (i.e., protein levels of SIRT-1 and PGC-1 alpha, and AMPK phosphorylation) in quadriceps of rats. Male Wistar rats at 3 (young) and 18 months (middle-aged rats) of age were divided into nonexercised (NE) and exercised at 0.8 or 1.2 km/h. The rats were trained on treadmill, 50 min per day, 5 days per week, during 8 weeks. Forty-eight hours after the last training session, muscles were removed, homogenized, and analyzed using biochemical and western blot techniques. Our results showed that: (a) running at 0.8 km/h decreased the inflammatory proteins and increased the metabolic proteins compared with NE rats; (b) these responses were lower for the inflammatory proteins and higher for the metabolic proteins in young rats compared with middle-aged rats; (c) running at 1.2 km/h decreased the inflammatory proteins and increased the metabolic proteins compared with 0.8 km/h; (d) these responses were similar between young and middle-aged rats when trained at 1.2 km. In summary, the age-related increases in inflammatory proteins, and the age-related declines in metabolic proteins can be reversed and largely improved by treadmill training.
C1 [Oliveira, Nara R. C.; Marques, Scherolin O.; Luciano, Thais F.; Pieri, Bruno L. S.; Engelmann, Julia; Scaini, Gisele; Streck, Emilio L.; Pinho, Ricardo A.; De Souza, Claudio T.] Extremo Catarinense Univ UNESC, Lab Exercise Biochem & Physiol, Hlth Sci Unit, BR-88806000 Criciuma, SC, Brazil.
   [Pauli, Jose R.; Ropelle, Eduardo R.] Univ Estadual Campinas, Fac Sci Appl, BR-13083872 Limeira, SP, Brazil.
   [Pauli, Jose R.; Moura, Leandro P.] Sao Paulo State Univ UNESP, Inst Biociencias, Post Grad Program Motr Sci, BR-13506900 Rio Claro, SP, Brazil.
   [Caperuto, Erico] Univ Sao Judas Tadeu, Human Movement Lab, BR-03166000 Sao Paulo, Brazil.
   [Lira, Fabio S.] Sao Paulo State Univ, Dept Phys Educ, Immunometab Res Grp, BR-19060900 Presidente Prudente, SP, Brazil.
   [Silva, Adelino S. R.] Univ Sao Paulo, Sch Phys Educ & Sport Ribeirao Preto, BR-14040907 Ribeirao Preto, SP, Brazil.
RP De Souza, CT (reprint author), Extremo Catarinense Univ UNESC, Lab Exercise Biochem & Physiol, Hlth Sci Unit, BR-88806000 Criciuma, SC, Brazil.
EM ctsouza@unesc.net
RI Pinho, Ricardo/G-2643-2012; Lira, Fabio/M-9922-2014
OI Pinho, Ricardo/0000-0003-3116-4553; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   Universidade do Extremo Sul Catarinense (UNESC)
FX This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and Universidade do Extremo Sul
   Catarinense (UNESC).
CR ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303
   Bayod S, 2012, EXP GERONTOL, V47, P925, DOI 10.1016/j.exger.2012.08.004
   Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340
   Betik AC, 2009, AM J PHYSIOL-REG I, V297, pR744, DOI 10.1152/ajpregu.90959.2008
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178
   Chabi B, 2008, AGING CELL, V7, P2, DOI 10.1111/j.1474-9726.2007.00347.x
   Della Gata P. A., BRAIN BEHAV IN PRESS
   Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017
   FISCHER JC, 1985, CLIN CHIM ACTA, V153, P23, DOI 10.1016/0009-8981(85)90135-4
   Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0
   Gianni P, 2004, EXP GERONTOL, V39, P1391, DOI 10.1016/j.exger.2004.06.002
   Hutter E, 2007, AGING CELL, V6, P245, DOI 10.1111/j.1474-9726.2007.00282.x
   Jensen TE, 2012, J PHYSIOL-LONDON, V590, P1069, DOI 10.1113/jphysiol.2011.224972
   Jorgensen SB, 2005, FASEB J, V19, P1146, DOI 10.1096/fj.04-3144fje
   Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Koltai E, 2012, AM J PHYSIOL-REG I, V303, pR127, DOI 10.1152/ajpregu.00337.2011
   Lanza IR, 2010, ACTA PHYSIOL, V199, P529, DOI 10.1111/j.1748-1716.2010.02124.x
   Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665
   Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268
   Ljubicic V, 2009, AGING CELL, V8, P394, DOI 10.1111/j.1474-9726.2009.00483.x
   McCarty MF, 2004, MED HYPOTHESES, V63, P334, DOI 10.1016/j.mehy.2004.01.043
   McKenna MJ, 2008, J APPL PHYSIOL, V104, P288, DOI 10.1152/japplphysiol.01037.2007
   Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107
   Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033
   Pardo PS, 2011, AGING-US, V3, P430, DOI 10.18632/aging.100312
   Picard M, 2011, AGING CELL, V10, P1047, DOI 10.1111/j.1474-9726.2011.00745.x
   Picard Martin, 2010, Aging Cell, V9, P1032, DOI 10.1111/j.1474-9726.2010.00628.x
   Porcu M, 2005, TRENDS PHARMACOL SCI, V26, P94, DOI 10.1016/j.tips.2004.12.009
   Rasmussen UF, 2003, EXP GERONTOL, V38, P877, DOI 10.1016/S0531-5565(03)00092-5
   Reznick RM, 2007, CELL METAB, V5, P151, DOI 10.1016/j.cmet.2007.01.008
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Sasaki T, 2006, AGING CELL, V5, P413, DOI 10.1111/j.1474-9726.2006.00235.x
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   SHEPHERD D, 1969, BIOCHEM J, V114, P597, DOI 10.1042/bj1140597
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Suwa M, 2008, METABOLISM, V57, P986, DOI 10.1016/j.metabol.2008.02.017
   Tilstra JS, 2012, J CLIN INVEST, V122, P2601, DOI 10.1172/JCI45785
   Tobina T, 2011, J SPORT MED PHYS FIT, V51, P683
   Winder WW, 1997, J APPL PHYSIOL, V82, P219
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599
NR 45
TC 15
Z9 15
U1 3
U2 13
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2014
AR 987017
DI 10.1155/2014/987017
PG 11
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA AJ6TN
UT WOS:000337829000001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jalooli, A
   Hussin, N
   Noor, RM
   Jung, JJ
AF Jalooli, Ali
   Hussin, Nornazlita
   Noor, Rafidah Md
   Jung, Jason J.
TI RETRACTED: Public Alerts on Landslide Natural Disaster Using Vehicular
   Communications (Retracted article. See pg. 23458, 2015)
SO INTERNATIONAL JOURNAL OF DISTRIBUTED SENSOR NETWORKS
LA English
DT Article; Retracted Publication
ID DEBRIS FLOWS; NETWORKS; SYSTEM
AB Landslide is a serious geological disaster that has severe impact on road safety, traffic flow efficiency, and environment preservation. It is important to develop a landslide warning system to recognize the sharpness of the landslide. However, there are several problems (e. g., the quality of the collected sensor data) to reduce the performance of the system (e. g., false alarms). Thereby, this study aims to design a landslide detection technique based on (i) motion detection and (ii) cross movement methods. They are applied in a detection phase, in order to identify the degree of landslide influence on road capacity by considering vehicles dimensions. Roadway landslide information dissemination (RLID) detects the landslide based on several image processing techniques, and determines the current condition by considering landslide level of road safety. As a result, landslide information can be disseminated to vehicles encountering the target area by using infrastructure-to-vehicle (I2V) and vehicle-to-vehicle (V2V) communications, in order to reduce crash likelihood and to increase traffic flow efficiency. Experimental results have shown that the proposed method in the detection phase can identify the degree of landslide influence on road capacity and monitor the level of effect on road safety.
C1 [Jalooli, Ali; Hussin, Nornazlita; Noor, Rafidah Md] Univ Malaya UM, Dept Comp Syst & Technol, Kuala Lumpur 50603, Malaysia.
   [Jung, Jason J.] Yeungnam Univ, Dept Comp Engn, Gyongsan 712749, South Korea.
RP Jung, JJ (reprint author), Yeungnam Univ, Dept Comp Engn, Gyongsan 712749, South Korea.
EM j2jung@gmail.com
OI Jung, Jason/0000-0003-0050-7445; Md Noor, Rafidah/0000-0001-6266-2390
FU Ministry of Higher Education (MOHE); University of Malaya
   [HIR-MOHEB00009]; BK21+ Program of the National Research Foundation
   (NRF) of Korea; Yeungnam University Research Grant
FX This work is supported by the Ministry of Higher Education (MOHE) and
   University of Malaya (Project no. HIR-MOHEB00009) and by the BK21+
   Program of the National Research Foundation (NRF) of Korea. Also, this
   work was supported by the 2013 Yeungnam University Research Grant.
CR Aleotti P, 2004, ENG GEOL, V73, P247, DOI 10.1016/j.enggeo.2004.01.007
   Angeli MG, 2000, ENG GEOL, V55, P133, DOI 10.1016/S0013-7952(99)00122-2
   [Anonymous], 2013, WEIGHTS DIMENSIONS V
   Badoux A, 2009, NAT HAZARDS, V49, P517, DOI 10.1007/s11069-008-9303-x
   Baum R, 2010, LANDSLIDES, V7, P259, DOI 10.1007/s10346-009-0177-0
   Berti M, 2012, J GEOPHYS RES-EARTH, V117, DOI 10.1029/2012JF002367
   Chandra S, 2003, J TRANSP ENG-ASCE, V129, P155, DOI 10.1061/(ASCE)0733-947X(2003)129:2(155)
   Cheng HT, 2011, MECH SYST SIGNAL PR, V25, P2020, DOI 10.1016/j.ymssp.2010.11.009
   COROMINAS J, 2000, P 8 INT S LANDSL CAR
   Filippi F, 2010, PROCD SOC BEHV, V2, P6332, DOI 10.1016/j.sbspro.2010.04.042
   Gao HX, 2007, ROCK SOIL MECH, V28, P1055
   Guzzetti F, 2007, METEOROL ATMOS PHYS, V98, P239, DOI 10.1007/s00703-007-0262-7
   Limlahapun P., 2009, P ICROS SICE INT JOI, P2639
   Lin YW, 2010, J INF SCI ENG, V26, P913
   Malet JP, 2005, NAT HAZARD EARTH SYS, V5, P71, DOI 10.5194/nhess-5-71-2005
   Marcucci E, 2008, TRANSPORTATION, V35, P269, DOI 10.1007/s11116-007-9147-3
   Pantelidis L, 2011, B ENG GEOL ENVIRON, V70, P395, DOI 10.1007/s10064-010-0328-5
   Saha AK, 2005, INT J GEOGR INF SCI, V19, P1149, DOI 10.1080/13658810500105887
   Sardari M, 2010, J INF SCI ENG, V26, P867
   Schoch E, 2008, IEEE COMMUN MAG, V46, P119, DOI 10.1109/MCOM.2008.4689254
   Stein W. J., 2007, MITIGATION STRATEGIE
   Wang HuiLi, 2012, Proceedings of the XVI International Silage Conference, Hameenlinna, Finland, 2-4 July 2012, P200
   Weiland R.J., 2000, TRANSPORTATION NEW M
   White I.D, 1992, ENV SYSTEMS INTRO TE
   Wieczorek GF, 2005, S-P BKS GEOPHYS SCI, P325
   Wilson R.C., 2012, LANDSLIDE HAZARD RIS, P493
NR 26
TC 3
Z9 3
U1 1
U2 23
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1550-1329
EI 1550-1477
J9 INT J DISTRIB SENS N
JI Int. J. Distrib. Sens. Netw.
PY 2014
AR 969864
DI 10.1155/2014/969864
PG 7
WC Computer Science, Information Systems; Telecommunications
SC Computer Science; Telecommunications
GA AJ1WY
UT WOS:000337447800001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Berg, M
   Ejnell, H
   Kovacs, A
   Nayakawde, N
   Patil, PB
   Joshi, M
   Aziz, L
   Radberg, G
   Hajizadeh, S
   Olausson, M
   Sumitran-Holgersson, S
AF Berg, Malin
   Ejnell, Hasse
   Kovacs, Aniko
   Nayakawde, Nikhil
   Patil, Pradeep B.
   Joshi, Meghnad
   Aziz, Luaay
   Radberg, Goran
   Hajizadeh, Shahin
   Olausson, Michael
   Sumitran-Holgersson, Suchitra
TI RETRACTED: Replacement of a Tracheal Stenosis with a Tissue-Engineered
   Human Trachea Using Autologous Stem Cells: A Case Report (Retracted
   article. See vol. 22, pg. 829, 2016)
SO TISSUE ENGINEERING PART A
LA English
DT Article; Retracted Publication
ID CROSS-MATCH TEST; TRANSPLANTATION
AB Cell-based therapies involving tissue engineering represent interesting and potentially important strategies for the treatment of patients with various disorders. In this study, using a detergent-enzymatic method, we prepared an intact three-dimensional scaffold of an extracellular matrix derived from a human cadaver donor trachea, which we repopulated with autologous stem cells and implanted into a 76-year-old patient with tracheal stenosis including the lower part of the larynx. Although the graft provided the patient with an open airway, a week after the surgery, the mucous membrane of the graft was covered by a 1-2mm thick fungal infection, which was treated with local and systemic antifungal therapy. The airway lumen was postoperatively controlled by fiber endoscopy and found stable and sufficient. However, after 23 days, the patient died due to cardiac arrest but with a patent, open, and stable tracheal transplant and intact anastomoses. Histopathological results of the transplanted tracheal graft during autopsy showed a squamous but not ciliated epithelium, neovascularization, bundles of alpha-sma-positive muscle cells, serous glands, and nerve fibers with S-100-positive nerve cells in the submucosa and intact chondrocytes in the cartilage. Our findings suggest that although autologous stem cells-engineered tracheal matrices may represent a tool for clinical tracheal replacement, further preclinical studies are required for generating functional airway grafts and long-term effects of such grafts.
C1 [Berg, Malin; Ejnell, Hasse; Nayakawde, Nikhil; Patil, Pradeep B.; Aziz, Luaay] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Otolaryngol Head & Neck Surg, Gothenburg, Sweden.
   [Kovacs, Aniko; Hajizadeh, Shahin] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Pathol, Gothenburg, Sweden.
   [Nayakawde, Nikhil; Patil, Pradeep B.; Joshi, Meghnad; Olausson, Michael; Sumitran-Holgersson, Suchitra] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Transplantat Surg, Gothenburg, Sweden.
   [Radberg, Goran] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Thorac Surg, Gothenburg, Sweden.
RP Sumitran-Holgersson, S (reprint author), Sahlgrenska Sci Pk, Lab Transplantat & Regenerat Med, Medicinaregatan 8AS, S-41346 Gothenburg, Sweden.
EM suchitra.holgersson@gu.se
RI Olausson, Michael/E-5822-2012
OI Olausson, Michael/0000-0002-3949-9430
FU Government LUA ALF
FX This study was financed by the Government LUA ALF grants to S.S.H. and
   M.O.
CR Alam M, 2011, AM J TRANSPLANT, V11, P1488, DOI 10.1111/j.1600-6143.2011.03598.x
   Alheim M, 2010, TISSUE ANTIGENS, V75, P269, DOI 10.1111/j.1399-0039.2009.01439.x
   Badylak SF, 2007, BIOMATERIALS, V28, P3587, DOI 10.1016/j.biomaterials.2007.04.043
   Baiguera S, 2010, BIOMATERIALS, V31, P8931, DOI 10.1016/j.biomaterials.2010.08.005
   Breimer ME, 2009, TRANSPLANTATION, V87, P549, DOI 10.1097/TP.0b013e3181949d4e
   Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057
   Delaere P, 2010, NEW ENGL J MED, V362, P138, DOI 10.1056/NEJMoa0810653
   Grillo HC, 2002, ANN THORAC SURG, V73, P1995, DOI 10.1016/S0003-4975(02)03564-6
   Jungebluth P, 2011, LANCET, V378, P1997, DOI 10.1016/S0140-6736(11)61715-7
   Jungebluth P, 2009, J THORAC CARDIOV SUR, V138, P586, DOI 10.1016/j.jtcvs.2008.09.085
   Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6
   Mark EJ, 2008, AM J SURG PATHOL, V32, P1138, DOI 10.1097/PAS.0b013e3181648d4a
   Shieh SJ, 2005, SURGERY, V137, P1, DOI 10.1016/j.surg.2004.04.002
   Sprangers B, 2011, TRANSPLANTATION, V92, P251, DOI 10.1097/TP.0b013e31822094d1
   Suh SW, 2001, ASAIO J, V47, P496
NR 15
TC 32
Z9 35
U1 2
U2 23
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD JAN
PY 2014
VL 20
IS 1-2
BP 389
EP 397
DI 10.1089/ten.tea.2012.0514
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA AI9TO
UT WOS:000337280600036
PM 24004248
DA 2018-12-27
ER

PT S
AU Tang, XJ
   Wang, ZQ
   Wang, XT
   Meng, XN
   Lv, HQ
AF Tang, Xiaojun
   Wang, Zhenqing
   Wang, Xintao
   Meng, Xiangnan
   Lv, Hongqing
BE Milazzo, A
   Aliabadi, MH
TI RETRACTED: Effects of ceramic particle reinforcement distribution on the
   penetration of FGM armor (Retracted Article)
SO ADVANCES IN FRACTURE AND DAMAGE MECHANICS XII
SE Key Engineering Materials
LA English
DT Proceedings Paper; Retracted Publication
CT 12th International Conference on Fracture and Damage Mechanics (FDM
   2013)
CY SEP 17-19, 2013
CL Sardinia, ITALY
DE functionally graded material armor; two power-law function;
   anti-penetration; metal-ceramic composite
AB In this paper, ANSYS/LS-DYNA software is used to simulate the process of armor-piercing projectile vertical penetrate metal matrix functionally graded material (FGM) armor reinforced by ceramic particles with the distribution of two power-law function along the thickness direction. The ceramic particle volume fraction varies from layer to layer along the armor thickness while ceramic particles' total volume fraction remains unchanged. Four different ceramic particles distribution armors with the same total volume fraction are simulated. And the effects of the two power-law function types on the penetration of functionally graded material armor are investigated. The results show that the ballistic resistance of ceramic particle reinforced functionally graded armors is better than homogeneous ceramic particle reinforced armor with the same total volume fraction. Meanwhile, the larger the ceramic particles volume fraction on target surface is, the better ballistic resistance of functionally graded armors will be.
C1 [Tang, Xiaojun; Wang, Zhenqing; Wang, Xintao; Meng, Xiangnan; Lv, Hongqing] Harbin Engn Univ, Coll Aerosp & Civil Engn, Harbin 150001, Peoples R China.
RP Tang, XJ (reprint author), Harbin Engn Univ, Coll Aerosp & Civil Engn, Harbin 150001, Peoples R China.
EM tangxiaojun2214@163.cm; wangzhenqing@hrbeu.edu.cn; daibiao3@163.com;
   mengxiangnan214@yahoo.com.cn; lvhongqing@hrbeu.edu.cn
CR Bruek H A, 2000, INT J SOLIDS STRUCT, V37, P6383
   Chakraborty A, 2003, INT J SOLIDS STRUCT, V40, P2421, DOI 10.1016/S0020-7683(03)00029-5
   JIANG Bao-quan, 2005, EXPLOSION SHOCK WAVE, V256, P493
   JIANG Zhi-gang, 2010, ACTA ARMAMENTARII, V315, P603
   LI Yu-long, 2005, ACTA MATERIAE COMPOS, V224, P58
NR 5
TC 0
Z9 0
U1 2
U2 19
PU TRANS TECH PUBLICATIONS LTD
PI STAFA-ZURICH
PA LAUBLSRUTISTR 24, CH-8717 STAFA-ZURICH, SWITZERLAND
SN 1013-9826
J9 KEY ENG MATER
PY 2014
VL 577-578
BP 577
EP 580
DI 10.4028/www.scientific.net/KEM.577-578.577
PG 4
WC Engineering, Mechanical; Materials Science, Multidisciplinary; Mechanics
SC Engineering; Materials Science; Mechanics
GA BA5IR
UT WOS:000336693900145
DA 2018-12-27
ER

PT J
AU Xu, JN
   Liu, X
   Wang, H
   Hu, CM
   Luo, QH
   Zhou, QQ
AF Xu, J. N.
   Liu, X.
   Wang, H.
   Hu, C. M.
   Luo, Q. H.
   Zhou, Q. Q.
TI RETRACTED: Effects of destrin pathway mutations on the gene expression
   profile (Retracted article. See vol. 13, pg. 10599, 2014)
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article; Retracted Publication
DE ADF/Cofilin; Cytoskeleton dynamics; Pathway crosstalk
ID ACTIN CYTOSKELETON REORGANIZATION; SERUM RESPONSE FACTOR; DEPOLYMERIZING
   FACTOR; EPITHELIAL-CELLS; BETA; MICE; PHOSPHOINOSITIDES; CROSSTALK;
   REGULATOR; PROTEIN
AB This study aimed to explore the interaction and crosstalk between pathways in response to destrin mutations. All the pathways from the MINT database were downloaded, a protein-protein interaction network was then constructed, and the crosstalk between pathways was investigated, in particular, the overlap of 2 significant pathway analysis results. As expected, the results showed that regulation of the actin cytoskeleton was the significant pathway of destrin mutations in mice. Further analysis indicated that 28 significant pathways cross-talked with the pathway regulating the actin cytoskeleton. Importantly, 3 pathways, including regulation of actin cytoskeleton pathway, pathways in cancer, and the B cell receptor signaling pathway were linked by inositol phosphate metabolism based on crosstalk analysis of Gene Ontology relationships among pathways. All of these pathways have been demonstrated to participate in cytoskeleton dynamics. These findings might provide valuable insights into cytoskeleton dynamic abnormalities in destrin mutations of corneal diseases.
C1 [Xu, J. N.; Liu, X.; Wang, H.; Hu, C. M.; Luo, Q. H.; Zhou, Q. Q.] Third Mil Med Univ, Southwest Hosp, Dept Vis, Chongqing, Peoples R China.
RP Wang, H (reprint author), Third Mil Med Univ, Southwest Hosp, Dept Vis, Chongqing, Peoples R China.
EM wanghuiwhdr@hotmail.com
CR Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Aranda B, 2010, NUCLEIC ACIDS RES, V38, pD525, DOI 10.1093/nar/gkp878
   Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353
   Ceol A, 2009, NUCLEIC ACIDS RES, V37, pD532
   Cursiefen C, 2005, AM J PATHOL, V166, P1367, DOI 10.1016/S0002-9440(10)62355-3
   Dawson DG, 2009, CORNEAL SURG THEORY, P57
   Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015-007-0004-8
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ikeda S, 2003, HUM MOL GENET, V12, P1029, DOI 10.1093/hmg/ddg112
   Ispanovic E, 2006, AM J PHYSIOL-CELL PH, V291, pC579, DOI 10.1152/ajpcell.00300.2005
   Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42
   Li Y, 2008, BIOINFORMATICS, V24, P1442, DOI 10.1093/bioinformatics/btn200
   Li ZJ, 2009, CURR EYE RES, V34, P646, DOI 10.1080/02713680903007139
   Liu ZP, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S11
   Maciver SK, 2002, GENOME BIOL, V3
   Miano JM, 2008, PHYSIOL GENOMICS, V34, P6, DOI 10.1152/physiolgenomics.90243.2008
   Miano JM, 2007, AM J PHYSIOL-CELL PH, V292, pC70, DOI 10.1152/ajpcell.00386.2006
   Moustakas A, 2008, FEBS LETT, V582, P2051, DOI 10.1016/j.febstet.2008.03.027
   Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Saarikangas J, 2010, PHYSIOL REV, V90, P259, DOI 10.1152/physrev.00036.2009
   Samaj J, 2004, J EXP BOT, V55, P189, DOI 10.1093/jxb/erh012
   Sharma S, 2009, J IMMUNOL, V182, P329, DOI 10.4049/jimmunol.182.1.329
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Stark C, 2011, NUCLEIC ACIDS RES, V39, pD698, DOI 10.1093/nar/gkq1116
   Tokuraku K, 2001, BIOCHEM CELL BIOL, V79, P773, DOI 10.1139/bcb-79-6-773
   Van Rheenen J, 2007, J CELL BIOL, V179, P1247, DOI 10.1083/jcb.200706206
   Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200
   Verdoni AM, 2008, PHYSIOL GENOMICS, V34, P9, DOI 10.1152/physiolgenomics.00285.2007
   Verdoni AM, 2010, GENETICS, V186, P147, DOI 10.1534/genetics.110.117309
   Zhang W, 2008, MOL VIS, V14, P1929
   Zhao HX, 2010, BIOPHYS J, V98, P2327, DOI 10.1016/j.bpj.2010.01.046
NR 32
TC 0
Z9 0
U1 2
U2 6
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2014
VL 13
IS 2
BP 2628
EP 2637
DI 10.4238/2014.April.8.5
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AI3AC
UT WOS:000336729500031
PM 24782051
OA Bronze
DA 2018-12-27
ER

PT J
AU Tseng, PY
   Lu, WC
   Hsieh, MJ
   Chien, SY
   Chen, MK
AF Tseng, Pao-Yu
   Lu, Wei-Cheng
   Hsieh, Ming-Ju
   Chien, Su-Yu
   Chen, Mu-Kuan
TI RETRACTED: Tanshinone IIA Induces Apoptosis in Human Oral Cancer KB
   Cells through a Mitochondria-Dependent Pathway (Retracted article. See
   vol. 0, art no 949485, 2017)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID SALVIA-MILTIORRHIZA BUNGE; NECK-CANCER; ADVANCED HEAD;
   RADIATION-THERAPY; PROTEIN FAMILY; PHASE-III; DEATH; CHEMORADIOTHERAPY;
   FLUOROURACIL; CHEMOTHERAPY
AB Tanshinone IIA (Tan IIA), an active phytochemical in the dried root of Salvia miltiorrhiza Bunge, has shown an antiproliferative activity on various human cancer cell lines including nasopharyngeal carcinoma cells. However, the effects of Tan IIA on human oral cancer cells are still unknown. This study aimed to investigate the antiproliferative effects of Tan IIA on human oral cancer KB cells and explored the possible underlying mechanism. Treatment of KB cells with Tan IIA suppressed cell proliferation/viability and induced cell death in a dose-dependent manner through sulforhodamine B colorimetric assay. Observation of cell morphology revealed the involvement of apoptosis in the Tan IIA-induced growth inhibition on KB cells. Cell cycle analysis showed a cell cycle arrest in G(2)/M phase on Tan IIA-treated cells. The dissipation of mitochondrial membrane potential observed by flow cytometry and the expression of activated caspases with the cleaved poly (ADP-ribose) polymerase under immunoblotting analysis indicated that Tan IIA-induced apoptosis in KB cells was mediated through the mitochondria-dependent caspase pathway. These observations suggested that Tan IIA could be a potential anticancer agent for oral cancer.
C1 [Tseng, Pao-Yu; Chen, Mu-Kuan] Changhua Christian Hosp, Dept Otorhinolaryngol Head & Neck Surg, Changhua 500, Taiwan.
   [Lu, Wei-Cheng; Hsieh, Ming-Ju] Changhua Christian Hosp, Canc Res Ctr, Changhua 500, Taiwan.
   [Hsieh, Ming-Ju; Chen, Mu-Kuan] Chung Shan Med Univ, Inst Med, Taichung 500, Taiwan.
   [Hsieh, Ming-Ju] Chung Shan Med Univ, Sch Optometry, Taichung 402, Taiwan.
   [Chien, Su-Yu] Changhua Christian Hosp, Dept Pharm, 135 Nanxiao St, Changhua 500, Taiwan.
   [Chien, Su-Yu] China Med Univ, Sch Pharm, Taichung 404, Taiwan.
   [Chien, Su-Yu] Chang Jung Christian Univ, Coll Hlth Sci, Tainan 711, Taiwan.
RP Chien, SY (reprint author), Changhua Christian Hosp, Dept Pharm, 135 Nanxiao St, Changhua 500, Taiwan.
EM 2655@cch.org.tw; 53780@cch.org.tw
FU Changhua Christian Hospital Research
FX This research was financially supported by Changhua Christian Hospital
   Research grant.
CR Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0
   Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008
   Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103
   Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233
   Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269
   Chen Ren-zhao, 2007, Dongbei Shida Xuebao (Ziran Kexue Ban), V39, P1
   Clarke SJ, 1999, CLIN PHARMACOKINET, V36, P99, DOI 10.2165/00003088-199936020-00002
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Hitt R, 2005, J CLIN ONCOL, V23, P8636, DOI 10.1200/JCO.2004.00.1990
   Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470-2045(03)01277-4
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Kies MS, 2010, J CLIN ONCOL, V28, P8, DOI 10.1200/JCO.2009.23.0425
   KUMAR N, 1981, J BIOL CHEM, V256, P435
   Levine B, 2009, CELL DEATH DIFFER, V16, P1, DOI 10.1038/cdd.2008.139
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Li YI, 2008, LIFE SCI, V83, P557, DOI 10.1016/j.lfs.2008.08.003
   Lorch JH, 2011, LANCET ONCOL, V12, P153, DOI 10.1016/S1420-2045(10)20279-5
   McDonald ER, 2000, INT J ONCOL, V16, P871
   Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Nutting CM, 2008, NEW ENGL J MED, V358, P1076
   Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014
   Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956
   Psyrri A, 2004, J CLIN ONCOL, V22, P3061, DOI 10.1200/JCO.2004.01.108
   Rinehart J, 2005, OTOLARYNG HEAD NECK, V132, P69, DOI 10.1016/j.otohns.2004.08.006
   Sairafianpour M, 2001, J NAT PROD, V64, P1398, DOI 10.1021/np010032f
   Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594
   Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208
   Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019
   Sung HJ, 1999, EXP MOL MED, V31, P174, DOI 10.1038/emm.1999.28
   Wang XD, 2001, GENE DEV, V15, P2922
   Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002
   Yang LJ, 2005, J BIOMED SCI, V12, P347, DOI 10.1007/s11373-005-0973-z
   Yuan SL, 2004, WORLD J GASTROENTERO, V10, P2024, DOI 10.3748/wjg.v10.i14.2024
   Yuan Shulan, 2002, Journal of West China University of Medical Sciences, V33, P84
   Zhou LL, 2008, LIFE SCI, V83, P394, DOI 10.1016/j.lfs.2008.07.011
   Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0
NR 37
TC 8
Z9 8
U1 4
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
AR 540516
DI 10.1155/2014/540516
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AH7MJ
UT WOS:000336317100001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yang, CL
   Hou, CY
   Zhang, HP
   Wang, DW
   Ma, Y
   Zhang, YQ
   Xu, XY
   Bi, ZG
   Geng, S
AF Yang, Chenglin
   Hou, Chunying
   Zhang, Hepeng
   Wang, Dewei
   Ma, Yan
   Zhang, Yunqi
   Xu, Xiaoyan
   Bi, Zhenggang
   Geng, Shuo
TI RETRACTED: miR-126 Functions as a Tumor Suppressor in Osteosarcoma by
   Targeting Sox2 (Retracted article. See vol. 19, 2018)
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article; Retracted Publication
DE tumor suppressor; miR-126; sex-determining region Y-box 2; osteosarcoma
ID CELL-PROLIFERATION; INITIATING CELLS; SELF-RENEWAL; CANCER; EXPRESSION;
   MICRORNAS; SURVIVAL; SRY
AB Osteosarcoma (OS) is the most common malignant bone tumor in children and young adults, the early symptoms and signs of which are non-specific. The discovery of microRNAs (miRNAs) provides a new avenue for the early diagnosis and treatment of OS. miR-126 has been reported to be highly expressed in vascularized tissues, and is recently widely studied in cancers. Herein, we explored the expression and significance of miR-126 in OS. Using TaqMan RT-PCR analysis, we analyzed the expression of miR-126 in 32 paired OS tumor tissues and 4 OS cell lines and found that miR-126 was consistently under-expressed in OS tissues and cell lines compared with normal bone tissues and normal osteoblast cells (NHOst), respectively. As miR-126 is significantly decreased in OS tissues and cell lines, we sought to compensate for its loss through exogenous transfection into MG-63 cells with a miR-126 mimic. Ectopic expression of miR-126 inhibited cell proliferation, migration and invasion, and induced apoptosis of MG-63 cells. Moreover, bioinformatic prediction suggested that the sex-determining region Y-box 2 (Sox2) is a target gene of miR-126. Using mRNA and protein expression analysis, luciferase assays and rescue assays, we demonstrate that restored expression of Sox2 dampened miR-126-mediated suppression of tumor progression, which suggests the important role of miR-126/Sox2 interaction in tumor progression. Taken together, our data indicate that miR-126 functions as a tumor suppressor in OS, which exerts its activity by suppressing the expression of Sox2.
C1 [Yang, Chenglin; Hou, Chunying; Zhang, Hepeng; Wang, Dewei; Ma, Yan; Zhang, Yunqi; Xu, Xiaoyan; Bi, Zhenggang; Geng, Shuo] Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Harbin 150001, Heilongjiang, Peoples R China.
RP Geng, S (reprint author), Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Harbin 150001, Heilongjiang, Peoples R China.
EM yangchenglindoctor@gmail.com; chunying_hou@126.com;
   zhanghepengdoctor@gmail.com; wdw19761224@gmail.com;
   mayandoctor@gmail.com; zhangyunqidoctor@gmail.com; xxydoctor@gmail.com;
   bizhenggang@163.com; shuogeng.hmu@gmail.com
FU Fundamental Research Funds for the Returnees of Education Department of
   Heilongjiang Province of China [1253HQ003]; National Natural Science
   Foundation of China [81271984]
FX This research was supported through the Fundamental Research Funds for
   the Returnees of Education Department of Heilongjiang Province of China
   (1253HQ003) and National Natural Science Foundation of China (81271984).
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405
   BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0
   Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131
   Carroll KL, 1999, J PEDIATR ORTHOPED, V19, P785, DOI 10.1097/00004694-199911000-00017
   Collignon J, 1996, DEVELOPMENT, V122, P509
   Deng ZQ, 2013, J BIOL CHEM, V288, P319, DOI 10.1074/jbc.M112.418830
   Guo XD, 2013, CELL RES, V23, P142, DOI 10.1038/cr.2012.180
   Gurtan AM, 2013, J MOL BIOL, V425, P3582, DOI 10.1016/j.jmb.2013.03.007
   Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105
   Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960
   Jia XP, 2011, J MOL CELL BIOL, V3, P230, DOI 10.1093/jmcb/mjr002
   Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6
   Leonardo TR, 2012, NAT CELL BIOL, V14, P1114, DOI 10.1038/ncb2613
   Li J, 2013, CANCER LETT, V329, P84, DOI 10.1016/j.canlet.2012.10.019
   Lin F, 2012, CELL PROLIFERAT, V45, P207, DOI 10.1111/j.1365-2184.2012.00812.x
   Liu B, 2009, LUNG CANCER, V66, P169, DOI 10.1016/j.lungcan.2009.01.010
   Meister J, 2010, THESCIENTIFICWORLDJO, V10, P2090, DOI 10.1100/tsw.2010.198
   Miao JL, 2013, TUMOR BIOL, V34, P2093, DOI 10.1007/s13277-013-0940-7
   Namlos HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048086
   Nikolic Iva, 2010, J Angiogenes Res, V2, P9, DOI 10.1186/2040-2384-2-9
   Otsubo T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016617
   Pierz KA, 2001, J PEDIATR ORTHOPED, V21, P412, DOI 10.1097/00004694-200105000-00028
   Rabinowicz R, 2012, J PEDIAT HEMATOL ONC, V34, P421, DOI 10.1097/MPH.0b013e31826157ce
   Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z
   Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007
   Song L, 2013, ARCH BIOCHEM BIOPHYS, V535, P128, DOI 10.1016/j.abb.2013.04.001
   Sun C, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0503-1
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang ZG, 2014, PEDIATR BLOOD CANCER, V61, P206, DOI 10.1002/pbc.24763
   Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409
   Xu JQ, 2013, TUMOR BIOL, V34, P3871, DOI 10.1007/s13277-013-0974-x
   YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635
   Zhang YS, 2012, J BIOL CHEM, V287, P41514, DOI 10.1074/jbc.M112.404871
NR 34
TC 35
Z9 37
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2014
VL 15
IS 1
BP 423
EP 437
DI 10.3390/ijms15010423
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA AG9YM
UT WOS:000335776100024
PM 24384842
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Asabella, AN
   Cascini, GL
   Altini, C
   Paparella, D
   Notaristefano, A
   Rubini, G
AF Asabella, Artor Niccoli
   Cascini, Giuseppe Lucio
   Altini, Corinna
   Paparella, Domenico
   Notaristefano, Antonio
   Rubini, Giuseppe
TI RETRACTED: The Copper Radioisotopes: A Systematic Review with Special
   Interest to Cu-64 (Retracted article. See art no 3860745, 2018)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review; Retracted Publication
ID INDUCED NUCLEAR-REACTIONS; EXCITATION-FUNCTIONS; IN-VIVO; ZN-62/CU-62
   GENERATOR; MYOCARDIAL-ISCHEMIA; PROTON IRRADIATION; MEDICAL CYCLOTRON;
   ANION-EXCHANGE; IMAGING AGENT; TUMOR HYPOXIA
AB Copper (Cu) is an important trace element in humans; it plays a role as a cofactor for numerous enzymes and other proteins crucial for respiration, iron transport, metabolism, cell growth, and hemostasis. Natural copper comprises two stable isotopes, Cu-63 and Cu-65, and 5 principal radioisotopes for molecular imaging applications (Cu-60, Cu-61, Cu-62, and Cu-64) and in vivo targeted radiation therapy (Cu-64 and Cu-67). The two potential ways to produce Cu radioisotopes concern the use of the cyclotron or the reactor. A noncopper target is used to produce noncarrier-added Cu thanks to a chemical separation from the target material using ion exchange chromatography achieving a high amount of radioactivity with the lowest possible amount of nonradioactive isotopes. In recent years, Cu isotopes have been linked to antibodies, proteins, peptides, and nanoparticles for preclinical and clinical research; pathological conditions that influence Cu metabolism such as Menkes syndrome, Wilson disease, inflammation, tumor growth, metastasis, angiogenesis, and drug resistance have been studied. We aim to discuss all Cu radioisotopes application focusing on Cu-64 and in particular its form (CuCl2)-Cu-64 that seems to be the most promising for its half-life, radiation emissions, and stability with chelators, allowing several applications in oncological and nononcological fields.
C1 [Asabella, Artor Niccoli; Altini, Corinna; Paparella, Domenico; Notaristefano, Antonio; Rubini, Giuseppe] Univ Bari Aldo Moro, I-70124 Bari, Italy.
   [Cascini, Giuseppe Lucio] Univ Catanzaro Magna Graecia, I-88100 Catanzaro, Italy.
RP Asabella, AN (reprint author), Univ Bari Aldo Moro, Piazza G Cesare 11, I-70124 Bari, Italy.
EM artor.niccoliasabella@uniba.it
RI Niccoli Asabella, Artor/M-1745-2015
OI Niccoli Asabella, Artor/0000-0002-1227-029X; Rubini,
   Giuseppe/0000-0003-1972-3308; cascini, giuseppe
   lucio/0000-0003-0332-2606
CR Al Rayyes AH, 2011, NUKLEONIKA, V56, P259
   Alliot C, 2011, RADIOCHIM ACTA, V99, P627, DOI 10.1524/ract.2011.1821
   Anderson CJ, 2009, CANCER BIOTHER RADIO, V24, P379, DOI 10.1089/cbr.2009.0674
   Asad AH, 2012, AIP CONF PROC, V1509, P91, DOI 10.1063/1.4773947
   Basken NE, 2008, NUCL MED BIOL, V35, P281, DOI 10.1016/j.nucmedbio.2007.11.009
   Belicchi-Ferrari M, 2005, J MED CHEM, V48, P1671, DOI 10.1021/jm049529n
   Bertini I, 2010, COORDIN CHEM REV, V254, P506, DOI 10.1016/j.ccr.2009.07.024
   Bourgeois M, 2011, NUCL MED REV, V14, P90, DOI 10.5603/NMR.2011.00022
   Cafagna D, 2012, RADIOL MED, V117, P293, DOI 10.1007/s11547-011-0708-3
   Chao KSC, 2001, INT J RADIAT ONCOL, V49, P1171, DOI 10.1016/S0360-3016(00)01433-4
   Ciccone MM, 2011, VASC HEALTH RISK MAN, V7, P129, DOI 10.2147/VHRM.S16582
   Das SS, 2012, APPL RADIAT ISOTOPES, V70, P365, DOI 10.1016/j.apradiso.2011.10.011
   Dehdashti F, 2003, EUR J NUCL MED MOL I, V30, P844, DOI 10.1007/s00259-003-1130-4
   Dolley SG, 2006, CZECH J PHYS, V56, pD539
   Donsante A, 2010, AM J MED GENET A, V152A, P2529, DOI 10.1002/ajmg.a.33632
   Ehst D. A., AIP C P, V1509, P157
   Evangelista L, 2013, CURR RADIOPHARM, V6, P117, DOI 10.2174/18744710113069990020
   Ferreira CL, 2010, EUR J NUCL MED MOL I, V37, P2117, DOI 10.1007/s00259-010-1506-1
   Fodero-Tavoletti MT, 2010, J ALZHEIMERS DIS, V20, P49, DOI 10.3233/JAD-2010-1359
   Fujibayashi Y, 1999, NUCL MED BIOL, V26, P117, DOI 10.1016/S0969-8051(98)00049-3
   Fujibayashi Y, 1997, J NUCL MED, V38, P1155
   Fukumura T, 2004, RADIOCHIM ACTA, V92, P209, DOI 10.1524/ract.92.4.209.35593
   Fukumura T, 2006, NUCL MED BIOL, V33, P821, DOI 10.1016/j.nucmedbio.2006.05.003
   Gadaleta CD, 2013, RADIOLOGY, V267, P627, DOI 10.1148/radiol.12120198
   Hancock CN, 2011, FREE RADICAL BIO MED, V50, P110, DOI 10.1016/j.freeradbiomed.2010.10.696
   Hao GY, 2009, APPL RADIAT ISOTOPES, V67, P511, DOI 10.1016/j.apradiso.2008.12.004
   Holschneider DP, 2004, NEUROSCI BIOBEHAV R, V28, P449, DOI 10.1016/j.neubiorev.2004.06.007
   Ikawa M, 2011, NUCL MED BIOL, V38, P945, DOI 10.1016/j.nucmedbio.2011.02.016
   Ikawa M, 2009, MITOCHONDRION, V9, P144, DOI 10.1016/j.mito.2009.01.011
   Inoue KI, 2009, MEDIAT INFLAMM, DOI 10.1155/2009/101659
   Isozaki M, 2011, EUR J NUCL MED MOL I, V38, P1075, DOI 10.1007/s00259-011-1734-z
   Katabuchi T, 2008, J RADIOANAL NUCL CH, V277, P467, DOI 10.1007/s10967-007-7144-9
   Kozempel J, 2007, RADIOCHIM ACTA, V95, P75, DOI 10.1524/ract.2007.95.2.75
   Kozempel J, 2012, RADIOCHIM ACTA, V100, P419, DOI 10.1524/ract.2012.1939
   Locke LW, 2009, J NUCL MED, V50, P790, DOI 10.2967/jnumed.108.056127
   Ma DS, 2002, NUCL MED BIOL, V29, P91, DOI 10.1016/S0969-8051(01)00287-6
   Maiti M, 2011, APPL RADIAT ISOTOPES, V69, P316, DOI 10.1016/j.apradiso.2010.11.019
   McCarthy DW, 1999, NUCL MED BIOL, V26, P351, DOI 10.1016/S0969-8051(98)00113-9
   McCarthy DW, 1997, NUCL MED BIOL, V24, P35, DOI 10.1016/S0969-8051(96)00157-6
   Medvedev DG, 2012, APPL RADIAT ISOTOPES, V70, P423, DOI 10.1016/j.apradiso.2011.10.007
   Nahrendorf M, 2008, CIRCULATION, V117, P379, DOI 10.1161/CIRCULATIONAHA.107.741181
   Niccoli-Asabella Artor, 2013, Recenti Progressi in Medicina, V104, P73, DOI 10.1701/1241.13709
   Niccoli-Asabella A, 2013, NUCL MED COMMUN, V34, P32, DOI 10.1097/MNM.0b013e32835ae545
   Niccoli-Asabella A, 2011, HELL J NUCL MED, V14, P311
   Obata A, 2003, NUCL MED BIOL, V30, P535, DOI 10.1016/S0969-8051(03)00024-6
   Packard AB, 2002, NUCL MED BIOL, V29, P289, DOI 10.1016/S0969-8051(02)00285-8
   Peng FY, 2006, J NUCL MED, V47, P1649
   Pfeifer A, 2012, J NUCL MED, V53, P1207, DOI 10.2967/jnumed.111.101469
   PIEL H, 1992, RADIOCHIM ACTA, V57, P1
   Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3
   Rowshanfarzad P, 2006, APPL RADIAT ISOTOPES, V64, P1563, DOI 10.1016/j.apradiso.2005.11.012
   Shokeen M, 2009, ACCOUNTS CHEM RES, V42, P832, DOI 10.1021/ar800255q
   Smith NA, 2012, APPL RADIAT ISOTOPES, V70, P2377, DOI 10.1016/j.apradiso.2012.07.009
   Smith SV, 1996, RADIOCHIM ACTA, V75, P65
   Sprague JE, 2007, J NUCL MED, V48, P311
   Srivastava SC, 2012, SEMIN NUCL MED, V42, P151, DOI 10.1053/j.semnuclmed.2011.12.004
   Stoll T, 2002, RADIOCHIM ACTA, V90, P309, DOI 10.1524/ract.2002.90.6.309
   Subramanian Indu, 2002, Curr Neurol Neurosci Rep, V2, P317, DOI 10.1007/s11910-002-0007-4
   Sun XK, 2002, J MED CHEM, V45, P469, DOI 10.1021/jm0103817
   Szelecsenyi F, 2006, APPL RADIAT ISOTOPES, V64, P789, DOI 10.1016/j.apradiso.2006.01.011
   Szelecsenyi F, 2005, J RADIOANAL NUCL CH, V263, P539, DOI 10.1007/s10967-005-0089-y
   Szelecsenyi F, 2004, NUCL INSTRUM METH B, V222, P364, DOI 10.1016/j.nimb.2004.03.013
   Szelecsenyi F, 2002, NUCL INSTRUM METH B, V187, P153, DOI 10.1016/S0168-583X(01)00923-5
   Szelecsenyi F, 2003, APPL RADIAT ISOTOPES, V58, P377, DOI 10.1016/S0969-8043(02)00345-7
   SZELECSENYI F, 1993, APPL RADIAT ISOTOPES, V44, P575, DOI 10.1016/0969-8043(93)90172-7
   Szelecsenyi F, 2009, NUCL INSTRUM METH B, V267, P1877, DOI 10.1016/j.nimb.2009.03.097
   Szelecsenyi F., 2007, P INT C NUCL DAT SCI, P1395
   Szymanski P, 2012, BIOMETALS, V25, P1089, DOI 10.1007/s10534-012-9578-y
   Takahashi N, 2001, ANN NUCL MED, V15, P293, DOI 10.1007/BF02987849
   Vimalnath KV, 2011, J RADIOANAL NUCL CH, V290, P221, DOI 10.1007/s10967-011-1301-x
   Wadas TJ, 2007, CURR PHARM DESIGN, V13, P3, DOI 10.2174/138161207779313768
   Wang H, 2012, MOL IMAGING BIOL, V14, P14, DOI 10.1007/s11307-011-0483-5
   Williams HA, 2005, EUR J NUCL MED MOL I, V32, P1473, DOI 10.1007/s00259-005-1906-9
   Zhang Y, 2013, EUR J NUCL MED MOL I, V40, P759, DOI 10.1007/s00259-012-2334-2
   ZINN KR, 1994, CANCER-AM CANCER SOC, V73, P774, DOI 10.1002/1097-0142(19940201)73:3+<774::AID-CNCR2820731305>3.0.CO;2-L
NR 75
TC 17
Z9 17
U1 3
U2 37
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
AR 786463
DI 10.1155/2014/786463
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AH6CT
UT WOS:000336219000001
PM 24895611
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hoang, HH
   Cung, TNP
   Truong, DK
   Hwang, D
   Jung, JJ
AF Hanh Huu Hoang
   Tai Nguyen-Phuoc Cung
   Duy Khanh Truong
   Hwang, Dosam
   Jung, Jason J.
TI RETRACTED: Semantic Information Integration with Linked Data Mashups
   Approaches (Retracted article. See pg. 31342, 2015)
SO INTERNATIONAL JOURNAL OF DISTRIBUTED SENSOR NETWORKS
LA English
DT Article; Retracted Publication
ID DOMAIN; APIS; WEB
AB The introduction of semantic web and Linked Data helps facilitate sharing of data on the Internet more easily. Subsequently, the resource description framework (RDF) is the standard in publishing structured data resources on the Internet and is used in interconnecting with other data resources. To remedy the data integration issues of the traditional web mashups, the semantic web technology uses the Linked Data based on RDF data model as the unified data model for combining, aggregating, and transforming data from heterogeneous data resources to build Linked Data mashups. There have been tremendous amounts of efforts of semantic web community to enable Linked Data mashups but there is still lack of a systematic survey on concepts, technologies, applications, and challenges. Therefore, in this paper, we investigate in detail semantic mashups research and application approaches in the information integration. This paper also presents a Linked Data mashup application as an illustration of the proposed approaches.
C1 [Hanh Huu Hoang; Duy Khanh Truong] Hue Univ, Hue City 530000, Vietnam.
   [Hanh Huu Hoang; Hwang, Dosam; Jung, Jason J.] Yeungnam Univ, Kyongsan 712749, Gyeongbuk, South Korea.
   [Tai Nguyen-Phuoc Cung] Hue Ind Coll, Hue City 530000, Vietnam.
RP Jung, JJ (reprint author), Yeungnam Univ, 280 Daehak Ro, Kyongsan 712749, Gyeongbuk, South Korea.
EM j2jung@gmail.com
FU Vietnam's National Foundation for Science and Technology Development
   (NAFOSTED) [102.02-2010.14.]; Yeungnam University; National Research
   Foundation of Korea
FX This work was sponsored by Vietnam's National Foundation for Science and
   Technology Development (NAFOSTED) in the framework of the Grant no.
   102.02-2010.14. This work was supported by the Yeungnam University
   research grants in 2011. Also, it was partially supported by the BK21+
   of the National Research Foundation of Korea.
CR [Anonymous], 2014, GOOGLEDEVELOPERS MQL
   Berners-Lee T., 2006, LINKED DATA DESIGN I
   Cano A., 2013, SEMANTIC MASHUPS, P321
   Dell'Aglio D., 2013, SEMANTIC MASHUPS INT, P287, DOI DOI 10.1007/978-3-642-36403-7_
   Endres-Niggemeyer B., 2013, SEMANTIC MASHUPS
   Ennals R, 2007, SIGMOD RECORD, V36, P27, DOI 10.1145/1361348.1361355
   Hartig O., 2010, DATENBANK SPEKTRUM, V10, P57, DOI DOI 10.1007/S13222-010-0021-7
   Heath T, 2011, LINKED DATA EVOLVING
   Heder M., 2013, SEMANTIC MASHUPS, P119
   Huynh D. F., 2007, P 16 INT C WORLD WID, P737, DOI DOI 10.1145/1242572.1242672
   Huynh DF, 2008, J WEB SEMANT, V6, P274, DOI 10.1016/j.websem.2008.09.005
   Jarrar M., 2009, P WORKSH LINK DAT WE
   Jung JJ, 2012, INFORM SYST FRONT, V14, P953, DOI 10.1007/s10796-011-9315-z
   Jung JJ, 2012, EXPERT SYST APPL, V39, P6897, DOI 10.1016/j.eswa.2012.01.006
   Le-Phuoc D., 2009, P 18 INT C WORLD WID, P581, DOI DOI 10.1145/1526709.1526788
   Maximilien E. M., LECT NOTES COMPUTER, V4749, P13
   Ort E., 2007, MASHUP STYLES 1
   Sahoo SS, 2008, J BIOMED INFORM, V41, P752, DOI 10.1016/j.jbi.2008.02.006
   Schulz A., 2013, SEMANTIC MASHUPS, P237
   Tuchinda R., 2008, P 13 INT C INT US IN, P139, DOI DOI 10.1145/1378773.1378792
NR 20
TC 3
Z9 3
U1 1
U2 17
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1550-1329
EI 1550-1477
J9 INT J DISTRIB SENS N
JI Int. J. Distrib. Sens. Netw.
PY 2014
AR 813875
DI 10.1155/2014/813875
PG 12
WC Computer Science, Information Systems; Telecommunications
SC Computer Science; Telecommunications
GA AG8PR
UT WOS:000335681200001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Tan, CQ
   Gao, X
   Guo, L
   Huang, H
AF Tan, Chang-qiang
   Gao, Xia
   Guo, Lang
   Huang, He
TI RETRACTED: Exogenous IL-4-Expressing Bone Marrow Mesenchymal Stem Cells
   for the Treatment of Autoimmune Sensorineural Hearing Loss in a Guinea
   Pig Model (Retracted article. artn: 9539385, 2017)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID INNER-EAR DISEASE; INDUCED COLITIS; STROMAL CELLS; IN-VIVO; THERAPY;
   EXPRESSION; MIGRATION; ARTHRITIS; IL-4
AB Bone marrow mesenchymal stem cells (BMSCs) expressing recombinant IL-4 have the potential to remediate inflammatory diseases. We thus investigated whether BMSCs expressing exogenous IL-4 could alleviate autoimmune sensorineural hearing loss. BMSCs isolated from guinea pigs were transfected with recombinant lentivirus expressing IL-4. A total of 33 animals were divided into three groups. Group A received scala tympani injection of IL-4-expressing BMSCs, and Group B received control vectorexpressing BMSCs, and Group C received phosphate-buffered saline. The distribution of implanted BMSCs in the inner ears was assessed by immunohistochemistry and fluorescence microscopy. Auditory brain-stem response (ABR) was monitored to evaluate the auditory changes. Following BMSCs transplantation, the threshold levels of ABR wave III decreased in Groups A and B and significant differences were observed between these two groups(P < 0.05). Transplanted BMSCs distributed in the scala tympani and scala vestibuli. In some ears with hearing loss, there was a decrease in the number of spiral ganglion cells and varying degrees of endolymphatic hydrops or floccule. Following transplantation, the lentivirus-infected BMSCs migrated to the inner ear and produced IL-4. Our results demonstrate that, upon transplantation, BMSCs and BMSCs expressing recombinant IL-4 have the ability to remediate the inflammatory injury in autoimmune inner ear diseases.
C1 [Tan, Chang-qiang; Huang, He] Nanjing Univ Technol, Coll Biotechnol & Pharmaceut Engn, State Key Lab Mat Oriented Chem Engn, Nanjing 210009, Jiangsu, Peoples R China.
   [Tan, Chang-qiang; Gao, Xia] Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Otolaryngol Head & Neck Surg, Nanjing 210008, Jiangsu, Peoples R China.
   [Guo, Lang] Nanjing Stomatol Hosp, Dept Otolaryngol, Nanjing 210008, Jiangsu, Peoples R China.
RP Huang, H (reprint author), Nanjing Univ Technol, Coll Biotechnol & Pharmaceut Engn, State Key Lab Mat Oriented Chem Engn, 5 Xinmofan Rd, Nanjing 210009, Jiangsu, Peoples R China.
EM hhuang1016@163.com
FU China National Natural Science Foundation [81070789]
FX The study was supported by China National Natural Science Foundation
   (no. 81070789).
CR Chen QQ, 2013, WORLD J GASTROENTERO, V19, P4702, DOI 10.3748/wjg.v19.i29.4702
   Chen W. B., 2010, J SE U MED SCI EDITI, V29, P262
   Fawzy Sohair Ahmed, 2013, International Journal of Stem Cells, V6, P92
   FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x
   Furukawa H, 2008, TRANSPLANTATION, V85, P437, DOI 10.1097/TP.0b013e31816026e7
   Gao ZQ, 2012, EXP THER MED, V4, P993, DOI 10.3892/etm.2012.707
   Geurts J, 2007, GENE THER, V14, P1632, DOI 10.1038/sj.gt.3303022
   Gong SS, 2002, ACTA OTO-LARYNGOL, V122, P5, DOI 10.1080/00016480252775652
   Greco SJ, 2012, THER DELIV, V3, P997, DOI 10.4155/TDE.12.69
   Herraiz C, 2010, ACTA OTORRINOLAR ESP, V61, P225, DOI [10.1016/j.otorri.2009.12.008, 10.1016/j.otorri.2009.03.008]
   Ho SH, 2004, BIOCHEM BIOPH RES CO, V321, P759, DOI 10.1016/j.bbrc.2004.07.028
   Lisignoli G, 2001, CONNECT TISSUE RES, V42, P49, DOI 10.3109/03008200109014248
   Liu NM, 2013, J CELL BIOCHEM, V114, P2677, DOI 10.1002/jcb.24615
   MacFarlane RJ, 2013, EXPERT OPIN THER TAR, V17, P243, DOI 10.1517/14728222.2013.746954
   Maeda Y, 2012, ACTA OTO-LARYNGOL, V132, P4, DOI 10.3109/00016489.2011.619571
   MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501
   McDonough AK, 2008, CURR OPIN RHEUMATOL, V20, P131, DOI 10.1097/BOR.0b013e3282f51031
   Okano T, 2006, MOL THER, V14, P866, DOI 10.1016/j.ymthe.2006.06.012
   Ryu C. H., 2013, BIOMED RES INT, V2013, DOI [10.1155/2013/696738, DOI 10.1155/2013/696738, 10.1155/2013/69673823710456]
   Scherer HU, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3036
   Sharif S, 2007, NEUROREPORT, V18, P351, DOI 10.1097/WNR.0b013e3280287a9a
   Wang JR, 2010, LARYNGOSCOPE, V120, P2478, DOI 10.1002/lary.21060
   Xenellis J, 2006, OTOLARYNG HEAD NECK, V134, P940, DOI 10.1016/j.otohns.2005.03.081
   Xiao Y, 2014, GENET MOL RES, V13, P11, DOI 10.4238/2014.January.3.2
   Yang DZ, 2013, CELL REPROGRAM, V15, P206, DOI 10.1089/cell.2012.0046
   Yi T, 2012, ARCH PHARM RES, V35, P213, DOI 10.1007/s12272-012-0202-z
NR 26
TC 7
Z9 7
U1 4
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
AR 856019
DI 10.1155/2014/856019
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AG2JB
UT WOS:000335241200001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Naeini, AE
   Daneshmand, D
   Khorvash, F
   Chitsaz, A
AF Naeini, Alireza E.
   Daneshmand, Dana
   Khorvash, Farzin
   Chitsaz, Ahmad
TI RETRACTED: Vogt-Koyanagi-Harada syndrome presenting with
   encephalopathy(Retracted article. See vol. 18, pg. 367, 2015)
SO ANNALS OF INDIAN ACADEMY OF NEUROLOGY
LA English
DT Article; Retracted Publication
DE Autoimmunity; encephalopathy; human leukocyte antigen;
   Vogt-Koyanagi-Harada syndrome
ID DISEASE
AB Vogt-Koyanagi-Harada (VKH) is a rare syndrome affecting tissues containing melanocytes. The possibility of its autoimmune pathogenesis is supported by high frequent HLA-DR4 presentation, commonly associated with other autoimmune diseases. Eyes are the main affected organs, resulting in blindness. Brain disease is a late-onset event, and is extremely rare. Here, we are reporting a 57-year-old woman, a known case of VKH syndrome, presenting with brain encephalopathy several decades after the initial presentation. We think this long period between initial presentation and presentation of encephalopathy due to VKH syndrome has not been described before. She was treated with corticosteroids and discharged home with a good general condition.
C1 [Naeini, Alireza E.; Daneshmand, Dana; Khorvash, Farzin] Isfahan Univ Med Sci, Infect & Trop Dis Dept, Esfahan, Iran.
   [Chitsaz, Ahmad] Isfahan Univ Med Sci, Neurol Dept, Esfahan, Iran.
RP Naeini, AE (reprint author), 106,Razi Med Bldg,Shams Abadi St, Esfahan 8134776514, Iran.
EM a_emami35@yahoo.com
RI emami-naeini, alireza/C-5625-2018; khorash, farin/C-6424-2018
OI emami-naeini, alireza/0000-0001-5072-3301; khorash,
   farin/0000-0003-2542-9885
CR Andreoli Christopher M., 2006, International Ophthalmology Clinics, V46, P111, DOI 10.1097/00004397-200604620-00011
   Chee Soon-Phaik, 2007, International Ophthalmology, V27, P137, DOI 10.1007/s10792-006-9009-6
   Fang W, 2008, CURR EYE RES, V33, P517, DOI 10.1080/02713680802233968
   Hashimoto T, 2009, J CLIN NEUROSCI, V16, P593, DOI 10.1016/j.jocn.2008.05.029
   Lohman B D, 2011, AJNR Am J Neuroradiol, V32, pE169, DOI 10.3174/ajnr.A2279
   Rao Narsing A., 2007, International Ophthalmology, V27, P195, DOI 10.1007/s10792-006-9021-x
   Read R W, 2000, Curr Opin Ophthalmol, V11, P437, DOI 10.1097/00055735-200012000-00009
   Sheu SJ, 2005, CURR OPIN NEUROL, V18, P323, DOI 10.1097/01.wco.0000169753.31321.4e
   Tang Y, 2010, J NEUROL NEUROSUR PS, V81, P941, DOI 10.1136/jnnp.2009.184432
NR 9
TC 1
Z9 1
U1 3
U2 7
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0972-2327
EI 1998-3549
J9 ANN INDIAN ACAD NEUR
JI Ann. Indian Acad. Neurol.
PD JAN-MAR
PY 2014
VL 17
IS 1
BP 128
EP 129
DI 10.4103/0972-2327.128585
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AF6OZ
UT WOS:000334835700032
PM 24753681
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Tan, CQ
   Gao, X
   Cai, WJ
   Qian, XY
   Lu, L
   Huang, H
AF Tan, Chang-qiang
   Gao, Xia
   Cai, Wen-jun
   Qian, Xiao-yun
   Lu, Ling
   Huang, He
TI RETRACTED: Experimental Study of Local Inner Ear Gene Therapy for
   Controlling Autoimmune Sensorineural Hearing Loss (Retracted article.
   See Art no 6809643, 2017)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID T-CELLS; IN-VIVO; ADENOASSOCIATED VIRUS; GUINEA-PIG; FAS LIGAND;
   INTERLEUKIN-10; MICE; APOPTOSIS; ARTHRITIS; DISEASE
AB This study aimed to investigate the efficacy of gene therapy for treating autoimmune sensorineural hearing loss (ASHL) via local administration of a recombinant adenovirus vector containing the Fas ligand or interleukin IL-10 gene. Guinea pigs were divided into four groups, with different microinjections in the scala tympani. Group A were injected with FasL-EGFP, B with IL-10-EGFP, C with EGFP, and D with artificial perilymph. Seven days later, auditory brain-stem response (ABR) was tested, and the temporal bone was stained and observed by light microscopy. The spiral ligament and basement membrane were observed using transmission electron microscopy. FasL and IL-10 expression were examined using immunofluorescence histochemistry. Immunohistochemical analysis showed that the recombinant adenovirus vector in Groups A, B, and C can transfect the stria vascularis, the spiral ligament, the organ of Corti, the spiral ganglion, the region surrounding the small blood vessel in the modiolus, and the cochlear bone wall. Compared with those in Groups C and D, the ABR wave III mean thresholds were significantly lower and the inner ear immunoinflammatory responses in Groups A and B were significantly alleviated. Inhibition of immunoinflammatory response alleviated immunoinflammatory injury and auditory dysfunction. This technique shows potential as a novel therapy for ASHL.
C1 [Tan, Chang-qiang; Huang, He] Nanjing Univ Technol, Coll Biotechnol & Pharmaceut Engn, State Key Lab Mat Oriented Chem Engn, 5 Xinmofan Rd, Nanjing 210009, Jiangsu, Peoples R China.
   [Gao, Xia; Qian, Xiao-yun; Lu, Ling] Nanjing Univ, Sch Med, Affiliated Hosp, Nanjing Drum Tower Hosp, Nanjing 210008, Jiangsu, Peoples R China.
   [Cai, Wen-jun] Southeast Univ, Affiliated Zhongda Hosp, Dept Otolaryngol, Nanjing 210009, Jiangsu, Peoples R China.
RP Huang, H (reprint author), Nanjing Univ Technol, Coll Biotechnol & Pharmaceut Engn, State Key Lab Mat Oriented Chem Engn, 5 Xinmofan Rd, Nanjing 210009, Jiangsu, Peoples R China.
EM hhuang1016@163.com
FU General Project of the National Natural Science Foundation of China
   [81070789]
FX This study was supported by the General Project of the National Natural
   Science Foundation of China (81070789).
CR Batteux F, 1999, J IMMUNOL, V162, P603
   Bulfone-Paus S, 2000, TRANSPLANTATION, V69, P1386, DOI 10.1097/00007890-200004150-00030
   Fukui H, 2013, HEARING RES, V297, P99, DOI 10.1016/j.heares.2012.11.017
   Hillhouse EE, 2010, IMMUNOL CELL BIOL, V88, P771, DOI 10.1038/icb.2010.84
   Husseman J, 2009, ADV OTO-RHINO-LARYNG, V66, P37, DOI 10.1159/000218206
   Jansen T, 2010, NEURO-ONCOLOGY, V12, P482, DOI 10.1093/neuonc/nop052
   Jin Y, 2004, GENE THER, V11, P982, DOI 10.1038/sj.gt.3302260
   Lalwani AK, 1996, GENE THER, V3, P588
   Liu Yingpeng, 2007, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V21, P748
   Matsuda R, 2012, INVEST OPHTH VIS SCI, V53, P7235, DOI 10.1167/iovs.12-10587
   MCCABE BF, 1989, AM J OTOL, V10, P196
   MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501
   Raphael Y, 1996, NEUROSCI LETT, V207, P137, DOI 10.1016/0304-3940(96)12499-X
   Tan C, 1998, Lin Chuang Er Bi Yan Hou Ke Za Zhi, V12, P407
   Thomas PB, 2010, INVEST OPHTH VIS SCI, V51, P5137, DOI 10.1167/iovs.10-5423
   van de Loo FAJ, 2002, RHEUM DIS CLIN N AM, V28, P127, DOI 10.1016/S0889-857X(03)00073-5
   Xu AJ, 2010, MOL CELL BIOCHEM, V344, P163, DOI 10.1007/s11010-010-0539-x
   Yagi M, 1999, HUM GENE THER, V10, P813, DOI 10.1089/10430349950018562
   Yu H, 2012, INT IMMUNOPHARMACOL, V13, P499, DOI 10.1016/j.intimp.2012.05.015
   Zhang HG, 2002, IMMUNOL RES, V26, P235, DOI 10.1385/IR:26:1-3:235
   Zhang W, 2012, INT IMMUNOL, V24, P379, DOI 10.1093/intimm/dxs041
NR 21
TC 1
Z9 1
U1 4
U2 18
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
AR 134658
DI 10.1155/2014/134658
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AF5NQ
UT WOS:000334760600001
PM 24804196
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Park, J
   Bok, K
   Seong, D
   Kim, S
   Yoo, J
AF Park, Junho
   Bok, Kyoungsoo
   Seong, Dongook
   Kim, Sanglae
   Yoo, Jaesoo
TI RETRACTED: A Data Gathering Method Based on a Mobile Sink for Minimizing
   the Data Loss in Wireless Sensor Networks (Retracted article. See pg.
   43187, 2015)
SO INTERNATIONAL JOURNAL OF DISTRIBUTED SENSOR NETWORKS
LA English
DT Article; Retracted Publication
ID LIFETIME
AB The sensor nodes near to the fixed sink node suffer from the quickly exhausted energy. For this, many methods have been researched to distribute the energy consumption into all wireless sensor nodes using a mobile sink. Since the mobile sink changes its location in the network continuously, it has limited time to communicate with the sensor nodes and needs the time to move to each sensor node. Therefore, before the mobile sink approaches the sensor node, the node can collect huge data by event occurrence. It causes the memory overflow of the sensor node and then the data loss. We propose a novel data gathering method based on a mobile sink considering the data loss in wireless sensor networks. The proposed scheme actively sends the stored data to the mobile sink by considering the amount of collected data in the cluster header and the mobile patterns of the sink node. By doing so, it minimizes the data loss of each sensor node. To show the superiority, we compare it with the existing scheme. Our experimental results show that our proposed scheme minimizes the data loss and has similar network lifetime over the existing scheme based on a mobile sink.
C1 [Park, Junho] Agcy Def Dev, Taejon 305600, South Korea.
   [Bok, Kyoungsoo; Seong, Dongook; Yoo, Jaesoo] Chungbuk Natl Univ, Sch Informat & Commun Engn, Cheongju 361763, South Korea.
   [Kim, Sanglae] Samsung Elect Co Ltd, Software Ctr, Suwon 443742, South Korea.
RP Yoo, J (reprint author), Chungbuk Natl Univ, Sch Informat & Commun Engn, 52 Naesudong Ro, Cheongju 361763, South Korea.
EM yjs@chungbuk.ac.kr
FU MSIP (Ministry of Science, ICT and Future Planning), Republic of Korea,
   under the ITRC (Information Technology Research Center) Support Program
   [NIPA-2014-H0301-14-1022]; MSIP (Ministry of Science, ICT and Future
   Planning), Republic of Korea, under the C-ITRC (Convergence Information
   Technology Research Center) Support Program [NIPA-2014-H0401-14-1007];
   National Research Foundation of Korea (NRF) Grant - Korea government
   (MSIP) [2013R1A2A2A01015710]
FX This research was supported by the MSIP (Ministry of Science, ICT and
   Future Planning), Republic of Korea, under the ITRC (Information
   Technology Research Center) Support Program (NIPA-2014-H0301-14-1022)
   and the C-ITRC (Convergence Information Technology Research Center)
   Support Program (NIPA-2014-H0401-14-1007) supervised by the NIPA
   (National IT Industry Promotion Agency) and by the National Research
   Foundation of Korea (NRF) Grant funded by the Korea government (MSIP)
   (no. 2013R1A2A2A01015710).
CR Dong Ook Seong, 2010, Journal of KISS: Computing Practices, V16, P561
   Handy MJ, 2002, 2002 4TH INTERNATIONAL WORKSHOP ON MOBILE AND WIRELESS COMMUNICATION NETWORK, P368, DOI 10.1109/MWCN.2002.1045790
   Jung JJ, 2011, EXPERT SYST APPL, V38, P6107, DOI 10.1016/j.eswa.2010.11.017
   Kahn J.M., 1999, P 5 ANN ACM IEEE INT, P271, DOI DOI 10.1145/313451.313558
   Luo J, 2005, IEEE INFOCOM SER, P1735
   Luo J, 2006, LECT NOTES COMPUT SC, V4026, P480
   Madden S, 2002, USENIX ASSOCIATION PROCEEDINGS OF THE FIFTH SYMPOSIUM ON OPERATING SYSTEMS DESIGN AND IMPLEMENTATION, P131, DOI 10.1145/1060289.1060303
   WU FJ, 2009, P 10 INT C MOB DAT M, P293
   Wu M, 2010, J NETW COMPUT APPL, V35, P646, DOI 10.1016/j.jnca.2010.03.013
   Yao Y, 2002, SIGMOD REC, V31, P9
   Younis O, 2004, IEEE T MOBILE COMPUT, V3, P366, DOI 10.1109/TMC.2004.41
   Zhao WR, 2005, IEEE INFOCOM SER, P1407
NR 12
TC 1
Z9 1
U1 1
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1550-1477
J9 INT J DISTRIB SENS N
JI Int. J. Distrib. Sens. Netw.
PY 2014
AR 920636
DI 10.1155/2014/920636
PG 7
WC Computer Science, Information Systems; Telecommunications
SC Computer Science; Telecommunications
GA AF9OV
UT WOS:000335045300001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Li, PC
   Zhang, JL
AF Li, Peng-Cheng
   Zhang, Jian-Liang
TI RETRACTED: A Prediction Model of Phosphorus Distribution between
   CaO-SiO2-MgO-FeO-Fe2O3-P2O5 Slags and Liquid Iron (Retracted article.
   See vol. 54, pg. 2663, 2014)
SO ISIJ INTERNATIONAL
LA English
DT Article; Retracted Publication
DE phosphorous distribution; mass action concentration; structural units;
   ion and molecule coexistence theory
ID FETO-(CAO+MGO)-(SIO2+P2O5) PHOSPHATE SLAGS; HOT METAL; SYSTEM; MGO;
   DEPHOSPHORIZATION; STEEL
AB CaO-SiO2-MgO-FeO-Fe2O3-P2O5 slags is typical in the basic oxygen steelmaking(BOS) process. Phosphate distribution between slags and liquid iron is an index of the phosphorus holding capacity of the slag, which determines the phosphorus content achievable in the finished steel. In this study, a thermodynamic model for calculating phosphorus distribution between CaO-SiO2-MgO-FeO-Fe2O3-P2O5 slags and liquid iron, i.e., IMCT-L-p model, has been developed coupled with a developed thermodynamic model for calculating mass action concentrations of structural units, le., IMCT-N, model, based on ion and molecule coexistence theory. Simple binary basicity R have a large effect on equilibrium mole number En; of structural units in CaO-SiO2-MgO-FeO-Fe2O3-P2O5 slags, the formula of equilibrium mole number Sigma n(i), against the simple binary basicity R of slags can be regressed as Sigma n(i) = 2.604 - 3.029*exp(-R12.339), and the fitting degree is 0.995. The comparison of the calculated phosphorous distribution by IMCT-L-p model with the measured phosphorous distribution reported from different literatures shows that the agreement between the calculated phosphorous distribution and measured phosphorous distribution is good. Meanwhile, some other L prediction models have also been taken into consideration for calculating phosphate distribution between CaO-SiO2-MgO-FeO-Fe2O3-P2O5 slags and liquid iron, and the results shows that IMCT-L-p model have more accuracy compared with other L, prediction models. The developed IMCT-L-p model can quantitatively calculate the respective contribution of FeO, CaO+FetO and MgO+FetO in the slags. A significant difference of dephosphorziation abilities among FetO, CaO+FetO and MgO+FetO can be found as approximately 0.00%, 99.98%, 0.01%. Meanwhile, the phosphorus in liquid iron can be effectively extracted by CaO+FetO in slags to form complex molecules 3CaO center dot P2O5 which made the main contribution to dephosphorizaiton in CaO-SiO2-MgO-FeO-Fe2O3-P2O8 slags.
C1 [Li, Peng-Cheng; Zhang, Jian-Liang] Univ Sci & Technol Beijing, State Key Lab Adv Met, Beijing 100083, Peoples R China.
   [Li, Peng-Cheng; Zhang, Jian-Liang] Univ Sci & Technol Beijing, Sch Met & Ecol Engn, Beijing 100083, Peoples R China.
   [Li, Peng-Cheng] Chinese Acad Sci, State Key Lab Multiphase Complex Syst, Inst Proc Engn, Beijing 100190, Peoples R China.
RP Li, PC (reprint author), Univ Sci & Technol Beijing, State Key Lab Adv Met, Beijing 100083, Peoples R China.
EM lipengcheng000@126.com
CR BALAJIVA K, 1946, J IRON STEEL I, V153, pP115
   Basu S, 2007, METALL MATER TRANS B, V38, P357, DOI 10.1007/s11663-007-9057-y
   BOOKEY JB, 1952, J IRON STEEL I, V172, P61
   BORGIANNI C, 1977, METALL TRANS B, V8, P147, DOI 10.1007/BF02656363
   Chen J. X., 2010, HDB COMMON FIGURES T
   Colclough T. P., 1923, J IRON STEEL I, V107, P267
   Colclough TP, 1925, T FARADAY SOC, V21, P0202, DOI 10.1039/tf9252100202
   Eisenhuttenleute V. D., 1995, SLAG ATLAS, P23
   Espejo V, 1995, METALL MATER TRANS B, V26, P257, DOI 10.1007/BF02660967
   Gaye H., 1984, P 2 INT S MET SLAGS, P357
   HEALY GW, 1970, J IRON STEEL I, V208, P664
   Herty C. H., 1926, T A I M E, V73, P1107
   Jian Z, 2004, RARE METALS, V23, P209
   Kobayashi Y, 2004, ISIJ INT, V44, P21, DOI 10.2355/isijinternational.44.21
   Marukawa K., 1981, TETSU TO HAGANE, V67, P323
   MORI K, 1985, METALL TRANS B, V16, P303, DOI 10.1007/BF02679721
   NAGABAYASHI R, 1988, TETSU TO HAGANE, V74, P1577
   NAGABAYASHI R, 1988, TETSU TO HAGANE, V74, P1770
   Narita K., 1969, KOBE STEEL ENG REP, V1, P25
   REIN RH, 1965, T METALL SOC AIME, V233, P415
   Shi CB, 2010, ISIJ INT, V50, P1362, DOI 10.2355/isijinternational.50.1362
   Sommerville I. D., 1985, T IRON STEEL SOC, V6, P29
   SUITO H, 1984, T IRON STEEL I JPN, V24, P40
   SUITO H, 1981, T IRON STEEL I JPN, V21, P250
   SUITO H, 1995, ISIJ INT, V35, P258, DOI 10.2355/isijinternational.35.258
   Suito H., 1979, TETSU TO HAGANE, V65, P1848
   The Japan Society for the Promotion of Science, 1988, 19 COMM STEELM STEEL, P279
   Turkdogan E. T., 1980, PHYS CHEM HIGH TEMPE, P8
   Turkdogan ET, 2000, ISIJ INT, V40, P964, DOI 10.2355/isijinternational.40.964
   TURKDOGAN ET, 1953, J IRON STEEL I, V175, P393
   Verein Deutscher Eisenhuttenleute, 1995, SLAG ATLAS
   Yang XM, 2014, STEEL RES INT, V85, P347, DOI 10.1002/srin.201200138
   Yang XM, 2009, ISIJ INT, V49, P1828, DOI 10.2355/isijinternational.49.1828
   Zhang J, 2001, CALPHAD, V25, P343, DOI 10.1016/S0364-5916(01)00054-2
   Zhang J., 1986, J BEIJING U IRON STE, V8, P1
   Zhang J., 1995, J UNIV SCI TECHNOL B, V17, P418
   Zhang J., 1991, J UNIV SCI TECHNOL B, V13, P214
   Zhang J., 1988, J BEIJING U IRON STE, V10, P1
   Zhang J., 2007, COMPUTATIONAL THERMO, P252
   Zhang Jian, 1998, Acta Metallurgica Sinica, V34, P742
NR 40
TC 5
Z9 5
U1 3
U2 27
PU IRON STEEL INST JAPAN KEIDANREN KAIKAN
PI TOKYO
PA TEKKO KAIKAN-5F, 3-2-10, NIHONBASHI-KAYABACHO, TOKYO, CHUO-KU 103-0025,
   JAPAN
SN 0915-1559
EI 1347-5460
J9 ISIJ INT
JI ISIJ Int.
PY 2014
VL 54
IS 4
BP 756
EP 765
DI 10.2355/isijinternational.54.756
PG 10
WC Metallurgy & Metallurgical Engineering
SC Metallurgy & Metallurgical Engineering
GA AF6KO
UT WOS:000334824200007
OA Bronze
DA 2018-12-27
ER

PT J
AU Wang, X
   Chen, JM
   Tong, H
AF Wang, Xian
   Chen, Jun-min
   Tong, Hui
TI RETRACTED: Iterative Schemes by a New Generalized Resolvent for a
   Monotone Mapping and a Relatively Weak Nonexpansive Mapping (Retracted
   article. See 279526, 2014)
SO JOURNAL OF APPLIED MATHEMATICS
LA English
DT Article; Retracted Publication
ID CONVERGENCE THEOREMS; BANACH-SPACES
AB We introduce a new generalized resolvent in a Banach space and discuss some of its properties. Using these properties, we obtain an iterative scheme for finding a point which is a fixed point of relatively weak nonexpansive mapping and a zero of monotone mapping. Furthermore, strong convergence of the scheme to a point which is a fixed point of relatively weak nonexpansive mapping and a zero of monotone mapping is proved.
C1 [Wang, Xian; Chen, Jun-min; Tong, Hui] Hebei Univ, Coll Math & Comp, Baoding 071002, Peoples R China.
RP Wang, X (reprint author), Hebei Univ, Coll Math & Comp, Baoding 071002, Peoples R China.
EM wangxian133@126.com
FU Natural Science Foundation of Hebei Province [A2010000191, A2012201054];
   Planning Guide of Research and Development of Science and Technology of
   Hebei Province, Baoding City [12ZJ001]; Youth Foundation of China
   [11101115]
FX This work was supported by the Natural Science Foundation of Hebei
   Province (nos. A2010000191 and A2012201054), the Planning Guide of
   Research and Development of Science and Technology of Hebei Province,
   Baoding City (no. 12ZJ001), and the Youth Foundation of China (no.
   11101115).
CR Alber Y. I., 1996, THEORY APPL NONLINEA, V178, P15
   Cioranescu I, 1990, GEOMETRY BANACH SPAC
   Ibaraki T, 2007, J APPROX THEORY, V149, P1, DOI 10.1016/j.jat.2007.04.003
   Li JL, 2004, J MATH ANAL APPL, V295, P115, DOI 10.1016/j.jmaa.2004.03.010
   Pascali D., 1978, SBURLAN NONLINEAR MA
   Reich S., 1979, APPL NONLINEAR ANAL, P335
   Su YF, 2008, NONLINEAR ANAL-THEOR, V68, P3657, DOI 10.1016/j.na.2007.04.008
   Zegeye H, 2009, NONLINEAR ANAL-THEOR, V70, P2707, DOI 10.1016/j.na.2008.03.058
NR 8
TC 0
Z9 0
U1 2
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1110-757X
EI 1687-0042
J9 J APPL MATH
JI J. Appl. Math.
PY 2014
AR 603186
DI 10.1155/2014/603186
PG 6
WC Mathematics, Applied
SC Mathematics
GA AF5HY
UT WOS:000334745800001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Li, PC
   Zhang, JL
AF Li, Peng-cheng
   Zhang, Jian-liang
TI RETRACTED: Representation of Dephosphorization Ability for
   CaO-Containing Slags Based on the Ion and Molecule Coexistence Theory
   (Retracted article. See vol. 54, pg. 2663, 2014)
SO ISIJ INTERNATIONAL
LA English
DT Article; Retracted Publication
DE phosphorous distribution; mass action concentration; structural units;
   ion and molecule coexistence theory; CaO-containing slags
ID FETO-(CAO+MGO)-(SIO2+P2O5) PHOSPHATE SLAGS; CAO-SIO2-MGO-AL2O3
   IRONMAKING SLAGS; FEO-CONTAINING SLAGS; MASS-ACTION LAW; LIQUID-IRON;
   PHOSPHORUS DISTRIBUTION; THERMODYNAMIC ACTIVITIES; MOLTEN IRON; SULFUR
   DISTRIBUTION; MGO
AB A thermodynamic model for calculating phosphorous distribution between several slag systems and hot metal has been developed by coupling with a developed thermodynamic model for calculating mass action concentrations of iron oxides based on the ion and molecule coexistence theory (IMCT). The calculated mass action concentrations of iron oxides in the several CaO-containing slags can be applied to represent reaction ability of iron oxides, like classic concept of activity. The developed thermodynamic model for calculating phosphorus distribution can quantitatively calculate the respective contribution of free components, and the sum of the respective contribution of free components. The comparison of the calculated total phosphorous distribution with all available measured phosphorous distribution reported in literatures shows that the agreement between the calculated total phosphorous distribution and measured phosphorous distribution is good. This reliable agreement indicates that the IMCT-L-P model can be successfully applied to predict the phosphorous distribution for CaO-FeO-Fe2O3-P2O5 slags, CaO-SiO2-FeO-Fe2O3-P2O5 slags, CaO-SiO2-FeO-Fe2O3-Al2O3-P2O5 slags, CaO-SiO2-FeO-MgO-P2O5 slags, CaO-SiO2-FeO-Fe2O3-MgO-P2O5 slags and CaO-SiO2-MgO-FeO-Fe2O3-MnO-P2O5 slags in a temperature range from 1 823 K to 1 973 K.
C1 [Li, Peng-cheng; Zhang, Jian-liang] Univ Sci & Technol Beijing, State Key Lab Adv Met, Beijing 100083, Peoples R China.
   [Li, Peng-cheng] Chinese Acad Sci, State Key Lab Multiphase Complex Syst, Inst Proc Engn, Beijing 100190, Peoples R China.
RP Li, PC (reprint author), Univ Sci & Technol Beijing, State Key Lab Adv Met, Beijing 100083, Peoples R China.
EM lipengcheng000@126.com
CR BALAJIVA K, 1946, J IRON STEEL I, V153, pP115
   Ban-ya S., 1982, TETSU TO HAGANE, V68, P261
   Ban-ya S., 1980, TETSU TO HAGANE, V66, P1484
   Barin I., 1977, THERMOCHEMICAL PROPE, P392
   Basu S, 2008, METALL MATER TRANS B, V39, P447, DOI 10.1007/s11663-008-9148-4
   Basu S, 2007, METALL MATER TRANS B, V38, P623, DOI 10.1007/s11663-007-9063-0
   Basu S, 2007, METALL MATER TRANS B, V38, P357, DOI 10.1007/s11663-007-9057-y
   Basu S, 2007, ISIJ INT, V47, P766, DOI 10.2355/isijinternational.47.766
   Bodsworth 7. C., 1959, J IRON STEEL I, V193, P13
   BOOKEY JB, 1952, J IRON STEEL I, V172, P61
   BORGIANNI C, 1977, METALL TRANS B, V8, P147, DOI 10.1007/BF02656363
   BYGDEN J, 1994, STEEL RES, V65, P421, DOI 10.1002/srin.199401187
   Chen J. X., 2010, HDB COMMON FIGURES T
   Choudhary SK, 2007, IRONMAK STEELMAK, V34, P343, DOI 10.1179/174328107X168002
   Deo B, 2005, IRONMAK STEELMAK, V32, P54, DOI 10.1179/174328105X23969
   Eisenhuttenleute V. D., 1995, SLAG ATLAS, P23
   Eisenhuttenleute V. D., 1995, SLAG ATLAS
   Elliott J. F., 1955, J MET, V7, P485
   Fredriksson P, 2004, STEEL RES INT, V75, P357, DOI 10.1002/srin.200405781
   Fredriksson P, 2004, STEEL RES INT, V75, P240, DOI 10.1002/srin.200405951
   Fujita H., 1968, TETSU TO HAGANE, V54, P359
   Gaye H., 1984, P 2 INT S MET SLAGS, P357
   Guo H, 2010, CHINESE CHEM LETT, V21, P229, DOI 10.1016/j.cclet.2009.10.001
   HEALY GW, 1970, J IRON STEEL I, V208, P664
   Ide K., 2000, IRON STEELMAKER, V27, P65
   INOUE R, 1983, T IRON STEEL I JPN, V23, P578
   Ishikawa M, 2006, ISIJ INT, V46, P530, DOI 10.2355/isijinternational.46.530
   Iwase M., 1984, T IRON STEEL SOC AIM, V4, P69
   Jian Z, 2004, RARE METALS, V23, P209
   Knacke O., 1991, THERMOCHEMICAL PROPE, P1836
   Liu SH, 2001, METALL MATER TRANS B, V32, P31, DOI 10.1007/s11663-001-0005-y
   Lv Q., 2008, J SHANGHAI U, V12, P466
   Marukawa K., 1981, TETSU TO HAGANE, V67, P323
   Morales AT, 1997, METALL MATER TRANS B, V28, P1111, DOI 10.1007/s11663-997-0067-6
   MORI K, 1985, METALL TRANS B, V16, P303, DOI 10.1007/BF02679721
   NAGABAYASHI R, 1988, TETSU TO HAGANE, V74, P1577
   NAGABAYASHI R, 1988, TETSU TO HAGANE, V74, P1770
   Narita K., 1969, KOBE STEEL ENG REP, V19, P25
   NASSARALLA C, 1992, METALL TRANS B, V23, P117, DOI 10.1007/BF02651847
   Niekerk W H, 1998, METALL MATER TRANS B, V29, P147
   Oeters F., 1994, METALLURGY STEELMAKI, P46
   OGURA T, 1992, METALL TRANS B, V23, P459, DOI 10.1007/BF02649665
   Pal J, 2010, ISIJ INT, V50, P105, DOI 10.2355/isijinternational.50.105
   REIN RH, 1965, T METALL SOC AIME, V233, P415
   Richardson F. D., 1974, PHYS CHEM MELTS META, P87
   Shi CB, 2010, ISIJ INT, V50, P1362, DOI 10.2355/isijinternational.50.1362
   Sigworth G. K., 1974, Metal Science, V8, P298
   Sommerville I. D., 1985, T IRON STEEL SOC, V6, P29
   SUITO H, 1984, T IRON STEEL I JPN, V24, P40
   SUITO H, 1981, T IRON STEEL I JPN, V21, P250
   SUITO H, 1984, T IRON STEEL I JPN, V24, P301
   Suito H., 1979, TETSU TO HAGANE, V65, P1848
   Taniguchi Y, 1997, ISIJ INT, V37, P956, DOI 10.2355/isijinternational.37.956
   Tao DP, 2006, METALL MATER TRANS B, V37, P1091
   Taylor CR, 1943, T AM I MIN MET ENG, V154, P228
   The Japan Society for the Promotion of Science, 1988, 19 COMM STEELM STEEL, P279
   TIMUCIN M, 1992, J AM CERAM SOC, V75, P1399, DOI 10.1111/j.1151-2916.1992.tb04200.x
   TING T, 1986, TETSU TO HAGANE, V72, P225, DOI 10.2355/tetsutohagane1955.72.2_225
   Turkdogan E. T., 1980, PHYS CHEM HIGH TEMPE, P8
   Turkdogan ET, 2000, ISIJ INT, V40, P964, DOI 10.2355/isijinternational.40.964
   WANIBE Y, 1973, ARCH EISENHUTTENWES, V44, P711, DOI 10.1002/srin.197302469
   WINKLER TB, 1946, T AM I MIN MET ENG, V167, P111
   WRAMPELMEYER JC, 1989, STEEL RES, V60, P539, DOI 10.1002/srin.198901701
   Yang XM, 2009, ISIJ INT, V49, P1828, DOI 10.2355/isijinternational.49.1828
   YOUNG RW, 1992, IRONMAK STEELMAK, V19, P201
   Zhang J, 2001, CALPHAD, V25, P343, DOI 10.1016/S0364-5916(01)00054-2
   Zhang J., 1986, J BEIJING U IRON STE, V8, P1
   Zhang J., 1995, J UNIV SCI TECHNOL B, V17, P418
   Zhang J., 1991, J UNIV SCI TECHNOL B, V13, P214
   Zhang J., 1988, J BEIJING U IRON STE, V10, P1
   Zhang J., 2007, COMPUTATIONAL THERMO, P252
   Zhang JA, 2002, J UNIV SCI TECHNOL B, V9, P90
   Zhang Jian, 1998, Acta Metallurgica Sinica, V34, P742
NR 73
TC 3
Z9 3
U1 5
U2 18
PU IRON STEEL INST JAPAN KEIDANREN KAIKAN
PI TOKYO
PA TEKKO KAIKAN-5F, 3-2-10, NIHONBASHI-KAYABACHO, TOKYO, CHUO-KU 103-0025,
   JAPAN
SN 0915-1559
EI 1347-5460
J9 ISIJ INT
JI ISIJ Int.
PY 2014
VL 54
IS 3
BP 567
EP 577
DI 10.2355/isijinternational.54.567
PG 11
WC Metallurgy & Metallurgical Engineering
SC Metallurgy & Metallurgical Engineering
GA AD8II
UT WOS:000333509300015
OA Bronze
DA 2018-12-27
ER

PT J
AU Yan, C
   Yang, B
   Yu, ZC
AF Yan, Chao
   Yang, Bin
   Yu, Zhicheng
TI RETRACTED: Methanol-induced conformation transition of gland fibroin
   monitored by FTIR spectroscopy and terahertz spectroscopy (Retracted
   article. See vol. 139, pg. 6310, 2014)
SO ANALYST
LA English
DT Article; Retracted Publication
ID TIME-DOMAIN SPECTROSCOPY; PROTEIN SECONDARY STRUCTURE; MORI SILK
   FIBROIN; SOLID-STATE NMR; BOMBYX-MORI; INFRARED-SPECTROSCOPY;
   VIBRATIONAL-MODES; SPECTRA
AB Silk fibroin extracted from the gland of Bombyx mori silkworm is employed as an ideal system to investigate its conformation transition in methanol/D2O solution. The transition process was monitored by Fourier transform infrared (FTIR) spectroscopy coupled with terahertz time domain spectroscopy (THz-TDS). Analysis of FTIR spectra suggests that, with increasing time of treatment, an increasing band at 1634 cm(-1) is observed indicating the formation of beta-pleated sheets coincident with the loss of intensity of a band at 1673 cm(-1) indicating decrease of the random coil structure. In addition, there is a burst phase of 33% occurring during the first 2 minutes when the gland fibroin membranes are immersed into methanol/D2O solution. THz spectra present distinct features for conformations of silk fibroin, in combination with the results obtained from FTIR; the peaks observed at 1.54 THz (51 cm(-1)), 1.67 THz (55 cm(-1)), and 1.84 THz (61 cm(-1)) can be attributed to a beta-pleated sheet, alpha-helix, and random coil, respectively. Intensity change of bands centered at 1.54 THz and 1.84 THz confirms the formation of the beta-pleated sheet and the disappearance of the random coil. Kinetic curves obtained from THz spectra indicate that the methanol-induced conformation transition from the random coil to the beta-pleated sheet is fitted with an exponential function. The results suggest that THz-TDS presents great potential as a complementary approach in studying the secondary structure of a protein, providing significant insight into the silk-spinning process in vivo.
C1 [Yan, Chao; Yang, Bin; Yu, Zhicheng] Zhejiang Sci Tech Univ, Key Lab Adv Text Mat & Mfg Technol, Hangzhou, Zhejiang, Peoples R China.
   [Yu, Zhicheng] Ecol Engn Res Ctr Dyeing & Finishing Technol, Hangzhou, Zhejiang, Peoples R China.
RP Yang, B (reprint author), Zhejiang Sci Tech Univ, Key Lab Adv Text Mat & Mfg Technol, Hangzhou, Zhejiang, Peoples R China.
EM yangbin5959@yahoo.com.cn
FU scientific research innovation fund in Zhejiang province [YK2011055];
   Key Laboratory of Terahertz Optoelectronics at Capital Normal University
FX The authors would like to acknowledge the financial support provided by
   the scientific research innovation fund in Zhejiang province
   (YK2011055), as well as an open project of Key Laboratory of Terahertz
   Optoelectronics at Capital Normal University.
CR Albert R. S., 2011, ANALYST, V136, P1733
   Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142-9612(02)00353-8
   Arora A, 2012, ANALYST, V137, P575, DOI 10.1039/c2an15820e
   Asakura T, 2005, MACROMOLECULES, V38, P7397, DOI 10.1021/ma050936y
   ASAKURA T, 1984, MACROMOLECULES, V17, P1075, DOI 10.1021/ma00135a017
   ASAKURA T, 1983, MACROMOLECULES, V16, P1024, DOI 10.1021/ma00240a043
   Burnett AD, 2009, ANALYST, V134, P1658, DOI 10.1039/b817839a
   BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307
   Dong AC, 2006, ANAL BIOCHEM, V351, P282, DOI 10.1016/j.ab.2006.01.008
   Dorney TD, 2001, J OPT SOC AM A, V18, P1562, DOI 10.1364/JOSAA.18.001562
   Duvillaret L, 1999, APPL OPTICS, V38, P409, DOI 10.1364/AO.38.000409
   ECKERT K, 1977, BIOPOLYMERS, V16, P2549, DOI 10.1002/bip.1977.360161116
   Feng XX, 2007, J BIOMAT SCI-POLYM E, V18, P1443, DOI 10.1163/156856207782246786
   Fischer BM, 2002, PHYS MED BIOL, V47, P3807, DOI 10.1088/0031-9155/47/21/319
   Goldberg ME, 2005, PROTEIN SCI, V14, P2781, DOI 10.1110/ps.051687205
   Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202
   He MX, 2006, OPT COMMUN, V259, P389, DOI 10.1016/j.optcom.2005.08.029
   Jin HJ, 2004, BIOMATERIALS, V25, P1039, DOI 10.1016/S0142-9612(03)00609-4
   JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145
   Kong J, 2007, ACTA BIOCH BIOPH SIN, V39, P549, DOI 10.1111/j.1745-7270.2007.00320.x
   Leahy-Hoppa MR, 2007, CHEM PHYS LETT, V434, P227, DOI 10.1016/j.cplett.2006.12.015
   Li Ning, 2005, OPT EXPRESS, V13, p6750~6755
   Liu HB, 2007, J PHARM SCI-US, V96, P927, DOI 10.1002/jps.20782
   Ma L, 2010, SPECTROSC SPECT ANAL, V30, P3047, DOI 10.3964/j.issn.1000-0593(2010)11-3047-05
   Omenetto FG, 2008, NAT PHOTONICS, V2, P641, DOI 10.1038/nphoton.2008.207
   Panilaitis B, 2003, BIOMATERIALS, V24, P3079, DOI 10.1016/S0142-9612(03)00158-3
   Qian JH, 1996, ANAL BIOCHEM, V236, P208, DOI 10.1006/abio.1996.0158
   SAITO H, 1984, MACROMOLECULES, V17, P1405, DOI 10.1021/ma00137a018
   Sanchez A. R., 2011, ANALYST, V136, P1733
   Shao ZZ, 2002, NATURE, V418, P741, DOI 10.1038/418741a
   Shen YC, 2004, VIB SPECTROSC, V35, P111, DOI 10.1016/j.vibspec.2003.12.004
   SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001
   Taday PF, 2003, J BIOL PHYS, V29, P109, DOI 10.1023/A:1024424205309
   Unger RE, 2004, BIOMATERIALS, V25, P1069, DOI [10.1016/S0142-9612(03)00619-7, 10.1016/S0142-9612(03)00630-6]
   Walther M, 2002, BIOPOLYMERS, V67, P310, DOI 10.1002/bip.10106
   Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853
   Yamaguchi M, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1857080
   Yamamoto K, 2005, BIOPHYS J, V89, pL22, DOI 10.1529/biophysj.105.067447
   Yan C, 2014, ANAL METHODS-UK, V6, P248, DOI 10.1039/c3ay41358f
   Yan C, 2013, ANAL LETT, V46, P946, DOI 10.1080/00032719.2012.747098
   Zhang WJ, 2013, CHINESE PHYS B, V22, DOI 10.1088/1674-1056/22/2/023701
   Zhou P, 2004, BIOCHEMISTRY-US, V43, P11302, DOI 10.1021/bi049344i
NR 42
TC 6
Z9 6
U1 5
U2 57
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2014
VL 139
IS 8
BP 1967
EP 1972
DI 10.1039/c3an01547e
PG 6
WC Chemistry, Analytical
SC Chemistry
GA AD2RC
UT WOS:000333081800021
PM 24588004
DA 2018-12-27
ER

PT J
AU Qureshi, SA
   Masood, I
   Hashmi, M
   Hanninen, S
   Sarwar, M
   Jameel, A
AF Qureshi, S. A.
   Masood, I.
   Hashmi, M.
   Hanninen, S.
   Sarwar, M.
   Jameel, A.
TI RETRACTED: Noise Reduction of Electrocardiographic Signals using Wavelet
   Transforms (Retracted Article)
SO ELEKTRONIKA IR ELEKTROTECHNIKA
LA English
DT Article; Retracted Publication
DE Electrocardiogram; de-noising; noise; stationary wavelet transform;
   signal-to-noise ratio
AB It has always been a critical issue to extract original signal having low signal-to-noise ratio (SNR) buried in heavy noise and interferences. Since the amplitude of the electrocardiogram (ECG) signal is smaller so while gathering and recording it may mix with various kinds of noises and interferences. In this paper, wavelet thresholding de-noising method based on stationary wavelet transform (SWT) is proposed in de-noising of ECG signal. In addition, this paper compares various de-noising methods to validate the proposed de-noising method. The improved de-noising method ensures that the geometrical characteristics of the original ECG are retained as well as efficiently suppresses additive noises. The experimental results reveal that the SWT method is better than traditional wavelet de-noising methods to maintain original shape of ECG waveform having improved SNR.
C1 [Qureshi, S. A.; Masood, I.; Jameel, A.] UET, Dept Elect Engn, Lahore, Pakistan.
   [Hashmi, M.; Hanninen, S.] VTT Tech Res Ctr Finland, Energy Syst Knowledge Ctr, FI-02044 Espoo, Finland.
   [Sarwar, M.] PUCIT, Lahore, Pakistan.
RP Qureshi, SA (reprint author), UET, Dept Elect Engn, Lahore, Pakistan.
EM murtaza.hashmi@vtt.fi
FU Department of Electrical Engineering, University of Engineering and
   Technology (UET), Lahore, Pakistan
FX This research was funded by the Department of Electrical Engineering,
   University of Engineering and Technology (UET), Lahore, Pakistan.
CR Hashmi M, 2012, INT J ELEC POWER, V43, P1185, DOI 10.1016/j.ijepes.2012.06.035
   Mark R. G., 2004, CLIN ELECTROCARDIOGR
   Masood I., 2008, THESIS UET LAHORE
   Misiti M., 2009, MATLAB WAVELET TOOLB
   Su Li, 2005, 27 ANN C P IEEE ENG
   Welbell C., 2007, BIOMEDICAL INSTRUMEN
   Zhang Wei, 2005, P 7 INT POW ENG C NO, P1
NR 7
TC 1
Z9 2
U1 2
U2 10
PU KAUNAS UNIV TECHNOLOGY
PI KAUNAS
PA KAUNAS UNIV TECHNOL, DEPT ELECTRONICS ENGINEERING, STUDENTU STR 50,
   KAUNAS, LT-51368, LITHUANIA
SN 1392-1215
J9 ELEKTRON ELEKTROTECH
JI Elektron. Elektrotech.
PY 2014
VL 20
IS 3
BP 29
EP 32
DI 10.5755/j01.eee.20.3.6676
PG 4
WC Engineering, Electrical & Electronic
SC Engineering
GA AD6UN
UT WOS:000333396800005
DA 2018-12-27
ER

PT J
AU Ren, ZB
   Wang, HQ
   Feng, B
   Gu, CY
   Ma, YC
   Chen, H
   Li, BL
   Liu, LY
AF Ren, Zhibin
   Wang, Heqiu
   Feng, Bin
   Gu, Chenyu
   Ma, Yongchun
   Chen, Hong
   Li, Bingling
   Liu, Lanying
TI RETRACTED: A cross-sectional study on perception of stigma by Chinese
   schizophrenia patients (Retracted article. See vol. 11, pg. 895, 2015)
SO NEUROPSYCHIATRIC DISEASE AND TREATMENT
LA English
DT Article; Retracted Publication
DE schizophrenia; stigma; Brief Psychiatric Rating Scale (BPRS); Positive
   and Negative Syndrome Scale (PANSS); Clinical Global Impression-Severity
   (CGI-S) scale; Stigma Scale for Mental Illness (SSMI-C)
ID MENTAL-ILLNESS; SELF-STIGMA; OUTPATIENTS; DISCRIMINATION; EXPERIENCES;
   PEOPLE
AB Objective: In this cross-sectional study, we sought to assess the extent of internalized stigma among inpatients and outpatients with schizophrenia in the People's Republic of China and to investigate whether education level correlated with the experience of stigma.
   Methods: Schizophrenia patients were evaluated using the Brief Psychiatric Rating Scale (BPRS), the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions-Severity of Illness (CGI-S) scale and the Stigma Scale for Mental Illness (SSMI-C). Patients were categorized into high education and low education groups, according to their educational levels.
   Results: One hundred thirty-three subjects were included in the study. Their mean course of illness was 4.32 +/- 6.14 years (range: 1 month to 15 years). Their mean BPRS score was 19.87 +/- 5.46, their mean PANSS score was 44.11 +/- 13.1, and their mean CGI-S score was 2.22 +/- 0.81. In addition, their mean SSMI-C score was 6.49 +/- 0.9. The mean SSMI-C score of patients who have received high school education or above was 7.15 +/- 0.98, which was markedly higher than that of patients who have received middle school education or below, which was 5.75 +/- 0.79 (P<0.05). Before the study most patients (92.5%, 123/133) took atypical drugs.
   Conclusion: Education level impacts on the perception of stigma by schizophrenia patients, and more psychoeducation should be undertaken to improve patients' knowledge about schizophrenia.
C1 [Ren, Zhibin; Wang, Heqiu; Feng, Bin; Gu, Chenyu; Ma, Yongchun; Chen, Hong; Li, Bingling; Liu, Lanying] Zhejiang Chinese Med Univ, Tongde Hosp, Dept Psychiat, Hangzhou 310012, Zhejiang, Peoples R China.
RP Wang, HQ (reprint author), Zhejiang Chinese Med Univ, Tongde Hosp, Dept Psychiat, Gucui Rd 234, Hangzhou 310012, Zhejiang, Peoples R China.
EM wangheqiu2008@163.com
FU Zhejiang Province Key Science and Technology Innovation project
   [2012R10049-07]; Zhejiang Province medical scientific research fund
   project [2012KYA039]
FX This study was supported by the Zhejiang Province Key Science and
   Technology Innovation project (2012R10049-07) and the Zhejiang Province
   medical scientific research fund project (2012KYA039).
CR Angermeyer MC, 2003, SOC PSYCH PSYCH EPID, V38, P526, DOI 10.1007/s00127-003-0676-6
   [Anonymous], 2001, Lancet, V357, P1055
   Brohan E, 2010, SCHIZOPHR RES, V122, P232, DOI 10.1016/j.schres.2010.02.1065
   Brohan E, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-80
   Chee CYI, 2005, SOC PSYCH PSYCH EPID, V40, P648, DOI 10.1007/s00127-005-0932-z
   Chen Y., 2000, SHANGHAI ARCH PSYCHI, V12, P153
   Freudenreich O, 2004, J CLIN PSYCHIAT, V65, P1372, DOI 10.4088/JCP.v65n1012
   Fung KMT, 2007, INT J SOC PSYCHIATR, V53, P408, DOI 10.1177/0020764007078342
   [高士元 Gao Shiyuan], 2005, [中国心理卫生杂志, Chinese Mental Health Journal], V19, P82
   Guy W., 1976, ECDEU ASSESSMENT MAN
   Huang PR, 2009, CHIN MED ETH, V22, P72
   KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261
   Levav I, 2001, NEW UNDERSTANDING NE
   [耿峰 GENG Feng], 2010, [中国心理卫生杂志, Chinese Mental Health Journal], V24, P343
   Nan H, 2010, SHANGHAI ARCH PSYCHI, V22, P316
   OVERALL JE, 1962, PSYCHOL REP, V10, P799
   Phillips MR, 2002, BRIT J PSYCHIAT, V181, P488, DOI 10.1192/bjp.181.6.488
   Prince PN, 2002, PSYCHIATR REHABIL J, V25, P323, DOI 10.1037/h0095005
   Ritsher JB, 2004, PSYCHIAT RES, V129, P257, DOI 10.1016/j.psychres.2004.08.003
   Sartorius N, 1998, LANCET, V352, P1058, DOI 10.1016/S0140-6736(98)08008-8
   Schulze B, 2003, SOC SCI MED, V56, P299, DOI 10.1016/S0277-9536(02)00028-X
   World Health Organization (WHO), 1993, ICD 10 CLASS MENT BE
   Xiang YT, 2008, QUAL LIFE RES, V17, P27, DOI 10.1007/s11136-007-9285-2
   Zhang MY, 1990, SHANGHAI ARCH PSYCHI, V2, P1999
   Zhang WJ, 2013, INT J MENT HEALTH SY, V7, DOI 10.1186/1752-4458-7-22
NR 25
TC 2
Z9 2
U1 3
U2 16
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2021
J9 NEUROPSYCH DIS TREAT
JI Neuropsychiatr. Dis. Treat.
PY 2014
VL 10
BP 535
EP 540
DI 10.2147/NDT.S54115
PG 6
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AD6SG
UT WOS:000333390600001
PM 24707179
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Thai, HT
   Choi, DH
AF Huu-Tai Thai
   Choi, Dong-Ho
TI RETRACTED: Zeroth-order shear deformation theory for functionally graded
   plates resting on elastic foundation (Retracted article. See vol. 88,
   pg. 244, 2014)
SO INTERNATIONAL JOURNAL OF MECHANICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Functionally graded plate; Elastic foundation; Plate theory; Bending;
   Vibration
ID FREE-VIBRATION ANALYSIS; LAMINATED COMPOSITE PLATES; SANDWICH PLATES;
   THICK PLATES
AB This paper presents a zeroth-order shear deformation theory for bending and vibration analyses of functionally graded plates resting on elastic foundation. In the present theory, the shear deformation effect is incorporated in the in-plane displacements through the use of shear forces instead of rotational displacements as in existing shear deformation theories. Equations of motion and boundary conditions are derived from Hamilton's principle. Analytical solutions of simply supported plates are presented, and the obtained results are compared with available solutions to verify the accuracy of the present theory. Numerical results show that the present theory gives a very good prediction of bending and vibration responses of functionally graded plates resting on elastic foundation. (C) 2013 Published by Elsevier Ltd.
C1 [Huu-Tai Thai] Univ New S Wales, Sch Civil & Environm Engn, Sydney, NSW 2052, Australia.
   [Huu-Tai Thai; Choi, Dong-Ho] Hanyang Univ, Dept Civil & Environm Engn, Seoul 133791, South Korea.
RP Choi, DH (reprint author), Hanyang Univ, Dept Civil & Environm Engn, 17 Haengdang Dong, Seoul 133791, South Korea.
EM t.thai@unsw.edu.au; samga@hanyang.ac.kr
FU WCU (World Class University) program through the National Research
   Foundation of Korea; Ministry of Education, Science and Technology
   [R32-2008-000-20042-0]; Korea Ministry of Land, Transportation Maritime
   Affairs (MLTM) through Core Research Project 1 of Super Long Span Bridge
   RD Center
FX This research was supported by WCU (World Class University) program
   through the National Research Foundation of Korea funded by the Ministry
   of Education, Science and Technology (R32-2008-000-20042-0). This work
   is a part of a research project supported by the Korea Ministry of Land,
   Transportation Maritime Affairs (MLTM) through Core Research Project 1
   of Super Long Span Bridge R&D Center. The authors wish to express their
   gratitude for the financial support.
CR Ait Atmane H, 2010, INT J MECH MATER DES, V6, P113
   Baferani AH, 2011, COMPOS STRUCT, V93, P1842, DOI 10.1016/j.compstruct.2011.01.020
   Benyoucef S, 2010, MECH COMPOS MATER, V46, P425, DOI 10.1007/s11029-010-9159-5
   Carrera E, 2008, AIAA J, V46, P194, DOI 10.2514/1.32490
   Carrera E, 2011, COMPOS PART B-ENG, V42, P123, DOI 10.1016/j.compositesb.2010.10.005
   Chen CS, 2009, J REINF PLAST COMP, V28, P1215, DOI 10.1177/0731684408088884
   Fallah A, 2013, ARCH APPL MECH, V83, P177, DOI 10.1007/s00419-012-0645-1
   Fares ME, 2009, COMPOS STRUCT, V91, P296, DOI 10.1016/j.compstruct.2009.05.008
   Ferreira AJM, 2011, COMPOS PART B-ENG, V42, P1276, DOI 10.1016/j.compositesb.2011.01.031
   Ferreira AJM, 2005, COMPUT STRUCT, V83, P2225, DOI 10.1016/j.compstruc.2005.04.002
   Hosseini-Hashemi S, 2010, APPL MATH MODEL, V34, P1276, DOI 10.1016/j.apm.2009.08.008
   Thai HT, 2013, APPL MATH MODEL, V37, P3269, DOI 10.1016/j.apm.2012.08.008
   Jha DK, 2013, COMPOS STRUCT, V96, P799, DOI 10.1016/j.compstruct.2012.09.034
   Kitipornchai S, 2006, COMPUT METHOD APPL M, V195, P1075, DOI 10.1016/j.cma.2005.01.016
   Lu CF, 2009, MECH ADV MATER STRUC, V16, P576, DOI 10.1080/15376490903138888
   Mantari JL, 2013, COMPOS PART B-ENG, V45, P268, DOI 10.1016/j.compositesb.2012.05.036
   Mantari JL, 2012, COMPOS STRUCT, V94, P2561, DOI 10.1016/j.compstruct.2012.02.019
   Mantari JL, 2012, COMPOS STRUCT, V94, P714, DOI 10.1016/j.compstruct.2011.09.007
   MINDLIN RD, 1951, J APPL MECH-T ASME, V18, P31
   Natarajan S, 2012, FINITE ELEM ANAL DES, V57, P32, DOI 10.1016/j.finel.2012.03.006
   Neves AMA, 2013, COMPOS PART B-ENG, V44, P657, DOI 10.1016/j.compositesb.2012.01.089
   Neves AMA, 2012, COMPOS STRUCT, V94, P1814, DOI 10.1016/j.compstruct.2011.12.005
   Neves AMA, 2012, COMPOS PART B-ENG, V43, P711, DOI 10.1016/j.compositesb.2011.08.009
   Pasternak P.L., 1954, GOSUEDARSTVENNOE IZA, V1, P1
   Ray MC, 2003, J APPL MECH-T ASME, V70, P374, DOI [10.1115/1.1558077, 10.1115/1.158077]
   REDDY JN, 1984, J APPL MECH-T ASME, V51, P745, DOI 10.1115/1.3167719
   Reddy JN, 2000, INT J NUMER METH ENG, V47, P663, DOI 10.1002/(SICI)1097-0207(20000110/30)47:1/3<663::AID-NME787>3.0.CO;2-8
   Reddy JN, 2011, INT J AEROSPACE LIGH, V1, P1
   REISSNER E, 1945, J APPL MECH-T ASME, V12, pA69
   Shimpi RP, 1999, AIAA J, V37, P524, DOI 10.2514/2.750
   Sobhy M, 2013, COMPOS STRUCT, V99, P76, DOI 10.1016/j.compstruct.2012.11.018
   Talha M, 2010, APPL MATH MODEL, V34, P3991, DOI 10.1016/j.apm.2010.03.034
   Thai HT, 2013, COMPOS STRUCT, V99, P172, DOI 10.1016/j.compstruct.2012.11.030
   Thai HT, 2013, COMPOS STRUCT, V96, P165, DOI 10.1016/j.compstruct.2012.08.025
   Thai HT, 2012, COMPOS PART B-ENG, V43, P2335, DOI 10.1016/j.compositesb.2011.11.062
   Thai HT, 2011, COMPOS SCI TECHNOL, V71, P1850, DOI 10.1016/j.compscitech.2011.08.016
   Winkler E, 1867, LEHRE ELASTICITAET F
   Xiang S, 2013, EUR J MECH A-SOLID, V37, P336, DOI 10.1016/j.euromechsol.2012.08.005
   Xiang S, 2011, COMPOS STRUCT, V93, P2826, DOI 10.1016/j.compstruct.2011.05.022
   Yang J, 2005, INT J MECH SCI, V47, P1519, DOI [10.1016/j.ijmecsci.2005.06.006, 10.1016/j.ijmensci.2005.06.006]
   Zenkour AM, 2009, INT J MECH SCI, V51, P869, DOI 10.1016/j.ijmecsci.2009.09.026
NR 41
TC 5
Z9 5
U1 4
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7403
EI 1879-2162
J9 INT J MECH SCI
JI Int. J. Mech. Sci.
PD JAN
PY 2014
VL 78
BP 35
EP 43
DI 10.1016/j.ijmecsci.2013.09.020
PG 9
WC Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA AB4PU
UT WOS:000331773200005
DA 2018-12-27
ER

PT J
AU Chemloul, NS
AF Chemloul, N. Sad
TI RETRACTED: Experimental study of the drag reduction in turbulent pipe
   flow (Retracted article. See vol. 83, pg. 809, 2015)
SO ENERGY
LA English
DT Article; Retracted Publication
DE Drag reduction; Shear stress; Turbulent flow; Polymer
ID DIRECT NUMERICAL-SIMULATION; REDUCING POLYMER ADDITIVES; NON-NEWTONIAN
   FLUIDS; CHANNEL FLOW; DEGRADATION
AB In this work two-component LDV (Laser Doppler Velocimetry) technique was used to measure the effect of polymer on the drag reduction in a fully developed turbulent pipe flow. The Reynolds number based on the mean velocity, the pipe diameter and the local viscosity at the wall is approximately 10,000. The polymer solutions with three different concentrations are used and have been chosen such that maximum drag reduction occurs. The amount of drag reduction found is 60-70%. Our experimental results are compared with results obtained with water and with a very dilute solution which exhibits only a small amount of drag reduction.
   This study is focused on the observation of turbulence statistics (mean velocities and turbulence intensities) and on the various contributions to the total shear stress. The latter consists of a turbulent, a solvent (viscous) and a polymeric part. The polymers are found to contribute significantly to the total stress. With respect to the mean velocity profile, the results show a thickening of the buffer layer and an increase in the slope of the logarithmic profile. With respect to the turbulence statistics the results show that for the streamwise velocity fluctuations an increase of the root mean square at low polymer concentration but a return to values comparable to those for water at higher concentrations. The root mean square of the normal velocity fluctuations shows a strong decrease. Also the Reynolds (turbulent) shear stress and the correlation coefficient between the streamwise and the normal components are drastically reduced over the entire pipe diameter. In all cases the Reynolds stress stays definitely non-zero at maximum drag reduction. The consequence of the drop of the Reynolds stress is a large polymer stress, which can be 60% of the total stress. The kinetic-energy balance of the mean flow shows a large transfer of energy directly to the polymers instead of the route by turbulence. The kinetic energy of the turbulence suggests a possibly negative polymeric dissipation of turbulent energy. (C) 2013 Elsevier Ltd. All rights reserved.
C1 Univ Ibn Khaldoun, Dept Mech Engn, Tiaret, Algeria.
RP Chemloul, NS (reprint author), Univ Ibn Khaldoun, Dept Mech Engn, Tiaret, Algeria.
EM sad_1260@yahoo.fr
CR Batchelor G. K., 1967, INTRO FLUID DYNAMICS
   Benzi R, 2004, EUROPHYS LETT, V68, P825, DOI 10.1209/epl/i2004-10282-6
   Benzi R, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.078302
   Bird R. B., 1987, DYNAMICS POLYM LIQUI, V1
   Den Toonder JMJ, 1995, THESIS DELFT U NETHE
   DenToonder JMJ, 1997, J FLUID MECH, V337, P193, DOI 10.1017/S0022112097004850
   DENTOONDER JMJ, 1995, APPL SCI RES, V55, P63
   Dimitropoulos CD, 1998, J NON-NEWTON FLUID, V79, P433, DOI 10.1016/S0377-0257(98)00115-3
   Draad AA, 1998, J FLUID MECH, V377, P267, DOI 10.1017/S0022112098003139
   Draad AA., 1996, LAMINAR TURBULENT TR
   Gampert B, 1989, IUTAM S STRUCT TURB, P223
   Gyr A., 1995, DRAG REDUCTION TURBU
   HARDER KJ, 1991, PHILOS T ROY SOC A, V336, P19, DOI 10.1098/rsta.1991.0064
   Hunt JCR, 1999, FLUID DYN RES, V24, P375, DOI 10.1016/S0169-5983(99)00009-X
   INTERTHAL W, 1985, COLLOID POLYM SCI, V263, P217, DOI 10.1007/BF01415508
   KENIS PR, 1971, J APPL POLYM SCI, V15, P607, DOI 10.1002/app.1971.070150309
   L'vov VS, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.244503
   Lumley J. L., 1973, Journal of Polymer Science, Macromolecular Reviews, V7, P263, DOI 10.1002/pol.1973.230070104
   LUMLEY JL, 1969, ANNU REV FLUID MECH, V1, P367, DOI 10.1146/annurev.fl.01.010169.002055
   Mc Comb W, 1990, FLUID PHYS TURBULENC
   PINHO FT, 1990, J NON-NEWTON FLUID, V34, P129, DOI 10.1016/0377-0257(90)80015-R
   Procaccia I, 2008, REV MOD PHYS, V80, P225, DOI 10.1103/RevModPhys.80.225
   SCHLICHTING H, 1987, BOUNDARY LAYER THEOR
   Sreenivasan KR, 2000, J FLUID MECH, V409, P149, DOI 10.1017/S0022112099007818
   Sureshkumar R, 1997, PHYS FLUIDS, V9, P743, DOI 10.1063/1.869229
   Tennekes H, 1973, 1 COURSE TURBULENCE
   Tiederman WG, 1989, IUTAM S STRUCT TURB, P187
   Toms B.A., 1949, Proceedings of the 1st International Congress on Rheology
   VIRK PS, 1975, AICHE J, V21, P625, DOI 10.1002/aic.690210402
   VIRK PS, 1967, J FLUID MECH, V30, P305, DOI 10.1017/S0022112067001442
   VIRK PS, 1970, ASME J APPL MECH, V37, P480
   Warholic MD, 1999, J FLUID MECH, V388, P1, DOI 10.1017/S0022112099004498
   Warholic MD, 1999, EXP FLUIDS, V27, P461, DOI 10.1007/s003480050371
   WEI T, 1992, J FLUID MECH, V245, P619, DOI 10.1017/S0022112092000600
   White CM, 2008, ANNU REV FLUID MECH, V40, P235, DOI 10.1146/annurev.fluid.40.111406.102156
   WILLMARTH WW, 1987, PHYS FLUIDS, V30, P933, DOI 10.1063/1.866278
   Yang SQ, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2920275
   Yang SQ, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1924650
NR 38
TC 4
Z9 4
U1 3
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0360-5442
EI 1873-6785
J9 ENERGY
JI Energy
PD JAN 1
PY 2014
VL 64
BP 818
EP 827
DI 10.1016/j.energy.2013.10.055
PG 10
WC Thermodynamics; Energy & Fuels
SC Thermodynamics; Energy & Fuels
GA AA0VE
UT WOS:000330814700076
DA 2018-12-27
ER

PT J
AU Geng, HN
   Li, Q
AF Geng, Haining
   Li, Qiu
TI RETRACTED: Development of microstructure and chemical composition of
   hydration products of slag activated by ordinary Portland cement
   (Retracted article. See vol. 102, pg. 222, 2015)
SO MATERIALS CHARACTERIZATION
LA English
DT Article; Retracted Publication
DE Calcium-silicate-hydrate (C-S-H); TEM; SEM; EDX; Layered double
   hydroxide (LDH)
ID BLAST-FURNACE SLAG; C-S-H; BLENDED CEMENTS; PART I; CHEMISTRY; PASTES;
   MINERALOGY; NMR
AB Granulated blast-furnace slag was activated by Ca(OH)(2) formed during ordinary Portland cement hydration when used as supplementary cementitious materials together with ordinary Portland cement. Slag hydrated through diffusion controlled process and the microstructure and chemical composition of hydration products affected by the chemical composition of slag. In this study, the microstructure and chemical composition development of slag hydration was observed by TEM-EDX and found to be through the diffusion of Ca, Al and Si, and in situ formation of Mg-Al layered double hydroxide. Inner product calcium silicate hydrates (C-S-H) gel formed within the rim of the slag particles after the whole slag particle was diffused. The addition of slag into ordinary Portland cement reduced Ca/Si ratio, increased Al/Si ratio of C-S-H gel comparing to ordinary Portland cement paste. Mg/Al ratio of Mg-Al layered double hydroxide in the hydration products was around 2. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Geng, Haining; Li, Qiu] Wuhan Univ Technol, Sch Mat Sci & Technol, Wuhan 430070, Peoples R China.
   [Li, Qiu] Univ Leeds, Sch Civil Engn, Leeds LS2 9JT, W Yorkshire, England.
   [Li, Qiu] Wuhan Univ Technol, Minist Educ, Green Bldg Mat & Mfg Engn Res Ctr, Wuhan 430070, Peoples R China.
RP Li, Q (reprint author), Wuhan Univ Technol, Sch Mat Sci & Technol, Wuhan 430070, Peoples R China.
EM qiu.li.cn@gmail.com
CR Adolfsson D, 2011, CEMENT CONCRETE RES, V41, P865, DOI 10.1016/j.cemconres.2011.04.003
   Ben Haha M, 2012, CEMENT CONCRETE RES, V42, P74, DOI 10.1016/j.cemconres.2011.08.005
   Ben Haha M, 2011, CEMENT CONCRETE RES, V41, P955, DOI 10.1016/j.cemconres.2011.05.002
   Ben Haha M, 2011, CEMENT CONCRETE RES, V41, P301, DOI 10.1016/j.cemconres.2010.11.016
   Bohac M, 2009, MATER CHARACT, V60, P729, DOI 10.1016/j.matchar.2008.11.011
   Brough AR, 2002, CEMENT CONCRETE RES, V32, P865, DOI 10.1016/S0008-8846(02)00717-2
   DUCHESNE J, 1995, ADV CEM BASED MATER, V2, P43
   Escalante-Garcia JI, 2003, J AM CERAM SOC, V86, P2148, DOI 10.1111/j.1151-2916.2003.tb03623.x
   Escalante-Garcia JI, 2000, ADV CEM RES, V12, P121, DOI 10.1680/adcr.2000.12.3.121
   Feret R., 1939, SLAGS MANUFACTURE CE
   Garcia-Lodeiro I., 2010, CEMENT CONCRETE RES, V40, P27
   Gruskovnjak A, 2008, CEMENT CONCRETE RES, V38, P983, DOI 10.1016/j.cemconres.2008.03.004
   Gruskovnjak A, 2006, ADV CEM RES, V18, P119, DOI 10.1680/adcr.2006.18.3.119
   Harrisson A, 1986, MATER RES SOC S P, V86, P199
   Hill J, 2002, CEMENT CONCRETE COMP, V24, P191, DOI 10.1016/S0958-9465(01)00041-5
   Juenger MCG, 2011, CEMENT CONCRETE RES, V41, P1232, DOI 10.1016/j.cemconres.2010.11.012
   Kocaba V., 2009, DEV EVALUATION METHO
   Kocaba V, 2012, CEMENT CONCRETE RES, V42, P511, DOI 10.1016/j.cemconres.2011.11.010
   Konsta-Gdoutos MS, 2003, CEMENT CONCRETE RES, V33, P1269, DOI 10.1016/S0008-8846(03)00061-9
   Krivenko PV., 1986, SYNTHESIS BINDERS RE
   Le Saout G, 2011, J AM CERAM SOC, V94, P4541, DOI 10.1111/j.1551-2916.2011.04828.x
   Li C, 2010, CEMENT CONCRETE RES, V40, P1341, DOI 10.1016/j.cemconres.2010.03.020
   Li Q., 2009, NATURE EARLY AGE HYD
   Malolepszy J, 1986, P 8 INT C CHEM CEM, V65, P108
   Regourd M., 1980, 7 INT C CHEM CEM, V1
   Richardson IG, 2000, CEMENT CONCRETE COMP, V22, P259, DOI 10.1016/S0958-9465(00)00022-6
   RICHARDSON IG, 1992, J MATER SCI, V27, P6204, DOI 10.1007/BF01133772
   RICHARDSON IG, 1994, CEMENT CONCRETE RES, V24, P813, DOI 10.1016/0008-8846(94)90002-7
   RICHARDSON IG, 1993, J AM CERAM SOC, V76, P2285, DOI 10.1111/j.1151-2916.1993.tb07765.x
   ROY DM, 1992, MATER RES SOC SYMP P, V245, P153
   Roy DM, MRS P
   Sawyer J. L., 1985, U. S. Patent No, Patent No. [4,509,985, 4509985, USP 4509985]
   Song S, 2000, J MATER SCI, V35, P249, DOI 10.1023/A:1004742027117
   Song SJ, 1999, CEMENT CONCRETE RES, V29, P159, DOI 10.1016/S0008-8846(98)00212-9
   Talling B, 1989, FLY ASH SILICA FUME, V2, P1519
   Tanaka H, 1983, P 1 INT C FLY ASH SI, V79, P963
   Taylor H. F. W., 1997, CEMENT CHEM
   Thomas JJ, 2012, CEMENT CONCRETE RES, V42, P377, DOI 10.1016/j.cemconres.2011.11.003
   Wang SD, 2000, ADV CEM RES, V12, P163, DOI 10.1680/adcr.2000.12.4.163
   WANG SD, 1995, CEMENT CONCRETE RES, V25, P561, DOI 10.1016/0008-8846(95)00045-E
   WU XQ, 1990, CEMENT CONCRETE RES, V20, P961, DOI 10.1016/0008-8846(90)90060-B
NR 41
TC 4
Z9 4
U1 5
U2 39
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1044-5803
EI 1873-4189
J9 MATER CHARACT
JI Mater. Charact.
PD JAN
PY 2014
VL 87
BP 149
EP 158
DI 10.1016/j.matchar.2013.11.012
PG 10
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering; Materials Science, Characterization & Testing
SC Materials Science; Metallurgy & Metallurgical Engineering
GA AA9OA
UT WOS:000331421600017
DA 2018-12-27
ER

PT J
AU Chen, HX
   Tang, C
   Liu, MG
   Zhou, B
   Kuang, Y
   Yuan, T
   Chen, P
AF Chen, Hongxu
   Tang, Chun
   Liu, Menggang
   Zhou, Bo
   Kuang, Yi
   Yuan, Tao
   Chen, Ping
TI RETRACTED: Association of XRCC1 gene single nucleotide polymorphisms and
   susceptibility to pancreatic cancer in Chinese (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Pancreatic cancer; XRCC1 gene; Cancer susceptibility; Single nucleotide
   polymorphisms; Molecular markers
ID BODY-MASS INDEX; COMMERCIAL CATTLE; REPAIR GENES; RISK-FACTORS;
   ADENOCARCINOMA; SURVIVAL; SMOKING; COHORT; DNA
AB The human X-ray repair cross-complementing group 1 gene (XRCC1) is an important candidate gene for affecting pancreatic cancer (PC) risk. The objective of this study was to detect whether the c.1471G > A and c.1686C > G polymorphisms of XRCC1 gene influence PC risk. The association of XRCC1 genetic variants with PC risk was analyzed in 328 PC patients and 350 controls by the polymerase chain reaction-restriction fragment length polymorphism and created restriction site-polymerase chain reaction method. Our data suggested that the genotypes and alleles from these two genetic variants were statistically associated with PC risk. For c.1471G > A, the AA genotype was associated with the decreased risk of developing PC compared to GG wild genotype (odds ratio (OR) = 0.43, 95 % confidence intervals (CI) 0.26-0.70, chi-squared (chi (2)) = 11.91, P = 0.001). For c.1686C > G, the risk of PC was significantly lower for GG genotype in comparing to CC wild genotype (OR = 0.48, 95 % CI 0.29-0.81, chi (2) = 7.98, P = 0.005). The A allele of c.1471G > A and G allele of c.1686C > G genetic variants could contribute to decrease the risk of PC (for c.1471G > A: A vs G, OR = 0.65, 95 % CI 0.52-0.82, chi (2) = 13.71, P < 0.001, for c.1686C > G: G vs C, OR = 0.70, 95 % CI 0.55-0.88, chi (2) = 9.42, P = 0.002). Our findings indicate that the c.1471G > A and c.1686C > G polymorphisms of XRCC1 gene are associated with PC risk in Chinese population.
C1 [Chen, Hongxu; Tang, Chun; Liu, Menggang; Zhou, Bo; Kuang, Yi; Yuan, Tao; Chen, Ping] Third Mil Med Univ, Daping Hosp, Dept Hepatobiliary Surg, Chongqing 400042, Peoples R China.
RP Chen, P (reprint author), Third Mil Med Univ, Daping Hosp, Dept Hepatobiliary Surg, 10 Changjiangzhilu Daping, Chongqing 400042, Peoples R China.
EM pingchen_12@sina.com
CR Chu D, 2010, J PANCREAS, V11, P203
   Duell EJ, 2002, CANCER RES, V62, P4630
   HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P3606, DOI 10.1093/nar/17.9.3606
   Hung RJ, 2005, AM J EPIDEMIOL, V162, P925, DOI 10.1093/aje/kwi318
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Landi S, 2009, MUTAT RES-REV MUTAT, V681, P299, DOI 10.1016/j.mrrev.2008.12.001
   Larsson SC, 2007, INT J CANCER, V120, P1993, DOI 10.1002/ijc.22535
   Li DH, 2006, J CLIN ONCOL, V24, P1720, DOI 10.1200/JCO.2005.04.4206
   Li DH, 2007, INT J CANCER, V120, P1748, DOI 10.1002/ijc.22301
   Li J, 2006, CANC DETECT PREV, V30, P284
   Lin Yingsong, 2001, Asian Pac J Cancer Prev, V2, P271
   Lowenfels AB, 2006, BEST PRACT RES CL GA, V20, P197, DOI 10.1016/j.bpg.2005.10.001
   Lowenfels AB, 2003, PANCREATOLOGY, V3, P1, DOI 10.1159/000069140
   Luo JH, 2007, CANCER CAUSE CONTROL, V18, P603, DOI 10.1007/s10552-007-9002-z
   Mandal RK, 2010, ASIAN PAC J CANCER P, V11, P1601
   McWilliams RR, 2008, CANCER RES, V68, P4928, DOI 10.1158/0008-5472.CAN-07-5539
   Nakao M, 2012, J EPIDEMIOL, V22, P477, DOI 10.2188/jea.JE20120010
   Nitsche C, 2011, DIGEST DIS, V29, P235, DOI 10.1159/000323933
   Tanaka M, 2011, CANCER-AM CANCER SOC, V117, P744, DOI 10.1002/cncr.25510
   Yuan ZR, 2013, MOL BIOL REP, V40, P1947, DOI 10.1007/s11033-012-2251-2
   Yuan ZR, 2013, MOL BIOL REP, V40, P7, DOI 10.1007/s11033-012-1934-z
   Yuan ZR, 2012, GENE, V505, P190, DOI 10.1016/j.gene.2012.05.010
   Zhao Chun-Jiang, 2003, Yichuan, V25, P327
NR 23
TC 2
Z9 2
U1 4
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2014
VL 35
IS 1
BP 27
EP 32
DI 10.1007/s13277-013-1001-y
PG 6
WC Oncology
SC Oncology
GA AA4UE
UT WOS:000331091000004
PM 23893380
DA 2018-12-27
ER

PT J
AU Tian, X
   Ma, P
   Sui, CG
   Li, Y
   Fu, LY
   Jiang, T
   Wang, Y
   Jiang, YH
AF Tian, Xin
   Ma, Ping
   Sui, Chengguang
   Li, Yan
   Fu, Liye
   Jiang, Tao
   Wang, Yang
   Jiang, Youhong
TI RETRACTED: Comprehensive assessment of the association between tumor
   necrosis factor alpha G238A polymorphism and liver cancer risk
   (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Liver cancer; Tumor necrosis factor-alpha; Polymorphism
ID CHRONIC HEPATITIS-B; C VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; GENE
   POLYMORPHISMS; MOLECULAR-MECHANISMS; TNF; SUSCEPTIBILITY; POPULATION;
   METAANALYSIS; CLEARANCE
AB Tumor necrosis factor alpha (TNF-alpha) has been suggested to play an important role in the development and liver cancer. TNF-alpha 238 G/A polymorphism was hypothesized to increase the risk of liver cancer, but findings from previous studies were controversial. To explore a more precise estimation of the relationship between TNF-alpha 238 G/A polymorphism and liver cancer, we performed a meta-analysis. PubMed, Embase, and China Biology Medicine databases were searched for all publications on this association through March 12, 2013. Odds ratios (ORs) with its 95 % confidence intervals (CIs) were used to assess the strength of this association. Eleven studies with 1,406 liver cancer cases and 2,386 noncancer controls were included into this meta-analysis. Overall, there was a significant association between TNF-alpha 238 G/A polymorphism and increased risk of liver cancer under all three genetic models (A vs. G, OR 1.51, 95 % CI 1.20-1.89, P < 0.001, I (2) = 37.7 %; AG vs. GG, OR 1.49, 95 % CI 1.01-2.21, P = 0.045, I (2) = 53.2 %; AA/AG vs. GG, OR 1.76, 95 % CI 1.35-2.30, P < 0.001, I (2) = 36.5 %). The sensitivity analysis further strengthened the validity of the positive association. Subgroup analysis of nine studies from Asian countries showed that there was a significant association between TNF-alpha 238 G/A polymorphism and increased risk of liver cancer in Asians (A vs. G, OR 1.35, 95 % CI 1.03-1.76, P = 0.027, I (2) = 40.2 %; AA/AG vs. GG, OR 1.56, 95 % CI 1.14-2.15, P = 0.006, I (2) = 41.9 %). In conclusion, TNF-alpha 238 G/A polymorphism is significantly associated with increased risk of liver cancer, especially in Asians.
C1 [Tian, Xin; Ma, Ping; Sui, Chengguang; Li, Yan; Fu, Liye; Jiang, Tao; Wang, Yang; Jiang, Youhong] China Med Univ, Hosp 1, Canc Res Inst, Dept Mol Oncol, Shenyang 110001, Peoples R China.
RP Jiang, YH (reprint author), China Med Univ, Hosp 1, Canc Res Inst, Dept Mol Oncol, Shenyang 110001, Peoples R China.
EM youhongj19@hotmail.com
CR Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580
   Ashkenazi A, 2008, J CLIN ONCOL, V26, P3621, DOI 10.1200/JCO.2007.15.7198
   Asim M, 2011, HEPATOL INT, V5, P428
   Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X
   Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628
   Chen XM, 2011, INT J BIOL MARKER, V26, P181, DOI 10.5301/JBM.2011.8580
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ding B, 2012, INT J GYNECOL CANCER, V22, P213, DOI 10.1097/IGC.0b013e3182375aed
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Heneghan Michael A, 2003, Int J Gastrointest Cancer, V34, P19
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HUANG HL, 2007, PROGR ANATOMICAL SCI, V13, P11
   Jeng JE, 2007, NEOPLASIA, V9, P987, DOI 10.1593/neo.07781
   Jeng JE, 2009, MEDICINE, V88, P349, DOI 10.1097/MD.0b013e3181c10477
   Jung KW, 2009, CLIN CHIM ACTA, V407, P16, DOI 10.1016/j.cca.2009.06.013
   Kummee P, 2007, J VIRAL HEPATITIS, V14, P841, DOI 10.1111/j.1365-2893.2007.00880.x
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   McCracken M, 2007, CA-CANCER J CLIN, V57, P190, DOI 10.3322/canjclin.57.4.190
   Niro GA, 2005, LIVER INT, V25, P1175, DOI 10.1111/j.1478-3231.2005.01166.x
   Ognjanovic S, 2009, CARCINOGENESIS, V30, P758, DOI 10.1093/carcin/bgn286
   Sakamoto T, 2008, CANCER LETT, V271, P98, DOI 10.1016/j.canlet.2008.05.036
   Seitz HK, 2007, NAT REV CANCER, V7, P599, DOI 10.1038/nrc2191
   Shitani M, 2012, TUMOR BIOL, V33, P1307, DOI 10.1007/s13277-012-0378-3
   TEIXEIRA AC, 2010, J HEPATOL S1, V52, pS236
   ten Hagen TLM, 2008, IMMUNOL REV, V222, P299, DOI 10.1111/j.1600-065X.2008.00619.x
   Villanueva A, 2011, GASTROENTEROLOGY, V140, P1410, DOI 10.1053/j.gastro.2011.03.006
   Villanueva A, 2010, ANNU REV MED, V61, P317, DOI 10.1146/annurev.med.080608.100623
   Walczak H, 2011, IMMUNOL REV, V244, P9, DOI 10.1111/j.1600-065X.2011.01066.x
   Wang BB, 2010, PATHOLOGY, V42, P674, DOI 10.3109/00313025.2010.523696
   Wang J, 2011, INT J IMMUNOGENET, V38, P311, DOI 10.1111/j.1744-313X.2011.01014.x
   Wang X, 2008, ACTA PHARMACOL SIN, V29, P1275, DOI 10.1111/j.1745-7254.2008.00889.x
   Wang Y, 2003, HEPATOLOGY, V37, P65, DOI 10.1053/jhep.2003.50017
   Wullaert A, 2007, ENDOCR REV, V28, P365, DOI 10.1210/er.2006-0031
   Yang CL, 2012, TUMOR BIOL, V33, P1535, DOI 10.1007/s13277-012-0405-4
   Zhou P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022092
   Zhu H, 2012, GENE, V509, P206, DOI 10.1016/j.gene.2012.08.027
NR 36
TC 6
Z9 6
U1 6
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2014
VL 35
IS 1
BP 103
EP 109
DI 10.1007/s13277-013-1012-8
PG 7
WC Oncology
SC Oncology
GA AA4UE
UT WOS:000331091000014
PM 23943369
DA 2018-12-27
ER

PT J
AU Li, ZC
   Zhang, LM
   Wang, HB
   Ma, JX
   Sun, JZ
AF Li, Zhen-Cai
   Zhang, Li-Ming
   Wang, Hai-Bin
   Ma, Jun-Xun
   Sun, Jun-Zhong
TI RETRACTED: Curcumin inhibits lung cancer progression and metastasis
   through induction of FOXO1 (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Curcumin; Lung cancer; FOXO1; ERK1/2 signaling
ID FORKHEAD TRANSCRIPTION FACTORS; COLON-CANCER; THERAPY; DEATH
AB Recent population studies provide clues that the use of curcumin may be associated with reduced incidence and improved prognosis of certain cancers. In the present study, we demonstrated that curcumin acted as a growth inhibitor for lung cancer cells. Our results found that curcumin inhibited cell proliferation, which was associated with upregulation of the cyclin-dependent kinase inhibitors, p27 and p21, and downregulation of cyclin D1. In addition, we showed that curcumin induced the expression of forkhead box protein O1 (FOXO1) through activation of extracellular signal-regulated kinase 1/2 signaling. These findings provide evidence for a mechanism that may contribute to the antineoplastic effects of curcumin and justify further work to explore potential roles for activators of FOXO1 in the prevention and treatment of lung cancer.
C1 [Li, Zhen-Cai] Chinese PLA, Gen Hosp, Affiliated Hosp 1, Dept Ultrasound, Beijing 100048, Peoples R China.
   [Zhang, Li-Ming] Chinese Peoples Liberat Army, Hosp 535, Huaihua 418000, Hunan, Peoples R China.
   [Wang, Hai-Bin; Ma, Jun-Xun; Sun, Jun-Zhong] Gen Hosp Chinese PLA, Affiliated Hosp 1, Dept Oncol, Beijing 100048, Peoples R China.
RP Sun, JZ (reprint author), Gen Hosp Chinese PLA, Affiliated Hosp 1, Dept Oncol, Beijing 100048, Peoples R China.
EM Sjunzh07@163.com
FU National Natural Science Foundation of China [81071839]; Capital Medical
   Development Foundation of China
FX This study was supported by the National Natural Science Foundation of
   China (No. 81071839), Capital Medical Development Foundation of China
   (2007-2040).
CR Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629
   Dorai T, 2004, CANCER LETT, V215, P129, DOI 10.1016/j.canlet.2004.07.013
   GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002
   Maekawa T, 2009, ONCOL REP, V22, P57, DOI 10.3892/or_00000406
   Manju V, 2005, CLIN CHIM ACTA, V358, P60, DOI 10.1016/j.cccn.2005.02.018
   Nessa MU, 2012, ANTICANCER RES, V32, P4843
   Saha S, 2012, ANTICANCER RES, V32, P2567
   Sangodkar J, 2012, J CLIN INVEST, V122, P2637, DOI 10.1172/JCI62058
   Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002
   Shehzad A, 2012, FUTURE ONCOL, V8, P179, DOI [10.2217/fon.11.145, 10.2217/FON.11.145]
   Sinha R, 2003, J Postgrad Med, V49, P222
   Spiro SG, 2005, AM J RESP CRIT CARE, V172, P523, DOI 10.1164/rccm.200504-531OE
   Spiro SG, 2010, RESPIROLOGY, V15, P44, DOI 10.1111/j.1440-1843.2009.01674.x
   Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190
   Yogosawa S, 2012, J NAT PROD, V75, P2088, DOI 10.1021/np300465f
NR 18
TC 26
Z9 27
U1 3
U2 18
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2014
VL 35
IS 1
BP 111
EP 116
DI 10.1007/s13277-013-1013-7
PG 6
WC Oncology
SC Oncology
GA AA4UE
UT WOS:000331091000015
PM 23888319
DA 2018-12-27
ER

PT J
AU Jin, B
   Dong, P
   Li, KY
   Shen, B
   Xie, J
AF Jin, Bin
   Dong, Pin
   Li, Keyong
   Shen, Bin
   Xie, Jin
TI RETRACTED: Meta-analysis of the association between GSTT1 null genotype
   and risk of nasopharyngeal carcinoma in Chinese (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Nasopharyngeal carcinoma; GSTT1; Meta-analysis
ID POLYMORPHISMS; CANCER; GSTM1; TRANSFERASES; GSTP1; EAST
AB Glutathione S-transferase T1 (GSTT1) null genotype has been proven to be associated with risks of many cancers. There were also many studies assessing on the association between GSTT1 null genotype and nasopharyngeal carcinoma risk in Chinese, but the findings from those studies were inconsistent. We performed a meta-analysis to provide a more precise assessment on the effect of GSTT1 null genotype on nasopharyngeal carcinoma risk. The PubMed and Wanfang databases were searched to identify eligible case-control studies on the association between GSTT1 null genotype and risk of nasopharyngeal carcinoma in Chinese. The pooled odds ratios (OR) with corresponding 95 % confidence intervals (95 % CI) were used to assess the association. Eight case-control studies with a total of 3,702 individuals were finally included in the meta-analysis. Meta-analysis of a total of eight studies showed that GSTT1 null genotype was significantly associated with increased risk of nasopharyngeal carcinoma in Chinese (OR = 2.27; 95 % CI 1.41-3.67; P = 0.001). The finding from cumulative meta-analysis showed that there was a trend of more obvious association between GSTT1 null genotype and risk of nasopharyngeal carcinoma in Chinese as data accumulated by publication year. Therefore, the GSTT1 null genotype is significantly associated with increased risk of nasopharyngeal carcinoma in Chinese.
C1 [Jin, Bin; Dong, Pin; Li, Keyong; Shen, Bin; Xie, Jin] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 1, Dept Otolaryngol & Head & Neck Surg, Shanghai 200080, Peoples R China.
RP Xie, J (reprint author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 1, Dept Otolaryngol & Head & Neck Surg, Shanghai 200080, Peoples R China.
EM doctorjinjiaotong@live.cn
CR Cao Su-Mei, 2011, Chin J Cancer, V30, P114
   Chakroun A, 2011, EUR ANN OTORHINOLARY, V128, P127, DOI 10.1016/j.anorl.2010.10.007
   Cheng YJ, 2003, CANCER EPIDEM BIOMAR, V12, P179
   Deng Zhuo-lin, 2004, Zhonghua Zhongliu Zazhi, V26, P598
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423
   Fang M, 2013, TUMOUR BIOL
   Guo XC, 2008, CANCER EPIDEM BIOMAR, V17, P1760, DOI 10.1158/1055-9965.EPI-08-0149
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang GL, 2011, ASIAN PAC J CANCER P, V12, P2329
   Jia WH, 2012, SEMIN CANCER BIOL, V22, P117, DOI 10.1016/j.semcancer.2012.01.009
   Jiang Y, 2011, ASIAN PAC J CANCER P, V12, P3097
   Lee AWM, 2012, SEMIN RADIAT ONCOL, V22, P233, DOI 10.1016/j.semradonc.2012.03.008
   Liao ZL, 2005, J GUANGXI MED U, V22, P372
   Liu ZG, 2003, J GUANGXI MED U, V20, P161
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Muellerleile P, 2006, AM J PUBLIC HEALTH, V96, P515, DOI 10.2105/AJPH.2003.036343
   Sharma R, 2004, ANTIOXID REDOX SIGN, V6, P289, DOI 10.1089/152308604322899350
   Tian SZ, 2007, THESIS ZHONGSHAN U
   Wei YP, 2012, CHIN GERMAN J CLIN O, V11, P138
   Yu WM, 2009, J LARYNGOL OTOL, V123, P1067, DOI 10.1017/S0022215109005623
   Zhao Y, 2013, TUMOR BIOL, V34, P1691, DOI 10.1007/s13277-013-0706-2
   Zhuo XL, 2009, ARCH MED RES, V40, P299, DOI 10.1016/j.arcmed.2009.03.006
NR 25
TC 4
Z9 4
U1 3
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2014
VL 35
IS 1
BP 345
EP 349
DI 10.1007/s13277-013-1047-x
PG 5
WC Oncology
SC Oncology
GA AA4UE
UT WOS:000331091000044
PM 23949879
DA 2018-12-27
ER

PT J
AU Sun, HL
   Han, B
   Zhai, HP
   Cheng, XH
   Ma, K
AF Sun, Hong-Li
   Han, Bing
   Zhai, Hong-Peng
   Cheng, Xin-Hua
   Ma, Kai
TI RETRACTED: Association between glutathione S-transferase M1 null
   genotype and risk of gallbladder cancer: a meta-analysis (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Gallbladder cancer; GSTM1; Meta-analysis
ID POLYMORPHISMS; SUSCEPTIBILITY; MANAGEMENT; CARCINOMA; GENES; GSTM1;
   GSTT1
AB Glutathione S-transferases (GSTs) are a family of enzymes which are involved in the detoxification of potential carcinogens. Glutathione S-transferase M1 (GSTM1) null genotype can impair the enzyme activity of GSTs and is suspected to increase the susceptibility to gallbladder cancer. Previous studies investigating the association between GSTM1 null genotype and risk of gallbladder cancer reported inconsistent findings. To quantify the association between GSTM1 null genotype and risk of gallbladder cancer, we performed a meta-analysis of published studies. We searched PubMed, Embase, and Wanfang databases for all possible studies. We estimated the pooled odds ratio (OR) with its 95 % confidence interval (95 % CI) to assess the association. Meta-analysis of total included studies showed that GSTM1 null genotype was not associated with gallbladder cancer risk (OR = 1.13, 95 % CI 0.88-1.46, P = 0.332). Subgroup analysis by ethnicity showed that there was no association between GSTM1 null genotype and risk of gallbladder cancer in both Caucasians and Asians. However, meta-analysis of studies with adjusted estimations showed that GSTM1 null genotype was associated with increased risk of gallbladder cancer (OR = 1.46, 95 % CI 1.02-2.09, P = 0.038). Thus, this meta-analysis shows that GSTM1 null genotype is likely to be associated with risk of gallbladder cancer. More studies with well design and large sample size are needed to further validate the association between GSTM1 null genotype and gallbladder cancer.
C1 [Sun, Hong-Li; Han, Bing; Cheng, Xin-Hua; Ma, Kai] China Med Univ, Shengjing Hosp, Dept Biliary & Vasc Surg, Shenyang 110004, Peoples R China.
   [Zhai, Hong-Peng] Fengtian Hosp, Shenyang Med Coll, Dept Gen Surg, Shenyang 110004, Peoples R China.
RP Ma, K (reprint author), China Med Univ, Shengjing Hosp, Dept Biliary & Vasc Surg, Shenyang 110004, Peoples R China.
EM drmakai@126.com
CR DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eslick GD, 2010, GASTROENTEROL CLIN N, V39, P307, DOI 10.1016/j.gtc.2010.02.011
   Gao Jing, 2009, Tumor, V29, P145
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Horgan AM, 2012, J CLIN ONCOL, V30, P1934, DOI 10.1200/JCO.2011.40.5381
   Jayaraman S, 2010, GASTROENTEROL CLIN N, V39, P331, DOI 10.1016/j.gtc.2010.02.006
   Kimura A, 2008, ASIAN PAC J CANCER P, V9, P391
   LIU Y, 2012, COMMUN ACM, V5, P480
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marahatta SB, 2006, CANCER LETT, V236, P276, DOI 10.1016/j.canlet.2005.05.020
   Marsh RD, 2012, J SURG ONCOL, V106, P332, DOI 10.1002/jso.23028
   Mishra RR, 2010, HEPATOB PANCREAT DIS, V9, P129
   Oakley A, 2011, DRUG METAB REV, V43, P138, DOI 10.3109/03602532.2011.558093
   Pandey SN, 2006, BIOMARKERS, V11, P250, DOI 10.1080/13547500600648697
   Rai R, 2011, EUR J CANCER PREV, V20, P77, DOI 10.1097/CEJ.0b013e328341e371
   Srivastava K, 2011, MUTAT RES-REV MUTAT, V728, P67, DOI 10.1016/j.mrrev.2011.06.002
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Tsuchiya Y, 2007, CLIN BIOCHEM, V40, P881, DOI 10.1016/j.clinbiochem.2007.04.005
   Tsuchiya Y, 2010, INT J BIOL MARKER, V25, P75
   Wang B, 2010, J HEPATOL, V53, P508, DOI 10.1016/j.jhep.2010.03.026
   Zhang RG, 2011, MOL BIOL REP, V38, P2491, DOI 10.1007/s11033-010-0386-6
   Zhu AX, 2010, ONCOLOGIST, V15, P168, DOI 10.1634/theoncologist.2009-0302
NR 26
TC 2
Z9 2
U1 4
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2014
VL 35
IS 1
BP 501
EP 505
DI 10.1007/s13277-013-1070-y
PG 5
WC Oncology
SC Oncology
GA AA4UE
UT WOS:000331091000065
PM 24136740
DA 2018-12-27
ER

PT J
AU Xu, W
   Wang, F
   Ying, L
   Wang, HH
AF Xu, Wei
   Wang, Fa
   Ying, Li
   Wang, Hong-Hui
TI RETRACTED: Association between glutathione S-transferase M1 null variant
   and risk of bladder cancer in Chinese Han population (Retracted article.
   See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Bladder cancer; Glutathione S-transferase M1; Meta-analysis
ID GENETIC-VARIANTS; METAANALYSIS; SUSCEPTIBILITY; POLYMORPHISMS; GSTM1;
   GSTT1; T1; P1
AB Glutathione S-transferase M1 (GSTM1) is one of the most important families of phase II isoenzymes known to detoxify a variety of electrophilic compounds and carcinogens. The GSTM1 null variant is associated with decreased enzyme activity, and it has been assumed to be associated with bladder cancer. The association between the GSTM1 null variant and bladder cancer in the Chinese Han population was unclear owing to the obvious inconsistency from published studies. To quantify the association between the GSTM1 null variant and bladder cancer in the Chinese Han population, we carried out the meta-analysis. We estimated the pooled odds ratio (OR) with its 95 % confidence interval (95 % CI) to assess the association. Eight studies with a total of 3,887 individuals were finally included into the meta-analysis. Overall, there was an obvious association between the GSTM1 null variant and risk of bladder cancer in the Chinese Han population (OR = 1.61, 95 % CI 1.41-1.84, P < 0.001). There was no heterogeneity across those eight studies (I (2) = 0 %). The cumulative meta-analyses showed a trend of more obvious association between the GSTM1 null variant and risk of bladder cancer in the Chinese Han population as data accumulated by year. There was no obvious evidence of publication bias in the meta-analysis. In conclusion, the GSTM1 null variant is significantly associated with risk of bladder cancer in the Chinese Han population.
C1 [Xu, Wei; Wang, Fa; Ying, Li; Wang, Hong-Hui] Harbin Med Univ, Affiliated Hosp 2, Dept Intervent Radiol, Harbin 150086, Peoples R China.
RP Wang, HH (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Intervent Radiol, Harbin 150086, Peoples R China.
EM honghuiharbin@sina.com
CR Cash HL, 2012, INT J CANCER, V130, P1151, DOI 10.1002/ijc.26098
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fu J.-S., 2009, THESIS
   [郝刚跃 Hao Gangyue], 2002, [中华泌尿外科杂志, Chinese Journal of Urology], V23, P344
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jacobs BL, 2010, CA-CANCER J CLIN, V60, P244, DOI 10.3322/caac.20077
   Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8
   Kumar V, 2011, ASIAN PAC J CANCER P, V12, P2221
   Ma QW, 2002, BIOMED ENVIRON SCI, V15, P253
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mitra AP, 2009, ANNU REV PATHOL-MECH, V4, P251, DOI 10.1146/annurev.pathol.4.110807.092230
   Muellerleile P, 2006, AM J PUBLIC HEALTH, V96, P515, DOI 10.2105/AJPH.2003.036343
   Sanyal S, 2004, CARCINOGENESIS, V25, P729, DOI 10.1093/carcin/bgh058
   Schmitz-Drager BJ, 2011, EUR UROL, V60, P721, DOI 10.1016/j.eururo.2011.07.065
   [邵常霞 SHAO ChangXia], 2006, [肿瘤, Tumor], V26, P346
   Shao JF, 2008, INT J UROL, V15, P216, DOI 10.1111/j.1442-2042.2007.01915.x
   [邵剑锋 SHAO JianFeng], 2006, [肿瘤, Tumor], V26, P352
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Simic T, 2009, NAT REV UROL, V6, P281, DOI 10.1038/nrurol.2009.49
   Song DK, 2009, CANCER DETECT PREV, V32, P416, DOI 10.1016/j.cdp.2009.02.003
   Srivastava DSL, 2005, EUR UROL, V48, P339, DOI 10.1016/j.eururo.2005.02.007
   Wang B, 2010, J HEPATOL, V53, P508, DOI 10.1016/j.jhep.2010.03.026
   Wang ZL, 2013, TUMOR BIOL, V34, P1651, DOI 10.1007/s13277-013-0698-y
   Ye YQ, 2008, CANCER-AM CANCER SOC, V112, P2467, DOI 10.1002/cncr.23472
   Zhang Y, 2013, TUMOR BIOL, V34, P973, DOI 10.1007/s13277-012-0633-7
   Zhu Y, 2012, MOL BIOL REP, V39, P685, DOI 10.1007/s11033-011-0786-2
NR 30
TC 3
Z9 3
U1 3
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2014
VL 35
IS 1
BP 773
EP 777
DI 10.1007/s13277-013-1105-4
PG 5
WC Oncology
SC Oncology
GA AA4UE
UT WOS:000331091000098
PM 24022663
DA 2018-12-27
ER

PT J
AU Luo, SY
   Guo, L
   Li, Y
   Wang, SM
AF Luo, Shayang
   Guo, Lei
   Li, Yan
   Wang, Shouman
TI RETRACTED: Vitamin D receptor gene ApaI polymorphism and breast cancer
   susceptibility: a meta-analysis (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE VDR; Breast cancer; Meta-analysis
ID D METABOLISM; GRAPHICAL TEST; RISK; ASSOCIATION; VARIANTS; EXPOSURE;
   WOMEN; BIAS
AB Vitamin D receptor (VDR) principally mediates the anticancer activities of vitamin D. Many studies investigated the association between VDR gene ApaI polymorphism and breast cancer, but the results were inconclusive. We performed this meta-analysis to evaluate the association between VDR gene ApaI polymorphism and breast cancer. Twelve studies with a total of 8,254 subjects were identified from PubMed and Wanfang databases. The pooled odds ratio (OR) and confidence intervals (95 % CI) were used to assess the association. The meta-analysis indicated that VDR gene ApaI polymorphism was not associated with risk of breast cancer (a vs. A: OR = 0.97, 95 % CI 0.91-1.04, P = 0.378; aa vs. AA: OR = 0.97, 95 % CI 0.85-1.10, P = 0.618; aa vs. AA + Aa: OR = 1.00, 95 % CI 0.89-1.12, P = 0.972; aa + Aa vs. AA: OR = 0.95, 95 % CI 0.82-1.11, P = 0.550). Subgroup analysis by ethnicity further showed that VDR gene ApaI polymorphism was not associated with risk of breast cancer in both Asians and Caucasians. These data from the meta-analysis indicate that VDR gene ApaI polymorphism is not associated with breast cancer susceptibility.
C1 [Luo, Shayang; Guo, Lei; Li, Yan; Wang, Shouman] Cent S Univ, Xiangya Hosp, Dept Breast Surg, Changsha 410008, Hunan, Peoples R China.
RP Wang, SM (reprint author), Cent S Univ, Xiangya Hosp, Dept Breast Surg, Changsha 410008, Hunan, Peoples R China.
EM wangshoudo@sina.cn
CR Anderson LN, 2011, CANCER EPIDEM BIOMAR, V20, P1708, DOI 10.1158/1055-9965.EPI-11-0300
   Azad AK, 2013, INT J CANCER, V132, P2520, DOI 10.1002/ijc.27946
   Barcellos-Hoff MH, 2013, CLIN CANCER RES, V19, P541, DOI 10.1158/1078-0432.CCR-12-2241
   Bauer SR, 2013, MEDICINE, V92, P123, DOI 10.1097/MD.0b013e3182943bc2
   Chakraborty A, 2009, CANCER DETECT PREV, V32, P386, DOI 10.1016/j.canep.2009.04.012
   Cline J, 2012, TOP COMPANION ANIM M, V27, P159, DOI 10.1053/j.tcam.2012.09.004
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Cui J, 2001, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V18, P286
   Curran JE, 1999, INT J CANCER, V83, P723, DOI 10.1002/(SICI)1097-0215(19991210)83:6<723::AID-IJC4>3.3.CO;2-V
   Dalessandri KM, 2012, J AM COLL SURGEONS, V215, P652, DOI 10.1016/j.jamcollsurg.2012.06.413
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duplancic D, 2013, CLIN INTERV AGING, V8, P149, DOI 10.2147/CIA.S38349
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Engel LS, 2012, CANCER EPIDEM BIOMAR, V21, P1856, DOI 10.1158/1055-9965.EPI-12-0551
   Geng S, 2013, METABOLISM, V62, P768, DOI 10.1016/j.metabol.2013.01.003
   Grant DJ, 2013, GYNECOL ONCOL, V129, P173, DOI 10.1016/j.ygyno.2012.12.027
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hou MF, 2002, BREAST CANCER RES TR, V74, P1, DOI 10.1023/A:1016048900049
   Huang HP, 2012, INT J NURS PRACT, V18, P589, DOI 10.1111/ijn.12005
   Huang J, 2013, TUMOR BIOL, V34, P1833, DOI 10.1007/s13277-013-0724-0
   Jiao ZJ, 2013, TUMOR BIOL, V34, P1225, DOI 10.1007/s13277-013-0665-7
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   McCullough ML, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1642
   Mishra DK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057967
   Patani N, 2013, INT J CANCER, V133, P1, DOI 10.1002/ijc.27997
   Raimondi S, 2009, CARCINOGENESIS, V30, P1170, DOI 10.1093/carcin/bgp103
   Sillanpaa P, 2004, PHARMACOGENETICS, V14, P239, DOI 10.1097/01.fpc.0000114724.42625.70
   Stevens KN, 2013, CANCER RES, V73, P2025, DOI 10.1158/0008-5472.CAN-12-1699
   Stuck AE, 1998, BRIT MED J, V316, P469, DOI 10.1136/bmj.316.7129.469
   Tang CB, 2009, BREAST CANCER RES TR, V117, P391, DOI 10.1007/s10549-008-0262-4
   van der Rhee H, 2013, EUR J CANCER, V49, P1422, DOI 10.1016/j.ejca.2012.11.001
   Yang L, 2012, CELL IMMUNOL, V279, P160, DOI 10.1016/j.cellimm.2012.10.002
NR 32
TC 7
Z9 7
U1 5
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2014
VL 35
IS 1
BP 785
EP 790
DI 10.1007/s13277-013-1107-2
PG 6
WC Oncology
SC Oncology
GA AA4UE
UT WOS:000331091000100
PM 24048755
DA 2018-12-27
ER

PT J
AU Chen, HX
   Zhou, B
   Lan, X
   Wei, D
   Yuan, T
   Chen, P
AF Chen, Hongxu
   Zhou, Bo
   Lan, Xiang
   Wei, Dong
   Yuan, Tao
   Chen, Ping
TI RETRACTED: Association between single-nucleotide polymorphisms of OGG1
   gene and pancreatic cancer risk in Chinese Han population (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Pancreatic cancer; OGG1 gene; Single-nucleotide polymorphisms; Cancer
   susceptibility
ID BODY-MASS INDEX; COMMERCIAL CATTLE; REPAIR GENES; DNA; SURVIVAL; SMOKING
AB The purpose of this study was to test the association between single-nucleotide polymorphisms (SNPs) of 8-oxoguanine DNA glycosylase (OGG1) gene and susceptibility to pancreatic cancer (PC). A total of 347 PC patients and 364 healthy subjects were enrolled in this case-control study. The c.269C > A genetic variant was investigated using the created restriction site-polymerase chain reaction method. The c.627T > C genetic variant was identified by the polymerase chain reaction-restriction fragment length polymorphism method. Our data indicated that the alleles and genotypes frequencies of these two SNPs were statistically different in PC cases and controls. As for c.269C > A, the AA genotype was statistically associated with decreased PC susceptibility compared to CC wild genotype (odds ratio (OR) = 0.44, 95 % confidence interval (CI) 0.27-0.73, P = 0.001). As for c.627T > C, statistically significant decreased PC susceptibility was detected in CC genotype compared to TT wild genotype (OR = 0.57, 95 % CI 0.35-0.94, P = 0.028). The allele A of c.269C > A and allele C of c.627T > C might be associated with a protection from PC (for c.269C > A, A versus (vs.) C, OR = 0.69, 95 % CI 0.55-0.86, P < 0.001; for c.627T > C, C vs. T, OR = 0.72, 95 % CI 0.58-0.91, P = 0.005). Results from this study indicate that the c.269C > A and c.627T > C SNPs of OGG1 gene are associated with PC susceptibility in Chinese Han ethnicity.
C1 [Chen, Hongxu; Zhou, Bo; Lan, Xiang; Wei, Dong; Yuan, Tao; Chen, Ping] Third Mil Med Univ, Daping Hosp, Dept Hepatobiliary Surg, Chongqing 400042, Peoples R China.
RP Chen, P (reprint author), Third Mil Med Univ, Daping Hosp, Dept Hepatobiliary Surg, 10 Changjiangzhilu Daping, Chongqing 400042, Peoples R China.
EM pingchen_13@163.com
CR Chu D, 2010, J PANCREAS, V11, P203
   Duell EJ, 2008, CANCER EPIDEM BIOMAR, V17, P1470, DOI 10.1158/1055-9965.EPI-07-2797
   HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P3606, DOI 10.1093/nar/17.9.3606
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Landi S, 2009, MUTAT RES-REV MUTAT, V681, P299, DOI 10.1016/j.mrrev.2008.12.001
   Larsson SC, 2007, INT J CANCER, V120, P1993, DOI 10.1002/ijc.22535
   Li DH, 2006, J CLIN ONCOL, V24, P1720, DOI 10.1200/JCO.2005.04.4206
   Li DH, 2007, INT J CANCER, V120, P1748, DOI 10.1002/ijc.22301
   Li DH, 2009, CLIN CANCER RES, V15, P740, DOI 10.1158/1078-0432.CCR-08-1607
   Lin Yingsong, 2001, Asian Pac J Cancer Prev, V2, P271
   Lowenfels AB, 2006, BEST PRACT RES CL GA, V20, P197, DOI 10.1016/j.bpg.2005.10.001
   Lowenfels AB, 2003, PANCREATOLOGY, V3, P1, DOI 10.1159/000069140
   Luo JH, 2007, CANCER CAUSE CONTROL, V18, P603, DOI 10.1007/s10552-007-9002-z
   McWilliams RR, 2008, CANCER RES, V68, P4928, DOI 10.1158/0008-5472.CAN-07-5539
   Nakao M, 2012, J EPIDEMIOL, V22, P477, DOI 10.2188/jea.JE20120010
   Nitsche C, 2011, DIGEST DIS, V29, P235, DOI 10.1159/000323933
   Tanaka M, 2011, CANCER-AM CANCER SOC, V117, P744, DOI 10.1002/cncr.25510
   Yuan ZR, 2013, MOL BIOL REP, V40, P1947, DOI 10.1007/s11033-012-2251-2
   Yuan ZR, 2013, MOL BIOL REP, V40, P7, DOI 10.1007/s11033-012-1934-z
   Yuan ZR, 2012, GENE, V505, P190, DOI 10.1016/j.gene.2012.05.010
   Zhang JJ, 2011, INT J MOL EPIDEMIOL, V2, P236
   Zhao Chun-Jiang, 2003, Yichuan, V25, P327
NR 22
TC 6
Z9 7
U1 6
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2014
VL 35
IS 1
BP 809
EP 813
DI 10.1007/s13277-013-1111-6
PG 5
WC Oncology
SC Oncology
GA AA4UE
UT WOS:000331091000103
PM 23999824
DA 2018-12-27
ER

PT J
AU Wen, XY
   Liu, H
   Yu, KL
   Liu, Y
AF Wen, Xiaoyang
   Liu, Hui
   Yu, Kailong
   Liu, Yang
TI RETRACTED: Matrix metalloproteinase 2 expression and survival of
   patients with osteosarcoma: a meta-analysis (Retracted article)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Matrix metalloproteinase 2; Osteosarcoma; Meta-analysis
ID EWINGS-SARCOMA; ASSOCIATION; DISEASE; CANCER
AB A number of studies investigated the impact of matrix metalloproteinase 2 (MMP2) expression on the survival of patients with osteosarcoma, but no consistent results were reported. To derive a more precise estimate of the prognostic role of MMP2 expression in patients with osteosarcoma, we systematically reviewed the published studies and carried out a meta-analysis. Cohort studies assessing the prognostic role of MMP2 expression in patients with osteosarcoma were included. Pooled risk ratio (RR) with 95 % confidence intervals (95%CI) was used to assess the prognostic role of MMP2 expression. Five cohort studies were eligible in the meta-analysis. Overall, high MMP2 expression was associated with increased risk of mortality in patients with osteosarcoma during the follow-up (fixed effects RR = 2.14, 95%CI 1.66-2.75, P < 0.001). Sensitivity analysis suggested that the pooled RR was stable and omitting a single study did not change the significance of the pooled RR. There was some possibility of publication bias risk in the meta-analysis. In conclusion, the meta-analysis suggests that osteosarcoma patients with high MMP2 expression have poorer prognosis compared with those with low MMP2 expression.
C1 [Wen, Xiaoyang; Liu, Hui; Yu, Kailong; Liu, Yang] Xinyu Peoples Hosp, Dept Orthoped Surg, Xinyu 338025, Jiangxi, Peoples R China.
RP Liu, Y (reprint author), Xinyu Peoples Hosp, Dept Orthoped Surg, Xinyu 338025, Jiangxi, Peoples R China.
EM liuyxinyuj@126.com
CR Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dong W, 2011, ACTA BIOCH BIOPH SIN, V43, P840, DOI 10.1093/abbs/gmr085
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Grimer RJ, 2005, LANCET ONCOL, V6, P85, DOI 10.1016/S1470-2045(05)01734-1
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Kushlinsky NE, 2010, B EXP BIOL MED+, V149, P233, DOI 10.1007/s10517-010-0914-3
   Li WX, 2006, ZHEJIANG MED J, V28, P691
   Malats W, 2005, LANCET ONCOL, V6, P678
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Morrison CJ, 2009, CURR OPIN CELL BIOL, V21, P645, DOI 10.1016/j.ceb.2009.06.006
   Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135
   Osborne TS, 2012, J COMP PATHOL, V146, P132, DOI 10.1016/j.jcpa.2011.12.007
   Poletajew Slawomir, 2011, Ortop Traumatol Rehabil, V13, P537
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Sun C, 2010, MED RECAPITULATE, V16, P3833
   Ta H, 2009, CANCER METAST REV, V28, P247, DOI 10.1007/s10555-009-9186-7
   Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205
   Uchibori M, 2006, INT J ONCOL, V28, P33
   Xu J, 2010, CHINESE CLIN ONCOLOG, V15, P222
   Yamamura T, 2002, LUNG CANCER-J IASLC, V35, P249, DOI 10.1016/S0169-5002(01)00431-7
   Zintzaras E, 2008, J CLIN EPIDEMIOL, V61, P634, DOI 10.1016/j.jclinepi.2007.12.011
NR 24
TC 20
Z9 21
U1 4
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2014
VL 35
IS 1
BP 845
EP 848
DI 10.1007/s13277-013-1116-1
PG 4
WC Oncology
SC Oncology
GA AA4UE
UT WOS:000331091000108
PM 24037915
DA 2018-12-27
ER

PT J
AU Serban, IL
   Hogas, M
   Ciobica, A
   Dobrin, R
   Petrariu, F
AF Serban, Ionela Lacramioara
   Hogas, Mihai
   Ciobica, Alin
   Dobrin, Romeo
   Petrariu, Florin
TI RETRACTED: THE EFFECTS OF CHRONIC MANGANESE ADMINISTRATION ON BLOOD
   PRESSURE IN RATS (Retracted article. See vol. 68, pg. 883, 2016)
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Manganese; chronic; blood pressure; rat
ID SPRAGUE-DAWLEY RATS; DIETARY MANGANESE; MICROMOLAR CONCENTRATIONS;
   NITRIC-OXIDE; CONTRACTION; DEFICIENCY; NEUROTOXICITY; METABOLISM; MN; MO
AB Several trace elements, including manganese (Mn), affect the cardiovascular system and are implicated in some cardiovascular disease mechanisms. The effects of Mn on the vascular system, such as in the control of blood flow and blood pressure, are not completely understood. Thus, the main objective of the present study was to determine the effects of a 45-day exposure to two different doses of Mn on blood pressure values of male Wistar rats. Our results showed a significant time effect (p < 0.001, ANOVA, repeated measures) on the values of blood pressure measurements during 45 days of Mn treatment of rats with two doses (3 mg/kg/day and 10 mg/kg/day). Additionally, we observed significant differences in the values of blood pressure measurements, especially on days 2 (p < 0.001), 9 (p < 0.05), 24 (p < 0.05), 28 (p < 0.01) and 43 (p < 0.05). Further studies are necessary in order to establish the mechanism and relevance of Mn in this area of research.
C1 [Serban, Ionela Lacramioara; Hogas, Mihai; Dobrin, Romeo; Petrariu, Florin] Gr T Popa Univ Med & Pharm, Dept Physiol, Iasi 700115, Romania.
   [Ciobica, Alin] Alexandru Ioan Cuza Univ, Iasi 700506, Romania.
   [Ciobica, Alin] Romanian Acad, Ctr Biomed Res, Iasi Branch, Iasi 700506, Romania.
RP Serban, IL (reprint author), Gr T Popa Univ Med & Pharm, Dept Physiol, Iasi 700115, Romania.
CR Bild W, 2013, J PHYSIOL BIOCHEM, V69, P147, DOI 10.1007/s13105-012-0162-2
   Ciobica A, 2012, J MED BIOCHEM, V31, P83, DOI 10.2478/v10011-011-0053-z
   GRAY B, 1992, BIOCHEM J, V281, P795, DOI 10.1042/bj2810795
   Hogas M, 2011, ARCH BIOL SCI, V63, P1031, DOI 10.2298/ABS1104031H
   JAMIESON DD, 1983, CLIN EXP PHARMACOL P, V10, P511, DOI 10.1111/j.1440-1681.1983.tb00219.x
   Kalea AZ, 2005, J NUTR BIOCHEM, V16, P44, DOI 10.1016/j.jnutbio.2004.09.002
   KASTEN TP, 1994, EUR J PHARMACOL, V253, P35, DOI 10.1016/0014-2999(94)90754-4
   KLIMISTAVANTZIS DJ, 1993, NUTR RES, V13, P953, DOI 10.1016/S0271-5317(05)80598-6
   Klos KJ, 2006, EUR J NEUROL, V13, P1139, DOI 10.1111/j.1468-1331.2006.01407.x
   Mergler D, 1997, ENVIRON RES, V73, P92, DOI 10.1006/enrs.1997.3710
   Ponzoni S, 2000, PROG NEURO-PSYCHOPH, V24, P307, DOI 10.1016/S0278-5846(99)00090-1
   Schutte A E, 2003, Cardiovasc J S Afr, V14, P81
   Shukakidze A, 2003, Neurosci Behav Physiol, V33, P263
   Taylor PN, 1997, BIOL TRACE ELEM RES, V60, P69, DOI 10.1007/BF02783310
   Vezer T, 2007, AM J IND MED, V50, P841, DOI 10.1002/ajim.20485
   Vukojevic V, 2009, ARCH BIOL SCI, V61, P835, DOI 10.2298/ABS0904835V
   Yan M, 1998, BIOL TRACE ELEM RES, V64, P75, DOI 10.1007/BF02783326
   Yan M, 2001, BIOL TRACE ELEM RES, V82, P159, DOI 10.1385/BTER:82:1-3:159
   Yang PY, 1998, BIOL TRACE ELEM RES, V64, P275, DOI 10.1007/BF02783343
   Yang PY, 1998, J NUTR BIOCHEM, V9, P324, DOI 10.1016/S0955-2863(98)00010-2
NR 20
TC 1
Z9 1
U1 4
U2 23
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2014
VL 66
IS 1
BP 157
EP 160
DI 10.2298/ABS1401157L
PG 4
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 301SM
UT WOS:000330552400023
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Petkovic, D
   Iqbal, J
   Shamshirband, S
   Gani, A
   Pavlovic, ND
   Kiah, MLM
AF Petkovic, Dalibor
   Iqbal, Javed
   Shamshirband, Shahaboddin
   Gani, Abdullah
   Pavlovic, Nenad D.
   Kiah, Miss Laiha Mat
TI RETRACTED: Kinetostatic Analysis of Passively Adaptive Robotic Finger
   with Distributed Compliance (Retracted article. See vol. 9, art no
   1687814017710527, 2017)
SO ADVANCES IN MECHANICAL ENGINEERING
LA English
DT Article; Retracted Publication
ID TOPOLOGY OPTIMIZATION; MECHANISMS; DESIGN; GRIPPER
AB Gripping and holding objects are key tasks for robotic manipulators. The development of universal fingers able to pick up unfamiliar objects of widely varying shapes and surfaces is a very challenging task. Passively compliant underactuated mechanisms are one way to obtain the finger which could accommodate to any irregular and sensitive grasping object. The aim of the underactuation is to use the power of one actuator to drive the open and close motion of the finger. The underactuation can morph shapes of the finger to accommodate to different objects. As a result, the underactuated fingers require less complex control algorithms. The fully compliant mechanism has multiple degrees of freedom and can be considered as an underactuated mechanism. This paper presents a new design of the adaptive underactuated compliant finger designed by topology optimization. The main points of this paper are in explanation of kinetostatic analysis of the proposed finger structure using approximate rigid-body model with added concentrated compliance in every single joint of the finger. The results can be used as estimation for gripping force or finger displacement.
C1 [Petkovic, Dalibor; Pavlovic, Nenad D.] Univ Nis, Fac Mech Engn, Dept Mechatron, Nish 18000, Serbia.
   [Iqbal, Javed] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Software Engn, Kuala Lumpur 50603, Malaysia.
   [Shamshirband, Shahaboddin] Islamic Azad Univ, Chalous Branch, Dept Comp Sci, Chalous 46615397, Iran.
   [Gani, Abdullah; Kiah, Miss Laiha Mat] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Comp Syst & Technol, Kuala Lumpur 50603, Malaysia.
RP Iqbal, J (reprint author), Univ Malaya, Fac Comp Sci & Informat Technol, Dept Software Engn, Kuala Lumpur 50603, Malaysia.
EM javediqbal6000@siswa.um.edu.my
RI Shamshirband, Shahaboddin/K-2544-2013; Mat Kiah, Miss Laiha/B-2767-2010;
   Gani, Abdullah/C-2888-2009
OI Shamshirband, Shahaboddin/0000-0002-6605-498X; Mat Kiah, Miss
   Laiha/0000-0002-1240-5406; Gani, Abdullah/0000-0002-4388-020X; Pavlovic,
   Nenad D./0000-0002-8438-7606; Petkovic, Dalibor/0000-0003-1680-1163
FU Bright Spark Program at University of Malaya; Ministry of Education,
   Science and Technological Development, Republic of Serbia [TP35005];
   Advanced Fundamental Research Grant [RP012C-13AFR]; Research and
   development of new generation wind turbines of high-energy efficiency
   [TP35005]
FX The corresponding author would like to acknowledge the financial support
   of the Bright Spark Program at University of Malaya. This paper is
   supported by Project Grant TP35005 "Research and development of new
   generation wind turbines of high-energy efficiency" (2011-2014) financed
   by Ministry of Education, Science and Technological Development,
   Republic of Serbia. The last author would like to acknowledge Big Data
   and Mobile Cloud for Collaborative Experiments, funded by Advanced
   Fundamental Research Grant. RP012C-13AFR.
CR Anuar N. B., 2010, P INF SEC S AFR C IS
   Anuar NB, 2013, SECUR COMMUN NETW, V6, P1087, DOI 10.1002/sec.673
   Aukes D, 2011, IEEE INT C INT ROBOT, P1373, DOI 10.1109/IROS.2011.6048839
   Ball R., 1900, TREATISE THEORY SCRE
   Bendsoe M. P., 2003, TOPOLOGY OPTIMIZATIO
   Birglen L., 2005, P IEEE INT C ROB AUT, P2320
   Birglen L, 2009, J MECH ROBOT, V1, DOI 10.1115/1.3046139
   Carrozza MC, 2004, AUTON ROBOT, V16, P125, DOI 10.1023/B:AURO.0000016863.48502.98
   Ciocarlie M, 2010, IEEE INT CONF ROBOT, P1292, DOI 10.1109/ROBOT.2010.5509793
   Fukaya N., 2000, 2000 IEEE RSJ INT C, P1754
   Hunt K. H, 1978, KINEMATIC GEOMETRY M
   Kim J. H., 1991, P 5 INT C ADV ROB IC, P603
   Kota S, 2003, P SOC PHOTO-OPT INS, V5054, P24, DOI 10.1117/12.483869
   Lu K.-J., 2003, P DETC 03 ASME 2003, P693
   Lu KJ, 2005, J INTEL MAT SYST STR, V16, P307, DOI 10.1177/1045389X05050104
   Lu KJ, 2003, J INTEL MAT SYST STR, V14, P379, DOI 10.1177/104538903035563
   Lu KJ, 2002, P SOC PHOTO-OPT INS, V4693, P161, DOI 10.1117/12.455253
   Luo M., 2005, P 8 INT S ART INT RO, P907
   Montambault S, 2001, J MECH DESIGN, V123, P367, DOI 10.1115/1.1374198
   Murray R.M., 1994, MATH INTRO ROBOTIC M
   Nguyen V.-D., 1986, P IEEE INT C ROB AUT, V3, P1368
   Petkovic D., 2012, 11 INT SAUM C SYST A
   Petkovic D., 2012, BERICHTE ILMENAUER M
   Petkovic D., 1975, INT J ADV MANUF TECH, V67, P865
   Petkovic D, 2013, IND ROBOT, V40, P610, DOI 10.1108/IR-12-2012-452
   Petkovic D, 2012, APPL MECH MATER, V162, P316, DOI 10.4028/www.scientific.net/AMM.162.316
   Shamshirband S, 2013, ENG APPL ARTIF INTEL, V26, P2105, DOI 10.1016/j.engappai.2013.04.010
   Sigmund O, 1997, MECH STRUCT MACH, V25, P493, DOI 10.1080/08905459708945415
   Sigmund O, 2001, STRUCT MULTIDISCIP O, V21, P120, DOI 10.1007/s001580050176
   Sigmund O, 1994, THESIS TU DENMARK
   Staffetti E, 2002, 2002 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS I-IV, PROCEEDINGS, P2848, DOI 10.1109/ROBOT.2002.1013664
   Staffetti E, 2009, IEEE T AUTOM SCI ENG, V6, P80, DOI 10.1109/TASE.2008.917041
NR 32
TC 4
Z9 4
U1 5
U2 27
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1687-8140
J9 ADV MECH ENG
JI Adv. Mech. Eng.
PY 2014
AR 145648
DI 10.1155/2014/145648
PG 13
WC Thermodynamics; Engineering, Mechanical
SC Thermodynamics; Engineering
GA 301VV
UT WOS:000330561100001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Cole, GD
   Francis, DP
AF Cole, Graham D.
   Francis, Darrel P.
TI RETRACTED: Research failure can result in lost lives (Retracted article.
   See vol. 14, 2014)
SO EUROPEAN HEART JOURNAL
LA English
DT News Item; Retracted Publication
ID PERIOPERATIVE CARDIAC MORTALITY; NONCARDIAC SURGERY; RISK PATIENTS;
   DECREASE-IV; FLUVASTATIN; BISOPROLOL; REDUCTION
C1 [Cole, Graham D.; Francis, Darrel P.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Int Ctr Circulatory Hlth, London, England.
RP Cole, GD (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Int Ctr Circulatory Hlth, London, England.
EM g.cole@imperial.ac.uk
CR Atrocitology White M., 2011, ATROCITOLOGY HUMANIT
   Bouri S, 2013, HEART, DOI [10.1136/heartjnl-2013-304262, DOI 10.1136/HEARTJNL-2013-304262.PUBLISHED]
   Cole G, 2011, EUR J HEART FAIL, V13, P234, DOI 10.1093/eurjhf/hfq214
   Duke L, 1996, WASHINGTON POST
   Dunkelgrun M, 2009, ANN SURG, V249, P921, DOI 10.1097/SLA.0b013e3181a77d00
   Eckhardt W, 1987, WORLD MILITARY SOCIA
   Fitzgerald MA, 1991, TIMES LONDON
   Francis DP, 2013, INT J CARDIOL, V168, P3381, DOI 10.1016/j.ijcard.2013.04.152
   Kiernan B, 2004, CENTURY GENOCIDE CRI, P248
   Poldermans D, 2009, EUR HEART J, V30, P2769, DOI 10.1093/eurheartj/ehp337
   Poldermans D, 2009, EUR HEART J SUPPL, V11, pA9, DOI 10.1093/eurheartj/sup004
   Price N, 2003, DAY             1208
   Ranstam J, 2000, CONTROL CLIN TRIALS, V21, P415, DOI 10.1016/S0197-2456(00)00069-6
   Schouten O, 2004, AM HEART J, V148, P1047, DOI 10.1016/j.ahj.2004.05.046
   Schwartz PJ, 1999, EUR HEART J, V20, P1152, DOI 10.1053/euhj.1999.1677
   Totten S., 1997, CENTURY GENOCIDE EYE
   Uganda PB, 1998, OLD SAYBROOK, P23
   Wasswa H, 2005, UGANDAS 1 PRIME MINI
   Wilf-Miron R, 2003, QUAL SAF HEALTH CARE, V12, P35, DOI 10.1136/qhc.12.1.35
   Wilmshurst Peter, 2007, Med Leg J, V75, P3
NR 20
TC 1
Z9 1
U1 2
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD JAN
PY 2014
VL 35
IS 3
BP 135
EP 137
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 300CG
UT WOS:000330441400007
DA 2018-12-27
ER

PT J
AU Eirale, C
   Tol, JL
   Whiteley, R
   Chalabi, H
   Holmich, P
AF Eirale, Cristiano
   Tol, Johannes L.
   Whiteley, Rod
   Chalabi, Hakim
   Holmich, Per
TI RETRACTED: Different injury pattern in goalkeepers compared to field
   players: A three-year epidemiological study of professional football
   (Retracted article. See vol. 18, pg. 119, 2015)
SO JOURNAL OF SCIENCE AND MEDICINE IN SPORT
LA English
DT Article; Retracted Publication
DE Epidemiology; Football; Injury; Incidence; Goalkeepers; Groin
ID SOCCER PLAYERS; YOUTH SOCCER; RISK-FACTORS; LEAGUE; HIP
AB Objectives: Goalkeepers have a specific physiological and biomechanical profile including hip loading with increased frontal plane kinetics and explosive side jumps. The aim of this study is to analyze the injury incidence in professional goalkeepers and to compare this with field players.
   Design: Descriptive Epidemiology Study.
   Methods: Prospective (3 seasons, 2008-2011) registration of injuries and exposure of first division professional footballers of Qatar.
   Results: Of the 527 players, 49 were goalkeepers. Sixty-seven injuries occurred during 17.858 h of exposure. Goalkeepers had a lower total (p = 0.01) and training (p = 0.007) injury incidence than field players, while there was no injury difference during matches (p = 0.279). Moreover, goalkeepers presented a lower incidence of injuries that were: non contact (p = 0.002), traumatic (p < 0.001), strains (p < 0.001), thigh (p < 0.001), and hamstring (p = 0.038). Adductor strains were the most common subtype of injury for goalkeepers and this incidence was higher in goalkeepers than in field players (p = 0.045). In goalkeepers, mean lay off time for adductor strains was 2.5 times longer than for hamstring strains. More than one third of the overuse injuries were hip and groin injuries. While the overall and lower body injury incidence in goalkeepers was lesser than in field players, upper body incidence was higher.
   Conclusions: Football goalkeepers have a peculiar injury epidemiology, possibly due to their specific physiological and biomechanical performance requirements. Goalkeepers are prone to acute adductor and overuse hip and groin injuries, while muscle strains, in particular located in the hamstrings, are lower compared with field players. Specific prevention program should be implemented in this category of footballers. (C) 2013 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.
C1 [Eirale, Cristiano; Tol, Johannes L.; Holmich, Per] Aspetar Qatar Orthoped & Sports Med Hosp, Dept Sports Med, Doha, Qatar.
   [Holmich, Per] Univ Copenhagen Hosp, Arthroscop Ctr Amager, Hvidovre, Denmark.
   [Whiteley, Rod] Aspetar Qatar Orthoped & Sports Med Hosp, Dept Rehabil, Doha, Qatar.
   [Whiteley, Rod] Qatar Univ Sydney, Dept Physiotherapy, Sydney, NSW, Australia.
   [Chalabi, Hakim] Aspetar Qatar Orthoped & Sports Med Hosp, Doha, Qatar.
RP Eirale, C (reprint author), Aspetar Qatar Orthoped & Sports Med Hosp, Dept Sports Med, Doha, Qatar.
EM Cristiano.eirale@aspetar.com
CR Andersen TE, 2004, BRIT J SPORT MED, V38, P626, DOI 10.1136/bjsm.2003.007955
   Aoki H, 2012, AM J SPORT MED, V40, P1006, DOI 10.1177/0363546512438695
   Arnason A, 2004, AM J SPORT MED, V32, p5S, DOI 10.1177/0363546503258912
   Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341
   Carling C, 2010, INT J SPORTS MED, V31, P271, DOI 10.1055/s-0029-1243646
   Charnock BL, 2009, SPORT BIOMECH, V8, P223, DOI 10.1080/14763140903229500
   Dauty M, 2011, INT J SPORTS MED, V32, P965, DOI 10.1055/s-0031-1283188
   Di Salvo V, 2008, J SPORT MED PHYS FIT, V48, P443
   Eirale C, 2012, SCAND J MED SCI SPOR, V22, P323, DOI 10.1111/j.1600-0838.2010.01227.x
   Ekstrand J, 2012, KNEE SURG SPORTS TRA
   Engebretsen AH, 2010, AM J SPORT MED, V38, P2051, DOI 10.1177/0363546510375544
   Faude O, 2005, AM J SPORT MED, V33, P1694, DOI 10.1177/0363546505275011
   FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001
   Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003
   Gail MH, 2000, ENCY EPIDEMIOLOGIC M
   Hagglund M, 2013, AM J SPORT MED, V41, P327, DOI 10.1177/0363546512470634
   Ibrahim A, 2007, J Orthop Surg (Hong Kong), V15, P46
   Le Gall F, 2006, AM J SPORT MED, V34, P928, DOI 10.1177/0363546505283271
   Morgan BE, 2001, AM J SPORT MED, V29, P426, DOI 10.1177/03635465010290040701
   Niedfeldt MW, 2011, CURR SPORT MED REP, V10, P324, DOI 10.1249/JSR.0b013e318237be53
   Nilsson M, 2013, CLIN J SPORT MED
   Sandelin J, 1985, Br J Sports Med, V19, P30
   Schmitt KU, 2008, SPORTVERLETZ SPORTSC, V22, P159, DOI 10.1055/s-2008-1027584
   Schmitt KU, 2010, BRIT J SPORT MED, V44, P426, DOI 10.1136/bjsm.2008.048058
   Schmitt KU, 2010, J SPORT SCI, V28, P53, DOI 10.1080/02640410903369927
   Spratford W, 2009, SPORT BIOMECH, V8, P235, DOI 10.1080/14763140903229526
   SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505
   Wilkinson W H, 1978, Br J Sports Med, V12, P43
   Woods C, 2004, BRIT J SPORT MED, V38, P36, DOI 10.1136/bjsm.2002.002352
   Ziv G, 2011, INT J SPORT PHYSIOL, V6, P509, DOI 10.1123/ijspp.6.4.509
NR 30
TC 7
Z9 7
U1 2
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1440-2440
EI 1878-1861
J9 J SCI MED SPORT
JI J. Sci. Med. Sport
PD JAN
PY 2014
VL 17
IS 1
BP 34
EP 38
DI 10.1016/j.jsams.2013.05.004
PG 5
WC Sport Sciences
SC Sport Sciences
GA 295ZO
UT WOS:000330155100008
PM 23770326
DA 2018-12-27
ER

PT J
AU Perroud, N
   Dayer, A
   Piguet, C
   Nallet, A
   Fevre, S
   Malafosse, A
   Aubry, JM
AF Perroud, Nader
   Dayer, Alexandre
   Piguet, Camille
   Nallet, Audrey
   Fevre, Sophie
   Malafosse, Alain
   Aubry, Jean-Michel
TI RETRACTED: Childhood maltreatment and methylation of the glucocorticoid
   receptor gene NR3C1 in bipolar disorder (Retracted article. See vol.
   205, pg. 249, 2014)
SO BRITISH JOURNAL OF PSYCHIATRY
LA English
DT Article; Retracted Publication
ID PITUITARY-ADRENAL AXIS; SEXUAL-ABUSE; EPIGENETIC REGULATION; STRESS;
   TRAUMA; PREVALENCE; BEHAVIOR; HISTORY; ILLNESS; BRAIN
AB Background Early-life adversities represent risk factors for the development of bipolar affective disorder and are associated with higher severity of the disorder. This may be the consequence of a sustained alteration of the hypothalamic-pituitary-adrenal (HPA) axis resulting from epigenetic modifications of the gene coding for the glucocorticoid receptor (NR3C1).
   Aims To investigate whether severity of childhood maltreatment is associated with increased methylation of the exon 1(F) NR3C1 promoter in bipolar disorder.
   Method A sample of people with bipolar disorder (n=99) were assessed for childhood traumatic experiences. The percentage of NR3C1 methylation was measured for each participant.
   Results The higher the number of trauma events, the higher was the percentage of NR3C1 methylation (beta = 0.52, 95% Cl 0.46-0.59, P << 0.0001). The severity of each type of maltreatment (sexual, physical and emotional) was also associated with NR3C1 methylation status.
   Conclusions Early-life adversities have a sustained effect on the HPA axis through epigenetic processes and this effect may be measured in peripheral blood. This enduring biological impact of early trauma may alter the development of the brain and lead to adult psychopathological disorder.
C1 [Perroud, Nader; Dayer, Alexandre] Univ Geneva, Univ Hosp Geneva, Serv Psychiat Specialties, Dept Mental Hlth & Psychiat, CH-1211 Geneva 4, Switzerland.
   [Perroud, Nader; Dayer, Alexandre; Nallet, Audrey; Fevre, Sophie; Malafosse, Alain] Univ Geneva, Dept Psychiat, CH-1211 Geneva 4, Switzerland.
   [Dayer, Alexandre] Univ Geneva, Dept Basic Neurosci, CH-1211 Geneva 4, Switzerland.
   [Piguet, Camille] Univ Geneva, Fac Med, Dept Neurosci, CH-1211 Geneva 4, Switzerland.
   [Malafosse, Alain] Univ Hosp Geneva, Dept Genet Med & Labs, Psychiat Genet Unit, Geneva, Switzerland.
   [Aubry, Jean-Michel] Univ Hosp Geneva, Dept Mental Hlth & Psychiat, Serv Psychiat Specialties, Bipolar Programme, Geneva, Switzerland.
RP Perroud, N (reprint author), Univ Hosp Geneva HUG, Serv Psychiat Specialties, TRE Programme, 22 Rue Lausanne, CH-1202 Geneva, Switzerland.
OI Dayer, Alexandre/0000-0002-4490-9780
FU Swiss National Foundation [32003B_125469/1]; NCCR Synapsy
   [320030_132853]; AXA Research Foundation; Swiss National Science
   Foundation
FX This research was supported by grants from the Swiss National Foundation
   (32003B_125469/1 and by the NCCR Synapsy to 320030_132853 to A.M.) and
   by the AXA Research Foundation to A M. C.P. is supported by a grant from
   the Swiss National Science Foundation.
CR Angst J, 2011, EUR ARCH PSY CLIN N, V261, P21, DOI 10.1007/s00406-010-0120-3
   Bassett D, AUST NZ J PSYCHIAT, V46, P327
   Be Bellis MD, 1999, BIOL PSYCHIAT, V45, P1271
   Bernstein D., 1998, CHILDHOOD TRAUMA QUE
   Bilinski P, 2012, ANN AGR ENV MED, V19, P491
   Carballo JJ, 2008, J AFFECT DISORDERS, V109, P57, DOI 10.1016/j.jad.2007.12.225
   Conus P, 2010, BIPOLAR DISORD, V12, P244, DOI 10.1111/j.1399-5618.2010.00813.x
   Coulston CM, 2012, AUST NZ J PSYCHIAT, V46, P506, DOI 10.1177/0004867412445528
   Coulston CM, AUST NZ J PSYCHIAT, V46, P506
   Daban C, 2005, PSYCHIAT CLIN N AM, V28, P469, DOI 10.1016/j.psc.2005.01.005
   Darnaudery M, 2008, BRAIN RES REV, V57, P571, DOI 10.1016/j.brainresrev.2007.11.004
   Etain B, 2008, BIPOLAR DISORD, V10, P867, DOI 10.1111/j.1399-5618.2008.00635.x
   Etain B, 2010, J TRAUMA STRESS, V23, P376, DOI 10.1002/jts.20532
   FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7
   First M. B., 1996, STRUCTURED CLIN INTE
   Frodl T, 2013, NEUROBIOL DIS, V52, P24, DOI 10.1016/j.nbd.2012.03.012
   Garno JL, 2005, BRIT J PSYCHIAT, V186, P121, DOI 10.1192/bjp.186.2.121
   Goldberg JF, 2005, J PSYCHIAT RES, V39, P595, DOI 10.1016/j.jpsychires.2004.11.002
   Goldstein BI, 2008, BIPOLAR DISORD, V10, P469, DOI 10.1111/j.1399-5618.2008.00584.x
   Labonte B, 2012, ARCH GEN PSYCHIAT, V69, P722, DOI 10.1001/archgenpsychiatry.2011.2287
   Leverich GS, 2006, LANCET, V367, P1040, DOI 10.1016/S0140-6736(06)68450-X
   Leverich GS, 2002, BIOL PSYCHIAT, V51, P288, DOI 10.1016/S0006-3223(01)01239-2
   Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639
   MacMillan HL, 1997, JAMA-J AM MED ASSOC, V278, P131, DOI 10.1001/jama.278.2.131
   McGowan PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014739
   McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270
   Oberlander TF, 2008, EPIGENETICS-US, V3, P97, DOI 10.4161/epi.3.2.6034
   Perroud N, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.60
   Radtke KM, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.21
   Romero S, 2009, J AFFECT DISORDERS, V112, P144, DOI 10.1016/j.jad.2008.04.005
   Salvadore G, 2010, J CLIN PSYCHIAT, V71, P1488, DOI 10.4088/JCP.09r05259gre
   Watson S, 2004, BRIT J PSYCHIAT, V184, P496, DOI 10.1192/bjp.184.6.496
   Weaver ICG, 2007, J NEUROSCI, V27, P1756, DOI 10.1523/JNEUROSCI.4164-06.2007
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Yates T. M., 2007, J EMOTIONAL ABUSE, V7, P9, DOI DOI 10.1300/J135V07N02_
NR 35
TC 42
Z9 42
U1 2
U2 39
PU ROYAL COLLEGE OF PSYCHIATRISTS
PI LONDON
PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG,
   ENGLAND
SN 0007-1250
EI 1472-1465
J9 BRIT J PSYCHIAT
JI Br. J. Psychiatry
PD JAN
PY 2014
VL 204
IS 1
BP 30
EP 35
DI 10.1192/bjp.bp.112.120055
PG 6
WC Psychiatry
SC Psychiatry
GA 289MH
UT WOS:000329686100008
PM 23743517
OA Bronze
DA 2018-12-27
ER

PT J
AU Safarinejad, MR
   Taghva, A
   Shafiei, N
   Safarinejad, S
AF Safarinejad, M. R.
   Taghva, A.
   Shafiei, N.
   Safarinejad, S.
TI RETRACTED: Impact of polymorphisms in the oestrogen receptors alpha and
   beta (ESR1, ESR2) genes on risk of vasculogenic erectile dysfunction
   (Retracted Article)
SO ANDROLOGY
LA English
DT Article; Retracted Publication
DE genetic association studies; genotype; Impotence; oestrogen receptor;
   polymorphism; single; nucleotide; vasculogenic
AB Erection is principally a vascular phenomenon. Oestrogen affects the vascular system in various ways. Oestrogen effects are mediated by oestrogen receptors (ERs). We examined the relationship of two polymorphisms in ESR-alpha (ER-1) (rs2234693 and rs9340799) and two polymorphisms in ESR-b (ER-2) (rs4986938 and rs1256049) with risk of vasculogenic erectile dysfunction (VED). The rs2234693 (ER-alpha PvuII), rs9340799 (ER-alpha XbaI), rs4986938 (ER-beta AluI) and rs1256049 (ER-beta RsaI) were genotyped using polymerase chain reaction-restriction fragment length polymorphism technique. Serum levels of sex hormone-binding globulin (SHBG), total testosterone, free testosterone (fT), total oestradiol (E2) and free oestradiol (free E2) were also measured. A total of 266 men with VED and 532 healthy controls were recruited into this study. The ER-alpha PvuII C allele (OR = 4.2; 95% CI: 2.79-8.43, p = 0.001), ER-alpha XbaI A allele (OR = 4.87; 95% CI: 2.75-8.64, p = 0.001), ER-beta RsaI A allele (OR= 0.37; 95% CI: 0.24-0.66, p = 0.001) and ER-beta AluI A allele (OR = 0.29; 95% CI: 0.16-0.57, p = 0.001) were significantly associated with VED. Subjects with ER-alpha PvuII CC and ER-alpha XbaI AA genotypes had highest serum levels of E2, and subjects with ER-beta RsaI AA and ER-beta AluI AA genotypes had lowest serum levels of E2. Patients with lower serum levels of E2 had more sever VED and more mixed vascular type VED. In haplotype analysis, PvuII C-XbaI A increased the risk of developing VED by more than eightfold, in contrast, RsaI A-AluI A haplotype had protective effect (OR = 0.53; 95% CI: 0.34-0.76, p = 0.002). The ER-alpha and ER-beta gene polymorphisms and haplotypes are associated with presence, type and severity of VED.
C1 [Safarinejad, M. R.; Shafiei, N.; Safarinejad, S.] Clin Ctr Urol Dis Diag, Tehran, Iran.
   [Safarinejad, M. R.; Shafiei, N.; Safarinejad, S.] Private Clin Specialized Urol & Androl Genet, Tehran, Iran.
   [Taghva, A.] Aja Univ Med Sci, Fac Med, Dept Psychiat, Tehran, Iran.
RP Safarinejad, MR (reprint author), Clin Ctr Urol Dis Diag, POB 19395-1849, Tehran, Iran.
EM info@safarinejad.com
NR 0
TC 1
Z9 1
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-2919
EI 2047-2927
J9 ANDROLOGY-US
JI Andrology
PD JAN
PY 2014
VL 2
IS 1
DI 10.1111/j.2047-2927.2013.00097.x
PG 9
WC Andrology
SC Endocrinology & Metabolism
GA 276EC
UT WOS:000328729900022
OA Bronze
DA 2018-12-27
ER

PT J
AU Sun, XJ
   Fa, PP
   Cui, ZW
   Xia, Y
   Sun, L
   Li, ZS
   Tang, AF
   Gui, YT
   Cai, ZM
AF Sun, Xiaojuan
   Fa, Pingping
   Cui, Zhiwen
   Xia, Ye
   Sun, Liang
   Li, Zesong
   Tang, Aifa
   Gui, Yaoting
   Cai, Zhiming
TI RETRACTED: The EDA-containing cellular fibronectin induces
   epithelial-mesenchymal transition in lung cancer cells through integrin
   alpha 9 beta 1-mediated activation of PI3-K/AKT and Erk1/2 (Retracted
   article. See vol. 36, pg. 1452, 2015)
SO CARCINOGENESIS
LA English
DT Article; Retracted Publication
ID EXTRACELLULAR-MATRIX; CARCINOMA-CELLS; EIIIA SEGMENT; EXPRESSION;
   PROLIFERATION; FIBROBLASTS; TISSUE; PROGRESSION; METASTASIS; INVASION
AB Cellular fibronectin (cFN) is one of the main components of tissue extracellular matrices and is involved in multiple physiologic and pathologic processes such as embryogenesis, wound healing, inflammation and tumor progression. The function of fibronectin in regulating normal cell adhesion and migration is well documented, but its function in cancer progression is only partially unraveled. We have reported previously that fibronectin stimulates the proliferation and survival of non-small lung carcinoma cells through upregulation of pro-oncogenic signals related to cyclooxygenase-2/phosphatidylinositol-3-kinase/protein kinase B (COX-2/PI3-K/AKT)/mammalian target of rapamycin triggered by activation of the integrin alpha 5 beta 1. Here, we extend these studies by showing that fibronectin promotes epithelial-mesenchymal transition (EMT) in lung cancer cells. We found that cFN, but not plasma fibronectin or type 1 collagen, induces lung carcinoma cell scattering in vitro, promotes cell migration and invasion of Matrigel and stimulates the expression of the mesenchymal marker alpha-smooth muscle actin while decreasing the expression of the epithelial marker E-cadherin through PI3-K and Erk pathways. Interestingly, the extra domain A (EDA) within cFN was found to be crucial for this process, as confirmed by testing cells overexpressing EDA or cells exposed to EDA-containing matrices. We found that the integrin alpha 9, but not alpha 5, mediated cFN-induced EMT as silencing integrin alpha 9 neutralized cFN-induced EMT. Overall, our findings show that the EDA domain within cFN induces EMT in lung carcinoma cells through integrin alpha 9-mediated activation of PI3-K and Erk.
C1 [Sun, Xiaojuan; Sun, Liang; Li, Zesong; Tang, Aifa; Cai, Zhiming] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Tumor Clin Immune Gene Therapy Engn Lab, Dept Biobank,Shenzhen Peoples Hosp 2, Shenzhen 518035, Peoples R China.
   [Sun, Xiaojuan] Guangdong Med Coll, Affiliated Hosp, Dept Cent Lab, Zhanjiang 524023, Peoples R China.
   [Fa, Pingping; Cui, Zhiwen; Xia, Ye; Gui, Yaoting] Peking Univ, Shenzhen Hosp, Inst Urol, Shenzhen PKU HKUST Med Ctr,Guangdong & Shenzhen K, Shenzhen 518036, Peoples R China.
   [Cui, Zhiwen; Xia, Ye] Peking Univ, Shenzhen Hosp, Dept Urol, Shenzhen 518036, Peoples R China.
RP Sun, XJ (reprint author), Shenzhen Univ, Affiliated Hosp 1, Shenzhen Tumor Clin Immune Gene Therapy Engn Lab, Dept Biobank,Shenzhen Peoples Hosp 2, 3002 West Sungang Rd, Shenzhen 518035, Peoples R China.
EM xiaojuan26@gmail.com
FU National Natural Science Foundation of China [81101584]; National
   Natural Science Foundation of China General Program [81372507]; Major
   State Basic Research Development Program of China (973 Program)
   [2014CB745200]; Shenzhen Peacock Plan for Higher Level Experts Aboard
   [KQC201106020032A]; Major Basic Research Development Program of Shenzhen
   [JCYJ20120614155816670]
FX National Natural Science Foundation of China (81101584); National
   Natural Science Foundation of China General Program (81372507); Major
   State Basic Research Development Program of China (973 Program
   2014CB745200); Shenzhen Peacock Plan for Higher Level Experts Aboard
   (KQC201106020032A); Major Basic Research Development Program of Shenzhen
   (JCYJ20120614155816670).
CR Arai H, 1997, AM J PATHOL, V151, P403
   Astrof S, 2007, DEV BIOL, V311, P11, DOI 10.1016/j.ydbio.2007.07.005
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Burnham EL, 2007, ALCOHOL CLIN EXP RES, V31, P675, DOI 10.1111/j.1530-0277.2007.00352.x
   Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216
   De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398
   De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925
   Duffy MJ, 2008, J PATHOL, V214, P283, DOI 10.1002/path.2282
   GRINNELL F, 1984, J CELL BIOCHEM, V26, P107, DOI 10.1002/jcb.240260206
   Gupta SK, 2009, J CELL SCI, V122, P2043, DOI 10.1242/jcs.041632
   Han SW, 2006, ONCOGENE, V25, P4341, DOI 10.1038/sj.onc.1209460
   Han SW, 2007, J BIOL CHEM, V282, P7961, DOI 10.1074/jbc.M610308200
   Han SW, 2005, CANCER LETT, V219, P71, DOI 10.1016/j.canlet.2004.07.040
   Han SW, 2006, CANCER RES, V66, P315, DOI 10.1158/0008-55472.CAN-05-2367
   Harima A, 2008, HEMATOLOGY, V13, P236, DOI 10.1179/102453308X348315
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   HIBI K, 1994, ONCOGENE, V9, P611
   Higgins DF, 2008, CELL CYCLE, V7, P1128, DOI 10.4161/cc.7.9.5804
   Hong KO, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-28
   Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223
   Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311
   Kaspar M, 2006, INT J CANCER, V118, P1331, DOI 10.1002/IJC.21677
   Labat-Robert J, 2002, SEMIN CANCER BIOL, V12, P187, DOI 10.1016/S1044-579X(02)00022-6
   Leiss M, 2008, CURR OPIN CELL BIOL, V20, P502, DOI 10.1016/j.ceb.2008.06.001
   Liao YF, 2002, J BIOL CHEM, V277, P14467, DOI 10.1074/jbc.M201100200
   Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585-008-9182-2
   Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295
   Matsumoto E, 1999, JPN J CANCER RES, V90, P320, DOI 10.1111/j.1349-7006.1999.tb00750.x
   Menrad A, 2005, EXPERT OPIN THER TAR, V9, P491, DOI 10.1517/14728222.9.3.491
   MORO L, 1992, INT J CANCER, V51, P692, DOI 10.1002/ijc.2910510505
   Muro AF, 2008, AM J RESP CRIT CARE, V177, P638, DOI 10.1164/rccm.200708-1291OC
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142
   Ramirez AM, 2006, AM J TRANSPLANT, V6, P2080, DOI 10.1111/j.1600-6143.2006.01430.x
   Ritzenthaler JD, 2008, MOL BIOSYST, V4, P1160, DOI 10.1039/b800533h
   Roman J, 2004, FASEB J, V18, P1436, DOI 10.1096/fj.03-0826fje
   Romberger DJ, 1997, INT J BIOCHEM CELL B, V29, P939, DOI 10.1016/S1357-2725(96)00172-0
   Ryu S, 1999, CANCER LETT, V146, P103, DOI 10.1016/S0304-3835(99)00259-1
   Shinde AV, 2008, J BIOL CHEM, V283, P2858, DOI 10.1074/jbc.M708306200
   Singh P, 2004, J INVEST DERMATOL, V123, P1176, DOI 10.1111/j.0022-202X.2004.23485.x
   Singh P, 2009, J INVEST DERMATOL, V129, P217, DOI 10.1038/jid.2008.201
   STOKER M, 1985, J CELL SCI, V77, P209
   Strippoli R, 2008, DIS MODEL MECH, V1, P264, DOI 10.1242/dmm.001321
   Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053
   White ES, 2008, J PATHOL, V216, P1, DOI 10.1002/path.2388
   White ES, 2003, AM J RESP CRIT CARE, V168, P436, DOI 10.1164/rccm.200301-041OC
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
NR 49
TC 30
Z9 31
U1 3
U2 25
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2014
VL 35
IS 1
BP 184
EP 191
DI 10.1093/carcin/bgt276
PG 8
WC Oncology
SC Oncology
GA 281WB
UT WOS:000329130600022
PM 23929437
OA Bronze
DA 2018-12-27
ER

PT J
AU Han, L
   Wang, YF
   Guo, XJ
   Zhou, YB
   Zhang, JM
   Wang, N
   Jiang, JH
   Ma, F
   Wang, QD
AF Han, Li
   Wang, Yafeng
   Guo, Xiaojuan
   Zhou, Yubing
   Zhang, Jingmin
   Wang, Ning
   Jiang, Jinhua
   Ma, Fang
   Wang, Qingduan
TI RETRACTED: Downregulation of MDR1 Gene by Cepharanthine Hydrochloride Is
   Related to the Activation of c-Jun/JNK in K562/ADR Cells(Retracted
   article. See Artn.4729643,2016)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID MEDIATED MULTIDRUG-RESISTANCE; JUN NH2-TERMINAL KINASE; IN-VITRO;
   TRANSCRIPTION FACTOR; CELL-LINE; CANCER; JNK; EXPRESSION; REVERSAL;
   INHIBITORS
AB The purpose of the study was to determine the signal transduction mechanism of cepharanthine hydrochloride (CH) on reversing tumor multidrug resistance. RT-PCR and Western blot analysis were used to determine the effects of CH on the expression of MDR1 mRNA and P-glycoprotein in K562/ADR cells when CH was used alone and combined with SP600125, a JNK inhibitor, to explore the effects of CH on JNK pathway. Western blot analysis was used to determine the effects of CH on c-Jun protein expression and phosphorylation, to explore the regulating effects of CH on c-Jun and phosphorylated c-Jun (p-c-Jun) proteins. Our results showed that the inhibitory effect of CH on MDR1 mRNA increased with the concentrations of CH (5.0, 10.0, and 20.0 mu M) and the inhibitory effects of CH on MDR1 mRNA and P-glycoprotein increased with the incubation time of CH (0, 12, 24, 36, and 48 hours). The inhibitory effect was weakened after CH combined with SP600125. The expressions of c-Jun and p-c-Jun proteins increased with the incubation time of CH (0, 6, 12, and 24 hours). These findings suggest that CH downregulated the expressions of MDR1 mRNA and P-glycoprotein in a time and concentration manner; the mechanism may be mediated via activating c-Jun/JNK pathway.
C1 [Han, Li; Guo, Xiaojuan] Nanyang Inst Technol, Zhang Zhongjing Coll Chinese Med, Nanyang, Peoples R China.
   [Wang, Yafeng; Zhang, Jingmin] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450052, Henan, Peoples R China.
   [Zhou, Yubing] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou 450052, Henan, Peoples R China.
   [Zhang, Jingmin; Wang, Ning; Jiang, Jinhua; Ma, Fang; Wang, Qingduan] Zhengzhou Univ, Henan Acad Med & Pharmaceut Sci, Zhengzhou 450052, Henan, Peoples R China.
RP Wang, QD (reprint author), Zhengzhou Univ, Henan Acad Med & Pharmaceut Sci, Zhengzhou 450052, Henan, Peoples R China.
EM wangqd@zzu.edu.cn
FU Social Welfare Projects for Scientific Research of Henan Province, China
FX This work was supported by grants from Social Welfare Projects for
   Scientific Research of Henan Province, China.
CR Albanito L, 2011, GLIA, V59, P1879, DOI 10.1002/glia.21244
   Bray F, 2006, NAT REV CANCER, V6, P63, DOI 10.1038/nrc1781
   Choi YK, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/741985
   Deferme S, 2002, J PHARM PHARMACOL, V54, P1213, DOI 10.1211/002235702320402053
   Dong XW, 2010, NANOMEDICINE-UK, V5, P597, DOI [10.2217/nnm.10.35, 10.2217/NNM.10.35]
   Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3
   Enokida H, 2002, JPN J CANCER RES, V93, P1037, DOI 10.1111/j.1349-7006.2002.tb02481.x
   Furusawa S, 2007, LIFE SCI, V80, P1073, DOI 10.1016/j.lfs.2006.12.001
   Goldman B, 2003, J NATL CANCER I, V95, P255, DOI 10.1093/jnci/95.4.255
   Gyemant N, 2010, BRIT J CANCER, V103, P178, DOI 10.1038/sj.bjc.6605716
   Haginaka J, 2013, ANAL BIOCHEM, V434, P202, DOI 10.1016/j.ab.2012.11.010
   Huang C., 2014, TUMOR, V34
   Igari Ryosuke, 2010, Brain and Nerve (Tokyo), V62, P273
   Kinoshita M, 2007, BIOCHEM BIOPH RES CO, V353, P515, DOI 10.1016/j.bbrc.2006.12.055
   Miao ZH, 2003, CANCER RES, V63, P4527
   Nemoto K, 1991, Gan To Kagaku Ryoho, V18, P81
   Pan Q. W. Y., 2014, BIOMED RES INT, V2014
   Peng You-mei, 2012, Yaoxue Xuebao, V47, P594
   Perez-Tomas R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077
   Romiti N, 2008, PLANTA MED, V74, P264, DOI 10.1055/s-2008-1034308
   Seubwai W., CANC SCI, V101, P1590
   Shtil AA, 2005, INT REV CYTOL, V246, P1, DOI 10.1016/S0074-7696(05)46001-5
   Song Yu-cheng, 2005, Yaoxue Xuebao, V40, P204
   Sui H, 2011, CARCINOGENESIS, V32, P667, DOI 10.1093/carcin/bgr016
   Sullivan K, 2011, BONE, V49, P1311, DOI 10.1016/j.bone.2011.09.043
   Valesio EG, 2013, J APPL TOXICOL, V33, P32, DOI 10.1002/jat.1708
   Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361
   Zhou J, 2006, CANCER RES, V66, P445, DOI 10.1158/0008-5472.CAN-05-1779
   Zhu AX, 2010, ANN SURG ONCOL, V17, P1247, DOI 10.1245/s10434-010-0975-6
NR 29
TC 12
Z9 12
U1 2
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
AR 164391
DI 10.1155/2014/164391
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AX5QR
UT WOS:000346982600001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hart, L
   Pehkonen, E
   Ahtee, M
AF Hart, Lynn
   Pehkonen, Erkki
   Ahtee, Maija
TI RETRACTED: Young students' drawings reveal perceptions of mathematics
   class in Finland and the USA (Retracted article)
SO RESEARCH IN MATHEMATICS EDUCATION
LA English
DT Article; Retracted Publication
DE students' drawings; communication; mathematics
AB In this paper we analyse drawings made by students from the U.S. and Finland when asked to draw their mathematics class. This activity was given to students from 8 classes (n = 131, 9-10 years old) in Finland and 5 classes (n = 94, 8-9 years old) in the U.S. Two separate analyses were conducted: an a priori coding of all drawings and an in-depth analysis of 3 drawings from each country. The coding of drawings focused on students' conceptions about communication and teaching in mathematics. The in-depth analyses captured additional aspects of the class. The results show that the U.S. students have greater self-confidence with respect to knowing/learning mathematics than their Finnish counterparts. In addition, U.S. comments during class were more related to the lesson (teaching), and their teachers gave more feedback. However, little meaningful differences in the overall communication patterns in the Finnish and U.S. classrooms were found.
C1 [Hart, Lynn] Georgia State Univ, Dept Early Childhood Educ, Atlanta, GA 30303 USA.
   [Pehkonen, Erkki; Ahtee, Maija] Univ Helsinki, Dept Teacher Educ, Helsinki, Finland.
RP Hart, L (reprint author), Georgia State Univ, Dept Early Childhood Educ, Atlanta, GA 30303 USA.
EM lhart@gsu.edu
CR Allen B., 1998, EDUC STUD MATH, V35, P1, DOI DOI 10.1023/A:1003019020131
   Aronsson K, 1996, BRIT J DEV PSYCHOL, V14, P301, DOI 10.1111/j.2044-835X.1996.tb00707.x
   Aunola K, 2004, J EDUC PSYCHOL, V96, P699, DOI 10.1037/0022-0663.96.4.699
   Barlow CM, 2011, APPL COGNITIVE PSYCH, V25, P480, DOI 10.1002/acp.1716
   Berry J., 2000, EDUC STUD MATH, V43, P65, DOI DOI 10.1023/A:1017523230758
   Bragg L, 2007, MATH EDUC RES J, V19, P29, DOI 10.1007/BF03217448
   Dahlgren A., 2010, P MAVI 16 C JUN 26 2, P77
   DARLING-HAMMOND Linda, 2010, FLAT WORLD ED
   Davis R. B., 1990, JRME MONOGRAPH, V4
   De Angelis T, 2003, AM PSYCHOL ASSOC, V34, P60
   Falk CF, 2009, EUR J PERSONALITY, V23, P183, DOI 10.1002/per.715
   Hannula MS, 2007, ZDM-INT J MATH EDUC, V39, P197, DOI 10.1007/s11858-007-0022-7
   Harrison LJ, 2007, EARLY CHILD RES Q, V22, P55, DOI 10.1016/j.ecresq.2006.10.003
   Kress G., 2001, MULTIMODAL TEACHING
   Murphy PK, 2004, J EXP EDUC, V72, P69, DOI 10.3200/JEXE.72.2.69-92
   Nathan MJ, 2003, COGNITION INSTRUCT, V21, P175, DOI 10.1207/S1532690XCI2102_03
   Organization for Economic Cooperation and Development [OECD], 2010, PISA 2009 WHAT STUD, V1
   Pehkonen E., 2011, CURRENT STATE RES MA, P182
   Remesal A, 2009, RES SOCIOCULT INFLU, P25
   Rolka K, 2011, ZDM-INT J MATH EDUC, V43, P521, DOI 10.1007/s11858-011-0330-9
   Schoenfeld AH, 1987, COGNITIVE SCI MATH E, P189
   Stiles D. A., 2008, WORLD CULTURES EJOUR, V16, P1
   Tikkanen P., 2011, KASIKIRJA MATE UNPUB
   Tikkanen P., 2008, THESIS
   Weber S, 1996, TEACH TEACH EDUC, V12, P303, DOI 10.1016/0742-051X(95)00040-Q
NR 25
TC 4
Z9 4
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1479-4802
EI 1754-0178
J9 RES MATH EDUCAT
JI Res. Math. Educ.
PY 2014
VL 16
IS 1
BP 18
EP 37
DI 10.1080/14794802.2013.876155
PG 20
WC Education & Educational Research
SC Education & Educational Research
GA V74GP
UT WOS:000211765800002
DA 2018-12-27
ER

PT J
AU Tian, F
   Schattschneider, P
   Stoger-Pollach, M
AF Tian, Feng
   Schattschneider, Peter
   Stoger-Pollach, Micheal
TI RETRACTED: The post-peak spectra in electron energy loss near edge
   structure(Retracted article. See vol. 147, pg. 164, 2014)
SO ULTRAMICROSCOPY
LA English
DT Article; Retracted Publication
DE Post-peak spectrum; ELNES; Electron microscopy; Quantitative analysis
ID SPECTROSCOPY; EXCHANGE
AB The origin of post-peak spectra in electron energy loss near edge structure (ELNES) spectra of pure Ni and NiO is investigated through ab initio calculation. Contrary to the general view that post-peak spectra in ELNES are generated by transitions to continuum states, it is found that orbit hybridization is the main cause of post-peak spectra in the low energy range above the Fermi level based on the calculation of electronic structure and ELNES. Reasons for the intensity differences of the simulated and experimental spectra are discussed. This work contributes to the understanding of ELNES and to the quantification of ELNES spectra. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Tian, Feng] Shanghai Univ Sci & Technol, Sch Mat Sci & Engn, Shanghai 200093, Peoples R China.
   [Schattschneider, Peter] Vienna Univ Technol, Inst Solid State Phys, A-1040 Vienna, Austria.
   [Stoger-Pollach, Micheal] Vienna Univ Technol, Serv Ctr Electron Microscopy, A-1040 Vienna, Austria.
RP Tian, F (reprint author), Shanghai Univ Sci & Technol, Sch Mat Sci & Engn, Shanghai 200093, Peoples R China.
EM ftian@usst.edu.cn
OI Schattschneider, Peter/0000-0002-1225-7554
FU National Natural Science Foundation of China [51271124]
FX F. Tian acknowledges financial support of the National Natural Science
   Foundation of China (51271124).
CR Becke AD, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2213970
   BECKE AD, 1989, PHYS REV A, V39, P3761, DOI 10.1103/PhysRevA.39.3761
   Blaha P., 2001, WIEN2K AUGMENTED PLA
   BLOCHL PE, 1994, PHYS REV B, V49, P16223, DOI 10.1103/PhysRevB.49.16223
   Egerton R.F., 1996, ELECT ENERGY LOSS SP
   Hebert C, 2007, MICRON, V38, P12, DOI 10.1016/j.micron.2006.03.010
   Jorissen K., 2007, THESIS U ANTWERP
   Koller D, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.195134
   Muller DA, 1998, PHYS REV B, V58, P11970, DOI 10.1103/PhysRevB.58.11970
   Nicholls RJ, 2008, J PHYS CONF SER, V126, DOI 10.1088/1742-6596/126/1/012038
   PEARSON DH, 1988, APPL PHYS LETT, V53, P1405, DOI 10.1063/1.100457
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Potapov PL, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.045106
   Schattschneider P., 1986, FUNDAMENTALS INELAST
   Tran F, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.155108
   Villars P., 1996, PEARSONS HDB CRYSTAL
NR 16
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3991
EI 1879-2723
J9 ULTRAMICROSCOPY
JI Ultramicroscopy
PD JAN
PY 2014
VL 136
BP 160
EP 164
DI 10.1016/j.ultramic.2013.10.008
PG 5
WC Microscopy
SC Microscopy
GA 264NK
UT WOS:000327884700020
PM 24184390
DA 2018-12-27
ER

PT J
AU Sharma, M
   Devi, M
AF Sharma, Monika
   Devi, Mridula
TI RETRACTED: Probiotics: A Comprehensive Approach toward Health Foods
   (Retracted article. See vol. 55, pg. 1632, 2015)
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Review; Retracted Publication
DE Probiotics; prebiotics; health benefits; probiotic strains
ID ANTIBIOTIC-ASSOCIATED DIARRHEA; LACTIC-ACID BACTERIA;
   IMMUNODEFICIENCY-VIRUS-INFECTION; PLACEBO-CONTROLLED TRIAL; FERMENTED
   MILK PRODUCT; LACTOBACILLUS-ACIDOPHILUS; GASTROINTESTINAL-TRACT;
   DOUBLE-BLIND; FUNCTIONAL FOODS; SACCHAROMYCES-BOULARDII
AB Food products containing probiotics and prebiotics are an important development in Health foods, which enhance health promoting microbial flora in the intestine. Probiotic refers to viable microorganism that promotes or support a beneficial balance of the autochthonous microbial population of the gastrointestinal tract. A number of genera of bacteria (and yeast) are used as probiotics, including Lactobacillus, Leuconostoc, Pediococcus, Bifidobacterium, Saccharomyces, and Enterococcus, but the main species believed to have probiotic characteristics are Lactobacillus acidophilus, Bifidobacterium spp., and L. casei. Probiotics can reduce diarrheal incidence, lactose intolerance, lower serum cholesterol, stimulate the immune system, control infections, act as antibiotics, suppress tumors, and protect against colon or bladder cancer by maintaining a healthy intestinal microflora balance. Lactic acid bacteria produce biopreservatives such as lactic acid, hydrogen peroxide, and bacteriocins that are used to retard both spoilage and the growth of pathogenic bacteria. Food, particularly dairy products are considered as an ideal vehicle for delivering probiotic bacteria to the human gastrointestinal tract. Cereals being rich source of prebiotics such as -glucan and arabinoxylan, galacto-, and fructooligosaccharides are considered for development of probiotic foods. Good manufacturing practices must be applied in the manufacture of probiotic foods with quality assurance, and shelf-life conditions established.
C1 [Sharma, Monika; Devi, Mridula] Cent Inst Post Harvest Engn & Technol, Food Grains & Oilseeds Proc Div, Ludhiana, Punjab, India.
RP Devi, M (reprint author), Cent Inst Post Harvest Engn & Technol, Food Grains & Oilseeds Proc Div, Ludhiana, Punjab, India.
EM mridulads4@gmail.com
CR AGERBAEK M, 1995, EUR J CLIN NUTR, V49, P346
   Al-Sheddy I, 1999, J FOOD SCI, V64, P336, DOI 10.1111/j.1365-2621.1999.tb15895.x
   Alakomi HL, 2000, APPL ENVIRON MICROB, V66, P2001, DOI 10.1128/AEM.66.5.2001-2005.2000
   Andersson H., 2001, Scandinavian Journal of Nutrition/Naringsforskning, V45, P58, DOI 10.1080/11026480410033539
   [Anonymous], 1988, B WORLD HEALTH ORGAN, V66, P709
   Ashraf H, 1996, B WORLD HEALTH ORGAN, V74, P479
   Barbosa TM, 2005, APPL ENVIRON MICROB, V71, P968, DOI 10.1128/AEM.71.2.968-978.2005
   Bartlett JG, 2002, NEW ENGL J MED, V346, P334, DOI 10.1056/NEJMcp011603
   BAYLESS TM, 1971, GASTROENTEROLOGY, V60, P605
   Bengmark S, 1996, WORLD J SURG, V20, P474, DOI 10.1007/s002689900075
   Benno Y, 1986, BIFIDOBACTERIA MICRO, V5, P13
   Bernaola A. G., 2010, COCHRANE COLLABORATI, p[11, 1]
   BIRGE SJ, 1967, NEW ENGL J MED, V276, P445, DOI 10.1056/NEJM196702232760805
   Brunser O, 2010, BIOACTIVE FOODS IN PROMOTING HEALTH: PROBIOTICS AND PREBIOTICS, P73, DOI 10.1016/B978-0-12-374938-3.00006-2
   Charalampopoulos D, 2002, INT J FOOD MICROBIOL, V79, P131, DOI 10.1016/S0168-1605(02)00187-3
   CHAVAN UD, 1988, J FOOD SCI, V53, P1574, DOI 10.1111/j.1365-2621.1988.tb09329.x
   Cheplin HA, 1923, BOSTON MED SURG J, V189, P405, DOI 10.1056/NEJM192309201891204
   CHIKAI T, 1987, LIPIDS, V22, P669, DOI 10.1007/BF02533948
   Collins MD, 1999, AM J CLIN NUTR, V69, p1052S, DOI 10.1093/ajcn/69.5.1052s
   Corcionivoschi N., 2010, Innovative Romanian Food Biotechnology, V6, P1
   Corcionivoschi N., 2009, PROBIOTICELE LA TIMP
   Correa NBO, 2005, J CLIN GASTROENTEROL, V39, P385, DOI 10.1097/01.mcg.0000159217.47419.5b
   Corthesy B, 2007, J NUTR, V137, p781S, DOI 10.1093/jn/137.3.781S
   Cutting S. M., 2010, FOOD MICROBIOL, V10, P10
   Daly C., 1998, AGR FOOD SCI FINLAND, V7, P219
   de Roos NM, 1999, EUR J CLIN NUTR, V53, P277, DOI 10.1038/sj.ejcn.1600722
   Del Piano M, 2006, Dig Liver Dis, V38 Suppl 2, pS248, DOI 10.1016/S1590-8658(07)60004-8
   DONG MY, 1987, DIAGN MICR INFEC DIS, V7, P1, DOI 10.1016/0732-8893(87)90063-0
   Donohue D C, 1996, Asia Pac J Clin Nutr, V5, P25
   Drasar B. S., 1990, HUMAN MICROBIAL ECOL, P95
   Duggan C, 2002, AM J CLIN NUTR, V75, P789
   EDWARDS C, 1993, P NUTR SOC, V52, P375, DOI 10.1079/PNS19930073
   Elmer GW, 2001, GASTROENTEROL CLIN N, V30, P837, DOI 10.1016/S0889-8553(05)70213-2
   FAO/WHO, 2001, HLTH NUTR PROP PROB
   FAO/WHO-Food and Agriculture Organization of the United Nations/World Health Organization, 2002, GUID EV PROB FOOD LO
   FAUVEAU V, 1992, ACTA PAEDIATR, V81, P12, DOI 10.1111/j.1651-2227.1992.tb12365.x
   Felley C, 2003, BEST PRACT RES CL GA, V17, P785, DOI 10.1016/S1521-6918(03)00070-2
   Finegold SM, 2002, CLIN INFECT DIS, V35, pS6, DOI 10.1086/341914
   Fuller R, 1997, SCAND J GASTROENTERO, V32, P28, DOI 10.1080/00365521.1997.11720714
   FULLER R, 1991, GUT, V32, P439, DOI 10.1136/gut.32.4.439
   Fuller R., 1997, PROBIOTICS 2 APPL PR
   Fuller R., 1992, PROBIOTICS SCI BASIS
   Gagnon M, 2004, INT J FOOD MICROBIOL, V92, P69, DOI 10.1016/j.ijfoodmicro.2003.07.010
   GASSER F, 1994, B I PASTEUR, V92, P45
   Geier MS, 2006, CANCER BIOL THER, V5, P1265, DOI 10.4161/cbt.5.10.3296
   Gibson G. R., 2003, Gut flora, nutrition, immunity and health, P52
   Gibson G. R., 2009, CANADIAN J DIE PRACT, V70, P25
   Gilat T., 1972, GASTROENTEROLOGY, V102, P1269
   GILLILAND SE, 1985, APPL ENVIRON MICROB, V49, P377
   Gionchetti P, 2000, GASTROENTEROLOGY, V119, P305, DOI 10.1053/gast.2000.9370
   Goktepe I., 2006, Probiotics in food safety and human health, P285
   Gomes AMP, 1999, TRENDS FOOD SCI TECH, V10, P139, DOI 10.1016/S0924-2244(99)00033-3
   Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007
   Gronlund MM, 2000, ARCH DIS CHILD, V83, pF186, DOI 10.1136/fn.83.3.F186
   Guarino A, 2009, CURR OPIN GASTROEN, V25, P18, DOI 10.1097/MOG.0b013e32831b4455
   Guslandi M, 2000, DIGEST DIS SCI, V45, P1462, DOI 10.1023/A:1005588911207
   HAENEL H, 1975, Progress in Food and Nutrition Science, V1, P21
   Hamilton-Miller J. M. T., 2001, Microbial Ecology in Health and Disease, V13, P212, DOI 10.1080/089106001753341282
   Hamilton-Miller JMT, 2003, BRIT J NUTR, V90, P845, DOI 10.1079/BJN2003954
   HENRIKSSON R, 1995, SUPPORT CARE CANCER, V3, P81, DOI 10.1007/BF00343926
   HILLIER SL, 1992, OBSTET GYNECOL, V79, P369, DOI 10.1097/00006250-199203000-00008
   Holm F., 2003, WORLD INGREDIENTS, V2, P52
   Holzapfel WH, 1998, INT J FOOD MICROBIOL, V41, P85, DOI 10.1016/S0168-1605(98)00044-0
   Holzapfel WH, 2002, FOOD RES INT, V35, P109, DOI 10.1016/S0963-9969(01)00171-5
   Holzapfel WH, 2001, AM J CLIN NUTR, V73, p365S, DOI 10.1093/ajcn/73.2.365s
   Hoyos A B, 1999, Int J Infect Dis, V3, P197, DOI 10.1016/S1201-9712(99)90024-3
   Johnson S, 2000, PEDIATR INFECT DIS J, V19, P972, DOI 10.1097/00006454-200010000-00007
   Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8
   Kalliomaki Marko, 2003, Curr Opin Allergy Clin Immunol, V3, P15, DOI 10.1097/00130832-200302000-00003
   Katina K, 2007, J CEREAL SCI, V46, P348, DOI 10.1016/j.jcs.2007.07.006
   Katz JA, 2006, J CLIN GASTROENTEROL, V40, P249, DOI 10.1097/00004836-200603000-00017
   KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406
   Khetarpaul N., 1990, TROPICAL SCI, V31, P131
   KIM CR, 1995, J FOOD SCI, V60, P25, DOI 10.1111/j.1365-2621.1995.tb05598.x
   Korschunov VM, 1996, J MED MICROBIOL, V44, P70, DOI 10.1099/00222615-44-1-70
   KRETCHMER N, 1972, SCI AM, V227, P70, DOI 10.1038/scientificamerican1072-70
   Krishnakumar V, 2001, DAIRY IND INT, V66, P38
   La Rosa M, 2003, Minerva Pediatr, V55, P447
   Lavermicocca P., 2006, DIGEST LIVER DIS, V38, P295
   LIDBECK A, 1992, Microbial Ecology in Health and Disease, V5, P59
   LIN SY, 1989, J DAIRY SCI, V72, P2885, DOI 10.3168/jds.S0022-0302(89)79439-X
   Loessner M, 2003, APPL ENVIRON MICROB, V69, P1854, DOI 10.1128/AEM.69.3.1854-1857.2003
   Lorri Wilbald, 1993, International Journal of Food Sciences and Nutrition, V44, P29, DOI 10.3109/09637489309017420
   LUCKEY TD, 1972, AM J CLIN NUTR, V25, P1292
   Mackay A.D., 1999, CLIN MICROBIOL INFEC, V5, P290, DOI DOI 10.1111/J.1469-0691.1999.TB00144.X
   Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9
   Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x
   MALHOTRA SL, 1977, MED HYPOTHESES, V3, P122, DOI 10.1016/0306-9877(77)90024-X
   Mattila-Sandholm T, 2002, INT DAIRY J, V12, P173, DOI 10.1016/S0958-6946(01)00099-1
   Mattila-Sandholm T, 1999, TRENDS FOOD SCI TECH, V10, P393, DOI 10.1016/S0924-2244(00)00029-7
   Mazza G., 2008, HDB FERMENTED FOODS
   McFarland Lynne V, 2007, Travel Med Infect Dis, V5, P97, DOI 10.1016/j.tmaid.2005.10.003
   McIntosh G H, 1996, Asia Pac J Clin Nutr, V5, P48
   Menard S, 2004, GUT, V53, P821, DOI 10.1136/gut.2003.026252
   Metchnikoff E, 1907, PROLONGATION LIFE OP
   METCHNIKOFF LE, 2004, PROLONGATION LIFE OP
   Meyer AL, 2006, ANN NUTR METAB, V50, P282, DOI 10.1159/000091687
   Michida H, 2006, BIOCHEM ENG J, V28, P73, DOI 10.1016/j.bej.2005.09.004
   Miller TL, 2002, J PEDIATR GASTR NUTR, V34, P353, DOI 10.1097/00005176-200204000-00005
   Miller TL, 1997, J PEDIATR-US, V130, P766, DOI 10.1016/S0022-3476(97)80020-0
   Mombelli B, 2000, INT J ANTIMICROB AG, V16, P531, DOI 10.1016/S0924-8579(00)00322-8
   NANJI AA, 1994, P SOC EXP BIOL MED, V205, P243
   O'Riordan K, 1998, J APPL MICROBIOL, V85, P103, DOI 10.1046/j.1365-2672.1998.00474.x
   O'Sullivan MA, 2000, DIGEST LIVER DIS, V32, P294, DOI 10.1016/S1590-8658(00)80021-3
   Ouwehand AC, 1999, INT DAIRY J, V9, P43, DOI 10.1016/S0958-6946(99)00043-6
   Patel HM, 2004, BIOTECHNOL PROGR, V20, P110, DOI 10.1021/bp034176r
   Pelletier X, 2001, EUR J CLIN NUTR, V55, P509, DOI 10.1038/sj.ejcn.1601169
   PERDIGON G, 1986, J FOOD PROTECT, V49, P986, DOI 10.4315/0362-028X-49.12.986
   PERDIGON G, 1990, J FOOD PROTECT, V53, P404, DOI 10.4315/0362-028X-53.5.404
   Pineiro M, 2007, J NUTR, V137, p850S, DOI 10.1093/jn/137.3.850S
   Playne MJ, 2003, AUST J DAIRY TECHNOL, V58, P242
   Plummer Martyn, 2004, IARC Sci Publ, P311
   Puupponen-Pimia R, 2002, TRENDS FOOD SCI TECH, V13, P3, DOI 10.1016/S0924-2244(02)00020-1
   Ranadheera RDCS, 2010, FOOD RES INT, V43, P1, DOI 10.1016/j.foodres.2009.09.009
   Rautio M, 1999, CLIN INFECT DIS, V28, P1159, DOI 10.1086/514766
   Ray B., 1992, FOOD BIOPRESERVATIVE, P125
   REDDY GV, 1983, J FOOD PROTECT, V46, P8, DOI 10.4315/0362-028X-46.1.8
   Reid G, 1998, INT DAIRY J, V8, P555, DOI 10.1016/S0958-6946(98)00075-2
   Rembacken BJ, 1999, LANCET, V354, P635, DOI 10.1016/S0140-6736(98)06343-0
   Rettger L. F., 1935, LACTOBACILLUS ACIDOP
   Richelsen B, 1996, EUR J CLIN NUTR, V50, P811
   Rivera-Espinoza Y, 2010, FOOD MICROBIOL, V27, P1, DOI 10.1016/j.fm.2008.06.008
   Roberfroid M. B., 2008, HDB PREBIOTICS
   Ross RP, 2002, AUST J DAIRY TECHNOL, V57, P71
   Saarela M, 2000, J BIOTECHNOL, V84, P197, DOI 10.1016/S0168-1656(00)00375-8
   SALMINEN E, 1988, CLIN RADIOL, V39, P435, DOI 10.1016/S0009-9260(88)80296-4
   Salminen S., 1993, LACTIC ACID BACTERIA
   Salovaara H., 1998, LACTIC ACID BACTERIA, P115
   Sanders ME, 1998, INT DAIRY J, V8, P341, DOI 10.1016/S0958-6946(98)00056-9
   Sanders ME, 1999, ANTON LEEUW INT J G, V76, P293, DOI 10.1023/A:1002029204834
   Sanni AI, 1999, FOOD CHEM, V65, P35, DOI 10.1016/S0308-8146(98)00132-0
   Scheinbach S, 1998, BIOTECHNOL ADV, V16, P581, DOI 10.1016/S0734-9750(98)00002-0
   Schiffrin EJ, 1997, AM J CLIN NUTR, V66, P515
   SCHILLINGER U, 1991, J APPL BACTERIOL, V70, P473, DOI 10.1111/j.1365-2672.1991.tb02743.x
   SCHORLING JB, 1990, AM J EPIDEMIOL, V132, P144, DOI 10.1093/oxfordjournals.aje.a115626
   Seki H, 2003, PEDIATR INT, V45, P86, DOI 10.1046/j.1442-200X.2003.01671.x
   Sepp E, 2005, CLIN EXP ALLERGY, V35, P1141, DOI 10.1111/j.1365-2222.2005.02315.x
   Shah N. P., 2002, ENCY DAIRY SCI, P141
   Shah NP, 2007, INT DAIRY J, V17, P1262, DOI 10.1016/j.idairyj.2007.01.014
   Shah NP, 2004, AGRO FOOD IND HI TEC, V15, P13
   Shah NP, 2001, FOOD TECHNOL-CHICAGO, V55, P46
   SHAHANI KM, 1980, AM J CLIN NUTR, V33, P2448, DOI 10.1093/ajcn/33.11.2448
   Shalev E, 1996, ARCH FAM MED, V5, P593, DOI 10.1001/archfami.5.10.593
   Sheehan VM, 2007, INNOV FOOD SCI EMERG, V8, P279, DOI 10.1016/j.ifset.2007.01.007
   Shortt C, 1999, TRENDS FOOD SCI TECH, V10, P411, DOI 10.1016/S0924-2244(00)00035-2
   Singh R., 2007, IDF B, V415, P11
   Sloan AE, 2006, FOOD TECHNOL-CHICAGO, V60, P22
   Smolyansky J, 2010, BIOACTIVE FOODS IN PROMOTING HEALTH: PROBIOTICS AND PREBIOTICS, P43, DOI 10.1016/B978-0-12-374938-3.00003-7
   Spinosa MR, 2000, RES MICROBIOL, V151, P361, DOI 10.1016/S0923-2508(00)00159-5
   Starling S., 2010, INDIAN PROBIOTICS MA
   Stiles ME, 1997, INT J FOOD MICROBIOL, V36, P1, DOI 10.1016/S0168-1605(96)01233-0
   Suarez FL, 1997, FOOD TECHNOL-CHICAGO, V51, P74
   SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2
   Suvarna V. C., 2005, CURR SCI, V88, P2005
   TANKANOW RM, 1990, DICP ANN PHARMAC, V24, P382, DOI 10.1177/106002809002400408
   Tannis A., 2008, PROBIOTIC RESCUE YOU, P13
   Tannis A., 2008, ALLERGIES PROBIOTICS, P107
   Trois L, 2008, J TROP PEDIATRICS, V54, P19, DOI 10.1093/tropej/fmm066
   Trois L, 2010, BIOACTIVE FOODS IN PROMOTING HEALTH: PROBIOTICS AND PREBIOTICS, P229, DOI 10.1016/B978-0-12-374938-3.00015-3
   Tuohy KM, 2007, J APPL MICROBIOL, V102, P1026, DOI 10.1111/j.1365-2672.2006.03154.x
   Tuohy KM, 2003, DRUG DISCOV TODAY, V8, P692, DOI 10.1016/S1359-6446(03)02746-6
   Tuomola E, 2001, AM J CLIN NUTR, V73, p393S, DOI 10.1093/ajcn/73.2.393s
   Vanderhoof JA, 2001, AM J CLIN NUTR, V73, p1152S
   VERGIN F, 1954, HIPPOKRATES, V25, P116
   Waldeck F., 1990, PHYSL MENSCHEN
   Wittenberg D, 2004, J PEDIATR GASTR NUTR, V39, pS640, DOI 10.1097/00005176-200406002-00010
   Ziemer CJ, 1998, INT DAIRY J, V8, P473, DOI 10.1016/S0958-6946(98)00071-5
NR 167
TC 30
Z9 31
U1 3
U2 174
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PD JAN 1
PY 2014
VL 54
IS 4
BP 537
EP 552
DI 10.1080/10408398.2011.594185
PG 16
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA 265IX
UT WOS:000327945700009
PM 24237003
DA 2018-12-27
ER

PT J
AU Wetzel, L
   Zadrazil, M
   Paternostro-Sluga, T
   Authried, G
   Kozek-Langenecker, S
   Scharbert, G
AF Wetzel, Leonore
   Zadrazil, Markus
   Paternostro-Sluga, Tatjana
   Authried, Georg
   Kozek-Langenecker, Sibylle
   Scharbert, Gisela
TI RETRACTED: Intravenous nonopioid analgesic drugs in chronic low back
   pain patients on chronic opioid treatment A crossover, randomised,
   double-blinded, placebo-controlled study (Retracted article. See vol.
   32, pg. 287, 2015)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHRONIC NONCANCER PAIN; OUTCOME
   MEASURES; PRIMARY-CARE; QUESTIONNAIRE; MANAGEMENT; DISEASE; TRIALS
AB BACKGROUNDAddition of nonopioid analgesic drugs reduces pain and opioid requirements in acute low back pain. In noncancer chronic low back pain (CLBP), the efficacy of a combined regimen to reduce breakthrough pain has not been proven so far.OBJECTIVEEvaluation of the effects of intravenous (i.v.) nonopioid analgesic drugs on pain intensity and lumbar mobility in CLBP patients on chronic opioid therapy.DESIGNRandomised, placebo-controlled, double blinded, crossover study.SETTINGVienna General Hospital, Austria, from December 2002 to May 2004.PATIENTSThirty-six adults with CLBP on chronic opioid therapy. Inclusion criteria are as follows: American Society of Anesthesiologists' physical status less than 3, visual analogue scale (VAS) more than 4 and no known allergy to any of the used drugs.INTERVENTIONAfter written informed consent and VAS assessment, any oral nonopioid analgesic drug (NSAIDs, metamizol, paracetamol) was replaced by placebo 10 days before the first test infusion as a washout period. Coanalgesics (anticonvulsants, antidepressants) were maintained. Each patient received randomly four i.v. test infusions of diclofenac 75mg (and orphenadrine 30mg), parecoxib 40mg, paracetamol 1g and isotonic saline. A washout time of 72h was allowed between each infusion.MAIN OUTCOME MEASURESPrimary outcome was as follows: VAS pain intensity (0 to 100mm) at inclusion, before and within 30min after infusion. Secondary outcomes were as follows: Roland-Morris questionnaire, McGill pain questionnaire and a test panel of physical functioning for spinal mobility, muscular endurance, balance and coordination. The differences in means of the above assessments among the groups were analysed.RESULTSWe found an improvement in VAS from the day of inclusion to the day of each appointment. We observed no improvement in pain intensity (VAS) or in any of the physical functioning tests immediately before versus after administration of the four i.v. drugs. Reductions in sensory, affective and cognitive dimensions of the McGill pain questionnaire were statistically significant in the diclofenac group. A trend of McGill pain questionnaire improvement existed in the other groups.CONCLUSIONThe present data show that the anticipation of an i.v. infusion of nonopioid analgesic drug improves VAS significantly, probably through expectation-related mechanisms. However, single dose i.v. infusions of nonopioid analgesic drugs fail to improve pain intensity and spinal mobility in CLBP patients on chronic opioid treatment, even immediately after the infusion.
C1 [Wetzel, Leonore; Zadrazil, Markus; Authried, Georg; Scharbert, Gisela] Dept Anaesthesia Intens Care & Pain Management, Vienna, Austria.
   [Paternostro-Sluga, Tatjana] Med Univ Vienna, Dept Phys Med & Rehabil, Vienna, Austria.
   [Kozek-Langenecker, Sibylle] Evangel Hosp Vienna, Dept Anaesthesia & Intens Care, Vienna, Austria.
RP Wetzel, L (reprint author), Dept Anaesthesia Intens Care & Pain Management, Vienna, Austria.
EM leonore.wetzel@meduniwien.ac.at
FU Department of Anesthesiology, General Intensive Care and Pain Control,
   Vienna Medical University, Vienna, Austria.
FX Financial support and sponsorship: this work was financially supported
   by the Department of Anesthesiology, General Intensive Care and Pain
   Control, Vienna Medical University, Vienna, Austria.
CR Alphs L, 2012, INT J NEUROPSYCHOPH, V15, P1003, DOI 10.1017/S1461145711001738
   AMLIE E, 1987, SPINE, V12, P473, DOI 10.1097/00007632-198706000-00010
   Benedetti F, 2006, PAIN, V121, P133, DOI 10.1016/j.pain.2005.12.016
   Campbell H, 2006, SPINE, V31, P815, DOI 10.1097/01.brs.0000207257.64215.03
   Chapman JR, 2011, SPINE, V36, pS54, DOI 10.1097/BRS.0b013e31822ef74d
   Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006
   DEYO RA, 1994, SPINE, V19, pS2032, DOI 10.1097/00007632-199409151-00003
   DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057
   DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192
   Enright PL, 2003, CHEST, V123, P387, DOI 10.1378/chest.123.2.387
   FROST M, 1982, PHYS THER, V62, P1431, DOI 10.1093/ptj/62.10.1431
   Kalso E, 2005, CURR MED RES OPIN, V21, P1819, DOI 10.1185/030079905X65303
   Kuijpers T, 2011, EUR SPINE J, V20, P40, DOI 10.1007/s00586-010-1541-4
   Lee HF, 2012, PAIN, V153, P1301, DOI 10.1016/j.pain.2012.03.018
   MACRAE IF, 1969, ANN RHEUM DIS, V28, P584, DOI 10.1136/ard.28.6.584
   Ott E, 2003, J THORAC CARDIOV SUR, V125, P1481, DOI 10.1016/S0022-5223(3)00125-9
   Petersen GL, 2012, PAIN, V153, P1292, DOI 10.1016/j.pain.2012.03.011
   PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x
   Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003
   Reid MC, 2002, J GEN INTERN MED, V17, P173, DOI 10.1046/j.1525-1497.2002.10435.x
   Roelofs PDDM, 2008, SPINE, V33, P1766, DOI 10.1097/BRS.0b013e31817e69d3
   Rossignol M, 1996, SPINE, V21, P2893, DOI 10.1097/00007632-199612150-00021
   STEIN C, 1988, PAIN, V32, P251, DOI 10.1016/0304-3959(88)90074-7
   van Tulder MW, 2000, SPINE, V25, P2501, DOI 10.1097/00007632-200010010-00013
   vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012
   Wiesinger GF, 1999, SPINE, V24, P1099, DOI 10.1097/00007632-199906010-00009
NR 26
TC 13
Z9 13
U1 2
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD JAN
PY 2014
VL 31
IS 1
BP 35
EP 40
DI 10.1097/EJA.0b013e328365ae28
PG 6
WC Anesthesiology
SC Anesthesiology
GA 259VP
UT WOS:000327554700006
PM 24141646
OA Bronze
DA 2018-12-27
ER

PT J
AU Liu, MY
   Guo, L
   Liu, Y
   Pei, Y
   Li, N
   Jin, MM
   Ma, LC
   Li, ZB
   Sun, BR
   Li, CL
AF Liu, Minyan
   Guo, Lei
   Liu, Yu
   Pei, Yu
   Li, Nan
   Jin, Mengmeng
   Ma, Lichao
   Li, Zhibing
   Sun, Banruo
   Li, Chunlin
TI RETRACTED: Adipose stromal-vascular fraction-derived paracrine factors
   regulate adipogenesis (Retracted article. See vol. 411, pg. 403, 2016)
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Adipogenesis; Paracrine factors; Stromal vascular fraction; Adipose
ID ADIPOCYTE DIFFERENTIATION; FAT-CELLS; EXPRESSION; OBESITY; SIZE;
   INHIBITION; SECRETOME; INSULIN; ORIGIN; TISSUE
AB Visceral and subcutaneous adipose tissue depots have distinct features and contribute differentially to metabolic disease. Therefore, the adipogenic potential of different fat depots was investigated and found to be higher in subcutaneous compared with visceral stromal-vascular fraction (SVF), which contains adipocyte precursor cells. This increased differentiation capacity was not due to elevated numbers of Lin(-)Sca1(+)CD29(+)CD34(+)Pref1(+) precursor cells, as the number of preadipocytes was higher in visceral than in subcutaneous SVF. The secreted heat-sensitive factors from the SVF inhibited adipocyte differentiation more in visceral than in subcutaneous SVF. In order to explore secreted proteins that potentially inhibit differentiation, the secretome of murine SVF was analyzed by mass spectrometry, which resulted in the identification of 113 secreted proteins with an overlap of 42 % between subcutaneous and visceral SVF. Comparison of the mRNA expression in SVF from both depots revealed 16 transcripts that were significantly expressed more in visceral than in subcutaneous SVF. A functional differentiation screen identified seven potential inhibitory candidates: biglycan, decorin, bone morphogenic protein 1, epidermal growth factor-containing fibulin-like extracellular matrix protein 2, elastin microfibril interfacer 1, matrix gla protein, and Sparc-like 1. For further verification, murine recombinant decorin or Sparc-like 1 was added to the media during the differentiation process leading to a dose-dependent decrease in adipogenesis. Further analysis will be necessary to assess the impact of the other candidates on adipocyte differentiation.
C1 [Liu, Minyan; Liu, Yu; Pei, Yu; Li, Nan; Jin, Mengmeng; Ma, Lichao; Li, Zhibing; Sun, Banruo; Li, Chunlin] Chinese Peoples Liberat Army Gen Hosp, Dept Elderly Endocrinol, Beijing 100853, Peoples R China.
   [Guo, Lei] Capital Med Univ, Beijing Tiantan Hosp, Dept Obstet & Gynecol, Beijing 100050, Peoples R China.
RP Li, CL (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Elderly Endocrinol, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM chunlinli301@126.com
CR Alvarez-Llamas G, 2007, MOL CELL PROTEOMICS, V6, P589, DOI 10.1074/mcp.M600265-MCP200
   Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265
   Gesta S, 2006, P NATL ACAD SCI USA, V103, P6676, DOI 10.1073/pnas.0601752103
   Hansen LH, 1998, MOL ENDOCRINOL, V12, P1140, DOI 10.1210/me.12.8.1140
   HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345
   Jernas M, 2006, FASEB J, V20, P1540, DOI 10.1096/fj.05-5678fje
   Joe AWB, 2009, STEM CELLS, V27, P2563, DOI 10.1002/stem.190
   Kim J, 2010, PROTEOMICS, V10, P394, DOI 10.1002/pmic.200900218
   LIVINGST.JN, 1972, SCIENCE, V177, P626, DOI 10.1126/science.177.4049.626
   Marques BG, 1998, AM J PHYSIOL-REG I, V275, pR1898, DOI 10.1152/ajpregu.1998.275.6.R1898
   O'Connell J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009997
   Rajashekhar G, 2008, STEM CELLS, V26, P2674, DOI 10.1634/stemcells.2008-0277
   Rodeheffer MS, 2008, CELL, V135, P240, DOI 10.1016/j.cell.2008.09.036
   Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Selvarajan S, 2001, NAT CELL BIOL, V3, P267, DOI 10.1038/35060059
   Shi YG, 2004, NAT REV DRUG DISCOV, V3, P695, DOI 10.1038/nrd1469
   Skurk T, 2007, J CLIN ENDOCR METAB, V92, P1023, DOI 10.1210/jc.2006-1055
   Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902
   Tchkonia T, 2002, AM J PHYSIOL-REG I, V282, pR1286, DOI 10.1152/ajpregu.00653.2001
   Wajchenberg BL, 2000, ENDOCR REV, V21, P697, DOI 10.1210/er.21.6.697
   Wilson A, 2007, ANN NY ACAD SCI, V1106, P64, DOI 10.1196/annals.1392.021
   Xing H, 1997, ENDOCRINOLOGY, V138, P2776, DOI 10.1210/en.138.7.2776
   Zhou H, 2009, ACTA BIOCH BIOPH SIN, V41, P910, DOI 10.1093/abbs/gmp085
NR 25
TC 4
Z9 4
U1 3
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN
PY 2014
VL 385
IS 1-2
BP 115
EP 123
DI 10.1007/s11010-013-1820-6
PG 9
WC Cell Biology
SC Cell Biology
GA 264EG
UT WOS:000327859200013
PM 24122418
DA 2018-12-27
ER

PT J
AU Jabbari, M
AF Jabbari, Masoud
TI RETRACTED: Elucidating of rotation speed in friction stir welding of
   pure copper: Thermal modeling (Retracted article. See vol. 109, pg. 399,
   2015)
SO COMPUTATIONAL MATERIALS SCIENCE
LA English
DT Article; Retracted Publication
DE Rotation speed; FSW; Pure copper; Thermal modeling
ID MICROSTRUCTURE; EVOLUTION; ALUMINUM
AB In this paper, a thermal model is developed and used to simulate the friction stir welding of pure copper plates with the thickness of 4 mm in the constant traverse speed of 25 mm/min and five different rotation speeds. The mechanical deformation (plastic deformation) is neglected in the developed thermal model, hence the mechanical force in the process is taken to account in the heat generation equations. A moving coordinate system is used for modeling of the tool movement during the welding process. The generated heat is then used to model the grain growth in the copper plates, and consequently the mechanical properties of the copper plates. We then compare the numerical results with the results obtained from the series of experiments. Analysis of metallographic images show that increasing of the rotation speed results in increase of grain size in the nugget zone, which confirmes the numerical results. Vickers hardness tests were conducted on the weld samples and the maximum hardness obtained in rotation speed of 900 rpm. Results of the tensile tests and their comparison with that of the base metal showed that the maximum strength and the minimum elongation achieved again in this rotation speed. Yield strength and ultimate tensile strength increased with decrease in grain size in the nugget region and the yield strength obeyed the new proposed Hall-Petch relationship. (C) 2013 Elsevier B.V. All rights reserved.
C1 Tech Univ Denmark, Dept Mech Engn, DK-2800 Lyngby, Denmark.
RP Jabbari, M (reprint author), Tech Univ Denmark, Dept Mech Engn, DK-2800 Lyngby, Denmark.
EM mjab@mek.dtu.dk
CR Colligan K, 1999, WELD J, V78, p229S
   Guerra M, 2003, MATER CHARACT, V49, P95
   Harper JME, 1999, J APPL PHYS, V86, P2516, DOI 10.1063/1.371086
   Li Y, 1999, SCRIPTA MATER, V40, P1041, DOI 10.1016/S1359-6462(99)00062-7
   Liu G, 1997, SCRIPTA MATER, V37, P355, DOI 10.1016/S1359-6462(97)00093-6
   Mahoney MW, 1998, METALL MATER TRANS A, V29, P1955, DOI 10.1007/s11661-998-0021-5
   Mishra RS, 2005, MAT SCI ENG R, V50, P1, DOI 10.1016/j.mser.2005.07.001
   Nakata K., 2005, Welding International, V19, P929, DOI 10.1533/wint.2005.3519
   Rhodes CG, 2003, SCRIPTA MATER, V48, P1451, DOI 10.1016/S1359-6462(03)00082-4
   Schmidt HB, 2008, SCRIPTA MATER, V58, P332, DOI 10.1016/j.scriptamat.2007.10.008
   Schmidt HJ, 1999, GEN RELAT GRAVIT, V31, P1, DOI 10.1023/A:1018877418337
   Shen JJ, 2010, MATER DESIGN, V31, P3937, DOI 10.1016/j.matdes.2010.03.027
   Song M, 2003, INT J MACH TOOL MANU, V43, P605, DOI 10.1016/S0890-6955(03)00022-1
   Thomas W. M., 1991, Patent Appl. No. PCT/GB, Patent No. 92102203
   Xie GM, 2007, SCRIPTA MATER, V57, P73, DOI 10.1016/j.scriptamat.2007.03.048
NR 15
TC 6
Z9 6
U1 3
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-0256
EI 1879-0801
J9 COMP MATER SCI
JI Comput. Mater. Sci.
PD JAN
PY 2014
VL 81
BP 296
EP 302
DI 10.1016/j.commatsci.2013.08.040
PG 7
WC Materials Science, Multidisciplinary
SC Materials Science
GA 251OU
UT WOS:000326940300043
DA 2018-12-27
ER

PT J
AU Ziari, SD
   Bahrpaima, K
   Sharafi, Z
AF Ziari, S. Doshman
   Bahrpaima, Kh
   Sharafi, Z.
TI RETRACTED: (Liquid plus liquid) equilibria of quaternary systems
   containing water, phosphoric acid, dichloromethane and
   1,2-dichloroethane (Retracted article. See vol. 121, pg. 220, 2018)
SO JOURNAL OF CHEMICAL THERMODYNAMICS
LA English
DT Article; Retracted Publication
DE Quaternary mixtures; Phosphoric acid; Dichloromethane;
   1,2-Dichloroethane; NRTL
ID TERNARY AQUEOUS MIXTURES; PHASE-EQUILIBRIA; TOLUENE; METHANOL;
   2-ETHYL-1-HEXANOL; EXTRACTION
AB Experimental (liquid + liquid) equilibrium (LLE) data were obtained for the extraction of phosphoric acid from water by mixed-solvents (dichloromethane, 1,2-dichloroethane) at different ratios at T = 298.15 K and ambient pressure. The measured binodal curves and tie-line data for quaternary mixtures of (water + phosphoric acid + dichloromethane, 1,2-dichloroethane) are presented. The measured tie-line data have been correlated using the NRTL activity coefficient model to obtain the binary interaction parameters of these components. The NRTL model predicted the equilibrium compositions of the quaternary mixtures and the deviation which is not too low. The results show that the mixed-solvent (25% dichloromethane, 75% 1,2-dicholoroethane) has a higher separation factor than the other ratios of this mixed-solvent at the temperature studied. (C) 2013 Published by Elsevier Ltd.
C1 [Ziari, S. Doshman; Sharafi, Z.] Islamic Azad Univ, Marvdasht Branch, Dept Chem, Marvdasht, Iran.
   [Bahrpaima, Kh] Islamic Azad Univ, Firoozabad Branch, Dept Chem, Firoozabad 74715117, Fars, Iran.
RP Bahrpaima, K (reprint author), Islamic Azad Univ, Firoozabad Branch, Dept Chem, Firoozabad 74715117, Fars, Iran.
EM Kh.bahrpyma@iauf.ac.ir
FU Research Council of Islamic Azad University, Firoozabad Branch
FX We gratefully acknowledge the financial support from the Research
   Council of Islamic Azad University, Firoozabad Branch.
CR Bahrpaima K, 2013, J CHEM THERMODYN, V58, P385, DOI 10.1016/j.jct.2012.06.001
   BEVIA FR, 1983, FLUID PHASE EQUILIBR, V10, P77, DOI 10.1016/0378-3812(83)80006-5
   BIZOT J, 1967, B SOC CHIM FR, P151
   Doulabi FSM, 2006, J CHEM THERMODYN, V38, P405, DOI 10.1016/j.jct.2005.06.007
   Ghanadzadeh A, 2010, FLUID PHASE EQUILIBR, V291, P90, DOI 10.1016/j.fluid.2009.12.033
   Ghanadzadeh A, 2009, J CHEM ENG DATA, V54, P1009, DOI 10.1021/je8008792
   Ghanadzadeh H, 2008, J CHEM THERMODYN, V40, P879, DOI 10.1016/j.jct.2008.01.001
   Gomez-Siurana A, 2001, IND ENG CHEM RES, V40, P892, DOI 10.1021/ie000065a
   Kim JK, 2005, J CHEM ENG DATA, V50, P625, DOI 10.1021/je0496488
   Mohsen-Nia A, 2006, FLUID PHASE EQUILIBR, V239, P1, DOI 10.1016/j.fluid.2005.10.018
   Mohsen-Nia M, 2007, J CHEM THERMODYN, V39, P1085, DOI 10.1016/j.jct.2006.12.008
   Mohsen-Nia M, 2006, J CHEM THERMODYN, V38, P1285, DOI 10.1016/j.jct.2006.02.011
   Mohsen-Nia M, 2006, J CHEM ENG DATA, V51, P1316, DOI 10.1021/je060061y
   Othmer DF, 1942, IND ENG CHEM, V34, P690, DOI 10.1021/ie50390a011
   RENON H, 1968, AICHE J, V14, P135, DOI 10.1002/aic.690140124
   Sandler S.I., 1998, CHEM ENG THERMODYNAM
   Vakili-Nezhaad GR, 2004, J CHEM THERMODYN, V36, P341, DOI 10.1016/j.jct.2003.11.011
   Won DB, 2002, FLUID PHASE EQUILIBR, V193, P217, DOI 10.1016/S0378-3812(01)00732-4
NR 18
TC 4
Z9 4
U1 0
U2 16
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0021-9614
EI 1096-3626
J9 J CHEM THERMODYN
JI J. Chem. Thermodyn.
PD JAN
PY 2014
VL 68
BP 327
EP 331
DI 10.1016/j.jct.2013.05.016
PG 5
WC Thermodynamics; Chemistry, Physical
SC Thermodynamics; Chemistry
GA 242VI
UT WOS:000326271100043
DA 2018-12-27
ER

PT J
AU Petschner, P
   Viola, T
   Csaba, A
   Kirilly, E
   Ando, RD
   Laszlo, T
   Gyorgy, B
AF Petschner, Peter
   Viola Tamasi
   Csaba Adori
   Kirilly, Eszter
   Ando, Romeo D.
   Laszlo Tothfalusi
   Gyorgy Bagdy
TI RETRACTED: Gene expression analysis indicates CB1 receptor upregulation
   in the hippocampus and neurotoxic effects in the frontal cortex 3 weeks
   after single-dose MDMA administration in Dark Agouti rats(Retracted
   article. See vol. 17, 2016)
SO BMC GENOMICS
LA English
DT Article; Retracted Publication
DE MDMA; Ecstasy; Endocannabinoid; CB1; Addiction; Cognition; Memory; Rat;
   Gene expression; Microarray
ID SHORT-TERM-MEMORY; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; SEROTONIN
   TRANSPORTER; BODY-TEMPERATURE; WORKING-MEMORY; BASAL GANGLIA; ECSTASY
   USE; RATS; RESPONSES; USERS
AB Background: 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") is a widely used recreational drug known to impair cognitive functions on the long-run. Both hippocampal and frontal cortical regions have well established roles in behavior, memory formation and other cognitive tasks and damage of these regions is associated with altered behavior and cognitive functions, impairments frequently described in heavy MDMA users. The aim of this study was to examine the hippocampus, frontal cortex and dorsal raphe of Dark Agouti rats with gene expression arrays (Illumina RatRef bead arrays) looking for possible mechanisms and new candidates contributing to the effects of a single dose of MDMA (15 mg/kg) 3 weeks earlier.
   Results: The number of differentially expressed genes in the hippocampus, frontal cortex and the dorsal raphe were 481, 155, and 15, respectively. Gene set enrichment analysis of the microarray data revealed reduced expression of 'memory' and 'cognition', 'dendrite development' and 'regulation of synaptic plasticity' gene sets in the hippocampus, parallel to the upregulation of the CB1 cannabinoid-and Epha4, Epha5, Epha6 ephrin receptors. Downregulated gene sets in the frontal cortex were related to protein synthesis, chromatin organization, transmembrane transport processes, while 'dendrite development', 'regulation of synaptic plasticity' and 'positive regulation of synapse assembly' gene sets were upregulated. Changes in the dorsal raphe region were mild and in most cases not significant.
   Conclusion: The present data raise the possibility of new synapse formation/synaptic reorganization in the frontal cortex three weeks after a single neurotoxic dose of MDMA. In contrast, a prolonged depression of new neurite formation in the hippocampus is suggested by the data, which underlines the particular vulnerability of this brain region after the drug treatment. Finally, our results also suggest the substantial contribution of CB1 receptor and endocannabinoid mediated pathways in the hippocampal impairments. Taken together the present study provides evidence for the participation of new molecular candidates in the long-term effects of MDMA.
C1 [Petschner, Peter; Csaba Adori; Kirilly, Eszter; Ando, Romeo D.; Laszlo Tothfalusi; Gyorgy Bagdy] Semmelweis Univ, Dept Pharmacodynam, H-1089 Budapest, Hungary.
   [Viola Tamasi] Semmelweis Univ, Dept Genet Cell & Immunobiol, H-1089 Budapest, Hungary.
   [Petschner, Peter; Gyorgy Bagdy] MTA SE Neuropsychopharmacol & Neurochem Res Grp, Budapest, Hungary.
RP Gyorgy, B (reprint author), Semmelweis Univ, Dept Pharmacodynam, Nagyvarad Ter 4, H-1089 Budapest, Hungary.
EM bag13638@iif.hu
RI Petschner, Peter/O-1697-2017; Bagdy, Gyorgy/O-3893-2017
OI Petschner, Peter/0000-0002-3198-858X; Bagdy, Gyorgy/0000-0001-8141-3410
FU European Commission
FX This manuscript was supported by the European Commission Framework 6.
   Integrated Project NEWMOOD. We'd like to thank to Timothy A. Hinsley,
   who performed the data normalization.
CR Acsady L, 2007, PROG BRAIN RES, V163, P577, DOI 10.1016/S0079-6123(07)63031-3
   Adori C, 2006, J COMP NEUROL, V497, P251, DOI 10.1002/cne.20994
   Adori C, 2011, PSYCHOPHARMACOLOGY, V213, P377, DOI 10.1007/s00213-010-2041-2
   Adori C, 2010, NEUROSCI LETT, V478, P56, DOI 10.1016/j.neulet.2010.04.061
   Alttoa A, 2010, EUR NEUROPSYCHOPHARM, V20, P288, DOI 10.1016/j.euroneuro.2009.09.005
   Andres P, 2003, CORTEX, V39, P871, DOI 10.1016/S0010-9452(08)70868-2
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   BAKER KG, 1990, J COMP NEUROL, V301, P147, DOI 10.1002/cne.903010202
   Balogh B, 2004, PSYCHOPHARMACOLOGY, V173, P296, DOI 10.1007/s00213-004-1787-9
   Berghuis P, 2007, SCIENCE, V316, P1212, DOI 10.1126/science.1137406
   Biezonski DK, 2010, J NEUROCHEM, V112, P951, DOI 10.1111/j.1471-4159.2009.06515.x
   Bolstad B., 2013, PREPROCESSCORE COLLE, P1
   Bond AJ, 2004, PSYCHOPHARMACOLOGY, V171, P331, DOI 10.1007/s00213-003-1585-9
   Bourgin C, 2007, J CELL BIOL, V178, P1295, DOI 10.1083/jcb.200610139
   BROENING HW, 1995, J PHARMACOL EXP THER, V275, P325
   Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221
   Capela JP, 2009, MOL NEUROBIOL, V39, P210, DOI 10.1007/s12035-009-8064-1
   Chayer C, 2001, Curr Neurol Neurosci Rep, V1, P547, DOI 10.1007/s11910-001-0060-4
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Colado MI, 1999, BRIT J PHARMACOL, V126, P911, DOI 10.1038/sj.bjp.0702373
   D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395
   Dalley JW, 2004, NEUROSCI BIOBEHAV R, V28, P771, DOI 10.1016/j.neubiorev.2004.09.006
   den Hollander B, 2012, J NEUROL NEUROSUR PS, V83, P83, DOI 10.1136/jnnp.2010.228387
   Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7
   Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311
   Easton N, 2006, J PSYCHOPHARMACOL, V20, P194, DOI 10.1177/0269881106061153
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fernandez-Castillo N, 2012, GENES BRAIN BEHAV, V11, P38, DOI 10.1111/j.1601-183X.2011.00735.x
   Ferrington L, 2006, EUR J NEUROSCI, V24, P509, DOI 10.1111/j.1460-9568.2006.04923.x
   Gao PP, 1999, P NATL ACAD SCI USA, V96, P4073, DOI 10.1073/pnas.96.7.4073
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gerlai R, 1999, J NEUROSCI, V19, P9538
   Gerra G, 2003, PSYCHIAT RES, V120, P115, DOI 10.1016/S0165-1781(03)00175-6
   Goonawardena AV, 2010, LEARN MEMORY, V17, P502, DOI 10.1101/lm.1893710
   GORDON CJ, 1991, PHARMACOL BIOCHEM BE, V38, P339, DOI 10.1016/0091-3057(91)90288-D
   Green AR, 2005, BRIT J PHARMACOL, V146, P306, DOI 10.1038/sj.bjp.0706318
   Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3
   Greenberg ME, 2009, J NEUROSCI, V29, P12764, DOI 10.1523/JNEUROSCI.3566-09.2009
   Guellmar A, 2009, J COMP NEUROL, V517, P645, DOI 10.1002/cne.22198
   Gulyas AI, 1999, NEUROCHEM INT, V34, P359, DOI 10.1016/S0197-0186(99)00041-8
   Gyongyosi N, BRAIN RES
   Gyongyosi N, 2010, J NEURAL TRANSM, V117, P285, DOI 10.1007/s00702-009-0357-z
   Hampson RE, 1999, LIFE SCI, V65, P715, DOI 10.1016/S0024-3205(99)00294-5
   Hampson RE, 2000, J NEUROSCI, V20, P8932
   Han Dawn D., 2006, BMC Pharmacology, V6, P6, DOI 10.1186/1471-2210-6-6
   Herrero MT, 2002, CHILD NERV SYST, V18, P386, DOI 10.1007/s00381-002-0604-1
   Hill MN, 2009, JAMA-J AM MED ASSOC, V301, P1165, DOI 10.1001/jama.2009.369
   Honda H, 1998, J THEOR BIOL, V192, P235, DOI 10.1006/jtbi.1998.0662
   Hruska M, 2012, MOL CELL NEUROSCI, V50, P35, DOI 10.1016/j.mcn.2012.03.004
   Karageorgiou J, 2009, NEUROIMAGE, V46, P817, DOI 10.1016/j.neuroimage.2009.02.029
   Kay C, 2011, NEUROBIOL LEARN MEM, V95, P473, DOI 10.1016/j.nlm.2011.02.010
   Kirilly E, 2008, INT J NEUROPSYCHOPH, V11, P795, DOI 10.1017/S1461145708008535
   Kolbrich EA, 2008, J CLIN PSYCHOPHARM, V28, P432, DOI 10.1097/JCP.0b013e31817ef470
   KOSOFSKY BE, 1987, SYNAPSE, V1, P153, DOI 10.1002/syn.890010204
   Kovacs GG, 2007, NEUROPATH APPL NEURO, V33, P193, DOI 10.1111/j.1365-2990.2006.00790.x
   Lazary J, 2011, TRENDS PHARMACOL SCI, V32, P270, DOI 10.1016/j.tips.2011.02.013
   Lee AM, 1996, DNA CELL BIOL, V15, P817, DOI 10.1089/dna.1996.15.817
   Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453
   LICHTMAN AH, 1995, PSYCHOPHARMACOLOGY, V119, P282, DOI 10.1007/BF02246292
   Lopez-Moreno JA, 2008, ADDICT BIOL, V13, P160, DOI 10.1111/j.1369-1600.2008.00105.x
   Lu Y, 2008, NEUROBIOL LEARN MEM, V89, P312, DOI 10.1016/j.nlm.2007.08.018
   Madronal N, 2012, CEREB CORTEX, V22, P550, DOI 10.1093/cercor/bhr103
   Malberg JE, 1998, J NEUROSCI, V18, P5086
   Martinez-Turrillas R, 2006, NEUROSCI LETT, V402, P126, DOI 10.1016/j.neulet.2006.03.055
   Mayberg HS, 1999, AM J PSYCHIAT, V156, P675
   McCann UD, 2005, NEUROPSYCHOPHARMACOL, V30, P1741, DOI 10.1038/sj.npp.1300736
   McCann UD, 1999, PSYCHOPHARMACOLOGY, V147, P56, DOI 10.1007/s002130051142
   Mechan AO, 2002, BRIT J PHARMACOL, V135, P170, DOI 10.1038/sj.bjp.0704442
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994
   Nawata Y, 2010, NEUROPSYCHOPHARMACOL, V35, P515, DOI 10.1038/npp.2009.158
   Nulsen CE, 2010, NEUROPSYCHOL REV, V20, P21, DOI 10.1007/s11065-009-9124-z
   Parrott AC, 2000, DRUG ALCOHOL DEPEN, V60, P105, DOI 10.1016/S0376-8716(99)00146-5
   Pearson RD, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-211
   R Core Team, 2012, R LANG ENV STAT COMP
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Savelieva KV, 2008, NEUROSCI LETT, V438, P205, DOI 10.1016/j.neulet.2008.04.013
   Seitz RJ, 2009, BRAIN RES REV, V60, P368, DOI 10.1016/j.brainresrev.2009.02.003
   Seniow J, 2012, FRONT NEUROL NEUROSC, V30, P50, DOI 10.1159/000333407
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Stetler RA, 2010, PROG NEUROBIOL, V92, P184, DOI 10.1016/j.pneurobio.2010.05.002
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   Thiriet N, 2002, FASEB J, V16, P1887, DOI 10.1096/fj.02-0502com
   TORK I, 1985, RAT NERVOUS SYSTEM, P43
   Vitalis T, 2008, EUR J NEUROSCI, V28, P1705, DOI 10.1111/j.1460-9568.2008.06484.x
   Vollenweider FX, 1998, NEUROPSYCHOPHARMACOL, V19, P241, DOI 10.1016/S0893-133X(98)00013-X
NR 90
TC 8
Z9 8
U1 4
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD DEC 30
PY 2013
VL 14
AR 930
DI 10.1186/1471-2164-14-930
PG 15
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AC0XK
UT WOS:000332218600001
PM 24378229
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Panda, JJ
   Yandrapu, S
   Kadam, RS
   Chauhan, VS
   Kompella, UB
AF Panda, Jiban J.
   Yandrapu, Sarath
   Kadam, Rajendra S.
   Chauhan, Virander S.
   Kompella, Uday B.
TI RETRACTED: Self-assembled phenylalanine-alpha,beta-dehydrophenylalanine
   nanotubes for sustained intravitreal delivery of a multi-targeted
   tyrosine kinase inhibitor (Retracted article. See vol. 237, pg. 186,
   2016)
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Retracted Publication
DE Self-assembly; Dipeptide nanotubes; Pazopanib; Drug delivery;
   Noninvasive ocular fluorophotometry
ID OCULAR DRUG-DELIVERY; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; RELEASE GANCICLOVIR; POSTERIOR SEGMENT; PEPTIDE NANOTUBES;
   PAZOPANIB; NANOPARTICLES; DIPEPTIDE; THERAPY
AB Current standard of care for sustained back of the eye drug delivery is surgical placement or injection of large, slow release implants using a relatively large 22 gauge needle. We designed novel dipeptide (phenylalanine-alpha,beta,dehydrophenylalanine; Phe-Delta Phe) based nanotubes with a diameter of similar to 15-30 nm and a length of similar to 1500 nm that could be injected with a 33 gauge needle for sustained intravitreal delivery of pazopanib, a multi targeted tyrosine kinase inhibitor. The drug could be loaded during nanotube assembly or post loaded after nanotube formation, with the former being more efficient at 25% w/w pazopanib loading and similar to 55% loading efficiency. Plain and peptide loaded nanotube were non-cytoloxic to retinal pigment epithelial cells even at a concentration of 200 mu g/ml. Following intravitreal injection of fluorescently labeled nanotubes using a 33 gauge needle in a rat model, the nanotube persistence and drug delivery were monitored using noninvasive fluorophotometry, electron microscopy and mass spectrometry analysis. Nanotubes persisted in the vitreous humor during the 15 days study and pazopanib levels in the vitreous humor, retina, and choroid-RPE at the end of the study were 4.5, 5, and 2.5-folds higher, respectively, compared to the plain drug. Thus, Phe-Delta Phe nanotubes allow intravitreal injections with a small gauge needle and sustain drug delivery. (C) 2013 Elsevier B.V. All rights reserved,
C1 [Panda, Jiban J.; Chauhan, Virander S.] Int Ctr Genet Engn & Biotechnol, New Delhi 110067, India.
   [Panda, Jiban J.; Yandrapu, Sarath; Kadam, Rajendra S.; Kompella, Uday B.] Univ Colorado Anschutz Med Campus, Dept Pharmaceut Sci, Nanomed & Drug Delivery Lab, Aurora, CO 80045 USA.
   [Kompella, Uday B.] Univ Colorado Anschutz Med Campus, Dept Ophthalmol, Aurora, CO 80045 USA.
   [Kompella, Uday B.] Univ Colorado Anschutz Med Campus, Dept Bioengn, Aurora, CO 80045 USA.
RP Kompella, UB (reprint author), Univ Colorado Anschutz Med Campus, Dept Pharmaceut Sci, 12850 E Montview Blvd, Aurora, CO 80045 USA.
EM uday.kompella@ucdenver.edu
FU UNESCO-L'Oreal for Young Women in Science Programme; NIH [EY018940,
   EY017533]
FX We are thankful to UNESCO-L'Oreal for Young Women in Science Programme
   for fellowship to JJP. This work was supported in part by the NIH grants
   EY018940 and EY017533. We are thankful to Rinku Baid for assistance with
   intravitreal injections.
CR Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Choonara YE, 2010, J PHARM SCI-US, V99, P2219, DOI 10.1002/jps.21987
   Crowder TM, 2003, GUIDE PHARM PARTICUL
   Davis JL, 2004, CURR OPIN MOL THER, V6, P195
   De Stefano VS, 2011, CLIN EXP OPHTHALMOL, V39, P236, DOI 10.1111/j.1442-9071.2010.02447.x
   Emami J, 2006, J PHARM PHARM SCI, V9, P169
   ENGLISH ML, 1978, BIOCHEM BIOPH RES CO, V83, P1464, DOI 10.1016/0006-291X(78)91385-2
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gazit E, 2007, CHEM SOC REV, V36, P1263, DOI 10.1039/b605536m
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gupta H, 2010, NANOMED-NANOTECHNOL, V6, P324, DOI 10.1016/j.nano.2009.10.004
   Gupta M, 2007, ADV MATER, V19, P858, DOI 10.1002/adma.200601774
   Heimann H., 2007, INTRAVITREAL INJECTI
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Hurwitz HI, 2009, CLIN CANCER RES, V15, P4220, DOI 10.1158/1078-0432.CCR-08-2740
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jang YC, 2005, PEDIATR ANESTH, V15, P1140, DOI 10.1111/j.1460-9591.2005.01648.x
   Kang SJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1043, DOI 10.1001/archophthalmol.2009.185
   Kozak I, 2006, RETINA-J RET VIT DIS, V26, P679, DOI 10.1097/00006982-200607000-00015
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Loftsson T, 2008, PHARMAZIE, V63, P171, DOI 10.1691/ph.2008.7322
   Lu YJ, 2006, AAPS J, V8, pE466, DOI 10.1208/aapsj080355
   MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324
   Mishra A, 2008, LANGMUIR, V24, P4571, DOI 10.1021/la7034533
   Nagarwal RC, 2009, J CONTROL RELEASE, V136, P2, DOI 10.1016/j.jconrel.2008.12.018
   Nielsen GD, 1996, ARCH TOXICOL, V70, P319, DOI 10.1007/s002040050281
   Panda J.J., 2013, NANOMEDICINE-UK
   Panda JJ, 2008, BIOMACROMOLECULES, V9, P2244, DOI 10.1021/bm800404z
   Panda JJ, 2011, THER DELIV, V2, P193, DOI 10.4155/TDE.10.93
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Podar K, 2006, P NATL ACAD SCI USA, V103, P19478, DOI 10.1073/pnas.0609329103
   Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387
   Rodrigues EB, 2011, J OCUL PHARMACOL TH, V27, P197, DOI 10.1089/jop.2010.0082
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rowe R. C., 2009, HDB PHARM EXCIPIENTS
   Rudra JS, 2012, ACS NANO, V6, P1557, DOI 10.1021/nn204530r
   SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023
   de Groot NS, 2007, BIOPHYS J, V92, P1732, DOI 10.1529/biophysj.106.096677
   Scanlon S, 2008, NANO TODAY, V3, P22, DOI 10.1016/S1748-0132(08)70041-0
   Seyfoddin A, 2010, DRUG DELIV, V17, P467, DOI 10.3109/10717544.2010.483257
   Sharma DK, 2010, AAPS J, V12, P455, DOI 10.1208/s12248-010-9205-1
   Shekunov BY, 2007, PHARM RES, V24, P203, DOI 10.1007/s11095-006-9146-7
   Shelke NB, 2011, DRUG DELIV TRANSL RE, V1, P76, DOI 10.1007/s13346-010-0009-8
   SMITH TJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P255, DOI 10.1001/archopht.1992.01080140111037
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4
   Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Thakur A, 2011, MICROVASC RES, V82, P346, DOI 10.1016/j.mvr.2011.09.001
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tolentino MJ, 2009, CURR MOL MED, V9, P973, DOI 10.2174/156652409789712783
   Vauthey S, 2002, P NATL ACAD SCI USA, V99, P5355, DOI 10.1073/pnas.072089599
   Wadhwa S, 2009, CURR PHARM DESIGN, V15, P2724, DOI 10.2174/138161209788923886
   Yafai Y, 2011, EUR J PHARMACOL, V666, P12, DOI 10.1016/j.ejphar.2011.05.016
NR 57
TC 15
Z9 15
U1 4
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 28
PY 2013
VL 172
IS 3
BP 1151
EP 1160
DI 10.1016/j.jconrel.2013.09.016
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 272WH
UT WOS:000328492800057
PM 24075925
DA 2018-12-27
ER

PT J
AU Zhang, WZ
   Li, X
   Shang, XF
   Zhao, QC
   Hu, YF
   Xu, X
   He, R
   Duan, LQ
   Zhang, F
AF Zhang, Wenzhi
   Li, Xu
   Shang, Xifu
   Zhao, Qichun
   Hu, Yefeng
   Xu, Xiang
   He, Rui
   Duan, Liqun
   Zhang, Feng
TI RETRACTED: Gene expression analysis in response to osmotic stimuli in
   the intervertebral disc with DNA microarray (Retracted article. See vol.
   20, pg. 32, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Intervertebral disc; Top-scoring pair; Osmotic pressure; Osmotic stimuli
ID NUCLEUS PULPOSUS CELLS; MESSENGER-RNA; VOLUME CHANGE; PROTEIN; MATRIX;
   POLYMORPHISMS; METABOLISM; OSMOLARITY; KINASE; CANCER
AB Background: Intervertebral disc (IVD) cells experience a broad range of physicochemical stimuli under physiologic conditions, including alterations in their osmotic environment. At present, the molecular mechanisms underlying osmotic regulation in IVD cells are poorly understood. This study aims to screen genes affected by changes in osmotic pressure in cells of subjects aged 29 to 63 years old, with top-scoring pair (TSP) method.
   Methods: Gene expression data set GSE1648 was downloaded from Gene Expression Omnibus database, including four hyper-osmotic stimuli samples, four iso-osmotic stimuli samples, and three hypo-osmotic stimuli samples. A novel, simple method, referred to as the TSP, was used in this study. Through this method, there was no need to perform data normalization and transformation before data analysis.
   Results: A total of five pairs of genes ((CYP2A6, FNTB), (PRPF8, TARDBP), (RPS5, OAZ1), (SLC25A3, NPM1) and (CBX3, SRSF9)) were selected based on the TSP method. We inferred that all these genes might play important roles in response to osmotic stimuli and age in IVD cells. Additionally, hyper-osmotic and iso-osmotic stimuli conditions were adverse factors for IVD cells.
   Conclusions: We anticipate that our results will provide new thoughts and methods for the study of IVD disease.
C1 [Zhang, Wenzhi; Li, Xu; Shang, Xifu; Zhao, Qichun; Hu, Yefeng; Xu, Xiang; He, Rui; Duan, Liqun; Zhang, Feng] Anhui Prov Hosp, Dept Orthopaed, Hefei 230001, Peoples R China.
RP Li, X (reprint author), Anhui Prov Hosp, Dept Orthopaed, 17 Rd Lujiang, Hefei 230001, Peoples R China.
EM lixu.aph@gmail.com
FU Natural Science Foundation of Anhui Province of China [11040606Q10];
   Foundation of Anhui Educational Committee [KJ2011Z202]
FX This work was supported by the Natural Science Foundation of Anhui
   Province of China (No. 11040606Q10) and by the Foundation of Anhui
   Educational Committee (No. KJ2011Z202).
CR Abbott RD, 2012, J ORTHOP RES, V30, P482, DOI 10.1002/jor.21534
   Altarescu G, 2011, ISR MED ASSOC J, V13, P87
   Bell IM, 2002, J MED CHEM, V45, P2388, DOI 10.1021/jm010531d
   Benz K, 2012, EUR SPINE J, V21, P1758, DOI 10.1007/s00586-012-2443-4
   Boyd LM, 2005, ANN BIOMED ENG, V33, P1071, DOI 10.1007/s10439-005-5775-y
   Chen J, 2002, BIOCHEM BIOPH RES CO, V293, P932, DOI 10.1016/S0006-291X(02)00314-5
   Cheng CC, 2009, J CELL PHYSIOL, V221, P668, DOI 10.1002/jcp.21904
   Dumont J, 2007, ARTERIOSCL THROM VAS, V27, P2120, DOI 10.1161/ATVBAHA.107.150458
   Farinola N, 2007, PHARMACOGENOMICS, V8, P151, DOI 10.2217/14622416.8.2.151
   Geman D, 2004, STAT APPL GENET MOL, V3, P19, DOI DOI 10.2202/1544-6115.1071
   Gruber HE, 2004, SPINE, V29, P2223, DOI 10.1097/01.brs.0000142225.07927.29
   Gruber HE, 2002, BIOTECH HISTOCHEM, V77, P37, DOI 10.1080/714028168
   Haschtmann D, 2006, J ORTHOP RES, V24, P1957, DOI 10.1002/jor.20243
   JABS EW, 1994, HUM GENET, V93, P600
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4
   Krause A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009849
   Krishnakumar D, 2012, FUND CLIN PHARMACOL, V26, P295, DOI 10.1111/j.1472-8206.2010.00917.x
   Lapointe JM, 2012, VET PATHOL, V49, P1054, DOI 10.1177/0300985812439723
   Le Visage C, 2006, SPINE, V31, P2036, DOI 10.1097/01.brs.0000231442.05245.87
   Lee KI, 2012, SPINE, V37, P452, DOI 10.1097/BRS.0b013e31823c8603
   Li S, 2008, J ANAT, V213, P725, DOI 10.1111/j.1469-7580.2008.00998.x
   Liu H, 2005, J AM SOC NEPHROL, V16, P1985, DOI 10.1681/ASN.20004090768
   LIU QR, 1993, DNA CELL BIOL, V12, P149, DOI 10.1089/dna.1993.12.149
   Ma Z, 2006, MOL CELL BIOL, V26, P9016, DOI 10.1128/MCB.01383-06
   Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07
   Maubaret CG, 2011, INVEST OPHTH VIS SCI, V52, P9304, DOI 10.1167/iovs.11-8372
   MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b
   Mukherji M, 2006, BIOCHEMISTRY-US, V45, P15529, DOI 10.1021/bi060971c
   Pritchard S, 2004, ANN BIOMED ENG, V32, P103, DOI 10.1023/B:ABME.0000007795.69001.35
   Pritchard S, 2002, BIOPHYS J, V83, P2502, DOI 10.1016/S0006-3495(02)75261-2
   Seilhean D, 2009, ACTA NEUROPATHOL, V118, P561, DOI 10.1007/s00401-009-0545-9
   Smolders L, 2013, THESIS UTRECHT U UTR
   Tamaki Y, 2011, DRUG METAB PHARMACOK, V26, P516, DOI 10.2133/dmpk.DMPK-11-RG-046
   Tan AC, 2005, BIOINFORMATICS, V21, P3896, DOI 10.1093/bioinformatics/bti631
   Vasta V, 2009, GENOME MED, V1, DOI 10.1186/gm100
   Winslow DGCdADQNRL, 2004, STAT APPL GENET MOL, V3, P1071
   Wuertz K, 2007, J ORTHOP RES, V25, P1513, DOI 10.1002/jor.20436
   Xu L, 2005, BIOINFORMATICS, V21, P3905, DOI 10.1093/bioinformatics/bti647
   Yamashita T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2303
   Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653
   Zhou J, 2009, J BIOL CHEM, V284, P9648, DOI 10.1074/jbc.M808708200
   Zhu J, 2007, BBA-MOL CELL RES, V1773, P1087, DOI 10.1016/j.bbamcr.2007.04.016
NR 43
TC 2
Z9 2
U1 4
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD DEC 27
PY 2013
VL 18
AR 62
DI 10.1186/2047-783X-18-62
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AC1ZX
UT WOS:000332297900001
PM 24369767
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Khatri, I
   Tang, Z
   Hiate, T
   Liu, Q
   Ishikawa, R
   Ueno, K
   Shirai, H
AF Khatri, I.
   Tang, Z.
   Hiate, T.
   Liu, Q.
   Ishikawa, R.
   Ueno, K.
   Shirai, H.
TI RETRACTED: Optical and carrier transport properties of graphene oxide
   based crystalline-Si/organic Schottky junction solar cells (Retracted
   article. See vol. 116, 239904, 2014)
SO JOURNAL OF APPLIED PHYSICS
LA English
DT Article; Retracted Publication
ID ELECTRICAL-PROPERTIES; FILMS; POLY(3,4-ETHYLENEDIOXYTHIOPHENE);
   FLEXIBILITY; ELECTRODES; PEDOT; METAL
AB We investigated the graphene oxide (GO) based n-type crystalline silicon (c-Si)/conductive poly(ethylene dioxythiophene):poly(styrenesulfonate)(PEDOT:PSS) Schottky junction devices with optical characterization and carrier transport measurement techniques. The optical transmittance in the UV region decreased markedly for the films with increasing the concentration of GO whereas it increased markedly in the visible-infrared regions. Spectroscopic ellipsometry revealed that the ordinary and extraordinary index of refraction increased with increasing the concentration of GO. The hole mobility also increased from 1.14 for pristine film to 1.85 cm(2)/V s for the 12-15 wt. % GO modified film with no significant increases of carrier concentration. The highest conductivity was found for a 15 wt. % GO modified PEDOT:PSS film:the c-Si/PEDOT:PSS:GO device using this sample exhibited a relatively high power conversion efficiency of 11.04%. In addition, the insertion of a 2-3 nm-thick GO thin layer at the c-Si/PEDOT:PSS interface suppressed the carrier recombination efficiency of dark electron and photo-generated hole at the anode, resulting in the increased photovoltaic performance. This study indicates that the GO can be good candidates for hole transporting layer of c-Si/PEDOT:PSS Schottky junction solar cell. (C) 2013 AIP Publishing LLC.
C1 [Khatri, I.; Tang, Z.; Hiate, T.; Liu, Q.; Ishikawa, R.; Ueno, K.; Shirai, H.] Saitama Univ, Grad Sch Sci & Engn, Saitama 3388570, Japan.
RP Khatri, I (reprint author), Saitama Univ, Grad Sch Sci & Engn, Saitama 3388570, Japan.
OI Ueno, Keiji/0000-0002-5535-9382; Ishikawa, Ryo/0000-0002-6924-2580
FU Japan Science and Technology Agency (JST); Ministry of Education,
   Culture, Sports, Science and Technology of Japan
FX This study was partially supported by the Japan Science and Technology
   Agency (JST) grant and the Grant-in-Aid for Scientific Research from the
   Ministry of Education, Culture, Sports, Science and Technology of Japan.
   The authors wish to express their appreciation to Mr. Kunitoshi Mimura
   and Mrs. Maiko Tsuji of Mitsubishi Gas Chemical, Ltd. for supplying GO
   precursor. Also thanks to Mr. Takumi Moriyama, Mr. Masayuki Sakurai, and
   Mrs. Nataliya Navatoba-Gabain of Horiba-Jobin Yvon, Ltd. for the SE
   measurements.
CR Aasmundtveit KE, 1999, SYNTHETIC MET, V101, P561, DOI 10.1016/S0379-6779(98)00315-4
   ANDERSON RL, 1962, SOLID STATE ELECTRON, V5, P341, DOI 10.1016/0038-1101(62)90115-6
   Anthopoulos TD, 2001, PHYS STATUS SOLIDI A, V186, P89, DOI 10.1002/1521-396X(200107)186:1<89::AID-PSSA89>3.0.CO;2-3
   Avasthi S, 2011, ADV MATER, V23, P5762, DOI 10.1002/adma.201102712
   Crispin X, 2006, CHEM MATER, V18, P4354, DOI 10.1021/cm061032+
   Eda G, 2010, ADV MATER, V22, P505, DOI 10.1002/adma.200901996
   FAN FR, 1978, J CHEM PHYS, V69, P3334, DOI 10.1063/1.436987
   Fujiwara H, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.075109
   HAINES WG, 1978, J APPL PHYS, V49, P304, DOI 10.1063/1.324386
   Hiate T., THIN SOLID FIL UNPUB
   Hirata M, 2004, CARBON, V42, P2929, DOI 10.1016/j.carbon.2004.07.003
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017
   Jellison GE, 1996, APPL PHYS LETT, V69, P2137, DOI 10.1063/1.118155
   Jellison GE, 1996, APPL PHYS LETT, V69, P371, DOI 10.1063/1.118064
   Kaltenbrunner M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1772
   KAUER E, 1965, PHILIPS TECH REV, V26, P33
   Kim EG, 2008, J AM CHEM SOC, V130, P16880, DOI 10.1021/ja806389b
   Lampert M. A., 1970, CURRENT INJECTION SO
   Liu QM, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.4709615
   Pettersson LAA, 1998, THIN SOLID FILMS, V313, P356, DOI 10.1016/S0040-6090(97)00846-8
   Pettersson LAA, 2002, ORG ELECTRON, V3, P143, DOI 10.1016/S1566-1199(02)00051-4
   Rose A., 1978, CONCEPT PHOTOCONDUCT
   SHANTHI E, 1980, J APPL PHYS, V51, P6243, DOI 10.1063/1.327610
   Sharma GD, 1996, MAT SCI ENG B-SOLID, V41, P222, DOI 10.1016/S0921-5107(96)01673-X
   SHOCKLEY W, 1952, PHYS REV, V87, P835, DOI 10.1103/PhysRev.87.835
   Taguchi M., 2009, P 24 EUR PHOT SOL EN, P1690
   Tsunomura Y, 2009, SOL ENERG MAT SOL C, V93, P670, DOI 10.1016/j.solmat.2008.02.037
   Yamashita M, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3647574
   Yin B, 2010, J NANOSCI NANOTECHNO, V10, P1934, DOI 10.1166/jnn.2010.2107
   Yip HL, 2012, ENERG ENVIRON SCI, V5, P5994, DOI 10.1039/c2ee02806a
NR 30
TC 3
Z9 3
U1 7
U2 75
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0021-8979
EI 1089-7550
J9 J APPL PHYS
JI J. Appl. Phys.
PD DEC 21
PY 2013
VL 114
IS 23
AR 234506
DI 10.1063/1.4847515
PG 7
WC Physics, Applied
SC Physics
GA 280UR
UT WOS:000329056800060
DA 2018-12-27
ER

PT J
AU Wang, Q
   Zhou, J
   Zhong, DW
   Wang, QW
   Huang, JS
AF Wang, Qin
   Zhou, Jun
   Zhong, Dewu
   Wang, Qunwei
   Huang, Jiangsheng
TI RETRACTED: Ferroportin in the progression and prognosis of
   hepatocellular carcinoma (Retracted article. See vol. 20, 38, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Ferroportin; Hepatocellular carcinoma; Prognosis
ID GLOBAL CANCER STATISTICS; IRON-RESPONSIVE ELEMENT; TUMOR-GROWTH; MICE;
   EXPRESSION; PROTEINS; OVEREXPRESSION; TRANSPORTER; CHELATORS; HEPCIDIN
AB Background: Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor in men and the seventh in women and understanding the molecular mechanisms of HCC and establishing more effective therapies are critical and urgent issues. Our objective was to study the expression of ferroportin in hepatocellular carcinoma (HCC) tissue samples and the relationship between ferroportin expression and HCC characteristics.
   Methods: Sixty HCC tissues and their corresponding para-cancer liver tissues (PCLT) were obtained from sixty HCC patients who had undergone hepatectomy in the Second Xiangya Hospital of Central South University. Ten normal liver tissue samples were also obtained as a control. Immunohistochemistry (IHC) was performed to analyze the ferroportin expression in HCC, and the relationship between ferroportin expression and HCC clinical pathological characteristics also was analyzed. For the evaluation of IHC results, the comprehensive scoring criteria were met according to the staining intensity and the number of positive staining cells. Western blotting was performed to detect the expression level of ferroportin in HCC cell lines.
   Results: Ferroportin expression in HCC tissue was significantly lower compared to PCLT and normal liver tissue (P < 0.05). Moreover, ferroportin expression was related to liver cancer cell de-differentiation, the severity degree in TNM staging, Edmondson-Steiner grading, intrahepatic metastasis and portal vein invasion. In addition, high expression of ferroportin was observed in normal human liver cell lines L02 and HL7702, whereas weak positive expression and even negative expression of ferroportin were observed in HCC cell lines FOCUS, MHCC-97H, HepG2 and SMMC-7721. Furthermore, among the four kinds of HCC cell lines, the expression level of ferroportin was the lowest in MHCC-97H cells.
   Conclusions: Ferroportin expression level declines along with the progression of liver cancer, suggesting that the reduction of ferroportin may serve as an important marker for poor HCC prognosis and as a new therapeutic target.
C1 [Wang, Qin] Cent S Univ, Dept Gynecol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Zhou, Jun; Wang, Qunwei; Huang, Jiangsheng] Cent S Univ, Dept Minimal Invas Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Zhong, Dewu] Cent S Univ, Dept Gen Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
RP Zhou, J (reprint author), Cent S Univ, Dept Minimal Invas Surg, Xiangya Hosp 2, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.
EM zhoujun0006@126.com
CR Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   Alkhateeb AA, 2013, BREAST CANCER RES TR, V137, P733, DOI 10.1007/s10549-012-2405-x
   Anderson GJ, 2012, CLIN EXP PHARMACOL P, V39, P719, DOI 10.1111/j.1440-1681.2011.05661.x
   Beutler E, 2003, BLOOD CELL MOL DIS, V31, P305, DOI 10.1016/S1079-9796(03)00165-7
   Boult J, 2008, CLIN CANCER RES, V14, P379, DOI 10.1158/1078-0432.CCR-07-1054
   Buss JL, 2004, CURR TOP MED CHEM, V4, P1623, DOI 10.2174/1568026043387269
   Canonne-Hergaux F, 2006, AM J PHYSIOL-GASTR L, V290, pG156, DOI 10.1152/ajpgi.00227.2005
   Chen GH, 2007, CARCINOGENESIS, V28, P785, DOI 10.1093/carcin/bgl210
   Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010
   Daniels TR, 2006, CLIN IMMUNOL, V121, P159, DOI 10.1016/j.clim.2006.06.006
   Donovan A, 2000, NATURE, V403, P776
   Finberg KE, 2011, HEMATOL-AM SOC HEMAT, P532, DOI 10.1182/asheducation-2011.1.532
   Galy B, 2008, CELL METAB, V7, P79, DOI 10.1016/j.cmet.2007.10.006
   Green DA, 2001, CLIN CANCER RES, V7, P3574
   HANN HWL, 1988, CANCER RES, V48, P4168
   HANN HWL, 1991, CANCER-AM CANCER SOC, V68, P2407, DOI 10.1002/1097-0142(19911201)68:11<2407::AID-CNCR2820681113>3.0.CO;2-N
   Holmstrom P, 2006, LIVER INT, V26, P976, DOI 10.1111/j.1478-3231.2006.01316.x
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kovacevic Z, 2010, CURR DRUG DELIV
   Lymboussaki A, 2003, J HEPATOL, V39, P710, DOI 10.1016/S0168-8278(03)00408-2
   Maffettone C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010163
   McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6
   Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scisignal.3001127, 10.1126/scitranslmed.3001127]
   Pogribny IP, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2641
   Rice AE, 2009, J MOL BIOL, V386, P717, DOI 10.1016/j.jmb.2008.12.063
   Schlesinger S, 2013, INT J CANCER, V132, P645, DOI 10.1002/ijc.27645
   SIEGERS CP, 1988, CANCER LETT, V41, P251, DOI 10.1016/0304-3835(88)90285-6
   SMITH AG, 1990, CARCINOGENESIS, V11, P437, DOI 10.1093/carcin/11.3.437
   THELANDER L, 1983, BIOCHEM BIOPH RES CO, V110, P859, DOI 10.1016/0006-291X(83)91040-9
   Torti SV, 2011, CANCER RES, V71, P1511, DOI 10.1158/0008-5472.CAN-10-3614
   Whitnall M, 2006, P NATL ACAD SCI USA, V103, P14901, DOI 10.1073/pnas.0604979103
   Wu LJC, 2004, BRAIN RES, V1001, P108, DOI 10.1016/j.brainres.2003.10.066
   Zhang DL, 2009, CELL METAB, V9, P461, DOI 10.1016/j.cmet.2009.03.006
NR 38
TC 7
Z9 8
U1 4
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD DEC 20
PY 2013
VL 18
AR 59
DI 10.1186/2047-783X-18-59
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 294VJ
UT WOS:000330075300001
PM 24360312
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU De la Herran-Arita, AK
   Kornum, BR
   Mahlios, J
   Jiang, W
   Lin, L
   Hou, TY
   Macaubas, C
   Einen, M
   Plazzi, G
   Crowe, C
   Newell, EW
   Davis, MM
   Mellins, ED
   Mignot, E
AF De la Herran-Arita, Alberto K.
   Kornum, Birgitte Rahbek
   Mahlios, Josh
   Jiang, Wei
   Lin, Ling
   Hou, Tieying
   Macaubas, Claudia
   Einen, Mali
   Plazzi, Giuseppe
   Crowe, Catherine
   Newell, Evan W.
   Davis, Mark M.
   Mellins, Elizabeth D.
   Mignot, Emmanuel
TI RETRACTED: CD4(+) T Cell Autoimmunity to Hypocretin/Orexin and
   Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in Narcolepsy
   (Retracted article. See vol. 6, 247rt1, 2014)
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article; Retracted Publication
ID CATAPLEXY; VIRUS; VACCINATION; ONSET; SUSCEPTIBILITY; ASSOCIATION;
   POPULATION; INFECTIONS; DEFICIENCY; ANTIBODIES
AB Narcolepsy, a disorder strongly associated with human leukocyte antigen (HLA)-DQA1*01:02/DQB1*06:02 (DQ0602), is characterized by excessive daytime sleepiness, cataplexy, and rapid eye movement sleep abnormalities. It is caused by the loss of similar to 70,000 posterior hypothalamic neurons that produce the wake-promoting neuropeptide hypocretin (HCRT) (orexin). We identified two DQ0602-binding HCRT epitopes, HCRT56-68 and HCRT87-99, that activated a sub-population of CD4(+) T cells in narcolepsy patients but not in DQ0602-positive healthy control subjects. Because of the established association of narcolepsy with the 2009 H1N1 influenza A strain (pH1N1), we administered a seasonal influenza vaccine (containing pH1N1) to patients with narcolepsy and found an increased frequency of circulating HCRT56-68- and HCRT87-99-reactive T cells. We also identified a hemagglutinin (HA) pHA1 epitope specific to the 2009 H1N1 strain, pHA1(275-287), with homology to HCRT56-68 and HCRT87-99. In vitro stimulation of narcolepsy CD4+ T cells with pH1N1 proteins or pHA1275-287 increased the frequency of HCRT56-68-and HCRT87-99-reactive T cells. Our data indicate the presence of CD4(+) T cells that are reactive to HCRT in narcolepsy patients and possible molecular mimicry between HCRT and a similar epitope in influenza pH1N1, pHA1(275-287).
C1 [De la Herran-Arita, Alberto K.; Kornum, Birgitte Rahbek; Mahlios, Josh; Lin, Ling; Einen, Mali; Mignot, Emmanuel] Stanford Sch Med, Ctr Sleep Sci & Med, Palo Alto, CA 94304 USA.
   [Kornum, Birgitte Rahbek] Glostrup Cty Hosp, Dept Diagnost, Mol Sleep Lab, DK-2600 Glostrup, Denmark.
   [Kornum, Birgitte Rahbek] Glostrup Cty Hosp, Danish Ctr Sleep Med, Dept Clin Neurophysiol, DK-2600 Glostrup, Denmark.
   [Jiang, Wei; Hou, Tieying; Macaubas, Claudia; Mellins, Elizabeth D.] Stanford Sch Med, Dept Pediat, Palo Alto, CA 94305 USA.
   [Plazzi, Giuseppe] Univ Bologna, IRCCS Inst Neurol Sci, I-40123 Bologna, Italy.
   [Plazzi, Giuseppe] Univ Bologna, Dept Biomed & NeuroMotor Sci, I-40123 Bologna, Italy.
   [Crowe, Catherine] Mater Private Sleep Lab, Dublin 7, Ireland.
   [Newell, Evan W.; Davis, Mark M.; Mellins, Elizabeth D.; Mignot, Emmanuel] Stanford Sch Med, Program Immunol, Palo Alto, CA 94305 USA.
RP Mignot, E (reprint author), Stanford Sch Med, Ctr Sleep Sci & Med, Palo Alto, CA 94304 USA.
EM mellins@stanford.edu; mignot@stanford.edu
RI Kornum, Birgitte/K-9193-2015
OI Kornum, Birgitte/0000-0002-2515-9451; Newell, Evan/0000-0002-2889-243X;
   Plazzi, Giuseppe/0000-0002-1051-0472
FU NIH [P50 NS23724, U19AI057229, R21 AI095813]; Danish Council for
   Independent Research [09-066348]; Stanford Institute for Immunity,
   Transplantation and Infection; GlaxoSmithKline [104642]; Jazz
   Pharmaceutical [108095]; Stanford School of Medicine
FX The study was supported by NIH grants P50 NS23724 (E. M.), U19AI057229
   (M. M. D., E. D. M., and E. M.), and R21 AI095813 (E. D. M.); The Danish
   Council for Independent Research 09-066348 (B. R. K.); Stanford
   Institute for Immunity, Transplantation and Infection (E. D. M. and E.
   M.); GlaxoSmithKline SPO #104642 (E. M.); and Jazz Pharmaceutical SPO
   #108095 (E. M.). A.K.D.H.-A. is a recipient of the Stanford School of
   Medicine Dean's Postdoctoral Fellowship Award.
CR Andlauer O, 2013, JAMA NEUROL, V70, P891, DOI 10.1001/jamaneurol.2013.1589
   Aran A, 2009, SLEEP, V32, P979, DOI 10.1093/sleep/32.8.979
   Belongia EA, 2010, JAMA-J AM MED ASSOC, V304, P1091, DOI 10.1001/jama.2010.1277
   Black JL, 2006, INT REV PSYCHIATR, V17, P461, DOI 10.1080/02646830500381492
   Black JL, 2005, SLEEP, V28, P427, DOI 10.1093/sleep/28.4.427
   Cvetkovic-Lopes V, 2010, J CLIN INVEST, V120, P713, DOI 10.1172/JCI41366
   Dauvilliers Y, 2013, BRAIN, V136, P2486, DOI 10.1093/brain/awt187
   Dauvilliers Y, 2010, SLEEP, V33, P1428, DOI 10.1093/sleep/33.11.1428
   Deloumeau A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013320
   Demachi-Okamura A, 2008, CANCER SCI, V99, P1633, DOI 10.1111/j.1349-7006.2008.00852.x
   Faraco J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003270
   Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062
   Fraser JD, 2008, IMMUNOL REV, V225, P226, DOI 10.1111/j.1600-065X.2008.00681.x
   Girard MP, 2011, VACCINE, V29, P6191, DOI [10.1016/j.vaccine.2011.08.031, 10.1016/j.vaccine.2011.06.085]
   Girard MP, 2010, VACCINE, V28, P4895, DOI [10.1016/j.vaccine.2010.05.031, 10.1016/j.vaccine.2010.07.034]
   Han F, 2012, TISSUE ANTIGENS, V80, P328, DOI 10.1111/j.1399-0039.2012.01948.x
   Han F., 2013, PLOS GENET, V9, DOI DOI 10.1371/JOURNAL.PGEN.1003880
   Han F, 2013, ANN NEUROL, V73, P560, DOI 10.1002/ana.23799
   Han F, 2011, ANN NEUROL, V70, P410, DOI 10.1002/ana.22587
   Han Lei, 2011, Journal of Public Health and Epidemiology, V3, P254
   Heier MS, 2013, SLEEP MED, V14, P867, DOI 10.1016/j.sleep.2013.03.020
   Holland CJ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00629
   Hou TY, 2011, J IMMUNOL, V187, P2442, DOI 10.4049/jimmunol.1100255
   Koepsell TD, 2010, J SLEEP RES, V19, P80, DOI 10.1111/j.1365-2869.2009.00756.x
   Kornum BR, 2011, CURR OPIN NEUROBIOL, V21, P897, DOI 10.1016/j.conb.2011.09.003
   Liblau RS, 2013, TRENDS NEUROSCI, V36, P315, DOI 10.1016/j.tins.2013.01.008
   Longstreth WT, 2009, SLEEP MED, V10, P422, DOI 10.1016/j.sleep.2008.05.009
   Luca G, 2013, J SLEEP RES, V22, P482, DOI 10.1111/jsr.12044
   Mignot E, 2002, ARCH NEUROL-CHICAGO, V59, P1553, DOI 10.1001/archneur.59.10.1553
   Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16
   Mignot E, 2001, AM J HUM GENET, V68, P686, DOI 10.1086/318799
   Miller E, 2013, BMJ-BRIT MED J, V356, DOI [10.1136/bmj.f794pmid:23444425, DOI 10.1136/BMJ.F794PMID:23444425]
   Moris P, 2011, J CLIN IMMUNOL, V31, P443, DOI 10.1007/s10875-010-9490-6
   Nohynek H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033536
   Partinen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033723
   Peyron C, 2000, NAT MED, V6, P991
   Quarona V, 2013, CYTOM PART B-CLIN CY, V84B, P207, DOI 10.1002/cyto.b.21092
   SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376
   Scammell TE, 2006, SLEEP, V29, P601, DOI 10.1093/sleep/29.5.601
   Schmitt L, 1999, P NATL ACAD SCI USA, V96, P6581, DOI 10.1073/pnas.96.12.6581
   Sidney J, 2010, J IMMUNOL, V185, P4189, DOI 10.4049/jimmunol.1001006
   Siebold C, 2004, P NATL ACAD SCI USA, V101, P1999, DOI 10.1073/pnas.0308458100
   Sriwilaijaroen N, 2012, P JPN ACAD B-PHYS, V88, P226, DOI 10.2183/pjab.88.226
   Su LF, 2013, IMMUNITY, V38, P373, DOI 10.1016/j.immuni.2012.10.021
   Szakacs A, 2013, NEUROLOGY, V80, P1315, DOI 10.1212/WNL.0b013e31828ab26f
   Tanaka S, 2006, SLEEP, V29, P633, DOI 10.1093/sleep/29.5.633
   Taubenberger JK, 2010, PUBLIC HEALTH REP, V125, P16, DOI 10.1177/00333549101250S305
   Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1
NR 48
TC 43
Z9 43
U1 3
U2 32
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD DEC 18
PY 2013
VL 5
IS 216
AR 216ra176
DI 10.1126/scitranslmed.3007762
PG 13
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 278MN
UT WOS:000328894500003
PM 24353159
DA 2018-12-27
ER

PT J
AU Fu, LJ
   Wang, B
AF Fu, Ling-jie
   Wang, Bing
TI RETRACTED: Investigation of the hub genes and related mechanism in
   ovarian cancer via bioinformatics analysis (Retracted article. See vol.
   8, 15, 2015)
SO JOURNAL OF OVARIAN RESEARCH
LA English
DT Article; Retracted Publication
DE Ovarian cancer; Protein-protein interaction network; Network module;
   Molecular mechanism
ID CYCLIN D1; EXPRESSION; MUTATIONS; NETWORKS; TUMORS; VEGF;
   OVEREXPRESSION; AMPLIFICATION; EXPLORATION; SURVIVAL
AB Background: Ovarian cancer is a cancerous growth arising from the ovary.
   Objective: This study was aimed to explore the molecular mechanism of the development and progression of the ovarian cancer.
   Methods: We first identified the differentially expressed genes (DEGs) between the ovarian cancer samples and the healthy controls by analyzing the GSE14407 affymetrix microarray data, and then the functional enrichments of the DEGs were investigated. Furthermore, we constructed the protein-protein interaction network of the DEGs using the STRING online tools to find the genes which might play important roles in the progression of ovarian cancer. In addition, we performed the enrichment analysis to the PPI network.
   Results: Our study screened 659 DEGs, including 77 up- and 582 down-regulated genes. These DEGs were enriched in pathways such as Cell cycle, p53 signaling pathway, Pathways in cancer and Drug metabolism. CCNE1, CCNB2 and CYP3A5 were the significant genes identified from these pathways. Protein-protein interaction (PPI) network was constructed and network Module A was found closely associated with ovarian cancer. Hub nodes such as VEGFA, CALM1, BIRC5 and POLD1 were found in the PPI network. Module A was related to biological processes such as mitotic cell cycle, cell cycle, nuclear division, and pathways namely Cell cycle, Oocyte meiosis and p53 signaling pathway.
   Conclusions: It indicated that ovarian cancer was closely associated to the dysregulation of p53 signaling pathway, drug metabolism, tyrosine metabolism and cell cycle. Besides, we also predicted genes such as CCNE1, CCNB2, CYP3A5 and VEGFA might be target genes for diagnosing the ovarian cancer.
C1 [Fu, Ling-jie] Shengjing Hosp China Med Univ, Dept Obstet & Gynaecol, Shenyang 110004, Peoples R China.
   [Wang, Bing] Shengjing Hosp China Med Univ, Dept Ultrasound, Shenyang 110004, Peoples R China.
RP Fu, LJ (reprint author), Shengjing Hosp China Med Univ, Dept Obstet & Gynaecol, 36 Sanhao St, Shenyang 110004, Peoples R China.
EM flina0413@163.com
FU National Natural Science Foundation of China [30100104]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No.30100104).
CR Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   Bains RK, 2013, BMC GENET, V14, DOI 10.1186/1471-2156-14-34
   Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025
   Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306
   Bowen NJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-71
   DeRycke MS, 2010, AM J CLIN PATHOL, V134, P835, DOI 10.1309/AJCPGXK0FR4MHIHB
   Downie D, 2005, CLIN CANCER RES, V11, P7369, DOI 10.1158/1078-0432.CCR-05-0466
   Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gilks CB, 2004, INT J GYNECOL PATHOL, V23, P200, DOI 10.1097/01.pgp.0000130446.84670.93
   Goff BA, 2000, CANCER, V89, P2068, DOI 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z
   Herr D, 2012, GYNECOL ONCOL, V127, P210, DOI 10.1016/j.ygyno.2012.05.002
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jabbour AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031428
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jia H, 2003, PROTEIN EXPRES PURIF, V27, P104, DOI 10.1016/S1046-5928(02)00576-4
   Junker BH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-219
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Maraziotis IA, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-93
   MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439
   Morotti M, 2013, EXPERT OPIN INV DRUG, V22, P1265, DOI 10.1517/13543784.2013.816282
   Nakayama K, 2006, CANCER BIOL THER, V5, P779, DOI 10.4161/cbt.5.7.2751
   Nakayama N, 2010, CANCER-AM CANCER SOC, V116, P2621, DOI 10.1002/cncr.24987
   Reles A, 2001, CLIN CANCER RES, V7, P2984
   Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412
   Rodriguez-Antona C, 2006, ONCOGENE, V25, P1679, DOI 10.1038/sj.onc.1209377
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Srihari S, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S17-S16
   Stav D, 2007, INT J BIOL MARKER, V22, P108
   Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373
   Team R, 2007, BOOK R LANG ENV STAT
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034
   Willner J, 2007, HUM PATHOL, V38, P607, DOI 10.1016/j.humpath.2006.10.007
   Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569
NR 37
TC 8
Z9 9
U1 4
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757-2215
J9 J OVARIAN RES
JI J. Ovarian Res.
PD DEC 17
PY 2013
VL 6
AR 92
DI 10.1186/1757-2215-6-92
PG 8
WC Reproductive Biology
SC Reproductive Biology
GA 295SZ
UT WOS:000330137100001
PM 24341673
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Gao, JL
   Zhan, Y
   Chen, J
   Wang, LN
   Yang, JP
AF Gao, Jianling
   Zhan, Ying
   Chen, Jun
   Wang, Lina
   Yang, Jianping
TI RETRACTED: Triptolide ameliorates lipopolysaccharide-induced acute lung
   injury in rats (Retracted article. See vol. 20, 35, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Triptolide; Lipopolysaccharide; Acute lung injury; Immunosuppressive
   agents; Toll-like receptor 4
ID RESPIRATORY-DISTRESS-SYNDROME; RECEPTOR 4; ENDOTOXIN; INFLAMMATION;
   VENTILATION; EXPRESSION; INHIBITOR; FAILURE; SEPSIS; MODEL
AB Background: Acute lung injury (ALI) is a serious clinical syndrome with a high rate of mortality. In this study, the effects of triptolide on lipopolysaccharide (LPS)-induced ALI in rats were investigated.
   Methods: Sixty-five male Sprague Dawley rats(approved by ethics committee of the First Affiliated Hospital of Soochow University) were randomly divided into five groups. The control group was injected with 2.5 mL saline/kg body weight via the tail vein and intraperitoneally with 1% dimethyl sulfoxide (DMSO) (n = 5). The L group was administered with 0.2% LPS dissolved in saline (5 mg/kg) to induce ALI via the tail vein (n = 15). The TP1, TP2, and TP3 groups were treated as rats in the L group and then intraperitoneally injected with 25, 50, and 100 mu g triptolide/kg body weight, respectively (15 rats per group). Blood samples from the left heart artery were taken for blood gas analysis at 1 hour before injection and at 1, 3, 6, and 12 hours after saline and DMSO administration in the control group, LPS injection in the L group, and triptolide injection in the TP1, TP2, and TP3 groups. Lung wet-to-dry weight (W/D) ratio, diffuse alveolar damage (DAD) score, TNF-alpha levels, and mRNA and protein expression of toll-like receptor 4 (TLR4) were analyzed.
   Results: Compared with the control group, the arterial partial pressure of oxygen (PaO2) declined (P < 0.05), the W/D ratio and DAD score increased (P < 0.05), and TNF-alpha levels in serum and bronchoalveolar lavage fluid (BALF) and mRNA and protein expression of TLR4 were significantly increased in the L group (P < 0.05). Compared with the L group, PaO2 significantly increased in the TP2 and TP3 groups (P < 0.05), while the W/D ratio and DAD score were significantly decreased in the TP2 and TP3 groups (P < 0.05). TNF-alpha levels and mRNA and protein expression of TLR4 were significantly decreased in the TP2 and TP3 groups compared with the L group (P < 0.05).
   Conclusions: Triptolide can ameliorate LPS-induced ALI by reducing the release of the inflammatory mediator TNF-alpha and inhibiting TLR4 expression.
C1 [Gao, Jianling; Zhan, Ying; Chen, Jun; Wang, Lina; Yang, Jianping] Suzhou Univ, Affiliated Hosp 1, Dept Anesthesiol, Suzhou 215006, Jiangsu, Peoples R China.
RP Yang, JP (reprint author), Suzhou Univ, Affiliated Hosp 1, Dept Anesthesiol, Shizi St 188, Suzhou 215006, Jiangsu, Peoples R China.
EM jianpingyangsz@hotmail.com
CR ALBERT RK, 1987, AM REV RESPIR DIS, V135, P628
   Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602
   Baumgarten G, 2006, EUR J ANAESTH, V23, P1041, DOI 10.1017/S0265021506001098
   Beasley MB, 2002, ARCH PATHOL LAB MED, V126, P1064
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082
   BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913
   Chu SJ, 2005, CHEST, V128, P327, DOI 10.1378/chest.128.1.327
   Hoyle GW, 2010, AM J PHYSIOL-LUNG C, V298, pL830, DOI 10.1152/ajplung.00014.2010
   Hua F, 2011, BLOOD COAGUL FIBRIN, V22, P480, DOI 10.1097/MBC.0b013e328346ef56
   Itoh T, 2007, AM J PHYSIOL-LUNG C, V293, pL446, DOI 10.1152/ajplung.00412.2005
   Klawitter M., 2012, EUR SPINE J, V21, P850, DOI DOI 10.1007/S00586-011-1919-Y
   Laffey JG, 2004, AM J RESP CRIT CARE, V169, P46, DOI 10.1164/rccm.200205-394OC
   Liu QY, 2011, INT IMMUNOPHARMACOL, V11, P377, DOI 10.1016/j.intimp.2011.01.012
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Morrison SG, 2005, J IMMUNOL, V175, P7536, DOI 10.4049/jimmunol.175.11.7536
   Quintel M, 1998, CRIT CARE MED, V26, P833, DOI 10.1097/00003246-199805000-00013
   Roger T, 2009, P NATL ACAD SCI USA, V106, P2348, DOI 10.1073/pnas.0808146106
   Rojas M, 2005, AM J PHYSIOL-LUNG C, V288, pL333, DOI 10.1152/ajplung.00334.2004
   STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364
   Tengchaisri T, 1998, CANCER LETT, V133, P169, DOI 10.1016/S0304-3835(98)00222-5
   vanHelden HPM, 1997, EXP LUNG RES, V23, P297, DOI 10.3109/01902149709039228
   WEISS SM, 1994, CRIT CARE CLIN, V10, P197
   Wu FX, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/406435
   XING Z, 1994, AM J RESP CELL MOL, V10, P148, DOI 10.1165/ajrcmb.10.2.8110470
   Yu C, 2011, FITOTERAPIA, V82, P709, DOI 10.1016/j.fitote.2011.02.011
   Yuan XY, 2008, CANCER EPIDEM BIOMAR, V17, P3621, DOI 10.1158/1055-9965.EPI-08-0742
   Zhao GH, 2000, AM J PHYSIOL-LUNG C, V279, pL958
   Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088
NR 30
TC 11
Z9 13
U1 3
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD DEC 17
PY 2013
VL 18
AR 58
DI 10.1186/2047-783X-18-58
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 294VF
UT WOS:000330074900001
PM 24345260
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hiyama, T
   Ozeki, N
   Mogi, M
   Yamaguchi, H
   Kawai, R
   Nakata, K
   Kondo, A
   Nakamura, H
AF Hiyama, Taiki
   Ozeki, Nobuaki
   Mogi, Makio
   Yamaguchi, Hideyuki
   Kawai, Rie
   Nakata, Kazuhiko
   Kondo, Ayami
   Nakamura, Hiroshi
TI RETRACTED: Matrix Metalloproteinase-3 in Odontoblastic Cells Derived
   from Ips Cells: Unique Proliferation Response as Odontoblastic Cells
   Derived from ES Cells (Retracted article. See vol. 13, art no E0198542 ,
   2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID HUMAN ARTICULAR CHONDROCYTES; NECROSIS-FACTOR-ALPHA; DENTAL-PULP CELLS;
   DIFFERENTIAL EXPRESSION; PERIAPICAL LESIONS; OSTEOBLASTIC CELLS;
   STEM-CELLS; TISSUE; ACTIVATION; INTERLEUKIN-1-BETA
AB We previously reported that matrix metalloproteinase (MMP)-3 accelerates wound healing following dental pulp injury. In addition, we reported that a proinflammatory cytokine mixture (tumor necrosis factor-alpha, interleukin (IL)-1 beta and interferon-gamma) induced MMP-3 activity in odontoblast-like cells derived from mouse embryonic stem (ES) cells, suggesting that MMP-3 plays a potential unique physiological role in wound healing and regeneration of dental pulp in odontoblast-like cells. In this study, we tested the hypothesis that upregulation of MMP-3 activity by IL-1 beta promotes proliferation and apoptosis of purified odontoblast-like cells derived from induced pluripotent stem (iPS) and ES cells. Each odontoblast-like cell was isolated and incubated with different concentrations of IL-1 beta. MMP-3 mRNA and protein expression were assessed using RTPCR and western blotting, respectively. MMP-3 activity was measured using immunoprecipitation and a fluorescence substrate. Cell proliferation and apoptosis were determined using ELISA for BrdU and DNA fragmentation, respectively. siRNA was used to reduce MMP-3 transcripts in these cells. Treatment with IL-1 beta increased MMP-3 mRNA and protein levels, and MMP-3 activity in odontoblast-like cells. Cell proliferation was found to markedly increase with no changes in apoptosis. Endogenous tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 were constitutively expressed during all experiments. The exocytosis inhibitor, Exo1, potently suppressed the appearance of MMP-3 in the conditioned medium. Treatment with siRNA against MMP-3 suppressed an IL-1 beta-induced increase in MMP-3 expression and activity, and also suppressed cell proliferation, but unexpectedly increased apoptosis in these cells (P<0.05). Exogenous MMP-3 was found to induce cell proliferation in odontoblast-like cells derived from iPS cells and ES cells. This siRNA-mediated increase in apoptosis could be reversed with exogenous MMP-3 stimulation (P<0.05). Taken together, IL-1 beta induced MMP-3-regulated cell proliferation and suppressed apoptosis in odontoblast-like cells derived from iPS and ES cells.
C1 [Hiyama, Taiki; Ozeki, Nobuaki; Yamaguchi, Hideyuki; Kawai, Rie; Nakata, Kazuhiko; Nakamura, Hiroshi] Aichi Gakuin Univ, Sch Dent, Dept Endodont, Nagoya, Aichi 464, Japan.
   [Mogi, Makio; Kondo, Ayami] Aichi Gakuin Univ, Sch Pharm, Dept Med Biochem, Nagoya, Aichi 464, Japan.
RP Ozeki, N (reprint author), Aichi Gakuin Univ, Sch Dent, Dept Endodont, 1-100 Kusumoto Cho, Nagoya, Aichi 464, Japan.
EM ozeki@g.agu.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [22791853]
FX This work was supported by a grant (No. 22791853 to NO) from the program
   Grants-in-Aid for Young Scientists (B) from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Abd-Elmeguid A, 2012, J ENDODONT, V38, P75, DOI 10.1016/j.joen.2011.10.005
   BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262
   Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035
   Cheng WD, 2013, INT ORTHOP, V37, P2065, DOI 10.1007/s00264-013-1990-6
   Eba H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052523
   Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933
   Paula-Silva FWG, 2010, J ENDODONT, V36, P231, DOI 10.1016/j.joen.2009.10.030
   Ge XP, 2009, ARTHRITIS RHEUM-US, V60, P2714, DOI 10.1002/art.24779
   Goda S, 2008, J DENT RES, V87, P782, DOI 10.1177/154405910808700805
   Gusman H, 2002, EUR J ORAL SCI, V110, P353, DOI 10.1034/j.1600-0722.2002.21347.x
   HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0
   Kawaguchi J, 2005, BONE, V36, P758, DOI 10.1016/j.bone.2004.07.019
   Kawai R., 2013, ORAL DIS
   Kessenbrock K, 2013, CELL STEM CELL, V13, P300, DOI 10.1016/j.stem.2013.06.005
   Kim RH, 2013, J ENDODONT, V39, P57, DOI 10.1016/j.joen.2012.09.006
   Koyama N, 2009, J MED INVESTIG, V56, P247, DOI 10.2152/jmi.56.247
   Koyama Y, 2008, BIOCHEM BIOPH RES CO, V371, P659, DOI 10.1016/j.bbrc.2008.04.064
   Ma B, 2012, ARTHRITIS RHEUM-US, V64, P2589, DOI 10.1002/art.34425
   Manka SW, 2012, P NATL ACAD SCI USA, V109, P12461, DOI 10.1073/pnas.1204991109
   Mogi M, 2004, BONE, V35, P507, DOI 10.1016/j.bone.2004.03.003
   Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Noguchi F, 2009, J ENDODONT, V35, P668, DOI 10.1016/j.joen.2009.01.016
   Ozeki N, 2002, ARCH ORAL BIOL, V47, P511, DOI 10.1016/S0003-9969(02)00035-3
   Ozeki N., 2013, ORAL DIS
   Ozeki N, 2013, PLOS ONE IN PRESS
   Palosaari H, 2003, EUR J ORAL SCI, V111, P117, DOI 10.1034/j.1600-0722.2003.00026.x
   Shimizukawa R, 2005, GENESIS, V42, P47, DOI 10.1002/gene.20122
   Shin SJ, 2002, J ENDODONT, V28, P313, DOI 10.1097/00004770-200204000-00013
   Song Z, 2012, J ENDODONT, V38, P1592, DOI 10.1016/j.joen.2012.09.023
   STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131
   SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TANIISHII N, 1995, ORAL MICROBIOL IMMUN, V10, P213, DOI 10.1111/j.1399-302X.1995.tb00145.x
   Teles J C, 1967, Rev Bras Odontol, V25, P305
   Tseng WY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063963
   Vanderford NL, 2010, ISLETS, V2, P334, DOI 10.4161/isl.2.5.13095
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Wahlgren J, 2002, INT ENDOD J, V35, P897, DOI 10.1046/j.1365-2591.2002.00587.x
   Westermarck J, 1999, FASEB J, V13, P781
   Wisithphrom K, 2006, J ENDODONT, V32, P853, DOI 10.1016/j.joen.2006.03.017
   WOESSNER JF, 1991, FASEB J, V5, P2145
   Yamaguchi H, 2013, J ENDOD IN PRESS
   Zheng L, 2009, AM J PATHOL, V175, P1905, DOI 10.2353/ajpath.2009.080705
   Zhong S, 2012, J ENDODONT, V38, P746, DOI 10.1016/j.joen.2012.02.020
NR 46
TC 16
Z9 16
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 16
PY 2013
VL 8
IS 12
AR e83563
DI 10.1371/journal.pone.0083563
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276GD
UT WOS:000328735700132
PM 24358294
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Niture, SK
   Gnatt, A
   Jaiswal, AK
AF Niture, Suryakant K.
   Gnatt, Averell
   Jaiswal, Anil K.
TI RETRACTED: Oncogene PKC epsilon controls INrf2-Nrf2 interaction in
   normal and cancer cells through phosphorylation of INrf2(Retracted
   article. See vol. 130, pg. 815, 2017)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE Nrf2; INrf2 (Keap1); PKC epsilon; Cell survival; Lung cancer
ID PROTEIN-KINASE-C; OXIDATIVE STRESS; GENE-EXPRESSION; E3 LIGASE; NRF2;
   KEAP1; MICE; DETOXIFICATION; ACCUMULATION; ACTIVATION
AB The INrf2 (Keap1)-Nrf2 cell sensor complex has a crucial role in protection against chemical-and radiation-induced oxidative stress and cellular transformation. INrf2, in association with Cul3-Rbx1, ubiquitylates and degrades Nrf2. Exposure to stressors leads to stabilization of Nrf2 and the coordinated activation of cytoprotective proteins and cellular protection. However, the molecular signal(s) that regulate control of Nrf2 by INrf2 remain elusive. In this report, we demonstrate that phosphorylation of INrf2 at Ser599 and Ser602 by the oncoprotein PKC epsilon is essential for INrf2-Nrf2 interaction, and the subsequent ubiquitylation and degradation of Nrf2. Inhibition of PKCe, knockdown of PKCe and the INrf2S602A mutant all failed to phosphorylate INrf2, leading to loss of the INrf2-Nrf2 interaction, Nrf2 degradation and enhanced cytoprotection and drug resistance. Molecular modeling analyses revealed that phosphorylation of S599 exposes the deeply buried S602 for phosphorylation and enhanced INrf2-Nrf2 interaction. Analysis of human lung and liver tumor protein arrays showed lower PKC epsilon and higher Nrf2 levels, which presumably promoted cancer cell survival and drug resistance. In conclusion, phosphorylation of INrf2 by PKC epsilon leads to regulation of Nrf2, with significant implications for the survival of cancer cells, which often express lower levels of PKC epsilon.
C1 [Niture, Suryakant K.; Gnatt, Averell; Jaiswal, Anil K.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA.
RP Jaiswal, AK (reprint author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 West Baltimore St, Baltimore, MD 21201 USA.
EM ajaiswal@som.umaryland.edu
FU National Institutes of Health [RO1 ES012265]
FX This work was supported by the National Institutes of Health [grant
   number RO1 ES012265]. Deposited in PMC for release after 12 months.
CR Basu A, 2007, CELL SIGNAL, V19, P1633, DOI 10.1016/j.cellsig.2007.04.008
   Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098
   Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029
   Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501
   Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102
   Hu XM, 2006, MOL CELL BIOL, V26, P940, DOI 10.1128/MCB.26.3.940-954.2006
   Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200
   Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200
   Lee OH, 2007, J BIOL CHEM, V282, P36412, DOI 10.1074/jbc.M706517200
   Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200
   Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11
   Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016
   Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626
   Niture SK, 2013, FREE RADICAL BIO MED, V57, P119, DOI 10.1016/j.freeradbiomed.2012.12.014
   Niture SK, 2012, J BIOL CHEM, V287, P9873, DOI 10.1074/jbc.M111.312694
   Niture SK, 2011, J BIOL CHEM, V286, P28821, DOI 10.1074/jbc.M111.255042
   Niture SK, 2009, J CELL SCI, V122, P4452, DOI 10.1242/jcs.058537
   Niwa K, 2002, FREE RADICAL RES, V36, P1147, DOI 10.1080/1071576021000016409
   Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013
   Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10
   Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538
   Shelton P, 2013, FASEB J, V27, P414, DOI 10.1096/fj.12-217257
   Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105
   Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974
NR 31
TC 5
Z9 6
U1 3
U2 12
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD DEC 15
PY 2013
VL 126
IS 24
BP 5657
EP 5669
DI 10.1242/jcs.133819
PG 13
WC Cell Biology
SC Cell Biology
GA 275OL
UT WOS:000328686600012
PM 24127568
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Deng, BY
   Hua, YQ
   Cai, ZD
AF Deng, Bi-Yong
   Hua, Ying-Qi
   Cai, Zheng-Dong
TI RETRACTED: Establishing an osteosarcoma associated protein-protein
   interaction network to explore the pathogenesis of osteosarcoma
   (Retracted article. See vol. 20, 40, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Osteosarcoma; Differentially expressed genes; Protein-protein
   interaction network; Pathway enrichment analysis
ID GENE-EXPRESSION; DIFFERENTIATION; SYSTEM; CHEMOTHERAPY; METASTASIS;
   MIGRATION; ACTIVATOR; MODEL
AB Background: The aim of this study was to establish an osteosarcoma (OS) associated protein-protein interaction network and explore the pathogenesis of osteosarcoma.
   Methods: The gene expression profile GSE9508 was downloaded from the Gene Expression Omnibus database, including five samples of non-malignant bone (the control), seven samples for non-metastatic patients (six of which were analyzed in duplicate), and 11 samples for metastatic patients (10 of which were analyzed in duplicate). Differentially expressed genes (DEGs) between osteosarcoma and control samples were identified by packages in R with the threshold of |logFC (fold change)| > 1 and false discovery rate < 0.05. Osprey software was used to construct the interaction network of DEGs, and genes at protein-protein interaction (PPI) nodes with high degrees were identified. The Database for Annotation, Visualization and Integrated Discovery and WebGestalt software were then used to perform functional annotation and pathway enrichment analyses for PPI networks, in which P < 0.05 was considered statistically significant.
   Results: Compared to the control samples, the expressions of 42 and 341 genes were altered in non-metastatic OS and metastatic OS samples, respectively. A total of 15 significantly enriched functions were obtained with Gene Ontology analysis (P < 0.05). The DEGs were classified and significantly enriched in three pathways, including the tricarboxylic acid cycle, lysosome and axon guidance. Genes such as HRAS, IDH3A, ATP6ap1, ATP6V0D2, SEMA3F and SEMA3A were involved in the enriched pathways.
   Conclusions: The hub genes from metastatic OS samples are not only bio-markers of OS, but also help to improve therapies for OS.
C1 [Deng, Bi-Yong; Hua, Ying-Qi; Cai, Zheng-Dong] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped Surg, Shanghai 200072, Peoples R China.
RP Hua, YQ (reprint author), Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped Surg, 301 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
EM huayingqihyq@gmail.com; caizhengdongdr@hotmail.com
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   BACCI G, 1993, CANCER, V72, P3227, DOI 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C
   Bacci G, 1997, CANCER-AM CANCER SOC, V79, P245
   Bielenberg DR, 2007, CANCER METAST REV, V26, P421, DOI 10.1007/s10555-007-9097-4
   Bihani T, 2004, CELL CYCLE, V3, P1201
   Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r23
   Broadhead ML, 2011, EXPERT OPIN THER TAR, V15, P169, DOI 10.1517/14728222.2011.546351
   BRODEY RS, 1969, CLIN ORTHOP RELAT R, P54
   Dudoit S, 2003, STAT SCI, V18, P71, DOI 10.1214/ss/1056397487
   Duncan D, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S4-P10
   Endo-Munoz L, 2010, CANCER RES, V70, P7063, DOI 10.1158/0008-5472.CAN-09-4291
   Fisher JL, 2001, CLIN CANCER RES, V7, P1654
   Fujita A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-469
   Handa A, 2000, INT J ONCOL, V17, P291
   Hogue C. W., 2006, CURR PROTOC BIOINFOR
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Jensen ED, 2010, J CELL BIOCHEM, V109, P672, DOI 10.1002/jcb.22462
   Kang HG, 2007, J ORTHOP RES, V25, P696, DOI 10.1002/jor.20323
   Kawakami T, 2002, CANCER, V95, P2196, DOI 10.1002/cncr.10936
   Khanna C, 2001, CANCER RES, V61, P3750
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim T, 2009, BIOCHEM BIOPH RES CO, V390, P585, DOI 10.1016/j.bbrc.2009.10.010
   Laverdiere C, 2005, CLIN CANCER RES, V11, P2561, DOI 10.1158/1078-0432.CCR-04-1089
   Lu XY, 2008, MOL CANCER RES, V6, P937, DOI 10.1158/1541-7786.MCR-07-2115
   Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9-4-422
   Mori K, 2007, ONCOL REP, V18, P1365
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Murthy M Bhanu, 2011, J Indian Soc Periodontol, V15, P190, DOI 10.4103/0972-124X.85659
   Narazaki M, 2006, J NATL CANCER I, V98, P294, DOI 10.1093/jnci/djj099
   Ottaviani G, 2010, PEDIAT ADOLESCENT OS, P3, DOI DOI 10.1007/978-1-4419-0284-9
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Song B, 2010, RES MOL MECH CHEMORE
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Yang DQ, 2012, J BONE MINER RES, V27, P1695, DOI 10.1002/jbmr.1623
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
NR 39
TC 3
Z9 3
U1 2
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD DEC 14
PY 2013
VL 18
AR 57
DI 10.1186/2047-783X-18-57
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 294VC
UT WOS:000330074600001
PM 24330838
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jiang, XH
   Yu, BQ
   Qu, W
   He, JW
AF Jiang, Xinhua
   Yu, Baoqing
   Qu, Wei
   He, Jiawen
TI RETRACTED: Meta-analysis on the efficacy of tourniquet on ankle trauma
   surgery(Retracted article. See vol. 20, 34, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Tourniquet; Limb trauma; Ankle; Operation; Meta-analysis
ID TOTAL KNEE ARTHROPLASTY; PNEUMATIC TOURNIQUET; HOSPITALIZED-PATIENTS;
   INTERNAL-FIXATION; RISK-FACTORS; SURGERY; PAIN; FRACTURES;
   COMPLICATIONS; ISCHEMIA
AB Background: In our study, we used meta-analysis to study the efficacy of the tourniquet on ankle trauma surgery. Postoperative infection rate, deep venous thrombosis incidence, hospital stay, and joint range of motion were studied to compare the tourniquet and non-tourniquet groups and provide certain references for clinical decision.
   Methods: We searched PubMed, MEDLINE, EMBASE, and the Cochrane controlled trials register for all publications about the efficacy of tourniquet published before November 2012. The quality of included studies was evaluated by two estimators. I-2-test and Q-statistic were used for heterogeneity analysis. When there was heterogeneity between studies, the random effects model analysis was applied or else the fixed effects model analysis was used.
   Results: Three studies were included with 166 patients suffering from ankle trauma surgery. There was no statistical difference (P > 0.05) between the tourniquet and non-tourniquet groups on operation time (mean difference (MD) -5.45, 95% confidence intervals (CI): (-13.98, 3.09)), postoperative infection rate (relative risk (RR) 1.83, 95% CI: (0.65, 5.12)), and deep venous thrombosis incidence (RR 4.13, 95% CI: (0.47, 36.17)). But statistical significances were observed on hospital stays (MD 3.17, 95% CI: (1.39, 4.95)) and joint range of motion (MD -5.25, 95% CI: (-9.61, -0.89)).
   Conclusions: In general, the efficacy of the tourniquet group is comparable to that of the non-tourniquet group. The non-tourniquet group achieved greater benefits for the joint range of motion and reduced the hospital stay. However, a larger number of primary studies is still required for future evaluation of tourniquet efficacy on ankle trauma surgery.
C1 [Jiang, Xinhua; Yu, Baoqing; Qu, Wei; He, Jiawen] Fudan Univ, Shanghai Pudong Hosp, Pudong Med Ctr, Dept Orthopaed, Shanghai 201399, Peoples R China.
RP Jiang, XH (reprint author), Fudan Univ, Shanghai Pudong Hosp, Pudong Med Ctr, Dept Orthopaed, 2800 Gongwei Rd, Shanghai 201399, Peoples R China.
EM jiangxinhua@hotmail.com
CR ABDELSALAM A, 1995, J BONE JOINT SURG BR, V77B, P250
   Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307
   BURRIS JF, 1991, NEW ENGL J MED, V325, P210
   Chung Lien-Hsiang, 2011, Orthopedics, V34, P15, DOI 10.3928/01477447-20101123-05
   Classen DC, 1997, OBSTET GYNECOL SURV, V52, P291
   Collins TC, 1999, ANN SURG, V230, P251, DOI 10.1097/00000658-199908000-00016
   Cox Efrem M, 2010, Iowa Orthop J, V30, P104
   Estebe JP, 2011, EUR J ANAESTH, V28, P404, DOI 10.1097/EJA.0b013e328346d5a9
   Finsen V, 1997, J BONE JOINT SURG BR, V79B, P99, DOI 10.1302/0301-620X.79B1.7069
   Fukuda A, 2007, ARCH ORTHOP TRAUM SU, V127, P671, DOI 10.1007/s00402-006-0244-0
   Higgins JP, 2008, COCHRANE HDB SYSTEMA
   Horlocker TT, 2006, ANESTH ANALG, V102, P950, DOI 10.1213/01.ane.0000194875.05587.7e
   IRVING GA, 1985, J BONE JOINT SURG BR, V67, P297
   Kalla Timothy P, 2003, J Foot Ankle Surg, V42, P68, DOI 10.1016/S1067-2516(03)70004-0
   KLENERMAN L, 1995, J BONE JOINT SURG BR, V77B, P174
   Konrad G, 2005, CLIN ORTHOP RELAT R, P189, DOI 10.1097/01.blo.0000151849.37260.0a
   KREBS DE, 1989, PHYS THER, V69, P803, DOI 10.1093/ptj/69.10.803
   MAFFULLI N, 1993, J BONE JOINT SURG AM, V75A, P700, DOI 10.2106/00004623-199305000-00009
   Mohan A, 2011, J HAND SURG-EUR VOL, V36E, P215, DOI 10.1177/1753193410390845
   Mowafi HA, 2008, ANESTH ANALG, V107, P1422, DOI 10.1213/ane.0b013e318181f689
   Olivecrona C, 2013, INT ORTHOP, V37, P827, DOI 10.1007/s00264-013-1826-4
   Omeroglu H, 1997, FOOT ANKLE INT, V18, P798
   SAPEGA AA, 1985, J BONE JOINT SURG AM, V67A, P303, DOI 10.2106/00004623-198567020-00018
   Smith T O, 2010, Foot Ankle Surg, V16, P3, DOI 10.1016/j.fas.2009.03.006
   Smith TO, 2010, KNEE, V17, P141, DOI 10.1016/j.knee.2009.06.007
   Smith TO, 2009, KNEE, V16, P317, DOI 10.1016/j.knee.2009.01.004
   Tai TW, 2011, KNEE SURG SPORT TR A, V19, P1121, DOI 10.1007/s00167-010-1342-7
   Tetro AM, 2001, CAN J SURG, V44, P33
   Tibrewal SB, 2001, INT ORTHOP, V24, P347, DOI 10.1007/s002640000180
   VANSANT JP, 1990, CLIN NUCL MED, V15, P783, DOI 10.1097/00003072-199011000-00001
NR 30
TC 2
Z9 3
U1 3
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD DEC 10
PY 2013
VL 18
AR 55
DI 10.1186/2047-783X-18-55
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 294UT
UT WOS:000330073700001
PM 24325911
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Xu, XB
   Zhang, H
   Zhou, P
   Chen, L
AF Xu, Xinbao
   Zhang, Hui
   Zhou, Ping
   Chen, Lei
TI RETRACTED: Meta-analysis of the efficacy of pancreatoduodenectomy with
   extended lymphadenectomy in the treatment of pancreatic cancer
   (Retracted article. See vol. 13, pg. 125, 2015)
SO WORLD JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE Pancreatic cancer; Pancreatoduodenectomy with extended lymphadenectomy;
   Standard pancreatoduodenectomy; Meta-analysis
ID STANDARD PANCREATICODUODENECTOMY; RETROPERITONEAL LYMPHADENECTOMY;
   PERIAMPULLARY ADENOCARCINOMA; DISTAL GASTRECTOMY; SURGICAL-TREATMENT;
   HEAD; CARCINOMA; RESECTION; SURVIVAL; DISSECTION
AB Background: The purpose of this meta-analysis is to compare the efficacy of pancreatoduodenectomy (PD) with extended lymphadenectomy (PD/ELND) versus standard PD in the treatment of pancreatic cancer, with the hope of providing evidence for clinical practice.
   Methods: The retrieval of relevant literature published before September 2012 was carried out on PubMed, Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) by computer. Information was extracted according to Cochrane systematic review methods, and analyzed using software Stata 11.0.
   Results: Five prospective randomized controlled trials (RCTs) were included in this meta-analysis of 555 cases (278 in the PD/ELND group and 277 in the standard PD group). The PD/ELND group showed a significantly lower 3-year survival rate (relative risk (RR) = 1.46, 95% confidence interval (CI) 1.03 to approximately 2.06, P = 0.034), prolonged operative time (weighted mean difference WMD = -1.03, 95% CI -1.96 to approximately -0.10, P = 0.029) and higher incidence of postoperative complications (RR = 0.56, 95% CI 0.42 to approximately 0.77, P = 0.000) by comparing with standard PD group. Besides, no significant difference was observed in the 1-year survival rate (RR = 0.87, 95% CI 0.60 to approximately 1.25, P = 0.69), 5-year survival rate (RR = 1.04, 95% CI 0.68 to approximately 1.58, P = 0.854), postoperative mortality (RR = 1.14, 95% CI 0.43 to approximately 3.00, P = 0.789), length of stay (WMD = -0.32, 95% CI -2.57 to approximately 1.94, P = 0.784) and the amount of blood transfusions (WMD = -0.14, 95% CI -0.36 to approximately 0.08, P = 0.213).
   Conclusions: PD/ELND does not have an advantage over standard PD in the survival rate for patients with pancreatic cancer, but does increase operative time and incidences of postoperative complications.
C1 [Xu, Xinbao; Zhang, Hui] AF Gen Hosp Chinese Peoples Liberat Army, Dept Hepatobiliary Surg, Beijing 100142, Peoples R China.
   [Zhou, Ping] AF Gen Hosp Chinese Peoples Liberat Army, Dept Radiotherapy, Beijing 100142, Peoples R China.
   [Chen, Lei] Peking Univ, Peoples Hosp, Dept Hepatobiliary Surg, Beijing 100044, Peoples R China.
RP Xu, XB (reprint author), AF Gen Hosp Chinese Peoples Liberat Army, Dept Hepatobiliary Surg, Beijing 100142, Peoples R China.
EM xu_xinbao@sohu.com
CR Chisholm EJ, 2009, LARYNGOSCOPE, V119, P1135, DOI 10.1002/lary.20236
   Cserni G, 2004, BRIT J SURG, V91, P1245, DOI 10.1002/bjs.4725
   Farnell MB, 2005, SURGERY, V138, P618, DOI 10.1016/j.surg.2005.06.044
   FORTNER JG, 1973, SURGERY, V73, P307
   Han SS, 2007, HEPATO-GASTROENTEROL, V54, P1831
   Iqbal N, 2009, EJSO-EUR J SURG ONC, V35, P79, DOI 10.1016/j.ejso.2008.01.002
   ISHIKAWA O, 1988, ANN SURG, V208, P215, DOI 10.1097/00000658-198808000-00014
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   KAYAHARA M, 1995, SURGERY, V117, P616, DOI 10.1016/S0039-6060(95)80003-4
   Kim T, 2006, CANCER-AM CANCER SOC, V106, P4, DOI 10.1002/cncr.21568
   Loos M, 2008, ANN NY ACAD SCI, V1138, P169, DOI 10.1196/annals.1414.024
   MANABE T, 1989, CANCER, V64, P1132, DOI 10.1002/1097-0142(19890901)64:5<1132::AID-CNCR2820640528>3.0.CO;2-V
   Mukaiya M, 1998, WORLD J SURG, V22, P248, DOI 10.1007/s002689900378
   Naganuma T, 1998, PANCREAS, V16, P355, DOI 10.1097/00006676-199804000-00024
   Nimura Y, 2012, J HEPATO-BIL-PAN SCI, V19, P230, DOI 10.1007/s00534-011-0466-6
   Pedrazzoli S, 1998, ANN SURG, V228, P508, DOI 10.1097/00000658-199810000-00007
   Riall TS, 2005, J GASTROINTEST SURG, V9, P1191, DOI 10.1016/j.gassur.2005.08.034
   SATAKE K, 1992, SURG GYNECOL OBSTET, V175, P259
   Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484
   Warshaw A, 2005, J GASTROINTEST SURG, V9, P1204
   Yeo CJ, 2002, ANN SURG, V236, P355, DOI 10.1097/01.SLA.0000027272.08464.0B
   Zetoune T, 2010, ANN SURG ONCOL, V17, P3287, DOI 10.1245/s10434-010-1137-6
NR 22
TC 12
Z9 14
U1 2
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7819
J9 WORLD J SURG ONCOL
JI World J. Surg. Oncol.
PD DEC 10
PY 2013
VL 11
AR 311
DI 10.1186/1477-7819-11-311
PG 8
WC Oncology; Surgery
SC Oncology; Surgery
GA 291YT
UT WOS:000329869500001
PM 24321394
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ying, HC
   Lv, J
   Ying, TS
   Jin, SS
   Shao, JR
   Wang, LL
   Xu, HY
   Yuan, B
   Yang, Q
AF Ying, Huanchun
   Lv, Jing
   Ying, Tianshu
   Jin, Shanshan
   Shao, Jingru
   Wang, Lili
   Xu, Hongying
   Yuan, Bin
   Yang, Qing
TI RETRACTED: Gene-gene interaction network analysis of ovarian cancer
   using TCGA data (Retracted article. See vol. 8, 18, 2015)
SO JOURNAL OF OVARIAN RESEARCH
LA English
DT Article; Retracted Publication
DE Differentially expressed genes; Function and pathway annotation;
   Gene-gene interaction network; Functional modules
ID TUMOR-SUPPRESSOR; RISK; CARCINOGENESIS; SUSCEPTIBILITY; IDENTIFICATION;
   ASSOCIATION; EXPRESSION; VARIANTS; PATHWAYS; BIOLOGY
AB Background: The Cancer Genome Atlas (TCGA) Data portal provides a platform for researchers to search, download, and analysis data generated by TCGA. The objective of this study was to explore the molecular mechanism of ovarian cancer pathogenesis.
   Methods: Microarray data of ovarian cancer were downloaded from TCGA database, and Limma package in R language was used to identify the differentially expressed genes (DEGs) between ovarian cancer and normal samples, followed by the function and pathway annotations of the DEGs. Next, NetBox software was used to for the gene-gene interaction (GGI) network construction and the corresponding modules identification, and functions of genes in the modules were screened using DAVID.
   Results: Our studies identified 332 DEGs, including 146 up-regulated genes which mainly involved in the cell cycle related functions and cell cycle pathway, and 186 down-regulated genes which were enriched in extracellular region par function, and Ether lipid metabolism pathway. GGI network was constructed by 127 DEGs and their significantly interacted 209 genes (LINKERs). In the top 10 nodes ranked by degrees in the network, 5 were LINKERs. Totally, 7 functional modules in the network were selected, and they were enriched in different functions and pathways, such as mitosis process, DNA replication and DNA double-strand synthesis, lipid synthesis processes and metabolic pathways. AR, BRCA1, TFDP1, FOXM1, CDK2, and DBF4 were identified as the transcript factors of the 7 modules.
   Conclusion: our data provides a comprehensive bioinformatics analysis of genes, functions, and pathways which may be involved in the pathogenesis of ovarian cancer.
C1 [Ying, Huanchun; Ying, Tianshu; Jin, Shanshan; Shao, Jingru; Wang, Lili; Yang, Qing] China Med Univ, Shengjing Hosp, Dept Gynecol & Obstet, Shenyang 110004, Liaoning Provin, Peoples R China.
   [Lv, Jing; Yuan, Bin] Fifth Hosp Shenyang, Dept Oncol, Shenyang 110023, Peoples R China.
   [Xu, Hongying] Ninth Hosp Shenyang, Dept Gynecol & Obstet, Shenyang 110024, Peoples R China.
RP Ying, HC (reprint author), China Med Univ, Shengjing Hosp, Dept Gynecol & Obstet, 36 Sanhao St, Shenyang 110004, Liaoning Provin, Peoples R China.
EM huanchunyiing@hotmail.com
FU Liaoning Province Doctor Startup Fund of Natural Science Foundation
   [20071047]; Scientific Research Project of Higher Education Program of
   Liaoning Provincial Department of Education [2009A724]; Liaoning Science
   and Technology Project [2010225032]; Natural Science Foundation of China
   [81372486]
FX This study was supported by Liaoning Province Doctor Startup Fund of
   Natural Science Foundation (20071047); The Scientific Research Project
   of Higher Education Program of Liaoning Provincial Department of
   Education (2009A724); Liaoning Science and Technology Project
   (2010225032) and Natural Science Foundation of China (81372486).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bell D, 2011, INTEGRATED GENOMIC A
   Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005592
   Bolton KL, 2012, J INTERN MED, V271, P366, DOI 10.1111/j.1365-2796.2011.02509.x
   Braun R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055037
   Chang H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-484
   Chea E, 2012, REGULATION PLANAR CE
   Elattar A, 2012, GYNECOL ONCOL, V124, P142, DOI 10.1016/j.ygyno.2011.09.004
   Gayther SA, 2007, CANCER RES, V67, P3027, DOI 10.1158/0008-5472.CAN-06-3261
   Gentleman R, 2005, STAT BIOL HLTH
   Ghafouri-Fard S, 2012, FUTURE ONCOL, V8, P961
   Grzankowski KS, 2011, CANCER CONTROL, V18, P52
   Joshi-Tope G, 2005, NUCLEIC ACIDS RES, V33, pD428, DOI 10.1093/nar/gki072
   Kanehisa M, 2002, NOVARTIS FDN S
   Kimura N, 2002, GENES CELLS, V7, P435, DOI 10.1046/j.1365-2443.2002.00529.x
   Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006
   Liang D, 2010, CANCER RES, V70, P9765, DOI 10.1158/0008-5472.CAN-10-0130
   Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2
   Montagnoli A, 2010, CLIN CANCER RES, V16, P4503, DOI 10.1158/1078-0432.CCR-10-0185
   Pacurari M, 2011, TOXICOL APPL PHARM, V255, P18, DOI 10.1016/j.taap.2011.05.012
   Perales G, 2010, BIOMARKERS, V15, P470, DOI 10.3109/1354750X.2010.485332
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689
   Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653
   Shin SM, 2006, GASTROENTEROLOGY, V130, P2074, DOI 10.1053/j.gastro.2006.03.055
   Somwar R, 2011, P NATL ACAD SCI USA, V108, P16375, DOI 10.1073/pnas.1113554108
   Tatarano S, 2011, INT J ONCOL, V39, P13, DOI 10.3892/ijo.2011.1012
   Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55
   Wan SM, 2012, ASIAN PAC J CANCER P, V13, P3997, DOI 10.7314/APJCP.2012.13.8.3997
   YING H, 2013, J OVARIAN RES, V6, P1, DOI DOI 10.1186/1757-2215-6-1
   Zhang SY, 2011, GYNECOL ONCOL, V121, P353, DOI 10.1016/j.ygyno.2011.01.020
NR 34
TC 11
Z9 12
U1 1
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757-2215
J9 J OVARIAN RES
JI J. Ovarian Res.
PD DEC 6
PY 2013
VL 6
AR 88
DI 10.1186/1757-2215-6-88
PG 9
WC Reproductive Biology
SC Reproductive Biology
GA 279EU
UT WOS:000328944000001
PM 24314048
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Qian, YN
   Bi, Q
AF Qian, Yining
   Bi, Qi
TI RETRACTED: Systematic study of cilostazol on secondary stroke
   prevention: a meta-analysis (Retracted article. See vol. 20, 39, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Cilostazol; Ischemic stroke; Systematic reviews
ID RANDOMIZED CONTROLLED-TRIALS; ACUTE ISCHEMIC-STROKE; DOUBLE-BLIND; BRAIN
   INFARCTION; RISK; ASPIRIN; INHIBITOR; THERAPY; ATHEROSCLEROSIS;
   TICLOPIDINE
AB Background: To study the efficacy and safety of cilostazol on ischemic stroke prevention and treatment, systematic reviews of related clinical randomized controlled trials were analyzed.
   Methods: We searched the main databases for eligible trials including literature from January 1966 to November 2012 in MEDLINE, reports from 1980 to November 2012 in EMBASE, and all the studies published in EBSCO, Springer, Ovid, and Cochrane library citations. We also searched for keywords, including cilostazol and aspirin. RewMan 5.0 software was used to conduct the meta-analysis.
   Results: Our search yielded five eligible trials. The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0.78, 95% confidence interval (CI) (0.59, 1.04)). Additionally, both magnetic resonance angiography (MRA) and transcranial Doppler (TCD) examination showed that cilostazol could significantly decrease the incidence of intracranial artery stenosis exacerbation (MRA: combined OR 0.22, 95% CI (0.07, 0.68); TCD: combined OR 0.17, 95% CI (0.05, 0.51)). In terms of adverse reactions, there were slightly fewer incidences of major bleeding with cilostazol than with aspirin (combined OR 0.38, 95% CI (0.24, 0.60)), and there was no difference in the number of heart palpitations between cilostazol and aspirin. However, the incidence of gastrointestinal disorders, dizziness, and headaches caused by cilostazol was greater.
   Conclusions: Cilostazol might be a more effective and safer alternative to aspirin for patients with ischemic stroke. Further studies are required to confirm whether cilostazol is a suitable therapeutic option for secondary stroke prevention in larger cohorts of patients with ischemic stroke.
C1 [Qian, Yining; Bi, Qi] Capital Med Univ, Beijing Anzhen Hosp, Dept Neurol, Beijing 100029, Peoples R China.
RP Bi, Q (reprint author), Capital Med Univ, Beijing Anzhen Hosp, Dept Neurol, Beijing 100029, Peoples R China.
EM biqidoctor@163.com
CR Ansara AJ, 2012, ANN PHARMACOTHER, V46, P394, DOI 10.1345/aph.1Q420
   *ANT TRIAL COLL, 1994, BMJ-BRIT MED J, V308, P81
   Bath PMW, 2000, STROKE, V31, P1770, DOI 10.1161/01.STR.31.7.1770
   Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043
   GENT M, 1988, STROKE, V19, P1203, DOI 10.1161/01.STR.19.10.1203
   Goto S, 2005, ATHEROSCLEROSIS SUPP, V6, P3, DOI 10.1016/j.atherosclerosissup.2005.09.002
   Gotoh F, 2000, J Stroke Cerebrovasc Dis, V9, P147, DOI 10.1053/jscd.2000.7216
   Guo JJ, 2009, NEUROSCI BULL, V25, P383, DOI 10.1007/s12264-009-6192-2
   Harms H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002158
   HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541
   He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930
   HENON H, 1995, STROKE, V26, P392, DOI 10.1161/01.STR.26.3.392
   Hollander M, 2003, STROKE, V34, P2367, DOI 10.1161/01.STR.0000091393.32060.0E
   Huang YI, 2008, LANCET NEUROL, V7, P494, DOI 10.1016/S1474-4422(08)70094-2
   Ikeda Y, 1999, THROMB HAEMOSTASIS, V82, P435
   Kai Yutaka, 2011, Surg Neurol Int, V2, P8, DOI 10.4103/2152-7806.76145
   Kamal AK, 2011, COCHRANE DB SYST REV, V1
   Kambayashi J, 2003, CURR PHARM DESIGN, V9, P2289, DOI 10.2174/1381612033453910
   Kubo M, 2003, STROKE, V34, P2349, DOI 10.1161/01.STR.0000090348.52943.A2
   Kwon SU, 2005, STROKE, V36, P782, DOI 10.1161/01.STR.0000157667.06542.b7
   Lee YS, 2011, CEREBROVASC DIS, V32, P65, DOI 10.1159/000327036
   LEVINE SR, 1992, STROKE, V23, pI29
   Liu YG, 2001, CARDIOVASC DRUG REV, V19, P369, DOI 10.1111/j.1527-3466.2001.tb00076.x
   Lugnier C, 2006, PHARMACOL THERAPEUT, V109, P366, DOI 10.1016/j.pharmthera.2005.07.003
   Mijajlovic MD, 2013, ACTA NEUROL SCAND, V128, P213, DOI 10.1111/ane.12111
   Patel Dipesh S, 2012, Indian J Psychol Med, V34, P124, DOI 10.4103/0253-7176.101776
   Rother J, 2008, CEREBROVASC DIS, V25, P366, DOI 10.1159/000120687
   Sallustio F, 2010, CURR VASC PHARMACOL, V8, P363, DOI 10.2174/157016110791112331
   Serebruany VL, 2005, AM J CARDIOL, V95, P1218, DOI 10.1016/j.amjcard.2005.01.049
   Shinoda-Tagawa T, 2002, DIABETOLOGIA, V45, P188, DOI 10.1007/s00125-001-0740-2
   Shinohara Y, 2010, LANCET NEUROL, V9, P959, DOI 10.1016/S1474-4422(10)70198-8
   Symeonidis A, 2002, AM J HEMATOL, V71, P24, DOI 10.1002/ajh.10150
   Touboul PJ, 2000, CIRCULATION, V102, P313
   Urbano LA, 2004, CEREBROVASC DIS, V17, P74, DOI 10.1159/000074800
   Wilhite DB, 2003, J VASC SURG, V38, P710, DOI 10.1016/S0741-5214(03)01029-2
NR 35
TC 13
Z9 13
U1 2
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD DEC 6
PY 2013
VL 18
AR 53
DI 10.1186/2047-783X-18-53
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 273MK
UT WOS:000328538800001
PM 24313983
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yue, Y
   Yang, YM
   Shi, L
   Wang, ZR
AF Yue, Yuan
   Yang, Yumin
   Shi, Lei
   Wang, Zuoren
TI RETRACTED: Upregulated expression levels of ADAM10 and EGFR and
   downregulated expression levels of E-cadherin in hepatocellular
   carcinomas (Retracted article. See vol. 7, pg. 1803, 2014)
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article; Retracted Publication
DE hepatocellular carcinoma; ADAM10; epidermal growth factor receptor;
   E-cadherin
ID CANCER CELLS; N-CADHERIN; PROGRESSION; METASTASIS; ADHESION; INVASION
AB The aim of this study was to investigate the expression and significance of a disintegrin and metalloproteinase 10 (ADAM10), epidermal growth factor receptor (EGFR) and E-cadherin protein in hepatocellular carcinomas. The expression levels of ADAM10, EGFR and E-cadherin were analyzed in 40 cases of hepatocellular carcinoma using immunohistochemistry and quantitative polymerase chain reaction (qPCR). The expression levels of ADAM10, EGFR and E-cadherin were significantly correlated with portal vein thrombosis, intrahepatic metastasis, differentiation degree and tumor size (P<0.05). In hepatocellular carcinoma, the expression levels of ADAM10 and EGFR were increased and the levels of E-cadherin were decreased compared with those in the adjacent tissues. The elevated expression levels of ADAM10 and EGFR may be associated with the malignancy of the tumors. E-cadherin expression is negatively correlated with the degree of malignancy. The detection of ADAM10, EGFR and E-cadherin expression levels may contribute to an understanding of the oncogenesis and development of hepatocellular carcinomas.
C1 [Yue, Yuan] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Pharm, Xian 710061, Shaanxi, Peoples R China.
   [Yang, Yumin] Hosp Luonan, Luonan 726100, Shaanxi, Peoples R China.
   [Shi, Lei; Wang, Zuoren] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian 710061, Shaanxi, Peoples R China.
RP Shi, L (reprint author), Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, 277 Yanta Xi Rd, Xian 710061, Shaanxi, Peoples R China.
EM s81145558@gmail.com
FU Shaanxi Province Key Project [2009K12-02]
FX This study was supported by the Shaanxi Province Key Project (grant no.
   2009K12-02).
CR Blaschuk OW, 2009, EUR J PHARMACOL, V625, P195, DOI 10.1016/j.ejphar.2009.05.033
   Bonaccorsi L, 2004, J CANCER RES CLIN, V130, P604, DOI 10.1007/s00432-004-0581-8
   [陈勤（综述） CHEN Qin], 2008, [中国癌症杂志, China Oncology], V18, P142
   Cikos S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-113
   Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991
   Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806
   [蒋丽 JIANG Li], 2007, [南京医科大学学报. 自然科学版, Acta Universitatis Medicinalis Nanjing], V27, P523
   Lascombe I, 2006, CLIN CANCER RES, V12, P2780, DOI 10.1158/1078-0432.CCR-05-2387
   Li XR, 2006, SHI JIE HUA REN XIAO, V14, P100
   Liu PCC, 2006, CANCER BIOL THER, V5, P657, DOI 10.4161/cbt.5.6.2708
   Luo HR, 2010, INT J ONCOL, V37, P853, DOI 10.3892/ijo_00000736
   Mazzocca A, 2005, CANCER RES, V65, P4728, DOI 10.1158/0008-5472.CAN-04-4449
   Okano JI, 2008, BASIC CLIN PHARMACOL, V102, P543, DOI 10.1111/j.1742-7843.2008.00231.x
   Pyo SW, 2007, J CRANIO MAXILL SURG, V35, P1, DOI 10.1016/j.jcms.2006.11.004
   Rocks N, 2006, BRIT J CANCER, V94, P724, DOI 10.1038/sj.bjc.6602990
   Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137
   Walker JL, 2005, CYTOKINE GROWTH F R, V16, P395, DOI 10.1016/j.cytogfr.2005.03.003
   Yap AS, 2007, CURR OPIN CELL BIOL, V19, P508, DOI 10.1016/j.ceb.2007.09.008
   刘传文, 2008, [南方医科大学学报, Journal of Southern Medical University], V28, P808
NR 19
TC 4
Z9 4
U1 2
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2013
VL 6
IS 6
BP 1380
EP 1384
DI 10.3892/etm.2013.1340
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AA0KA
UT WOS:000330782800007
PM 24255666
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Wang, ZL
   Li, GD
AF Wang Zonglin
   Li Guodong
TI RETRACTED: Experimental method and prediction model for autogenous
   shrinkage of high performance concrete (Retracted article. See vol. 165,
   pg. 976, 2018)
SO CONSTRUCTION AND BUILDING MATERIALS
LA English
DT Article; Retracted Publication
DE High performance concrete (HPC); Autogenous shrinkage (AS); Experimental
   method; Prediction model
ID CEMENTITIOUS MATERIALS; FLY-ASH; PASTE
AB This paper presents the experimental results and prediction model for autogenous shrinkage (AS) of high performance concrete (HPC) with various water to cementitious materials ratios (w/cm), the replacement ratio of fly ash (FA), air content (AC), and aggregate to cementitious materials paste ratios (ACMR). These results are based on an experimental method for AS in HPC with a mold of low-density flexible corrugated pipe (LDFCP), which can continuously and automatically test AS after adding water. The results demonstrate the simplicity and accuracy of this experimental method. HPC with FA exhibited smaller AS than ordinary concrete with no FA with the same w/cm and higher replacement ratios of FA resulted in less AS. For the same content of FA, larger values of w/cm yielded less AS. The effect of AC on AS was optimum content and the effect of ACMR was an inverse ratio. A proposed prediction model can be successfully used to estimate the effects of w/cm, FA, AC and ACMR on the development of AS in HPC. Crown Copyright (C) 2013 Published by Elsevier Ltd. All rights reserved.
C1 [Wang Zonglin; Li Guodong] Harbin Inst Technol, Sch Transportat Sci & Engn, Harbin 150090, Peoples R China.
RP Li, GD (reprint author), Harbin Inst Technol, Sch Transportat Sci & Engn, Harbin 150090, Peoples R China.
EM happy_liguodong@163.com
CR Aitcin PC, 1999, CONCRETE INT, V21, P54
   Anlan Cal, 2005, J MAT SCI ENG, V23, P575
   Brooks J.J., 1998, P INT WORKSH AUT SHR, P195
   CEB-FIP, 2000, STRUCT CONCR TXB BEH, V1, P43
   Chan YW, 2004, P INT WORKSH AUT SHR, P221
   Chu I, 2012, CONSTR BUILD MATER, V35, P171, DOI 10.1016/j.conbuildmat.2012.03.005
   Craeye B., 2006, INT RILEM C VOL CHAN, P21
   Dilger W. H., 2000, ACI SPEC PUBL, V194, P361
   Holt E, 2004, CEMENT CONCRETE COMP, V26, P521, DOI 10.1016/s0958-9465(03)00068-4
   JENSEN OM, 1995, MATER STRUCT, V28, P406
   Jiang LH, 1999, CEMENT CONCRETE RES, V29, P631, DOI 10.1016/S0008-8846(99)00034-4
   Jiang ZW, 2005, CEMENT CONCRETE RES, V35, P1539, DOI 10.1016/j.cemconres.2004.06.028
   JONASSON JE, 2000, P INT RILEM WORKSH S, V17, P507
   Lee HK, 2003, MAG CONCRETE RES, V55, P507, DOI 10.1680/macr.55.6.507.37600
   Lee KM, 2006, CEMENT CONCRETE RES, V36, P1279, DOI 10.1016/j.cemconres.2006.01.005
   Li Y, 2010, CONSTR BUILD MATER, V24, P1855, DOI 10.1016/j.conbuildmat.2010.04.018
   Liu He, 2009, Journal of Highway and Transportation Research and Development, V26, P38
   Mak SL, 1998, P INT WORKSH AUT SHR, P155
   Miyazawa S, 2001, CREEP SHRINKAGE DURA, P735
   Persson BSM., 1998, P INT WORKSH AUT SHR, P105
   Tazawa E, 1997, MAG CONCRETE RES, V49, P15, DOI 10.1680/macr.1997.49.178.15
   TAZAWA E, 1995, CEMENT CONCRETE RES, V25, P281, DOI 10.1016/0008-8846(95)00010-0
   Tazawa E, 1994, P INT RILEM S THERM, P221
   TAZAWA E, 1998, P INT WORKSH AUT SHR, P1
   Tazawa E., 1993, P 5 INT RILEM S CREE, P159
   Tazawa E, 1991, CAJ P CEMENT CONCRET, V45, P528
   Tertnkhajornkit P, 2005, CEMENT CONCRETE RES, V35, P473, DOI 10.1016/j.cemconres.2004.07.010
   [田倩 Tian Qian], 2005, [建筑材料学报, Journal of building materials], V8, P82
   Tian Qian, 2009, Journal of the Chinese Ceramic Society, V37, P39
   [肖佳 Xiao Jia], 2011, [建筑材料学报, Journal of Building Materials], V14, P604
   Zhang J, 2012, CONSTR BUILD MATER, V29, P230, DOI 10.1016/j.conbuildmat.2011.09.022
   Zhang J, 2011, J MATER CIVIL ENG, V23, P312, DOI 10.1061/(ASCE)MT.1943-5533.0000171
   Zhang MH, 2003, CEMENT CONCRETE RES, V33, P1687, DOI 10.1016/s0008-8846(03)00149-2
NR 33
TC 4
Z9 5
U1 4
U2 24
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0950-0618
EI 1879-0526
J9 CONSTR BUILD MATER
JI Constr. Build. Mater.
PD DEC
PY 2013
VL 49
BP 400
EP 406
DI 10.1016/j.conbuildmat.2013.08.053
PG 7
WC Construction & Building Technology; Engineering, Civil; Materials
   Science, Multidisciplinary
SC Construction & Building Technology; Engineering; Materials Science
GA 281DT
UT WOS:000329080900046
DA 2018-12-27
ER

PT J
AU Wang, W
   Tang, JW
   Wang, LT
   Chen, XB
AF Wang Wei
   Tang Jia-Wei
   Wang Le-Tian
   Chen Xiao-Bing
TI RETRACTED: High-temperature piezoelectirc thin films of
   0.20BiInO(3)-0.80PbTiO(3) deposited by pulsed laser deposition
   (Retracted Article)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
DE thin films; pulsed laser deposition; ferroelectricity; piezoelectricity
ID MORPHOTROPIC PHASE-BOUNDARY; CERAMICS; FERROELECTRICS; TRANSITION
AB High-temperature piezoelectric thin films of 0.20BiInO(3)-0.80PbTiO(3) (20BI-PT) were prepared via pulsed laser deposition and investigated by comparison with 0.15BiInO(3)-0.85PbTiO(3)(15BI-PT). XRD patterns show that (100) peak of 20BI-PT has been split, indicating a higher tetragnality than in 15BI-PT. FESEM images reveal some triangular grains corresponding to [111]-oriented grains in 20BI-PT. The remanent polarization (P-I) and coercive field (E-c) of 20BI-PT are similar to 28 mu C/cm(2) and similar to 120 kV/cm, respectively. It is shown that the transverse piezoelectric coefficient e(31,f) keeps almost the same in 20BI-PT and 15BI-PT. The temperature dependence of dielectric permittivity in 20BI-PT reveals a higher Curie temperature (590 degrees C) than that in 15BI-PT and no apparent frequency dependence is detected. Rayleigh analyses are performed to identify the extrinsic contributions to dielectric nonlinearity for different x. It is seen that x = 0.15 exhibits greater extrinsic contributions to dielectric nonlinearity than the other compositions.
C1 [Wang Wei; Tang Jia-Wei; Wang Le-Tian; Chen Xiao-Bing] Yangzhou Univ, Coll Phys Sci & Technol, Yangzhou 225002, Peoples R China.
RP Wang, W (reprint author), Yangzhou Univ, Coll Phys Sci & Technol, Yangzhou 225002, Peoples R China.
EM wangwei@yzu.edu.cn
FU National Natural Science Foundation of China [51072177]; Natural Science
   Foundation of the Higher Education Institutions of Jiangsu Province,
   China [08KJB140011]
FX Project supported by the National Natural Science Foundation of China
   (Grant No. 51072177), and the Natural Science Foundation of the Higher
   Education Institutions of Jiangsu Province, China (Grant No.
   08KJB140011).
CR Damjanovic D, 1996, J PHYS D APPL PHYS, V29, P2057, DOI 10.1088/0022-3727/29/7/046
   Eitel RE, 2002, JPN J APPL PHYS 1, V41, P2099, DOI 10.1143/JJAP.41.2099
   Eitel RE, 2001, JPN J APPL PHYS 1, V40, P5999, DOI 10.1143/JJAP.40.5999
   Gharb NB, 2005, J APPL PHYS, V97, DOI 10.1063/1.1857054
   Grinberg I, 2005, J APPL PHYS, V98, DOI 10.1063/1.2128049
   Ihlefeld JF, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4742171
   Ko SW, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3250165
   Lee SY, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.4718528
   Liu P, 2000, ACTA PHYS SIN-CH ED, V49, P2300
   Nino JC, 2004, J MATER RES, V19, P568, DOI 10.1557/jmr.2004.19.2.568
   Noguchi YJ, 2000, JPN J APPL PHYS 2, V39, pL1259, DOI 10.1143/JJAP.39.L1259
   Qin B, 2007, P 16 IEEE INT S APPL, P616
   Randall C. A., 2004, HIGH PERFORMANCE HIG
   SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551
   Shimakawa Y, 2000, PHYS REV B, V61, P6559, DOI 10.1103/PhysRevB.61.6559
   Shrout T R, 2004, J MATER RES, V19, P2185
   Sun PN, 2009, CHINESE PHYS B, V18, P1658, DOI 10.1088/1674-1056/18/4/063
   TURNER RC, 1994, APPL ACOUST, V41, P299, DOI 10.1016/0003-682X(94)90091-4
   Wen H, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2739326
   Wilke RHT, 2012, SENSOR ACTUAT A-PHYS, V173, P152, DOI 10.1016/j.sna.2011.10.030
   Yang N, 2000, ACTA PHYS SIN-CH ED, V49, P2225
   Zhang SJ, 2005, J MATER RES, V20, P2067, DOI 10.1557/JMR.2005.0254
   Zheng JJ, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4801473
NR 23
TC 0
Z9 0
U1 9
U2 18
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD DEC
PY 2013
VL 62
IS 23
AR 237701
DI 10.7498/aps.62.237701
PG 6
WC Physics, Multidisciplinary
SC Physics
GA 279AQ
UT WOS:000328931400048
DA 2018-12-27
ER

PT J
AU Kang, YK
   Lee, W
   Kang, B
   Kang, H
AF Kang, Yong Koo
   Lee, Woojoo
   Kang, Byunghoon
   Kang, Hannah
TI RETRACTED: Memory-Enhancing Effects of Silk Fibroin-Derived Peptides in
   Scopolamine-Treated Mice(Retracted article. See vol. 26, pg. 2228, 2016)
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE Peptide; memory; fibroin; silk; scopolamine
ID MEMBRANE
AB Although enzyme-hydrolyzed silk fibroin has been reported to enhance cognitive function before, it has been still unknown which peptides can improve memory. Here we report that amino acid sequences of three novel peptides were identified from fibroin hydrolysate. Fibroin hydrolysate was obtained by hydrolysis with protease after partial hydrolysis with 5 M CaCl2. Synthesized peptides derived from these sequences improved scopolamine-induced memory impairments in mice. We confirmed this hydrolysate had effects that improved learning and memory abilities by performing the Rey-Kim test. From this hydrolysate of silk fibroin, amino acid sequences of eight peptides were identified by LC-MS/MS. Three peptides (GAGAGTGSSGFGPY, GAGAGSGAGSGAGAGSGAGAGY, and SGAGSGAGAGSGAGAGSGA) were synthesized to investigate whether they could improve memory. Passive avoidance test and Morris water maze test were performed, and all peptides showed memory-enhancing abilities on scopolamine-induced memory impairments in mice. In this study, we identified three novel peptides that could improve memory, and that silk fibroin hydrolysate was a mixture of various active peptides that could enhance memory.
C1 [Kang, Yong Koo; Kang, Byunghoon; Kang, Hannah] BrainOn Inc, Seoul 150037, South Korea.
   [Lee, Woojoo] Inha Univ, Dept Stat, Inchon 402751, South Korea.
RP Kang, YK (reprint author), BrainOn Inc, Seoul 150037, South Korea.
EM yongkoo@ibrainon.com
CR AKAI H, 1999, SHOKUHIN KAIHATSU, V34, P45
   Chen Kaili, 1996, Journal of Sericultural Science of Japan, V65, P131
   Gill I, 1996, ENZYME MICROB TECH, V18, P162, DOI 10.1016/0141-0229(95)00097-6
   Gotoh K, 2000, BIOSCI BIOTECH BIOCH, V64, P1664, DOI 10.1271/bbb.64.1664
   HANAWA T, 1995, CHEM PHARM BULL, V43, P284
   Igarashi K, 2006, BIOSCI BIOTECH BIOCH, V70, P517, DOI 10.1271/bbb.70.517
   Ikegawa Y, 2012, BIOSCI BIOTECH BIOCH, V76, P473, DOI 10.1271/bbb.110748
   Kim D.K., 2004, KOREAN J ANAT, V37, P519
   Kim DK, 2005, J HEALTH SCI, V51, P317, DOI 10.1248/jhs.51.317
   Kim DK, 2001, J KOREAN FIBER SOC, V38, P105
   Kim ED, 2009, BIOL PHARM BULL, V32, P427, DOI 10.1248/bpb.32.427
   KIM HG, 1999, REY KIM MEMORY TEST
   Kim MK, 1996, Kor. Patent, Patent No. 98712
   Lezak M. D, 1983, NEUROPSYCHOLOGICAL A
   Luo J, 1993, 2 INT SILK C CHIN, P73
   Meisel H, 1997, LIVEST PROD SCI, V50, P125, DOI 10.1016/S0301-6226(97)00083-3
   MINOURA N, 1995, BIOCHEM BIOPH RES CO, V208, P511, DOI 10.1006/bbrc.1995.1368
   MINOURA N, 1990, BIOMATERIALS, V11, P430, DOI 10.1016/0142-9612(90)90100-5
   Myhrer T, 2003, BRAIN RES REV, V41, P268, DOI 10.1016/S0165-0173(02)00268-0
   Nahm JH, 1995, RDA J AGR SCI, V37, P145
   Oh SR, 2013, BIOL PHARM BULL, V36, P82, DOI 10.1248/bpb.b12-00681
   Qian JH, 1997, BIOSENS BIOELECTRON, V12, P1213, DOI 10.1016/S0956-5663(97)00056-0
   Rey A, 1964, EXAMEN CLIN PSYCHOL
   Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286
   이상형, 2004, THE KOREAN JOURNAL OF Physiology & Pharmacology, V8, P307
   Takano R, 1991, SOV PHYS-CRYSTALLOGR, V60, P358
   Yeo J.H., 2004, KOREAN J SERIC SCI, V46, P23
NR 27
TC 8
Z9 9
U1 3
U2 18
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #507,  635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL
   135-703, SOUTH KOREA
SN 1017-7825
EI 1738-8872
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD DEC
PY 2013
VL 23
IS 12
BP 1779
EP 1784
DI 10.4014/jmb.1308.08059
PG 6
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 282AO
UT WOS:000329142700016
PM 24043122
DA 2018-12-27
ER

PT J
AU Clay, JR
AF Clay, John R.
TI RETRACTED: A novel analysis of excitatory currents during an action
   potential from suprachiasmatic nucleus neurons (Retracted article. See
   vol. 112, pg. 2668, 2014)
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article; Retracted Publication
DE action potential clamp; suprachiasmatic nucleus neurons; mathematical
   models
ID EFFICIENT ACTION-POTENTIALS; POTASSIUM CURRENT; CALCIUM CURRENTS;
   DYNAMIC CLAMP; CHANNEL; SODIUM; INACTIVATION; MODEL; ELECTROPHYSIOLOGY;
   MECHANISM
AB A new application of the action potential (AP) voltage-clamp technique is described based on computational analysis. An experimentally recorded AP is digitized. The resulting V-i vs. t(i) data set is applied to mathematical models of the ionic conductances underlying excitability for the cell from which the AP was recorded to test model validity. The method is illustrated for APs from suprachiasmatic nucleus (SCN) neurons and the underlying tetrodotoxin-sensitive Na+ current, I-Na, and the Ca2+ current, I-Ca. Voltage-step recordings have been made for both components from SCN neurons (Jackson et al. 2004). The combination of voltage-step and AP clamp results provides richer constraints for mathematical models of voltage-gated ionic conductances than either set of results alone, in particular the voltage-step results. For SCN neurons the long-term goal of this work is a realistic mathematical model of the SCN AP in which the equations for I-Na and I-Ca obtained from this analysis will be a part. Moreover, the method described in this report is general. It can be applied to any excitable cell.
C1 [Clay, John R.] NINDS, NIH, Bethesda, MD 20892 USA.
RP Clay, JR (reprint author), Twinbrook TN-41,5625 Fishers Lane, Rockville, MD 20852 USA.
EM jrclay@ninds.nih.gov
FU National Institute of Neurological Disorders and Stroke, National
   Institutes of Health, Bethesda, Maryland
FX This research was supported by the Intramural Research Program of the
   National Institute of Neurological Disorders and Stroke, National
   Institutes of Health, Bethesda, Maryland.
CR Alle H, 2009, SCIENCE, V325, P1405, DOI 10.1126/science.1174331
   Bean BP, 2007, NAT REV NEUROSCI, V8, P451, DOI 10.1038/nrn2148
   BOUSKILA Y, 1995, J PHYSIOL-LONDON, V488, P339, DOI 10.1113/jphysiol.1995.sp020970
   Carter BC, 2009, NEURON, V64, P898, DOI 10.1016/j.neuron.2009.12.011
   Clay JR, 2013, PROG BIOPHYS MOL BIO, V111, P1, DOI 10.1016/j.pbiomolbio.2012.08.005
   Clay JR, 2009, FRONT CELL NEUROSCI, V3, DOI 10.3389/neuro.03.020.2009
   Crotty P, 2006, J NEUROPHYSIOL, V96, P1237, DOI 10.1152/jn.01204.2005
   Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647
   DOERR T, 1989, PFLUG ARCH EUR J PHY, V413, P599, DOI 10.1007/BF00581808
   Engel D, 2005, NEURON, V45, P405, DOI 10.1016/j.neuron.2004.12.048
   FOHLMEISTER JF, 1985, BIOPHYS J, V48, P375, DOI 10.1016/S0006-3495(85)83794-2
   Fox JJ, 2002, AM J PHYSIOL-HEART C, V282, pH516, DOI 10.1152/ajpheart.00612.2001
   Goaillard JM, 2006, PHYSIOLOGY, V21, P197, DOI 10.1152/physiol.00063.2005
   Goldman David E., 1943, JOUR GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37
   HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764
   HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310
   HUANG RC, 1993, P NATL ACAD SCI USA, V90, P11806, DOI 10.1073/pnas.90.24.11806
   HUANG RC, 1993, J NEUROPHYSIOL, V70, P1692
   Itri JN, 2010, J NEUROPHYSIOL, V103, P632, DOI 10.1152/jn.00670.2009
   Itri JN, 2005, NAT NEUROSCI, V8, P650, DOI 10.1038/nn1448
   Jackson AC, 2004, J NEUROSCI, V24, P7985, DOI 10.1523/JNEUROSCI.2146-04.2004
   KAY AR, 1991, J PHYSIOL-LONDON, V437, P27, DOI 10.1113/jphysiol.1991.sp018581
   LLINAS R, 1982, P NATL ACAD SCI-BIOL, V79, P2415, DOI 10.1073/pnas.79.7.2415
   LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071
   Milescu LS, 2008, BIOPHYS J, V95, P66, DOI 10.1529/biophysj.107.118190
   Purvis LK, 2005, J NEUROPHYSIOL, V93, P723, DOI 10.1152/jn.00703.2004
   Sengupta B, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000840
   Sim CK, 2007, J BIOL RHYTHM, V22, P445, DOI 10.1177/0748730407306041
   STANDEN NB, 1982, PROC R SOC SER B-BIO, V217, P101, DOI 10.1098/rspb.1982.0097
   Tuckwell HC, 2012, PROG NEUROBIOL, V96, P1, DOI 10.1016/j.pneurobio.2011.09.010
   VANDENBERG CA, 1991, BIOPHYS J, V60, P1511, DOI 10.1016/S0006-3495(91)82186-5
   VANDENBERG CA, 1991, BIOPHYS J, V60, P1499, DOI 10.1016/S0006-3495(91)82185-3
   Wilders R, 2006, J PHYSIOL-LONDON, V576, P349, DOI 10.1113/jphysiol.2006.115840
NR 33
TC 2
Z9 2
U1 1
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
EI 1522-1598
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD DEC
PY 2013
VL 110
IS 11
BP 2574
EP 2579
DI 10.1152/jn.00462.2013
PG 6
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 278JJ
UT WOS:000328886300008
PM 24047903
OA Green Published
DA 2018-12-27
ER

PT J
AU Wang, W
   Yan, HC
   Dou, CW
   Su, YL
AF Wang, Wei
   Yan, Haicheng
   Dou, Changwu
   Su, Youle
TI RETRACTED: Human leptin triggers proliferation of A549 cells via
   blocking endoplasmic reticulum stress-related apoptosis (Retracted
   article. See vol. 79, pg. 1423, 2014)
SO BIOCHEMISTRY-MOSCOW
LA English
DT Article; Retracted Publication
DE apoptosis; ER stress; cell growth; leptin; TRAF2; XPB1
ID LUNG-CANCER CELLS; MEDIATED APOPTOSIS; EXPRESSION; ATF4
AB Lung cancer is a disease characterized by uncontrolled cell growth in tissues of the lung. Leptin is a pleiotropic hormone with antiapoptotic and proliferative roles involved in several systems. However, there is no known antiapoptotic mechanism of leptin in non-small cell lung cancer (NSCLC). So, we investigated the antiapoptotic mechanism of leptin in NSCLC. Proliferation, apoptosis, and the specific mechanism of leptin-transfected cells were analyzed in this study. Leptin, p-Perk, IRE1, cleaved ATF6, spliced XBP1, eIF2-alpha, TRAF2, CHOP, and caspase 12 proteins were detected by Western blot, and endoplasmic reticulum (ER) stress-related mRNA was detected by semi-quantitative reverse transcription PCR (RT-PCR). Leptin in A549 and transfected cells inhibited cisplatin-activated ER stress-associated mRNA transcription and activation of proteins. ER stress unfolded protein response (UPR) proteins, PERK and ATF6, were involved in leptin-triggered apoptosis. XBP1 and TRAF2 were increased significantly when treated with cisplatin in A549-siLPT and non-transfected cells. CHOP expression was blocked in A549 and transfected cells (LPT-PeP and LPT-EX cells). In conclusion, leptin can promote the proliferation of A549 cells through blocking ER stress-mediated apoptosis. This blocking is mediated by the p-Perk and ATF6 pathway through blocking activation of CHOP.
C1 [Wang, Wei] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, Guangzhou 510120, Guangdong, Peoples R China.
   [Yan, Haicheng; Dou, Changwu; Su, Youle] Inner Mongolia Med Univ, Affiliated Hosp, Hohhot 010051, Peoples R China.
RP Dou, CW (reprint author), Inner Mongolia Med Univ, Affiliated Hosp, Hohhot 010051, Peoples R China.
EM changwudou@126.com
CR Al Husaini H, 2009, J THORAC ONCOL, V4, P251, DOI 10.1097/JTO.0b013e31819518fc
   Ben SB, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1030, DOI 10.1134/S0006297911090070
   Caldefie-Chezet F, 2005, BIOCHEM BIOPH RES CO, V334, P737, DOI 10.1016/j.bbrc.2005.06.077
   Cherasse Y, 2007, NUCLEIC ACIDS RES, V35, P5954, DOI 10.1093/nar/gkm642
   Duan HY, 2012, BIOCHEMISTRY-MOSCOW+, V77, P261, DOI 10.1134/S0006297912030042
   Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221
   Geng YT, 2012, BIOMED PHARMACOTHER, V66, P419, DOI 10.1016/j.biopha.2012.03.002
   Hung JY, 2010, LUNG CANCER, V68, P355, DOI 10.1016/j.lungcan.2009.07.017
   Li XQ, 2013, BIOCHEMISTRY-MOSCOW+, V78, P102, DOI 10.1134/S0006297913010136
   Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   Nemukhin AV, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1044, DOI 10.1134/S0006297909090132
   Petersen I, 2001, ANAL CELL PATHOL, V22, P111, DOI 10.1155/2001/374304
   Terzidis A, 2009, ONCOLOGY-BASEL, V76, P19, DOI 10.1159/000177952
   Turpaev KT, 2002, BIOCHEMISTRY-MOSCOW+, V67, P281, DOI 10.1023/A:1014819832003
   Wang Q, 2005, CANCER DETECT PREV, V29, P544, DOI 10.1016/j.cdp.2005.09.010
   Wang X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014602
   Wang X, 2009, BMB REP, V42, P444, DOI 10.5483/BMBRep.2009.42.7.444
   Xuan BQ, 2009, J VIROL, V83, P3463, DOI 10.1128/JVI.02307-08
NR 19
TC 3
Z9 4
U1 2
U2 10
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 0320-9725
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD DEC
PY 2013
VL 78
IS 12
BP 1333
EP 1341
DI 10.1134/S0006297913120031
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 274QR
UT WOS:000328621700003
PM 24460967
DA 2018-12-27
ER

PT J
AU Xu, JQ
   Liu, P
   Si, MJ
   Ding, XY
AF Xu, Jian-Qiang
   Liu, Ping
   Si, Ming-Jue
   Ding, Xiao-Yi
TI RETRACTED: MicroRNA-126 inhibits osteosarcoma cells proliferation by
   targeting Sirt1 (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE MicroRNA-126; Sirt1; Osteosarcoma; Cell proliferation
ID TRANSCRIPTION FACTORS; BREAST-CANCER; IN-VITRO; DEACETYLASE;
   TUMORIGENESIS; REGULATOR; MECHANISM; INVASION; PATHWAY; MIR-126
AB Numerous studies have recently suggested that miRNAs contribute to the development of various types of human cancer as well as to their proliferation and metastasis. The aim of this study was to investigate the functional significance of miR-126 and to identify its possible target genes in osteosarcoma (OS) cells. Here, we found that expression level of miR-126 was reduced in osteosarcoma cells in comparison with the adjacent normal tissues. The enforced expression of miR-126 was able to inhibit cell proliferation in U2OS and MG62 cells, while miR-126 antisense oligonucleotides (antisense miR-126) promoted cell proliferation. At the molecular level, our results further revealed that expression of Sirt1, a member of histone deacetylase, was negatively regulated by miR-126. Therefore, the data reported here demonstrate that miR-126 is an important regulator in osteosarcoma, which will contribute to better understanding of the important misregulated miRNAs in osteosarcoma cells.
C1 [Xu, Jian-Qiang] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Orthopaed, Shanghai 200025, Peoples R China.
   [Liu, Ping] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
   [Si, Ming-Jue; Ding, Xiao-Yi] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Radiol, Shanghai 200025, Peoples R China.
RP Ding, XY (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Radiol, 197,Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
EM xiaoyiding@yeah.net
FU National Natural Science Foundation of China [81072188]
FX This work was supported by The National Natural Science Foundation of
   China (81072188).
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Elangovan S, 2011, CANCER RES, V71, P6654, DOI 10.1158/0008-5472.CAN-11-1446
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   He CL, 2009, BIOCHEM BIOPH RES CO, V388, P35, DOI 10.1016/j.bbrc.2009.07.101
   Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085
   Jusufovic E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045577
   Kemper JK, 2009, CELL METAB, V10, P392, DOI 10.1016/j.cmet.2009.09.009
   Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500
   Klein MJ, 2006, AM J CLIN PATHOL, V125, P555, DOI 10.1309/UC6KQHLD9LV2KENN
   Li GD, 2012, CELL PHYSIOL BIOCHEM, V30, P1481, DOI 10.1159/000343336
   Li N, 2013, MOL CELL BIOCHEM, V380, P107, DOI 10.1007/s11010-013-1664-0
   Li Y, 2009, EUR J PHARMACOL, V609, P13, DOI 10.1016/j.ejphar.2009.03.004
   Mao JH, 2012, ONCOL LETT, V4, P1125, DOI 10.3892/ol.2012.863
   Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6
   Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200
   Oka S, 2011, CELL METAB, V14, P598, DOI 10.1016/j.cmet.2011.10.001
   Portmann S, 2013, MOL CANCER THER, V12, P499, DOI 10.1158/1535-7163.MCT-12-0700
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Tan ML, 2009, CANCER BIOL THER, V8, P106, DOI 10.4161/cbt.8.2.7385
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011
   Wu ZY, 2011, MED ONCOL, V28, P1469, DOI 10.1007/s12032-010-9563-7
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690
   Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906
NR 29
TC 26
Z9 27
U1 5
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2013
VL 34
IS 6
BP 3871
EP 3877
DI 10.1007/s13277-013-0974-x
PG 7
WC Oncology
SC Oncology
GA 270BP
UT WOS:000328292100075
PM 23877372
DA 2018-12-27
ER

PT J
AU Yin, YH
   Feng, LD
   Sun, J
AF Yin, Yihua
   Feng, Lingda
   Sun, Jing
TI RETRACTED: Association between glutathione S-transferase M 1 null
   genotype and risk of ovarian cancer: a meta-analysis (Retracted article.
   See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Ovarian cancer; GSTM1; Meta-analysis; Polymorphism
ID GSTM1; GSTT1; POLYMORPHISM; SUSCEPTIBILITY; CARCINOMA; THERAPIES; GENES;
   LOCI
AB Though previous studies investigated the association between glutathione S-transferase M 1 (GSTM1) null genotype and ovarian cancer risk, the effect of GSTM1 null genotype on ovarian cancer risk was still unclear. To comprehensively quantify the association between GSTM1 null genotype and ovarian cancer risk, we performed a meta-analysis. Eleven studies from ten publications were identified from PubMed database. The pooled odds ratio (OR) with its 95 % confidence interval (CI) was used to assess the association. Meta-analysis of the total 11 studies showed that GSTM1 null genotype was not associated with ovarian cancer risk (OR = 1.03, 95 % CI 0.92-1.14, P = 0.625). The cumulative meta-analyses showed a trend of no association between GSTM1 null genotype and ovarian cancer risk as information accumulated by year. There was no evidence of publication bias in the meta-analysis. Meta-analysis of the 11 available studies shows that GSTM1 null genotype is not associated with ovarian cancer risk.
C1 [Yin, Yihua; Feng, Lingda; Sun, Jing] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Dept Gynecol, Shanghai 200040, Peoples R China.
RP Yin, YH (reprint author), Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Dept Gynecol, Shanghai 200040, Peoples R China.
EM yihuatongji@live.cn
CR Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   Baxter SW, 2001, CARCINOGENESIS, V22, P63, DOI 10.1093/carcin/22.1.63
   Beral V, 2012, LANCET ONCOL, V13, P946, DOI 10.1016/S1470-2045(12)70322-4
   Bolton KL, 2012, J INTERN MED, V271, P366, DOI 10.1111/j.1365-2796.2011.02509.x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gates MA, 2008, CANCER EPIDEM BIOMAR, V17, P2436, DOI 10.1158/1055-9965.EPI-08-0399
   Gayther SA, 2012, INT J GYNECOL CANCER, V22, pS12, DOI 10.1097/IGC.0b013e318251ca4e
   Goodman JE, 2000, CANCER EPIDEM BIOMAR, V9, P1373
   Hall M, 2013, BRIT J CANCER, V108, P250, DOI 10.1038/bjc.2012.541
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396
   Hengstler JG, 1998, CANCER LETT, V130, P43, DOI 10.1016/S0304-3835(98)00123-2
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Khokhrin D V, 2012, Genetika, V48, P901
   Lallas TA, 2000, CANCER EPIDEM BIOMAR, V9, P587
   Liliac L, 2012, HISTOL HISTOPATHOL, V27, P707, DOI 10.14670/HH-27.707
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Morari EC, 2006, J CANCER RES CLIN, V132, P521, DOI 10.1007/s00432-006-0099-3
   Muellerleile P, 2006, AM J PUBLIC HEALTH, V96, P515, DOI 10.2105/AJPH.2003.036343
   Oliveira C, 2012, DIS MARKERS, V33, P155, DOI 10.3233/DMA-2012-0920
   Sarhanis P, 1996, BRIT J CANCER, V74, P1757, DOI 10.1038/bjc.1996.626
   Spurdle AB, 2001, CARCINOGENESIS, V22, P67, DOI 10.1093/carcin/22.1.67
   Wang B, 2010, J HEPATOL, V53, P508, DOI 10.1016/j.jhep.2010.03.026
   Zhu Y, 2012, MOL BIOL REP, V39, P685, DOI 10.1007/s11033-011-0786-2
   Ziebarth AJ, 2012, CLIN OBSTET GYNECOL, V55, P156, DOI 10.1097/GRF.0b013e31824b1699
NR 26
TC 2
Z9 2
U1 5
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2013
VL 34
IS 6
BP 4059
EP 4063
DI 10.1007/s13277-013-0995-5
PG 5
WC Oncology
SC Oncology
GA 270BP
UT WOS:000328292100095
PM 23884605
DA 2018-12-27
ER

PT J
AU Weng, YX
   Chen, YH
   Chen, JH
   Liu, YT
   Bao, TF
AF Weng, Yuxiong
   Chen, Yanhua
   Chen, Jianghai
   Liu, Yutian
   Bao, Tengfei
TI RETRACTED: Common genetic variants in the microRNA biogenesis pathway
   are associated with malignant peripheral nerve sheath tumor risk in a
   Chinese population (Retracted article. See vol. 39, pg. 664, 2015)
SO CANCER EPIDEMIOLOGY
LA English
DT Article; Retracted Publication
DE Genetic variants; miRNA; MPNST
ID RENAL-CELL CARCINOMA; NEUROFIBROMATOSIS TYPE-1; DICER1 MUTATIONS; CANCER
   RISK; EXPRESSION; SURVIVAL; TUMORIGENESIS; POLYMORPHISMS; RECURRENCE;
   PROGNOSIS
AB Purpose: The role of microRNAs (miRNAs) in tumorigenesis has been well established. Genetic variants in the miRNA biogenesis pathway genes may modify cancer development and survival by affecting the miRNA biogenesis. Our aim is to investigate the association of polymorphisms in the miRNA biogenesis pathway genes and malignant peripheral nerve sheath tumor (MPNST) risk among neurofibromatosis type 1 (NF1) patients. Methods: A case-control study was performed to analyze 53 SNPs in 11 miRNA biogenesis pathway genes in 356 patients (200 patients with NF1 and 156 patients with both NF1 and MPNST) in China. Association analysis was performed in an additive genetic model by logistics regression. Results: Four SNPs (DDX5 rs1991401, OR = 1.79, 95% CI, 1.34-2.38, P = 7.90 x 10(-5); DROSHA rs10719, OR = 1.64, 95% CI, 1.23-2.20, P = 8.76 x 10(-4); AGO2 rs7005286, OR = 0.48, 95% CI, 0.32-0.72, P = 3.46 x 10(-4); GEMIN4 rs7813, OR = 0.50, 95% CI, 0.34-0.72, P = 2.65 x 10(-4)) were significantly associated with MPNST risk. A strong gene-dose effect with increased MPNST risk (P for trend < 0.001) was observed. Conclusions: Genetic variants in the miRNA biogenesis pathway genes may modify MPNST risk both individually and jointly. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Weng, Yuxiong; Chen, Yanhua; Chen, Jianghai; Liu, Yutian; Bao, Tengfei] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Dept Hand Surg, Wuhan 430030, Hubei, Peoples R China.
RP Weng, YX (reprint author), Huazhong Univ Sci & Technol, Wuhan Union Hosp, Dept Hand Surg, Wuhan 430030, Hubei, Peoples R China.
EM wenyuxiongpaper2@yeah.net
CR Brems H, 2009, LANCET ONCOL, V10, P508, DOI 10.1016/S1470-2045(09)70033-6
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chai GL, 2010, CANCER SCI, V101, P1997, DOI [10.1111/j.1349-7006.2010.1616.x, 10.1111/j.1349-7006.2010.01616.x]
   Clague J, 2010, MOL CARCINOGEN, V49, P183, DOI 10.1002/mc.20588
   Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311
   Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577
   Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51
   Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903
   Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334
   Horikawa Y, 2008, CLIN CANCER RES, V14, P7956, DOI 10.1158/1078-0432.CCR-08-1199
   Iorio MV, 2012, CARCINOGENESIS, V33, P1126, DOI 10.1093/carcin/bgs140
   Itani S, 2012, J CANCER RES CLIN, V138, P1501, DOI 10.1007/s00432-012-1223-1
   Katz D, 2009, EXPERT REV MOL MED, V11e30
   Kim MS, 2010, J PATHOL, V221, P139, DOI 10.1002/path.2683
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Lee HC, 2010, J CANCER RES CLIN, V136, P1073, DOI 10.1007/s00432-009-0754-6
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Liang D, 2010, CANCER RES, V70, P9765, DOI 10.1158/0008-5472.CAN-10-0130
   Lin J, 2010, CARCINOGENESIS, V31, P1805, DOI 10.1093/carcin/bgq168
   Lin YX, 2011, CANCER BIOTHER RADIO, V26, P365, DOI 10.1089/cbr.2010.0914
   Liu JM, 2012, DNA CELL BIOL, V31, P1296, DOI 10.1089/dna.2011.1600
   Ma HX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047544
   Muralidhar B, 2007, J PATHOL, V212, P368, DOI 10.1002/path.2179
   O'Connell RM, 2012, ANN REV IMMUNOL
   Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   SORENSEN SA, 1986, NEW ENGL J MED, V314, P1010, DOI 10.1056/NEJM198604173141603
   Sung H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-195
   Sung H, 2012, CANCER EPIDEM BIOMAR, V21, P1385, DOI 10.1158/1055-9965.EPI-12-0600
   Sung H, 2011, BREAST CANCER RES TR, V130, P939, DOI 10.1007/s10549-011-1656-2
   Wang P, 2009, CANCER RES, V69, P8157, DOI 10.1158/0008-5472.CAN-09-1996
   Wang Z, 2010, BRAIN RES, V134614-625
   Yang HS, 2008, CANCER RES, V68, P2530, DOI 10.1158/0008-5472.CAN-07-5991
   Zhang XF, 2010, CARCINOGENESIS, V31, P2118, DOI 10.1093/carcin/bgq177
NR 35
TC 5
Z9 6
U1 4
U2 22
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1877-7821
EI 1877-783X
J9 CANCER EPIDEMIOL
JI Cancer Epidemiol.
PD DEC
PY 2013
VL 37
IS 6
BP 913
EP 916
DI 10.1016/j.canep.2013.05.003
PG 4
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 269OO
UT WOS:000328251000023
PM 23763827
DA 2018-12-27
ER

PT J
AU Song, ZG
   Ren, H
   Gao, S
   Zhao, TS
   Wang, XC
   Zhang, SJ
   Zhao, X
   Jia, LL
   Sun, JW
   Hao, JH
AF Song, Zhenguo
   Ren, He
   Gao, Song
   Zhao, Tiansuo
   Wang, Xiuchao
   Zhang, Shengjie
   Zhao, Xiao
   Jia, Lingling
   Sun, Junwei
   Hao, Jihui
TI RETRACTED: The hypoxia-inducible factor-1 regulates the microRNA185
   expression through binding to hypoxia response elements sequence 2
   (Retracted article. See vol. 32, 6, 2015)
SO MEDICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE MiR185; HIF-1; Pancreatic cancer; HRE2
ID CANCER; IDENTIFICATION; ACTIVATION; PROGNOSIS; PROTEIN; SYSTEM; ALPHA
AB This study aimed to investigate the interaction and regulatory mechanism of microRNA185 (miR185) and hypoxia-inducible factor-1 (HIF-1) in pancreatic cancer. The significance of miR185 on the clinicopathologic characteristics and prognosis was further explored. qRT-PCR and immunohistochemistry examined miR185 and HIF-1 expression of tumor tissues. Western blot analyzed HIF-1 protein expression. We regulated HIF-1 via transfection to observe the impact of HIF-1 on miR185 expression. ChIP sequencing and dual luciferase identified binding sites of HIF-1 and miR185. MiR185 expression was significantly higher in pancreatic tumors. MiR185 closely associated with tumor size, pTNM stage, lymph node, and perneural invasion. After hypoxic culture, both HIF-1 and miR185 expression of MiaPaCa2 and AsPc1 cells increased significantly. Up-or down-regulating HIF-1 expression via transfection leads to synchronous alteration of miR185. In ChIP sequencing, only the HRE2 (-938 bp) was significantly brighter under hypoxia among four hypoxia response elements' (HREs) sequence of miR185 promoter. After pGL3-miR185 and HIF-1 over-expressing plasmids co-transfect the MiaPaCa2 cells, its relative expression of bioluminescence increased. MiR185 expression was significantly higher in tumor tissues and closely associated with the clinical features of pancreatic cancer. Expression of HIF-1 in pancreatic cancer cells increased in hypoxia. HIF-1 may bind to HRE2 of miR185 and initiate its transcription.
C1 [Song, Zhenguo; Ren, He; Gao, Song; Zhao, Tiansuo; Wang, Xiuchao; Zhang, Shengjie; Zhao, Xiao; Jia, Lingling; Sun, Junwei; Hao, Jihui] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Dept Pancreat Canc, Tianjin, Peoples R China.
   [Song, Zhenguo] Tianjin Med Univ Canc Inst & Hosp, Dept Anesthesiol, Tianjin, Peoples R China.
   [Song, Zhenguo] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Operating Ctr, Tianjin, Peoples R China.
RP Hao, JH (reprint author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Dept Pancreat Canc, Tianjin, Peoples R China.
EM szzg1001@sina.com
CR Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031
   Brown LM, 2006, MOL PHARMACOL, V69, P411, DOI 10.1124/mol.105.015743
   Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160
   Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012
   Devlin C, 2011, IUBMB LIFE, V63, P94, DOI [10.1002/iub.00427, 10.1002/iub.427]
   Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019
   Grentzmann G, 1998, RNA, V4, P479
   Han ZB, 2008, CARCINOGENESIS, V29, P1853, DOI 10.1093/carcin/bgn066
   Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597
   Kizaka-Kondoh S, 2009, ADV DRUG DELIVER REV, V61, P623, DOI 10.1016/j.addr.2009.01.006
   Knaup KX, 2009, MOL CANCER RES, V7, P88, DOI 10.1158/1541-7786.MCR-08-0288
   Liu R, 2012, CLIN CHEM, V58, P610, DOI 10.1373/clinchem.2011.172767
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maynard MA, 2007, CELL MOL LIFE SCI, V64, P2170, DOI 10.1007/s00018-007-7082-2
   Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Sun HC, 2007, INT J ONCOL, V30, P1359
   Sun W, 2010, ANNU REV BIOMED ENG, V12, P1, DOI 10.1146/annurev-bioeng-070909-105314
   Takahashi Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006677
   Yao Y, 2009, MOL MED REP, V2, P963, DOI 10.3892/mmr_00000199
   Zhao TS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043399
NR 21
TC 4
Z9 4
U1 4
U2 16
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD DEC
PY 2013
VL 30
IS 4
AR UNSP 756
DI 10.1007/s12032-013-0756-8
PG 10
WC Oncology
SC Oncology
GA 264EC
UT WOS:000327858800007
PM 24198204
DA 2018-12-27
ER

PT J
AU Vimal, S
   Majeed, SA
   Taju, G
   Nambi, KSN
   Raj, NS
   Madan, N
   Farook, MA
   Rajkumar, T
   Gopinath, D
   Hameed, ASS
AF Vimal, S.
   Majeed, S. Abdul
   Taju, G.
   Nambi, K. S. N.
   Raj, N. Sundar
   Madan, N.
   Farook, M. A.
   Rajkumar, T.
   Gopinath, D.
   Hameed, A. S. Sahul
TI RETRACTED: Chitosan tripolyphosphate (CS/TPP) nanoparticles:
   Preparation, characterization and application for gene delivery in
   shrimp(Retracted article. See vol. 168, pg. 91, 2017)
SO ACTA TROPICA
LA English
DT Article; Retracted Publication
DE CS/TPP nanoparticles; pVP28 DNA; In vivo gene expression; Real-time PCR;
   Immuno-dot blot
ID SYNDROME VIRUS WSSV; PLASMID DNA; PROTEIN DELIVERY; MOLECULAR-WEIGHT;
   DRUG-DELIVERY; ORAL DELIVERY; CONTROLLED-RELEASE; IN-VIVO; CARRIERS;
   SYSTEM
AB The present study examines the use of CS/TPP nanoparticles for gene delivery in different tissues of shrimp through oral route. The viral gene of WSSV was used to construct DNA vaccines using pcDNA 3.1, a eukaryotic expression vector and the constructs were named as pVP28. The CS/TPP nanoparticles were synthesized by ionic gelation process and these particles were characterized. The structure and morphology of the nanoparticles were studied by field emission scanning electron microscopy (FE-SEM) and FTIR (Fourier Transform Infrared Spectra). The cytotoxicity of CS/TPP nanoparticles was evaluated by MTT assay using fish cell line. The expression of gene was confirmed by Immuno-dot blot, ELISA and RT-PCR analyses. The results indicate that DNA can be easily delivered into shrimp by feeding with CS/TPP nanoparticles. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Vimal, S.; Majeed, S. Abdul; Taju, G.; Nambi, K. S. N.; Raj, N. Sundar; Madan, N.; Farook, M. A.; Rajkumar, T.; Gopinath, D.; Hameed, A. S. Sahul] C Abdul Hakeem Coll, OIE Reference Lab WTD, Aquaculture Biotechnol Div, PG & Res Dept Zool, Melvisharam 632509, Tamil Nadu, India.
RP Hameed, ASS (reprint author), C Abdul Hakeem Coll, OIE Reference Lab WTD, Aquaculture Biotechnol Div, PG & Res Dept Zool, Melvisharam 632509, Tamil Nadu, India.
EM cah_sahul@hotmail.com
FU Department of Science and Technology, Government of India, New Delhi,
   India under the Indo-Sri Lankan program
FX The authors thank the management of C. Abdul Hakeem College for
   providing the facilities to carry out this work. This work was funded by
   Department of Science and Technology, Government of India, New Delhi,
   India under the Indo-Sri Lankan program.
CR Aspden TJ, 1996, EUR J PHARM SCI, V4, P23, DOI 10.1016/0928-0987(95)00026-7
   Bozkir A, 2004, J DRUG TARGET, V12, P281, DOI 10.1080/10611860410001714162
   Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
   Calvo P, 1997, PHARMACEUT RES, V14, P1431, DOI 10.1023/A:1012128907225
   Capan Y, 1999, PHARMACEUT RES, V16, P509, DOI 10.1023/A:1018862827426
   Carrello Gomez B., 1997, INT J PHARMACEUT, V148, P231
   Chang PS, 1998, AQUACULTURE, V164, P233, DOI 10.1016/S0044-8486(98)00189-6
   Chen SC, 1998, J VIROL, V72, P5757
   Chinnasamy T., 2011, AQUACULTURE, V318, P262
   Csaba N., 2009, INT J PHARM, V382
   Cuna M., 2009, P CONTR REL SOC, V136, P2887
   Fernandez Urrusuno R., 1999, PHARM RES, V16, P1576
   Gan Q, 2005, COLLOID SURFACE B, V44, P65, DOI 10.1016/j.colsurfb.2005.06.001
   Gan Q, 2007, COLLOID SURFACE B, V59, P24, DOI 10.1016/j.colsurfb.2007.04.009
   Garnett MC, 1999, CRIT REV THER DRUG, V16, P147
   Hameed ASS, 2003, DIS AQUAT ORGAN, V57, P157, DOI 10.3354/dao057157
   Hameed ASS, 2001, AQUACULTURE, V201, P179, DOI 10.1016/S0044-8486(01)00525-7
   Hirosue S, 2001, J CONTROL RELEASE, V70, P231, DOI 10.1016/S0168-3659(00)00353-9
   Ishii T, 2001, BBA-BIOMEMBRANES, V1514, P51, DOI 10.1016/S0005-2736(01)00362-5
   Janes KA, 2003, J APPL POLYM SCI, V88, P2769, DOI 10.1002/app.12016
   Katas H, 2006, J CONTROL RELEASE, V115, P216, DOI 10.1016/j.jconrel.2006.07.021
   Kumar SR, 2008, FISH SHELLFISH IMMUN, V25, P47, DOI 10.1016/j.fsi.2007.12.004
   Lam T.D., 2006, J CHEM, V44, P105
   Lavertu M, 2006, BIOMATERIALS, V27, P4815, DOI 10.1016/j.biomaterials.2006.04.029
   Lee M, 2001, PHARMACEUT RES, V18, P427, DOI 10.1023/A:1011037807261
   Lee SY, 2002, FISH SHELLFISH IMMUN, V12, P421, DOI 10.1006/fsim.2002.0420
   Leong KW, 1998, J CONTROL RELEASE, V53, P183, DOI 10.1016/S0168-3659(97)00252-6
   Lightner A., 1996, HDB SHRIMP PATHOLOGY
   Lleres D, 2001, CHEM PHYS LIPIDS, V111, P59, DOI 10.1016/S0009-3084(01)00147-5
   MacLaughlin FC, 1998, J CONTROL RELEASE, V56, P259, DOI 10.1016/S0168-3659(98)00097-2
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8
   Mohammadpourdounighi N, 2010, NANOMED-NANOTECHNOL, V6, P137, DOI 10.1016/j.nano.2009.06.002
   Mumper R., 1995, P INT S CONTR REL BI, P178
   Pan Y, 2002, INT J PHARM, V249, P139, DOI 10.1016/S0378-5173(02)00486-6
   Rajesh Kumar S., 2009, FISH SHELLFISH IMMUN, V26, P429
   Ramos EA, 2005, MAR BIOTECHNOL, V7, P89, DOI 10.1007/s10126-004-3018-0
   Richardson SCW, 1999, INT J PHARMACEUT, V178, P231, DOI 10.1016/S0378-5173(98)00378-0
   Rojanarata T, 2008, EUR J PHARM BIOPHARM, V70, P207, DOI 10.1016/j.ejpb.2008.04.022
   Romoren K, 2002, J CONTROL RELEASE, V85, P215, DOI 10.1016/S0168-3659(02)00278-X
   Roy K, 1999, NAT MED, V5, P387
   Sakai S, 2002, BIOMATERIALS, V23, P4177, DOI 10.1016/S0142-9612(02)00159-X
   Sambrook J, 1989, MOL CLONING LAB MANU
   Shu X, 2000, INT J PHARM, V201, P51, DOI 10.1016/S0378-5173(00)00403-8
   SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771
   Takeuchi H, 2001, ADV DRUG DELIVER REV, V47, P39, DOI 10.1016/S0169-409X(00)00120-4
   Tian JY, 2008, VET IMMUNOL IMMUNOP, V126, P220, DOI 10.1016/j.vetimm.2008.07.002
   Vila A, 2004, EUR J PHARM BIOPHARM, V57, P123, DOI 10.1016/j.ejpb.2003.09.006
   Vimal S, 2012, AQUACULTURE, V358, P14, DOI 10.1016/j.aquaculture.2012.06.012
   Wang SL, 2009, CANCER GENET CYTOGEN, V190, P8, DOI 10.1016/j.cancergencyto.2008.10.013
   Wei H, 2007, BIOMATERIALS, V28, P99, DOI 10.1016/j.biomaterials.2006.08.030
   Xu YM, 2003, INT J PHARM, V250, P215, DOI 10.1016/S0378-5173(02)00548-3
   Yang WJ, 2009, J BIOMED NANOTECHNOL, V5, P591, DOI 10.1166/jbn.2009.1067
NR 52
TC 53
Z9 54
U1 3
U2 76
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD DEC
PY 2013
VL 128
IS 3
BP 486
EP 493
DI 10.1016/j.actatropica.2013.07.013
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 263RD
UT WOS:000327824800006
PM 23906611
DA 2018-12-27
ER

PT J
AU Rigane, G
   Bouaziz, M
   Sayadi, S
   Ben Salem, R
AF Rigane, Ghayth
   Bouaziz, Mohamed
   Sayadi, Sami
   Ben Salem, Ridha
TI RETRACTED: Effect of Storage on Refined Olive Oil Composition:
   Stabilization by Addition of Chlorophyll Pigments and Squalene
   (Retracted article. See vol. 63, pg. 309, 2014)
SO JOURNAL OF OLEO SCIENCE
LA English
DT Article; Retracted Publication
DE refined olive oil; squalene; chlorophyll pigments; Chemlali; oxidative
   stability
ID NATURAL ANTIOXIDANTS; LEAVES; CULTIVARS; PHENOLICS; FRACTION; TREE
AB Refined olive oil has been analyzed in order to evaluate the influence of storage time on their quality after enrichment with chlorophyll pigments and squalene. At the end of the storage, chlorophyll pigments decomposed for more than 90%, while, carotene pigment loss was lower showing up to 75% in all oil samples stored at 20 degrees C and 50 degrees C. The reduction of total phenolic compounds exhibited similar degradation profiles, reducing by 81% for enriched refined olive oil stored at 20 degrees C and 50 degrees C after six months. For all studied samples, squalene content decreased significantly (p<0.05) only after four months of storage. Oils with added pure squalene had the lower peroxide values (52 meq O-2 center dot kg(-1)) at the end of storage at 20 degrees C. After six months of storage the oxidative stability increased to 1 h 28 min and 2 h 06 min for refined olive oil stored at 20 degrees C enriched with chlorophyll + squalene and only by squalene, respectively. Therefore, squalene supplemented with 800 mg . kg(-1) exhibited favorable antioxidant effects and is preferable for effectively avoiding oxidation. This study could provide useful information for industry to produce high-stability vegetable oil.
C1 [Rigane, Ghayth; Ben Salem, Ridha] Univ Sfax, Lab Chim Organ Phys, UR11ES74, Fac Sci Sfax, Sfax 3000, Tunisia.
   [Rigane, Ghayth] Univ Kairouan, Fac Sci & Tech Sidi Bouzid, Dept Chim Phys, Sidi Bouzid 9100, Tunisia.
   [Bouaziz, Mohamed; Sayadi, Sami] Univ Sfax, Ctr Biotechnol Sfax, Lab Bioproc Environm, Sfax 3018, Tunisia.
RP Rigane, G (reprint author), Univ Sfax, Lab Chim Organ Phys, UR11ES74, Fac Sci Sfax, BP 1171, Sfax 3000, Tunisia.
EM gaith.rigane@yahoo.fr
RI Sayadi, Sami/K-8031-2017
OI Sayadi, Sami/0000-0002-2115-2981
FU Tunisian Ministry of Higher Education and Scientific Research
FX The authors thank the Tunisian Ministry of Higher Education and
   Scientific Research for financial support and are grateful to Professor
   Mohamed Rigane for useful discussions about the English.
CR BOLLAND JL, 1949, J CHEM SOC, P492, DOI 10.1039/jr9490000492
   Bouaziz M, 2005, EUR J LIPID SCI TECH, V107, P497, DOI 10.1002/ejlt.200501166
   Bouaziz M, 2008, FOOD CHEM, V108, P253, DOI 10.1016/j.foodchem.2007.10.074
   Bouaziz M, 2010, EUR J LIPID SCI TECH, V112, P894, DOI 10.1002/ejlt.200900166
   *EEC, 2003, OFF J EUR COMMUNIT L, V295, P57
   Giuffrida D, 2007, FOOD CHEM, V101, P833, DOI 10.1016/j.foodchem.2005.12.030
   Grigoriadou D, 2007, FOOD CHEM, V105, P675, DOI 10.1016/j.foodchem.2006.12.065
   International Olive Council, 2010, COIT15NC3
   Mendez AI, 2007, FOOD CONTROL, V18, P521, DOI 10.1016/j.foodcont.2005.12.012
   Jaber H, 2012, EUR J LIPID SCI TECH, V114, P1274, DOI 10.1002/ejlt.201100176
   Kiritsakis A. K., 1992, ACEITE OLIVA
   Lanfer-Marquez UM, 2005, FOOD RES INT, V38, P885, DOI 10.1016/j.foodres.2005.02.012
   Lee OH, 2009, BIORESOURCE TECHNOL, V100, P6107, DOI 10.1016/j.biortech.2009.06.059
   Manzi P, 1998, J SCI FOOD AGR, V77, P115, DOI 10.1002/(SICI)1097-0010(199805)77:1<115::AID-JSFA13>3.3.CO;2-E
   MINGUEZMOSQUERA MI, 1991, J AM OIL CHEM SOC, V68, P332, DOI 10.1007/BF02657688
   Morello JR, 2004, FOOD CHEM, V85, P357, DOI 10.1016/j.foodchem.2003.07.012
   Owen RW, 2000, FOOD CHEM TOXICOL, V38, P647, DOI 10.1016/S0278-6915(00)00061-2
   Perez-Bonilla M, 2006, J CHROMATOGR A, V1112, P311, DOI 10.1016/j.chroma.2005.12.055
   Psomiadou E, 2002, J AGR FOOD CHEM, V50, P716, DOI 10.1021/jf0108462
   Rastrelli L, 2002, J AGR FOOD CHEM, V50, P5566, DOI 10.1021/jf011063j
   Rigane G, 2013, J SCI FOOD AGR, V93, P1242, DOI 10.1002/jsfa.5864
   Rigane G, 2013, J SCI FOOD AGR, V93, P527, DOI 10.1002/jsfa.5815
   Rigane G, 2011, J FOOD SCI, V76, pC965, DOI 10.1111/j.1750-3841.2011.02290.x
   SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144
NR 24
TC 5
Z9 5
U1 2
U2 44
PU JAPAN OIL CHEMISTS SOC
PI TOKYO
PA YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO,
   103-0027, JAPAN
SN 1345-8957
EI 1347-3352
J9 J OLEO SCI
JI J. Oleo Sci.
PD DEC
PY 2013
VL 62
IS 12
BP 981
EP 987
DI 10.5650/jos.62.981
PG 7
WC Chemistry, Applied; Food Science & Technology
SC Chemistry; Food Science & Technology
GA 263TI
UT WOS:000327830500002
PM 24292349
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhang, FE
   Mao, B
   Zhou, MY
   Zhang, JQ
AF Zhang, Fu-En
   Mao, Bin
   Zhou, Ming-Yang
   Zhang, Jian-Qun
TI RETRACTED: Left ventricular rupture without obstructive coronary artery
   disease (Retracted article. See vol. 45, pg. 958, 2014)
SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
LA English
DT Editorial Material; Retracted Publication
DE Cardiac rupture; Computed tomographic angiography; Surgical treatment
C1 [Zhang, Fu-En; Mao, Bin; Zhou, Ming-Yang; Zhang, Jian-Qun] Capital Med Univ, Beijing Anzhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Dept Cardiac Surg, Beijing, Peoples R China.
RP Zhang, JQ (reprint author), Beijing Anzhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Dept Cardiac Surg, Beijing 100029, Peoples R China.
EM doczjq@yahoo.cn
NR 0
TC 1
Z9 1
U1 3
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1010-7940
EI 1873-734X
J9 EUR J CARDIO-THORAC
JI Eur. J. Cardio-Thorac. Surg.
PD DEC
PY 2013
VL 44
IS 6
BP 1148
EP 1149
DI 10.1093/ejcts/ezt260
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 258BF
UT WOS:000327432200034
PM 23682011
OA Bronze
DA 2018-12-27
ER

PT J
AU Magierowski, M
   Jasnos, K
   Pawlik, M
   Krzysiek-Maczka, G
   Ptak-Belowska, A
   Olszanecki, R
   Kwiecien, S
   Korbut, R
   Brzozowski, T
AF Magierowski, Marcin
   Jasnos, Katarzyna
   Pawlik, Michal
   Krzysiek-Maczka, Gracjana
   Ptak-Belowska, Agata
   Olszanecki, Rafal
   Kwiecien, Slawomir
   Korbut, Ryszard
   Brzozowski, Tomasz
TI RETRACTED: Role of Angiotensin-(1-7) in Gastroprotection against
   Stress-Induced Ulcerogenesis. The Involvement of Mas Receptor, Nitric
   Oxide, Prostaglandins, and Sensory Neuropeptides (Retracted article. See
   vol. 353, pg. 563, 2015)
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article; Retracted Publication
ID INDUCED GASTRIC-LESIONS; ASYMMETRIC DIMETHYLARGININE; CYCLOOXYGENASE
   (COX)-1; GASTROINTESTINAL-TRACT; EXPERIMENTAL-MODEL; OXIDATIVE STRESS;
   INDUCED INJURY; II RECEPTOR; IN-VIVO; MUCOSA
AB Angiotensin-(1-7) [Ang-(1-7)] is a major vasoactive metabolite of angiotensin I (Ang I), both being important components of the renin-angiotensin system (RAS). Ang-(1-7) acting via Mas receptor was documented in kidneys, heart, brain, and gastrointestinal (GI)-tract. We studied the gastroprotective activity of exogenous Ang-(1-7) in rats exposed to water immersion and restraint stress (WRS) without or with A-779 [D-Ala7-Ang-(1-7), an antagonist of Ang-(1-7) Mas receptors], AVE 0991 (5-formyl-4-methoxy-2-phenyl-1[[4-[2-(ethylaminocarbonyl-sulfonamido)-5-isobutyl-3-thienyl]-phenyl]-methyl]-imidazole), the agonist of Ang-(1-7) receptor, as well as the inhibition of nitricoxide (NO) synthase, the suppression of cyclo-oxygenase (COX)-1 (indomethacin, SC-560 [5-(4-chloro-phenyl)-1-(4-methoxyphenyl)3-trifluoromethyl-pyrazole]), the activity COX-2 (rofecoxib), and denervation with capsaicin. The mRNA expression of constitutively expressed nitric-oxide synthase (cNOS), inducible nitric-oxide synthase (iNOS), interleukin (IL)-1 beta, and tumor necrosis factor (TNF)-alpha was analyzed by reverse transcription polymerase chain reaction. The WRS lesions were dose-dependently reduced by pretreatment with Ang-(1-7), which also caused an increase in gastric blood flow (GBF) and luminal content of NO. COX-1 and COX-2 inhibitors or L-NNA (N5-[imino(nitroamino)methyl]-L-ornithine) reversed the reduction in lesion number and the rise in GBF evoked by Ang-(1-7). Ang II augmented the WRS lesions, decreased GBF and increased the plasma IL-1 beta and TNF-alpha levels. Capsaicin denervation attenuated the reduction of Ang-(1-7)induced gastric lesions and the rise in GBF; these effects were restored by supplementation with calcitonin gene-related peptide (CGRP). The cNOS mRNA was upregulated while iNOS, IL-1 beta and TNF-alpha mRNAs were downregulated in Ang-(1-7)-pretreated rats. We conclude that Ang-(1-7), in contrast to Ang II, which worsened WRS ulcerogenesis, affords potent gastro-protection against WRS ulcerogenesis via an increase in GBF mediated by NO, endogenous prostaglandins, sensory neuro-peptides, and anti-inflammatory action involving the inhibition of proinflammatory markers iNOS, IL-1 beta, and TNF-alpha.
C1 [Magierowski, Marcin; Jasnos, Katarzyna; Pawlik, Michal; Krzysiek-Maczka, Gracjana; Ptak-Belowska, Agata; Kwiecien, Slawomir; Brzozowski, Tomasz] Jagiellonian Univ, Coll Med, Dept Physiol, PL-31531 Krakow, Poland.
   [Olszanecki, Rafal; Korbut, Ryszard] Jagiellonian Univ, Coll Med, Dept Pharmacol, PL-31531 Krakow, Poland.
RP Brzozowski, T (reprint author), Jagiellonian Univ, Coll Med, Dept Physiol, 16 Grzegorzecka St, PL-31531 Krakow, Poland.
EM mpbrzozo@cyf-kr.edu.pl
OI Kwiecien, Slawomir/0000-0002-4806-8042
FU National Science Centre in Poland [N N402 479937, 4799/B/P01/2009/37]
FX This work was supported by National Science Centre in Poland [Grant N
   N402 479937; 4799/B/P01/2009/37 (to T. B.)].
CR Bayorh MA, 1999, J GRAVIT PHYSL, V6, P115
   Bregonzio C, 2004, ANN NY ACAD SCI, V1018, P351, DOI 10.1196/annals.1296.044
   Bregonzio C, 2003, AM J PHYSIOL-GASTR L, V285, pG414, DOI 10.1152/ajpgi.00058.2003
   Brzozowski T, 2004, J PHARMACOL EXP THER, V310, P116, DOI 10.1124/jpet.104.065128
   Brzozowski T, 2012, CURR MED CHEM, V19, P55, DOI 10.2174/092986712803413953
   Brzozowski T, 2000, J PHYSIOLOGY-PARIS, V94, P83, DOI 10.1016/S0928-4257(00)00145-5
   Brzozowski T, 2008, REGUL PEPTIDES, V148, P6, DOI 10.1016/j.regpep.2008.02.003
   Brzozowski T, 2006, J PHARMACOL EXP THER, V319, P477, DOI 10.1124/jpet.106.105932
   Carl-McGrath S, 2009, PATHOLOGY, V41, P419, DOI 10.1080/00313020902885037
   Casselbrant A, 2009, AM J PHYSIOL-GASTR L, V297, pG1019, DOI 10.1152/ajpgi.00255.2009
   Chung IM, 2010, ATHEROSCLEROSIS, V213, P109, DOI 10.1016/j.atherosclerosis.2010.08.052
   Clark MA, 2001, J CARDIOVASC PHARM, V37, P437, DOI 10.1097/00005344-200104000-00011
   de Castro CH, 2005, HYPERTENSION, V46, P937, DOI 10.1161/01.HYP.0000175813.04375.8a
   Ender F., 1993, Acta Physiologica Hungarica, V81, P13
   Fandriks L, 2011, ACTA PHYSIOL, V201, P157, DOI 10.1111/j.1748-1716.2010.02165.x
   Filaretova LP, 1998, AM J PHYSIOL-GASTR L, V274, pG1024, DOI 10.1152/ajpgi.1998.274.6.G1024
   Garg M, 2012, ALIMENT PHARM THER, V35, P414, DOI 10.1111/j.1365-2036.2011.04971.x
   Gemici B, 2010, J SURG RES, V161, P126, DOI 10.1016/j.jss.2009.07.018
   Goldstein DS, 2002, STRESS, V5, P54, DOI 10.1080/10253890290012345
   Greco AJ, 2006, CAN J PHYSIOL PHARM, V84, P1163, DOI 10.1139/Y06-053
   Hallersund P, 2011, J RENIN-ANGIO-ALDO S, V12, P54, DOI 10.1177/1470320310379066
   Hasegawa G, 2009, EUR J PHARMACOL, V605, P164, DOI 10.1016/j.ejphar.2009.01.001
   Heinemann A, 1999, ALIMENT PHARM THER, V13, P347
   Hirasawa K, 2002, J HISTOCHEM CYTOCHEM, V50, P275, DOI 10.1177/002215540205000215
   JAISWAL N, 1993, HYPERTENSION, V21, P900, DOI 10.1161/01.HYP.21.6.900
   Jawen J, 2012, J PHYSIOL PHARMACOL, V63, P77
   Konturek PC, 2011, J PHYSIOL PHARMACOL, V62, P591
   Konturek PC, 2009, J PHYSIOL PHARMACOL, V60, P41
   Konturek PC, 2001, J PHYSIOLOGY-PARIS, V95, P361, DOI 10.1016/S0928-4257(01)00049-3
   Kwiecien S, 2007, J PHYSIOL PHARMACOL, V58, P149
   Kwiecien S, 2012, J PHYSIOL PHARMACOL, V63, P515
   Kwiecien S, 2012, J PHYSIOL PHARMACOL, V63, P143
   Lemarie CA, 2009, CIRC RES, V105, P852, DOI 10.1161/CIRCRESAHA.109.196576
   Liao XX, 2011, MOL MED REP, V4, P1145, DOI 10.3892/mmr.2011.570
   Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006
   Merai AH, 2009, PHARMACOLOGY, V84, P93, DOI 10.1159/000228726
   Morsy M, 2009, PHARMAZIE, V64, P590, DOI 10.1691/ph.2009.9581
   Mou DC, 1998, CHINESE MED J-PEKING, V111, P309
   Nakagiri A, 2010, J PHYSIOL PHARMACOL, V61, P171
   Neves LAA, 2000, REGUL PEPTIDES, V95, P99, DOI 10.1016/S0167-0115(00)00164-6
   Oliveira MA, 1999, PEPTIDES, V20, P1195
   Olszanecki R, 2009, J PHYSIOL PHARMACOL, V60, P191
   Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005
   Pavel J, 2008, ANN NY ACAD SCI, V1148, P360, DOI 10.1196/annals.1410.006
   Pawlik M, 2011, J PHYSIOL PHARMACOL, V62, P75
   Pawlik MW, 2012, GASTROENTEROLOGY S1, V142
   Pinheiro SVB, 2004, HYPERTENSION, V44, P490, DOI 10.1161/01.HYP.0000141438.64887.42
   ROBERT A, 1979, GASTROENTEROLOGY, V77, P761
   Saavedra JM, 2005, REGUL PEPTIDES, V128, P227, DOI 10.1016/j.regpep.2004.12.015
   Saavedra JM, 2006, NEUROPSYCHOPHARMACOL, V31, P1123, DOI 10.1038/sj.npp.1300921
   Saavedra JM, 2011, PSYCHONEUROENDOCRINO, V36, P1, DOI 10.1016/j.psyneuen.2010.10.001
   Sampaio WO, 2007, HYPERTENSION, V49, P185, DOI 10.1161/01.HYP.0000251865.35728.2f
   Santos R. A. S., 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P383, DOI 10.2174/156801605774322373
   Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100
   Santos RAS, 2006, CARDIOVASC DRUG REV, V24, P239, DOI 10.1111/j.1527-3466.2006.00239.x
   Santos SHS, 2012, REGUL PEPTIDES, V178, P64, DOI 10.1016/j.regpep.2012.06.009
   Satoh H, 2013, J PHARMACOL EXP THER, V344, P189, DOI 10.1124/jpet.112.199182
   Shiotani A, 2011, DIGEST DIS SCI, V56, P465, DOI 10.1007/s10620-010-1382-3
   Stegbauer J, 2004, CARDIOVASC RES, V61, P352, DOI 10.1016/j.cardiores.2003.11.017
   Szlachcic A, 2013, CURR PHARM DESIGN, V19, P90
   Takeuchi K, 2010, ADV CLIN CHEM, V51, P121, DOI 10.1016/S0065-2423(10)51005-9
   Tani T, 2008, MOL CELL BIOCHEM, V315, P185, DOI 10.1007/s11010-008-9806-5
   TARNAWSKI A, 1988, J CLIN GASTROENTEROL, V10, pS35, DOI 10.1097/00004836-198812001-00008
   Tom B, 2003, INT J BIOCHEM CELL B, V35, P792, DOI 10.1016/S1357-2725(02)00273-X
   Xu P, 2008, HYPERTENSION, V51, P574, DOI 10.1161/HYPERTENSIONAHA.107.102764
   Xu P, 2011, AM J PHYSIOL-REG I, V300, pR804, DOI 10.1152/ajpregu.00222.2010
   Yousif MHM, 2012, PHARMACOL RES, V66, P269, DOI 10.1016/j.phrs.2012.05.001
NR 67
TC 11
Z9 11
U1 2
U2 15
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD DEC
PY 2013
VL 347
IS 3
BP 717
EP 726
DI 10.1124/jpet.113.207233
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 258IQ
UT WOS:000327453200019
PM 24049058
OA Bronze
DA 2018-12-27
ER

PT J
AU Barnett, RLE
AF Barnett, R. -L. Etienne
TI RETRACTED: Dislocated words. The challenges of ghostly writings
   (Retracted article. See vol. 42, pg. 359, 2015)
SO NEOHELICON
LA French
DT Article; Retracted Publication
AB Sociologists and historians of genealogical filiations invoke modernity as the dissolution of traditional communities that formerly, albeit oft tacitly, bound descendants to ancestors. So as to invent oneself spontaneously and without restraint, the modern figure breaks with the strictures of the past, forging a path toward liberation. This newly-minted "emancipation" gives way to a sense of discomfortable culpability among contemporary "scribes." In quest of remedy, they fashion a space, at once disturbing yet inviting to the ghosts and spectres of primogenitors, a space that both supports and distorts the words of heir(s). In such an optic, Sylvie Germain (1954) and Jean Rouaud (1952), G,rard Mac, (1946), Pierre Michon (1945) and Pierre Bergounioux (1949) are powerfully haunted writers. As beneficiaries/successors, their gestures recall past lives and their words replicate their forebearers' inflections and manner of verbal discourse. They are, as such, dispossessed of a familial past that represents little but ruin and grief, yet possessed by those absent beings who intrude obsessively on their consciousness and speech. They are heirs torn apart by a melancholy that extends to the grave of their "predecessors." Contemporary literature vies with this spectral theme to analyze the ambivalence occasioned by such haunting refrains: artistic victims, orphans and parricidal vestiges of a family past, significantly impacted by the unconscious and linguistic upheavals that accompany such compelling loss.
C1 [Barnett, R. -L. Etienne] Univ Provost, Atlanta, GA 30302 USA.
   [Barnett, R. -L. Etienne] Clark Atlanta Univ, Atlanta, GA 30314 USA.
   [Barnett, R. -L. Etienne] CNRS, F-75005 Paris, France.
RP Barnett, RLE (reprint author), Univ Provost, Atlanta, GA 30302 USA.
EM rl_barnett@msn.com
CR Abraham N., 1987, LECORCE OU LE NOYAU
   Barnett R.-L.E., 2012, TUDES DE LANGUE ET D, V78, P68
   Barnett R.-L. E., 2012, DEGRES REVUE DE SYNT, V108, P53
   Barnett R.-L. E., 2013, EXEGESE, V11, P102
   Bergounioux P., 1994, LA TOUSSAINT
   Carlat D., 2007, TEMOINS DE LINACTUEL
   Dechaux J.-H., 1997, LE SOUVENIR DES MORT
   DEMANZE Laurent, 2008, ENCRES ORPHELINES PI
   Derrida J., 2012, HISTOIRE DU MENSONGE
   Derrida J., 2001, RE SISTANCES DE LA P
   Eco U., 2007, DALLALBERO AL LABIRI
   Foucault M., 2008, LARCHE OLOGIE DU SAV
   FREUD Sigmund, 1968, METAPSYCHOLOGIE
   Germain S., 1992, LENFANT MEDUSE
   Germain S., 1991, LA PLEURANTE DES RUE
   Germain S., 2002, COULEURS DE LINVISIB
   GOTMAN A., 1988, HERITER
   Goulet Alain, 2006, SYLVIE GERMAIN OEUVR
   Hamel J.-F., 2006, REVENANCES DE LHISTO
   MACE Gerard, 1980, EX LIBRIS NERVAL COR
   Michon P., 2007, LE ROI VIENT QUAND I
   Michon Pierre, 1997, TROIS AUTEURS
   Michon Pierre, 1996, VIES MINUSCULES
   Nancy J.-L., 1996, TRE SINGULIER PLURIE
   NORA Pierre, 1992, LIEUX MEMOIRE
   Rouaud J., 1996, LE MONDE A PEU PRES
   Rouaud J., 1998, POUR VOS CADEAUX
   Rouaud J., 1990, LES CHAMPS DHONNEUR
   Schmitt J.-C., 1994, LES REVENANTS LES VI
   Trevisan C., 2001, LES FABLES DU DEUIL
   Viart D., 2001, ECRITURES DU RESSASS, P58
   Viart D., 2008, LA LITTE RATURE FRAN
NR 32
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0324-4652
EI 1588-2810
J9 NEOHELICON
JI Neohelicon
PD DEC
PY 2013
VL 40
IS 2
BP 509
EP 520
DI 10.1007/s11059-013-0210-0
PG 12
WC Literature
SC Literature
GA 253LX
UT WOS:000327089400009
DA 2018-12-27
ER

PT J
AU Zhou, DL
   Jiang, X
   Ding, WX
   Zheng, LJ
   Yang, L
   Zheng, CZ
   Lu, LS
AF Zhou, Donglei
   Jiang, Xun
   Ding, Weixing
   Zheng, Lijun
   Yang, Lei
   Zheng, Chengzhu
   Lu, Liesheng
TI RETRACTED: siRNA-participated chemotherapy: an efficient and specific
   therapeutic against gastric cancer (Retracted article. See vol. 141, pg.
   2069, 2015)
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE siRNA; FGFR; Gastric cancer; Cisplatin
ID GROWTH-FACTOR-RECEPTOR; SMALL INTERFERING RNA; INHIBITS TUMOR-GROWTH;
   BREAST-CANCER; CELL-PROLIFERATION; MULTIDRUG-RESISTANCE; DIFFERENTIAL
   EXPRESSION; MALIGNANT PROGRESSION; ENHANCED RADIATION; SYSTEMIC DELIVERY
AB This study aims to investigate the role of siRNA silencing fibroblast growth factor receptor (FGFR) expression in promoting chemotherapy effect of gastric cancer and to explore its mechanism.
   Human gastric cancer cells MGC80-3 were divided into four groups: control group, cisplatin group (2 mu g/L), cisplatin (2 mu g/L) + siRNA group and siRNA group. The expressions of FGFR in four groups were detected by immunofluorescence. The cell proliferation and apoptosis were detected by MTT assay and flow cytometry. The protein expression levels of vascular endothelial growth factor receptor (VEGFR), caspase-3 and Bax were detected by Western blot. Further, animal model of gastric cancer was established and divided into four groups as in vitro experiment. The expression of FGFR mRNA in tumor tissue was detected by the real-time fluorescence quantitative polymerase chain reaction. The size of tumor was measured to analyze the effects of treatment. Histopathological detections were performed by hematoxylin and eosin staining and immunohistochemistry.
   For in vitro experiment, significant decrease inFGFR expression, inhibition of proliferation and promotion of apoptosis were observed in siRNA-treated cells, so as cisplatin group. siRNA also resulted in the reduction of VEGFR and rise in apoptosis-related protein (caspase-3). As for the experiment in vivo, siRNA also suppressed the expression of FGFR and enhanced tumor shrink. Furthermore, the co-administration of siRNA and cisplatin revealed a more excellent antitumor effect than other therapies.
   siRNA can effectively suppress FGFR expression and cell proliferation, but promote apoptosis in vitro and also inhibit tumor growth and FGFR production in vivo. siRNA-participated chemotherapy may provide an efficient therapeutic approach to treat gastric cancer.
C1 [Zhou, Donglei; Jiang, Xun; Ding, Weixing; Zheng, Lijun; Yang, Lei; Lu, Liesheng] Tongji Univ, Peoples Hosp 10, Dept Gen Surg, Shanghai 200072, Peoples R China.
   [Zheng, Chengzhu] Second Mil Med Univ, Changhai Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
RP Lu, LS (reprint author), Tongji Univ, Peoples Hosp 10, Dept Gen Surg, 301 Yanchang Middle Rd, Shanghai 200072, Peoples R China.
EM luleishenga@hotmail.com
CR Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0
   Adachi Y, 2008, DIGEST SURG, V19, P333
   AVILES A, 1988, Sangre (Saragossa), V33, P522
   Bai AL, 2010, CANCER RES, V70, P7630, DOI 10.1158/0008-5472.CAN-10-1489
   Bertuccio P, 2009, INT J CANCER, V125, P666, DOI 10.1002/ijc.24290
   Bittoni A, 2010, EUR REV MED PHARMACO, V14, P309
   Bosetti C, 2005, ANN ONCOL, V16, P489, DOI 10.1093/annonc/mdi086
   Boulikas T, 2003, ONCOL REP, V10, P1663
   Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Chang H, 2007, CANCER GENE THER, V14, P677, DOI 10.1038/sj.cgt.7701063
   Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003
   Chen YC, 2010, MOL THER, V18, P1650, DOI 10.1038/mt.2010.136
   Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]
   Collis SJ, 2003, CANCER RES, V63, P1550
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498
   Dubikovskaya EA, 2008, P NATL ACAD SCI USA, V105, P12128, DOI 10.1073/pnas.0805374105
   Eberhardt W, 1998, J CLIN ONCOL, V16, P622, DOI 10.1200/JCO.1998.16.2.622
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Ferlay J, 2010, IARC CANC BASE
   FLEMING TP, 1992, CANCER RES, V52, P4550
   Fujii M, 2010, SURG TODAY, V40, P295, DOI 10.1007/s00595-009-4148-9
   Ganju N, 2002, BIOCHEM BIOPH RES CO, V291, P1258, DOI 10.1006/bbrc.2002.6584
   Gao LF, 2005, ACTA PHARMACOL SIN, V26, P377, DOI 10.1111/j.1745-7254.2005.00053.x
   Giordano A, 2012, WORLD J CLIN ONCOL, V3, P128, DOI 10.5306/wjco.v3.i9.128
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Hammond SM, 2006, TRENDS MOL MED, V12, P99, DOI 10.1016/j.molmed.2006.01.004
   Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5
   Hara T, 1998, LAB INVEST, V78, P1143
   Herold-Mende C, 1999, LAB INVEST, V79, P1573
   Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565
   Huynh H, 2008, CLIN CANCER RES, V14, P6146, DOI 10.1158/1078-0432.CCR-08-0509
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kato M, 2004, J UROLOGY, V172, P863, DOI 10.1097/01.ju.0000136315.80057.99
   Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1
   Kim SH, 2008, J CONTROL RELEASE, V129, P107, DOI 10.1016/j.jconrel.2008.03.008
   Kitabwalla M, 2002, NEW ENGL J MED, V347, P1364, DOI 10.1056/NEJMcibr022294
   Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331
   Kurokawa T, 2004, INT J CANCER, V109, P926, DOI 10.1002/ijc.20057
   L'Hote CGM, 2005, EXP CELL RES, V304, P417, DOI 10.1016/j.yexcr.2004.11.012
   Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035
   Leung SY, 1999, CANCER RES, V59, P159
   Li W, 2006, INT J GYNECOL CANCER, V16, P1620, DOI 10.1111/j.1525-1438.2006.00636.x
   Li XQ, 2012, WORLD J GASTROENTERO, V18, P882, DOI 10.3748/wjg.v18.i9.882
   Li XP, 2004, BIOCHEM BIOPH RES CO, V315, P212, DOI 10.1016/j.bbrc.2004.01.045
   Liang ZX, 2005, CANCER RES, V65, P967
   Liu Z, 2010, TOXICOL IN VITRO, V24, P142, DOI 10.1016/j.tiv.2009.08.002
   Mallmann MR, 2012, DEEP INSIGHT SECTION, P765
   Marme F, 2010, ANN ONCOL, V21, P1636, DOI 10.1093/annonc/mdq017
   Maxwell MM, 2009, CURR PHARM DESIGN, V15, P3977, DOI 10.2174/138161209789649295
   MOR O, 1993, CANCER GENET CYTOGEN, V65, P111, DOI 10.1016/0165-4608(93)90217-A
   Nagane M, 1996, CANCER RES, V56, P5079
   Nagini S, 2012, WORLD J GASTRO ONCOL, V4, P156, DOI 10.4251/wjgo.v4.i7.156
   Naimi B, 2002, PROSTATE, V52, P245, DOI 10.1002/pros.10104
   Nan H, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-172
   Niller HH, 2009, SEMIN CANCER BIOL, V19, P158, DOI 10.1016/j.semcancer.2009.02.012
   Oh YK, 2009, ADV DRUG DELIVER REV, V61, P850, DOI 10.1016/j.addr.2009.04.018
   Ohtsu A, 2006, J CLIN ONCOL, V24, P2188, DOI 10.1200/JCO.2006.05.9758
   Pakunlu RI, 2004, CANCER RES, V64, P6214, DOI 10.1158/0008-5472.CAN-04-0001
   Pal A, 2005, INT J ONCOL, V26, P1087
   PALACIO I, 1991, ANN ONCOL, V2, P521, DOI 10.1093/oxfordjournals.annonc.a058008
   Park K, 2010, BIOMATERIALS, V31, P5258, DOI 10.1016/j.biomaterials.2010.03.018
   Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606
   Poeck H, 2008, NAT MED, V14, P1256, DOI 10.1038/nm.1887
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Qin Q, 2004, NEUROSCI LETT, V372, P17, DOI 10.1016/j.neulet.2004.08.075
   Raballo R, 2000, J NEUROSCI, V20, P5012
   Reed JC, 1996, J CLIN INVEST, V97, P2403, DOI 10.1172/JCI118684
   Roidl A, 2010, ONCOGENE, V29, P1543, DOI 10.1038/onc.2009.432
   Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Sheng HM, 1998, CANCER RES, V58, P362
   Silahtaroglu A, 2010, ESSAYS BIOCHEM, V48, P165, DOI [10.1042/bse0480165, 10.1042/BSE0480165]
   Terme M, 2013, CANCER RES, V73, P539, DOI 10.1158/0008-5472.CAN-12-2325
   Tong AW, 2005, CURR OPIN MOL THER, V7, P114
   Toyota M, 2000, J GASTROENTEROL, V35, P727, DOI 10.1007/s005350070030
   Tsujimoto H, 1997, VIRCHOWS ARCH, V431, P383, DOI 10.1007/s004280050115
   Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126
   Wallace KB, 2003, PHARMACOL TOXICOL, V93, P105, DOI 10.1034/j.1600-0773.2003.930301.x
   Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603
   YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484
   Yamamoto M, 1996, CANCER RES, V56, P384
NR 86
TC 5
Z9 5
U1 3
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD DEC
PY 2013
VL 139
IS 12
BP 2057
EP 2070
DI 10.1007/s00432-013-1492-3
PG 14
WC Oncology
SC Oncology
GA 251MB
UT WOS:000326932000010
PM 24077839
DA 2018-12-27
ER

PT J
AU El-Wakeil, NE
AF El-Wakeil, Nabil E.
TI RETRACTED: Botanical Pesticides and Their Mode of Action (Retracted
   article. See vol. 70, pg. 115, 2018)
SO GESUNDE PFLANZEN
LA English
DT Review; Retracted Publication
DE Plant-biopesticide; Pyrethrum; Neem; Essential oils; Antifeedants;
   Repellents
ID PLANT ESSENTIAL OILS; SPODOPTERA-LITTORALIS LARVAE; DIAMONDBACK MOTH
   LEPIDOPTERA; AZADIRACHTA-INDICA JUSS,A.; INTEGRATED PEST-MANAGEMENT;
   APHIS-CRACCIVORA KOCH; COTTON LEAFWORM; DROSOPHILA-MELANOGASTER;
   BACILLUS-THURINGIENSIS; VOLATILE CONSTITUENTS
AB Pest management is facing economic and ecological challenge worldwide due to human and environmental hazards caused by majority of the synthetic pesticide chemicals. Identification of novel effective insecticidal compounds is essential to combat increasing resistance rates. Botanical pesticides have long been touted as attractive alternatives to synthetic chemical pesticides for pest management because botanicals reputedly pose little threat to the environment or to human health. The body of scientific literature documenting bioactivity of plant derivatives to arthropod pests continues to expand, yet only a handful of botanicals are currently used in agriculture in the industrialized world, and there are few prospects for commercial development of new botanical products. Pyrethrum and neem are well established commercially, pesticides based on plant essential oils have entered the marketplace, and the use of rotenone appears to be waning. A number of plant substances have been considered for use as pest antifeedants, repellents and toxicants, but apart from some natural mosquito repellents, a little commercial success has ensued for plant substances that modify arthropod behavior. Several factors appear to limit the success of botanicals, most notably regulatory barriers and the availability of competing products (newer synthetics and fermentation products) that are cost-effective and relatively safe compared with their predecessors. In the context of agricultural pest management, botanical pesticides are best suited for use in organic food production in industrialized countries but can play a much greater role in the production and postharvest protection of food in developing countries.
   Botanicals have been in use for a long time for pest control. The compounds offer many environmental advantages. However, their uses during the 20th century have been rather marginal compared with other bio-control methods of pests and pathogens. Improvement in the understanding of plant allelochemical mechanisms of activity offer new prospects for using these substances in crop protection. I'm trying in this article to present different kinds of botanical pesticides came from different recourses and their mode of actions as well as I will try to examine the reasons behind their limited use (disadvantages) and the actual crop protection developments involving biopesticides of plant origin for organic or traditional agricultures to keep our environment clean and safer for humankind and animals.
C1 [El-Wakeil, Nabil E.] Natl Res Ctr, Pests & Plant Protect Dept, Cairo, Egypt.
   [El-Wakeil, Nabil E.] Univ Halle Wittenberg, Inst Agr & Nutr Sci, Halle, Germany.
RP El-Wakeil, NE (reprint author), Natl Res Ctr, Pests & Plant Protect Dept, Cairo, Egypt.
EM nabil.el-wakeil@landw.uni-halle.de
OI El-Wakeil, Nabil/0000-0002-0882-5547
CR Abd El-Aziz SE, 1997, UMWELTSCHUTZ, V70, P62
   Abd El-Aziz Shadia E., 1997, Journal of the Egyptian German Society of Zoology, V22, P117
   Abdallah SA, 2004, EGYPT J BIOL PEST CO, V14, P165
   Abdel-Khalek Amira, 2011, Archives of Phytopathology and Plant Protection, V44, P441, DOI 10.1080/03235400903093105
   ABDELGALEIL SAM, 2005, J APPL SCI RES, V1, P234
   Abdelgaleil SAM, 2008, BIORESOURCE TECHNOL, V99, P5947, DOI 10.1016/j.biortech.2007.10.043
   Abdelgaleil SAM, 2010, APPL ENTOMOL ZOOL, V45, P425, DOI 10.1303/aez.2010.425
   Adel Manal M., 2010, Archives of Phytopathology and Plant Protection, V43, P1098, DOI 10.1080/03235400802285562
   Akhtar Y, 2003, J INSECT BEHAV, V16, P811, DOI 10.1023/B:JOIR.0000018322.45068.a9
   Alburo R, 1987, PHILIPP QUAR CUL SOC, V15, P151
   Allan EJ, 2002, PLANT CELL REP, V21, P374, DOI 10.1007/s00299-002-0523-3
   Amer S. A. A., 2005, Acta Phytopathologica et Entomologica Hungarica, V40, P409, DOI 10.1556/APhyt.40.2005.3-4.23
   Amer S. A. A., 2002, Acta Phytopathologica et Entomologica Hungarica, V37, P281, DOI 10.1556/APhyt.37.2002.1-3.27
   Antonious GF, 2004, J ENVIRON SCI HEAL B, V39, P491, DOI [10.1081/LESB-200026682, 10.1081/PFC-200026682]
   Arcury TA, 2006, ENVIRON HEALTH PERSP, V114, P923, DOI 10.1289/ehp.8531
   Ascher KRS, 2002, PERSIAN LILAC CHINAB, P770
   Atkinson BL, 2004, J AGR FOOD CHEM, V52, P280, DOI 10.1021/jf0304425
   Auger J, 2002, BIOPESTICIDES ORIGIN, P77
   Bakkali F, 2008, FOOD CHEM TOXICOL, V46, P446, DOI 10.1016/j.fct.2007.09.106
   Belmain S, 2001, PESTICIDE OUTLOOK, V12, P233
   Belmain SR, 2001, FOOD CHEM TOXICOL, V39, P287, DOI 10.1016/S0278-6915(00)00134-4
   BERNAYS EA, 1991, J CHEM ECOL, V17, P2519, DOI 10.1007/BF00994599
   BERNAYS EA, 1990, ENTOMOL EXP APPL, V54, P53, DOI 10.1111/j.1570-7458.1990.tb01311.x
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Bloomquist JR, 2008, PESTIC BIOCHEM PHYS, V91, P17, DOI 10.1016/j.pestbp.2007.12.002
   Bloomquist JR, 2003, ARCH INSECT BIOCHEM, V54, P145, DOI 10.1002/arch.10112
   Bloomquist JR, 1996, ANNU REV ENTOMOL, V41, P163, DOI 10.1146/annurev.en.41.010196.001115
   Boeke S, 2004, INT J PEST MANAGE, V50, P1, DOI 10.1080/09670870310001619282
   Boeke SJ, 2004, J STORED PROD RES, V40, P423, DOI 10.1016/S0022-474X(03)00046-8
   Bomford MK, 1996, ENTOMOL EXP APPL, V81, P307, DOI 10.1046/j.1570-7458.1996.00101.x
   Bradburry S. P., 1989, REV ENVIRON CONTAM T, V108, P134
   Brown AE, 2005, P ION GNSS LONG BEAC, P1
   Buckle J, 2003, CLIN AROMATHERAPY ES, P416
   Bussaman P, 2012, SACC PSYCHE, P1, DOI [10.1155/2012/309046, DOI 10.1155/2012/309046]
   BUSSAMAN P, 2012, PSYCHE-J ENTOMOL
   BUTA JG, 1993, PHYTOCHEMISTRY, V32, P859, DOI 10.1016/0031-9422(93)85220-L
   Cabizza M, 2004, J AGR FOOD CHEM, V52, P288, DOI 10.1021/jf034987a
   Caboni P, 2002, J AGR FOOD CHEM, V50, P3491, DOI 10.1021/jf020076+
   Cabras P, 2002, J AGR FOOD CHEM, V50, P2576, DOI 10.1021/jf011430r
   CAGEN SZ, 1984, TOXICOL APPL PHARM, V76, P270, DOI 10.1016/0041-008X(84)90008-5
   Carpinella MC, 2003, J AGR FOOD CHEM, V51, P369, DOI 10.1021/jf025811w
   Casanova H, 2002, J AGR FOOD CHEM, V50, P6389, DOI 10.1021/jf0257244
   CASIDA J E, 1973, P329
   Casida JE, 1995, PYRETHRUM FLOWERS PR, P356
   Cespedes CL, 2006, ADV PHYTOMED, V3, P1
   Cespedes CL, 2000, J AGR FOOD CHEM, V48, P1903, DOI 10.1021/jf990443q
   Charleston DS, 2004, THESIS WAGENINGEN U, P176
   CHEN W, 1995, J APPL ENTOMOL, V119, P367, DOI 10.1111/j.1439-0418.1995.tb01302.x
   Childs FJ, 2001, IMPROVEMENT NEEM ITS, P32
   Chiu SF, 1988, INSECTICIDES PLANT O, P69
   Coats J.R., 1991, ACS SYM SER, V449, P306
   COATS JR, 1989, ENVIRON TOXICOL CHEM, V8, P671, DOI 10.1002/etc.5620080805
   COATS JR, 1994, ANNU REV ENTOMOL, V39, P489, DOI 10.1146/annurev.en.39.010194.002421
   COATS JR, 1990, ENVIRON HEALTH PERSP, V87, P255, DOI 10.2307/3431033
   Coppen JJW, 1995, FLAVOURS FRAGRANCES, P101
   Copping LG, 2000, PEST MANAG SCI, V56, P651, DOI 10.1002/1526-4998(200008)56:8<651::AID-PS201>3.0.CO;2-U
   Copping LG, 2001, BIOPESTICIDE MANUAL, P528
   Davies IH, 1985, PYRETHROID INSECTICI, P440
   DELAPLANE KS, 1992, J ECON ENTOMOL, V85, P2118, DOI 10.1093/jee/85.6.2118
   Deng A. L., 2009, African Journal of Environmental Science and Technology, V3, P108
   Dev S., 1997, INSECTICIDES NATURAL, P365
   Dimetry Nadia Z., 2012, Archives of Phytopathology and Plant Protection, V45, P1138, DOI 10.1080/03235408.2012.657932
   Dimetry Nadia Z., 2010, Archives of Phytopathology and Plant Protection, V43, P700, DOI 10.1080/03235400802144454
   Dimetry Nadia Z., 1997, Insect Science and its Application, V17, P395
   DIMETRY NZ, 1993, J APPL ENTOMOL, V116, P308, DOI 10.1111/j.1439-0418.1993.tb01201.x
   Dosemeci M, 2002, ANN OCCUP HYG, V46, P245, DOI 10.1093/annhyg/mef011
   El-Hawary Fatma M. A., 2006, Bulletin of the National Research Centre (Cairo), V31, P545
   El-Hosary R. A., 2011, The Journal of American Science, V7, P563
   El-Sayed EI, 1982, B ENTOMOL SOC, V13, P39
   El-Sayed EI, 1982, B ENTOMOL SOC, V13, P49
   El-Sebai TN, 2005, B ENTOMOL SOC EGYPT, V31, P229
   El-Shazly AM, 2005, PHARMAZIE, V60, P949
   El-Wakeil N, 2013, SIDE EFFECTS INSECTI, P3
   El-Wakeil N.E., 2006, Archives of Phytopathology and Plant Protection, V39, P445, DOI 10.1080/03235400500356160
   Enan E, 2001, COMP BIOCHEM PHYS C, V130, P325, DOI 10.1016/S1532-0456(01)00255-1
   Enan EE, 2005, INSECT BIOCHEM MOLEC, V35, P309, DOI 10.1016/j.ibmb.2004.12.007
   Enan EE, 2005, ARCH INSECT BIOCHEM, V59, P161, DOI 10.1002/arch.20076
   Fang NB, 1998, P NATL ACAD SCI USA, V95, P3380, DOI 10.1073/pnas.95.7.3380
   Farone WA, 2002, U.S. Patent, Patent No. [6,419,941, 6419941]
   FENG RY, 1995, PESTIC BIOCHEM PHYS, V53, P34, DOI 10.1006/pest.1995.1052
   Fields PG, 2001, J STORED PROD RES, V37, P359, DOI 10.1016/S0022-474X(00)00038-2
   Floris I, 2004, J ECON ENTOMOL, V97, P187, DOI 10.1603/0022-0493-97.2.187
   Forget G, 1993, IMPACT PESTICIDE USE, P335
   Fradin MS, 2002, NEW ENGL J MED, V347, P13, DOI 10.1056/NEJMoa011699
   Gebbinck EAK, 2002, PHYTOCHEMISTRY, V61, P737, DOI 10.1016/S0031-9422(02)00174-7
   Gilkeson LA, 2000, INTEGRATED PEST MANA, P130
   Glynne-Jones A., 2001, Pesticide Outlook, V12, P195, DOI 10.1039/b108601b
   Gonzalez-Coloma A, 2002, J CHEM ECOL, V28, P117, DOI 10.1023/A:1013566919874
   GRUNDY DL, 1985, PESTIC BIOCHEM PHYS, V23, P383, DOI 10.1016/0048-3575(85)90100-2
   Guerrero A, 2004, MINI-REV MED CHEM, V4, P757
   Guerrero A, 2005, CURR MED CHEM, V12, P461, DOI 10.2174/0929867053363126
   Hayes Jr W. J, 1982, PESTICIDES STUDIED M, P672
   HAYNES KF, 1988, ANNU REV ENTOMOL, V33, P149, DOI 10.1146/annurev.en.33.010188.001053
   Hedin PA, 1997, PHYTOCHEMICALS PEST, P372
   Henn T, 1991, 1307 U ILL URB CHAMP, V1307
   HOLLINGWORTH RM, 1994, BIOCHEM SOC T, V22, P230, DOI 10.1042/bst0220230
   Hussein HI, 2005, J PEST CONT ENV SCI, V13, P15
   Immaraju JA, 1998, PESTIC SCI, V54, P285, DOI 10.1002/(SICI)1096-9063(1998110)54:3<285::AID-PS802>3.0.CO;2-E
   Ismail A. I., 2004, Egyptian Journal of Biological Pest Control, V14, P175
   Isman M., 1999, Pesticide Outlook, V10, P68
   Isman M., 2002, Pesticide Outlook, V13, P152, DOI 10.1039/b206507j
   Isman M. B., 2005, Biopesticides of plant origin, P283
   Isman MB, 2000, CROP PROT, V19, P603, DOI 10.1016/S0261-2194(00)00079-X
   Isman MB, 2006, ANNU REV ENTOMOL, V51, P45, DOI 10.1146/annurev.ento.51.110104.151146
   Isman MB, 2004, NEEM: TODAY AND IN THE NEW MILLENNIUM, P33, DOI 10.1007/1-4020-2596-3_3
   ISMAN MB, 1993, PESTIC SCI, V38, P57, DOI 10.1002/ps.2780380109
   Isman MB, 1997, PHYTOPARASITICA, V25, P339, DOI 10.1007/BF02981099
   Isman MB, 1996, RECENT ADV PHYTOCHEM, V30, P155
   Isman MB, 2008, PEST MANAG SCI, V64, P8, DOI 10.1002/ps.1470
   Jacobson M, 1989, FOCUS PHYTOCHEMICAL, V1, P178
   Jayasekara TK, 2005, J CHEM ECOL, V31, P303, DOI 10.1007/s10886-005-1342-0
   Johnson HA, 2000, BIOLOGICALLY ACTIVE NATURAL PRODUCTS: PHARMACEUTICALS, P173
   Katz J, 1996, AM J EMERG MED, V14, P475, DOI 10.1016/S0735-6757(96)90157-6
   Keane S, 1999, INSECT BIOCHEM MOLEC, V29, P1097, DOI 10.1016/S0965-1748(99)00088-0
   Khambay BPS, 2003, PEST MANAG SCI, V59, P174, DOI 10.1002/ps.632
   Khater HF, 2012, ECOSMART BIORATIONAL, P17
   Kostyukovsky M, 2002, PEST MANAG SCI, V58, P1101, DOI 10.1002/ps.548
   Koul O, 2001, PHYTOCHEMICAL BIOPES, P223
   Kraus W, 2002, AZADIRACHTA INDICA A, P39
   Kubo I., 2000, Revista Latinoamericana de Quimica, V28, P7
   KUKEL CF, 1994, CAN J PHYSIOL PHARM, V72, P104, DOI 10.1139/y94-016
   KURITA N, 1981, AGR BIOL CHEM TOKYO, V45, P945, DOI 10.1080/00021369.1981.10864635
   Leatemia JA, 2004, INT J PEST MANAGE, V50, P129, DOI 10.1080/096708704100001691821
   Leatemia JA, 2004, PHYTOPARASITICA, V32, P30, DOI 10.1007/BF02980856
   LEWIS MA, 1993, PESTIC BIOCHEM PHYS, V45, P15, DOI 10.1006/pest.1993.1003
   LONDERSHAUSEN M, 1991, PESTIC SCI, V33, P427, DOI 10.1002/ps.2780330405
   LOWERY DT, 1995, PHYTOPARASITICA, V23, P297, DOI 10.1007/BF02981422
   Maistrello L, 2001, J ECON ENTOMOL, V94, P1532, DOI 10.1603/0022-0493-94.6.1532
   Marco GJ, 1987, SILENT SPRING REVISI, P214
   MATSUZAKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1417, DOI 10.1080/00021369.1991.10870753
   McLaughlin GA, 1973, HIST PYRETHRUM, P3
   McLaughlin JL, 1997, ACS SYM SER, V658, P117
   Mikolajczak KL, 1988, U.S. Patent, Patent No. [4,855,319, 4855319]
   Miyazawa M, 1997, J AGR FOOD CHEM, V45, P677, DOI 10.1021/jf960398b
   Moeschler H.F., 1987, U.S. Patent, Patent No. 4689323
   Morse S, 2002, EXP AGR, V38, P469, DOI 10.1017/S0014479702000480
   Narahashi T, 1976, EFFECTS INSECTICIDES, P327
   NATHANSON JA, 1993, P NATL ACAD SCI USA, V90, P9645, DOI 10.1073/pnas.90.20.9645
   National research council, 2000, FUT ROL PEST US AGR, P301
   National Research Council, 1992, NEEM TREE SOLV GLOB, P141
   Naumann K, 1996, AM BEE J, V136, P518
   Ngoh SP, 1998, PESTIC SCI, V54, P261, DOI 10.1002/(SICI)1096-9063(1998110)54:3<261::AID-PS794>3.0.CO;2-C
   OKUNO Y, 1986, TOXICOL APPL PHARM, V83, P157, DOI 10.1016/0041-008X(86)90333-9
   Pavela R, 2008, AGROCIENCIA-MEXICO, V42, P573
   Perry AS, 1998, INSECTICIDES AGR ENV, P261, DOI [10.1007/978-3-662-03656-3, DOI 10.1007/978-3-662-03656-3]
   Pesticide Action Network, 2004, PEST REG COUNTR
   Peterson C., 2001, Pesticide Outlook, V12, P154, DOI 10.1039/b106296b
   PHILOGENE BJR, 1984, J CHEM ECOL, V10, P115, DOI 10.1007/BF00987648
   Philogene BJR, 2005, BIOPESTICIDES PLANT, P1
   Pittarelli GW, 1993, U.S. Patent, Patent No. [5,260,281, 5260281US]
   Prakash A, 1997, BOT PESTICIDES AGR, P461
   Priestley CM, 2003, BRIT J PHARMACOL, V140, P1363, DOI 10.1038/sj.bjp.0705542
   QUARLES W, 1996, IPM PRACT, V18, P16
   Ratra GS, 2001, TOXICOL LETT, V122, P215, DOI 10.1016/S0378-4274(01)00366-6
   Rattan RS, 2010, CROP PROT, V29, P913, DOI 10.1016/j.cropro.2010.05.008
   Regnault-Roger C, 2005, BIOPESTICIDES PLANT, P313
   Regnault-Roger C, 2008, PHARM BIOL, V46, P41, DOI 10.1080/13880200701729794
   REGNAULTROGER C, 1993, J CHEM ECOL, V19, P1233, DOI 10.1007/BF00987383
   Rembold H, 2002, MELIA VOLKENSII GURK, P827
   RICE PJ, 1994, PESTIC SCI, V41, P195, DOI 10.1002/ps.2780410305
   RICHARDS AG, 1945, J CELL COMPAR PHYSL, V26, P57, DOI 10.1002/jcp.1030260108
   RYAN MF, 1988, J CHEM ECOL, V14, P1965, DOI 10.1007/BF01013489
   SALAMA HS, 1970, CURR SCI INDIA, V39, P497
   SALAMA HS, 1988, INSECT SCI APPL, V9, P573, DOI 10.1017/S1742758400005026
   Sallam AA, 2009, J PLANT DIS PROTECT, V116, P283, DOI 10.1007/BF03356325
   Sallena RC, 1989, INSECTICIDES PLANT O, P213
   Sammour Elham A., 2011, Archives of Phytopathology and Plant Protection, V44, P655, DOI 10.1080/03235400903266495
   SCHMUTTERER H, 1990, ANNU REV ENTOMOL, V35, P271, DOI 10.1146/annurev.en.35.010190.001415
   Schmutterer H., 2002, THE NEEM TREE
   SHARABY A, 1988, INSECT SCI APPL, V9, P77, DOI 10.1017/S1742758400010079
   SHEPARD HH, 1951, CHEM ACTION INSECTIC, P504
   Spollen KM, 1996, J ECON ENTOMOL, V89, P1379, DOI 10.1093/jee/89.6.1379
   Stroh J, 1998, B ENVIRON CONTAM TOX, V60, P923, DOI 10.1007/s001289900716
   Tamayo MC, 2000, PLANTA, V211, P62, DOI 10.1007/s004250000258
   Tang JD, 1997, J ECON ENTOMOL, V90, P732, DOI 10.1093/jee/90.3.732
   THACKER JMR, 2002, INTRO ARTHROPOD PEST, P343
   Thibout E, 1996, ACTA BOT GALLICA, V143, P137, DOI 10.1080/12538078.1996.10515333
   Thibout E, 1997, ACTA BOT GALLICA, V144, P419, DOI 10.1080/12538078.1997.10515781
   Trumble John T., 2002, American Entomologist, V48, P7
   VIJVERBERG HPM, 1982, NATURE, V295, P601, DOI 10.1038/295601a0
   Wan MT, 1996, B ENVIRON CONTAM TOX, V56, P432, DOI 10.1007/s001289900062
   Ware G. W., 1983, Pesticides: theory and application.
   WARE GW, 1988, PESTICIDE BOOK
   WEINZIERL RA, 2000, BIOL BIOTECHNOLOGICA, P101
   WHITTAKER RH, 1971, SCIENCE, V171, P757, DOI 10.1126/science.171.3973.757
   YAMAMOTO C, 1970, Experimental Brain Research, V10, P159
   Zhao JZ, 2002, J ECON ENTOMOL, V95, P430, DOI 10.1603/0022-0493-95.2.430
NR 187
TC 39
Z9 48
U1 2
U2 214
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0367-4223
EI 1439-0345
J9 GESUNDE PFLANZ
JI Gesunde Pflanz.
PD DEC
PY 2013
VL 65
IS 4
BP 125
EP 149
DI 10.1007/s10343-013-0308-3
PG 25
WC Agronomy
SC Agriculture
GA 249TU
UT WOS:000326800800001
DA 2018-12-27
ER

PT J
AU Ni, PP
AF Ni, Pengpeng
TI RETRACTED: VERIFICATION OF APPLICABILITY OF MACRO-ELEMENT IMPLEMENTATION
   IN A FINITE ELEMENT CODE FOR SHALLOW FOUNDATIONS (Retracted article. See
   vol. 14, 1493001, 2014)
SO INTERNATIONAL JOURNAL OF STRUCTURAL STABILITY AND DYNAMICS
LA English
DT Article; Retracted Publication
DE Macro-element model; shallow foundations; soil-structure interaction;
   large-scale cyclic laboratory tests; finite element method
ID SOIL-STRUCTURE INTERACTION; BEHAVIOR; SHAKING; TESTS; MODEL
AB Practical design theory usually considers a fully uncoupled behavior of soil-foundation and superstructure and neglects the nonlinearities occurred at the foundation level. However, there is a growing awareness of considering soil-foundation plasticity in the seismic analysis and design. In this paper, the theoretical framework of a macro-element model for structures resting on shallow foundations is brie y introduced. Nonlinear constitutive law to represent the mechanical property of the soil-foundation-structure system is formulated in terms of a set of generalized force and displacement parameters. The evolution of ultimate loading surface of shallow foundations is governed by the combination of three independent nonlinear mechanisms (soil plasticization, uplift, and sliding of the footing). The mechanisms of sliding at the soil-footing interface and of soil yielding in the vicinity of the footing are irreversible and dissipative; on the other hand, the mechanism of uplift is reversible and nondissipative. Bounding surface concept is adopted in line with the surface of ultimate loads of the foundation in the space of force parameters. The proposed macro-element model is implemented in a finite element program, SeismoStruct, which serves as a practical tool for dynamic analyses of structures with comprehensive illustration of all the nonlinearities including the one occurred at the foundation level. The validation of such macro-element implementation is carried out by comparisons with experimental results of large-scale cyclic laboratory tests within the framework of European research project TRISEE, as well as the numerical simulations conducted by a set of Matlab codes.
C1 Inst Adv Study, UMR Grad Sch IUSS Pavia, ROSE Programme, I-27100 Pavia, Italy.
RP Ni, PP (reprint author), Inst Adv Study, UMR Grad Sch IUSS Pavia, ROSE Programme, Via Ferrata 1, I-27100 Pavia, Italy.
EM pengpeng.ni@ce.queensu.ca
FU Category A Scholarship; European Commission; Erasmus Mundus
   programme-Master in Earthquake Engineering and Engineering Seismology
   (MEEES)
FX This paper was partially funded by the Italian Department of Civil
   Protection and by the Rete dei Laboratori Universitari di Ingegneria
   Sismica (ReLUIS), in the framework of the DPC-RELUIS Research Programme
   (2010-2013) Line 2, "Displacement-based vulnerability assessment". The
   author gratefully acknowledges the funding supports from the Category A
   Scholarship, which is directly sponsored by the European Commission,
   under the scope of its Erasmus Mundus programme-Master in Earthquake
   Engineering and Engineering Seismology (MEEES).
CR Ambraseys N, 2002, INTERNET SITE EUROPE
   Brinch-Hansen J., 1970, B DANISH GEOTECHNICA, V28
   BUTTERFIELD R., 1980, JOURNEE GEOTECHNIQUE, P128
   CEN, 2003, 19981 CEN PREN
   Chatzigogos CT, 2011, INT J NUMER ANAL MET, V35, P902, DOI 10.1002/nag.934
   Chatzigogos CT, 2009, SOIL DYN EARTHQ ENG, V29, P765, DOI 10.1016/j.soildyn.2008.08.009
   Chatzigogos CT, 2007, SOILS FOUND, V47, P783, DOI 10.3208/sandf.47.783
   Correia A. A., 2011, THESIS PAVIA
   Cremer C, 2002, J EARTHQUAKE ENG, V6, P175, DOI 10.1142/S1363246902000747
   Cremer C, 2001, INT J NUMER ANAL MET, V25, P1257, DOI 10.1002/nag.175
   Faccioli E., 1998, 3D SITES EFFECTS SOI
   Figini R, 2012, EARTHQ ENG STRUCT D, V41, P475, DOI 10.1002/eqe.1140
   Figini R., 2010, THESIS POLITECNICO M
   Gazetas G, 1991, FDN ENG HDB, P553
   Gazetas G, 2007, GEOTECH GEOL EARTHQ, V6, P185
   Grange S, 2008, INT J NUMER ANAL MET, V32, P1205, DOI 10.1002/nag.664
   Iervolino I, 2010, B EARTHQ ENG, V8, P339, DOI 10.1007/s10518-009-9146-1
   Ni P., 2012, THESIS EUROPEAN SCH
   Ni PP, 2014, STRUCT INFRASTRUCT E, V10, P1211, DOI 10.1080/15732479.2013.802813
   Ni PP, 2013, EUR J ENVIRON CIV EN, V17, P507, DOI 10.1080/19648189.2013.771111
   NOVA R, 1991, GEOTECHNIQUE, V41, P243, DOI 10.1680/geot.1991.41.2.243
   Paolucci R, 1997, J EARTHQ ENG, V1, P563, DOI 10.1080/13632469708962378
   Paolucci R, 2008, EARTHQ ENG STRUCT D, V37, P577, DOI 10.1002/eqe.773
   Pecker A., 2006, 4 ATH LECT GEOT ENG
   Priestley M. J. N., 2005, 2005 NZ SOC EARTHQ E
   Shirato M, 2008, SOILS FOUND, V48, P693, DOI 10.3208/sandf.48.693
   Ugalde J. A., 2007, 4 INT C EARTHQ GEOT
   Wolf JP, 1988, SOIL STRUCTURE INTER
NR 28
TC 2
Z9 2
U1 3
U2 20
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0219-4554
EI 1793-6764
J9 INT J STRUCT STAB DY
JI Int. J. Struct. Stab. Dyn.
PD DEC
PY 2013
VL 13
IS 8
AR 1350041
DI 10.1142/S0219455413500417
PG 24
WC Engineering, Civil; Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA 248RY
UT WOS:000326720500008
DA 2018-12-27
ER

PT J
AU Benedetto, A
AF Benedetto, Antonio
TI RETRACTED: Protein dynamics by neutron scattering (Retracted article.
   See vol. 209, pg. 56, 2016)
SO BIOPHYSICAL CHEMISTRY
LA English
DT Article; Retracted Publication
DE Protein dynamical transition; Fragile-to-strong dynamical crossover;
   Mean Square Displacement; Lysozyme; Bioprotectant; Elastic Neutron
   Scattering
ID SELF-DISTRIBUTION FUNCTION; MEAN-SQUARE DISPLACEMENT; BIOLOGICAL
   MACROMOLECULES; HYDRATION WATER; ENZYME-ACTIVITY; TRANSITION; PUZZLE
AB Neutron scattering techniques represent a powerful tool for characterizing both the structure and dynamical properties of bio-systems, for example, proteins and membranes interacting with their solvents. In this paper, Elastic Neutron Scattering (ENS) data collected at the Institut Laue-Langevin (Grenoble, France) on dry and D2O hydrated lysozyme by varying hydration level are presented, and compared with previously published data on the same protein system, also with the addition of bio-protectants. The data have been collected with three different spectrometers, i.e. IN13, IN10 and IN4. This set of ENS data gives direct access to the temperature behavior of both (i) the Mean Square Displacement (MSD) and (ii) the characteristic system relaxation time. As a result, an explicative hypothesis on the relationship between the so-called "protein dynamical transition" (PDT) and the "fragile-to-strong dynamical crossover" (FSC) is formulated. Furthermore, by taking into proper account the effect of the finite instrumental energy resolution of the used spectrometers, the vibrational MSD of dry and hydrated lysozyme is calculated. The vibrational MSD of the lysozyme in the dry state resulted to be higher than the one in the hydrated state; the latter reaches the former at a temperature value of T = 220 K that corresponds to the temperature at which the FSC occurs. As a result, a cage effect resulting from the hydration water on the protein surface is hypothesized and subsequently linked to the FSC. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Benedetto, Antonio] Univ Coll Dublin, Sch Phys, Dublin 4, Ireland.
   [Benedetto, Antonio] Univ Sydney, Sydney Med Sch, Sch Med Sci, Sydney, NSW 2006, Australia.
RP Benedetto, A (reprint author), Univ Coll Dublin, Sch Phys, Belfield Campus, Dublin 4, Ireland.
EM antonio.benedetto@ucd.ie
RI Benedetto, Antonio/F-3105-2011
OI Benedetto, Antonio/0000-0002-9324-8595
FU Societa' Italiana di Biofisica Pura ed Applicata (SIBPA); European Union
   under a Marie Curie Intra-European Fellowship for Career Development
   (IEF) within the 7th European Community Framework Programme
FX Dr. A. Benedetto acknowledges the Societa' Italiana di Biofisica Pura ed
   Applicata (SIBPA) for awarding him the national Menestrina-Borsellino
   Prize in recognition of his PhD Thesis, the results of which are
   partially reported in this paper.; Dr. A. Benedetto acknowledges the
   support from the European Union under a Marie Curie Intra-European
   Fellowship for Career Development (IEF) within the 7th European
   Community Framework Programme.
CR Becker T, 2004, BIOPHYS J, V87, P1436, DOI 10.1529/biophysj.104.042226
   Bee M, 1988, QUASIELASTIC NEUTRON
   Capaccioli S, 2012, J PHYS CHEM B, V116, P1745, DOI 10.1021/jp2057892
   Careri G, 1998, PROG BIOPHYS MOL BIO, V70, P223, DOI 10.1016/S0079-6107(98)00030-3
   Chen SH, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2372491
   Chen SH, 2006, P NATL ACAD SCI USA, V103, P9012, DOI 10.1073/pnas.0602474103
   Chen SH, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.189803
   Chu XQ, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.011908
   Daniel RM, 1998, BIOPHYS J, V75, P2504, DOI 10.1016/S0006-3495(98)77694-5
   Doster W, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.098101
   DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0
   Doster W, 2008, EUR BIOPHYS J BIOPHY, V37, P591, DOI 10.1007/s00249-008-0274-3
   Frauenfelder H, 2009, P NATL ACAD SCI USA, V106, P5129, DOI 10.1073/pnas.0900336106
   Gregory R. B., 1995, PROTEIN SOLVENT INTE
   Khodadadi S, 2008, J PHYS CHEM B, V112, P14273, DOI 10.1021/jp8059807
   Khodadadi S, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2927871
   Kneller GR, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2711207
   Kurkal V, 2005, BIOPHYS J, V89, P1282, DOI 10.1529/biophysj.104.058677
   Lee AL, 2001, NATURE, V411, P501, DOI 10.1038/35078119
   Liu L, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.117802
   Magazu S, 2008, J MOL STRUCT, V882, P140, DOI 10.1016/j.molstruc.2007.09.022
   Magazu S, 2012, EUR BIOPHYS J BIOPHY, V41, P361, DOI 10.1007/s00249-011-0760-x
   Magazu S., 2013, CHEM PHYS
   Magazu S, 2008, J PHYS CHEM B, V112, P8936, DOI 10.1021/jp711930b
   Magazu S, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.4758775
   Magazu S, 2012, J PHYS CHEM B, V116, P6068, DOI 10.1021/jp300926f
   Magazu S, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3641870
   Magazu S, 2011, J PHYS CHEM B, V115, P7736, DOI 10.1021/jp111421m
   Magazu S, 2011, J NON-CRYST SOLIDS, V357, P664, DOI 10.1016/j.jnoncrysol.2010.06.075
   Magazu S, 2010, J PHYS CHEM B, V114, P9268, DOI 10.1021/jp102436y
   Magazu S, 2010, BBA-PROTEINS PROTEOM, V1804, P49, DOI 10.1016/j.bbapap.2009.09.017
   Magazu S, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.041915
   Mamontov E, 2010, J BIOL PHYS, V36, P291, DOI 10.1007/s10867-009-9184-6
   Nickels JD, 2013, CHEM PHYS, V424, P7, DOI 10.1016/j.chemphys.2012.11.021
   Pawlus S, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.108103
   Pieper J, 2007, BIOCHEMISTRY-US, V46, P11398, DOI 10.1021/bi700179s
   RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0
   Schiro G, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.128102
   Sokolov AP, 2008, CHEM PHYS, V345, P212, DOI 10.1016/j.chemphys.2007.07.013
   Swenson J, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.189801
   Swenson J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.247802
   TEETER MM, 1991, ANNU REV BIOPHYS BIO, V20, P577, DOI 10.1146/annurev.biophys.20.1.577
   VANHOVE L, 1954, PHYS REV, V95, P249, DOI 10.1103/PhysRev.95.249
   Volino F., 1978, SPECTROSCOPIC METHOD
   Young RD, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.158102
   Zaccai G, 2000, SCIENCE, V288, P1604, DOI 10.1126/science.288.5471.1604
NR 46
TC 6
Z9 6
U1 1
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-4622
EI 1873-4200
J9 BIOPHYS CHEM
JI Biophys. Chem.
PD DEC 1
PY 2013
VL 182
SI SI
BP 16
EP 22
DI 10.1016/j.bpc.2013.07.007
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA 225OF
UT WOS:000324971500004
PM 23953400
DA 2018-12-27
ER

PT J
AU Li, X
   Li, D
   Zhuang, Y
   Shi, Q
   Wei, W
   Ju, XL
AF Li, Xue
   Li, Dong
   Zhuang, Yong
   Shi, Qing
   Wei, Wei
   Ju, Xiuli
TI RETRACTED: Overexpression of miR-708 and Its Targets in the Childhood
   Common Precursor B-Cell ALL (Retracted article. See vol.64,pg.0,2017)
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article; Retracted Publication
DE miRNA; pediatric acute lymphoblastic leukemia; regulatory region; target
   gene
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; MICRORNAS; RELAPSE; DIFFERENTIATION; GENES
AB BackgroundThe critical function of microRNAs in the pathogenesis and prognosis of hematopoietic cancer has become increasingly apparent. However, only a few miRNAs have been reported to be altered in acute lymphocytic leukemia (ALL).
   ProceduresTo uncover aberrantly expressed miRNAs in pediatric B-cell ALL, our study employed genome-wide miRNA microarray analysis and stem-loop real-time quantitative polymerase chain reaction (qRT-PCR) to examine common precursor B-cell ALL samples. The target genes of miRNA-708 were then identified and verified by bioinformatics, dual-luciferase reporter assay, qRT-PCR, and Western blot.
   ResultsSignificant upregulation of miR-708, miR-210, and miR-181b, and downregulation of miR-345 and miR-27a were observed in common precursor B-cell ALL (common-ALL) samples (P<0.05). In addition, elevated expression of miR-708 and miR-181b were found in high-risk common-ALL compared to standard and intermediate ones. miR-708 inhibited luciferase reporter activity by binding to the 3-untranslated regions (3-UTRs) of CNTFR, NNAT, and GNG12 mRNA in HEK-293 cell line and suppressed the protein levels of CNTFR, NNAT, and GNG12 in Jurkat cells. In addition, mRNA levels of CNTFR and NNAT, but not of GNG12, were found to be downregulated in high risk common-ALL samples. Mutational analysis revealed that miR-708 binds to the 394-400bp sequence region of the 3-UTR of CNTFR mRNA.
   ConclusionThe expression level of miR-708 reflects differences among the clinical types of common-ALL, and CNTFR, NNAT, and GNG12 were identified as targets of miR-708. Pediatr Blood Cancer 2013;60:2060-2067. (c) 2013 Wiley Periodicals, Inc.
C1 [Li, Xue; Zhuang, Yong; Wei, Wei; Ju, Xiuli] Shandong Univ, Qilu Hosp, Dept Pediat, Cryomed Lab, Jinan 250012, Shandong, Peoples R China.
   [Li, Dong; Shi, Qing] Shandong Univ, Qilu Hosp, Cryomed Lab, Jinan 250012, Shandong, Peoples R China.
RP Ju, XL (reprint author), Shandong Univ, Qilu Hosp, Dept Pediat, Cryomed Lab, Jinan 250012, Shandong, Peoples R China.
EM shellysdcn07@gmail.com
FU Shandong Province Natural Science Foundation [ZR2011HM007,
   2010G0020213]; Major State Basic Research Development Program
   [2012CB96650481102710]; Innovation Fund Project of Shandong University
   [2012ZD023]
FX Grant sponsor: Shandong Province Natural Science Foundation; Grant
   numbers: ZR2011HM007; 2010G0020213; Grant sponsor: Major State Basic
   Research Development Program; Grant number: 2012CB966504 & 81102710;
   Grant sponsor: Innovation Fund Project of Shandong University; Grant
   number: 2012ZD023
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Coustan-Smith E, 2000, BLOOD, V96, P2691
   David W, 2004, J CLIN ONCOL, V22, P361
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Evans HK, 2001, GENOMICS, V77, P99, DOI 10.1006/geno.2001.6612
   Gao C, 2012, AM J HEMATOL, V87, P1022, DOI 10.1002/ajh.23307
   Han BW, 2011, HUM MOL GENET, V20, P4903, DOI 10.1093/hmg/ddr428
   Ju XL, 2009, PEDIATR HEMAT ONCOL, V26, P1, DOI 10.1080/08880010802378338
   Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032
   Kelley CL, 2010, INFLAMM RES, V59, P15
   Kotani A, 2009, BLOOD, V114, P4169, DOI 10.1182/blood-2008-12-191619
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858
   Nancy YI, 1992, CELL, V69, P1121
   Pedro PM, 2010, NATURE, V467, P86
   Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2
   Schotte D, 2012, LEUKEMIA, V26, P1, DOI 10.1038/leu.2011.151
   Schotte D, 2011, LEUKEMIA, V25, P1389, DOI 10.1038/leu.2011.105
   Steven JK, 2002, CARCINOGENESIS, V23, P559
   Uzunel M, 2003, BRIT J HAEMATOL, V122, P788, DOI 10.1046/j.1365-2141.2003.04495.x
   Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007826
   Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110
NR 25
TC 15
Z9 15
U1 3
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD DEC
PY 2013
VL 60
IS 12
BP 2060
EP 2067
DI 10.1002/pbc.24583
PG 8
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 232HX
UT WOS:000325484900031
PM 23970374
DA 2018-12-27
ER

PT J
AU Bahrpaima, K
   Sajadi, H
   Shafiee, A
AF Bahrpaima, Kh
   Sajadi, H.
   Shafiee, A.
TI RETRACTED: Phase behaviour of aqueous mixtures of acetic acid with
   isomers of xylene (Retracted article. See vol. 121, pg. 219, 2018)
SO JOURNAL OF CHEMICAL THERMODYNAMICS
LA English
DT Article; Retracted Publication
DE Liquid-liquid equilibrium; Xylene isomers; Xylenes; NRTL model
ID LIQUID-LIQUID EQUILIBRIUM; WATER; PLUS; SYSTEM; ACID+2-ETHYL-1-HEXANOL;
   25-DEGREES-C
AB (Liquid-liquid) equilibrium (LLE) data of the solubility curves and tie-line compositions have been determined for mixtures of (water + acetic acid + organic solvent (o-xylene, m-xylene or p-xylene)) at T = 298.15 K and atmospheric pressure. The mixed isomers (xylenes) are also used as a mixed-solvent like the individual isomers and phase behaviour of (water + acetic acid + xylenes) is investigated. The experimental LLE data were correlated using the NRTL model, and the binary interaction parameters were obtained. Distribution coefficients and separation factors have been evaluated for the immiscibility region. The reliability of the experimental tie-lines has been confirmed by using Othmer-Tobias correlation. (c) 2013 Elsevier Ltd. All rights reserved.
C1 [Bahrpaima, Kh; Sajadi, H.; Shafiee, A.] Islamic Azad Univ, Firoozabad Branch, Dept Chem, Firoozabad 74715117, Fars, Iran.
RP Bahrpaima, K (reprint author), Islamic Azad Univ, Firoozabad Branch, Dept Chem, Firoozabad 74715117, Fars, Iran.
EM Kh.bahrpyma@iauf.ac.ir
FU Research Council of Islamic Azad University, Firoozabad Branch
FX We gratefully acknowledge the financial support from the Research
   Council of Islamic Azad University, Firoozabad Branch.
CR Bahrpaima K, 2013, J CHEM THERMODYN, V58, P385, DOI 10.1016/j.jct.2012.06.001
   Chafer A, 2008, FLUID PHASE EQUILIBR, V271, P76, DOI 10.1016/j.fluid.2008.07.001
   Darwish NA, 2002, FLUID PHASE EQUILIBR, V200, P277, DOI 10.1016/S0378-3812(02)00039-0
   Ghanadzadeh A, 2010, FLUID PHASE EQUILIBR, V291, P90, DOI 10.1016/j.fluid.2009.12.033
   Ghanadzadeh A, 2009, J CHEM ENG DATA, V54, P1009, DOI 10.1021/je8008792
   Ghanadzadeh H, 2008, J CHEM THERMODYN, V40, P879, DOI 10.1016/j.jct.2008.01.001
   Ghanadzadeh H, 2004, J CHEM THERMODYN, V36, P1001, DOI 10.1016/j.jct.2004.07.021
   GOMIS V, 1995, FLUID PHASE EQUILIBR, V106, P203, DOI 10.1016/0378-3812(94)02622-8
   GOVINDARAJAN M, 1995, FLUID PHASE EQUILIBR, V108, P269, DOI 10.1016/0378-3812(95)02693-9
   Hu S, 2010, FLUID PHASE EQUILIBR, V293, P73, DOI 10.1016/j.fluid.2010.01.005
   Ince E, 2005, FLUID PHASE EQUILIBR, V238, P33, DOI 10.1016/j.fluid.2005.09.013
   Ince E, 2005, FLUID PHASE EQUILIBR, V230, P58, DOI 10.1016/j.fluid.2004.11.025
   Ince E, 2006, J CHEM THERMODYN, V38, P1669, DOI 10.1016/j.jct.2006.03.012
   Kirbaslar SI, 2005, J CHEM THERMODYN, V37, P1256, DOI 10.1016/j.jct.2005.03.003
   Letcher TM, 2001, J CHEM THERMODYN, V33, P1643, DOI 10.1006/jcht.2000.0763
   Mohsen-Nia M, 2009, J CHEM THERMODYN, V41, P859, DOI 10.1016/j.jct.2009.02.004
   Mohsen-Nia M, 2006, J CHEM ENG DATA, V51, P1316, DOI 10.1021/je060061y
   NAGATA I, 1990, THERMOCHIM ACTA, V170, P243, DOI 10.1016/0040-6031(90)80543-8
   Othmer DF, 1942, IND ENG CHEM, V34, P690, DOI 10.1021/ie50390a011
   PRINCE RGH, 1957, CHEM ENG SCI, V6, P245, DOI 10.1016/0009-2509(57)85027-1
   RENON H, 1968, AICHE J, V14, P135, DOI 10.1002/aic.690140124
   Tan TC, 1999, FLUID PHASE EQUILIBR, V163, P243, DOI 10.1016/S0378-3812(99)00231-9
NR 22
TC 2
Z9 2
U1 2
U2 14
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0021-9614
EI 1096-3626
J9 J CHEM THERMODYN
JI J. Chem. Thermodyn.
PD DEC
PY 2013
VL 67
BP 148
EP 152
DI 10.1016/j.jct.2013.08.001
PG 5
WC Thermodynamics; Chemistry, Physical
SC Thermodynamics; Chemistry
GA 227SE
UT WOS:000325133600020
DA 2018-12-27
ER

PT J
AU Ghaffari, M
   Kinsman, W
   Zhou, Y
   Murali, S
   Burlingame, Q
   Lin, M
   Ruoff, RS
   Zhang, QM
AF Ghaffari, M.
   Kinsman, W.
   Zhou, Y.
   Murali, S.
   Burlingame, Q.
   Lin, M.
   Ruoff, R. S.
   Zhang, Q. M.
TI RETRACTED: Aligned Nano-Porous Microwave Exfoliated Graphite Oxide Ionic
   Actuators with High Strain and Elastic Energy Density (Retracted
   article. See vol. 28, pg. 9453, 2016)
SO ADVANCED MATERIALS
LA English
DT Article; Retracted Publication
ID NETWORK COMPOSITE ACTUATORS; POLYMER ACTUATORS; ELECTROMECHANICAL
   RESPONSE; ARTIFICIAL MUSCLES; LIQUIDS; GRAPHENE; ELECTRODES; SENSORS;
   NANOCOMPOSITES; DEVICES
AB A high-density aligned nanoporous activated microwave exfoliated graphite oxide (aMEGO) ionic actuator is studied. Before applying an external electric field, the cations and anions are randomly distributed in the composite. After applying the electric field, ions ingress in between the aligned aMEGO sheets through the nanopores to compensate the charges on the electrodes, resulting in the separation of neighboring sheets and unidirectional electro actuation.
C1 [Ghaffari, M.; Kinsman, W.] Penn State Univ, Dept Mat Sci & Engn, Mat Res Inst, University Pk, PA 16802 USA.
   [Zhou, Y.; Burlingame, Q.] Penn State Univ, Dept Elect Engn, Mat Res Inst, University Pk, PA 16802 USA.
   [Murali, S.; Ruoff, R. S.] Univ Texas Austin, Dept Mech Engn & Mat Sci, Austin, TX 78712 USA.
   [Murali, S.; Ruoff, R. S.] Univ Texas Austin, Engn Program, Austin, TX 78712 USA.
   [Lin, M.] Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA.
   [Zhang, Q. M.] Penn State Univ, Dept Mat Sci & Engn, Dept Elect Engn, Mat Res Inst, University Pk, PA 16802 USA.
   [Zhang, Q. M.] Tsinghua Univ, Sch Mat Sci & Engn, Beijing, Peoples R China.
RP Zhang, QM (reprint author), Penn State Univ, Dept Mat Sci & Engn, Dept Elect Engn, Mat Res Inst, University Pk, PA 16802 USA.
EM Qxz1@psu.edu
RI Zhou, Yue/J-4524-2014; Ruoff, Rodney/K-3879-2015
OI Zhou, Yue/0000-0003-3894-4130; 
FU NSF [CMMI-1130437]; AFOSR [FA9550-11-1-0192]; Electrical Engineering
   Department of the Penn State University; US Department of Energy (DOE)
   [DE-SC001951]
FX The authors wish to thank Zhigang Suo for discussions. The work at Penn
   State was supported by NSF under grant number CMMI-1130437(MG and WK),
   AFOSR under grant number FA9550-11-1-0192 (YZ, ML and QMZ), and the
   Electrical Engineering Department of the Penn State University (QB). SM
   and RSR appreciate support by the US Department of Energy (DOE) under
   Award no. DE-SC001951.
CR Bar-Cohen Y, 2008, MRS BULL, V33, P173, DOI 10.1557/mrs2008.42
   Baughman RH, 1999, SCIENCE, V284, P1340, DOI 10.1126/science.284.5418.1340
   Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047
   Bennett MD, 2004, SENSOR ACTUAT A-PHYS, V115, P79, DOI 10.1016/j.sna.2004.03.043
   Calvert P, 2008, MRS BULL, V33, P207, DOI 10.1557/mrs2008.46
   Conway B. E., 1999, ELECTROCHEMICAL SUPE
   Dikin DA, 2007, NATURE, V448, P457, DOI 10.1038/nature06016
   Foroughi J, 2011, SCIENCE, V334, P494, DOI 10.1126/science.1211220
   Giurgiutiu V, 1996, J INTEL MAT SYST STR, V7, P656, DOI 10.1177/1045389X9600700605
   Hahn M, 2006, CARBON, V44, P2523, DOI 10.1016/j.carbon.2006.05.002
   Hara S, 2005, SMART MATER STRUCT, V14, P1501, DOI 10.1088/0964-1726/14/6/042
   HERBERT JM, 1982, FERROELECTRIC TRANSD, V3
   Jarosik A, 2006, J MOL LIQ, V123, P43, DOI 10.1016/j.molliq.2005.06.001
   Kaneko M, 1999, SYNTHETIC MET, V102, P1350, DOI 10.1016/S0379-6779(98)00235-5
   Knoblauch M, 2003, NAT MATER, V2, P600, DOI 10.1038/nmat960
   Liang QZ, 2011, ACS NANO, V5, P2392, DOI 10.1021/nn200181e
   Lima MD, 2012, SCIENCE, V338, P928, DOI 10.1126/science.1226762
   Liu P., 2007, US Patent, Patent No. [7, 205, 699 B1, 7205699]
   Liu S, 2010, ADV FUNCT MATER, V20, P3266, DOI 10.1002/adfm.201000570
   Liu S, 2010, POLYM INT, V59, P321, DOI 10.1002/pi.2771
   Liu Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep00973
   Liu Y, 2012, SENSOR ACTUAT A-PHYS, V181, P70, DOI 10.1016/j.sna.2012.05.002
   Liu Y, 2012, MACROMOLECULES, V45, P5128, DOI 10.1021/ma300591a
   Lu W, 2002, SCIENCE, V297, P983, DOI 10.1126/science.1072651
   Madden JDW, 2004, IEEE J OCEANIC ENG, V29, P706, DOI 10.1109/JOE.2004.833135
   Maugis D, 2000, CONTACT ADHESION RUP
   NEWNHAM RE, 1978, MATER RES BULL, V13, P525, DOI 10.1016/0025-5408(78)90161-7
   OSADA Y, 1985, CHEM LETT, P1285, DOI 10.1246/cl.1985.1285
   Perline R., 2000, SCIENCE, V287, P836
   Putz KW, 2011, ACS NANO, V5, P6601, DOI 10.1021/nn202040c
   Putz KW, 2010, ADV FUNCT MATER, V20, P3322, DOI 10.1002/adfm.201000723
   Ruch PW, 2009, ELECTROCHIM ACTA, V54, P4451, DOI 10.1016/j.electacta.2009.03.022
   Sahin O, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/44/445717
   Shahinpoor M, 1998, SMART MATER STRUCT, V7, pR15, DOI 10.1088/0964-1726/7/6/001
   Smela E, 1999, ADV MATER, V11, P953
   Spinks GM, 2002, ADV MATER, V14, P1728, DOI 10.1002/1521-4095(20021203)14:23<1728::AID-ADMA1728>3.0.CO;2-8
   Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996
   Xie XJ, 2010, ACS NANO, V4, P6050, DOI 10.1021/nn101563x
   Zhang QM, 2002, NATURE, V419, P284, DOI 10.1038/nature01021
   Zhang QM, 1998, SCIENCE, V280, P2101, DOI 10.1126/science.280.5372.2101
   Zhou X., 2009, APPL PHYS LETT, V94, P16290
   Zhu SE, 2011, NANO LETT, V11, P977, DOI 10.1021/nl103618e
   Zhu YW, 2011, SCIENCE, V332, P1537, DOI 10.1126/science.1200770
NR 43
TC 8
Z9 8
U1 6
U2 125
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD NOV 20
PY 2013
VL 25
IS 43
BP 6277
EP 6283
DI 10.1002/adma.201301370
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AA3BL
UT WOS:000330967800017
PM 23963747
DA 2018-12-27
ER

PT J
AU Sooraj, KP
   Seo, KH
   Wang, B
   Lee, JY
AF Sooraj, K. P.
   Seo, Kyong-Hwan
   Wang, Bin
   Lee, June-Yi
TI RETRACTED: Recent drought events over the central Indian region: Pacific
   Ocean origin and insights from moisture budgets (Retracted article. See
   vol. 34, pg. 3480, 2014)
SO INTERNATIONAL JOURNAL OF CLIMATOLOGY
LA English
DT Article; Retracted Publication
DE Indian summer monsoon; extended breaks; recent droughts; CP El Nino
   events; convective activity over WNP; moisture budget; moist processes
ID ASIAN SUMMER MONSOON; SURFACE-TEMPERATURE ANOMALIES; 30-50 DAY
   VARIABILITY; EL-NINO; INTERANNUAL VARIABILITY; NORTHWEST PACIFIC;
   HEAT-SOURCES; ENSO; CLIMATE; OSCILLATION
AB Analysis of rainfall variation over the central Indian (CI) region, using a high resolution rainfall gridded data set over the Indian longitudes, shows that the recent decade (1998-2009) has large number of drought events, compared with the earlier two decades (1979-1997). Improved understanding of the underlying mechanism responsible for these summer monsoon droughts is important because of their profound socio-economic impact over this region. Our analysis here reveals that most of the recent droughts are associated with extended break events (breaks lasting more than 7 d) and that the process responsible for it may also be the mechanism responsible for these droughts. Sub-seasonal diagnostics, focusing on such drought-producing break monsoon events, show prominent structures resembling the central Pacific (CP) El Nino warming over central equatorial Pacific Ocean. We then performed sub-seasonal moisture budget diagnostics using newly available European Centre for Medium Range Weather Forecasts (ECMWF) interim reanalysis. The primary aim is to identify the various moist processes through which the break monsoon conditions are initiated and maintained over CI, thus leading to large-scale drought conditions. The budget diagnostic shows that dry advection is the principal moisture process to initiate drought-producing break conditions over CI. The primary processes leading to dry advection are as follows: the enhanced rainfall over western north Pacific (WNP) induces cyclonic circulation anomalies to its northwest as a Rossby wave response, and the northerlies at the poleward of this circulation advect dry air of low moisture content from continental subtropics to south Asia. The present result also indicates that the enhanced radiative cooling over CI plays an important role in maintaining such break conditions. A direct implication of our research is that observational efforts are essential to monitor the three-dimensional moisture distribution over the south Asian monsoon region, for a better understanding of these drought-producing break monsoon events.
C1 [Sooraj, K. P.; Seo, Kyong-Hwan] Pusan Natl Univ, Dept Atmospher Sci, Pusan 609734, South Korea.
   [Wang, Bin; Lee, June-Yi] Univ Hawaii, Int Pacific Res Ctr, Honolulu, HI 96822 USA.
RP Seo, KH (reprint author), Pusan Natl Univ, Dept Atmospher Sci, Pusan 609734, South Korea.
EM khseo@pusan.ac.kr
RI Lee, June-Yi/D-5752-2012
OI Lee, June-Yi/0000-0002-3986-9753
FU Pusan National University; Korea Meteorological Administration [CATER
   2012-3071]
FX K. P. Sooraj sincerely thanks Dr Rajeevan of National Aerospace Research
   Laboratory, India, for kindly providing the high-resolution gridded
   rainfall datasets for performing analysis on the recent monsoon years.
   He expresses his sincere gratitude to Dr Jan Hafner and Dr H Annamalai
   of International Pacific Research Centre, Hawaii, for fruitful
   discussions on the moisture diagnostics. He also thanks Dr K. Ashok for
   his suggestions during the progression of this work. This work was
   supported by the 2011 Postdoc Development Program of Pusan National
   University, and the Korea Meteorological Administration Research and
   Development Program under Grant CATER 2012-3071.
CR An SI, 2000, J CLIMATE, V13, P2044, DOI 10.1175/1520-0442(2000)013<2044:ICOTSO>2.0.CO;2
   Annamalai H, 1999, MON WEATHER REV, V127, P1157, DOI 10.1175/1520-0493(1999)127<1157:TMEAVO>2.0.CO;2
   Annamalai H, 2005, J ATMOS SCI, V62, P2726, DOI 10.1175/JAS3504.1
   Annamalai H, 2005, Q J ROY METEOR SOC, V131, P805, DOI 10.1256/qj.04.08
   Annamalai H, 2010, J ATMOS SCI, V67, P589, DOI 10.1175/2009JAS2991.1
   Annamalai H, 2001, CLIM DYNAM, V18, P85, DOI 10.1007/s003820100161
   Ashok K, 2001, GEOPHYS RES LETT, V28, P4499, DOI 10.1029/2001GL013294
   Ashok K, 2007, J GEOPHYS RES-OCEANS, V112, DOI 10.1029/2006JC003798
   Behera SK, 1999, GEOPHYS RES LETT, V26, P3001, DOI 10.1029/1999GL010434
   Chandrasekar A, 1998, J METEOROL SOC JPN, V76, P841, DOI 10.2151/jmsj1965.76.6_841
   Charney JG, 1981, MONSOON DYNAMICS
   Chen G, 2010, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032562
   GILL AE, 1980, Q J ROY METEOR SOC, V106, P447, DOI 10.1002/qj.49710644905
   Goswami BN, 2005, S-P B ENVIRON SCI, P19, DOI 10.1007/3-540-27250-X_2
   Goswami BN, 2001, J CLIMATE, V14, P1180, DOI 10.1175/1520-0442(2001)014<1180:IOAIVO>2.0.CO;2
   Holton JR, 1982, INTRO DYNAMIC METEOR
   Huffman GJ, 2007, J HYDROMETEOROL, V8, P38, DOI 10.1175/JHM560.1
   Huffman GJ, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040000
   JU JH, 1995, Q J ROY METEOR SOC, V121, P1133, DOI 10.1002/qj.49712152509
   Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2
   Kao HY, 2009, J CLIMATE, V22, P615, DOI 10.1175/2008JCLI2309.1
   Krishnan K, 2000, J ATMOS SCI, V57, P1354, DOI 10.1175/1520-0469(2000)057<1354:DOBITI>2.0.CO;2
   Kug JS, 2009, J CLIMATE, V22, P1499, DOI 10.1175/2008JCLI2624.1
   Kumar KK, 2006, SCIENCE, V314, P115, DOI 10.1126/science.1131152
   Kumar KK, 1999, SCIENCE, V284, P2156, DOI 10.1126/science.284.5423.2156
   Kumar V, 2005, CURR SCI INDIA, V88, P602
   Larkin NK, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022860
   Latif M, 1997, J CLIMATE, V10, P2221, DOI 10.1175/1520-0442(1997)010<2221:GWDVOE>2.0.CO;2
   Lau NC, 2006, ASIAN MONSOON
   Li T, 2005, TERR ATMOS OCEAN SCI, V16, P285, DOI 10.3319/TAO.2005.16.2.285(A)
   Liebmann B, 1996, B AM METEOROL SOC, V77, P1275
   Matsuno T, 1966, J METEOR SOC JAPAN, V44, P25, DOI [DOI 10.2151/JMSJ1965.44.1_25, 10.2151/jmsj1965.44.1_25]
   Mujumdar M, 2007, CLIM DYNAM, V28, P743, DOI 10.1007/s00382-006-0208-7
   NEELIN JD, 1987, MON WEATHER REV, V115, P3, DOI 10.1175/1520-0493(1987)115<0003:MTCBOT>2.0.CO;2
   Pradhan PK, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2011JD015666
   Rajeevan M, 2006, CURR SCI INDIA, V91, P296
   Ramamurthy R., 1969, MONSOONS INDIA SOM 4, V18, P13
   RASMUSSON EM, 1982, MON WEATHER REV, V110, P354, DOI 10.1175/1520-0493(1982)110<0354:VITSST>2.0.CO;2
   Raymond DJ, 2000, J ATMOS SCI, V57, P1286, DOI 10.1175/1520-0469(2000)057<1286:THCAAR>2.0.CO;2
   Saith N, 2006, INT J CLIMATOL, V26, P1361, DOI 10.1002/joc.1317
   Saji NH, 1999, NATURE, V401, P360, DOI 10.1038/43854
   Seo KH, 2007, MON WEATHER REV, V135, P1807, DOI 10.1175/MWR3369.1
   SHUKLA J, 1975, J ATMOS SCI, V32, P503, DOI 10.1175/1520-0469(1975)032<0503:EOASST>2.0.CO;2
   SIKKA DR, 1980, MON WEATHER REV, V108, P1840, DOI 10.1175/1520-0493(1980)108<1840:OTMCZA>2.0.CO;2
   Simmons A, 2007, ECMWF NEWSLETTER, V110, P25
   Smith TM, 2004, J CLIMATE, V17, P2466, DOI 10.1175/1520-0442(2004)017<2466:IEROS>2.0.CO;2
   Soman MK, 1997, Q J ROY METEOR SOC, V123, P309, DOI 10.1002/qj.49712353804
   Sperber KR, 2008, CLIM DYNAM, V31, P345, DOI 10.1007/s00382-008-0367-9
   Sperber KR, 2000, Q J ROY METEOR SOC, V126, P2545, DOI 10.1002/qj.49712656810
   Su H, 2002, J ATMOS SCI, V59, P2694, DOI 10.1175/1520-0469(2002)059<2694:TMFTPD>2.0.CO;2
   Sulochana Gadgil, 2006, Economic and Political Weekly, V41, P4887
   Turner AG, 2012, NAT CLIM CHANGE, V2, P587, DOI 10.1038/NCLIMATE1495
   Webster PJ, 1999, NATURE, V401, P356, DOI 10.1038/43848
   Webster PJ, 1998, J GEOPHYS RES-OCEANS, V103, P14451, DOI 10.1029/97JC02719
   Weng HY, 2009, CLIM DYNAM, V32, P663, DOI 10.1007/s00382-008-0394-6
   Yanai M, 1998, J CLIMATE, V11, P463, DOI 10.1175/1520-0442(1998)011<0463:SAIVOA>2.0.CO;2
   Yeh SW, 2009, NATURE, V461, P511, DOI 10.1038/nature08316
   Yun KS, 2008, J GEOPHYS RES, V113, DOI 10. 1029/2008JD009901
NR 58
TC 2
Z9 2
U1 2
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-8418
EI 1097-0088
J9 INT J CLIMATOL
JI Int. J. Climatol.
PD NOV 15
PY 2013
VL 33
IS 13
BP 2781
EP 2798
DI 10.1002/joc.3627
PG 18
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA 238XR
UT WOS:000325985900002
OA Bronze
DA 2018-12-27
ER

PT J
AU Kong, DY
   Chen, HM
   Chen, WQ
   Liu, SY
   Wang, H
   Wu, TW
   Lu, HD
   Kong, QZ
   Huang, XD
   Lu, ZX
AF Kong, Deyong
   Chen, Heming
   Chen, Weiqun
   Liu, Shuiyi
   Wang, Hui
   Wu, Tangwei
   Lu, Hongda
   Kong, Qingzhi
   Huang, Xiaodong
   Lu, Zhongxin
TI RETRACTED: Gene expression profiling analysis of hepatocellular
   carcinoma (Retracted article. See vol. 20, 31, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Bioinformatics method; Gene expression profiling; Hepatocellular
   carcinoma
ID HEPATITIS-B-VIRUS; LIVER-CANCER; RISK-FACTORS; RECURRENCE; PREDICTION;
   GENDER; MICE; DISEASE; LISTS
AB Background: Primary hepatocellular carcinoma (HCC) is one of the most common malignancies in the world. However, the molecular pathogenesis of HCC is not well-understood, and the prognosis for patients with HCC remains very poor.
   Methods: To disclose detailed genetic mechanisms in hepatocellular carcinoma (HCC) with a view toward development of novel therapeutic targets, we analyzed expression profiles HCCs and their corresponding noncancerous tissues by using bioinformatics method.
   Results: In this paper, we report the identification of genes whose expression has been altered and the changed bio-pathways during hepatocarcinogenesis. Hepatoma cells infect intracellular and intercellular signal transduction through Focal adhesion and cause abnormal expression of important intracellular signaling pathway. In addition, it is worth mentioning that some small molecules still restored to the state similar to normal cells, such as bambuterol and lovastatin. This member gene set would serve as a pool of lead gene targets for the identification and development of novel diagnostic and therapeutic biomarkers to greatly improve the clinical management of HCC patients with different risks of recurrence after curative partial hepatectomy.
   Conclusions: The study has great significance for gene therapy and pharmacotherapy and provides a new treatment entry point and a potential new clinical drug for HCC patients.
C1 [Kong, Deyong; Wang, Hui; Wu, Tangwei; Lu, Zhongxin] Cent Hosp Wuhan, Dept Lab Med, Wuhan 430014, Peoples R China.
   [Chen, Heming] Cent S Univ, Xiangya Hosp 2, Dept Cardiovasc & Thorac Surg, Changsha 410078, Hunan, Peoples R China.
   [Chen, Weiqun; Kong, Qingzhi; Huang, Xiaodong; Lu, Zhongxin] Cent Hosp Wuhan, Dept Cent Lab, Wuhan 430014, Peoples R China.
   [Chen, Weiqun; Liu, Shuiyi; Lu, Hongda; Kong, Qingzhi; Huang, Xiaodong; Lu, Zhongxin] Canc Res Inst Wuhan, Wuhan 430014, Peoples R China.
   [Lu, Hongda; Kong, Qingzhi] Cent Hosp Wuhan, Dept Oncol, Wuhan 430014, Peoples R China.
RP Huang, XD (reprint author), Cent Hosp Wuhan, Dept Cent Lab, Wuhan 430014, Peoples R China.
EM huangxiaodong88@163.com; lzx71@yahoo.com
FU National Natural Sciences Foundation of China [81071921, 81372325];
   National High Technology Research and Development Program (863 Program),
   China [2011AA02A111]; Natural Sciences Foundation of Hubei Province
   [2012FFB05905]; Yellow Crane talent plan Foundation; Wuhan Public Health
   Bureau [WX11A03]
FX This project was supported by grants from the National Natural Sciences
   Foundation of China (81071921; 81372325), the National High Technology
   Research and Development Program (863 Program), China (2011AA02A111),
   the Natural Sciences Foundation of Hubei Province (2012FFB05905), The
   Yellow Crane talent plan Foundation and the research fund of the Wuhan
   Public Health Bureau (WX11A03).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Ashizawa Tatsuto, 2005, Gastric Cancer, V8, P124, DOI 10.1007/s10120-005-0315-x
   Bolondi L, 2001, GUT, V48, P251, DOI 10.1136/gut.48.2.251
   FARINATI F, 1990, J HEPATOL, V11, P297, DOI 10.1016/0168-8278(90)90211-9
   Gentleman R, 2005, STAT BIOL HLTH SERIE
   Ghebranious N, 1998, HEPATOLOGY, V27, P383, DOI 10.1002/hep.510270211
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Iizuka N, 2003, LANCET, V361, P923, DOI 10.1016/S0140-6736(03)12775-4
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kurokawa Y, 2004, J HEPATOL, V41, P284, DOI 10.1016/j.jhep.2004.04.031
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375
   Nakatani T, 2001, JPN J CANCER RES, V92, P249, DOI 10.1111/j.1349-7006.2001.tb01089.x
   Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485
   Porta C, 2008, ANN ONCOL, V19, P353, DOI 10.1093/annonc/mdm448
   R-Development Core Team, 2010, R LANG ENV STAT COMP
   Rogers AB, 2007, CANCER RES, V67, P11536, DOI 10.1158/0008-5472.CAN-07-1479
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Stuver SO, 1998, SEMIN CANCER BIOL, V8, P299, DOI 10.1006/scbi.1998.0079
   Thomas MB, 2005, J CLIN ONCOL, V23, P2892, DOI 10.1200/JCO.2005.03.196
   TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501
   Wang SM, 2007, CLIN CANCER RES, V13, P6275, DOI 10.1158/1078-0432.CCR-06-2236
   Wen ZN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018278
   Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843
   YEH FS, 1989, CANCER RES, V49, P2506
   ZAMAN SN, 1985, LANCET, V1, P1357
NR 27
TC 3
Z9 3
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD NOV 14
PY 2013
VL 18
AR 44
DI 10.1186/2047-783X-18-44
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 273LV
UT WOS:000328537300002
PM 24229431
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, N
   Mo, YX
   Ching, WY
AF Li, Neng
   Mo, Yuxiang
   Ching, Wai-Yim
TI RETRACTED: The bonding, charge distribution, spin ordering, optical, and
   elastic properties of four MAX phases Cr(2)AX (A=Al or Ge, X=C or N):
   From density functional theory study (Retracted article. See vol. 115,
   109901, 2014)
SO JOURNAL OF APPLIED PHYSICS
LA English
DT Article; Retracted Publication
ID TOTAL-ENERGY CALCULATIONS; WAVE BASIS-SET; AB-INITIO;
   MECHANICAL-PROPERTIES; CR2GEC; METALS; MO; CR
AB In this work, we assess a full spectrum of properties (chemical bonding, charge distribution, spin ordering, optical, and elastic properties) of Cr(2)AC (A = Al, Ge) and their hypothetical nitride counterparts Cr(2)AN (A = Al, Ge) based on density functional theory calculations. The calculated total energy values indicate that a variety of spin ordering of these four compounds depending on interlayer-interactions between M-A and M-X within the sublattice, which is supported by bonding analysis. MAX phase materials are discovered to possess exotic magnetic properties which indicates that these materials could serve as promising candidates for novel layered magnetic materials for various electronic and spintronic applications. Further analysis of optical properties for two polarization vectors of Cr(2)AX shows that the reflectivity is high in the visible-ultraviolet region up to similar to 15 eV suggesting Cr(2)AX as a promising candidate for use as a coating material. The elastic coefficients (C-ij) and bulk mechanical properties [bulk modulus (K), shear modulus (G), Young's modulus (E), Poisson's ratio (eta), and Pugh ratio (G/K)] of these four Cr(2)AX compounds are also calculated and analyzed, which pave the way to predict or design new MAX phases that are less brittle or tougher by having a lower G/K value or higher eta. (C) 2013 AIP Publishing LLC.
C1 [Li, Neng] Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Photovolta & Solar Energy, Shenzhen 518055, Peoples R China.
   [Li, Neng; Mo, Yuxiang; Ching, Wai-Yim] Univ Missouri, Dept Phys & Astron, Kansas City, MO 64110 USA.
RP Li, N (reprint author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Photovolta & Solar Energy, Shenzhen 518055, Peoples R China.
EM lineng@umkc.edu
OI Li, Neng/0000-0001-9633-6702
FU US Department of Energy (DOE)-National Energy Technology Laboratory
   [DE-FE0005865]; Natural Science Foundation of Shenzhen
   [JCYJ20130402113127530]; Office of Basic Science of DOE
   [DE-AC03-76SF00098]
FX This work was supported by the US Department of Energy (DOE)-National
   Energy Technology Laboratory under Grant No. DE-FE0005865. This work was
   also supported by the Natural Science Foundation of Shenzhen under Grant
   No. JCYJ20130402113127530. This research used the resources of the
   National Energy Research Scientific Computing Center supported by the
   Office of Basic Science of DOE under Contract No. DE-AC03-76SF00098.
CR Barsoum MW, 2011, J AM CERAM SOC, V94, P4123, DOI 10.1111/j.1551-2916.2011.04886.x
   Barsoum MW, 2011, ANNU REV MATER RES, V41, P195, DOI 10.1146/annurev-matsci-062910-100448
   Blaha P., 2001, WIEN2K AUGMENTED PLA
   Born M., 1954, DYNAMICAL THEORY CRY
   Bouhemadou A, 2009, APPL PHYS A-MATER, V96, P959, DOI 10.1007/s00339-009-5106-5
   Cabioch T, 2013, J EUR CERAM SOC, V33, P897, DOI 10.1016/j.jeurceramsoc.2012.10.008
   Ching W. Y., 2012, ELECT STRUCTURE METH
   Ching WY, 2013, J AM CERAM SOC, V96, P2292, DOI 10.1111/jace.12376
   CHING WY, 1990, J AM CERAM SOC, V73, P3135, DOI 10.1111/j.1151-2916.1990.tb06430.x
   Cover MF, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/30/305403
   Dahlqvist M, 2013, J APPL PHYS, V113, DOI 10.1063/1.4808239
   Dahlqvist M, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.220403
   Dahlqvist M, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.220102
   Drulis MK, 2008, J APPL PHYS, V104, DOI 10.1063/1.2956511
   Eklund P, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.035502
   Eklund P, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.075424
   Eklund P, 2010, THIN SOLID FILMS, V518, P1851, DOI 10.1016/j.tsf.2009.07.184
   Greaves GN, 2011, NAT MATER, V10, P823, DOI [10.1038/NMAT3134, 10.1038/nmat3134]
   Haddad N, 2008, J APPL PHYS, V104, DOI 10.1063/1.2960340
   HILL R, 1952, P PHYS SOC LOND A, V65, P349, DOI 10.1088/0370-1298/65/5/307
   Ingason AS, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.195502
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558
   Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0
   Lane NJ, 2011, J AM CERAM SOC, V94, P3473, DOI 10.1111/j.1551-2916.2011.04609.x
   Mattesini M, 2013, J PHYS-CONDENS MAT, V25, DOI 10.1088/0953-8984/25/3/035601
   Mo YX, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.165122
   Mockute A, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.094113
   MULLIKEN RS, 1955, J CHEM PHYS, V23, P1841, DOI 10.1063/1.1740589
   NIELSEN OH, 1983, PHYS REV LETT, V50, P697, DOI 10.1103/PhysRevLett.50.697
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Phatak NA, 2009, J ALLOY COMPD, V475, P629, DOI 10.1016/j.jallcom.2008.07.102
   Ramzan M, 2012, SOLID STATE COMMUN, V152, P1147, DOI 10.1016/j.ssc.2012.03.044
   Ramzan M, 2011, PHYS STATUS SOLIDI-R, V5, P122, DOI 10.1002/pssr.201004508
   Reuss A., 1929, MATH MECH, V9, P49
   Savin A, 1997, ANGEW CHEM INT EDIT, V36, P1809
   Scabarozi TH, 2012, SCRIPTA MATER, V66, P85, DOI 10.1016/j.scriptamat.2011.10.001
   Sun ZM, 2005, J PHYS-CONDENS MAT, V17, pL15, DOI 10.1088/0953-8984/17/2/L02
   Voigt W, 1928, LEHRBUCH KRISTALLPYS
   Yang J. Y., 2009, ANN REV MATER RES, V39, P415
   Zhou W, 2009, J APPL PHYS, V106, DOI 10.1063/1.3187912
NR 41
TC 6
Z9 6
U1 3
U2 32
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0021-8979
EI 1089-7550
J9 J APPL PHYS
JI J. Appl. Phys.
PD NOV 14
PY 2013
VL 114
IS 18
AR 183503
DI 10.1063/1.4829485
PG 8
WC Physics, Applied
SC Physics
GA 255TB
UT WOS:000327261800014
DA 2018-12-27
ER

PT J
AU Qin, HY
   Qu, CY
   Yamaza, T
   Yang, RL
   Lin, X
   Duan, XY
   Akiyama, K
   Liu, Y
   Zhang, QZ
   Chen, CD
   Chen, YB
   Qi, HH
   Feng, XH
   Le, AD
   Shi, ST
AF Qin, Haiyan
   Qu, Cunye
   Yamaza, Takayoshi
   Yang, Ruili
   Lin, Xia
   Duan, Xue-Yan
   Akiyama, Kentaro
   Liu, Yi
   Zhang, Qunzhou
   Chen, Chider
   Chen, Yibu
   Qi, Hank Heng
   Feng, Xin-Hua
   Le, Anh D.
   Shi, Songtao
TI RETRACTED: Ossifying Fibroma Tumor Stem Cells Are Maintained by
   Epigenetic Regulation of a TSP1/TGF-beta/SMAD3 Autocrine Loop (Retracted
   article. See vol. 16, pg. 569, 2015)
SO CELL STEM CELL
LA English
DT Article; Retracted Publication
ID TGF-BETA; BONE-FORMATION; THROMBOSPONDIN-1; ACTIVATION; MECHANISMS;
   GROWTH; PROLIFERATION; METHYLATION; CANCER; NOTCH
AB Abnormal stem cell function makes a known contribution to many malignant tumors, but the role of stem cells in benign tumors is not well understood. Here, we show that ossifying fibroma (OF) contains a stem cell population that resembles mesenchymal stem cells (OFMSCs) and is capable of generating OF-like tumor xenografts. Mechanistically, OFMSCs show enhanced TGF-beta signaling that induces aberrant proliferation and deficient osteogenesis via Notch and BMP signaling pathways, respectively. The elevated TGF-beta activity is tightly regulated by JHDM1D-mediated epigenetic regulation of thrombospondin-1 (TSP1), forming a JHDM1D/TSP1/TGF-beta/SMAD3 autocrine loop. Inhibition of TGF-beta signaling in OFMSCs can rescue their abnormal osteogenic differentiation and elevated proliferation rate. Furthermore, chronic activation of TGF-beta can convert normal MSCs into OF-like MSCs via establishment of this JHDM1D/TSP1/TGF-beta/SMAD3 autocrine loop. These results reveal that epigenetic regulation of TGF-beta signaling in MSCs governs the benign tumor phenotype in OF and highlight TGF-beta signaling as a candidate therapeutic target.
C1 [Qin, Haiyan; Qu, Cunye; Yamaza, Takayoshi; Yang, Ruili; Akiyama, Kentaro; Liu, Yi; Chen, Chider; Shi, Songtao] Univ So Calif, Herman Ostrow Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA.
   [Lin, Xia; Feng, Xin-Hua] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
   [Duan, Xue-Yan; Feng, Xin-Hua] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Zhang, Qunzhou; Le, Anh D.] Univ Penn, Dept Oral & Maxillofacial Surg & Pharmacol, Sch Dent Med & Penn Med, Hosp Univ Penn, Philadelphia, PA 19104 USA.
   [Chen, Yibu] Univ So Calif, Keck Sch Med, Norris Med Lib, Los Angeles, CA 90033 USA.
   [Qi, Hank Heng] Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA.
RP Shi, ST (reprint author), Univ So Calif, Herman Ostrow Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA.
EM songtaos@usc.edu
FU National Institute of Dental and Craniofacial Research; National
   Institutes of Health, Department of Health and Human Services
   [R01DE017449, R01 DE019932]; California Institute for Regenerative
   Medicine [RN1-00572]
FX We thank Yan Jin of the Fourth Military University for assistance with
   microarrays. We appreciate the assistance from Drs. Diana V. Messadi and
   Russell Christensen of UCLA in the confirmation of diagnosis for all OF
   samples used in this study. This work was supported by grants from the
   National Institute of Dental and Craniofacial Research, the National
   Institutes of Health, Department of Health and Human Services
   (R01DE017449 and R01 DE019932 to S.S.) and a grant from the California
   Institute for Regenerative Medicine (RN1-00572 to S.S.).
CR Bechtel W, 2010, NAT MED, V16, P544, DOI 10.1038/nm.2135
   Boukamp P, 1997, J CELL PHYSIOL, V173, P256, DOI 10.1002/(SICI)1097-4652(199711)173:2<256::AID-JCP31>3.0.CO;2-B
   Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Colmenero-Ruiz C, 2011, J ORAL MAXIL SURG, V69, P2055, DOI 10.1016/j.joms.2010.10.001
   Engin F, 2010, BONE, V46, P274, DOI 10.1016/j.bone.2009.05.027
   Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501
   Gondivkar SM, 2011, ORAL ONCOL, V47, P804, DOI 10.1016/j.oraloncology.2011.06.014
   Ikegaki N, 2013, P NATL ACAD SCI USA, V110, P6097, DOI 10.1073/pnas.1118262110
   Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   MacDonald-Jankowski DS, 2009, DENTOMAXILLOFAC RAD, V38, P495, DOI 10.1259/dmfr/70933621
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Pedrozo HA, 1999, ENDOCRINOLOGY, V140, P5806, DOI 10.1210/en.140.12.5806
   Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011
   PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P49, DOI 10.1002/jbmr.5650050109
   Pimenta FJ, 2006, ORAL ONCOL, V42, P735, DOI 10.1016/j.oraloncology.2005.11.019
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qi HH, 2010, NATURE, V466, P503, DOI 10.1038/nature09261
   Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035
   Roelen Bernard A J, 2003, J Orthop Sci, V8, P740, DOI 10.1007/s00776-003-0702-2
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Uccelli A, 2007, TRENDS IMMUNOL, V28, P219, DOI 10.1016/j.it.2007.03.001
   Valdez JM, 2012, CELL STEM CELL, V11, P676, DOI 10.1016/j.stem.2012.07.003
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343
   Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798
   Williams JP, 2008, CELL STEM CELL, V3, P658, DOI 10.1016/j.stem.2008.10.003
   Xu Q, 2009, BRIT J CANCER, V101, P303, DOI 10.1038/sj.bjc.6605142
   Yamaza T, 2011, J DENT RES, V90, P317, DOI 10.1177/0022034510387796
   Zama M, 2004, PLAST RECONSTR SURG, V113, P970, DOI 10.1097/01.PRS.0000105629.56850.AA
   Zhang QZ, 2009, PLOS ONE, V4, pA192, DOI 10.1371/journal.pone.0007798
NR 41
TC 7
Z9 8
U1 2
U2 27
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD NOV 7
PY 2013
VL 13
IS 5
BP 577
EP 589
DI 10.1016/j.stem.2013.08.010
PG 13
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VX
UT WOS:000329571500010
PM 24209761
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Nassirpour, R
   Mehta, PP
   Yin, MJ
AF Nassirpour, Rounak
   Mehta, Pramod P.
   Yin, Min-Jean
TI RETRACTED: miR-122 Regulates Tumorigenesis in Hepatocellular Carcinoma
   by Targeting AKT3 (Retracted article. See vol. 12, art no e0184778,
   2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID HEPATITIS-C VIRUS; LIVER-SPECIFIC MICRORNA; HUMAN CANCERS; EXPRESSION;
   GENOMICS; KINASE; CELLS
AB MicroRNAs (miRNAs) have been implicated in the orchestration of diverse cellular processes including differentiation, proliferation, and apoptosis and are believed to play pivotal roles as oncogenes and tumor suppressors. miR-122, a liver specific miRNA, is significantly down-regulated in most hepatocellular carcinomas (HCCs) but its role in tumorigenesis remains poorly understood. Here we identify AKT3 as a novel and direct target of miR-122. Restoration of miR-122 expression in HCC cell lines decreases AKT3 levels, inhibits cell migration and proliferation, and induces apoptosis. These anti-tumor phenotypes can be rescued by reconstitution of AKT3 expression indicating the essential role of AKT3 in miR-122 mediated HCC transformation. In vivo, restoration of miR-122 completely inhibited xenograft growth of HCC tumor in mice. Our data strongly suggest that miR-122 is a tumor suppressor that targets AKT3 to regulate tumorigenesis in HCCs and a potential therapeutic candidate for liver cancer.
C1 [Nassirpour, Rounak; Mehta, Pramod P.; Yin, Min-Jean] Pfizer Worldwide Res & Dev, Oncol Res, San Diego, CA USA.
RP Yin, MJ (reprint author), Pfizer Worldwide Res & Dev, Oncol Res, San Diego, CA USA.
EM min-jean.yin@pfizer.com
FU Pfizer Inc.
FX All authors are current full time employees of Pfizer Inc., whose
   company funded this study. There are no patents, products in development
   or marked products to declare. This does not alter the authors'
   adherence to all the PLOS ONE policies on sharing data and materials.
CR Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chang JH, 2008, J VIROL, V82, P8215, DOI 10.1128/JVI.02575-07
   Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004
   Hsu SH, 2012, J CLIN INVEST, V122, P2871, DOI 10.1172/JCI63539
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Stambolic V, 2006, TRENDS CELL BIOL, V16, P461, DOI 10.1016/j.tcb.2006.07.001
   Thorgeirsson SS, 2006, HEPATOLOGY, V43, pS145, DOI 10.1002/hep.21063
   Tsai WC, 2012, J CLIN INVEST, V122, P2884, DOI 10.1172/JCI63455
   Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806
   Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158
   Xu H, 2010, HEPATOLOGY, V52, P1431, DOI 10.1002/hep.23818
   Xu YM, 2011, CANCER LETT, V310, P160, DOI 10.1016/j.canlet.2011.06.027
NR 29
TC 47
Z9 52
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 7
PY 2013
VL 8
IS 11
AR e79655
DI 10.1371/journal.pone.0079655
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 254KD
UT WOS:000327162900043
PM 24244539
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ciaudo, C
   Jay, F
   Okamoto, I
   Chen, CJ
   Sarazin, A
   Servant, N
   Barillot, E
   Heard, E
   Voinnet, O
AF Ciaudo, Constance
   Jay, Florence
   Okamoto, Ikuhiro
   Chen, Chong-Jian
   Sarazin, Alexis
   Servant, Nicolas
   Barillot, Emmanuel
   Heard, Edith
   Voinnet, Olivier
TI RETRACTED: RNAi-Dependent and Independent Control of LINE1 Accumulation
   and Mobility in Mouse Embryonic Stem Cells (Retracted article. See vol.
   9, e1005519, 2015)
SO PLOS GENETICS
LA English
DT Article; Retracted Publication
ID X-CHROMOSOME INACTIVATION; SMALL INTERFERING RNAS; L1
   RETROTRANSPOSITION; DNA METHYLATION; CULTURED-CELLS; HETEROCHROMATIN
   FORMATION; ARGONAUTE PROTEINS; GENE-EXPRESSION; SELF-RENEWAL; DICER
AB In most mouse tissues, long-interspersed elements-1 (L1s) are silenced via methylation of their 5'-untranslated regions (5'-UTR). A gradual loss-of-methylation in pre-implantation embryos coincides with L1 retrotransposition in blastocysts, generating potentially harmful mutations. Here, we show that Dicer- and Ago2-dependent RNAi restricts L1 accumulation and retrotransposition in undifferentiated mouse embryonic stem cells (mESCs), derived from blastocysts. RNAi correlates with production of Dicer-dependent 22-nt small RNAs mapping to overlapping sense/antisense transcripts produced from the L1 5'-UTR. However, RNA-surveillance pathways simultaneously degrade these transcripts and, consequently, confound the anti-L1 RNAi response. In Dicer(-/-) mESC complementation experiments involving ectopic Dicer expression, L1 silencing was rescued in cells in which microRNAs remained strongly depleted. Furthermore, these cells proliferated and differentiated normally, unlike their non-complemented counterparts. These results shed new light on L1 biology, uncover defensive, in addition to regulatory roles for RNAi, and raise questions on the differentiation defects of Dicer(-/-) mESCs.
C1 [Ciaudo, Constance; Jay, Florence; Sarazin, Alexis; Voinnet, Olivier] Swiss Fed Inst Technol, Dept Biol, Chair RNA Biol, Zurich, Switzerland.
   [Ciaudo, Constance; Okamoto, Ikuhiro; Chen, Chong-Jian; Heard, Edith] Inst Curie, CNRS, UMR3215, F-75231 Paris, France.
   [Jay, Florence; Voinnet, Olivier] Univ Zurich, Life Sci Zurich Grad Sch, Plant Sci program, Zurich, Switzerland.
   [Chen, Chong-Jian; Servant, Nicolas; Barillot, Emmanuel] Inst Curie, Paris, France.
   [Servant, Nicolas; Barillot, Emmanuel] INSERM, U900, Paris, France.
   [Servant, Nicolas; Barillot, Emmanuel] Mines ParisTech, Fontainebleau, France.
RP Ciaudo, C (reprint author), Swiss Fed Inst Technol, Dept Biol, Chair RNAi & Genome Integr, Zurich, Switzerland.
EM voinneto@ethz.ch
RI Heard, Edith/D-7197-2017; Ciaudo, Constance/A-2014-2012
OI Heard, Edith/0000-0001-8052-7117; Ciaudo, Constance/0000-0002-0857-4506;
   BARILLOT, Emmanuel/0000-0003-2724-2002; Servant,
   Nicolas/0000-0003-1678-7410; Sarazin, Alexis/0000-0002-1869-5192
FU ANR grant "RNA ES"; ERC [ERC-210890]; Prix Liliane Bettencourt for Life
   Sciences; Federation of European Biochemical Societies
FX This work was supported by the ANR grant "RNA ES"; to both EH and OV.
   OV's laboratory was further supported by an ERC Young Investigator Award
   (Grant ERC-210890 "Frontiers of RNAi") and Prix Liliane Bettencourt for
   Life Sciences. EH is a member of the European Network of excellence
   "Epigenesis". CC was supported by a post-doctoral fellowship from the
   Federation of European Biochemical Societies. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Arand J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002750
   Aravin AA, 2008, MOL CELL, V31, P785, DOI 10.1016/j.molcel.2008.09.003
   Babiarz JE, 2008, GENE DEV, V22, P2773, DOI 10.1101/gad.1705308
   Beck CR, 2011, ANNU REV GENOM HUM G, V12, P187, DOI 10.1146/annurev-genom-082509-141802
   Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Billy E, 2001, PNAS, V98, P11443
   Calabrese JM, 2007, P NATL ACAD SCI USA, V104, P18097, DOI 10.1073/pnas.0709193104
   Chen C, 2012, BIOINFORMATICS, V28, P3
   Chow JC, 2010, CELL, V141, P956, DOI 10.1016/j.cell.2010.04.042
   Ciaudo C, 2006, PLOS GENET, V2, P874, DOI 10.1371/journal.pgen.0020094
   Derrien B, 2012, P NATL ACAD SCI USA, V109, P15942, DOI 10.1073/pnas.1209487109
   Dueck A, 2012, NUCLEIC ACIDS RES, V40, P9850, DOI 10.1093/nar/gks705
   Fagegaltier D, 2009, P NATL ACAD SCI USA, V106, P21258, DOI 10.1073/pnas.0809208105
   Goodier JL, 2001, GENOME RES, V11, P1677, DOI 10.1101/gr.198301
   Gruntman E, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-371
   Gy I, 2007, PLANT CELL, V19, P3451, DOI 10.1105/tpc.107.055319
   Henderson IR, 2010, EPIGENETICS-US, V5, P47, DOI 10.4161/epi.5.1.10560
   HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0
   Houseley J, 2009, CELL, V136, P763, DOI 10.1016/j.cell.2009.01.019
   HOWLETT SK, 1991, DEVELOPMENT, V113, P119
   Hu QD, 2012, NAT STRUCT MOL BIOL, V19, P1168, DOI 10.1038/nsmb.2400
   Ip J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002919
   Johnston M, 2010, MOL BIOL CELL, V21, P1462, DOI 10.1091/mbc.E09-10-0885
   Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505
   Kano H, 2009, GENE DEV, V23, P1303, DOI 10.1101/gad.1803909
   Kazazian H.H, 2011, MOBILE DNA FINDING T
   Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608
   Maillart P, 2013, ANTIVIRAL R IN PRESS
   MATLIK K, 2006, J BIOMED BIOTECHNOL, P1
   Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007
   Moreno AB, 2013, NUCLEIC ACIDS RES, V41, P4699, DOI 10.1093/nar/gkt152
   Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102
   Naas TP, 1998, EMBO J, V17, P590, DOI 10.1093/emboj/17.2.590
   Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418
   Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022
   Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032
   PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133
   Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399
   Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0
   Prak ETL, 2003, P NATL ACAD SCI USA, V100, P1832, DOI 10.1073/pnas.0337627100
   Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230
   Rosenbloom KR, 2012, NUCLEIC ACIDS RES, V41, P56
   Slotkin RK, 2009, CELL, V136, P461, DOI 10.1016/j.cell.2008.12.038
   Smibert P, 2013, HOMEOSTATIC CONTROL, P1
   Smith ZD, 2012, NATURE, V484, P339, DOI 10.1038/nature10960
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   Su H, 2009, GENE DEV, V23, P304, DOI 10.1101/gad.1749809
   SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718
   Tam OH, 2008, NATURE, V453, P534, DOI 10.1038/nature06904
   Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299
   Teixeira FK, 2009, SCIENCE, V323, P1600, DOI 10.1126/science.1165313
   Tsumura A, 2006, GENES CELLS, V11, P805, DOI 10.1111/j.1365-2443.2006.00984.x
   Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064
   Wang DM, 2012, GENE DEV, V26, P693, DOI 10.1101/gad.182758.111
   Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969
   Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908
   WENG A, 1995, DEVELOPMENT, V121, P2853
   Xiao S, 2012, CELL, V149, P1381, DOI 10.1016/j.cell.2012.04.029
   Xie Y, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1076
   Yamanaka S, 2013, NATURE, V493, P557, DOI 10.1038/nature11716
   Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141
   Zaratiegui M, 2007, CELL, V128, P763, DOI 10.1016/j.cell.2007.02.016
NR 63
TC 26
Z9 26
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7390
EI 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD NOV
PY 2013
VL 9
IS 11
AR e1003791
DI 10.1371/journal.pgen.1003791
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 299BG
UT WOS:000330369000001
PM 24244175
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Blatt, SH
AF Blatt, Samantha H.
TI RETRACTED: Joined at the Hip? A Paleoepidemiological Study of
   Developmental Dysplasia of the Hip and Its Relation to Swaddling
   Practices Among Indigenous Peoples of North America (Retracted article.
   See vol. 26, pg. 290, 2014)
SO AMERICAN JOURNAL OF HUMAN BIOLOGY
LA English
DT Article; Retracted Publication
ID CONGENITAL DISLOCATION; SEASONAL-VARIATION; NATURAL-HISTORY; OS PUBIS;
   POPULATION; INSTABILITY; DISEASE; ABNORMALITIES; EPIDEMIOLOGY; PREGNANCY
AB ObjectivesClinical prevalence of developmental dysplasia of the hip (DDH) is the highest among modern indigenous populations of North America, yet no systematic study of the paleoepidemiology of this group exists. This study discusses the skeletal criteria, epidemiology, pathophysiology, and risk factors for DDH. A range of cases of DDH from an archaeological Native American population are described, and the clinical and prehistoric prevalence of DDH among indigenous populations of North America are calculated and discussed within a biocultural perspective.
   MethodsPelves of 390 adults from the Late Prehistoric (1490 BP70) Buffalo site, West Virginia were examined for DDH. Morphology of true and false acetabula was classified and other changes of the pelvis, lower limb, and spine were noted along with cranial deformation, providing evidence of infant restriction. Prevalence of DDH among living and archaeological indigenous peoples of North America were calculated and compared.
   ResultsDDH was identified in eighteen adults from Buffalo, resulting in a prevalence of 46.15, within the range reported in modern indigenous groups in North America. However, there is a significant difference between the DDH prevalence in prehistory and today in the target population.
   ConclusionsIndigenous peoples of North America have the highest reported global prevalence of DDH today and in prehistory. The etiology of DDH suggests that components of both genetic predisposition and swaddling practices have combined to create a high-risk environment for the development of DDH, contributing to its high prevalence within archaeological populations, like Buffalo, and modern Native American/Aboriginal groups within North America. Am. J. Hum. Biol. 25:821-834, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 Boise State Univ, Dept Anthropol, Boise, ID 83725 USA.
RP Blatt, SH (reprint author), Boise State Univ, Dept Anthropol, 1910 Univ Dr, Boise, ID 83725 USA.
EM samanthablatt@boisetate.edu
CR Abd el-Kader Shaheen M, 1989, J R Coll Surg Edinb, V34, P85
   Abdinejad F, 1996, MED J ISLAMIC REPUB, V9, P275
   AKSOY M, 1967, BLUT, V15, P153, DOI 10.1007/BF01633414
   Andersson JE, 2002, J PEDIATR ORTHOPED, V22, P88, DOI 10.1097/00004694-200201000-00019
   Ando M, 1993, PREVENTION CONGENITA
   ANDREN LARS, 1963, ACTA ORTHOPAED SCAND, V33, P127, DOI 10.3109/17453676308999841
   Aufderheide AC, 1997, CAMBRIDGE ENCY HUMAN
   BARLOW TG, 1962, J BONE JOINT SURG BR, V44, P292
   Blatt SH, 2012, AM J PHYS ANTHROPOL, V147, P101
   Blatt SH, 2010, AM J PHYS ANTHROPOL, P69
   Blatt SH, 2013, THESIS OHIO STATE U
   Blondiaux J, 1991, INT J OSTEOARCHAEOL, V1, P203
   BOWER C, 1987, CLIN ORTHOP RELAT R, P37
   Buikstra J. E., 1994, ARKANSAS ARCHAEOLOGI
   Caiola Enrico, 2007, J Pediatr, V150, P320, DOI 10.1016/j.jpeds.2006.12.029
   CARR AJ, 1993, J BONE JOINT SURG BR, V75, P76
   Cederholm M, 2005, BJOG-INT J OBSTET GY, V112, P394, DOI 10.1111/j.1471-0528.2005.00413.x
   Ceylaner G, 2008, ACTA ORTHOP TRAUMATO, V42, P289, DOI 10.3944/AOTT.2008.289
   Chan A, 1999, LANCET, V354, P1514, DOI 10.1016/S0140-6736(98)12469-8
   Chan A, 1997, ARCH DIS CHILD, V76, pF94, DOI 10.1136/fn.76.2.F94
   CLABEAUX MS, 1977, B NEW YORK ACAD MED, V53, P338
   CLAUSEN I, 1988, ACTA OBSTET GYN SCAN, V67, P595, DOI 10.3109/00016348809004270
   COLEMAN SS, 1968, CLIN ORTHOP RELAT R, P179
   Coodin FJ, 1975, ANN R COLL PHYS SURG, V8, P69
   Cook R, 2007, SUNWATCH FORT ANCIEN
   CORRIGAN C, 1950, CAN MED ASSOC J, V62, P535
   Cvjeticanin S, 2005, Genetika, V41, P1142
   Dai J, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2540
   Dezateux C, 2007, LANCET, V369, P1541, DOI 10.1016/S0140-6736(07)60710-7
   Dogruel H, 2008, INT ORTHOP, V32, P415, DOI 10.1007/s00264-007-0333-x
   Drooker P, 2000, E FORT ANCIENT MORTU
   Drusini A, 1987, INT J ANTHR, V2, P247
   Feldman G, 2010, CLIN ORTHOP RELAT R, V468, P337, DOI 10.1007/s11999-009-1073-6
   Forst J, 1997, ARCH ORTHOP TRAUM SU, V116, P209, DOI 10.1007/s004020050100
   Franco P, 2005, PEDIATRICS, V115, P1307, DOI 10.1542/peds.2004-1460
   Ghibely A, 1990, Acta Orthop Belg, V56, P37
   GOLDSTEIN MS, 1957, AM J PHYS ANTHROPOL, V15, P299, DOI 10.1002/ajpa.1330150311
   Gregg J B, 1981, Plains Anthropol, V26, P287
   Gulati V, 2013, WORLD J ORTHOP, V4, P32, DOI 10.5312/wjo.v4.i2.32
   GUNTHER A, 1993, PUBLIC HEALTH, V107, P9, DOI 10.1016/S0033-3506(05)80487-1
   HADLOW V, 1988, J BONE JOINT SURG BR, V70, P740
   Hanson LH, 1975, 5 W VIRG GEOL EC SUR
   Harcke HT, 1999, PEDIATRICS, V103, P152, DOI 10.1542/peds.103.1.152
   Hartig-Andreasen C, 2013, ACTA ORTHOP, V84, P60, DOI 10.3109/17453674.2013.765626
   HEIKKILA E, 1984, ACTA ORTHOP SCAND, V55, P125, DOI 10.3109/17453678408992322
   Helmsted A, 1983, J PED ORTHOP, V3, P491
   HINDERAKER T, 1994, ACTA ORTHOP SCAND, V65, P239, DOI 10.3109/17453679408995446
   HOAGLUND FT, 1981, INT ORTHOP, V4, P243
   Holck P, 1991, INT J OSTEOARCHAEOL, V1, P199
   Hooton EA, 1920, PAP PEABODY MUS, V8, P131
   Hooton EA, 1930, INDIANS PECOS PUEBLO, P530
   HOUSTON CS, 1979, J CAN ASSOC RADIOL, V30, P218
   Houston CS, 1988, MUSK OX, V36, P5
   ISHIDA K, 1977, CLIN ORTHOP RELAT R, P167
   Ishikawa N, 2008, J PEDIATR ORTHOPED, V28, P432, DOI 10.1097/BPO.0b013e318168d167
   Jacobsen S, 2006, CLIN ORTHOP RELAT R, P239, DOI 10.1097/01.blo.0000201151.91206.50
   Jacobsen S, 2006, ACTA ORTHOP, V77, P8
   JENSEN BA, 1986, ACTA ORTHOP SCAND, V57, P362, DOI 10.3109/17453678608994412
   Jiang Jun, 2003, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V20, P193
   Kamath SU, 2004, J PEDIATR ORTHOPED, V24, P265, DOI 10.1097/01241398-200405000-00005
   Karp HN, 2008, PEDIATRICS, V121, P1075, DOI 10.1542/peds.2008-0299
   KATZ Z, 1985, OBSTET GYNECOL, V65, P775
   KELSEY JL, 1977, INT J EPIDEMIOL, V6, P269, DOI 10.1093/ije/6.3.269
   KRAUS BS, 1957, J BONE JOINT SURG AM, V39, P448
   Kremli MK, 2003, SAUDI MED J, V24, P1118
   Krogman WM, 1986, HUMAN SKELETON FOREN
   KUTLU A, 1992, J PEDIATR ORTHOPED, V12, P598
   LAHR MM, 1992, J ARCHAEOL SCI, V19, P639, DOI 10.1016/0305-4403(92)90034-Z
   LARCHET M, 1994, ARCH PEDIATRIE, V1, P1093
   Lehtola VP, 2004, SAMI PEOPLE: TRADITIONS IN TRANSITION, P1
   LIPTON EL, 1965, PEDIATRICS, V35, P521
   Loder Randall T, 2011, ISRN Orthop, V2011, P238607, DOI 10.5402/2011/238607
   LOVEJOY CO, 1985, AM J PHYS ANTHROPOL, V68, P15, DOI 10.1002/ajpa.1330680103
   LOVELAND CJ, 1985, PLAINS ANTHROPOL, V30, P29
   Lowry CA, 2005, J BONE JOINT SURG BR, V87B, P984, DOI 10.1302/0301-620X.87B7.16073
   MacFarlane A, 1980, J MATERN CHILD HLTH, P13
   MacLennan AH, 1997, ACTA OBSTET GYN SCAN, V76, P760, DOI 10.3109/00016349709024343
   Mafart B, 2007, INT J OSTEOARCHAEOL, V17, P26, DOI 10.1002/oa.857
   Mahan ST, 2008, PEDIATRICS, V121, P177, DOI 10.1542/peds.2007-1618
   Mamouri GH, 2004, INTERNET J PED NEONA, V4
   McPherron A, 1967, ANTHR PAP MUS ANTHR, V30, P214
   MEINDL RS, 1985, AM J PHYS ANTHROPOL, V68, P29, DOI 10.1002/ajpa.1330680104
   Merbs CF, 1985, HLTH DIS PREHISTORIC, V34, P115
   Miles JS, 1975, ORTHOPEDIC PROBLEMS
   Mirdad T, 2002, W AFR J MED, V21, P281
   Mitchell PD, 2008, INT J OSTEOARCHAEOL, V18, P61, DOI 10.1002/oa.919
   Mitchell PD, 2011, AM J PHYS ANTHROPOL, V144, P479, DOI 10.1002/ajpa.21448
   Mitchell PD, 2007, J PEDIATR ORTHOPED, V27, P890, DOI 10.1097/bpo.0b013e31815a6091
   Morse D, 1969, ILLINOIS STATE MUSEU, V15
   Morse DF, 1963, ANTHR PAPES MUSEUM A, V21, P93
   Moussa M, 2007, SAUDI MED J, V28, P1059
   Noordin S, 2010, ORTHOP REV, V2, P73, DOI 10.4081/or.2010.e19
   Ortner D. J., 2003, IDENTIFICATION PATHO
   Pearson C, 2013, HUFFINGTON POST
   PFEIFFER S, 1984, AM J PHYS ANTHROPOL, V65, P181, DOI 10.1002/ajpa.1330650210
   PHENICE TW, 1969, AM J PHYS ANTHROPOL, V30, P297, DOI 10.1002/ajpa.1330300214
   PRATT WB, 1982, CLIN ORTHOP RELAT R, P69
   RABIN DL, 1965, AM J PUBLIC HEALTH N, V55, P1
   Romero M I, 1989, Rev Chil Pediatr, V60, P268
   ROPER A, 1976, J BONE JOINT SURG BR, V58, P155
   Roposch A, 2007, RADIOLOGY, V242, P355, DOI 10.1148/radiol.2422051937
   Samborska B, 1986, Ginekol Pol, V57, P102
   SAUGSTAD LF, 1991, EUR J OBSTET GYN R B, V41, P197, DOI 10.1016/0028-2243(91)90024-F
   Schoenecker PL, 2007, PEDIATRICS, V119, P652, DOI 10.1542/peds.2006-2953
   Siffel C, 2005, BIRTH DEFECTS RES A, V73, P655, DOI 10.1002/bdra.20207
   SKIRVING AP, 1984, J INHERIT METAB DIS, V7, P27, DOI 10.1007/BF01805617
   SLATER BCS, 1964, BRIT J PREV SOC MED, V18, P1
   Smith DW, 1979, J PEDIAT, V76, P653
   Snow CE, 1948, U KENTUCKY REPORTS A, V4, P514
   Stein-Zamir C, 2008, PEDIATR INT, V50, P341, DOI 10.1111/j.1442-200X.2008.02575.x
   STEVENSON RE, 1967, PEDIATRICS, V40, P33
   Storer SK, 2006, AM FAM PHYSICIAN, V74, P1310
   Taboridze I I, 1991, Ortop Travmatol Protez, P23
   Tegnander A, 1999, ACTA ORTHOP SCAND, V70, P335, DOI 10.3109/17453679908997820
   Terjesen T, 1996, J BONE JOINT SURG BR, V78B, P636
   THIEME W T, 1968, Journal of Bone and Joint Surgery British Volume, V50-B, P546
   Timmler Tomasz, 2005, Chir Narzadow Ruchu Ortop Pol, V70, P301
   UDEN A, 1988, ACTA ORTHOP SCAND, V59, P667, DOI 10.3109/17453678809149421
   Wakefield EG, 1937, AM J MED SCI, V193, P488
   WALKER JM, 1977, CAN MED ASSOC J, V116, P501
   Wang EB, 2012, J BONE JOINT SURG AM, V94A, P1071, DOI 10.2106/JBJS.K.00720
   Wheeler RL, 1985, ANTHR RES PAPERS, V34, P79
   Wientroub S, 2000, J BONE JOINT SURG AM, V82A, P1004, DOI 10.2106/00004623-200007000-00012
   WILTSE LL, 1976, CLIN ORTHOP RELAT R, P23
   WYNNE-DAVIES R, 1970, Journal of Medical Genetics, V7, P315, DOI 10.1136/jmg.7.4.315
   WYNNEDAVIES R, 1982, J MED GENET, V19, P321, DOI 10.1136/jmg.19.5.321
   Yamada Y, 1993, PREVENTION CONGENITA, P27
NR 127
TC 1
Z9 3
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-0533
EI 1520-6300
J9 AM J HUM BIOL
JI Am. J. Hum. Biol.
PD NOV
PY 2013
VL 25
IS 6
BP 821
EP 834
DI 10.1002/ajhb.22458
PG 14
WC Anthropology; Biology
SC Anthropology; Life Sciences & Biomedicine - Other Topics
GA 273WC
UT WOS:000328566000011
PM 24123551
DA 2018-12-27
ER

PT J
AU Tanaka, R
   Takayama, J
   Takaoka, M
   Sugino, Y
   Ohkita, M
   Matsumura, Y
AF Tanaka, Ryosuke
   Takayama, Junji
   Takaoka, Masanori
   Sugino, Yohko
   Ohkita, Mamoru
   Matsumura, Yasuo
TI RETRACTED: Oligomycin, an F1Fo-ATPase Inhibitor, Protects Against
   Ischemic Acute Kidney Injury in Male but Not in Female Rats (Retracted
   article. See vol. 126, pg. 291, 2014)
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE ischemic acute kidney injury; sex difference; ATP depletion;
   F1Fo-ATPase; oligomycin
ID ACUTE-RENAL-FAILURE; REPERFUSION INJURY; MITOCHONDRIAL ATPASE;
   ISCHEMIA/REPERFUSION; ESTROGENS; CELLS; NA+,K+-ATPASE; TOXICITY; BRAIN
AB We investigated the effects of oligomycin, an F1Fo-ATPase inhibitor, on ischemic acute kidney injury in male and female rats. Ischemic acute kidney injury was induced by clamping the left renal artery and vein for 45 or 60 min followed by reperfusion, 2 weeks after contralateral nephrectomy. Renal dysfunction and histological renal damage were observed 1 day after reperfusion in both male and female rats, although these renal injuries were more marked in male rats than in female rats. Intravenous bolus injection of oligomycin (0.5 mg/kg) 5 min before ischemia markedly attenuated the ischemia/reperfusion-induced renal injury in male rats. However, oligomycin did not show the protective effect in female rats subjected to ischemia/reperfusion-induced renal injury. Pre-ischemic treatment with oligomycin suppressed partly but significantly ischemia-induced renal ATP depletion only in male rats. These results indicate that oligomycin prevents the onset of ischemic acute kidney injury in male but not in female rats, and the effect is accompanied by suppression of the ATP depletion only in the male rat kidney during ischemia, thereby suggesting that the ATP hydrolysis pathway by mitochondrial F1Fo-ATPase induces a sex difference in ischemic acute kidney injury.
C1 [Tanaka, Ryosuke; Takayama, Junji; Sugino, Yohko; Ohkita, Mamoru; Matsumura, Yasuo] Osaka Univ Pharmaceut Sci, Lab Pathol & Mol Pharmacol, Takatsuki, Osaka 5691094, Japan.
   [Takaoka, Masanori] Osaka Univ Pharmaceut Sci, Lab Cell Biol, Takatsuki, Osaka 5691094, Japan.
RP Matsumura, Y (reprint author), Osaka Univ Pharmaceut Sci, Lab Pathol & Mol Pharmacol, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan.
EM ymatsumura@gly.oups.ac.jp
CR BASTIN J, 1987, KIDNEY INT, V31, P1239, DOI 10.1038/ki.1987.137
   Caramelo C, 1996, CIRC RES, V79, P1031, DOI 10.1161/01.RES.79.5.1031
   Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183
   Fekete A, 2004, J PHYSIOL-LONDON, V555, P471, DOI 10.1113/jphysiol.2003.054825
   Fekete A, 2006, AM J PHYSIOL-RENAL, V291, pF806, DOI 10.1152/ajprenal.00080.2006
   Grover GJ, 2008, INT J BIOCHEM CELL B, V40, P2698, DOI 10.1016/j.biocel.2008.06.013
   Grover GJ, 2004, AM J PHYSIOL-HEART C, V287, pH1747, DOI 10.1152/ajpheart.01019.2003
   Hutchens MP, 2008, ANESTH ANALG, V107, P239, DOI 10.1213/ane.0b013e318178ca42
   JENNINGS RB, 1991, J MOL CELL CARDIOL, V23, P1383, DOI 10.1016/0022-2828(91)90185-O
   Kim J, 2006, J BIOL CHEM, V281, P20349, DOI 10.1074/jbc.M512740200
   KRAMAR R, 1984, AGENTS ACTIONS, V15, P660, DOI 10.1007/BF01966788
   Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315
   Mattson MP, 1997, NEUROREPORT, V8, P3817, DOI 10.1097/00001756-199712010-00031
   Muller V, 2002, KIDNEY INT, V62, P1364, DOI 10.1046/j.1523-1755.2002.00590.x
   Neugarten J, 1997, J AM SOC NEPHROL, V8, P1240
   Takayama J, 2007, BIOL PHARM BULL, V30, P1905, DOI 10.1248/bpb.30.1905
   Tanaka R, 2013, EUR J PHARMACOL, V714, P397, DOI 10.1016/j.ejphar.2013.07.008
   Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207
   Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813
   VANWHY SK, 1994, J CLIN INVEST, V94, P1518, DOI 10.1172/JCI117492
   Wang XF, 2006, MOL PHARMACOL, V70, P395, DOI 10.1124/mol.106.022384
   WEINBERG JM, 1991, KIDNEY INT, V39, P476, DOI 10.1038/ki.1991.58
   Zheng JB, 1999, J STEROID BIOCHEM, V68, P65, DOI 10.1016/S0960-0760(98)00161-7
   Zheng JB, 1999, EUR J PHARMACOL, V368, P95, DOI 10.1016/S0014-2999(99)00012-6
NR 24
TC 5
Z9 5
U1 2
U2 13
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604,
   JAPAN
SN 1347-8613
EI 1347-8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD NOV
PY 2013
VL 123
IS 3
BP 227
EP 234
DI 10.1254/jphs.13069FP
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 275FT
UT WOS:000328662400003
PM 24162022
DA 2018-12-27
ER

PT J
AU Mahesh, MS
   Mohini, M
   Jha, P
   Sawant, SP
   Kundu, SS
   Kuhad, RC
AF Mahesh, Munnurpal Satyanarayana
   Mohini, Madhu
   Jha, Pankaj
   Sawant, Sanjay Pandurang
   Kundu, Shivlal Singh
   Kuhad, Ramesh Chander
TI RETRACTED: Nutritional evaluation of wheat straw treated with
   Crinipellis sp in Sahiwal calves (Retracted article. See vol. 46, pg.
   589, 2014)
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article; Retracted Publication
DE Digestibility; Lignin; Ruminant feed; Wheat straw; White-rot fungus
ID WHITE-ROT FUNGI; SOLID-STATE BIOCONVERSION; IN-VITRO DIGESTIBILITY; OIL
   PALM FRONDS; GAS-PRODUCTION; FEED; DEGRADABILITY; FERMENTATION;
   ROUGHAGES; CATTLE
AB Wheat straw was subjected to solid-state fermentation (SSF) with lignolytic white-rot fungus (WRF) Crinipellis sp. for 5 days to improve the nutritive value and digestibility. The fungal treatment caused a significant (P < 0.05) decrease in cell wall constituents viz., neutral detergent fiber (NDF), acid detergent fiber (ADF), hemicellulose, lignin, and cellulose to the extent of 10.4, 11.2, 8.7, 8.7, and 12.1 %, respectively, with increase (P < 0.05) in crude protein (CP) (51.6%) and ash (25.8%) contents in fungal treated wheat straw (FT-WS) than untreated wheat straw (UT-WS). Further, in vitro gas production, in vitro true dry matter digestibility and in vitro true organic matter digestibility at 48 h, metabolizable energy (ME) content, microbial biomass production, and short-chain fatty acids synthesis were significantly (P < 0.05) higher in FT-WS. In vivo feeding trial in 10 Sahiwal calves (8-12 months) comprised of (1) control group (T1) fed with ad libitum chopped UT-WS and (2) treatment group (T2) offered with ad libitum chopped FT-WS, in addition to supplementation of groundnut cake and green berseem (Trifolium alexandrium) forage to both groups. Digestibility of nutrients for dry matter (DM), organic matter, CP, NDF, ADF, hemicellulose, cellulose, and total carbohydrates were significantly (P < 0.05) higher in T2 compared to T1. Moreover, daily DM (P < 0.05), digestible crude protein (P < 0.01), and ME intakes were also higher (P < 0.05) in group T2 with higher (P < 0.05) nitrogen (N) retention, which resulted in significantly (P < 0.05) higher average daily gain in body weight (135 vs. 102 g/day). It was concluded that SSF with WRF Crinipellis sp. holds potential in upgrading the nutritional worth of wheat straw for feeding growing calves.
C1 [Mahesh, Munnurpal Satyanarayana; Mohini, Madhu; Jha, Pankaj; Sawant, Sanjay Pandurang; Kundu, Shivlal Singh] Deemed Univ, Natl Dairy Res Inst, Dairy Cattle Nutr Div, Karnal 132001, Haryana, India.
   [Kuhad, Ramesh Chander] Univ Delhi South Campus, Dept Microbiol, Lignocellulose Biotechnol Lab, New Delhi 110021, India.
RP Mahesh, MS (reprint author), Deemed Univ, Natl Dairy Res Inst, Dairy Cattle Nutr Div, Karnal 132001, Haryana, India.
EM drmaheshmsvet@gmail.com
CR A. O. A. C, 2005, OFFICIAL METHODS ANA
   AKIN DE, 1993, APPL ENVIRON MICROB, V59, P4274
   Akinfemi A., 2010, LIVESTOCK RES RURAL, V22
   [Anonymous], 1997, OFFICIAL METHODS ANA
   Arora DS, 2009, BIORESOURCES, V4, P909
   Basu S, 2002, J BIOSCI BIOENG, V93, P25, DOI 10.1016/S1389-1723(02)80049-4
   BLUMMEL M, 1993, ANIM FEED SCI TECH, V40, P109, DOI 10.1016/0377-8401(93)90150-I
   Blummel M, 1997, J ANIM PHYSIOL AN N, V77, P24, DOI 10.1111/j.1439-0396.1997.tb00734.x
   Chumpawadee S., 2007, Pakistan Journal of Nutrition, V6, P607
   De Boever JL, 2005, ANIM FEED SCI TECH, V123, P255, DOI 10.1016/j.anifeedsci.2005.04.019
   DIASDASILVA AA, 1986, ANIM FEED SCI TECH, V14, P67, DOI 10.1016/0377-8401(86)90007-6
   Getachew G, 2002, J AGR SCI, V139, P341, DOI 10.1017/S0021859602002393
   Goering H. K., 1970, AGR HDB, V379
   Hassim HA, 2012, CAN J ANIM SCI, V92, P79, DOI 10.4141/CJAS2011-097
   KAKKAR V K, 1990, Indian Journal of Animal Nutrition, V7, P267
   Keller FA, 2003, APPL BIOCHEM BIOTECH, V105, P27, DOI 10.1385/ABAB:105:1-3:27
   Krishnamoorthy U, 2010, ANIM FEED SCI TECH, V160, P167, DOI 10.1016/j.anifeedsci.2010.07.007
   Krishnamoorthy U., 1991, ARCH ANIM NUTR, V5, P521
   Menke K. H., 1988, ANIM RES DEV, V28, P7, DOI DOI 10.1016/S0301-6226(01)00298-6.PALMQUIST
   Okano Kanji, 2005, Animal Science Journal, V76, P147, DOI 10.1111/j.1740-0929.2005.00250.x
   Okano K, 2009, ANIM FEED SCI TECH, V152, P278, DOI 10.1016/j.anifeedsci.2009.04.021
   Omer H. A. A., 2012, Journal of Agricultural Science (Toronto), V4, P257
   Orskov ER, 1999, PREV VET MED, V38, P179, DOI 10.1016/S0167-5877(98)00123-8
   Rahman MM, 2011, ANIM FEED SCI TECH, V169, P157, DOI 10.1016/j.anifeedsci.2011.06.014
   Ramirez-Bribiesca JE, 2010, INDIAN J ANIM SCI, V80, P754
   Ranjhan S.K, 1998, NUTR REQUIREMENT LIV
   Robertson J. B., 1981, ANAL DIETARY FIBER F, V9, P123
   Rodrigues MAM, 2008, ANIM FEED SCI TECH, V141, P326, DOI 10.1016/j.anifeedsci.2007.06.015
   Russel J. B, 1988, J ANIM SCI, V76, P1955
   Sallam S. M. A., 2007, J APPL SCI RES, V3, P33
   Salman F. M., 2008, International Journal of Agriculture and Biology, V10, P412
   Shrivastava B, 2012, BIORESOURCE TECHNOL, V107, P347, DOI 10.1016/j.biortech.2011.12.096
   Shrivastava B, 2011, BIODEGRADATION, V22, P823, DOI 10.1007/s10532-010-9408-2
   Snedecor GW, 1994, STAT METHODS
   SNIFFEN CJ, 1992, J ANIM SCI, V70, P3562
   Van Soest P. J, 1994, NUTR ECOLOGY RUMINAN
   VANSOEST PJ, 1991, J DAIRY SCI, V74, P3583, DOI 10.3168/jds.S0022-0302(91)78551-2
   Villas-Boas SG, 2002, ANIM FEED SCI TECH, V98, P1, DOI 10.1016/S0377-8401(02)00017-2
   Walli T. K., 1991, Indian Journal of Animal Nutrition, V8, P227
   Wyman CE, 2007, TRENDS BIOTECHNOL, V25, P153, DOI 10.1016/j.tibtech.2007.02.009
   Yu HB, 2009, BIORESOURCE TECHNOL, V100, P5170, DOI 10.1016/j.biortech.2009.05.049
   Zadrazil F, 1995, BIORESOURCE TECHNOL, V54, P85, DOI 10.1016/0960-8524(95)00119-0
NR 42
TC 3
Z9 5
U1 2
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-4747
EI 1573-7438
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD NOV
PY 2013
VL 45
IS 8
BP 1817
EP 1823
DI 10.1007/s11250-013-0440-1
PG 7
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA 258AX
UT WOS:000327431300025
PM 23839599
DA 2018-12-27
ER

PT J
AU Khan, F
   Pal, D
   Ghosh, A
   Cameotra, SS
AF Khan, Fazlurrahman
   Pal, Deepika
   Ghosh, Anuradha
   Cameotra, Swaranjit Singh
TI RETRACTED: Degradation of 2,4-dinitroanisole (DNAN) by metabolic
   cooperative activity of Pseudomonas sp strain FK357 and Rhodococcus
   imtechensis strain RKJ300 (Retracted article. See vol. 117, pg. 830,
   2014)
SO CHEMOSPHERE
LA English
DT Article; Retracted Publication
DE Biodegradation; Co-culture; 2,4-Dinitroanisole (DNAN); 2,4-Dinitrophenol
   (2,4-DNP); Hydride-Meisenheimer complex
ID INSENSITIVE MUNITIONS COMPOUND; FLUIDIZED-BED BIOREACTORS;
   VANILLATE-O-DEMETHYLASE; FORMALDEHYDE DETOXIFICATION;
   BACTERIAL-DEGRADATION; MOLECULAR-BASIS; MIXED CULTURE;
   2,4-DINITROPHENOL; MINERALIZATION; BIODEGRADATION
AB 2,4-Dinitroanisole (DNAN) is an insensitive explosive ingredient used by many defense agencies as a replacement for 2,4,6-trinitrotoluene. Although the biotransformation of DNAN under anaerobic condition has been reported, aerobic microbial degradation pathway has not been elucidated. An n-methyl-4-nitroaniline degrading bacterium Pseudomonas sp. strain FK357 transformed DNAN into 2,4-dinitrophenol (2,4-DNP) as an end product. Interestingly, when strain FK357 was co-cultured with a 2,4-DNP degrading Rhodococcus imtechensis strain RKJ300, complete and high rate of DNAN degradation was observed with no accumulation of intermediates. Enzyme assay using cell extracts of strain FK357 demonstrated that O-demethylation reaction is the first step of DNAN degradation with formation of 2,4-DNP and formaldehyde as intermediates. Subsequently, 2,4-DNP was degraded by strain RKJ300 via the formation of hydride-Meisenheimer complex. The present study clearly demonstrates that complete degradation of DNAN occurs as a result of the metabolic cooperative activity of two members within a bacterial consortium. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Khan, Fazlurrahman; Pal, Deepika; Ghosh, Anuradha; Cameotra, Swaranjit Singh] Inst Microbial Technol, Sect 39A, Chandigarh 160036, India.
RP Cameotra, SS (reprint author), Inst Microbial Technol, Sect 39A, Chandigarh 160036, India.
EM ssc@imtech.res.in
FU CSIR
FX FK, DP, and AG acknowledge their research fellowship awards from CSIR.
   This is the IMTECH communication number 070/2013.
CR Abe T, 2005, J BACTERIOL, V187, P2030, DOI 10.1128/JB.187.6.2030-2037.2005
   ADROER N, 1990, APPL MICROBIOL BIOT, V33, P217, DOI 10.1007/BF00176528
   Arfmann HA, 1997, APPL ENVIRON MICROB, V63, P3458
   Arnett CM, 2009, MICROBES ENVIRON, V24, P72, DOI 10.1264/jsme2.ME08556
   Barreiros L, 2003, ENVIRON MICROBIOL, V5, P944, DOI 10.1046/j.1462-2920.2003.00492.x
   Behrend C, 1999, APPL ENVIRON MICROB, V65, P1372
   BERMAN MH, 1992, APPL ENVIRON MICROB, V58, P925
   Boddu VM, 2008, J CHEM ENG DATA, V53, P1120, DOI 10.1021/je7006764
   Boonchan S, 2000, APPL ENVIRON MICROB, V66, P1007, DOI 10.1128/AEM.66.3.1007-1019.2000
   Bouchez M, 1999, BIODEGRADATION, V10, P429, DOI 10.1023/A:1008382030604
   BRUNEL F, 1988, J BACTERIOL, V170, P4924, DOI 10.1128/jb.170.10.4924-4930.1988
   CARTWRIGHT NJ, 1967, BIOCHEM J, V102, P826, DOI 10.1042/bj1020826
   Chongcharoen R, 2005, MICROBIOL-SGM, V151, P2615, DOI 10.1099/mic.0.27912-0
   Chudgar R.J., 2000, DYES AZO KIRK OTHMER
   De Souza ML, 1998, APPL ENVIRON MICROB, V64, P178
   Diaz E, 2004, INT MICROBIOL, V7, P173
   DRAIZE JH, 1948, J PHARMACOL EXP THER, V93, P26
   Ebert S, 1999, J BACTERIOL, V181, P2669
   Fazlurrahman, 2009, LETT APPL MICROBIOL, V49, P721, DOI 10.1111/j.1472-765X.2009.02724.x
   Ghosh A, 2006, INT J SYST EVOL MICR, V56, P1965, DOI 10.1099/ijs.0.63939-0
   Ghosh A, 2010, ENVIRON SCI TECHNOL, V44, P1069, DOI 10.1021/es9034123
   Herman PL, 2005, J BIOL CHEM, V280, P24759, DOI 10.1074/jbc.M500597200
   Hibi M, 2005, FEMS MICROBIOL LETT, V253, P237, DOI 10.1016/j.femsle.2005.09.036
   Janssen DB, 2005, ENVIRON MICROBIOL, V7, P1868, DOI 10.1111/j.1462-2920.2005.00966.x
   KARLSON U, 1993, J BACTERIOL, V175, P1467
   Karpouzas DG, 2006, ADV MICROB PHYSIOL, V51, P119, DOI 10.1016/S0065-2911(06)51003-3
   Khan F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062178
   LENKE H, 1992, APPL ENVIRON MICROB, V58, P2928
   Lister DL, 1996, APPL ENVIRON MICROB, V62, P94
   Marx CJ, 2004, J BACTERIOL, V186, P2173, DOI 10.1128/JB.186.7.2173-2178.2004
   Morawski B, 2000, J BACTERIOL, V182, P1383, DOI 10.1128/JB.182.5.1383-1389.2000
   Naidu D, 2001, J BACTERIOL, V183, P3276, DOI 10.1128/JB.183.11.3276-3281.2001
   Perreault NN, 2012, BIODEGRADATION, V23, P287, DOI 10.1007/s10532-011-9508-7
   Platten WE, 2010, CHEMOSPHERE, V81, P1131, DOI 10.1016/j.chemosphere.2010.08.044
   Providenti MA, 2006, J BACTERIOL, V188, P3862, DOI 10.1128/JB.01675-05
   Rao B, 2013, SCI TOTAL ENVIRON, V443, P692, DOI 10.1016/j.scitotenv.2012.11.033
   Roca A, 2008, MICROB BIOTECHNOL, V1, P158, DOI 10.1111/j.1751-7915.2007.00014.x
   SAURETIGNAZI G, 1988, BIOCHIMIE, V70, P1385, DOI 10.1016/S0300-9084(88)80001-4
   Summers RM, 2011, MICROBIOL-SGM, V157, P583, DOI 10.1099/mic.0.043612-0
   SUTHERLAND JB, 1986, APPL ENVIRON MICROB, V52, P98
   Wang ZY, 2006, BIOTECHNOL LETT, V28, P617, DOI 10.1007/s10529-006-0023-6
   White GF, 1996, APPL ENVIRON MICROB, V62, P637
   Wittich RM, 1999, J IND MICROBIOL BIOT, V23, P353, DOI 10.1038/sj.jim.2900740
   Xu ZH, 2011, LANGMUIR, V27, P13773, DOI 10.1021/la202560t
NR 44
TC 6
Z9 7
U1 3
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-6535
EI 1879-1298
J9 CHEMOSPHERE
JI Chemosphere
PD NOV
PY 2013
VL 93
IS 11
BP 2883
EP 2888
DI 10.1016/j.chemosphere.2013.09.005
PG 6
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 260BM
UT WOS:000327570000032
PM 24075532
DA 2018-12-27
ER

PT J
AU Kfir, I
AF Kfir, Isaac
TI RETRACTED: Al-Qaeda: From Global Network to Local Franchise (Retracted
   article. See vol. 26, pg. 257, 2014)
SO TERRORISM AND POLITICAL VIOLENCE
LA English
DT Book Review; Retracted Publication
C1 [Kfir, Isaac] Syracuse Univ, Syracuse, NY 13244 USA.
RP Kfir, I (reprint author), Syracuse Univ, Syracuse, NY 13244 USA.
CR Hellmich Christina, 2011, AL QAEDA GLOBAL NETW
NR 1
TC 1
Z9 1
U1 2
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0954-6553
EI 1556-1836
J9 TERROR POLIT VIOLENC
JI Terror. Polit. Violence
PD NOV 1
PY 2013
VL 25
IS 5
BP 843
EP 845
DI 10.1080/09546553.2013.842377
PG 3
WC International Relations; Political Science
SC International Relations; Government & Law
GA 256FM
UT WOS:000327295100010
DA 2018-12-27
ER

PT J
AU Lee, CK
   Lee, W
AF Lee, Chul-Ku
   Lee, Wooram
TI RETRACTED: The Effect of Magnetic Fields for Laser Welding Process using
   Carbon Steel (Retracted article. See vol. 15, pg. 587, 2014)
SO INTERNATIONAL JOURNAL OF PRECISION ENGINEERING AND MANUFACTURING
LA English
DT Article; Retracted Publication
DE Laser; Welding; Magnetic field; Carbon steel(SCP1-S); COMSOL
ID MELT FLOW; ALUMINUM-ALLOYS; FILLER WIRE; MODEL; OPTIMIZATION;
   REGRESSION; FORCE
AB A Multi-physics numerical model was developed to investigate the influence of a steady magnetic field aligned perpendicular to the welding direction during partial penetration fiber laser beam welding of carbon steel(SCP1-S) in down hand position. Two-dimensional fluid dynamics including phase transition and electromagnetic field partial differential equations were successfully solved with the finite element differential equation solver COMSOL Multiphysic 3.5. The use of magnetic fields to influence weld bead shape and dilution in laser welding of SCP1-S alloys was recently suggested However; the interaction mechanisms between the SCP1-S melt and the magnetic field are not understood in detail yet, and consequently, the selection of process parameters is so far purely empirical. In this paper, recent results of a study to elucidate interaction mechanisms between a laser-induced melt pool and a magnetic field will be reported and discussed Based on analytical models for the main potential interaction mechanisms, the relevance to typical welding conditions was assessed The flow pattern in the melt as well as the weld bead geometry was significantly changed by the induced Lorentz force distribution in the liquid metal. The governing mechanisms identified were implemented into a COMSOL model for laser welding and the effect of the magnetic field on the resulting melt flow was investigated To validate the results, welding trials were performed on a model system allowing to easily visualizing the effect of melt flow on melt bead dynamics using optical microscopy.
C1 [Lee, Chul-Ku; Lee, Wooram] Seoul Natl Univ Sci & Technol, Dept Mech & Automot Engn, Seoul, South Korea.
RP Lee, W (reprint author), Seoul Natl Univ Sci & Technol, Dept Mech & Automot Engn, Seoul, South Korea.
EM wooramlee@seoultech.co.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF); Ministry of Education, Science and Technology
   [20110026755]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (20110026755).
CR Ambrosy G, 2006, P SPIE INT SOC OPTIC, V6346
   ASAI S, 1982, T IRON STEEL I JPN, V22, P126
   Avilov V. V., 2008, INT WORKSH THERM FOR, V31, P413
   Bachmann M, 2013, INT J HEAT MASS TRAN, V60, P309, DOI 10.1016/j.ijheatmasstransfer.2013.01.015
   Berger P, 2011, PHYSCS PROC, V12, P241, DOI 10.1016/j.phpro.2011.03.031
   BRENT AD, 1988, NUMER HEAT TRANSFER, V13, P297
   Choi SH, 2012, INT J PRECIS ENG MAN, V13, P845, DOI 10.1007/s12541-012-0110-7
   Dennis BH, 2002, INT J HEAT FLUID FL, V23, P269, DOI 10.1016/S0142-727X(02)00174-1
   Fuhrich T, 2001, J LASER APPL, V13, P178, DOI 10.2351/1.1404412
   Gatzen M, 2012, PHYSCS PROC, V39, P59, DOI 10.1016/j.phpro.2012.10.014
   Gatzen M, 2011, PHYSCS PROC, V12, P56, DOI 10.1016/j.phpro.2011.03.008
   Gatzen M, 2010, PHYSCS PROC, V5, P317, DOI 10.1016/j.phpro.2010.08.058
   KAYS WM, 1994, J HEAT TRANS-T ASME, V116, P284, DOI 10.1115/1.2911398
   KEENE BJ, 1993, INT MATER REV, V38, P157, DOI 10.1179/imr.1993.38.4.157
   Kim TW, 2011, INT J PRECIS ENG MAN, V12, P313, DOI 10.1007/s12541-011-0041-8
   Lee WR, 2011, T KOREAN SOC MEC ENG, V35, P1655, DOI 10.3795/KSME-A.2011.35.12.1655
   Leong KH, 1999, J LASER APPL, V11, P109, DOI 10.2351/1.521881
   Li K, 2012, INT J PRECIS ENG MAN, V13, P641, DOI 10.1007/s12541-012-0083-6
   Marcel B., 2012, J PHYS D, V45
   Matsunawa A, 2001, SCI TECHNOL WELD JOI, V6, P351, DOI 10.1179/stw.2001.6.6.351
   Park H, 1999, J LASER APPL, V11, P143, DOI 10.2351/1.521890
   Rogers E., 2007, P COMSOL C
   Schneider A, 2013, PHYSCS PROC, V41, P4, DOI 10.1016/j.phpro.2013.03.045
   Shcheglov PY, 2013, LASER PHYS, V23, DOI 10.1088/1054-660X/23/1/016001
   Shcheglov PY, 2011, LASER PHYS LETT, V8, P475, DOI 10.1002/lapl.201110010
   Tang Z, 2010, PHYSCS PROC, V5, P125, DOI 10.1016/j.phpro.2010.08.037
   Tarng YS, 1999, INT J MACH TOOL MANU, V39, P1427, DOI 10.1016/S0890-6955(99)00013-9
   Velde O, 2001, INT J HEAT MASS TRAN, V44, P2751, DOI 10.1016/S0017-9310(00)00299-4
   Vollertsen F, 2006, J LASER APPL, V18, P28, DOI 10.2351/1.2164477
   Xu ZD, 2013, MATER DESIGN, V49, P736, DOI 10.1016/j.matdes.2012.12.059
   Zhang YA, 2011, J MATER PROCESS TECH, V211, P944, DOI 10.1016/j.jmatprotec.2010.01.001
   Zhou J, 2007, INT J HEAT MASS TRAN, V50, P2217, DOI 10.1016/j.ijheatmasstransfer.2006.10.040
NR 32
TC 3
Z9 4
U1 2
U2 58
PU KOREAN SOC PRECISION ENG
PI SEOUL
PA RM 306, KWANGMYUNG BLDG, 5-4 NONHYUN-DONG, KANGNAM-GU, SEOUL, 135-010,
   SOUTH KOREA
SN 2234-7593
EI 2005-4602
J9 INT J PRECIS ENG MAN
JI Int. J. Precis. Eng. Manuf.
PD NOV
PY 2013
VL 14
IS 11
BP 1915
EP 1923
DI 10.1007/s12541-013-0260-2
PG 9
WC Engineering, Manufacturing; Engineering, Mechanical
SC Engineering
GA 248AT
UT WOS:000326666800006
DA 2018-12-27
ER

PT J
AU Smith, MM
   Sommer, AJ
   Starkoff, BE
   Devor, ST
AF Smith, Michael M.
   Sommer, Allan J.
   Starkoff, Brooke E.
   Devor, Steven T.
TI RETRACTED: CROSSFIT-BASED HIGH-INTENSITY POWER TRAINING IMPROVES MAXIMAL
   AEROBIC FITNESS AND BODY COMPOSITION (Retracted article. See vol. 31,
   pg. E76, 2017)
SO JOURNAL OF STRENGTH AND CONDITIONING RESEARCH
LA English
DT Article; Retracted Publication
DE interval training; aerobic fitness; body composition; crossfit; power
   training
ID PERFORMANCE
AB The purpose of this study was to examine the effects of a crossfit-based high-intensity power training (HIPT) program on aerobic fitness and body composition. Healthy subjects of both genders (23 men, 20 women) spanning all levels of aerobic fitness and body composition completed 10 weeks of HIPT consisting of lifts such as the squat, deadlift, clean, snatch, and overhead press performed as quickly as possible. Additionally, this crossfit-based HIPT program included skill work for the improvement of traditional Olympic lifts and selected gymnastic exercises. Body fat percentage was estimated using whole-body plethysmography, and maximal aerobic capacity (V.o(2)max) was measured by analyzing expired gasses during a Bruce protocol maximal graded treadmill test. These variables were measured again after 10 weeks of training and compared for significant changes using a paired t-test. Results showed significant (p < 0.05) improvements of V.o(2)max in men (43.10 +/- 1.40 to 48.96 +/- 1.42 ml<bold></bold>kg(-1)<bold></bold>min(-1)) and women (35.98 +/- 1.60 to 40.22 +/- 1.62 ml<bold></bold>kg(-1)<bold></bold>min(-1)) and decreased body fat percentage in men (22.2 +/- 1.3 to 18.0 +/- 1.3) and women (26.6 +/- 2.0 to 23.2 +/- 2.0). These improvements were significant across all levels of initial fitness. Significant correlations between absolute oxygen consumption and oxygen consumption relative to body weight was found in both men (r = 0.83, p < 0.001) and women (r = 0.94, p < 0.001), indicating that HIPT improved V.o(2)max scaled to body weight independent of changes to body composition. Our data show that HIPT significantly improves V.o(2)max and body composition in subjects of both genders across all levels of fitness.
C1 [Smith, Michael M.; Sommer, Allan J.; Starkoff, Brooke E.; Devor, Steven T.] Ohio State Univ, Columbus, OH 43210 USA.
RP Devor, ST (reprint author), Ohio State Univ, Columbus, OH 43210 USA.
EM devor.3@osu.edu
OI Starkoff, Brooke/0000-0002-7454-3804
CR Bergeron MF, 2011, CURR SPORT MED REP, V10, P383, DOI 10.1249/JSR.0b013e318237bf8a
   Biaggi RR, 1999, AM J CLIN NUTR, V69, P898
   BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395
   BRUCE R A, 1969, Progress in Cardiovascular Diseases, V11, P371, DOI 10.1016/0033-0620(69)90027-9
   Burgomaster KA, 2005, J APPL PHYSIOL, V98, P1985, DOI 10.1152/japplphysiol.01095.2004
   Crouter SE, 2006, EUR J APPL PHYSIOL, V98, P139, DOI 10.1007/s00421-006-0255-0
   DEMPSTER P, 1995, MED SCI SPORT EXER, V27, P1692
   Kilding AE, 2012, INT J SPORTS MED, V33, P359, DOI 10.1055/s-0031-1297999
   Osterdahl M, 2008, EUR J CLIN NUTR, V62, P682, DOI 10.1038/sj.ejcn.1602790
   Perry CGR, 2007, J APPL PHYSIOL, V102, P1022, DOI 10.1152/japplphysiol.01215.2006
   SIRI WE, 1993, NUTRITION, V9, P481
   Snell PG, 2007, MED SCI SPORT EXER, V39, P103, DOI 10.1249/01.mss.0000241641.75101.64
   TREMBLAY A, 1994, METABOLISM, V43, P814, DOI 10.1016/0026-0495(94)90259-3
   Trilk JL, 2011, EUR J APPL PHYSIOL, V111, P1591, DOI 10.1007/s00421-010-1777-z
NR 14
TC 63
Z9 65
U1 4
U2 149
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1064-8011
EI 1533-4287
J9 J STRENGTH COND RES
JI J. Strength Cond. Res.
PD NOV
PY 2013
VL 27
IS 11
BP 3159
EP 3172
DI 10.1519/JSC.0b013e318289e59f
PG 14
WC Sport Sciences
SC Sport Sciences
GA 245WS
UT WOS:000326495200030
PM 23439334
DA 2018-12-27
ER

PT J
AU Zimmerman, MA
   Tak, E
   Ehrentraut, SF
   Kaplan, M
   Giebler, A
   Weng, TT
   Choi, DS
   Blackburn, MR
   Kam, I
   Eltzschig, HK
   Grenz, A
AF Zimmerman, Michael A.
   Tak, Eunyoung
   Ehrentraut, Stefan F.
   Kaplan, Maria
   Giebler, Antasia
   Weng, Tingting
   Choi, Doo-Sup
   Blackburn, Michael R.
   Kam, Igal
   Eltzschig, Holger K.
   Grenz, Almut
TI RETRACTED: Equilibrative Nucleoside Transporter (ENT)-1-Dependent
   Elevation of Extracellular Adenosine Protects the Liver During Ischemia
   and Reperfusion (Retracted article. See vol.66,pg.1366,2017)
SO HEPATOLOGY
LA English
DT Article; Retracted Publication
ID INDUCIBLE FACTOR-I; ACUTE LUNG INJURY; ECTO-5'-NUCLEOTIDASE CD73;
   TISSUE-DAMAGE; HYPOXIA; RECEPTOR; INFLAMMATION; DISEASE; MICE;
   MECHANISMS
AB Ischemia and reperfusion-elicited tissue injury contributes to morbidity and mortality of hepatic surgery and during liver transplantation. Previous studies implicated extracellular adenosine signaling in liver protection. Based on the notion that extracellular adenosine signaling is terminated by uptake from the extracellular towards the intracellular compartment by way of equilibrative nucleoside transporters (ENTs), we hypothesized a functional role of ENTs in liver protection from ischemia. During orthotopic liver transplantation in humans, we observed higher expressional levels of ENT1 than ENT2, in conjunction with repression of ENT1 and ENT2 transcript and protein levels following warm ischemia and reperfusion. Treatment with the pharmacologic ENT inhibitor dipyridamole revealed elevations of hepatic adenosine levels and robust liver protection in a murine model of liver ischemia and reperfusion. Studies in gene-targeted mice for Ent1 or Ent2 demonstrated selective protection from liver injury in Ent1(-/-) mice. Treatment with selective adenosine receptor antagonists indicated a contribution of Adora2b receptor signaling in ENT-dependent liver protection. Conclusion: These findings implicate ENT1 in liver protection from ischemia and reperfusion injury and suggest ENT inhibitors may be of benefit in the prevention or treatment of ischemic liver injury.
C1 [Zimmerman, Michael A.; Kaplan, Maria; Kam, Igal] Univ Colorado, Dept Surg, Div Transplant Surg, Aurora, CO USA.
   [Tak, Eunyoung; Giebler, Antasia; Eltzschig, Holger K.; Grenz, Almut] Univ Colorado, Dept Anesthesiol, Mucosal Inflammat Program, Aurora, CO USA.
   [Ehrentraut, Stefan F.] Univ Colorado, Mucosal Inflammat Program, Aurora, CO USA.
   [Weng, Tingting; Blackburn, Michael R.] Univ Texas Hlth Sci Ctr Texas, Dept Biochem & Mol Biol, Houston, TX USA.
   [Choi, Doo-Sup] Mayo Clin, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA.
RP Eltzschig, HK (reprint author), Univ Colorado Denver, Dept Anesthesiol, Mucosal Inflammat Program, 12700 E 19th Ave,Mailstop B112,Res Complex 2,Rm 7, Aurora, CO 80045 USA.
EM holger.eltzschig@ucdenver.edu; almut.grenz@ucdenver.edu
RI Choi, Doo-Sup/G-9474-2012
OI Blackburn, Michael/0000-0002-1394-9966; Ehrentraut,
   Stefan/0000-0001-5747-6737
FU American Heart Association; National Heart Institute [R01 DK097075,
   R01-HL0921, R01-DK083385, R01-HL098294, POIHL114457-01]; Crohn's and
   Colitis Foundation of America (CCFA);  [1 KO8HL103900-01]
FX The present research work was supported by 1 KO8HL103900-01 to MZ, an
   American Heart Association Grant to AG and National Heart Institute
   Grants R01 DK097075, R01-HL0921, R01-DK083385, R01-HL098294,
   POIHL114457-01 and a grant by the Crohn's and Colitis Foundation of
   America (CCFA) to HKE.
CR Aherne CM, 2011, BBA-BIOMEMBRANES, V1808, P1329, DOI 10.1016/j.bbamem.2010.05.016
   Blackburn Michael R, 2009, Handb Exp Pharmacol, P215, DOI 10.1007/978-3-540-89615-9_8
   Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159
   Choi DS, 2004, NAT NEUROSCI, V7, P855, DOI 10.1038/nn1288
   Chouker A, 2012, TRANSPLANTATION, V94, P894, DOI 10.1097/TP.0b013e31826a9a46
   CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547
   Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203
   Eckle T, 2008, CIRCULATION, V118, P166, DOI 10.1161/CIRCULATIONAHA.107.758516
   Eckle T, 2008, BLOOD, V111, P2024, DOI 10.1182/blood-2007-10-117044
   Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127
   Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697
   Eckle T, 2006, AM J PHYSIOL-HEART C, V291, pH2533, DOI 10.1152/ajpheart.00472.2006
   Eltzschig HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066
   Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177
   Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891
   Eltzschig HK, 2006, BLOOD, V108, P1602, DOI 10.1182/blood-2006-02-001016
   Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   Eltzschig HK, 2009, EXPERT OPIN THER TAR, V13, P1267, DOI 10.1517/14728220903241666
   Grenz A, 2008, PLOS MED, V5, P968, DOI 10.1371/journal.pmed.0050137
   Grenz A, 2012, J CLIN INVEST, V122, P693, DOI 10.1172/JCI60214
   Hart ML, 2008, GASTROENTEROLOGY, V135, P1739, DOI 10.1053/j.gastro.2008.07.064
   Hart ML, 2008, AM J PHYSIOL-GASTR L, V294, pG1431, DOI 10.1152/ajpgi.00083.2008
   Hart ML, 2011, J IMMUNOL, V186, P4367, DOI 10.4049/jimmunol.0903617
   Hart ML, 2010, J IMMUNOL, V184, P4017, DOI 10.4049/jimmunol.0901851
   Hart ML, 2009, J IMMUNOL, V182, P3965, DOI 10.4049/jimmunol.0802193
   Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   Ji HF, 2012, LIVER TRANSPLANT, V18, P659, DOI 10.1002/lt.23399
   Ke BB, 2013, HEPATOLOGY, V57, P1203, DOI 10.1002/hep.26100
   Koeppen M, 2011, ADV PHARMACOL, V61, P145, DOI 10.1016/B978-0-12-385526-8.00006-0
   Lappas CM, 2006, J EXP MED, V203, P2639, DOI 10.1084/jem.20061097
   Lasley RD, 2007, AM J PHYSIOL-HEART C, V292, pH426, DOI 10.1152/ajpheart.00675.2006
   Liu W, 2011, PROTEOMICS, V11, P3556, DOI 10.1002/pmic.201100157
   Loffler M, 2007, ARTERIOSCL THROM VAS, V27, P1004, DOI 10.1161/ATVBAHA.106.126714
   McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491
   Morote-Garcia JC, 2009, GASTROENTEROLOGY, V136, P607, DOI 10.1053/j.gastro.2008.10.037
   Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a
   Peng Z, 2009, J CLIN INVEST, V119, P582, DOI 10.1172/JCI37409
   Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685
   Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731
   Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337
   Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915
   Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933
   Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667
   Zhang Y, 2013, AM J TRANSPLANT, V13, P56, DOI 10.1111/j.1600-6143.2012.04316.x
   Zhang YJ, 2011, NAT MED, V17, P79, DOI 10.1038/nm.2280
   Zhou Y, 2011, J IMMUNOL, V186, P1097, DOI 10.4049/jimmunol.1002907
NR 48
TC 25
Z9 25
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD NOV
PY 2013
VL 58
IS 5
BP 1766
EP 1778
DI 10.1002/hep.26505
PG 13
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 243OZ
UT WOS:000326327600026
PM 23703920
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Pan, TY
AF Pan, Tongyan
TI RETRACTED: Coniferyl-alcohol lignin as a bio-antioxidant for petroleum
   asphalt: A quantum chemistry based atomistic study (Retracted article.
   See vol. 144, pg. 441, 2015)
SO FUEL
LA English
DT Article; Retracted Publication
DE Atomistic modeling; Asphalt; Oxidative aging; Coniferyl alcohol; Lignin
ID ELECTRONEGATIVITY EQUALIZATION METHOD; IRON OXIDATION; STEEL SURFACE;
   SPECTROSCOPY; PASSIVATION; MOLECULES; MECHANISM; SULFUR
AB Petroleum asphalt is an important base material for many industrial applications, such as the binding and waterproofing component in road pavements and roof shingles. Being an organic end product of petroleum serving under the general open-to-air conditions, asphalt can lose the desired rheological properties with time due to oxidative hardening or aging that frequently leads to increase in viscosity, separation of components, and loss of cohesion and adhesion, and thereby becomes hardened. A common practice to alleviate asphalt aging today is using different chemical additives or modifiers as antioxidants. The current state of knowledge in asphalt oxidation and antioxidant evaluation is focused on monitoring the degradation in asphalt's physical properties, mainly the viscosity and ductility, which although satisfying direct engineering needs does not contribute to the fundamental understanding of the aging and anti-aging mechanisms. Within this context, this study was initiated to study the anti-oxidation mechanisms of bio-based additives, using the coniferyl-alcohol lignin as an example, by developing a quantum chemistry based chemophysical environment in which the various chemical reactions among asphalt components, anti-oxidative additive and oxygen, as well as the incurred physical changes can be studied. The techniques of X-ray photoelectron spectroscopy (XPS) was used to prove the validity of the modified and unmodified asphalt models, from which the XPS results showed high agreement to the model predictions. (C) 2013 Elsevier Ltd. All rights reserved.
C1 Catholic Univ Amer, Washington, DC 20064 USA.
RP Pan, TY (reprint author), Catholic Univ Amer, 620 Michigan Ave NE, Washington, DC 20064 USA.
EM pan@cua.edu
CR Berendsen HJC, 1984, J CHEM PHYS, V81
   Bishara SW, 2005, 42 PET ASPH RES C CH
   Boeriu CG, 2004, IND CROP PROD, V20, P205, DOI 10.1016/j.indcrop.2004.04.022
   Boerjan W, 2003, ANNU REV PLANT BIOL, V54, P519, DOI 10.1146/annurev.arplant.54.031902.134938
   Branthaver J. F., 1993, SHRPA368 NAT RES COU, V2
   Brink DL, 1966, ADV CHEM SER, V177
   Bryan C. C., 1954, US Patent, Patent No. [2 ,692,291, 2692291]
   Carbognani L., 1992, INTEVEP SA TECH REPO
   Chenoweth K, 2008, J PHYS CHEM A, V112, P1040, DOI 10.1021/jp709896w
   CORBETT LW, 1969, ANAL CHEM, V41, P576, DOI 10.1021/ac60273a004
   Davis T. C., 1967, P ASS ASPHALT PAVING, V36, P1
   Dizhbite T, 2004, BIORESOURCE TECHNOL, V95, P309, DOI 10.1016/j.biortech.2004.02.024
   Gelius U., 1970, Physica Scripta, V2, DOI 10.1088/0031-8949/2/1-2/014
   Griffin RL, 1959, J CHEM ENG DATA, V4, P349
   Hveem FN, 1959, PROGR REPORT ZACA WI, V277, P1
   JANSSENS GOA, 1995, J PHYS CHEM-US, V99, P3251, DOI 10.1021/j100010a041
   KELEMEN SR, 1990, FUEL, V69, P939, DOI 10.1016/0016-2361(90)90001-7
   Keten S, 2012, J MECH BEHAV BIOMED, V5, P32, DOI 10.1016/j.jmbbm.2011.08.017
   Kuzina S. I., 1993, J POLYM SCI A, VA35, P798
   Lindberg BJ, 1970, PHYS SCRIPTA, V1, P288
   LUCENA MCC, 2004, MAT RES, V7, P529, DOI DOI 10.1590/S1516-14392004000400004
   McNichol D., 2005, PAVING WAY ASPHALT A
   MORTIER WJ, 1986, J AM CHEM SOC, V108, P4315, DOI 10.1021/ja00275a013
   Njo SL, 1998, J MOL CATAL A-CHEM, V134, P79, DOI 10.1016/S1381-1169(98)00024-7
   Pan T, 2011, INT J ELECTROCHEM SC, V2
   Pan T, 2011, ELECTROCATALYSIS-US, V2, P307, DOI 10.1007/s12678-011-0068-8
   Pan TY, 2011, ACTA METALL SIN-ENGL, V24, P415, DOI 10.11890/1006-7191-116-415
   Pan TY, 2011, MATER LETT, V65, P3223, DOI 10.1016/j.matlet.2011.07.024
   Pan TY, 2011, CHEM PHYS LETT, V511, P315, DOI 10.1016/j.cplett.2011.06.041
   Parr R.G., 1989, DENSITY FUNCTIONAL T
   Petersen J.C., 1993, TRANSPORT RES REC, V1391, P1
   Petersen J. C., 1984, T RES REC, V999, P13
   Petersen J.C., 1983, P ASS ASPHALT PAVING, V52, P32
   Petersen JC, 1998, PET SCI TECHNOL, V16, P1023, DOI 10.1080/10916469808949823
   Petersen JC, 1998, TRANSPORT RES REC, P47, DOI 10.3141/1638-06
   Plancher H., 1976, P ASS ASPHALT PAVING, V45, P1
   Ruan YH, 2003, ENERG FUEL, V17, P991, DOI 10.1021/ef020221l
   RUIZ JM, 1982, ANAL CHEM, V54, P688, DOI 10.1021/ac00241a020
   STORM DA, 1994, ENERG FUEL, V8, P561, DOI 10.1021/ef00045a007
   van Duin ACT, 2001, J PHYS CHEM A, P105
   VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98
   White RM, 1970, P ASS ASPHALT PAVING, V39, P498
NR 42
TC 5
Z9 5
U1 2
U2 53
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0016-2361
EI 1873-7153
J9 FUEL
JI Fuel
PD NOV
PY 2013
VL 113
BP 454
EP 466
DI 10.1016/j.fuel.2013.06.003
PG 13
WC Energy & Fuels; Engineering, Chemical
SC Energy & Fuels; Engineering
GA 211UR
UT WOS:000323937300054
DA 2018-12-27
ER

PT J
AU Shih, BY
   Chen, CY
   Chen, ZS
AF Shih, Bih-Yaw
   Chen, Chen-Yuan
   Chen, Zih-Siang
TI RETRACTED: An Empirical Study of an Internet Marketing Strategy for
   Search Engine Optimization (Retracted article. See vol. 26, pg. 294,
   2016)
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Article; Retracted Publication
DE Search engine optimization (SEO); Social networking sites (SNS); Search
   engine; Search engine marketing (SEM); Internet marketing
ID NONLINEAR STRUCTURAL SYSTEMS; FUZZY LYAPUNOV METHOD; STABILITY ANALYSIS;
   IEEE 802.15.4; TIME-DELAY; MODEL; PERFORMANCE; SATISFACTION; MANAGEMENT;
   QUALITY
AB Over the past few years, more and more Internet visitors are reaching websites through search engines rather than through direct links from another web page. Search engines have come to occupy a prominent position in the online world and are being used to find all kinds of information including things, events, people, and places. The search engine is also coming to play a greater role as a critical link between firms that use the Internet to build their image and find their target customers. How to achieve a high ranking in such search results given certain search words or phrases has become an issue of much interest in Internet marketing. The purpose of the current study is to develop a search engine optimization (SEO) mechanism that can be used by an enterprise to improve the ranking of its website in the search engine results. Social networking sites are included in our exploration of Internet marketing strategy. The proposed mechanism is then applied in the operations of an online ebook store. The website rankings obtained from two well-known online search engines (Google and Yahoo) are evaluated in efforts to explore a better strategy to ensure higher rankings. The results reveal that a well-designed SEO strategy, with the incorporation of social networking, can effectively enhance the website's visibility and exposure. Such a strategy will eventually contribute to overall site traffic and improve interaction with customers. (c) 2012 Wiley Periodicals, Inc.
C1 [Shih, Bih-Yaw; Chen, Chen-Yuan; Chen, Zih-Siang] Natl Pingtung Univ Educ, Dept & Grad Sch Comp Sci, Pingtung 90003, Taiwan.
   [Chen, Chen-Yuan] Natl Kaohsiung First Univ Sci & Technol, Dept Informat Management, Kaohsiung 811, Taiwan.
   [Chen, Chen-Yuan] Natl Cheng Kung Univ, GEODAC, Tainan 701, Taiwan.
   [Chen, Zih-Siang] Natl Sun Yat Sen Univ, Dept Comp Sci & Engn, Kaohsiung 80424, Taiwan.
RP Chen, CY (reprint author), 4-18 Minsheng Rd, Pingtung City 90003, Pingtung County, Taiwan.
EM cyc@mail.npue.edu.tw
FU National Science Council, Republic of China [NSC 98-2221-E-153-004, NSC
   99-2628-E-153-001, NSC 100-2628-E-153-001]
FX We appreciate the financial support in the form of research grants to
   Chen-Yuan Chen from the National Science Council, Republic of China
   (Grant Nos. NSC 98-2221-E-153-004, NSC 99-2628-E-153-001, and NSC
   100-2628-E-153-001). We are also most grateful for the constructive
   suggestions of the anonymous reviewers, all of which led to the making
   of several corrections and suggestions that have greatly aided us in the
   presentation of this article. In addition, we thank Cheng-Hsuan Tsai and
   Chen-Ping Chiu, of the Department and Graduate School of Computer
   Science at the National Pingtung University of Education, for help with
   the literature corrections.
CR Baxter R, 2010, FACIAL PLAST SURG, V26, P39, DOI 10.1055/s-0029-1245063
   Boyd DM, 2007, J COMPUT-MEDIAT COMM, V13, P210, DOI [10.1111/j.1083-6101.2007.00393.x, 10.1111/j.1083-6101.2007.00367.x]
   Burns E., 2008, US CORE SEARCH RANKI
   Cegarra J, 2008, HUM FACTOR ERGON MAN, V18, P603, DOI 10.1002/hfm.20129
   Chen C. W., 2010, J VIBRATION CONTROL, DOI 10.1177/1077546309352827
   Chen C. Y., 2011, J VIBRATION CONTROL, DOI 10.1177/1077546310397561
   Chen CY, 2011, INT J INNOV COMPUT I, V7, P5245
   Chen CY, 2011, J MAR SCI TECH-JAPAN, V16, P100, DOI 10.1007/s00773-010-0112-z
   Chen CW, 2007, INT J ARTIF INTELL T, V16, P545, DOI 10.1142/S0218213007003400
   Chen CW, 2007, J VIB CONTROL, V13, P1519, DOI 10.1177/1077546307073690
   Chen CW, 2007, ENG COMPUTATION, V24, P116, DOI 10.1108/02644400710729536
   Chen CW, 2011, J VIB CONTROL, V17, P1693, DOI 10.1177/1077546310379625
   Chen CW, 2010, MATH PROBL ENG, DOI 10.1155/2010/120403
   Chen CW, 2011, NEURAL COMPUT APPL, V20, P527, DOI 10.1007/s00521-011-0576-8
   Chen CW, 2011, APPL SOFT COMPUT, V11, P2735, DOI 10.1016/j.asoc.2010.11.004
   Chen CW, 2010, J MAR SCI TECH-TAIW, V18, P644
   Chen CW, 2010, J VIB CONTROL, V16, P1651, DOI 10.1177/1077546309104185
   Chen CW, 2010, ENG COMPUTATION, V27, P186, DOI 10.1108/02644401011022364
   Chen CW, 2010, INT J INNOV COMPUT I, V6, P1793
   Chen CW, 2009, MATH COMPUT SIMULAT, V80, P402, DOI 10.1016/j.matcom.2009.08.001
   Chen CW, 2009, INT J UNCERTAIN FUZZ, V17, P705, DOI 10.1142/S0218488509006224
   Chen CW, 2009, INT J UNCERTAIN FUZZ, V17, P667, DOI 10.1142/S0218488509006200
   Chen CW, 2009, EXPERT SYST APPL, V36, P4765, DOI 10.1016/j.eswa.2008.06.062
   Chen CW, 2011, INT J PHYS SCI, V6, P4492
   Chen CW, 2011, INT J PHYS SCI, V6, P3585
   Correa T, 2010, COMPUT HUM BEHAV, V26, P247, DOI 10.1016/j.chb.2009.09.003
   Dou WY, 2010, MIS QUART, V34, P261
   Duffy VG, 1997, HUM FACTOR ERGON MAN, V7, P351, DOI 10.1002/(SICI)1520-6564(199723)7:4<351::AID-HFM6>3.0.CO;2-2
   Evans MP, 2007, INTERNET RES, V17, P21, DOI 10.1108/10662240710730470
   Gefen D., 2000, J ASSOC INF SYST, V1, P1, DOI DOI 10.17705/1JAIS
   Huang CM, 2008, HUM FACTOR ERGON MAN, V18, P621, DOI 10.1002/hfm.20130
   Hwang A., 2010, TAIWAN MARKET 2010 O
   Jayaswal P, 2011, J VIB CONTROL, V17, P1131, DOI 10.1177/1077546310361858
   Kane GC, 2009, HARVARD BUS REV, V87, P45
   Kang YS, 2010, COMPUT HUM BEHAV, V26, P353, DOI 10.1016/j.chb.2009.11.006
   Khalid HM, 2000, HUM FACTORS ERGONOM, V10, P99, DOI 10.1002/(SICI)1520-6564(200024)10:1<99::AID-HFM6>3.0.CO;2-S
   Killoran JB, 2009, IEEE T PROF COMMUN, V52, P254, DOI 10.1109/TPC.2009.2025309
   Kisiel R., 2010, AUTOMOTIVE NEWS, V84, P24
   Kumar A, 2004, J CONSUM RES, V30, P602, DOI 10.1086/380292
   Lee W. I., 2010, HUMAN FACTORS ERGONO, DOI 10. 1002/hfm. 20253
   Lee WI, 2011, AFR J BUS MANAGE, V5, P722
   Lee WI, 2010, IRAN J PUBLIC HEALTH, V39, P15
   Lee WI, 2010, AFR J BUS MANAGE, V4, P448
   Lee WI, 2010, INT J INNOV COMPUT I, V6, P1805
   Leung GTC, 2010, HUM FACTOR ERGON MAN, V20, P567, DOI 10.1002/hfm.20198
   Malaga R. A., 2009, REV BUSINESS RES, V9, P132
   Malaga RA, 2010, ADV COMPUT, V78, P1, DOI 10.1016/S0065-2458(10)78001-3
   Malaga RA, 2008, COMMUN ACM, V51, P147, DOI 10.1145/1409360.1409388
   Marichal GN, 2011, J VIB CONTROL, V17, P931, DOI 10.1177/1077546310366264
   McGee M., 2010, FACEBOOK MOST POPULA
   McPherson RF, 2006, HUM FACTORS ERGONOM, V16, P385, DOI 10.1002/hfm.20059
   Metin M, 2011, J VIB CONTROL, V17, P1525, DOI 10.1177/1077546310381099
   Moran M., 2006, SEARCH ENGINE MARKET
   Raisinghani M., 2005, ELECT COMMERCE ORG, V3, P1
   Shih B. Y., 2011, HUMAN FACTORS ERGONO, DOI 10.1002/hfm.20272
   Shih B. Y., 2011, J VIBRATION CONTROL, DOI 10.1177/1077546311407649
   Shih B. Y., 2011, COMPUTER APPL ENG ED, DOI 10.1002/cae.20478
   Shih BY, 2011, J VIB CONTROL, V17, P1567, DOI 10.1177/1077546310372004
   Shih BY, 2010, INT J INNOV COMPUT I, V6, P5511
   Shih BY, 2010, INT J PHYS SCI, V5, P884
   Shih BY, 2011, SCI RES ESSAYS, V6, P5342
   Shih BY, 2011, INT J PHYS SCI, V6, P5054
   Shih CH, 2011, INT J INNOV COMPUT I, V7, P2225
   Shih CH, 2010, MATH PROBL ENG, DOI 10.1155/2010/481438
   Smith S., 2004, MEDIA, V5, P24
   Tung WF, 2009, HUM FACTOR ERGON MAN, V19, P494, DOI 10.1002/hfm.20147
   Viney D., 2008, GET TOP GOOGLE TIPS
   Wu JN, 2005, INFORM SYST RES, V16, P334, DOI 10.1287/isre.1050.0071
NR 68
TC 25
Z9 25
U1 5
U2 159
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-8471
EI 1520-6564
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD NOV
PY 2013
VL 23
IS 6
BP 528
EP 540
DI 10.1002/hfm.20348
PG 13
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 239BF
UT WOS:000325995800003
DA 2018-12-27
ER

PT J
AU Cortes, VA
   Busso, D
   Mardones, P
   Maiz, A
   Arteaga, A
   Nervi, F
   Rigotti, A
AF Cortes, Victor A.
   Busso, Dolores
   Mardones, Pablo
   Maiz, Alberto
   Arteaga, Antonio
   Nervi, Flavio
   Rigotti, Attilio
TI RETRACTED: Advances in the physiological and pathological implications
   of cholesterol (Retracted article. See vol. 90, pg. 996, 2015)
SO BIOLOGICAL REVIEWS
LA English
DT Review; Retracted Publication
DE cholesterol; mevalonate pathway; atherosclerosis; nuclear receptors;
   Alzheimer's disease
ID LIVER-X-RECEPTORS; CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA-PEPTIDE;
   APOLIPOPROTEIN-A-I; BINDING CASSETTE TRANSPORTERS;
   HIGH-DENSITY-LIPOPROTEINS; STEROL SYNTHESIS RATES; LEMLI-OPITZ-SYNDROME;
   HMG COA REDUCTASE; CELLULAR CHOLESTEROL
AB Cholesterol has evolved to fulfill sophisticated biophysical, cell signalling, and endocrine functions in animal systems. At the cellular level, cholesterol is found in membranes where it increases both bilayer stiffness and impermeability to water and ions. Furthermore, cholesterol is integrated into specialized lipid-protein membrane microdomains with critical topographical and signalling functions. At the organismal level, cholesterol is the precursor of all steroid hormones, including gluco- and mineralo-corticoids, sex hormones, and vitamin D, which regulate carbohydrate, sodium, reproductive, and bone homeostasis, respectively. This sterol is also the immediate precursor of bile acids, which are important for intestinal absorption of dietary lipids as well as energy homeostasis and glucose regulation. Complex mechanisms maintain cholesterol within physiological ranges and the dysregulation of these mechanisms results in embryonic or adult diseases, caused by either excessive or reduced tissue cholesterol levels. The causative role of cholesterol in these conditions has been demonstrated by genetic and pharmacological manipulations in animal models of human disease that are discussed herein. Importantly, the understanding of basic aspects of cholesterol biology has led to the development of high-impact pharmaceutical therapies during the past century. The continuing effort to offer successful treatments for prevalent cholesterol-related diseases, such as atherosclerosis and neurodegenerative disorders, warrants further interdisciplinary research in the coming decades.
C1 [Cortes, Victor A.; Busso, Dolores; Mardones, Pablo; Maiz, Alberto; Arteaga, Antonio; Rigotti, Attilio] Pontificia Univ Catolica Chile, Fac Med, Sch Med, Dept Nutr Diabet & Metab, Santiago, Chile.
   [Nervi, Flavio] Pontificia Univ Catolica Chile, Fac Med, Sch Med, Dept Gastroenterol, Santiago, Chile.
RP Cortes, VA (reprint author), Pontificia Univ Catolica Chile, Fac Med, Sch Med, Dept Nutr Diabet & Metab, Marcoleta 367 Edif Gastroenterol 4 Piso, Santiago, Chile.
EM vcortes@med.puc.cl
RI Busso, Dolores/I-3047-2016
OI Busso, Dolores/0000-0003-2113-1926; Cortes, Victor/0000-0002-1658-0965
FU Fondecyt [11100168, 11090064, 1100020, 1110712]; Conicyt (Programa de
   Insercion en la Academia) [79100018, 79090028]
FX The authors thank Ashlee Stiles and Susan Smalley for their kind help in
   editing the text and their valuable scientific suggestions. V.A.C. is
   funded by Fondecyt # 11100168 and Conicyt (Programa de Insercion en la
   Academia) # 79100018. D.B. is funded by Fondecyt # 11090064 and Conicyt
   (Programa de Insercion en la Academia) # 79090028. F.N. is funded by
   Fondecyt # 1100020. A. R. is funded by Fondecyt # 1110712.
CR Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628
   Andersson HC, 2002, AM J MED GENET, V113, P315, DOI 10.1002/ajmg.10873
   Aoki K, 2003, STROKE, V34, P875, DOI 10.1161/01.STR.0000064320.73388.C6
   APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025
   Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263
   Baranowski M, 2008, J PHYSIOL PHARMACOL, V59, P31
   Barrett PJ, 2012, SCIENCE, V336, P1168, DOI 10.1126/science.1219988
   Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200
   Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087
   Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771
   Bjorkhem I, 2001, J BIOL CHEM, V276, P37004, DOI 10.1074/jbc.M103828200
   BLOCH K, 1965, SCIENCE, V150, P19, DOI 10.1126/science.150.3692.19
   BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790
   BLOCH KE, 1979, CRC CR REV BIOCH MOL, V7, P1, DOI 10.3109/10409237909102566
   Bowman G. L., 2012, CURRENT GERONTOLOGY, V2012
   Briand F, 2010, J LIPID RES, V51, P763, DOI 10.1194/jlr.M001552
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5
   BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311
   BROWN MS, 1980, J LIPID RES, V21, P505
   Burke KT, 2009, J LIPID RES, V50, P1146, DOI 10.1194/jlr.M800538-JLR200
   Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228
   Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200
   Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013
   Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Cortes V, 2005, REV MED CHILE, V133, P1483, DOI 10.4067/S0034-98872005001200011
   Crowder CM, 2001, J BIOL CHEM, V276, P44369, DOI 10.1074/jbc.C100535200
   Deane R, 2008, J CLIN INVEST, V118, P4002, DOI 10.1172/JCI36663
   DeBose-Boyd RA, 2008, CELL RES, V18, P609, DOI 10.1038/cr.2008.61
   DeMattos RB, 2001, NEUROCHEM INT, V39, P415, DOI 10.1016/S0197-0186(01)00049-3
   Di Paolo G, 2011, NAT REV NEUROSCI, V12, P284, DOI 10.1038/nrn3012
   Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI [10.1194/jlr.r400004, 10.1194/jlr.r400004-JLR200]
   DIETSCHY JM, 1993, J LIPID RES, V34, P1637
   Duran-Sandoval D, 2005, J BIOL CHEM, V280, P29971, DOI 10.1074/jbc.M501931200
   Edison RJ, 2005, NEW ENGL J MED, V352, P2759, DOI 10.1056/NEJM200506303522622
   Edison RJ, 2007, PEDIATRICS, V120, P723, DOI 10.1542/peds.2006-1939
   Engelking LJ, 2005, J CLIN INVEST, V115, P2489, DOI 10.1172/JCI125614
   Engelking LJ, 2004, J CLIN INVEST, V113, P1168, DOI 10.1172/JCI200420978
   Engelking LJ, 2006, J CLIN INVEST, V116, P2356, DOI 10.1172/JCI28988
   FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774
   Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100
   Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035
   FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8
   FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082
   Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x
   Gilk SD, 2010, J BACTERIOL, V192, P6154, DOI 10.1128/JB.00818-10
   Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022
   GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4
   Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749
   HADDAD IA, 1986, J BIOL CHEM, V261, P3268
   Haines TH, 2001, PROG LIPID RES, V40, P299, DOI 10.1016/S0163-7827(01)00009-1
   Hauser PS, 2011, PROG LIPID RES, V50, P62, DOI 10.1016/j.plipres.2010.09.001
   Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342
   Herz J, 2009, CURR OPIN LIPIDOL, V20, P190, DOI 10.1097/MOL.0b013e32832d3a10
   Herz J, 2009, J LIPID RES, V50, pS287, DOI 10.1194/jlr.R800077-JLR200
   Holtzman DM, 2012, COLD SPRING HARBOR P, V2
   Honzumi S, 2011, BBA-MOL CELL BIOL L, V1811, P1136, DOI 10.1016/j.bbalip.2011.08.009
   Horton JD, 2009, J LIPID RES, V50, pS172, DOI 10.1194/jlr.R800091-JLR200
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Howe D, 2006, CELL MICROBIOL, V8, P496, DOI 10.1111/j.1462-5822.2005.00641.x
   Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040
   Hui L, 2012, LIFE SCI, V91, P1159, DOI 10.1016/j.lfs.2012.04.039
   Huster D, 2005, BIOPHYS J, V88, P1838, DOI 10.1529/biophysj.104.048926
   Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336
   Im SS, 2011, CIRC RES, V108, P996, DOI 10.1161/CIRCRESAHA.110.226878
   Inagaki T, 2006, P NATL ACAD SCI USA, V103, P3920, DOI 10.1073/pnas.0509592103
   Jakobsson T, 2012, TRENDS PHARMACOL SCI, V33, P394, DOI 10.1016/j.tips.2012.03.013
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010
   Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820
   Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299
   Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423
   Kim WS, 2008, J NEUROCHEM, V104, P1145, DOI 10.1111/j.1471-4159.2007.05099
   Klein A, 2006, HEPATOLOGY, V43, P126, DOI 10.1002/hep.20985
   Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200
   Kotti T, 2008, P NATL ACAD SCI USA, V105, P11394, DOI 10.1073/pnas.0805556105
   Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103
   Kurzchalia TV, 2003, NAT CELL BIOL, V5, P684, DOI 10.1038/ncb0803-684
   Kwon HJ, 2009, CELL, V137, P1213, DOI 10.1016/j.cell.2009.03.049
   LaDu MJ, 1998, J NEUROCHEM, V70, P2070
   Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798
   LANGE Y, 1983, J BIOL CHEM, V258, P5130
   Lange Y, 1999, J LIPID RES, V40, P2264
   Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137
   Leiva A, 2011, ATHEROSCLEROSIS, V217, P299, DOI 10.1016/j.atherosclerosis.2011.05.036
   Li YK, 2004, J BIOL CHEM, V279, P37030, DOI 10.1074/jbc.M405195200
   Linck LM, 2000, PRENATAL DIAG, V20, P238, DOI 10.1002/(SICI)1097-0223(200003)20:3<238::AID-PD792>3.3.CO;2-N
   Lindegaard ML, 2008, HUM MOL GENET, V17, P3806, DOI 10.1093/hmg/ddn278
   Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8
   Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238
   Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362
   Matyash V, 2001, MOL BIOL CELL, V12, P1725, DOI 10.1091/mbc.12.6.1725
   Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354
   McConihay JA, 2000, J LIPID RES, V41, P424
   McKenney JM, 2012, J AM COLL CARDIOL, V59, P2344, DOI 10.1016/j.jacc.2012.03.007
   Merris M, 2003, J LIPID RES, V44, P172, DOI 10.1194/jlr.M200323-JLR200
   Miao B, 2004, J LIPID RES, V45, P1410, DOI 10.1194/jlr.M300450
   MISHKEL MA, 1974, CAN MED ASSOC J, V111, P775
   MOCKEL B, 1994, J NEUROCHEM, V62, P788
   MODELL W, 1967, SCIENCE, V156, P346, DOI 10.1126/science.156.3773.346
   Muldoon MF, 2000, AM J MED, V108, P538, DOI 10.1016/S0002-9343(00)00353-3
   Muldoon MF, 2004, AM J MED, V117, P823, DOI 10.1016/j.amjmed.2004.07.041
   Naik SU, 2006, CIRCULATION, V113, P90, DOI 10.1161/CIRCULATIONAHA.105.560177
   Nieweg K, 2009, J NEUROCHEM, V109, P125, DOI 10.1111/j.1471-4159.2009.05917.x
   Nissen SE, 2006, NEW ENGL J MED, V354, P1253, DOI 10.1056/NEJMoa054699
   Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226
   Olson RE, 1998, J NUTR, V128, p439S, DOI 10.1093/jn/128.2.439S
   Ong WY, 1997, NEUROSCIENCE, V79, P359, DOI 10.1016/S0306-4522(96)00608-2
   Ory DS, 2004, CIRC RES, V95, P660, DOI 10.1161/01.RES.0000143422.83209.be
   Palinski W, 2007, NUTR REV, V65, pS182, DOI 10.1301/nr.2007.dec.S182-S187
   Pandey AK, 2008, P NATL ACAD SCI USA, V105, P4376, DOI 10.1073/pnas.0711159105
   Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365
   Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4
   Pfenninger KH, 2009, NAT REV NEUROSCI, V10, P251, DOI 10.1038/nrn2593
   Pfrieger FW, 2011, PROG LIPID RES, V50, P357, DOI 10.1016/j.plipres.2011.06.002
   Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195
   PITAS RE, 1987, J BIOL CHEM, V262, P14352
   Plass JRM, 2002, HEPATOLOGY, V35, P589, DOI 10.1053/jhep.2002.31724
   Porter FD, 2003, CURR OPIN PEDIATR, V15, P607, DOI 10.1097/00008480-200312000-00011
   Quan G, 2003, DEV BRAIN RES, V146, P87, DOI 10.1016/j.devbrainres.2003.09.015
   Radhakrishnan A, 2008, CELL METAB, V8, P512, DOI 10.1016/j.cmet.2008.10.008
   Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X
   Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200
   Repa JJ, 2007, J NEUROSCI, V27, P14470, DOI 10.1523/JNEUROSCI.4823-07.2007
   Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037
   Rodriguez-Acebes S, 2009, BIOCHEM J, V420, P305, DOI 10.1042/BJ20081909
   ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570
   ROUX C, 1966, CR SOC BIOL, V160, P1353
   Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859
   Sadowski MJ, 2006, P NATL ACAD SCI USA, V103, P18787, DOI 10.1073/pnas.0604011103
   Saher G, 2012, NAT MED, V18, P1130, DOI 10.1038/nm.2833
   SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407
   Santander N. G., 2012, HUMAN MOL G IN PRESS, DOI 10.1093/hmg/dds510
   Schipper HM, 2011, NEUROBIOL AGING, V32, P778, DOI 10.1016/j.neurobiolaging.2009.04.021
   Schmid KE, 2003, AM J PHYSIOL-GASTR L, V285, pG796, DOI 10.1152/ajpgi.00226.2003
   Schulman IG, 2010, ADV DRUG DELIVER REV, V62, P1307, DOI 10.1016/j.addr.2010.07.002
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390
   Simons M, 2007, CURR OPIN NEUROBIOL, V17, P533, DOI 10.1016/j.conb.2007.08.003
   Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d
   Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200
   Stefulj J, 2009, CIRC RES, V104, P600, DOI 10.1161/CIRCRESAHA.108.185066
   Stein EA, 2012, NEW ENGL J MED, V366, P1108, DOI 10.1056/NEJMoa1105803
   Steinberg D, 2004, J LIPID RES, V45, P1583, DOI 10.1194/jlr.R400003.JLR200
   STEINBERG D, 1961, J CLIN INVEST, V40, P884, DOI 10.1172/JCI104323
   Steinhauer J, 2009, CURR OPIN GENET DEV, V19, P308, DOI 10.1016/j.gde.2009.04.006
   STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098
   Su YR, 2005, CIRCULATION, V111, P2373, DOI 10.1161/01.CIR.0000164236.19860.13
   Svoboda JA, 1999, CRIT REV BIOCHEM MOL, V34, P49, DOI 10.1080/10409239991209183
   Tabas I, 2004, CELL DEATH DIFFER, V11, pS12, DOI 10.1038/sj.cdd.4401444
   Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452
   Tabas I, 2010, CIRC RES, V107, P839, DOI 10.1161/CIRCRESAHA.110.224766
   Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799
   Tardif JC, 2004, CIRCULATION, V110, P3372, DOI 10.1161/01.CIR.0000147777.12010.EF
   Tarr PT, 2008, J LIPID RES, V49, P169, DOI 10.1194/jlr.M700364-JLR200
   Tint GS, 2006, J LIPID RES, V47, P1535, DOI 10.1194/jlr.M600141-JLR200
   TURLEY SD, 1995, J LIPID RES, V36, P67
   Turley SD, 1996, J LIPID RES, V37, P1953
   van der Hoorn JWA, 2011, BRIT J PHARMACOL, V162, P1553, DOI 10.1111/j.1476-5381.2010.01168.x
   van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330
   Vance JE, 2010, BBA-MOL CELL BIOL L, V1801, P806, DOI 10.1016/j.bbalip.2010.02.007
   Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700
   Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697
   Vetrivel KS, 2010, BBA-MOL CELL BIOL L, V1801, P860, DOI 10.1016/j.bbalip.2010.03.007
   WAELSCH HEINRICH, 1940, JOUR BIOL CHEM, V135, P297
   Wang ML, 2010, CELL METAB, V12, P166, DOI 10.1016/j.cmet.2010.05.016
   Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101
   Waterham HR, 2006, FEBS LETT, V580, P5442, DOI 10.1016/j.febslet.2006.07.027
   Waterham HR, 2001, AM J HUM GENET, V69, P685, DOI 10.1086/323473
   Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776
   Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460
   Willnow TE, 2007, DEVELOPMENT, V134, P3239, DOI 10.1242/dev.004408
   WOLMAN M, 1995, CLIN PEDIATR, V34, P207, DOI 10.1177/000992289503400406
   Woollett LA, 2011, PLACENTA, V32, pS218, DOI 10.1016/j.placenta.2011.01.011
   Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006
   Yanagisawa K, 2002, ANN NY ACAD SCI, V977, P384, DOI 10.1111/j.1749-6632.2002.tb04841.x
   Yao L, 2007, BBA-MOL CELL BIOL L, V1771, P1372, DOI 10.1016/j.bbalip.2007.09.002
   Yi P, 2006, SCIENCE, V313, P1301, DOI 10.1126/science.1127704
   Yoshida S, 2005, J LIPID RES, V46, P2168, DOI 10.1194/jlr.M500096-JLR200
   Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399
   Zhang H, 2012, J NEUROCHEM, V120, P9, DOI 10.1111/j.1471-4159.2011.07519.x
NR 187
TC 11
Z9 13
U1 2
U2 47
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-7931
EI 1469-185X
J9 BIOL REV
JI Biol. Rev.
PD NOV
PY 2013
VL 88
IS 4
BP 825
EP 843
DI 10.1111/brv.12025
PG 19
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 229KM
UT WOS:000325262600004
PM 23445165
DA 2018-12-27
ER

PT J
AU Zamanipoor, MH
   Dincer, TD
   Zisu, B
   Jayasena, V
AF Zamanipoor, Mohammad Hasan
   Dincer, Tuna Derya
   Zisu, Bogdan
   Jayasena, Vijay
TI RETRACTED: Nucleation and growth rates of lactose as affected by
   ultrasound in aqueous solutions (Retracted article. See vol. 96, pg.
   425, 2016)
SO DAIRY SCIENCE & TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Lactose; Sonocrystallisation; Modelling
ID ANTI-SOLVENT; ASSISTED CRYSTALLIZATION; CRYSTAL HABIT;
   SONOCRYSTALLIZATION; RECOVERY; ACETONE
AB The impact of ultrasound on promoting the crystallisation process including an increase in nucleation rate and the formation of more uniform crystals from a large number of substances has been reported in previous studies. This study aimed to investigate the effectiveness of ultrasound in enhancing the crystallisation process of lactose and to model the effects of ultrasonic variables on nucleation rate, growth rate, and size distribution of lactose crystals in aqueous solutions. Ultrasound was applied to the lactose in water solutions at the constant frequency of 20 kHz and at 22 +/- 1 A degrees C using an ultrasonic probe. Spectrophotometry and direct microscopy techniques were used to measure the responses under study. The data were analysed by Design Expert software for modelling. The variables that significantly (P < 0.05) affected the responses were lactose concentration and amplitude, with concentration being the most significant. The sonicated sample at the optimal sonication conditions had 10.6 times higher nucleation rate and 5.6 times higher yield as compared to the control. The results of this study emphasised the potential effects of ultrasonic treatment in promoting the nucleation rate and yield in the manufacture of lactose. Furthermore, the fact that sonication time had no significant effect (P > 0.05) on the responses implied that sonication duration can be kept to a minimum to save on energy and costs.
C1 [Zamanipoor, Mohammad Hasan] Curtin Univ, Sch Biomed Sci, Perth, WA 6845, Australia.
   [Dincer, Tuna Derya; Jayasena, Vijay] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Publ Hlth, Food Sci & Technol Program, Perth, WA 6845, Australia.
   [Zisu, Bogdan] Dairy Innovat Australia Ltd, Werribee, Vic 3030, Australia.
RP Zamanipoor, MH (reprint author), Curtin Univ, Sch Biomed Sci, GPO Box U1987, Perth, WA 6845, Australia.
EM zamanipoor@gmail.com; v.jayasena@curtin.edu.au
FU Dairy Innovation Australia Ltd.
FX This research has been funded by Dairy Innovation Australia Ltd. Their
   financial support and permission to publish is gratefully acknowledged.
CR Brito ABN, 2007, CRYST RES TECHNOL, V42, P583, DOI 10.1002/crat.200610867
   Bund RK, 2007, ULTRASON SONOCHEM, V14, P143, DOI 10.1016/j.ultsonch.2006.06.003
   de Castro MDL, 2007, ULTRASON SONOCHEM, V14, P717, DOI 10.1016/j.ultsonch.2006.12.004
   Dhumal RS, 2008, PHARM RES-DORDR, V25, P2835, DOI 10.1007/s11095-008-9653-9
   Guo Z, 2005, J CRYST GROWTH, V273, P555, DOI 10.1016/j.jcrysgro.2004.09.049
   HEM SL, 1967, ULTRASONICS, V5, P202, DOI 10.1016/0041-624X(67)90061-3
   Kougoulos E, 2010, J CRYST GROWTH, V312, P3509, DOI 10.1016/j.jcrysgro.2010.09.022
   Li H, 2006, ULTRASON SONOCHEM, V13, P359, DOI 10.1016/j.ultsonch.2006.01.002
   McLeod J, 2011, INT DAIRY J, V21, P455, DOI 10.1016/j.idairyj.2011.01.006
   Myers R. H., 1995, RESPONSE SURFACE MET
   Parsons AR, 2003, CHEM ENG RES DES, V81, P700, DOI 10.1205/026387603322150552
   Patel SR, 2009, CRYST RES TECHNOL, V44, P889, DOI 10.1002/crat.200900227
   Patist A, 2008, INNOV FOOD SCI EMERG, V9, P147, DOI 10.1016/j.ifset.2007.07.004
   VISSER RA, 1982, NETH MILK DAIRY J, V36, P89
NR 14
TC 4
Z9 4
U1 3
U2 42
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1958-5586
EI 1958-5594
J9 DAIRY SCI TECHNOL
JI Dairy Sci. Technol.
PD NOV
PY 2013
VL 93
IS 6
BP 595
EP 604
DI 10.1007/s13594-012-0106-1
PG 10
WC Food Science & Technology
SC Food Science & Technology
GA 223SS
UT WOS:000324830700002
DA 2018-12-27
ER

PT J
AU Ashokkumar, S
   Ravi, S
   Velmurugan, S
AF Ashokkumar, S.
   Ravi, S.
   Velmurugan, S.
TI RETRACTED: Green synthesis of silver nanoparticles from Gloriosa superba
   L. leaf extract and their catalytic activity (Retracted article. See
   vol. 115, pg. 388, 2013)
SO SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
LA English
DT Article; Retracted Publication
DE Nanoparticles; Green synthesis; Gloriosa superba extract; Methylene blue
ID METHYLENE-BLUE; GOLD NANOPARTICLES; NANOSCALE IRON; RAPID SYNTHESIS;
   PLANT-EXTRACT; BIOSYNTHESIS; PHOTOLUMINESCENCE; REDUCTION; AG;
   LUMINESCENCE
AB The present work focuses the use of aqueous extract of Gloriosa superba Linn. (Glory Lily) for producing silver nanoparticles (AgNPs) from silver nitrate aqueous solution. Phytochemical analysis of the extract revealed the presence of alkaloid, amino acids, carbohydrates and proteins in the extract and they serve as effective reducing and capping agents for converting silver nitrate to silver nanoparticles. The nanopartides were characterised by UV (Ultra violet), FT-IR (Fourier Transform Infrared), XRD (X-ray diffraction), TEM (Transmission Electron Microscope) SEM-EDX (Scanning Electron Microscopy-Energy Dispersive X-ray), and PL (Photoluminescence) studies. Moreover, the catalytic activity of synthesized AgNPs in the reduction of methylene blue was studied by UV-vis spectrophotometer. The synthesized AgNPs are observed to have a good catalytic activity on the reduction of methylene blue by G. superba extract which is confirmed by the decrease in absorbance maximum values of methylene blue with respect to time using UV-vis spectrophotometer. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Ashokkumar, S.] Annamalai Univ, Dept Phys, Annamalainagar 608002, Tamil Nadu, India.
   [Ravi, S.; Velmurugan, S.] Annamalai Univ, Dept Engg Phys, Annamalainagar 608002, Tamil Nadu, India.
RP Ravi, S (reprint author), Annamalai Univ, Dept Engg Phys, Annamalainagar 608002, Tamil Nadu, India.
EM ambedravi@gmail.com
CR Ahmad A, 2003, LANGMUIR, V19, P3550, DOI 10.1021/la026772l
   Ahmad A, 2002, J AM CHEM SOC, V124, P12108, DOI 10.1021/ja0272960o
   Alqudami A, 2007, PLASMONICS, V2, P5, DOI 10.1007/s11468-006-9019-2
   Bankar A, 2010, COLLOID SURFACE A, V368, P58, DOI 10.1016/j.colsurfa.2010.07.024
   Bar H, 2009, COLLOID SURFACE A, V339, P134, DOI 10.1016/j.colsurfa.2009.02.008
   Beversluis MR, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.115433
   Bharde AA, 2008, LANGMUIR, V24, P5787, DOI 10.1021/la704019p
   BOYD GT, 1986, PHYS REV B, V33, P7923, DOI 10.1103/PhysRevB.33.7923
   Burhenne J, 2008, J CHROMATOGR B, V863, P273, DOI 10.1016/j.jchromb.2008.01.028
   Cao JS, 2005, J NANOPART RES, V7, P499, DOI 10.1007/s11051-005-4412-x
   Chandrasekharan DK, 2011, CANCER BIOTHER RADIO, V26, P249, DOI 10.1089/cbr.2010.0862
   Chen SS, 2004, J NANOPART RES, V6, P639, DOI 10.1007/s11051-004-6672-2
   Dwivedi AD, 2010, COLLOID SURFACE A, V369, P27, DOI 10.1016/j.colsurfa.2010.07.020
   Edison TJI, 2012, PROCESS BIOCHEM, V47, P1351, DOI 10.1016/j.procbio.2012.04.025
   Eisa WH, 2011, MATER CHEM PHYS, V128, P109, DOI 10.1016/j.matchemphys.2011.02.076
   GILLHAM RW, 1994, GROUND WATER, V32, P958, DOI 10.1111/j.1745-6584.1994.tb00935.x
   Gnanadesigan M, 2011, ASIAN PAC J TROP MED, V4, P799, DOI 10.1016/S1995-7645(11)60197-1
   Guo L, 2001, PHYS CHEM CHEM PHYS, V3, P1661, DOI 10.1039/b009951l
   Jha AK, 2009, BIOCHEM ENG J, V43, P303, DOI 10.1016/j.bej.2008.10.016
   Kamat PV, 2002, J PHYS CHEM B, V106, P7729, DOI 10.1021/jp0209289
   Kanel SR, 2005, ENVIRON SCI TECHNOL, V39, P1291, DOI 10.1021/es048991u
   Kaviya S, 2012, MATER LETT, V67, P64, DOI 10.1016/j.matlet.2011.09.023
   Krishnaraj C, 2010, COLLOID SURFACE B, V76, P50, DOI 10.1016/j.colsurfb.2009.10.008
   Kundu S, 2002, B MATER SCI, V25, P577, DOI 10.1007/BF02710555
   Lin A, 2007, OPT EXPRESS, V15, P6374, DOI 10.1364/OE.15.006374
   Lin YT, 2008, SEP PURIF TECHNOL, V64, P26, DOI 10.1016/j.seppur.2008.08.012
   Liqin L., 2010, J CHEM ENG, V162, P852
   Mallick K, 2006, MATER CHEM PHYS, V97, P283, DOI 10.1016/j.matchemphys.2005.08.011
   MOORADIAN A, 1969, PHYS REV LETT, V22, P185, DOI 10.1103/PhysRevLett.22.185
   Moreno-Manas M, 2003, ACCOUNTS CHEM RES, V36, P638, DOI 10.1021/ar020267y
   MubarakAli D, 2011, COLLOID SURFACE B, V85, P360, DOI 10.1016/j.colsurfb.2011.03.009
   Njagi EC, 2011, LANGMUIR, V27, P264, DOI 10.1021/la103190n
   Qin YQ, 2010, COLLOID SURFACE A, V372, P172, DOI 10.1016/j.colsurfa.2010.10.013
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Rajakumar G, 2011, ACTA TROP, V118, P196, DOI 10.1016/j.actatropica.2011.03.003
   Ren ML, 2005, BIOSENS BIOELECTRON, V21, P433, DOI 10.1016/j.bios.2004.08.052
   Sathishkumar M, 2009, J HAZARD MATER, V171, P400, DOI 10.1016/j.jhazmat.2009.06.014
   Shahverdi AR, 2007, PROCESS BIOCHEM, V42, P919, DOI 10.1016/j.procbio.2007.02.005
   Shankar SS, 2004, J COLLOID INTERF SCI, V275, P496, DOI 10.1016/j.jcis.2004.03.003
   Sheny DS, 2011, SPECTROCHIM ACTA A, V79, P254, DOI 10.1016/j.saa.2011.02.051
   Small JM, 2007, ANAL BIOANAL CHEM, V387, P2881, DOI 10.1007/s00216-007-1140-3
   Srikanth H, 2001, APPL PHYS LETT, V79, P3503, DOI 10.1063/1.1419237
   Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989
   Sun YG, 2003, NANO LETT, V3, P955, DOI 10.1021/nl034312m
   Tripathy A, 2010, J NANOPART RES, V12, P237, DOI 10.1007/s11051-009-9602-5
   Valle-Orta M, 2008, J PHYS CHEM B, V112, P14427, DOI 10.1021/jp802773r
   Wang CB, 1997, ENVIRON SCI TECHNOL, V31, P2154, DOI 10.1021/es970039c
   Wang HF, 2005, P NATL ACAD SCI USA, V102, P15752, DOI 10.1073/pnas.0504892102
   Wani IA, 2011, MATER LETT, V65, P520, DOI 10.1016/j.matlet.2010.11.003
   Wilcoxon JP, 1998, J CHEM PHYS, V108, P9137, DOI 10.1063/1.476360
   Xu H., 2002, J NANOSCI NANOTECHNO, V4, P254
   Xu JZ, 2009, J SEP SCI, V32, P4193, DOI 10.1002/jssc.200900364
   Yilmaz M, 2011, MATER CHEM PHYS, V130, P1195, DOI 10.1016/j.matchemphys.2011.08.068
   Zhang WZ, 2006, CHEM PHYS, V330, P495, DOI 10.1016/j.chemphys.2006.09.029
   Zhao Y, 2006, SPECTROCHIM ACTA A, V65, P1003, DOI 10.1016/j.saa.2006.01.010
NR 55
TC 39
Z9 39
U1 2
U2 73
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1386-1425
J9 SPECTROCHIM ACTA A
JI Spectroc. Acta Pt. A-Molec. Biomolec. Spectr.
PD NOV
PY 2013
VL 115
BP 388
EP 392
DI 10.1016/j.saa.2013.06.050
PG 5
WC Spectroscopy
SC Spectroscopy
GA 214RH
UT WOS:000324152700046
PM 23860402
DA 2018-12-27
ER

PT J
AU Zhao, B
   Wang, QL
   Zhang, CR
AF Zhao, Bin
   Wang, Qilei
   Zhang, Cunrui
TI RETRACTED: Fabrication and electromagnetic characteristics of microwave
   absorbers containing Li0.35Zn0.3Fe2.35O4 micro-belts and nickel-coated
   carbon fibers(Retracted article.See vol.435, pg.223, 2017)
SO JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS
LA English
DT Article; Retracted Publication
DE Carbon fiber; Layered structure; Electrical property; Electron
   microscopy; Surface treatment
ID CARBON-FIBER COMPOSITE; ABSORPTION PROPERTIES; STRUCTURAL DESIGN;
   FERRITE; POLYPROPYLENE; IRON; NANOCOMPOSITES; FILAMENTS; NI
AB Li0.35Zn0.3Fe2.35O4 micro-belts were prepared by cotton template. The nickel-coated carbon fibers were obtained by electroless plating method. The formation mechanism of the ferrite micro-belt was studied. The electromagnetic properties of the microwave absorbers were investigated in the frequency range of 30-6000 MHz. The double-layer absorbers have better microwave absorption properties than the nickel-coated carbon fibers single-layer absorbers and the microwave absorption properties of the composites are influenced by the thickness of the absorber. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Zhao, Bin] Taiyuan Univ Technol, Key Lab Adv Transducers & Intelligent Control Sys, Minist Educ, Taiyuan 030024, Peoples R China.
   [Wang, Qilei; Zhang, Cunrui] Chinese Peoples Armed Police Forces Acad, Langfang 065000, Hebei, Peoples R China.
RP Zhao, B (reprint author), Taiyuan Univ Technol, Key Lab Adv Transducers & Intelligent Control Sys, Minist Educ, Taiyuan 030024, Peoples R China.
EM zbtyut@126.com
CR AHMAD MS, 1990, J MATER SCI, V25, P3083, DOI 10.1007/BF00587654
   AHMAD MS, 1992, POLYM COMPOSITE, V13, P53, DOI 10.1002/pc.750130108
   Chen MX, 2011, MATER DESIGN, V32, P3013, DOI 10.1016/j.matdes.2010.12.043
   DILIELLO V, 1990, J MATER SCI, V25, P706, DOI 10.1007/BF00714098
   Ding DH, 2011, J MATER SCI, V46, P2709, DOI 10.1007/s10853-010-5140-x
   Feng YB, 2007, J MAGN MAGN MATER, V318, P8, DOI 10.1016/j.jmmm.2007.04.012
   Han Z, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3177067
   Hwang Y, 2006, MATER LETT, V60, P3277, DOI 10.1016/j.matlet.2006.03.010
   KIM SS, 1994, IEEE T MAGN, V30, P4554, DOI 10.1109/20.334146
   Liao ZQ, 2010, IEEE MAGN LETT, V1, DOI 10.1109/LMAG.2010.2076400
   Liu JR, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2775804
   Liu JR, 2004, J MAGN MAGN MATER, V271, pL147, DOI [10.1016/j.jmmm.2003.12.1386, 10.1016/j.jmmm.2003.12.01386]
   Liu JR, 2003, CHEM LETT, V32, P394, DOI 10.1246/cl.2003.394
   Lu GG, 1996, COMPOS SCI TECHNOL, V56, P193, DOI 10.1016/0266-3538(95)00143-3
   Mercier D, 2000, PHYS REV B, V62, P532, DOI 10.1103/PhysRevB.62.532
   Peng CH, 2005, MAT SCI ENG B-SOLID, V117, P27, DOI 10.1016/j.mseb.2004.10.022
   Qing YC, 2011, J MAGN MAGN MATER, V323, P600, DOI 10.1016/j.jmmm.2010.10.021
   ROUSSELLE D, 1993, J APPL PHYS, V74, P475, DOI 10.1063/1.355256
   Shen GZ, 2007, MATER CHEM PHYS, V105, P268, DOI 10.1016/j.matchemphys.2007.04.056
   SHUI XP, 1995, J ELECTRON MATER, V24, P107, DOI 10.1007/BF02659630
   Shui XP, 2000, J MATER SCI, V35, P1773, DOI 10.1023/A:1004784720338
   Snoek J. L., DISPERSION ABSORPTIO, P207
   Sun GB, 2011, CHEM MATER, V23, P1587, DOI 10.1021/cm103441u
   Wang M, 2009, J MAGN MAGN MATER, V321, P3442, DOI 10.1016/j.jmmm.2009.06.040
   Wu KH, 2008, COMPOS SCI TECHNOL, V68, P132, DOI 10.1016/j.compscitech.2007.05.028
   Yang CM, 2009, REACT FUNCT POLYM, V69, P137, DOI 10.1016/j.reactfunctpolym.2008.12.008
   Yang YL, 2005, NANO LETT, V5, P2131, DOI 10.1021/nl051375r
   Zhang XF, 2007, J PHYS D APPL PHYS, V40, P5383, DOI 10.1088/0022-3727/40/17/056
   Zhang XZ, 2010, CEMENT CONCRETE COMP, V32, P726, DOI 10.1016/j.cemconcomp.2010.07.013
NR 29
TC 5
Z9 7
U1 4
U2 56
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-8853
EI 1873-4766
J9 J MAGN MAGN MATER
JI J. Magn. Magn. Mater.
PD NOV
PY 2013
VL 345
BP 249
EP 254
DI 10.1016/j.jmmm.2013.06.017
PG 6
WC Materials Science, Multidisciplinary; Physics, Condensed Matter
SC Materials Science; Physics
GA 213HB
UT WOS:000324045300043
DA 2018-12-27
ER

PT J
AU Qiao, DH
   Meyer, K
   Friedl, A
AF Qiao, Dianhua
   Meyer, Kristy
   Friedl, Andreas
TI RETRACTED: Glypican 1 Stimulates S Phase Entry and DNA Replication in
   Human Glioma Cells and Normal Astrocytes (Retracted article. See vol.
   36, pg. 2105, 2016)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID SKP2 AUTOINDUCTION LOOP; TRANSGENIC MICE; BRAIN CANCER; CYCLE;
   GLIOBLASTOMA; GENE; P53; INSTABILITY; INHIBITORS; STABILITY
AB Malignant gliomas are highly lethal neoplasms with limited treatment options. We previously found that the heparan sulfate proteoglycan glypican 1 (GPC1) is universally and highly expressed in human gliomas. In this study, we investigated the biological activity of GPC1 expression in both human glioma cells and normal astrocytes in vitro. Expression of GPC1 inactivates the G(1)/S checkpoint and strongly stimulates DNA replication. Constitutive expression of GPC1 causes DNA rereplication and DNA damage, suggesting a mutagenic activity for GPC1. GPC1 expression leads to a significant downregulation of the tumor suppressors pRb, Cip/Kip cyclin-dependent kinase inhibitors (CKIs), and CDH1, and upregulation of the pro-oncogenic proteins cyclin E, cyclin-dependent kinase 2 (CDK2), Skp2, and Cdt1. These GPC1-induced changes are accompanied by a significant reduction in all types of D cyclins, which is independent of serum supplementation. It is likely that GPC1 stimulates the so-called Skp2 autoinduction loop, independent of cyclin D-CDK4/6. Knockdown of Skp2, CDK2, or cyclin E, three key elements within the network modulated by GPC1, results in a reduction of the S phase and aneuploid fractions, implying a functional role for these regulators in GPC1-induced S phase entry and DNA rereplication. In addition, a significant activation of both the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways by GPC1 is seen in normal human astrocytes even in the presence of growth factor supplement. Both pathways are constitutively activated in human gliomas. The surprising magnitude and the mitogenic and mutagenic nature of the effect exerted by GPC1 on the cell cycle imply that GPC1 may play an important role in both glioma tumorigenesis and growth.
C1 [Qiao, Dianhua; Meyer, Kristy; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
   [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, Madison, WI 53705 USA.
   [Friedl, Andreas] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
RP Friedl, A (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
EM afriedl@wisc.edu
FU UWCCC [P30 CA014520]; Biomedical Laboratory Research and Development
   Service of the VA Office of Research and Development [I01BX000137]
FX This work was supported by UWCCC core grant P30 CA014520 and by award
   number I01BX000137 from the Biomedical Laboratory Research and
   Development Service of the VA Office of Research and Development.
CR Asundi VK, 1998, GENE, V206, P255, DOI 10.1016/S0378-1119(97)00594-5
   Boily G, 2004, BRIT J CANCER, V90, P1606, DOI 10.1038/sj.bjc.6601716
   Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153
   Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210
   Castro A, 2005, ONCOGENE, V24, P314, DOI 10.1038/sj.onc.1207973
   Davidson IF, 2006, MOL CELL, V24, P433, DOI 10.1016/j.molcel.2006.09.010
   Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703
   Fico A, 2011, CELL MOL LIFE SCI, V68, P923, DOI 10.1007/s00018-007-7471-6
   Fransson LA, 2004, CELL MOL LIFE SCI, V61, P1016, DOI 10.1007/s00018-004-3445-0
   Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742
   Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820
   Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242
   Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596
   Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818
   Huse JT, 2009, BRAIN PATHOL, V19, P132, DOI 10.1111/j.1750-3639.2008.00234.x
   Jen YHLD, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-33
   Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295
   Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851
   Lin HC, 1999, CANCER RES, V59, P807
   Litwack ED, 1998, DEV DYNAM, V211, P72, DOI 10.1002/(SICI)1097-0177(199801)211:1<72::AID-AJA7>3.0.CO;2-4
   Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010
   Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200
   Maddalena AS, 1999, BRAIN PATHOL, V9, P627
   Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3
   Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010
   Qi WQ, 2003, RADIAT RES, V160, P217, DOI 10.1667/RR3038
   Qiao DH, 2012, J BIOL CHEM, V287, P5898, DOI 10.1074/jbc.M111.325282
   Sclafani RA, 2007, ANNU REV GENET, V41, P237, DOI 10.1146/annurev.genet.41.110306.130308
   Seo J, 2005, ONCOGENE, V24, P8176, DOI 10.1038/sj.onc.1208881
   Siebzehnrubl FA, 2011, GLIA, V59, P1135, DOI 10.1002/glia.21143
   Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004
   Su G, 2006, AM J PATHOL, V168, P2014, DOI 10.2353/ajpath.2006.050800
   Symeonidou IE, 2012, FEBS LETT, V586, P2803, DOI 10.1016/j.febslet.2012.07.042
   Truong LN, 2011, J MOL CELL BIOL, V3, P13, DOI 10.1093/jmcb/mjq052
   Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Xouri G, 2007, CELL CYCLE, V6, P1549, DOI 10.4161/cc.6.13.4455
   Yung Y, 2007, J CELL BIOL, V178, P741, DOI 10.1083/jcb.200703034
   Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443
NR 45
TC 15
Z9 15
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 2013
VL 33
IS 22
BP 4408
EP 4421
DI 10.1128/MCB.00238-13
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 240LX
UT WOS:000326099000005
PM 24019070
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Mohiuddine, SA
   Mursaleen, M
   Alotaibi, A
AF Mohiuddine, S. A.
   Mursaleen, M.
   Alotaibi, A.
TI RETRACTED: The Hausdorff measure of noncompactness for some matrix
   operators (Retracted article. See vol. 117, pg. 221, 2015)
SO NONLINEAR ANALYSIS-THEORY METHODS & APPLICATIONS
LA English
DT Article; Retracted Publication
DE Sequence spaces; Matrix transformations; Hausdorff measure of
   noncompactness; Compact operators
ID DIFFERENCE SEQUENCE-SPACES; COMPACT-OPERATORS; L(P); EQUATIONS
AB Recently, the sequence spaces l(infinity)(lambda), c(lambda), c(0)(lambda), and l(p)(lambda)- have been defined and studied by Mursaleen and Noman (cf. Mursaleen and Noman, 2011 [5,61). In this paper, we obtain estimates for the norms of the bounded linear operators L-A defined by the matrix classes (l(p)(lambda), Y) (1 <= P < infinity), where Y = c(0), c, l(infinity) and l(1). We also find conditions to obtain the corresponding subclasses of compact matrix operators by using the Hausdorff measure of noncompactness. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Mohiuddine, S. A.; Alotaibi, A.] King Abdulaziz Univ, Dept Math, Fac Sci, Jeddah 21589, Saudi Arabia.
   [Mursaleen, M.] Aligarh Muslim Univ, Dept Math, Aligarh 202002, Uttar Pradesh, India.
RP Mohiuddine, SA (reprint author), King Abdulaziz Univ, Dept Math, Fac Sci, POB 80203, Jeddah 21589, Saudi Arabia.
EM mohiuddine@gmail.com; mursaleenm@gmail.com; mathker11@hotmail.com
RI Mursaleen, M./A-6146-2013; Mohiuddine, Syed Abdul/J-2314-2012
OI Mursaleen, M./0000-0003-4128-0427; Mohiuddine, Syed
   Abdul/0000-0002-9050-9104
FU King Abdulaziz University, Jeddah, Saudi Arabia
FX The authors gratefully acknowledge the financial support from King
   Abdulaziz University, Jeddah, Saudi Arabia.
CR Akhmerov R.R, 1992, OPERATOR THEORY ADV, V55
   Banas J, 2001, J COMPUT APPL MATH, V137, P363, DOI 10.1016/S0377-0427(00)00708-1
   Banas J., 1980, LECT NOTES PURE APPL, V60
   Banas J., 2013, ABSTR APPL ANAL, V2013, DOI DOI 10.1155/2013/819315.ARTICLE
   Banas J, 2012, CENT EUR J MATH, V10, P2003, DOI 10.2478/s11533-012-0120-9
   Basar F, 2011, APPL MATH COMPUT, V217, P5199, DOI 10.1016/j.amc.2010.12.007
   Basarir M, 2011, IRAN J SCI TECHNOL A, V35, P279
   Basarir M, 2012, J MATH ANAL APPL, V391, P67, DOI 10.1016/j.jmaa.2012.02.031
   Darbo Gabriele, 1955, REND SEMIN MAT U PAD, V24, P84
   de Malafosse B., 2006, INT J MATH MATH SCI, V2006, P1
   de Malafosse B, 2006, J MATH ANAL APPL, V323, P131, DOI 10.1016/j.jmaa.2005.10.024
   GOLDENSTEIN L. S., 1965, STUDIES ALGEBRA MATH, P45
   GOLDENSTEIN L. S., 1957, UCEN ZAP KISHINEVSK, V29, P29
   Kara EE, 2011, J MATH ANAL APPL, V379, P499, DOI 10.1016/j.jmaa.2011.01.028
   Kuratowski K, 1930, FUND MATH, V15, P301
   Malkowsky E., 2010, MODERN METHODS ANAL, P86
   Malkowsky E., 2000, ZB RAD, V9, P143
   Malkowsky E, 2011, B KOREAN MATH SOC, V48, P1093, DOI 10.4134/BKMS.2011.48.5.1093
   Malkowsky E, 2008, JORDAN J MATH STAT, V1, P1
   Mursaleen M, 2013, MATH INEQUAL APPL, V16, P207, DOI 10.7153/mia-16-15
   Mursaleen M, 2013, CAN MATH BULL, V56, P388, DOI 10.4153/CMB-2011-170-7
   Mursaleen M, 2012, NONLINEAR ANAL-THEOR, V75, P2111, DOI 10.1016/j.na.2011.10.011
   Mursaleen M, 2012, LINEAR ALGEBRA APPL, V436, P41, DOI 10.1016/j.laa.2011.06.014
   Mursaleen M, 2011, OPER MATRICES, V5, P473
   Mursaleen M, 2011, COMPUT MATH APPL, V62, P814, DOI 10.1016/j.camwa.2011.06.011
   Mursaleen M, 2011, FILOMAT, V25, P33, DOI 10.2298/FIL1102033M
   Mursaleen M, 2010, NONLINEAR ANAL-THEOR, V73, P2541, DOI 10.1016/j.na.2010.06.030
   Mursaleen M, 2010, MATH COMPUT MODEL, V52, P603, DOI 10.1016/j.mcm.2010.04.006
   Mursaleen M., 2012, ABSTR APPL ANAL, V2012, P20
   Mursaleen M, 2011, MATH COMMUN, V16, P383
   Toledano J. M. Ayerbe, 1997, MEASURES NONCOMPACTN
   Wilansky A., 1984, N HOLLAND MATH STUDI, V85
NR 32
TC 7
Z9 8
U1 3
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0362-546X
EI 1873-5215
J9 NONLINEAR ANAL-THEOR
JI Nonlinear Anal.-Theory Methods Appl.
PD NOV
PY 2013
VL 92
BP 119
EP 129
DI 10.1016/j.na.2013.07.007
PG 11
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 217JU
UT WOS:000324356600011
DA 2018-12-27
ER

PT J
AU Ma, CY
   Wang, WJ
   Wang, J
   Miao, CY
   Li, SL
   Zhang, QY
AF Ma, C. Y.
   Wang, W. J.
   Wang, J.
   Miao, C. Y.
   Li, S. L.
   Zhang, Q. Y.
TI RETRACTED: Structural, morphological, optical and photoluminescence
   properties of HfO2 thin films (Retracted article. See vol. 665, pg. 198,
   2018)
SO THIN SOLID FILMS
LA English
DT Article; Retracted Publication
DE Hafnium dioxide; Sputtering; Optical Properties; Luminescence
ID DEPOSITION; HAFNIA; ZIRCONIA; OXIDE
AB Nanocrystalline monoclinic HfO2 films with an average crystal size of 4.2-14.8 nm were sputter deposited under controlled temperatures and their structural characteristics and optical and photoluminescence properties have been evaluated. Structural investigations indicate that monoclinic HfO2 films grown at higher temperatures above 400 degrees C are highly oriented along the (-111) direction. The lattice expansion increases with diminishing HfO2 crystalline size below 6.8 nm while maximum lattice expansion occurs with highly oriented monoclinic HfO2 of crystalline size about 14.8 nm. The analysis of atomic force microscopy shows that the film growth at 600 degrees C can be attributed to the surface-diffusion-dominated growth. The intensity of the shoulderlike band that initiates at similar to 5.7 eV and saturates at 5.94 eV shows continued increase with increasing crystalline size, which is intrinsic to nanocrystalline monoclinic HfO2 films. Optical band gap varies in the range 5.40 +/- 0.03-5.60 +/- 0.03 eV and is slightly decreased with the increase in crystalline size. The luminescence band at 4.0 eV of HfO2 films grown at room temperature can be ascribed to the vibronic transition of excited OH center dot radical while the emission at 3.2-3.3 eV for the films grown at all temperatures was attributed to the radiative recombination at impurity and/or defect centers. (C) 2013 Elsevier B. V. All rights reserved.
C1 [Ma, C. Y.; Wang, W. J.; Wang, J.; Miao, C. Y.; Li, S. L.; Zhang, Q. Y.] Dalian Univ Technol, Minist Educ, Key Lab Mat Modificat Laser Ion & Electron Beams, Dalian 116024, Peoples R China.
RP Ma, CY (reprint author), Dalian Univ Technol, Minist Educ, Key Lab Mat Modificat Laser Ion & Electron Beams, Dalian 116024, Peoples R China.
EM chunyuma@dlut.edu.cn
RI Zhang, Qingyu/O-8472-2015
FU National Natural Science Foundation of China [10605009, 10774018];
   Fundamental Research Funds for the Central Universities [DUT11LK44]
FX The work is supported by the National Natural Science Foundation of
   China under grant nos. 10605009 and 10774018 and Fundamental Research
   Funds for the Central Universities no. DUT11LK44.
CR Aarik J, 2004, THIN SOLID FILMS, V466, P41, DOI 10.1016/j.tsf.2004.01.110
   Armelao L, 2007, ADV FUNCT MATER, V17, P1671, DOI 10.1002/adfm.200600458
   Bharathi KK, 2010, J APPL PHYS, V108, DOI 10.1063/1.3499325
   Biscarini F, 1997, PHYS REV LETT, V78, P2389, DOI 10.1103/PhysRevLett.78.2389
   Bruns S, 2012, THIN SOLID FILMS, V520, P4122, DOI 10.1016/j.tsf.2011.07.014
   Cherkaoui K., 2001, J APPL PHYS, V104
   Ciapponi A, 2009, J LUMIN, V129, P1786, DOI 10.1016/j.jlumin.2009.02.026
   Hoppe EE, 2007, J APPL PHYS, V101, DOI 10.1063/1.2750406
   Ito T, 2005, J APPL PHYS, V97, DOI 10.1063/1.1856220
   Kiisk V, 2010, PHYSICA B, V405, P758, DOI 10.1016/j.physb.2009.09.101
   Li HJ, 2011, THIN SOLID FILMS, V520, P212, DOI 10.1016/j.tsf.2011.07.037
   Nguyen NV, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2126136
   Ni J, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2952288
   Nishide T, 2000, THIN SOLID FILMS, V371, P61, DOI 10.1016/S0040-6090(00)01010-5
   Pemmaraju C.D., 2004, PHYS REV LETT, V94
   Rastorguev AA, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.235315
   Sayan S, 2002, J VAC SCI TECHNOL A, V20, P507, DOI 10.1116/1.1450584
   Wang SJ, 2003, APPL PHYS LETT, V82, P2047, DOI 10.1063/1.1565182
   Wilk GD, 2001, J APPL PHYS, V89, P5243, DOI 10.1063/1.1361065
NR 19
TC 16
Z9 16
U1 1
U2 47
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0040-6090
J9 THIN SOLID FILMS
JI Thin Solid Films
PD OCT 31
PY 2013
VL 545
BP 279
EP 284
DI 10.1016/j.tsf.2013.08.068
PG 6
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied; Physics, Condensed Matter
SC Materials Science; Physics
GA 223QD
UT WOS:000324820800046
DA 2018-12-27
ER

PT J
AU Wang, T
   Xuan, XY
   Li, M
   Gao, P
   Zheng, YL
   Zang, WQ
   Zhao, GQ
AF Wang, Tao
   Xuan, Xiaoyan
   Li, Min
   Gao, Ping
   Zheng, Yuling
   Zang, Wenqiao
   Zhao, Guoqiang
TI RETRACTED: Astragalus saponins affect proliferation, invasion and
   apoptosis of gastric cancer BGC-823 cells (Retracted article. See vol.
   12, art no 9, 2017)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Gastric cancer; Proliferation; Invasion; Apoptosis
ID IN-VITRO; MEMBRANACEUS BUNGE; CYPRINUS-CARPIO; COMMON CARP;
   POLYSACCHARIDES; EXPRESSION; RADIX; RSK2; MICE; OVEREXPRESSION
AB Background: Astragalus memebranaceus is a traditional Chinese herbal medicine used in treatment of common cold, diarrhea, fatigue, anorexia and cardiac diseases. Recently, there are growing evidences that Astragalus extract may be a potential anti-tumorigenic agent. Some research showed that the total saponins obtained from Astragalus membranaceus possess significant antitumorigenic activity. Gastric cancer is one of the most frequent cancers in the world, almost two-thirds of gastric cancer cases and deaths occur in less developed regions. But the effect of Astragalus membranaceus on proliferation, invasion and apoptosis of gastric cancer BGC-823 cells remains unclear.
   Methods: Astragalus saponins were extracted. Cells proliferation was determined by CCK-8 assay. Cell cycle and apoptosis were detected by the flow cytometry. Boyden chamber was used to evaluate the invasion and metastasis capabilities of BGC-823 cells. Tumor growth was assessed by subcutaneous inoculation of cells into BALB/c nude mice.
   Results: The results demonstrated that total Astragalus saponins could inhibit human gastric cancer cell growth both in vitro and in vivo, in additional, Astragalus saponins deceased the invasion ability and induced the apoptosis of gastric cancer BGC-823 cells.
   Conclusions: Total Astragalus saponins inhibited human gastric cancer cell growth, decreased the invasion ability and induced the apoptosis. This suggested the possibility of further developing Astragalus as an alternative treatment option, or perhaps using it as adjuvant chemotherapeutic agent in gastric cancer therapy.
C1 [Wang, Tao; Gao, Ping] Henan Univ TCM, Affiliated Hosp 1, Dept Hematotumor, Zhengzhou, Peoples R China.
   [Xuan, Xiaoyan; Li, Min; Zang, Wenqiao; Zhao, Guoqiang] Zhengzhou Univ, Coll Basic Med Sci, Dept Microbiol & Immunol, Zhengzhou 450052, Peoples R China.
   [Zheng, Yuling] Henan Univ TCM, Zhengzhou, Peoples R China.
RP Zang, WQ (reprint author), Zhengzhou Univ, Coll Basic Med Sci, Dept Microbiol & Immunol, Zhengzhou 450052, Peoples R China.
EM zangwenqiao@sina.com; zhaogq@zzu.edu.cn
FU Henan province science and technology research projects [122102310550]
FX This study was supported by Henan province science and technology
   research projects (122102310550).
CR Cho YY, 2012, CARCINOGENESIS, V33, P2529, DOI 10.1093/carcin/bgs271
   Cui R, 2003, CANCER CHEMOTH PHARM, V51, P75, DOI 10.1007/s00280-002-0532-5
   Duan Ping, 2002, Zhongguo Zhong Xi Yi Jie He Za Zhi, V22, P515
   Eisinger-Mathason TSK, 2010, STEROIDS, V75, P191, DOI 10.1016/j.steroids.2009.12.010
   Gawecka JE, 2012, J BIOL CHEM, V287, P43424, DOI 10.1074/jbc.M112.423046
   Hilinski MK, 2012, BIOORG MED CHEM LETT, V22, P3244, DOI 10.1016/j.bmcl.2012.03.033
   Jia R, 2012, FISH PHYSIOL BIOCHEM, V38, P871, DOI 10.1007/s10695-011-9575-z
   Jin JC, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-135
   Karimi P, 2012, SCI WORLD J, DOI 10.1100/2012/615670
   Kathy KW, 2009, INT J CANCER, V125, P1082
   Kim W, 2012, PHYTOTHER RES, V26, P1418, DOI 10.1002/ptr.4756
   Liu J, 2013, ACTA PHARMACOL SIN, V34, P137, DOI 10.1038/aps.2012.133
   Liu J, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/479426
   Liu J, 2011, BIOL PHARM BULL, V34, P1404, DOI 10.1248/bpb.34.1404
   Ma XQ, 2002, J AGR FOOD CHEM, V50, P4861, DOI 10.1021/jf0202279
   Na D, 2009, WORLD J GASTROENTERO, V15, P570, DOI 10.3748/wjg.15.570
   Peng C, 2012, J BIOL CHEM, V287, P25881, DOI 10.1074/jbc.M112.359521
   RITTENHOUSE JR, 1991, J UROLOGY, V146, P486, DOI 10.1016/S0022-5347(17)37830-8
   Shan L, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-76
   Shao BM, 2004, BIOCHEM BIOPH RES CO, V320, P1103, DOI 10.1016/j.bbrc.2004.06.065
   Shiner RJ, 2011, ONCOGENE, V30, P3513
   Sotoudeh K, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-57
   Sun YX, 2008, COMP BIOCHEM PHYS C, V147, P293, DOI 10.1016/j.cbpc.2007.11.003
   Tang L, 2010, J NAT MED-TOKYO, V64, P182, DOI 10.1007/s11418-009-0381-1
   Tin MMY, 2007, CARCINOGENESIS, V28, P1347, DOI 10.1093/carcin/bgl238
   van Jaarsveld MTM, 2013, EUR J CANCER, V49, P345, DOI 10.1016/j.ejca.2012.08.024
   Wang PC, 2008, CHINESE MED J-PEKING, V121, P231
   WANG Y, 1992, MOL BIOTHER, V4, P143
   Wang YP, 2002, ACTA PHARMACOL SIN, V23, P263
   Wu JJ, 2013, INT J ONCOL, V43, P1643, DOI 10.3892/ijo.2013.2085
   Yang B, 2013, INT J BIOL MACROMOL, V62, P287, DOI 10.1016/j.ijbiomac.2013.09.016
   Yuan CT, 2008, INT IMMUNOPHARMACOL, V8, P51, DOI 10.1016/j.intimp.2007.10.009
   Zee-Cheng Robert K.-Y, 1992, Methods and Findings in Experimental and Clinical Pharmacology, V14, P725
   Zhang BQ, 2005, BIOL PHARM BULL, V28, P1450, DOI 10.1248/bpb.28.1450
   Zhang WD, 2006, PLANTA MED, V72, P4, DOI 10.1055/s-2005-873126
   Zhao X Z, 1992, Zhongguo Zhong Xi Yi Jie He Za Zhi, V12, P669
   Zhao XZ, 1992, ZHONGGUO ZHONG XI YI, V12, P645
   Zheng Z, 1998, Chin J Biotechnol, V14, P93
NR 38
TC 23
Z9 25
U1 3
U2 22
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD OCT 24
PY 2013
VL 8
AR 179
DI 10.1186/1746-1596-8-179
PG 6
WC Pathology
SC Pathology
GA 247TU
UT WOS:000326645500001
PM 24152941
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kain, P
   Boyle, SM
   Tharadra, SK
   Guda, T
   Pham, C
   Dahanukar, A
   Ray, A
AF Kain, Pinky
   Boyle, Sean Michael
   Tharadra, Sana Khalid
   Guda, Tom
   Christine Pham
   Dahanukar, Anupama
   Ray, Anandasankar
TI RETRACTED: Odour receptors and neurons for DEET and new insect
   repellents (Retracted article. See vol. 536, 2016)
SO NATURE
LA English
DT Article; Retracted Publication
ID IONOTROPIC GLUTAMATE RECEPTORS; VOLATILE ORGANIC-COMPOUNDS;
   ANOPHELES-GAMBIAE; AEDES-AEGYPTI; MALARIA MOSQUITO; ODORANT RECEPTOR;
   CELLULAR BASIS; DROSOPHILA; IDENTIFICATION; BEHAVIOR
AB There are major impediments to finding improved DEET alternatives because the receptors causing olfactory repellency are unknown, and new chemicals require exorbitant costs to determine safety for human use. Here we identify DEET-sensitive neurons in a pit-like structure in the Drosophila melanogaster antenna called the sacculus. They express a highly conserved receptor, Ir40a, and flies in which these neurons are silenced or Ir40a is knocked down lose avoidance to DEET. We used a computational structure-activity screen of >400,000 compounds that identified >100 natural compounds as candidate repellents. We tested several and found that most activate Ir40a(+) neurons and are repellents for Drosophila. These compounds are also strong repellents for mosquitoes. The candidates contain chemicals that do not dissolve plastic, are affordable and smell mildly like grapes, with three considered safe in human foods. Our findings pave the way to discover new generations of repellents that will help fight deadly insect-borne diseases worldwide.
C1 [Kain, Pinky; Tharadra, Sana Khalid; Guda, Tom; Dahanukar, Anupama; Ray, Anandasankar] Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA.
   [Boyle, Sean Michael; Dahanukar, Anupama; Ray, Anandasankar] Univ Calif Riverside, Genet Genom & Bioinformat Program, Riverside, CA 92521 USA.
   [Christine Pham; Dahanukar, Anupama; Ray, Anandasankar] Univ Calif Riverside, Neurosci Program, Riverside, CA 92521 USA.
   [Dahanukar, Anupama; Ray, Anandasankar] Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA.
RP Ray, A (reprint author), Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA.
EM anand.ray@ucr.edu
RI Kain, Pinky/A-9893-2014
FU Whitehall Foundation; NINDS [R21NS074332, R56AI099778, R01AI087785]
FX We thank A. Ganguly and D. Carter for help with calcium imaging; Z.
   Wisotsky for help with gustatory experiments; D. MacWilliam for help
   with olfactory experiments; J. Wang for sharing the NFAT transgenic fly
   line; and R. Benton for sharing the Ir40a-Gal4 fly line. This work was
   partly funded by a Whitehall Foundation grant to A. D., an R21NS074332
   (NINDS) to A. D. and A. R., and an R56AI099778 (NIAID) and R01AI087785
   (NIAID) to A. R. The granting agencies had no role in experimental
   design or analysis.
CR Abramson CI, 2010, J INSECT SCI, V10, DOI 10.1673/031.010.12201
   Abuin L, 2011, NEURON, V69, P44, DOI 10.1016/j.neuron.2010.11.042
   Ai M, 2010, NATURE, V468, P691, DOI 10.1038/nature09537
   [Anonymous], 2007, FLAV FRAGR 2007 2008
   [Anonymous], 2007, DRAGON SOFTWARE WIND
   Benton R, 2009, CELL, V136, P149, DOI 10.1016/j.cell.2008.12.001
   Bohbot JD, 2012, NEUROPHARMACOLOGY, V62, P2086, DOI 10.1016/j.neuropharm.2012.01.004
   Bostrom J, 2003, J MOL GRAPH MODEL, V21, P449, DOI 10.1016/S1093-3263(02)00204-8
   Carey AF, 2010, NATURE, V464, P66, DOI 10.1038/nature08834
   Chang C. C., 2001, LIBSVM LIB SUPPORT V
   Corbel V, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-47
   Cork A, 1996, MED VET ENTOMOL, V10, P269, DOI 10.1111/j.1365-2915.1996.tb00742.x
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411
   Curran AM, 2005, J CHEM ECOL, V31, P1607, DOI 10.1007/s10886-005-5801-4
   de Bruyne M, 1999, J NEUROSCI, V19, P4520
   DeGennaro M, 2013, NATURE, V498, P487, DOI 10.1038/nature12206
   Ditzen M, 2008, SCIENCE, V319, P1838, DOI 10.1126/science.1153121
   El-Sayed A. M., 2009, PHEROBASE DATABASE I
   Gallagher M, 2008, BRIT J DERMATOL, V159, P780, DOI 10.1111/j.1365-2133.2008.08748.x
   GUPTA RK, 2007, INSECT REPELLENTS PR, P195
   Haddad R, 2008, NAT METHODS, V5, P425, DOI 10.1038/NMETH.1197
   Hallem EA, 2006, CELL, V125, P143, DOI 10.1016/j.cell.2006.01.050
   Hou XW, 2004, J STORED PROD RES, V40, P47, DOI 10.1016/S0022-474X(02)00063-2
   Karatzoglou A., 2006, J STAT SOFTW
   Katritzky AR, 2008, P NATL ACAD SCI USA, V105, P7359, DOI 10.1073/pnas.0800571105
   Kline DL, 2003, J MED ENTOMOL, V40, P463, DOI 10.1603/0022-2585-40.4.463
   KLOCKE JA, 1987, J CHEM ECOL, V13, P2131, DOI 10.1007/BF01012562
   Klun JA, 2004, J MED ENTOMOL, V41, P418, DOI 10.1603/0022-2585-41.3.418
   Knudsen JT, 2006, BOT REV, V72, P1, DOI 10.1663/0006-8101(2006)72[1:DADOFS]2.0.CO;2
   Krajick K, 2006, SCIENCE, V313, P36, DOI 10.1126/science.313.5783.36
   Lee Y, 2010, NEURON, V67, P555, DOI 10.1016/j.neuron.2010.07.006
   Liu C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000467
   Logan JG, 2008, J CHEM ECOL, V34, P308, DOI 10.1007/s10886-008-9436-0
   Masuyama K, 2012, J NEUROGENET, V26, P89, DOI 10.3109/01677063.2011.642910
   Meijerink J, 2000, J CHEM ECOL, V26, P1367, DOI 10.1023/A:1005475422978
   Mumcuoglu KY, 1996, ENTOMOL EXP APPL, V78, P309, DOI 10.1111/j.1570-7458.1996.tb00795.x
   Pellegrino M, 2011, NATURE, V478, P511, DOI 10.1038/nature10438
   Pelz D, 2006, J NEUROBIOL, V66, P1544, DOI 10.1002/neu.20333
   Reeder NL, 2001, J ECON ENTOMOL, V94, P1584, DOI 10.1603/0022-0493-94.6.1584
   Silbering AF, 2011, J NEUROSCI, V31, P13357, DOI 10.1523/JNEUROSCI.2360-11.2011
   Stanczyk NM, 2010, P NATL ACAD SCI USA, V107, P8575, DOI 10.1073/pnas.1001313107
   SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2
   Syed Z, 2008, P NATL ACAD SCI USA, V105, P13598, DOI 10.1073/pnas.0805312105
   Syed Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017705
   Tentschert J, 2000, NATURWISSENSCHAFTEN, V87, P377, DOI 10.1007/s001140050745
   Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398
   Turner SL, 2011, NATURE, V474, P87, DOI 10.1038/nature10081
   Turner SL, 2009, NATURE, V461, P277, DOI 10.1038/nature08295
   Walker JD, 2003, ENVIRON TOXICOL CHEM, V22, P1870, DOI 10.1897/01-454
   Weiss LA, 2011, NEURON, V69, P258, DOI 10.1016/j.neuron.2011.01.001
   Xia YF, 2008, P NATL ACAD SCI USA, V105, P6433, DOI 10.1073/pnas.0801007105
   ZENG XN, 1991, J CHEM ECOL, V17, P1469, DOI 10.1007/BF00983777
   Zeng XN, 1996, J CHEM ECOL, V22, P237, DOI 10.1007/BF02055096
NR 53
TC 73
Z9 77
U1 7
U2 161
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 24
PY 2013
VL 502
IS 7472
BP 507
EP +
DI 10.1038/nature12594
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 238YN
UT WOS:000325988400045
PM 24089210
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Miravete, V
   Roura-Pascual, N
   Dunn, RR
   Gomez, C
AF Miravete, Veronica
   Roura-Pascual, Nuria
   Dunn, Robert R.
   Gomez, Crisanto
TI RETRACTED: How many and which ant species are being accidentally moved
   around the world? (Retracted article. See vol. 10, 20140504, 2014)
SO BIOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE biological invasions; exotic species; formicidae; richness estimator
AB Human transportation facilitates the dispersal of exotic ants, but few studies have quantified the magnitude and geography of these movements. We used several non-parametric indexes to estimate the number of species successfully introduced to or established in newregions. We also compared their source bio-geographic realms to assess the importance of the geographical origin in determining the likelihood of establishment after introduction. Data on exotic ants derive from studies of three temperate regions. Our results suggest that the numbers of introduced or established ants may be much larger than the numbers so far documented. Ants introduced or established in new regions tend to arrive from the same or neighbouring realms, as would be expected if exotic species tend to match climates and if arrival/establishment is dependent upon higher trade rates from neighbouring countries.
C1 [Miravete, Veronica; Roura-Pascual, Nuria; Gomez, Crisanto] Univ Girona, Dept Ciencies Ambientals, Fac Ciencies, Girona 17071, Catalonia, Spain.
   [Roura-Pascual, Nuria] Ctr Tecnol Forestal Catalunya, Solsona 25280, Catalonia, Spain.
   [Dunn, Robert R.] N Carolina State Univ, Dept Biol, WM Keck Ctr Behav Biol, Raleigh, NC 27695 USA.
RP Miravete, V (reprint author), Univ Girona, Dept Ciencies Ambientals, Fac Ciencies, Campus Montilivi, Girona 17071, Catalonia, Spain.
EM veronica.miravete@gmail.com
OI Dunn, Robert/0000-0002-6030-4837
FU MICINN [CGL2010-16451, CSD2008-00040]; US DOE PER award
   [DE-FG02-08ER64510]; NASA [ROSES-NNX09AK22G]; NSF [0953390]
FX V.M. and C. G. received support from MICINN grant (CGL2010-16451),
   N.R-P. from MICINN grant (CSD2008-00040) and R. R. D. from US DOE PER
   award (DE-FG02-08ER64510), NASA Biodiversity grant (ROSES-NNX09AK22G)
   and NSF Career grant (0953390).
CR Boer B, 2008, ENTOMOL BER, V68, P121
   Boer B, 2003, ENTOMOL BER, V63, P54
   Bolton B, 1995, NEW GEN CATALOGUE AN
   Brose U, 2003, ECOLOGY, V84, P2364, DOI 10.1890/02-0558
   Chao A, 2010, PROGRAM SPADE SPECIE
   Fisher BL, 2007, ANTS N AM GUIDE GENE
   Guenard B, 2011, P NATL ACAD SCI USA, V109, P7368, DOI [10.1073/pnas.1113867109, DOI 10.1073/PNAS.1113867109)]
   Lester PJ, 2005, DIVERS DISTRIB, V11, P279, DOI 10.1111/j.1366-9516.2005.00169.x
   LOWE S, 2000, ALIENS, P1
   McGlynn TP, 1999, J BIOGEOGR, V26, P535, DOI 10.1046/j.1365-2699.1999.00310.x
   Simberloff D, 2009, ANNU REV ECOL EVOL S, V40, P81, DOI 10.1146/annurev.ecolsys.110308.120304
   Suarez AV, 2005, P NATL ACAD SCI USA, V102, P17032, DOI 10.1073/pnas.0506119102
   Suarez AV, 2009, ANT ECOLOGY, P233
   WARWICK D, 2007, ANTS NZ
   Williamson M., 1996, BIOL INVASIONS
   Wittenborn Daniela, 2011, NeoBiota, V10, P47, DOI 10.3897/neobiota.10.1047
NR 16
TC 3
Z9 5
U1 2
U2 27
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1744-9561
EI 1744-957X
J9 BIOL LETTERS
JI Biol. Lett.
PD OCT 23
PY 2013
VL 9
IS 5
AR 20130540
DI 10.1098/rsbl.2013.0540
PG 4
WC Biology; Ecology; Evolutionary Biology
SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences &
   Ecology; Evolutionary Biology
GA 297XY
UT WOS:000330289600035
PM 23945211
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Mahmoud, WE
   Bronstein, LM
   Al-Hazmi, F
   Al-Noaiser, F
   Al-Ghamdi, AA
AF Mahmoud, Waleed E.
   Bronstein, Lyudmila M.
   Al-Hazmi, Faten
   Al-Noaiser, Fowzia
   Al-Ghamdi, A. A.
TI RETRACTED: Development of Fe/Fe3O4 Core-Shell Nanocubes as a Promising
   Magnetic Resonance Imaging Contrast Agent (Retracted article. See vol.
   30, pg. 7622, 2014)
SO LANGMUIR
LA English
DT Article; Retracted Publication
ID IRON-OXIDE NANOPARTICLES; SIZE; FE; NANOCOMPOSITES; NANOCRYSTALS
AB Here, we report the synthesis, characterization, and properties of Fe/Fe3O4 core shell nanocubes prepared via a simple route. It includes NaBH4 reduction of FeCl3 in an ethylene glycol solution in the presence of 2-mercaptopropionic acid (surfactant) and trisodium citrate (cosurfactant) followed by surface oxidation with trimethylamine N-oxide. The morphology and structure of Fe/Fe3O4 core shell nanocubes were characterized using transmission electron microscopy (TEM), high-resolution TEM, selected area electron diffraction, X-ray powder diffraction, and X-ray photoelectron spectroscopy. All of the methods confirm a Fe/Fe3O4 core shell structure of nanocubes. Magnetic measurements revealed that the Fe/Fe3O4 core/shell nanocubes are superparamagnetic at 300 K with a saturation magnetization of 129 emu/g. The T-2 weighted imaging and the T-2 relaxation time showed high MRI contrast and sensitivity, making these nanocubes viable candidates as enhanced MRI contrast agents.
C1 [Mahmoud, Waleed E.; Bronstein, Lyudmila M.; Al-Hazmi, Faten; Al-Noaiser, Fowzia; Al-Ghamdi, A. A.] King Abdulaziz Univ, Fac Sci, Jeddah, Saudi Arabia.
   [Mahmoud, Waleed E.] Suez Canal Univ, Fac Sci, Dept Phys, Ismailia, Egypt.
   [Bronstein, Lyudmila M.] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
RP Mahmoud, WE (reprint author), King Abdulaziz Univ, Fac Sci, Jeddah, Saudi Arabia.
EM w_e_mahmoud@yahoo.com; lybronst@indiana.edu
RI Al-Ghamdi, Ahmed/A-1324-2015; Faculty of, Sciences, KAU/E-7305-2017
OI Al-Ghamdi, Ahmed/0000-0002-5409-3770; 
FU Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah
   [GR-33-7]; DSR
FX This project was funded by the Deanship of Scientific Research (DSR),
   King Abdulaziz University, Jeddah, under grant no. (GR-33-7). We,
   therefore, acknowledge with thanks DSR technical and financial support.
CR Chen HW, 2009, ACS APPL MATER INTER, V1, P2134, DOI 10.1021/am900262j
   de Montferrand C, 2013, ACTA BIOMATER, V9, P6150, DOI 10.1016/j.actbio.2012.11.025
   Dumestre F, 2004, SCIENCE, V303, P821, DOI 10.1126/science.1092641
   FUKASAWA T, 1993, ANAL CHIM ACTA, V281, P413, DOI 10.1016/0003-2670(93)85200-4
   Guardia P, 2010, CHEM COMMUN, V46, P6108, DOI 10.1039/c0cc01179g
   Hasanzadeh J, 2012, J OPTOELECTRON ADV M, V14, P473
   Hatakeyama M, 2011, J MATER CHEM, V21, P5959, DOI 10.1039/c0jm04381h
   Hu Y, 2013, LANGMUIR, V29, P9156, DOI 10.1021/la402119s
   Huang XL, 2011, ACS NANO, V5, P4037, DOI 10.1021/nn200629g
   Huber DL, 2005, SMALL, V1, P482, DOI 10.1002/smll.200500006
   Khurshid H, 2013, NANOSCALE, V5, P7942, DOI 10.1039/c3nr02596a
   Khurshid H, 2013, J MAGN MAGN MATER, V331, P17, DOI 10.1016/j.jmmm.2012.10.049
   Kim D, 2007, J AM CHEM SOC, V129, P5812, DOI 10.1021/ja070667m
   Kimling J, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.174406
   Liu JW, 2010, LANGMUIR, V26, P19066, DOI 10.1021/la102944h
   Margeat O, 2005, PROG SOLID STATE CH, V33, P71, DOI 10.1016/j.progsolidstchem.2005.11.002
   Mehdaoui B, 2011, ADV FUNCT MATER, V21, P4573, DOI 10.1002/adfm.201101243
   Nakajima R, 1999, PHYS REV B, V59, P6421, DOI 10.1103/PhysRevB.59.6421
   Ni X., 2009, J COLLOID INTERF SCI, V341, P18
   O'Kelly C, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/43/435604
   Peng S, 2006, J AM CHEM SOC, V128, P10676, DOI 10.1021/ja063969h
   Qi BH, 2007, CHEM LETT, V36, P722, DOI 10.1246/cl.2007.722
   Roca AG, 2006, NANOTECHNOLOGY, V17, P2783, DOI 10.1088/0957-4484/17/11/010
   Shavel A, 2007, ADV FUNCT MATER, V17, P3870, DOI 10.1002/adfm.200700494
   Shukoor MI, 2008, J MAGN MAGN MATER, V320, P2339, DOI 10.1016/j.jmmm.2008.04.160
   Signorini L., 2003, PHYS REV B, V68
   Sun SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852
   Sun SK, 2013, ANAL CHEM, V85, P8436, DOI 10.1021/ac401879y
   Taratula O, 2006, J PHYS CHEM B, V110, P6506, DOI 10.1021/jp0570317
   Trunova AV, 2008, J APPL PHYS, V104, DOI 10.1063/1.3005985
   Wang HB, 2012, SOLID STATE SCI, V14, P1256, DOI 10.1016/j.solidstatesciences.2012.06.012
   Yu LL, 2012, J APPL PHYS, V111, DOI 10.1063/1.3676203
   Zhang BB, 2012, ACS APPL MATER INTER, V4, P6479, DOI 10.1021/am301301f
   Zhao NN, 2010, SMALL, V6, P2558, DOI 10.1002/smll.201001218
   Zhou S, 2012, J MATER CHEM, V22, P8263, DOI 10.1039/c2jm16783b
   Zhu JH, 2012, J MATER CHEM, V22, P835, DOI 10.1039/c1jm14172d
   Zhu JH, 2012, ENVIRON SCI TECHNOL, V46, P977, DOI 10.1021/es2014133
   Zhu Y, 2011, J ALLOY COMPD, V509, P8549, DOI 10.1016/j.jallcom.2011.05.115
NR 38
TC 14
Z9 14
U1 5
U2 109
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD OCT 22
PY 2013
VL 29
IS 42
BP 13095
EP 13101
DI 10.1021/la403158d
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 242AJ
UT WOS:000326209500026
PM 24079275
DA 2018-12-27
ER

PT J
AU Wang, SH
   Li, HJ
   Wang, JJ
   Wang, D
AF Wang, Shaohua
   Li, Hanjun
   Wang, Jingjie
   Wang, Dan
TI RETRACTED: Expression of microRNA-497 and its prognostic significance in
   human breast cancer (Retracted article. See vol. 10, pg. 9, 2015)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE MicroRNA-497; Breast cancer; qRT-PCR; Disease-free survival; Overall
   survival
ID GENE-EXPRESSION; APOPTOSIS; GROWTH; CELLS; BIOMARKERS; RECEPTOR;
   MARKERS; METASTASIS; MALIGNANCY; MIRNAS
AB Objective: Dysregulation of microRNAs (miRNAs) plays critical roles in tumor progression. The aim of this study was to investigate the clinicopathologic and prognostic significance of miR-497 expression in human breast cancer (BC).
   Methods: Taqman qRT-PCR assay was performed to detect the expression of microRNA (miR)-497 in 30 pairs of BC tissues and corresponding noncancerous breast tissues. Additionally, the expression of this miRNA was detected in another 128 BC tissues and its correlations with clinicopathologic features of patients were analyzed. Kaplan-Meier analyses were used to assess survival of patients. Univariate and multivariate analyses were performed using the Cox proportional hazards model to analyze the prognostic significance of miR-497 expression.
   Results: Our data indicated that the relative level of miR-497 expression in BC tissues was significantly lower than that in corresponding noncancerous breast tissues (P = 0.0046). Of 128 BC patients, 74 (57.8%) were placed in the high-miR-497 group and 54 (42.2%) were placed in the low-miR-497 group. By statistical analyses, low miR-497 expression was observed to be closely correlated with higher differentiation grade, positive HER-2 expression, higher incidence of lymph node metastasis and advanced clinical stage. Moreover, patients with high miR-497 expression had better 5-year disease-free and overall survival compared with the low miR-497 group (P = 0.0124 and 0.0018, respectively). Univariate and multivariate analyses indicated that low miR-497 expression was an independent poor prognostic factor for BC patients.
   Conclusions: Our data provided the first evidence that downregulation of miR-497 was correlated with BC progression, and miR-497 might be a potential molecular biomarker for predicting the prognosis of patients.
C1 [Wang, Shaohua; Li, Hanjun; Wang, Jingjie; Wang, Dan] Nanjing Univ, Jinling Hosp, Sch Med, Dept Gen Surg, Nanjing 210002, Jiangsu, Peoples R China.
RP Wang, SH (reprint author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Gen Surg, 315 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM wangsh_nanjing@163.com
CR Anindo MIK, 2012, INT J SURG, V10, P443, DOI 10.1016/j.ijsu.2012.08.006
   Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Carleton M, 2007, CELL CYCLE, V6, P2127, DOI 10.4161/cc.6.17.4641
   Cho WCS, 2012, EXPERT REV MOL DIAGN, V12, P315, DOI [10.1586/erm.12.21, 10.1586/ERM.12.21]
   Cortez Maria Angelica, 2012, Recent Results Cancer Res, V195, P151, DOI 10.1007/978-3-642-28160-0_13
   Creevey L, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-23
   Criscitiello C, 2010, CURR OPIN ONCOL, V22, P552, DOI 10.1097/CCO.0b013e32833de186
   ELLEDGE RM, 1992, SEMIN ONCOL, V19, P244
   Farazi TA, 2013, ADV EXP MED BIOL, V774, P1, DOI 10.1007/978-94-007-5590-1_1
   Furuta M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060155
   Goldmann T, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-2
   Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214
   HAYES DF, 1993, ANN ONCOL, V4, P807, DOI 10.1093/oxfordjournals.annonc.a058385
   HE L, 2004, NAT REV GENET, V5, P522
   Hong L, 2012, GENE, V507, P135, DOI 10.1016/j.gene.2012.07.025
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jin Q, 2008, J MAMMARY GLAND BIOL, V13, P485, DOI 10.1007/s10911-008-9107-3
   Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912
   Ke XS, 2003, CURR OPIN CHEM BIOL, V7, P516, DOI 10.1016/S1367-5931(03)00075-9
   Landskroner-Eiger S, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006643
   Lehmann U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-109
   Lerebours F, 2013, INT J CANCER, V133, P1614, DOI 10.1002/ijc.28171
   Listowski MA, 2013, CELL MOL BIOL LETT, V18, P34, DOI 10.2478/s11658-012-0038-z
   Luo M, 2013, SURGERY, V153, P836, DOI 10.1016/j.surg.2012.12.004
   Luzna P, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-114
   Mao ZG, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-79
   Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032
   Muyal JP, 2009, DIAGN PATHOL, V4, DOI 10.1186/1746-1596-4-9
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Profumo Valentina, 2013, Critical Reviews in Oncogenesis, V18, P341
   Seccareccia E, 2012, GROWTH HORM IGF RES, V22, P193, DOI 10.1016/j.ghir.2012.09.003
   Shen J, 2013, CANCER LETT, V329, P125, DOI 10.1016/j.canlet.2012.11.001
   Shen L, 2012, EXP THER MED, V3, P475, DOI 10.3892/etm.2011.428
   Shi M, 2009, CANCER TREAT REV, V35, P328, DOI 10.1016/j.ctrv.2008.12.002
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Tang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051702
   Wang L, 2013, ASIAN PAC J CANCER P, V14, P3499, DOI 10.7314/APJCP.2013.14.6.3499
   Weigel MT, 2010, ENDOCR-RELAT CANCER, V17, pR245, DOI 10.1677/ERC-10-0136
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Zhao WY, 2013, BIOCHEM BIOPH RES CO, V435, P466, DOI 10.1016/j.bbrc.2013.05.010
   Zhou X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039011
   Zhu W, 2012, MED ONCOL, V29, P384, DOI 10.1007/s12032-010-9797-4
NR 43
TC 33
Z9 35
U1 3
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD OCT 21
PY 2013
VL 8
AR 172
DI 10.1186/1746-1596-8-172
PG 7
WC Pathology
SC Pathology
GA 289YJ
UT WOS:000329718200001
PM 24143964
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ramalingam, RJ
   Kannan, AM
AF Ramalingam, R. Jothi
   Kannan, A. M.
TI RETRACTED: Hydrogen production by an anaerobic photocatalytic reforming
   using palladium nanoparticle on boron and nitrogen doped TiO2 catalysts
   (Retracted article. See vol. 39, pg. 11830, 2014)
SO INTERNATIONAL JOURNAL OF HYDROGEN ENERGY
LA English
DT Article; Retracted Publication
DE Photocatalysts; Anaerobic photocatalytic reforming; Hydrogen generation;
   Palladium nanopartide
ID VISIBLE-LIGHT PHOTOCATALYSIS; TITANIUM-DIOXIDE; STRONTIUM-TITANATE; DFT
   CALCULATIONS; IRRADIATION; WATER; SRTIO3; SPECTROSCOPY; H-2
AB The present work reports the renewable hydrogen production by an anaerobic photocatalytic reforming of glucose and methanol, using noble-metal and hetero-atom substituted TiO2 and sol gel method prepared SrTiO3 as photocatalysts. XRD and SEM-EDX analysis confirm the typical anatase and rutile phase formation for B, N-doped TiO2 samples and palladium and other doped element existence confirmed by EDX analysis. These catalysts are preferred due to their identical wide band gap values of semiconductor oxide material. Interestingly, sol gel method prepared B, N-doped TiO2 catalyst show higher activity compared to SrTiO3. The sluggishness of the photocatalytic transformation on SrTiO3 might be the reason for poor hydrogen evolution with 1% glucose solution under visible light. Pd@B9N5-TiO2 prepared by sol-gel and Pd-photo deposition methods show very high hydrogen evolution (1000 mu mol/g) from glucose aqueous solution compared to reported B, N-TiO2 catalyst and also exhibit good stability upon long time irradiation. Copyright (C) 2013, Hydrogen Energy Publications, LLC. Published by Elsevier Ltd. All rights reserved.
C1 [Ramalingam, R. Jothi] Veltech Dr RR & Dr SR Tech Univ, Dept Chem, R&D Ctr, Chennai 600062, Tamil Nadu, India.
   [Kannan, A. M.] Arizona State Univ, Dept Engn, Coll Technol & Innovat, Mesa, AZ 85212 USA.
RP Kannan, AM (reprint author), Arizona State Univ, Dept Engn, Coll Technol & Innovat, Mesa, AZ 85212 USA.
EM amk@asu.edu
RI M. Kannan, Arunachala/A-2484-2008
OI M. Kannan, Arunachala/0000-0002-8412-1680
CR Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051
   Asahi R, 2007, CHEM PHYS, V339, P57, DOI 10.1016/j.chemphys.2007.07.041
   BARD AJ, 1982, J PHYS CHEM-US, V86, P172, DOI 10.1021/j100391a008
   Bell S, 2013, INT J HYDROGEN ENERG, V38, P6938, DOI 10.1016/j.ijhydene.2013.02.147
   Burnside S, 1999, J PHYS CHEM B, V103, P9328, DOI 10.1021/jp9913867
   CARDONA M, 1965, PHYS REV, V140, pA651, DOI 10.1103/PhysRev.140.A651
   Chen D, 2006, IND ENG CHEM RES, V45, P4110, DOI 10.1021/ie0600902
   Chen XB, 2004, J PHYS CHEM B, V108, P15446, DOI 10.1021/jp0469160
   Czoska AM, 2011, PHYS CHEM CHEM PHYS, V13, P136, DOI 10.1039/c0cp00143k
   Di Valentin C, 2005, J PHYS CHEM B, V109, P11414, DOI 10.1021/jp051756t
   DOMEN K, 1986, J PHYS CHEM-US, V90, P292, DOI 10.1021/j100274a018
   Finazzi E, 2009, J PHYS CHEM C, V113, P220, DOI 10.1021/jp8072238
   Gopal NO, 2008, J AM CHEM SOC, V130, P2760, DOI 10.1021/ja711424d
   Huang BS, 2013, CHEM ENG J, V223, P854, DOI 10.1016/j.cej.2013.03.076
   Konta R, 2004, J PHYS CHEM B, V108, P8992, DOI 10.1021/jp049556p
   Liu G, 2009, J AM CHEM SOC, V131, P12868, DOI 10.1021/ja903463q
   Livraghi S, 2006, J AM CHEM SOC, V128, P15666, DOI 10.1021/ja064164c
   Melo MD, 2011, J BRAZIL CHEM SOC, V22, P1399, DOI 10.1590/S0103-50532011000800002
   Miyauchi M, 2004, LANGMUIR, V20, P232, DOI 10.1021/la0353125
   Moon SC, 2000, CATAL TODAY, V58, P125, DOI 10.1016/S0920-5861(00)00247-9
   Navaladian S, 2009, NANOSCALE RES LETT, V4, P181, DOI 10.1007/s11671-008-9223-4
   NOZIK AJ, 1978, ANNU REV PHYS CHEM, V29, P189, DOI 10.1146/annurev.pc.29.100178.001201
   Sakthivel S, 2004, J PHYS CHEM B, V108, P19384, DOI 10.1021/jp046857q
   Sakthivel S, 2003, ANGEW CHEM INT EDIT, V42, P4908, DOI 10.1002/anie.200351577
   Su WY, 2008, LANGMUIR, V24, P3422, DOI 10.1021/la701645y
   Umebayashi T, 2002, APPL PHYS LETT, V81, P454, DOI 10.1063/1.1493647
   Valentina G, 2009, NANOSCI NANOTECHNOL, V1, P128
   WRIGHTON MS, 1976, J AM CHEM SOC, V98, P2774, DOI 10.1021/ja00426a017
   Yu JC, 2003, CHEM MATER, V15, P2280, DOI 10.1021/cm0340781
   Zhao W, 2004, J AM CHEM SOC, V126, P4782, DOI 10.1021/ja0396753
NR 30
TC 5
Z9 5
U1 10
U2 87
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0360-3199
EI 1879-3487
J9 INT J HYDROGEN ENERG
JI Int. J. Hydrog. Energy
PD OCT 17
PY 2013
VL 38
IS 31
BP 13572
EP 13578
DI 10.1016/j.ijhydene.2013.08.060
PG 7
WC Chemistry, Physical; Electrochemistry; Energy & Fuels
SC Chemistry; Electrochemistry; Energy & Fuels
GA 252JC
UT WOS:000327000000010
DA 2018-12-27
ER

PT J
AU Khan, F
   Vyas, B
   Pal, D
   Cameotra, SS
AF Khan, Fazlurrahman
   Vyas, Bhawna
   Pal, Deepika
   Cameotra, Swaranjit Singh
TI RETRACTED: Aerobic Degradation of N-Methyl-4-Nitroaniline (MNA) by
   Pseudomonas sp Strain FK357 Isolated from Soil (Retracted article. See
   vol. 9, pg. e102855, 2014)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID FLUIDIZED-BED BIOREACTORS; P-NITROPHENOL; FORMALDEHYDE DETOXIFICATION;
   5-NITROANTHRANILIC ACID; NITROAROMATIC COMPOUNDS; PURINE ALKALOIDS;
   ARTHROBACTER SP; PUTIDA STRAIN; BIODEGRADATION; ANILINE
AB N-Methyl-4-nitroaniline (MNA) is used as an additive to lower the melting temperature of energetic materials in the synthesis of insensitive explosives. Although the biotransformation of MNA under anaerobic condition has been reported, its aerobic microbial degradation has not been documented yet. A soil microcosms study showed the efficient aerobic degradation of MNA by the inhabitant soil microorganisms. An aerobic bacterium, Pseudomonas sp. strain FK357, able to utilize MNA as the sole carbon, nitrogen, and energy source, was isolated from soil microcosms. HPLC and GC-MS analysis of the samples obtained from growth and resting cell studies showed the formation of 4-nitroaniline (4-NA), 4-aminophenol (4-AP), and 1, 2, 4-benzenetriol (BT) as major metabolic intermediates in the MNA degradation pathway. Enzymatic assay carried out on cell-free lysates of MNA grown cells confirmed N-demethylation reaction is the first step of MNA degradation with the formation of 4-NA and formaldehyde products. Flavin-dependent transformation of 4-NA to 4-AP in cell extracts demonstrated that the second step of MNA degradation is a monooxygenation. Furthermore, conversion of 4-AP to BT by MNA grown cells indicates the involvement of oxidative deamination (release of NH2 substituent) reaction in third step of MNA degradation. Subsequent degradation of BT occurs by the action of benzenetriol 1, 2-dioxygenase as reported for the degradation of 4-nitrophenol. This is the first report on aerobic degradation of MNA by a single bacterium along with elucidation of metabolic pathway.
C1 [Khan, Fazlurrahman; Vyas, Bhawna; Pal, Deepika; Cameotra, Swaranjit Singh] CSIR, Environm Biotechnol & Microbial Biochem Lab, Inst Microbial Technol, Sect 39A, Chandigarh, India.
RP Cameotra, SS (reprint author), CSIR, Environm Biotechnol & Microbial Biochem Lab, Inst Microbial Technol, Sect 39A, Chandigarh, India.
EM ssc@imtech.res.in
FU Research Associateship from the Department of Biotechnology (DBT),
   India; DST; UGC India
FX FK acknowledges the financial support from the Research Associateship
   from the Department of Biotechnology (DBT), India. BV and DP acknowledge
   for their research fellowship awards from DST and UGC India,
   respectively. This is the IMTECH communication number 50/2013. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ADROER N, 1990, APPL MICROBIOL BIOT, V33, P217, DOI 10.1007/BF00176528
   Agrawal JP, 1998, PROG ENERG COMBUST, V24, P1, DOI 10.1016/S0360-1285(97)00015-4
   ALEXANDER M, 1992, SCIENCE, V258, P874, DOI 10.1126/science.258.5084.874
   Arnett CM, 2009, MICROBES ENVIRON, V24, P72, DOI 10.1264/jsme2.ME08556
   ASANO Y, 1993, BIOSCI BIOTECH BIOCH, V57, P1286, DOI 10.1271/bbb.57.1286
   BEUNINK J, 1990, APPL MICROBIOL BIOT, V34, P108
   BLECHER R, 1977, H-S Z PHYSIOL CHEM, V358, P807, DOI 10.1515/bchm2.1977.358.2.807
   Boyd DR, 2006, ORG BIOMOL CHEM, V4, P181, DOI 10.1039/b513226f
   CARTWRIGHT NJ, 1967, BIOCHEM J, V102, P826, DOI 10.1042/bj1020826
   Chauhan A, 2010, ENVIRON SCI TECHNOL, V44, P3435, DOI 10.1021/es9024172
   Chongcharoen R, 2005, MICROBIOL-SGM, V151, P2615, DOI 10.1099/mic.0.27912-0
   Das Nilanjana, 2011, Biotechnol Res Int, V2011, P941810, DOI 10.4061/2011/941810
   Fazlurrahman, 2009, LETT APPL MICROBIOL, V49, P721, DOI 10.1111/j.1472-765X.2009.02724.x
   Fukumori F, 1997, J BACTERIOL, V179, P399, DOI 10.1128/jb.179.2.399-408.1997
   Ghosh A, 2010, ENVIRON SCI TECHNOL, V44, P1069, DOI 10.1021/es9034123
   Gisi MR, 2003, J BACTERIOL, V185, P2786, DOI 10.1128/JB.185.9.2786-2792.2003
   Hibi M, 2005, FEMS MICROBIOL LETT, V253, P237, DOI 10.1016/j.femsle.2005.09.036
   JAIN RK, 1994, APPL ENVIRON MICROB, V60, P3030
   Kadiyala V, 1998, APPL ENVIRON MICROB, V64, P2479
   Katsivela E, 1999, APPL ENVIRON MICROB, V65, P1405
   Khan F, 2013, J HAZARD MATER, V254, P72, DOI 10.1016/j.jhazmat.2013.03.021
   Khan F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062178
   Lessner DJ, 2002, APPL ENVIRON MICROB, V68, P634, DOI 10.1128/AEM.68.2.634-641.2002
   Liang O, 2005, MICROBIOL-SGM, V151, P3435, DOI 10.1099/mic.0.28137-0
   Liu Z, 2002, APPL MICROBIOL BIOT, V58, P679, DOI 10.1007/s00253-002-0933-8
   LOIDL M, 1990, ARCH MICROBIOL, V155, P56, DOI 10.1007/BF00291275
   Marx CJ, 2004, J BACTERIOL, V186, P2173, DOI 10.1128/JB.186.7.2173-2178.2004
   MCCLURE NC, 1986, J GEN MICROBIOL, V132, P2209
   NISHINO SF, 1995, APPL ENVIRON MICROB, V61, P2308
   NISHINO SF, 1993, APPL ENVIRON MICROB, V59, P2520
   Nolan LC, 2008, BIOTECHNOL LETT, V30, P1879, DOI 10.1007/s10529-008-9791-5
   O'Neill C, 2000, APPL MICROBIOL BIOT, V53, P249, DOI 10.1007/s002530050016
   Padda RS, 2003, ENVIRON TOXICOL CHEM, V22, P2293, DOI 10.1897/02-220
   Perreault NN, 2012, ENVIRON SCI TECHNOL, V46, P6035, DOI 10.1021/es301047d
   Perry LL, 2007, J BACTERIOL, V189, P7563, DOI 10.1128/JB.01849-06
   Platten WE, 2010, CHEMOSPHERE, V81, P1131, DOI 10.1016/j.chemosphere.2010.08.044
   Providenti MA, 2006, J BACTERIOL, V188, P3862, DOI 10.1128/JB.01675-05
   Purohit V, 2000, CHEM RES TOXICOL, V13, P673, DOI 10.1021/tx000002x
   Qu Y, 2011, J BACTERIOL, V193, P3057, DOI 10.1128/JB.01188-10
   Qu Y, 2010, APPL ENVIRON MICROB, V76, P1417, DOI 10.1128/AEM.02816-09
   Robidoux PY, 2000, ENVIRON TOXICOL CHEM, V19, P1764, DOI 10.1897/1551-5028(2000)019<1764:CTOECI>2.3.CO;2
   Roca A, 2008, MICROB BIOTECHNOL, V1, P158, DOI 10.1111/j.1751-7915.2007.00014.x
   Saupe A, 1999, CHEMOSPHERE, V39, P2325, DOI 10.1016/S0045-6535(99)00141-1
   Schafer A, 1996, BIODEGRADATION, V7, P249, DOI 10.1007/BF00058184
   Shettigar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051162
   Shin KA, 2009, APPL ENVIRON MICROB, V75, P2694, DOI 10.1128/AEM.02198-08
   Soccol Carlos R., 2003, Indian Journal of Experimental Biology, V41, P1030
   Summers RM, 2012, J BACTERIOL, V194, P2041, DOI 10.1128/JB.06637-11
   Summers RM, 2011, MICROBIOL-SGM, V157, P583, DOI 10.1099/mic.0.043612-0
   Travkin VM, 2003, J ENVIRON SCI HEAL B, V38, P121, DOI 10.1081/PFC-120018443
   Urata M, 2004, BIOSCI BIOTECH BIOCH, V68, P2457, DOI 10.1271/bbb.68.2457
   Wei M, 2010, BIODEGRADATION, V21, P915, DOI 10.1007/s10532-010-9351-2
   White GF, 1996, APPL ENVIRON MICROB, V62, P637
   WOOLFOLK CA, 1975, J BACTERIOL, V123, P1088
   ZEYER J, 1985, APPL ENVIRON MICROB, V50, P447
   Zhao JS, 2001, APPL ENVIRON MICROB, V67, P1388, DOI 10.1128/AEM.67.3.1388-1391.2001
   Zissi U, 1996, WATER SCI TECHNOL, V34, P495, DOI 10.1016/0273-1223(96)00684-1
NR 57
TC 3
Z9 3
U1 1
U2 46
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2013
VL 8
IS 10
AR e75046
DI 10.1371/journal.pone.0075046
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 233FK
UT WOS:000325552200007
PM 24116023
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Prezioso, D
   Iacono, F
   Di Lauro, G
   Illiano, E
   Romeo, G
   Ruffo, A
   Russo, N
   Amato, B
AF Prezioso, Domenico
   Iacono, Fabrizio
   Di Lauro, Giovanni
   Illiano, Ester
   Romeo, Giuseppe
   Ruffo, Antonio
   Russo, Nicola
   Amato, Bruno
TI RETRACTED: Stress urinary incontinence: long-term results of
   laparoscopic Burch colposuspension (Retracted article. See vol. 16, 26,
   2016)
SO BMC SURGERY
LA English
DT Article; Retracted Publication
AB Background: The open Burch colposuspension, first described in 1961 had been widely employed for the surgical treatment of women with stress urinary incontinence (SUI) caused by urethral hypermobility. We evaluated the long-term efficacy of laparoscopic Burch colposuspension (LBC) for SUI in women.
   Methods: A randomized prospective trial was conducted from September 2010 to January 2013. The extraperitoneal laparoscopic Burch colposuspension was performed by an operator on 96 women, mean age was 54,3 +/- 3,7 years all of whom suffered from SUI or mixed urinary incontinence. Patients completed a self-administered the Short Form-36 (SF-36), the Physical Component Summary (PCS) and Mental Component Summary (MCS), the Short Urinary Distress Inventory (SUDI) and Short Incontinence Impact Questionnaire (SIIQ). at both baseline and follow up(6 weeks, 6 months, 18 months postoperatively). The Genito-Urinary Treatment Satisfaction Scale (GUTSS) was used to assess satisfaction with surgery.
   Results: After follow up was recorded an improvement of questionnaries scores. The general health score is improved after surgery (2,60 +/- 1.02 versus 2,76 +/- 1.06) with p = 0.09. The PCS baseline score is 46.29 +/- 10.95 versus 49.54 +/- 10.41 after treatment with p = 0.01, so there was a significant baseline to follow up improvement. The MCS improved also, infact baseline score is 42.19 +/- 12.57 versus 42.70 +/- 13.03 with p = 0.87. The SUDI baseline score is 50.22 +/- 20.73 versus 23.92 +/- 17.90, while SIIQ score is 49.98 +/- 23.90 versus 31.40 +/- 23.83 with p < 0.01. In both questionnaires there is an improvement. Satisfaction with treatment outcomes from the GUTSS at 6-month follow up is 29.5 +/- 6.3 with p = 0.46.
   Conclusion: The LBC has significant advantages, without any apparent compromise in short-term and long term outcomes.
C1 [Prezioso, Domenico; Iacono, Fabrizio; Illiano, Ester; Romeo, Giuseppe; Ruffo, Antonio; Russo, Nicola] Univ Naples Federico II, Dept Urol, I-80131 Naples, Italy.
   [Di Lauro, Giovanni] Hosp Santa Maria delle Grazie, Naples, Italy.
   [Amato, Bruno] Univ Naples Federico II, Dept Gen Geriatr Oncol Surg & Adv Technol, I-80131 Naples, Italy.
RP Illiano, E (reprint author), Univ Naples Federico II, Dept Urol, Via S Pansini 5, I-80131 Naples, Italy.
EM ester.illiano@inwind.it
OI Amato, Bruno/0000-0002-4262-8467; Iacono, Fabrizio/0000-0003-1064-649X;
   Illiano, Ester/0000-0001-5660-1815
CR Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
   ALCALAY M, 1995, BRIT J OBSTET GYNAEC, V102, P740, DOI 10.1111/j.1471-0528.1995.tb11434.x
   Batislam Ertan, 2000, International Urology and Nephrology, V32, P47, DOI 10.1023/A:1007143815433
   Bezerra CA, 1999, J BRAS UROL, V25, P68
   Brenner B, 2001, NEW ZEAL MED J, V114, P146
   BURCH JC, 1961, AM J OBSTET GYNECOL, V81, P281, DOI 10.1016/S0002-9378(16)36367-0
   Cooper MJW, 1996, AUST NZ J OBSTET GYN, V36, P36, DOI 10.1111/j.1479-828X.1996.tb02919.x
   Cornish A., 2001, Neurourology and Urodynamics, V20, P506
   Dean NM, 2006, COCHRANE DB SYST REV, V3, P245
   Doret M, 2000, J Gynecol Obstet Biol Reprod (Paris), V29, P650
   Downey RG, 1998, J GEN PSYCHOL, V125, P179
   Drouin J, 1999, UROLOGY, V54, P808, DOI 10.1016/S0090-4295(99)00235-6
   ERIKSEN BC, 1990, ACTA OBSTET GYN SCAN, V69, P45, DOI 10.3109/00016349009021038
   Fatthy H, 2001, J AM ASSOC GYN LAP, V8, P99, DOI 10.1016/S1074-3804(05)60557-9
   Fayers PM, 2000, QUALITY LIFE ASSESSM
   Ferland RD, 1999, J AM ASSOC GYN LAP, V6, P217, DOI 10.1016/S1074-3804(99)80107-8
   Hawthorne G, 2000, N117 CTR HLTH PROGR
   Jelovsek JE, 2008, BJOG-INT J OBSTET GY, V115, P219, DOI 10.1111/j.1471-0528.2007.01592.x
   JOLLEYS JV, 1988, BRIT MED J, V296, P1300, DOI 10.1136/bmj.296.6632.1300
   Lapitan MC, 2003, COCHRANE DB SYST REV, V3, P217
   LIU CY, 1993, J REPROD MED, V38, P526
   LIU CY, 1993, J AM ASSOC GYN LAP, V1, P31, DOI 10.1016/S1074-3804(05)80755-8
   Lobel RW, 1997, J AM ASSOC GYN LAP, V4, P341, DOI 10.1016/S1074-3804(05)80225-7
   Lobel RW, 1998, J AM ASSOC GYN LAP, V91, P55
   McCall WA, 1922, MEASURE ED
   McDougall Elspeth M., 1999, Journal of Urology, V161, P105
   McDougall EM, 2001, UROL CLIN N AM, V28, P145, DOI 10.1016/S0094-0143(01)80016-1
   Meltomaa S, 1997, Tech Urol, V3, P216
   Miannay E, 1998, EUR J OBSTET GYN R B, V79, P159, DOI 10.1016/S0301-2115(98)00029-3
   Miklos JR, 2000, UROLOGY, V56, P64, DOI 10.1016/S0090-4295(00)00510-0
   Moehrer B, 2003, BJOG-INT J OBSTET GY, V110, P230, DOI 10.1016/S1470-0328(02)02050-5
   Moehrer B, 2003, LAPAROSCOPIC COLPOSU
   Myers DL, 2000, J REPROD MED, V45, P939
   NEZHAT CH, 1994, J AM ASSOC GYN LAP, V1, P339, DOI 10.1016/S1074-3804(05)80799-6
   Ou CS, 1999, J LAPAROENDOSC ADV A, V9, P249, DOI 10.1089/lap.1999.9.249
   Papasakelariou C, 1997, J AM ASSOC GYN LAP, V4, P185, DOI 10.1016/S1074-3804(97)80007-2
   Persson J, 2002, ACTA OBSTET GYN SCAN, V81, P1066
   Petri E, 2001, TXB FEMALE UROLOGY U, P513
   Radomski SB, 1996, J UROLOGY, V155, P515, DOI 10.1016/S0022-5347(01)66437-1
   Rortveit G, 2003, NEW ENGL J MED, V348, P900, DOI 10.1056/NEJMoa021788
   ROSS JW, 1995, INT UROGYNECOL J, V6, P323
   Saidi MH, 1998, OBSTET GYNECOL, V92, P619, DOI 10.1016/S0029-7844(98)00266-X
   Sharifi-Aghdas Farzaneh, 2005, Urol J, V2, P175
   Speights SE, 2000, J AM ASSOC GYN LAP, V7, P515, DOI 10.1016/S1074-3804(05)60365-9
   Tamussino KF, 1999, AM J OBSTET GYNECOL, V181, P1347, DOI 10.1016/S0002-9378(99)70375-3
   UEBERSAX JS, 1995, NEUROUROL URODYNAM, V14, P131, DOI 10.1002/nau.1930140206
   Valpas A, 2003, ACTA OBSTET GYN SCAN, V82, P665, DOI 10.1034/j.1600-0412.2003.00163.x
   Vancaillie T G, 1991, J Laparoendosc Surg, V1, P169, DOI 10.1089/lps.1991.1.169
   Ware JE, 1993, SF 36 HLTH SURVEY MA
   WOLF JS, 1995, J UROLOGY, V154, P959, DOI 10.1016/S0022-5347(01)66943-X
NR 50
TC 5
Z9 6
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2482
J9 BMC SURG
JI BMC Surg.
PD OCT 8
PY 2013
VL 13
SU 2
AR S38
DI 10.1186/1471-2482-13-S2-S38
PG 6
WC Surgery
SC Surgery
GA V39GL
UT WOS:000209399400018
PM 24268031
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Rocco, N
   Rispoli, C
   Pagano, G
   Rengo, G
   Compagna, R
   Danzi, M
   Accurso, A
   Amato, B
AF Rocco, Nicola
   Rispoli, Corrado
   Pagano, Gennaro
   Rengo, Giuseppe
   Compagna, Rita
   Danzi, Michele
   Accurso, Antonello
   Amato, Bruno
TI RETRACTED: Breast cancer surgery in elderly patients: postoperative
   complications and survival (Retracted article. See vol. 15, pg. 2, 2015)
SO BMC SURGERY
LA English
DT Article; Retracted Publication
ID POPULATION-BASED COHORT; INTERNATIONAL SOCIETY; GERIATRIC ONCOLOGY;
   WOMEN; COMORBIDITY; MORTALITY; MANAGEMENT; DIAGNOSIS; IMPACT; AGE
AB Aims and background: Old age is associated with comorbidity and decreased functioning which influences treatment decisions in elderly breast cancer patients. The purpose of this study was to identify risk factors for complications after breast cancer surgery in elderly patients, and to assess mortality in patients with postoperative complications.
   Methods: We retrospectively considered all female patients aged 65 years and older with invasive and in situ breast cancer who were diagnosed and treated between 1997 and 2012 in the Department of General and Geriatric Surgery of the University of Naples "Federico II".
   Results and conclusion: 449 patients received surgery, of whom 18,2% (n = 82) developed one or more postoperative complications. The odds ratio of having postoperative complications show an increase with age, reaching statistical significance only for patients older than 85 [OR 5,75 (95% confidence interval 2,38-14,04); p < 0,001]. Number of concomitant diseases [OR 2,51 (95% CI 1,17 - 5,45); p = 0,01 for 3 or more concomitant diseases] and polypharmacy [OR 16,7 (95% CI 9,12 - 30,58); p < 0,0001) are associated to an increased risk of postoperative complications. Overall survival was worse in patients with postoperative complications [HR 2,06 (95% CI 1,52-2,70), p < 0,001]. This increased risk of mortality is probably due to geriatric parameters such as comorbidity or poor physical function, more than to higher complication rates.
C1 [Rocco, Nicola] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy.
   [Rispoli, Corrado] Cardinale Ascalesi Hosp, ASL NA1, Dept Gen Surg, Naples, Italy.
   [Pagano, Gennaro; Rengo, Giuseppe] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy.
   [Compagna, Rita; Danzi, Michele; Accurso, Antonello; Amato, Bruno] Univ Naples Federico II, Dept Gen Geriatr Oncol Surg & Adv Technol, Naples, Italy.
RP Amato, B (reprint author), Univ Naples Federico II, Dept Gen Geriatr Oncol Surg & Adv Technol, Naples, Italy.
EM bramato@unina.it
OI Amato, Bruno/0000-0002-4262-8467
CR Amato B, 2012, MINERVA CHIR, V67, P445
   [Anonymous], 2013, NCCN GUIDELINES VERS
   Bastiaannet E, 2010, BREAST CANCER RES TR, V124, P801, DOI 10.1007/s10549-010-0898-8
   Biganzoli L, 2012, LANCET ONCOL, V13, pE148, DOI 10.1016/S1470-2045(11)70383-7
   Braithwaite D, 2010, J NATL CANCER I, V102, P1468, DOI 10.1093/jnci/djq344
   de Blacam C, 2012, ANN SURG, V255, P551, DOI 10.1097/SLA.0b013e318246c294
   Dignam JJ, 2009, CANCER-AM CANCER SOC, V115, P5272, DOI 10.1002/cncr.24617
   Guralnik JM, 1996, ANN EPIDEMIOL, V6, P376, DOI 10.1016/S1047-2797(96)00060-9
   Houterman S, 2004, BRIT J CANCER, V90, P2332, DOI 10.1038/sj.bjc.6601844
   Land LH, 2012, BREAST CANCER RES TR, V131, P1013, DOI 10.1007/s10549-011-1819-1
   Lavelle K, 2007, BRIT J CANCER, V96, P1197, DOI 10.1038/sj.bjc.6603709
   Lietzen LW, 2012, EJSO-EUR J SURG ONC, V38, P407, DOI 10.1016/j.ejso.2012.02.184
   Louwman WJ, 2005, EUR J CANCER, V41, P779, DOI 10.1016/j.ejca.2004.12.025
   Patnaik JL, 2011, J NATL CANCER I, V103, P1101, DOI 10.1093/jnci/djr188
   Pilotto A, 2010, CIRC-HEART FAIL, V3, P14, DOI 10.1161/CIRCHEARTFAILURE.109.865022
   Rispoli C, 2009, BMC GERIATR, V9, pA98
   Rispoli C., 2009, BMC GERIATRICS S1, V9, pA46
   Rocco N, 2010, BMC GERIATRICS S1, V10, pA31
   Serra R, 2013, ANN VASC SURG, V13
   van de Water W, 2012, BRIT J SURG, V99, P813, DOI 10.1002/bjs.8743
   van de Water W, 2012, JAMA-J AM MED ASSOC, V307, P590, DOI 10.1001/jama.2012.84
   Vitug AF, 2007, SURG CLIN N AM, V87, P431, DOI 10.1016/j.suc.2007.01.005
   *WHO, 1992, INT STAT CLASS DIS R, P1
   Wildiers H, 2007, LANCET ONCOL, V8, P1101, DOI 10.1016/S1470-2045(07)70378-9
   Zulman DM, 2011, J GEN INTERN MED, V26, P783, DOI 10.1007/s11606-010-1629-x
NR 25
TC 15
Z9 16
U1 4
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2482
J9 BMC SURG
JI BMC Surg.
PD OCT 8
PY 2013
VL 13
SU 2
AR S25
DI 10.1186/1471-2482-13-S2-S25
PG 6
WC Surgery
SC Surgery
GA V39GL
UT WOS:000209399400005
PM 24267004
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Rocco, N
   Rispoli, C
   Pagano, G
   Ascione, S
   Compagna, R
   Danzi, M
   Accurso, A
   Amato, B
AF Rocco, Nicola
   Rispoli, Corrado
   Pagano, Gennaro
   Ascione, Silvio
   Compagna, Rita
   Danzi, Michele
   Accurso, Antonello
   Amato, Bruno
TI RETRACTED: Undertreatment of breast cancer in the elderly (Retracted
   article. See vol. 16, 25, 2016)
SO BMC SURGERY
LA English
DT Article; Retracted Publication
ID AXILLARY DISSECTION; OLDER; SURVIVAL; WOMEN; TRIALS; STAGE; AGE;
   RECOMMENDATIONS; RECRUITMENT; NETHERLANDS
AB Aims: The effect of undertreatment with adjuvant hormonal therapy, chemotherapy or radiation was studied in elderly women with breast cancer.
   Methods: A prospectively maintained database was used to identify women undergoing potentially curative surgery between 1997 and 2011. The presentation, pathologic findings, treatment and outcomes of 449 women over 65 were compared to the findings in 1049 younger patients. Moreover, conventionally treated and undertreated elderly patients were identified and their characteristics and outcomes were compared.
   Results: Both young and old patients presented most frequently with mammographic findings, but older patients presented more frequently with mammographic masses while younger patients presented more frequently with mammographic calcifications. Cancers of older patients were signicantly more favorable than cancers in younger patients with more infiltrating lobular, fewer ductal carcinoma in situ and more frequently estrogen receptor positive and fewer were poorly differentiated. Elderly patients had less axillary surgery, less adjuvant radiation therapy and more hormonal therapy. Fourty-six percent of the 449 elderly patients were undertreated by conventional criteria. Undertreated patients were more frequently in situ, better differentiated, smaller, and more often estrogen receptor positive. Forty-four percent of the undertreated patients died during follow-up without disease recurrence.
   Conclusions: Despite undertreatment, local and distant disease-free survival was comparable to patients who were not undertreated.
C1 [Rocco, Nicola] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy.
   [Rispoli, Corrado] Cardinale Ascalesi Hosp ASL NA1, Dept Gen Surg, Naples, Italy.
   [Pagano, Gennaro; Ascione, Silvio] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy.
   [Compagna, Rita; Danzi, Michele; Accurso, Antonello; Amato, Bruno] Univ Naples Federico II, Dept Gen Geriatr Oncol Surg & Adv Technol, Naples, Italy.
RP Amato, B (reprint author), Univ Naples Federico II, Dept Gen Geriatr Oncol Surg & Adv Technol, Naples, Italy.
EM bramato@unina.it
OI Amato, Bruno/0000-0002-4262-8467
CR Amato B, 2012, MINERVA CHIR, V67, P445
   Bastiaannet E, 2010, BREAST CANCER RES TR, V124, P801, DOI 10.1007/s10549-010-0898-8
   Biganzoli L, 2012, LANCET ONCOL, V13, pE148, DOI 10.1016/S1470-2045(11)70383-7
   Bland KI, 1999, J AM COLL SURGEONS, V188, P586, DOI 10.1016/S1072-7515(99)00056-3
   Bouchardy C, 2003, J CLIN ONCOL, V21, P3580, DOI 10.1200/JCO.2003.02.046
   Bouchardy C, 2007, J CLIN ONCOL, V25, P1858, DOI 10.1200/JCO.2006.10.4208
   DeMichele A, 2003, CANCER-AM CANCER SOC, V97, P2150, DOI 10.1002/cncr.11338
   Diab SG, 2000, J NATL CANCER I, V92, P550, DOI 10.1093/jnci/92.7.550
   Gajdos C, 2001, J AM COLL SURGEONS, V192, P698, DOI 10.1016/S1072-7515(01)00832-8
   Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90
   Gross CP, 2005, J CLIN ONCOL, V23, P4755, DOI 10.1200/JCO.2005.14.365
   Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706
   Puts MTE, 2010, SUPPORT CARE CANCER, V18, P969, DOI 10.1007/s00520-010-0883-0
   Rengo F, 2012, J NEPHROL, V25, pS73, DOI 10.5301/jn.5000164
   Rispoli C, 2009, BMC GERIATR, V9, pA98
   Rispoli C., 2009, BMC GERIATRICS S1, V9, pA46
   Rocco N, 2010, BMC GERIATRICS S1, V10, pA31
   SATARIANO WA, 1994, ANN INTERN MED, V120, P104, DOI 10.7326/0003-4819-120-2-199401150-00002
   Serra R, 2013, ANN VASC SURG
   Townsley CA, 2005, J CLIN ONCOL, V23, P3112, DOI 10.1200/JCO.2005.00.141
   US Census Bureau, 2013, CENS 2000 SUMM FIL 1
   van de Water W, 2012, BRIT J SURG, V99, P813, DOI 10.1002/bjs.8743
   Wanebo HJ, 1997, ANN SURG, V225, P579, DOI 10.1097/00000658-199705000-00014
   Weggelaar I, 2011, BREAST J, V17, P239, DOI 10.1111/j.1524-4741.2011.01074.x
NR 24
TC 17
Z9 17
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2482
J9 BMC SURG
JI BMC Surg.
PD OCT 8
PY 2013
VL 13
SU 2
AR S26
DI 10.1186/1471-2482-13-S2-S26
PG 6
WC Surgery
SC Surgery
GA V39GL
UT WOS:000209399400006
PM 24267104
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jin, Y
   Da, W
AF Jin, Yong
   Da, Wei
TI RETRACTED: Screening of key genes in gastric cancer with DNA microarray
   analysis (Retracted article. See vol. 20, 30, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Differentially expressed gene; Functional enrichment analysis; Gastric
   cancer; Interaction network; Pathway analysis
ID EXPRESSION PATTERNS; ENRICHMENT ANALYSIS; STOMACH-CANCER; IMMUNE ESCAPE;
   RAD21 GENE; REG-IV; BIOMARKERS; METASTASIS; DATABASE; CELLS
AB Background: The aim of this study was to identify key genes and novel potential therapeutic targets related to gastric cancer (GC) by comparing cancer tissue samples and healthy control samples using DNA microarray analysis.
   Methods: Microarray data set GSE19804 was downloaded from Gene Expression Omnibus. Preprocessing and differential analysis were conducted with of R statistical software packages, and a number of differentially expressed genes (DEGs) were obtained. Cluster analysis was also done with gene expression values. Functional enrichment analysis was performed for all the DEGs with DAVID tools. The significantly up- and downregulated genes were selected out and their interactors were retrieved with STRING and HitPredict, followed by construction of networks. For all the genes in the two networks, GeneCodis was chosen for gene function annotation.
   Results: A total of 638 DEGs were identified, and we found that SPP1 and FABP4 were the markedly up- and downregulated genes, respectively. Cell cycle and regulation of proliferation were the most significantly overrepresented functional terms in up- and downregulated genes. In addition, extracellular matrix-receptor interaction was found to be significant in the SPP1-included interaction network.
   Conclusions: A range of DEGs were obtained for GC. These genes not only provided insights into the pathogenesis of GC but also could develop into biomarkers for diagnosis or treatment.
C1 [Jin, Yong; Da, Wei] Shanghai Jiao Tong Univ, Peoples Hosp Affiliated 6, Dept Gastroenterol, Shanghai 200233, Peoples R China.
RP Da, W (reprint author), Shanghai Jiao Tong Univ, Peoples Hosp Affiliated 6, Dept Gastroenterol, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM d_a_w_e_i@hotmail.com
CR Allgayer H, 2009, HEREDITARY TUMORS GE, P501, DOI [10.1002/9783527627523.ch30, DOI 10.1002/9783527627523.CH30]
   Atienza JM, 2005, MOL CANCER THER, V4, P361
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   Bennett MW, 1999, GUT, V44, P156, DOI 10.1136/gut.44.2.156
   Bijian K, 2004, AM J PHYSIOL-RENAL, V286, pF255, DOI 10.1152/ajprenal.00259.2003
   Carmona-Saez P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r3
   Chen J, 2011, WORLD J GASTROENTERO, V17, P2860, DOI 10.3748/wjg.v17.i23.2860
   DeRisi J, 1996, NAT GENET, V14, P457
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Dong Yan, 2008, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V24, P16
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fujita A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-469
   Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017
   He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022
   Himoudi N, 2007, CANCER IMMUNOL IMMUN, V56, P1381, DOI 10.1007/s00262-007-0294-3
   Hippo Y, 2002, CANCER RES, V62, P233
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6
   Jang JS, 2004, ONCOL RES, V14, P491
   Kerrien S, 2012, NUCLEIC ACIDS RES, V40, pD841, DOI 10.1093/nar/gkr1088
   Krejs GJ, 2010, DIGEST DIS, V28, P600, DOI 10.1159/000320277
   Lei YL, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005397
   Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403
   Lin XD, 2012, DNA CELL BIOL, V31, P511, DOI 10.1089/dna.2011.1344
   Lodish H., 2004, MOL CELL BIOL
   Ludwig JA, 2005, NAT REV CANCER, V5, P845, DOI 10.1038/nrc1739
   Mitani Y, 2007, ONCOGENE, V26, P4383, DOI 10.1038/sj.onc.1210215
   Nakajima TE, 2009, J GASTROENTEROL, V44, P685, DOI 10.1007/s00535-009-0063-5
   Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881
   Nam D, 2008, BRIEF BIOINFORM, V9, P189, DOI 10.1093/bib/bbn001
   Nogales-Cadenas R, 2009, NUCLEIC ACIDS RES, V37, pW317, DOI 10.1093/nar/gkp416
   Oue N, 2009, INT J CANCER, V125, P2383, DOI 10.1002/ijc.24624
   Patil A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-100
   Patil A, 2011, NUCLEIC ACIDS RES, V39, pD744, DOI 10.1093/nar/gkq897
   Pollard KS, 2005, STAT BIOL HEALTH, P249
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Ryu JW, 2003, J KOREAN MED SCI, V18, P505, DOI 10.3346/jkms.2003.18.4.505
   Supernat A, 2012, ONCOL LETT, V4, P727, DOI 10.3892/ol.2012.794
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Tabas-Madrid D, 2012, NUCLEIC ACIDS RES, V40, pW478, DOI 10.1093/nar/gks402
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Xu ZG, 2012, ANAT REC, V295, P1446, DOI 10.1002/ar.22521
   Yamamoto G, 2006, VIRCHOWS ARCH, V448, P435, DOI 10.1007/s00428-005-0132-y
   Yasui W, 2004, CANCER SCI, V95, P385, DOI 10.1111/j.1349-7006.2004.tb03220.x
   Zhao ZS, 2011, J SURG ONCOL, V104, P525, DOI 10.1002/jso.21984
NR 45
TC 6
Z9 6
U1 1
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD OCT 4
PY 2013
VL 18
AR 37
DI 10.1186/2047-783X-18-37
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 242UT
UT WOS:000326269000001
PM 24093889
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Nitta, K
   Iimuro, S
   Imai, E
   Matsuo, S
   Makino, H
   Akizawa, T
   Watanabe, T
   Ohashi, Y
   Hishida, A
AF Nitta, Kosaku
   Iimuro, Satoshi
   Imai, Enyu
   Matsuo, Seiichi
   Makino, Hirofumi
   Akizawa, Tadao
   Watanabe, Tsuyoshi
   Ohashi, Yasuo
   Hishida, Akira
TI RETRACTED: Risk factors for increased left ventricular hypertrophy in
   patients with chronic kidney disease (Retracted article. See vol. 21,
   pg. 1146, 2017)
SO CLINICAL AND EXPERIMENTAL NEPHROLOGY
LA English
DT Article; Retracted Publication
DE Chronic kidney disease; Left ventricular hypertrophy; Hypertension; Body
   mass index; Albuminuria; Mineral metabolism; Antihypertensive agent
ID CHRONIC-RENAL-FAILURE; CARDIOVASCULAR-DISEASE; GENERAL-POPULATION;
   ALL-CAUSE; MORTALITY; WOMEN; PATHOPHYSIOLOGY; PRESSURE; OBESITY; COHORT
AB Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the predialysis period has not been fully examined.
   We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study in order to identify factors that are associated with increased LVMI in patients with stage 3-5 CKD. LVH was defined as LVMI > 125 g/m(2) in male patients and > 110 g/m(2) in female patients.
   We analyzed baseline characteristics in 1185 participants (male 63.7 %, female 36.3 %). Diabetes mellitus was the underlying disease in 41.3 % of patients, and mean age was 61.8 +/- A 11.1 years. LVH was detected in 21.7 % of patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease (odds ratio [OR] 0.574; 95 % confidence interval [CI] 0.360-0.916; P = 0.020), systolic blood pressure (OR 1.179; 95 % CI 1.021-1.360; P = 0.025), body mass index (OR 1.135; 95 % CI 1.074-1.200; P < 0.001), and serum calcium level (OR 0.589; 95 % CI 0.396-0.876; P = 0.009).
   Cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.
C1 [Nitta, Kosaku] Tokyo Womens Med Univ, Dept Med, Kidney Ctr, Shinjuku Ku, Tokyo 1628666, Japan.
   [Iimuro, Satoshi; Ohashi, Yasuo] Univ Tokyo, Dept Biostat, Sch Publ Hlth, Tokyo, Japan.
   [Imai, Enyu; Matsuo, Seiichi] Nagoya Univ, Dept Nephrol, Grad Sch Med, Nagoya, Aichi 4648601, Japan.
   [Makino, Hirofumi] Okayama Univ, Dept Med & Clin Sci, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
   [Akizawa, Tadao] Showa Univ, Dept Nephrol, Tokyo, Japan.
   [Watanabe, Tsuyoshi] Fukushima Med Univ, Dept Internal Med 3, Fukushima, Japan.
   [Hishida, Akira] Yaizu City Hosp, Shizuoka, Japan.
RP Nitta, K (reprint author), Tokyo Womens Med Univ, Dept Med, Kidney Ctr, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.
EM knitta@kc.twmu.ac.jp
FU Kyowa-Hakko-Kirin Co. Ltd.
FX Sponsor: Kyowa-Hakko-Kirin Co. Ltd.
CR Alpert MA, 2001, AM J MED SCI, V321, P225, DOI 10.1097/00000441-200104000-00003
   Covic A, 2009, NEPHROL DIAL TRANSPL, V24, P1506, DOI 10.1093/ndt/gfn613
   DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Guerra F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016630
   Imai E, 2008, HYPERTENS RES, V31, P1101, DOI 10.1291/hypres.31.1101
   Imai Enyu, 2007, Clin Exp Nephrol, V11, P156, DOI 10.1007/s10157-007-0463-x
   Imai E, 2010, CLIN EXP NEPHROL, V14, P558, DOI 10.1007/s10157-010-0328-6
   Imai E, 2009, CLIN EXP NEPHROL, V13, P621, DOI 10.1007/s10157-009-0199-x
   Irie F, 2006, KIDNEY INT, V69, P1264, DOI 10.1038/sj.ki.5000284
   Japanese Society of Dialysis Therapy, 2011, OV REG DIAL TREATM J
   Kotsis V, 2010, J HYPERTENS, V28, P1065, DOI 10.1097/HJH.0b013e3283370e5e
   Kurth T, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2392
   Levin A, 1999, AM J KIDNEY DIS, V34, P125, DOI 10.1016/S0272-6386(99)70118-6
   Levin A, 1996, AM J KIDNEY DIS, V27, P347, DOI 10.1016/S0272-6386(96)90357-1
   Locatelli F, 2001, NEPHROL DIAL TRANSPL, V16, P459, DOI 10.1093/ndt/16.3.459
   London G, 2001, NEPHROL DIAL TRANSPL, V16, P3, DOI 10.1093/ndt/16.suppl_2.3
   Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034
   McCullough PA, 2004, CURR OPIN NEPHROL HY, V13, P591, DOI 10.1097/00041552-200411000-00003
   McCullough PA, 2008, AM HEART J, V156, P277, DOI 10.1016/j.ahj.2008.02.024
   McMahon LP, 2004, J AM SOC NEPHROL, V15, P1640, DOI 10.1097/01.ASN.0000130566.69170.5E
   Meisinger C, 2006, EUR HEART J, V27, P1245, DOI 10.1093/eurheartj/ehi880
   Miura K, 2009, CIRCULATION, V119, P1892, DOI 10.1161/CIRCULATIONAHA.108.823112
   Muiesan ML, 2012, J HYPERTENS, V30, P2378, DOI 10.1097/HJH.0b013e328359b6a9
   Nardi E, 2009, J HYPERTENS, V27, P633, DOI 10.1097/HJH.0b013e3283220ecd
   *NAT KIDN FDN, 2002, AM J KIDNEY DIS S, V39, pS1, DOI DOI 10.1053/AJKD.2002.30571.PUBMED:11904577
   Ninomiya T, 2005, KIDNEY INT, V68, P228, DOI 10.1111/j.1523-1755.2005.00397.x
   Nitta K, 2011, CLIN EXP NEPHROL, V15, P187, DOI 10.1007/s10157-010-0374-0
   Paoletti E, 2005, AM J KIDNEY DIS, V46, P320, DOI 10.1053/j.ajkd.2005.04.031
   REICHEK N, 1981, CIRCULATION, V63, P1391, DOI 10.1161/01.CIR.63.6.1391
   Tucker B, 1997, NEPHROL DIAL TRANSPL, V12, P724, DOI 10.1093/ndt/12.4.724
   Verhave JC, 2003, J AM SOC NEPHROL, V14, P1330, DOI 10.1097/01.ASN.0000060573.77611.73
   Yamashita T, 2011, CLIN EXP NEPHROL, V15, P831, DOI 10.1007/s10157-011-0501-6
NR 33
TC 17
Z9 20
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1342-1751
EI 1437-7799
J9 CLIN EXP NEPHROL
JI Clin. Exp. Nephrol.
PD OCT
PY 2013
VL 17
IS 5
BP 730
EP 742
DI 10.1007/s10157-012-0758-4
PG 13
WC Urology & Nephrology
SC Urology & Nephrology
GA 238RU
UT WOS:000325966600032
PM 23318981
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Pan, TY
   Yu, QF
   Lloyd, S
AF Pan, Tongyan
   Yu, Qifeng
   Lloyd, Stephen
TI RETRACTED: Quantum-Chemistry-Based Study of Beech-Wood Lignin as an
   Antioxidant of Petroleum Asphalt (Retracted article. See vol. 26,
   08514001, 2014)
SO JOURNAL OF MATERIALS IN CIVIL ENGINEERING
LA English
DT Article; Retracted Publication
DE Asphalts; Binders (material); Aging (material); Chemical properties;
   Oxidation; Wood; Quantum chemistry; Asphalt binder; Oxidative aging;
   Bio-based additives; X-ray photoelectron spectroscopy
ID ELECTRONEGATIVITY EQUALIZATION METHOD; REACTIVE FORCE-FIELD;
   MOLECULAR-DYNAMICS; IRON OXIDATION; STEEL SURFACE; SPECTROSCOPY;
   PASSIVATION; MECHANISM; CONCRETE; REAXFF
AB Oxidative hardening or aging of asphalt binder can lead to increase in viscosity, separation of components, loss of cohesion and adhesion, and eventually the degraded engineering performances. A common practice to minimize asphalt aging has been to use chemical additives or modifiers as antioxidants. The current state of knowledge in asphalt oxidation and antioxidant evaluation concentrates on monitoring the degradation in asphalt's physical properties, mainly the viscosity and ductility. Such practices although satisfying direct engineering needs does not contribute to the fundamental understanding of the asphalt aging and antiaging mechanisms. As such, this study was initiated to study the antioxidation mechanisms of bio-based additives, using the beech-wood lignin as an example, by developing a quantum-chemistry based chemophysical environment in which the various chemical reactions among asphalt components, antioxidative ingredients and oxygen molecules, as well as the incurred physical changes can be studied. The techniques of X-ray photoelectron spectroscopy (XPS) were used to prove the validity of the modified and unmodified asphalt models.
C1 [Pan, Tongyan; Yu, Qifeng; Lloyd, Stephen] Catholic Univ Amer, Washington, DC 20064 USA.
RP Pan, TY (reprint author), Catholic Univ Amer, 620 Michigan Ave NE, Washington, DC 20064 USA.
EM pan@cua.edu; yuq@cua.edu; 34lloyd@cardinalmail.cua.edu
CR BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Boeriu CG, 2004, IND CROP PROD, V20, P205, DOI 10.1016/j.indcrop.2004.04.022
   Boerjan W, 2003, ANNU REV PLANT BIOL, V54, P519, DOI 10.1146/annurev.arplant.54.031902.134938
   Branthaver J. F., 1993, SHRPA368 NAT RES COU, V2
   BRINK DL, 1966, ADV CHEM SER, P177
   Carbognani L., 1992, MOL STRUCTURE ASPHAL
   Chenoweth K, 2008, J PHYS CHEM A, V112, P1040, DOI 10.1021/jp709896w
   CORBETT LW, 1969, ANAL CHEM, V41, P576, DOI 10.1021/ac60273a004
   Dizhbite T, 2004, BIORESOURCE TECHNOL, V95, P309, DOI 10.1016/j.biortech.2004.02.024
   Gelius U., 1970, Physica Scripta, V2, DOI 10.1088/0031-8949/2/1-2/014
   Griffin RL, 1959, J CHEM ENG DATA, V4, P349
   Hveem F.N., 1959, SPECIAL TECHNICAL PU, V277, P1
   JANSSENS GOA, 1995, J PHYS CHEM-US, V99, P3251, DOI 10.1021/j100010a041
   KELEMEN SR, 1990, FUEL, V69, P939, DOI 10.1016/0016-2361(90)90001-7
   Keten S, 2012, J MECH BEHAV BIOMED, V5, P32, DOI 10.1016/j.jmbbm.2011.08.017
   Kuzina S. I., 1993, J POLYM SCI A, VA35, P798
   Lindberg B. J., 1970, Physica Scripta, V1, P286, DOI 10.1088/0031-8949/1/5-6/020
   LUCENA MCC, 2004, MAT RES, V7, P529, DOI DOI 10.1590/S1516-14392004000400004
   McNichol D., 2005, PAVING WAY ASPHALT A
   MORTIER WJ, 1986, J AM CHEM SOC, V108, P4315, DOI 10.1021/ja00275a013
   NIMZ H, 1974, ANGEW CHEM INT EDIT, V13, P313, DOI 10.1002/anie.197403131
   Njo SL, 1998, J MOL CATAL A-CHEM, V134, P79, DOI 10.1016/S1381-1169(98)00024-7
   Pan T, 2011, ELECTROCATALYSIS-US, V2, P307, DOI 10.1007/s12678-011-0068-8
   Pan TY, 2011, ACTA METALL SIN-ENGL, V24, P415, DOI 10.11890/1006-7191-116-415
   Pan TY, 2011, INT J ELECTROCHEM SC, V6, P4967
   Pan TY, 2011, MATER LETT, V65, P3223, DOI 10.1016/j.matlet.2011.07.024
   Pan TY, 2011, CHEM PHYS LETT, V511, P315, DOI 10.1016/j.cplett.2011.06.041
   Pan TY, 2008, J ASSOC ASPHALT PAV, V77, P773
   Parr R. G., 1989, DENSITY FUNCTIONAL T
   Petersen J.C., 1993, TRANSPORT RES REC, V1391, P1
   Petersen J. C., 1984, T RES REC, V999, P13
   Petersen JC, 1998, PET SCI TECHNOL, V16, P1023, DOI 10.1080/10916469808949823
   Petersen JC, 1998, TRANSPORT RES REC, P47, DOI 10.3141/1638-06
   Ruan YH, 2003, ENERG FUEL, V17, P991, DOI 10.1021/ef020221l
   RUIZ JM, 1982, ANAL CHEM, V54, P688, DOI 10.1021/ac00241a020
   Shi X, 2009, OPEN CIVIL ENG J, V3, P16
   STORM DA, 1994, ENERG FUEL, V8, P561, DOI 10.1021/ef00045a007
   Tutumluer E., 2005, UILUENG20052006 FED
   van Duin ACT, 2001, J PHYS CHEM A, V105, P9396, DOI 10.1021/jp004368u
   VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98
NR 40
TC 4
Z9 5
U1 3
U2 45
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 0899-1561
EI 1943-5533
J9 J MATER CIVIL ENG
JI J. Mater. Civ. Eng.
PD OCT 1
PY 2013
VL 25
IS 10
BP 1477
EP 1488
DI 10.1061/(ASCE)MT.1943-5533.0000684
PG 12
WC Construction & Building Technology; Engineering, Civil; Materials
   Science, Multidisciplinary
SC Construction & Building Technology; Engineering; Materials Science
GA 218XK
UT WOS:000324465800014
DA 2018-12-27
ER

PT J
AU Moriyama, Y
   Takeda, H
AF Moriyama, Yuuta
   Takeda, Hiroyuki
TI RETRACTED: Evolution and development of the homocercal caudal fin in
   teleosts(Retracted article. See vol. 59, pg. 104, 2017)
SO DEVELOPMENT GROWTH & DIFFERENTIATION
LA English
DT Review; Retracted Publication
DE caudal skeleton; evo-devo; homocercal fin; teleost; zic
ID MEDAKA ORYZIAS-LATIPES; AXIAL SKELETON; TAIL; EXPRESSION; MORPHOLOGY;
   ORIGIN; FISHES; MUTANT; GENES; TRUNK
AB The vertebrate caudal skeleton is one of the most innovative structures in vertebrate evolution and has been regarded as an excellent model for functional morphology, a discipline that relates a structure to its function. Teleosts have an internally-asymmetrical caudal fin, called the homocercal caudal fin, formed by the upward bending of the caudal-most portion of the body axis, the ural region. This homocercal type of the caudal fin ensures powerful and complex locomotion and is thought to be one of the most important evolutionary innovations for teleosts during adaptive radiation in an aquatic environment. In this review, we summarize the past and present research of fish caudal skeletons, especially focusing on the homocercal caudal fin seen in teleosts. A series of studies with a medaka spontaneous mutant have provided important insight into the evolution and development of the homocercal caudal skeleton. By comparing developmental processes in various vertebrates, we propose a scenario for acquisition and morphogenesis of the homocercal caudal skeleton during vertebrate evolution.
C1 [Moriyama, Yuuta] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan.
   [Takeda, Hiroyuki] Univ Tokyo, Dept Biol Sci, Bunkyo Ku, Tokyo, Japan.
RP Moriyama, Y (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan.
EM yuutamoriyama@iam.u-tokyo.ac.jp
RI TAKEDA, HIROYUKI/G-4950-2014
FU Ministry of Education, Science, Sports and Culture of Japan; KAKENHI;
   Japan Society for the Promotion of Science (JSPS)
FX This work was supported by research grants from the Ministry of
   Education, Science, Sports and Culture of Japan, from KAKENHI
   (Grant-in-Aid for Scientific Research). Y.M was supported by the Japan
   Society for the Promotion of Science (JSPS).
CR AFFLECK RJ, 1950, P ZOOL SOC LOND, V120, P349, DOI 10.1111/j.1096-3642.1950.tb00954.x
   AGASSIZ A, 1878, P AM ACAD ARTS SCI, V14, P65
   Agassiz Louis, 1833, RECHERCHES POISSONS, P1833
   Benton M., 1990, VERTEBRATE PALEONTOL
   Bird NC, 2003, DEV DYNAM, V228, P337, DOI 10.1002/dvdy.10387
   Britz R, 2005, J MORPHOL, V266, P1, DOI 10.1002/jmor.10243
   Colbert E. H., 2004, COLBERTS EVOLUTION V
   Dollo L., 1895, PHYLOGENIE DIPNEUSTE
   Dong W, 2012, TOXICOL SCI, V125, P91, DOI 10.1093/toxsci/kfr284
   Emery C., 1880, FIERASFER STUDI INTO
   Fujita K, 1990, CAUDAL SKELETON TELE
   Gaston-Massuet C, 2005, DEV DYNAM, V233, P1110, DOI 10.1002/dvdy.20417
   Gerhardt John, 1997, CELLS EMBRYOS EVOLUT
   Goodrich E. S., 1930, STUDIES STRUCTURES D, P98
   Gosline W. A., 1971, FUNCTIONAL MORPHOLOG
   Gosline WA, 1997, ICHTHYOL RES, V44, P137, DOI 10.1007/BF02678693
   Gould S. J., 1977, ONTOGENY PHYLOGENY
   Gregory W. K., 1907, ANN NY ACAD SCI, V17, P437
   Grunbaum T, 2010, J MORPHOL, V271, P12, DOI 10.1002/jmor.10775
   Huxley T. H., 1859, DEV SOME PARTS SKELE
   ISHIKAWA Y, 1990, J MORPHOL, V205, P219, DOI 10.1002/jmor.1052050209
   Iwamatsu T, 2004, MECH DEVELOP, V121, P605, DOI 10.1016/j.mod.2004.03.012
   Janvier P., 2003, EARLY VERTEBRATES
   Jollie M., 1972, CHORDATE MORPHOLOGY
   Kardong KV., 2008, VERTEBRATES COMP ANA
   KAUFMAN MH, 1992, ATLAS MOUSE DEV
   Kawanishi T, 2013, DEVELOPMENT, V140, P1486, DOI 10.1242/dev.088567
   Kolliker A., 1860, END WIRBELSAULE GANO
   Kusakabe R, 2011, DEV BIOL, V350, P217, DOI 10.1016/j.ydbio.2010.10.029
   LAUDER G V, 1983, Bulletin of the Museum of Comparative Zoology, V150, P95
   Lauder GV, 2000, AM ZOOL, V40, P101, DOI 10.1668/0003-1569(2000)040[0101:FOTCFD]2.0.CO;2
   LAUDER GV, 1982, J ZOOL, V197, P483, DOI 10.1111/jzo.1982.197.4.483
   LAUDER GV, 1989, AM ZOOL, V29, P85
   LONG JA, 1995, RISE FISHES 500 MILL
   Lotz T., 1864, Z WISS ZOOL, V14, P81
   McCoy F, 1848, ANN MAGAZINE NATURAL, V2, P115
   Metscher BD, 2001, SYST ASSOC SPEC VOL, V61, P333
   Mise T, 2008, GENESIS, V46, P185, DOI 10.1002/dvg.20381
   Moriyama Y, 2012, CURR BIOL, V22, P601, DOI 10.1016/j.cub.2012.01.063
   Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449
   Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2
   Nelson J. S., 2006, FISHES WORLD
   NYBELIN ORVAR, 1963, ARK ZOOL, V15, P485
   Ohtsuka M, 2004, MECH DEVELOP, V121, P873, DOI 10.1016/j.mod.2004.04.006
   Okabe M, 2004, P NATL ACAD SCI USA, V101, P17716, DOI 10.1073/pnas.0406116101
   Owen R., 1848, ARCHETYPE HOMOLOGIES
   PATTERSON C, 1982, AM ZOOL, V22, P241
   Regan C. T., 1910, Annals & Magazine of Natural History, V5
   Reilly SM, 1997, BIOL J LINN SOC, V60, P119
   Richardson MK, 2003, J MORPHOL, V257, P348, DOI 10.1002/jmor.10119
   Rohr KB, 1999, MECH DEVELOP, V85, P147, DOI 10.1016/S0925-4773(99)00044-1
   Romer AS, 1977, VERTEBRATE BODY
   Ryder J. A., 1886, ORIGIN HETEROCERCY E
   Schmalhansen JJ, 1913, Z WISS ZOOL ABT A, V104, P1
   Shimada A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2643
   SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0
   Suzuki T, 2003, DEV GROWTH DIFFER, V45, P435
   Takamatsu N, 2007, DEV GENES EVOL, V217, P263, DOI 10.1007/s00427-007-0137-4
   Tamiya G, 1997, DEV GROWTH DIFFER, V39, P531
   Tomita H., 1969, ZOOL MAG, V78, P58
   Totton AK, 1914, P ZOOL SOC LOND, V1914, P251
   True JR, 2002, ANNU REV CELL DEV BI, V18, P53, DOI 10.1146/annurev.cellbio.18.020402.140619
   von Dassow G, 1999, J EXP ZOOL, V285, P307, DOI 10.1002/(SICI)1097-010X(19991215)285:4<307::AID-JEZ2>3.3.CO;2-M
   VONBAER KE, 1835, UNTERSUCHUNGEN ENTWI
   Wagner GP, 1996, EVOLUTION, V50, P967, DOI 10.1111/j.1558-5646.1996.tb02339.x
   Whitehouse R. H., 1918, REC INDIAN MUS, V5, P135
   Whitehouse RH, 1910, P ZOOL SOC LOND, V1910, P590
   Wilga CD, 2004, NATURE, V430, P850, DOI 10.1038/430850a
   Yabumoto Y, 2008, PALEONTOL RES, V12, P329, DOI 10.2517/prpsj.12.329
   Yano T, 2013, J ANAT, V222, P100, DOI 10.1111/j.1469-7580.2012.01491.x
   Zheng W, 2011, PLOS ONE, V6, pe24019
NR 71
TC 7
Z9 7
U1 2
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1592
EI 1440-169X
J9 DEV GROWTH DIFFER
JI Dev. Growth Diff.
PD OCT
PY 2013
VL 55
IS 8
BP 687
EP 698
DI 10.1111/dgd.12088
PG 12
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 234CE
UT WOS:000325616500001
PM 24102138
DA 2018-12-27
ER

PT J
AU Thapar, R
   Choudhry, S
   Sinha, A
   Bali, R
   Shukla, D
AF Thapar, Raveena
   Choudhry, Swati
   Sinha, Anju
   Bali, Ruchita
   Shukla, Deepika
TI RETRACTED: Pink tooth phenomenon: An enigma? (Retracted article. See
   vol. 38, pg. 122, 2016)
SO JOURNAL OF FORENSIC AND LEGAL MEDICINE
LA English
DT Review; Retracted Publication
DE Pink tooth; Hemoglobin; Dentine; Forensic
ID TEETH
AB Background: The appearance of pink teeth is a common phenomenon which has been observed after death in certain circumstances on post-mortem examination. Extra fibrinolytic activity of pulp facilitates rapid breakdown of red blood cells and diffusion of hemoglobin and its derivatives to flow into dentine. Methods and results: We reviewed various studies on pink tooth phenomenon which have stated the various factors that lead to pink tooth formation. Most of the authors have stressed that post-mortem pink teeth must not be considered as a reliable odontological parameter for determining cause of death. Conclusion: No correlation has been found between the occurrence of pink teeth and the cause of death but condition of the surroundings certainly plays an important role in the development of this phenomenon. This paper reviews the factors and conditions responsible for formation of pink teeth. (C) 2013 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved.
C1 [Thapar, Raveena; Choudhry, Swati; Sinha, Anju; Bali, Ruchita] SBB Dent Coll, Dept Oral Pathol, Ghaziabad, India.
   [Shukla, Deepika] Babu Banarsi Das Dent Coll, Dept Oral Pathol, Lucknow, Uttar Pradesh, India.
RP Thapar, R (reprint author), SBB Dent Coll, Dept Oral Pathol, Ghaziabad, India.
EM koolravs83@gmail.com
CR BEELEY JA, 1973, J FORENSIC SCI SOC, V13, P297, DOI 10.1016/S0015-7368(73)70829-X
   Borrman H, AM J FORENSIC MED PA, V8, P127
   BRONDUM N, 1987, AM J FOREN MED PATH, V8, P127, DOI 10.1097/00000433-198708020-00008
   Campobasso CP, 2006, AM J FOREN MED PATH, V27, P313, DOI 10.1097/01.paf.0000233544.58567.81
   CLARK DH, 1984, MED SCI LAW, V24, P130, DOI 10.1177/002580248402400214
   Dhattarwal SK, 2006, J INDIAN SOC TOXICOL, V2, P40
   Dye TJ, THESIS U BRADFORD
   Gustafson G., 1970, THOMAS ORAL PATHOLOG, P1115
   Ikeda N, 1988, J FORENSIC SCI, V33, P119
   Kirkham W R, 1977, J Forensic Sci, V22, P119
   Miles AEW, 1953, MED SCI INV CHRIST C, P147
   Miller SC, 1957, ORAL DIAGNOSIS TREAT, P253
   Ortmann C, 1998, INT J LEGAL MED, V111, P35
   SAINIO P, 1990, Proceedings of the Finnish Dental Society, V86, P29
   Sainio P, 1990, FINLAND DENT SOC, V86
   Soriano Evelyne-Pessoa, 2009, MED ORAL PATOL ORAL, V14, P337
   TAKAHASHI T, 1983, CRYOBIOLOGY, V20, P507, DOI 10.1016/0011-2240(83)90039-1
   Van Vyk CW, 1988, J ODONTOSTOMATOL, V6, P35
   Van Vyk CW, 1989, AM J FOREN MED PATH, V10, P134
   Van Vyk CW, 1987, J ODONTOSTOMATOL, V5, P41
   WHITTAKER DK, 1976, BRIT DENT J, V140, P100, DOI 10.1038/sj.bdj.4803706
NR 21
TC 3
Z9 3
U1 3
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1752-928X
EI 1532-2009
J9 J FORENSIC LEG MED
JI J. Forensic Leg. Med.
PD OCT
PY 2013
VL 20
IS 7
BP 912
EP 914
DI 10.1016/j.jflm.2013.07.004
PG 3
WC Medicine, Legal
SC Legal Medicine
GA 232HS
UT WOS:000325484400023
PM 24112344
DA 2018-12-27
ER

PT J
AU Wang, JC
   Du, YC
   Sun, K
   Sun, YB
   Pan, C
   Zhao, Y
AF Wang Jincheng
   Du Youcheng
   Sun Kai
   Sun Yibo
   Pan Chen
   Zhao Yi
TI RETRACTED: Organoclays prepared from montmorillonites with
   tetramethylolphosphonium chloride in different pH conditions (Retracted
   article. See vol. 277, pg. 310, 2015)
SO POWDER TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Montmorillonite; Tetramethylolphosphonium chloride; Preparation;
   Characterization
ID NANOCOMPOSITES; CLAY; SURFACTANTS; ADSORPTION; PHOSPHONIUM;
   ORGANOBENTONITE; POLYACRYLAMIDE; POLYMERIZATION; TEMPERATURE; BEHAVIOR
AB Alkylammonium montmorillonite (MMT) has onset temperature of degradation in the same temperature range used for compounding thermoplastics, thus, requiring more thermally stable organic cations. In the current study, phosphonium ions were exchanged in the interlayer of MMT. Na-MMT was modified with quaternary phosphonium salts, tetramethylolphosphonium chloride (THPC), via ion-exchange reactions, in different pH value conditions. The interlayer space, interlamellar structure, thermal stability, and surface morphology of these organic montmorillonites (THPC-OMMTs) were investigated by Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), X-ray diffraction (XRD), scanning electron microscopy (SEM)-energy dispersing spectrometer (EDS) as well as transmission electron microscopy (TEM). FTIR analysis revealed that the organic modification was successfully achieved due to the bands at 3626 and 3421 cm(-1) referring to -OH stretching region in THPC. TGA results indicated that the thermal stability of these THPC-OMMTs was obviously improved compared with that of MMT with different degradation modes. XRD analysis clarified that the interlayer spacing of Na-MMT was changed from 1.43 to 1.26-1.58 nm in the organoclays prepared in different pH values. The SEM-EDS results provided the evidence that THPC was intercalated throughout the interlayer spaces or adsorbed onto the clay surface in different conditions. TEM micrographs demonstrated a partially intercalated and aggregated morphology together with the increased silicate gallery spacing. In conclusions, in the acid conditions, THPC was more stable and conducive for intercalation, and the interlayer spacing of montmorillonite had been expanded and possessed good thermal stabilities due to steric hindering and thermal stability of the surfactant. (C) 2013 Published by Elsevier B.V.
C1 [Wang Jincheng; Du Youcheng; Sun Kai; Sun Yibo; Pan Chen; Zhao Yi] Shanghai Univ Engn Sci, Coll Chem & Chem Engn, Shanghai 201620, Peoples R China.
RP Wang, JC (reprint author), Shanghai Univ Engn Sci, Coll Chem & Chem Engn, Shanghai 201620, Peoples R China.
EM wjc406@263.net
FU National Natural Science Funds [51173102, 51210105020]; Shu Guang'
   project [10SG53]; Shanghai Municipal Education Commission; Shanghai
   Education Development Foundation; Shanghai Talent Development Fund [23];
   Construction of Innovative Team on Natural Source of Pharmaceutical
   Engineering Project [XKCZ1205]; Special Funds for Science and Technology
   Development of Shanghai University of Engineering Science [2012td10,
   2012zh05]; Capacity-building of Local University Project by Science and
   Technology Commission of Shanghai Municipality [11490501500]; Students
   Research and Training Project of Shanghai University of Engineering
   Science [2012xs57, cx1204001, cs1204007, cy1204003]
FX This work was financially supported by the "National Natural Science
   Funds (Project No. 51173102 and No. 51210105020)", "Shu Guang' project
   (Project No. 10SG53) supported by Shanghai Municipal Education
   Commission and Shanghai Education Development Foundation", "Shanghai
   Talent Development Fund (Project (2012) No. 23)", "Construction of
   Innovative Team on Natural Source of Pharmaceutical Engineering Project
   (Project No. XKCZ1205)", "Special Funds for Science and Technology
   Development of Shanghai University of Engineering Science (Project Nos.
   2012td10 and 2012zh05)", "Capacity-building of Local University Project
   by Science and Technology Commission of Shanghai Municipality (Project
   No. 11490501500)", and "Students Research and Training Project of
   Shanghai University of Engineering Science (Project Nos. 2012xs57,
   cx1204001, cs1204007, and cy1204003).
CR Annabi-Bergaya F, 2008, MICROPOR MESOPOR MAT, V107, P141, DOI 10.1016/j.micromeso.2007.05.064
   Arroyo M, 2006, J NANOSCI NANOTECHNO, V6, P2151, DOI 10.1166/jnn.2006.346
   Balek V, 2008, J THERM ANAL CALORIM, V92, P191, DOI 10.1007/s10973-007-8761-9
   BLOOM SM, 1970, J CHEM SOC CHEM COMM, P870, DOI 10.1039/c29700000870
   Bottino FA, 2003, MACROMOL RAPID COMM, V24, P1079, DOI 10.1002/marc.200300054
   Bourbigot S, 2003, J POLYM SCI POL PHYS, V41, P3188, DOI 10.1002/polb.10707
   Choi YS, 2003, POLYMER, V44, P8147, DOI 10.1016/j.polymer.2003.10.041
   Chung C, 2012, BIOMACROMOLECULES, V13, P3912, DOI 10.1021/bm3015279
   Deng YJ, 2006, SOIL SCI SOC AM J, V70, P297, DOI 10.2136/sssaj2005.0200
   Dmitry V.M., 2011, INORG CHIM ACTA, V379, P23
   Fang CQ, 2013, POLYM TEST, V32, P953, DOI 10.1016/j.polymertesting.2013.04.006
   Fang SL, 2009, J APPL POLYM SCI, V113, P1664, DOI 10.1002/app.30288
   Gao Z, 2001, J THERM ANAL CALORIM, V64, P467, DOI 10.1023/A:1011514110413
   Greesh N, 2008, J COLLOID INTERF SCI, V319, P2, DOI 10.1016/j.jcis.2007.10.019
   He HP, 2010, APPL CLAY SCI, V48, P67, DOI 10.1016/j.clay.2009.11.024
   He HP, 2006, J COLLOID INTERF SCI, V295, P202, DOI 10.1016/j.jcis.2005.08.013
   Hedley CB, 2007, APPL CLAY SCI, V35, P180, DOI 10.1016/j.clay.2006.09.005
   LUCKEN EAC, 1966, J CHEM SOC A, P1357, DOI 10.1039/j19660001357
   Mittal V, 2012, APPL CLAY SCI, V56, P103, DOI 10.1016/j.clay.2011.11.029
   Musso TB, 2010, APPL CLAY SCI, V48, P438, DOI 10.1016/j.clay.2010.02.001
   NALWA HS, 2004, ENCY NANOSCIENCE NAN, V8, P791
   Nunes JS, 2006, COLLOID SURFACE A, V275, P148, DOI 10.1016/j.colsurfa.2005.09.033
   Jalil MER, 2013, APPL CLAY SCI, V71, P55, DOI 10.1016/j.clay.2012.11.005
   Sedaghat M, 2012, PHYS MED BIOL, V57, P5981, DOI 10.1088/0031-9155/57/19/5981
   Shen W, 2009, CHINESE SCI BULL, V54, P265, DOI 10.1007/s11434-008-0361-y
   Shen YH, 2001, CHEMOSPHERE, V44, P989, DOI 10.1016/S0045-6535(00)00564-6
   Shi K.Q., 2007, CHINA LEATHER, V36, P23
   SRINIVASAN SK, 1991, CATAL LETT, V10, P279, DOI 10.1007/BF00772082
   Sun CF, 2013, ADV MATER RES-SWITZ, V683, P361, DOI 10.4028/www.scientific.net/AMR.683.361
   Sun HG, 2013, COLLOID SURFACE A, V426, P26, DOI 10.1016/j.colsurfa.2013.03.008
   Vazquez A, 2008, APPL CLAY SCI, V41, P24, DOI 10.1016/j.clay.2007.10.001
   Wang CC, 2004, J COLLOID INTERF SCI, V280, P27, DOI 10.1016/j.jcis.2004.07.009
   Wang DY, 2003, POLYM DEGRAD STABIL, V82, P309, DOI 10.1016/S0141-3910(03)00184-8
   Wang JC, 2006, HIGH PERFORM POLYM, V18, P325, DOI 10.1177/0954008306061768
   Xie W, 2001, CHEM MATER, V13, P2979, DOI 10.1021/cm010305s
   Xu MZ, 2003, POLYMER, V44, P6387, DOI 10.1016/S0032-3861(03)00653-0
   Yariv S, 1992, MODERN APPROACH WETT
   Yilmaz N, 2004, APPL CLAY SCI, V27, P223, DOI 10.1016/j.clay.2004.08.001
   Yilmaz O, 2012, EUR POLYM J, V48, P1683, DOI 10.1016/j.eurpolymj.2012.07.010
   Zhang JH, 2013, MATER DESIGN, V50, P322, DOI 10.1016/j.matdes.2013.02.072
   Zhu LZ, 2000, ENVIRON SCI TECHNOL, V34, P2997, DOI 10.1021/es991460z
NR 41
TC 6
Z9 6
U1 3
U2 48
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0032-5910
EI 1873-328X
J9 POWDER TECHNOL
JI Powder Technol.
PD OCT
PY 2013
VL 247
BP 178
EP 187
DI 10.1016/j.powtec.2013.07.014
PG 10
WC Engineering, Chemical
SC Engineering
GA 229BC
UT WOS:000325235800024
DA 2018-12-27
ER

PT J
AU Yuan, Y
   Cui, SX
   Wang, Y
   Ke, HN
   Wang, RQ
   Lou, HX
   Gao, ZH
   Qu, XJ
AF Yuan, Yi
   Cui, Shu-Xiang
   Wang, Yan
   Ke, Han-Ni
   Wang, Rui-Qi
   Lou, Hong-Xiang
   Gao, Zu-Hua
   Qu, Xian-Jun
TI RETRACTED: Acetyl-11-keto-beta-boswellic acid (AKBA) prevents human
   colonic adenocarcinoma growth through modulation of multiple signaling
   pathways (Retracted article. See vol. 1850, pg. 253, 2015)
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article; Retracted Publication
DE Colon adenocarcinoma; Acetyl-11-keto-beta-boswellic acid (AKBA);
   Aspirin; Anti-inflammation; Apoptosis; Toxicity
ID NF-KAPPA-B; MACROCYCLIC BISBIBENZYL COMPOUND; PROSTATE-CANCER CELLS;
   TUMOR-NECROSIS-FACTOR; COLORECTAL ADENOMAS; RANDOMIZED-TRIAL; BOSWELLIC
   ACIDS; RICCARDIN D-26; IN-VITRO; ASPIRIN
AB Background: Acetyl-11-keto-beta-boswellic acid (AKBA) is a derivative of boswellic acid. We have previously reported that AKBA can reduce the number and size of colonic adenomatous polyps in the APC(Min/+) mouse model. In this study, we evaluated the effect of AKBA on human colonic adenocarcinoma growth. Its efficacy and toxicity were compared with those of the non-steroidal anti-inflammatory drug aspirin.
   Methods: The inhibition of cancer cell growth was estimated by colorimetric and clonogenic assay. Cell cycle distribution was analyzed by the flow cytometry assay. Annexin V-FITC/PI staining and JC-1 fluorescence probe assays were performed to determine the apoptotic cells. Further experiment was carried out in mice with HT-29 xenografts. AKBA was orally administered for 24 days. The HT-29 xenografts were removed for TUNEL staining and western blotting analysis. Blood was obtained for clinical chemical analysis, and samples of organs were sectioned for microscopic assessment.
   Results: AKBA significantly inhibited human colon adenocarcinoma growth, showing arrest of the cell cycle in G(1)-phase and induction of apoptosis. AKBA administration in mice effectively delayed the growth of HT-29 xenografts without signs of toxicity. The activity of AKBA was more potent than that of aspirin. Western blotting suggested that this activity may arise from its multiple effects on the activation of apoptotic proteins, suppression of inflammatory cytokines and modulation of EGFR and ATM/P53 signaling pathways in the HT-29 xenografts.
   Conclusions: AKBA prevents the growth of colonic adenocarcinoma through modulation of multiple signaling pathways.
   General significance: AKBA could be a promising agent in the prevention of colonic adenocarcinomas. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Yuan, Yi; Ke, Han-Ni; Wang, Rui-Qi; Lou, Hong-Xiang; Qu, Xian-Jun] Shandong Univ, Dept Pharmacol, Sch Pharmaceut Sci, Key Lab Chem Biol, Jinan 250100, Peoples R China.
   [Cui, Shu-Xiang] Capital Med Univ, Ctr Food & Drugs Evaluat, Beijing, Peoples R China.
   [Wang, Yan] Shandong Acad Med Sci, Dept Pharmacol, Inst Mat Med, Jinan, Peoples R China.
   [Gao, Zu-Hua] McGill Univ, Dept Pathol, Montreal, PQ, Canada.
   [Gao, Zu-Hua] Capital Med Univ, You Ann Hosp, Dept Pathol, Beijing, Peoples R China.
RP Gao, ZH (reprint author), McGill Univ, Dept Pathol, Montreal, PQ, Canada.
EM zu-hua.gao@mcgill.ca; qxj@sdu.edu.cn
FU Natural Science Foundation of China [91229113, 81173090, 81072665]
FX This work was supported by the Natural Science Foundation of China
   (Grant nos. 91229113, 81173090 and 81072665).
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
   Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628
   Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735
   Bishnoi Mahendra, 2006, Indian Journal of Experimental Biology, V44, P128
   Chhavi, 2010, BIOSCI TRENDS, V4, P103
   Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X
   De Rosa Marina, 2004, Hum Mutat, V23, P523
   Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211
   Garcia-Albeniz X, 2011, BEST PRACT RES CL GA, V25, P461, DOI 10.1016/j.bpg.2011.10.015
   Greene ER, 2011, PROSTAG OTH LIPID M, V96, P27, DOI 10.1016/j.prostaglandins.2011.08.004
   Guillen-Ahlers H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009070
   Han W, 2012, CANCER LETT, V318, P124, DOI 10.1016/j.canlet.2012.01.011
   Horikawa I, 2011, AGING-US, V3, P26, DOI 10.18632/aging.100271
   Hossain MA, 2012, INT J ONCOL, V40, P1636, DOI 10.3892/ijo.2012.1359
   Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534
   Kraus Sarah, 2013, Recent Results Cancer Res, V191, P95, DOI 10.1007/978-3-642-30331-9_5
   Kuno T, 2013, CARCINOGENESIS, V34, P361, DOI 10.1093/carcin/bgs348
   Kwong LN, 2009, ADV EXP MED BIOL, V656, P85, DOI 10.1007/978-1-4419-1145-2_8
   Lalithakumari K, 2006, TOXICOL MECH METHOD, V16, P199, DOI [10.1080/15376520600620232, 10.1080/1537652060020232]
   Liu FY, 2012, J BIOL CHEM, V287, P25530, DOI 10.1074/jbc.M112.356279
   Liu HP, 2013, INT J CANCER, V132, P2667, DOI 10.1002/ijc.27929
   Lu M, 2008, CANCER RES, V68, P1180, DOI 10.1158/0008-5472.CAN-07-2978
   Luqman S, 2010, PHYTOTHER RES, V24, P949, DOI 10.1002/ptr.3171
   Manzano A, 2012, SCI WORLD J, DOI 10.1100/2012/327341
   Moussaieff A, 2007, MOL PHARMACOL, V72, P1657, DOI 10.1124/mol.107.038810
   Mueller KL, 2012, TRANSL ONCOL, V5, P327, DOI 10.1593/tlo.12163
   Oh JH, 2011, ONCOGENE, V30, P3345, DOI 10.1038/onc.2011.52
   Qu XJ, 2004, J UROLOGY, V172, P733, DOI 10.1097/01.ju.0000130751.83953.55
   Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8
   Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633
   Sansom OJ, 2001, CANCER RES, V61, P7060
   Sengupta K, 2011, MOL CELL BIOCHEM, V354, P189, DOI 10.1007/s11010-011-0818-1
   Shen G, 2007, CANCER RES, V67, P9937, DOI 10.1158/0008-5472.CAN-07-1112
   Shen HL, 2011, EXP HEMATOL, V39, P558, DOI 10.1016/j.exphem.2011.01.013
   Siemoneit U, 2008, BIOCHEM PHARMACOL, V75, P503, DOI 10.1016/j.bcp.2007.09.010
   Singh S, 2008, PHYTOMEDICINE, V15, P400, DOI 10.1016/j.phymed.2007.11.019
   Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057
   Wang DZ, 2004, CELL CYCLE, V3, P1512, DOI 10.4161/cc.3.12.1288
   West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6
   Wolf MJ, 2010, ONCOGENE, V29, P5006, DOI 10.1038/onc.2010.260
   Yuan HQ, 2008, BIOCHEM PHARMACOL, V75, P2112, DOI 10.1016/j.bcp.2008.03.005
   Yue B, 2013, BBA-GEN SUBJECTS, V1830, P2194, DOI 10.1016/j.bbagen.2012.10.011
   Yue B, 2013, CANCER LETT, V328, P104, DOI 10.1016/j.canlet.2012.09.002
   Yue P, 2011, EUR J CANCER, V47, P1115, DOI 10.1016/j.ejca.2011.01.017
   Zins K, 2007, CANCER RES, V67, P1038, DOI 10.1158/0008-5472.CAN-06-2295
NR 46
TC 8
Z9 9
U1 2
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD OCT
PY 2013
VL 1830
IS 10
BP 4907
EP 4916
DI 10.1016/j.bbagen.2013.06.039
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 210SN
UT WOS:000323854900054
PM 23850473
DA 2018-12-27
ER

PT J
AU Zhang, H
   Liu, W
   Hu, JJ
   Liu, RZ
AF Zhang, Hui
   Liu, Wei
   Hu, Jin-Ju
   Liu, Rui-Zhi
TI RETRACTED: Evaluation of elite table tennis players' technique
   effectiveness(Retracted article. See vol. 35, pg. 1326, 2017)
SO JOURNAL OF SPORTS SCIENCES
LA English
DT Article; Retracted Publication
DE table tennis; technique effectiveness evaluation; competition
   performance
AB This study constructed a technique effectiveness evaluation formula for table tennis players based on the relationship between the scoring rate and usage rate of techniques and established the evaluation criteria through the examination of 224 matches of the world's top 35 players. It also built a competition performance formula with the score difference theory for the exploration of the correlation between player technique effectiveness and competition performance. The results showed the three indices - the technique effectiveness of the first and third strokes (TE1,3), the second and fourth strokes (TE2,4) and the after fourth strokes (TE>4) - could help better evaluate the technique effectiveness of elite players. The comparative analysis of Chinese elite table tennis players and players from other countries and regions revealed that Chinese players as a whole were excellent in all the examined techniques except in the male's first and third strokes; while players from other countries and regions were overall general. The case analysis of two world top players further indicated that correlation analysis of technique effectiveness and competition performance could help identify the technique indices highly correlated with player competition performance.
C1 [Zhang, Hui; Liu, Rui-Zhi] Shanghai Univ Sport, China Table Tennis Coll, Shanghai 200438, Peoples R China.
   [Liu, Wei] Shanghai Univ Sport, Sch Econ & Management, Shanghai 200438, Peoples R China.
   [Hu, Jin-Ju] Shanghai Univ Sport, Sch Sport Journalism & Foreign Studies, Shanghai 200438, Peoples R China.
RP Zhang, H (reprint author), Shanghai Univ Sport, China Table Tennis Coll, Qing Yuan Huan Rd 650, Shanghai 200438, Peoples R China.
EM huizhang@sus.edu.cn
FU Shanghai Key Lab of Human Performance (Shanghai University of Sport)
   [11DZ2261100]; Shanghai Science and Technology Commission [10490503700]
FX This work was supported by the grants from Shanghai Key Lab of Human
   Performance (Shanghai University of Sport)(No. 11DZ2261100) and Shanghai
   Science and Technology Commission (No. 10490503700).
CR LI Jinliang, 2004, J BEIJING SPORT U, V27, P830
   Li Jinliang, 1998, J BEIJING U PHYS ED, V21, P71
   Li Z., 2009, J BEIJING SPORT U, V10, P26
   Li Z., 1989, CHINA SPORTS SCI TEC, V3, P15
   Li Z., 1991, J BEIJING I PHYS ED, V2, P95
   Li Z., 1997, J TIANJIN I PHYS ED, V12, P70
   LI Zhenbiao, 2008, J TUS, V23, P428
   Meng Xian-ming, 2010, Computer Engineering, V36, P28
   Meng Xian-ming, 2009, Computer Engineering and Applications, V45, P8, DOI 10.3778/j.issn.1002-8331.2009.36.003
   Wang H., 2010, THESIS BEIJING SPORT
   Wang J., 2010, THESIS SHANGHAI U SP
   WANG Jie, 2009, J SHANGHAI U SPORT, V33, P87
   Wang L, 2008, METHODS APPL SPORTS
   Wang Y., 2007, P 8 CHIN NAT CONV SP, P107
   Wu H., 1989, J NATL RES I SPORTS, V1, P32
   Xiao Y., 2008, SPORT SCI RES, V6, P19
   Yu L., 2008, J SHANGHAI U SPORT, V32, P39
   Yu L., 2008, CHINA SPORT SCI, V10, P41
   YU Li-juan, 2009, CHINA SPORT SCI TECH, V6, P8
   Zhai H., 2011, J SHANDONG I PHYS ED, V2, P78
   Zhang H., 2008, SPORT SCI RES, V6, P6
   Zhang X., 2004, THESIS BEIJING SPORT
   Zhang X., 2002, J BEIJING U PHYS ED, V3, P396
   Zhang X., 2000, J TIANJIN I PHYS ED, V3, P65
   Zhang Y., 2006, CHINA SPORT SCI TECH, V1, P99
   ZHAO Yang-qing, 2008, J SHANGHAI U SPORT, V32, P83
NR 26
TC 18
Z9 18
U1 7
U2 30
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0264-0414
EI 1466-447X
J9 J SPORT SCI
JI J. Sports Sci.
PD OCT 1
PY 2013
VL 31
IS 14
BP 1526
EP 1534
DI 10.1080/02640414.2013.792948
PG 9
WC Sport Sciences
SC Sport Sciences
GA 224QW
UT WOS:000324904200004
PM 23687933
DA 2018-12-27
ER

PT J
AU Herdegen, M
   Nadachowska-Brzyska, K
   Konowalik, A
   Babik, W
   Radwan, J
AF Herdegen, M.
   Nadachowska-Brzyska, K.
   Konowalik, A.
   Babik, W.
   Radwan, J.
TI RETRACTED: Heterozygosity, sexual ornament and body size in the crested
   newt(Retracted article. See vol.300,pg.324,2016)
SO JOURNAL OF ZOOLOGY
LA English
DT Article; Retracted Publication
DE sexual selection; heterozygosity-fitness correlation; amphibians;
   Triturus cristatus
ID MAJOR HISTOCOMPATIBILITY COMPLEX; SALMON SALMO-SALAR; MATE CHOICE;
   INBREEDING DEPRESSION; FITNESS CORRELATIONS; TRITURUS-CRISTATUS; GENETIC
   QUALITY; NO EVIDENCE; MELOSPIZA-MELODIA; AGE-DETERMINATION
AB Both genome-wide heterozygosity and heterozygosity at major histocompatibility complex (MHC) genes are often associated with higher fitness. Recent theoretical work indicates that sexual ornaments may reveal information about individual heterozygosity, and that preference for such ornaments may benefit females via the increased heterozygosity of their progeny. Here, we used path analysis to investigate the direct and indirect (via body size used as an index of condition) effects of heterozygosity at six microsatellite loci and the MHC class IIDAB gene on the size of a sexual ornament, the crest, in the crested newt Triturus cristatus. We found that microsatellite heterozygosity, but not MHC heterozygosity, significantly predicted male body size, and that male body size significantly predicted crest height. However, there was no direct effect of MHC or microsatellite heterozygosity on crest height. Furthermore, microsatellite heterozygosity significantly increased with age, indicating that it had a positive effect on survival. Overall, our results are consistent with the hypothesis that heterozygosity determines condition, and that variation in condition is expressed as variation in sexual ornamentation.
C1 [Herdegen, M.; Nadachowska-Brzyska, K.] Jagiellonian Univ, Inst Environm Sci, Krakow, Poland.
   [Konowalik, A.] Univ Wroclaw, Dept Evolutionary Biol & Conservat Vertebrates, PL-50138 Wroclaw, Poland.
   [Babik, W.] Polish Acad Sci, Inst Systemat & Evolut Anim, Krakow, Poland.
   [Radwan, J.] Adam Mickiewicz Univ, Inst Environm Biol, Fac Biol, PL-61614 Poznan, Poland.
RP Radwan, J (reprint author), Adam Mickiewicz Univ, Inst Environm Biol, Fac Biol, Ul Umultowska 89, PL-61614 Poznan, Poland.
EM jradwan@amu.edu.pl
OI Babik, Wieslaw/0000-0002-1698-6615
FU Jagiellonian University [DS/WBINOZ/INOS/762/10]
FX This work was supported by Jagiellonian University
   DS/WBINOZ/INOS/762/10.
CR ANDERSSON M, 1986, EVOLUTION, V40, P804, DOI 10.1111/j.1558-5646.1986.tb00540.x
   Andersson M., 1994, SEXUAL SELECTION
   Andersson M, 2006, TRENDS ECOL EVOL, V21, P296, DOI 10.1016/j.tree.2006.03.015
   Babik W, 2009, MOL ECOL, V18, P769, DOI 10.1111/j.1365-294X.2008.04057.x
   Balloux F, 2004, MOL ECOL, V13, P3021, DOI 10.1111/j.1365-294X.2004.02318.x
   Bonneaud C, 2006, P R SOC B, V273, P1111, DOI 10.1098/rspb.2005.3325
   Brown JL, 1997, BEHAV ECOL, V8, P60, DOI 10.1093/beheco/8.1.60
   CASTANET J, 1990, ANN SCI NAT ZOOL, V11, P191
   Chapman JR, 2009, MOL ECOL, V18, P2746, DOI 10.1111/j.1365-294X.2009.04247.x
   Chapuis MP, 2007, MOL BIOL EVOL, V24, P621, DOI 10.1093/molbev/msl191
   Charlesworth D, 2009, NAT REV GENET, V10, P783, DOI 10.1038/nrg2664
   Darwin C., 1871, DESCENT MAN SELECTIO
   Eizaguirre C, 2009, MOL ECOL, V18, P3316, DOI 10.1111/j.1365-294X.2009.04243.x
   Ekblom R, 2004, MOL ECOL, V13, P3821, DOI 10.1111/j.1365-294X.2004.02361.x
   Fisher R. A., 1930, GENETICAL THEORY NAT
   Forstmeier W, 2012, MOL ECOL, V21, P3237, DOI 10.1111/j.1365-294X.2012.05593.x
   FRANCILLON H, 1979, ACTA ZOOL-STOCKHOLM, V60, P223
   Fromhage L, 2009, EVOLUTION, V63, P684, DOI 10.1111/j.1558-5646.2008.00575.x
   Garant D, 2005, BEHAV ECOL SOCIOBIOL, V57, P240, DOI 10.1007/s00265-004-0854-x
   Gittins S.P., 1982, British Journal of Herpetology, V6, P249
   GREEN AJ, 1991, ANIM BEHAV, V41, P367, DOI 10.1016/S0003-3472(05)80489-0
   HEDLUND L, 1990, J ZOOL, V220, P33, DOI 10.1111/j.1469-7998.1990.tb04292.x
   Hoffman JI, 2007, NATURE, V445, P912, DOI 10.1038/nature05558
   Hoglund J, 2002, P ROY SOC B-BIOL SCI, V269, P711, DOI 10.1098/rspb.2001.1937
   Hunt J, 2004, TRENDS ECOL EVOL, V19, P329, DOI 10.1016/j.tree.2004.03.035
   Jourdan-Pineau H, 2012, EVOLUTION, V66, P3624, DOI 10.1111/j.1558-5646.2012.01705.x
   Kempenaers B, 2007, ADV STUD BEHAV, V37, P189, DOI 10.1016/S0065-3454(07)37005-8
   Krupa AP, 2002, CONSERV GENET, V3, P87
   Lampert KP, 2006, BEHAV ECOL SOCIOBIOL, V59, P796, DOI 10.1007/s00265-005-0125-5
   Landry C, 2001, P ROY SOC B-BIOL SCI, V268, P1279, DOI 10.1098/rspb.2001.1659
   Lerner L. M., 1954, GENETIC HOMEOSTASIS
   Malmgren JC, 2008, ETHOL ECOL EVOL, V20, P71, DOI 10.1080/08927014.2008.9522545
   Marsh DM, 2001, CONSERV BIOL, V15, P40, DOI 10.1046/j.1523-1739.2001.00129.x
   Aparicio JM, 2011, ANIM BEHAV, V81, P1271, DOI 10.1016/j.anbehav.2011.03.017
   MITTON JB, 1993, HEREDITY, V71, P59, DOI 10.1038/hdy.1993.107
   Paterson S, 1997, P ROY SOC B-BIOL SCI, V264, P1813, DOI 10.1098/rspb.1997.0250
   Pemberton J, 2004, TRENDS ECOL EVOL, V19, P613, DOI 10.1016/j.tree.2004.09.010
   Penn DJ, 2002, P NATL ACAD SCI USA, V99, P11260, DOI 10.1073/pnas.162006499
   Piertney SB, 2006, HEREDITY, V96, P7, DOI 10.1038/sj.hdy.6800724
   Prokop ZM, 2010, EVOL ECOL, V24, P827, DOI 10.1007/s10682-009-9341-1
   R Development Core Team, 2008, R LANG ENV STAT COMP
   Radwan J, 2008, GENETICA, V134, P113, DOI 10.1007/s10709-007-9203-0
   Reid JM, 2006, AM NAT, V168, P1, DOI 10.1086/504852
   Reid JM, 2010, EVOLUTION, V64, P973, DOI 10.1111/j.1558-5646.2009.00865.x
   Reid JM, 2005, P ROY SOC B-BIOL SCI, V272, P481, DOI 10.1098/rspb.2004.2983
   Richardson DS, 2005, P ROY SOC B-BIOL SCI, V272, P759, DOI 10.1098/rspb.2004.3028
   Rousset F, 2008, MOL ECOL RESOUR, V8, P103, DOI 10.1111/j.1471-8286.2007.01931.x
   Rowe L, 1996, P ROY SOC B-BIOL SCI, V263, P1415, DOI 10.1098/rspb.1996.0207
   Rozenblut B, 2005, J MORPHOL, V265, P304, DOI 10.1002/jmor.10344
   Ryder TB, 2010, BEHAV ECOL, V21, P203, DOI 10.1093/beheco/arp176
   Sauermann U, 2001, HUM GENET, V108, P249, DOI 10.1007/s004390100485
   Slate J, 2004, HEREDITY, V93, P255, DOI 10.1038/sj.hdy.6800485
   SMIRINA EM, 1986, ZOOL ZH, V65, P1526
   Sommer S, 2005, BEHAV ECOL SOCIOBIOL, V58, P181, DOI 10.1007/s00265-005-0909-7
   Spurgin LG, 2010, P ROY SOC B-BIOL SCI, V277, P979, DOI 10.1098/rspb.2009.2084
   Szulkin M, 2010, EVOLUTION, V64, P1202, DOI 10.1111/j.1558-5646.2010.00966.x
   Tomkins JL, 2004, TRENDS ECOL EVOL, V19, P323, DOI 10.1016/j.tree.2004.03.029
   Westerdahl H, 2004, MOL ECOL, V13, P2465, DOI 10.1111/j.1365-294X.2004.02238.x
   ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3
NR 59
TC 7
Z9 7
U1 3
U2 62
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0952-8369
EI 1469-7998
J9 J ZOOL
JI J. Zool.
PD OCT
PY 2013
VL 291
IS 2
BP 146
EP 153
DI 10.1111/jzo.12056
PG 8
WC Zoology
SC Zoology
GA 226AZ
UT WOS:000325007900007
DA 2018-12-27
ER

PT J
AU Jiao, WC
   Zhang, FH
   Zhao, XQ
   Hu, JH
   Suh, JW
AF Jiao, Wence
   Zhang, Fenghua
   Zhao, Xinqing
   Hu, Jiehan
   Suh, Joo-Won
TI RETRACTED: A Novel Alkaloid from Marine-Derived Actinomycete
   Streptomyces xinghaiensis with Broad-Spectrum Antibacterial and
   Cytotoxic Activities (Retracted article. See vol. 13, art no e0200376,
   2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ACINETOBACTER-BAUMANNII; SALINISPORA-TROPICA; NATURAL-PRODUCTS; CHIRAL
   SULFUR; SULFOXIDE; METABOLITES; ANTIBIOTICS; CHEMISTRY; DISCOVERY;
   AGENTS
AB Due to the increasing emergence of drug-resistant bacteria and tumor cell lines, novel antibiotics with antibacterial and cytotoxic activities are urgently needed. Marine actinobacteria are rich sources of novel antibiotics, and here we report the discovery of a novel alkaloid, xinghaiamine A, from a marine-derived actinomycete Streptomyces xinghaiensis NRRL B24674(T). Xinghaiamine A was purified from the fermentation broth, and its structure was elucidated based on extensive spectroscopic analysis, including 1D and 2D NMR spectrum as well as mass spectrometry. Xinghaiamine A was identified to be a novel alkaloid with highly symmetric structure on the basis of sulfoxide functional group, and sulfoxide containing compound has so far never been reported in microorganisms. Biological assays revealed that xinghaiamine A exhibited broad-spectrum antibacterial activities to both Gram-negative persistent hospital pathogens (e. g. Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli) and Gram-positive ones, which include Staphylococcus aureus and Bacillus subtilis. In addition, xinghaiamine A also exhibited potent cytotoxic activity to human cancer cell lines of MCF-7 and U-937 with the IC50 of 0.6 and 0.5 mu M, respectively.
C1 [Jiao, Wence; Zhao, Xinqing] Dalian Univ Technol, Sch Life Sci & Biotechnol, Dalian, Peoples R China.
   [Zhang, Fenghua] Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China.
   [Hu, Jiehan] Chinese Acad Sci, Dalian Inst Chem Phys, Dalian, Peoples R China.
   [Suh, Joo-Won] Myongji Univ, Div Biosci & Bioinformat, Yongin, South Korea.
RP Zhao, XQ (reprint author), Dalian Univ Technol, Sch Life Sci & Biotechnol, Dalian, Peoples R China.
EM xqzhao@dlut.edu.cn
FU Next-Generation BioGreen 21 program of the rural development
   Administration, Republic of Korea [PJ0080932011]; Key Laboratory of
   Marine Bio-resources Sustainable Utilization [LMB111002]; state key
   laboratory open program from Key Laboratory of Bioreactor Engineering,
   East China University of Science and Technology
FX This work was supported by the Next-Generation BioGreen 21 program of
   the rural development Administration, Republic of Korea (No.
   PJ0080932011). The authors also acknowledge the financial support by the
   state key laboratory open program from Key Laboratory of Marine
   Bio-resources Sustainable Utilization (No. LMB111002), and the state key
   laboratory open program from Key Laboratory of Bioreactor Engineering,
   East China University of Science and Technology. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aiello A, 2012, MAR DRUGS, V10, P51, DOI 10.3390/md10010051
   Barber JM, 2011, J NAT PROD, V74, P809, DOI 10.1021/np100868t
   Blunt JW, 2013, NAT PROD REP, V30, P237, DOI 10.1039/c2np20112g
   BURRES NS, 1989, CANCER RES, V49, P2935
   de Kraker MEA, 2011, ANTIMICROB AGENTS CH, V55, P1598, DOI 10.1128/AAC.01157-10
   Feling RH, 2003, ANGEW CHEM INT EDIT, V42, P355, DOI 10.1002/anie.200390115
   Graham SK, 2010, AUST J CHEM, V63, P867, DOI 10.1071/CH09617
   Hornickova J, 2009, CZECH J FOOD SCI, V27, pS232, DOI 10.17221/610-CJFS
   Jensen PR, 2005, ANTON LEEUW INT J G, V87, P43, DOI 10.1007/s10482-004-6540-1
   Kondratyuk TP, 2012, MAR DRUGS, V10, P451, DOI 10.3390/md10020451
   Kubec R, 2002, J NAT PROD, V65, P960, DOI 10.1021/np020064i
   Kwon HC, 2006, J AM CHEM SOC, V128, P1622, DOI 10.1021/ja0558948
   LAKE RJ, 1988, TETRAHEDRON LETT, V29, P2255, DOI 10.1016/S0040-4039(00)86725-8
   Lee KH, 2010, J MICROBIOL BIOTECHN, V20, P1672, DOI 10.4014/jmb.1007.07035
   MAKARIEVA TN, 1995, J NAT PRODUCTS, V58, P254, DOI 10.1021/np50116a015
   Maldonado LA, 2005, INT J SYST EVOL MICR, V55, P1759, DOI 10.1099/ijs.0.63625-0
   Manivasagan P, 2013, MICROBIOL RES, V168, P311, DOI 10.1016/j.micres.2013.02.002
   MARKS HS, 1992, J AGR FOOD CHEM, V40, P2098, DOI 10.1021/jf00023a012
   McConnell MJ, 2013, FEMS MICROBIOL REV, V37, P130, DOI 10.1111/j.1574-6976.2012.00344.x
   MURATA O, 1991, TETRAHEDRON LETT, V32, P3539, DOI 10.1016/0040-4039(91)80827-S
   Peleg AY, 2008, CLIN MICROBIOL REV, V21, P538, DOI 10.1128/CMR.00058-07
   Prilezhaeva E.N., 2000, RUSS CHEM REV, V69, P367, DOI DOI 10.1002/CHIN.200045296
   Raju R, 2010, ORG LETT, V12, P5158, DOI 10.1021/ol102162d
   Rose P, 2005, NAT PROD REP, V22, P351, DOI 10.1039/b417639c
   Wang F, 2012, J MICROBIOL, V50, P770, DOI 10.1007/s12275-012-2154-x
   Wang J, 2003, J BIOL CHEM, V278, P44424, DOI 10.1074/jbc.M307625200
   Williams PG, 2005, J ORG CHEM, V70, P6196, DOI 10.1021/jo050511
   Xu ZB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057050
   Zhao XQ, 2009, INT J SYST EVOL MICR, V59, P2870, DOI 10.1099/ijs.0.009878-0
   Zotchev SB, 2012, J BIOTECHNOL, V158, P168, DOI 10.1016/j.jbiotec.2011.06.002
NR 30
TC 14
Z9 16
U1 3
U2 49
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 1
PY 2013
VL 8
IS 10
AR e75994
DI 10.1371/journal.pone.0075994
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 231OR
UT WOS:000325427100033
PM 24098415
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Khan, F
   Kumari, M
   Cameotra, SS
AF Khan, Fazlurrahman
   Kumari, Munesh
   Cameotra, Swaranjit Singh
TI RETRACTED: Biodegradation of the Allelopathic Chemical m-Tyrosine by
   Bacillus aquimaris SSC5 Involves the Homogentisate Central Pathway
   (Retracted article. See vol. 9, e102854, 2014)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID PSEUDOMONAS-PUTIDA; META-TYROSINE; 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE;
   L-PHENYLALANINE; PHENOLIC-ACIDS; SP NOV.; DEGRADATION; SOIL; CATABOLISM;
   PROTEIN
AB m-Tyrosine is an amino acid analogue, exuded from the roots of fescue grasses, which acts as a potent allelopathic and a broad spectrum herbicidal chemical. Although the production and toxic effects of m-tyrosine are known, its microbial degradation has not been documented yet. A soil microcosm study showed efficient degradation of m-tyrosine by the inhabitant microorganisms. A bacterial strain designated SSC5, that was able to utilize m-tyrosine as the sole source of carbon, nitrogen, and energy, was isolated from the soil microcosm and was characterized as Bacillus aquimaris. Analytical methods such as HPLC, GC-MS, and H-1-NMR performed on the resting cell samples identified the formation of 3-hydroxyphenylpyruvate (3-OH-PPA), 3-hydroxyphenylacetate (3-OH-PhAc), and homogentisate (HMG) as major intermediates in the m-tyrosine degradation pathway. Enzymatic assays carried out on cell-free lysates of m-tyrosine-induced cells confirmed transamination reaction as the first step of m-tyrosine degradation. The intermediate 3-OH-PhAc thus obtained was further funneled into the HMG central pathway as revealed by a hydroxylase enzyme assay. Subsequent degradation of HMG occurred by ring cleavage catalyzed by the enzyme homogentisate 1, 2-dioxygenase. This study has significant implications in terms of understanding the environmental fate of m-tyrosine as well as regulation of its phytotoxic effect by soil microorganisms.
C1 [Khan, Fazlurrahman; Kumari, Munesh; Cameotra, Swaranjit Singh] CSIR, Inst Microbial Technol, Chandigarh, India.
RP Cameotra, SS (reprint author), CSIR, Inst Microbial Technol, Chandigarh, India.
EM ssc@imtech.res.in
FU UGC, India
FX We thank the reviewers and the editor for their helpful suggestions to
   improve our paper. FK thanks DBT for the Research Associateship and MK
   acknowledges her research fellowship from UGC, India. This is the IMTECH
   communication number 16/2013.
CR Al Hamdi B, 2001, AGRON J, V93, P43
   ANDERSON JPE, 1982, AGRONOMY, V9, P831
   Arias-Barrau E, 2005, J BIOL CHEM, V280, P26435, DOI 10.1074/jbc.M501988200
   Arias-Barrau E, 2004, J BACTERIOL, V186, P5062, DOI 10.1128/jb.186.15.5062-5077.2004
   ARONSON JN, 1965, J BACTERIOL, V90, P38
   ARONSON JN, 1967, J BACTERIOL, V93, P1174
   ARUNACHALAM U, 1992, J BIOL CHEM, V267, P25848
   Bais HP, 2003, SCIENCE, V301, P1377, DOI 10.1126/science.1083245
   Bertin C, 2007, P NATL ACAD SCI USA, V104, P16964, DOI 10.1073/pnas.0707198104
   BLAKLEY ER, 1972, CAN J MICROBIOL, V18, P1247, DOI 10.1139/m72-193
   BLUM U, 1988, SOIL BIOL BIOCHEM, V20, P793, DOI 10.1016/0038-0717(88)90084-3
   Blum U, 1998, J CHEM ECOL, V24, P685, DOI 10.1023/A:1022394203540
   Carreira A, 2001, APPL ENVIRON MICROB, V67, P3463, DOI 10.1128/AEM.67.8.3463-3468.2001
   DEBOER L, 1988, ARCH MICROBIOL, V149, P459, DOI 10.1007/BF00425588
   DENOYA CD, 1994, J BACTERIOL, V176, P5312
   Deutsch JC, 1997, J CHROMATOGR B, V690, P1, DOI 10.1016/S0378-4347(96)00411-2
   Duke SO, 2007, P NATL ACAD SCI USA, V104, P16729, DOI 10.1073/pnas.0707837104
   Ehlers BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026321
   Fazlurrahman, 2009, LETT APPL MICROBIOL, V49, P721, DOI 10.1111/j.1472-765X.2009.02724.x
   FernandezCanon JM, 1997, ANAL BIOCHEM, V245, P218, DOI 10.1006/abio.1996.9957
   Gurer-Orhan H, 2006, BIOCHEM J, V395, P277, DOI 10.1042/BJ20051964
   Haney RL, 2008, RENEW AGR FOOD SYST, V23, P171, DOI 10.1017/S174217050800224X
   Huang TF, 2012, PHYTOCHEMISTRY, V75, P60, DOI 10.1016/j.phytochem.2011.09.018
   HUGGINS TG, 1993, J BIOL CHEM, V268, P12341
   Inderjit, 2006, TRENDS PLANT SCI, V11, P574, DOI 10.1016/j.tplants.2006.10.004
   Inderjit, 1996, BOT REV, V62, P186, DOI 10.1007/BF02857921
   Inderjit, 2005, PLANT SOIL, V247, P227, DOI DOI 10.1007/S11104-004-0159-X
   INDERJIT PJL, 2008, PLOS ONE, V3, pE2536, DOI DOI 10.1371/JOURNAL.PONE.0002536
   Kaur H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004700
   Kaur I, 2012, INT J SYST EVOL MICR, V62, P2897, DOI 10.1099/ijs.0.035691-0
   Khan F, 2013, J HAZARD MATER, V254, P72, DOI 10.1016/j.jhazmat.2013.03.021
   Khan F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062178
   KITTELL BL, 1989, J BACTERIOL, V171, P5458, DOI 10.1128/jb.171.10.5458-5466.1989
   Levy E, 1994, BIOL CONTROL PLANT P, P300
   LINDSTEDT S, 1977, BIOCHEMISTRY-US, V16, P3369, DOI 10.1021/bi00634a013
   Macias FA, 2005, J AGR FOOD CHEM, V53, P554, DOI 10.1021/jf048702l
   Matayatsuk C, 2007, REDOX REP, V12, P219, DOI 10.1179/135100007X200272
   Mendez V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017583
   Molnar GA, 2005, FREE RADICAL RES, V39, P1359, DOI 10.1080/10715760500307107
   NAIR MG, 1990, J CHEM ECOL, V16, P353, DOI 10.1007/BF01021770
   Nishino SF, 2006, APPL ENVIRON MICROB, V72, P1040, DOI 10.1128/AEM.72.2.1040-1044.2006
   OLIVERA ER, 1994, EUR J BIOCHEM, V221, P375, DOI 10.1111/j.1432-1033.1994.tb18749.x
   Perreault NN, 2012, ENVIRON SCI TECHNOL, V46, P6035, DOI 10.1021/es301047d
   Perry LG, 2007, J CHEM ECOL, V33, P2337, DOI 10.1007/s10886-007-9383-1
   POMETTO AL, 1985, APPL ENVIRON MICROB, V49, P727
   Prakash D, 2011, APPL ENVIRON MICROB, V77, P6606, DOI 10.1128/AEM.00685-11
   RETTENMAIER H, 1983, FEMS MICROBIOL LETT, V19, P193, DOI 10.1111/j.1574-6968.1983.tb00540.x
   Rodriguez-Rojas A, 2009, MICROBIOL-SGM, V155, P1050, DOI 10.1099/mic.0.024745-0
   Schmaler-Ripcke J, 2009, APPL ENVIRON MICROB, V75, P493, DOI 10.1128/AEM.02077-08
   SCHMIDT SK, 1988, J CHEM ECOL, V14, P1561, DOI 10.1007/BF01012522
   SEEGMILLER J, 1961, J BIOL CHEM, V236, P774
   Serre L, 1999, STRUCT FOLD DES, V7, P977, DOI 10.1016/S0969-2126(99)80124-5
   Shaw LJ, 2006, ENVIRON MICROBIOL, V8, P1867, DOI 10.1111/j.1462-2920.2006.01141.x
   Shettigar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051162
   SMITH LC, 1964, ARCH BIOCHEM BIOPHYS, V105, P424, DOI 10.1016/0003-9861(64)90026-8
   SPARNINS VL, 1976, J BACTERIOL, V127, P362
   Teufel R, 2010, P NATL ACAD SCI USA, V107, P14390, DOI 10.1073/pnas.1005399107
   VANBERKEL WJH, 1991, EUR J BIOCHEM, V201, P585
   VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9
   Weston LA, 2003, CRIT REV PLANT SCI, V22, P367, DOI 10.1080/713610861
   Winn M, 2010, NAT PROD REP, V27, P279, DOI 10.1039/b816215h
   YABUUCHI E, 1972, International Journal of Systematic Bacteriology, V22, P53
   Yoon JH, 2003, INT J SYST EVOL MICR, V53, P1297, DOI 10.1099/ijs.0.02365-0
NR 63
TC 5
Z9 5
U1 2
U2 41
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 1
PY 2013
VL 8
IS 10
AR e75928
DI 10.1371/journal.pone.0075928
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 231OR
UT WOS:000325427100027
PM 24098407
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, WX
   Wu, H
   Song, C
AF Li, Weixing
   Wu, Han
   Song, Chao
TI RETRACTED: TGF-beta 1 -509C/T (or +869T/C) polymorphism might be not
   associated with hepatocellular carcinoma risk (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Transforming growth factor-beta 1; Hepatocellular carcinoma;
   Polymorphism; Meta-analysis
ID B-VIRUS INFECTION; CANCER-RISK; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE
   POLYMORPHISMS; METAANALYSIS; CIRRHOSIS; DISEASE; BETA-1
AB Many studies have reported the role of transforming growth factor-beta 1 (TGF-beta 1) -509C/T or +869T/C polymorphism with hepatocellular carcinoma (HCC) risk. However, these studies have yielded conflicting results. Hence, we performed this meta-analysis to investigate the association between TGF-beta 1 -509C/T or +869T/C polymorphism and HCC. A total of 11 studies including 2,577 HCC cases and 4,107 controls were included in the meta-analysis. Overall, TGF-beta 1 -509C/T (or +869T/C) polymorphism was not associated with HCC risk (homogeneous co-dominant model: OR = 1.29, 95 % CI = 0.88-1.89; heterogeneous co-dominant model: OR = 1.15, 95 % CI = 0.91-1.45; dominant model: OR = 1.14, 95 % CI = 0.87-1.48; recessive model: OR = 1.15, 95 % CI = 0.89-1.49). In the subgroup analysis, TGF-beta 1 -509C/T (or +869T/C) polymorphism was significantly associated with HCC risk in Caucasians under the recessive model (OR = 1.65, 95 % CI = 1.07-2.55) but not in other genetic models. In addition, we did not observe significant association in Asians under all genetic models. In conclusion, our meta-analysis indicates that TGF-beta 1 -509C/T (or +869T/C) polymorphism was not associated with risk of HCC, although a marginal association was found for Caucasians. However, a study with the larger sample size is needed to further evaluate gene-environment interaction on the association.
C1 [Li, Weixing; Wu, Han; Song, Chao] Zhejiang Prov Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
RP Li, WX (reprint author), Zhejiang Prov Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
EM weixingli2010@126.com
FU Zhejiang Medicine, Health, and Science [2010KYB127]; Zhejiang Province
   Chinese Medicine Research Program [2012ZA130]; Zhejiang Gong Yi Xing
   Technology Application Project [2012C33025]
FX The work was funded by Zhejiang Medicine, Health, and Science
   (2010KYB127); Zhejiang Province Chinese Medicine Research Program
   (2012ZA130); and Zhejiang Gong Yi Xing Technology Application Project
   (2012C33025)
CR DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Falleti E, 2008, CYTOKINE, V44, P256, DOI 10.1016/j.cyto.2008.08.008
   Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93
   Kim YJ, 2003, EXP MOL MED, V35, P196, DOI 10.1038/emm.2003.27
   Kwon Oh Sang, 2003, Korean J Gastroenterol, V42, P212
   Liu Y, 2012, ASIAN PAC J CANCER P, V13, P4683, DOI 10.7314/APJCP.2012.13.9.4683
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Migita K, 2005, J HEPATOL, V42, P505, DOI 10.1016/j.jhep.2004.11.026
   Niu H, 2012, DNA CELL BIOL, V31, P706, DOI 10.1089/dna.2011.1426
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Qi P, 2009, CANCER IMMUNOL IMMUN, V58, P1433, DOI 10.1007/s00262-009-0660-4
   Qin JN, 2009, THESIS GUANGXI MED U, P1
   Radwan MI, 2012, CYTOKINE, V60, P271, DOI 10.1016/j.cyto.2012.05.010
   Wang YD, 2013, CYTOKINE, V61, P181, DOI 10.1016/j.cyto.2012.09.014
   Wei ZH, 2012, CANC RES CLIN, V24, P447, DOI DOI 10.3760/CMA.J.ISSN.1006-9801.2012.07.005]
   Woo SU, 2010, BREAST CANCER RES TR, V124, P481, DOI 10.1007/s10549-010-0871-6
   Xiang TX, 2012, HEPATOL RES, V42, P583, DOI 10.1111/j.1872-034X.2011.00958.x
   Xin ZH, 2012, MOL CARCINOGEN, V51, pE123, DOI 10.1002/mc.21876
   Yang Y, 2012, EXP THER MED, V3, P513, DOI 10.3892/etm.2011.418
   [杨艳 Yang Yan], 2011, [中国公共卫生, China Public Health], V27, P1383
   Zhang CF, 2012, ANN HUM GENET, V76, P363, DOI 10.1111/j.1469-1809.2012.00717.x
   Zhang ZJ, 2008, THESIS ANHUI VOCATIO, P1
NR 23
TC 4
Z9 4
U1 5
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2013
VL 34
IS 5
BP 2675
EP 2681
DI 10.1007/s13277-013-0818-8
PG 7
WC Oncology
SC Oncology
GA 227AK
UT WOS:000325079200027
PM 23653379
DA 2018-12-27
ER

PT J
AU Chen, XZ
   Xue, F
   Xie, TH
   Luo, C
AF Chen, Xianzhen
   Xue, Fei
   Xie, Tianhao
   Luo, Chun
TI RETRACTED: Silencing of the Smad nuclear interacting protein 1 (SNIP1)
   by siRNA inhibits proliferation and induces apoptosis in pituitary
   adenoma cells (Retracted article. See vol. 36, pg. 7301, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Pituitary adenoma; SNIP1; siRNA; Apoptosis; Cell cycle arrest
ID FHA DOMAIN; GENE; EXPRESSION
AB Smad nuclear interacting protein 1 (SNIP1) gene encodes a protein that contains a conservative C-terminal forkhead-associated domain and functions as a transcriptional coactivator to regulate cell proliferation and cancer progression. This study aimed to investigate the clinical and biological significance of SNIP1 expression in pituitary adenoma. We analyzed SNIP1 expressions in mouse fibroblast L929 cells and mouse pituitary adenoma AtT-20 cells by Western blotting. SNIP1 gene knockdown by small interfering RNA (siRNA) transfection was performed to evaluate SNIP1 function in pituitary adenoma cell lines. As expected, SNIP1 was found to be upregulated in pituitary adenoma cells. The mRNA and protein levels of SNIP1 were inhibited in AtT-20 cells transfected with siRNAs, which led to decreased proliferation, increased apoptosis, and cycle arrest of pituitary adenoma cells. Concomitantly, c-Myc and cyclin D1 protein levels were reduced. These findings may provide novel targets for the treatment of pituitary adenoma.
C1 [Chen, Xianzhen; Xie, Tianhao; Luo, Chun] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai 200003, Peoples R China.
   [Xue, Fei] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Neurosurg, Shanghai 200072, Peoples R China.
RP Luo, C (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, 415 FengYang Rd, Shanghai 200003, Peoples R China.
EM luochunchunch1365@hotmail.com
CR Beckers A, 2013, ENDOCR REV, V34, P239, DOI 10.1210/er.2012-1013
   Colao A, 2011, EXPERT OPIN PHARMACO, V12, P1561, DOI 10.1517/14656566.2011.568478
   Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3
   Fujii M, 2006, MOL CELL, V24, P771, DOI 10.1016/j.molcel.2006.11.006
   Greenman Y, 2009, BEST PRACT RES CL EN, V23, P625, DOI 10.1016/j.beem.2009.05.005
   Larsson LG, 2006, MOL CELL, V24, P811, DOI 10.1016/j.molcel.2006.12.003
   Liang XH, 2011, ORAL ONCOL, V47, P92, DOI 10.1016/j.oraloncology.2010.11.014
   Murat CB, 2012, BRAZ J MED BIOL RES, V45, P851, DOI 10.1590/S0100-879X2012007500115
   Roche KC, 2004, ONCOGENE, V23, P8185, DOI 10.1038/sj.onc.1208025
   Tagliati F, 2010, ENDOCRINOLOGY, V151, P4635, DOI 10.1210/en.2010-0441
   Tapar K, 1997, Arkh Patol, V59, P7
   Witzel II, 2010, BIOCHEM SOC T, V38, P217, DOI 10.1042/BST0380217
NR 12
TC 2
Z9 2
U1 3
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2013
VL 34
IS 5
BP 3071
EP 3076
DI 10.1007/s13277-013-0873-1
PG 6
WC Oncology
SC Oncology
GA 227AK
UT WOS:000325079200075
PM 23897559
DA 2018-12-27
ER

PT J
AU He, J
   Xu, GL
AF He, Juan
   Xu, Guili
TI RETRACTED: LEP gene variant is associated with prostate cancer but not
   with colorectal cancer (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE LEP gene; Polymorphism; Prostate cancer; Colorectal cancer;
   Meta-analysis
ID OBESITY-RELATED GENES; ADIPOKINE GENES; -2548 G/A; RISK; POLYMORPHISM;
   METAANALYSIS; DISEASE; BIAS
AB The leptin (LEP) gene has been considered to be implicated in the development of cancer. However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of LEP rs7799039 variant with colorectal and prostate cancer risk. Published literatures from PubMed and Embase were retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed or random effects model. A total of five studies (2,596 colorectal cancer cases and 3,240 controls) for association of LEP rs7799039 variant with colorectal cancer, and three studies (1,343 prostate cancer cases and 1,238 controls) for association with prostate cancer were included in the meta-analysis. For colorectal cancer, there was no significant association of LEP rs7799039 variant with this disease under homogeneous co-dominant model (OR = 0.88, 95 % CI = 0.75-1.02), heterogeneous co-dominant model (OR = 1.00, 95 % CI = 0.89-1.13) and dominant model (OR = 0.97, 95 % CI = 0.87-1.08); however, there was a marginal association under recessive model (OR = 0.87, 95 % CI = 0.76-0.99). For prostate cancer, there was significant association of LEP rs7799039 variant with this disease under homogeneous co-dominant model (OR = 1.33, 95 % CI = 1.06-1.67) and recessive model (OR = 1.26, 95 % CI = 1.05-1.51), but not under heterogeneous co-dominant model (OR = 1.24, 95 % CI = 0.87-1.77) and dominant model (OR = 1.30, 95 % CI = 1.84). The present meta-analysis demonstrated that the LEP rs7799039 variant was associated with prostate cancer, but not with colorectal cancer.
C1 [He, Juan; Xu, Guili] Chengdu Mil Command, Kunming Gen Hosp, Dept Pharm, Kunming 650032, Peoples R China.
RP Xu, GL (reprint author), Chengdu Mil Command, Kunming Gen Hosp, Dept Pharm, Kunming 650032, Peoples R China.
EM xuguili2000@126.com
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777
   He BS, 2012, MOL BIOL REP, V39, P3117, DOI 10.1007/s11033-011-1076-8
   Hoffstedt J, 2002, HORM METAB RES, V34, P355, DOI 10.1055/s-2002-33466
   Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060777
   Loffreda S, 1998, FASEB J, V12, P57
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Moore SC, 2009, INT J CANCER, V124, P869, DOI 10.1002/ijc.24043
   Partida-Perez M, 2010, CANCER BIOMARK, V7, P117, DOI 10.3233/CBM-2010-0154
   Pechlivanis S, 2009, EUR J ENDOCRINOL, V160, P933, DOI 10.1530/EJE-09-0039
   Ribeiro R, 2004, PROSTATE, V59, P268, DOI 10.1002/pros.20004
   Russo VC, 2004, ENDOCRINOLOGY, V145, P4103, DOI 10.1210/en.2003-1767
   Slattery ML, 2008, INT J CANCER, V122, P1611, DOI 10.1002/ijc.23135
   Tsilidis KK, 2009, CANCER CAUSE CONTROL, V20, P1739, DOI 10.1007/s10552-009-9427-7
   Vasku A, 2009, INT J COLORECTAL DIS, V24, P289, DOI 10.1007/s00384-008-0553-6
   Wang LQ, 2012, BREAST CANCER RES TR, V136, P231, DOI 10.1007/s10549-012-2228-9
   Wang MH, 2009, PROSTATE, V69, P874, DOI 10.1002/pros.20933
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
NR 20
TC 5
Z9 5
U1 3
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2013
VL 34
IS 5
BP 3131
EP 3136
DI 10.1007/s13277-013-0881-1
PG 6
WC Oncology
SC Oncology
GA 227AK
UT WOS:000325079200082
PM 23754448
DA 2018-12-27
ER

PT J
AU Wu, D
   Jiang, HL
   Gu, QH
   Zhang, D
   Li, ZW
AF Wu, Dan
   Jiang, Honglei
   Gu, Qiuhong
   Zhang, Dan
   Li, Zhiwei
TI RETRACTED: Association between XRCC1 Arg399Gln polymorphism and
   hepatitis virus-related hepatocellular carcinoma risk in Asian
   population (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE XRCC1; Hepatitis; Hepatocellular carcinoma
ID DNA-REPAIR GENES; LIVER-DISEASE; CANCER; METAANALYSIS; SUSCEPTIBILITY;
   PATHOGENESIS; BIAS
AB To investigate the association between X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk, we performed a systematic meta-analysis of eligible case-control studies. Eligible studies were identified from the PubMed, Embase, and Chinese National Knowledge Infrastructure databases up to March 2013. The odds ratios (ORs) and corresponding 95 % confidence interval (95 % CI) of XRCC1 Arg399Gln polymorphism in hepatitis virus-related hepatocellular carcinoma cases compared with those in controls were calculated. The meta-analysis was performed using fixed-effect or random-effect methods according to the absence or presence of heterogeneity. This meta-analysis included 1,558 cases with hepatitis virus-related hepatocellular carcinoma and 1,338 controls. Meta-analysis of available data showed that there was no association between XRCC1 Arg399Gln polymorphism and risk of hepatitis virus-related hepatocellular carcinoma under all contrast models (Gln vs. Arg: fixed-effect OR = 0.92, 95 % CI 0.82-1.04, P = 0.18; GlnGln vs. ArgArg: random-effect OR = 0.79, 95 % CI 0.50-1.25, P = 0.32; GlnGln/ArgGln vs. ArgArg: fixed-effect OR = 0.92, 95 % CI 0.79-1.07, P = 0.28; and GlnGln vs. ArgArg/ArgGln: random-effect OR = 0.83, 95 % CI 0.52-1.34, P = 0.45). Sensitivity analysis further showed that there was no association between XRCC1 Arg399Gln polymorphism and risk of hepatitis B-related hepatocellular carcinoma under all contrast models (Gln vs. Arg: fixed-effect OR = 0.93, 95 % CI 0.82-1.05, P = 0.25; GlnGln vs. ArgArg: fixed-effect OR = 0.86, 95 % CI 0.64-1.16, P = 0.32; GlnGln/ArgGln vs. ArgArg: fixed-effect OR = 0.93, 95 % CI 0.80-1.10, P = 0.41; and GlnGln vs. ArgArg/ArgGln: fixed-effect OR = 0.85, 95 % CI 0.63-1.13, P = 0.26). Our meta-analysis of the available data did not find an obvious effect of XRCC1 Arg399Gln polymorphism on hepatitis-related hepatocellular carcinoma. More well-designed studies with large sample are needed to further verify the effect.
C1 [Wu, Dan; Gu, Qiuhong; Zhang, Dan; Li, Zhiwei] China Med Univ, Shengjing Hosp, Dept Infect Dis, Shenyang 110004, Peoples R China.
   [Jiang, Honglei] China Med Univ, Affiliated Hosp 4, Dept Hepatobiliary Surg, Shenyang 110004, Peoples R China.
RP Li, ZW (reprint author), China Med Univ, Shengjing Hosp, Dept Infect Dis, Sanhao St 36, Shenyang 110004, Peoples R China.
EM zhiweisy@sina.com
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bose S, 2013, GENE, V519, P231, DOI 10.1016/j.gene.2013.02.025
   Brennan P, 2011, LANCET ONCOL, V12, P399, DOI 10.1016/S1470-2045(10)70126-1
   Chen CC, 2005, INT J EPIDEMIOL, V34, P1310, DOI 10.1093/ije/dyi191
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934
   Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087
   Ginsberg G, 2011, MUTAT RES-REV MUTAT, V727, P1, DOI 10.1016/j.mrrev.2011.02.001
   Gulnaz A, 2013, EUR J GASTROEN HEPAT, V25, P166, DOI 10.1097/MEG.0b013e328359a775
   Han Y N, 2004, CHIN HEPATOL, P235
   Jung SW, 2012, J HEPATOL, V57, P621, DOI 10.1016/j.jhep.2012.04.039
   Kiran M, 2009, MOL CELL BIOCHEM, V327, P7, DOI 10.1007/s11010-009-0035-3
   Liu F, 2011, LIVER INT, V31, P804, DOI 10.1111/j.1478-3231.2011.02508.x
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Qian BY, 2011, LUNG CANCER, V73, P138, DOI 10.1016/j.lungcan.2010.11.018
   Ren Y, 2008, CHIN J CLIN HEPATOL, V24, P361
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Tiniakos DG, 2010, ANNU REV PATHOL-MECH, V5, P145, DOI 10.1146/annurev-pathol-121808-102132
   Webster DP, 2009, LANCET INFECT DIS, V9, P108, DOI 10.1016/S1473-3099(09)70020-9
   Xue HP, 2011, AM J EPIDEMIOL, V173, P363, DOI 10.1093/aje/kwq378
NR 24
TC 6
Z9 6
U1 4
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2013
VL 34
IS 5
BP 3265
EP 3269
DI 10.1007/s13277-013-0899-4
PG 5
WC Oncology
SC Oncology
GA 227AK
UT WOS:000325079200099
PM 23780894
DA 2018-12-27
ER

PT J
AU Kalariya, NM
   Shoeb, M
   Reddy, ABM
   Sawhney, R
   Ramana, KV
AF Kalariya, Nilesh M.
   Shoeb, Mohammad
   Reddy, Aramati B. M.
   Sawhney, Rahul
   Ramana, Kota V.
TI RETRACTED: Piceatannol suppresses endotoxin-induced ocular inflammation
   in rats (Retracted Article. See vol.17,pg.439,2013)
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Uveitis; Piceatannol; Inflammation; NF-kappa B; Rats
ID KAPPA-B ACTIVATION; INDUCED UVEITIS; SIGNALING PATHWAY;
   EPITHELIAL-CELLS; RESVERATROL; EXPRESSION; AUTOIMMUNE; CYTOKINES;
   CANCER; POLYPHENOL
AB Anti-inflammatory effect of piceatannol, a naturally occurring polyphenol and a potent free radical scavenger, on ocular inflammation is not known. We examined the anti-inflammatory role of piceatannol in ocular inflammatory response due to endotoxin-induced uveitis (EIU) in rats. EIU was induced in Lewis rats by subcutaneous injection of lipopolysaccharide (LPS; 150 ug/rat). Piceatannol (30 mg/kg body wt, i.p) was injected either 2 h prior to or 1 h post LPS induction. A significant increase in the number of infiltrating cells, total protein, and various cytokines and chemokines in AqH were observed in the EIU rat eyes as compared to control groups. However, pre- or post-treatment of piceatannol significantly blocked the LPS-induced changes. Further, piceatannol also suppressed the expression of cyclooxygenase-2 (Cox-2), inducible nitric oxide synthase (iNOS) and activation of NF-kappa B in the ciliary bodies as well as retina. Further, piceatannol also inhibited the expression of Cox-2, iNOS, and phosphorylation of NF-kappa B in primary human non-pigmented ciliary epithelial cells (HNPECs) treated with LPS. Similarly, piceatannol also diminished LPS-induced level of NO and prostaglandin E2 in HNPECs. Thus our results demonstrate an anti-inflammatory role of piceatannol in suppressing ocular inflammation induced by endotoxin in rats. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Kalariya, Nilesh M.] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
   [Kalariya, Nilesh M.] Univ Texas Med Branch, Sch Nursing, Galveston, TX 77555 USA.
   [Shoeb, Mohammad; Reddy, Aramati B. M.; Sawhney, Rahul; Ramana, Kota V.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
RP Ramana, KV (reprint author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
EM kvramana@utmb.edu
FU National Institutes of Health (NIH) [EY015891]
FX This work was supported by the National Institutes of Health (NIH) Grant
   EY015891.
CR Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490
   Carnahan M C, 2000, Curr Opin Ophthalmol, V11, P478, DOI 10.1097/00055735-200012000-00016
   Caspi RR., 2003, CURR PROTOC IMMUNOL, V15.6, P1
   Choi KH, 2010, CARDIOVASC RES, V85, P836, DOI 10.1093/cvr/cvp359
   Curnow SJ, 2006, CURR OPIN OPHTHALMOL, V17, P532, DOI 10.1097/ICU.0b013e32801094b5
   DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873
   Jin CY, 2006, PHARMACOL RES, V54, P461, DOI 10.1016/j.phrs.2006.09.005
   Jin HY, 2011, FEBS LETT, V585, P3457, DOI 10.1016/j.febslet.2011.10.002
   Jin XH, 2006, INVEST OPHTH VIS SCI, V47, P2562, DOI 10.1167/iovs.05-1429
   Kalariya NM, 2011, INVEST OPHTH VIS SCI, V52, P5144, DOI 10.1167/iovs.10-7047
   Kalariya NM, 2010, INVEST OPHTH VIS SCI, V51, P5105, DOI 10.1167/iovs.09-4873
   Keino Hiroshi, 2010, Nippon Ganka Gakkai Zasshi, V114, P944
   Kim EY, 2008, IMMUNOL LETT, V120, P1, DOI 10.1016/j.imlet.2008.07.008
   Kim YH, 2008, INT IMMUNOPHARMACOL, V8, P1695, DOI 10.1016/j.intimp.2008.08.003
   Larrosa M, 2004, EUR J NUTR, V43, P275, DOI 10.1007/s00394-004-0471-5
   Liu D, 2009, NUTR CANCER, V61, P855, DOI 10.1080/01635580903285080
   Makena PS, 2007, FOOD CHEM TOXICOL, V45, P1899, DOI 10.1016/j.fct.2007.04.007
   Morales P, 2012, J APPL TOXICOL, V32, P986, DOI 10.1002/jat.1725
   Nguyen QD, 2011, OPHTHALMOLOGY, V118, P184, DOI 10.1016/j.ophtha.2010.03.029
   NUSSENBLATT RB, 1990, INT OPHTHALMOL, V14, P303, DOI 10.1007/BF00163549
   Ovesna Z, 2006, ONCOL REP, V16, P617
   Piotrowska H, 2012, MUTAT RES-REV MUTAT, V750, P60, DOI 10.1016/j.mrrev.2011.11.001
   Rhayem Y, 2008, CHEM PHYS LIPIDS, V155, P48, DOI 10.1016/j.chemphyslip.2008.06.001
   Richard N, 2005, MOL NUTR FOOD RES, V49, P431, DOI 10.1002/mnfr.200400099
   Saxena A, 2013, ANTIOXID REDOX SIGN, V18, P1249, DOI 10.1089/ars.2012.4643
   Sijssens KM, 2008, OCUL IMMUNOL INFLAMM, V16, P211, DOI 10.1080/09273940802409969
   Son PS, 2010, CARCINOGENESIS, V31, P1442, DOI 10.1093/carcin/bgq099
   Suzuki J, 2011, INVEST OPHTH VIS SCI, V52, P6565, DOI 10.1167/iovs.11-7331
   Suzuki Y, 2006, EXP EYE RES, V82, P275, DOI 10.1016/j.exer.2005.06.023
   Wang J, 2011, MOL VIS, V17
   Wesolowska O, 2009, BBA-BIOMEMBRANES, V1788, P1851, DOI 10.1016/j.bbamem.2009.06.005
   Wung BS, 2006, PHARMACOL RES, V53, P113, DOI 10.1016/j.phrs.2005.09.006
   Yadav UCS, 2007, INVEST OPHTH VIS SCI, V48, P4634, DOI 10.1167/iovs.07-0485
   Yadav UCS, 2011, INVEST OPHTH VIS SCI, V52, P8076, DOI 10.1167/iovs.11-7830
   Youn J, 2009, NUTR CANCER, V61, P847, DOI 10.1080/01635580903285072
NR 36
TC 12
Z9 12
U1 2
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2013
VL 17
IS 2
BP 439
EP 446
DI 10.1016/j.intimp.2013.07.007
PG 8
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 227OC
UT WOS:000325122200039
PM 23892029
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Dehkordi, MG
   Daliri, MR
   Ayatollahi, A
   Ayatollahi, F
AF Dehkordi, Masoud Ghaderi
   Daliri, Mohammad Reza
   Ayatollahi, Ahmad
   Ayatollahi, Fazael
TI RETRACTED: Pose invariant face recognition using biological inspired
   features based on ensemble of classifiers (Retracted article. See vol.
   25, pg. 1287, 2014)
SO JOURNAL OF VISUAL COMMUNICATION AND IMAGE REPRESENTATION
LA English
DT Article; Retracted Publication
DE View-independent face recognition; Visual ventral stream; HMAX; C1
   features; Ensemble of classifiers; Bootstrapping; Scale and translation
   invariant features; Diversity; CMU-PIE database; FERET face database
ID MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; OBJECT RECOGNITION;
   RECEPTIVE-FIELDS; EXPERTS; MIXTURE; MODEL; IMAGE; IDENTIFICATION;
   EIGENSPACES
AB This paper introduces a new method for view-independent face recognition by means of features inspired by the human's visual ventral stream and ensemble of classifiers. Several sets of scale and translation invariant features are first extracted. The feature vectors are then given to a new method of ensemble of classifiers. Diversity is a crucial condition for obtaining accurate ensembles. Diversity in our method is obtained by using bootstrapped replicas of the training vectors. Different training vectors are randomly drawn from the training vectors and are connected together to form diverse training sets. Experiments were performed to validate the method on the CMU-PIE and FERET face databases. Comparison with some of the most related methods indicates that the proposed method yields better recognition rate in view independent face recognition. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Dehkordi, Masoud Ghaderi; Daliri, Mohammad Reza; Ayatollahi, Ahmad] Iran Univ Sci & Technol, Fac Elect Engn, Tehran 1684613114, Iran.
   [Ayatollahi, Fazael] Amirkabir Univ Technol, Fac Elect Engn, Tehran, Iran.
RP Daliri, MR (reprint author), Iran Univ Sci & Technol, Fac Elect Engn, Tehran 1684613114, Iran.
EM daliri@iust.ac.ir
RI Daliri, Mohammad Reza/S-9308-2018; Ayatollahi, Ahmad/S-5984-2018
CR Blanz V, 2003, IEEE T PATTERN ANAL, V25, P1063, DOI 10.1109/TPAMI.2003.1227983
   BLASDEL GG, 1992, J NEUROSCI, V12, P3139
   Borji A, 2008, NEURAL PROCESS LETT, V28, P97, DOI 10.1007/s11063-008-9084-y
   Bowyer KW, 2006, COMPUT VIS IMAGE UND, V101, P1, DOI 10.1016/j.cviu.2005.05.005
   Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1007/BF00058655
   Cootes TF, 2002, IMAGE VISION COMPUT, V20, P657, DOI 10.1016/S0262-8856(02)00055-0
   Du S, 2006, J FRANKLIN I, V343, P596, DOI 10.1016/j.jfranklin.2006.08.006
   Ebrahimpour R., 2010, INT J COMPUT ELECT E, V2, P1793
   Ebrahimpour R, 2008, COMPUT VIS IMAGE UND, V111, P195, DOI 10.1016/j.cviu.2007.10.003
   Ebrahimpour R, 2008, J FRANKLIN I, V345, P87, DOI 10.1016/j.jfranklin.2007.06.004
   Ebrahimpour R, 2008, NEUROCOMPUTING, V71, P1103, DOI 10.1016/j.neucom.2007.08.021
   Ebrahimpour R, 2011, MACH VISION APPL, V22, P421, DOI 10.1007/s00138-009-0232-9
   El Aroussi M, 2011, SIGNAL PROCESS, V91, P38, DOI 10.1016/j.sigpro.2010.06.005
   Franc V., 2005, THESIS CZECH TU, V25
   FUKUSHIMA K, 1980, BIOL CYBERN, V36, P193, DOI 10.1007/BF00344251
   Gabor D., 1946, Journal of the Institution of Electrical Engineers. III. Radio and Communication Engineering, V93, P429
   Gao XB, 2009, NEUROCOMPUTING, V72, P3742, DOI 10.1016/j.neucom.2009.06.001
   Guo GD, 2009, PROC CVPR IEEE, P112, DOI 10.1109/CVPRW.2009.5206681
   Hajiany A, 2009, INT CONF INTELL SYST, P1425, DOI 10.1109/ISDA.2009.57
   He L.M., 2007, P 6 INT C MACH LEARN, P19
   HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455
   HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837
   Kim TK, 2006, IEEE T CIRC SYST VID, V16, P1096, DOI 10.1109/TCSVT.2006.881197
   Kim TK, 2004, LECT NOTES COMPUT SC, V3138, P565
   Kirby M., IEEE T PATTERN ANAL, V12
   Kuncheba L., 2005, INFORM FUSION, V6, P3, DOI DOI 10.1016/J.INFFUS.2004.04.009
   Lu JW, 2003, IEEE T NEURAL NETWOR, V14, P117, DOI 10.1109/TNN.2002.806629
   Meyers E, 2008, INT J COMPUT VISION, V76, P93, DOI 10.1007/s11263-007-0058-8
   Moghaddam B, 1997, IEEE T PATTERN ANAL, V19, P696, DOI 10.1109/34.598227
   Moore S, 2011, COMPUT VIS IMAGE UND, V115, P541, DOI 10.1016/j.cviu.2010.12.001
   Mu Y, 2010, NEUROCOMPUTING, V73, P895, DOI 10.1016/j.neucom.2009.09.017
   Phillips PJ, 1998, IMAGE VISION COMPUT, V16, P295, DOI 10.1016/S0262-8856(97)00070-X
   Polikar R., 2006, IEEE Circuits and Systems Magazine, V6, P21, DOI 10.1109/MCAS.2006.1688199
   Prabhu U, 2011, IEEE T PATTERN ANAL, V33, P1952, DOI 10.1109/TPAMI.2011.123
   Riesenhuber M, 1999, NAT NEUROSCI, V2, P1019
   Rokach L, 2010, ARTIF INTELL REV, V33, P1, DOI 10.1007/s10462-009-9124-7
   Serre T., 2006, THESIS MIT CAMBRIDGE
   Serre T, 2004, TECHNICAL REPORT
   Serre T, 2007, P NATL ACAD SCI USA, V104, P6424, DOI 10.1073/pnas.0700622104
   Serre T, 2007, IEEE T PATTERN ANAL, V29, P411, DOI 10.1109/TPAMI.2007.56
   Sim T, 2003, IEEE T PATTERN ANAL, V25, P1615, DOI 10.1109/TPAMI.2003.1251154
   Song D., 2009, C1 UNITS SCENE CLASS, P1
   Tan XY, 2006, PATTERN RECOGN, V39, P1725, DOI 10.1016/j.patcog.2006.03.013
   Wiskott L, 1997, IEEE T PATTERN ANAL, V19, P775, DOI 10.1109/34.598235
   Zhang L, 2006, IEEE T PATTERN ANAL, V28, P351, DOI 10.1109/TPAMI.2006.53
   Zhang X, 2009, PATTERN RECOGN, V42, P2876, DOI 10.1016/j.patcog.2009.04.017
   Zhao W, 2003, ACM COMPUT SURV, V35, P399, DOI 10.1145/954339.954342
NR 47
TC 2
Z9 2
U1 1
U2 22
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1047-3203
EI 1095-9076
J9 J VIS COMMUN IMAGE R
JI J. Vis. Commun. Image Represent.
PD OCT
PY 2013
VL 24
IS 7
BP 968
EP 976
DI 10.1016/j.jvcir.2013.06.007
PG 9
WC Computer Science, Information Systems; Computer Science, Software
   Engineering
SC Computer Science
GA 223YP
UT WOS:000324848700021
DA 2018-12-27
ER

PT J
AU Liao, MH
AF Liao, M. H.
TI RETRACTED: The demonstration of a highly efficient SiGe Type-II
   hetero-junction solar cell with an optimal stress design (Retracted
   article. See vol. 665, pg. 197, 2018)
SO THIN SOLID FILMS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT International Conference on Technological Advances of Thin Films &
   Surface Coatings
CY JUL 15-17, 2012
CL Singapore, SINGAPORE
DE Solar cell; SiGe/Si type-II hetero-structure; Nano-surface trench
   structure
AB Highly efficient surface-textured SiGe-based solar cell with top surface trench structure and optimized SiGe/Si type-II hetero-junction design is proposed. The surface-textured structure results in a significant reduction of the surface reflectance from 32% to similar to 10% in the visible light region with an obvious photonic crystal effect, which can be simulated by finite differential time domain calculations. By varying the top surface trench spacing, broadband antireflection can be realized and total absorption rate greatly enhanced. Moreover, SiGe/Si hetero-structure substrate has also been implemented to enhance the solar cell efficiency by an additional 3% in this work, not only due to the originally higher absorption rate in the SiGe-based material but also due to the enhanced SiGe/Si type-II hetero-structure substrate design. The offset and discontinuousness of the energy band between the Si substrate and the strained Si0.9Ge0.1 type-II hetero-junction structure resulted in higher local electron-hole carrier concentration, which is confined in the Si cap and SiGe quantum well structure, and the longer non-radiative Auger carrier recombination lifetime as measured by femtosecond transient absorption measurements. The integration of these two key technologies-nano-level surface trench structure and optimization of the SiGe/Si type-II hetero-structure, led to highly efficient (similar to 18% for the stable production and 21% for the peak record) nano-surface textured SiGe-based solar cell being achieved and demonstrated in this work. (C) 2013 Published by Elsevier B.V.
C1 Natl Taiwan Univ, Dept Mech Engn, Taipei 10764, Taiwan.
RP Liao, MH (reprint author), Natl Taiwan Univ, Dept Mech Engn, Taipei 10764, Taiwan.
EM mhliaoa@ntu.edu.tw
RI Arumugam, Thirumagal/C-3408-2014
FU National Science Council (NSC), Taiwan [100-2221-E-002-253-,
   101-2218-E-002-010-, 101-2628-E-002-018-MY3]; Ministry of Economic
   Affairs (MEA), Taiwan [101-EC-17-A-01-S1-219]
FX This work is supported by National Science Council (NSC), Taiwan, under
   the Grant Nos. 100-2221-E-002-253-, 101-2218-E-002-010-, and
   101-2628-E-002-018-MY3, and Ministry of Economic Affairs (MEA), Taiwan,
   under the Grant No. 101-EC-17-A-01-S1-219. The helpful discussions and
   the useful supports from Chair Yang and Prof. Liu, National Taiwan
   University, Taiwan, R. O. C., are also highly appreciated.
CR Cheng TH, 2009, J APPL PHYS, V105, DOI 10.1063/1.3117523
   Danzilio David, 2007, U. S. Patent, Patent No. 7309832
   Li Y.L., 2011, INT EL DEV M, P504
   Liao MH, 2011, IEEE T NANOTECHNOL, V10, P770, DOI 10.1109/TNANO.2010.2077647
   Liao MH, 2007, J APPL PHYS, V102, DOI 10.1063/1.2777686
   Liao MH, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1937989
   Liao MMH, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3155211
   Liao MH, 2011, IEEE T NANOTECHNOL, V10, P774, DOI 10.1109/TNANO.2010.2077680
   Luque A, 2011, J APPL PHYS, V110, DOI 10.1063/1.3600702
   Pei TH, 2011, J APPL PHYS, V109, DOI 10.1063/1.3567296
   Suh W, 2005, J APPL PHYS, V98, DOI 10.1063/1.1999031
   YAMADA T, 1995, SOLID STATE ELECTRON, V38, P881, DOI 10.1016/0038-1101(94)00123-W
NR 12
TC 5
Z9 5
U1 1
U2 19
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0040-6090
J9 THIN SOLID FILMS
JI Thin Solid Films
PD OCT 1
PY 2013
VL 544
BP 112
EP 115
DI 10.1016/j.tsf.2013.04.100
PG 4
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied; Physics, Condensed Matter
SC Materials Science; Physics
GA 216UC
UT WOS:000324309100023
DA 2018-12-27
ER

PT J
AU Jiang, BH
   Takashima, S
   Hakucho, T
   Hodaka, N
   Yasuhiko, T
   Masahiko, H
AF Jiang, Binghu
   Takashima, Shodayu
   Hakucho, Tomoaki
   Hodaka, Numasaki
   Yasuhiko, Tomita
   Masahiko, Higashiyama
TI RETRACTED: Adenocarcinoma of the lung with scattered consolidation:
   Radiological-pathological correlation and prognosis (Retracted article.
   See vol. 84, pg. 1828, 2015)
SO EUROPEAN JOURNAL OF RADIOLOGY
LA English
DT Article; Retracted Publication
DE Scattered consolidation; Adenocarcinoma; Lung; Prognosis
ID SECTION COMPUTED-TOMOGRAPHY; PERIPHERAL ADENOCARCINOMA; CT FINDINGS;
   CLASSIFICATION; SOCIETY; CANCER
AB Purpose: To investigate the clinicopathological features and prognosis in patients with adenocarcinoma of the lung with scattered consolidation (ALSC).
   Materials and methods: Between January 2006 and March 2010, 139 consecutive patients with lung adenocarcinoma of <= 3 cm, who underwent pulmonary resection for lung cancer, were investigated retrospectively. Radiologic classification was based on the findings of thin-section CT such as the presence of consolidation or ground-glass opacity (GGO). Type I (n = 15) and Type II (n = 14), showed a pure GGO and a mixed GGO with consolidation <50%, respectively. Type IV (n = 38) and Type V (n = 52) showed a mixed GGO with consolidation >= 50% and a pure consolidation, respectively. Type III (n = 20) was the adenocarcinoma of the lung with scattered consolidation (ALSC). The clinicopathological features and prognosis of ALSC was investigated with comparative analysis and survival analysis.
   Results: Because of the similar recurrence rate for Type I and Type II (P = 1.000), Type IV and Type V (P = 0.343), we merged Type I and Type II as Type I + II, Type IV and Type V as Type IV + V, respectively. In the 20 (14.4%) patients with ALSC, lymph node metastasis was not observed, and it was rare in lymphatic invasion and vascular invasion. On the basis of IASLC/ATS/ERS 2011 classification, 80% of the ALSC were preinvasive lesions. In Noguchi classification, there was no significant difference between Type I + II and ALSC (P = 0.260). The prognosis of ALSC was similar to Type I + II (P = 0.408), but better than Type IV + V (P = 0.040).
   Conclusion: Adenocarcinoma of the lung with scattered consolidation (ALSC) on thin-section CT was a relatively favorable prognostic factor. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Jiang, Binghu] Nanjing Med Univ, Thorac Med Ctr, BenQ Hosp, Nanjing 210019, Jiangsu, Peoples R China.
   [Jiang, Binghu] Nanjing Med Univ, Dept Radiol, BenQ Hosp, Nanjing 210019, Jiangsu, Peoples R China.
   [Jiang, Binghu; Takashima, Shodayu; Hakucho, Tomoaki; Hodaka, Numasaki] Osaka Univ, Grad Sch Med, Dept Diagnost Radiol Imaging, Div Allied Hlth Sci, Suita, Osaka 5650871, Japan.
   [Yasuhiko, Tomita; Masahiko, Higashiyama] Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari Ku, Osaka 5370025, Japan.
RP Jiang, BH (reprint author), Osaka Univ, Grad Sch Med, Dept Diagnost Radiol Imaging, Div Allied Hlth Sci, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan.
EM mbhh@live.cn
CR Aoki T, 2001, RADIOLOGY, V220, P803, DOI 10.1148/radiol.2203001701
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   HOLMES CE, 1995, ANN THORAC SURG, V60, P615
   Matsunaga T, 2013, INTERACT CARDIOV TH, V16, P445, DOI 10.1093/icvts/ivs520
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#
   Ohde Y, 2003, LUNG CANCER, V42, P303, DOI 10.1016/j.tungcan.2003.07.001
   SHIMOSATO Y, 1980, AM J SURG PATHOL, V4, P365, DOI 10.1097/00000478-198008000-00005
   Suzuki K, 2006, ANN THORAC SURG, V81, P413, DOI 10.1016/j.athoracsur.2005.07.058
   Suzuki K, 2000, ANN THORAC SURG, V69, P893, DOI 10.1016/S0003-4975(99)01331-4
   Suzuki K, 2011, J THORAC ONCOL, V6, P751, DOI 10.1097/JTO.0b013e31821038ab
   Takashima S, 2003, AM J ROENTGENOL, V180, P817, DOI 10.2214/ajr.180.3.1800817
   Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221
   Yoshikawa K, 2002, ANN THORAC SURG, V73, P1055, DOI 10.1016/S0003-4975(01)03466-X
NR 14
TC 5
Z9 5
U1 6
U2 20
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0720-048X
EI 1872-7727
J9 EUR J RADIOL
JI Eur. J. Radiol.
PD OCT
PY 2013
VL 82
IS 10
BP E623
EP E627
DI 10.1016/j.ejrad.2013.06.010
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 211UF
UT WOS:000323935900019
PM 23860407
DA 2018-12-27
ER

PT J
AU Guo, Y
   Qiu, LJ
AF Guo, Yong
   Qiu, Li-Juan
TI RETRACTED: Genome-Wide Analysis of the Dof Transcription Factor Gene
   Family Reveals Soybean-Specific Duplicable and Functional
   Characteristics (Retracted article. See vol. 11, e0167019, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID DOMAIN PROTEINS; ARABIDOPSIS-THALIANA; FACTOR DATABASE; SALICYLIC-ACID;
   EXPRESSION; SEQUENCE; DNA; EVOLUTIONARY; PLANTS; RICE
AB The Dof domain protein family is a classic plant-specific zinc-finger transcription factor family involved in a variety of biological processes. There is great diversity in the number of Dof genes in different plants. However, there are only very limited reports on the characterization of Dof transcription factors in soybean (Glycine max). In the present study, 78 putative Dof genes were identified from the whole-genome sequence of soybean. The predicted GmDof genes were non-randomly distributed within and across 19 out of 20 chromosomes and 97.4% (38 pairs) were preferentially retained duplicate paralogous genes located in duplicated regions of the genome. Soybean-specific segmental duplications contributed significantly to the expansion of the soybean Dof gene family. These Dof proteins were phylogenetically clustered into nine distinct subgroups among which the gene structure and motif compositions were considerably conserved. Comparative phylogenetic analysis of these Dof proteins revealed four major groups, similar to those reported for Arabidopsis and rice. Most of the GmDofs showed specific expression patterns based on RNA-seq data analyses. The expression patterns of some duplicate genes were partially redundant while others showed functional diversity, suggesting the occurrence of sub-functionalization during subsequent evolution. Comprehensive expression profile analysis also provided insights into the soybean-specific functional divergence among members of the Dof gene family. Cis-regulatory element analysis of these GmDof genes suggested diverse functions associated with different processes. Taken together, our results provide useful information for the functional characterization of soybean Dof genes by combining phylogenetic analysis with global gene-expression profiling.
C1 [Guo, Yong; Qiu, Li-Juan] Chinese Acad Agr Sci, Inst Crop Sci, Natl Key Facil Crop Gene Resources & Genet Improv, Beijing 100193, Peoples R China.
RP Qiu, LJ (reprint author), Chinese Acad Agr Sci, Inst Crop Sci, Natl Key Facil Crop Gene Resources & Genet Improv, Beijing 100193, Peoples R China.
EM qiulijuan@caas.cn
FU National Natural Science Foundation of China [31071446, 31271753];
   Fundamental Research Funds for ICS-CAAS; State High-tech Research and
   Development Program [2013AA102602]; National Transgenic Major Program
   [2013ZX08004-001, 2013ZX08004-002]
FX This work was supported by the National Natural Science Foundation of
   China (31071446 and 31271753), the Fundamental Research Funds for
   ICS-CAAS (Grant to Y. G.), the State High-tech Research and Development
   Program (2013AA102602) and the National Transgenic Major Program
   (2013ZX08004-001 and 2013ZX08004-002). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bailey TL, 2006, NUCLEIC ACIDS RES, V34, pW369, DOI 10.1093/nar/gkl198
   Cai XF, 2013, J INTEGR PLANT BIOL, V55, P552, DOI 10.1111/jipb.12043
   Cannon Ethalinda K S, 2011, Int J Plant Genomics, V2011, P373875, DOI 10.1155/2011/373875
   Cannon SB, 2011, BREEDING SCI, V61, P437, DOI 10.1270/jsbbs.61.437
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078
   Do JH, 2008, MOL CELLS, V25, P279
   Dong GQ, 2007, PLANT MOL BIOL, V63, P73, DOI 10.1007/s11103-006-9073-3
   Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149
   Fornara F, 2009, DEV CELL, V17, P75, DOI 10.1016/j.devcel.2009.06.015
   Goodstein DM, 2012, NUCLEIC ACIDS RES, V40, pD1178, DOI 10.1093/nar/gkr944
   Gualberti G, 2002, PLANT CELL, V14, P1253, DOI 10.1105/tpc.010491
   Guo An-Yuan, 2007, Yichuan, V29, P1023, DOI 10.1360/yc-007-1023
   Guo AY, 2008, NUCLEIC ACIDS RES, V36, pD966, DOI 10.1093/nar/gkm841
   Guo Y, 2009, PLANT CELL, V21, P3518, DOI 10.1105/tpc.108.064139
   Hernando-Amado S, 2012, BMC PLANT BIOL, V12, DOI 10.1186/1471-2229-12-202
   Higo K, 1999, NUCLEIC ACIDS RES, V27, P297, DOI 10.1093/nar/27.1.297
   Imaizumi T, 2005, SCIENCE, V309, P293, DOI 10.1126/science.1110586
   Kang HG, 2003, PLANT J, V35, P362, DOI 10.1046/j.1365-313X.2003.01812.x
   Kang HG, 2000, PLANT J, V21, P329, DOI 10.1046/j.1365-313x.2000.00678.x
   Kaul S, 2000, NATURE, V408, P796
   Kim HS, 2010, PLANT J, V64, P524, DOI 10.1111/j.1365-313X.2010.04346.x
   Konishi M, 2007, PLANT PHYSIOL BIOCH, V45, P623, DOI 10.1016/j.plaphy.2007.05.001
   Krohn NM, 2002, J BIOL CHEM, V277, P32438, DOI 10.1074/jbc.M203814200
   Kushwaha H, 2011, MOL BIOL REP, V38, P5037, DOI 10.1007/s11033-010-0650-9
   Lavin M, 2005, SYST BIOL, V54, P575, DOI 10.1080/10635150590947131
   Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088
   Librado P, 2009, BIOINFORMATICS, V25, P1451, DOI 10.1093/bioinformatics/btp187
   Lijavetzky D, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-17
   Liu Y, 2011, PLANT GROWTH REGUL, V63, P225, DOI 10.1007/s10725-010-9519-0
   Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151
   Mochida K, 2010, BIOINFORMATICS, V26, P290, DOI 10.1093/bioinformatics/btp645
   Moreno-Risueno MA, 2007, MOL GENET GENOMICS, V277, P379, DOI 10.1007/s00438-006-0186-9
   Negi J, 2013, CURR BIOL, V23, P479, DOI 10.1016/j.cub.2013.02.001
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   Papi M, 2000, GENE DEV, V14, P28
   Park DH, 2003, PLANT J, V34, P161, DOI 10.1046/j.0960-7412.2003.001605.x
   Plesch G, 2001, PLANT J, V28, P455, DOI 10.1046/j.1365-313X.2001.01166.x
   Qu LJ, 2006, CURR OPIN PLANT BIOL, V9, P544, DOI 10.1016/j.pbi.2006.07.005
   Quevillon E, 2005, NUCLEIC ACIDS RES, V33, pW116, DOI 10.1093/nar/gki442
   Riano-Pachon DM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-42
   Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105
   Schlueter JA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-330
   Schmutz J, 2010, NATURE, V463, P178, DOI 10.1038/nature08670
   Shaw LM, 2009, FUNCT INTEGR GENOMIC, V9, P485, DOI 10.1007/s10142-009-0130-2
   Skirycz A, 2008, PLANT J, V56, P779, DOI 10.1111/j.1365-313X.2008.03641.x
   Stormo GD, 2000, GENOME RES, V10, P394, DOI 10.1101/gr.10.4.394
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tavazoie S, 1999, NAT GENET, V22, P281
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tian AG, 2004, THEOR APPL GENET, V108, P903, DOI 10.1007/s00122-003-1499-2
   Tuskan GA, 2006, SCIENCE, V313, P1596, DOI 10.1126/science.1128691
   Wang HW, 2007, PLANT J, V52, P716, DOI 10.1111/j.1365-313X.2007.03268.x
   Ward JM, 2005, PLANT CELL, V17, P475, DOI 10.1105/tpc.104.027722
   Washio K, 2003, PLANT PHYSIOL, V133, P850, DOI 10.1104/pp.103.027334
   Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315
   Wei PC, 2010, PLANT PHYSIOL, V153, P1031, DOI 10.1104/pp.110.153247
   Yanagisawa S, 2004, P NATL ACAD SCI USA, V101, P7833, DOI 10.1073/pnas.0402267101
   Yanagisawa S, 2004, PLANT CELL PHYSIOL, V45, P386, DOI 10.1093/pcp/pch055
   Yanagisawa S, 1998, PLANT CELL, V10, P75, DOI 10.1105/tpc.10.1.75
   Yanagisawa S, 1997, EUR J BIOCHEM, V250, P403, DOI 10.1111/j.1432-1033.1997.0403a.x
   Yanagisawa S, 2000, PLANT J, V21, P281, DOI 10.1046/j.1365-313x.2000.00685.x
   Yanagisawa S, 2002, TRENDS PLANT SCI, V7, P555, DOI 10.1016/S1360-1385(02)02362-2
   Yang XH, 2006, PLANT PHYSIOL, V142, P820, DOI 10.1104/pp.106.083642
   Zhang H, 2011, NUCLEIC ACIDS RES, V39, pD1114, DOI 10.1093/nar/gkq1141
NR 65
TC 37
Z9 44
U1 1
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2013
VL 8
IS 9
AR e76809
DI 10.1371/journal.pone.0076809
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 231NL
UT WOS:000325423500178
PM 24098807
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Singhal, RK
   Samariya, A
   Kumar, S
   Xing, YT
   Jain, DC
   Dolia, SN
   Deshpande, UP
   Shripathi, T
   Saitovitch, EB
AF Singhal, R. K.
   Samariya, Arvind
   Kumar, Sudhish
   Xing, Y. T.
   Jain, D. C.
   Dolia, S. N.
   Deshpande, U. P.
   Shripathi, T.
   Saitovitch, Elisa B.
TI RETRACTED: Study of defect-induced ferromagnetism in hydrogenated
   anatase TiO2:Co (vol 107, 113916, 2010) (Retracted article. See vol.
   116, 059902, 2014)
SO JOURNAL OF APPLIED PHYSICS
LA English
DT Correction; Retracted Publication
C1 [Singhal, R. K.; Samariya, Arvind; Jain, D. C.; Dolia, S. N.] Univ Rajasthan, Dept Phys, Jaipur 302055, Rajasthan, India.
   [Kumar, Sudhish] ML Sukhadia Univ, Dept Phys, Udaipur 313002, India.
   [Xing, Y. T.; Saitovitch, Elisa B.] CBPF, BR-22290180 Rio De Janeiro, Brazil.
   [Deshpande, U. P.; Shripathi, T.] UGC DAE CSR, Indore 452001, India.
RP Singhal, RK (reprint author), Univ Rajasthan, Dept Phys, Jaipur 302055, Rajasthan, India.
EM Singhal46@yahoo.co.in
CR Singhal RK, 2010, J APPL PHYS, V107, DOI 10.1063/1.3431396
NR 1
TC 2
Z9 2
U1 4
U2 34
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-8979
EI 1089-7550
J9 J APPL PHYS
JI J. Appl. Phys.
PD SEP 28
PY 2013
VL 114
IS 12
AR 129902
DI 10.1063/1.4824175
PG 1
WC Physics, Applied
SC Physics
GA 231CR
UT WOS:000325391100085
DA 2018-12-27
ER

PT J
AU Ghaffari, M
   Zhou, Y
   Xu, HP
   Lin, MR
   Kim, TY
   Ruoff, RS
   Zhang, QM
AF Ghaffari, Mehdi
   Zhou, Yue
   Xu, Haiping
   Lin, Minren
   Kim, Tae Young
   Ruoff, Rodney S.
   Zhang, Q. M.
TI RETRACTED: High-Volumetric Performance Aligned Nano-Porous Microwave
   Exfoliated Graphite Oxide-based Electrochemical Capacitors (Retracted
   article. See vol. 28, pg. 9453, 2016)
SO ADVANCED MATERIALS
LA English
DT Article; Retracted Publication
DE nano-porous microwave exfoliated graphite oxide (aMEGO); supercapacitor;
   volumetric performance; ionic liquid; high density aMEGO (A-aMEGO)
ID DOUBLE-LAYER CAPACITORS; WALLED CARBON NANOTUBES; ENERGY DENSITY;
   SUPERCAPACITOR ELECTRODES; IMPEDANCE SPECTROSCOPY; COMPOSITE ELECTRODES;
   ACTIVATED CARBONS; PORE-SIZE; GRAPHENE; STORAGE
C1 [Zhou, Yue; Zhang, Q. M.] Penn State Univ, Dept Elect Engn, Mat Res Inst, University Pk, PA 16802 USA.
   [Ghaffari, Mehdi] Penn State Univ, Dept Mat Sci & Engn, Mat Res Inst, University Pk, PA 16802 USA.
   [Xu, Haiping] Shanghai Second Polytech Univ, Sch Urban Dev & Environm Engn, Shanghai 201209, Peoples R China.
   [Lin, Minren] Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA.
   [Kim, Tae Young; Ruoff, Rodney S.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA.
   [Kim, Tae Young; Ruoff, Rodney S.] Univ Texas Austin, Mat Sci & Engn Program, Austin, TX 78712 USA.
RP Zhang, QM (reprint author), Penn State Univ, Dept Elect Engn, Mat Res Inst, University Pk, PA 16802 USA.
EM Qxz1@psu.edu
RI Zhou, Yue/J-4524-2014; Mohd Jasni, Mohamad Redwani/E-7555-2015; Ruoff,
   Rodney/K-3879-2015
OI Zhou, Yue/0000-0003-3894-4130; Mohd Jasni, Mohamad
   Redwani/0000-0003-4036-4856; 
FU NSF [CMMI-1130437]; AFOSR [FA9550-11-1-0192]; U.S. Department of Energy
   (DOE) [DE-SC0001951]
FX The work at Penn State was supported by NSF under grant number
   CMMI-1130437(MG) and AFOSR under grant number FA9550-11-1-0192 (YZ, ML
   and QMZ). RSR appreciates support from the U.S. Department of Energy
   (DOE) under award DE-SC0001951.
CR Barbieri O, 2005, CARBON, V43, P1303, DOI 10.1016/j.carbon.2005.01.001
   Burke A, 2007, ELECTROCHIM ACTA, V53, P1083, DOI 10.1016/j.electacta.2007.01.011
   Chen PC, 2010, ACS NANO, V4, P4403, DOI 10.1021/nn100856y
   Cheng Q, 2011, PHYS CHEM CHEM PHYS, V13, P17615, DOI 10.1039/c1cp21910c
   Cheng Q, 2011, CARBON, V49, P2917, DOI 10.1016/j.carbon.2011.02.068
   Chmiola J, 2010, SCIENCE, V328, P480, DOI 10.1126/science.1184126
   Chu BJ, 2006, SCIENCE, V313, P334, DOI 10.1126/science.1127798
   Conway B. E., 1999, ELECTROCHEMICAL SUPE
   Frackowiak E, 2002, CARBON, V40, P1775, DOI 10.1016/S0008-6223(02)00045-3
   Frackowiak E, 2001, CARBON, V39, P937, DOI 10.1016/S0008-6223(00)00183-4
   Frackowiak E, 2000, APPL PHYS LETT, V77, P2421, DOI 10.1063/1.1290146
   Futaba DN, 2006, NAT MATER, V5, P987, DOI 10.1038/nmat1782
   Gogotsi Y, 2011, SCIENCE, V334, P917, DOI 10.1126/science.1213003
   Izadi-Najafabadi A, 2010, ADV MATER, V22, pE235, DOI 10.1002/adma.200904349
   Janes A, 2004, SURF SCI, V560, P145, DOI 10.1016/j.susc.2004.04.026
   Kim TY, 2011, ACS NANO, V5, P436, DOI 10.1021/nn101968p
   Lajnef W, 2007, J POWER SOURCES, V168, P553, DOI 10.1016/j.jpowsour.2007.02.049
   Liang QZ, 2011, ACS NANO, V5, P2392, DOI 10.1021/nn200181e
   Lin R, 2009, J ELECTROCHEM SOC, V156, pA7, DOI 10.1149/1.3002376
   Liu CG, 2010, NANO LETT, V10, P4863, DOI 10.1021/nl102661q
   Liu Y, 2012, SENSOR ACTUAT A-PHYS, V181, P70, DOI 10.1016/j.sna.2012.05.002
   Miller JR, 2008, SCIENCE, V321, P651, DOI 10.1126/science.1158736
   Murali S., 2013, NANO ENERGY, DOI 10.1016/j.nanoen.2013.01.007
   Obreja VVN, 2008, PHYSICA E, V40, P2596, DOI 10.1016/j.physe.2007.09.044
   Peng C, 2010, ENERG ENVIRON SCI, V3, P1499, DOI 10.1039/c0ee00228c
   Pumera M, 2011, ENERG ENVIRON SCI, V4, P668, DOI 10.1039/c0ee00295j
   Qu DY, 1998, J POWER SOURCES, V74, P99, DOI 10.1016/S0378-7753(98)00038-X
   Segalini J, 2010, ELECTROCHIM ACTA, V55, P7489, DOI 10.1016/j.electacta.2010.01.003
   Simon P., 2012, ACCOUNTS CHEM RES
   Simon P, 2008, NAT MATER, V7, P845, DOI 10.1038/nmat2297
   Song HK, 1999, ELECTROCHIM ACTA, V44, P3513, DOI 10.1016/S0013-4686(99)00121-8
   Srinivas G, 2012, ENERG ENVIRON SCI, V5, P6453, DOI 10.1039/c2ee21100a
   Stoller MD, 2008, NANO LETT, V8, P3498, DOI 10.1021/nl802558y
   Stoller MD, 2011, ENERG ENVIRON SCI, V4, P4685, DOI 10.1039/c1ee02322e
   Sun YQ, 2011, ENERG ENVIRON SCI, V4, P1113, DOI 10.1039/c0ee00683a
   Taberna PL, 2003, J ELECTROCHEM SOC, V150, pA292, DOI 10.1149/1.1543948
   Wang DW, 2009, ACS NANO, V3, P1745, DOI 10.1021/nn900297m
   Wang Y, 2009, J PHYS CHEM C, V113, P13103, DOI 10.1021/jp902214f
   Wu ZS, 2010, ACS NANO, V4, P5835, DOI 10.1021/nn101754k
   Zhang JT, 2011, ENERG ENVIRON SCI, V4, P4009, DOI 10.1039/c1ee01354h
   Zhu YW, 2011, SCIENCE, V332, P1537, DOI 10.1126/science.1200770
   Zhu Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2234
NR 42
TC 84
Z9 84
U1 6
U2 263
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD SEP 20
PY 2013
VL 25
IS 35
BP 4879
EP 4885
DI 10.1002/adma.201301243
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 261VN
UT WOS:000327692800007
PM 23946189
DA 2018-12-27
ER

PT J
AU Wang, SB
   Liu, DB
   Mao, BQ
AF Wang, Shi-bo
   Liu, Dong-bing
   Mao, Bing-quan
TI RETRACTED: THE MECHANISM OF FORMING BIMODAL POLYETHYLENE BY BIS (IMINO)
   PYRIDYL IRON (II) PRECATALYST WITH TRIETHYLALUMINUM (Retracted article.
   See iss 12, Dec 20 2013)
SO ACTA POLYMERICA SINICA
LA Chinese
DT Article; Retracted Publication
DE Catalyst; Iron; Polymerization; Polyethylene (PE)
ID ETHYLENE POLYMERIZATION; CATALYST; COMPLEX; ACTIVATORS
AB The iron complex LFeCl2 (1) (L = 2, 6-bis [(2, 4, 6-trimethylphenylimino) ethyl] pyridine) / triethylaluminum (TEA) catalyzed ethylene polymerization under different conditions. Bimodal polyethylene (PE),which had different molecular weights and molecular weight distributions (MWD),was prepared under various polymerization temperatures and the molar ratios of Al/Fe. The catalytic system had high activity of the ethylene polymerization and the produced polyethylene always had special molecular structure with the molecular weight distribution of two peaks by the GPC. Then the catalytic system was characterized through the in situ UV-Vis absorption spectra. A new applicable mechanism was proposed with the combination of the UV-Vis and the GPC results. There were two different kinds of catalytic species in the catalytic system at the same time. The distinctive behaviors of the catalytic system could result from the two different kinds of catalytic species that formed the bimodal PE. The two kinds of catalytic species had different structures and had some relationship. One kind of catalytic species produced the large molecular weight section of the bimodal PE, the other kind of catalytic species produced the small molecular weight section of the bimodal PE. The two kinds of catalytic species could transform each other under different conditions, which would benefit the production of the PE with different chain structures.
C1 [Wang, Shi-bo; Liu, Dong-bing; Mao, Bing-quan] Sinopec Beijing Res Inst Chem Ind, Polyolefins Natl Engn & Res Ctr, Beijing 100013, Peoples R China.
RP Wang, SB (reprint author), Sinopec Beijing Res Inst Chem Ind, Polyolefins Natl Engn & Res Ctr, Beijing 100013, Peoples R China.
EM wangsb.bjhy@sinopec.com
CR Britovsek GJP, 1999, J AM CHEM SOC, V121, P8728, DOI 10.1021/ja990449w
   Bryliakov KP, 2004, ORGANOMETALLICS, V23, P5375, DOI 10.1021/om0497184
   Chen Huilin, 1997, ORGANOTRANSITION MET, p203~205
   Gorl C, 2011, APPL CATAL A-GEN, V403, P25, DOI 10.1016/j.apcata.2011.06.010
   Guo LH, 2010, ORGANOMETALLICS, V29, P2118, DOI 10.1021/om9010356
   Karpiniec SS, 2012, ORGANOMETALLICS, V31, P3439, DOI 10.1021/om300084s
   Lu Xiyan, 1997, ORGANOTRANSITION MET, p16~22
   Luo HK, 2002, J MOL CATAL A-CHEM, V177, P195, DOI 10.1016/S1381-1169(01)00275-8
   Mao Bingquan, 2003, PETROCHEMICAL TECH S, V32, p525~527
   Martinez J, 2008, J PHYS CHEM C, V112, P5023, DOI 10.1021/jp7106439
   Radhakrishnan K, 2003, MACROMOL RAPID COMM, V24, P251, DOI 10.1002/marc.200390036
   Small BL, 1998, J AM CHEM SOC, V120, P4049, DOI 10.1021/ja9802100
   Song SJ, 2011, INORG CHIM ACTA, V376, P373, DOI 10.1016/j.ica.2011.06.037
   Talsi EP, 2001, MACROMOL CHEM PHYSIC, V202, P2046, DOI 10.1002/1521-3935(20010601)202:10<2046::AID-MACP2046>3.0.CO;2-3
   Wang Q, 2002, MACROMOL RAPID COMM, V23, P639, DOI 10.1002/1521-3927(20020701)23:10/11<639::AID-MARC639>3.0.CO;2-A
   Zhao WZ, 2012, POLYMER, V53, P130, DOI [10.1016/j.Polymer.2011.11.024, 10.1016/j.polymer.2011.11.024]
NR 16
TC 1
Z9 1
U1 7
U2 18
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1000-3304
J9 ACTA POLYM SIN
JI Acta Polym. Sin.
PD SEP 20
PY 2013
IS 9
BP 1172
EP 1176
DI 10.3724/SP.J.1105.013.12396
PG 5
WC Polymer Science
SC Polymer Science
GA 252KQ
UT WOS:000327004000008
DA 2018-12-27
ER

PT J
AU Szpakowicz, A
   Pepinski, W
   Waszkiewicz, E
   Maciorkowska, D
   Skawronska, M
   Niemcunowicz-Janica, A
   Milewski, R
   Dobrzycki, S
   Musial, WJ
   Kaminski, KA
AF Szpakowicz, Anna
   Pepinski, Witold
   Waszkiewicz, Ewa
   Maciorkowska, Dominika
   Skawronska, Malgorzata
   Niemcunowicz-Janica, Anna
   Milewski, Robert
   Dobrzycki, Slawomir
   Musial, Wlodzimierz Jerzy
   Kaminski, Karol Adam
TI RETRACTED: Polymorphism of 9p21.3 Locus Is Associated with 5-Year
   Survival in High-Risk Patients with Myocardial Infarction (Retracted
   article. See vol. 9, e95513, 2014)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID GENOME-WIDE ASSOCIATION; CORONARY-ARTERY-DISEASE; CHROMOSOME 9P21;
   VARIANTS; ONSET; MORTALITY; REGISTRY; DEATH
AB Objective: The rs1333049, rs10757278 and rs4977574 are single nucleotide polymorphisms (SNPs) of chromosome 9p21 locus that are associated with prevalence of acute coronary syndromes (ACS). The rs1333049 SNP was also associated with cardiac outcome 6 months post ACS. No data concerning their association with long term prognosis after myocardial infarction is available. The aim of our study was to investigate the association of the 9p21.3 locus with 5-year overall mortality in patients with ST-elevation myocardial infarction (STEMI) treated invasively.
   Materials and Methods: We performed a retrospective analysis of data collected prospectively in a registry of consecutive patients with STEMI treated with primary PCI. Genotyping was performed with a TaqMan method. The analyzed end-point was total 5-year mortality.
   Results: The study group comprised 589 patients: 25.3% of females (n = 149), mean age 62.4 +/- 11.9 years, total 5-year mortality 16.6% (n = 98). When all the study group was analyzed, no significant differences in mortality were found between the genotypes. However, in high-risk patients (Grace risk score >= 155 points, n = 238), low-risk homozygotes had significantly better 5-year survival compared to other genotypes. The hazard ratio associated with high-risk genotype (high-risk homozygote or heterozygote) was: HR = 2.9 (95% CI 1.4-6.1) for the rs4977574 polymorphism, HR = 2.6 (1.25-5.3) for the rs1333049 one and HR = 2.35 (1.2-4.6) for the rs10757278 one (Cox proportional hazards model).
   Conclusions: The 9p21.3 locus is associated with 5-year mortality in high-risk patients with STEMI. This finding, due to very high effect size, could potentially be applied into clinical practice, if appropriate methods are elaborated.
C1 [Szpakowicz, Anna; Waszkiewicz, Ewa; Musial, Wlodzimierz Jerzy; Kaminski, Karol Adam] Med Univ Bialystok, Dept Cardiol, Bialystok, Poland.
   [Pepinski, Witold; Skawronska, Malgorzata; Niemcunowicz-Janica, Anna] Med Univ Bialystok, Dept Forens Med, Bialystok, Poland.
   [Maciorkowska, Dominika; Dobrzycki, Slawomir] Med Univ Bialystok, Dept Invas Cardiol, Bialystok, Poland.
   [Milewski, Robert] Med Univ Bialystok, Dept Stat & Med Informat, Bialystok, Poland.
RP Kaminski, KA (reprint author), Med Univ Bialystok, Dept Cardiol, Bialystok, Poland.
EM fizklin@wp.pl
RI Milewski, Robert/S-6539-2018; Skawronska, Malgorzata/U-9251-2018;
   Szpakowicz, Anna/T-4059-2018; Tarasiuk, Ewa/Y-1757-2018; Pepinski,
   Witold/U-9250-2018
OI Milewski, Robert/0000-0001-6241-8283; Skawronska,
   Malgorzata/0000-0002-1237-4240; Szpakowicz, Anna/0000-0002-4665-5227;
   Tarasiuk, Ewa/0000-0002-0614-1352; Pepinski, Witold/0000-0003-1244-2247;
   Kaminski, Karol/0000-0002-9465-2581; Niemcunowicz-Janica,
   Anna/0000-0003-2807-8312
FU National Science Center, Poland [N N 402 529139]
FX This work was supported by National Science Center, Poland [N N 402
   529139]. The funder had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ardissino D, 2011, J AM COLL CARDIOL, V58, P426, DOI 10.1016/j.jacc.2010.11.075
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Butterworth AS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002260
   Buysschaert I, 2010, EUR HEART J, V31, P1132, DOI 10.1093/eurheartj/ehq053
   CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27
   CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824
   Cugino D, 2012, NUTR METAB CARDIOVAS, V22, P619, DOI 10.1016/j.numecd.2010.11.010
   Ellis KL, 2010, CIRC-CARDIOVASC GENE, V3, P286, DOI 10.1161/CIRCGENETICS.109.917443
   Gioli-Pereira L, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-61
   Granger CB, 2003, ARCH INTERN MED, V163, P2345, DOI 10.1001/archinte.163.19.2345
   Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842
   Kalinina N, 2004, ARTERIOSCL THROM VAS, V24, P1391, DOI 10.1161/01.ATV.0000133605.89421.79
   Kathiresan S, 2009, NAT GENET, V41, P334, DOI 10.1038/ng.327
   Koch W, 2011, ATHEROSCLEROSIS, V217, P220, DOI 10.1016/j.atherosclerosis.2011.03.014
   Lee JY, 2013, J HUM GENET, V58, P120, DOI 10.1038/jhg.2012.124
   Nambi V, 2012, ATHEROSCLEROSIS, V222, P135, DOI 10.1016/j.atherosclerosis.2012.01.028
   Newton-Cheh C, 2009, CIRCULATION, V120, P2062, DOI 10.1161/CIRCULATIONAHA.109.879049
   O'Donnell CJ, 2011, CIRCULATION, V124, P2855, DOI 10.1161/CIRCULATIONAHA.110.974899
   Patel RS, 2010, EUR HEART J, V31, P3017, DOI 10.1093/eurheartj/ehq272
   Peng WH, 2009, CLIN CHEM LAB MED, V47, P917, DOI 10.1515/CCLM.2009.215
   Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEMJoa072366
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Scheffold T, 2011, BMC CARDIOVASC DISOR, V11, DOI 10.1186/1471-2261-11-9
   Schmid M, 2000, ONCOGENE, V19, P5747, DOI 10.1038/sj.onc.1203942
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Takeuchi F, 2012, EUR J HUM GENET, V20, P333, DOI 10.1038/ejhg.2011.184
   Wang W, 2011, CHINESE MED J-PEKING, V124, P66, DOI 10.3760/cma.j.issn.0366-6999.2011.01.013
   Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364
   Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693
NR 29
TC 5
Z9 5
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2013
VL 8
IS 9
AR e72333
DI 10.1371/journal.pone.0072333
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 242KO
UT WOS:000326240100005
PM 24069144
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Liu, ZC
   Zhang, WY
   Fan, SJ
   Wang, L
   Jiao, L
AF Liu, Zhongchao
   Zhang, Wenyi
   Fan, Saijun
   Wang, Liang
   Jiao, Ling
TI RETRACTED: Changes in the electron paramagnetic resonance spectra of
   albumin-associated spin-labeled stearic acid as a diagnostic parameter
   of colorectal cancer (Retracted article. See vol. 14, pg. 156, 2016)
SO WORLD JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE Colorectal cancer; Discriminant analysis; EPR/ESR; Spin probe
ID HUMAN SERUM-ALBUMIN; BINDING-SITES; FATTY-ACIDS; REVEALS
AB Background: With more than 940,000 new colorectal cancer cases worldwide each year, there is no better way for colorectal cancer routine screening. The aim of this study was to investigate whether the fatty acid binding to albumin is detectably and significantly altered in colorectal cancer patients when compared with healthy people, in order to find a better way for colorectal cancer diagnosis.
   Methods: One hundred and forty-one patients operatively treated for colorectal cancer were included in the examination, and 180 healthy people were also enrolled as controls. Commercial 16-doxyl stearic acid was used as spin probe. Serum albumin was analyzed by electron paramagnetic resonance (EPR) with spin probe. Discriminant analysis was carried out using the measured EPR spectra by SPSS 20.0.
   Results: Of the original grouped cases, 89.4% were correctly classified. Of the cross-validated grouped cases, 86.9% were correctly classified. Using Fisher linear discriminant analysis we were able to develop a mathematical model allowing for identification of colorectal cancer patients based on five values (both relative intensity and peak width) which are obtained from the EPR spectrum.
   Conclusions: Cancer-associated alterations to albumin can be assessed by spin-label EPR. The potential applications for this diagnostic technique are significant and represent a cost-effective means for screening patients with cancer. Spin probe for diagnosis of colorectal cancer might be a useful tool and further studies should take place in order to investigate all stages of colorectal cancer patients.
C1 [Jiao, Ling] Chinese Acad Med Sci, Inst Radiat Med, Dept Radiat Protect Ctr, Tianjin 300192, Peoples R China.
   Peking Union Med Coll, Tianjin Key Lab Mol Nucl Med, Tianjin 300192, Peoples R China.
RP Jiao, L (reprint author), Chinese Acad Med Sci, Inst Radiat Med, Dept Radiat Protect Ctr, 238 Baidi Rd, Tianjin 300192, Peoples R China.
EM ljiao.irm@163.com
CR Berezin MY, 2007, PHOTOCHEM PHOTOBIOL, V83, P1371, DOI 10.1111/j.1751-1097.2007.00173.x
   Bhattacharya AA, 2000, J MOL BIOL, V303, P721, DOI 10.1006/jmbi.2000.4158
   Chalya PL, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-88
   Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869
   de Noo ME, 2006, EUR J CANCER, V42, P1068, DOI 10.1016/j.ejca.2005.12.023
   Duffy MJ, 2007, EUR J CANCER, V43, P1348, DOI 10.1016/j.ejca.2007.03.021
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Gammerman A, 2008, STAT APPL GENET MOL, V7
   GE MT, 1990, BIOCHIM BIOPHYS ACTA, V1036, P228
   Gelos M, 2010, INT J COLORECTAL DIS, V25, P119, DOI 10.1007/s00384-009-0777-0
   Gurachevsky A, 2007, P INT SOC MAGN RESON, V15, P1323
   Gurachevsky A, 2008, CLIN CHEM LAB MED, V46, P1203, DOI 10.1515/CCLM.2008.260
   Kalnina I, 2010, CANCER BIOMARK, V7, P91, DOI 10.3233/CBM-2010-0151
   Kazmierczak SC, 2006, CLIN CHEM, V52, P2129, DOI 10.1373/clinchem.2006.073148
   Kurtzhals P, 1995, BIOCHEM J, V312, P725, DOI 10.1042/bj3120725
   Mehta AI, 2003, DIS MARKERS, V19, P1
   Peters T., 1995, ALL ALBUMIN BIOCH GE
   Rhodes Christopher J., 2011, Science Progress, V94, P16, DOI 10.3184/003685011X12982218769939
   Seidel Peter, 2005, Z Med Phys, V15, P265
NR 19
TC 3
Z9 3
U1 3
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7819
J9 WORLD J SURG ONCOL
JI World J. Surg. Oncol.
PD SEP 11
PY 2013
VL 11
AR 223
DI 10.1186/1477-7819-11-223
PG 5
WC Oncology; Surgery
SC Oncology; Surgery
GA 217AG
UT WOS:000324328100001
PM 24025321
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wang, LS
   Zang, WD
   Xie, DL
   Ji, WD
   Pan, YS
   Li, ZQ
   Shen, JW
   Shi, YY
AF Wang, Lishan
   Zang, Weidong
   Xie, Dongli
   Ji, Weidong
   Pan, Yaosheng
   Li, Zhiqiang
   Shen, Jiawei
   Shi, Yongyong
TI RETRACTED: Drug-Eluting Stents for Acute Coronary Syndrome: A
   Meta-Analysis of Randomized Controlled Trials (Retracted article. See
   vol. 11, e0160297, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ACUTE MYOCARDIAL-INFARCTION; ARTERY-DISEASE; PACLITAXEL; METAANALYSIS;
   EFFICACY; SAFETY; REVASCULARIZATION; INTERVENTION
AB Background: Drug-eluting stents (DES) are increasingly used for treatment of acute coronary syndrome (ACS). However, clinical efficacy and safety of various types of DES is not well established in these subjects. We therefore evaluated clinical utility of second-generation and first-generation DES in patients with ACS by conducting a meta-analysis.
   Methods: A search of Medline, Embase, the Cochrane databases, and Web of Science was made. Randomized controlled trials (RCTs) which compared second-generation DES (everolimus-eluting stents [EES] or zotarolimus-eluting stents [ZES]) versus first-generation DES (sirolimus-eluting stents [SES] or paclitaxe-eluting stents [PES]) in patients with ACS and provided data on clinical efficacy or safety endpoints were included. Pooled estimates were calculated using random-effects model.
   Result: A total of 2,757 participants with ACS in 6 RCTs were included. Compared with first-generation one, second-generation DES trended to be associated with the decreased incidence of definite or probable stent thrombosis in ACS patients (risk ratio [RR] = 0.60, 95% confidence intervals [CI] 0.33 to 1.07, p = 0.09). However, the rate of target lesion revascularization (TLR) significantly increased in second-generation DES (RR = 2.08, 95% CI 1.25 to 3.47, p = 0.005). There were no significant differences in the incidence of major adverse cardiac events (MACEs), all-cause death, cardiac death, and recurrent myocardial infarction between the two arms (all p > 0.10). The second-generation EES showed a tendency towards lower risk of MACEs (p = 0.06) and a beneficial effect on reducing stent thrombosis episodes (p = 0.009), while the second-generation ZES presented an increased occurrence of MACEs (p = 0.02) and TLR (p = 0.003).
   Conclusion: Second-generation DES, especially EES, appeared to present a lower risk of stent thrombosis, whereas second-generation ZES might increase the need for repeat revascularization in ACS patients. During coronary interventional therapy, DES class should be adequately considered in order to maximize clinical benefit of DES implantation in these specific subjects.
C1 [Wang, Lishan; Ji, Weidong; Pan, Yaosheng; Li, Zhiqiang; Shen, Jiawei; Shi, Yongyong] Shanghai Jiao Tong Univ, Minist Educ, Bio Inst X, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China.
   [Wang, Lishan; Zang, Weidong; Xie, Dongli] FengHe ShangHai Informat Technol Co Ltd, Shanghai, Peoples R China.
   [Ji, Weidong; Pan, Yaosheng; Shi, Yongyong] Shanghai Changning Mental Hlth Ctr, Shanghai, Peoples R China.
   [Ji, Weidong; Pan, Yaosheng; Shi, Yongyong] Shanghai Jiao Tong Univ, Inst Neuropsychiat Sci & Syst Biol Med, Shanghai 200030, Peoples R China.
RP Shi, YY (reprint author), Shanghai Jiao Tong Univ, Minist Educ, Bio Inst X, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China.
EM shiyongyong@gmail.com
FU Natural Science Foundation of China [81130022, 81272302, 31000553,
   81121001]; National 863 project [2012AA02A515]; 973 Program
   [2010CB529600]; Program for Changjiang Scholars and Innovative Research
   Team in University [IRT1025]; Foundation for the Author of National
   Excellent Doctoral Dissertation of China [201026]; Shanghai Municipal
   Education Commission and Shanghai Education Development Foundation
   [12SG17]; Shanghai Rising-Star Program [12QA1401900]
FX This work was supported by the Natural Science Foundation of China
   (81130022, 81272302, 31000553, 81121001), the National 863 project
   (2012AA02A515), the 973 Program (2010CB529600), Program for Changjiang
   Scholars and Innovative Research Team in University (IRT1025) the
   Foundation for the Author of National Excellent Doctoral Dissertation of
   China (201026), the "Shu Guang'' project supported by Shanghai Municipal
   Education Commission and Shanghai Education Development Foundation
   (12SG17), and Shanghai Rising-Star Program (12QA1401900). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alazzoni A, 2012, THROMBOSIS
   Choi CU, 2009, CIRC J, V73, P2229, DOI 10.1253/circj.CJ-08-1086
   Chung WY, 2012, CHINESE MED J-PEKING, V125, P3373, DOI 10.3760/cma.j.issn.0366-6999.2012.19.003
   De Luca G, 2012, ARCH INTERN MED, V172, P611, DOI 10.1001/archinternmed.2012.758
   Di Lorenzo E, 2009, JACC-CARDIOVASC INTE, V2, P515, DOI 10.1016/j.jcin.2009.03.012
   Greenhalgh J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004587.pub2
   Hofma SH, 2012, J AM COLL CARDIOL, V60, P381, DOI 10.1016/j.jacc.2012.01.073
   Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kandzari DE, 2006, J AM COLL CARDIOL, V48, P2440, DOI 10.1016/j.jacc.2006.08.035
   Kang WC, 2011, EUROINTERVENTION, V7, P936, DOI 10.4244/EIJV7I8A148
   Kedhi E, 2010, LANCET, V375, P201, DOI 10.1016/S0140-6736(09)62127-9
   Kim HK, 2010, AM J CARDIOL, V105, P813, DOI 10.1016/j.amjcard.2009.11.009
   Lee CW, 2009, AM J CARDIOL, V104, P1370, DOI 10.1016/j.amjcard.2009.06.059
   Martin-Reyes R, 2012, INT J CARDIOL, V160, P181, DOI 10.1016/j.ijcard.2011.04.004
   Palmerini T, 2012, LANCET, V379, P1393, DOI 10.1016/S0140-6736(12)60324-9
   Park DW, 2010, J AM COLL CARDIOL, V56, P1187, DOI 10.1016/j.jacc.2010.03.086
   Pfisterer M, 2006, J AM COLL CARDIOL, V48, P2584, DOI 10.1016/j.jacc.2006.10.026
   Sabate M, 2012, LANCET, V380, P1482, DOI 10.1016/S0140-6736(12)61223-9
   Sawada T, 2013, INT J CARDIOL, V168, P960, DOI 10.1016/j.ijcard.2012.10.043
   Stone GW, 2007, NEW ENGL J MED, V356, P998, DOI 10.1056/NEJMoa067193
   Stone GW, 2010, NEW ENGL J MED, V362, P1663, DOI 10.1056/NEJMoa0910496
   Stone GW, 2009, NEW ENGL J MED, V360, P1946, DOI 10.1056/NEJMoa0810116
   Tada T, 2013, AM HEART J, V165, P80, DOI 10.1016/j.ahj.2012.10.019
   Thim T, 2012, EUR J CLIN INVEST, V42, P1047, DOI 10.1111/j.1365-2362.2012.02692.x
   Valgimigli M, 2005, JAMA-J AM MED ASSOC, V293, P2109, DOI 10.1001/jama.293.17.2109
   Zhang SN, 2011, AM J CARDIOL, V108, P1207, DOI 10.1016/j.amjcard.2011.06.035
NR 27
TC 4
Z9 4
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 5
PY 2013
VL 8
IS 9
AR e72895
DI 10.1371/journal.pone.0072895
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219CG
UT WOS:000324481600041
PM 24039815
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Berthier, A
   Jimenez-Sainz, J
   Pulido, R
AF Berthier, Arnaud
   Jimenez-Sainz, Judit
   Pulido, Rafael
TI RETRACTED: PINK1 regulates histone H3 trimethylation and gene expression
   by interaction with the polycomb protein EED/WAIT1 (Retracted article.
   See vol. 111, pg. 16225, 2014)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE cell differentiation; apoptosis
ID NF-KAPPA-B; PARKINSONS-DISEASE; MITOCHONDRIAL DYSFUNCTION; CELL
   DIFFERENTIATION; KINASE PINK1; PTEN; PHOSPHORYLATION; METHYLATION;
   COMPLEX; ROLES
AB Mutations in PTEN-induced putative kinase 1 (PINK1) gene are associated to early-onset recessive forms of Parkinson disease. PINK1 function is related to mitochondria homeostasis, but the molecular pathways in which PINK1 is involved are largely unknown. Here, we report the identification of the embryonic ectoderm development polycomb histone-methylation modulator (EED/WAIT1) as a PINK1-interacting and -regulated protein. The PINK1: EED/WAIT1 physical interaction was mediated by the PINK1 kinase domain and the EED/WAIT1 40 amino acid ending with tryptophan and aspartate (WD40)-repeat region, and PINK1 phosphorylated EED/WAIT1 in vitro. PINK1 associated with EED/WAIT1 in cells and relocated EED/WAIT1 to the mitochondria. This interaction reduced the trimethylation of lysine 27 from histone H3, which affected polycomb-regulated gene transcription during RA differentiation of SH-SY5Y human neuroblastoma cells. Our findings unveil a pathway by which PINK1 regulates histone methylation and gene expression through the polycomb repressor complex.
C1 [Berthier, Arnaud; Pulido, Rafael] CSIC, Inst Biomed Valencia, Valencia 46010, Spain.
   [Berthier, Arnaud; Jimenez-Sainz, Judit; Pulido, Rafael] Ctr Invest Principe Felipe, Valencia 46012, Spain.
   [Pulido, Rafael] Hosp Cruces, BioCruces Hlth Res Inst, Baracaldo 48903, Spain.
   [Pulido, Rafael] Ikerbasque, Bilbao 48011, Spain.
RP Berthier, A (reprint author), CSIC, Inst Biomed Valencia, Valencia 46010, Spain.
EM aberthier@ibv.csic.es; rafael.pulidomurillo@osakidetza.net
FU Fundacio Gent per Gent (Spain); Ministerio de Educacion y Ciencia
   (Spain) [SAF2009-10226]; Ministerio de Educacion y Ciencia (Fondo
   Europeo de Desarrollo Regional) [SAF2009-10226]; Fondo de
   Investigaciones Sanitarias-Instituto de Salud Carlos III-Ministerio de
   Sanidad (Spain)
FX We thank Pascual Sanz for his generous support, Celine Tarrega for
   critical reading of the manuscript and cooperation, and Isabel Rogla for
   expert technical assistance. This work was supported by a Fundacio Gent
   per Gent (Spain) Grant, Ministerio de Educacion y Ciencia (Spain and
   Fondo Europeo de Desarrollo Regional) Grant SAF2009-10226, and a
   fellowship from Fondo de Investigaciones Sanitarias-Instituto de Salud
   Carlos III-Ministerio de Sanidad (Spain) (to J.J.-S.).
CR Aldiri I, 2012, DEV BIOL, V367, P91, DOI 10.1016/j.ydbio.2012.04.030
   Andres-Pons A, 2012, CELL SIGNAL, V24, P577, DOI 10.1016/j.cellsig.2011.10.012
   Anichtchik O, 2008, J NEUROSCI, V28, P8199, DOI 10.1523/JNEUROSCI.0979-08.2008
   Beilina A, 2005, P NATL ACAD SCI USA, V102, P5703, DOI 10.1073/pnas.0500617102
   Berthier A, 2011, HUM PATHOL, V42, P75, DOI 10.1016/j.humpath.2010.05.016
   Billia F, 2011, P NATL ACAD SCI USA, V108, P9572, DOI 10.1073/pnas.1106291108
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chen Y, 2013, SCIENCE, V340, P471, DOI 10.1126/science.1231031
   Cheung P, 2005, MOL ENDOCRINOL, V19, P563, DOI 10.1210/me.2004-0496
   d'Amora M, 2011, J CHEM NEUROANAT, V41, P73, DOI 10.1016/j.jchemneu.2010.11.004
   Gandhi S, 2009, MOL CELL, V33, P627, DOI 10.1016/j.molcel.2009.02.013
   Han ZF, 2007, STRUCTURE, V15, P1306, DOI 10.1016/j.str.2007.08.007
   Haque ME, 2008, P NATL ACAD SCI USA, V105, P1716, DOI 10.1073/pnas.0705363105
   Hardy J, 2006, ANN NEUROL, V60, P389, DOI 10.1002/ana.21022
   Henn IH, 2007, J NEUROSCI, V27, P1868, DOI 10.1523/JNEUROSCI.5537-06.2007
   Kim Y, 2008, BIOCHEM BIOPH RES CO, V377, P975, DOI 10.1016/j.bbrc.2008.10.104
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Lee ER, 2007, STEM CELLS, V25, P2191, DOI 10.1634/stemcells.2007-0203
   Lesage Suzanne, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS66, DOI 10.1016/S1353-8020(11)70022-0
   Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Marongiu R, 2009, J NEUROCHEM, V108, P1561, DOI 10.1111/j.1471-4159.2009.05932.x
   Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837
   Mills RD, 2008, J NEUROCHEM, V105, P18, DOI 10.1111/j.1471-4159.2008.05249.x
   Montgomery ND, 2007, J MOL BIOL, V374, P1145, DOI 10.1016/j.jmb.2007.10.040
   Murata H, 2011, J BIOL CHEM, V286, P7182, DOI 10.1074/jbc.M110.179390
   Narendra DP, 2011, ANTIOXID REDOX SIGN, V14, P1929, DOI 10.1089/ars.2010.3799
   Ng J, 1997, MOL CELL BIOL, V17, P6663, DOI 10.1128/MCB.17.11.6663
   PAHLMAN S, 1995, EUR J CANCER, V31A, P453, DOI 10.1016/0959-8049(95)00033-F
   Pilsl A, 2012, ACTA NEUROPATHOL, V123, P173, DOI 10.1007/s00401-011-0902-3
   Plun-Favreau H, 2007, NAT CELL BIOL, V9, P1243, DOI 10.1038/ncb1644
   Prezioso C, 2011, FEBS LETT, V585, P2067, DOI 10.1016/j.febslet.2011.04.062
   Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172
   Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84
   Rietzler M, 1998, J BIOL CHEM, V273, P27459, DOI 10.1074/jbc.273.42.27459
   Sha D, 2010, HUM MOL GENET, V19, P352, DOI 10.1093/hmg/ddp501
   Shiba K, 2009, BIOCHEM BIOPH RES CO, V383, P331, DOI 10.1016/j.bbrc.2009.04.006
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Singer MS, 1998, GENETICS, V150, P613
   Svineng G, 2008, CONNECT TISSUE RES, V49, P197, DOI 10.1080/03008200802143166
   Tie F, 2005, BIOCHEM BIOPH RES CO, V332, P622, DOI 10.1016/j.bbrc.2005.04.157
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Weihofen A, 2009, BIOCHEMISTRY-US, V48, P2045, DOI 10.1021/bi8019178
   Witte V, 2004, MOL CELL, V13, P179, DOI 10.1016/S1097-2765(04)00004-8
   Xiao YT, 2011, INT J BIOCHEM CELL B, V43, P474, DOI 10.1016/j.biocel.2011.01.005
   Zhou C, 2008, P NATL ACAD SCI USA, V105, P12022, DOI 10.1073/pnas.0802814105
NR 48
TC 10
Z9 10
U1 2
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 3
PY 2013
VL 110
IS 36
BP 14729
EP 14734
DI 10.1073/pnas.1216844110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 211DY
UT WOS:000323886200056
PM 23959866
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Negrato, CA
   Gomes, MB
AF Negrato, Carlos Antonio
   Gomes, Marilia Brito
TI RETRACTED: Low birth weight: causes and consequences (Retracted article.
   See vol. 6, 60, 2014)
SO DIABETOLOGY & METABOLIC SYNDROME
LA English
DT Review; Retracted Publication
ID FOR-GESTATIONAL-AGE; CHILDREN BORN SMALL; THRIFTY PHENOTYPE HYPOTHESIS;
   CORONARY-HEART-DISEASE; BODY-MASS INDEX; CATCH-UP GROWTH; DEPENDENT
   DIABETES-MELLITUS; ADVERSE PREGNANCY OUTCOMES; REDUCED FETAL-GROWTH;
   INSULIN-RESISTANCE
AB During our phylogenetic evolution we have selected genes, the so called thrifty genes, that can help to maximize the amount of energy stored from every consumed calorie. An imbalance in the amount of stored calories can lead to many diseases. In the early 80's the distinguished English epidemiologist David Barker, formulated a hypothesis suggesting that many events that occur during the intrauterine life and early in infancy can influence the occurrence of many diseases that will develop in adulthood. This theory proposes that under-nutrition and other insult or adverse stimulus in utero and during infancy can permanently change the body's structure, physiology and metabolism. The lasting or lifelong effects of under-nutrition will depend on the period in the development at which it occurs. The clues that led Barker to his conclusions started to be discovered when he was studying the temporal trends in the incidence of ischemic heart disease in England and Wales. Examining data found in The Hertfordshire records, collected in the beginning of the last century, he found that the rates of mortality by ischemic heart disease was much higher in children born in less affluent counties and mostly in those with low birth weight. After his initial findings a myriad of diseases have been found to be linked to low birth weight and under-nutrition in utero and in the neonatal period. These diseases were then nominated adult diseases with fetal origin. Epidemiological studies that led to these findings suggest that in utero and early postnatal life have critical importance for long-term programming of health and disease, opening unique chances for primary prevention of chronic diseases.
C1 [Negrato, Carlos Antonio] Baurus Diabet Assoc, Dept Internal Med, BR-17012433 Bauru, Brazil.
   [Gomes, Marilia Brito] State Univ Hosp Rio de Janeiro, Dept Internal Med, Diabet Unit, Rio De Janeiro, Brazil.
RP Negrato, CA (reprint author), Baurus Diabet Assoc, Dept Internal Med, BR-17012433 Bauru, Brazil.
EM carlosnegrato@uol.com.br
RI Negrato, Carlos/F-8363-2013
CR Adair LS, 2003, HYPERTENSION, V41, P451, DOI 10.1161/01.HYP.0000054212.23528.B2
   Ahluwalia IB, 2001, OBSTET GYNECOL, V97, P649, DOI 10.1016/S0029-7844(01)01324-2
   Alkalay A L, 1998, J Perinatol, V18, P142
   Andersen AMN, 2004, INT J EPIDEMIOL, V33, P92, DOI 10.1093/ije/dyg195
   Antoniades L, 2003, RHEUMATOLOGY, V42, P791, DOI 10.1093/rheumatology/keg227
   Barker D. J. P, 1998, MOTHERS BABIES HLTH
   Barker DJP, 2006, HYPERTENSION, V48, P357, DOI 10.1161/01.HYP.0000236552.04251.42
   BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095
   BARKER DJP, 1989, LANCET, V2, P577
   Barker DJP, 2004, J AM COLL NUTR, V23, p588S, DOI 10.1080/07315724.2004.10719428
   Barker DJP, 2003, INT J EPIDEMIOL, V32, P876, DOI 10.1093/ije/dyg293
   Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235
   BARKER DJP, 1986, LANCET, V1, P1077
   Barrenas ML, 2003, BRIT MED J, V327, P1199, DOI 10.1136/bmj.327.7425.1199
   Bergvall N, 2007, CIRCULATION, V115, P2931, DOI 10.1161/CIRCULATIONAHA.107.674812
   Bernstein IM, 2000, AM J OBSTET GYNECOL, V182, P198, DOI 10.1016/S0002-9378(00)70513-8
   Bhargava SK, 2004, NEW ENGL J MED, V350, P865, DOI 10.1056/NEJMoa035698
   Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808
   Bryan SM, 2006, HORM RES, V65, P19, DOI 10.1159/000091502
   Cianfarani S, 1999, ARCH DIS CHILD, V81, pF71, DOI 10.1136/fn.81.1.F71
   Clausen JO, 1997, AM J EPIDEMIOL, V146, P23
   Clausson B, 1998, BRIT J OBSTET GYNAEC, V105, P1011, DOI 10.1111/j.1471-0528.1998.tb10266.x
   Clayton PE, 2007, J CLIN ENDOCR METAB, V92, P804, DOI 10.1210/jc.2006-2017
   Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310
   de Rooij SR, 2006, DIABETOLOGIA, V49, P637, DOI 10.1007/s00125-005-0136-9
   Dennison EM, 2005, PEDIATR RES, V57, P582, DOI 10.1203/01.PDR.0000155754.67821.CA
   El-Osta A, 2008, J EXP MED, V205, P2409, DOI 10.1084/jem.20081188
   Eriksson J, 2000, HYPERTENSION, V36, P790, DOI 10.1161/01.HYP.36.5.790
   Eriksson JG, 2001, BRIT MED J, V322, P949, DOI 10.1136/bmj.322.7292.949
   FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91
   Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837
   Forsen T, 2000, ANN INTERN MED, V133, P176, DOI 10.7326/0003-4819-133-3-200008010-00008
   Gale CR, 2004, BRIT J PSYCHIAT, V184, P28, DOI 10.1192/bjp.184.1.28
   HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248
   Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5
   Hamilton Brady E, 2005, Natl Vital Stat Rep, V54, P1
   Harder T, 2007, AM J EPIDEMIOL, V165, P849, DOI 10.1093/aje/kwk071
   Hediger ML, 1998, ARCH PEDIAT ADOL MED, V152, P1225
   Hoy WE, 2005, J AM SOC NEPHROL, V16, P2557, DOI 10.1681/ASN.2005020172
   Ibanez L, 2001, CLIN ENDOCRINOL, V55, P667, DOI 10.1046/j.1365-2265.2001.01399.x
   Innes K, 2000, AM J EPIDEMIOL, V152, P1121, DOI 10.1093/aje/152.12.1121
   Jancevska A, 2012, Prilozi, V33, P47
   Jaquet D, 2005, DIABETOLOGIA, V48, P849, DOI 10.1007/s00125-005-1724-4
   Jaquet D, 2000, J CLIN ENDOCR METAB, V85, P1041
   Kajantie E, 2008, INT J EPIDEMIOL, V37, P280, DOI 10.1093/ije/dyn012
   Kajantie E, 2006, J CLIN ENDOCR METAB, V91, P4953, DOI 10.1210/jc.2006-1093
   Karlberg J, 1995, PEDIATR RES, V28, P219
   Karlberg JPE, 1997, HORM RES, V48, P17, DOI 10.1159/000191279
   KAUFMAN FR, 2005, DIABESITY OBESITY DI
   Kensara OA, 2005, AM J CLIN NUTR, V82, P980
   Law CM, 2002, CIRCULATION, V105, P1088, DOI 10.1161/hc0902.104677
   Lee PA, 2003, PEDIATRICS, V111, P1253, DOI 10.1542/peds.111.6.1253
   Leger J, 1997, BRIT MED J, V315, P341
   Leon DA, 1996, BRIT MED J, V312, P401
   Li CY, 2001, DIABETES CARE, V24, P2035, DOI 10.2337/diacare.24.12.2035
   LUCAS A, 1991, CIBA F SYMP, V156, P38
   Luo ZC, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.6.e72
   Main KM, 2006, HORM RES, V65, P116, DOI 10.1159/000091516
   Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2
   McIntire DD, 1999, NEW ENGL J MED, V340, P1234, DOI 10.1056/NEJM199904223401603
   Mellemkjaer L, 2003, CANCER CAUSE CONTROL, V14, P61, DOI 10.1023/A:1022570305704
   Morin I, 2005, BJOG-INT J OBSTET GY, V112, P145, DOI 10.1111/j.1471-0528.2004.00311.x
   Nair MKC, 2009, INDIAN PEDIATR, V46, pS43
   NEEL JV, 1962, AM J HUM GENET, V14, P353
   Negrato CA, 2013, J APPL ORAL SCI, V21, P1, DOI 10.1590/1678-7757201302106
   Negrato CA, 2012, DIABETOL METAB SYNDR, V4, DOI 10.1186/1758-5996-4-41
   Neugebauer R, 2005, JAMA-J AM MED ASSOC, V294, P621, DOI 10.1001/jama.294.5.621
   Noeker M, 2006, KLIN PADIATR, V218, P249, DOI 10.1055/s-2005-836635
   O'Keeffe MJ, 2003, PEDIATRICS, V112, P301, DOI 10.1542/peds.112.2.301
   Ozanne SE, 1999, P NUTR SOC, V58, P615, DOI 10.1017/S0029665199000804
   Plagemann A, 2012, BEST PRACT RES CL EN, V26, P641, DOI 10.1016/j.beem.2012.03.008
   Plagemann A, 2010, J PERINAT MED, V38, P393, DOI 10.1515/JPM.2010.051
   Plagemann A, 2009, J PHYSIOL-LONDON, V587, P4963, DOI 10.1113/jphysiol.2009.176156
   Porrello ER, 2008, CLIN EXP PHARMACOL P, V35, P1358, DOI 10.1111/j.1440-1681.2008.05036.x
   Ramadhani MK, 2006, ATHEROSCLEROSIS, V184, P21, DOI 10.1016/j.atherosclerosis.2005.03.022
   Rapaport R, 2005, ACTA PAEDIATR, V94, P1348, DOI 10.1080/08035250510043860
   Rasmussen EL, 2005, DIABETES CARE, V28, P151, DOI 10.2337/diacare.28.1.151
   Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9
   RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701
   Saenger P, 2007, ENDOCR REV, V28, P219, DOI 10.1210/er.2006-0039
   Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396
   Strauss RS, 2000, JAMA-J AM MED ASSOC, V283, P625, DOI 10.1001/jama.283.5.625
   Taipale P, 2001, OBSTET GYNECOL, V97, P189, DOI 10.1016/S0029-7844(00)01131-5
   Vikse BE, 2008, J AM SOC NEPHROL, V19, P151, DOI 10.1681/ASN.2007020252
   Whincup PH, 1997, DIABETOLOGIA, V40, P319, DOI 10.1007/s001250050681
   Xiong X, 2006, BJOG-INT J OBSTET GY, V113, P135, DOI 10.1111/j.1471-0528.2005.00827.x
NR 86
TC 15
Z9 18
U1 2
U2 53
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1758-5996
J9 DIABETOL METAB SYNDR
JI Diabetol. Metab. Syndr.
PD SEP 2
PY 2013
VL 5
AR 49
DI 10.1186/1758-5996-5-49
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 210LH
UT WOS:000323834300001
PM 24128325
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Bhattacharjee, S
   Osman, F
   Feeney, L
   Lorenz, A
   Bryer, C
   Whitby, MC
AF Bhattacharjee, Sonali
   Osman, Fekret
   Feeney, Laura
   Lorenz, Alexander
   Bryer, Claire
   Whitby, Matthew C.
TI RETRACTED: MHF1-2/CENP-S-X performs distinct roles in centromere
   metabolism and genetic recombination (Retracted article. See vol. 8, art
   no. 180010, 2018)
SO OPEN BIOLOGY
LA English
DT Article; Retracted Publication
DE anaphase bridge; centromere; DNA helicase; DNA replication; homologous
   recombination
ID COMPLEMENTATION GROUP-M; FANCONI-ANEMIA PATHWAY; STALLED REPLICATION
   FORKS; HOMOLOGOUS RECOMBINATION; FISSION YEAST;
   SCHIZOSACCHAROMYCES-POMBE; DNA-REPAIR; PROMOTES RECOMBINATION; HOLLIDAY
   JUNCTIONS; BRANCH MIGRATION
AB The histone-fold proteins Mhf1/CENP-S and Mhf2/CENP-X performtwo important functions in vertebrate cells. First, they are components of the constitutive centromere-associated network, aiding kinetochore assembly and function. Second, they work with the FANCM DNA translocase to promote DNA repair. However, it has been unclear whether there is crosstalk between these roles. We showthat Mhf1 and Mhf2 in fission yeast, as in vertebrates, serve a dual function, aidingDNA repair/recombination and localizing to centromeres to promote chromosome segregation. Importantly, these functions are distinct, with the former being dependent on their interaction with the FANCM orthologue Fml1 and the latter not. Together with Fml1, they play a second role in aiding chromosome segregation by processing sister chromatid junctions. However, a failure of this activity does not manifest dramatically increased levels of chromosome missegregation due to the Mus81-Eme1 endonuclease, which acts as a failsafe to resolve DNA junctions before the end of mitosis.
C1 [Bhattacharjee, Sonali; Osman, Fekret; Feeney, Laura; Lorenz, Alexander; Bryer, Claire; Whitby, Matthew C.] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England.
RP Whitby, MC (reprint author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.
EM matthew.whitby@bioch.ox.ac.uk
RI Lorenz, Alexander/B-4735-2008
OI Lorenz, Alexander/0000-0003-1925-3713; Feeney,
   Laura/0000-0002-6416-849X; Whitby, Matthew/0000-0003-0951-3374
FU Wellcome Trust [090767/Z/09/Z]; K. Pathak Clarendon Scholarship from
   Exeter College, University of Oxford
FX This work was supported by a grant (090767/Z/09/Z) from the Wellcome
   Trust. S. B. was supported by a K. Pathak Clarendon Scholarship from
   Exeter College, University of Oxford.
CR Ahn JS, 2005, EMBO J, V24, P2011, DOI 10.1038/sj.emboj.7600670
   Amano M, 2009, J CELL BIOL, V186, P173, DOI 10.1083/jcb.200903100
   Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y
   Bakker ST, 2009, HUM MOL GENET, V18, P3484, DOI 10.1093/hmg/ddp297
   Blackford AN, 2012, HUM MOL GENET, V21, P2005, DOI 10.1093/hmg/dds013
   Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882
   Ciccia A, 2007, MOL CELL, V25, P331, DOI 10.1016/j.molcel.2007.01.003
   Crismani W, 2012, SCIENCE, V336, P1588, DOI 10.1126/science.1220381
   Deans AJ, 2009, MOL CELL, V36, P943, DOI 10.1016/j.molcel.2009.12.006
   Doe CL, 2004, NUCLEIC ACIDS RES, V32, P5570, DOI 10.1093/nar/gkh853
   Gallo-Fernandez M, 2012, NUCLEIC ACIDS RES, V40, P8325, DOI 10.1093/nar/gks599
   Gari K, 2008, P NATL ACAD SCI USA, V105, P16107, DOI 10.1073/pnas.0804777105
   Gari K, 2008, MOL CELL, V29, P141, DOI 10.1016/j.molcel.2007.11.032
   Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B
   Heyer WD, 2010, ANNU REV GENET, V44, P113, DOI 10.1146/annurev-genet-051710-150955
   Kee Y, 2010, GENE DEV, V24, P1680, DOI 10.1101/gad.1955310
   Kim JM, 2008, BLOOD, V111, P5215, DOI 10.1182/blood-2007-09-113092
   Lambert S, 2010, MOL CELL, V39, P346, DOI 10.1016/j.molcel.2010.07.015
   Lorenz A, 2012, SCIENCE, V336, P1585, DOI 10.1126/science.1220111
   Malvezzi F, 2013, EMBO J, V32, P409, DOI 10.1038/emboj.2012.356
   Matos J, 2011, CELL, V147, P158, DOI 10.1016/j.cell.2011.08.032
   McFarlane RJ, 2010, TRENDS GENET, V26, P209, DOI 10.1016/j.tig.2010.02.005
   Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626
   Moreira IS, 2007, PROTEINS, V68, P803, DOI 10.1002/prot.21396
   MORENO S, 1991, METHOD ENZYMOL, V194, P795
   Mosedale G, 2005, NAT STRUCT MOL BIOL, V12, P763, DOI 10.1038/nsmb981
   Nandi S, 2012, NUCLEIC ACIDS RES, V40, P9584, DOI 10.1093/nar/gks715
   Nishino T, 2013, EMBO J, V32, P424, DOI 10.1038/emboj.2012.348
   Nishino T, 2012, CELL, V148, P487, DOI 10.1016/j.cell.2011.11.061
   Osman F, 2003, MOL CELL, V12, P761, DOI 10.1016/S1097-2765(03)00343-5
   Osman F, 2007, DNA REPAIR, V6, P1004, DOI 10.1016/j.dnarep.2007.02.019
   Osman Fekret, 2009, V521, P535, DOI [10.1007/978-1-60327-817-5_31, 10.1007/978-1-60327-815-7_31]
   Prakash R, 2009, GENE DEV, V23, P67, DOI 10.1101/gad.1737809
   Rosado IV, 2009, NUCLEIC ACIDS RES, V37, P4360, DOI 10.1093/nar/gkp365
   Schleiffer A, 2012, NAT CELL BIOL, V14, P604, DOI 10.1038/ncb2493
   Singh TR, 2010, MOL CELL, V37, P879, DOI 10.1016/j.molcel.2010.01.036
   Singh TR, 2009, BLOOD, V114, P174, DOI 10.1182/blood-2009-02-207811
   Sofueva S, 2011, NUCLEIC ACIDS RES, V39, P6568, DOI 10.1093/nar/gkr340
   Sun W, 2008, MOL CELL, V32, P118, DOI 10.1016/j.molcel.2008.08.024
   Tao YY, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1779
   UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x
   Vinciguerra P, 2010, J CLIN INVEST, V120, P3834, DOI 10.1172/JCI43391
   Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159
   Whitby MC, 2010, DNA REPAIR, V9, P224, DOI 10.1016/j.dnarep.2009.12.012
   Whitby MC, 1998, J BIOL CHEM, V273, P35063, DOI 10.1074/jbc.273.52.35063
   Yan ZJ, 2010, MOL CELL, V37, P865, DOI 10.1016/j.molcel.2010.01.039
   Zeitlin SG, 2009, P NATL ACAD SCI USA, V106, P15762, DOI 10.1073/pnas.0908233106
   Zheng XF, 2011, DNA REPAIR, V10, P1034, DOI 10.1016/j.dnarep.2011.08.002
NR 48
TC 23
Z9 27
U1 1
U2 6
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 2046-2441
J9 OPEN BIOL
JI Open Biol
PD SEP
PY 2013
VL 3
IS 9
AR 130102
DI 10.1098/rsob.130102
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 298EA
UT WOS:000330305700005
PM 24026537
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Mudakkar, SR
   Uppal, JY
   Zaman, K
   Naseem, I
   Shah, GUD
AF Mudakkar, Syeda Rabab
   Uppal, Jamshed Y.
   Zaman, Khalid
   Naseem, Imran
   Shah, Ghias Ud Din
TI RETRACTED: Foreign exchange risk in a managed float regime: A case study
   of Pakistani rupee (Retracted article. See vol. 45, pg. 289, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Value at Risk; Risk measure; GARCH; Extreme value theory; Back-testing
ID RETURNS; MARKETS
AB The study examines applicability and performance of Value-at-Risk (VaR) models with respect to foreign exchange risk assessment within a managed float regime. Pakistani rupee offers an instructive case as it seems to manage its currency mainly against the US dollar, but to a lesser extent against the euro. We find that the distributional characteristics are quite different for the two currencies. We also find that the dynamic processes are remarkably different for the two exchange rates. The results indicate that compared with alternative competing models, the foreign exchange risk is better modeled using VaR based on Extreme Value Theory. Our findings underscore the importance of correctly specifying the return model in a dynamic framework. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Mudakkar, Syeda Rabab] Ctr Math & Stat Sci, Lahore Sch Econ, Lahore, Pakistan.
   [Uppal, Jamshed Y.] Catholic Univ Amer, Dept Business & Econ, Washington, DC 20064 USA.
   [Zaman, Khalid; Naseem, Imran; Shah, Ghias Ud Din] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM drrabab@lahoreschool.edu.pk; uppal@cua.edu; khalidzaman@ciit.net.pk;
   drimran@ciit.net.pk; ghias@ciit.net.pk
CR Ajili W, 2008, WORLD SCI STUD INT E, V3, P11
   Akbar F., 2009, SBP RES B, V5, P11
   Al Janabi MAM, 2006, J RISK FINANC, V7, P273, DOI 10.1108/15265940610664951
   BALKEMA AA, 1974, ANN PROBAB, V2, P792, DOI 10.1214/aop/1176996548
   BOLLERSLEV T, 1992, J ECONOMETRICS, V52, P5, DOI 10.1016/0304-4076(92)90064-X
   BOOTHE P, 1987, J INT ECON, V22, P297, DOI 10.1016/S0022-1996(87)80025-9
   Calvo GA, 2002, Q J ECON, V117, P379, DOI 10.1162/003355302753650274
   Chou RY, 2005, J MONEY CREDIT BANK, V37, P561, DOI 10.1353/mcb.2005.0027
   de Jesus R, 2013, N AM J ECON FINANC, V24, P139, DOI 10.1016/j.najef.2012.06.001
   Diebold F. X., 2000, J RISK FINANCE, V1, P30, DOI DOI 10.1108/EB043443
   Embrechts P., 1997, MODELING EXTREME EVE
   Engel Charles, 1993, ECON REV, VQ, P43
   Fisher RA, 1928, P CAMB PHILOS SOC, V24, P180
   Genberg Hans, 2004, INT MON FUND C WASH
   Hooy C. W., 2004, ASIAN ECON J, V18, P261
   Hull J., 1998, J RISK, V1
   Janjua M.A., 2007, LAHORE J EC, P125
   Kemal M. A., 2005, 20 ANN GEN M C PAK S
   KOEDIJK KG, 1990, J INT ECON, V29, P93, DOI 10.1016/0022-1996(90)90065-T
   Longin F, 2001, J FINANC, V56, P649, DOI 10.1111/0022-1082.00340
   Longin FM, 1996, J BUS, V69, P383, DOI 10.1086/209695
   Maps Dennis S, 2009, 25772 MPRA
   McNeil A., 2000, WORKING PAPER
   McNeil A., 1997, ASTIN BULL, V27, P117, DOI DOI 10.2143/AST.27.1.563210
   McNeil Alexander J., 1999, EXTREME VALUE THEORY
   Mussa M., 1986, CARNEGIE-ROCHESTER C, V25, P117, DOI DOI 10.1016/0167-2231(86)90039-4
   Nath C. C., 2003, WORKING PAPER SERIES
   PICKANDS J, 1975, ANN STAT, V3, P119
   Poon SH, 2003, J ECON LIT, V41, P478, DOI 10.1257/002205103765762743
   Purevsuren J., 2010, WORKING PAPER
   Rajan R., 2011, 322 ADBI
   Wang ZR, 2010, J APPL STAT, V37, P265, DOI 10.1080/02664760902846114
   Zardad A, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-292
NR 33
TC 1
Z9 1
U1 2
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD SEP
PY 2013
VL 35
BP 409
EP 417
DI 10.1016/j.econmod.2013.07.030
PG 9
WC Economics
SC Business & Economics
GA 287HG
UT WOS:000329532100050
DA 2018-12-27
ER

PT J
AU Tanguler, H
AF Tanguler, Hasan
TI RETRACTED: Influence of Temperatures and Fermentation Behaviour of Mixed
   Cultures of Williopsis saturnus var. saturnus and Saccharomyces
   cerevisiae Associated with Winemaking (Retracted article. See vol. 23,
   pg. 772, 2017)
SO FOOD SCIENCE AND TECHNOLOGY RESEARCH
LA English
DT Article; Retracted Publication
DE white wine; temperature; Williopsis saturnus var. saturnus;
   Saccharomyces cerevisiae; flavour compounds; isoamyl acetate
ID VOLATILE BY-PRODUCTS; WINE FERMENTATION; KLOECKERA-APICULATA; JUICE
   FERMENTATION; GLYCEROL CONTENT; AROMA COMPOUNDS; YEASTS; GROWTH; CELLS;
   IMMOBILIZATION
AB Up to now, this has been the first study in which the influences of fermentation temperature on the yeast growth and the production of yeast-derived volatile compounds during the fermentation of Emir grape must at various temperatures were examined. The results demonstrate that the fermentation temperature plays an important role compared to all tested variables. Fermentations were completed in 6, 8 and 14 days at 12, 18 and 24 degrees C, respectively. Increase in temperature resulted in an increase in glycerol, total acidity, acetic and tartaric acid, 2-methyl butanol, propan-1-ol, isobutanol, acetaldehyde and acetone, but in a decrease in ethanol, malic and citric acid, isoamyl acetate, ethyl acetate, isobutyl acetate, ethyl butyrate and ethyl hexanoate. Moreover, these mixed culture fermentations formed higher amounts of isoamyl acetate in comparison with pure culture of S. cerevisiae. According to chemical composition and volatile compounds the differences between obtained wines were found generally significant.
C1 Nigde Univ, Dept Food Engn, TR-51245 Nigde, Turkey.
RP Tanguler, H (reprint author), Nigde Univ, Dept Food Engn, TR-51245 Nigde, Turkey.
EM htanguler@nigde.edu.tr
OI Tanguler, Hasan/0000-0001-6425-9896
CR Andorra I, 2010, FOOD RES INT, V43, P773, DOI 10.1016/j.foodres.2009.11.014
   [Anonymous], 1990, REC METH INT AN VINS, P368
   Balli D, 2003, PROCESS BIOCHEM, V39, P499, DOI 10.1016/S0032-9592(03)00133-X
   Bardi E, 1997, PROCESS BIOCHEM, V32, P579, DOI 10.1016/S0032-9592(97)00022-8
   Barre P., 1993, WINE MICROBIOLOGY BI, P421
   Beltran G, 2008, INT J FOOD MICROBIOL, V121, P169, DOI 10.1016/j.ijfoodmicro.2007.11.030
   Berry D.R., 1995, FERMENTED BEVERAGE P, P32
   Bilbao A, 1997, LETT APPL MICROBIOL, V24, P37, DOI 10.1046/j.1472-765X.1997.00340.x
   Blanco P, 2008, J IND MICROBIOL BIOT, V35, P183, DOI 10.1007/s10295-007-0282-9
   BOULTON RB, 1996, PRINCIPLES PRACTICES, P604
   Ciani M, 2006, INT J FOOD MICROBIOL, V108, P239, DOI 10.1016/j.ijfoodmicro.2005.11.012
   Ciani M, 1996, APPL ENVIRON MICROB, V62, P128
   Clemente-Jimenez JM, 2005, INT J FOOD MICROBIOL, V98, P301, DOI [10.1016/j.ijfoodmicro.2004.06.007, 10.1016/j.ijfoodchem.2004.06.007]
   Comitini F, 2011, FOOD MICROBIOL, V28, P873, DOI 10.1016/j.fm.2010.12.001
   Cortes S, 2010, J SCI FOOD AGR, V90, P121, DOI 10.1002/jsfa.3794
   Erten H, 2002, WORLD J MICROB BIOT, V18, P373
   Erten H, 2010, LETT APPL MICROBIOL, V50, P474, DOI 10.1111/j.1472-765X.2010.02822.x
   Erten H, 2006, J I BREWING, V112, P232, DOI 10.1002/j.2050-0416.2006.tb00718.x
   Etievant P. X., 1991, VOLATILE COMPOUNDS F, P483
   Fleet G. H., 1993, WINE MICROBIOLOGY BI, P27, DOI DOI 10.1016/S0168-1605(03)00245-9
   Fleet GH, 2003, INT J FOOD MICROBIOL, V86, P11, DOI 10.1016/S0168-1605(03)00245-9
   Gil JV, 1996, J FOOD SCI, V61, P1247, DOI 10.1111/j.1365-2621.1996.tb10971.x
   Granchi L, 2002, FEMS YEAST RES, V2, P403, DOI 10.1111/j.1567-1364.2002.tb00110.x
   HEARD GM, 1985, APPL ENVIRON MICROB, V50, P727
   Henschke PA, 1993, WINE MICROBIOLOGY BI, P77
   Ikonomopoulou M, 2003, APPL BIOCHEM BIOTECH, V104, P23, DOI 10.1385/ABAB:104:1:23
   Jolly N. P., 2003, South African Journal of Enology and Viticulture, V24, P55
   Kandylis P, 2010, BIORESOURCE TECHNOL, V101, P7484, DOI 10.1016/j.biortech.2010.04.031
   Kourkoutas Y, 2001, J AGR FOOD CHEM, V49, P1417, DOI 10.1021/jf000942n
   Lee PR, 2010, FOOD MICROBIOL, V27, P853, DOI 10.1016/j.fm.2010.05.010
   Lee PR, 2012, FOOD RES INT, V45, P177, DOI 10.1016/j.foodres.2011.10.011
   Lee PR, 2012, LWT-FOOD SCI TECHNOL, V46, P84, DOI 10.1016/j.lwt.2011.10.022
   Mallouchos A, 2003, FOOD CHEM, V80, P109, DOI 10.1016/S0308-8146(02)00247-9
   Manzanares P, 2011, MOLECULAR WINE MICROBIOLOGY, P85, DOI 10.1016/B978-0-12-375021-1.10004-9
   Masneuf-Pomarede I, 2006, INT J FOOD MICROBIOL, V108, P385, DOI 10.1016/j.ijfoodmicro.2006.01.001
   Mateo JJ, 2001, FOOD RES INT, V34, P307, DOI 10.1016/S0963-9969(00)00168-X
   Mendoza L, 2010, CURR RES TOP APPL MI, V2, P908
   Mendoza LM, 2011, J IND MICROBIOL BIOT, V38, P1777, DOI 10.1007/s10295-011-0964-1
   Molina AM, 2007, APPL MICROBIOL BIOT, V77, P675, DOI 10.1007/s00253-007-1194-3
   Moreira N, 2008, INT J FOOD MICROBIOL, V124, P231, DOI [10.1016/j.ijfoodmicro.2008.03.025, 10.1016/ijfoodmicro.2008.03.025]
   Patel S, 2003, J FOOD COMPOS ANAL, V16, P469, DOI 10.1016/S0889-1575(03)00021-8
   Perez-Nevado F, 2006, INT J FOOD MICROBIOL, V108, P336, DOI 10.1016/j.ijfoodmicro.2005.12.012
   Reddy LVA, 2011, FOOD BIOPROD PROCESS, V89, P487, DOI 10.1016/j.fbp.2010.11.007
   Reddy LV, 2008, PROCESS BIOCHEM, V43, P748, DOI 10.1016/j.procbio.2008.02.020
   Sarris D, 2009, ENG LIFE SCI, V9, P29, DOI 10.1002/elsc.200800059
   Sener A, 2007, TURK J AGRIC FOR, V31, P349
   SIMPSON RF, 1979, FOOD TECHNOL AUST, V31, P516
   Smogrovicova D, 1999, PROCESS BIOCHEM, V34, P785, DOI 10.1016/S0032-9592(98)00154-X
   Soden A., 2000, Australian Journal of Grape and Wine Research, V6, P21, DOI 10.1111/j.1755-0238.2000.tb00158.x
   Styger G, 2011, J IND MICROBIOL BIOT, V38, P1145, DOI 10.1007/s10295-011-1018-4
   Suarez-Lepe JA, 2012, TRENDS FOOD SCI TECH, V23, P39, DOI 10.1016/j.tifs.2011.08.005
   Torija MJ, 2003, INT J FOOD MICROBIOL, V80, P47, DOI 10.1016/S0168-1605(02)00144-7
   Toro ME, 2002, WORLD J MICROB BIOT, V18, P347
   Trinh TTT, 2010, S AFR J ENOL VITIC, V31, P116
   Trinh T.T.T., 2011, THESIS NATL U SINGAP, P116
   Trinh TTT, 2011, INT J FOOD SCI TECH, V46, P130, DOI 10.1111/j.1365-2621.2010.02462.x
   Viana F, 2011, INT J FOOD MICROBIOL, V151, P235, DOI 10.1016/j.ijfoodmicro.2011.09.005
   Yilmaztekin M, 2009, FOOD CHEM, V112, P290, DOI 10.1016/j.foodchem.2008.05.079
   Zohre DE, 2002, PROCESS BIOCHEM, V38, P319, DOI 10.1016/S0032-9592(02)00086-9
NR 59
TC 3
Z9 3
U1 5
U2 24
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1344-6606
J9 FOOD SCI TECHNOL RES
JI Food Sci. Technol. Res.
PD SEP
PY 2013
VL 19
IS 5
BP 781
EP 793
PG 13
WC Food Science & Technology
SC Food Science & Technology
GA 240YT
UT WOS:000326134300008
DA 2018-12-27
ER

PT J
AU Khan, MA
   Khan, MZ
   Zaman, K
   Khan, MM
   Zahoor, H
AF Khan, Muhammad Azhar
   Khan, Muhammad Zahir
   Zaman, Khalid
   Khan, Muhammad Mushtaq
   Zahoor, Hina
TI RETRACTED: Causal links between greenhouse gas emissions, economic
   growth and energy consumption in Pakistan: A fatal disorder of society
   (Retracted article. See vol. 45, pg. 902, 2015)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE Energy consumption; Economic growth; Greenhouse gas emissions;
   Cointegration; Pakistan
ID NUMERICAL DISTRIBUTION-FUNCTIONS; AUTOREGRESSIVE TIME-SERIES; CARBON
   EMISSIONS; UNIT-ROOT; LEVEL RELATIONSHIPS; COINTEGRATION; TESTS;
   INFERENCE
AB This study investigates the long-run and the causal relationship between greenhouse gas emissions, economic growth per unit of energy use and energy consumption in Pakistan by using cointegration theory and Granger causality test. In addition, this study compares the influencing magnitude of greenhouse gas emissions on energy consumption by employing variance decomposition techniques over a 36-year time period, i.e., between 1975 and 2011. The study employed the Johansen cointegration technique to estimate the long-run relationship between the variables, Granger causality test to find the influencing directions while variance decomposition was used to compare the influencing magnitude between the variables. The study was limited to a few variables, including greenhouse gas emissions (such as agricultural methane emissions; agricultural nitrous oxide emissions; CO2 emissions and combustible renewables and waste); GDP per unit of energy use and energy consumption, in order to manage robust data analysis. Finding suggests that energy consumption acts as an important driver for increase in greenhouse gas emissions in Pakistan. The results indicate that on average, causality runs from energy consumption to greenhouse gas emissions but not vice versa. Energy consumption does not Granger cause agricultural nitrous oxide emissions via both routes which confirm 'neutrality causal hypotheses' between the variables. Greenhouse gas emissions are closely associated with economic growth per unit of energy use and energy consumption in Pakistan. Variance decomposition analysis shows that among all the greenhouse gas emissions, combustible renewables and waste exerted the largest contribution to changes in energy consumption in Pakistan. The results suggest that consuming energy by industries is becoming more increasing by every coming day, but it signifies the fact that emissions caused by consuming the energy is causing harm to the society by enlarge, and it reaches to the conclusion where we are heading toward a systematic fatal disorder of our society. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Khan, Muhammad Azhar] Univ Haripur, Dept Econ, Haripur, Pakistan.
   [Khan, Muhammad Zahir] Islamia Univ Bahawalpur, Bahawalpur, Pakistan.
   [Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Khan, Muhammad Mushtaq; Zahoor, Hina] COMSATS Inst Informat Technol, Humanities Dept, Abbottabad, Pakistan.
RP Khan, MA (reprint author), Univ Haripur, Dept Econ, Haripur, Pakistan.
EM azhar.phd100@yahoo.com; zahirpanian@yahoo.com; khalidzaman@ciit.net.pk;
   khanmm@ciit.net.pk; hinazahoor@ciit.net.pk
CR ACS, 2013, CLIM CHANG PUBL POL
   Adler JH., 2000, GREENHOUSE POLICY RE
   Al-mulali U, 2012, ENERGY, V46, P156, DOI 10.1016/j.energy.2012.08.043
   Ali G, 2012, RENEW SUST ENERG REV, V16, P775, DOI 10.1016/j.rser.2011.09.003
   Ali T, 2013, APPL ENERG, V104, P466, DOI 10.1016/j.apenergy.2012.11.047
   Bastianoni S, 2004, ECOL ECON, V49, P253, DOI 10.1016/j.ecolecon.2004.01.018
   Chow GC, 2007, 152 CEPS
   DICKEY DA, 1981, ECONOMETRICA, V49, P1057, DOI 10.2307/1912517
   DICKEY DA, 1979, J AM STAT ASSOC, V74, P427, DOI 10.2307/2286348
   Energy Information Administration (EIA), 2004, GREENH GAS CLIM CHAN
   ENGLE RF, 1987, ECONOMETRICA, V55, P251, DOI 10.2307/1913236
   EU, 2008, ADDR SOC DIM ENV POL
   FANKHAUSER S, 1994, ENERGY J, V15, P157
   GoP. Government of Pakistan, 2012, GOV PAK EC SURV PAK
   GoP. Government of Pakistan, 2011, GOV PAK EC SURV PAK
   GPF, 2008, ENV DEGR AGR
   Hamit-Haggar M, 2012, ENERG ECON, V34, P358, DOI 10.1016/j.eneco.2011.06.005
   Haupt J., 2012, UNEXPECTED CONNECTIO
   Helm D, TOO GOOD BE TRUE UKS
   Herz WJ, 1997, POLICY PLANNING REDU
   IFAD, 2012, COMB ENV DEGR
   JOHANSEN S, 1990, OXFORD B ECON STAT, V52, P169, DOI 10.1111/j.1468-0084.1990.mp52002003.x
   JOHANSEN S, 1988, J ECON DYN CONTROL, V12, P231, DOI 10.1016/0165-1889(88)90041-3
   Lee CC, 2006, ENERG POLICY, V34, P1086, DOI 10.1016/j.empol.2005.04.023
   Mackinnon JG, 1999, J APPL ECONOM, V14, P563, DOI 10.1002/(SICI)1099-1255(199909/10)14:5<563::AID-JAE530>3.3.CO;2-I
   Mackinnon JG, 1996, J APPL ECONOMET, V11, P601, DOI 10.1002/(SICI)1099-1255(199611)11:6<601::AID-JAE417>3.0.CO;2-T
   Marcotullio PJ, 2012, GLOBAL ENVIRON CHANG, V22, P944, DOI 10.1016/j.gloenvcha.2012.07.002
   Parry M. L., 2007, 4 IPCC
   Pesaran MH, 2001, J APPL ECONOM, V16, P289, DOI 10.1002/jae.616
   Shahbaz M, 2013, 43272 MPRA
   Shahbaz M, 2012, ECON MODEL, V29, P2310, DOI 10.1016/j.econmod.2012.06.027
   Soytas U, 2007, ECOL ECON, V62, P482, DOI 10.1016/j.ecolecon.2006.07.009
   Soytas U, 2009, ECOL ECON, V68, P1667, DOI 10.1016/j.ecolecon.2007.06.014
   TODA HY, 1995, J ECONOMETRICS, V66, P225, DOI 10.1016/0304-4076(94)01616-8
   UNDP, 2001, ENV EN EN DIS MAN CL
   United Nations Environment Programme (UNEP), 2007, ASS POL INSTR RED GR
   World Bank, 2012, WORLD DEV IND 2012
   Zaman K, 2013, RENEW SUST ENERG REV, V19, P107, DOI 10.1016/j.rser.2012.11.013
   Zaman K, 2012, ECON MODEL, V29, P1632, DOI 10.1016/j.econmod.2012.05.024
   Zhang XP, 2009, ECOL ECON, V68, P2706, DOI 10.1016/j.ecolecon.2009.05.011
NR 40
TC 22
Z9 22
U1 3
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD SEP
PY 2013
VL 25
BP 166
EP 176
DI 10.1016/j.rser.2013.04.002
PG 11
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA 236WT
UT WOS:000325830900013
DA 2018-12-27
ER

PT J
AU Zong, K
   Lu, SH
   Wang, H
   Sun, YX
   Liu, JB
   Yan, H
AF Zong, Kai
   Lu, SiHeng
   Wang, Hao
   Sun, YuXiu
   Liu, JingBing
   Yan, Hui
TI RETRACTED: Cu2ZnSnSe4 quantum dots with controllable size and quantum
   confinement effect(Retracted article. See vol. 15, 2163, 2013)
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article; Retracted Publication
DE Cu2ZnSnSe4; Quantum dots; Quantum confinement; Band gap
ID SENSITIZED SOLAR-CELLS; SEMICONDUCTOR NANOCRYSTALS; ELECTRON-TRANSFER;
   EFFICIENCY; NANOPARTICLES; CONVERSION; ABSORBER
AB Cu2ZnSnSe4 quantum dots (QDs) with controllable sizes have been synthesized via a hot-injection method. The diameters of the QDs range from 3.2 to 10.1 nm with the tunable band gap from 1.27 to 1.54 eV by adjusting the reaction temperatures from 180 to 240 degrees C. Structural and Raman scattering data confirm that Cu2ZnSnSe4 is obtained without other secondary phases. The band gaps of the QDs with diameters less than 4.6 nm show an obvious blue shift to higher energy due to quantum confinement effect. It indicates that the Cu2ZnSnSe4 QDs can be a potential candidate for quantum-dot-sensitized solar cells in the future.
C1 [Zong, Kai; Lu, SiHeng; Wang, Hao; Sun, YuXiu; Liu, JingBing; Yan, Hui] Beijing Univ Technol, Coll Mat Sci & Engn, Beijing 100124, Peoples R China.
   [Wang, Hao; Yan, Hui] Chengdu Green Energy & Green Mfg Technol R&D Ctr, Chengdu 610207, Peoples R China.
   [Sun, YuXiu] Tianjin Normal Univ, Coll Chem, Tianjin Key Lab Struct & Performance Funct Mol, Tianjin 300387, Peoples R China.
RP Wang, H (reprint author), Chengdu Green Energy & Green Mfg Technol R&D Ctr, Chengdu 610207, Peoples R China.
EM haowang@bjut.edu.cn
FU Natural Science Foundation of Beijing [2122005]; Tianjin City
   Application Foundation; Advanced Technology Research Program
   [12JCZDJC21700]
FX The authors would like to acknowledge the financial support from the
   Natural Science Foundation of Beijing (No. 2122005), Tianjin City
   Application Foundation and Advanced Technology Research Program
   (12JCZDJC21700).
CR Altosaar M, 2008, PHYS STATUS SOLIDI A, V205, P167, DOI 10.1002/pssa.200776839
   Bang JH, 2011, ACS NANO, V5, P9421, DOI 10.1021/nn204350w
   Cao Y, 2013, ACS APPL MATER INTER, V5, P479, DOI 10.1021/am302522c
   Debnath R, 2010, J AM CHEM SOC, V132, P5952, DOI 10.1021/ja1013695
   Diguna LJ, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2757130
   Gonzalez-Pedro V, 2010, ACS NANO, V4, P5783, DOI 10.1021/nn101534y
   Grossberg M, 2009, THIN SOLID FILMS, V517, P2489, DOI 10.1016/j.tsf.2008.11.024
   Guo Q, 2010, J AM CHEM SOC, V132, P17384, DOI 10.1021/ja108427b
   Kamat PV, 2012, ACCOUNTS CHEM RES, V45, P1906, DOI 10.1021/ar200315d
   Kamat PV, 2008, J PHYS CHEM C, V112, P18737, DOI 10.1021/jp806791s
   Khare A, 2011, CHEM COMMUN, V47, P11721, DOI 10.1039/c1cc14687d
   Lee HJ, 2009, LANGMUIR, V25, P7602, DOI 10.1021/la900247r
   Lee H, 2009, NANO LETT, V9, P4221, DOI 10.1021/nl902438d
   Lee YL, 2009, ADV FUNCT MATER, V19, P604, DOI 10.1002/adfm.200800940
   Liu WC, 2013, J MATER CHEM A, V1, P3182, DOI 10.1039/c3ta00357d
   Luther JM, 2010, ADV MATER, V22, P3704, DOI 10.1002/adma.201001148
   Nozik AJ, 2005, INORG CHEM, V44, P6893, DOI 10.1021/ic0508425
   Persson C, 2011, J APPL PHYS, V107
   Riha SC, 2011, ACS APPL MATER INTER, V3, P58, DOI 10.1021/am1008584
   Riha SC, 2009, J AM CHEM SOC, V131, P12054, DOI 10.1021/ja9044168
   Steinhagen C, 2009, J AM CHEM SOC, V131, P12554, DOI 10.1021/ja905922j
   Tisdale WA, 2010, SCIENCE, V328, P1543, DOI 10.1126/science.1185509
   Todorov TK, 2010, ADV MATER, V22, pE156, DOI 10.1002/adma.200904155
   Xu CY, 2001, J RAMAN SPECTROSC, V32, P862, DOI 10.1002/jrs.773
   Xu J, 2012, J PHYS CHEM C, V116, P19718, DOI 10.1021/jp306628m
   Yin Y, 2005, NATURE, V437, P664, DOI 10.1038/nature04165
NR 26
TC 3
Z9 3
U1 1
U2 36
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD SEP
PY 2013
VL 15
IS 9
AR UNSP 1947
DI 10.1007/s11051-013-1947-0
PG 7
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 217PA
UT WOS:000324370200072
DA 2018-12-27
ER

PT J
AU Hagemann, T
AF Hagemann, T.
TI RETRACTED: Utilising Pre-clinical Models to Refine Immune Modulation in
   Pancreatic Cancer(Retracted article. See vol.239,pg.384,2016)
SO JOURNAL OF PATHOLOGY
LA English
DT Meeting Abstract; Retracted Publication
CT 7th Joint Meeting of the British-Division of the
   International-Academy-of-Pathology and the
   Pathological-Society-of-Great-Britain-and-Ireland
CY JUN 18-21, 2013
CL Univ Edinburgh, Div Pathol, Edinburgh, SCOTLAND
SP Int Acad Pathol, British Div, Pathol Soc Great Britain & Ireland, Univ Edinburgh
HO Univ Edinburgh, Div Pathol
C1 [Hagemann, T.] Barts Canc Inst, London, England.
NR 0
TC 1
Z9 1
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD SEP
PY 2013
VL 231
SU 1
BP 9
EP 9
PG 1
WC Oncology; Pathology
SC Oncology; Pathology
GA 217DK
UT WOS:000324336700029
DA 2018-12-27
ER

PT J
AU Shu, XL
   Zhang, YS
   Xu, H
   Kang, K
   Cai, DL
AF Shu, Xiaoliang
   Zhang, Yongsheng
   Xu, Han
   Kang, Kai
   Cai, Donglian
TI RETRACTED: Brain-derived neurotrophic factor inhibits glucose
   intolerance after cerebral ischemia (Retracted article. See vol. 9, pg.
   844, 2014)
SO NEURAL REGENERATION RESEARCH
LA English
DT Article; Retracted Publication
DE neural regeneration; brain injury; cerebral ischemic stress;
   brain-derived neurotrophic factor; insulin receptor; cerebral
   ischemia/reperfusion injury; hypothalamus; diabetes mellitus;
   hyperglycemia; glucose intolerance; grants-supported paper;
   neuroregeneration
ID CITRIFOLIA FRUIT JUICE; DIABETIC-RATS; INSULIN-RESISTANCE; NEURONAL
   DAMAGE; SKELETAL-MUSCLE; ENERGY-BALANCE; IN-VIVO; MICE; BDNF; METABOLISM
AB Brain-derived neurotrophic factor is associated with the insulin signaling pathway and glucose metabolism. We hypothesized that expression of brain-derived neurotrophic factor and its receptor may be involved in glucose intolerance following ischemic stress. To verify this hypothesis, this study aimed to observe the changes in brain-derived neurotrophic factor and tyrosine kinase B receptor expression in glucose metabolism-associated regions following cerebral ischemic stress in mice. At day 1 after middle cerebral artery occlusion, the expression levels of brain-derived neurotrophic factor were significantly decreased in the ischemic cortex, hypothalamus, liver, skeletal muscle, and pancreas. The expression levels of tyrosine kinase B receptor were decreased in the hypothalamus and liver, and increased in the skeletal muscle and pancreas, but remained unchanged in the cortex. Intrahypothalamic administration of brain-derived neurotrophic factor (40 ng) suppressed the decrease in insulin receptor and tyrosine-phosphorylated insulin receptor expression in the liver and skeletal muscle, and inhibited the overexpression of gluconeogenesis-associated phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in the liver of cerebral ischemic mice. However, serum insulin levels remained unchanged. Our experimental findings indicate that brain-derived neurotrophic factor can promote glucose metabolism, reduce gluconeogenesis, and decrease blood glucose levels after cerebral ischemic stress. The low expression of brain-derived neurotrophic factor following cerebral ischemia may be involved in the development of glucose intolerance.
C1 [Shu, Xiaoliang; Xu, Han; Kang, Kai] Tongji Univ, Affiliated Dongfang Hosp, Dept Nutr, Shanghai 200120, Peoples R China.
   [Zhang, Yongsheng] Guangxi Med Univ, Affiliated Hosp 1, Dept Nutr, Nanning 530027, Guangxi Zhuang, Peoples R China.
   [Cai, Donglian] Second Mil Med Univ Chinese PLA, Affiliated Changhai Hosp, Dept Nutr, Shanghai 200433, Peoples R China.
RP Zhang, YS (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Nutr, Nanning 530027, Guangxi Zhuang, Peoples R China.
EM zhangyshhn@sina.com
FU Talent Foundation of the Affiliated Hospital of Guangxi Medical College
   in China [08026]; Youth Researcher Foundation of Guangxi Medical College
   in China [08012]; Scientific Research Foundation from Science and
   Technology Bureau of Shanghai City [074119048]
FX This study was supported by the Talent Foundation of the Affiliated
   Hospital of Guangxi Medical College in China, No. 08026; Youth
   Researcher Foundation of Guangxi Medical College in China, No. 08012;
   Scientific Research Foundation from Science and Technology Bureau of
   Shanghai City, No. 074119048.
CR Ahmed MS, 2012, ISLETS, V4, P343, DOI [10.4161/islets.22283, 10.4161/isl.22283]
   Akil H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025097
   Auer RN, 1998, NEUROLOGY, V51, pS39, DOI 10.1212/WNL.51.3_Suppl_3.S39
   Benzler J, 2012, BIOCHEM J, V447, P175, DOI 10.1042/BJ20120834
   Casalbore P, 2010, J CELL PHYSIOL, V224, P710, DOI 10.1002/jcp.22170
   Cheah YS, 2012, NAT REV ENDOCRINOL, V8, P588, DOI 10.1038/nrendo.2012.97
   Collino M, 2009, DIABETES, V58, P235, DOI 10.2337/db08-0691
   de la Monte SM, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-13
   Dhungel S, 2011, NEUROSCIENCE, V199, P225, DOI 10.1016/j.neuroscience.2011.09.051
   Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0
   Fekete C, 2006, ENDOCRINOLOGY, V147, P520, DOI 10.1210/en.2005-0956
   Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   Han BH, 2000, J NEUROSCI, V20, P5775
   Hanyu O, 2003, DIABETES OBES METAB, V5, P27, DOI 10.1046/j.1463-1326.2003.00238.x
   Harada S, 2011, J PHARMACOL SCI, V115, P155, DOI 10.1254/jphs.10264FP
   Harada S, 2010, J NAT MED-TOKYO, V64, P468, DOI 10.1007/s11418-010-0437-2
   Harada S, 2009, BRAIN RES, V1279, P174, DOI 10.1016/j.brainres.2009.05.014
   Harada S, 2009, BIOL PHARM BULL, V32, P405, DOI 10.1248/bpb.32.405
   Herpfer I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046004
   Imai J, 2008, SCIENCE, V322, P1250, DOI 10.1126/science.1163971
   KAHN BB, 1992, J CLIN ENDOCR METAB, V74, P1101, DOI 10.1210/jc.74.5.1101
   Kuroda A, 2003, METABOLISM, V52, P203, DOI 10.1053/meta.2003.50026
   Li SJ, 2010, P NATL ACAD SCI USA, V107, P3441, DOI 10.1073/pnas.0914798107
   Li ZG, 2004, LIFE SCI, V76, P249, DOI 10.1016/j.lfs.2004.03.039
   Lima SS, 2010, NUTR NEUROSCI, V13, P21, DOI 10.1179/147683010X12611460763805
   Lin YT, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-126
   Mattson MP, 2004, AGEING RES REV, V3, P445, DOI 10.1016/j.arr.2004.08.001
   *MIN SCI TECHN PEO, 2006, GUID SUGG CAR US LAB
   Mochizuki N, 2008, EXP NEUROL, V211, P194, DOI 10.1016/j.expneurol.2008.01.027
   Nakagawa T, 2000, DIABETES, V49, P436, DOI 10.2337/diabetes.49.3.436
   Nibuya M, 1999, NEUROSCI LETT, V267, P81, DOI 10.1016/S0304-3940(99)00335-3
   Nonomura T, 2001, Int J Exp Diabetes Res, V2, P201, DOI 10.1155/EDR.2001.201
   Prasad RC, 2005, J ETHNOPHARMACOL, V96, P295, DOI 10.1016/j.jep.2004.09.024
   Rizk NN, 2006, BRAIN RES, V1096, P204, DOI 10.1016/j.brainres.2006.04.060
   Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003
   Shiuchi T, 2009, CELL METAB, V10, P466, DOI 10.1016/j.cmet.2009.09.013
   Shonesy BC, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.12.002
   Sunwoo YY, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/682720
   Takahashi M, 2000, JPN J PHARMACOL, V84, P259, DOI 10.1254/jjp.84.259
   Tonra JR, 1999, DIABETES, V48, P588, DOI 10.2337/diabetes.48.3.588
   Tsao D, 2008, ENDOCRINOLOGY, V149, P1038, DOI 10.1210/en.2007-1166
   Tsuchida A, 2001, DIABETOLOGIA, V44, P555, DOI 10.1007/s001250051661
   Uchino H, 1997, J CEREBR BLOOD F MET, V17, P1303, DOI 10.1097/00004647-199712000-00005
   Ulrich-Lai YM, 2011, J COMP NEUROL, V519, P1301, DOI 10.1002/cne.22571
   Uyama N, 2004, ANAT REC PART A, V280A, P808, DOI 10.1002/ar.a.20086
   Walker EA, 2007, J BIOL CHEM, V282, P27030, DOI 10.1074/jbc.M704144200
   Xu BJ, 2003, NAT NEUROSCI, V6, P736, DOI 10.1038/nn1073
   Yamada T, 2007, ENDOCR J, V54, P497, DOI 10.1507/endocrj.KR-106
   Zhang RL, 2003, EXP NEUROL, V184, P746, DOI 10.1016/S0014-4886(03)00296-6
   Zick Y, 2004, BIOCHEM SOC T, V32, P812, DOI 10.1042/BST0320812
NR 50
TC 4
Z9 8
U1 4
U2 20
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD SEP
PY 2013
VL 8
IS 25
BP 2370
EP 2378
DI 10.3969/j.issn.1673-5374.2013.25.008
PG 9
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA 229CL
UT WOS:000325239300008
PM 25206547
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Nirmala, MJ
   Mukherjee, A
   Chandrasekaran, N
AF Nirmala, M. Joyce
   Mukherjee, Amitava
   Chandrasekaran, N.
TI RETRACTED: Design and Formulation Technique of a Novel Drug Delivery
   System for Azithromycin and its Anti-Bacterial Activity Against
   Staphylococcus aureus (Retracted article. See vol. 15, pg. 511, 2014)
SO AAPS PHARMSCITECH
LA English
DT Article; Retracted Publication
DE antibacterial activity; azithromycin; cinnamon oil; fluorescence;
   thermodynamic stability
ID ANTIMICROBIAL ACTIVITY; PHYSICOCHEMICAL INVESTIGATIONS; BIOLOGICAL
   MICROEMULSIONS; NANOEMULSION FORMULATION; ACRIDINE-ORANGE; EMULSION
   COLOR; CINNAMON OIL; WATER; NANOPARTICLES; STABILITY
AB Azithromycin, an important member of the azalide subclass is effective against both Gram-positive and Gram-negative organisms. Certain physicochemical properties of the drug like poor water solubility and relatively low bioavailability of 37% due to incomplete absorption after ingestion, aroused the need for the development of a novel drug delivery system to enhance the solubilization potential and antibacterial activity against Staphylococcus aureus at a very low concentration. Cinnamon oil (Cinnamonum zeylanicum)-based microemulsion system formulated using non-ionic surfactant, Tween 20, and water was characterized. The drug-incorporated system F4 (oil to surfactant ratio of 1:4 (v/v)) showed enhanced solubilization of the drug, droplet diameter of 5-8 nm, and a good thermodynamic stability. The effect of surfactant concentration exhibited a negative correlation with droplet size diameter and turbidity and a positive correlation with stability and viscosity. The system was investigated for its antibacterial activity that demonstrated a significantly higher activity at a minimum concentration (4 mu g/ml) of the novel drug-loaded system in comparison with the conventional formulation (128 mu g/ml). Examination through scanning electron microscopy analysis further confirmed a considerable morphologic variation due to alteration in the membrane permeability of the microemulsion-treated system. The small droplet size of the microemulsion system and the antibacterial property of cinnamon oil, together, accounts clearly for the enhanced efficacy of the new formulated system F4 and not just azithromycin alone. Staining with acridine orange/ethidium bromide dyes as examined through fluorescence microscopy also substantiated with the results of membrane permeability of bacteria. Thus, our study discloses a potential oral drug delivery system of azithromycin with improved biocompatibility.
C1 [Nirmala, M. Joyce; Mukherjee, Amitava; Chandrasekaran, N.] VIT Univ, Ctr Nanobiotechnol, Vellore 632014, Tamil Nadu, India.
RP Chandrasekaran, N (reprint author), VIT Univ, Ctr Nanobiotechnol, Vellore 632014, Tamil Nadu, India.
EM nchandrasekaran@vit.ac.in
OI Mukherjee, Amitava/0000-0001-8682-4278
CR Acharya A, 2002, J COLLOID INTERF SCI, V245, P163, DOI 10.1006/jcis.2001.7980
   Acharya A, 2001, INT J PHARMACEUT, V229, P213, DOI 10.1016/S0378-5173(01)00863-8
   Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P5, DOI 10.1093/jac/48.suppl_1.5
   ARCHER GL, 1994, ANTIMICROB AGENTS CH, V38, P2231, DOI 10.1128/AAC.38.10.2231
   Arora SC, 2010, J ADV PHARM TECHNOL, V1, P221
   Ashley DJ, 1980, J CLIN PATHOL, V13, P336
   Badiceanu CD, 2009, FARMACIA, V57, P473
   Bagwe RP, 2001, CRIT REV THER DRUG, V18, P77
   Baker JR, 2003, US Patent, P6, Patent No. [559,189, 20036559189]
   BARRY AL, 1989, EUR J CLIN MICROBIOL, V8, P544, DOI 10.1007/BF01967477
   BARRY AL, 1987, ANTIMICROB AGENTS CH, V31, P343, DOI 10.1128/AAC.31.2.343
   BAUER AW, 1966, AM J CLIN PATHOL, V45, P493
   Champney WS, 1998, CURR MICROBIOL, V36, P119, DOI 10.1007/s002849900290
   Chayani N, 2009, INDIAN J MED MICROBI, V27, P107, DOI 10.4103/0255-0857.45361
   Chen HB, 2006, INT J PHARM, V315, P52, DOI 10.1016/j.ijpharm.2006.02.015
   CONSTANTINIDES PP, 1995, INT J PHARM, V115, P225, DOI 10.1016/0378-5173(94)00272-7
   Crosseley KB, 1997, STAPHYLOCOCCI HUMAN
   Dalai S, 2012, TOXICOL RES-UK, V1, P116, DOI 10.1039/c2tx00012a
   Damasceno BPGL, 2012, J BIOMED NANOTECHNOL, V8, P290, DOI 10.1166/jbn.2012.1374
   Dinos GP, 2001, MOL PHARMACOL, V59, P1441
   Duraipandiyan Veeramuthu, 2006, BMC Complement Altern Med, V6, P35, DOI 10.1186/1472-6882-6-35
   ELEINI DID, 1976, J COLLOID INTERF SCI, V54, P348, DOI 10.1016/0021-9797(76)90314-3
   Fatouros Dimitrios G, 2007, Ther Clin Risk Manag, V3, P591
   Ghosh V, 2013, ULTRASON SONOCHEM, V20, P338, DOI 10.1016/j.ultsonch.2012.08.010
   Goni P, 2009, FOOD CHEM, V116, P982, DOI 10.1016/j.foodchem.2009.03.058
   Gupta S, 2006, DRUG DELIV, V13, P193, DOI 10.1080/10717540500455983
   Gupta S, 2005, DRUG DELIV, V12, P267, DOI 10.1080/10717540500176373
   Gupta S, 2011, CURR SCI INDIA, V101, P174
   Hamidi M, 2012, MACROMOL BIOSCI, V12, P144, DOI 10.1002/mabi.201100193
   He CX, 2010, EXPERT OPIN DRUG DEL, V7, P445, DOI 10.1517/17425241003596337
   HOEPELMAN IM, 1995, INT J ANTIMICROB AG, V5, P145, DOI 10.1016/0924-8579(95)00009-W
   Hou LX, 2007, FOOD CONTROL, V18, P1350, DOI 10.1016/j.foodcont.2006.03.007
   Hunter RP, 2003, J VET PHARMACOL THER, V26, P117, DOI 10.1046/j.1365-2885.2003.00464.x
   Jakopec S, 2006, TOXICOL IN VITRO, V20, P217, DOI 10.1016/j.tiv.2005.06.008
   Klancnik A, 2010, J MICROBIOL METH, V81, P121, DOI 10.1016/j.mimet.2010.02.004
   Lala S, 2006, J DRUG TARGET, V14, P171, DOI 10.1080/10611860600497765
   Lauretti F, 2003, J VIROL METHODS, V114, P29, DOI 10.1016/j.jviromet.2003.08.005
   Lawrence MJ, 2000, ADV DRUG DELIVER REV, V45, P89, DOI 10.1016/S0169-409X(00)00103-4
   Lucia A, 2012, PHOL, V3, P158
   Luke DR, 1997, CLIN PHARMACOL THER, V61, P641, DOI 10.1016/S0009-9236(97)90098-9
   Mason TG, 2006, J PHYS-CONDENS MAT, V18, pR635, DOI 10.1088/0953-8984/18/41/R01
   Matan N, 2006, INT J FOOD MICROBIOL, V107, P180, DOI 10.1016/j.ijfoodmicro.2005.07.007
   MAZZEI T, 1993, J ANTIMICROB CHEMOTH, V31, P1
   McClements DJ, 2002, CURR OPIN COLLOID IN, V7, P451, DOI 10.1016/S1359-0294(02)00075-4
   McClements DJ, 2002, ADV COLLOID INTERFAC, V97, P63, DOI 10.1016/S0001-8686(01)00047-1
   Mitra N, 1996, INDIAN J BIOCHEM BIO, V33, P206
   Mitra N, 1996, INDIAN J BIOCH BIOPH, V31, P115
   Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013
   Nafisi S, 2007, J MOL STRUCT, V827, P35, DOI 10.1016/j.molstruc.2006.05.004
   Nagarajan R, 2000, LANGMUIR, V16, P6400, DOI 10.1021/la991578t
   Navarro FP, 2012, J BIOMED NANOTECHNOL, V8, P730, DOI 10.1166/jbn.2012.1430
   Park Y, 2012, J NANOSCI NANOTECHNO, V12, P7087, DOI 10.1166/jnn.2012.6575
   PAUL BK, 1991, INDIAN J BIOCHEM BIO, V28, P174
   Ping H, 2010, FOOD CHEM TOXICOL, V48, P2344, DOI 10.1016/j.fct.2010.05.069
   RETSEMA J, 1987, ANTIMICROB AGENTS CH, V31, P1939, DOI 10.1128/AAC.31.12.1939
   Sarangi S, 2012, J ASIAN EARTH SCI, V52, P1, DOI 10.1016/j.jseaes.2012.02.004
   Shafiq S, 2007, J BIOMED NANOTECHNOL, V3, P28, DOI 10.1166/jbn.2007.008
   Shah KA, 2009, J BIOMED NANOTECHNOL, V5, P396, DOI 10.1166/jbn.2009.1048
   SHINODA K, 1969, J COLLOID INTERF SCI, V30, P258, DOI 10.1016/S0021-9797(69)80012-3
   Singh G, 2007, FOOD CHEM TOXICOL, V45, P1650, DOI 10.1016/j.fct.2007.02.031
   Stokes DJ, 2003, PHILOS T ROY SOC A, V361, P2771, DOI 10.1098/rsta.2003.1279
   Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023
   Talegaonkar Sushama, 2008, Recent Pat Drug Deliv Formul, V2, P238
   Tzortzakis NG, 2009, INNOV FOOD SCI EMERG, V10, P97, DOI 10.1016/j.ifset.2008.09.002
   Wang R, 2009, INNOV FOOD SCI EMERG, V10, P289, DOI 10.1016/j.ifset.2008.12.002
   Yu HS, 2007, PHARMACOL BIOCHEM BE, V87, P164, DOI 10.1016/j.pbb.2007.04.013
   Yuan Y, 2006, INT J PHARM, V321, P117, DOI 10.1016/j.ijpharm.2006.06.021
NR 67
TC 3
Z9 4
U1 3
U2 25
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD SEP
PY 2013
VL 14
IS 3
BP 1045
EP 1054
DI 10.1208/s12249-013-9993-6
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 219DZ
UT WOS:000324487200015
PM 23800858
OA Green Published
DA 2018-12-27
ER

PT J
AU Dou, YF
   Liu, TL
AF Dou, Yifan
   Liu, Tianliang
TI RETRACTED: Exploring the value of installed base: Pricing information
   goods under value depreciation and consumer social learning (Retracted
   article. See vol. 22, pg. 505, 2013)
SO JOURNAL OF SYSTEMS SCIENCE AND SYSTEMS ENGINEERING
LA English
DT Article; Retracted Publication
DE Information goods; pricing strategies; product depreciation; consumer
   social learning
ID WORD-OF-MOUTH; DURABLE-GOODS; NETWORK EXTERNALITIES; MARKETS; MONOPOLY;
   DIFFERENTIATION; UNCERTAINTY; COMPETITION; STRATEGY; REVIEWS
AB While last decade has witnessed a rapid growth of digital economy, there is limited understanding in literature on whether the conventional wisdom on pricing strategy still holds for information goods. On one hand, information goods, similar to durable goods, are subject to value depreciation; on the other, they differ from traditional goods in negligible marginal cost and the sensitivity to social influences. This paper develops a two-period, game-theoretic model to investigate optimal pricing strategy of information goods. On one dimension, two different depreciation mechanisms (self- and time-depreciation) are considered; on the other, two prevalent pricing schemes (perpetual licensing and subscription-fee models) are studied. We obtain closed-form solutions in all scenarios. Our findings suggest that vendors of time-depreciation information goods should adopt subscription-fee model to attract early adopters and exploit social influences, while the vendors of self-depreciation information goods should strategically balance between depreciation and social influences. Interestingly, as social influences become strong enough, the difference between pricing schemes diminishes and the tradeoff between candidate strategies vanishes. We also extend the model to static pricing in which the vendor commits to future price. We discover that the superiority of subscription-fee model might be overturned under static pricing. Our results above also imply that building consumer feedback and interaction systems could be helpful for minimizing the potential loss of a suboptimal pricing scheme.
C1 [Dou, Yifan; Liu, Tianliang] Beihang Univ, Sch Econ & Management, Beijing 100191, Peoples R China.
RP Dou, YF (reprint author), Beihang Univ, Sch Econ & Management, Beijing 100191, Peoples R China.
EM dou@buaa.edu.cn; liutianliang@buaa.edu.cn
FU National Natural Science Foundation of China [71271001, 70901046,
   71302002]
FX This work was supported by the National Natural Science Foundation of
   China under Grant No. 71271001, 70901046, and 71302002. This is an
   extended work of the paper entitled "Pricing Information Goods in the
   Presence of Product Depreciation and Word-of-Mouth Effects", which was
   published in the Proceedings of 10th International Conference of System
   Science and System Engineering and recommended for publication in this
   journal by the International Program Committee of the conference.
CR BAGNOLI M, 1989, J POLIT ECON, V97, P1459, DOI 10.1086/261663
   Bakos Y, 1999, MANAGE SCI, V45, P1613, DOI 10.1287/mnsc.45.12.1613
   BANERJEE AV, 1992, Q J ECON, V107, P797, DOI 10.2307/2118364
   BASS FM, 1969, MANAGE SCI, V15, P215, DOI 10.1287/mnsc.15.5.215
   Bhargava H.K, 2000, J MANAGE INFORM SYST, V21, P201
   Bhargava HK, 2008, MANAGE SCI, V54, P1029, DOI 10.1287/mnsc.1070.0773
   Bhargava HK, 2001, J MANAGE INFORM SYST, V18, P89, DOI 10.1080/07421222.2001.11045681
   BULOW JI, 1982, J POLIT ECON, V90, P314, DOI 10.1086/261058
   Chen YB, 2008, MANAGE SCI, V54, P477, DOI 10.1287/mnsc.1070.0810
   Cheng HK, 2012, INFORM SYST RES, V23, P488, DOI 10.1287/isre.1110.0348
   Chevalier JA, 2006, J MARKETING RES, V43, P345, DOI 10.1509/jmkr.43.3.345
   Chien HK, 2008, MARKET SCI, V27, P1012, DOI 10.1287/mksc.1070.0356
   Choudhary V, 2005, MANAGE SCI, V51, P1120, DOI 10.1287/mnsc.1050.0383
   Choudhary V., 2007, P 40 HAW INT C SYST
   Choudhary V, 2010, INFORM SYST RES, V21, P78, DOI 10.1287/isre.1080.0203
   COASE RH, 1972, J LAW ECON, V15, P143, DOI 10.1086/466731
   CONLISK J, 1984, Q J ECON, V99, P489, DOI 10.2307/1885961
   Desai P, 1998, MANAGE SCI, V44, pS19, DOI 10.1287/mnsc.44.11.S19
   Desai PS, 1999, MARKET SCI, V18, P42, DOI 10.1287/mksc.18.1.42
   Dou YF, 2013, INFORM SYST RES, V24, P164, DOI 10.1287/isre.1120.0463
   ELLISON G, 1993, J POLIT ECON, V101, P612, DOI 10.1086/261890
   Forman C, 2008, INFORM SYST RES, V19, P291, DOI 10.1287/isre.1080.0193
   Fudenberg D., 1991, GAME THEORY
   Godes D, 2009, MARKET SCI, V28, P721, DOI 10.1287/mksc.1080.0444
   Hu J.Y., 2005, THESIS MIT
   Huang K.W, 2005, PRICING MODELS UNPUB
   Jing B, 2011, MARKET SCI, V30, P851, DOI 10.1287/mksc.1110.0649
   KATZ ML, 1985, AM ECON REV, V75, P424
   Lee D, 2008, PROD OPER MANAG, V17, P12, DOI 10.3401/poms.1070.0005
   MacKie-Mason J.K, 1995, PRICING INTERN UNPUB
   McFadden DL, 1996, J POLIT ECON, V104, P683, DOI 10.1086/262038
   Parker GG, 2005, MANAGE SCI, V51, P1494, DOI 10.1287/mnsc.1050.0400
   Shapiro C, 1999, INFORM RULES
   STOKEY NL, 1981, BELL J ECON, V12, P112, DOI 10.2307/3003511
   Sun BH, 2004, MARKET SCI, V23, P243, DOI 10.1287/mksc.1040.0058
   Sundararajan A, 2004, MANAGE SCI, V50, P1660, DOI 10.1287/mnsc.1040.0291
   Varian H.R, 1995, PRICING INFROM UNPUB
   Varian H. R, 1997, VERSIONING INF UNPUB
   Varian HR, 2000, J IND ECON, V48, P473
   Zhang J, 2010, J MANAGE INFORM SYST, V27, P39, DOI 10.2753/MIS0742-1222270103
   Zhang JJ, 2010, MARKET SCI, V29, P315, DOI 10.1287/mksc.1090.0500
NR 41
TC 1
Z9 2
U1 3
U2 38
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1004-3756
EI 1861-9576
J9 J SYST SCI SYST ENG
JI J. Syst. Sci. Syst. Eng.
PD SEP
PY 2013
VL 22
IS 3
BP 362
EP 382
DI 10.1007/s11518-013-5224-7
PG 21
WC Operations Research & Management Science
SC Operations Research & Management Science
GA 223QA
UT WOS:000324820400006
DA 2018-12-27
ER

PT J
AU Xu, YH
   Luo, SW
   Liu, Y
   Li, J
   Lu, Y
   Jia, ZG
   Zhao, QH
   Ma, XP
   Yang, MH
   Zhao, Y
   Chen, P
   Guo, Y
AF Xu, Yahong
   Luo, Shunwen
   Liu, Yang
   Li, Jian
   Lu, Yi
   Jia, Zhigang
   Zhao, Qihua
   Ma, Xiaoping
   Yang, Minghui
   Zhao, Yue
   Chen, Ping
   Guo, Yu
TI RETRACTED: Integrated gene network analysis and text mining revealing
   PIK3R1 regulated by miR-127 in human bladder cancer (Retracted article.
   See vol. 20, 43, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Bladder cancer; miRNA; phosphoinositide 3-kinase
ID MICRORNA TARGETS; PHOSPHOINOSITIDE 3-KINASE; DATABASE; PATHWAY; ALPHA
AB Background: Cancer is the result of a complex multistep process that involves the accumulation of sequential alterations of several genes, including those encoding microRNAs (miRNAs) that have critical roles in the regulation of gene expression. In this study, we aimed to predict potential mechanisms of bladder cancer related miRNAs and target genes by bioinformatics analyses.
   Methods: Here we used the method of text mining to identify nine miRNAs in bladder cancer and adopted protein-protein interaction analysis to identify interaction sites between these miRNAs and related-target genes.
   Results: There are two relationship types between bladder cancer and its related miRNAs: causal and unspecified. The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment test showed that there were three pathways related to four miRNA targeted genes. The remaining five miRNAs annotated to disease are not enriched in the KEGG pathways. Of these, PIK3R1 is the overlapping gene among 38 genes in the cancer and bladder cancer pathways.
   Conclusions: These findings provide new insights into the role of miRNAs in the pathway of cancer and give us a hypothesis that miR-127 might play a similar role in regulation and control of PIK3R1.
C1 [Xu, Yahong; Luo, Shunwen; Liu, Yang; Li, Jian; Lu, Yi; Jia, Zhigang; Zhao, Qihua; Ma, Xiaoping; Yang, Minghui; Guo, Yu] 452nd Hosp Peoples Liberat Army, Dept Urol, Chengdu 610021, Peoples R China.
   [Zhao, Yue] 452nd Hosp Peoples Liberat Army, Cadre Aircrew Div, Chengdu 610021, Peoples R China.
   [Chen, Ping] 452nd Hosp Peoples Liberat Army, Dept Nursing, Chengdu 610021, Peoples R China.
RP Xu, YH (reprint author), 452nd Hosp Peoples Liberat Army, Dept Urol, Chengdu 610021, Peoples R China.
EM xuyahong@medmail.com.cn
CR Bernhart SH, 2006, ALGORITHM MOL BIOL, V1, DOI 10.1186/1748-7188-1-3
   Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Catto JWF, 2009, CANCER RES, V69, P8472, DOI 10.1158/0008-5472.CAN-09-0744
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dyrskjot L, 2009, CANCER RES, V69, P4851, DOI 10.1158/0008-5472.CAN-08-4043
   Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114
   Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527
   Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599
   Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Jiang QH, 2009, NUCLEIC ACIDS RES, V37, pD98, DOI 10.1093/nar/gkn714
   Knowles MA, 2009, CANCER METAST REV, V28, P305, DOI 10.1007/s10555-009-9198-3
   Larsson SC, 2008, EUR J CANCER, V44, P2655, DOI 10.1016/j.ejca.2008.07.012
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lin TX, 2009, J UROLOGY, V181, P1372, DOI 10.1016/j.juro.2008.10.149
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   LU QA, 2010, MICRORNA 221 SILENCI, V28, P635, DOI DOI 10.1016/J.UROLONC.2009.06.005
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4
   Meliker JR, 2007, TRACE METALS OTHER, V9, P551, DOI 10.1016/S0927-5215(06)09021-7
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sethupathy P, 2006, RNA, V12, P192, DOI 10.1261/rna.2239606
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shariat SF, 2009, UROL ONCOL-SEMIN ORI, V27, P653, DOI 10.1016/j.urolonc.2009.07.020
   Sun M, 2001, CANCER RES, V61, P5985
   Terauchi Y, 1999, NAT GENET, V21, P230
   Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794
   Volanisa D, 2010, TOXICOL LETT, V193, P131, DOI 10.1016/j.toxlet.2009.12.018
   Wang XW, 2008, BIOINFORMATICS, V24, P325, DOI 10.1093/bioinformatics/btm595
   Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056
   Zeegers MPA, 2004, WORLD J UROL, V21, P392, DOI 10.1007/s00345-003-0382-8
NR 32
TC 3
Z9 3
U1 1
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD SEP 1
PY 2013
VL 18
AR 29
DI 10.1186/2047-783X-18-29
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 214PX
UT WOS:000324147400001
PM 24004856
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yang, HS
   Park, SH
   Choi, JR
   Kim, JG
AF Yang, Hyun Seung
   Park, So Hyun
   Choi, Jung Ran
   Kim, June-Gone
TI RETRACTED: Isolated central retinal artery occlusion as an initial
   presentation of paroxysmal nocturnal hemoglobinuria and successful
   long-term prevention of systemic thrombosis with eculizumab (Retracted
   article. See vol. 58, pg. 307, 2014)
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article; Retracted Publication
DE Anemia; Embolization; Paroxysmal nocturnal hemoglobinuria; Retinal
   artery occlusion; Thrombosis
ID COMPLEMENT INHIBITOR ECULIZUMAB; GIANT-CELL ARTERITIS;
   PLASMINOGEN-ACTIVATOR; FIBRINOLYSIS; EMBOLISM
AB To report on isolated central retinal artery occlusion (CRAO) as an initial presentation in two patients with undiagnosed paroxysmal nocturnal hemoglobinuria (PNH).
   CRAO related to the aggravation of PNH was observed in 2 of 98 consecutive PNH patients for 10 years. Ocular and systemic manifestations were evaluated before and after systemic steroid, eculizumab and anticoagulant administration with adjuvant ocular treatments.
   Two young patients presented with complaints of acute painless monocular vision loss. In both cases, fundus examination revealed retinal edema and a cherry-red spot in the macula, consistent with CRAO. On systemic evaluation, severe anemia and thrombocytopenia were observed, and simultaneously thrombogenic processes were suggested by increased d-dimers, fibrinogen degradation products and/or portal vein thrombosis. PNH testing of red blood cells revealed a CD55 and CD59 deficiency consistent with PNH in both cases. The systemic complications typically associated with thrombosis were not observed for the following several months with early conservative treatments including eculizumab.
   Acute blindness from CRAO can be a unique manifestation of undiagnosed PNH and its subsequent aggravation. Systemic evaluations including PNH testing, especially in young CRAO patients, are strongly recommended for early detection of the further systemic thrombogenic processes.
C1 [Yang, Hyun Seung; Kim, June-Gone] Asan Med Ctr, Dept Ophthalmol, Seoul 138736, South Korea.
   [Park, So Hyun; Choi, Jung Ran] Seoul Cent Vet Hosp, Dept Internal Med, Seoul, South Korea.
RP Kim, JG (reprint author), Asan Med Ctr, Dept Ophthalmol, 388-1 Pungnap 2 Dong, Seoul 138736, South Korea.
EM junekim@amc.seoul.kr
CR Bi S, 2011, NEUROSCIENCES, V16, P267
   CHARNESS ME, 1991, NEUROLOGY, V41, P1698, DOI 10.1212/WNL.41.10.1698
   Fukumoto Y, 1998, JPN CIRC J, V62, P61, DOI 10.1253/jcj.62.61
   Hauser AC, 2003, ANN HEMATOL, V82, P299, DOI 10.1007/s00277-003-0639-8
   Hillmen P, 2007, BLOOD, V110, P4123, DOI 10.1182/blood-2007-06-095646
   Hillmen P, 2010, AM J HEMATOL, V85, P553, DOI 10.1002/ajh.21757
   Hugel B, 1999, BLOOD, V93, P3451
   Ieko M, 2007, CLIN CHIM ACTA, V386, P38, DOI 10.1016/j.cca.2007.07.023
   Lee RJ, 1999, BLOOD, V94, p108B
   MATZKIN DC, 1992, OPHTHALMOLOGY, V99, P68
   MCMULLIN MF, 1994, J INTERN MED, V235, P85, DOI 10.1111/j.1365-2796.1994.tb01037.x
   PLOUG M, 1992, BLOOD, V79, P1447
   Pournaras JAC, 2010, ACTA OPHTHALMOL, V88, pe34, DOI 10.1111/j.1755-3768.2008.01366.x
   Ramus J, 2003, J ROY SOC MED, V96, P406, DOI 10.1258/jrsm.96.8.406
   Ratra D, 2012, INDIAN J OPHTHALMOL, V60, P95, DOI 10.4103/0301-4738.94049
   Rumelt S, 1999, AM J OPHTHALMOL, V128, P733, DOI 10.1016/S0002-9394(99)00359-1
   Scheuerle Alexander F., 2009, International Ophthalmology, V29, P187, DOI 10.1007/s10792-007-9188-9
   Schumacher M, 2010, OPHTHALMOLOGY, V117, P1367, DOI 10.1016/j.ophtha.2010.03.061
   Van Bijnen STA, 2012, J THROMB HAEMOST, V10, P1, DOI 10.1111/j.1538-7836.2011.04562.x
   Yamazaki T, 2005, EUR NEUROL, V53, P217, DOI 10.1159/000086735
   Ziakas PD, 2007, J THROMB HAEMOST, V5, P642, DOI 10.1111/j.1538-7836.2007.02379.x
   Ziakas PD, 2008, CURR VASC PHARMACOL, V6, P347, DOI 10.2174/157016108785909742
NR 22
TC 1
Z9 1
U1 4
U2 13
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2013
VL 57
IS 5
BP 424
EP 428
DI 10.1007/s10384-013-0252-x
PG 5
WC Ophthalmology
SC Ophthalmology
GA 214IV
UT WOS:000324126900002
PM 23765390
DA 2018-12-27
ER

PT J
AU Derosa, G
   Cicero, AFG
   Carbone, A
   Querci, F
   Fogari, E
   D'Angelo, A
   Maffioli, P
AF Derosa, Giuseppe
   Cicero, Arrigo Francesco Giuseppe
   Carbone, Anna
   Querci, Fabrizio
   Fogari, Elena
   D'Angelo, Angela
   Maffioli, Pamela
TI RETRACTED: Evaluation of safety and efficacy of a fixed
   olmesartan/amlodipine combination therapy compared to single
   monotherapies (Retracted article. See vol. 14, pg. 1647, 2015)
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review; Retracted Publication
DE amlodipine; combination therapy; hypertension; interleukins; olmesartan
ID DIABETIC HYPERTENSIVE PATIENTS; WEIBEL-PALADE BODIES; BLOOD-PRESSURE;
   INSULIN-RESISTANCE; ENDOTHELIAL-CELLS; AMLODIPINE; OLMESARTAN; VISFATIN;
   SERUM; TRIAL
AB Background: Hypertension is known to be one of the main risk factors for cardiovascular disease.
   Objectives: To evaluate the safety and efficacy of a fixed olmesartan/amlodipine (Olme/Amlo) combination in improving blood pressure control, lipid profile, insulin sensitivity and some inflammatory and insulin resistance markers. Two hundred and seventy-six hypertensive patients were randomly assigned to olmesartan 20 mg, amlodipine 10 mg or a single pill containing an Olme/Amlo combination 20/5 mg for 12 months. We evaluated after 6 and 12 months: body weight, body mass index (BMI), systolic and diastolic blood pressure (SBP and DBP, respectively), fasting plasma glucose (FPG), fasting plasma insulin (FPI), lipid profile, vaspin, visfatin, interleukins 8 and 10 (IL-8 and IL-10, respectively). Patients also underwent an euglycemic, hyperinsulinemic clamp.
   Results: Olme/Amlo combination was more effective in decreasing SBP, and DPB compared to single monotherapies after 12 months. Olme/Amlo combination, but not amlodipine, decreased FPG after 12 months. FPI and HOMA index were decreased, and M value increased by Olme/Amlo combination compared to olmesartan monotherapy, and to amlodipine monotherapy. Olme/Amlo significantly decreased IL-8 and IL-10 better than each monotherapy.
   Conclusions: Olme/Amlo single pill combination can be a safe and effective option to reduce blood pressure, improve insulin sensitivity and decrease inflammatory markers.
C1 [Derosa, Giuseppe; Fogari, Elena; D'Angelo, Angela; Maffioli, Pamela] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy.
   [Cicero, Arrigo Francesco Giuseppe] Univ Bologna, Internal Med Aging & Kidney Dis Dept, I-40138 Bologna, Italy.
   [Carbone, Anna] Hosp SantAngelo Lodigiano, Hosp Ctr Diabet, Lodi, Italy.
   [Querci, Fabrizio] Osped Pesenti Fenaroli, Bergamo, Italy.
RP Derosa, G (reprint author), Univ Pavia, Dept Internal Med & Therapeut, Ple C Golgi 2, I-27100 Pavia, Italy.
EM giuseppe.derosa@unipv.it
OI Cicero, Arrigo/0000-0002-4367-3884; Derosa, Giuseppe/0000-0003-3573-4760
CR Aguilar M, 1999, DIABETIC MED, V16, P716
   Chrysant SG, 2008, CLIN THER, V30, P587, DOI 10.1016/j.clinthera.2008.04.002
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, P214
   Derosa G, 2011, EXPERT OPIN DRUG SAF, V10, P795, DOI 10.1517/14740338.2011.585966
   Derosa G, 2010, HYPERTENS RES, V33, P790, DOI 10.1038/hr.2010.85
   Derosa G, 2010, EXPERT REV CARDIOVAS, V8, P835, DOI [10.1586/erc.10.51, 10.1586/ERC.10.51]
   Derosa G, 2010, HYPERTENS RES, V33, P209, DOI 10.1038/hr.2009.212
   FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605
   Fogari R, 2004, AM J HYPERTENS, V17, P823, DOI 10.1016/j.amjhyper.2004.06.005
   Fogari R, 2012, CLIN CARDIOL, V35, P359, DOI 10.1002/clc.21994
   Fogari R, 2012, EXPERT OPIN PHARMACO, V13, P1091, DOI 10.1517/14656566.2012.683175
   Fogari R, 2012, EUR J GASTROEN HEPAT, V24, P164, DOI 10.1097/MEG.0b013e32834ba188
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Fukao K, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-79
   Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243
   Groux H, 2003, J AUTOIMMUN, V20, P281, DOI 10.1016/S0896-8411(03)00044-1
   Gurbel PA, 2008, AM HEART J, V155, P56, DOI 10.1016/j.ahj.2007.08.021
   Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569
   Hida K, 2005, P NATL ACAD SCI USA, V102, P10610, DOI 10.1073/pnas.0504703102
   Hug C, 2005, SCIENCE, V307, P366, DOI 10.1126/science.1106933
   Kannel WB, 1996, JAMA-J AM MED ASSOC, V275, P1571, DOI 10.1001/jama.275.20.1571
   Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021
   KLOSE S, 1978, J CLIN CHEM CLIN BIO, V15, P121
   Korner A, 2007, J CLIN ENDOCR METAB, V92, P4783, DOI 10.1210/jc.2007-1304
   Lichtenstein AH, 2006, ARTERIOSCL THROM VAS, V26, P2186, DOI 10.1161/01.ATV.0000238352.25222.5e
   Liu LS, 2005, J HYPERTENS, V23, P2157, DOI 10.1097/01.hjh.0000194120.42722.ac
   Mancia G, 2009, J HYPERTENS, V27, P2121, DOI 10.1097/HJH.0b013e328333146d
   Martinez-Martin FJ, 2011, J HUM HYPERTENS, V25, P346, DOI 10.1038/jhh.2010.104
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Miura S, 2005, CURR HYPERTENS REV, V1, P115, DOI 10.2174/1573402054022285
   Mizia-Stec K, 2002, INTERNAL MED, V13, P115
   Steckelings UM, 2009, FUND CLIN PHARMACOL, V23, P693, DOI 10.1111/j.1472-8206.2009.00780.x
   Teramoto T, 2008, HYPERTENS RES, V31, P2011, DOI 10.1291/hypres.31.2011
   Utgaard JO, 1998, J EXP MED, V188, P1751, DOI 10.1084/jem.188.9.1751
   WAHLEFELD AW, 1974, METHOD ENZYMAT AN, P18
   Winer B. J., 1971, STAT PRINCIPLES EXPT
   Wolff B, 1998, J EXP MED, V188, P1757, DOI 10.1084/jem.188.9.1757
NR 39
TC 8
Z9 8
U1 2
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD SEP
PY 2013
VL 12
IS 5
BP 621
EP 629
DI 10.1517/14740338.2013.816674
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 206AW
UT WOS:000323488900004
PM 23815562
DA 2018-12-27
ER

PT J
AU Wildbaum, G
   Shahar, E
   Katz, R
   Karin, N
   Etzioni, A
   Pollack, S
AF Wildbaum, Gizi
   Shahar, Eduardo
   Katz, Rina
   Karin, Nathan
   Etzioni, Amos
   Pollack, Shimon
TI RETRACTED: Continuous G-CSF therapy for isolated chronic mucocutaneous
   candidiasis: Complete clinical remission with restoration of IL-17
   secretion (Retracted article. See vol. 141, pg. 1167, 2018)
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter; Retracted Publication
ID IMMUNITY
C1 [Wildbaum, Gizi; Shahar, Eduardo; Karin, Nathan; Etzioni, Amos; Pollack, Shimon] Technion Israel Inst Technol, Rappaport Fac Med, Dept Immunol, Haifa, Israel.
   [Shahar, Eduardo; Katz, Rina; Etzioni, Amos; Pollack, Shimon] Rambam Hlth Care Campus, Inst Allergy Immunol & AIDS, Haifa, Israel.
RP Wildbaum, G (reprint author), Technion Israel Inst Technol, Rappaport Fac Med, Dept Immunol, Haifa, Israel.
EM pollack@rambam.health.gov.il
CR Cypowyj S, 2012, EUR J IMMUNOL, V42, P2246, DOI 10.1002/eji.201242605
   Hanna S, 2011, J ALLERGY CLIN IMMUN, V127, P1433, DOI 10.1016/j.jaci.2011.03.026
   Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958
   McGeachy MJ, 2011, NAT IMMUNOL, V12, P521, DOI 10.1038/ni.2044
   Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764
   Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983
   SHAHAR E, 1995, LANCET, V346, P974, DOI 10.1016/S0140-6736(95)91599-0
   Tamiya T, 2012, ARTERIOSCLER THROMB, P981
   TIAN SS, 1994, BLOOD, V84, P1760
   Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957
NR 10
TC 32
Z9 34
U1 1
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD SEP
PY 2013
VL 132
IS 3
BP 761
EP 764
DI 10.1016/j.jaci.2013.04.018
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 207OS
UT WOS:000323612000037
PM 23791509
DA 2018-12-27
ER

PT J
AU Zhao, HY
   Zhao, HY
   Wang, Y
   Jing, H
   Ding, Q
   Xue, J
AF Zhao, Hongyan
   Zhao, Hongying
   Wang, Yu
   Jing, Huang
   Ding, Qian
   Xue, Jun
TI RETRACTED: Randomized clinical trial of arginine-supplemented enteral
   nutrition versus standard enteral nutrition in patients undergoing
   gastric cancer surgery (Retracted article. See vol. 141, pg. 573, 2015)
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE Arginine; Malnutrition; Gastric cancer; Enteral nutrition
ID NITRIC-OXIDE; IMMUNONUTRITION; COMPLICATIONS; APOPTOSIS; METAANALYSIS;
   MORTALITY; CARCINOMA; SURVIVAL; CELLS; HEAD
AB Significant malnutrition exists in a high percentage of patients with gastric cancer. It is, therefore, crucial to establish an effective means to provide nutrition for these patients. This prospective, randomized, double-blinded clinical trial aims to assess the long-term survival of arginine-supplementation enteral nutrition versus standard enteral nutrition in malnourished patients with gastric cancer.
   The control group (36 cases) received postoperative standard enteral nutrition. Meanwhile, the arginine-supplementation group (37 cases) adopted the same nutrition product but enriched with arginine (9.0 g/L). The primary study objective was overall survival (OS). Secondary endpoints were progression-free survival (PFS); serum parameters including total protein, albumin, proalbumin, and transferrin obtained on preoperative day 1, postoperative day 2, and day 12; CD4(+) and CD8(+) T cells, natural killer (NK) cells, immunoglobulin M (IgM), and immunoglobulin G (IgG) obtained on preoperative day 1 and postoperative day 7.
   No significant differences in baseline characteristics were observed between groups. The group receiving arginine-enriched nutrition had a significantly better OS (P = 0.03, 41 vs. 30.5 months) and better PFS (P = 0.02, 18 vs. 11.5 months). On postoperative day 7, CD4(+) T cells, NK cells, IgM and IgG levels of the arginine-supplemented group increased prominently and were significantly higher than those of the control group and those on preoperative day 1. There is no significant difference in the serum total protein, albumin, proalbumin, and transferrin levels between the two arms.
   Arginine-supplemented enteral nutrition significantly improves long-term survival and restores immunity in malnourished gastric cancer.
C1 [Zhao, Hongyan] Daqing Oilfield Gen Hosp, Dept Intens Care Unit, Daqing 163001, Peoples R China.
   [Zhao, Hongying] Daqing Longnan Hosp, Dept Oncol, Daqing 163453, Peoples R China.
   [Wang, Yu] Daqing Longnan Hosp, Dept Gen Surg, Daqing 163453, Peoples R China.
   [Jing, Huang; Ding, Qian; Xue, Jun] Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.
RP Xue, J (reprint author), Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.
EM xuejuntju@163.com
CR BANI D, 1995, CANCER RES, V55, P5272
   Bosetti C, 2008, ANN ONCOL, V19, P631, DOI 10.1093/annonc/mdm597
   Buijs N, 2010, AM J CLIN NUTR, V92, P1151, DOI 10.3945/ajcn.2010.29532
   Chen Da Wei, 2005, Asian J Surg, V28, P121, DOI 10.1016/S1015-9584(09)60275-X
   Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601
   Gianotti L, 1999, JPEN-PARENTER ENTER, V23, P314, DOI 10.1177/0148607199023006314
   Gil-Rendo A, 2006, Clin Transl Oncol, V8, P354, DOI 10.1007/s12094-006-0182-x
   Griffiths RD, 2005, POSTGRAD MED J, V81, P629, DOI 10.1136/pgmj.2005.033399
   Kelley JR, 2003, J CLIN EPIDEMIOL, V56, P1, DOI 10.1016/S0895-4356(02)00534-6
   Lin MT, 1996, ANN SURG, V223, P84, DOI 10.1097/00000658-199601000-00012
   Lind DS, 2004, J NUTR, V134, p2837S, DOI 10.1093/jn/134.10.2837S
   Liu H, 2012, J DIGEST DIS, V13, P401, DOI 10.1111/j.1751-2980.2012.00596.x
   MEGUID MM, 1988, AM J SURG, V156, P341, DOI 10.1016/S0002-9610(88)80182-X
   MERIMEE TJ, 1969, NEW ENGL J MED, V280, P1434, DOI 10.1056/NEJM196906262802603
   MESSMER UK, 1994, FEBS LETT, V355, P23
   MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008
   Nicotera P, 1995, ADV NEUROIMMUNOL, V5, P411, DOI 10.1016/0960-5428(95)00025-9
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Roder JD, 1998, CANCER-AM CANCER SOC, V82, P621, DOI 10.1002/(SICI)1097-0142(19980215)82:4<621::AID-CNCR2>3.3.CO;2-2
   Senkal M, 1999, ARCH SURG-CHICAGO, V134, P1309, DOI 10.1001/archsurg.134.12.1309
   Stechmiller JK, 2004, AM J CRIT CARE, V13, P17
   Sungurtekin H, 2004, J AM COLL NUTR, V23, P227, DOI 10.1080/07315724.2004.10719365
   van Bokhorst-de van der Schueren MAE, 2001, AM J CLIN NUTR, V73, P323
   Vissers YLJ, 2005, AM J CLIN NUTR, V81, P1142
   Weimann A, 2006, CLIN NUTR, V25, P224, DOI 10.1016/j.clnu.2006.01.015
   Yang L, 2006, WORLD J GASTROENTERO, V12, P17, DOI 10.3748/wjg.v12.i1.17
   Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505
   Zheng YM, 2007, ASIA PAC J CLIN NUTR, V16, P253
NR 28
TC 16
Z9 22
U1 1
U2 37
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD SEP
PY 2013
VL 139
IS 9
BP 1465
EP 1470
DI 10.1007/s00432-013-1466-5
PG 6
WC Oncology
SC Oncology
GA 202WG
UT WOS:000323250700004
PM 23812551
DA 2018-12-27
ER

PT J
AU Oh, CS
   Han, CS
AF Oh, Chang-Sup
   Han, Chang-Suk
TI RETRACTED: Microstructure and strengthening mechanism of Ni3Al
   intermetallic compound (Retracted article. See vol. 21, pg. 616, 2015)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE intermetallics; aging; mechanical properties; transmission electron
   microscopy (TEM); strengthening mechanism
ID SINGLE-CRYSTALS; FLOW-STRESS; ALLOY; ASYMMETRY; DISLOCATIONS;
   DEFORMATION; TEMPERATURE
AB Structural studies have been performed on precipitation hardening found in Ni3Al-base ordered alloys using transmission electron microscopy. The gamma' phase hardens appreciably by the fine precipitation of disordered gamma. The strength of gamma' increases over the temperature range of experiment by the precipitation of fine gamma particles. The peak temperature where a maximum strength was obtained shifted to higher temperature. Superlattice dislocations dissociate into fourfold Shockley partial dislocations in a uniform supersaturated solid solution of the gamma' phase. Dislocations are attracted into the disordered gamma phase and dissociate further in the particles. At any stage of aging, dislocations cut through the particles and the Orowan bypassing process does not occur even in the overaged stage of this alloy system. When the applied stress is removed, the dislocations make cross slip into (010) plane, while those in gamma precipitates remain on the (111) primary slip plane. The increase of high temperature strength in gamma' containing gamma precipitates is due to the restraint of cross slip of dislocations from (111) to (010) by the dispersion of disordered gamma particles. The orientation dependence of strength is decreased by the fine precipitation of a disordered gamma phase.
C1 [Oh, Chang-Sup] Korea Inst Sci & Technol Informat, Reseat Program, Taejon 305806, South Korea.
   [Han, Chang-Suk] Hoseo Univ, Dept Def Sci & Technol, Asancity 336795, Chungnam, South Korea.
RP Han, CS (reprint author), Hoseo Univ, Dept Def Sci & Technol, 165 Sechul Ri, Asancity 336795, Chungnam, South Korea.
EM hancs@hoseo.edu
FU Reseat program of KISTI through NRF; MEST
FX This research was supported by Reseat program of KISTI through NRF
   funded by MEST.
CR ARDELL AJ, 1985, METALL TRANS A, V16, P2131, DOI 10.1007/BF02670416
   ARZT E, 1988, ACTA METALL MATER, V36, P1053, DOI 10.1016/0001-6160(88)90159-9
   Baluc N., 1988, I PHYS C SER, V98, P463
   BROWN LM, 1973, SCRIPTA METALL MATER, V7, P815, DOI 10.1016/0036-9748(73)90270-6
   Chun D. H., 2005, J KOREAN INST MET MA, V43, P801
   EZZ SS, 1987, ACTA METALL MATER, V35, P1879, DOI 10.1016/0001-6160(87)90133-7
   EZZ SS, 1982, ACTA METALL MATER, V30, P921, DOI 10.1016/0001-6160(82)90198-5
   FOREMAN AJE, 1966, PHILOS MAG, V14, P911, DOI 10.1080/14786436608244762
   FRIEDEL J, 1982, PHILOS MAG A, V45, P271, DOI 10.1080/01418618208244300
   Han CS, 2011, KOREAN J MET MATER, V49, P137, DOI 10.3365/KJMM.2011.49.2.137
   HEREDIA FE, 1986, ACTA METALL MATER, V34, P279, DOI 10.1016/0001-6160(86)90198-7
   HIRSCH PB, 1965, PHILOS MAG, V12, P881, DOI 10.1080/14786436508228118
   Khan T., 1986, SCRIPTA METALL, V20, P1395
   Kim I. S., 2011, KOREAN J MET MAT, V49, P112
   Kim IS, 2011, KOREAN J MET MATER, V49, P535, DOI 10.3365/KJMM.2011.49.7.535
   KOCKS UF, 1966, PHILOS MAG, V13, P541, DOI 10.1080/14786436608212647
   Song SH, 2004, MET MATER-INT, V10, P307, DOI 10.1007/BF03185978
   STATONBEVAN AE, 1975, PHYS STATUS SOLIDI A, V29, P613, DOI 10.1002/pssa.2210290232
   VEYSSIERE P, 1988, PHIL MAG LETT, V57, P17, DOI 10.1080/09500838808227792
   VEYSSIERE P, 1984, PHILOS MAG A, V49, P45, DOI 10.1080/01418618408233427
NR 20
TC 2
Z9 2
U1 4
U2 34
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD SEP
PY 2013
VL 19
IS 5
BP 941
EP 948
DI 10.1007/s12540-013-5006-2
PG 8
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 203IA
UT WOS:000323284200006
DA 2018-12-27
ER

PT J
AU Zebracki, M
AF Zebracki, Martin
TI RETRACTED: Right to Space: Moving Towards Sexual Citizenship Beyond the
   Nation State (Retracted article. See vol. 46, pg. 592, 2014)
SO ANTIPODE
LA English
DT Article; Retracted Publication
ID GEOGRAPHIES
C1 [Zebracki, Martin] Wageningen Univ, Cultural Geog Grp, NL-6700 AP Wageningen, Netherlands.
   [Zebracki, Martin] Univ Utrecht, Utrecht, Netherlands.
   [Zebracki, Martin] Vrije Univ Brussel, Brussels, Belgium.
RP Zebracki, M (reprint author), Wageningen Univ, Cultural Geog Grp, NL-6700 AP Wageningen, Netherlands.
EM martin.zebracki@wur.nl
CR Bell D., 1995, MAPPING DESIRE GEOGR
   Bell David, 2000, SEXUAL CITIZEN QUEER
   Browne K., 2007, GEOGRAPHIES SEXUALIT
   Browne K, 2010, GENDER PLACE CULT, V17, P573, DOI 10.1080/0966369X.2010.503104
   De Lauretis Teresa., 1991, DIFFERENCES, V3, piii
   Hubbard P., 2011, CITIES SEXUALITIES
   Johnston L., 2010, SPACE PLACE SEX GEOG
   Oswin N, 2008, PROG HUM GEOG, V32, P89, DOI 10.1177/0309132507085213
   Puar Jasbir K, 2007, TERRORIST ASSEMBLAGE
   Taylor Y, 2010, GENDER SEX SOC SCI, P1, DOI 10.1057/9780230304093
NR 10
TC 1
Z9 1
U1 2
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0066-4812
EI 1467-8330
J9 ANTIPODE
JI Antipode
PD SEP
PY 2013
VL 45
IS 4
BP 785
EP 788
DI 10.1111/anti.12022
PG 4
WC Geography
SC Geography
GA 196IA
UT WOS:000322766300002
DA 2018-12-27
ER

PT J
AU Crowther, GS
AF Crowther, G. Scott
TI RETRACTED: Frozen Soil Strength Criteria for Lateral Pile Analysis
   (Retracted article. See vol. 29, 08214001, 2015)
SO JOURNAL OF COLD REGIONS ENGINEERING
LA English
DT Article; Retracted Publication
DE Frozen; Soil; Strength; Lateral; Pile; Permafrost; p-y
ID LOADED PILES; PERMAFROST
AB This paper presents a design approach to analyze the effects of lateral loads on piles embedded in a layered frozen soil profile. This design approach makes use of a commercially available computer program that uses curves to model lateral pile loading and soil interaction. Shear strength and strain criteria for both fine- and coarse-grained frozen soil are presented for use in constructing curves. These strength criteria are parameterized based on frozen soil temperature and load duration. Inuvik lateral pile load test results and deflections calculated using the strength criteria are compared. Deflections and moments are also calculated using the strength criteria for two Prudhoe Bay, Alaska, lateral pile load cases.
C1 Crowther Associates, Anchorage, AK 99515 USA.
RP Crowther, GS (reprint author), Crowther Associates, 1632 Bellevue Circle, Anchorage, AK 99515 USA.
EM crowther@alaska.net
CR [Anonymous], LPILE
   Gregory D. R., 2003, J COLD REG ENG, V17, P90
   Hetenyi M., 1946, BEAMS ELASTIC FDN
   Matlock HS., 1970, P 2 ANN OFFSH TECHN, V1, P577, DOI DOI 10.4043/1204-MS
   NEUKIRCHNER RJ, 1987, J GEOTECH ENG-ASCE, V113, P1, DOI 10.1061/(ASCE)0733-9410(1987)113:1(1)
   NIXON JF, 1984, CAN GEOTECH J, V21, P431, DOI 10.1139/t84-047
   Reese L. C., 1975, P SEMINAR SERIES DES
   Reese L.C., 1977, J GEOTECH ENG DIV AS, V103, P287
   Rowley R. K., 1973, P 2 INT C PERM USSR, P712
   ROWLEY RK, 1975, CAN GEOTECH J, V12, P510, DOI 10.1139/t75-057
   Sayles F. H., 1974, 252 COLD REG RES ENG
   Sayles F. H., 1968, 190 COLD REG RES ENG
   WEAVER JS, 1981, CAN GEOTECH J, V18, P357, DOI 10.1139/t81-043
   Yuanlin Z., 1987, 8710 COLD REG ENG LA
NR 14
TC 2
Z9 3
U1 2
U2 25
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 0887-381X
EI 1943-5495
J9 J COLD REG ENG
JI J. Cold Reg. Eng.
PD SEP 1
PY 2013
VL 27
IS 3
BP 155
EP 167
DI 10.1061/(ASCE)CR.1943-5495.0000058
PG 13
WC Engineering, Environmental; Engineering, Civil; Geosciences,
   Multidisciplinary
SC Engineering; Geology
GA 198XX
UT WOS:000322958400003
DA 2018-12-27
ER

PT J
AU Leung, CK
   Wang, Y
   Deonarine, A
   Tang, L
   Prasse, S
   Choe, KP
AF Leung, Chi K.
   Wang, Ying
   Deonarine, Andrew
   Tang, Lanlan
   Prasse, Stephanie
   Choe, Keith P.
TI RETRACTED: A Negative-Feedback Loop between the
   Detoxification/Antioxidant Response Factor SKN-1 and Its Repressor
   WDR-23 Matches Organism Needs with Environmental Conditions (Retracted
   article. See vol. 35, pg. 3254, 2015)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID OXIDATIVE-STRESS-RESPONSE; TRANSCRIPTION FACTOR SKN-1;
   CAENORHABDITIS-ELEGANS; ANTAGONISTIC PLEIOTROPY; C. ELEGANS; LIFE-SPAN;
   MOLECULAR-MECHANISMS; KEAP1-NRF2 PATHWAY; NRF2 ACTIVATION; CANCER-CELLS
AB Negative-feedback loops between transcription factors and repressors in responses to xenobiotics, oxidants, heat, hypoxia, DNA damage, and infection have been described. Although common, the function of feedback is largely unstudied. Here, we define a negative-feedback loop between the Caenorhabditis elegans detoxification/antioxidant response factor SKN-1/Nrf and its repressor wdr-23 and investigate its function in vivo. Although SKN-1 promotes stress resistance and longevity, we find that tight regulation by WDR-23 is essential for growth and reproduction. By disabling SKN-1 transactivation of wdr-23, we reveal that feedback is required to set the balance between growth/reproduction and stress resistance/longevity. We also find that feedback is required to set the sensitivity of a core SKN-1 target gene to an electrophile. Interestingly, the effect of feedback on target gene induction is greatly reduced when the stress response is strongly activated, presumably to ensure maximum activation of cytoprotective genes during potentially fatal conditions. Our work provides a framework for understanding the function of negative feedback in inducible stress responses and demonstrates that manipulation of feedback alone can shift the balance of competing animal processes toward cell protection, health, and longevity.
C1 [Choe, Keith P.] Univ Florida, Dept Biol, Gainesville, FL 32610 USA.
   Univ Florida, Genet Inst, Gainesville, FL USA.
RP Choe, KP (reprint author), Univ Florida, Dept Biol, Gainesville, FL 32610 USA.
EM kchoe@ufl.edu
FU NSF grant [IOS-1120130]; University of Florida Research Opportunity Seed
   Fund Award
FX This work was funded by NSF grant IOS-1120130 to K.P.C. and a University
   of Florida Research Opportunity Seed Fund Award.
CR Aithal KB, 2012, INTEGR CANCER THER, V11, P68, DOI 10.1177/1534735411403477
   An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803
   An JH, 2005, P NATL ACAD SCI USA, V102, P16275, DOI 10.1073/pnas.0508105102
   BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715
   Blagosklonny MV, 2010, CELL CYCLE, V9, P3151, DOI 10.4161/cc.9.16.13120
   BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q
   BRENNER S, 1974, GENETICS, V77, P71
   Choe KP, 2007, AM J PHYSIOL-CELL PH, V293, pC915, DOI 10.1152/ajpcell.00126.2007
   Choe KP, 2012, DRUG METAB REV, V44, P209, DOI 10.3109/03602532.2012.684799
   Choe KP, 2009, MOL CELL BIOL, V29, P2704, DOI 10.1128/MCB.01811-08
   Contrino S, 2012, NUCLEIC ACIDS RES, V40, pD1082, DOI 10.1093/nar/gkr921
   Curran SP, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030056
   Dupuy D, 2004, GENOME RES, V14, P2169, DOI 10.1101/gr.2497604
   Flemming AJ, 2000, P NATL ACAD SCI USA, V97, P5285, DOI 10.1073/pnas.97.10.5285
   Frokjaer-Jensen C, 2008, NAT GENET, V40, P1375, DOI 10.1038/ng.248
   Frokjaer-Jensen C, 2012, NAT METHODS, V9, P117, DOI 10.1038/nmeth.1865
   Giudice A, 2010, METHODS MOL BIOL, V647, P37, DOI 10.1007/978-1-60761-738-9_3
   Hasegawa K, 2004, TOXICOL LETT, V152, P183, DOI 10.1016/j.toxlet.2004.04.037
   Hasegawa K, 2008, TOXICOL SCI, V101, P215, DOI 10.1093/toxsci/kfm276
   Hasegawa K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011194
   Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221
   Hochmuth CE, 2011, CELL STEM CELL, V8, P188, DOI 10.1016/j.stem.2010.12.006
   Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006
   Inoue H, 2005, GENE DEV, V19, P2278, DOI 10.1101/gad.1324805
   Ji RR, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000512
   Kahn NW, 2008, BIOCHEM J, V409, P205, DOI 10.1042/BJ20070521
   Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002
   Kapahi P, 2010, ADV EXP MED BIOL, V694, P30
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   KIONTKE K, 2005, WORMBOOK
   Kundu JK, 2010, PHARM RES-DORDR, V27, P999, DOI 10.1007/s11095-010-0096-8
   Lee OH, 2007, J BIOL CHEM, V282, P36412, DOI 10.1074/jbc.M706517200
   Leiser SF, 2010, MOL CELL BIOL, V30, P871, DOI 10.1128/MCB.01145-09
   Leroi AM, 2005, MECH AGEING DEV, V126, P421, DOI 10.1016/j.mad.2004.07.012
   Leung CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062166
   Leung CK, 2011, JOVE-J VIS EXP, DOI 10.3791/2745
   Leung CK, 2012, FREE RADICAL BIO MED, V52, P937, DOI 10.1016/j.freeradbiomed.2011.12.009
   Ljubuncic P, 2009, GERONTOLOGY, V55, P205, DOI 10.1159/000200772
   LoPachin RM, 2012, ENVIRON HEALTH PERSP, V120, P1650, DOI 10.1289/ehp.1205432
   Lozano E, 2006, CURR BIOL, V16, P493, DOI 10.1016/j.cub.2006.01.048
   Lu X, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000984
   Morck C, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-39
   Okuyama T, 2010, J BIOL CHEM, V285, P30274, DOI 10.1074/jbc.M110.146274
   Oliveira RP, 2009, AGING CELL, V8, P524, DOI 10.1111/j.1474-9726.2009.00501.x
   Park SK, 2009, AGING CELL, V8, P258, DOI 10.1111/j.1474-9726.2009.00473.x
   Prasad SN, 2013, NEUROCHEM RES, V38, P330, DOI 10.1007/s11064-012-0924-9
   Pruser Kaci N, 2011, Front Biosci (Schol Ed), V3, P41, DOI 10.2741/s130
   Przybysz AJ, 2009, MECH AGEING DEV, V130, P357, DOI 10.1016/j.mad.2009.02.004
   Robida-Stubbs S, 2012, CELL METAB, V15, P713, DOI 10.1016/j.cmet.2012.04.007
   Rodriguez CE, 2004, TOXICOLOGY, V201, P185, DOI 10.1016/j.tox.2004.04.016
   Ruland J, 2011, NAT IMMUNOL, V12, P709, DOI 10.1038/ni.2055
   Ruvinsky I, 2003, DEVELOPMENT, V130, P5133, DOI 10.1242/dev.00711
   Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654
   Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105
   Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278
   Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045
   Sun MM, 2009, NEUROL RES, V31, P23, DOI 10.1179/174313208X332959
   Sykiotis GP, 2008, DEV CELL, V14, P76, DOI 10.1016/j.devcel.2007.12.002
   Sykiotis GP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3112re3
   Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x
   Tsai JJ, 2013, NAT CELL BIOL, V15, P309, DOI 10.1038/ncb2699
   Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030
   Ungewitter E, 2009, MECH AGEING DEV, V130, P10, DOI 10.1016/j.mad.2008.06.002
   Voellmy R, 2007, ADV EXP MED BIOL, V594, P89
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095
   Webb JD, 2009, CELL MOL LIFE SCI, V66, P3539, DOI 10.1007/s00018-009-0147-7
   WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x
   Winston WM, 2007, P NATL ACAD SCI USA, V104, P10565, DOI 10.1073/pnas.0611282104
   Yates MS, 2009, CARCINOGENESIS, V30, P1024, DOI 10.1093/carcin/bgp100
   Yeger-Lotem E, 2004, P NATL ACAD SCI USA, V101, P5934, DOI 10.1073/pnas.0306752101
   Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589
   Zhao G, 2012, G3-GENES GENOM GENET, V2, P469, DOI 10.1534/g3.111.001081
   Zhu YJ, 2008, NEUROCHEM RES, V33, P2310, DOI 10.1007/s11064-008-9730-9
NR 75
TC 7
Z9 9
U1 2
U2 16
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD SEP
PY 2013
VL 33
IS 17
BP 3524
EP 3537
DI 10.1128/MCB.00245-13
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 196ZY
UT WOS:000322817600012
PM 23836880
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Qin, SX
   Yang, YP
   Jiang, YS
AF Qin, Shuxin
   Yang, Yiping
   Jiang, Yongshi
TI RETRACTED: Model-based 3D tracking of an articulated hand from single
   depth images (Retracted article. See vol. 34, pg. 2199, 2013)
SO PATTERN RECOGNITION LETTERS
LA English
DT Article; Retracted Publication
DE Tracking; Articulated hand; Depth image; Particle swarm optimization
ID HUMAN MOTION TRACKING; POSE ESTIMATION
AB This paper presents a novel solution to the problem of tracking the 3D position, orientation and full articulation of a human hand from single depth images. We choose the model-based approach and treat the tracking task as an optimization problem. A new objective function based on depth information is presented to quantify the discrepancy between the appearance of hypothesized instances of a hand model and actual hand observations. Sequential Particle Swarm Optimization method is proposed to minimize the objective function for sequential optimization. An semi-automatic hand location method is adopted to predict hand region for sequential tracking. A GPU-based implementation of the proposed method is well designed to address the computational intensity. Extensive experimental results demonstrate qualitatively and quantitatively that tracking of an articulated hand can be achieved in real-time. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Qin, Shuxin; Yang, Yiping; Jiang, Yongshi] Chinese Acad Sci, Inst Automat, Beijing 100190, Peoples R China.
RP Qin, SX (reprint author), Chinese Acad Sci, Inst Automat, 95 ZhongGuanCun Dong Rd, Beijing 100190, Peoples R China.
EM shuxin.qin@ia.ac.cn
FU CASIA - Beijing CAS X-Vision Digital Technology Co., Ltd. Joint Lab of
   Information Visualization
FX This work is supported by CASIA - Beijing CAS X-Vision Digital
   Technology Co., Ltd. Joint Lab of Information Visualization.
CR Albrecht I., 2003, P ACM SIGGRAPH EUR S, P109
   Athitsos V., 2003, P IEEE COMP SOC C CO, V2, P11
   Bratton D, 2007, 2007 IEEE SWARM INTELLIGENCE SYMPOSIUM, P120, DOI 10.1109/SIS.2007.368035
   Brown JA, 2012, IEEE T VIS COMPUT GR, V18, P68, DOI 10.1109/TVCG.2011.34
   Delaney Martin, 2008, Proj Inf Perspect, P1
   Erol A, 2007, COMPUT VIS IMAGE UND, V108, P52, DOI 10.1016/j.cviu.2006.10.012
   Gall J, 2010, INT J COMPUT VISION, V87, P75, DOI 10.1007/s11263-008-0173-1
   Guo F, 2007, IEEE IMAGE PROC, P357
   Hamer H, 2009, IEEE I CONF COMP VIS, P1475, DOI 10.1109/ICCV.2009.5459282
   John V, 2010, IMAGE VISION COMPUT, V28, P1530, DOI 10.1016/j.imavis.2010.03.008
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/ICNN.1995.488968
   Moeslund TB, 2006, COMPUT VIS IMAGE UND, V104, P90, DOI 10.1016/j.cviu.2006.08.002
   Oikonomidis I, 2012, PROC CVPR IEEE, P1862, DOI 10.1109/CVPR.2012.6247885
   Oikonomidis I., 2010, P AS C COMP VIS ACCV, P744
   Oikonomidis I., 2011, P BMVC
   Romero Javier, 2009, 2009 9th IEEE-RAS International Conference on Humanoid Robots (Humanoids 2009), P87, DOI 10.1109/ICHR.2009.5379596
   Rosales R, 2001, EIGHTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOL I, PROCEEDINGS, P378, DOI 10.1109/ICCV.2001.937543
   Shotton J., 2011, P IEEE COMP SOC C CO, V2, P7
   Stenger B., 2001, P IEEE COMP SOC C CO, pII
   Sudderth E.B., 2004, P IEEE C COMP VIS PA, V12, P189
   Teleb H., 2012, 2012 International Conference on Systems and Informatics (ICSAI 2012), P107, DOI 10.1109/ICSAI.2012.6223225
   Thayananthan A, 2008, PATTERN RECOGN LETT, V29, P1302, DOI 10.1016/j.patrec.2008.02.004
   Wang R. Y., 2009, ACM T GRAPHICS, V28
   Wu Y, 2000, PROC CVPR IEEE, P88, DOI 10.1109/CVPR.2000.854749
   Zhao X, 2011, IEEE T IMAGE PROCESS, V20, P1141, DOI 10.1109/TIP.2010.2076820
   Zhou HY, 2008, BIOMED SIGNAL PROCES, V3, P1, DOI 10.1016/j.bspc.2007.09.001
   Zou B, 2009, PATTERN RECOGN, V42, P1559, DOI 10.1016/j.patcog.2003.12.024
NR 27
TC 1
Z9 3
U1 3
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-8655
EI 1872-7344
J9 PATTERN RECOGN LETT
JI Pattern Recognit. Lett.
PD SEP 1
PY 2013
VL 34
IS 12
BP 1437
EP 1445
DI 10.1016/j.patrec.2013.05.010
PG 9
WC Computer Science, Artificial Intelligence
SC Computer Science
GA 179QT
UT WOS:000321537100015
DA 2018-12-27
ER

PT J
AU Maisonneuve, E
   Castro-Camargo, M
   Gerdes, K
AF Maisonneuve, Etienne
   Castro-Camargo, Manuela
   Gerdes, Kenn
TI RETRACTED: (p)ppGpp Controls Bacterial Persistence by Stochastic
   Induction of Toxin-Antitoxin Activity (Retracted article. See vol. 172,
   pg. 1135, 2018)
SO CELL
LA English
DT Article; Retracted Publication
ID ESCHERICHIA-COLI; STRINGENT RESPONSE; CONDITIONAL COOPERATIVITY;
   INORGANIC POLYPHOSPHATE; MYCOBACTERIUM-TUBERCULOSIS; GUANOSINE
   TETRAPHOSPHATE; CONTROLLED EXPRESSION; PROTEIN-SYNTHESIS; RIBOSOMAL-RNA;
   IN-VIVO
AB Persistence refers to the phenomenon in which isogenic populations of antibiotic-sensitive bacteria produce rare cells that transiently become multidrug tolerant. Whether slow growth in a rare subset of cells underlies the persistence phenotype has not be examined in wild-type bacteria. Here, we show that an exponentially growing population of wildtype Escherichia coli cells produces rare cells that stochastically switch into slow growth, that the slow-growing cells are multidrug tolerant, and that they are able to resuscitate. The persistence phenotype depends hierarchically on the signaling nucleotide (p)ppGpp, Lon protease, inorganic polyphosphate, and toxin-antitoxins. We show that the level of (p)ppGpp varies stochastically in a population of exponentially growing cells and that the high (p)ppGpp level in rare cells induces slow growth and persistence. (p)ppGpp triggers slow growth by activating toxin-antitoxin loci through a regulatory cascade depending on inorganic polyphosphate and Lon protease.
C1 [Maisonneuve, Etienne; Castro-Camargo, Manuela; Gerdes, Kenn] Newcastle Univ, Inst Cell & Mol Biosci, Ctr Bacterial Cell Biol, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
RP Gerdes, K (reprint author), Newcastle Univ, Inst Cell & Mol Biosci, Ctr Bacterial Cell Biol, Richardson Rd, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
EM kenn.gerdes@ncl.ac.uk
RI Gerdes, Kenn/M-2420-2014
OI Gerdes, Kenn/0000-0002-7462-4612; maisonneuve,
   Etienne/0000-0003-3451-1223
FU European Research Council [294517]; Novo Nordisk Fonden [NNF12OC0000638]
FX We thank David Holden, Sophie Helaine, and Heath Murray for critical
   reading of the manuscript and a reviewer for suggesting the
   "microstarvation" model. We further thank the members of the Gerdes
   group and members of the Centre for Bacterial Cell Biology for
   stimulating discussions. This work was funded by a European Research
   Council Advanced Investigator Grant (294517; "PERSIST") to K.G.
CR Afif H, 2001, MOL MICROBIOL, V41, P73, DOI 10.1046/j.1365-2958.2001.02492.x
   AKIYAMA M, 1993, J BIOL CHEM, V268, P633
   AKIYAMA M, 1992, J BIOL CHEM, V267, P22556
   Allison KR, 2011, NATURE, V473, P216, DOI 10.1038/nature10069
   [Anonymous], PLOS GENET, V9
   Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390
   Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327
   Battesti A, 2011, ANNU REV MICROBIOL, V65, P189, DOI 10.1146/annurev-micro-090110-102946
   Bigger JW, 1944, LANCET, V2, P497
   BLACK DS, 1991, J BACTERIOL, V173, P5732, DOI 10.1128/jb.173.18.5732-5739.1991
   Cataudella I, 2012, NUCLEIC ACIDS RES, V40, P6424, DOI 10.1093/nar/gks297
   Christensen-Dalsgaard M, 2006, MOL MICROBIOL, V62, P397, DOI 10.1111/j.1365-2958.2006.05385.x
   Christensen-Dalsgaard M, 2010, MOL MICROBIOL, V75, P333, DOI 10.1111/j.1365-2958.2009.06969.x
   CROOKE E, 1994, J BIOL CHEM, V269, P6290
   Dahl JL, 2003, P NATL ACAD SCI USA, V100, P10026, DOI 10.1073/pnas.1631248100
   Dalebroux ZD, 2010, MICROBIOL MOL BIOL R, V74, P171, DOI 10.1128/MMBR.00046-09
   Nguyen D, 2011, SCIENCE, V334, P982, DOI 10.1126/science.1211037
   Dorr T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000317
   Dubnau D, 2006, MOL MICROBIOL, V61, P564, DOI 10.1111/j.1365-2958.2006.05249.x
   Eldar A, 2010, NATURE, V467, P167, DOI 10.1038/nature09326
   English BP, 2011, P NATL ACAD SCI USA, V108, pE365, DOI 10.1073/pnas.1102255108
   Garcia-Pino A, 2010, CELL, V142, P101, DOI 10.1016/j.cell.2010.05.039
   Gefen O, 2008, P NATL ACAD SCI USA, V105, P6145, DOI 10.1073/pnas.0711712105
   Ghosh S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-18
   GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8
   HANSEN MT, 1975, J BACTERIOL, V122, P585
   HARSHMAN RB, 1971, BIOCHEMISTRY-US, V10, P3980, DOI 10.1021/bi00797a027
   Kanjee U, 2012, MOL MICROBIOL, V85, P1029, DOI 10.1111/j.1365-2958.2012.08177.x
   Keren I, 2004, J BACTERIOL, V186, P8172, DOI 10.1128/JB.18624.8172-8180.2004
   Keren I, 2004, FEMS MICROBIOL LETT, V230, P13, DOI 10.1016/S0378-1097(03)00856-5
   Korch SB, 2003, MOL MICROBIOL, V50, P1199, DOI 10.1046/j.1365-2958.2003.03779.x
   Kuroda A, 1997, J BIOL CHEM, V272, P21240, DOI 10.1074/jbc.272.34.21240
   Kuroda A, 2001, SCIENCE, V293, P705, DOI 10.1126/science.1061315
   Kussell E, 2005, SCIENCE, V309, P2075, DOI 10.1126/science.1114383
   LAFFLER T, 1974, CELL, V3, P47, DOI 10.1016/0092-8674(74)90036-1
   LaFleur MD, 2010, ANTIMICROB AGENTS CH, V54, P39, DOI 10.1128/AAC.00860-09
   Levin BR, 2006, NAT REV MICROBIOL, V4, P556, DOI 10.1038/nrmicro1445
   Lewis K, 2007, NAT REV MICROBIOL, V5, P48, DOI 10.1038/nrmicro1557
   Lewis K, 2010, ANNU REV MICROBIOL, V64, P357, DOI 10.1146/annurev.micro.112408.134306
   Lidstrom ME, 2010, NAT CHEM BIOL, V6, P705, DOI [10.1038/NCHEMBIO.436, 10.1038/nchembio.436]
   Losick R, 2008, SCIENCE, V320, P65, DOI 10.1126/science.1147888
   Maisonneuve E, 2011, P NATL ACAD SCI USA, V108, P13206, DOI 10.1073/pnas.1100186108
   MOYED HS, 1983, J BACTERIOL, V155, P768
   Mulcahy LR, 2010, J BACTERIOL, V192, P6191, DOI 10.1128/JB.01651-09
   Overgaard M, 2008, MOL MICROBIOL, V69, P841, DOI 10.1111/j.1365-2958.2008.06313.x
   Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x
   Primm TP, 2000, J BACTERIOL, V182, P4889, DOI 10.1128/JB.182.17.4889-4898.2000
   RODIONOV DG, 1995, J BACTERIOL, V177, P4224, DOI 10.1128/jb.177.15.4224-4229.1995
   Rotem E, 2010, P NATL ACAD SCI USA, V107, P12541, DOI 10.1073/pnas.1004333107
   RYALS J, 1982, J BACTERIOL, V151, P1261
   Shyp V, 2012, EMBO REP, V13, P835, DOI 10.1038/embor.2012.106
   Sternberg C, 1999, APPL ENVIRON MICROB, V65, P4108
   Sureka K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001771
   SVITIL AL, 1993, J BIOL CHEM, V268, P2307
   TOSA T, 1971, J BACTERIOL, V106, P972
   TUOMANEN E, 1986, J GEN MICROBIOL, V132, P1297
   Vazquez-Laslop N, 2006, J BACTERIOL, V188, P3494, DOI 10.1128/JB.188.10.3494-3497.2006
   Veening JW, 2008, ANNU REV MICROBIOL, V62, P193, DOI 10.1146/annurev.micro.62.081307.163002
   Wexselblatt E, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002925
   Wexselblatt E, 2010, BIOORGAN MED CHEM, V18, P4485, DOI 10.1016/j.bmc.2010.04.064
   Winther KS, 2012, NUCLEIC ACIDS RES, V40, P4347, DOI 10.1093/nar/gks029
   Zhao J, 2008, PLOS BIOL, V6, P1306, DOI 10.1371/journal.pbio.0060150
NR 62
TC 298
Z9 307
U1 1
U2 119
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 29
PY 2013
VL 154
IS 5
BP 1140
EP 1150
DI 10.1016/j.cell.2013.07.048
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 209OE
UT WOS:000323767300025
PM 23993101
OA Bronze
DA 2018-12-27
ER

PT J
AU Jiang, PF
   Zhu, T
   Gao, JD
   Gao, F
   Mao, SS
   Zhao, WT
   Gu, WZ
   Yu, HM
AF Jiang, P. F.
   Zhu, T.
   Gao, J. D.
   Gao, F.
   Mao, S. S.
   Zhao, W. T.
   Gu, W. Z.
   Yu, H. M.
TI RETRACTED: THE EFFECT OF MATERNAL INFECTION ON COGNITIVE DEVELOPMENT AND
   HIPPOCAMPUS NEURONAL APOPTOSIS, PROLIFERATION AND DIFFERENTIATION IN THE
   NEONATAL RATS(Retracted article. See vol. 254, pg. 476, 2013)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE maternal infection; cognitive performance; proliferation;
   differentiation; ERK signaling pathway
ID FIBRILLARY ACIDIC PROTEIN; DENTATE GYRUS; CELL-PROLIFERATION;
   INTRAUTERINE INFECTION; SIGNAL-TRANSDUCTION; NEUROTROPHIC FACTOR; ADULT
   NEUROGENESIS; CEREBRAL-ISCHEMIA; DEVELOPING RAT; BRAIN
AB Many epidemiological reports stated a strong association between maternal infection and development of cerebral palsy, which is a major cause of cognitive impairment. The pathophysiological mechanism of intrauterine inflammation is complex. Recently, it was demonstrated that inflammation has a modulating effect on adult neurogenesis. In this study, we discovered the effect of maternal infection to hippocampal neuronal apoptosis, proliferation and differentiation, and cognitive development in the developing brains of neonatal rats. Morris water maze test was used to assess learning and memory. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay was used to determine neuronal apoptosis, immunostaining was conducted to assess neurogenesis, and Western blot for extracellular signal-regulated kinase (ERK), cyclic AMP responsive element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) expression in the hippocampus. Results demonstrated that maternal infection increased neuronal apoptosis and significantly impaired spatial learning and memory ability. Maternal infection significantly increased cell proliferation, accompanied by an increased expression of ERK (P3-P7), CREB (P3-P7) and BDNF (P3). On P28, there was no significant difference of cell survival and differentiation in two groups. These results suggest that variation in ERK activity and subsequent expression of its downstream targets, including CREB and BDNF might contribute, at least partially, to modulation of inflammation related cell proliferation, survival and differentiation. Maternal infection increased hippocampal neuronal apoptosis and affected cell proliferation and differentiation in neonatal rats, which may be regarded as an etiological factor in cognitive development impairment. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Jiang, P. F.; Gao, J. D.; Gao, F.; Mao, S. S.] Zhejiang Univ, Sch Med, Childrens Hosp, Dept Neurol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhu, T.] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Crit Care Med, Hangzhou 310016, Zhejiang, Peoples R China.
   [Zhao, W. T.; Yu, H. M.] Zhejiang Univ, Sch Med, Childrens Hosp, Dept Neonatol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Gu, W. Z.] Zhejiang Univ, Sch Med, Childrens Hosp, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China.
RP Yu, HM (reprint author), Zhejiang Univ, Sch Med, Childrens Hosp, Dept Neonatol, Hangzhou 310003, Zhejiang, Peoples R China.
EM yuhuimin@yahoo.com.cn
FU National Natural Science Foundation of China [81201511]; Health Bureau
   of Zhejiang Province [2010KYB064]; Education Bureau of Zhejiang Province
   [Y201225805]; Family Planning Commission of Zhejiang Province
   [JSW2012-A011]
FX This work was supported by Grants from National Natural Science
   Foundation of China (81201511), Health Bureau of Zhejiang Province
   (2010KYB064), Education Bureau of Zhejiang Province (Y201225805) and
   Family Planning Commission of Zhejiang Province (JSW2012-A011). We
   sincerely thank Guifeng Xiao for assistance with the confocal imaging.
CR Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003
   Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747
   Back SA, 2007, STROKE, V38, P724, DOI 10.1161/01.STR.0000254729.27386.05
   BARNES CA, 1994, J NEUROSCI, V14, P5793
   Basu A, 2005, J CEREBR BLOOD F MET, V25, P17, DOI 10.1038/sj.jcbfm.9600002
   Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x
   Buser JR, 2012, ANN NEUROL, V71, P93, DOI 10.1002/ana.22627
   Chen B, 2001, BIOL PSYCHIAT, V50, P260, DOI 10.1016/S0006-3223(01)01083-6
   Choi YS, 2008, GLIA, V56, P791, DOI 10.1002/glia.20653
   Creson TK, 2009, J MOL NEUROSCI, V37, P123, DOI 10.1007/s12031-008-9122-2
   Fagel DM, 2006, EXP NEUROL, V199, P77, DOI 10.1016/j.expneurol.2005.04.006
   Fatemi SH, 2002, MOL PSYCHIATR, V7, P633, DOI 10.1038/sj.mp.4001046
   Felling RJ, 2006, J NEUROSCI, V26, P4359, DOI 10.1523/JNEUROSCI.1898-05.2006
   Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5
   Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0
   Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548
   Hao Y, 2004, J NEUROSCI
   Howell OW, 2003, J NEUROCHEM, V86, P646, DOI 10.1046/j.1471-4159.2003.01895.x
   Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629
   Jiang PF, 2012, BRAIN RES, V1459, P1, DOI 10.1016/j.brainres.2012.03.058
   Kafa IM, 2010, ACTA NEUROBIOL EXP, V70, P246
   Kempermann G, 2003, BIOL PSYCHIAT, V54, P499, DOI 10.1016/S000-3223(03)00319-6
   Kodamo M, 2004, BIOL PSYCHIAT, V56, P570, DOI 10.1016/j.biopsych.2004.07.008
   Kuczewski N, 2008, J NEUROSCI, V28, P7013, DOI 10.1523/JNEUROSCI.1673-08.2008
   Kwon DS, 2006, EUR J CELL BIOL, V85, P1189, DOI 10.1016/j.ejcb.2006.06.001
   Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x
   Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867
   Magavi SS, 2000, NATURE, V405, P951
   Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3
   Messaris E, 2010, CRIT CARE MED, V38, P209, DOI 10.1097/CCM.0b013e3181b4a972
   Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0
   Pencea V, 2001, J NEUROSCI, V21, P6706
   Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0
   Romero R, 2003, J NUTR, V133, p1668S, DOI 10.1093/jn/133.5.1668S
   Rosenzweig ES, 2003, NAT NEUROSCI, V6, P609, DOI 10.1038/nn1053
   Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0
   Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817
   Semmler A, 2005, J CHEM NEUROANAT, V30, P144, DOI 10.1016/j.jchemneu.2005.07.003
   Shen Y, 2009, NEUROPATHOLOGY, V29, P528, DOI 10.1111/j.1440-1789.2009.01005.x
   Shetty AK, 2004, HIPPOCAMPUS, V14, P595, DOI 10.1002/hipo.10206
   Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8
   Tian HP, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-139
   Wiskott L, 2006, HIPPOCAMPUS, V16, P329, DOI 10.1002/hipo.20167
   Yan XB, 2007, NEUROPHARMACOLOGY, V53, P487, DOI 10.1016/j.neuropharm.2007.06.020
   Yang Z, 2006, NEUROSCIENCE, V139, P555, DOI 10.1016/j.neuroscience.2005.12.059
   Yu HM, 2004, NEUROPATHOLOGY, V24, P136, DOI 10.1111/j.1440-1789.2003.00539.x
   Zhu DY, 2004, P NATL ACAD SCI USA, V101, P9453, DOI 10.1073/pnas.0401063101
NR 47
TC 5
Z9 6
U1 2
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD AUG 29
PY 2013
VL 246
BP 422
EP 434
DI 10.1016/j.neuroscience.2013.04.021
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 174PN
UT WOS:000321168000038
PM 23597829
DA 2018-12-27
ER

PT J
AU Jiang, CF
   Shi, B
   Shi, J
   Yuan, ZL
   Xie, WF
AF Jiang, Cai-feng
   Shi, Bin
   Shi, Jian
   Yuan, Zong-li
   Xie, Wei-fen
TI RETRACTED: New proposal for the serum ascites albumin gradient cut-off
   value in Chinese ascitic patients (Retracted article. See vol. 10, pg.
   12, 2015)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Ascites; Cirrhosis; Portal hypertension; SAAG
ID RECEIVER OPERATING CHARACTERISTICS; DIFFERENTIAL-DIAGNOSIS;
   PROTEIN-CONCENTRATION; EXUDATIVE ASCITES; LIVER-DISEASE; SEPARATION;
   FLUID
AB Background: Serum ascites albumin gradient (SAAG) has been recognized as a reliable marker in the differential diagnosis of ascites. The etiological background of cirrhosis is rather different between western countries and eastern countries. The threshold of SAAG in Chinese ascitic patients has not been evaluated yet. The aim of this study was to define a new reasonable threshold of SAAG in Chinese ascitic patients.
   Methods: Adult patients with ascites admitted to the Shanghai Changzheng Hospital from Jan 2004 to Jun 2010 were retrospectively analyzed. The diagnostic criteria for cirrhotic ascites are clinical manifestations, radiological features and esophageal-gastric varicosis, or histopathology. Serum was detected by chemical method using a commercial kit. We used receiver operating characteristic (ROC) analysis to achieve maximal sensitivity and specificity of SAAG.
   Results: The mean value of SAAG in portal-hypertension-related ascites was significantly higher than that in the non-portal-hypertension-related ascites (21.15 +/- 4.38 g/L vs 7.48 +/- 3.64 g/L, P = 0.002). The SAAG cut-off value under 12.50 g/L predicted portal hypertension ascites with the sensitivity of 99.20%, specificity of 95.10% and accuracy of 97.65%.
   Conclusions: SAAG is useful to distinguish portal-hypertension-related ascites and non-portal-hypertension-related ascites, and 12.50 g/L might present as a more reasonable threshold in Chinese ascitic patients.
C1 [Jiang, Cai-feng; Shi, Bin; Shi, Jian; Yuan, Zong-li; Xie, Wei-fen] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Gastroenterol, Shanghai 200003, Peoples R China.
RP Xie, WF (reprint author), Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Gastroenterol, Fengyang Rd, Shanghai 200003, Peoples R China.
EM weifenxie@medmail.com.cn
CR Bjelakovic G, 2003, ACTA FACULTATIS MED, V20, P209
   Das Bibhuti B., 2001, Indian Journal of Pediatrics, V68, P511, DOI 10.1007/BF02723242
   HOEFS JC, 1983, J LAB CLIN MED, V102, P260
   HOEFS JC, 1992, HEPATOLOGY, V16, P396, DOI 10.1002/hep.1840160218
   Johnson ME, 2008, PSYCHOL REP, V102, P695, DOI 10.2466/PR0.102.3.695-705
   KAJANI MA, 1990, DIGEST DIS SCI, V35, P33, DOI 10.1007/BF01537219
   Karoo ROS, 2003, POSTGRAD MED J, V79, P292, DOI 10.1136/pmj.79.931.292
   LEE CM, 1992, CANCER, V70, P2057, DOI 10.1002/1097-0142(19921015)70:8<2057::AID-CNCR2820700807>3.0.CO;2-H
   LIGHT RW, 1972, ANN INTERN MED, V77, P507, DOI 10.7326/0003-4819-77-4-507
   MAUER K, 1988, DIGEST DIS SCI, V33, P1208, DOI 10.1007/BF01536667
   McHutchison JG, 1997, SEMIN LIVER DIS, V17, P191, DOI 10.1055/s-2007-1007197
   Obaid Shakil A, 1996, AM J MED, V100, P179
   Paddock FK, 1940, NEW ENGL J MED, V223, P1010, DOI 10.1056/NEJM194012192232503
   PARE P, 1983, GASTROENTEROLOGY, V85, P240
   RECTOR WG, 1984, AM J MED, V77, P83, DOI 10.1016/0002-9343(84)90440-6
   RUNYON BA, 1992, ANN INTERN MED, V117, P215, DOI 10.7326/0003-4819-117-3-215
   Starling E H, 1896, J Physiol, V19, P312
   Torres E, 1998, AM J GASTROENTEROL, V93, P2172
   Wixted JT, 2008, LEARN MEMORY, V15, P687, DOI 10.1101/lm.1077708
NR 19
TC 5
Z9 5
U1 2
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD AUG 23
PY 2013
VL 8
AR 143
DI 10.1186/1746-1596-8-143
PG 5
WC Pathology
SC Pathology
GA 215VX
UT WOS:000324240000002
PM 23971938
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Abdulsid, A
   Fletcher, A
   Lyall, F
AF Abdulsid, Akrem
   Fletcher, Alexander
   Lyall, Fiona
TI RETRACTED: Heat Shock Protein 27 Is Spatially Distributed in the Human
   Placenta and Decreased during Labor (Retracted article. See vol. 13, art
   no E0199803, 2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID OXIDATIVE STRESS; HEAT-SHOCK-PROTEIN-27; EXPRESSION; HSP27
AB Placental oxidative stress is a feature of human labor. Heat shock proteins (HSPs) play a key role in cellular stress. We hypothesized that placental expression of the small HSP 27 would be altered during labor and expression would vary in different regions of the placenta. Six women in labor who delivered vaginally and 6 women not in labor, who were delivered by Cesarean section, were recruited. Four equally spaced pieces were sampled from the inner, middle and outer regions of each placenta (total 12 samples per placenta). HSP 27 expression was investigated by Western blot analysis and RT-PCR. For non-labor, there was less HSP 27 protein in the inner placenta region compared with both the middle region (p<0.05) and outer region (p<0.05). For labor, there was also less HSP 27 protein in the inner region compared with both the middle (p<0.02) and outer region (p<0.01). When the 3 regions of the placenta were compared for non-labor versus labor there was less HSP 27 in the labor group at both the inner (p<0.05) and middle regions (p<0.005) compared to non-labor. Similar to HSP 27 protein, there was less HSP 27 mRNA in the labor group in both the inner region (p<0.05) and middle region (p<0.02) compared to non-labor. This study suggests that placental HSP 27 may play a role in labor and is spatially controlled. The results have important implications for how data obtained from studies in the placenta can be influenced by sampling methods.
C1 [Abdulsid, Akrem; Fletcher, Alexander; Lyall, Fiona] Univ Glasgow, Sch Med, Inst Med Genet, Yorkhill Hosp, Glasgow, Lanark, Scotland.
RP Lyall, F (reprint author), Univ Glasgow, Sch Med, Inst Med Genet, Yorkhill Hosp, Glasgow, Lanark, Scotland.
EM fiona.lyall@glasgow.ac.uk
FU Libyan Government
FX This work was supported by a PhD scholarship to E Abdulside from Libyan
   Government-administered By University of Glasgow. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Abdulsid A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054540
   Borges TJ, 2012, FRONT IMMUNOL, V95, P1
   BRAR HS, 1988, AM J OBSTET GYNECOL, V158, P952, DOI 10.1016/0002-9378(88)90100-7
   Burton GJ, 2011, BEST PRACT RES CL OB, V25, P287, DOI 10.1016/j.bpobgyn.2010.10.016
   Canete P, 2012, GYNECOL OBSTET INVES, V73, P248, DOI 10.1159/000334408
   Challis JRG, 2000, ENDOCR REV, V21, P514, DOI 10.1210/er.21.5.514
   Cindrova-Davies T, 2007, AM J PATHOL, V171, P1168, DOI 10.2353/ajpath.2007.070528
   Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096
   De AK, 2000, J IMMUNOL, V165, P3951, DOI 10.4049/jimmunol.165.7.3951
   Garrido C, 2012, INT J BIOCHEM CELL B, V44, P1588, DOI 10.1016/j.biocel.2012.02.022
   Ghayour-Mobarhan M, 2012, CLIN CHIM ACTA, V413, P15, DOI 10.1016/j.cca.2011.04.005
   GIBB WL, 2006, PHYSL REPROD, P2925
   Herman A, 2002, ULTRASOUND OBST GYN, V19, P278, DOI 10.1046/j.1469-0705.2002.00557.x
   Lanneau D, 2010, THESCIENTIFICWORLDJO, V10, P1543, DOI 10.1100/tsw.2010.152
   Li DG, 1996, SHOCK, V5, P320, DOI 10.1097/00024382-199605000-00002
   MacIntyre DA, 2008, ENDOCRINOLOGY, V149, P245, DOI 10.1210/en.2007-0662
   Martin-Ventura JL, 2004, CIRCULATION, V110, P2216, DOI 10.1161/01.CIR.0000136814.87170.B1
   Matalon ST, 2008, J CELL BIOCHEM, V103, P719, DOI 10.1002/jcb.21476
   Myatt L, 2004, HISTOCHEM CELL BIOL, V122, P369, DOI 10.1007/s00418-004-0677-x
   Petraglia F, 2010, ENDOCR REV, V31, P783, DOI 10.1210/er.2009-0019
   Roberts JM, 2012, PREGNANCY HYPERTENS, V2, P72, DOI 10.1016/j.preghy.2012.01.001
   Wataba Koya, 2004, Medical Electron Microscopy, V37, P170
NR 22
TC 6
Z9 7
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 22
PY 2013
VL 8
IS 8
AR e71127
DI 10.1371/journal.pone.0071127
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 218ZA
UT WOS:000324470700011
PM 23990930
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kig, C
   Beullens, M
   Beke, L
   Van Eynde, A
   Linders, JT
   Brehmer, D
   Bollen, M
AF Kig, Cenk
   Beullens, Monique
   Beke, Lijs
   Van Eynde, Aleyde
   Linders, Johannes T.
   Brehmer, Dirk
   Bollen, Mathieu
TI RETRACTED: Maternal Embryonic Leucine Zipper Kinase (MELK) Reduces
   Replication Stress in Glioblastoma Cells (Retracted article. See vol.
   292, pg. 12786, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ASYMMETRIC NEUROBLAST DIVISIONS; PROTEIN-KINASE; STEM-CELLS;
   SINGLE-CELL; IN-VIVO; S-PHASE; DNA; PHOSPHORYLATION; CHECKPOINT; PATHWAY
AB Maternal embryonic leucine zipper kinase (MELK) belongs to the subfamily of AMP-activated Ser/Thr protein kinases. The expression of MELK is very high in glioblastoma-type brain tumors, but it is not clear how this contributes to tumor growth. Here we show that the siRNA-mediated loss of MELK in U87 MG glioblastoma cells causes a G(1)/S phase cell cycle arrest accompanied by cell death or a senescence-like phenotype that can be rescued by the expression of siRNA-resistant MELK. This cell cycle arrest is mediated by an increased expression of p21(WAF1/CIP1), an inhibitor of cyclin-dependent kinases, and is associated with the hypophosphorylation of the retinoblastoma protein and the down-regulation of E2F target genes. The increased expression of p21 can be explained by the consecutive activation of ATM (ataxia telangiectasia mutated), Chk2, and p53. Intriguingly, the activation of p53 in MELK-deficient cells is not due to an increased stability of p53 but stems from the loss of MDMX(mouse double minute-X), an inhibitor of p53 transactivation. The activation of the ATM-Chk2 pathway in MELK-deficient cells is associated with the accumulation of DNA double-strand breaks during replication, as demonstrated by the appearance of gamma H2AXfoci. Replication stress in these cells is also illustrated by an increased number of stalled replication forks and a reduced fork progression speed. Our data indicate that glioblastoma cells have elevated MELK protein levels to better cope with replication stress during unperturbed S phase. Hence, MELK inhibitors hold great potential for the treatment of glioblastomas as such or in combination with DNA-damaging therapies.
C1 [Kig, Cenk; Beullens, Monique; Van Eynde, Aleyde; Bollen, Mathieu] Univ Louvain, Lab Biosignaling & Therapeut, Dept Cellular & Mol Med, B-3000 Louvain, Belgium.
   [Beke, Lijs; Linders, Johannes T.; Brehmer, Dirk] Janssen Res & Dev, B-2340 Beerse, Belgium.
RP Bollen, M (reprint author), Univ Louvain, Lab Biosignaling & Therapeut, Dept Cellular & Mol Med, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.
EM Mathieu.Bollen@med.kuleuven.be
FU National Science Foundation Flanders Grant [G.0.686.10.N.10]
FX This work was supported by National Science Foundation Flanders Grant
   G.0.686.10.N.10.
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Alao JP, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-51
   Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x
   Badouel C, 2006, CELL CYCLE, V5, P883, DOI 10.4161/cc.5.8.2683
   Badouel C, 2010, EXP CELL RES, V316, P2166, DOI 10.1016/j.yexcr.2010.04.019
   Bensimon A, 2011, FEBS LETT, V585, P1625, DOI 10.1016/j.febslet.2011.05.013
   Beullens M, 2005, J BIOL CHEM, V280, P40003, DOI 10.1074/jbc.M507274200
   Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351
   Castelli S, 2012, BIOL CHEM, V393, P1327, DOI 10.1515/hsz-2012-0240
   Chien SC, 2013, GENETICS, V193, P897, DOI 10.1534/genetics.112.148106
   Choi S, 2011, BIOCHEM BIOPH RES CO, V412, P207, DOI 10.1016/j.bbrc.2011.07.060
   Conti C, 2007, CELL CYCLE, V6, P2760, DOI 10.4161/cc.6.22.4932
   Cordes S, 2006, DEVELOPMENT, V133, P2747, DOI 10.1242/dev.02447
   Davezac N, 2002, ONCOGENE, V21, P7630, DOI 10.1038/sj.onc.1205870
   Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Gray D, 2005, CANCER RES, V65, P9751, DOI 10.1158/0008-5472.CAN-04-4531
   Gu CY, 2013, STEM CELLS, V31, P870, DOI 10.1002/stem.1322
   Hecht SM, 2000, J NAT PROD, V63, P158, DOI 10.1021/np990549f
   HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608
   Hurov KE, 2010, GENE DEV, V24, P1939, DOI 10.1101/gad.1934210
   Joshi K, 2013, STEM CELLS, V31, P1051, DOI 10.1002/stem.1358
   Jung H, 2008, J BIOL CHEM, V283, P34541, DOI 10.1074/jbc.M807219200
   Krempler A, 2007, CELL CYCLE, V6, P1682, DOI 10.4161/cc.6.14.4480
   Kuner R, 2013, J MOL MED, V91, P237, DOI 10.1007/s00109-012-0949-1
   Le Page Y, 2011, J CELL SCI, V124, P958, DOI 10.1242/jcs.069567
   LeBron C, 2006, EMBO J, V25, P1196, DOI 10.1038/sj.emboj.7601032
   Lee MH, 2006, SEMIN CANCER BIOL, V16, P225, DOI 10.1016/j.semcancer.2006.03.009
   Lin ML, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1650
   Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110
   Marie SKN, 2008, INT J CANCER, V122, P807, DOI 10.1002/ijc.23189
   Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362
   Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451
   MIRZAYANS R, 2012, J BIOMED BI IN PRESS
   Nakano I, 2005, J CELL BIOL, V170, P413, DOI 10.1083/jcb.200412115
   Nakano I, 2011, NEURO-ONCOLOGY, V13, P622, DOI 10.1093/neuonc/nor023
   Niesler CU, 2007, EXP PHYSIOL, V92, P207, DOI 10.1113/expphysiol.2006.034736
   SCHWAB RA, 2011, J VIS EXP IN PRESS
   Schwarz JK, 2003, MOL CANCER RES, V1, P598
   SCUDIERO DA, 1988, CANCER RES, V48, P4827
   Seiler JA, 2007, MOL CELL BIOL, V27, P5806, DOI 10.1128/MCB.02278-06
   Seong HA, 2002, BIOCHEM J, V361, P597, DOI 10.1042/0264-6021:3610597
   Seong HA, 2012, J BIOL CHEM, V287, P20797, DOI 10.1074/jbc.M112.347757
   SHAPIRO HM, 1988, PRACTICAL FLOW CYTOM, P133
   Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X
   Shono T, 2002, CANCER RES, V62, P1069
   Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471
   Sperka T, 2012, NAT REV MOL CELL BIO, V13, P579, DOI 10.1038/nrm3420
   STROBER W, 2001, CURR PROTOCOLS IMMUN, V21
   Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012
   TYRSTED G, 1982, BIOCHEM PHARMACOL, V31, P3107, DOI 10.1016/0006-2952(82)90087-9
   Verlinden L, 2005, J BIOL CHEM, V280, P37319, DOI 10.1074/jbc.M503587200
   Vulsteke V, 2004, J BIOL CHEM, V279, P8642, DOI 10.1074/jbc.M311466200
   Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106
NR 54
TC 26
Z9 26
U1 2
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 16
PY 2013
VL 288
IS 33
BP 24200
EP 24212
DI 10.1074/jbc.M113.471433
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 302NO
UT WOS:000330611400058
PM 23836907
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Alimohammadi, S
   Hobbenaghi, R
   Javanbakht, J
   Kheradmand, D
   Mortezaee, R
   Tavakoli, M
   Khadivar, F
   Akbari, H
AF Alimohammadi, Samad
   Hobbenaghi, Rahim
   Javanbakht, Javad
   Kheradmand, Danial
   Mortezaee, Reza
   Tavakoli, Maryam
   Khadivar, Farshid
   Akbari, Hamid
TI RETRACTED: Protective and antidiabetic effects of extract from Nigella
   sativa on blood glucose concentrations against streptozotocin
   (STZ)-induced diabetic in rats: an experimental study with
   histopathological evaluation(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Nigella Sativa; Streptozotocin; Hypoglycemic; Rat
ID OXIDATIVE STRESS; OIL; COMPLICATIONS; THYMOQUINONE; MELLITUS
AB Background: Diabetes in humans induces chronic complications such as cardiovascular damage, cataracts and retinopathy, nephropathy and polyneuropathy. The most common animal model of human diabetes is streptozotocin (STZ)-induced diabetes in the rat. The present study investigated the effects of Nigella sativa hydroalcholic extract on glucose concentrations in streptozotocin (STZ) diabetic rats.
   Methods: In this study Twenty-five Wister-Albino rats (aged 8-9 weeks and weighing 200-250 g) were tested. Rats were divided into five experimental groups (control, untreated STZ-diabetic (60 mg/kg B. W., IP), treated STZ-diabetic with hydroalcholic extract of Nigella Sativa (NS) (5 mg/kg B. W, IP), treated STZ-diabetic with hydroalcholic extract of NS (10 mg/kg B. W., IP) and treated STZ-diabetic with hydroalcholic extract of NS (20 mg/kg B. W., IP and 32 days were evaluated to assess its effect on fasting blood glucose (FBG), and in different groups fasting blood glucose (FBG) and body weight (BW) were measured in the particular days (1, 16 and 32). At the end of the study, the animals were fasted overnight, anaesthetized with an intraperitoneal injection of sodium pentobarbital (60 mg/kg), and sacrificed for obtaining tissues samples (liver, pancreases). The number of islets and cells were counted and the islet diameters were determined by calibrated micrometer. The glycogen content in the liver was examined by Periodic Acid-Schiff (PAS) staining.
   Results: Treatment with NS (5 mg/kg b.w.) markedly increased BW gain and the FBG level was significantly (p<0.001) reduced when compared to the control. Histopathological examination showed that the NS (5 mg/kg b.w.) partially recovered hepatic glycogen content and protected the great deal of the pancreatic islet cells. The number of islets, cells and islets diameter were found statistically significant when compared to the control (p<0.01, p<0.05).
   Conclusions: Higher doses of NS did not exhibit any therapeutic effect. These results showed that hydroalcholic extract of NS at low doses has hypoglycemic effect and ameliorative effect on regeneration of pancreatic islets and may be used as a therapeutic agent in the management of diabetes mellitus. The hypoglycemic effect observed could be due to amelioration of beta-cell, thus leading to increased insulin levels. Consequently, N. sativa may prove clinically useful in the treatment of diabetics and in the protection of beta-cells against streptozotocin.
   Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1845133011104231
C1 [Alimohammadi, Samad] Univ Tehran, Dept Physiol, Fac Vet Med, Tehran, Iran.
   [Hobbenaghi, Rahim] Urmia Univ, Dept Pathol, Fac Vet Med, Orumiyeh, Iran.
   [Javanbakht, Javad] Univ Tehran, Dept Pathol, Fac Vet Med, Tehran, Iran.
   [Kheradmand, Danial] Islamic Azad Univ Mashhad, Fac Med MD, Mashhad, Iran.
   [Mortezaee, Reza] Islamic Azad Univ, Mashhad Branch, Young Researchers Club & Elites, Mashahd, Iran.
   [Tavakoli, Maryam] Urmia Univ, Grad Fac Vet Med, Orumiyeh, Iran.
   [Khadivar, Farshid] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Akbari, Hamid] Urmia Univ, Dept Clin Sci, Fac Vet Med, Orumiyeh, Iran.
RP Alimohammadi, S (reprint author), Univ Tehran, Dept Physiol, Fac Vet Med, Tehran, Iran.
EM Samad.am84@gmail.com
RI TAVAKOLI, MITRA/N-1402-2016
OI TAVAKOLI, MITRA/0000-0003-2319-1543
CR Abdelmeguid NE, 2010, J DIABETES, V2, P256, DOI 10.1111/j.1753-0407.2010.00091.x
   AGARWAL R, 1979, INDIAN J EXP BIOL, V17, P1264
   Al-Hader Abdelfattah, 1993, International Journal of Pharmacognosy, V31, P96
   Alsaif Mohammed A, 2008, Pak J Biol Sci, V11, P1093
   Baurakiades E, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-101
   Baynes J.W., 1996, CURR OPIN ENDOCRINOL, V3, P277
   BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405
   Boulos L, 1983, MED PLANTS N AFRICA, P103
   El-Dakhakhny M, 2002, PLANTA MED, V68, P465, DOI 10.1055/s-2002-32084
   Fararh KM, 2002, RES VET SCI, V73, P279, DOI 10.1016/S0034-5288(02)00108-X
   Geng Dongsheng, 2009, Zhongguo Zhong Yao Za Zhi, V34, P2887
   GILLERY P, 1989, MED HYPOTHESES, V29, P47, DOI 10.1016/0306-9877(89)90167-9
   Grover JK, 2002, MOL CELL BIOCHEM, V241, P53, DOI 10.1023/A:1020870526014
   Haq A, 1999, INT J IMMUNOPHARMACO, V21, P283, DOI 10.1016/S0192-0561(99)00010-7
   HOUGHTON PJ, 1995, PLANTA MED, V61, P33, DOI 10.1055/s-2006-957994
   Javanbakht J, 2013, PATHOL BIOL PARIS, DOI [10.1016/j.patbio.2013.03.007, DOI 10.1016/J.PATBI0.2013.03.007]
   Kanter M, 2004, ANAT REC PART A, V279A, P685, DOI 10.1002/ar.a.20056
   Matkovics Bela, 1997, Acta Physiologica Hungarica, V85, P29
   Otani N, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-46
   Pari L, 2009, LIFE SCI, V85, P830, DOI 10.1016/j.lfs.2009.10.021
   Ramakrishna V, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-22
   Seven A, 2003, TOHOKU J EXP MED, V199, P205, DOI 10.1620/tjem.199.205
   Swamy SMK, 2000, J ETHNOPHARMACOL, V70, P1, DOI 10.1016/S0378-8741(98)00241-4
   van Bremen T, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-24
NR 24
TC 31
Z9 32
U1 2
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD AUG 15
PY 2013
VL 8
AR 137
DI 10.1186/1746-1596-8-137
PG 7
WC Pathology
SC Pathology
GA 215VT
UT WOS:000324239600001
PM 23947821
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Gangemi, G
   Gazzerro, P
   Fiore, D
   Proto, MC
   Butini, S
   Gemma, S
   Casagni, A
   Laezza, C
   Vitale, M
   Ligresti, A
   Di Marzo, V
   Zisterer, DM
   Nathwani, S
   Williams, DC
   Campiani, G
   Bifulco, M
AF Gangemi, Giuseppina
   Gazzerro, Patrizia
   Fiore, Donatella
   Proto, Maria Chiara
   Butini, Stefania
   Gemma, Sandra
   Casagni, Alice
   Laezza, Chiara
   Vitale, Mario
   Ligresti, Alessia
   Di Marzo, Vincenzo
   Zisterer, Daniela M.
   Nathwani, Seema
   Williams, D. Clive
   Campiani, Giuseppe
   Bifulco, Maurizio
TI RETRACTED: PBOX-15 induces apoptosis and improves the efficacy of
   oxaliplatin in human colorectal cancer cell lines (Retracted article.
   See vol. 728, pg. 190, 2014)
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Pyrrolo-1,5-benzoxazepine; Colorectal cancer; Combinatorial effect; FAAH
   inhibitor
ID ACID AMIDE HYDROLASE; COLON-CANCER; ENDOCANNABINOID SYSTEM; LEUKEMIA
   CELLS; IN-VITRO; FLUOROURACIL; LEUCOVORIN; THERAPY; TUBULIN; GROWTH
AB An emerging new class of targeted therapeutic molecules against the enzyme fatty acid amide hydrolase (FAAR) is a novel series of pyrrolo-1,5-benzoxa(thia)zepine compounds. A member of this family, pyrrolo-1,5-benzoxazepine-15 (PBOX-15), is a tubulin depolymerizing agent displaying a proapoptotic activity in a variety of human tumor cell types, including those derived from both solid and hematological malignancies, with minimal toxicity towards normal blood and bone marrow cells. In this study, we evaluated the PBOX-15-mediated effects in human colorectal cancer cell (CRC) lines. The compound, used at doses equal to or greater than 1 mu M inhibits the proliferation of human CRC cell lines in a dose- and time-dependent manner, inducing a significant cell cycle arrest in the G2/M phase. DNA fragmentation assays and western blot analysis demonstrated that treatments prolonged over 48 h triggered a strong activation of the intrinsic apoptotic pathway as indicated by activation of caspase-3, caspase-9 and PARR Moreover, nanomolar doses of PBOX-15, unable to cause microtubule depolymerization, significantly improved the oxaliplatin and 5-fluouracil-induced anti-proliferative effects in CRC cell lines.
   These results showed, for the first time that PBOX-15 represents a promising compound for the treatment of human CRC and a strong candidate for novel therapeutic options. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Gangemi, Giuseppina; Gazzerro, Patrizia; Fiore, Donatella; Proto, Maria Chiara] Univ Salerno, Dept Pharm, I-84084 Fisciano, SA, Italy.
   [Butini, Stefania; Gemma, Sandra; Casagni, Alice; Campiani, Giuseppe] Univ Siena, European Res Ctr Drug Discovery & Dev NatSynDrugs, I-53100 Siena, Italy.
   [Butini, Stefania; Gemma, Sandra; Casagni, Alice; Campiani, Giuseppe] Univ Siena, Dipartimento Farm Chim Tecnol, I-53100 Siena, Italy.
   [Ligresti, Alessia; Di Marzo, Vincenzo] CNR, Inst Biomol Chem, I-80078 Naples, Italy.
   [Zisterer, Daniela M.; Nathwani, Seema; Williams, D. Clive] Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland.
   [Laezza, Chiara] IEOS CNR, Inst Endocrinol & Expt Oncol, I-80131 Naples, Italy.
   [Vitale, Mario; Bifulco, Maurizio] Univ Salerno, Dept Med & Surg, I-84081 Baronissi, SA, Italy.
RP Bifulco, M (reprint author), Univ Salerno, Dept Med & Surg, Via S Allende, I-84081 Baronissi, SA, Italy.
EM maubiful@unisa.it
RI Ligresti, Alessia/B-7564-2015
OI Di Marzo, Vincenzo/0000-0002-1490-3070; Butini,
   Stefania/0000-0002-8471-0880; Bifulco, Maurizio/0000-0002-1771-4531
FU National Interest Research Projects [1407, prot. 20088SPEFN];
   Associazione Educazione e Ricerca Medica Salernitana (ERMES); FIRC
   (Italian Foundation for Cancer Research); Associazione Italiana per la
   Ricerca sul Cancro
FX This study was partially supported by the National Interest Research
   Projects (PRIN 2008, Grant "Design, synthesis and antitumor efficacy of
   new modulators of the endocannabinoid system", DM n. 1407, December 4,
   2008 prot. 20088SPEFN) and by the Associazione Educazione e Ricerca
   Medica Salernitana (ERMES).; M.C. P. was supported by fellowships from
   FIRC (Italian Foundation for Cancer Research).
CR Alberts SR, 2005, J CLIN ONCOL, V23, P9243, DOI 10.1200/JCO.2005.07.740
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Bifulco M, 2004, FASEB J, V18, P1606, DOI 10.1096/fj.04-1754fje
   Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547
   Bisogno T, 2002, CURR PHARM DESIGN, V8, P533, DOI 10.2174/1381612023395655
   Bright SA, 2010, BRIT J CANCER, V102, P1474, DOI 10.1038/sj.bjc.6605670
   Campiani G, 1996, J MED CHEM, V39, P3435, DOI 10.1021/jm960251b
   Cassidy J, 2004, J CLIN ONCOL, V22, P2084, DOI 10.1200/JCO.2004.11.069
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698
   Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Greene LM, 2008, MOL PHARMACOL, V73, P419, DOI 10.1124/mol.107.039024
   Ho WSV, 2005, HANDB EXP PHARMACOL, V168, P187
   Izzo AA, 2008, J MOL MED, V86, P89, DOI 10.1007/s00109-007-0248-4
   Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357
   Ligresti A, 2003, GASTROENTEROLOGY, V125, P677, DOI 10.1016/S0016-5085(03)00881-3
   Lysaght J, 2013, INT J ONCOL, V42, P239, DOI 10.3892/ijo.2012.1688
   Maginn EN, 2011, BRIT J CANCER, V104, P281, DOI 10.1038/sj.bjc.6606035
   Malfitano AM, 2011, EXPERT OPIN THER TAR, V15, P297, DOI 10.1517/14728222.2011.553606
   McElligott AM, 2009, CANCER RES, V69, P8366, DOI 10.1158/0008-5472.CAN-09-0131
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Mulligan JM, 2006, MOL PHARMACOL, V70, P60, DOI 10.1124/mol.105.021204
   Nathwani S.M., 2009, CANCER CHEMOTH PHARM, V66, P585
   Notarnicola M, 2008, SCAND J GASTROENTERO, V43, P66, DOI 10.1080/00365520701559011
   Parsels LA, 2011, CLIN CANCER RES, V17, P3706, DOI 10.1158/1078-0432.CCR-10-3082
   Proto MC, 2012, J CELL PHYSIOL, V227, P250, DOI 10.1002/jcp.22727
   Slattery ML, 2001, MUTAT RES-FUND MOL M, V483, P73, DOI 10.1016/S0027-5107(01)00228-7
   Takahashi N, 2002, CANCER RES, V62, P6909
   Talos F, 2010, ADV EXP MED BIOL, V676, P73
   Verma NK, 2008, J MOL MED-JMM, V86, P457, DOI 10.1007/s00109-008-0312-8
   Wada-Hiraike O, 2006, BIOCHEM SOC T, V34, P1114, DOI 10.1042/BST0341114
   Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
NR 34
TC 3
Z9 3
U1 2
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 15
PY 2013
VL 714
IS 1-3
BP 379
EP 387
DI 10.1016/j.ejphar.2013.07.011
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 207LN
UT WOS:000323601100050
PM 23872382
DA 2018-12-27
ER

PT J
AU Haghayeghi, R
   Kapranos, P
AF Haghayeghi, R.
   Kapranos, P.
TI RETRACTED: Direct-chill casting of wrought Al alloy under
   electromagnetic and ultrasonic combined fields (Retracted article. See
   vol. 181, pg. 182, 2016)
SO MATERIALS LETTERS
LA English
DT Article; Retracted Publication
DE Wrought aluminium alloy; Casting; Electromagnetic; Ultrasonic
ID ALUMINUM-ALLOYS; MECHANICAL-PROPERTIES; GRAIN-REFINEMENT; HEAT-TRANSFER;
   FLUID-FLOW; MICROSTRUCTURE; SOLIDIFICATION; COMBINATION; STRENGTH;
   BILLETS
AB This work is based on investigations on the influence of electromagnetic fields and ultrasonic vibrations in the resulting microstructure of an AA5457 aluminium wrought alloy. Two different agitation mechanisms, electromagnetic (EM) force field and ultrasonic treatment (UT), are compared as to their respective degree of grain refinement and as a result, a combination of the two methods (EM+UT) is developed and employed in the casting of an AA5754 billet. The application of the compound electromagnetic and ultrasonic fields under optimum conditions delivers a refined and homogeneously distributed as-cast microstructure with clear improvements in mechanical properties. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Haghayeghi, R.] Islamic Azad Univ, Sci & Res Branch, Dept Mat Engn, Tehran, Iran.
   [Kapranos, P.] Univ Sheffield, Dept Mat Sci & Engn, Sheffield S1 3JD, S Yorkshire, England.
RP Haghayeghi, R (reprint author), Islamic Azad Univ, Sci & Res Branch, Dept Mat Engn, Tehran, Iran.
EM Reza.Haghayeghi@Brunel.ac.uk
CR Aghayani MK, 2011, J ALLOY COMPD, V509, P114, DOI 10.1016/j.jallcom.2010.08.139
   Cui JZ, 2010, T NONFERR METAL SOC, V20, pS297, DOI 10.1016/S1003-6326(10)60487-6
   Easton M, 2005, METALL MATER TRANS A, V36A, P1911, DOI 10.1007/s11661-005-0054-y
   Eskin GI, 2001, ULTRASON SONOCHEM, V8, P319, DOI 10.1016/S1350-4177(00)00074-2
   ESKIN GI, 1998, ULTRASONIC TREATMENT
   Griffiths D., 1999, INTRO ELECTRODYNAMIC
   Haghayeghi R, 2009, J ALLOY COMPD, V485, P807, DOI 10.1016/j.jallcom.2009.06.085
   Iadicola MA, 2008, INT J PLASTICITY, V24, P2084, DOI 10.1016/j.ijplas.2008.03.003
   Kermanpur A, 2011, J MATER PROCESS TECH, V211, P222, DOI 10.1016/j.jmatprotec.2010.09.008
   MONDOLFO LF, 1976, ALUMINIUM ALLOYS STR
   Murty BS, 2002, INT MATER REV, V47, P3, DOI 10.1179/095066001225001049
   Shao ZW, 2011, MATER DESIGN, V32, P4216, DOI 10.1016/j.matdes.2011.04.035
   The ASTM Int, 2010, STANDARD TEST FOR DE
   Tsunekawa Y, 2001, MATER DESIGN, V22, P467, DOI 10.1016/S0261-3069(00)00079-0
   VIVES C, 1993, MAT SCI ENG A-STRUCT, V173, P169, DOI 10.1016/0921-5093(93)90209-W
   Yu JB, 2009, MATER DESIGN, V30, P4565, DOI 10.1016/j.matdes.2009.04.018
   Yu YD, 2013, MATER DESIGN, V44, P17, DOI 10.1016/j.matdes.2012.07.034
   Zhang HT, 2007, MAT SCI ENG A-STRUCT, V448, P189, DOI 10.1016/j.msea.2006.10.062
   Zhang HT, 2007, MAT SCI ENG A-STRUCT, V448, P177, DOI 10.1016/j.msea.2006.10.063
   Zhang YJ, 2005, MATER LETT, V59, P2174, DOI 10.1016/j.matlet.2005.02.058
   Zhang ZT, 2009, J ALLOY COMPD, V484, P458, DOI 10.1016/j.jallcom.2009.04.125
   Zuo Y, 2008, J MATER PROCESS TECH, V197, P109, DOI 10.1016/j.jmatprotec.2007.06.020
NR 22
TC 12
Z9 12
U1 3
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-577X
EI 1873-4979
J9 MATER LETT
JI Mater. Lett.
PD AUG 15
PY 2013
VL 105
BP 213
EP 215
DI 10.1016/j.matlet.2013.04.015
PG 3
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 173LO
UT WOS:000321081200058
DA 2018-12-27
ER

PT J
AU Zhang, W
   Wang, PJ
   Gao, MHLXL
   Gu, GJ
   Shao, ZH
AF Zhang, W.
   Wang, P. J.
   Gao, M. H. Li X. L.
   Gu, G. J.
   Shao, Z. H.
TI RETRACTED: 1H-MRS CAN MONITOR METABOLITES CHANGES OF LATERAL
   INTRAVENTRICULAR BDNF INFUSION INTO A MOUSE MODEL OF ALZHEIMER'S DISEASE
   IN VIVO(Retracted article. See vol. 254, pg. 477, 2013)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE proton magnetic resonance spectroscopy (1H-MRS); brain-derived
   neurotrophic factor (BDNF); infusion; Alzheimer's disease (AD); receptor
   tropomyosin-related kinase B (TrkB); Morris water maze (MWM)
ID MAGNETIC-RESONANCE-SPECTROSCOPY; NERVE GROWTH-FACTOR; MILD COGNITIVE
   IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; NEURAL STEM-CELLS; NEUROTROPHIC
   FACTOR; MR SPECTROSCOPY; TRANSGENIC MICE; NEURONAL DEGENERATION; BASAL
   FOREBRAIN
AB Proton magnetic resonance spectroscopy (1H-MRS) can provide noninvasive detection of brain metabolite changes in vivo in Alzheimer's disease (AD). AD is a prevalent neurodegenerative disorder characterized by deposition of p-amyloid peptides (A beta) in multiple brain regions. Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor whose level has been shown to be decreased in AD. BDNF supplementation can offer improvement in AD. However, the means of evaluation are still relatively limited. In the present study, 1H-MRS was applied to evaluate the therapeutic effects of bilateral intraventricular BDNF infusion into APP + PS1 (amyloid precursor protein + presenilin 1) transgenic mice. For comparison to the 1H-MRS changes in the prefrontal cortex, Morris water maze (MWM) test, Fluoro-Jade B staining and immunofluorescence for A beta, glial fibrillary acidic protein and tropomyosin-related kinase B (TrkB) were also performed. Our results showed that N-acetylaspartate (NAA) levels increased and myo-inositol levels decreased in Tg-BDNF mice compared with Tg-PBS mice. But NAA level in Tg-BDNF mice was still lower than that in wild-type mice at 6 weeks after infusion. These changes correlated with increased immunoreactivity of TrkB, reduced compact A beta peptide and FJB+ neurons in Tg-BDNF mice compared to Tg-PBS mice. However, Tg-BDNF mice did not present obvious changes in behavior in the MWM. Taken together, we suggest that 1H-MRS may be a sensitive means of evaluating metabolic changes in response to therapeutic strategies in AD. Moreover, BDNF, may be a viable means of offering trophic support during disease. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Zhang, W.; Wang, P. J.; Gao, M. H. Li X. L.; Gu, G. J.; Shao, Z. H.] Tongji Univ, Sch Med, Tongji Hosp, Dept Radiol, Shanghai 200065, Peoples R China.
RP Wang, PJ (reprint author), Tongji Univ, Sch Med, Tongji Hosp, Dept Radiol, 389 Xincun Rd, Shanghai 200065, Peoples R China.
EM peijunwang_tongji@163.com
CR Abraham CR, 2001, NEUROBIOL AGING, V22, P931, DOI 10.1016/S0197-4580(01)00302-5
   Arendash GW, 2001, BRAIN RES, V891, P42, DOI 10.1016/S0006-8993(00)03186-3
   Arnsten AFT, 2005, BIOL PSYCHIAT, V57, P1377, DOI 10.1016/j.bps.2004.08.019
   Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014
   BEHAR KL, 1983, P NATL ACAD SCI-BIOL, V80, P4945, DOI 10.1073/pnas.80.16.4945
   Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040
   Birnbaum SG, 2004, SCIENCE, V306, P882, DOI 10.1126/science.1100021
   Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7
   Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106
   Chen SW, 2009, J ELECTRON MATER, V38, P1, DOI 10.1007/s11664-008-0572-7
   Choi JK, 2010, NEUROPHARMACOLOGY, V59, P353, DOI 10.1016/j.neuropharm.2010.03.011
   den Heijer T, 2006, NEUROLOGY, V66, P540, DOI 10.1212/01.wnl.0000198256.54809.0e
   Elliott RC, 2001, J NEUROSCI RES, V66, P83, DOI 10.1002/jnr.1199
   Falini A, 2005, NEUROIMAGE, V26, P1159, DOI 10.1016/j.neuroimage.2005.03.005
   Garzon DJ, 2007, J NEUROSCI, V27, P2628, DOI 10.1523/JNEUROSCI.5053-06.2007
   Huang HJ, 2011, BRAIN RES, V1371, P150, DOI 10.1016/j.brainres.2010.11.043
   Jessen F, 2006, NEUROLOGY, V67, P528, DOI 10.1212/01.wnl.0000228218.68451.31
   Jones RS, 2004, NEUROL RES, V26, P488, DOI 10.1179/016164104225017640
   Kantarci K, 2004, NEUROLOGY, V63, P1393
   KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549
   Karlawish JHT, 2005, NEUROLOGY, V64, P1514, DOI 10.1212/01.WNL.0000160000.01742.9D
   KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506
   Kelly PH, 2003, NEUROBIOL AGING, V24, P365, DOI 10.1016/S0197-4580(02)00098-2
   Kiyota T, 2011, P NATL ACAD SCI USA, V108, pE1339, DOI 10.1073/pnas.1102349108
   Klein RL, 1999, NEUROSCIENCE, V90, P815, DOI 10.1016/S0306-4522(98)00537-5
   Laske C, 2006, J NEURAL TRANSM, V113, P1217, DOI 10.1007/s00702-005-0397-y
   Marjanska M, 2005, P NATL ACAD SCI USA, V102, P11906, DOI 10.1073/pnas.0505513102
   MASLIAH E, 1993, MED HYPOTHESES, V41, P334, DOI 10.1016/0306-9877(93)90078-5
   Modrego PJ, 2005, AM J PSYCHIAT, V162, P667, DOI 10.1176/appi.ajp.162.4.667
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   Mrak RE, 1996, J NEUROPATH EXP NEUR, V55, P273, DOI 10.1097/00005072-199603000-00002
   Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9
   Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912
   Peng SY, 2005, J NEUROCHEM, V93, P1412, DOI 10.1111/j.1471-4159.2005.03135.x
   Rae C, 2009, CLIN RADIOL, V64, P1042, DOI 10.1016/j.crad.2009.06.003
   Salat DH, 2001, ARCH NEUROL-CHICAGO, V58, P1403, DOI 10.1001/archneur.58.9.1403
   Schaeffer EL, 2009, PROG NEURO-PSYCHOPH, V33, P1087, DOI 10.1016/j.pnpbp.2009.06.024
   Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X
   Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0
   Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069
   Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239
   Valenzuela MJ, 2001, NEUROLOGY, V56, P592, DOI 10.1212/WNL.56.5.592
   Wirz KTS, 2013, NEUROBIOL AGING, V34, P1328, DOI 10.1016/j.neurobiolaging.2012.11.008
   Woo DC, 2010, BEHAV BRAIN RES, V211, P125, DOI 10.1016/j.bbr.2010.03.026
   Xuan AG, 2008, NEUROSCI LETT, V440, P331, DOI 10.1016/j.neulet.2008.05.107
   Yamamoto M, 2005, AM J PATHOL, V166, P1475, DOI 10.1016/S0002-9440(10)62364-4
   Youdim MBH, 2005, TRENDS PHARMACOL SCI, V26, P27, DOI 10.1016/j.tips.2004.11.007
   Zarranz J, 2004, REV NEUROLOGIA, V39, P576
NR 48
TC 5
Z9 6
U1 3
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD AUG 15
PY 2013
VL 245
BP 40
EP 49
DI 10.1016/j.neuroscience.2013.04.015
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 165OY
UT WOS:000320494400004
PM 23608100
DA 2018-12-27
ER

PT J
AU Shafiee, R
   Javanbakht, J
   Atyabi, N
   Bahrami, A
   Kheradmand, D
   Safaei, R
   Khadivar, F
   Hosseini, E
AF Shafiee, Radmehr
   Javanbakht, Javad
   Atyabi, Nahid
   Bahrami, Alimohammad
   Kheradmand, Danial
   Safaei, Reyhaneh
   Khadivar, Farshid
   Hosseini, Ehsan
TI RETRACTED: Comparative value of clinical, cytological, and
   histopathological features in feline mammary gland tumors; an
   experimental model for the study of human breast cancer(Retracted
   article. See vol. 11, 2013)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Pathology; Cytology; Cats; Mammary gland; Tumours
ID INVASIVE MICROPAPILLARY CARCINOMA; NEEDLE-ASPIRATION-CYTOLOGY;
   PROGNOSTIC FACTORS; BREAST-CANCER; DIAGNOSES; CATS; INADEQUATE;
   NEOPLASIA
AB Background: The diagnosis of breast lesions is usually confirmed by fine-needle aspiration cytology (FNAC) or histological biopsy. Although there is increasing literature regarding the advantages and limitations of both modalities, there is no literature regarding the accuracy of these modalities for diagnosing breast lesions in high-risk patients, who usually have lesions detected by screening. Moreover, few studies have been published regarding the cytopathology of mammary tumors in cats despite widespread use of the animal model for breast cancer formation and inhibition. The objective of the present study was to evaluate the diagnostic interest of cytological and histopathological analysis in feline mammary tumours (FMTs), in order to evaluate its possible value as an animal model.
   Methods: The study was performed in 3 female cats submitted to surgical resections of mammary tumours. The mammary tumours were excised by simple mastectomy or regional mastectomy, with or without the superficial inguinal lymph nodes. Female cats were of different breeds (1 siamese and 2 persians). Before surgical excision of the tumour, FNA cytology was performed using a 0.4 mm diameter needle attached to a 8 ml syringe held in a standard metal syringe holder. The cytological sample was smeared onto a glass slide and either air-dried for May-Grunwald-stain and masses were surgically removed, the tumours were grossly examined and tissue samples were fixed in 10%-buffered-formalin and embedded in paraffin. Sections 4 mu m thick were obtained from each sample and H&E stained.
   Results: Cytologically, atypical epithelial cells coupled to giant nucleus, chromatin anomalies, mitotic figures, spindle shape cells, anisocytosis with anisokaryosis and hyperchromasia were found. Histologically, these tumors are characterized by pleomorphic and polygonal cell population together with mitotic figures, necrotic foci and various numbers inflammatory foci. Also, spindle shaped cells, haemorrhage localized in the different regions, local invasiveness and enlarged nuclei were observed. The samples included 3 tumors of mammary glands mammary tumors were complex carcinomas (n = 2) and adenocarcinoma (n = 1). The histological grades of the 3 cases were as follows: grade II, (1/3); grade III, (2/3) with high mitotic index. The preferential localization of mammary neoplasms was in the inguinal lobe (1/3 case) and abdominal lobes (2/3 cases). Furthermore, 1case of the inguinal mass affected the left caudo-inguinal lobe and 2cases right cranio and caudo abdominal lobes.
   Conclusion: The study concluded that cytology could be used as a quick, rapid, field diagnostic technique in combination with histopathology for the diagnosis of feline mammary tumors (FMTs). Our findings in feline MTs indicate that FMTs could be useful as an animal model of human breast cancer. Moreover, because of the similarity of the cytohistopathological findings in the human and feline mammary gland tumours, it is possible to use the same cytopathological criteria applied in human pathology for the diagnosis of feline mammary gland tumours.
   Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2047361423103295
C1 [Shafiee, Radmehr; Khadivar, Farshid] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Javanbakht, Javad; Atyabi, Nahid; Safaei, Reyhaneh] Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
   [Bahrami, Alimohammad; Hosseini, Ehsan] Univ Ilam, Paravet Fac Ilam, Ilam, Iran.
   [Kheradmand, Danial] Islamic Azad Univ Mashhad, Fac Med, Mashhad, Iran.
RP Javanbakht, J (reprint author), Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
EM javadjavanbakht@ut.ac.ir
CR BIBBO M., 1997, COMPREHENSIVE CYTOPA
   Bofin AM, 2004, CYTOPATHOLOGY, V15, P297, DOI 10.1111/j.1365-2303.2004.00159.x
   Carpenter J. L., 1987, Diseases of the cat: medicine and surgery. Volume 1., P406
   Choi YD, 2004, ACTA CYTOL, V48, P801, DOI 10.1159/000326449
   CIATTO S, 1993, RADIOLOGY, V187, P757, DOI 10.1148/radiology.187.3.8388568
   Couto SS, 2002, VET PATHOL, V39, P33, DOI 10.1354/vp.39-1-33
   Cyrta J, 2012, CYTOPATHOLOGY, DOI [10.1111/cyt.12016, DOI 10.1111/CYT.12016.EPUB]
   DEGRAAF H, 1994, CYTOPATHOLOGY, V5, P294
   Dopke C, 2007, J COMP PATHOL, V137, P22, DOI 10.1016/j.jcpa.2007.03.005
   Engle G. C., 1973, Feline Practice, V3, P9
   GUPTA K., 2012, IOSR J PHARM, V2, P322
   Hahn KA, 1997, FELINE PRACT, V25, P5
   HAYDEN DW, 1971, J SMALL ANIM PRACT, V12, P687, DOI 10.1111/j.1748-5827.1971.tb06197.x
   HAYES AA, 1985, VET CLIN N AM-SMALL, V15, P513, DOI 10.1016/S0195-5616(85)50054-6
   HAYES HM, 1981, VET REC, V108, P476, DOI 10.1136/vr.108.22.476
   Haziroglu R, 2010, REV MED VET-TOULOUSE, V161, P212
   Hughes K, 2012, VET J, V194, P19, DOI 10.1016/j.tvjl.2012.05.008
   Ito T, 1996, J VET MED SCI, V58, P723, DOI 10.1292/jvms.58.723
   Karayannopoulou M, 2005, J COMP PATHOL, V133, P246, DOI 10.1016/j.jcpa.2005.05.003
   Khaki F, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-98
   Kondo H, 2009, J COMP PATHOL, V140, P127, DOI 10.1016/j.jcpa.2008.09.012
   Kuroda Hajime, 2004, Breast Cancer, V11, P169, DOI 10.1007/BF02968297
   Lin XY, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-174
   Mac Ewen EG, 1989, SMALL ANIMAL CLIN ON, P356
   MACEWEN EG, 1984, J AM VET MED ASSOC, V185, P201
   Misdorp B, 2001, HISTOLOGICAL CLASSIF, VVII
   Misdorp W., 2002, Tumors in domestic animals, P575, DOI 10.1002/9780470376928.ch12
   MISDORP W, 1999, HISTOLOGICAL CLASSIF, V7
   Morris J, 2013, J FELINE MED SURG, V15, P391, DOI 10.1177/1098612X13483237
   Morrison WB, 1998, CANCER IN DOGS AND CATS: MEDICAL AND SURGICAL MANAGEMENT, P591
   Moulton JE, 2001, TUMOURS DOMESTIC ANI, P318
   Moulton JE., 1990, TUMORS DOMESTIC ANIM, P518
   Owen L.M., 1980, TNM CLASSIFICATION T, P46
   Paterakos M, 1999, HUM PATHOL, V30, P1459, DOI 10.1016/S0046-8177(99)90168-5
   PATNAIK AK, 1975, J NATL CANCER I, V54, P855
   Ramalingam Preetha, 2003, Ann Diagn Pathol, V7, P112
   Rutteman GR, 2001, SMALL ANIMAL CLIN ON, P467
   Seixas F, 2007, VET PATHOL, V44, P842, DOI 10.1354/vp.44-6-842
   Sorenmo K, 2003, VET CLIN N AM-SMALL, V33, P573, DOI 10.1016/S0195-5616(03)00020-2
   Walsh MM, 2001, HUM PATHOL, V32, P583, DOI 10.1053/hupa.2001.24988
   WEIJER K, 1972, J NATL CANCER I, V49, P1697, DOI 10.1093/jnci/49.6.1697
   WEIJER K, 1983, J NATL CANCER I, V70, P709
   Yamada S, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-75
   Yamada S, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-61
   Yamaguchi R, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-53
   Zekioglu O, 2004, HISTOPATHOLOGY, V44, P18, DOI 10.1111/j.1365-2559.2004.01757.x
NR 46
TC 11
Z9 11
U1 2
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD AUG 13
PY 2013
VL 8
AR 136
DI 10.1186/1746-1596-8-136
PG 8
WC Pathology
SC Pathology
GA 215VS
UT WOS:000324239500001
PM 23941603
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Sengpiel, V
   Bacelis, J
   Myhre, R
   Myking, S
   Pay, AD
   Haugen, M
   Brantsaeter, AL
   Meltzer, HM
   Nilsen, RM
   Magnus, P
   Vollset, SE
   Nilsson, S
   Jacobsson, B
AF Sengpiel, Verena
   Bacelis, Jonas
   Myhre, Ronny
   Myking, Solveig
   Pay, Aase Devold
   Haugen, Margaretha
   Brantsaeter, Anne-Lise
   Meltzer, Helle Margrete
   Nilsen, Roy M.
   Magnus, Per
   Vollset, Stein Emil
   Nilsson, Staffan
   Jacobsson, Bo
TI RETRACTED: Folic acid supplementation, dietary folate intake during
   pregnancy and risk for spontaneous preterm delivery: a prospective
   observational cohort study (Retracted article. See vol. 14, 202, 2014)
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article; Retracted Publication
DE Pregnancy; Preterm delivery; Preterm birth; Gestational length; Folate;
   Folic acid supplementation
ID RANDOMIZED CONTROLLED-TRIAL; NEURAL-TUBE DEFECTS; LOW-BIRTH-WEIGHT;
   CHILD COHORT; NORWEGIAN MOTHER; FETAL-GROWTH; WOMEN; MOBA; PREVENTION;
   OUTCOMES
AB Background: Health authorities in numerous countries recommend periconceptional folic acid to pregnant women to prevent neural tube defects. The objective of this study was to examine the association of folic acid supplementation during different periods of pregnancy and of dietary folate intake with the risk of spontaneous preterm delivery (PTD).
   Methods: The Norwegian Mother and Child Cohort Study is a population-based prospective cohort study. A total of 65,668 women with singleton pregnancies resulting in live births in 1999-2009 were included. Folic acid supplementation was self-reported from 26 weeks before pregnancy until week 24 during pregnancy. At gestational week 22, the women completed a food frequency questionnaire, which allowed the calculation of their average total folate intake from foods and supplements for the first 4-5 months of pregnancy. Spontaneous PTD was defined as the spontaneous onset of delivery between weeks 22(+0) and 36(+6) (n = 1,628).
   Results: The median total folate intake was 266 mu g/d (interquartile range IQR 154-543) in the overall population and 540 mu g/d (IQR 369-651) in the supplement users. Eighty-three percent reported any folic acid supplementation from <8 weeks before to 24 weeks after conception while 42% initiated folic acid supplementation before their pregnancy. Cox regression analysis showed that the amount of folate intake from the diet (hazard ratio HR 1.16; confidence interval CI 0.65-2.08) and from the folic acid supplements (HR 1.04; CI 0.95-1.13) was not significantly associated with the risk of PTD. The initiation of folic acid supplementation more than 8 weeks before conception was associated with an increased risk for PTD (HR 1.19; CI 1.05-1.34) compared to no folic acid supplementation pre-conception. There was no significant association with PTD when supplementation was initiated within 8 weeks pre-conception (HR 1.01; CI 0.88-1.16). All analyses were adjusted for maternal characteristics and socioeconomic, health and dietary variables.
   Conclusions: Our findings do not support a protective effect of dietary folate intake or folic acid supplementation on spontaneous PTD. Pre-conceptional folic acid supplementation starting more than 8 weeks before conception was associated with an increased risk of PTD. These results require further investigation before discussing an expansion of folic acid supplementation guidelines.
C1 [Sengpiel, Verena; Bacelis, Jonas; Jacobsson, Bo] Sahlgrens Univ Hosp, Sahlgrenska Acad, Dept Obstet & Gynaecol, SE-41685 Gothenburg, Sweden.
   [Myhre, Ronny; Myking, Solveig; Jacobsson, Bo] Norwegian Inst Publ Hlth, Div Epidemiol, Dept Genes & Environm, NO-0403 Oslo, Norway.
   [Pay, Aase Devold] Oslo Univ Hosp, Dept Obstet, NO-0424 Oslo, Norway.
   [Haugen, Margaretha; Brantsaeter, Anne-Lise; Meltzer, Helle Margrete] Norwegian Inst Publ Hlth, Div Environm Med, Dept Exposure & Risk Assessment, NO-0403 Oslo, Norway.
   [Nilsen, Roy M.] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, NO-5018 Bergen, Norway.
   [Magnus, Per] Norwegian Inst Publ Hlth, Div Epidemiol, NO-0403 Oslo, Norway.
   [Vollset, Stein Emil] Norwegian Inst Publ Hlth, NO-5018 Bergen, Norway.
   [Vollset, Stein Emil] Univ Bergen, NO-5018 Bergen, Norway.
   [Nilsson, Staffan] Chalmers Univ Technol, SE-41296 Gothenburg, Sweden.
RP Sengpiel, V (reprint author), Sahlgrens Univ Hosp, Sahlgrenska Acad, Dept Obstet & Gynaecol, SE-41685 Gothenburg, Sweden.
EM verena.sengpiel@obgyn.gu.se
RI Jacobsson, Bo/O-8007-2014; Brantsaeter, Anne Lise/H-7014-2016
OI Jacobsson, Bo/0000-0001-5079-2374; Brantsaeter, Anne
   Lise/0000-0001-6315-7134; Bacelis, Jonas/0000-0002-2450-732X; Meltzer,
   Helle Margrete/0000-0002-3591-7017; Nilsson, Staffan/0000-0003-4748-0446
FU Norwegian Research Council [FUGE 183220/S10, FRIMEDKLI-05 ES236011];
   Swedish Medical Society [SLS 2008-21198]; Swedish government
   [ALFGBG-2863, ALFGBG-11522]
FX This work was supported by grants from the Norwegian Research Council
   (FUGE 183220/S10, FRIMEDKLI-05 ES236011), the Swedish Medical Society
   (SLS 2008-21198) and Swedish government grants to researchers in public
   health service (ALFGBG-2863, ALFGBG-11522). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alwan NA, 2010, BJOG-INT J OBSTET GY, V117, P821, DOI 10.1111/j.1471-0528.2010.02549.x
   [Anonymous], 1970, World Health Organ Tech Rep Ser, V457, P1
   Bailey RL, 2010, AM J CLIN NUTR, V91, P231, DOI 10.3945/ajcn.2009.28427
   BAUMSLAG N, 1970, BMJ-BRIT MED J, V1, P16, DOI 10.1136/bmj.1.5687.16
   Bergen NE, 2012, BJOG-INT J OBSTET GY, V119, P739, DOI 10.1111/j.1471-0528.2012.03321.x
   Brantsaeter AL, 2008, MATERN CHILD NUTR, V4, P28, DOI 10.1111/j.1740-8709.2007.00103.x
   Brantsaeter AL, 2007, ANN NUTR METAB, V51, P146, DOI 10.1159/000103275
   Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
   Bukowski R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000061
   Callaway L, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000077
   Catov JM, 2011, AM J CLIN NUTR, V94, P906, DOI 10.3945/ajcn.111.012393
   Charles DHM, 2005, PAEDIATR PERINAT EP, V19, P112, DOI 10.1111/j.1365-3016.2005.00633.x
   Czeizel AE, 2010, EUR J OBSTET GYN R B, V148, P135, DOI 10.1016/j.ejogrb.2009.10.016
   CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602
   CZEIZEL AE, 1994, ARCH GYNECOL OBSTET, V255, P131
   deBree A, 1997, EUR J CLIN NUTR, V51, P643, DOI 10.1038/sj.ejcn.1600467
   Dodd JM, 2008, OBSTET GYNECOL, V112, P127, DOI 10.1097/AOG.0b013e31817d0262
   Dunlop AL, 2012, REPROD SCI, V19, P939, DOI 10.1177/1933719112438442
   Fekete K, 2012, FAO FISHERIES REPORT, V11, P75
   Fekete K, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-75
   FLEMING AF, 1974, MED J AUSTRALIA, V2, P479
   FLETCHER J, 1971, J OBSTET GYN BR COMM, V78, P781
   Furness DLF, 2012, J MATERN-FETAL NEO M, V25, P1423, DOI 10.3109/14767058.2011.636463
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Hassan SS, 2011, ULTRASOUND OBST GYN, V38, P18, DOI 10.1002/uog.9017
   Haugen M, 2008, ANN NUTR METAB, V52, P272, DOI 10.1159/000146274
   Irgens LM, 2000, ACTA OBSTET GYN SCAN, V79, P435, DOI 10.1034/j.1600-0412.2000.079006435.x
   ISRAELS MCG, 1952, LANCET, V263, P214
   LAURITZEN J, FOODCALC
   Lockwood CJ, 2002, NEW ENGL J MED, V346, P282, DOI 10.1056/NEJM200201243460412
   Magnus P, 2006, INT J EPIDEMIOL, V35, P1146, DOI 10.1093/ije/dyl170
   Meltzer HM, 2008, MATERN CHILD NUTR, V4, P14, DOI 10.1111/j.1740-8709.2007.00104.x
   Moster D, 2008, NEW ENGL J MED, V359, P262, DOI 10.1056/NEJMoa0706475
   Nilsen RM, 2006, AM J CLIN NUTR, V84, P1134
   Nilsen RM, 2010, J NUTR, V140, P572, DOI 10.3945/jn.109.118158
   Nilsen RM, 2009, PAEDIATR PERINAT EP, V23, P597, DOI 10.1111/j.1365-3016.2009.01062.x
   Nordic Council of Ministers, 2004, NORD NUTR REC 2004, P287
   Norwegian Food Safety Authority Norwegian Directorate of Health Department of Nutrition-University of Oslo, MATV NORW FOOD TABL
   Papadopoulou E, 2013, EUR J NUTR, V52, P327, DOI 10.1007/s00394-012-0339-z
   Pennell CE, 2007, AM J OBSTET GYNECOL, V196, P107, DOI 10.1016/j.ajog.2006.03.109
   Rolschau J, 1999, EUR J OBSTET GYN R B, V87, P105, DOI 10.1016/S0301-2115(99)00084-6
   Romero R, 2012, AM J OBSTET GYNECOLO, V206
   Scholl TO, 1996, AM J CLIN NUTR, V63, P520
   Scholl TO, 1997, AM J EPIDEMIOL, V146, P134
   Scholl TO, 2000, AM J CLIN NUTR, V71, p1295S, DOI 10.1093/ajcn/71.5.1295s
   Shaw GM, 2011, AM J PERINAT, V28, P747, DOI [10.1055/s-0031-1280855, 10.1055/s-0031-1280855.]
   Shaw GM, 2004, PUBLIC HEALTH REP, V119, P170, DOI 10.1177/003335490411900210
   Siega-Riz AM, 2004, AM J OBSTET GYNECOL, V191, P1851, DOI 10.1016/j.ajog.2004.07.076
   Tamura T, 2006, AM J CLIN NUTR, V83, P993
   Timmermans S, 2009, BRIT J NUTR, V102, P777, DOI 10.1017/S0007114509288994
   WALD N, 1991, LANCET, V338, P131
   World Health Organization; Food and Agricultural Organization of the United Nations, 2004, VIT MIN REQ HUM NUTR, P53
NR 52
TC 6
Z9 9
U1 2
U2 26
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD AUG 12
PY 2013
VL 13
AR 160
DI 10.1186/1471-2393-13-160
PG 13
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 203SO
UT WOS:000323313800001
PM 23937678
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Shafiee, R
   Javanbakht, J
   Atyabi, N
   Kheradmand, P
   Kheradmand, D
   Bahrami, A
   Daraei, H
   Khadivar, F
AF Shafiee, Radmehr
   Javanbakht, Javad
   Atyabi, Nahid
   Kheradmand, Pegah
   Kheradmand, Danial
   Bahrami, Alimohammad
   Daraei, Hasti
   Khadivar, Farshid
TI RETRACTED: Diagnosis, classification and grading of canine mammary
   tumours as a model to study human breast cancer: an
   Clinico-Cytohistopathological study with environmental factors
   influencing public health and medicine(Retracted article. See vol.16,
   pg.83, 2016)
SO CANCER CELL INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Grading of tumours; Cytohistopathology; Dog; Mammary glands; Tumour
ID NEEDLE-ASPIRATION-CYTOLOGY; CARCINOMA IN-SITU; PROLIFERATIVE ACTIVITY;
   EPITHELIAL NEOPLASMS; VASCULOGENIC MIMICRY; HISTOLOGICAL GRADE;
   PROGNOSTIC-FACTORS; ESTROGEN-RECEPTOR; GLAND TUMORS; DOGS
AB Background: The human "Elston and Ellis grading method" was utilized in dogs with mammary tumor to examine its relation to prognosis in this species, based on a 2-year follow-up period. Although cytopathology is widely used for early diagnosis of human neoplasms, it is not commonly performed in veterinary medicine. Our objectives in this study were to identify cytopathology criteria of malignancy for canine mammary tumors and the frequency of different types of mammary lesions and their relationship with histologic grade was investigated. Another aim of this study was to differentiate the simple and adenocarcinoma tumors from the complex or mixed tumor described by Elston and Ellis grading method.
   Methods: The study was performed in 15 pure or mixed-breed female dogs submitted to surgical resections of mammary tumours. The mammary tumours were excised by simple mastectomy or regional mastectomy, with or without the superficial inguinal lymph nodes. Female dogs were mainly terriers (9 dogs) or mixed (3 dogs), the 3 other animals were a German shepherd, Dachshund and Pekingese. Before surgical excision of the tumour, FNAC was performed using a 0.6 mm diameter needle attached to a 10 ml syringe held in a standard metal syringe holder. The cytological sample was smeared onto a glass slide and either air-dried for May-Grunwald-stain, or ethanol-fixed for Papanicolaou stain and masses were surgically removed, the tumours were grossly examined and tissue samples were fixed in 10%-buffered-formalin and embedded in paraffin. Sections 4 mu m thick were obtained from each sample and H&E stained.
   Results: We obtained a correct cytohistological correlation in 14/15 cases (93.3%) when all cytopathological examinations were considered. Of the 15 cases examined, 2(13.3%) had well-differentiated (grade I), 6(40%) had moderately differentiated (grade II) and 7(46.7%) had poorly differentiated (grade III) tumours. Classification of all canine mammary gland lesions revealed 13(86.7%) malignant and 2(13.3%) benign tumors. The histological examination showed that the most common tumor types of mammary glands in bitches were: complex carcinoma, adenocarcinoma, malignant mixed tumour, benign mixed tumour, simple carcinoma- (5/15; 33.3%), (3/15; 20%), (3/15; 20%) and (2/15; 13.3%), respectively. Simple carcinoma and cystic hyperplasia were less common - (1/15; 6.7%), and (1/15; 6.7%), respectively. Moreover, the most often tumors occur in inguinal mammary (60%) and abdominal (27%) glands.
   Conclusions: Our results demonstrate that, because of the similarity of the cytohistopathological findings in the human and canine mammary gland tumours, it is possible to use the same cytopathological criteria applied in human pathology for the diagnosis of canine mammary gland tumours. Furthemoer, routine use of this human grading method would help the clinician to make a more accurate prognosis in the interests of post-surgical management in dogs with mammary carcinomas. Furthermore, this research will allow a more discriminating classification of mammary tumors and probably has a bearing on cytohistopathology, epidemiology, pathogenesis and prognosis. The most often tumors occur in inguinal mammary (60%) and abdominal (27%) glands. This interesting regional difference may be due to a) the duration of the growth before the diagnosis; b) the age of the dogs; and c) high prevelance of unspayed animals. Moreover, the most common type of tumor was complex carcinoma - 33.3% (5 cases).
C1 [Shafiee, Radmehr; Khadivar, Farshid] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Javanbakht, Javad; Atyabi, Nahid] Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
   [Kheradmand, Pegah] Semnan Univ Med Sci, Fac Med, Semnan, Iran.
   [Kheradmand, Danial] MD Grad Islamic Azad Univ Mashhad, Fac Med, Mashhad, Iran.
   [Bahrami, Alimohammad] Univ Ilam, MD Grad Paravet Fac Ilam, Ilam, Iran.
   [Daraei, Hasti] Alborz Univ Med Sci, Dept Environm Hlth Engn, Karaj, Iran.
RP Javanbakht, J (reprint author), Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
EM javadjavanbakht@ut.ac.ir
CR ALLEN SW, 1986, VET PATHOL, V23, P649, DOI 10.1177/030098588602300601
   Baker R, 2000, COLOR ATLAS CYTOLOGY, P253
   Benjamin SA, 1999, VET PATHOL, V36, P423, DOI 10.1354/vp.36-5-423
   Bibbo M, 1997, COMPREHENSIVE CYTOPA, P413
   Bofin AM, 2004, CYTOPATHOLOGY, V15, P297, DOI 10.1111/j.1365-2303.2004.00159.x
   Brody RS, 1983, J AM ANIM HOSP ASSOC, V35, P1961
   Brunelle M, 2006, VET PATHOL, V43, P656, DOI 10.1354/vp.43-5-656
   Cassali GD, 2007, CYTOPATHOLOGY, V18, P191, DOI 10.1111/j.1365-2303.2007.00412.x
   Choi YD, 2004, ACTA CYTOL, V48, P801, DOI 10.1159/000326449
   CIATTO S, 1993, RADIOLOGY, V187, P757, DOI 10.1148/radiology.187.3.8388568
   Clemente M, 2010, VET PATHOL, V47, P265, DOI 10.1177/0300985809353167
   Cyrta J, 2012, CYTOPATHOLOGY, V32, pe64
   De M, 2009, CAN VET J, V50, P506
   DEGRAAF H, 1994, CYTOPATHOLOGY, V5, P294
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Egenvall A, 2005, PREV VET MED, V69, P109, DOI 10.1016/j.prevetmed.2005.01.014
   EISENBERG AJ, 1986, ACTA CYTOL, V30, P135
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Ezerskyte A, 2011, VET ZOOTECH-LITH, V53, P3
   FIDLER IJ, 1967, J AM VET MED ASSOC, V151, P710
   Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6
   GILBERTSON SR, 1983, VET PATHOL, V20, P127, DOI 10.1177/030098588302000201
   GUPTA K., 2012, IOSR J PHARM, V2, P322
   HAMPE JF, 1974, B WORLD HEALTH ORGAN, V50, P111
   Haziroglu R, 2010, REV MED VET-TOULOUSE, V161, P212
   Hsu WL, 2009, VET J, V180, P116, DOI 10.1016/j.tvjl.2007.10.013
   Karayannopoulou M, 2005, J COMP PATHOL, V133, P246, DOI 10.1016/j.jcpa.2005.05.003
   Karayannopoulou M, 2001, J VET MED A, V48, P85, DOI 10.1046/j.1439-0442.2001.00336.x
   Karayannopoulou M, 1989, B HELLENIC VET MED S, V40, P111
   MacEwen EG, 1996, SMALL ANIMAL CLIN ON, V2, P356
   Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5
   Marconato L, 2009, JAVMA-J AM VET MED A, V235, P967, DOI 10.2460/javma.235.8.967
   Millanta F, 2005, RES VET SCI, V79, P225, DOI 10.1016/j.rvsc.2005.02.002
   Misdorp B, 2001, WHO INT HISTOLOGICAL, VVII
   Misdorp W., 2002, Tumors in domestic animals, P575, DOI 10.1002/9780470376928.ch12
   Misdorp W, 1999, HISTOLOGIC CLASSIFIC, P3
   Moe L, 2001, J REP FER S, P439
   Morris JS, 2009, VET J, V179, P422, DOI 10.1016/j.tvjl.2007.10.025
   Nieto A, 2000, VET PATHOL, V37, P239, DOI 10.1354/vp.37-3-239
   Paget J, 1854, HISTOPATHOLOGY, V153, P14
   Pamukcu M, 1962, VET J ANKARA U, V9, P1
   Rezaie A., 2009, Journal of Biological Sciences, V9, P333, DOI 10.3923/jbs.2009.333.338
   Rivera P, 2010, THESIS SWEDISH U AGR
   Rosen PP, 1993, TUMORS MAMMARY GLAND, P390
   Rungsipipat A, 1999, J VET MED SCI, V61, P27, DOI 10.1292/jvms.61.27
   Sarli G, 2002, J VET DIAGN INVEST, V14, P25, DOI 10.1177/104063870201400106
   Shirakawa K, 2001, CANCER RES, V61, P445
   Simeonov R., 2006, Bulgarian Journal of Veterinary Medicine, V9, P211
   Sood AK, 2001, AM J PATHOL, V158, P1279, DOI 10.1016/S0002-9440(10)64079-5
   Sorenmo K, 2003, VET CLIN N AM-SMALL, V33, P573, DOI 10.1016/S0195-5616(03)00020-2
   Tavasoly Abbas, 2013, Vet Res Forum, V4, P25
   Thuroczy J, 2007, J COMP PATHOL, V137, P122, DOI 10.1016/j.jcpa.2007.05.005
   Virnig BA, 2010, J NATL CANCER I, V102, P170, DOI 10.1093/jnci/djp482
   Vogl G, 2005, HISTOPATHOLOGY, V47, P617, DOI 10.1111/j.1365-2559.2005.02299.x
   Yang WY, 2006, J COMP PATHOL, V134, P70, DOI 10.1016/j.jcpa.2005.07.002
   Zatloukal J, 2005, ACTA VET BRNO, V74, P103, DOI 10.2754/avb200574010103
NR 56
TC 21
Z9 21
U1 4
U2 49
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD AUG 9
PY 2013
VL 13
AR 79
DI 10.1186/1475-2867-13-79
PG 11
WC Oncology
SC Oncology
GA 205NN
UT WOS:000323451100001
PM 23937693
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Guo, YP
AF Guo, Yueping
TI RETRACTED: Flap side edge noise modeling and prediction (Retracted
   article. See vol. 333, pg. 4403, 2014)
SO JOURNAL OF SOUND AND VIBRATION
LA English
DT Article; Retracted Publication
AB This paper presents a model for aircraft flap side edge noise prediction. The flap side edge noise is modeled as two components, respectively for the low and high frequency domain and corresponding to two noise generation mechanisms in the flap side edge flows. The high frequency noise mostly comes from the flow separation near the sharp corners of the flap, mainly in the forward half of the flap chord, and the low frequency component is largely due to the interactions between the large scale vortex structure and the sharp corners of the flap, occurring in the mid and aft half chord region of the flap where the rollup vortex is well established with significant vertical energy to be scattered into sound by the corners. The prediction model is developed from the theory of aerodynamic sound generation, relating the noise spectrum to the statistics of the surface pressure fluctuations in the vicinity of the flap side edges, the characteristic length and time scales in the flow, and the Green's function that accounts for the sound-flow coupling and propagation effects. For both the low and high frequency components, the individual physical mechanisms for the noise generation and propagation are analyzed to develop prediction models for the features of the radiated noise, such as the spectral shapes, the Mach number dependencies and the far field directivities. The individual models are validated by experimental data, showing good agreements between the developed prediction models and data. (C) 2013 Elsevier Ltd. All rights reserved.
C1 Boeing Co, Huntington Beach, CA 92647 USA.
RP Guo, YP (reprint author), Boeing Co, Mail Code H013-B308,5301 Balsa Ave, Huntington Beach, CA 92647 USA.
EM yueping.guo@boeing.com
FU NASA [NNL07AA03A]
FX The work reported here was conducted under NASA Contract NNL07AA03A,
   under the Fundamental Aeronautics Program. The author would like to
   thank the task monitor, Casey Burley of NASA LaRC, for her support and
   encouragement.
CR Brooks TF, 2003, J SOUND VIB, V261, P31, DOI 10.1006/S0022-460X(02)00939-2
   Brusniak L., 2006, 20062715 AIAA
   Davy R., 2002, 20022412 AIAA
   Davy R., 1998, 982335 AIAA
   Dobrzynski W., 1998, 982337 AIAA
   Dong T.Z., 1999, 991803 AIAA
   Fink M.R., 1979, FAARD7729
   FINK MR, 1979, J AIRCRAFT, V16, P659, DOI 10.2514/3.58586
   Guo Y.P., 2005, EMPIRICAL PREDICTION
   Guo Y.P., 2011, AIAA PAPER
   Guo Y.P., 2010, 20103837 AIAA
   Guo Y.P., 2009, NAS1NNL04AA11B NASA
   Guo Y.P., 2004, NAS100086 NASA
   Guo Y.P., 2006, INTERNOISE
   Guo Y.P., 1999, 991804 AIAA
   Guo Y.P., 1997, 971697 AIAA
   Guo YP, 2003, J AIRCRAFT, V40, P914, DOI 10.2514/2.6867
   Guo YP, 2003, AIAA J, V41, P1247, DOI 10.2514/2.2093
   Guo YP, 2000, J FLUID MECH, V403, P201, DOI 10.1017/S0022112099006989
   Guo YP, 2000, J FLUID MECH, V415, P175, DOI 10.1017/S0022112000008740
   Guo YP, 2012, J SOUND VIB, V331, P3567, DOI 10.1016/j.jsv.2012.03.016
   HARDIN JC, 1980, AIAA J, V18, P549, DOI 10.2514/3.7668
   Hayes J., 1997, 971594 AIAA
   Kendall J.M., 1980, 800035 AIAA
   Khorrami M.R., 1998, 982225 AIAA
   Khorrami M.R., 1997, SAE PAPER
   Khorrami MR, 1999, AIAA J, V37, P14, DOI 10.2514/2.687
   Mathias D.L., 1995, 950185 AIAA
   Mclnerny S.A., 1986, 861918 AIAA
   Meadows K.R., 1997, 971595 AIAA
   Miller W.R., 1980, THESIS UCLA
   Pott-Pollenski M., 2002, 20022470 AIAA
   Pott-Pollenski M., 2006, 20062567 AIAA
   Radeztsky R.H., 1998, 980700 AIAA
   Sen R, 1997, AIAA J, V35, P441, DOI 10.2514/2.149
   Sen R., 1997, AIRFRAME NOISE GENER
   Sen R., 2004, CR2004213255 NASA
   Smith M.G., 2003, 20033226 AIAA
   Streett C.L., 1998, 982226 AIAA
   Streett C.L., 1998, 980628 AIAA
   Ura H., 2008, 200819 AIAA
   WILLIAMS JE, 1969, PHILOS TR R SOC S-A, V264, P321, DOI 10.1098/rsta.1969.0031
NR 42
TC 5
Z9 6
U1 2
U2 17
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-460X
EI 1095-8568
J9 J SOUND VIB
JI J. Sound Vibr.
PD AUG 5
PY 2013
VL 332
IS 16
BP 3846
EP 3868
DI 10.1016/j.jsv.2013.02.029
PG 23
WC Acoustics; Engineering, Mechanical; Mechanics
SC Acoustics; Engineering; Mechanics
GA 185TK
UT WOS:000321993000017
DA 2018-12-27
ER

PT J
AU Lee, D
   Lee, KH
   Park, H
   Kim, SH
   Jin, T
   Cho, S
   Chung, JH
   Lim, S
   Park, S
AF Lee, Dajeong
   Lee, Kyung Hye
   Park, Hyelim
   Kim, Soo Hyuk
   Jin, Taewon
   Cho, Soyoung
   Chung, Ji Hyung
   Lim, Soyeon
   Park, Sungha
TI RETRACTED: The Effect of Soluble RAGE on Inhibition of Angiotensin
   II-Mediated Atherosclerosis in Apolipoprotein E Deficient Mice
   (Retracted article. See vol. 9, e108684, 2014)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID GLYCATION END-PRODUCTS; RAT CAROTID-ARTERY; CELL-SURFACE; RECEPTOR;
   INFLAMMATION; PROTEIN; EXPRESSION; SYSTEM; PROLIFERATION; RECRUITMENT
AB Background: The cross talk between RAGE and angiotensin II (AngII) activation may be important in the development of atherosclerosis. Soluble RAGE (sRAGE), a truncated soluble form of the receptor, acts as a decoy and prevents the inflammatory response mediated by RAGE activation. In this study, we sought to determine the effect of sRAGE in inhibiting AngII-induced atherosclerosis in apolipoprotein E knockout mice (Apo E KO).
   Methods and Results: 9 week old Apo E KO mice were infused subcutaneously with AngII (1 mu g/min/kg) and saline for 4 weeks using osmotic mini-pumps. The mice were divided into 4 groups 1. saline infusion and saline injection; 2. saline infusion and sRAGE injection; 3. AngII infusion and saline injection; 4. AngII infusion and sRAGE injection. Saline or 0.5 mu g, 1 mu g, to 2 mu g/day/mouse of sRAGE were injected intraperitoneally daily for 28 days. We showed that atherosclerotic plaque areas in the AngII-infused Apo E KO mice and markers of inflammation such as RAGE, ICAM-1, VCAM-1, and MCP-1 were increased in aorta compared to that of the Apo E KO mice. However, the treatment of 0.5 mu g, 1 mu g, and 2 mu g of sRAGE in AngII group resulted in the dose-dependent decrease in atherosclerotic plaque area. We also demonstrated that sRAGE decreased RAGE expression level as well as inflammatory cytokines and cell adhesion molecules in AngII or HMGB1 treated-rat aorta vascular smooth muscle cells.
   Conclusion: The results demonstrated that partical blockade of RAGE activation by sRAGE prevent AngII -induced atherosclerosis. Therefore these results suggested that first, RAGE activation may be important in mediating AngII-induced atherogenesis, and second, AngII activation is a major pathway in the development of atherosclerosis. Taken together, results from this study may provide the basis for future anti-atherosclerotic drug development mediated through RAGE activation.
C1 [Lee, Dajeong; Kim, Soo Hyuk; Jin, Taewon; Chung, Ji Hyung] Yonsei Univ, Grad Program Sci Aging, Seoul 120749, South Korea.
   [Lee, Dajeong; Kim, Soo Hyuk; Jin, Taewon; Chung, Ji Hyung] Yonsei Univ, Yonsei Res Inst Aging Sci, Seoul 120749, South Korea.
   [Lee, Kyung Hye] Kyung Hee Univ, Med Ctr, Med Sci Res Inst, Seoul, South Korea.
   [Lee, Dajeong; Park, Hyelim; Kim, Soo Hyuk; Jin, Taewon; Cho, Soyoung; Chung, Ji Hyung; Lim, Soyeon; Park, Sungha] Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea.
   [Park, Sungha] Yonsei Univ, Coll Med, Div Cardiol, Seoul, South Korea.
   [Cho, Soyoung; Lim, Soyeon] Yonsei Univ, Coll Med, Severance Integrat Res Inst Cerebral & Cardiovasc, Seoul, South Korea.
   [Park, Hyelim; Park, Sungha] Yonsei Univ, Brain Korea Project Med Sci 21, Seoul 120749, South Korea.
RP Lim, S (reprint author), Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea.
EM slim724@yuhs.ac; shpark0530@yuhs.ac
FU National Research Foundation [NRF-2010-0003855]; Korea Healthcare
   Technology R&D Project, Ministry for Health, Welfare and Family Affairs,
   Republic of Korea [A085136]
FX This work was supported by grants from the National Research Foundation
   Grant (NRF-2010-0003855) and the Korea Healthcare Technology R&D
   Project, Ministry for Health, Welfare and Family Affairs, Republic of
   Korea (A085136). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alexiou P, 2010, CURR MED CHEM, V17, P2232, DOI 10.2174/092986710791331086
   Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7
   Bierhaus A, 2006, CURR OPIN INVESTIG D, V7, P985
   Brewster UC, 2003, AM J MED SCI, V326, P15, DOI 10.1097/00000441-200307000-00003
   Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36
   Chae CU, 2001, HYPERTENSION, V38, P399, DOI 10.1161/01.HYP.38.3.399
   Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800
   Chen CY, 2012, J BIOL CHEM, V287, P44498, DOI 10.1074/jbc.M112.399790
   Cheng ZJ, 2005, MED SCI MONITOR, V11, pRA194
   Choi JW, 2011, BIOCHEM BIOPH RES CO, V410, P525, DOI 10.1016/j.bbrc.2011.06.016
   Dourron HM, 2005, AM J PHYSIOL-HEART C, V288, pH946, DOI 10.1152/ajpheart.00413.2004
   Dzau V, 2005, J HYPERTENS, V23, pS9, DOI 10.1097/01.hjh.0000165623.72310.dd
   Ihara Y, 2007, J MOL CELL CARDIOL, V43, P455, DOI 10.1016/j.yjmce.2007.07.044
   Jandeleit-Dahm K, 2008, CLIN EXP PHARMACOL P, V35, P329, DOI 10.1111/j.1440-1681.2007.04875.x
   Lee HW, 2008, REGUL PEPTIDES, V147, P72, DOI 10.1016/j.regpep.2008.01.004
   Lee SW, 2013, ARTHRITIS RHEUM
   Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704
   Lin L, 2009, FRONT BIOSCI-LANDMRK, V14, P1403, DOI 10.2741/3315
   Ling HP, 2013, J SURG RES, V179, pE227, DOI 10.1016/j.jss.2012.03.030
   Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006
   NEEPER M, 1992, J BIOL CHEM, V267, P14998
   Patole PS, 2005, KIDNEY INT, V68, P2582, DOI 10.1111/j.1523-1755.2005.00729.x
   Pueyo ME, 2000, ARTERIOSCL THROM VAS, V20, P645, DOI 10.1161/01.ATV.20.3.645
   Radeke HH, 2002, J BIOL CHEM, V277, P27535, DOI 10.1074/jbc.M200419200
   Rai V, 2012, J BIOL CHEM, V287, P5133, DOI 10.1074/jbc.M111.277731
   Saraff K, 2003, ARTERIOSCL THROM VAS, V23, P1621, DOI 10.1161/01.ATV.0000085631.76095.64
   SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987
   Vazzana N, 2009, INTERN EMERG MED, V4, P389, DOI 10.1007/s11739-009-0300-1
   Weaver M, 2006, AM J PHYSIOL-HEART C, V290, pH1933, DOI 10.1152/ajpheart.00690.2005
   Weiss D, 2001, CIRCULATION, V103, P448
   WOOLEY PH, 1993, J IMMUNOL, V151, P6602
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
   Yusuf S, 2000, NEW ENGL J MED, V342, P145
NR 33
TC 17
Z9 18
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 1
PY 2013
VL 8
IS 8
AR e69669
DI 10.1371/journal.pone.0069669
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219PB
UT WOS:000324518400020
PM 23936343
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wang, S
   Wang, Z
AF Wang, Shuai
   Wang, Zhou
TI RETRACTED: Epigenetic aberrant methylation of tumor suppressor genes in
   small cell lung cancer (Retracted article. See vol. 6, pg. E35, 2014)
SO JOURNAL OF THORACIC DISEASE
LA English
DT Review; Retracted Publication
DE Small cell lung cancer (SCLC); tumor suppressor gene (TSG); promotor
   methylation; hypermethylation
ID DNA METHYLATION; PROMOTER METHYLATION; ISLAND METHYLATION;
   COLORECTAL-CANCER; BREAST-CANCER; CPG ISLAND; HYPERMETHYLATION;
   EXPRESSION; INACTIVATION; METHYLTRANSFERASE
AB Small cell lung cancer (SCLC), a special type of lung cancer, is reputed to carry a poor prognosis. The morbidity of SCLC is increasing in China and other countries. A variety of DNA alterations associated with non-small cell lung cancer (NSCLC) have been described. However, genetic and epigenetic changes of SCLC are not well established. Few studies have demonstrated that epigenetic silencing of key tumor suppressor genes (TSGs) is pivotal to initiation and development of SCLC. Recently, promoter methylation of many TSGs have been identified in SCLC. These novel TSGs are potential tumor biomarkers for early diagnosis and prognostic prediction. Moreover, epigenetic promoter methylation of TSGs could be a target of intervention with a wide prospect of clinical application. This review summarizes recent studies on promoter methylation of TSGs in SCLC and aims to provide better understanding of the promoter methylation in tumorigenesis and progression of SCLC.
C1 [Wang, Shuai; Wang, Zhou] Shandong Univ, Prov Hosp, Dept Thorac Surg, Jinan 250021, Peoples R China.
RP Wang, Z (reprint author), Shandong Univ, Prov Hosp, Dept Thorac Surg, 324 Jingwu Rd, Jinan 250021, Peoples R China.
EM wz620226@hotmail.com
OI Wang, Shuai/0000-0001-8503-9024
FU National Natural Science Foundation of China [81172161]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81172161).
CR Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243
   Beck S, 2008, TRENDS GENET, V24, P231, DOI 10.1016/j.tig.2008.01.006
   Belinsky SA, 2003, CANCER RES, V63, P7089
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Cohen AJ, 2002, CHEST, V121, p27S, DOI 10.1378/chest.121.3_suppl.27S-a
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 2001, CANCER RES, V61, P3225
   Fukasawa M, 2006, J HUM GENET, V51, P368, DOI 10.1007/s10038-005-0355-4
   Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750
   Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459
   Grote HJ, 2006, CANCER CYTOPATHOL, V108, P129, DOI 10.1002/cncr.21717
   Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Iwasaki Y, 2010, ANN SURG ONCOL, V17, P2222, DOI 10.1245/s10434-010-0956-9
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kreisler A, 2010, ONCOGENE, V29, P5828, DOI 10.1038/onc.2010.321
   Li JS, 2013, CHIN J CANCER, V32, P3, DOI 10.5732/cjc.011.10381
   Nishioka M, 2002, P NATL ACAD SCI USA, V99, P12269, DOI 10.1073/pnas.192445899
   Nyiraneza C, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-9
   Oshita F, 2003, ONCOL REP, V10, P105
   Pelosi G, 2010, ANTICANCER RES, V30, P4269
   Pietanza MC, 2012, CLIN CANCER RES, V18, P1138, DOI 10.1158/1078-0432.CCR-11-2059
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Sameer AS, 2012, MOL MED REP, V5, P1053, DOI 10.3892/mmr.2012.740
   Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581
   Seike M, 2000, CLIN CANCER RES, V6, P4307
   Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Suzuki M, 2007, ANN SURG ONCOL, V14, P1397, DOI 10.1245/s10434-006-9089-6
   Toyooka S, 2001, MOL CANCER THER, V1, P61
   Travis WD, 2004, TUMOURS LUNG PLEURA, P9
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   Zhang Li-Xia, 2007, Ai Zheng, V26, P576
   Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451
   Zochbauer-Muller S, 2001, CANCER RES, V61, P3581
NR 37
TC 9
Z9 9
U1 2
U2 14
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2072-1439
EI 2077-6624
J9 J THORAC DIS
JI J. Thorac. Dis.
PD AUG
PY 2013
VL 5
IS 4
BP 532
EP 537
DI 10.3978/j.issn.2072-1439.2013.08.21
PG 6
WC Respiratory System
SC Respiratory System
GA 220PH
UT WOS:000324596800043
PM 23991313
DA 2018-12-27
ER

PT J
AU Sri, D
AF Sri, D.
TI RETRACTED: The management of spinal dural fistulas: a 13-year
   retrospective analysis (Retracted article. See vol. 28, pg. 297, 2014)
SO BRITISH JOURNAL OF NEUROSURGERY
LA English
DT Article; Retracted Publication
DE arteriovenous malformation; spinal dural fistula; Type I spinal
   duralarteriovenous malformation
ID CORD ARTERIOVENOUS SHUNTS
AB Introduction. Spinal Dural Fistulas (SDAVF) are the most common Spinal Vascular Malformation. The management of SDAVFs has revolved around embolization or surgical interruption. The management strategy employed at this centre is to attempt embolization as first line therapy and to opt for surgery in the event of failure. Method. This retrospective study looks at the management of 38 patients treated for SDAVFs at a tertiary centre over a 13-year period (1997-2010). Patient demographics, procedure and follow-up over a 6-12 month period (mean of approximately 10 months) were analyzed and qualitative assessment of patient outcome was assessed. Results. Patient ages ranged from 20 to 86 (mean 63.5), with 27 male and 11 female patients. Patients managed since 1995 with a combination of embolization and surgery report either improved symptoms or a return to normal were 73.7%. Micturition and bowel symptoms indicated more severe disability and were more likely to contribute to no improvement in overall outcome. Conclusions. This centre has in place a management strategy for SDAVF that contributes to both radiologically and symptomatically successful treatment.
C1 [Sri, D.] Addenbrookes Hosp, Dept Neurosurg, Cambridge, England.
RP Sri, D (reprint author), Royal Free Hosp, Pond St, London NW3 2QG, England.
EM denosshansri@gmail.com
CR Andres RH, 2008, NEURORADIOLOGY, V50, P869, DOI 10.1007/s00234-008-0425-3
   Kaufmann TJ, 2011, J NEUROSURG-SPINE, V14, P548, DOI 10.3171/2010.11.SPINE10178
   Krings T, 2010, NEUROSURG REV, V33, P1, DOI 10.1007/s10143-009-0204-6
   Narvid J, 2008, NEUROSURGERY, V62, P159, DOI [10.1227/01.NEU.0000296997.82103.47, 10.1227/01.NEU.0000311073.71733.C4]
   Rodesch G, 2003, EUR J RADIOL, V46, P221, DOI 10.1016/S0720-048X(03)00093-7
   Rodesch G, 2002, NEUROSURGERY, V51, P374, DOI 10.1097/00006123-200208000-00013
   Sivakumar W, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS098
   Steinmetz MP, 2004, NEUROSURGERY, V55, P77, DOI 10.1227/01.NEU.0000126878.95006.0F
NR 8
TC 2
Z9 3
U1 3
U2 11
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0268-8697
EI 1360-046X
J9 BRIT J NEUROSURG
JI Br. J. Neurosurg.
PD AUG
PY 2013
VL 27
IS 4
BP 471
EP 474
DI 10.3109/02688697.2012.757295
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 190DP
UT WOS:000322319000014
PM 23298375
DA 2018-12-27
ER

PT J
AU Liu, AG
   Gao, X
   Zhang, QB
   Cui, LQ
AF Liu, Aiguo
   Gao, Xuan
   Zhang, Qingbin
   Cui, Lianqun
TI RETRACTED: Cathepsin B inhibition attenuates cardiac dysfunction and
   remodeling following myocardial infarction by inhibiting the NLRP3
   pathway (Retracted article. See vol. 16, pg. 7873, 2017)
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article; Retracted Publication
DE cathepsin B; NLRP3; cardiac dysfunction; cardiac remodeling; myocardial
   infarction
ID IMAGE-ANALYSIS; HEART-DISEASE; INFLAMMASOME; RECEPTOR; EXPRESSION;
   CARDIOMYOPATHY; PATHOGENESIS; ACTIVATION; FIBROSIS; CELLS
AB Recently, cathepsin B has been demonstrated to be involved in myocardial infarction (MI). This study aimed to elucidate the effects of a specific cathepsin B inhibitor, CA-074Me, on cardiac dysfunction, remodeling and fibrosis following MI in a rat model. Furthermore, the potential mechanisms of action of this inhibitor were investigated. In the present study, Sprague-Dawley rats were anesthetized and subjected to a sham operation or left anterior descending coronary artery ligation, followed by intraperitoneal injection of CA-074Me (10 mg/kg/day) or an equal volume of vehicle for 4 weeks. Activation of the cathepsin B and NLRP3 pathway was detected. Cardiac function was assessed by echocardiography, while hypertrophy and fibrosis were determined by Masson's trichrome, immunofluorescence and morphometry. The results demonstrated that cathepsin B-NLRP3 activation was inhibited by CA-074Me treatment. Following such treatment for 4 weeks, the rats demonstrated smaller decreases in cardiac function, and a decrease in cardiomyocyte hypertrophy and the level of fibrosis. Cathepsin B inhibition significantly attenuated cardiac dysfunction, and reduced cardiomyocyte size and cardiac fibrosis in the experimental MI model, by inhibiting NLRP3 activation. This suggested that targeting the cathepsin B-NLRP3 pathway may represent a novel therapeutic strategy to prevent heart failure and remodeling following MI.
C1 [Liu, Aiguo; Cui, Lianqun] Shandong Univ, Dept Cardiol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.
   [Liu, Aiguo; Gao, Xuan; Zhang, Qingbin] Weifang Med Coll, Dept Cardiol, Shandong Yi Dou Cent Hosp, Weifang 262500, Shandong, Peoples R China.
RP Cui, LQ (reprint author), Shandong Univ, Dept Cardiol, Shandong Prov Hosp, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.
EM lianquncui@yeah.net
CR Abbate A, 2008, CIRCULATION, V117, P2670, DOI 10.1161/CIRCULATIONAHA.107.740233
   Abbate A, 2010, AM J CARDIOL, V105, P1371, DOI 10.1016/j.amjcard.2009.12.059
   Artlett Carol M, 2012, Open Rheumatol J, V6, P80, DOI 10.2174/1874312901206010080
   BORG TK, 1981, LAB INVEST, V44, P49
   Boyle AJ, 2005, J MOL CELL CARDIOL, V39, P213, DOI 10.1016/j.yjmcc.2005.03.008
   Bracey NA, 2013, EXP PHYSIOL, V98, P462, DOI 10.1113/expphysiol.2012.068338
   Bujak M, 2008, AM J PATHOL, V173, P57, DOI 10.2353/ajpath.2008.070974
   Bujak M, 2009, ARCH IMMUNOL THER EX, V57, P165, DOI 10.1007/s00005-009-0024-y
   Cavallo-Medved D, 2003, NEOPLASIA, V5, P507, DOI 10.1016/S1476-5586(03)80035-0
   Cheng XW, 2006, HYPERTENSION, V48, P979, DOI 10.1161/01.HYP.0000242331.99369.2f
   Duncan DJ, 2010, CELL CALCIUM, V47, P378, DOI 10.1016/j.ceca.2010.02.002
   Ge JB, 2006, EUR J HEART FAIL, V8, P284, DOI 10.1016/j.ejheart.2005.09.004
   Hirota SA, 2011, INFLAMM BOWEL DIS, V17, P1359, DOI 10.1002/ibd.21478
   Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790
   Jugdutt BI, 2003, CIRCULATION, V108, P1395, DOI 10.1161/01.CIR.0000085658.98621.49
   Kumaran KS, 2010, J BIOCHEM MOL TOXIC, V24, P115, DOI 10.1002/jbt.20319
   Lal A, 2004, CARDIOVASC RES, V64, P437, DOI 10.1016/j.cardiores.2004.08.004
   Lehr HA, 1999, J HISTOCHEM CYTOCHEM, V47, P119, DOI 10.1177/002215549904700113
   Lehr HA, 1997, J HISTOCHEM CYTOCHEM, V45, P1559, DOI 10.1177/002215549704501112
   MASSON P, 1929, J TECH METHODS, V12, P75
   Matarrese P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-207
   McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491
   Mezzaroma E, 2011, P NATL ACAD SCI USA, V108, P19725, DOI 10.1073/pnas.1108586108
   Niemi K, 2011, J IMMUNOL, V186, P6119, DOI 10.4049/jimmunol.1002843
   Saito T, 2004, J MOL CELL CARDIOL, V37, P71, DOI 10.1016/j.yjmce.2004.04.002
   STRAIN JE, 1983, CIRCULATION, V68, P1171, DOI 10.1161/01.CIR.68.6.1171
   Takaya T, 2010, CIRC J, V74, P723, DOI 10.1253/circj.CJ-09-0488
   Van Acker GJD, 2002, AM J PHYSIOL-GASTR L, V283, pG794, DOI 10.1152/ajpgi.00363.2001
   Van Tassell BW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033438
   Watanabe A, 2009, AM J PHYSIOL-GASTR L, V296, pG1248, DOI 10.1152/ajpgi.90223.2008
   Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538
   Xu JF, 2012, AM J RESP CRIT CARE, V185, P547, DOI 10.1164/rccm.201108-1574OC
   Yousef ZR, 2000, HEART, V83, P76, DOI 10.1136/heart.83.1.76
NR 33
TC 14
Z9 16
U1 2
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD AUG
PY 2013
VL 8
IS 2
BP 361
EP 366
DI 10.3892/mmr.2013.1507
PG 6
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA 190XS
UT WOS:000322377400008
PM 23732925
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ramos, CG
   Grilo, AM
   da Costa, PJP
   Feliciano, JR
   Leitao, JH
AF Ramos, Christian G.
   Grilo, Andre M.
   da Costa, Paulo J. P.
   Feliciano, Joana R.
   Leitao, Jorge H.
TI RETRACTED: MtvR Is a Global Small Noncoding Regulatory RNA in
   Burkholderia cenocepacia (Retracted article. See vol. 196, pg. 3981,
   2014)
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article; Retracted Publication
ID CYSTIC-FIBROSIS PATIENTS; ESCHERICHIA-COLI-HFQ; CEPACIA COMPLEX; J2315;
   PREDICTION; VIRULENCE; GENE; IDENTIFICATION; CONSTRUCTION; PATHOGEN
AB Burkholderia cenocepacia J2315 is a highly epidemic and transmissible clinical isolate of the Burkholderia cepacia complex (Bcc), a group of bacteria causing life-threatening respiratory infections among cystic fibrosis patients. This work describes the functional analysis of the 136-nucleotide (nt)-long MtvR small noncoding RNA (sRNA) from the Bcc member B. cenocepacia J2315, with homologues restricted to the genus Burkholderia. Bioinformatic target predictions revealed a total of 309 mRNAs to be putative MtvR targets. The mRNA levels corresponding to 17 of 19 selected genes were found to be affected when MtvR was either overexpressed or silenced. Analysis of the interaction between MtvR and the hfq mRNA, one of its targets, showed that the sRNA binds exclusively to the 5' untranslated region (UTR) of the hfq mRNA. This interaction resulted in decreased protein synthesis, suggesting a negative regulatory effect of MtvR on the RNA chaperone Hfq. Bacterial strains with MtvR silenced or overexpressed exhibited pleiotropic phenotypes related to growth and survival after several stresses, swimming and swarming motilities, biofilm formation, resistance to antibiotics, and ability to colonize and kill the nematode Caenorhabditis elegans. Together, the results indicate that the MtvR sRNA is a major posttranscriptional regulator in B. cenocepacia.
C1 [Leitao, Jorge H.] Univ Tecn Lisboa, Inst Super Tecn, Dept Bioengn, P-1096 Lisbon, Portugal.
   [Ramos, Christian G.; Grilo, Andre M.; da Costa, Paulo J. P.; Feliciano, Joana R.; Leitao, Jorge H.] Univ Tecn Lisboa, Inst Super Tecn, Inst Biotechnol & Bioengn, P-1096 Lisbon, Portugal.
RP Leitao, JH (reprint author), Univ Tecn Lisboa, Inst Super Tecn, Dept Bioengn, P-1096 Lisbon, Portugal.
EM jorgeleitao@ist.utl.pt
RI Ramos, Christian/A-8588-2010; Leitao, Jorge H./A-5122-2012; Feliciano,
   Joana/K-1473-2016
OI Ramos, Christian/0000-0003-0970-7750; Leitao, Jorge
   H./0000-0001-8850-274X; Feliciano, Joana/0000-0002-4906-676X
FU Fundacao Ciencia e Tecnologia (FCT), Portugal
   [PTDC/BIA-MIC/119091/2010]; FCT
FX This work was partially supported by Fundacao Ciencia e Tecnologia
   (FCT), Portugal, through contract PTDC/BIA-MIC/119091/2010; a
   postdoctoral grant to C.G.R.; and doctoral grants to A.M.G. and J.R.F.
   P.J.P.D.C. acknowledges a research grant from FCT.
CR AMANN RI, 1990, J BACTERIOL, V172, P762, DOI 10.1128/jb.172.2.762-770.1990
   Bazzini S, 2011, APPL MICROBIOL BIOT, V92, P887, DOI 10.1007/s00253-011-3616-5
   Chabelskaya S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000927
   Clinical and Laboratory Standards Institute, 2013, M100S23 CLIN LAB STA
   Coenye T, 2007, FEMS MICROBIOL LETT, V276, P83, DOI 10.1111/j.1574-6968.2007.00916.x
   Coenye T, 2011, ANTIMICROB AGENTS CH, V55, P1912, DOI 10.1128/AAC.01571-10
   Cunha MV, 2004, J CLIN MICROBIOL, V42, P3052, DOI 10.1128/JCM.42.7.3052-3058.2004
   Drevinek P, 2010, CLIN MICROBIOL INFEC, V16, P821, DOI 10.1111/j.1469-0691.2010.03237.x
   Gottesman S, 2005, TRENDS GENET, V21, P399, DOI 10.1016/j.tig.2005.05.008
   Hamad MA, 2010, APPL ENVIRON MICROB, V76, P3170, DOI 10.1128/AEM.03024-09
   Holden MTG, 2009, J BACTERIOL, V191, P261, DOI 10.1128/JB.01230-08
   Lefebre MD, 2002, APPL ENVIRON MICROB, V68, P5956, DOI 10.1128/AEM.68.12.5956-5964.2002
   Leitao JH, 2008, EUR J CLIN MICROBIOL, V27, P1101, DOI 10.1007/s10096-008-0552-0
   Leitao JH, 2010, APPL MICROBIOL BIOT, V87, P31, DOI 10.1007/s00253-010-2528-0
   Loutet SA, 2010, INFECT IMMUN, V78, P4088, DOI 10.1128/IAI.00212-10
   Papenfort K, 2010, CELL HOST MICROBE, V8, P116, DOI 10.1016/j.chom.2010.06.008
   Ramos CG, 2013, GENOMICS, V101, P139, DOI 10.1016/j.ygeno.2012.10.006
   Ramos CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047896
   Ramos CG, 2011, J BACTERIOL, V193, P1515, DOI 10.1128/JB.01375-10
   Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1021/rna.5248604
   Richards GR, 2011, BBA-GENE REGUL MECH, V1809, P525, DOI 10.1016/j.bbagrm.2011.07.013
   Sousa SA, 2010, MICROBIOL-SGM, V156, P896, DOI 10.1099/mic.0.035139-0
   Sousa SA, 2008, MICROB PATHOGENESIS, V45, P331, DOI 10.1016/j.micpath.2008.08.002
   Sun XG, 2002, NUCLEIC ACIDS RES, V30, P3662, DOI 10.1093/nar/gkf508
   Vecerek B, 2005, RNA, V11, P976, DOI 10.1261/rna.2360205
   Vecerek B, 2008, NUCLEIC ACIDS RES, V36, P133, DOI 10.1093/nar/gkm985
   Vogel J, 2011, NAT REV MICROBIOL, V9, P578, DOI 10.1038/nrmicro2615
   Zhao YL, 2008, BIOCHEM BIOPH RES CO, V372, P346, DOI 10.1016/j.bbrc.2008.05.046
   Zhou YN, 1998, J BACTERIOL, V180, P1154
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 30
TC 3
Z9 4
U1 2
U2 21
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
EI 1098-5530
J9 J BACTERIOL
JI J. Bacteriol.
PD AUG
PY 2013
VL 195
IS 16
BP 3514
EP 3523
DI 10.1128/JB.00242-13
PG 10
WC Microbiology
SC Microbiology
GA 188VX
UT WOS:000322226100002
PM 23729649
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Rhinn, H
   Fujita, R
   Qiang, L
   Cheng, R
   Lee, JH
   Abeliovich, A
AF Rhinn, Herve
   Fujita, Ryousuke
   Qiang, Liang
   Cheng, Rong
   Lee, Joseph H.
   Abeliovich, Asa
TI RETRACTED: Integrative genomics identifies APOE epsilon 4 effectors in
   Alzheimer's disease (Retracted article. See vol. 523, 2015)
SO NATURE
LA English
DT Article; Retracted Publication
ID AMYLOID PRECURSOR PROTEIN; LARGE GENE LISTS; APOLIPOPROTEIN-E; WIDE
   ASSOCIATION; COMMON VARIANTS; BETA PRODUCTION; BRAIN; EXPRESSION;
   PATHOLOGY; NETWORKS
AB Late-onset Alzheimer's disease (LOAD) risk is strongly influenced by genetic factors such as the presence of the apolipoprotein E epsilon 4 allele (referred to here as APOE4), as well as non-genetic determinants including ageing. To pursue mechanisms by which these affect human brain physiology and modify LOAD risk, we initially analysed whole-transcriptome cerebral cortex gene expression data in unaffected APOE4 carriers and LOAD patients. APOE4 carrier status was associated with a consistent transcriptomic shift that broadly resembled the LOAD profile. Differential co-expression correlation network analysis of the APOE4 and LOAD transcriptomic changes identified a set of candidate core regulatory mediators. Several of these-including APBA2, FYN, RNF219 and SV2A-encode known or novel modulators of LOAD associated amyloid beta A4 precursor protein (APP) endocytosis and metabolism. Furthermore, a genetic variant within RNF219 was found to affect amyloid deposition in human brain and LOAD age-of-onset. These data implicate an APOE4 associated molecular pathway that promotes LOAD.
C1 [Rhinn, Herve; Fujita, Ryousuke; Qiang, Liang; Abeliovich, Asa] Columbia Univ, Dept Pathol, New York, NY 10032 USA.
   [Rhinn, Herve; Fujita, Ryousuke; Qiang, Liang; Abeliovich, Asa] Columbia Univ, Dept Cell Biol, New York, NY 10032 USA.
   [Rhinn, Herve; Fujita, Ryousuke; Qiang, Liang; Abeliovich, Asa] Columbia Univ, Dept Neurol, New York, NY 10032 USA.
   [Rhinn, Herve; Fujita, Ryousuke; Qiang, Liang; Cheng, Rong; Lee, Joseph H.; Abeliovich, Asa] Columbia Univ, Taub Inst Alzheimers Dis & Aging Brain, New York, NY 10032 USA.
   [Lee, Joseph H.] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA.
   [Lee, Joseph H.] Columbia Univ, Dept Epidemiol, New York, NY 10032 USA.
RP Abeliovich, A (reprint author), Columbia Univ, Dept Pathol, 650 W 168th St, New York, NY 10032 USA.
EM aa900@columbia.edu
FU National Institutes of Health (NIH) [R01AG042317, R01NS064433];
   Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904];
   National Institute on Aging; National Institute of Biomedical Imaging
   and Bioengineering; Canadian Institutes of Health Research; NIH [P30
   AG010129, K01 AG030514];  [R37 AG015473];  [R01 MH084995]
FX We thank R. Mayeux, G. Di Paulo, S. Small and A. Rosenthal for comments
   on the manuscript; D. Holtzman and J. Cirrito for antibody reagents; and
   S. Bajjalieh and J. Yao for SV2A expression vectors. We are especially
   grateful to the many laboratories who contributed data sets included in
   this study. The work was supported by grants from the National
   Institutes of Health (NIH) (R01AG042317 and R01NS064433). J. H. L. and
   R. C. were partially funded by R37 AG015473 and R01 MH084995.
   Additionally, data collection and sharing for this project was funded by
   the Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH grant U01
   AG024904). ADNI is funded by the National Institute on Aging, the
   National Institute of Biomedical Imaging and Bioengineering, and through
   generous contributions from the following: Alzheimer's Association;
   Alzheimer's Drug Discovery Foundation; BioClinica; Biogen Idec;
   Bristol-Myers Squibb; Eisai; Elan Pharmaceuticals; Eli Lilly; F.
   Hoffmann-La Roche and its affiliated company Genentech; GE Healthcare;
   Innogenetics, NV; IXICO; Janssen Alzheimer Immunotherapy Research and
   Development; Johnson and Johnson Pharmaceutical Research and
   Development; Medpace; Merck; Meso Scale Diagnostics; NeuroRx Research;
   Novartis; Pfizer; Piramal Imaging; Servier; Synarc; and Takeda
   Pharmaceutical Company. The Canadian Institutes of Health Research is
   providing funds to support ADNI clinical sites in Canada. Private sector
   contributions are facilitated by the Foundation for the National
   Institutes of Health (http://fnih.org). The grantee organization is the
   Northern California Institute for Research and Education, and the study
   is coordinated by the Alzheimer's Disease Cooperative Study at the
   University of California, San Diego. ADNI data are disseminated by the
   Laboratory for Neuro Imaging at the University of California, Los
   Angeles. This research was also supported by NIH grants P30 AG010129 and
   K01 AG030514.
CR Bakker A, 2012, NEURON, V74, P467, DOI 10.1016/j.neuron.2012.03.023
   Barber MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009763
   Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934
   Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701
   Bossers K, 2010, BRAIN, V133, P3699, DOI 10.1093/brain/awq258
   Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156
   Cirrito JR, 2003, J NEUROSCI, V23, P8844
   Cirulli ET, 2010, EUR J HUM GENET, V18, P815, DOI 10.1038/ejhg.2010.2
   Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008
   Dik MG, 2001, NEUROLOGY, V57, P2217, DOI 10.1212/WNL.57.12.2217
   Fotinopoulou A, 2005, J BIOL CHEM, V280, P30768, DOI 10.1074/jbc.C500231200
   Furney SJ, 2011, MOL PSYCHIATR, V16, P1130, DOI 10.1038/mp.2010.123
   Ravetti MG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010153
   Hardy J, 2006, NEURON, V52, P3, DOI 10.1016/j.neuron.2006.09.016
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   He XY, 2007, J NEUROSCI, V27, P4052, DOI 10.1523/JNEUROSCI.3993-06.2007
   Hoe HS, 2008, J BIOL CHEM, V283, P6288, DOI 10.1074/jbc.M704140200
   Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang YD, 2006, NEUROLOGY, V66, pS79, DOI 10.1212/01.wnl.0000192102.41141.9e
   Hudson NJ, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000382
   Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Li H, 2008, ARCH NEUROL-CHICAGO, V65, P45, DOI 10.1001/archneurol.2007.3
   Liang DP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040498
   Lynch BA, 2004, P NATL ACAD SCI USA, V101, P9861, DOI 10.1073/pnas.0308208101
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Mailman MD, 2007, NAT GENET, V39, P1181
   Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S1-S7
   Miller JA, 2008, J NEUROSCI, V28, P1410, DOI 10.1523/JNEUROSCI.4098-07.2008
   Morris JC, 2010, ANN NEUROL, V67, P122, DOI 10.1002/ana.21843
   Mueller Susanne G, 2005, Alzheimers Dement, V1, P55, DOI 10.1016/j.jalz.2005.06.003
   Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801
   Pasinetti GM, 2001, J NEUROSCI RES, V65, P471, DOI 10.1002/jnr.1176
   Presson AP, 2009, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-95
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qiang L, 2011, CELL, V146, P359, DOI 10.1016/j.cell.2011.07.007
   Ramanan VK, 2014, MOL PSYCHIATR, V19, P351, DOI 10.1038/mp.2013.19
   Ray M, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-136
   Reiman EM, 2007, NEURON, V54, P713, DOI 10.1016/j.neuron.2007.05.022
   Reiman EM, 2009, P NATL ACAD SCI USA, V106, P6820, DOI 10.1073/pnas.0900345106
   Reverter A, 2010, BIOINFORMATICS, V26, P896, DOI 10.1093/bioinformatics/btq051
   Rhinn H, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2032
   Rhinn H, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-62
   Sanchez PE, 2012, P NATL ACAD SCI USA, V109, pE2895, DOI 10.1073/pnas.1121081109
   Sano Y, 2006, J BIOL CHEM, V281, P37853, DOI 10.1074/jbc.M609312200
   Selkoe Dennis J, 2003, Harvey Lect, V99, P23
   Soler-Lopez M, 2011, GENOME RES, V21, P364, DOI 10.1101/gr.114280.110
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Ullrich S, 2010, J BIOL CHEM, V285, P20664, DOI 10.1074/jbc.M109.055608
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735
   Voineagu I, 2011, NATURE, V474, P380, DOI 10.1038/nature10110
   Webster JA, 2009, AM J HUM GENET, V84, P445, DOI 10.1016/j.ajhg.2009.03.011
   Yao J, 2010, J NEUROSCI, V30, P5569, DOI 10.1523/JNEUROSCI.4781-09.2010
   Ye SM, 2005, P NATL ACAD SCI USA, V102, P18700, DOI 10.1073/pnas.0508693102
   Zhang B, 2013, CELL, V153, P707, DOI 10.1016/j.cell.2013.03.030
NR 57
TC 96
Z9 99
U1 2
U2 94
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 1
PY 2013
VL 500
IS 7460
BP 45
EP U62
DI 10.1038/nature12415
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 192VK
UT WOS:000322514800024
PM 23883936
DA 2018-12-27
ER

PT J
AU Mohanty, AK
   Senapati, M
   Beberta, S
   Lenka, SK
AF Mohanty, Aswini Kumar
   Senapati, Manas
   Beberta, Swapnasikta
   Lenka, Saroj Kumar
TI RETRACTED: Mass classification method in mammograms using correlated
   association rule mining (Retracted article. See vol. 27, pg. 251, 2016)
SO NEURAL COMPUTING & APPLICATIONS
LA English
DT Article; Retracted Publication
DE Association rule mining; Digitized mammograms; Texture features; Gray
   level cooccurrence matrix; The CorClass algorithm
ID CLUSTERED MICROCALCIFICATIONS; NEURAL-NETWORK; DIAGNOSIS; TISSUE
AB In this paper, we present an efficient computer-aided mass classification method in digitized mammograms using Association rule mining, which performs benign-malignant classification on region of interest that contains mass. One of the major mammographic characteristics for mass classification is texture. Association rule mining (ARM) exploits this important factor to classify the mass into benign or malignant. The statistical textural features used in characterizing the masses are mean, standard deviation, entropy, skewness, kurtosis and uniformity. The main aim of the method is to increase the effectiveness and efficiency of the classification process in an objective manner to reduce the numbers of false-positive of malignancies. Correlated association rule mining was proposed for classifying the marked regions into benign and malignant and 98.6% sensitivity and 97.4% specificity is achieved that is very much promising compare to the radiologist's sensitivity 75%.
C1 [Mohanty, Aswini Kumar] SOA Univ, Bhubaneswar, Orissa, India.
   [Senapati, Manas] Krupajal Engn Coll, Bhubaneswar, Orissa, India.
   [Beberta, Swapnasikta] BPUT, Rourkela, Orissa, India.
   [Lenka, Saroj Kumar] Mody Univ, Dept Comp Sci, Lakshmangarh 332311, Rajasthan, India.
RP Mohanty, AK (reprint author), SOA Univ, Bhubaneswar, Orissa, India.
EM asw_moh@yahoo.com; manas_senapati@sify.com; swapnasikta@gmail.com;
   lenka.sarojkumar@gmail.com
OI Lenka, Saroj/0000-0002-6282-2611
CR Abu-Amara F, 2009, INT J BIOMED IMAGING, DOI 10.1155/2009/680508
   Agrawal R., 1993, SIGMOD Record, V22, P207, DOI 10.1145/170035.170072
   Alginahi Y, 2004, 47 IEEE INT MIDW S C, P209
   Alginahi Y, 2008, P INT C DIG IM COMP, P220
   Alginahi Y, 2004, THESIS U WINDSOR WIN
   Bin Zheng, 1999, IJCNN'99. International Joint Conference on Neural Networks. Proceedings (Cat. No.99CH36339), P4181, DOI 10.1109/IJCNN.1999.830835
   BIRD RE, 1990, RADIOLOGY, V177, P587, DOI 10.1148/radiology.177.2.2217807
   Chan HP, 1997, PHYS MED BIOL, V42, P549, DOI 10.1088/0031-9155/42/3/008
   CHAN HP, 1995, PHYS MED BIOL, V40, P857, DOI 10.1088/0031-9155/40/5/010
   Cheng HD, 2006, PATTERN RECOGN, V39, P646, DOI 10.1016/j.patcog.2005.07.006
   Dua S, 2009, EXPERT SYST APPL, V36, P9250, DOI 10.1016/j.eswa.2008.12.050
   Duda R. O., 2001, PATTERN CLASSIFICATI
   Holmes G., 1994, Proceedings of the 1994 Second Australian and New Zealand Conference on Intelligent Information Systems (Cat. No.94TH8019), P357, DOI 10.1109/ANZIIS.1994.396988
   Kobylinski L, P INT MULT COMP SCI, P85
   Lairenjam B, 2009, LECT NOTES COMPUT SC, V5788, P465, DOI 10.1007/978-3-642-04394-9_57
   Lisboa PJG, 2000, NEURAL NETWORKS, V15, P11
   Oliver A, 2008, IEEE T INF TECHNOL B, V12, P55, DOI 10.1109/TITB.2007.903514
   Rajendran P., 2010, INT J COMPUT APPL, V1, P87, DOI DOI 10.5120/415-613
   Ribeiro MX, 2007, COMP MED SY, P47, DOI 10.1109/CBMS.2007.101
   Roselin R, 2010, IEEE EXPLORE, P1, DOI [10.1109/ICCCNT.2010.5592607, DOI 10.1109/ICCCNT.2010.5592607]
   Sahiner B, 1998, PHYS MED BIOL, V43, P2853, DOI 10.1088/0031-9155/43/10/014
   Sahiner B, 2001, IEEE T MED IMAGING, V20, P1275, DOI 10.1109/42.974922
   Sid-Ahmed MA, 1995, INT J ARTIF INTELL A, V1
   Thangavel K, 2009, International Journal of Recent Trends in Engineering, V2, P67
   Thangavel K, 2009, International Journal of Recent Trends in Engineering, V2, P233
   Tseng V. S., 2005, ICDE 05 TOK, P1180
   Veldkamp WJH, 2000, MED PHYS, V27, P2600, DOI 10.1118/1.1318221
   Vibha L, DAT ENG APPL S IDEAS, DOI 10.1109/IDEAS.2006.14
   Viton JL, 1996, OPT ENG, V35, P3453, DOI 10.1117/1.601107
   Wang X, 2004, CAN C EL COMP ENG, DOI [10.1109/CCECE.2004.1349689, DOI 10.1109/CCECE.2004.1349689]
   Wei LY, 2005, IEEE T MED IMAGING, V24, P371, DOI 10.1109/TMI.2004.842457
   Yang SC, 2005, BIOMED ENG-APP BAS C, V17, P215, DOI 10.4015/S1016237205000330
   Yun J, 2005, JOINGING ASS CLASSIF, P367
   Zimmermann A, 2004, LECT NOTES COMPUT SC, V3245, P60
NR 34
TC 5
Z9 5
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-0643
EI 1433-3058
J9 NEURAL COMPUT APPL
JI Neural Comput. Appl.
PD AUG
PY 2013
VL 23
IS 2
BP 273
EP 281
DI 10.1007/s00521-012-0857-x
PG 9
WC Computer Science, Artificial Intelligence
SC Computer Science
GA 187SM
UT WOS:000322139500003
DA 2018-12-27
ER

PT J
AU Huang, Y
   Liu, X
   Kuang, X
   Liao, DF
AF Huang, Yan
   Liu, Xin
   Kuang, Xin
   Liao, Duanfang
TI RETRACTED: CYP2D6 T188C variant is associated with lung cancer risk in
   the Chinese population (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE CYP2D6; Polymorphism; Lung cancer; Meta-analysis
ID METAANALYSIS; POLYMORPHISMS; GENES
AB The CYP2D6 gene has been suggested to play an important role in the pathogenesis of lung cancer. However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of CYP2D6 T188C variant with lung cancer. Published literature from PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang data were retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed- or random-effects model. A total of nine studies (1,516 lung cancer cases and 1,950 controls) for CYP2D6 T188C variant were included in the meta-analysis. The meta-analysis indicated that compared with CYP2D6 TT genotype, non-TT genotype (CC or CT) was significantly associated with lung cancer in the Chinese (OR = 1.61, 95 % CI = 1.38-1.87, p < 0.001), with no evidence of between-study heterogeneity (I (2) = 0.0 %, p = 0.991). The sensitivity analysis indicated that the association was stable and no publication bias was detected. The present meta-analysis supported the positive association of CYP2D6 T188C variant with lung cancer in the Chinese. Further large-scale studies with the consideration for gene-gene/gene-environment interactions should be conducted to investigate the association.
C1 [Huang, Yan; Liao, Duanfang] Univ South China, Hengyang, Peoples R China.
   [Huang, Yan; Kuang, Xin] Univ South China, Dept Tradit Chinese Med, Hosp Affiliated 1, Hengyang, Peoples R China.
   [Liu, Xin] Univ South China, Dept Anesthesiol, Hosp Affiliated 1, Hengyang, Peoples R China.
   [Liao, Duanfang] Hunan Univ Chinese Med, Changsha, Hunan, Peoples R China.
RP Liao, DF (reprint author), Hunan Univ Chinese Med, Changsha, Hunan, Peoples R China.
EM duanfangliao@163.com
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bradford LD, 2002, PHARMACOGENOMICS, V3, P229, DOI 10.1517/14622416.3.2.229
   Christensen PM, 1997, EUR J CLIN PHARMACOL, V51, P389, DOI 10.1007/s002280050219
   DALY AK, 1993, PHARMACOL THERAPEUT, V57, P129, DOI 10.1016/0163-7258(93)90053-G
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Gao Y, 1999, MUTAT RES-GEN TOX EN, V444, P441, DOI 10.1016/S1383-5718(99)00092-3
   Gu YF, 2007, CHIN MED J, V87, P3064
   GU YF, 2004, CHIN J LUNG CANC, V7, P112
   Guo Z, 2005, CHIN J LUNG CANC, V8, P89
   Jianfang Zhang, 2010, 44 ANN C INF SCI SYS, P1
   Li Wei-Ying, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P1042
   Liang GY, 2005, THESIS SE U, P1
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Piskac-Collier AL, 2011, GENE CHROMOSOME CANC, V50, P1, DOI 10.1002/gcc.20826
   van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7
   Yan Zhen, 2008, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V30, P564
   Zhou JL, 2011, ACAD J GUANGDONG COL, V27, P528
   Zhou LP, 2012, ASIAN PAC J CANCER P, V13, P3165, DOI 10.7314/APJCP.2012.13.7.3165
NR 18
TC 4
Z9 4
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2013
VL 34
IS 4
BP 2189
EP 2193
DI 10.1007/s13277-013-0755-6
PG 5
WC Oncology
SC Oncology
GA 184RZ
UT WOS:000321912500025
PM 23558964
DA 2018-12-27
ER

PT J
AU Liu, CB
   Wang, HB
AF Liu, Chibo
   Wang, Haibao
TI RETRACTED: XRCC3 T241M polymorphism is associated risk of hepatocellular
   carcinoma in the Chinese (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE XRCC3; Polymorphism; Hepatocellular carcinoma; Meta-analysis
ID DNA-REPAIR; THR241MET POLYMORPHISM; GUANGXI POPULATION; CANCER RISK;
   SUSCEPTIBILITY; METAANALYSIS
AB The X-ray repair cross-complementing group 3 (XRCC3) gene has been suggested to play an important role in the pathogenesis of hepatocellular carcinoma (HCC). However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of XRCC3 Thr241Met variant with HCC. The published literature from PubMed, Chinese National Knowledge Infrastructure, and Wan Fang data was retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed or random effects model. A total of five studies (1,531 HCC cancer cases and 1,952 controls) for XRCC3 Thr241Met variant were included in the meta-analysis. The meta-analysis showed that XRCC3 Thr241Met variant was associated with HCC risk under homogeneous codominant model (OR = 3.99, 95 % CI = 1.74-9.13) and recessive model (OR = 5.22, 95 % CI = 3.65-7.48), but not under heterogeneous codominant model (OR = 1.18, 95 % CI = 0.68-2.05) and dominant model (OR = 1.37, 95 % CI = 0.73-2.57). Subgroup analysis by ethnicity suggested that XRCC3 Thr241Met variant was associated with HCC risk in Chinese population, but not in Pakistani population. The present meta-analysis supported the positive association of XRCC3 Thr241Met variant with HCC in the Chinese. Further large-scale studies with the consideration for gene-gene/gene-environment interactions should be conducted to investigate the association.
C1 [Liu, Chibo] Taizhou Municipal Hosp, Dept Clin Lab, Taizhou 318000, Peoples R China.
   [Wang, Haibao] Taizhou Municipal Hosp, Dept Orthoped, Taizhou 318000, Peoples R China.
RP Wang, HB (reprint author), Taizhou Municipal Hosp, Dept Orthoped, 381 Zhong Shan Dong Rd, Taizhou 318000, Peoples R China.
EM wanghb1962@126.com
FU Zhejiang Medicine, Health, and Science [2010KYB127]; Zhejiang Province
   Chinese Medicine Research Program [2012ZA130]; Zhejiang Gong Yi Xing
   Technology Application Project [2012C33025]
FX The work was funded by Zhejiang Medicine, Health, and Science (no.
   2010KYB127), Zhejiang Province Chinese Medicine Research Program
   (2012ZA130), and Zhejiang Gong Yi Xing Technology Application Project
   (2012C33025).
CR Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fang F, 2011, MED ONCOL, V28, P999, DOI 10.1007/s12032-010-9591-3
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gulnaz A, 2013, EUR J GASTROEN HEPAT, V25, P166, DOI 10.1097/MEG.0b013e328359a775
   Han XC, 2012, HEPATO-GASTROENTEROL, V59, P2285, DOI 10.5754/hge12096
   He XF, 2012, MOL BIOL REP, V39, P5125, DOI 10.1007/s11033-011-1308-y
   Li F, 2011, UROLOGY, V77, P511
   Liu L, 2013, MOL BIOL REP, V40, P3943, DOI 10.1007/s11033-012-2471-5
   Liu W, THESIS FUDAN MED U, P1
   Long XD, 2008, ANN EPIDEMIOL, V18, P572, DOI 10.1016/j.annepidem.2008.03.003
   Long Xi-dai, 2008, Zhonghua Yixue Yichuanxue Zazhi, V25, P268
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Miller MC, 2001, TOXICOL LETT, V120, P269, DOI 10.1016/S0378-4274(01)00279-X
   Parikh S, 2007, AM J MED, V120, P194, DOI 10.1016/j.amjmed.2006.11.020
   Xu L, 2003, THESIS FUDAN U, P1
   Xu YH, 2013, TUMOR BIOL, V34, P865, DOI 10.1007/s13277-012-0619-5
   Yin QH, 2012, ASIAN PAC J CANCER P, V13, P5201, DOI 10.7314/APJCP.2012.13.10.5201
   Zeng XY, 2012, DNA CELL BIOL, V31, P1384, DOI 10.1089/dna.2012.1646
   Zipprich Jennifer, 2010, J Carcinog, V9, P4, DOI 10.4103/1477-3163.62535
NR 20
TC 8
Z9 8
U1 3
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2013
VL 34
IS 4
BP 2249
EP 2254
DI 10.1007/s13277-013-0765-4
PG 6
WC Oncology
SC Oncology
GA 184RZ
UT WOS:000321912500032
PM 23558966
DA 2018-12-27
ER

PT J
AU Li, F
   Liu, YL
   Fu, T
   Tong, WD
   Zhang, AP
AF Li, Fan
   Liu, Yuliang
   Fu, Tao
   Tong, Weidong
   Zhang, Anping
TI RETRACTED: Associations of three common polymorphisms in CD95 and CD95L
   promoter regions with gastric cancer risk (Retracted article. See April,
   2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE CD95; CD95L; Gastric cancer; Meta-analysis
ID CARDIAC ADENOCARCINOMA; FAS CD95; GENE; POPULATION; FAS/FASL; LESIONS
AB There are many studies performed to assess the associations of CD95 A670G and G1377A polymorphisms with gastric cancer, and the association of CD95L T844C polymorphism with gastric cancer risk, but the data are remaining controversial. To get a comprehensive assessment of the association above, we performed a meta-analysis of published studies. PubMed, Embase, Web of Science, and Wanfang Medicine databases were searched for eligible studies. There were eight studies including 3,790 subjects on CD95 A670G polymorphism, eight studies including 4,563 subjects on CD95 G1377A polymorphism, and eight studies including 4,563 subjects on CD95L T844C polymorphism. Overall, CD95 G1377A polymorphism was associated with a significantly increased risk of gastric cancer (for AA versus GG: odds ratio (OR) = 1.24, 95 % confidence interval (95 % CI) = 1.02-1.52, P = 0.030; for AA versus GG + GA: OR = 1.27, 95 % CI = 1.05-1.53, P = 0.012). However, there were no associations of CD95 A670G and CD95L T844C polymorphisms with gastric cancer. Subgroup analysis by ethnicity found similar associations in Asians, but the associations in Caucasians were still unclear owing to the lack of relevant data. Therefore, the outcomes of this meta-analysis show that there is a significant association between CD95 G1377A polymorphism and risk of gastric cancer.
C1 [Li, Fan; Liu, Yuliang; Fu, Tao; Tong, Weidong; Zhang, Anping] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Gen Surg, Chongqing 400042, Peoples R China.
   [Liu, Yuliang] Chongqing Med Univ, Affiliated Hosp 1, Dept Resp Med, Chongqing 400016, Peoples R China.
RP Zhang, AP (reprint author), Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Gen Surg, 10 Changjiangzhilu, Chongqing 400042, Peoples R China.
EM zhangaipingcq@163.com
FU General program of National Natural Science Foundation of China
   [81100259, 81000898, 81201841]; CSTC [2011jjA055];  [2010XQN31]
FX This work was supported by the General program of National Natural
   Science Foundation of China (no. 81100259, 81000898, and 81201841) and
   CSTC (2011jjA055) and Innovation Fund 2010XQN31.
CR Banzato PCA, 2013, REPROD SCI, V20, P1111, DOI 10.1177/1933719113477488
   Bossaller L, 2012, J IMMUNOL, V189, P5508, DOI 10.4049/jimmunol.1202121
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Cullen SP, 2013, MOL CELL, V49, P1034, DOI 10.1016/j.molcel.2013.01.025
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fujikura D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055321
   Haas SL, 2012, CURR OPIN CLIN NUTR, V15, P457, DOI 10.1097/MCO.0b013e3283566699
   Hsu PI, 2008, ANTICANCER RES, V28, P97
   Hu Y, 2011, SHANG DONG YI YAO, V51, P45
   Ikehara SK, 2006, J HUM GENET, V51, P927, DOI 10.1007/s10038-006-0040-2
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Karimi MY, 2013, CANCER INVEST, V31, P1, DOI 10.3109/07357907.2012.743555
   Kupcinskas J, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-112
   Kutumova E, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-13
   Liu L, 2011, CARCINOGENESIS, V32, P336, DOI 10.1093/carcin/bgq264
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Passadaki T, 2013, IN VIVO, V27, P285
   Saeki N, 2013, CANCER SCI, V104, P1, DOI 10.1111/cas.12042
   Selgrad M, 2012, HELICOBACTER, V17, P30, DOI 10.1111/j.1523-5378.2012.00980.x
   Tan IB, 2012, EXPERT REV GASTROENT, V6, P335, DOI [10.1586/egh.12.7, 10.1586/EGH.12.7]
   Wang ML, 2009, BIOCHEM GENET, V47, P559, DOI 10.1007/s10528-009-9264-0
   Zhang MeiJuan, 2011, Journal of Shandong University (Health Sciences), V49, P106
   Zhang MJ, 2010, SHANDONG MED J, V50, P36
   Zhang WM, 2012, HEPATO-GASTROENTEROL, V59, P141, DOI 10.5754/hge11300
   Zhou R, 2010, CHINESE J CANC PREVE, V17, P1609
   Zhou RM, 2010, J GASTROEN HEPATOL, V25, P555, DOI 10.1111/j.1440-1746.2009.06116.x
NR 26
TC 6
Z9 6
U1 3
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2013
VL 34
IS 4
BP 2293
EP 2298
DI 10.1007/s13277-013-0773-4
PG 6
WC Oncology
SC Oncology
GA 184RZ
UT WOS:000321912500038
PM 23681795
DA 2018-12-27
ER

PT J
AU Mallik, A
   Pal, B
   Kundu, P
   Basumajumdar, A
AF Mallik, Amit
   Pal, Biswajit
   Kundu, Paritosh
   Basumajumdar, Arunabha
TI RETRACTED: Crystallization behavior and microstructure of ErF3
   nanocrystals in an oxyfluoride glass (Retracted article. See vol.44,
   pg.2633, 2018)
SO CERAMICS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Oxyfluoride glass; Annealed glass; Crystallization mechanism;
   Microstructure-final
ID UP-CONVERSION LUMINESCENCE; THERMAL-ANALYSIS; PHASE-CHANGE; SOLID-STATE;
   KINETICS; TRANSPARENT; CERAMICS; VITROCERAMICS; TEMPERATURE; NUCLEATION
AB Nanocrystallization of ErF3 in oxyfluoride glass of composition 55SiO(2)center dot 20Al(2)O(3)center dot 15Na(2)O center dot 10ErF(3) (mol%) has been observed by its heat treatment above the glass transition temperature. The crystallization mechanism of this glass has been substantiated by the microstructural and compositional changes in the crystalline phase. Studies have been made through dilatometry, X-ray diffraction (XRD), transmission electron microscopy (TEM) and differential scanning calorimetry (DSC). Maximum crystal size of 20 nm has been obtained, on variation of heat treatment time and temperature. Transmission electron microscopy (TEM) images of the as-annealed glass before heat treatment showed nonoccurrence of phase separation on quenching the melt. But after heat treatment for 10 h at 620 degrees C, ordered regions of dark contrast (0.5 nm) with respect to the matrix had appeared. These regions are believed to be associated with the process of onset of nucleation of fluorite phase. (C) 2013 Published by Elsevier Ltd and Techna Group S.r.l.
C1 [Mallik, Amit; Kundu, Paritosh; Basumajumdar, Arunabha] Univ Calcutta, Dept Chem Technol, Kolkata 700009, India.
   [Pal, Biswajit] Univ Calcutta, St Pauls CM Coll, Dept Chem, Kolkata 700009, India.
RP Basumajumdar, A (reprint author), Univ Calcutta, Dept Chem Technol, 92A PC Rd, Kolkata 700009, India.
EM a.basumajumdar@gmail.com
FU University Grant Commissions (UGC); University Grant Commission (UGC),
   New Delhi, India
FX Financial support from the University Grant Commissions (UGC), under
   major research project is gratefully acknowledged. SEM and XRD
   facilities have been provided by the Technical education quality
   improvement program (TEQIP). One of the authors, AM thanks University
   Grant Commission (UGC), New Delhi, India, for providing Junior Research
   Fellowship (UGC-RGNF).
CR AINSLIE BJ, 1995, J NON-CRYST SOLIDS, V184, P225, DOI 10.1016/0022-3093(94)00658-X
   Alton J, 2002, CHEM ENG SCI, V57, P2503, DOI 10.1016/S0009-2509(02)00121-5
   AUGIS JA, 1978, J THERM ANAL, V13, P283, DOI 10.1007/BF01912301
   AUZEL F, 1975, J ELECTROCHEM SOC, V122, P101, DOI 10.1149/1.2134132
   Avrami M, 1941, J CHEM PHYS, V9, P177, DOI 10.1063/1.1750872
   Avrami M., 1940, Journal of Chemical Physics, V8, P212, DOI 10.1063/1.1750631
   Avrami M, 1939, J CHEM PHYS, V7, P1103, DOI 10.1063/1.1750380
   CAHN JW, 1956, ACTA METALL MATER, V4, P449, DOI 10.1016/0001-6160(56)90041-4
   CAHN JW, 1956, ACTA METALL MATER, V4, P572, DOI 10.1016/0001-6160(56)90158-4
   Chen DQ, 2007, OPT MATER, V29, P1693, DOI 10.1016/j.optmat.2006.09.002
   Cheng KG, 2001, J MATER SCI, V36, P1043, DOI 10.1023/A:1004804730399
   de Pablos-Martin A, 2011, J AM CERAM SOC, V94, P2420, DOI 10.1111/j.1551-2916.2011.04547.x
   Dejneka MJ, 1998, J NON-CRYST SOLIDS, V239, P149, DOI 10.1016/S0022-3093(98)00731-5
   Downing E, 1996, SCIENCE, V273, P1185, DOI 10.1126/science.273.5279.1185
   Ghosh S, 2010, J NANOPART RES, V12, P1905, DOI 10.1007/s11051-009-9753-4
   Grong O, 2000, ACTA MATER, V48, P445, DOI 10.1016/S1359-6454(99)00360-2
   Gugov I, 2011, J SOLID STATE CHEM, V184, P1001, DOI 10.1016/j.jssc.2011.03.017
   KISSINGER HE, 1957, ANAL CHEM, V29, P1702, DOI 10.1021/ac60131a045
   KISSINGER HE, 1956, J RES NAT BUR STAND, V57, P217, DOI 10.6028/jres.057.026
   Kukkonen LL, 2001, J NON-CRYST SOLIDS, V290, P25, DOI 10.1016/S0022-3093(01)00731-1
   MATUSITA K, 1980, J NON-CRYST SOLIDS, V38-9, P741, DOI 10.1016/0022-3093(80)90525-6
   OZAWA T, 1971, POLYMER, V12, P150, DOI 10.1016/0032-3861(71)90041-3
   Ozawa T, 2000, PURE APPL CHEM, V72, P2083, DOI 10.1351/pac200072112083
   Pan Z, 2007, J LUMIN, V126, P251, DOI 10.1016/j.jlumin.2006.07.021
   Park YJ, 2002, CERAM INT, V28, P669, DOI 10.1016/S0272-8842(02)00026-3
   Perez-Maqueda LA, 2003, J NON-CRYST SOLIDS, V320, P84, DOI 10.1016/S0022-3093(03)00023-1
   TRAN DC, 1984, J LIGHTWAVE TECHNOL, V2, P566, DOI 10.1109/JLT.1984.1073661
   WANG YH, 1993, APPL PHYS LETT, V63, P3268, DOI 10.1063/1.110170
   Yamada M, 1996, IEEE PHOTONIC TECH L, V8, P882, DOI 10.1109/68.502258
   Zeng FQ, 2008, J NON-CRYST SOLIDS, V354, P3428, DOI 10.1016/j.jnoncrysol.2008.03.008
NR 30
TC 4
Z9 4
U1 3
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0272-8842
EI 1873-3956
J9 CERAM INT
JI Ceram. Int.
PD AUG
PY 2013
VL 39
IS 6
BP 6107
EP 6112
DI 10.1016/j.ceramint.2013.01.028
PG 6
WC Materials Science, Ceramics
SC Materials Science
GA 162VY
UT WOS:000320295300012
DA 2018-12-27
ER

PT J
AU Wang, Y
   Bao, XR
AF Wang, Yu
   Bao, Xiaorong
TI RETRACTED: Effects of uric acid on endothelial dysfunction in early
   chronic kidney disease and its mechanisms (Retracted article. See vol.
   20, 44, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Early chronic kidney disease; Endothelial dysfunction; Lipid oxidation;
   Micro-inflammation; Oxidative stress; Uric acid
ID CHRONIC-RENAL-FAILURE; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE;
   OXIDATIVE STRESS; ALL-CAUSE; CLINICAL EPIDEMIOLOGY; PROGENITOR CELLS;
   NITRIC-OXIDE; MORTALITY; HYPERURICEMIA
AB Background: An increase in serum uric acid (UA) occurs during the early and middle stages of chronic kidney disease (CKD) and aggravates the deterioration of kidney function. This study aims to explore the relation between UA and endothelial dysfunction in early CKD and its mechanisms in a murine model.
   Methods: The experimental animals were randomly divided into three groups (n = 10): sham-operation group (control group), right nephrectomy only group (CKD group) and right nephrectomy with oxonic potassium group (CKD with hyperuricemia group). Furthermore, we analyzed the relation between UA and endothelial dysfunction indices in early CKD as well as its mechanisms.
   Results: Linear regression analysis showed that the level of serum UA had a significant positive correlation with serum endothelin-1 and the percentage of collagen I positive area, but a negative correlation with serum nitric oxide (NO) and NO/endothelin-1 ratio. In addition, the level of serum UA had significant positive correlations with serum malonaldehyde, serum C-reactive protein, serum oxidatively-modified low-density lipoprotein and serum low-density lipoprotein, but a negative correlation with serum superoxide dismutase.
   Conclusions: Endothelial dysfunction in the CKD group was significant and had a positive correlation with the level of serum UA. Endothelial dysfunction in early CKD with hyperuricemia is perhaps related to oxidative stress, micro-inflammation and lipid oxidation.
C1 [Wang, Yu; Bao, Xiaorong] Fudan Univ, Jinshan Hosp, Dept Nephrol, Shanghai 201508, Peoples R China.
RP Bao, XR (reprint author), Fudan Univ, Jinshan Hosp, Dept Nephrol, 1508 Longhang Rd, Shanghai 201508, Peoples R China.
EM jinshankidney_js@126.com
CR Abe M, 2011, J ATHEROSCLER THROMB, V18, P1018
   Annuk M, 2001, J AM SOC NEPHROL, V12, P2747
   Arici M, 2001, KIDNEY INT, V59, P407, DOI 10.1046/j.1523-1755.2001.059002407.x
   Choi JH, 2004, ARTERIOSCL THROM VAS, V24, P1246, DOI 10.1161/01.ATV.0000133488.56221.4a
   Drexler H, 1999, J MOL CELL CARDIOL, V31, P51, DOI 10.1006/jmcc.1998.0843
   Edwards NL, 2009, CURR OPIN RHEUMATOL, V21, P132, DOI 10.1097/BOR.0b013e3283257b96
   Fenster BE, 2003, AM HEART J, V146, P218, DOI 10.1016/S0002-8703(03)00087-X
   Filiopoulos V, 2012, RENAL FAILURE, V34, P510, DOI 10.3109/0886022X.2011.653753
   Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470
   FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637, DOI 10.1093/oxfordjournals.aje.a117479
   FRIDOVIC.I, 1965, J BIOL CHEM, V240, P2491
   FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0
   Gersch C, 2008, NUCLEOS NUCLEOT NUCL, V27, P967, DOI 10.1080/15257770802257952
   GERTLER MM, 1951, ANN INTERN MED, V34, P1421, DOI 10.7326/0003-4819-34-6-1421
   Goon PKY, 2006, NEOPLASIA, V8, P79, DOI 10.1593/neo.05592
   Hajhosseiny R, 2013, INT J CLIN PRACT, V67, P14, DOI 10.1111/j.1742-1241.2012.02954.x
   Jalal DI, 2013, AM J KIDNEY DIS, V61, P134, DOI 10.1053/j.ajkd.2012.07.021
   JOSSA F, 1994, J HUM HYPERTENS, V8, P677
   Kundhal K, 2005, NEPHRON CLIN PRACT, V101, pC47, DOI 10.1159/000086221
   Liao MT, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/691369
   Liese AD, 1999, EPIDEMIOLOGY, V10, P391, DOI 10.1097/00001648-199907000-00009
   Loomans CJM, 2005, ANTIOXID REDOX SIGN, V7, P1468, DOI 10.1089/ars.2005.7.1468
   Majumdar A, 2000, J ROY SOC MED, V93, P178, DOI 10.1177/014107680009300406
   Mazzali M, 2002, AM J PHYSIOL-RENAL, V282, pF991, DOI 10.1152/ajprenal.00283.2001
   Menon V, 2005, KIDNEY INT, V68, P766, DOI 10.1111/j.1523-1755.2005.00455.x
   Muntner P, 2002, J AM SOC NEPHROL, V13
   Niskanen LK, 2004, ARCH INTERN MED, V164, P1546, DOI 10.1001/archinte.164.14.1546
   Ohno I, 2011, NUCLEOS NUCLEOT NUCL, V30, P1039, DOI 10.1080/15257770.2011.611484
   Reinhart K, 2002, CRIT CARE MED, V30, pS302, DOI 10.1097/00003246-200205001-00021
   Thorin E, 2010, PFLUG ARCH EUR J PHY, V459, P951, DOI 10.1007/s00424-009-0763-y
   Vaziri ND, 2002, HYPERTENSION, V39, P135, DOI 10.1161/hy0102.100540
   Zharikov S, 2008, AM J PHYSIOL-CELL PH, V295, pC1183, DOI 10.1152/ajpcell.00075.2008
NR 32
TC 24
Z9 27
U1 2
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD JUL 30
PY 2013
VL 18
AR 26
DI 10.1186/2047-783X-18-26
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 198CW
UT WOS:000322900400001
PM 23895583
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Lee, SW
   Youn, H
   Kim, EJ
   Um, SJ
AF Lee, Sang-Wang
   Youn, HyeSook
   Kim, Eun-Joo
   Um, Soo-Jong
TI RETRACTED: Histone H2B Ubquitination Regulates Retinoic Acid Signaling
   through the Cooperation of ASXL1 and BAP1 (Retracted article. See vol.
   51, pg. 552, 2013)
SO MOLECULAR CELL
LA English
DT Article; Retracted Publication
ID NUCLEAR RECEPTORS; GENE-EXPRESSION; MYELOID TRANSFORMATION;
   CELL-DIFFERENTIATION; UBIQUITIN HYDROLASE; STEM-CELLS; MUTATIONS;
   POLYCOMB; MONOUBIQUITINATION; DEUBIQUITINATION
AB Despite the importance of retinoic acid (RA) signaling and histone monoubiquitination in determining cell fate, the underlying mechanism linking the two processes is poorly explored. We describe that additional sex comb-like 1 (ASXL1) represses RA receptor activity by cooperating with BRCA1-associated protein 1 (BAP1), which contains the ubiquitin C-terminal hydrolase (UCH) domain. Both the UCH- and ASXL1-binding domains of BAP1 were required for cooperation. In contrast to Drosophila BAP1, mammalian BAP1 cleaved ubiquitin from histone H2B. As supported by BAP1 mutants, ASXL1 was critical for BAP1 recruitment to chromatin and its activation therein. ASXL1 requirement was supported using Asxl1 null mice embryonic fibroblasts. Both ASXL1 and BAP1 were downregulated during RA-induced P19 cell differentiation with concomitant increase of ubiquitinated H2B, leading to activation of Hox genes. Our data demonstrate the critical role of ASXL1 cooperation with BAP1 in cell differentiation through the regulation of RA signaling associated with H2B ubiquitination.
C1 [Lee, Sang-Wang; Youn, HyeSook; Um, Soo-Jong] Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea.
   [Kim, Eun-Joo] Dankook Univ, Dept Mol Biol, Yongin 448701, Gyeonggi Do, South Korea.
   [Um, Soo-Jong] Chebigen Inc, Jeonbuk 561360, South Korea.
RP Um, SJ (reprint author), Sejong Univ, Dept Biosci & Biotechnol, 98 Gunja Dong, Seoul 143747, South Korea.
EM umsj@sejong.ac.kr
FU National Research Foundation of Korea (NRF); Ministry of Education,
   Science, and Technology (MEST) [2009-0079104, 2011-0006420]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science, and Technology (MEST) (grants 2009-0079104 and
   2011-0006420).
CR Abdel-Wahab O, 2013, LEUKEMIA, V27, P10, DOI 10.1038/leu.2012.288
   Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032
   Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1
   Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022
   BERG RW, 1990, DEV BIOL, V138, P123, DOI 10.1016/0012-1606(90)90182-I
   Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855
   Buszczak M, 2009, SCIENCE, V323, P248, DOI 10.1126/science.1165678
   Chambon P, 1996, FASEB J, V10, P940
   Cho YS, 2006, J BIOL CHEM, V281, P17588, DOI 10.1074/jbc.M512616200
   Chou WC, 2010, BLOOD, V116, P4086, DOI 10.1182/blood-2010-05-283291
   Alonso AGD, 2007, GENETICS, V176, P2099, DOI 10.1534/genetics.107.075739
   Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711
   Fisher CL, 2010, DEV BIOL, V337, P9, DOI 10.1016/j.ydbio.2009.10.004
   Fisher CL, 2006, GENE, V369, P109, DOI 10.1016/j.gene.2005.10.033
   Fisher CL, 2010, BLOOD, V115, P38, DOI 10.1182/blood-2009-07-230698
   Fuchs G, 2012, MOL CELL, V46, P662, DOI 10.1016/j.molcel.2012.05.023
   Gelsi-Boyer V, 2009, BRIT J HAEMATOL, V145, P788, DOI 10.1111/j.1365-2141.2009.07697.x
   Glass CK, 2000, GENE DEV, V14, P121
   Gurevich I, 2007, TOXICOL APPL PHARM, V223, P288, DOI 10.1016/j.taap.2007.05.019
   Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472
   Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003
   Hoischen A, 2011, NAT GENET, V43, P729, DOI 10.1038/ng.868
   HUSMANN M, 1989, DEV BIOL, V136, P194, DOI 10.1016/0012-1606(89)90141-3
   Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861
   JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271
   Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256
   Kang M, 2012, BIOCHEM BIOPH RES CO, V421, P621, DOI 10.1016/j.bbrc.2012.04.072
   Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022
   Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027
   Lee JH, 2005, J BIOL CHEM, V280, P41725, DOI 10.1074/jbc.M508312200
   Lee SW, 2010, J BIOL CHEM, V285, P18, DOI 10.1074/jbc.M109.065862
   Machida YJ, 2009, J BIOL CHEM, V284, P34179, DOI 10.1074/jbc.M109.046755
   Milne TA, 1999, MOL GEN GENET, V261, P753, DOI 10.1007/s004380050018
   Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712
   Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08
   Murali R, 2013, PATHOLOGY, V45, P116, DOI 10.1097/PAT.0b013e32835d0efb
   Nakagawa T, 2008, GENE DEV, V22, P37, DOI 10.1101/gad.1609708
   Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710
   O'Malley B, 2008, MOL ENDOCRINOL, V22, P2751, DOI 10.1210/me.2008-0297
   Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323
   Ross SA, 2000, PHYSIOL REV, V80, P1021
   Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Stock JK, 2007, NAT CELL BIOL, V9, P1428, DOI 10.1038/ncb1663
   Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912
   Weake VM, 2008, MOL CELL, V29, P653, DOI 10.1016/j.molcel.2008.02.014
   Wiesner T, 2011, NAT GENET, V43, P1018, DOI 10.1038/ng.910
   Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403
   Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025
NR 50
TC 4
Z9 5
U1 1
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD JUL 25
PY 2013
VL 51
IS 2
BP 200
EP 210
DI 10.1016/j.molcel.2013.06.005
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 191PD
UT WOS:000322424200008
PM 23850490
OA Bronze
DA 2018-12-27
ER

PT J
AU Warne, JP
   Varonin, JM
   Nielsen, SS
   Olofsson, LE
   Kaelin, CB
   Chua, S
   Barsh, GS
   Koliwad, SK
   Xu, AW
AF Warne, James P.
   Varonin, Jillian M.
   Nielsen, Sofie S.
   Olofsson, Louise E.
   Kaelin, Christopher B.
   Chua, Streamson, Jr.
   Barsh, Gregory S.
   Koliwad, Suneil K.
   Xu, Allison W.
TI RETRACTED: Coordinated Regulation of Hepatic Energy Stores by Leptin and
   Hypothalamic Agouti-Related Protein (Retracted article. See vol. 34, pg.
   13865, 2014)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID SYMPATHETIC-NERVOUS-SYSTEM; DIET-INDUCED OBESITY; FATTY LIVER-DISEASE;
   ADIPOSE TRIGLYCERIDE LIPASE; MESSENGER-RIBONUCLEIC-ACID; ADULT-MOUSE
   BRAIN; INSULIN-RESISTANCE; NEUROPEPTIDE-Y; AGRP-NEURONS; DIACYLGLYCEROL
   ACYLTRANSFERASE
AB Like obesity, prolonged food deprivation induces severe hepatic steatosis; however, the functional significance of this phenomenon is not well understood. In this study, we show that the fall in plasma leptin concentration during fasting is required for the development of hepatic steatosis in mice. Removal of leptin receptors from AGRP neurons diminishes fasting-induced hepatic steatosis. Furthermore, the suppressive effects of leptin on fasting-induced hepatic steatosis are absent in mice lacking the gene encoding agouti-related protein (Agrp), suggesting that this function of leptin is mediated by AGRP. Prolonged fasting leads to suppression of hepatic sympathetic activity, increased expression of acyl CoA:diacylglycerol acyltransferase-2 in the liver, and elevation of hepatic triglyceride content and all of these effects are blunted in the absence of AGRP. AGRP deficiency, despite having no effects on feeding or body adiposity in the free-fed state, impairs triglyceride and ketone body release from the liver during prolonged fasting. Furthermore, reducing CNS Agrp expression in wild-type mice by RNAi protected against the development of hepatic steatosis not only during starvation, but also in response to consumption of a high-fat diet. These findings identify the leptin-AGRP circuit as a critical modulator of hepatic triglyceride stores in starvation and suggest a vital role for this circuit in sustaining the supply of energy from the liver to extrahepatic tissues during periods of prolonged food deprivation.
C1 [Warne, James P.; Varonin, Jillian M.; Nielsen, Sofie S.; Olofsson, Louise E.; Koliwad, Suneil K.; Xu, Allison W.] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
   [Kaelin, Christopher B.; Barsh, Gregory S.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA.
   [Chua, Streamson, Jr.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA.
   [Chua, Streamson, Jr.] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA.
RP Xu, AW (reprint author), Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
EM axu@diabetes.ucsf.edu
FU National Institutes of Health [R01DK080427]; Diabetes and Endocrinology
   Research Center [P30DK063720]; University of California-San Francisco
   Program for Breakthrough Biomedical Research; New York Nutrition Obesity
   Research Center [P30DK026687]
FX This work was supported by National Institutes of Health (Grant
   #R01DK080427 to A.W.X. and core facilities funded by Diabetes and
   Endocrinology Research Center Grant #P30DK063720), the University of
   California-San Francisco Program for Breakthrough Biomedical Research,
   and the New York Nutrition Obesity Research Center (Grant #P30DK026687).
CR Al-Qassab H, 2009, CELL METAB, V10, P343, DOI 10.1016/j.cmet.2009.09.008
   Alkemade A, 2012, J CLIN ENDOCR METAB, V97, pE925, DOI 10.1210/jc.2011-3259
   Aponte Y, 2011, NAT NEUROSCI, V14, P351, DOI 10.1038/nn.2739
   Atasoy D, 2012, NATURE, V488, P172, DOI 10.1038/nature11270
   Baskin DG, 1999, HORM METAB RES, V31, P345, DOI 10.1055/s-2007-978751
   Baskin DG, 1999, DIABETES, V48, P828, DOI 10.2337/diabetes.48.4.828
   Breen TL, 2005, BRAIN RES, V1032, P141, DOI 10.1016/j.brainres.2004.11.008
   Brito MN, 2007, ENDOCRINOLOGY, V148, P5339, DOI 10.1210/en.2007-0621
   Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043
   BRODIE BB, 1966, J PHARMACOL EXP THER, V154, P493
   Brown MS, 2008, CELL METAB, V7, P95, DOI 10.1016/j.cmet.2007.12.009
   Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466
   Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422
   Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018
   Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200
   Chao PT, 2011, CELL METAB, V13, P573, DOI 10.1016/j.cmet.2011.02.019
   Ciofi P, 2009, ENDOCRINOLOGY, V150, P5509, DOI 10.1210/en.2009-0584
   Claret M, 2007, J CLIN INVEST, V117, P2325, DOI 10.1172/JCI31516
   Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085
   Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6
   de Wall EV, 2008, ENDOCRINOLOGY, V149, P1773, DOI 10.1210/en.2007-1132
   Diano S, 2011, NAT MED, V17, P1121, DOI 10.1038/nm.2421
   Ebihara K, 1999, DIABETES, V48, P2028, DOI 10.2337/diabetes.48.10.2028
   EGAWA M, 1991, AM J PHYSIOL, V260, pR328
   Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0
   Enriori PJ, 2007, CELL METAB, V5, P181, DOI 10.1016/j.cmet.2007.02.004
   Farooqi IS, 2009, AM J CLIN NUTR, V89, p980S, DOI 10.3945/ajcn.2008.26788C
   Gropp E, 2005, NAT NEUROSCI, V8, P1289, DOI 10.1038/nn1548
   Harris RBS, 2006, ENDOCRINOLOGY, V147, P1365, DOI 10.1210/en.2005-1156
   HAUDE W, 1991, NAHRUNG, V35, P1061
   He SQ, 2010, J BIOL CHEM, V285, P6706, DOI 10.1074/jbc.M109.064501
   HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206
   Hoggard N, 2004, CLIN ENDOCRINOL, V61, P31, DOI 10.1111/j.1365-2265.2004.02056.x
   Joly-Amado A, 2012, EMBO J, V31, P4276, DOI 10.1038/emboj.2012.250
   Jornayvaz FR, 2011, P NATL ACAD SCI USA, V108, P5748, DOI 10.1073/pnas.1103451108
   Kaelin CB, 2006, MOL ENDOCRINOL, V20, P2591, DOI 10.1210/me.2006-0107
   Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051
   Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392
   Konner AC, 2007, CELL METAB, V5, P438, DOI 10.1016/j.cmet.2007.05.004
   Korner J, 2001, J NEUROENDOCRINOL, V13, P959, DOI 10.1046/j.1365-2826.2001.00716.x
   Krashes MJ, 2011, J CLIN INVEST, V121, P1424, DOI 10.1172/JCI46229
   Landsberg L, 2006, CELL MOL NEUROBIOL, V26, P497, DOI 10.1007/s10571-006-9010-7
   LEBOEUF RC, 1994, J LIPID RES, V35, P121
   Leinninger GM, 2009, CELL METAB, V10, P89, DOI 10.1016/j.cmet.2009.06.011
   Leitner C, 2008, AM J PHYSIOL-REG I, V294, pR775, DOI 10.1152/ajpregu.00369.2007
   Li JY, 2000, ENDOCRINOLOGY, V141, P1942, DOI 10.1210/en.141.6.1942
   Luquet S, 2005, SCIENCE, V310, P683, DOI 10.1126/science.1115524
   Miyamoto L, 2012, J BIOL CHEM, V287, P40441, DOI 10.1074/jbc.M112.384545
   Mizuno TM, 1999, ENDOCRINOLOGY, V140, P4551, DOI 10.1210/en.140.10.4551
   Mizuno TM, 1999, ENDOCRINOLOGY, V140, P814, DOI 10.1210/en.140.2.814
   Moller L, 2008, CLIN SCI, V114, P547, DOI 10.1042/CS20070217
   Monetti M, 2007, CELL METAB, V6, P69, DOI 10.1016/j.cmet.2007.05.005
   Morita S, 2012, CELL TISSUE RES, V349, P589, DOI 10.1007/s00441-012-1421-9
   Mullier A, 2010, J COMP NEUROL, V518, P943, DOI 10.1002/cne.22273
   Newton AJ, 2013, ENDOCRINOLOGY, V154, P172, DOI 10.1210/en.2012-1643
   Nogueiras R, 2007, J CLIN INVEST, V117, P3475, DOI 10.1172/JC131743
   ODEA K, 1982, METABOLISM, V31, P896, DOI 10.1016/0026-0495(82)90178-0
   Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135
   Olofsson LE, 2013, P NATL ACAD SCI USA, V110, pE697, DOI 10.1073/pnas.1218284110
   Olpin SE, 2004, PROSTAG LEUKOTR ESS, V70, P293, DOI 10.1016/j.plefa.2003.06.003
   Postic C, 2008, J CLIN INVEST, V118, P829, DOI 10.1172/JCI34275
   Qian S, 2002, MOL CELL BIOL, V22, P5027, DOI 10.1128/MCB.22.14.5027-5035.2002
   Reid BN, 2008, J BIOL CHEM, V283, P13087, DOI 10.1074/jbc.M800533200
   Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257
   Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428
   Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200
   Schwartz MW, 2000, NATURE, V404, P661
   Shimomura I, 1999, NATURE, V401, P73
   SPECTOR S, 1965, J PHARMACOL EXP THER, V147, P86
   Takahashi KA, 2005, ENDOCRINOLOGY, V146, P1043, DOI 10.1210/en.2004-1397
   Timlin MT, 2005, AM J CLIN NUTR, V81, P35
   Tong QC, 2008, NAT NEUROSCI, V11, P998, DOI 10.1038/nn.2167
   Warne JP, 2011, CELL METAB, V14, P791, DOI 10.1016/j.cmet.2011.11.001
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wilson BD, 1999, ENDOCRINOLOGY, V140, P2387, DOI 10.1210/en.140.5.2387
   Wu JW, 2011, HEPATOLOGY, V54, P122, DOI 10.1002/hep.24338
   Wu Q, 2008, P NATL ACAD SCI USA, V105, P2687, DOI 10.1073/pnas.0712062105
   Wu Q, 2012, NATURE, V483, P594, DOI 10.1038/nature10899
   Wu Q, 2009, CELL, V137, P1225, DOI 10.1016/j.cell.2009.04.022
   Xu AW, 2005, PLOS BIOL, V3, P2168, DOI 10.1371/journal.pbio.0030415
   Xu AW, 2005, J CLIN INVEST, V115, P951, DOI 10.1172/JCI24301
   Yasuda T, 2004, EXP BIOL MED, V229, P235
   YOUNG JB, 1979, AM J PHYSIOL, V236, pE524
   YOUNG JB, 1977, SCIENCE, V196, P1473, DOI 10.1126/science.867049
   YOUNG JB, 1984, AM J PHYSIOL, V247, pE35
   Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043
NR 86
TC 7
Z9 7
U1 2
U2 18
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUL 17
PY 2013
VL 33
IS 29
BP 11972
EP 11985
DI 10.1523/JNEUROSCI.0830-13.2013
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 184MG
UT WOS:000321893500023
PM 23864684
OA Bronze, Green Published
DA 2018-12-27
ER

EF